[{"id": "Lepirudin_GEN", "text": "Drug: Lepirudin\nDescription: ...", "source": "Lepirudin"}, {"id": "Phylloquinone_GEN", "text": "Drug: Phylloquinone\nDescription: ...", "source": "Phylloquinone"}, {"id": "Calcium_GEN", "text": "Drug: Calcium\nDescription: ...", "source": "Calcium"}, {"id": "Lepirudin_GEN", "text": "Drug: Lepirudin\nDescription: Lepirudin is identical to natural hirudin except for substitution of leucine for isoleucine at the N-terminal end of the molecule and the absence of a sulfate group on the tyrosine at position 63. It is produced via yeast cells. Bayer ceased the production of lepirudin (Refludan) effective May 31, 2...", "source": "Lepirudin"}, {"id": "Lepirudin_CLIN", "text": "Drug: Lepirudin\nMechanism: Lepirudin forms a stable non-covalent complex with alpha-thrombin, thereby abolishing its ability to cleave fibrinogen and initiate the clotting cascade. The inhibition of thrombin prevents the blood ...\nToxicity: In case of overdose (eg, suggested by excessively high aPTT values) the risk of bleeding is increased....", "source": "Lepirudin"}, {"id": "Lepirudin_INT_St. John's Wort", "text": "Interaction: Lepirudin AND St. John's Wort\nDetails: The metabolism of Lepirudin can be increased when combined with St. John&#39;s Wort.\nRisk: Monitor closely.", "source": "Lepirudin + St. John's Wort"}, {"id": "Lepirudin_INT_Alfuzosin", "text": "Interaction: Lepirudin AND Alfuzosin\nDetails: The serum concentration of Alfuzosin can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Alfuzosin"}, {"id": "Lepirudin_INT_Acemetacin", "text": "Interaction: Lepirudin AND Acemetacin\nDetails: The risk or severity of bleeding can be increased when Lepirudin is combined with Acemetacin.\nRisk: Monitor closely.", "source": "Lepirudin + Acemetacin"}, {"id": "Lepirudin_INT_Apixaban", "text": "Interaction: Lepirudin AND Apixaban\nDetails: Apixaban may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Apixaban"}, {"id": "Lepirudin_INT_Edoxaban", "text": "Interaction: Lepirudin AND Edoxaban\nDetails: Edoxaban may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Edoxaban"}, {"id": "Lepirudin_INT_Rivaroxaban", "text": "Interaction: Lepirudin AND Rivaroxaban\nDetails: Lepirudin may increase the anticoagulant activities of Rivaroxaban.\nRisk: Monitor closely.", "source": "Lepirudin + Rivaroxaban"}, {"id": "Lepirudin_INT_Lovastatin", "text": "Interaction: Lepirudin AND Lovastatin\nDetails: The serum concentration of Lovastatin can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Lovastatin"}, {"id": "Lepirudin_INT_Urokinase", "text": "Interaction: Lepirudin AND Urokinase\nDetails: Urokinase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Urokinase"}, {"id": "Lepirudin_INT_Vorapaxar", "text": "Interaction: Lepirudin AND Vorapaxar\nDetails: The risk or severity of adverse effects can be increased when Vorapaxar is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Vorapaxar"}, {"id": "Lepirudin_INT_Midazolam", "text": "Interaction: Lepirudin AND Midazolam\nDetails: The serum concentration of Midazolam can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Midazolam"}, {"id": "Lepirudin_INT_Simvastatin", "text": "Interaction: Lepirudin AND Simvastatin\nDetails: The serum concentration of Simvastatin can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Simvastatin"}, {"id": "Lepirudin_INT_Cabergoline", "text": "Interaction: Lepirudin AND Cabergoline\nDetails: The serum concentration of Cabergoline can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Cabergoline"}, {"id": "Lepirudin_INT_Bromocriptine", "text": "Interaction: Lepirudin AND Bromocriptine\nDetails: The serum concentration of Bromocriptine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Bromocriptine"}, {"id": "Lepirudin_INT_Methylergometrine", "text": "Interaction: Lepirudin AND Methylergometrine\nDetails: The serum concentration of Methylergometrine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Methylergometrine"}, {"id": "Lepirudin_INT_Dihydroergotamine", "text": "Interaction: Lepirudin AND Dihydroergotamine\nDetails: The serum concentration of Dihydroergotamine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Dihydroergotamine"}, {"id": "Lepirudin_INT_Ergotamine", "text": "Interaction: Lepirudin AND Ergotamine\nDetails: The serum concentration of Ergotamine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ergotamine"}, {"id": "Lepirudin_INT_Ergoloid mesylate", "text": "Interaction: Lepirudin AND Ergoloid mesylate\nDetails: The serum concentration of Ergoloid mesylate can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ergoloid mesylate"}, {"id": "Lepirudin_INT_Ergonovine", "text": "Interaction: Lepirudin AND Ergonovine\nDetails: The serum concentration of Ergonovine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ergonovine"}, {"id": "Lepirudin_INT_Triazolam", "text": "Interaction: Lepirudin AND Triazolam\nDetails: The serum concentration of Triazolam can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Triazolam"}, {"id": "Lepirudin_INT_Hemin", "text": "Interaction: Lepirudin AND Hemin\nDetails: Hemin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Hemin"}, {"id": "Lepirudin_INT_Ethinyl Estradiol", "text": "Interaction: Lepirudin AND Ethinyl Estradiol\nDetails: The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ethinyl Estradiol"}, {"id": "Lepirudin_INT_Mestranol", "text": "Interaction: Lepirudin AND Mestranol\nDetails: The serum concentration of Mestranol can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Mestranol"}, {"id": "Lepirudin_INT_Estradiol", "text": "Interaction: Lepirudin AND Estradiol\nDetails: The serum concentration of Estradiol can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Estradiol"}, {"id": "Lepirudin_INT_Estrone sulfate", "text": "Interaction: Lepirudin AND Estrone sulfate\nDetails: The serum concentration of Estrone sulfate can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Estrone sulfate"}, {"id": "Lepirudin_INT_Synthetic Conjugated Estrogens, A", "text": "Interaction: Lepirudin AND Synthetic Conjugated Estrogens, A\nDetails: The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Synthetic Conjugated Estrogens, A"}, {"id": "Lepirudin_INT_Estrogens, esterified", "text": "Interaction: Lepirudin AND Estrogens, esterified\nDetails: The serum concentration of Estrogens, esterified can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Estrogens, esterified"}, {"id": "Lepirudin_INT_Chlorotrianisene", "text": "Interaction: Lepirudin AND Chlorotrianisene\nDetails: The serum concentration of Chlorotrianisene can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Chlorotrianisene"}, {"id": "Lepirudin_INT_Conjugated estrogens", "text": "Interaction: Lepirudin AND Conjugated estrogens\nDetails: The serum concentration of Conjugated estrogens can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Conjugated estrogens"}, {"id": "Lepirudin_INT_Estramustine", "text": "Interaction: Lepirudin AND Estramustine\nDetails: The serum concentration of Estramustine can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Estramustine"}, {"id": "Lepirudin_INT_Dienestrol", "text": "Interaction: Lepirudin AND Dienestrol\nDetails: The serum concentration of Dienestrol can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Dienestrol"}, {"id": "Lepirudin_INT_Diethylstilbestrol", "text": "Interaction: Lepirudin AND Diethylstilbestrol\nDetails: The serum concentration of Diethylstilbestrol can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Diethylstilbestrol"}, {"id": "Lepirudin_INT_Hexestrol", "text": "Interaction: Lepirudin AND Hexestrol\nDetails: The serum concentration of Hexestrol can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Hexestrol"}, {"id": "Lepirudin_INT_Methallenestril", "text": "Interaction: Lepirudin AND Methallenestril\nDetails: The serum concentration of Methallenestril can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Methallenestril"}, {"id": "Lepirudin_INT_Cyclosporine", "text": "Interaction: Lepirudin AND Cyclosporine\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Cyclosporine"}, {"id": "Lepirudin_INT_Garlic", "text": "Interaction: Lepirudin AND Garlic\nDetails: The serum concentration of Lepirudin can be decreased when it is combined with Garlic.\nRisk: Monitor closely.", "source": "Lepirudin + Garlic"}, {"id": "Lepirudin_INT_Tacrolimus", "text": "Interaction: Lepirudin AND Tacrolimus\nDetails: The metabolism of Tacrolimus can be decreased when combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tacrolimus"}, {"id": "Lepirudin_INT_Pethidine", "text": "Interaction: Lepirudin AND Pethidine\nDetails: The risk or severity of adverse effects can be increased when Lepirudin is combined with Pethidine.\nRisk: Monitor closely.", "source": "Lepirudin + Pethidine"}, {"id": "Lepirudin_INT_Alprazolam", "text": "Interaction: Lepirudin AND Alprazolam\nDetails: The serum concentration of Alprazolam can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Alprazolam"}, {"id": "Lepirudin_INT_Atorvastatin", "text": "Interaction: Lepirudin AND Atorvastatin\nDetails: The serum concentration of Atorvastatin can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Atorvastatin"}, {"id": "Lepirudin_INT_Boceprevir", "text": "Interaction: Lepirudin AND Boceprevir\nDetails: The serum concentration of Lepirudin can be decreased when it is combined with Boceprevir.\nRisk: Monitor closely.", "source": "Lepirudin + Boceprevir"}, {"id": "Lepirudin_INT_Carbamazepine", "text": "Interaction: Lepirudin AND Carbamazepine\nDetails: The metabolism of Lepirudin can be increased when combined with Carbamazepine.\nRisk: Monitor closely.", "source": "Lepirudin + Carbamazepine"}, {"id": "Lepirudin_INT_Clarithromycin", "text": "Interaction: Lepirudin AND Clarithromycin\nDetails: The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Clarithromycin"}, {"id": "Lepirudin_INT_Delavirdine", "text": "Interaction: Lepirudin AND Delavirdine\nDetails: The serum concentration of Delavirdine can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Delavirdine"}, {"id": "Lepirudin_INT_Estrone", "text": "Interaction: Lepirudin AND Estrone\nDetails: Estrone may decrease the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Estrone"}, {"id": "Lepirudin_INT_Polyestradiol phosphate", "text": "Interaction: Lepirudin AND Polyestradiol phosphate\nDetails: Polyestradiol phosphate may decrease the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Polyestradiol phosphate"}, {"id": "Lepirudin_INT_Genistein", "text": "Interaction: Lepirudin AND Genistein\nDetails: Genistein may decrease the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Genistein"}, {"id": "Lepirudin_INT_Quinestrol", "text": "Interaction: Lepirudin AND Quinestrol\nDetails: Quinestrol may decrease the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Quinestrol"}, {"id": "Lepirudin_INT_Synthetic Conjugated Estrogens, B", "text": "Interaction: Lepirudin AND Synthetic Conjugated Estrogens, B\nDetails: Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Synthetic Conjugated Estrogens, B"}, {"id": "Lepirudin_INT_Zeranol", "text": "Interaction: Lepirudin AND Zeranol\nDetails: Zeranol may decrease the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Zeranol"}, {"id": "Lepirudin_INT_Equol", "text": "Interaction: Lepirudin AND Equol\nDetails: Equol may decrease the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Equol"}, {"id": "Lepirudin_INT_Secoisolariciresinol", "text": "Interaction: Lepirudin AND Secoisolariciresinol\nDetails: Secoisolariciresinol may decrease the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Secoisolariciresinol"}, {"id": "Lepirudin_INT_Daidzein", "text": "Interaction: Lepirudin AND Daidzein\nDetails: Daidzein may decrease the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Daidzein"}, {"id": "Lepirudin_INT_Epimestrol", "text": "Interaction: Lepirudin AND Epimestrol\nDetails: Epimestrol may decrease the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Epimestrol"}, {"id": "Lepirudin_INT_Estriol", "text": "Interaction: Lepirudin AND Estriol\nDetails: Estriol may decrease the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Estriol"}, {"id": "Lepirudin_INT_Promestriene", "text": "Interaction: Lepirudin AND Promestriene\nDetails: Promestriene may decrease the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Promestriene"}, {"id": "Lepirudin_INT_Moxestrol", "text": "Interaction: Lepirudin AND Moxestrol\nDetails: Moxestrol may decrease the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Moxestrol"}, {"id": "Lepirudin_INT_Omacetaxine mepesuccinate", "text": "Interaction: Lepirudin AND Omacetaxine mepesuccinate\nDetails: The risk or severity of bleeding can be increased when Lepirudin is combined with Omacetaxine mepesuccinate.\nRisk: Monitor closely.", "source": "Lepirudin + Omacetaxine mepesuccinate"}, {"id": "Lepirudin_INT_Nefazodone", "text": "Interaction: Lepirudin AND Nefazodone\nDetails: The serum concentration of Nefazodone can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Nefazodone"}, {"id": "Lepirudin_INT_Aprotinin", "text": "Interaction: Lepirudin AND Aprotinin\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Aprotinin.\nRisk: Monitor closely.", "source": "Lepirudin + Aprotinin"}, {"id": "Lepirudin_INT_Allylestrenol", "text": "Interaction: Lepirudin AND Allylestrenol\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Allylestrenol.\nRisk: Monitor closely.", "source": "Lepirudin + Allylestrenol"}, {"id": "Lepirudin_INT_Etonogestrel", "text": "Interaction: Lepirudin AND Etonogestrel\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Etonogestrel.\nRisk: Monitor closely.", "source": "Lepirudin + Etonogestrel"}, {"id": "Lepirudin_INT_Medroxyprogesterone acetate", "text": "Interaction: Lepirudin AND Medroxyprogesterone acetate\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Medroxyprogesterone acetate.\nRisk: Monitor closely.", "source": "Lepirudin + Medroxyprogesterone acetate"}, {"id": "Lepirudin_INT_Dienogest", "text": "Interaction: Lepirudin AND Dienogest\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Dienogest.\nRisk: Monitor closely.", "source": "Lepirudin + Dienogest"}, {"id": "Lepirudin_INT_Progesterone", "text": "Interaction: Lepirudin AND Progesterone\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Progesterone.\nRisk: Monitor closely.", "source": "Lepirudin + Progesterone"}, {"id": "Lepirudin_INT_Norethisterone", "text": "Interaction: Lepirudin AND Norethisterone\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Norethisterone.\nRisk: Monitor closely.", "source": "Lepirudin + Norethisterone"}, {"id": "Lepirudin_INT_Hydroxyprogesterone caproate", "text": "Interaction: Lepirudin AND Hydroxyprogesterone caproate\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydroxyprogesterone caproate.\nRisk: Monitor closely.", "source": "Lepirudin + Hydroxyprogesterone caproate"}, {"id": "Lepirudin_INT_Desogestrel", "text": "Interaction: Lepirudin AND Desogestrel\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Desogestrel.\nRisk: Monitor closely.", "source": "Lepirudin + Desogestrel"}, {"id": "Lepirudin_INT_Dydrogesterone", "text": "Interaction: Lepirudin AND Dydrogesterone\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Dydrogesterone.\nRisk: Monitor closely.", "source": "Lepirudin + Dydrogesterone"}, {"id": "Lepirudin_INT_Gestodene", "text": "Interaction: Lepirudin AND Gestodene\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gestodene.\nRisk: Monitor closely.", "source": "Lepirudin + Gestodene"}, {"id": "Lepirudin_INT_Altrenogest", "text": "Interaction: Lepirudin AND Altrenogest\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Altrenogest.\nRisk: Monitor closely.", "source": "Lepirudin + Altrenogest"}, {"id": "Lepirudin_INT_Gestrinone", "text": "Interaction: Lepirudin AND Gestrinone\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gestrinone.\nRisk: Monitor closely.", "source": "Lepirudin + Gestrinone"}, {"id": "Lepirudin_INT_Medrogestone", "text": "Interaction: Lepirudin AND Medrogestone\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Medrogestone.\nRisk: Monitor closely.", "source": "Lepirudin + Medrogestone"}, {"id": "Lepirudin_INT_Nomegestrol", "text": "Interaction: Lepirudin AND Nomegestrol\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Nomegestrol.\nRisk: Monitor closely.", "source": "Lepirudin + Nomegestrol"}, {"id": "Lepirudin_INT_Gestonorone", "text": "Interaction: Lepirudin AND Gestonorone\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gestonorone.\nRisk: Monitor closely.", "source": "Lepirudin + Gestonorone"}, {"id": "Lepirudin_INT_Methylestrenolone", "text": "Interaction: Lepirudin AND Methylestrenolone\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Methylestrenolone.\nRisk: Monitor closely.", "source": "Lepirudin + Methylestrenolone"}, {"id": "Lepirudin_INT_Norgestrienone", "text": "Interaction: Lepirudin AND Norgestrienone\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Norgestrienone.\nRisk: Monitor closely.", "source": "Lepirudin + Norgestrienone"}, {"id": "Lepirudin_INT_Promegestone", "text": "Interaction: Lepirudin AND Promegestone\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Promegestone.\nRisk: Monitor closely.", "source": "Lepirudin + Promegestone"}, {"id": "Lepirudin_INT_Demegestone", "text": "Interaction: Lepirudin AND Demegestone\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Demegestone.\nRisk: Monitor closely.", "source": "Lepirudin + Demegestone"}, {"id": "Lepirudin_INT_Megestrol acetate", "text": "Interaction: Lepirudin AND Megestrol acetate\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Megestrol acetate.\nRisk: Monitor closely.", "source": "Lepirudin + Megestrol acetate"}, {"id": "Lepirudin_INT_Levonorgestrel", "text": "Interaction: Lepirudin AND Levonorgestrel\nDetails: The therapeutic efficacy of Lepirudin can be decreased when used in combination with Levonorgestrel.\nRisk: Monitor closely.", "source": "Lepirudin + Levonorgestrel"}, {"id": "Lepirudin_INT_Riociguat", "text": "Interaction: Lepirudin AND Riociguat\nDetails: The serum concentration of Riociguat can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Riociguat"}, {"id": "Lepirudin_INT_Rosuvastatin", "text": "Interaction: Lepirudin AND Rosuvastatin\nDetails: The serum concentration of Rosuvastatin can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Rosuvastatin"}, {"id": "Lepirudin_INT_Sildenafil", "text": "Interaction: Lepirudin AND Sildenafil\nDetails: The serum concentration of Sildenafil can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Sildenafil"}, {"id": "Lepirudin_INT_Temsirolimus", "text": "Interaction: Lepirudin AND Temsirolimus\nDetails: The risk or severity of adverse effects can be increased when Lepirudin is combined with Temsirolimus.\nRisk: Monitor closely.", "source": "Lepirudin + Temsirolimus"}, {"id": "Lepirudin_INT_Diltiazem", "text": "Interaction: Lepirudin AND Diltiazem\nDetails: The metabolism of Diltiazem can be decreased when combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Diltiazem"}, {"id": "Lepirudin_INT_Verapamil", "text": "Interaction: Lepirudin AND Verapamil\nDetails: The metabolism of Verapamil can be decreased when combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Verapamil"}, {"id": "Lepirudin_INT_Pentosan Polysulfate", "text": "Interaction: Lepirudin AND Pentosan Polysulfate\nDetails: Pentosan Polysulfate may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Pentosan Polysulfate"}, {"id": "Lepirudin_INT_Amitriptyline", "text": "Interaction: Lepirudin AND Amitriptyline\nDetails: The serum concentration of Amitriptyline can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Amitriptyline"}, {"id": "Lepirudin_INT_Protriptyline", "text": "Interaction: Lepirudin AND Protriptyline\nDetails: The serum concentration of Protriptyline can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Protriptyline"}, {"id": "Lepirudin_INT_Imipramine", "text": "Interaction: Lepirudin AND Imipramine\nDetails: The serum concentration of Imipramine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Imipramine"}, {"id": "Lepirudin_INT_Nortriptyline", "text": "Interaction: Lepirudin AND Nortriptyline\nDetails: The serum concentration of Nortriptyline can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Nortriptyline"}, {"id": "Lepirudin_INT_Trimipramine", "text": "Interaction: Lepirudin AND Trimipramine\nDetails: The serum concentration of Trimipramine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Trimipramine"}, {"id": "Lepirudin_INT_Doxepin", "text": "Interaction: Lepirudin AND Doxepin\nDetails: The serum concentration of Doxepin can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Doxepin"}, {"id": "Lepirudin_INT_Desipramine", "text": "Interaction: Lepirudin AND Desipramine\nDetails: The serum concentration of Desipramine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Desipramine"}, {"id": "Lepirudin_INT_Clomipramine", "text": "Interaction: Lepirudin AND Clomipramine\nDetails: The serum concentration of Clomipramine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Clomipramine"}, {"id": "Lepirudin_INT_Mirtazapine", "text": "Interaction: Lepirudin AND Mirtazapine\nDetails: The serum concentration of Mirtazapine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Mirtazapine"}, {"id": "Lepirudin_INT_Cyclobenzaprine", "text": "Interaction: Lepirudin AND Cyclobenzaprine\nDetails: The serum concentration of Cyclobenzaprine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Cyclobenzaprine"}, {"id": "Lepirudin_INT_Amineptine", "text": "Interaction: Lepirudin AND Amineptine\nDetails: The serum concentration of Amineptine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Amineptine"}, {"id": "Lepirudin_INT_Esmirtazapine", "text": "Interaction: Lepirudin AND Esmirtazapine\nDetails: The serum concentration of Esmirtazapine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Esmirtazapine"}, {"id": "Lepirudin_INT_Dosulepin", "text": "Interaction: Lepirudin AND Dosulepin\nDetails: The serum concentration of Dosulepin can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Dosulepin"}, {"id": "Lepirudin_INT_Tianeptine", "text": "Interaction: Lepirudin AND Tianeptine\nDetails: The serum concentration of Tianeptine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tianeptine"}, {"id": "Lepirudin_INT_Opipramol", "text": "Interaction: Lepirudin AND Opipramol\nDetails: The serum concentration of Opipramol can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Opipramol"}, {"id": "Lepirudin_INT_Dibenzepin", "text": "Interaction: Lepirudin AND Dibenzepin\nDetails: The serum concentration of Dibenzepin can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Dibenzepin"}, {"id": "Lepirudin_INT_Lofepramine", "text": "Interaction: Lepirudin AND Lofepramine\nDetails: The serum concentration of Lofepramine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Lofepramine"}, {"id": "Lepirudin_INT_Iprindole", "text": "Interaction: Lepirudin AND Iprindole\nDetails: The serum concentration of Iprindole can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Iprindole"}, {"id": "Lepirudin_INT_Amoxapine", "text": "Interaction: Lepirudin AND Amoxapine\nDetails: The serum concentration of Amoxapine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Amoxapine"}, {"id": "Lepirudin_INT_Abacavir", "text": "Interaction: Lepirudin AND Abacavir\nDetails: The serum concentration of Abacavir can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Abacavir"}, {"id": "Lepirudin_INT_Cyclophosphamide", "text": "Interaction: Lepirudin AND Cyclophosphamide\nDetails: The risk or severity of adverse effects can be increased when Lepirudin is combined with Cyclophosphamide.\nRisk: Monitor closely.", "source": "Lepirudin + Cyclophosphamide"}, {"id": "Lepirudin_INT_Digoxin", "text": "Interaction: Lepirudin AND Digoxin\nDetails: The serum concentration of Digoxin can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Digoxin"}, {"id": "Lepirudin_INT_Enfuvirtide", "text": "Interaction: Lepirudin AND Enfuvirtide\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Enfuvirtide"}, {"id": "Lepirudin_INT_Etravirine", "text": "Interaction: Lepirudin AND Etravirine\nDetails: The serum concentration of Etravirine can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Etravirine"}, {"id": "Lepirudin_INT_Dasatinib", "text": "Interaction: Lepirudin AND Dasatinib\nDetails: Dasatinib may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Dasatinib"}, {"id": "Lepirudin_INT_Deferasirox", "text": "Interaction: Lepirudin AND Deferasirox\nDetails: The risk or severity of adverse effects can be increased when Lepirudin is combined with Deferasirox.\nRisk: Monitor closely.", "source": "Lepirudin + Deferasirox"}, {"id": "Lepirudin_INT_Deoxycholic Acid", "text": "Interaction: Lepirudin AND Deoxycholic Acid\nDetails: The risk or severity of adverse effects can be increased when Lepirudin is combined with Deoxycholic Acid.\nRisk: Monitor closely.", "source": "Lepirudin + Deoxycholic Acid"}, {"id": "Lepirudin_INT_Ibritumomab tiuxetan", "text": "Interaction: Lepirudin AND Ibritumomab tiuxetan\nDetails: The risk or severity of adverse effects can be increased when Lepirudin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Lepirudin + Ibritumomab tiuxetan"}, {"id": "Lepirudin_INT_Ibrutinib", "text": "Interaction: Lepirudin AND Ibrutinib\nDetails: The risk or severity of adverse effects can be increased when Ibrutinib is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ibrutinib"}, {"id": "Lepirudin_INT_Nintedanib", "text": "Interaction: Lepirudin AND Nintedanib\nDetails: The risk or severity of adverse effects can be increased when Lepirudin is combined with Nintedanib.\nRisk: Monitor closely.", "source": "Lepirudin + Nintedanib"}, {"id": "Lepirudin_INT_Obinutuzumab", "text": "Interaction: Lepirudin AND Obinutuzumab\nDetails: The risk or severity of adverse effects can be increased when Lepirudin is combined with Obinutuzumab.\nRisk: Monitor closely.", "source": "Lepirudin + Obinutuzumab"}, {"id": "Lepirudin_INT_Collagenase clostridium histolyticum", "text": "Interaction: Lepirudin AND Collagenase clostridium histolyticum\nDetails: The risk or severity of adverse effects can be increased when Lepirudin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Lepirudin + Collagenase clostridium histolyticum"}, {"id": "Lepirudin_INT_Sugammadex", "text": "Interaction: Lepirudin AND Sugammadex\nDetails: Sugammadex may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Sugammadex"}, {"id": "Lepirudin_INT_Limaprost", "text": "Interaction: Lepirudin AND Limaprost\nDetails: The risk or severity of adverse effects can be increased when Limaprost is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Limaprost"}, {"id": "Lepirudin_INT_Tibolone", "text": "Interaction: Lepirudin AND Tibolone\nDetails: Tibolone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tibolone"}, {"id": "Lepirudin_INT_Ketorolac", "text": "Interaction: Lepirudin AND Ketorolac\nDetails: Ketorolac may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ketorolac"}, {"id": "Lepirudin_INT_Diclofenac", "text": "Interaction: Lepirudin AND Diclofenac\nDetails: Diclofenac may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Diclofenac"}, {"id": "Lepirudin_INT_Flurbiprofen", "text": "Interaction: Lepirudin AND Flurbiprofen\nDetails: Flurbiprofen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Flurbiprofen"}, {"id": "Lepirudin_INT_Bromfenac", "text": "Interaction: Lepirudin AND Bromfenac\nDetails: Bromfenac may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Bromfenac"}, {"id": "Lepirudin_INT_Nepafenac", "text": "Interaction: Lepirudin AND Nepafenac\nDetails: Nepafenac may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Nepafenac"}, {"id": "Lepirudin_INT_Etanercept", "text": "Interaction: Lepirudin AND Etanercept\nDetails: Etanercept may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Etanercept"}, {"id": "Lepirudin_INT_Masoprocol", "text": "Interaction: Lepirudin AND Masoprocol\nDetails: Masoprocol may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Masoprocol"}, {"id": "Lepirudin_INT_Adapalene", "text": "Interaction: Lepirudin AND Adapalene\nDetails: Adapalene may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Adapalene"}, {"id": "Lepirudin_INT_Mesalazine", "text": "Interaction: Lepirudin AND Mesalazine\nDetails: Mesalazine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Mesalazine"}, {"id": "Lepirudin_INT_Indomethacin", "text": "Interaction: Lepirudin AND Indomethacin\nDetails: Indomethacin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Indomethacin"}, {"id": "Lepirudin_INT_Pimecrolimus", "text": "Interaction: Lepirudin AND Pimecrolimus\nDetails: Pimecrolimus may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Pimecrolimus"}, {"id": "Lepirudin_INT_Nabumetone", "text": "Interaction: Lepirudin AND Nabumetone\nDetails: Nabumetone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Nabumetone"}, {"id": "Lepirudin_INT_Tenoxicam", "text": "Interaction: Lepirudin AND Tenoxicam\nDetails: Tenoxicam may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tenoxicam"}, {"id": "Lepirudin_INT_Celecoxib", "text": "Interaction: Lepirudin AND Celecoxib\nDetails: Celecoxib may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Celecoxib"}, {"id": "Lepirudin_INT_Tolmetin", "text": "Interaction: Lepirudin AND Tolmetin\nDetails: Tolmetin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tolmetin"}, {"id": "Lepirudin_INT_Rofecoxib", "text": "Interaction: Lepirudin AND Rofecoxib\nDetails: Rofecoxib may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Rofecoxib"}, {"id": "Lepirudin_INT_Piroxicam", "text": "Interaction: Lepirudin AND Piroxicam\nDetails: Piroxicam may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Piroxicam"}, {"id": "Lepirudin_INT_Fenoprofen", "text": "Interaction: Lepirudin AND Fenoprofen\nDetails: Fenoprofen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Fenoprofen"}, {"id": "Lepirudin_INT_Valdecoxib", "text": "Interaction: Lepirudin AND Valdecoxib\nDetails: Valdecoxib may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Valdecoxib"}, {"id": "Lepirudin_INT_Sulindac", "text": "Interaction: Lepirudin AND Sulindac\nDetails: Sulindac may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Sulindac"}, {"id": "Lepirudin_INT_Chloroquine", "text": "Interaction: Lepirudin AND Chloroquine\nDetails: Chloroquine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Chloroquine"}, {"id": "Lepirudin_INT_Mycophenolate mofetil", "text": "Interaction: Lepirudin AND Mycophenolate mofetil\nDetails: Mycophenolate mofetil may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Mycophenolate mofetil"}, {"id": "Lepirudin_INT_Naftifine", "text": "Interaction: Lepirudin AND Naftifine\nDetails: Naftifine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Naftifine"}, {"id": "Lepirudin_INT_Zileuton", "text": "Interaction: Lepirudin AND Zileuton\nDetails: Zileuton may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Zileuton"}, {"id": "Lepirudin_INT_Etodolac", "text": "Interaction: Lepirudin AND Etodolac\nDetails: Etodolac may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Etodolac"}, {"id": "Lepirudin_INT_Olopatadine", "text": "Interaction: Lepirudin AND Olopatadine\nDetails: Olopatadine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Olopatadine"}, {"id": "Lepirudin_INT_Mefenamic acid", "text": "Interaction: Lepirudin AND Mefenamic acid\nDetails: Mefenamic acid may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Mefenamic acid"}, {"id": "Lepirudin_INT_Naproxen", "text": "Interaction: Lepirudin AND Naproxen\nDetails: Naproxen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Naproxen"}, {"id": "Lepirudin_INT_Sulfasalazine", "text": "Interaction: Lepirudin AND Sulfasalazine\nDetails: Sulfasalazine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Sulfasalazine"}, {"id": "Lepirudin_INT_Phenylbutazone", "text": "Interaction: Lepirudin AND Phenylbutazone\nDetails: Phenylbutazone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Phenylbutazone"}, {"id": "Lepirudin_INT_Meloxicam", "text": "Interaction: Lepirudin AND Meloxicam\nDetails: Meloxicam may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Meloxicam"}, {"id": "Lepirudin_INT_Carprofen", "text": "Interaction: Lepirudin AND Carprofen\nDetails: Carprofen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Carprofen"}, {"id": "Lepirudin_INT_Diflunisal", "text": "Interaction: Lepirudin AND Diflunisal\nDetails: Diflunisal may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Diflunisal"}, {"id": "Lepirudin_INT_Suprofen", "text": "Interaction: Lepirudin AND Suprofen\nDetails: Suprofen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Suprofen"}, {"id": "Lepirudin_INT_Salicylic acid", "text": "Interaction: Lepirudin AND Salicylic acid\nDetails: Salicylic acid may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Salicylic acid"}, {"id": "Lepirudin_INT_Meclofenamic acid", "text": "Interaction: Lepirudin AND Meclofenamic acid\nDetails: Meclofenamic acid may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Meclofenamic acid"}, {"id": "Lepirudin_INT_Acetylsalicylic acid", "text": "Interaction: Lepirudin AND Acetylsalicylic acid\nDetails: Acetylsalicylic acid may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Acetylsalicylic acid"}, {"id": "Lepirudin_INT_Azelastine", "text": "Interaction: Lepirudin AND Azelastine\nDetails: Azelastine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Azelastine"}, {"id": "Lepirudin_INT_Oxaprozin", "text": "Interaction: Lepirudin AND Oxaprozin\nDetails: Oxaprozin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Oxaprozin"}, {"id": "Lepirudin_INT_Ketoprofen", "text": "Interaction: Lepirudin AND Ketoprofen\nDetails: Ketoprofen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ketoprofen"}, {"id": "Lepirudin_INT_Balsalazide", "text": "Interaction: Lepirudin AND Balsalazide\nDetails: Balsalazide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Balsalazide"}, {"id": "Lepirudin_INT_Mycophenolic acid", "text": "Interaction: Lepirudin AND Mycophenolic acid\nDetails: Mycophenolic acid may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Mycophenolic acid"}, {"id": "Lepirudin_INT_Ibuprofen", "text": "Interaction: Lepirudin AND Ibuprofen\nDetails: Ibuprofen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ibuprofen"}, {"id": "Lepirudin_INT_Leflunomide", "text": "Interaction: Lepirudin AND Leflunomide\nDetails: Leflunomide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Leflunomide"}, {"id": "Lepirudin_INT_Olsalazine", "text": "Interaction: Lepirudin AND Olsalazine\nDetails: Olsalazine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Olsalazine"}, {"id": "Lepirudin_INT_Lumiracoxib", "text": "Interaction: Lepirudin AND Lumiracoxib\nDetails: Lumiracoxib may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Lumiracoxib"}, {"id": "Lepirudin_INT_Magnesium salicylate", "text": "Interaction: Lepirudin AND Magnesium salicylate\nDetails: Magnesium salicylate may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Magnesium salicylate"}, {"id": "Lepirudin_INT_Salsalate", "text": "Interaction: Lepirudin AND Salsalate\nDetails: Salsalate may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Salsalate"}, {"id": "Lepirudin_INT_Choline magnesium trisalicylate", "text": "Interaction: Lepirudin AND Choline magnesium trisalicylate\nDetails: Choline magnesium trisalicylate may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Choline magnesium trisalicylate"}, {"id": "Lepirudin_INT_Antipyrine", "text": "Interaction: Lepirudin AND Antipyrine\nDetails: Antipyrine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Antipyrine"}, {"id": "Lepirudin_INT_Tiaprofenic acid", "text": "Interaction: Lepirudin AND Tiaprofenic acid\nDetails: Tiaprofenic acid may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tiaprofenic acid"}, {"id": "Lepirudin_INT_Etoricoxib", "text": "Interaction: Lepirudin AND Etoricoxib\nDetails: Etoricoxib may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Etoricoxib"}, {"id": "Lepirudin_INT_Castanospermine", "text": "Interaction: Lepirudin AND Castanospermine\nDetails: Castanospermine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Castanospermine"}, {"id": "Lepirudin_INT_Resveratrol", "text": "Interaction: Lepirudin AND Resveratrol\nDetails: Resveratrol may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Resveratrol"}, {"id": "Lepirudin_INT_Oxyphenbutazone", "text": "Interaction: Lepirudin AND Oxyphenbutazone\nDetails: Oxyphenbutazone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Oxyphenbutazone"}, {"id": "Lepirudin_INT_Niflumic Acid", "text": "Interaction: Lepirudin AND Niflumic Acid\nDetails: Niflumic Acid may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Niflumic Acid"}, {"id": "Lepirudin_INT_Nimesulide", "text": "Interaction: Lepirudin AND Nimesulide\nDetails: Nimesulide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Nimesulide"}, {"id": "Lepirudin_INT_Benoxaprofen", "text": "Interaction: Lepirudin AND Benoxaprofen\nDetails: Benoxaprofen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Benoxaprofen"}, {"id": "Lepirudin_INT_Metamizole", "text": "Interaction: Lepirudin AND Metamizole\nDetails: Metamizole may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Metamizole"}, {"id": "Lepirudin_INT_Zomepirac", "text": "Interaction: Lepirudin AND Zomepirac\nDetails: Zomepirac may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Zomepirac"}, {"id": "Lepirudin_INT_Pirfenidone", "text": "Interaction: Lepirudin AND Pirfenidone\nDetails: Pirfenidone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Pirfenidone"}, {"id": "Lepirudin_INT_SRT501", "text": "Interaction: Lepirudin AND SRT501\nDetails: SRT501 may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + SRT501"}, {"id": "Lepirudin_INT_PTC299", "text": "Interaction: Lepirudin AND PTC299\nDetails: PTC299 may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + PTC299"}, {"id": "Lepirudin_INT_Tarenflurbil", "text": "Interaction: Lepirudin AND Tarenflurbil\nDetails: Tarenflurbil may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tarenflurbil"}, {"id": "Lepirudin_INT_Apremilast", "text": "Interaction: Lepirudin AND Apremilast\nDetails: Apremilast may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Apremilast"}, {"id": "Lepirudin_INT_Andrographolide", "text": "Interaction: Lepirudin AND Andrographolide\nDetails: Andrographolide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Andrographolide"}, {"id": "Lepirudin_INT_Icatibant", "text": "Interaction: Lepirudin AND Icatibant\nDetails: Icatibant may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Icatibant"}, {"id": "Lepirudin_INT_exisulind", "text": "Interaction: Lepirudin AND exisulind\nDetails: exisulind may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + exisulind"}, {"id": "Lepirudin_INT_Lornoxicam", "text": "Interaction: Lepirudin AND Lornoxicam\nDetails: Lornoxicam may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Lornoxicam"}, {"id": "Lepirudin_INT_Aceclofenac", "text": "Interaction: Lepirudin AND Aceclofenac\nDetails: Aceclofenac may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Aceclofenac"}, {"id": "Lepirudin_INT_Zaltoprofen", "text": "Interaction: Lepirudin AND Zaltoprofen\nDetails: Zaltoprofen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Zaltoprofen"}, {"id": "Lepirudin_INT_Seratrodast", "text": "Interaction: Lepirudin AND Seratrodast\nDetails: Seratrodast may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Seratrodast"}, {"id": "Lepirudin_INT_Azapropazone", "text": "Interaction: Lepirudin AND Azapropazone\nDetails: Azapropazone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Azapropazone"}, {"id": "Lepirudin_INT_Felbinac", "text": "Interaction: Lepirudin AND Felbinac\nDetails: Felbinac may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Felbinac"}, {"id": "Lepirudin_INT_Tranilast", "text": "Interaction: Lepirudin AND Tranilast\nDetails: Tranilast may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tranilast"}, {"id": "Lepirudin_INT_Ferulic acid", "text": "Interaction: Lepirudin AND Ferulic acid\nDetails: Ferulic acid may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ferulic acid"}, {"id": "Lepirudin_INT_Parecoxib", "text": "Interaction: Lepirudin AND Parecoxib\nDetails: Parecoxib may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Parecoxib"}, {"id": "Lepirudin_INT_Salicylamide", "text": "Interaction: Lepirudin AND Salicylamide\nDetails: Salicylamide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Salicylamide"}, {"id": "Lepirudin_INT_Teriflunomide", "text": "Interaction: Lepirudin AND Teriflunomide\nDetails: Teriflunomide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Teriflunomide"}, {"id": "Lepirudin_INT_D-Limonene", "text": "Interaction: Lepirudin AND D-Limonene\nDetails: D-Limonene may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + D-Limonene"}, {"id": "Lepirudin_INT_Kebuzone", "text": "Interaction: Lepirudin AND Kebuzone\nDetails: Kebuzone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Kebuzone"}, {"id": "Lepirudin_INT_Isoxicam", "text": "Interaction: Lepirudin AND Isoxicam\nDetails: Isoxicam may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Isoxicam"}, {"id": "Lepirudin_INT_Indoprofen", "text": "Interaction: Lepirudin AND Indoprofen\nDetails: Indoprofen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Indoprofen"}, {"id": "Lepirudin_INT_Ibuproxam", "text": "Interaction: Lepirudin AND Ibuproxam\nDetails: Ibuproxam may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ibuproxam"}, {"id": "Lepirudin_INT_Floctafenine", "text": "Interaction: Lepirudin AND Floctafenine\nDetails: Floctafenine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Floctafenine"}, {"id": "Lepirudin_INT_Fenbufen", "text": "Interaction: Lepirudin AND Fenbufen\nDetails: Fenbufen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Fenbufen"}, {"id": "Lepirudin_INT_Etofenamate", "text": "Interaction: Lepirudin AND Etofenamate\nDetails: Etofenamate may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Etofenamate"}, {"id": "Lepirudin_INT_Epirizole", "text": "Interaction: Lepirudin AND Epirizole\nDetails: Epirizole may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Epirizole"}, {"id": "Lepirudin_INT_Loxoprofen", "text": "Interaction: Lepirudin AND Loxoprofen\nDetails: Loxoprofen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Loxoprofen"}, {"id": "Lepirudin_INT_Droxicam", "text": "Interaction: Lepirudin AND Droxicam\nDetails: Droxicam may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Droxicam"}, {"id": "Lepirudin_INT_Tolfenamic Acid", "text": "Interaction: Lepirudin AND Tolfenamic Acid\nDetails: Tolfenamic Acid may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tolfenamic Acid"}, {"id": "Lepirudin_INT_Clonixin", "text": "Interaction: Lepirudin AND Clonixin\nDetails: Clonixin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Clonixin"}, {"id": "Lepirudin_INT_Propacetamol", "text": "Interaction: Lepirudin AND Propacetamol\nDetails: Propacetamol may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Propacetamol"}, {"id": "Lepirudin_INT_Evening primrose oil", "text": "Interaction: Lepirudin AND Evening primrose oil\nDetails: Evening primrose oil may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Evening primrose oil"}, {"id": "Lepirudin_INT_Orgotein", "text": "Interaction: Lepirudin AND Orgotein\nDetails: Orgotein may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Orgotein"}, {"id": "Lepirudin_INT_Tepoxalin", "text": "Interaction: Lepirudin AND Tepoxalin\nDetails: Tepoxalin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tepoxalin"}, {"id": "Lepirudin_INT_Flunixin", "text": "Interaction: Lepirudin AND Flunixin\nDetails: Flunixin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Flunixin"}, {"id": "Lepirudin_INT_Curcumin", "text": "Interaction: Lepirudin AND Curcumin\nDetails: Curcumin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Curcumin"}, {"id": "Lepirudin_INT_E-6201", "text": "Interaction: Lepirudin AND E-6201\nDetails: E-6201 may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + E-6201"}, {"id": "Lepirudin_INT_Anisodamine", "text": "Interaction: Lepirudin AND Anisodamine\nDetails: Anisodamine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Anisodamine"}, {"id": "Lepirudin_INT_Duvelisib", "text": "Interaction: Lepirudin AND Duvelisib\nDetails: Duvelisib may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Duvelisib"}, {"id": "Lepirudin_INT_Triptolide", "text": "Interaction: Lepirudin AND Triptolide\nDetails: Triptolide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Triptolide"}, {"id": "Lepirudin_INT_Semapimod", "text": "Interaction: Lepirudin AND Semapimod\nDetails: Semapimod may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Semapimod"}, {"id": "Lepirudin_INT_Bucillamine", "text": "Interaction: Lepirudin AND Bucillamine\nDetails: Bucillamine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Bucillamine"}, {"id": "Lepirudin_INT_Lisofylline", "text": "Interaction: Lepirudin AND Lisofylline\nDetails: Lisofylline may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Lisofylline"}, {"id": "Lepirudin_INT_Nitroaspirin", "text": "Interaction: Lepirudin AND Nitroaspirin\nDetails: Nitroaspirin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Nitroaspirin"}, {"id": "Lepirudin_INT_Nafamostat", "text": "Interaction: Lepirudin AND Nafamostat\nDetails: Nafamostat may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Nafamostat"}, {"id": "Lepirudin_INT_Mizoribine", "text": "Interaction: Lepirudin AND Mizoribine\nDetails: Mizoribine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Mizoribine"}, {"id": "Lepirudin_INT_Apocynin", "text": "Interaction: Lepirudin AND Apocynin\nDetails: Apocynin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Apocynin"}, {"id": "Lepirudin_INT_Higenamine", "text": "Interaction: Lepirudin AND Higenamine\nDetails: Higenamine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Higenamine"}, {"id": "Lepirudin_INT_Tinoridine", "text": "Interaction: Lepirudin AND Tinoridine\nDetails: Tinoridine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tinoridine"}, {"id": "Lepirudin_INT_Parthenolide", "text": "Interaction: Lepirudin AND Parthenolide\nDetails: Parthenolide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Parthenolide"}, {"id": "Lepirudin_INT_Serrapeptase", "text": "Interaction: Lepirudin AND Serrapeptase\nDetails: Serrapeptase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Serrapeptase"}, {"id": "Lepirudin_INT_Alclofenac", "text": "Interaction: Lepirudin AND Alclofenac\nDetails: Alclofenac may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Alclofenac"}, {"id": "Lepirudin_INT_Fentiazac", "text": "Interaction: Lepirudin AND Fentiazac\nDetails: Fentiazac may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Fentiazac"}, {"id": "Lepirudin_INT_Tribenoside", "text": "Interaction: Lepirudin AND Tribenoside\nDetails: Tribenoside may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tribenoside"}, {"id": "Lepirudin_INT_Suxibuzone", "text": "Interaction: Lepirudin AND Suxibuzone\nDetails: Suxibuzone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Suxibuzone"}, {"id": "Lepirudin_INT_Bumadizone", "text": "Interaction: Lepirudin AND Bumadizone\nDetails: Bumadizone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Bumadizone"}, {"id": "Lepirudin_INT_Alminoprofen", "text": "Interaction: Lepirudin AND Alminoprofen\nDetails: Alminoprofen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Alminoprofen"}, {"id": "Lepirudin_INT_Flunoxaprofen", "text": "Interaction: Lepirudin AND Flunoxaprofen\nDetails: Flunoxaprofen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Flunoxaprofen"}, {"id": "Lepirudin_INT_Bufexamac", "text": "Interaction: Lepirudin AND Bufexamac\nDetails: Bufexamac may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Bufexamac"}, {"id": "Lepirudin_INT_Feprazone", "text": "Interaction: Lepirudin AND Feprazone\nDetails: Feprazone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Feprazone"}, {"id": "Lepirudin_INT_Difenpiramide", "text": "Interaction: Lepirudin AND Difenpiramide\nDetails: Difenpiramide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Difenpiramide"}, {"id": "Lepirudin_INT_Nifenazone", "text": "Interaction: Lepirudin AND Nifenazone\nDetails: Nifenazone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Nifenazone"}, {"id": "Lepirudin_INT_Lonazolac", "text": "Interaction: Lepirudin AND Lonazolac\nDetails: Lonazolac may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Lonazolac"}, {"id": "Lepirudin_INT_Tenidap", "text": "Interaction: Lepirudin AND Tenidap\nDetails: Tenidap may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tenidap"}, {"id": "Lepirudin_INT_Bendazac", "text": "Interaction: Lepirudin AND Bendazac\nDetails: Bendazac may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Bendazac"}, {"id": "Lepirudin_INT_Pranoprofen", "text": "Interaction: Lepirudin AND Pranoprofen\nDetails: Pranoprofen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Pranoprofen"}, {"id": "Lepirudin_INT_Propyphenazone", "text": "Interaction: Lepirudin AND Propyphenazone\nDetails: Propyphenazone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Propyphenazone"}, {"id": "Lepirudin_INT_Proglumetacin", "text": "Interaction: Lepirudin AND Proglumetacin\nDetails: Proglumetacin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Proglumetacin"}, {"id": "Lepirudin_INT_Guacetisal", "text": "Interaction: Lepirudin AND Guacetisal\nDetails: Guacetisal may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Guacetisal"}, {"id": "Lepirudin_INT_Bevonium", "text": "Interaction: Lepirudin AND Bevonium\nDetails: Bevonium may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Bevonium"}, {"id": "Lepirudin_INT_Ethenzamide", "text": "Interaction: Lepirudin AND Ethenzamide\nDetails: Ethenzamide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ethenzamide"}, {"id": "Lepirudin_INT_Carbaspirin calcium", "text": "Interaction: Lepirudin AND Carbaspirin calcium\nDetails: Carbaspirin calcium may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Carbaspirin calcium"}, {"id": "Lepirudin_INT_Mofebutazone", "text": "Interaction: Lepirudin AND Mofebutazone\nDetails: Mofebutazone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Mofebutazone"}, {"id": "Lepirudin_INT_Proquazone", "text": "Interaction: Lepirudin AND Proquazone\nDetails: Proquazone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Proquazone"}, {"id": "Lepirudin_INT_Benorilate", "text": "Interaction: Lepirudin AND Benorilate\nDetails: Benorilate may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Benorilate"}, {"id": "Lepirudin_INT_Pirprofen", "text": "Interaction: Lepirudin AND Pirprofen\nDetails: Pirprofen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Pirprofen"}, {"id": "Lepirudin_INT_Imidazole salicylate", "text": "Interaction: Lepirudin AND Imidazole salicylate\nDetails: Imidazole salicylate may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Imidazole salicylate"}, {"id": "Lepirudin_INT_Benzydamine", "text": "Interaction: Lepirudin AND Benzydamine\nDetails: Benzydamine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Benzydamine"}, {"id": "Lepirudin_INT_Tipranavir", "text": "Interaction: Lepirudin AND Tipranavir\nDetails: Tipranavir may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tipranavir"}, {"id": "Lepirudin_INT_Omega-3 fatty acids", "text": "Interaction: Lepirudin AND Omega-3 fatty acids\nDetails: Omega-3 fatty acids may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Omega-3 fatty acids"}, {"id": "Lepirudin_INT_Vitamin E", "text": "Interaction: Lepirudin AND Vitamin E\nDetails: Vitamin E may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Vitamin E"}, {"id": "Lepirudin_INT_Tositumomab", "text": "Interaction: Lepirudin AND Tositumomab\nDetails: The risk or severity of adverse effects can be increased when Lepirudin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Lepirudin + Tositumomab"}, {"id": "Lepirudin_INT_Dabigatran etexilate", "text": "Interaction: Lepirudin AND Dabigatran etexilate\nDetails: Lepirudin may increase the anticoagulant activities of Dabigatran etexilate.\nRisk: Monitor closely.", "source": "Lepirudin + Dabigatran etexilate"}, {"id": "Lepirudin_INT_Bivalirudin", "text": "Interaction: Lepirudin AND Bivalirudin\nDetails: Lepirudin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Bivalirudin"}, {"id": "Lepirudin_INT_Abciximab", "text": "Interaction: Lepirudin AND Abciximab\nDetails: Lepirudin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Lepirudin + Abciximab"}, {"id": "Lepirudin_INT_Becaplermin", "text": "Interaction: Lepirudin AND Becaplermin\nDetails: Lepirudin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Lepirudin + Becaplermin"}, {"id": "Lepirudin_INT_Dicoumarol", "text": "Interaction: Lepirudin AND Dicoumarol\nDetails: Lepirudin may increase the anticoagulant activities of Dicoumarol.\nRisk: Monitor closely.", "source": "Lepirudin + Dicoumarol"}, {"id": "Lepirudin_INT_Argatroban", "text": "Interaction: Lepirudin AND Argatroban\nDetails: Lepirudin may increase the anticoagulant activities of Argatroban.\nRisk: Monitor closely.", "source": "Lepirudin + Argatroban"}, {"id": "Lepirudin_INT_Ardeparin", "text": "Interaction: Lepirudin AND Ardeparin\nDetails: Lepirudin may increase the anticoagulant activities of Ardeparin.\nRisk: Monitor closely.", "source": "Lepirudin + Ardeparin"}, {"id": "Lepirudin_INT_Phenindione", "text": "Interaction: Lepirudin AND Phenindione\nDetails: Lepirudin may increase the anticoagulant activities of Phenindione.\nRisk: Monitor closely.", "source": "Lepirudin + Phenindione"}, {"id": "Lepirudin_INT_Fondaparinux sodium", "text": "Interaction: Lepirudin AND Fondaparinux sodium\nDetails: Lepirudin may increase the anticoagulant activities of Fondaparinux sodium.\nRisk: Monitor closely.", "source": "Lepirudin + Fondaparinux sodium"}, {"id": "Lepirudin_INT_Warfarin", "text": "Interaction: Lepirudin AND Warfarin\nDetails: Lepirudin may increase the anticoagulant activities of Warfarin.\nRisk: Monitor closely.", "source": "Lepirudin + Warfarin"}, {"id": "Lepirudin_INT_Phenprocoumon", "text": "Interaction: Lepirudin AND Phenprocoumon\nDetails: Lepirudin may increase the anticoagulant activities of Phenprocoumon.\nRisk: Monitor closely.", "source": "Lepirudin + Phenprocoumon"}, {"id": "Lepirudin_INT_Edetic Acid", "text": "Interaction: Lepirudin AND Edetic Acid\nDetails: Lepirudin may increase the anticoagulant activities of Edetic Acid.\nRisk: Monitor closely.", "source": "Lepirudin + Edetic Acid"}, {"id": "Lepirudin_INT_Heparin", "text": "Interaction: Lepirudin AND Heparin\nDetails: Lepirudin may increase the anticoagulant activities of Heparin.\nRisk: Monitor closely.", "source": "Lepirudin + Heparin"}, {"id": "Lepirudin_INT_Enoxaparin", "text": "Interaction: Lepirudin AND Enoxaparin\nDetails: Lepirudin may increase the anticoagulant activities of Enoxaparin.\nRisk: Monitor closely.", "source": "Lepirudin + Enoxaparin"}, {"id": "Lepirudin_INT_Acenocoumarol", "text": "Interaction: Lepirudin AND Acenocoumarol\nDetails: Lepirudin may increase the anticoagulant activities of Acenocoumarol.\nRisk: Monitor closely.", "source": "Lepirudin + Acenocoumarol"}, {"id": "Lepirudin_INT_Citric Acid", "text": "Interaction: Lepirudin AND Citric Acid\nDetails: Lepirudin may increase the anticoagulant activities of Citric Acid.\nRisk: Monitor closely.", "source": "Lepirudin + Citric Acid"}, {"id": "Lepirudin_INT_Ximelagatran", "text": "Interaction: Lepirudin AND Ximelagatran\nDetails: Lepirudin may increase the anticoagulant activities of Ximelagatran.\nRisk: Monitor closely.", "source": "Lepirudin + Ximelagatran"}, {"id": "Lepirudin_INT_Ancrod", "text": "Interaction: Lepirudin AND Ancrod\nDetails: Lepirudin may increase the anticoagulant activities of Ancrod.\nRisk: Monitor closely.", "source": "Lepirudin + Ancrod"}, {"id": "Lepirudin_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Lepirudin AND Pentaerythritol Tetranitrate\nDetails: Lepirudin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.\nRisk: Monitor closely.", "source": "Lepirudin + Pentaerythritol Tetranitrate"}, {"id": "Lepirudin_INT_Sulodexide", "text": "Interaction: Lepirudin AND Sulodexide\nDetails: Lepirudin may increase the anticoagulant activities of Sulodexide.\nRisk: Monitor closely.", "source": "Lepirudin + Sulodexide"}, {"id": "Lepirudin_INT_Idraparinux", "text": "Interaction: Lepirudin AND Idraparinux\nDetails: Lepirudin may increase the anticoagulant activities of Idraparinux.\nRisk: Monitor closely.", "source": "Lepirudin + Idraparinux"}, {"id": "Lepirudin_INT_Otamixaban", "text": "Interaction: Lepirudin AND Otamixaban\nDetails: Lepirudin may increase the anticoagulant activities of Otamixaban.\nRisk: Monitor closely.", "source": "Lepirudin + Otamixaban"}, {"id": "Lepirudin_INT_Danaparoid", "text": "Interaction: Lepirudin AND Danaparoid\nDetails: Lepirudin may increase the anticoagulant activities of Danaparoid.\nRisk: Monitor closely.", "source": "Lepirudin + Danaparoid"}, {"id": "Lepirudin_INT_Dalteparin", "text": "Interaction: Lepirudin AND Dalteparin\nDetails: Lepirudin may increase the anticoagulant activities of Dalteparin.\nRisk: Monitor closely.", "source": "Lepirudin + Dalteparin"}, {"id": "Lepirudin_INT_Ethyl biscoumacetate", "text": "Interaction: Lepirudin AND Ethyl biscoumacetate\nDetails: Lepirudin may increase the anticoagulant activities of Ethyl biscoumacetate.\nRisk: Monitor closely.", "source": "Lepirudin + Ethyl biscoumacetate"}, {"id": "Lepirudin_INT_Nadroparin", "text": "Interaction: Lepirudin AND Nadroparin\nDetails: Lepirudin may increase the anticoagulant activities of Nadroparin.\nRisk: Monitor closely.", "source": "Lepirudin + Nadroparin"}, {"id": "Lepirudin_INT_Dextran", "text": "Interaction: Lepirudin AND Dextran\nDetails: Lepirudin may increase the anticoagulant activities of Dextran.\nRisk: Monitor closely.", "source": "Lepirudin + Dextran"}, {"id": "Lepirudin_INT_Reviparin", "text": "Interaction: Lepirudin AND Reviparin\nDetails: Lepirudin may increase the anticoagulant activities of Reviparin.\nRisk: Monitor closely.", "source": "Lepirudin + Reviparin"}, {"id": "Lepirudin_INT_Certoparin", "text": "Interaction: Lepirudin AND Certoparin\nDetails: Lepirudin may increase the anticoagulant activities of Certoparin.\nRisk: Monitor closely.", "source": "Lepirudin + Certoparin"}, {"id": "Lepirudin_INT_Dextran 70", "text": "Interaction: Lepirudin AND Dextran 70\nDetails: Lepirudin may increase the anticoagulant activities of Dextran 70.\nRisk: Monitor closely.", "source": "Lepirudin + Dextran 70"}, {"id": "Lepirudin_INT_Desirudin", "text": "Interaction: Lepirudin AND Desirudin\nDetails: Lepirudin may increase the anticoagulant activities of Desirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Desirudin"}, {"id": "Lepirudin_INT_Dextran 40", "text": "Interaction: Lepirudin AND Dextran 40\nDetails: Lepirudin may increase the anticoagulant activities of Dextran 40.\nRisk: Monitor closely.", "source": "Lepirudin + Dextran 40"}, {"id": "Lepirudin_INT_Dextran 75", "text": "Interaction: Lepirudin AND Dextran 75\nDetails: Lepirudin may increase the anticoagulant activities of Dextran 75.\nRisk: Monitor closely.", "source": "Lepirudin + Dextran 75"}, {"id": "Lepirudin_INT_Protocatechualdehyde", "text": "Interaction: Lepirudin AND Protocatechualdehyde\nDetails: Lepirudin may increase the anticoagulant activities of Protocatechualdehyde.\nRisk: Monitor closely.", "source": "Lepirudin + Protocatechualdehyde"}, {"id": "Lepirudin_INT_Protein C", "text": "Interaction: Lepirudin AND Protein C\nDetails: Lepirudin may increase the anticoagulant activities of Protein C.\nRisk: Monitor closely.", "source": "Lepirudin + Protein C"}, {"id": "Lepirudin_INT_Antithrombin III human", "text": "Interaction: Lepirudin AND Antithrombin III human\nDetails: Lepirudin may increase the anticoagulant activities of Antithrombin III human.\nRisk: Monitor closely.", "source": "Lepirudin + Antithrombin III human"}, {"id": "Lepirudin_INT_Fondaparinux", "text": "Interaction: Lepirudin AND Fondaparinux\nDetails: Lepirudin may increase the anticoagulant activities of Fondaparinux.\nRisk: Monitor closely.", "source": "Lepirudin + Fondaparinux"}, {"id": "Lepirudin_INT_Letaxaban", "text": "Interaction: Lepirudin AND Letaxaban\nDetails: Lepirudin may increase the anticoagulant activities of Letaxaban.\nRisk: Monitor closely.", "source": "Lepirudin + Letaxaban"}, {"id": "Lepirudin_INT_Darexaban", "text": "Interaction: Lepirudin AND Darexaban\nDetails: Lepirudin may increase the anticoagulant activities of Darexaban.\nRisk: Monitor closely.", "source": "Lepirudin + Darexaban"}, {"id": "Lepirudin_INT_Gabexate", "text": "Interaction: Lepirudin AND Gabexate\nDetails: Lepirudin may increase the anticoagulant activities of Gabexate.\nRisk: Monitor closely.", "source": "Lepirudin + Gabexate"}, {"id": "Lepirudin_INT_Troxerutin", "text": "Interaction: Lepirudin AND Troxerutin\nDetails: Lepirudin may increase the anticoagulant activities of Troxerutin.\nRisk: Monitor closely.", "source": "Lepirudin + Troxerutin"}, {"id": "Lepirudin_INT_Fluindione", "text": "Interaction: Lepirudin AND Fluindione\nDetails: Lepirudin may increase the anticoagulant activities of Fluindione.\nRisk: Monitor closely.", "source": "Lepirudin + Fluindione"}, {"id": "Lepirudin_INT_Protein S human", "text": "Interaction: Lepirudin AND Protein S human\nDetails: Lepirudin may increase the anticoagulant activities of Protein S human.\nRisk: Monitor closely.", "source": "Lepirudin + Protein S human"}, {"id": "Lepirudin_INT_Melagatran", "text": "Interaction: Lepirudin AND Melagatran\nDetails: Lepirudin may increase the anticoagulant activities of Melagatran.\nRisk: Monitor closely.", "source": "Lepirudin + Melagatran"}, {"id": "Lepirudin_INT_Aminosalicylic Acid", "text": "Interaction: Lepirudin AND Aminosalicylic Acid\nDetails: Aminosalicylic Acid may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Aminosalicylic Acid"}, {"id": "Lepirudin_INT_dersalazine", "text": "Interaction: Lepirudin AND dersalazine\nDetails: dersalazine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + dersalazine"}, {"id": "Lepirudin_INT_Aloxiprin", "text": "Interaction: Lepirudin AND Aloxiprin\nDetails: Aloxiprin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Aloxiprin"}, {"id": "Lepirudin_INT_Hemoglobin crosfumaril", "text": "Interaction: Lepirudin AND Hemoglobin crosfumaril\nDetails: Hemoglobin crosfumaril may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Hemoglobin crosfumaril"}, {"id": "Lepirudin_INT_Methyl salicylate", "text": "Interaction: Lepirudin AND Methyl salicylate\nDetails: Methyl salicylate may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Methyl salicylate"}, {"id": "Lepirudin_INT_Trolamine salicylate", "text": "Interaction: Lepirudin AND Trolamine salicylate\nDetails: Trolamine salicylate may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Trolamine salicylate"}, {"id": "Lepirudin_INT_Alteplase", "text": "Interaction: Lepirudin AND Alteplase\nDetails: Alteplase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Alteplase"}, {"id": "Lepirudin_INT_Reteplase", "text": "Interaction: Lepirudin AND Reteplase\nDetails: Reteplase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Reteplase"}, {"id": "Lepirudin_INT_Anistreplase", "text": "Interaction: Lepirudin AND Anistreplase\nDetails: Anistreplase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Anistreplase"}, {"id": "Lepirudin_INT_Tenecteplase", "text": "Interaction: Lepirudin AND Tenecteplase\nDetails: Tenecteplase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tenecteplase"}, {"id": "Lepirudin_INT_Drotrecogin alfa", "text": "Interaction: Lepirudin AND Drotrecogin alfa\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Drotrecogin alfa"}, {"id": "Lepirudin_INT_Ticlopidine", "text": "Interaction: Lepirudin AND Ticlopidine\nDetails: Ticlopidine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ticlopidine"}, {"id": "Lepirudin_INT_Tirofiban", "text": "Interaction: Lepirudin AND Tirofiban\nDetails: Tirofiban may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tirofiban"}, {"id": "Lepirudin_INT_Cilostazol", "text": "Interaction: Lepirudin AND Cilostazol\nDetails: Cilostazol may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Cilostazol"}, {"id": "Lepirudin_INT_Defibrotide", "text": "Interaction: Lepirudin AND Defibrotide\nDetails: Defibrotide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Defibrotide"}, {"id": "Lepirudin_INT_Tinzaparin", "text": "Interaction: Lepirudin AND Tinzaparin\nDetails: Tinzaparin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tinzaparin"}, {"id": "Lepirudin_INT_Brinase", "text": "Interaction: Lepirudin AND Brinase\nDetails: Brinase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Brinase"}, {"id": "Lepirudin_INT_Saruplase", "text": "Interaction: Lepirudin AND Saruplase\nDetails: Saruplase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Saruplase"}, {"id": "Lepirudin_INT_Streptokinase", "text": "Interaction: Lepirudin AND Streptokinase\nDetails: Streptokinase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Streptokinase"}, {"id": "Lepirudin_INT_Anagrelide", "text": "Interaction: Lepirudin AND Anagrelide\nDetails: Anagrelide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Anagrelide"}, {"id": "Lepirudin_INT_Rosiglitazone", "text": "Interaction: Lepirudin AND Rosiglitazone\nDetails: Rosiglitazone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Rosiglitazone"}, {"id": "Lepirudin_INT_Desmoteplase", "text": "Interaction: Lepirudin AND Desmoteplase\nDetails: Desmoteplase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Desmoteplase"}, {"id": "Lepirudin_INT_Fibrinolysin", "text": "Interaction: Lepirudin AND Fibrinolysin\nDetails: Fibrinolysin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Fibrinolysin"}, {"id": "Lepirudin_INT_ALX-0081", "text": "Interaction: Lepirudin AND ALX-0081\nDetails: ALX-0081 may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + ALX-0081"}, {"id": "Lepirudin_INT_eplivanserine", "text": "Interaction: Lepirudin AND eplivanserine\nDetails: eplivanserine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + eplivanserine"}, {"id": "Lepirudin_INT_Astaxanthin", "text": "Interaction: Lepirudin AND Astaxanthin\nDetails: Astaxanthin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Astaxanthin"}, {"id": "Lepirudin_INT_Batroxobin", "text": "Interaction: Lepirudin AND Batroxobin\nDetails: Batroxobin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Batroxobin"}, {"id": "Lepirudin_INT_Ozagrel", "text": "Interaction: Lepirudin AND Ozagrel\nDetails: Ozagrel may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ozagrel"}, {"id": "Lepirudin_INT_Sarpogrelate", "text": "Interaction: Lepirudin AND Sarpogrelate\nDetails: Sarpogrelate may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Sarpogrelate"}, {"id": "Lepirudin_INT_Eplivanserin", "text": "Interaction: Lepirudin AND Eplivanserin\nDetails: Eplivanserin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Eplivanserin"}, {"id": "Lepirudin_INT_Eptifibatide", "text": "Interaction: Lepirudin AND Eptifibatide\nDetails: Eptifibatide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Eptifibatide"}, {"id": "Lepirudin_INT_Treprostinil", "text": "Interaction: Lepirudin AND Treprostinil\nDetails: Treprostinil may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Treprostinil"}, {"id": "Lepirudin_INT_Clopidogrel", "text": "Interaction: Lepirudin AND Clopidogrel\nDetails: Clopidogrel may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Clopidogrel"}, {"id": "Lepirudin_INT_Dipyridamole", "text": "Interaction: Lepirudin AND Dipyridamole\nDetails: Dipyridamole may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Dipyridamole"}, {"id": "Lepirudin_INT_Iloprost", "text": "Interaction: Lepirudin AND Iloprost\nDetails: Iloprost may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Iloprost"}, {"id": "Lepirudin_INT_Epoprostenol", "text": "Interaction: Lepirudin AND Epoprostenol\nDetails: Epoprostenol may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Epoprostenol"}, {"id": "Lepirudin_INT_Beraprost", "text": "Interaction: Lepirudin AND Beraprost\nDetails: Beraprost may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Beraprost"}, {"id": "Lepirudin_INT_Prasugrel", "text": "Interaction: Lepirudin AND Prasugrel\nDetails: Prasugrel may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Prasugrel"}, {"id": "Lepirudin_INT_Cangrelor", "text": "Interaction: Lepirudin AND Cangrelor\nDetails: Cangrelor may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Cangrelor"}, {"id": "Lepirudin_INT_Triflusal", "text": "Interaction: Lepirudin AND Triflusal\nDetails: Triflusal may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Triflusal"}, {"id": "Lepirudin_INT_Ticagrelor", "text": "Interaction: Lepirudin AND Ticagrelor\nDetails: Ticagrelor may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ticagrelor"}, {"id": "Lepirudin_INT_Ditazole", "text": "Interaction: Lepirudin AND Ditazole\nDetails: Ditazole may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ditazole"}, {"id": "Lepirudin_INT_Bemiparin", "text": "Interaction: Lepirudin AND Bemiparin\nDetails: Bemiparin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Bemiparin"}, {"id": "Lepirudin_INT_Parnaparin", "text": "Interaction: Lepirudin AND Parnaparin\nDetails: Parnaparin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Parnaparin"}, {"id": "Lepirudin_INT_Selexipag", "text": "Interaction: Lepirudin AND Selexipag\nDetails: Selexipag may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Selexipag"}, {"id": "Lepirudin_INT_Indobufen", "text": "Interaction: Lepirudin AND Indobufen\nDetails: Indobufen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Indobufen"}, {"id": "Lepirudin_INT_Clorindione", "text": "Interaction: Lepirudin AND Clorindione\nDetails: Clorindione may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Clorindione"}, {"id": "Lepirudin_INT_Picotamide", "text": "Interaction: Lepirudin AND Picotamide\nDetails: Picotamide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Picotamide"}, {"id": "Lepirudin_INT_Diphenadione", "text": "Interaction: Lepirudin AND Diphenadione\nDetails: Diphenadione may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Diphenadione"}, {"id": "Lepirudin_INT_Cloricromen", "text": "Interaction: Lepirudin AND Cloricromen\nDetails: Cloricromen may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Cloricromen"}, {"id": "Lepirudin_INT_Tioclomarol", "text": "Interaction: Lepirudin AND Tioclomarol\nDetails: Tioclomarol may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tioclomarol"}, {"id": "Lepirudin_INT_Milrinone", "text": "Interaction: Lepirudin AND Milrinone\nDetails: Milrinone may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Milrinone"}, {"id": "Lepirudin_INT_Epinastine", "text": "Interaction: Lepirudin AND Epinastine\nDetails: Epinastine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Epinastine"}, {"id": "Lepirudin_INT_Alprostadil", "text": "Interaction: Lepirudin AND Alprostadil\nDetails: Alprostadil may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Alprostadil"}, {"id": "Lepirudin_INT_Pentoxifylline", "text": "Interaction: Lepirudin AND Pentoxifylline\nDetails: Pentoxifylline may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Pentoxifylline"}, {"id": "Lepirudin_INT_Ridogrel", "text": "Interaction: Lepirudin AND Ridogrel\nDetails: Ridogrel may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ridogrel"}, {"id": "Lepirudin_INT_Sevoflurane", "text": "Interaction: Lepirudin AND Sevoflurane\nDetails: Sevoflurane may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Sevoflurane"}, {"id": "Lepirudin_INT_Tesmilifene", "text": "Interaction: Lepirudin AND Tesmilifene\nDetails: Tesmilifene may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Tesmilifene"}, {"id": "Lepirudin_INT_Ibudilast", "text": "Interaction: Lepirudin AND Ibudilast\nDetails: Ibudilast may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ibudilast"}, {"id": "Lepirudin_INT_Icosapent ethyl", "text": "Interaction: Lepirudin AND Icosapent ethyl\nDetails: Icosapent ethyl may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Icosapent ethyl"}, {"id": "Lepirudin_INT_Ifenprodil", "text": "Interaction: Lepirudin AND Ifenprodil\nDetails: Ifenprodil may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ifenprodil"}, {"id": "Lepirudin_INT_Trapidil", "text": "Interaction: Lepirudin AND Trapidil\nDetails: Trapidil may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Trapidil"}, {"id": "Lepirudin_INT_Naftopidil", "text": "Interaction: Lepirudin AND Naftopidil\nDetails: Naftopidil may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Naftopidil"}, {"id": "Lepirudin_INT_Ifetroban", "text": "Interaction: Lepirudin AND Ifetroban\nDetails: Ifetroban may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ifetroban"}, {"id": "Lepirudin_INT_Ketanserin", "text": "Interaction: Lepirudin AND Ketanserin\nDetails: Ketanserin may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ketanserin"}, {"id": "Lepirudin_INT_Butylphthalide", "text": "Interaction: Lepirudin AND Butylphthalide\nDetails: Butylphthalide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Butylphthalide"}, {"id": "Lepirudin_INT_Hydroxytyrosol", "text": "Interaction: Lepirudin AND Hydroxytyrosol\nDetails: Hydroxytyrosol may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Hydroxytyrosol"}, {"id": "Lepirudin_INT_Ramatroban", "text": "Interaction: Lepirudin AND Ramatroban\nDetails: Ramatroban may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ramatroban"}, {"id": "Lepirudin_INT_Linsidomine", "text": "Interaction: Lepirudin AND Linsidomine\nDetails: Linsidomine may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Linsidomine"}, {"id": "Lepirudin_INT_Buflomedil", "text": "Interaction: Lepirudin AND Buflomedil\nDetails: Buflomedil may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Buflomedil"}, {"id": "Lepirudin_INT_Relcovaptan", "text": "Interaction: Lepirudin AND Relcovaptan\nDetails: Relcovaptan may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Relcovaptan"}, {"id": "Lepirudin_INT_Ambroxol acefyllinate", "text": "Interaction: Lepirudin AND Ambroxol acefyllinate\nDetails: The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Ambroxol acefyllinate"}, {"id": "Lepirudin_INT_Theophylline", "text": "Interaction: Lepirudin AND Theophylline\nDetails: The serum concentration of Theophylline can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Theophylline"}, {"id": "Lepirudin_INT_Dyphylline", "text": "Interaction: Lepirudin AND Dyphylline\nDetails: The serum concentration of Dyphylline can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Dyphylline"}, {"id": "Lepirudin_INT_Aminophylline", "text": "Interaction: Lepirudin AND Aminophylline\nDetails: The serum concentration of Aminophylline can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Aminophylline"}, {"id": "Lepirudin_INT_Valproic Acid", "text": "Interaction: Lepirudin AND Valproic Acid\nDetails: The serum concentration of Valproic Acid can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Valproic Acid"}, {"id": "Lepirudin_INT_Zidovudine", "text": "Interaction: Lepirudin AND Zidovudine\nDetails: The serum concentration of Zidovudine can be decreased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Lepirudin + Zidovudine"}, {"id": "Cetuximab_GEN", "text": "Drug: Cetuximab\nDescription: ...", "source": "Cetuximab"}, {"id": "Cetuximab_GEN", "text": "Drug: Cetuximab\nDescription: Cetuximab is an epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions. Cet...", "source": "Cetuximab"}, {"id": "Cetuximab_CLIN", "text": "Drug: Cetuximab\nMechanism: Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epider...\nToxicity: Pulmonary Toxicity\r\n\r\nInterstitial lung disease (ILD) was reported in 3 of 633 (<0.5%) patients with advanced colorectal cancer receiving cetuximab. Interstitial pneumonitis with non-cardiogenic pulmo...", "source": "Cetuximab"}, {"id": "Cetuximab_INT_Belimumab", "text": "Interaction: Cetuximab AND Belimumab\nDetails: The risk or severity of adverse effects can be increased when Cetuximab is combined with Belimumab.\nRisk: Monitor closely.", "source": "Cetuximab + Belimumab"}, {"id": "Cetuximab_INT_Trastuzumab", "text": "Interaction: Cetuximab AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Trastuzumab"}, {"id": "Cetuximab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Cetuximab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Cetuximab_INT_Yellow fever vaccine", "text": "Interaction: Cetuximab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Yellow fever vaccine"}, {"id": "Cetuximab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Cetuximab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Cetuximab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Cetuximab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Cetuximab_INT_Rotavirus Vaccine", "text": "Interaction: Cetuximab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Rotavirus Vaccine"}, {"id": "Cetuximab_INT_G17DT", "text": "Interaction: Cetuximab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + G17DT"}, {"id": "Cetuximab_INT_INGN 201", "text": "Interaction: Cetuximab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + INGN 201"}, {"id": "Cetuximab_INT_INGN 225", "text": "Interaction: Cetuximab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + INGN 225"}, {"id": "Cetuximab_INT_Rindopepimut", "text": "Interaction: Cetuximab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Rindopepimut"}, {"id": "Cetuximab_INT_SRP 299", "text": "Interaction: Cetuximab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + SRP 299"}, {"id": "Cetuximab_INT_GI-5005", "text": "Interaction: Cetuximab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + GI-5005"}, {"id": "Cetuximab_INT_TG4010", "text": "Interaction: Cetuximab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + TG4010"}, {"id": "Cetuximab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Cetuximab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Rabies virus inactivated antigen, A"}, {"id": "Cetuximab_INT_Tecemotide", "text": "Interaction: Cetuximab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Tecemotide"}, {"id": "Cetuximab_INT_BCG vaccine", "text": "Interaction: Cetuximab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + BCG vaccine"}, {"id": "Cetuximab_INT_Rubella virus vaccine", "text": "Interaction: Cetuximab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Rubella virus vaccine"}, {"id": "Cetuximab_INT_Hepatitis A Vaccine", "text": "Interaction: Cetuximab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Hepatitis A Vaccine"}, {"id": "Cetuximab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Cetuximab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Salmonella typhi ty21a live antigen"}, {"id": "Cetuximab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Cetuximab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Cetuximab_INT_Paclitaxel", "text": "Interaction: Cetuximab AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Paclitaxel"}, {"id": "Cetuximab_INT_Docetaxel", "text": "Interaction: Cetuximab AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Docetaxel"}, {"id": "Cetuximab_INT_Cabazitaxel", "text": "Interaction: Cetuximab AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Cabazitaxel"}, {"id": "Cetuximab_INT_Digoxin", "text": "Interaction: Cetuximab AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Digoxin"}, {"id": "Cetuximab_INT_Acetyldigitoxin", "text": "Interaction: Cetuximab AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Acetyldigitoxin"}, {"id": "Cetuximab_INT_Deslanoside", "text": "Interaction: Cetuximab AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Deslanoside"}, {"id": "Cetuximab_INT_Ouabain", "text": "Interaction: Cetuximab AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Ouabain"}, {"id": "Cetuximab_INT_Digitoxin", "text": "Interaction: Cetuximab AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Digitoxin"}, {"id": "Cetuximab_INT_Cymarin", "text": "Interaction: Cetuximab AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Cymarin"}, {"id": "Cetuximab_INT_Proscillaridin", "text": "Interaction: Cetuximab AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Proscillaridin"}, {"id": "Cetuximab_INT_Metildigoxin", "text": "Interaction: Cetuximab AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Metildigoxin"}, {"id": "Cetuximab_INT_Peruvoside", "text": "Interaction: Cetuximab AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Peruvoside"}, {"id": "Cetuximab_INT_Lanatoside C", "text": "Interaction: Cetuximab AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Lanatoside C"}, {"id": "Cetuximab_INT_Gitoformate", "text": "Interaction: Cetuximab AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Gitoformate"}, {"id": "Cetuximab_INT_Acetyldigoxin", "text": "Interaction: Cetuximab AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Acetyldigoxin"}, {"id": "Cetuximab_INT_Oleandrin", "text": "Interaction: Cetuximab AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Oleandrin"}, {"id": "Cetuximab_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Cetuximab AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Digoxin Immune Fab (Ovine)"}, {"id": "Cetuximab_INT_Bevacizumab", "text": "Interaction: Cetuximab AND Bevacizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Bevacizumab"}, {"id": "Cetuximab_INT_Cyclophosphamide", "text": "Interaction: Cetuximab AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Cetuximab + Cyclophosphamide"}, {"id": "Dornase alfa_GEN", "text": "Drug: Dornase alfa\nDescription: Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves ...", "source": "Dornase alfa"}, {"id": "Dornase alfa_CLIN", "text": "Drug: Dornase alfa\nMechanism: Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5\u00b4-phosphodinucleotide and 5\u00b4-phosphooligonucleotide end products. It h...\nToxicity: Adverse reactions occur at a frequency of < 1/1000 and are usually mild and transient in nature. Reported adverse effects include chest pain (pleuritic/non-cardiac), fever, dyspepsia, voice alteration...", "source": "Dornase alfa"}, {"id": "Denileukin diftitox_GEN", "text": "Drug: Denileukin diftitox\nDescription: A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system....", "source": "Denileukin diftitox"}, {"id": "Denileukin diftitox_CLIN", "text": "Drug: Denileukin diftitox\nMechanism: Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak ...\nToxicity: ...", "source": "Denileukin diftitox"}, {"id": "Denileukin diftitox_INT_Trastuzumab", "text": "Interaction: Denileukin diftitox AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Trastuzumab"}, {"id": "Denileukin diftitox_INT_Paclitaxel", "text": "Interaction: Denileukin diftitox AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Paclitaxel"}, {"id": "Denileukin diftitox_INT_Docetaxel", "text": "Interaction: Denileukin diftitox AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Docetaxel"}, {"id": "Denileukin diftitox_INT_Cabazitaxel", "text": "Interaction: Denileukin diftitox AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Cabazitaxel"}, {"id": "Denileukin diftitox_INT_Digoxin", "text": "Interaction: Denileukin diftitox AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Digoxin"}, {"id": "Denileukin diftitox_INT_Acetyldigitoxin", "text": "Interaction: Denileukin diftitox AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Acetyldigitoxin"}, {"id": "Denileukin diftitox_INT_Deslanoside", "text": "Interaction: Denileukin diftitox AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Deslanoside"}, {"id": "Denileukin diftitox_INT_Ouabain", "text": "Interaction: Denileukin diftitox AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Ouabain"}, {"id": "Denileukin diftitox_INT_Digitoxin", "text": "Interaction: Denileukin diftitox AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Digitoxin"}, {"id": "Denileukin diftitox_INT_Cymarin", "text": "Interaction: Denileukin diftitox AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Cymarin"}, {"id": "Denileukin diftitox_INT_Proscillaridin", "text": "Interaction: Denileukin diftitox AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Proscillaridin"}, {"id": "Denileukin diftitox_INT_Metildigoxin", "text": "Interaction: Denileukin diftitox AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Metildigoxin"}, {"id": "Denileukin diftitox_INT_Peruvoside", "text": "Interaction: Denileukin diftitox AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Peruvoside"}, {"id": "Denileukin diftitox_INT_Lanatoside C", "text": "Interaction: Denileukin diftitox AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Lanatoside C"}, {"id": "Denileukin diftitox_INT_Gitoformate", "text": "Interaction: Denileukin diftitox AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Gitoformate"}, {"id": "Denileukin diftitox_INT_Acetyldigoxin", "text": "Interaction: Denileukin diftitox AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Acetyldigoxin"}, {"id": "Denileukin diftitox_INT_Oleandrin", "text": "Interaction: Denileukin diftitox AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Oleandrin"}, {"id": "Denileukin diftitox_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Denileukin diftitox AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Digoxin Immune Fab (Ovine)"}, {"id": "Denileukin diftitox_INT_Bevacizumab", "text": "Interaction: Denileukin diftitox AND Bevacizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Bevacizumab"}, {"id": "Denileukin diftitox_INT_Cyclophosphamide", "text": "Interaction: Denileukin diftitox AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Denileukin diftitox + Cyclophosphamide"}, {"id": "Etanercept_GEN", "text": "Drug: Etanercept\nDescription: Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain...", "source": "Etanercept"}, {"id": "Etanercept_CLIN", "text": "Drug: Etanercept\nMechanism: There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface recep...\nToxicity: ...", "source": "Etanercept"}, {"id": "Etanercept_INT_Adalimumab", "text": "Interaction: Etanercept AND Adalimumab\nDetails: The risk or severity of adverse effects can be increased when Adalimumab is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Adalimumab"}, {"id": "Etanercept_INT_Golimumab", "text": "Interaction: Etanercept AND Golimumab\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Golimumab.\nRisk: Monitor closely.", "source": "Etanercept + Golimumab"}, {"id": "Etanercept_INT_Rituximab", "text": "Interaction: Etanercept AND Rituximab\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Rituximab.\nRisk: Monitor closely.", "source": "Etanercept + Rituximab"}, {"id": "Etanercept_INT_Floctafenine", "text": "Interaction: Etanercept AND Floctafenine\nDetails: The risk or severity of adverse effects can be increased when Floctafenine is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Floctafenine"}, {"id": "Etanercept_INT_Acemetacin", "text": "Interaction: Etanercept AND Acemetacin\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Acemetacin.\nRisk: Monitor closely.", "source": "Etanercept + Acemetacin"}, {"id": "Etanercept_INT_Abatacept", "text": "Interaction: Etanercept AND Abatacept\nDetails: The risk or severity of infection can be increased when Etanercept is combined with Abatacept.\nRisk: Monitor closely.", "source": "Etanercept + Abatacept"}, {"id": "Etanercept_INT_Anakinra", "text": "Interaction: Etanercept AND Anakinra\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Anakinra.\nRisk: Monitor closely.", "source": "Etanercept + Anakinra"}, {"id": "Etanercept_INT_Belimumab", "text": "Interaction: Etanercept AND Belimumab\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Belimumab.\nRisk: Monitor closely.", "source": "Etanercept + Belimumab"}, {"id": "Etanercept_INT_Canakinumab", "text": "Interaction: Etanercept AND Canakinumab\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Canakinumab.\nRisk: Monitor closely.", "source": "Etanercept + Canakinumab"}, {"id": "Etanercept_INT_Certolizumab pegol", "text": "Interaction: Etanercept AND Certolizumab pegol\nDetails: Etanercept may increase the immunosuppressive activities of Certolizumab pegol.\nRisk: Monitor closely.", "source": "Etanercept + Certolizumab pegol"}, {"id": "Etanercept_INT_Cyclophosphamide", "text": "Interaction: Etanercept AND Cyclophosphamide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Cyclophosphamide.\nRisk: Monitor closely.", "source": "Etanercept + Cyclophosphamide"}, {"id": "Etanercept_INT_Infliximab", "text": "Interaction: Etanercept AND Infliximab\nDetails: Etanercept may increase the immunosuppressive activities of Infliximab.\nRisk: Monitor closely.", "source": "Etanercept + Infliximab"}, {"id": "Etanercept_INT_Natalizumab", "text": "Interaction: Etanercept AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Etanercept + Natalizumab"}, {"id": "Etanercept_INT_Pimecrolimus", "text": "Interaction: Etanercept AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Pimecrolimus"}, {"id": "Etanercept_INT_Rilonacept", "text": "Interaction: Etanercept AND Rilonacept\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Rilonacept.\nRisk: Monitor closely.", "source": "Etanercept + Rilonacept"}, {"id": "Etanercept_INT_Tocilizumab", "text": "Interaction: Etanercept AND Tocilizumab\nDetails: Tocilizumab may increase the immunosuppressive activities of Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Tocilizumab"}, {"id": "Etanercept_INT_Tofacitinib", "text": "Interaction: Etanercept AND Tofacitinib\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Tofacitinib.\nRisk: Monitor closely.", "source": "Etanercept + Tofacitinib"}, {"id": "Etanercept_INT_Vedolizumab", "text": "Interaction: Etanercept AND Vedolizumab\nDetails: The risk or severity of infection can be increased when Etanercept is combined with Vedolizumab.\nRisk: Monitor closely.", "source": "Etanercept + Vedolizumab"}, {"id": "Etanercept_INT_Dexketoprofen", "text": "Interaction: Etanercept AND Dexketoprofen\nDetails: The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Dexketoprofen"}, {"id": "Etanercept_INT_Ketorolac", "text": "Interaction: Etanercept AND Ketorolac\nDetails: The risk or severity of adverse effects can be increased when Ketorolac is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Ketorolac"}, {"id": "Etanercept_INT_Morniflumate", "text": "Interaction: Etanercept AND Morniflumate\nDetails: The risk or severity of adverse effects can be increased when Morniflumate is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Morniflumate"}, {"id": "Etanercept_INT_Omacetaxine mepesuccinate", "text": "Interaction: Etanercept AND Omacetaxine mepesuccinate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Omacetaxine mepesuccinate.\nRisk: Monitor closely.", "source": "Etanercept + Omacetaxine mepesuccinate"}, {"id": "Etanercept_INT_Talniflumate", "text": "Interaction: Etanercept AND Talniflumate\nDetails: The risk or severity of adverse effects can be increased when Talniflumate is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Talniflumate"}, {"id": "Etanercept_INT_BCG vaccine", "text": "Interaction: Etanercept AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + BCG vaccine"}, {"id": "Etanercept_INT_Sarilumab", "text": "Interaction: Etanercept AND Sarilumab\nDetails: Sarilumab may increase the immunosuppressive activities of Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Sarilumab"}, {"id": "Etanercept_INT_Torasemide", "text": "Interaction: Etanercept AND Torasemide\nDetails: Etanercept may decrease the diuretic activities of Torasemide.\nRisk: Monitor closely.", "source": "Etanercept + Torasemide"}, {"id": "Etanercept_INT_Furosemide", "text": "Interaction: Etanercept AND Furosemide\nDetails: Etanercept may decrease the diuretic activities of Furosemide.\nRisk: Monitor closely.", "source": "Etanercept + Furosemide"}, {"id": "Etanercept_INT_Bumetanide", "text": "Interaction: Etanercept AND Bumetanide\nDetails: Etanercept may decrease the diuretic activities of Bumetanide.\nRisk: Monitor closely.", "source": "Etanercept + Bumetanide"}, {"id": "Etanercept_INT_Etacrynic acid", "text": "Interaction: Etanercept AND Etacrynic acid\nDetails: Etanercept may decrease the diuretic activities of Etacrynic acid.\nRisk: Monitor closely.", "source": "Etanercept + Etacrynic acid"}, {"id": "Etanercept_INT_Piretanide", "text": "Interaction: Etanercept AND Piretanide\nDetails: Etanercept may decrease the diuretic activities of Piretanide.\nRisk: Monitor closely.", "source": "Etanercept + Piretanide"}, {"id": "Etanercept_INT_Lithium", "text": "Interaction: Etanercept AND Lithium\nDetails: The serum concentration of Lithium can be increased when it is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Lithium"}, {"id": "Etanercept_INT_Methotrexate", "text": "Interaction: Etanercept AND Methotrexate\nDetails: The serum concentration of Methotrexate can be increased when it is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Methotrexate"}, {"id": "Etanercept_INT_Tenofovir disoproxil", "text": "Interaction: Etanercept AND Tenofovir disoproxil\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Tenofovir disoproxil.\nRisk: Monitor closely.", "source": "Etanercept + Tenofovir disoproxil"}, {"id": "Etanercept_INT_Sodium phosphate", "text": "Interaction: Etanercept AND Sodium phosphate\nDetails: Sodium phosphate may increase the nephrotoxic activities of Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Sodium phosphate"}, {"id": "Etanercept_INT_Betrixaban", "text": "Interaction: Etanercept AND Betrixaban\nDetails: The risk or severity of bleeding can be increased when Betrixaban is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Betrixaban"}, {"id": "Etanercept_INT_Leflunomide", "text": "Interaction: Etanercept AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Etanercept + Leflunomide"}, {"id": "Etanercept_INT_Fingolimod", "text": "Interaction: Etanercept AND Fingolimod\nDetails: Etanercept may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Etanercept + Fingolimod"}, {"id": "Etanercept_INT_Roflumilast", "text": "Interaction: Etanercept AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Roflumilast"}, {"id": "Etanercept_INT_Cyclosporine", "text": "Interaction: Etanercept AND Cyclosporine\nDetails: Etanercept may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Etanercept + Cyclosporine"}, {"id": "Etanercept_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Etanercept AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Etanercept_INT_Yellow fever vaccine", "text": "Interaction: Etanercept AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Yellow fever vaccine"}, {"id": "Etanercept_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Etanercept AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Etanercept_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Etanercept AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Etanercept_INT_Rotavirus Vaccine", "text": "Interaction: Etanercept AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Rotavirus Vaccine"}, {"id": "Etanercept_INT_G17DT", "text": "Interaction: Etanercept AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + G17DT"}, {"id": "Etanercept_INT_INGN 201", "text": "Interaction: Etanercept AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + INGN 201"}, {"id": "Etanercept_INT_INGN 225", "text": "Interaction: Etanercept AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + INGN 225"}, {"id": "Etanercept_INT_Rindopepimut", "text": "Interaction: Etanercept AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Rindopepimut"}, {"id": "Etanercept_INT_SRP 299", "text": "Interaction: Etanercept AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + SRP 299"}, {"id": "Etanercept_INT_GI-5005", "text": "Interaction: Etanercept AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + GI-5005"}, {"id": "Etanercept_INT_TG4010", "text": "Interaction: Etanercept AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + TG4010"}, {"id": "Etanercept_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Etanercept AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Rabies virus inactivated antigen, A"}, {"id": "Etanercept_INT_Tecemotide", "text": "Interaction: Etanercept AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Tecemotide"}, {"id": "Etanercept_INT_Rubella virus vaccine", "text": "Interaction: Etanercept AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Rubella virus vaccine"}, {"id": "Etanercept_INT_Hepatitis A Vaccine", "text": "Interaction: Etanercept AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Hepatitis A Vaccine"}, {"id": "Etanercept_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Etanercept AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Salmonella typhi ty21a live antigen"}, {"id": "Etanercept_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Etanercept AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Hepatitis B Vaccine (Recombinant)"}, {"id": "Etanercept_INT_Diclofenac", "text": "Interaction: Etanercept AND Diclofenac\nDetails: The risk or severity of adverse effects can be increased when Diclofenac is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Diclofenac"}, {"id": "Etanercept_INT_Colestipol", "text": "Interaction: Etanercept AND Colestipol\nDetails: Colestipol can cause a decrease in the absorption of Etanercept resulting in a reduced serum concentration and potentially a decrease in efficacy.\nRisk: Monitor closely.", "source": "Etanercept + Colestipol"}, {"id": "Etanercept_INT_Colesevelam", "text": "Interaction: Etanercept AND Colesevelam\nDetails: Colesevelam can cause a decrease in the absorption of Etanercept resulting in a reduced serum concentration and potentially a decrease in efficacy.\nRisk: Monitor closely.", "source": "Etanercept + Colesevelam"}, {"id": "Etanercept_INT_Cholestyramine", "text": "Interaction: Etanercept AND Cholestyramine\nDetails: Cholestyramine can cause a decrease in the absorption of Etanercept resulting in a reduced serum concentration and potentially a decrease in efficacy.\nRisk: Monitor closely.", "source": "Etanercept + Cholestyramine"}, {"id": "Etanercept_INT_Amikacin", "text": "Interaction: Etanercept AND Amikacin\nDetails: Etanercept may decrease the excretion rate of Amikacin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Amikacin"}, {"id": "Etanercept_INT_Tobramycin", "text": "Interaction: Etanercept AND Tobramycin\nDetails: Etanercept may decrease the excretion rate of Tobramycin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Tobramycin"}, {"id": "Etanercept_INT_Gentamicin", "text": "Interaction: Etanercept AND Gentamicin\nDetails: Etanercept may decrease the excretion rate of Gentamicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Gentamicin"}, {"id": "Etanercept_INT_Neomycin", "text": "Interaction: Etanercept AND Neomycin\nDetails: Etanercept may decrease the excretion rate of Neomycin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Neomycin"}, {"id": "Etanercept_INT_Streptomycin", "text": "Interaction: Etanercept AND Streptomycin\nDetails: Etanercept may decrease the excretion rate of Streptomycin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Streptomycin"}, {"id": "Etanercept_INT_Valrubicin", "text": "Interaction: Etanercept AND Valrubicin\nDetails: Etanercept may decrease the excretion rate of Valrubicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Valrubicin"}, {"id": "Etanercept_INT_Streptozocin", "text": "Interaction: Etanercept AND Streptozocin\nDetails: Etanercept may decrease the excretion rate of Streptozocin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Streptozocin"}, {"id": "Etanercept_INT_Epirubicin", "text": "Interaction: Etanercept AND Epirubicin\nDetails: Etanercept may decrease the excretion rate of Epirubicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Epirubicin"}, {"id": "Etanercept_INT_Framycetin", "text": "Interaction: Etanercept AND Framycetin\nDetails: Etanercept may decrease the excretion rate of Framycetin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Framycetin"}, {"id": "Etanercept_INT_Daunorubicin", "text": "Interaction: Etanercept AND Daunorubicin\nDetails: Etanercept may decrease the excretion rate of Daunorubicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Daunorubicin"}, {"id": "Etanercept_INT_Spectinomycin", "text": "Interaction: Etanercept AND Spectinomycin\nDetails: Etanercept may decrease the excretion rate of Spectinomycin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Spectinomycin"}, {"id": "Etanercept_INT_Netilmicin", "text": "Interaction: Etanercept AND Netilmicin\nDetails: Etanercept may decrease the excretion rate of Netilmicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Netilmicin"}, {"id": "Etanercept_INT_Doxorubicin", "text": "Interaction: Etanercept AND Doxorubicin\nDetails: Etanercept may decrease the excretion rate of Doxorubicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Doxorubicin"}, {"id": "Etanercept_INT_Kanamycin", "text": "Interaction: Etanercept AND Kanamycin\nDetails: Etanercept may decrease the excretion rate of Kanamycin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Kanamycin"}, {"id": "Etanercept_INT_Idarubicin", "text": "Interaction: Etanercept AND Idarubicin\nDetails: Etanercept may decrease the excretion rate of Idarubicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Idarubicin"}, {"id": "Etanercept_INT_Paromomycin", "text": "Interaction: Etanercept AND Paromomycin\nDetails: Etanercept may decrease the excretion rate of Paromomycin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Paromomycin"}, {"id": "Etanercept_INT_Metrizamide", "text": "Interaction: Etanercept AND Metrizamide\nDetails: Etanercept may decrease the excretion rate of Metrizamide which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Metrizamide"}, {"id": "Etanercept_INT_Ribostamycin", "text": "Interaction: Etanercept AND Ribostamycin\nDetails: Etanercept may decrease the excretion rate of Ribostamycin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Ribostamycin"}, {"id": "Etanercept_INT_Geneticin", "text": "Interaction: Etanercept AND Geneticin\nDetails: Etanercept may decrease the excretion rate of Geneticin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Geneticin"}, {"id": "Etanercept_INT_Apramycin", "text": "Interaction: Etanercept AND Apramycin\nDetails: Etanercept may decrease the excretion rate of Apramycin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Apramycin"}, {"id": "Etanercept_INT_GENTAMICIN C1A", "text": "Interaction: Etanercept AND GENTAMICIN C1A\nDetails: Etanercept may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + GENTAMICIN C1A"}, {"id": "Etanercept_INT_Neamine", "text": "Interaction: Etanercept AND Neamine\nDetails: Etanercept may decrease the excretion rate of Neamine which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Neamine"}, {"id": "Etanercept_INT_SP1049C", "text": "Interaction: Etanercept AND SP1049C\nDetails: Etanercept may decrease the excretion rate of SP1049C which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + SP1049C"}, {"id": "Etanercept_INT_INNO-206", "text": "Interaction: Etanercept AND INNO-206\nDetails: Etanercept may decrease the excretion rate of INNO-206 which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + INNO-206"}, {"id": "Etanercept_INT_Amrubicin", "text": "Interaction: Etanercept AND Amrubicin\nDetails: Etanercept may decrease the excretion rate of Amrubicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Amrubicin"}, {"id": "Etanercept_INT_annamycin", "text": "Interaction: Etanercept AND annamycin\nDetails: Etanercept may decrease the excretion rate of annamycin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + annamycin"}, {"id": "Etanercept_INT_Arbekacin", "text": "Interaction: Etanercept AND Arbekacin\nDetails: Etanercept may decrease the excretion rate of Arbekacin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Arbekacin"}, {"id": "Etanercept_INT_Plicamycin", "text": "Interaction: Etanercept AND Plicamycin\nDetails: Etanercept may decrease the excretion rate of Plicamycin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Plicamycin"}, {"id": "Etanercept_INT_Puromycin", "text": "Interaction: Etanercept AND Puromycin\nDetails: Etanercept may decrease the excretion rate of Puromycin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Puromycin"}, {"id": "Etanercept_INT_Dihydrostreptomycin", "text": "Interaction: Etanercept AND Dihydrostreptomycin\nDetails: Etanercept may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Dihydrostreptomycin"}, {"id": "Etanercept_INT_Hygromycin B", "text": "Interaction: Etanercept AND Hygromycin B\nDetails: Etanercept may decrease the excretion rate of Hygromycin B which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Hygromycin B"}, {"id": "Etanercept_INT_Pirarubicin", "text": "Interaction: Etanercept AND Pirarubicin\nDetails: Etanercept may decrease the excretion rate of Pirarubicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Pirarubicin"}, {"id": "Etanercept_INT_Aclarubicin", "text": "Interaction: Etanercept AND Aclarubicin\nDetails: Etanercept may decrease the excretion rate of Aclarubicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Aclarubicin"}, {"id": "Etanercept_INT_Zorubicin", "text": "Interaction: Etanercept AND Zorubicin\nDetails: Etanercept may decrease the excretion rate of Zorubicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Zorubicin"}, {"id": "Etanercept_INT_Sabarubicin", "text": "Interaction: Etanercept AND Sabarubicin\nDetails: Etanercept may decrease the excretion rate of Sabarubicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Sabarubicin"}, {"id": "Etanercept_INT_Sisomicin", "text": "Interaction: Etanercept AND Sisomicin\nDetails: Etanercept may decrease the excretion rate of Sisomicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Sisomicin"}, {"id": "Etanercept_INT_Plazomicin", "text": "Interaction: Etanercept AND Plazomicin\nDetails: Etanercept may decrease the excretion rate of Plazomicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Plazomicin"}, {"id": "Etanercept_INT_Zoptarelin doxorubicin", "text": "Interaction: Etanercept AND Zoptarelin doxorubicin\nDetails: Etanercept may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Zoptarelin doxorubicin"}, {"id": "Etanercept_INT_GPX-150", "text": "Interaction: Etanercept AND GPX-150\nDetails: Etanercept may decrease the excretion rate of GPX-150 which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + GPX-150"}, {"id": "Etanercept_INT_Dibekacin", "text": "Interaction: Etanercept AND Dibekacin\nDetails: Etanercept may decrease the excretion rate of Dibekacin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Dibekacin"}, {"id": "Etanercept_INT_Micronomicin", "text": "Interaction: Etanercept AND Micronomicin\nDetails: Etanercept may decrease the excretion rate of Micronomicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Micronomicin"}, {"id": "Etanercept_INT_Isepamicin", "text": "Interaction: Etanercept AND Isepamicin\nDetails: Etanercept may decrease the excretion rate of Isepamicin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Isepamicin"}, {"id": "Etanercept_INT_Bekanamycin", "text": "Interaction: Etanercept AND Bekanamycin\nDetails: Etanercept may decrease the excretion rate of Bekanamycin which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Etanercept + Bekanamycin"}, {"id": "Etanercept_INT_Aliskiren", "text": "Interaction: Etanercept AND Aliskiren\nDetails: Etanercept may decrease the antihypertensive activities of Aliskiren.\nRisk: Monitor closely.", "source": "Etanercept + Aliskiren"}, {"id": "Etanercept_INT_Deferasirox", "text": "Interaction: Etanercept AND Deferasirox\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Deferasirox.\nRisk: Monitor closely.", "source": "Etanercept + Deferasirox"}, {"id": "Etanercept_INT_Desmopressin", "text": "Interaction: Etanercept AND Desmopressin\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Etanercept + Desmopressin"}, {"id": "Etanercept_INT_Grepafloxacin", "text": "Interaction: Etanercept AND Grepafloxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Grepafloxacin.\nRisk: Monitor closely.", "source": "Etanercept + Grepafloxacin"}, {"id": "Etanercept_INT_Enoxacin", "text": "Interaction: Etanercept AND Enoxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Enoxacin.\nRisk: Monitor closely.", "source": "Etanercept + Enoxacin"}, {"id": "Etanercept_INT_Pefloxacin", "text": "Interaction: Etanercept AND Pefloxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Pefloxacin.\nRisk: Monitor closely.", "source": "Etanercept + Pefloxacin"}, {"id": "Etanercept_INT_Trovafloxacin", "text": "Interaction: Etanercept AND Trovafloxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Trovafloxacin.\nRisk: Monitor closely.", "source": "Etanercept + Trovafloxacin"}, {"id": "Etanercept_INT_Nalidixic Acid", "text": "Interaction: Etanercept AND Nalidixic Acid\nDetails: Etanercept may increase the neuroexcitatory activities of Nalidixic Acid.\nRisk: Monitor closely.", "source": "Etanercept + Nalidixic Acid"}, {"id": "Etanercept_INT_Rosoxacin", "text": "Interaction: Etanercept AND Rosoxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Rosoxacin.\nRisk: Monitor closely.", "source": "Etanercept + Rosoxacin"}, {"id": "Etanercept_INT_Cinoxacin", "text": "Interaction: Etanercept AND Cinoxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Cinoxacin.\nRisk: Monitor closely.", "source": "Etanercept + Cinoxacin"}, {"id": "Etanercept_INT_Gatifloxacin", "text": "Interaction: Etanercept AND Gatifloxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Gatifloxacin.\nRisk: Monitor closely.", "source": "Etanercept + Gatifloxacin"}, {"id": "Etanercept_INT_Norfloxacin", "text": "Interaction: Etanercept AND Norfloxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Norfloxacin.\nRisk: Monitor closely.", "source": "Etanercept + Norfloxacin"}, {"id": "Etanercept_INT_Levofloxacin", "text": "Interaction: Etanercept AND Levofloxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Levofloxacin.\nRisk: Monitor closely.", "source": "Etanercept + Levofloxacin"}, {"id": "Etanercept_INT_Gemifloxacin", "text": "Interaction: Etanercept AND Gemifloxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Gemifloxacin.\nRisk: Monitor closely.", "source": "Etanercept + Gemifloxacin"}, {"id": "Etanercept_INT_Sparfloxacin", "text": "Interaction: Etanercept AND Sparfloxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Sparfloxacin.\nRisk: Monitor closely.", "source": "Etanercept + Sparfloxacin"}, {"id": "Etanercept_INT_Temafloxacin", "text": "Interaction: Etanercept AND Temafloxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Temafloxacin.\nRisk: Monitor closely.", "source": "Etanercept + Temafloxacin"}, {"id": "Etanercept_INT_Fleroxacin", "text": "Interaction: Etanercept AND Fleroxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Fleroxacin.\nRisk: Monitor closely.", "source": "Etanercept + Fleroxacin"}, {"id": "Etanercept_INT_Garenoxacin", "text": "Interaction: Etanercept AND Garenoxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Garenoxacin.\nRisk: Monitor closely.", "source": "Etanercept + Garenoxacin"}, {"id": "Etanercept_INT_Nemonoxacin", "text": "Interaction: Etanercept AND Nemonoxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Nemonoxacin.\nRisk: Monitor closely.", "source": "Etanercept + Nemonoxacin"}, {"id": "Etanercept_INT_Flumequine", "text": "Interaction: Etanercept AND Flumequine\nDetails: Etanercept may increase the neuroexcitatory activities of Flumequine.\nRisk: Monitor closely.", "source": "Etanercept + Flumequine"}, {"id": "Etanercept_INT_Pazufloxacin", "text": "Interaction: Etanercept AND Pazufloxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Pazufloxacin.\nRisk: Monitor closely.", "source": "Etanercept + Pazufloxacin"}, {"id": "Etanercept_INT_Prulifloxacin", "text": "Interaction: Etanercept AND Prulifloxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Prulifloxacin.\nRisk: Monitor closely.", "source": "Etanercept + Prulifloxacin"}, {"id": "Etanercept_INT_Sitafloxacin", "text": "Interaction: Etanercept AND Sitafloxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Sitafloxacin.\nRisk: Monitor closely.", "source": "Etanercept + Sitafloxacin"}, {"id": "Etanercept_INT_Oxolinic acid", "text": "Interaction: Etanercept AND Oxolinic acid\nDetails: Etanercept may increase the neuroexcitatory activities of Oxolinic acid.\nRisk: Monitor closely.", "source": "Etanercept + Oxolinic acid"}, {"id": "Etanercept_INT_Piromidic acid", "text": "Interaction: Etanercept AND Piromidic acid\nDetails: Etanercept may increase the neuroexcitatory activities of Piromidic acid.\nRisk: Monitor closely.", "source": "Etanercept + Piromidic acid"}, {"id": "Etanercept_INT_Rufloxacin", "text": "Interaction: Etanercept AND Rufloxacin\nDetails: Etanercept may increase the neuroexcitatory activities of Rufloxacin.\nRisk: Monitor closely.", "source": "Etanercept + Rufloxacin"}, {"id": "Etanercept_INT_Pipemidic acid", "text": "Interaction: Etanercept AND Pipemidic acid\nDetails: Etanercept may increase the neuroexcitatory activities of Pipemidic acid.\nRisk: Monitor closely.", "source": "Etanercept + Pipemidic acid"}, {"id": "Etanercept_INT_Digoxin", "text": "Interaction: Etanercept AND Digoxin\nDetails: The serum concentration of Digoxin can be increased when it is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Digoxin"}, {"id": "Etanercept_INT_Drospirenone", "text": "Interaction: Etanercept AND Drospirenone\nDetails: Etanercept may increase the hyperkalemic activities of Drospirenone.\nRisk: Monitor closely.", "source": "Etanercept + Drospirenone"}, {"id": "Etanercept_INT_Eplerenone", "text": "Interaction: Etanercept AND Eplerenone\nDetails: Etanercept may decrease the antihypertensive activities of Eplerenone.\nRisk: Monitor closely.", "source": "Etanercept + Eplerenone"}, {"id": "Etanercept_INT_Haloperidol", "text": "Interaction: Etanercept AND Haloperidol\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Haloperidol.\nRisk: Monitor closely.", "source": "Etanercept + Haloperidol"}, {"id": "Etanercept_INT_Hydralazine", "text": "Interaction: Etanercept AND Hydralazine\nDetails: Etanercept may decrease the antihypertensive activities of Hydralazine.\nRisk: Monitor closely.", "source": "Etanercept + Hydralazine"}, {"id": "Etanercept_INT_Pralatrexate", "text": "Interaction: Etanercept AND Pralatrexate\nDetails: The serum concentration of Pralatrexate can be increased when it is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Pralatrexate"}, {"id": "Etanercept_INT_Probenecid", "text": "Interaction: Etanercept AND Probenecid\nDetails: The serum concentration of Etanercept can be increased when it is combined with Probenecid.\nRisk: Monitor closely.", "source": "Etanercept + Probenecid"}, {"id": "Etanercept_INT_Treprostinil", "text": "Interaction: Etanercept AND Treprostinil\nDetails: The risk or severity of adverse effects can be increased when Treprostinil is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Treprostinil"}, {"id": "Etanercept_INT_Vancomycin", "text": "Interaction: Etanercept AND Vancomycin\nDetails: The serum concentration of Vancomycin can be increased when it is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Vancomycin"}, {"id": "Etanercept_INT_Methyclothiazide", "text": "Interaction: Etanercept AND Methyclothiazide\nDetails: The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Methyclothiazide"}, {"id": "Etanercept_INT_Chlorothiazide", "text": "Interaction: Etanercept AND Chlorothiazide\nDetails: The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Chlorothiazide"}, {"id": "Etanercept_INT_Hydrochlorothiazide", "text": "Interaction: Etanercept AND Hydrochlorothiazide\nDetails: The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Hydrochlorothiazide"}, {"id": "Etanercept_INT_Chlorthalidone", "text": "Interaction: Etanercept AND Chlorthalidone\nDetails: The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Chlorthalidone"}, {"id": "Etanercept_INT_Bendroflumethiazide", "text": "Interaction: Etanercept AND Bendroflumethiazide\nDetails: The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Bendroflumethiazide"}, {"id": "Etanercept_INT_Metolazone", "text": "Interaction: Etanercept AND Metolazone\nDetails: The therapeutic efficacy of Metolazone can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Metolazone"}, {"id": "Etanercept_INT_Hydroflumethiazide", "text": "Interaction: Etanercept AND Hydroflumethiazide\nDetails: The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Hydroflumethiazide"}, {"id": "Etanercept_INT_Indapamide", "text": "Interaction: Etanercept AND Indapamide\nDetails: The therapeutic efficacy of Indapamide can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Indapamide"}, {"id": "Etanercept_INT_Trichlormethiazide", "text": "Interaction: Etanercept AND Trichlormethiazide\nDetails: The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Trichlormethiazide"}, {"id": "Etanercept_INT_Polythiazide", "text": "Interaction: Etanercept AND Polythiazide\nDetails: The therapeutic efficacy of Polythiazide can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Polythiazide"}, {"id": "Etanercept_INT_Quinethazone", "text": "Interaction: Etanercept AND Quinethazone\nDetails: The therapeutic efficacy of Quinethazone can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Quinethazone"}, {"id": "Etanercept_INT_Cyclopenthiazide", "text": "Interaction: Etanercept AND Cyclopenthiazide\nDetails: The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Cyclopenthiazide"}, {"id": "Etanercept_INT_Mesalazine", "text": "Interaction: Etanercept AND Mesalazine\nDetails: Etanercept may increase the nephrotoxic activities of Mesalazine.\nRisk: Monitor closely.", "source": "Etanercept + Mesalazine"}, {"id": "Etanercept_INT_Balsalazide", "text": "Interaction: Etanercept AND Balsalazide\nDetails: Etanercept may increase the nephrotoxic activities of Balsalazide.\nRisk: Monitor closely.", "source": "Etanercept + Balsalazide"}, {"id": "Etanercept_INT_Olsalazine", "text": "Interaction: Etanercept AND Olsalazine\nDetails: Etanercept may increase the nephrotoxic activities of Olsalazine.\nRisk: Monitor closely.", "source": "Etanercept + Olsalazine"}, {"id": "Etanercept_INT_Denosumab", "text": "Interaction: Etanercept AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Denosumab"}, {"id": "Etanercept_INT_Sipuleucel-T", "text": "Interaction: Etanercept AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Sipuleucel-T"}, {"id": "Etanercept_INT_Trastuzumab", "text": "Interaction: Etanercept AND Trastuzumab\nDetails: Trastuzumab may increase the neutropenic activities of Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Trastuzumab"}, {"id": "Etanercept_INT_Risedronate", "text": "Interaction: Etanercept AND Risedronate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Risedronate.\nRisk: Monitor closely.", "source": "Etanercept + Risedronate"}, {"id": "Etanercept_INT_Etidronic acid", "text": "Interaction: Etanercept AND Etidronic acid\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Etidronic acid.\nRisk: Monitor closely.", "source": "Etanercept + Etidronic acid"}, {"id": "Etanercept_INT_Clodronic Acid", "text": "Interaction: Etanercept AND Clodronic Acid\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Clodronic Acid.\nRisk: Monitor closely.", "source": "Etanercept + Clodronic Acid"}, {"id": "Etanercept_INT_Pamidronate", "text": "Interaction: Etanercept AND Pamidronate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Pamidronate.\nRisk: Monitor closely.", "source": "Etanercept + Pamidronate"}, {"id": "Etanercept_INT_Zoledronic acid", "text": "Interaction: Etanercept AND Zoledronic acid\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Zoledronic acid.\nRisk: Monitor closely.", "source": "Etanercept + Zoledronic acid"}, {"id": "Etanercept_INT_Ibandronate", "text": "Interaction: Etanercept AND Ibandronate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Ibandronate.\nRisk: Monitor closely.", "source": "Etanercept + Ibandronate"}, {"id": "Etanercept_INT_Alendronic acid", "text": "Interaction: Etanercept AND Alendronic acid\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Alendronic acid.\nRisk: Monitor closely.", "source": "Etanercept + Alendronic acid"}, {"id": "Etanercept_INT_Technetium Tc-99m medronate", "text": "Interaction: Etanercept AND Technetium Tc-99m medronate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Technetium Tc-99m medronate.\nRisk: Monitor closely.", "source": "Etanercept + Technetium Tc-99m medronate"}, {"id": "Etanercept_INT_Technetium Tc-99m etidronate", "text": "Interaction: Etanercept AND Technetium Tc-99m etidronate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Technetium Tc-99m etidronate.\nRisk: Monitor closely.", "source": "Etanercept + Technetium Tc-99m etidronate"}, {"id": "Etanercept_INT_Tiludronic acid", "text": "Interaction: Etanercept AND Tiludronic acid\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Tiludronic acid.\nRisk: Monitor closely.", "source": "Etanercept + Tiludronic acid"}, {"id": "Etanercept_INT_Carboprost Tromethamine", "text": "Interaction: Etanercept AND Carboprost Tromethamine\nDetails: The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Carboprost Tromethamine"}, {"id": "Etanercept_INT_Dinoprostone", "text": "Interaction: Etanercept AND Dinoprostone\nDetails: The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Dinoprostone"}, {"id": "Etanercept_INT_Misoprostol", "text": "Interaction: Etanercept AND Misoprostol\nDetails: The therapeutic efficacy of Misoprostol can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Misoprostol"}, {"id": "Etanercept_INT_Gemeprost", "text": "Interaction: Etanercept AND Gemeprost\nDetails: The therapeutic efficacy of Gemeprost can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Gemeprost"}, {"id": "Etanercept_INT_Dinoprost", "text": "Interaction: Etanercept AND Dinoprost\nDetails: The therapeutic efficacy of Dinoprost can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Dinoprost"}, {"id": "Etanercept_INT_Sulprostone", "text": "Interaction: Etanercept AND Sulprostone\nDetails: The therapeutic efficacy of Sulprostone can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Sulprostone"}, {"id": "Etanercept_INT_Enprostil", "text": "Interaction: Etanercept AND Enprostil\nDetails: The therapeutic efficacy of Enprostil can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Enprostil"}, {"id": "Etanercept_INT_Folic Acid", "text": "Interaction: Etanercept AND Folic Acid\nDetails: The therapeutic efficacy of Folic Acid can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Folic Acid"}, {"id": "Etanercept_INT_Travoprost", "text": "Interaction: Etanercept AND Travoprost\nDetails: The therapeutic efficacy of Travoprost can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Travoprost"}, {"id": "Etanercept_INT_Latanoprost", "text": "Interaction: Etanercept AND Latanoprost\nDetails: The therapeutic efficacy of Latanoprost can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Latanoprost"}, {"id": "Etanercept_INT_Alprostadil", "text": "Interaction: Etanercept AND Alprostadil\nDetails: The therapeutic efficacy of Alprostadil can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Alprostadil"}, {"id": "Etanercept_INT_Bimatoprost", "text": "Interaction: Etanercept AND Bimatoprost\nDetails: The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Bimatoprost"}, {"id": "Etanercept_INT_Lubiprostone", "text": "Interaction: Etanercept AND Lubiprostone\nDetails: The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Lubiprostone"}, {"id": "Etanercept_INT_Iloprost", "text": "Interaction: Etanercept AND Iloprost\nDetails: The therapeutic efficacy of Iloprost can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Iloprost"}, {"id": "Etanercept_INT_Dinoprost Tromethamine", "text": "Interaction: Etanercept AND Dinoprost Tromethamine\nDetails: The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Dinoprost Tromethamine"}, {"id": "Etanercept_INT_Epoprostenol", "text": "Interaction: Etanercept AND Epoprostenol\nDetails: The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Epoprostenol"}, {"id": "Etanercept_INT_Prostaglandin B2", "text": "Interaction: Etanercept AND Prostaglandin B2\nDetails: The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Prostaglandin B2"}, {"id": "Etanercept_INT_Prostaglandin G2", "text": "Interaction: Etanercept AND Prostaglandin G2\nDetails: The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Prostaglandin G2"}, {"id": "Etanercept_INT_Beraprost", "text": "Interaction: Etanercept AND Beraprost\nDetails: The therapeutic efficacy of Beraprost can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Beraprost"}, {"id": "Etanercept_INT_Unoprostone", "text": "Interaction: Etanercept AND Unoprostone\nDetails: The therapeutic efficacy of Unoprostone can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Unoprostone"}, {"id": "Etanercept_INT_Tafluprost", "text": "Interaction: Etanercept AND Tafluprost\nDetails: The therapeutic efficacy of Tafluprost can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Tafluprost"}, {"id": "Etanercept_INT_Limaprost", "text": "Interaction: Etanercept AND Limaprost\nDetails: The therapeutic efficacy of Limaprost can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Limaprost"}, {"id": "Etanercept_INT_Fenprostalene", "text": "Interaction: Etanercept AND Fenprostalene\nDetails: The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Fenprostalene"}, {"id": "Etanercept_INT_Luprostiol", "text": "Interaction: Etanercept AND Luprostiol\nDetails: The therapeutic efficacy of Luprostiol can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Luprostiol"}, {"id": "Etanercept_INT_Prostalene", "text": "Interaction: Etanercept AND Prostalene\nDetails: The therapeutic efficacy of Prostalene can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Prostalene"}, {"id": "Etanercept_INT_Cloprostenol", "text": "Interaction: Etanercept AND Cloprostenol\nDetails: The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Cloprostenol"}, {"id": "Etanercept_INT_Fluprostenol", "text": "Interaction: Etanercept AND Fluprostenol\nDetails: The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Fluprostenol"}, {"id": "Etanercept_INT_Latanoprostene Bunod", "text": "Interaction: Etanercept AND Latanoprostene Bunod\nDetails: The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Latanoprostene Bunod"}, {"id": "Etanercept_INT_Lepirudin", "text": "Interaction: Etanercept AND Lepirudin\nDetails: Etanercept may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Etanercept + Lepirudin"}, {"id": "Etanercept_INT_Bivalirudin", "text": "Interaction: Etanercept AND Bivalirudin\nDetails: Etanercept may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Etanercept + Bivalirudin"}, {"id": "Etanercept_INT_Abciximab", "text": "Interaction: Etanercept AND Abciximab\nDetails: Etanercept may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Etanercept + Abciximab"}, {"id": "Etanercept_INT_Becaplermin", "text": "Interaction: Etanercept AND Becaplermin\nDetails: Etanercept may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Etanercept + Becaplermin"}, {"id": "Etanercept_INT_Dicoumarol", "text": "Interaction: Etanercept AND Dicoumarol\nDetails: Etanercept may increase the anticoagulant activities of Dicoumarol.\nRisk: Monitor closely.", "source": "Etanercept + Dicoumarol"}, {"id": "Etanercept_INT_Argatroban", "text": "Interaction: Etanercept AND Argatroban\nDetails: Etanercept may increase the anticoagulant activities of Argatroban.\nRisk: Monitor closely.", "source": "Etanercept + Argatroban"}, {"id": "Etanercept_INT_Ardeparin", "text": "Interaction: Etanercept AND Ardeparin\nDetails: Etanercept may increase the anticoagulant activities of Ardeparin.\nRisk: Monitor closely.", "source": "Etanercept + Ardeparin"}, {"id": "Etanercept_INT_Phenindione", "text": "Interaction: Etanercept AND Phenindione\nDetails: Etanercept may increase the anticoagulant activities of Phenindione.\nRisk: Monitor closely.", "source": "Etanercept + Phenindione"}, {"id": "Etanercept_INT_Fondaparinux sodium", "text": "Interaction: Etanercept AND Fondaparinux sodium\nDetails: Etanercept may increase the anticoagulant activities of Fondaparinux sodium.\nRisk: Monitor closely.", "source": "Etanercept + Fondaparinux sodium"}, {"id": "Etanercept_INT_Warfarin", "text": "Interaction: Etanercept AND Warfarin\nDetails: Etanercept may increase the anticoagulant activities of Warfarin.\nRisk: Monitor closely.", "source": "Etanercept + Warfarin"}, {"id": "Etanercept_INT_Pentosan Polysulfate", "text": "Interaction: Etanercept AND Pentosan Polysulfate\nDetails: Etanercept may increase the anticoagulant activities of Pentosan Polysulfate.\nRisk: Monitor closely.", "source": "Etanercept + Pentosan Polysulfate"}, {"id": "Etanercept_INT_Phenprocoumon", "text": "Interaction: Etanercept AND Phenprocoumon\nDetails: Etanercept may increase the anticoagulant activities of Phenprocoumon.\nRisk: Monitor closely.", "source": "Etanercept + Phenprocoumon"}, {"id": "Etanercept_INT_Edetic Acid", "text": "Interaction: Etanercept AND Edetic Acid\nDetails: Etanercept may increase the anticoagulant activities of Edetic Acid.\nRisk: Monitor closely.", "source": "Etanercept + Edetic Acid"}, {"id": "Etanercept_INT_Heparin", "text": "Interaction: Etanercept AND Heparin\nDetails: Etanercept may increase the anticoagulant activities of Heparin.\nRisk: Monitor closely.", "source": "Etanercept + Heparin"}, {"id": "Etanercept_INT_Enoxaparin", "text": "Interaction: Etanercept AND Enoxaparin\nDetails: Etanercept may increase the anticoagulant activities of Enoxaparin.\nRisk: Monitor closely.", "source": "Etanercept + Enoxaparin"}, {"id": "Etanercept_INT_Acenocoumarol", "text": "Interaction: Etanercept AND Acenocoumarol\nDetails: Etanercept may increase the anticoagulant activities of Acenocoumarol.\nRisk: Monitor closely.", "source": "Etanercept + Acenocoumarol"}, {"id": "Etanercept_INT_Citric Acid", "text": "Interaction: Etanercept AND Citric Acid\nDetails: Etanercept may increase the anticoagulant activities of Citric Acid.\nRisk: Monitor closely.", "source": "Etanercept + Citric Acid"}, {"id": "Etanercept_INT_Ximelagatran", "text": "Interaction: Etanercept AND Ximelagatran\nDetails: Etanercept may increase the anticoagulant activities of Ximelagatran.\nRisk: Monitor closely.", "source": "Etanercept + Ximelagatran"}, {"id": "Etanercept_INT_Ancrod", "text": "Interaction: Etanercept AND Ancrod\nDetails: Etanercept may increase the anticoagulant activities of Ancrod.\nRisk: Monitor closely.", "source": "Etanercept + Ancrod"}, {"id": "Etanercept_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Etanercept AND Pentaerythritol Tetranitrate\nDetails: Etanercept may increase the anticoagulant activities of Pentaerythritol Tetranitrate.\nRisk: Monitor closely.", "source": "Etanercept + Pentaerythritol Tetranitrate"}, {"id": "Etanercept_INT_Rivaroxaban", "text": "Interaction: Etanercept AND Rivaroxaban\nDetails: Etanercept may increase the anticoagulant activities of Rivaroxaban.\nRisk: Monitor closely.", "source": "Etanercept + Rivaroxaban"}, {"id": "Etanercept_INT_Sulodexide", "text": "Interaction: Etanercept AND Sulodexide\nDetails: Etanercept may increase the anticoagulant activities of Sulodexide.\nRisk: Monitor closely.", "source": "Etanercept + Sulodexide"}, {"id": "Etanercept_INT_Idraparinux", "text": "Interaction: Etanercept AND Idraparinux\nDetails: Etanercept may increase the anticoagulant activities of Idraparinux.\nRisk: Monitor closely.", "source": "Etanercept + Idraparinux"}, {"id": "Etanercept_INT_Apixaban", "text": "Interaction: Etanercept AND Apixaban\nDetails: Etanercept may increase the anticoagulant activities of Apixaban.\nRisk: Monitor closely.", "source": "Etanercept + Apixaban"}, {"id": "Etanercept_INT_Otamixaban", "text": "Interaction: Etanercept AND Otamixaban\nDetails: Etanercept may increase the anticoagulant activities of Otamixaban.\nRisk: Monitor closely.", "source": "Etanercept + Otamixaban"}, {"id": "Etanercept_INT_Dabigatran etexilate", "text": "Interaction: Etanercept AND Dabigatran etexilate\nDetails: Etanercept may increase the anticoagulant activities of Dabigatran etexilate.\nRisk: Monitor closely.", "source": "Etanercept + Dabigatran etexilate"}, {"id": "Etanercept_INT_Danaparoid", "text": "Interaction: Etanercept AND Danaparoid\nDetails: Etanercept may increase the anticoagulant activities of Danaparoid.\nRisk: Monitor closely.", "source": "Etanercept + Danaparoid"}, {"id": "Etanercept_INT_Dalteparin", "text": "Interaction: Etanercept AND Dalteparin\nDetails: Etanercept may increase the anticoagulant activities of Dalteparin.\nRisk: Monitor closely.", "source": "Etanercept + Dalteparin"}, {"id": "Etanercept_INT_Ferulic acid", "text": "Interaction: Etanercept AND Ferulic acid\nDetails: Etanercept may increase the anticoagulant activities of Ferulic acid.\nRisk: Monitor closely.", "source": "Etanercept + Ferulic acid"}, {"id": "Etanercept_INT_Ethyl biscoumacetate", "text": "Interaction: Etanercept AND Ethyl biscoumacetate\nDetails: Etanercept may increase the anticoagulant activities of Ethyl biscoumacetate.\nRisk: Monitor closely.", "source": "Etanercept + Ethyl biscoumacetate"}, {"id": "Etanercept_INT_Nadroparin", "text": "Interaction: Etanercept AND Nadroparin\nDetails: Etanercept may increase the anticoagulant activities of Nadroparin.\nRisk: Monitor closely.", "source": "Etanercept + Nadroparin"}, {"id": "Etanercept_INT_Edoxaban", "text": "Interaction: Etanercept AND Edoxaban\nDetails: Etanercept may increase the anticoagulant activities of Edoxaban.\nRisk: Monitor closely.", "source": "Etanercept + Edoxaban"}, {"id": "Etanercept_INT_Dextran", "text": "Interaction: Etanercept AND Dextran\nDetails: Etanercept may increase the anticoagulant activities of Dextran.\nRisk: Monitor closely.", "source": "Etanercept + Dextran"}, {"id": "Etanercept_INT_Reviparin", "text": "Interaction: Etanercept AND Reviparin\nDetails: Etanercept may increase the anticoagulant activities of Reviparin.\nRisk: Monitor closely.", "source": "Etanercept + Reviparin"}, {"id": "Etanercept_INT_Certoparin", "text": "Interaction: Etanercept AND Certoparin\nDetails: Etanercept may increase the anticoagulant activities of Certoparin.\nRisk: Monitor closely.", "source": "Etanercept + Certoparin"}, {"id": "Etanercept_INT_Dextran 70", "text": "Interaction: Etanercept AND Dextran 70\nDetails: Etanercept may increase the anticoagulant activities of Dextran 70.\nRisk: Monitor closely.", "source": "Etanercept + Dextran 70"}, {"id": "Etanercept_INT_Desirudin", "text": "Interaction: Etanercept AND Desirudin\nDetails: Etanercept may increase the anticoagulant activities of Desirudin.\nRisk: Monitor closely.", "source": "Etanercept + Desirudin"}, {"id": "Etanercept_INT_Dextran 40", "text": "Interaction: Etanercept AND Dextran 40\nDetails: Etanercept may increase the anticoagulant activities of Dextran 40.\nRisk: Monitor closely.", "source": "Etanercept + Dextran 40"}, {"id": "Etanercept_INT_Dextran 75", "text": "Interaction: Etanercept AND Dextran 75\nDetails: Etanercept may increase the anticoagulant activities of Dextran 75.\nRisk: Monitor closely.", "source": "Etanercept + Dextran 75"}, {"id": "Etanercept_INT_Protocatechualdehyde", "text": "Interaction: Etanercept AND Protocatechualdehyde\nDetails: Etanercept may increase the anticoagulant activities of Protocatechualdehyde.\nRisk: Monitor closely.", "source": "Etanercept + Protocatechualdehyde"}, {"id": "Etanercept_INT_Protein C", "text": "Interaction: Etanercept AND Protein C\nDetails: Etanercept may increase the anticoagulant activities of Protein C.\nRisk: Monitor closely.", "source": "Etanercept + Protein C"}, {"id": "Etanercept_INT_Antithrombin III human", "text": "Interaction: Etanercept AND Antithrombin III human\nDetails: Etanercept may increase the anticoagulant activities of Antithrombin III human.\nRisk: Monitor closely.", "source": "Etanercept + Antithrombin III human"}, {"id": "Etanercept_INT_Fondaparinux", "text": "Interaction: Etanercept AND Fondaparinux\nDetails: Etanercept may increase the anticoagulant activities of Fondaparinux.\nRisk: Monitor closely.", "source": "Etanercept + Fondaparinux"}, {"id": "Etanercept_INT_Letaxaban", "text": "Interaction: Etanercept AND Letaxaban\nDetails: Etanercept may increase the anticoagulant activities of Letaxaban.\nRisk: Monitor closely.", "source": "Etanercept + Letaxaban"}, {"id": "Etanercept_INT_Darexaban", "text": "Interaction: Etanercept AND Darexaban\nDetails: Etanercept may increase the anticoagulant activities of Darexaban.\nRisk: Monitor closely.", "source": "Etanercept + Darexaban"}, {"id": "Etanercept_INT_Nafamostat", "text": "Interaction: Etanercept AND Nafamostat\nDetails: Etanercept may increase the anticoagulant activities of Nafamostat.\nRisk: Monitor closely.", "source": "Etanercept + Nafamostat"}, {"id": "Etanercept_INT_Gabexate", "text": "Interaction: Etanercept AND Gabexate\nDetails: Etanercept may increase the anticoagulant activities of Gabexate.\nRisk: Monitor closely.", "source": "Etanercept + Gabexate"}, {"id": "Etanercept_INT_Troxerutin", "text": "Interaction: Etanercept AND Troxerutin\nDetails: Etanercept may increase the anticoagulant activities of Troxerutin.\nRisk: Monitor closely.", "source": "Etanercept + Troxerutin"}, {"id": "Etanercept_INT_Fluindione", "text": "Interaction: Etanercept AND Fluindione\nDetails: Etanercept may increase the anticoagulant activities of Fluindione.\nRisk: Monitor closely.", "source": "Etanercept + Fluindione"}, {"id": "Etanercept_INT_Protein S human", "text": "Interaction: Etanercept AND Protein S human\nDetails: Etanercept may increase the anticoagulant activities of Protein S human.\nRisk: Monitor closely.", "source": "Etanercept + Protein S human"}, {"id": "Etanercept_INT_Melagatran", "text": "Interaction: Etanercept AND Melagatran\nDetails: Etanercept may increase the anticoagulant activities of Melagatran.\nRisk: Monitor closely.", "source": "Etanercept + Melagatran"}, {"id": "Etanercept_INT_Fluorometholone", "text": "Interaction: Etanercept AND Fluorometholone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Fluorometholone.\nRisk: Monitor closely.", "source": "Etanercept + Fluorometholone"}, {"id": "Etanercept_INT_Beclomethasone dipropionate", "text": "Interaction: Etanercept AND Beclomethasone dipropionate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Beclomethasone dipropionate.\nRisk: Monitor closely.", "source": "Etanercept + Beclomethasone dipropionate"}, {"id": "Etanercept_INT_Betamethasone", "text": "Interaction: Etanercept AND Betamethasone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Betamethasone.\nRisk: Monitor closely.", "source": "Etanercept + Betamethasone"}, {"id": "Etanercept_INT_Triamcinolone", "text": "Interaction: Etanercept AND Triamcinolone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Triamcinolone.\nRisk: Monitor closely.", "source": "Etanercept + Triamcinolone"}, {"id": "Etanercept_INT_Hydrocortisone", "text": "Interaction: Etanercept AND Hydrocortisone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Hydrocortisone.\nRisk: Monitor closely.", "source": "Etanercept + Hydrocortisone"}, {"id": "Etanercept_INT_Prednisolone", "text": "Interaction: Etanercept AND Prednisolone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Prednisolone.\nRisk: Monitor closely.", "source": "Etanercept + Prednisolone"}, {"id": "Etanercept_INT_Fluocinonide", "text": "Interaction: Etanercept AND Fluocinonide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocinonide.\nRisk: Monitor closely.", "source": "Etanercept + Fluocinonide"}, {"id": "Etanercept_INT_Budesonide", "text": "Interaction: Etanercept AND Budesonide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Budesonide.\nRisk: Monitor closely.", "source": "Etanercept + Budesonide"}, {"id": "Etanercept_INT_Dexamethasone", "text": "Interaction: Etanercept AND Dexamethasone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Dexamethasone.\nRisk: Monitor closely.", "source": "Etanercept + Dexamethasone"}, {"id": "Etanercept_INT_Ciclesonide", "text": "Interaction: Etanercept AND Ciclesonide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Ciclesonide.\nRisk: Monitor closely.", "source": "Etanercept + Ciclesonide"}, {"id": "Etanercept_INT_Tixocortol", "text": "Interaction: Etanercept AND Tixocortol\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Tixocortol.\nRisk: Monitor closely.", "source": "Etanercept + Tixocortol"}, {"id": "Etanercept_INT_Fluocinolone Acetonide", "text": "Interaction: Etanercept AND Fluocinolone Acetonide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocinolone Acetonide.\nRisk: Monitor closely.", "source": "Etanercept + Fluocinolone Acetonide"}, {"id": "Etanercept_INT_Diflorasone", "text": "Interaction: Etanercept AND Diflorasone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Diflorasone.\nRisk: Monitor closely.", "source": "Etanercept + Diflorasone"}, {"id": "Etanercept_INT_Alclometasone", "text": "Interaction: Etanercept AND Alclometasone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Alclometasone.\nRisk: Monitor closely.", "source": "Etanercept + Alclometasone"}, {"id": "Etanercept_INT_Amcinonide", "text": "Interaction: Etanercept AND Amcinonide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Amcinonide.\nRisk: Monitor closely.", "source": "Etanercept + Amcinonide"}, {"id": "Etanercept_INT_Desoximetasone", "text": "Interaction: Etanercept AND Desoximetasone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Desoximetasone.\nRisk: Monitor closely.", "source": "Etanercept + Desoximetasone"}, {"id": "Etanercept_INT_Clocortolone", "text": "Interaction: Etanercept AND Clocortolone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Clocortolone.\nRisk: Monitor closely.", "source": "Etanercept + Clocortolone"}, {"id": "Etanercept_INT_Flurandrenolide", "text": "Interaction: Etanercept AND Flurandrenolide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Flurandrenolide.\nRisk: Monitor closely.", "source": "Etanercept + Flurandrenolide"}, {"id": "Etanercept_INT_Rimexolone", "text": "Interaction: Etanercept AND Rimexolone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Rimexolone.\nRisk: Monitor closely.", "source": "Etanercept + Rimexolone"}, {"id": "Etanercept_INT_Methylprednisolone", "text": "Interaction: Etanercept AND Methylprednisolone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Methylprednisolone.\nRisk: Monitor closely.", "source": "Etanercept + Methylprednisolone"}, {"id": "Etanercept_INT_Clobetasol propionate", "text": "Interaction: Etanercept AND Clobetasol propionate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Clobetasol propionate.\nRisk: Monitor closely.", "source": "Etanercept + Clobetasol propionate"}, {"id": "Etanercept_INT_Prednicarbate", "text": "Interaction: Etanercept AND Prednicarbate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Prednicarbate.\nRisk: Monitor closely.", "source": "Etanercept + Prednicarbate"}, {"id": "Etanercept_INT_Cortisone acetate", "text": "Interaction: Etanercept AND Cortisone acetate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Cortisone acetate.\nRisk: Monitor closely.", "source": "Etanercept + Cortisone acetate"}, {"id": "Etanercept_INT_Flunisolide", "text": "Interaction: Etanercept AND Flunisolide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Flunisolide.\nRisk: Monitor closely.", "source": "Etanercept + Flunisolide"}, {"id": "Etanercept_INT_Fluticasone propionate", "text": "Interaction: Etanercept AND Fluticasone propionate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Fluticasone propionate.\nRisk: Monitor closely.", "source": "Etanercept + Fluticasone propionate"}, {"id": "Etanercept_INT_Mometasone", "text": "Interaction: Etanercept AND Mometasone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Mometasone.\nRisk: Monitor closely.", "source": "Etanercept + Mometasone"}, {"id": "Etanercept_INT_Loteprednol", "text": "Interaction: Etanercept AND Loteprednol\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Loteprednol.\nRisk: Monitor closely.", "source": "Etanercept + Loteprednol"}, {"id": "Etanercept_INT_Fluticasone furoate", "text": "Interaction: Etanercept AND Fluticasone furoate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Fluticasone furoate.\nRisk: Monitor closely.", "source": "Etanercept + Fluticasone furoate"}, {"id": "Etanercept_INT_Difluprednate", "text": "Interaction: Etanercept AND Difluprednate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Difluprednate.\nRisk: Monitor closely.", "source": "Etanercept + Difluprednate"}, {"id": "Etanercept_INT_Medrysone", "text": "Interaction: Etanercept AND Medrysone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Medrysone.\nRisk: Monitor closely.", "source": "Etanercept + Medrysone"}, {"id": "Etanercept_INT_Prednisone", "text": "Interaction: Etanercept AND Prednisone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Prednisone.\nRisk: Monitor closely.", "source": "Etanercept + Prednisone"}, {"id": "Etanercept_INT_Estrone", "text": "Interaction: Etanercept AND Estrone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Estrone.\nRisk: Monitor closely.", "source": "Etanercept + Estrone"}, {"id": "Etanercept_INT_Flumethasone", "text": "Interaction: Etanercept AND Flumethasone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Flumethasone.\nRisk: Monitor closely.", "source": "Etanercept + Flumethasone"}, {"id": "Etanercept_INT_Fludrocortisone", "text": "Interaction: Etanercept AND Fludrocortisone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Fludrocortisone.\nRisk: Monitor closely.", "source": "Etanercept + Fludrocortisone"}, {"id": "Etanercept_INT_Desoxycorticosterone Pivalate", "text": "Interaction: Etanercept AND Desoxycorticosterone Pivalate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Desoxycorticosterone Pivalate.\nRisk: Monitor closely.", "source": "Etanercept + Desoxycorticosterone Pivalate"}, {"id": "Etanercept_INT_Paramethasone", "text": "Interaction: Etanercept AND Paramethasone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Paramethasone.\nRisk: Monitor closely.", "source": "Etanercept + Paramethasone"}, {"id": "Etanercept_INT_19-norandrostenedione", "text": "Interaction: Etanercept AND 19-norandrostenedione\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with 19-norandrostenedione.\nRisk: Monitor closely.", "source": "Etanercept + 19-norandrostenedione"}, {"id": "Etanercept_INT_5-androstenedione", "text": "Interaction: Etanercept AND 5-androstenedione\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with 5-androstenedione.\nRisk: Monitor closely.", "source": "Etanercept + 5-androstenedione"}, {"id": "Etanercept_INT_Androstenedione", "text": "Interaction: Etanercept AND Androstenedione\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Androstenedione.\nRisk: Monitor closely.", "source": "Etanercept + Androstenedione"}, {"id": "Etanercept_INT_Prasterone", "text": "Interaction: Etanercept AND Prasterone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Prasterone.\nRisk: Monitor closely.", "source": "Etanercept + Prasterone"}, {"id": "Etanercept_INT_Equilin", "text": "Interaction: Etanercept AND Equilin\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Equilin.\nRisk: Monitor closely.", "source": "Etanercept + Equilin"}, {"id": "Etanercept_INT_Pregnenolone", "text": "Interaction: Etanercept AND Pregnenolone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Pregnenolone.\nRisk: Monitor closely.", "source": "Etanercept + Pregnenolone"}, {"id": "Etanercept_INT_Equilenin", "text": "Interaction: Etanercept AND Equilenin\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Equilenin.\nRisk: Monitor closely.", "source": "Etanercept + Equilenin"}, {"id": "Etanercept_INT_Estrone sulfate", "text": "Interaction: Etanercept AND Estrone sulfate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Estrone sulfate.\nRisk: Monitor closely.", "source": "Etanercept + Estrone sulfate"}, {"id": "Etanercept_INT_Aldosterone", "text": "Interaction: Etanercept AND Aldosterone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Aldosterone.\nRisk: Monitor closely.", "source": "Etanercept + Aldosterone"}, {"id": "Etanercept_INT_Corticosterone", "text": "Interaction: Etanercept AND Corticosterone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Corticosterone.\nRisk: Monitor closely.", "source": "Etanercept + Corticosterone"}, {"id": "Etanercept_INT_Oleoyl-estrone", "text": "Interaction: Etanercept AND Oleoyl-estrone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Oleoyl-estrone.\nRisk: Monitor closely.", "source": "Etanercept + Oleoyl-estrone"}, {"id": "Etanercept_INT_16-Bromoepiandrosterone", "text": "Interaction: Etanercept AND 16-Bromoepiandrosterone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with 16-Bromoepiandrosterone.\nRisk: Monitor closely.", "source": "Etanercept + 16-Bromoepiandrosterone"}, {"id": "Etanercept_INT_HE3286", "text": "Interaction: Etanercept AND HE3286\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with HE3286.\nRisk: Monitor closely.", "source": "Etanercept + HE3286"}, {"id": "Etanercept_INT_anecortave acetate", "text": "Interaction: Etanercept AND anecortave acetate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with anecortave acetate.\nRisk: Monitor closely.", "source": "Etanercept + anecortave acetate"}, {"id": "Etanercept_INT_ME-609", "text": "Interaction: Etanercept AND ME-609\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with ME-609.\nRisk: Monitor closely.", "source": "Etanercept + ME-609"}, {"id": "Etanercept_INT_NCX 1022", "text": "Interaction: Etanercept AND NCX 1022\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with NCX 1022.\nRisk: Monitor closely.", "source": "Etanercept + NCX 1022"}, {"id": "Etanercept_INT_Prasterone sulfate", "text": "Interaction: Etanercept AND Prasterone sulfate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Prasterone sulfate.\nRisk: Monitor closely.", "source": "Etanercept + Prasterone sulfate"}, {"id": "Etanercept_INT_Istaroxime", "text": "Interaction: Etanercept AND Istaroxime\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Istaroxime.\nRisk: Monitor closely.", "source": "Etanercept + Istaroxime"}, {"id": "Etanercept_INT_fluasterone", "text": "Interaction: Etanercept AND fluasterone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with fluasterone.\nRisk: Monitor closely.", "source": "Etanercept + fluasterone"}, {"id": "Etanercept_INT_Desoxycorticosterone acetate", "text": "Interaction: Etanercept AND Desoxycorticosterone acetate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Desoxycorticosterone acetate.\nRisk: Monitor closely.", "source": "Etanercept + Desoxycorticosterone acetate"}, {"id": "Etanercept_INT_Formestane", "text": "Interaction: Etanercept AND Formestane\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Formestane.\nRisk: Monitor closely.", "source": "Etanercept + Formestane"}, {"id": "Etanercept_INT_Fluprednidene", "text": "Interaction: Etanercept AND Fluprednidene\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Fluprednidene.\nRisk: Monitor closely.", "source": "Etanercept + Fluprednidene"}, {"id": "Etanercept_INT_Fluocortolone", "text": "Interaction: Etanercept AND Fluocortolone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Fluocortolone.\nRisk: Monitor closely.", "source": "Etanercept + Fluocortolone"}, {"id": "Etanercept_INT_Difluocortolone", "text": "Interaction: Etanercept AND Difluocortolone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Difluocortolone.\nRisk: Monitor closely.", "source": "Etanercept + Difluocortolone"}, {"id": "Etanercept_INT_Fluprednisolone", "text": "Interaction: Etanercept AND Fluprednisolone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Fluprednisolone.\nRisk: Monitor closely.", "source": "Etanercept + Fluprednisolone"}, {"id": "Etanercept_INT_Dexamethasone isonicotinate", "text": "Interaction: Etanercept AND Dexamethasone isonicotinate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Dexamethasone isonicotinate.\nRisk: Monitor closely.", "source": "Etanercept + Dexamethasone isonicotinate"}, {"id": "Etanercept_INT_Melengestrol", "text": "Interaction: Etanercept AND Melengestrol\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Melengestrol.\nRisk: Monitor closely.", "source": "Etanercept + Melengestrol"}, {"id": "Etanercept_INT_Clobetasol", "text": "Interaction: Etanercept AND Clobetasol\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Clobetasol.\nRisk: Monitor closely.", "source": "Etanercept + Clobetasol"}, {"id": "Etanercept_INT_Anecortave", "text": "Interaction: Etanercept AND Anecortave\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Anecortave.\nRisk: Monitor closely.", "source": "Etanercept + Anecortave"}, {"id": "Etanercept_INT_Atamestane", "text": "Interaction: Etanercept AND Atamestane\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Atamestane.\nRisk: Monitor closely.", "source": "Etanercept + Atamestane"}, {"id": "Etanercept_INT_Cortexolone 17\u03b1-propionate", "text": "Interaction: Etanercept AND Cortexolone 17\u03b1-propionate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Cortexolone 17\u03b1-propionate.\nRisk: Monitor closely.", "source": "Etanercept + Cortexolone 17\u03b1-propionate"}, {"id": "Etanercept_INT_Clobetasone", "text": "Interaction: Etanercept AND Clobetasone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Clobetasone.\nRisk: Monitor closely.", "source": "Etanercept + Clobetasone"}, {"id": "Etanercept_INT_Ulobetasol", "text": "Interaction: Etanercept AND Ulobetasol\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Ulobetasol.\nRisk: Monitor closely.", "source": "Etanercept + Ulobetasol"}, {"id": "Etanercept_INT_Desonide", "text": "Interaction: Etanercept AND Desonide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Desonide.\nRisk: Monitor closely.", "source": "Etanercept + Desonide"}, {"id": "Etanercept_INT_Halcinonide", "text": "Interaction: Etanercept AND Halcinonide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Halcinonide.\nRisk: Monitor closely.", "source": "Etanercept + Halcinonide"}, {"id": "Etanercept_INT_Deflazacort", "text": "Interaction: Etanercept AND Deflazacort\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Deflazacort.\nRisk: Monitor closely.", "source": "Etanercept + Deflazacort"}, {"id": "Etanercept_INT_Flurbiprofen", "text": "Interaction: Etanercept AND Flurbiprofen\nDetails: The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Flurbiprofen"}, {"id": "Etanercept_INT_Bromfenac", "text": "Interaction: Etanercept AND Bromfenac\nDetails: The risk or severity of adverse effects can be increased when Bromfenac is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Bromfenac"}, {"id": "Etanercept_INT_Nepafenac", "text": "Interaction: Etanercept AND Nepafenac\nDetails: The risk or severity of adverse effects can be increased when Nepafenac is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Nepafenac"}, {"id": "Etanercept_INT_Masoprocol", "text": "Interaction: Etanercept AND Masoprocol\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Masoprocol.\nRisk: Monitor closely.", "source": "Etanercept + Masoprocol"}, {"id": "Etanercept_INT_Adapalene", "text": "Interaction: Etanercept AND Adapalene\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Adapalene.\nRisk: Monitor closely.", "source": "Etanercept + Adapalene"}, {"id": "Etanercept_INT_Indomethacin", "text": "Interaction: Etanercept AND Indomethacin\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Indomethacin.\nRisk: Monitor closely.", "source": "Etanercept + Indomethacin"}, {"id": "Etanercept_INT_Nabumetone", "text": "Interaction: Etanercept AND Nabumetone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Nabumetone.\nRisk: Monitor closely.", "source": "Etanercept + Nabumetone"}, {"id": "Etanercept_INT_Tenoxicam", "text": "Interaction: Etanercept AND Tenoxicam\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Tenoxicam.\nRisk: Monitor closely.", "source": "Etanercept + Tenoxicam"}, {"id": "Etanercept_INT_Celecoxib", "text": "Interaction: Etanercept AND Celecoxib\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Celecoxib.\nRisk: Monitor closely.", "source": "Etanercept + Celecoxib"}, {"id": "Etanercept_INT_Tolmetin", "text": "Interaction: Etanercept AND Tolmetin\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Tolmetin.\nRisk: Monitor closely.", "source": "Etanercept + Tolmetin"}, {"id": "Etanercept_INT_Rofecoxib", "text": "Interaction: Etanercept AND Rofecoxib\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Rofecoxib.\nRisk: Monitor closely.", "source": "Etanercept + Rofecoxib"}, {"id": "Etanercept_INT_Piroxicam", "text": "Interaction: Etanercept AND Piroxicam\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Piroxicam.\nRisk: Monitor closely.", "source": "Etanercept + Piroxicam"}, {"id": "Etanercept_INT_Fenoprofen", "text": "Interaction: Etanercept AND Fenoprofen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Fenoprofen.\nRisk: Monitor closely.", "source": "Etanercept + Fenoprofen"}, {"id": "Etanercept_INT_Valdecoxib", "text": "Interaction: Etanercept AND Valdecoxib\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Valdecoxib.\nRisk: Monitor closely.", "source": "Etanercept + Valdecoxib"}, {"id": "Etanercept_INT_Sulindac", "text": "Interaction: Etanercept AND Sulindac\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Sulindac.\nRisk: Monitor closely.", "source": "Etanercept + Sulindac"}, {"id": "Etanercept_INT_Chloroquine", "text": "Interaction: Etanercept AND Chloroquine\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Chloroquine.\nRisk: Monitor closely.", "source": "Etanercept + Chloroquine"}, {"id": "Etanercept_INT_Mycophenolate mofetil", "text": "Interaction: Etanercept AND Mycophenolate mofetil\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Mycophenolate mofetil.\nRisk: Monitor closely.", "source": "Etanercept + Mycophenolate mofetil"}, {"id": "Etanercept_INT_Naftifine", "text": "Interaction: Etanercept AND Naftifine\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Naftifine.\nRisk: Monitor closely.", "source": "Etanercept + Naftifine"}, {"id": "Etanercept_INT_Zileuton", "text": "Interaction: Etanercept AND Zileuton\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Zileuton.\nRisk: Monitor closely.", "source": "Etanercept + Zileuton"}, {"id": "Etanercept_INT_Etodolac", "text": "Interaction: Etanercept AND Etodolac\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Etodolac.\nRisk: Monitor closely.", "source": "Etanercept + Etodolac"}, {"id": "Etanercept_INT_Olopatadine", "text": "Interaction: Etanercept AND Olopatadine\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Olopatadine.\nRisk: Monitor closely.", "source": "Etanercept + Olopatadine"}, {"id": "Etanercept_INT_Mefenamic acid", "text": "Interaction: Etanercept AND Mefenamic acid\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Mefenamic acid.\nRisk: Monitor closely.", "source": "Etanercept + Mefenamic acid"}, {"id": "Etanercept_INT_Naproxen", "text": "Interaction: Etanercept AND Naproxen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Naproxen.\nRisk: Monitor closely.", "source": "Etanercept + Naproxen"}, {"id": "Etanercept_INT_Sulfasalazine", "text": "Interaction: Etanercept AND Sulfasalazine\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Sulfasalazine.\nRisk: Monitor closely.", "source": "Etanercept + Sulfasalazine"}, {"id": "Etanercept_INT_Phenylbutazone", "text": "Interaction: Etanercept AND Phenylbutazone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Phenylbutazone.\nRisk: Monitor closely.", "source": "Etanercept + Phenylbutazone"}, {"id": "Etanercept_INT_Meloxicam", "text": "Interaction: Etanercept AND Meloxicam\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Meloxicam.\nRisk: Monitor closely.", "source": "Etanercept + Meloxicam"}, {"id": "Etanercept_INT_Carprofen", "text": "Interaction: Etanercept AND Carprofen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Carprofen.\nRisk: Monitor closely.", "source": "Etanercept + Carprofen"}, {"id": "Etanercept_INT_Diflunisal", "text": "Interaction: Etanercept AND Diflunisal\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Diflunisal.\nRisk: Monitor closely.", "source": "Etanercept + Diflunisal"}, {"id": "Etanercept_INT_Suprofen", "text": "Interaction: Etanercept AND Suprofen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Suprofen.\nRisk: Monitor closely.", "source": "Etanercept + Suprofen"}, {"id": "Etanercept_INT_Salicylic acid", "text": "Interaction: Etanercept AND Salicylic acid\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Salicylic acid.\nRisk: Monitor closely.", "source": "Etanercept + Salicylic acid"}, {"id": "Etanercept_INT_Meclofenamic acid", "text": "Interaction: Etanercept AND Meclofenamic acid\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Meclofenamic acid.\nRisk: Monitor closely.", "source": "Etanercept + Meclofenamic acid"}, {"id": "Etanercept_INT_Acetylsalicylic acid", "text": "Interaction: Etanercept AND Acetylsalicylic acid\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Acetylsalicylic acid.\nRisk: Monitor closely.", "source": "Etanercept + Acetylsalicylic acid"}, {"id": "Etanercept_INT_Azelastine", "text": "Interaction: Etanercept AND Azelastine\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Azelastine.\nRisk: Monitor closely.", "source": "Etanercept + Azelastine"}, {"id": "Etanercept_INT_Oxaprozin", "text": "Interaction: Etanercept AND Oxaprozin\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Oxaprozin.\nRisk: Monitor closely.", "source": "Etanercept + Oxaprozin"}, {"id": "Etanercept_INT_Ketoprofen", "text": "Interaction: Etanercept AND Ketoprofen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Ketoprofen.\nRisk: Monitor closely.", "source": "Etanercept + Ketoprofen"}, {"id": "Etanercept_INT_Mycophenolic acid", "text": "Interaction: Etanercept AND Mycophenolic acid\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Mycophenolic acid.\nRisk: Monitor closely.", "source": "Etanercept + Mycophenolic acid"}, {"id": "Etanercept_INT_Ibuprofen", "text": "Interaction: Etanercept AND Ibuprofen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Ibuprofen.\nRisk: Monitor closely.", "source": "Etanercept + Ibuprofen"}, {"id": "Etanercept_INT_Lumiracoxib", "text": "Interaction: Etanercept AND Lumiracoxib\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Lumiracoxib.\nRisk: Monitor closely.", "source": "Etanercept + Lumiracoxib"}, {"id": "Etanercept_INT_Magnesium salicylate", "text": "Interaction: Etanercept AND Magnesium salicylate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Magnesium salicylate.\nRisk: Monitor closely.", "source": "Etanercept + Magnesium salicylate"}, {"id": "Etanercept_INT_Salsalate", "text": "Interaction: Etanercept AND Salsalate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Salsalate.\nRisk: Monitor closely.", "source": "Etanercept + Salsalate"}, {"id": "Etanercept_INT_Choline magnesium trisalicylate", "text": "Interaction: Etanercept AND Choline magnesium trisalicylate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Choline magnesium trisalicylate.\nRisk: Monitor closely.", "source": "Etanercept + Choline magnesium trisalicylate"}, {"id": "Etanercept_INT_Antipyrine", "text": "Interaction: Etanercept AND Antipyrine\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Antipyrine.\nRisk: Monitor closely.", "source": "Etanercept + Antipyrine"}, {"id": "Etanercept_INT_Tiaprofenic acid", "text": "Interaction: Etanercept AND Tiaprofenic acid\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Tiaprofenic acid.\nRisk: Monitor closely.", "source": "Etanercept + Tiaprofenic acid"}, {"id": "Etanercept_INT_Etoricoxib", "text": "Interaction: Etanercept AND Etoricoxib\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Etoricoxib.\nRisk: Monitor closely.", "source": "Etanercept + Etoricoxib"}, {"id": "Etanercept_INT_Castanospermine", "text": "Interaction: Etanercept AND Castanospermine\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Castanospermine.\nRisk: Monitor closely.", "source": "Etanercept + Castanospermine"}, {"id": "Etanercept_INT_Resveratrol", "text": "Interaction: Etanercept AND Resveratrol\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Resveratrol.\nRisk: Monitor closely.", "source": "Etanercept + Resveratrol"}, {"id": "Etanercept_INT_Oxyphenbutazone", "text": "Interaction: Etanercept AND Oxyphenbutazone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Oxyphenbutazone.\nRisk: Monitor closely.", "source": "Etanercept + Oxyphenbutazone"}, {"id": "Etanercept_INT_Niflumic Acid", "text": "Interaction: Etanercept AND Niflumic Acid\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Niflumic Acid.\nRisk: Monitor closely.", "source": "Etanercept + Niflumic Acid"}, {"id": "Etanercept_INT_Nimesulide", "text": "Interaction: Etanercept AND Nimesulide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Nimesulide.\nRisk: Monitor closely.", "source": "Etanercept + Nimesulide"}, {"id": "Etanercept_INT_Benoxaprofen", "text": "Interaction: Etanercept AND Benoxaprofen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Benoxaprofen.\nRisk: Monitor closely.", "source": "Etanercept + Benoxaprofen"}, {"id": "Etanercept_INT_Metamizole", "text": "Interaction: Etanercept AND Metamizole\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Metamizole.\nRisk: Monitor closely.", "source": "Etanercept + Metamizole"}, {"id": "Etanercept_INT_Zomepirac", "text": "Interaction: Etanercept AND Zomepirac\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Zomepirac.\nRisk: Monitor closely.", "source": "Etanercept + Zomepirac"}, {"id": "Etanercept_INT_Pirfenidone", "text": "Interaction: Etanercept AND Pirfenidone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Pirfenidone.\nRisk: Monitor closely.", "source": "Etanercept + Pirfenidone"}, {"id": "Etanercept_INT_SRT501", "text": "Interaction: Etanercept AND SRT501\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with SRT501.\nRisk: Monitor closely.", "source": "Etanercept + SRT501"}, {"id": "Etanercept_INT_PTC299", "text": "Interaction: Etanercept AND PTC299\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with PTC299.\nRisk: Monitor closely.", "source": "Etanercept + PTC299"}, {"id": "Etanercept_INT_Tarenflurbil", "text": "Interaction: Etanercept AND Tarenflurbil\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Tarenflurbil.\nRisk: Monitor closely.", "source": "Etanercept + Tarenflurbil"}, {"id": "Etanercept_INT_Apremilast", "text": "Interaction: Etanercept AND Apremilast\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Apremilast.\nRisk: Monitor closely.", "source": "Etanercept + Apremilast"}, {"id": "Etanercept_INT_Andrographolide", "text": "Interaction: Etanercept AND Andrographolide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Andrographolide.\nRisk: Monitor closely.", "source": "Etanercept + Andrographolide"}, {"id": "Etanercept_INT_Icatibant", "text": "Interaction: Etanercept AND Icatibant\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Icatibant.\nRisk: Monitor closely.", "source": "Etanercept + Icatibant"}, {"id": "Etanercept_INT_exisulind", "text": "Interaction: Etanercept AND exisulind\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with exisulind.\nRisk: Monitor closely.", "source": "Etanercept + exisulind"}, {"id": "Etanercept_INT_Lornoxicam", "text": "Interaction: Etanercept AND Lornoxicam\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Lornoxicam.\nRisk: Monitor closely.", "source": "Etanercept + Lornoxicam"}, {"id": "Etanercept_INT_Aceclofenac", "text": "Interaction: Etanercept AND Aceclofenac\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Aceclofenac.\nRisk: Monitor closely.", "source": "Etanercept + Aceclofenac"}, {"id": "Etanercept_INT_Zaltoprofen", "text": "Interaction: Etanercept AND Zaltoprofen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Zaltoprofen.\nRisk: Monitor closely.", "source": "Etanercept + Zaltoprofen"}, {"id": "Etanercept_INT_Seratrodast", "text": "Interaction: Etanercept AND Seratrodast\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Seratrodast.\nRisk: Monitor closely.", "source": "Etanercept + Seratrodast"}, {"id": "Etanercept_INT_Azapropazone", "text": "Interaction: Etanercept AND Azapropazone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Azapropazone.\nRisk: Monitor closely.", "source": "Etanercept + Azapropazone"}, {"id": "Etanercept_INT_Felbinac", "text": "Interaction: Etanercept AND Felbinac\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Felbinac.\nRisk: Monitor closely.", "source": "Etanercept + Felbinac"}, {"id": "Etanercept_INT_Tranilast", "text": "Interaction: Etanercept AND Tranilast\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Tranilast.\nRisk: Monitor closely.", "source": "Etanercept + Tranilast"}, {"id": "Etanercept_INT_Parecoxib", "text": "Interaction: Etanercept AND Parecoxib\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Parecoxib.\nRisk: Monitor closely.", "source": "Etanercept + Parecoxib"}, {"id": "Etanercept_INT_Salicylamide", "text": "Interaction: Etanercept AND Salicylamide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Salicylamide.\nRisk: Monitor closely.", "source": "Etanercept + Salicylamide"}, {"id": "Etanercept_INT_Teriflunomide", "text": "Interaction: Etanercept AND Teriflunomide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Teriflunomide.\nRisk: Monitor closely.", "source": "Etanercept + Teriflunomide"}, {"id": "Etanercept_INT_D-Limonene", "text": "Interaction: Etanercept AND D-Limonene\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with D-Limonene.\nRisk: Monitor closely.", "source": "Etanercept + D-Limonene"}, {"id": "Etanercept_INT_Kebuzone", "text": "Interaction: Etanercept AND Kebuzone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Kebuzone.\nRisk: Monitor closely.", "source": "Etanercept + Kebuzone"}, {"id": "Etanercept_INT_Isoxicam", "text": "Interaction: Etanercept AND Isoxicam\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Isoxicam.\nRisk: Monitor closely.", "source": "Etanercept + Isoxicam"}, {"id": "Etanercept_INT_Indoprofen", "text": "Interaction: Etanercept AND Indoprofen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Indoprofen.\nRisk: Monitor closely.", "source": "Etanercept + Indoprofen"}, {"id": "Etanercept_INT_Ibuproxam", "text": "Interaction: Etanercept AND Ibuproxam\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Ibuproxam.\nRisk: Monitor closely.", "source": "Etanercept + Ibuproxam"}, {"id": "Etanercept_INT_Fenbufen", "text": "Interaction: Etanercept AND Fenbufen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Fenbufen.\nRisk: Monitor closely.", "source": "Etanercept + Fenbufen"}, {"id": "Etanercept_INT_Etofenamate", "text": "Interaction: Etanercept AND Etofenamate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Etofenamate.\nRisk: Monitor closely.", "source": "Etanercept + Etofenamate"}, {"id": "Etanercept_INT_Epirizole", "text": "Interaction: Etanercept AND Epirizole\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Epirizole.\nRisk: Monitor closely.", "source": "Etanercept + Epirizole"}, {"id": "Etanercept_INT_Loxoprofen", "text": "Interaction: Etanercept AND Loxoprofen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Loxoprofen.\nRisk: Monitor closely.", "source": "Etanercept + Loxoprofen"}, {"id": "Etanercept_INT_Droxicam", "text": "Interaction: Etanercept AND Droxicam\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Droxicam.\nRisk: Monitor closely.", "source": "Etanercept + Droxicam"}, {"id": "Etanercept_INT_Tolfenamic Acid", "text": "Interaction: Etanercept AND Tolfenamic Acid\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Tolfenamic Acid.\nRisk: Monitor closely.", "source": "Etanercept + Tolfenamic Acid"}, {"id": "Etanercept_INT_Clonixin", "text": "Interaction: Etanercept AND Clonixin\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Clonixin.\nRisk: Monitor closely.", "source": "Etanercept + Clonixin"}, {"id": "Etanercept_INT_Propacetamol", "text": "Interaction: Etanercept AND Propacetamol\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Propacetamol.\nRisk: Monitor closely.", "source": "Etanercept + Propacetamol"}, {"id": "Etanercept_INT_Evening primrose oil", "text": "Interaction: Etanercept AND Evening primrose oil\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Evening primrose oil.\nRisk: Monitor closely.", "source": "Etanercept + Evening primrose oil"}, {"id": "Etanercept_INT_Orgotein", "text": "Interaction: Etanercept AND Orgotein\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Orgotein.\nRisk: Monitor closely.", "source": "Etanercept + Orgotein"}, {"id": "Etanercept_INT_Tepoxalin", "text": "Interaction: Etanercept AND Tepoxalin\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Tepoxalin.\nRisk: Monitor closely.", "source": "Etanercept + Tepoxalin"}, {"id": "Etanercept_INT_Flunixin", "text": "Interaction: Etanercept AND Flunixin\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Flunixin.\nRisk: Monitor closely.", "source": "Etanercept + Flunixin"}, {"id": "Etanercept_INT_Curcumin", "text": "Interaction: Etanercept AND Curcumin\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Curcumin.\nRisk: Monitor closely.", "source": "Etanercept + Curcumin"}, {"id": "Etanercept_INT_E-6201", "text": "Interaction: Etanercept AND E-6201\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with E-6201.\nRisk: Monitor closely.", "source": "Etanercept + E-6201"}, {"id": "Etanercept_INT_Anisodamine", "text": "Interaction: Etanercept AND Anisodamine\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Anisodamine.\nRisk: Monitor closely.", "source": "Etanercept + Anisodamine"}, {"id": "Etanercept_INT_Duvelisib", "text": "Interaction: Etanercept AND Duvelisib\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Duvelisib.\nRisk: Monitor closely.", "source": "Etanercept + Duvelisib"}, {"id": "Etanercept_INT_Triptolide", "text": "Interaction: Etanercept AND Triptolide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Triptolide.\nRisk: Monitor closely.", "source": "Etanercept + Triptolide"}, {"id": "Etanercept_INT_Semapimod", "text": "Interaction: Etanercept AND Semapimod\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Semapimod.\nRisk: Monitor closely.", "source": "Etanercept + Semapimod"}, {"id": "Etanercept_INT_Bucillamine", "text": "Interaction: Etanercept AND Bucillamine\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Bucillamine.\nRisk: Monitor closely.", "source": "Etanercept + Bucillamine"}, {"id": "Etanercept_INT_Lisofylline", "text": "Interaction: Etanercept AND Lisofylline\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Lisofylline.\nRisk: Monitor closely.", "source": "Etanercept + Lisofylline"}, {"id": "Etanercept_INT_Nitroaspirin", "text": "Interaction: Etanercept AND Nitroaspirin\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Nitroaspirin.\nRisk: Monitor closely.", "source": "Etanercept + Nitroaspirin"}, {"id": "Etanercept_INT_Indobufen", "text": "Interaction: Etanercept AND Indobufen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Indobufen.\nRisk: Monitor closely.", "source": "Etanercept + Indobufen"}, {"id": "Etanercept_INT_Mizoribine", "text": "Interaction: Etanercept AND Mizoribine\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Mizoribine.\nRisk: Monitor closely.", "source": "Etanercept + Mizoribine"}, {"id": "Etanercept_INT_Apocynin", "text": "Interaction: Etanercept AND Apocynin\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Apocynin.\nRisk: Monitor closely.", "source": "Etanercept + Apocynin"}, {"id": "Etanercept_INT_Higenamine", "text": "Interaction: Etanercept AND Higenamine\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Higenamine.\nRisk: Monitor closely.", "source": "Etanercept + Higenamine"}, {"id": "Etanercept_INT_Tinoridine", "text": "Interaction: Etanercept AND Tinoridine\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Tinoridine.\nRisk: Monitor closely.", "source": "Etanercept + Tinoridine"}, {"id": "Etanercept_INT_Parthenolide", "text": "Interaction: Etanercept AND Parthenolide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Parthenolide.\nRisk: Monitor closely.", "source": "Etanercept + Parthenolide"}, {"id": "Etanercept_INT_Serrapeptase", "text": "Interaction: Etanercept AND Serrapeptase\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Serrapeptase.\nRisk: Monitor closely.", "source": "Etanercept + Serrapeptase"}, {"id": "Etanercept_INT_Alclofenac", "text": "Interaction: Etanercept AND Alclofenac\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Alclofenac.\nRisk: Monitor closely.", "source": "Etanercept + Alclofenac"}, {"id": "Etanercept_INT_Fentiazac", "text": "Interaction: Etanercept AND Fentiazac\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Fentiazac.\nRisk: Monitor closely.", "source": "Etanercept + Fentiazac"}, {"id": "Etanercept_INT_Tribenoside", "text": "Interaction: Etanercept AND Tribenoside\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Tribenoside.\nRisk: Monitor closely.", "source": "Etanercept + Tribenoside"}, {"id": "Etanercept_INT_Suxibuzone", "text": "Interaction: Etanercept AND Suxibuzone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Suxibuzone.\nRisk: Monitor closely.", "source": "Etanercept + Suxibuzone"}, {"id": "Etanercept_INT_Bumadizone", "text": "Interaction: Etanercept AND Bumadizone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Bumadizone.\nRisk: Monitor closely.", "source": "Etanercept + Bumadizone"}, {"id": "Etanercept_INT_Alminoprofen", "text": "Interaction: Etanercept AND Alminoprofen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Alminoprofen.\nRisk: Monitor closely.", "source": "Etanercept + Alminoprofen"}, {"id": "Etanercept_INT_Flunoxaprofen", "text": "Interaction: Etanercept AND Flunoxaprofen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Flunoxaprofen.\nRisk: Monitor closely.", "source": "Etanercept + Flunoxaprofen"}, {"id": "Etanercept_INT_Bufexamac", "text": "Interaction: Etanercept AND Bufexamac\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Bufexamac.\nRisk: Monitor closely.", "source": "Etanercept + Bufexamac"}, {"id": "Etanercept_INT_Feprazone", "text": "Interaction: Etanercept AND Feprazone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Feprazone.\nRisk: Monitor closely.", "source": "Etanercept + Feprazone"}, {"id": "Etanercept_INT_Difenpiramide", "text": "Interaction: Etanercept AND Difenpiramide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Difenpiramide.\nRisk: Monitor closely.", "source": "Etanercept + Difenpiramide"}, {"id": "Etanercept_INT_Nifenazone", "text": "Interaction: Etanercept AND Nifenazone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Nifenazone.\nRisk: Monitor closely.", "source": "Etanercept + Nifenazone"}, {"id": "Etanercept_INT_Lonazolac", "text": "Interaction: Etanercept AND Lonazolac\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Lonazolac.\nRisk: Monitor closely.", "source": "Etanercept + Lonazolac"}, {"id": "Etanercept_INT_Tenidap", "text": "Interaction: Etanercept AND Tenidap\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Tenidap.\nRisk: Monitor closely.", "source": "Etanercept + Tenidap"}, {"id": "Etanercept_INT_Bendazac", "text": "Interaction: Etanercept AND Bendazac\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Bendazac.\nRisk: Monitor closely.", "source": "Etanercept + Bendazac"}, {"id": "Etanercept_INT_Pranoprofen", "text": "Interaction: Etanercept AND Pranoprofen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Pranoprofen.\nRisk: Monitor closely.", "source": "Etanercept + Pranoprofen"}, {"id": "Etanercept_INT_Propyphenazone", "text": "Interaction: Etanercept AND Propyphenazone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Propyphenazone.\nRisk: Monitor closely.", "source": "Etanercept + Propyphenazone"}, {"id": "Etanercept_INT_Proglumetacin", "text": "Interaction: Etanercept AND Proglumetacin\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Proglumetacin.\nRisk: Monitor closely.", "source": "Etanercept + Proglumetacin"}, {"id": "Etanercept_INT_Guacetisal", "text": "Interaction: Etanercept AND Guacetisal\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Guacetisal.\nRisk: Monitor closely.", "source": "Etanercept + Guacetisal"}, {"id": "Etanercept_INT_Bevonium", "text": "Interaction: Etanercept AND Bevonium\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Bevonium.\nRisk: Monitor closely.", "source": "Etanercept + Bevonium"}, {"id": "Etanercept_INT_Ethenzamide", "text": "Interaction: Etanercept AND Ethenzamide\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Ethenzamide.\nRisk: Monitor closely.", "source": "Etanercept + Ethenzamide"}, {"id": "Etanercept_INT_Carbaspirin calcium", "text": "Interaction: Etanercept AND Carbaspirin calcium\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Carbaspirin calcium.\nRisk: Monitor closely.", "source": "Etanercept + Carbaspirin calcium"}, {"id": "Etanercept_INT_Mofebutazone", "text": "Interaction: Etanercept AND Mofebutazone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Mofebutazone.\nRisk: Monitor closely.", "source": "Etanercept + Mofebutazone"}, {"id": "Etanercept_INT_Proquazone", "text": "Interaction: Etanercept AND Proquazone\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Proquazone.\nRisk: Monitor closely.", "source": "Etanercept + Proquazone"}, {"id": "Etanercept_INT_Benorilate", "text": "Interaction: Etanercept AND Benorilate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Benorilate.\nRisk: Monitor closely.", "source": "Etanercept + Benorilate"}, {"id": "Etanercept_INT_Pirprofen", "text": "Interaction: Etanercept AND Pirprofen\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Pirprofen.\nRisk: Monitor closely.", "source": "Etanercept + Pirprofen"}, {"id": "Etanercept_INT_Imidazole salicylate", "text": "Interaction: Etanercept AND Imidazole salicylate\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Imidazole salicylate.\nRisk: Monitor closely.", "source": "Etanercept + Imidazole salicylate"}, {"id": "Etanercept_INT_Benzydamine", "text": "Interaction: Etanercept AND Benzydamine\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Benzydamine.\nRisk: Monitor closely.", "source": "Etanercept + Benzydamine"}, {"id": "Etanercept_INT_Tacrolimus", "text": "Interaction: Etanercept AND Tacrolimus\nDetails: Etanercept may increase the nephrotoxic activities of Tacrolimus.\nRisk: Monitor closely.", "source": "Etanercept + Tacrolimus"}, {"id": "Etanercept_INT_Valsartan", "text": "Interaction: Etanercept AND Valsartan\nDetails: The risk or severity of adverse effects can be increased when Valsartan is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Valsartan"}, {"id": "Etanercept_INT_Olmesartan", "text": "Interaction: Etanercept AND Olmesartan\nDetails: The risk or severity of adverse effects can be increased when Olmesartan is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Olmesartan"}, {"id": "Etanercept_INT_Losartan", "text": "Interaction: Etanercept AND Losartan\nDetails: The risk or severity of adverse effects can be increased when Losartan is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Losartan"}, {"id": "Etanercept_INT_Candesartan cilexetil", "text": "Interaction: Etanercept AND Candesartan cilexetil\nDetails: The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Candesartan cilexetil"}, {"id": "Etanercept_INT_Eprosartan", "text": "Interaction: Etanercept AND Eprosartan\nDetails: The risk or severity of adverse effects can be increased when Eprosartan is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Eprosartan"}, {"id": "Etanercept_INT_Telmisartan", "text": "Interaction: Etanercept AND Telmisartan\nDetails: The risk or severity of adverse effects can be increased when Telmisartan is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Telmisartan"}, {"id": "Etanercept_INT_Irbesartan", "text": "Interaction: Etanercept AND Irbesartan\nDetails: The risk or severity of adverse effects can be increased when Irbesartan is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Irbesartan"}, {"id": "Etanercept_INT_Saprisartan", "text": "Interaction: Etanercept AND Saprisartan\nDetails: The risk or severity of adverse effects can be increased when Saprisartan is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Saprisartan"}, {"id": "Etanercept_INT_Tasosartan", "text": "Interaction: Etanercept AND Tasosartan\nDetails: The risk or severity of adverse effects can be increased when Tasosartan is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Tasosartan"}, {"id": "Etanercept_INT_Azilsartan medoxomil", "text": "Interaction: Etanercept AND Azilsartan medoxomil\nDetails: The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Azilsartan medoxomil"}, {"id": "Etanercept_INT_Candesartan", "text": "Interaction: Etanercept AND Candesartan\nDetails: The risk or severity of adverse effects can be increased when Candesartan is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Candesartan"}, {"id": "Etanercept_INT_Saralasin", "text": "Interaction: Etanercept AND Saralasin\nDetails: The risk or severity of adverse effects can be increased when Saralasin is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Saralasin"}, {"id": "Etanercept_INT_Sacubitril", "text": "Interaction: Etanercept AND Sacubitril\nDetails: The risk or severity of adverse effects can be increased when Sacubitril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Sacubitril"}, {"id": "Etanercept_INT_Forasartan", "text": "Interaction: Etanercept AND Forasartan\nDetails: The risk or severity of adverse effects can be increased when Forasartan is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Forasartan"}, {"id": "Etanercept_INT_Fimasartan", "text": "Interaction: Etanercept AND Fimasartan\nDetails: The risk or severity of adverse effects can be increased when Fimasartan is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Fimasartan"}, {"id": "Etanercept_INT_Ramipril", "text": "Interaction: Etanercept AND Ramipril\nDetails: The risk or severity of adverse effects can be increased when Ramipril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Ramipril"}, {"id": "Etanercept_INT_Fosinopril", "text": "Interaction: Etanercept AND Fosinopril\nDetails: The risk or severity of adverse effects can be increased when Fosinopril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Fosinopril"}, {"id": "Etanercept_INT_Trandolapril", "text": "Interaction: Etanercept AND Trandolapril\nDetails: The risk or severity of adverse effects can be increased when Trandolapril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Trandolapril"}, {"id": "Etanercept_INT_Benazepril", "text": "Interaction: Etanercept AND Benazepril\nDetails: The risk or severity of adverse effects can be increased when Benazepril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Benazepril"}, {"id": "Etanercept_INT_Enalapril", "text": "Interaction: Etanercept AND Enalapril\nDetails: The risk or severity of adverse effects can be increased when Enalapril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Enalapril"}, {"id": "Etanercept_INT_Moexipril", "text": "Interaction: Etanercept AND Moexipril\nDetails: The risk or severity of adverse effects can be increased when Moexipril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Moexipril"}, {"id": "Etanercept_INT_Lisinopril", "text": "Interaction: Etanercept AND Lisinopril\nDetails: The risk or severity of adverse effects can be increased when Lisinopril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Lisinopril"}, {"id": "Etanercept_INT_Perindopril", "text": "Interaction: Etanercept AND Perindopril\nDetails: The risk or severity of adverse effects can be increased when Perindopril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Perindopril"}, {"id": "Etanercept_INT_Quinapril", "text": "Interaction: Etanercept AND Quinapril\nDetails: The risk or severity of adverse effects can be increased when Quinapril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Quinapril"}, {"id": "Etanercept_INT_Captopril", "text": "Interaction: Etanercept AND Captopril\nDetails: The risk or severity of adverse effects can be increased when Captopril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Captopril"}, {"id": "Etanercept_INT_Cilazapril", "text": "Interaction: Etanercept AND Cilazapril\nDetails: The risk or severity of adverse effects can be increased when Cilazapril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Cilazapril"}, {"id": "Etanercept_INT_Spirapril", "text": "Interaction: Etanercept AND Spirapril\nDetails: The risk or severity of adverse effects can be increased when Spirapril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Spirapril"}, {"id": "Etanercept_INT_Enalaprilat", "text": "Interaction: Etanercept AND Enalaprilat\nDetails: The risk or severity of adverse effects can be increased when Enalaprilat is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Enalaprilat"}, {"id": "Etanercept_INT_Temocapril", "text": "Interaction: Etanercept AND Temocapril\nDetails: The risk or severity of adverse effects can be increased when Temocapril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Temocapril"}, {"id": "Etanercept_INT_Zofenopril", "text": "Interaction: Etanercept AND Zofenopril\nDetails: The risk or severity of adverse effects can be increased when Zofenopril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Zofenopril"}, {"id": "Etanercept_INT_Omapatrilat", "text": "Interaction: Etanercept AND Omapatrilat\nDetails: The risk or severity of adverse effects can be increased when Omapatrilat is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Omapatrilat"}, {"id": "Etanercept_INT_Imidapril", "text": "Interaction: Etanercept AND Imidapril\nDetails: The risk or severity of adverse effects can be increased when Imidapril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Imidapril"}, {"id": "Etanercept_INT_Delapril", "text": "Interaction: Etanercept AND Delapril\nDetails: The risk or severity of adverse effects can be increased when Delapril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Delapril"}, {"id": "Etanercept_INT_Rescinnamine", "text": "Interaction: Etanercept AND Rescinnamine\nDetails: The risk or severity of adverse effects can be increased when Rescinnamine is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Rescinnamine"}, {"id": "Etanercept_INT_Candoxatril", "text": "Interaction: Etanercept AND Candoxatril\nDetails: The risk or severity of adverse effects can be increased when Candoxatril is combined with Etanercept.\nRisk: Monitor closely.", "source": "Etanercept + Candoxatril"}, {"id": "Etanercept_INT_Triamterene", "text": "Interaction: Etanercept AND Triamterene\nDetails: Etanercept may decrease the antihypertensive activities of Triamterene.\nRisk: Monitor closely.", "source": "Etanercept + Triamterene"}, {"id": "Etanercept_INT_Amiloride", "text": "Interaction: Etanercept AND Amiloride\nDetails: Etanercept may decrease the antihypertensive activities of Amiloride.\nRisk: Monitor closely.", "source": "Etanercept + Amiloride"}, {"id": "Etanercept_INT_Spironolactone", "text": "Interaction: Etanercept AND Spironolactone\nDetails: Etanercept may decrease the antihypertensive activities of Spironolactone.\nRisk: Monitor closely.", "source": "Etanercept + Spironolactone"}, {"id": "Etanercept_INT_Esmolol", "text": "Interaction: Etanercept AND Esmolol\nDetails: Etanercept may decrease the antihypertensive activities of Esmolol.\nRisk: Monitor closely.", "source": "Etanercept + Esmolol"}, {"id": "Etanercept_INT_Betaxolol", "text": "Interaction: Etanercept AND Betaxolol\nDetails: Etanercept may decrease the antihypertensive activities of Betaxolol.\nRisk: Monitor closely.", "source": "Etanercept + Betaxolol"}, {"id": "Etanercept_INT_Metoprolol", "text": "Interaction: Etanercept AND Metoprolol\nDetails: Etanercept may decrease the antihypertensive activities of Metoprolol.\nRisk: Monitor closely.", "source": "Etanercept + Metoprolol"}, {"id": "Etanercept_INT_Atenolol", "text": "Interaction: Etanercept AND Atenolol\nDetails: Etanercept may decrease the antihypertensive activities of Atenolol.\nRisk: Monitor closely.", "source": "Etanercept + Atenolol"}, {"id": "Etanercept_INT_Timolol", "text": "Interaction: Etanercept AND Timolol\nDetails: Etanercept may decrease the antihypertensive activities of Timolol.\nRisk: Monitor closely.", "source": "Etanercept + Timolol"}, {"id": "Etanercept_INT_Carteolol", "text": "Interaction: Etanercept AND Carteolol\nDetails: Etanercept may decrease the antihypertensive activities of Carteolol.\nRisk: Monitor closely.", "source": "Etanercept + Carteolol"}, {"id": "Etanercept_INT_Propranolol", "text": "Interaction: Etanercept AND Propranolol\nDetails: Etanercept may decrease the antihypertensive activities of Propranolol.\nRisk: Monitor closely.", "source": "Etanercept + Propranolol"}, {"id": "Etanercept_INT_Labetalol", "text": "Interaction: Etanercept AND Labetalol\nDetails: Etanercept may decrease the antihypertensive activities of Labetalol.\nRisk: Monitor closely.", "source": "Etanercept + Labetalol"}, {"id": "Etanercept_INT_Bisoprolol", "text": "Interaction: Etanercept AND Bisoprolol\nDetails: Etanercept may decrease the antihypertensive activities of Bisoprolol.\nRisk: Monitor closely.", "source": "Etanercept + Bisoprolol"}, {"id": "Etanercept_INT_Pindolol", "text": "Interaction: Etanercept AND Pindolol\nDetails: Etanercept may decrease the antihypertensive activities of Pindolol.\nRisk: Monitor closely.", "source": "Etanercept + Pindolol"}, {"id": "Etanercept_INT_Carvedilol", "text": "Interaction: Etanercept AND Carvedilol\nDetails: Etanercept may decrease the antihypertensive activities of Carvedilol.\nRisk: Monitor closely.", "source": "Etanercept + Carvedilol"}, {"id": "Etanercept_INT_Acebutolol", "text": "Interaction: Etanercept AND Acebutolol\nDetails: Etanercept may decrease the antihypertensive activities of Acebutolol.\nRisk: Monitor closely.", "source": "Etanercept + Acebutolol"}, {"id": "Etanercept_INT_Nadolol", "text": "Interaction: Etanercept AND Nadolol\nDetails: Etanercept may decrease the antihypertensive activities of Nadolol.\nRisk: Monitor closely.", "source": "Etanercept + Nadolol"}, {"id": "Etanercept_INT_Levobunolol", "text": "Interaction: Etanercept AND Levobunolol\nDetails: Etanercept may decrease the antihypertensive activities of Levobunolol.\nRisk: Monitor closely.", "source": "Etanercept + Levobunolol"}, {"id": "Etanercept_INT_Metipranolol", "text": "Interaction: Etanercept AND Metipranolol\nDetails: Etanercept may decrease the antihypertensive activities of Metipranolol.\nRisk: Monitor closely.", "source": "Etanercept + Metipranolol"}, {"id": "Etanercept_INT_Sotalol", "text": "Interaction: Etanercept AND Sotalol\nDetails: Etanercept may decrease the antihypertensive activities of Sotalol.\nRisk: Monitor closely.", "source": "Etanercept + Sotalol"}, {"id": "Etanercept_INT_Nebivolol", "text": "Interaction: Etanercept AND Nebivolol\nDetails: Etanercept may decrease the antihypertensive activities of Nebivolol.\nRisk: Monitor closely.", "source": "Etanercept + Nebivolol"}, {"id": "Etanercept_INT_Alprenolol", "text": "Interaction: Etanercept AND Alprenolol\nDetails: Etanercept may decrease the antihypertensive activities of Alprenolol.\nRisk: Monitor closely.", "source": "Etanercept + Alprenolol"}, {"id": "Etanercept_INT_Bevantolol", "text": "Interaction: Etanercept AND Bevantolol\nDetails: Etanercept may decrease the antihypertensive activities of Bevantolol.\nRisk: Monitor closely.", "source": "Etanercept + Bevantolol"}, {"id": "Etanercept_INT_Practolol", "text": "Interaction: Etanercept AND Practolol\nDetails: Etanercept may decrease the antihypertensive activities of Practolol.\nRisk: Monitor closely.", "source": "Etanercept + Practolol"}, {"id": "Etanercept_INT_Penbutolol", "text": "Interaction: Etanercept AND Penbutolol\nDetails: Etanercept may decrease the antihypertensive activities of Penbutolol.\nRisk: Monitor closely.", "source": "Etanercept + Penbutolol"}, {"id": "Etanercept_INT_Oxprenolol", "text": "Interaction: Etanercept AND Oxprenolol\nDetails: Etanercept may decrease the antihypertensive activities of Oxprenolol.\nRisk: Monitor closely.", "source": "Etanercept + Oxprenolol"}, {"id": "Etanercept_INT_Platelet Activating Factor", "text": "Interaction: Etanercept AND Platelet Activating Factor\nDetails: Etanercept may decrease the antihypertensive activities of Platelet Activating Factor.\nRisk: Monitor closely.", "source": "Etanercept + Platelet Activating Factor"}, {"id": "Etanercept_INT_Celiprolol", "text": "Interaction: Etanercept AND Celiprolol\nDetails: Etanercept may decrease the antihypertensive activities of Celiprolol.\nRisk: Monitor closely.", "source": "Etanercept + Celiprolol"}, {"id": "Etanercept_INT_Bufuralol", "text": "Interaction: Etanercept AND Bufuralol\nDetails: Etanercept may decrease the antihypertensive activities of Bufuralol.\nRisk: Monitor closely.", "source": "Etanercept + Bufuralol"}, {"id": "Etanercept_INT_Bopindolol", "text": "Interaction: Etanercept AND Bopindolol\nDetails: Etanercept may decrease the antihypertensive activities of Bopindolol.\nRisk: Monitor closely.", "source": "Etanercept + Bopindolol"}, {"id": "Etanercept_INT_Bupranolol", "text": "Interaction: Etanercept AND Bupranolol\nDetails: Etanercept may decrease the antihypertensive activities of Bupranolol.\nRisk: Monitor closely.", "source": "Etanercept + Bupranolol"}, {"id": "Etanercept_INT_Indenolol", "text": "Interaction: Etanercept AND Indenolol\nDetails: Etanercept may decrease the antihypertensive activities of Indenolol.\nRisk: Monitor closely.", "source": "Etanercept + Indenolol"}, {"id": "Etanercept_INT_Befunolol", "text": "Interaction: Etanercept AND Befunolol\nDetails: Etanercept may decrease the antihypertensive activities of Befunolol.\nRisk: Monitor closely.", "source": "Etanercept + Befunolol"}, {"id": "Etanercept_INT_Arotinolol", "text": "Interaction: Etanercept AND Arotinolol\nDetails: Etanercept may decrease the antihypertensive activities of Arotinolol.\nRisk: Monitor closely.", "source": "Etanercept + Arotinolol"}, {"id": "Etanercept_INT_Talinolol", "text": "Interaction: Etanercept AND Talinolol\nDetails: Etanercept may decrease the antihypertensive activities of Talinolol.\nRisk: Monitor closely.", "source": "Etanercept + Talinolol"}, {"id": "Etanercept_INT_Landiolol", "text": "Interaction: Etanercept AND Landiolol\nDetails: Etanercept may decrease the antihypertensive activities of Landiolol.\nRisk: Monitor closely.", "source": "Etanercept + Landiolol"}, {"id": "Etanercept_INT_Bucindolol", "text": "Interaction: Etanercept AND Bucindolol\nDetails: Etanercept may decrease the antihypertensive activities of Bucindolol.\nRisk: Monitor closely.", "source": "Etanercept + Bucindolol"}, {"id": "Etanercept_INT_Cloranolol", "text": "Interaction: Etanercept AND Cloranolol\nDetails: Etanercept may decrease the antihypertensive activities of Cloranolol.\nRisk: Monitor closely.", "source": "Etanercept + Cloranolol"}, {"id": "Etanercept_INT_Mepindolol", "text": "Interaction: Etanercept AND Mepindolol\nDetails: Etanercept may decrease the antihypertensive activities of Mepindolol.\nRisk: Monitor closely.", "source": "Etanercept + Mepindolol"}, {"id": "Etanercept_INT_Epanolol", "text": "Interaction: Etanercept AND Epanolol\nDetails: Etanercept may decrease the antihypertensive activities of Epanolol.\nRisk: Monitor closely.", "source": "Etanercept + Epanolol"}, {"id": "Etanercept_INT_Tertatolol", "text": "Interaction: Etanercept AND Tertatolol\nDetails: Etanercept may decrease the antihypertensive activities of Tertatolol.\nRisk: Monitor closely.", "source": "Etanercept + Tertatolol"}, {"id": "Bivalirudin_GEN", "text": "Drug: Bivalirudin\nDescription: ...", "source": "Bivalirudin"}, {"id": "Phylloquinone_GEN", "text": "Drug: Phylloquinone\nDescription: ...", "source": "Phylloquinone"}, {"id": "Calcium_GEN", "text": "Drug: Calcium\nDescription: ...", "source": "Calcium"}, {"id": "Bivalirudin_GEN", "text": "Drug: Bivalirudin\nDescription: Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnatio...", "source": "Bivalirudin"}, {"id": "Bivalirudin_CLIN", "text": "Drug: Bivalirudin\nMechanism: Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to c...\nToxicity: Based on a study by Gleason et al., the no-observed-adverse-effect level (NOAEL) for bivalirudin, administered to rats via intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h....", "source": "Bivalirudin"}, {"id": "Bivalirudin_INT_St. John's Wort", "text": "Interaction: Bivalirudin AND St. John's Wort\nDetails: The metabolism of Bivalirudin can be increased when combined with St. John&#39;s Wort.\nRisk: Monitor closely.", "source": "Bivalirudin + St. John's Wort"}, {"id": "Bivalirudin_INT_Alfuzosin", "text": "Interaction: Bivalirudin AND Alfuzosin\nDetails: The serum concentration of Alfuzosin can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Alfuzosin"}, {"id": "Bivalirudin_INT_Acemetacin", "text": "Interaction: Bivalirudin AND Acemetacin\nDetails: The risk or severity of bleeding can be increased when Bivalirudin is combined with Acemetacin.\nRisk: Monitor closely.", "source": "Bivalirudin + Acemetacin"}, {"id": "Bivalirudin_INT_Apixaban", "text": "Interaction: Bivalirudin AND Apixaban\nDetails: Apixaban may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Apixaban"}, {"id": "Bivalirudin_INT_Edoxaban", "text": "Interaction: Bivalirudin AND Edoxaban\nDetails: Edoxaban may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Edoxaban"}, {"id": "Bivalirudin_INT_Rivaroxaban", "text": "Interaction: Bivalirudin AND Rivaroxaban\nDetails: Bivalirudin may increase the anticoagulant activities of Rivaroxaban.\nRisk: Monitor closely.", "source": "Bivalirudin + Rivaroxaban"}, {"id": "Bivalirudin_INT_Lovastatin", "text": "Interaction: Bivalirudin AND Lovastatin\nDetails: The serum concentration of Lovastatin can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Lovastatin"}, {"id": "Bivalirudin_INT_Urokinase", "text": "Interaction: Bivalirudin AND Urokinase\nDetails: Urokinase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Urokinase"}, {"id": "Bivalirudin_INT_Vorapaxar", "text": "Interaction: Bivalirudin AND Vorapaxar\nDetails: The risk or severity of adverse effects can be increased when Vorapaxar is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Vorapaxar"}, {"id": "Bivalirudin_INT_Midazolam", "text": "Interaction: Bivalirudin AND Midazolam\nDetails: The serum concentration of Midazolam can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Midazolam"}, {"id": "Bivalirudin_INT_Simvastatin", "text": "Interaction: Bivalirudin AND Simvastatin\nDetails: The serum concentration of Simvastatin can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Simvastatin"}, {"id": "Bivalirudin_INT_Cabergoline", "text": "Interaction: Bivalirudin AND Cabergoline\nDetails: The serum concentration of Cabergoline can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Cabergoline"}, {"id": "Bivalirudin_INT_Bromocriptine", "text": "Interaction: Bivalirudin AND Bromocriptine\nDetails: The serum concentration of Bromocriptine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Bromocriptine"}, {"id": "Bivalirudin_INT_Methylergometrine", "text": "Interaction: Bivalirudin AND Methylergometrine\nDetails: The serum concentration of Methylergometrine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Methylergometrine"}, {"id": "Bivalirudin_INT_Dihydroergotamine", "text": "Interaction: Bivalirudin AND Dihydroergotamine\nDetails: The serum concentration of Dihydroergotamine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Dihydroergotamine"}, {"id": "Bivalirudin_INT_Ergotamine", "text": "Interaction: Bivalirudin AND Ergotamine\nDetails: The serum concentration of Ergotamine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ergotamine"}, {"id": "Bivalirudin_INT_Ergoloid mesylate", "text": "Interaction: Bivalirudin AND Ergoloid mesylate\nDetails: The serum concentration of Ergoloid mesylate can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ergoloid mesylate"}, {"id": "Bivalirudin_INT_Ergonovine", "text": "Interaction: Bivalirudin AND Ergonovine\nDetails: The serum concentration of Ergonovine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ergonovine"}, {"id": "Bivalirudin_INT_Triazolam", "text": "Interaction: Bivalirudin AND Triazolam\nDetails: The serum concentration of Triazolam can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Triazolam"}, {"id": "Bivalirudin_INT_Hemin", "text": "Interaction: Bivalirudin AND Hemin\nDetails: Hemin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Hemin"}, {"id": "Bivalirudin_INT_Ethinyl Estradiol", "text": "Interaction: Bivalirudin AND Ethinyl Estradiol\nDetails: The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ethinyl Estradiol"}, {"id": "Bivalirudin_INT_Mestranol", "text": "Interaction: Bivalirudin AND Mestranol\nDetails: The serum concentration of Mestranol can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Mestranol"}, {"id": "Bivalirudin_INT_Estradiol", "text": "Interaction: Bivalirudin AND Estradiol\nDetails: The serum concentration of Estradiol can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Estradiol"}, {"id": "Bivalirudin_INT_Estrone sulfate", "text": "Interaction: Bivalirudin AND Estrone sulfate\nDetails: The serum concentration of Estrone sulfate can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Estrone sulfate"}, {"id": "Bivalirudin_INT_Synthetic Conjugated Estrogens, A", "text": "Interaction: Bivalirudin AND Synthetic Conjugated Estrogens, A\nDetails: The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Synthetic Conjugated Estrogens, A"}, {"id": "Bivalirudin_INT_Estrogens, esterified", "text": "Interaction: Bivalirudin AND Estrogens, esterified\nDetails: The serum concentration of Estrogens, esterified can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Estrogens, esterified"}, {"id": "Bivalirudin_INT_Chlorotrianisene", "text": "Interaction: Bivalirudin AND Chlorotrianisene\nDetails: The serum concentration of Chlorotrianisene can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Chlorotrianisene"}, {"id": "Bivalirudin_INT_Conjugated estrogens", "text": "Interaction: Bivalirudin AND Conjugated estrogens\nDetails: The serum concentration of Conjugated estrogens can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Conjugated estrogens"}, {"id": "Bivalirudin_INT_Estramustine", "text": "Interaction: Bivalirudin AND Estramustine\nDetails: The serum concentration of Estramustine can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Estramustine"}, {"id": "Bivalirudin_INT_Dienestrol", "text": "Interaction: Bivalirudin AND Dienestrol\nDetails: The serum concentration of Dienestrol can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Dienestrol"}, {"id": "Bivalirudin_INT_Diethylstilbestrol", "text": "Interaction: Bivalirudin AND Diethylstilbestrol\nDetails: The serum concentration of Diethylstilbestrol can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Diethylstilbestrol"}, {"id": "Bivalirudin_INT_Hexestrol", "text": "Interaction: Bivalirudin AND Hexestrol\nDetails: The serum concentration of Hexestrol can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Hexestrol"}, {"id": "Bivalirudin_INT_Methallenestril", "text": "Interaction: Bivalirudin AND Methallenestril\nDetails: The serum concentration of Methallenestril can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Methallenestril"}, {"id": "Bivalirudin_INT_Cyclosporine", "text": "Interaction: Bivalirudin AND Cyclosporine\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Cyclosporine"}, {"id": "Bivalirudin_INT_Garlic", "text": "Interaction: Bivalirudin AND Garlic\nDetails: The serum concentration of Bivalirudin can be decreased when it is combined with Garlic.\nRisk: Monitor closely.", "source": "Bivalirudin + Garlic"}, {"id": "Bivalirudin_INT_Tacrolimus", "text": "Interaction: Bivalirudin AND Tacrolimus\nDetails: The metabolism of Tacrolimus can be decreased when combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tacrolimus"}, {"id": "Bivalirudin_INT_Pethidine", "text": "Interaction: Bivalirudin AND Pethidine\nDetails: The risk or severity of adverse effects can be increased when Bivalirudin is combined with Pethidine.\nRisk: Monitor closely.", "source": "Bivalirudin + Pethidine"}, {"id": "Bivalirudin_INT_Alprazolam", "text": "Interaction: Bivalirudin AND Alprazolam\nDetails: The serum concentration of Alprazolam can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Alprazolam"}, {"id": "Bivalirudin_INT_Atorvastatin", "text": "Interaction: Bivalirudin AND Atorvastatin\nDetails: The serum concentration of Atorvastatin can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Atorvastatin"}, {"id": "Bivalirudin_INT_Boceprevir", "text": "Interaction: Bivalirudin AND Boceprevir\nDetails: The serum concentration of Bivalirudin can be decreased when it is combined with Boceprevir.\nRisk: Monitor closely.", "source": "Bivalirudin + Boceprevir"}, {"id": "Bivalirudin_INT_Carbamazepine", "text": "Interaction: Bivalirudin AND Carbamazepine\nDetails: The metabolism of Bivalirudin can be increased when combined with Carbamazepine.\nRisk: Monitor closely.", "source": "Bivalirudin + Carbamazepine"}, {"id": "Bivalirudin_INT_Clarithromycin", "text": "Interaction: Bivalirudin AND Clarithromycin\nDetails: The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Clarithromycin"}, {"id": "Bivalirudin_INT_Delavirdine", "text": "Interaction: Bivalirudin AND Delavirdine\nDetails: The serum concentration of Delavirdine can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Delavirdine"}, {"id": "Bivalirudin_INT_Estrone", "text": "Interaction: Bivalirudin AND Estrone\nDetails: Estrone may decrease the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Estrone"}, {"id": "Bivalirudin_INT_Polyestradiol phosphate", "text": "Interaction: Bivalirudin AND Polyestradiol phosphate\nDetails: Polyestradiol phosphate may decrease the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Polyestradiol phosphate"}, {"id": "Bivalirudin_INT_Genistein", "text": "Interaction: Bivalirudin AND Genistein\nDetails: Genistein may decrease the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Genistein"}, {"id": "Bivalirudin_INT_Quinestrol", "text": "Interaction: Bivalirudin AND Quinestrol\nDetails: Quinestrol may decrease the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Quinestrol"}, {"id": "Bivalirudin_INT_Synthetic Conjugated Estrogens, B", "text": "Interaction: Bivalirudin AND Synthetic Conjugated Estrogens, B\nDetails: Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Synthetic Conjugated Estrogens, B"}, {"id": "Bivalirudin_INT_Zeranol", "text": "Interaction: Bivalirudin AND Zeranol\nDetails: Zeranol may decrease the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Zeranol"}, {"id": "Bivalirudin_INT_Equol", "text": "Interaction: Bivalirudin AND Equol\nDetails: Equol may decrease the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Equol"}, {"id": "Bivalirudin_INT_Secoisolariciresinol", "text": "Interaction: Bivalirudin AND Secoisolariciresinol\nDetails: Secoisolariciresinol may decrease the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Secoisolariciresinol"}, {"id": "Bivalirudin_INT_Daidzein", "text": "Interaction: Bivalirudin AND Daidzein\nDetails: Daidzein may decrease the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Daidzein"}, {"id": "Bivalirudin_INT_Epimestrol", "text": "Interaction: Bivalirudin AND Epimestrol\nDetails: Epimestrol may decrease the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Epimestrol"}, {"id": "Bivalirudin_INT_Estriol", "text": "Interaction: Bivalirudin AND Estriol\nDetails: Estriol may decrease the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Estriol"}, {"id": "Bivalirudin_INT_Promestriene", "text": "Interaction: Bivalirudin AND Promestriene\nDetails: Promestriene may decrease the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Promestriene"}, {"id": "Bivalirudin_INT_Moxestrol", "text": "Interaction: Bivalirudin AND Moxestrol\nDetails: Moxestrol may decrease the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Moxestrol"}, {"id": "Bivalirudin_INT_Omacetaxine mepesuccinate", "text": "Interaction: Bivalirudin AND Omacetaxine mepesuccinate\nDetails: The risk or severity of bleeding can be increased when Bivalirudin is combined with Omacetaxine mepesuccinate.\nRisk: Monitor closely.", "source": "Bivalirudin + Omacetaxine mepesuccinate"}, {"id": "Bivalirudin_INT_Nefazodone", "text": "Interaction: Bivalirudin AND Nefazodone\nDetails: The serum concentration of Nefazodone can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Nefazodone"}, {"id": "Bivalirudin_INT_Aprotinin", "text": "Interaction: Bivalirudin AND Aprotinin\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Aprotinin.\nRisk: Monitor closely.", "source": "Bivalirudin + Aprotinin"}, {"id": "Bivalirudin_INT_Allylestrenol", "text": "Interaction: Bivalirudin AND Allylestrenol\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Allylestrenol.\nRisk: Monitor closely.", "source": "Bivalirudin + Allylestrenol"}, {"id": "Bivalirudin_INT_Etonogestrel", "text": "Interaction: Bivalirudin AND Etonogestrel\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Etonogestrel.\nRisk: Monitor closely.", "source": "Bivalirudin + Etonogestrel"}, {"id": "Bivalirudin_INT_Medroxyprogesterone acetate", "text": "Interaction: Bivalirudin AND Medroxyprogesterone acetate\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Medroxyprogesterone acetate.\nRisk: Monitor closely.", "source": "Bivalirudin + Medroxyprogesterone acetate"}, {"id": "Bivalirudin_INT_Dienogest", "text": "Interaction: Bivalirudin AND Dienogest\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Dienogest.\nRisk: Monitor closely.", "source": "Bivalirudin + Dienogest"}, {"id": "Bivalirudin_INT_Progesterone", "text": "Interaction: Bivalirudin AND Progesterone\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Progesterone.\nRisk: Monitor closely.", "source": "Bivalirudin + Progesterone"}, {"id": "Bivalirudin_INT_Norethisterone", "text": "Interaction: Bivalirudin AND Norethisterone\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Norethisterone.\nRisk: Monitor closely.", "source": "Bivalirudin + Norethisterone"}, {"id": "Bivalirudin_INT_Hydroxyprogesterone caproate", "text": "Interaction: Bivalirudin AND Hydroxyprogesterone caproate\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Hydroxyprogesterone caproate.\nRisk: Monitor closely.", "source": "Bivalirudin + Hydroxyprogesterone caproate"}, {"id": "Bivalirudin_INT_Desogestrel", "text": "Interaction: Bivalirudin AND Desogestrel\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Desogestrel.\nRisk: Monitor closely.", "source": "Bivalirudin + Desogestrel"}, {"id": "Bivalirudin_INT_Dydrogesterone", "text": "Interaction: Bivalirudin AND Dydrogesterone\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Dydrogesterone.\nRisk: Monitor closely.", "source": "Bivalirudin + Dydrogesterone"}, {"id": "Bivalirudin_INT_Gestodene", "text": "Interaction: Bivalirudin AND Gestodene\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Gestodene.\nRisk: Monitor closely.", "source": "Bivalirudin + Gestodene"}, {"id": "Bivalirudin_INT_Altrenogest", "text": "Interaction: Bivalirudin AND Altrenogest\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Altrenogest.\nRisk: Monitor closely.", "source": "Bivalirudin + Altrenogest"}, {"id": "Bivalirudin_INT_Gestrinone", "text": "Interaction: Bivalirudin AND Gestrinone\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Gestrinone.\nRisk: Monitor closely.", "source": "Bivalirudin + Gestrinone"}, {"id": "Bivalirudin_INT_Medrogestone", "text": "Interaction: Bivalirudin AND Medrogestone\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Medrogestone.\nRisk: Monitor closely.", "source": "Bivalirudin + Medrogestone"}, {"id": "Bivalirudin_INT_Nomegestrol", "text": "Interaction: Bivalirudin AND Nomegestrol\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Nomegestrol.\nRisk: Monitor closely.", "source": "Bivalirudin + Nomegestrol"}, {"id": "Bivalirudin_INT_Gestonorone", "text": "Interaction: Bivalirudin AND Gestonorone\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Gestonorone.\nRisk: Monitor closely.", "source": "Bivalirudin + Gestonorone"}, {"id": "Bivalirudin_INT_Methylestrenolone", "text": "Interaction: Bivalirudin AND Methylestrenolone\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Methylestrenolone.\nRisk: Monitor closely.", "source": "Bivalirudin + Methylestrenolone"}, {"id": "Bivalirudin_INT_Norgestrienone", "text": "Interaction: Bivalirudin AND Norgestrienone\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Norgestrienone.\nRisk: Monitor closely.", "source": "Bivalirudin + Norgestrienone"}, {"id": "Bivalirudin_INT_Promegestone", "text": "Interaction: Bivalirudin AND Promegestone\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Promegestone.\nRisk: Monitor closely.", "source": "Bivalirudin + Promegestone"}, {"id": "Bivalirudin_INT_Demegestone", "text": "Interaction: Bivalirudin AND Demegestone\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Demegestone.\nRisk: Monitor closely.", "source": "Bivalirudin + Demegestone"}, {"id": "Bivalirudin_INT_Megestrol acetate", "text": "Interaction: Bivalirudin AND Megestrol acetate\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Megestrol acetate.\nRisk: Monitor closely.", "source": "Bivalirudin + Megestrol acetate"}, {"id": "Bivalirudin_INT_Levonorgestrel", "text": "Interaction: Bivalirudin AND Levonorgestrel\nDetails: The therapeutic efficacy of Bivalirudin can be decreased when used in combination with Levonorgestrel.\nRisk: Monitor closely.", "source": "Bivalirudin + Levonorgestrel"}, {"id": "Bivalirudin_INT_Riociguat", "text": "Interaction: Bivalirudin AND Riociguat\nDetails: The serum concentration of Riociguat can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Riociguat"}, {"id": "Bivalirudin_INT_Rosuvastatin", "text": "Interaction: Bivalirudin AND Rosuvastatin\nDetails: The serum concentration of Rosuvastatin can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Rosuvastatin"}, {"id": "Bivalirudin_INT_Sildenafil", "text": "Interaction: Bivalirudin AND Sildenafil\nDetails: The serum concentration of Sildenafil can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Sildenafil"}, {"id": "Bivalirudin_INT_Temsirolimus", "text": "Interaction: Bivalirudin AND Temsirolimus\nDetails: The risk or severity of adverse effects can be increased when Bivalirudin is combined with Temsirolimus.\nRisk: Monitor closely.", "source": "Bivalirudin + Temsirolimus"}, {"id": "Bivalirudin_INT_Diltiazem", "text": "Interaction: Bivalirudin AND Diltiazem\nDetails: The metabolism of Diltiazem can be decreased when combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Diltiazem"}, {"id": "Bivalirudin_INT_Verapamil", "text": "Interaction: Bivalirudin AND Verapamil\nDetails: The metabolism of Verapamil can be decreased when combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Verapamil"}, {"id": "Bivalirudin_INT_Pentosan Polysulfate", "text": "Interaction: Bivalirudin AND Pentosan Polysulfate\nDetails: Pentosan Polysulfate may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Pentosan Polysulfate"}, {"id": "Bivalirudin_INT_Amitriptyline", "text": "Interaction: Bivalirudin AND Amitriptyline\nDetails: The serum concentration of Amitriptyline can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Amitriptyline"}, {"id": "Bivalirudin_INT_Protriptyline", "text": "Interaction: Bivalirudin AND Protriptyline\nDetails: The serum concentration of Protriptyline can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Protriptyline"}, {"id": "Bivalirudin_INT_Imipramine", "text": "Interaction: Bivalirudin AND Imipramine\nDetails: The serum concentration of Imipramine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Imipramine"}, {"id": "Bivalirudin_INT_Nortriptyline", "text": "Interaction: Bivalirudin AND Nortriptyline\nDetails: The serum concentration of Nortriptyline can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Nortriptyline"}, {"id": "Bivalirudin_INT_Trimipramine", "text": "Interaction: Bivalirudin AND Trimipramine\nDetails: The serum concentration of Trimipramine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Trimipramine"}, {"id": "Bivalirudin_INT_Doxepin", "text": "Interaction: Bivalirudin AND Doxepin\nDetails: The serum concentration of Doxepin can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Doxepin"}, {"id": "Bivalirudin_INT_Desipramine", "text": "Interaction: Bivalirudin AND Desipramine\nDetails: The serum concentration of Desipramine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Desipramine"}, {"id": "Bivalirudin_INT_Clomipramine", "text": "Interaction: Bivalirudin AND Clomipramine\nDetails: The serum concentration of Clomipramine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Clomipramine"}, {"id": "Bivalirudin_INT_Mirtazapine", "text": "Interaction: Bivalirudin AND Mirtazapine\nDetails: The serum concentration of Mirtazapine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Mirtazapine"}, {"id": "Bivalirudin_INT_Cyclobenzaprine", "text": "Interaction: Bivalirudin AND Cyclobenzaprine\nDetails: The serum concentration of Cyclobenzaprine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Cyclobenzaprine"}, {"id": "Bivalirudin_INT_Amineptine", "text": "Interaction: Bivalirudin AND Amineptine\nDetails: The serum concentration of Amineptine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Amineptine"}, {"id": "Bivalirudin_INT_Esmirtazapine", "text": "Interaction: Bivalirudin AND Esmirtazapine\nDetails: The serum concentration of Esmirtazapine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Esmirtazapine"}, {"id": "Bivalirudin_INT_Dosulepin", "text": "Interaction: Bivalirudin AND Dosulepin\nDetails: The serum concentration of Dosulepin can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Dosulepin"}, {"id": "Bivalirudin_INT_Tianeptine", "text": "Interaction: Bivalirudin AND Tianeptine\nDetails: The serum concentration of Tianeptine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tianeptine"}, {"id": "Bivalirudin_INT_Opipramol", "text": "Interaction: Bivalirudin AND Opipramol\nDetails: The serum concentration of Opipramol can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Opipramol"}, {"id": "Bivalirudin_INT_Dibenzepin", "text": "Interaction: Bivalirudin AND Dibenzepin\nDetails: The serum concentration of Dibenzepin can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Dibenzepin"}, {"id": "Bivalirudin_INT_Lofepramine", "text": "Interaction: Bivalirudin AND Lofepramine\nDetails: The serum concentration of Lofepramine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Lofepramine"}, {"id": "Bivalirudin_INT_Iprindole", "text": "Interaction: Bivalirudin AND Iprindole\nDetails: The serum concentration of Iprindole can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Iprindole"}, {"id": "Bivalirudin_INT_Amoxapine", "text": "Interaction: Bivalirudin AND Amoxapine\nDetails: The serum concentration of Amoxapine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Amoxapine"}, {"id": "Bivalirudin_INT_Abacavir", "text": "Interaction: Bivalirudin AND Abacavir\nDetails: The serum concentration of Abacavir can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Abacavir"}, {"id": "Bivalirudin_INT_Cyclophosphamide", "text": "Interaction: Bivalirudin AND Cyclophosphamide\nDetails: The risk or severity of adverse effects can be increased when Bivalirudin is combined with Cyclophosphamide.\nRisk: Monitor closely.", "source": "Bivalirudin + Cyclophosphamide"}, {"id": "Bivalirudin_INT_Digoxin", "text": "Interaction: Bivalirudin AND Digoxin\nDetails: The serum concentration of Digoxin can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Digoxin"}, {"id": "Bivalirudin_INT_Enfuvirtide", "text": "Interaction: Bivalirudin AND Enfuvirtide\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Enfuvirtide"}, {"id": "Bivalirudin_INT_Etravirine", "text": "Interaction: Bivalirudin AND Etravirine\nDetails: The serum concentration of Etravirine can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Etravirine"}, {"id": "Bivalirudin_INT_Dasatinib", "text": "Interaction: Bivalirudin AND Dasatinib\nDetails: Dasatinib may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Dasatinib"}, {"id": "Bivalirudin_INT_Deferasirox", "text": "Interaction: Bivalirudin AND Deferasirox\nDetails: The risk or severity of adverse effects can be increased when Bivalirudin is combined with Deferasirox.\nRisk: Monitor closely.", "source": "Bivalirudin + Deferasirox"}, {"id": "Bivalirudin_INT_Deoxycholic Acid", "text": "Interaction: Bivalirudin AND Deoxycholic Acid\nDetails: The risk or severity of adverse effects can be increased when Bivalirudin is combined with Deoxycholic Acid.\nRisk: Monitor closely.", "source": "Bivalirudin + Deoxycholic Acid"}, {"id": "Bivalirudin_INT_Ibritumomab tiuxetan", "text": "Interaction: Bivalirudin AND Ibritumomab tiuxetan\nDetails: The risk or severity of adverse effects can be increased when Bivalirudin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Bivalirudin + Ibritumomab tiuxetan"}, {"id": "Bivalirudin_INT_Ibrutinib", "text": "Interaction: Bivalirudin AND Ibrutinib\nDetails: The risk or severity of adverse effects can be increased when Ibrutinib is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ibrutinib"}, {"id": "Bivalirudin_INT_Nintedanib", "text": "Interaction: Bivalirudin AND Nintedanib\nDetails: The risk or severity of adverse effects can be increased when Bivalirudin is combined with Nintedanib.\nRisk: Monitor closely.", "source": "Bivalirudin + Nintedanib"}, {"id": "Bivalirudin_INT_Obinutuzumab", "text": "Interaction: Bivalirudin AND Obinutuzumab\nDetails: The risk or severity of adverse effects can be increased when Bivalirudin is combined with Obinutuzumab.\nRisk: Monitor closely.", "source": "Bivalirudin + Obinutuzumab"}, {"id": "Bivalirudin_INT_Collagenase clostridium histolyticum", "text": "Interaction: Bivalirudin AND Collagenase clostridium histolyticum\nDetails: The risk or severity of adverse effects can be increased when Bivalirudin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Bivalirudin + Collagenase clostridium histolyticum"}, {"id": "Bivalirudin_INT_Sugammadex", "text": "Interaction: Bivalirudin AND Sugammadex\nDetails: Sugammadex may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Sugammadex"}, {"id": "Bivalirudin_INT_Limaprost", "text": "Interaction: Bivalirudin AND Limaprost\nDetails: The risk or severity of adverse effects can be increased when Limaprost is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Limaprost"}, {"id": "Bivalirudin_INT_Tibolone", "text": "Interaction: Bivalirudin AND Tibolone\nDetails: Tibolone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tibolone"}, {"id": "Bivalirudin_INT_Ketorolac", "text": "Interaction: Bivalirudin AND Ketorolac\nDetails: Ketorolac may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ketorolac"}, {"id": "Bivalirudin_INT_Diclofenac", "text": "Interaction: Bivalirudin AND Diclofenac\nDetails: Diclofenac may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Diclofenac"}, {"id": "Bivalirudin_INT_Flurbiprofen", "text": "Interaction: Bivalirudin AND Flurbiprofen\nDetails: Flurbiprofen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Flurbiprofen"}, {"id": "Bivalirudin_INT_Bromfenac", "text": "Interaction: Bivalirudin AND Bromfenac\nDetails: Bromfenac may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Bromfenac"}, {"id": "Bivalirudin_INT_Nepafenac", "text": "Interaction: Bivalirudin AND Nepafenac\nDetails: Nepafenac may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Nepafenac"}, {"id": "Bivalirudin_INT_Etanercept", "text": "Interaction: Bivalirudin AND Etanercept\nDetails: Etanercept may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Etanercept"}, {"id": "Bivalirudin_INT_Masoprocol", "text": "Interaction: Bivalirudin AND Masoprocol\nDetails: Masoprocol may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Masoprocol"}, {"id": "Bivalirudin_INT_Adapalene", "text": "Interaction: Bivalirudin AND Adapalene\nDetails: Adapalene may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Adapalene"}, {"id": "Bivalirudin_INT_Mesalazine", "text": "Interaction: Bivalirudin AND Mesalazine\nDetails: Mesalazine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Mesalazine"}, {"id": "Bivalirudin_INT_Indomethacin", "text": "Interaction: Bivalirudin AND Indomethacin\nDetails: Indomethacin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Indomethacin"}, {"id": "Bivalirudin_INT_Pimecrolimus", "text": "Interaction: Bivalirudin AND Pimecrolimus\nDetails: Pimecrolimus may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Pimecrolimus"}, {"id": "Bivalirudin_INT_Nabumetone", "text": "Interaction: Bivalirudin AND Nabumetone\nDetails: Nabumetone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Nabumetone"}, {"id": "Bivalirudin_INT_Tenoxicam", "text": "Interaction: Bivalirudin AND Tenoxicam\nDetails: Tenoxicam may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tenoxicam"}, {"id": "Bivalirudin_INT_Celecoxib", "text": "Interaction: Bivalirudin AND Celecoxib\nDetails: Celecoxib may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Celecoxib"}, {"id": "Bivalirudin_INT_Tolmetin", "text": "Interaction: Bivalirudin AND Tolmetin\nDetails: Tolmetin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tolmetin"}, {"id": "Bivalirudin_INT_Rofecoxib", "text": "Interaction: Bivalirudin AND Rofecoxib\nDetails: Rofecoxib may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Rofecoxib"}, {"id": "Bivalirudin_INT_Piroxicam", "text": "Interaction: Bivalirudin AND Piroxicam\nDetails: Piroxicam may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Piroxicam"}, {"id": "Bivalirudin_INT_Fenoprofen", "text": "Interaction: Bivalirudin AND Fenoprofen\nDetails: Fenoprofen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Fenoprofen"}, {"id": "Bivalirudin_INT_Valdecoxib", "text": "Interaction: Bivalirudin AND Valdecoxib\nDetails: Valdecoxib may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Valdecoxib"}, {"id": "Bivalirudin_INT_Sulindac", "text": "Interaction: Bivalirudin AND Sulindac\nDetails: Sulindac may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Sulindac"}, {"id": "Bivalirudin_INT_Chloroquine", "text": "Interaction: Bivalirudin AND Chloroquine\nDetails: Chloroquine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Chloroquine"}, {"id": "Bivalirudin_INT_Mycophenolate mofetil", "text": "Interaction: Bivalirudin AND Mycophenolate mofetil\nDetails: Mycophenolate mofetil may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Mycophenolate mofetil"}, {"id": "Bivalirudin_INT_Naftifine", "text": "Interaction: Bivalirudin AND Naftifine\nDetails: Naftifine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Naftifine"}, {"id": "Bivalirudin_INT_Zileuton", "text": "Interaction: Bivalirudin AND Zileuton\nDetails: Zileuton may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Zileuton"}, {"id": "Bivalirudin_INT_Etodolac", "text": "Interaction: Bivalirudin AND Etodolac\nDetails: Etodolac may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Etodolac"}, {"id": "Bivalirudin_INT_Olopatadine", "text": "Interaction: Bivalirudin AND Olopatadine\nDetails: Olopatadine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Olopatadine"}, {"id": "Bivalirudin_INT_Mefenamic acid", "text": "Interaction: Bivalirudin AND Mefenamic acid\nDetails: Mefenamic acid may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Mefenamic acid"}, {"id": "Bivalirudin_INT_Naproxen", "text": "Interaction: Bivalirudin AND Naproxen\nDetails: Naproxen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Naproxen"}, {"id": "Bivalirudin_INT_Sulfasalazine", "text": "Interaction: Bivalirudin AND Sulfasalazine\nDetails: Sulfasalazine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Sulfasalazine"}, {"id": "Bivalirudin_INT_Phenylbutazone", "text": "Interaction: Bivalirudin AND Phenylbutazone\nDetails: Phenylbutazone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Phenylbutazone"}, {"id": "Bivalirudin_INT_Meloxicam", "text": "Interaction: Bivalirudin AND Meloxicam\nDetails: Meloxicam may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Meloxicam"}, {"id": "Bivalirudin_INT_Carprofen", "text": "Interaction: Bivalirudin AND Carprofen\nDetails: Carprofen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Carprofen"}, {"id": "Bivalirudin_INT_Diflunisal", "text": "Interaction: Bivalirudin AND Diflunisal\nDetails: Diflunisal may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Diflunisal"}, {"id": "Bivalirudin_INT_Suprofen", "text": "Interaction: Bivalirudin AND Suprofen\nDetails: Suprofen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Suprofen"}, {"id": "Bivalirudin_INT_Salicylic acid", "text": "Interaction: Bivalirudin AND Salicylic acid\nDetails: Salicylic acid may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Salicylic acid"}, {"id": "Bivalirudin_INT_Meclofenamic acid", "text": "Interaction: Bivalirudin AND Meclofenamic acid\nDetails: Meclofenamic acid may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Meclofenamic acid"}, {"id": "Bivalirudin_INT_Acetylsalicylic acid", "text": "Interaction: Bivalirudin AND Acetylsalicylic acid\nDetails: Acetylsalicylic acid may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Acetylsalicylic acid"}, {"id": "Bivalirudin_INT_Azelastine", "text": "Interaction: Bivalirudin AND Azelastine\nDetails: Azelastine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Azelastine"}, {"id": "Bivalirudin_INT_Oxaprozin", "text": "Interaction: Bivalirudin AND Oxaprozin\nDetails: Oxaprozin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Oxaprozin"}, {"id": "Bivalirudin_INT_Ketoprofen", "text": "Interaction: Bivalirudin AND Ketoprofen\nDetails: Ketoprofen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ketoprofen"}, {"id": "Bivalirudin_INT_Balsalazide", "text": "Interaction: Bivalirudin AND Balsalazide\nDetails: Balsalazide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Balsalazide"}, {"id": "Bivalirudin_INT_Mycophenolic acid", "text": "Interaction: Bivalirudin AND Mycophenolic acid\nDetails: Mycophenolic acid may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Mycophenolic acid"}, {"id": "Bivalirudin_INT_Ibuprofen", "text": "Interaction: Bivalirudin AND Ibuprofen\nDetails: Ibuprofen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ibuprofen"}, {"id": "Bivalirudin_INT_Leflunomide", "text": "Interaction: Bivalirudin AND Leflunomide\nDetails: Leflunomide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Leflunomide"}, {"id": "Bivalirudin_INT_Olsalazine", "text": "Interaction: Bivalirudin AND Olsalazine\nDetails: Olsalazine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Olsalazine"}, {"id": "Bivalirudin_INT_Lumiracoxib", "text": "Interaction: Bivalirudin AND Lumiracoxib\nDetails: Lumiracoxib may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Lumiracoxib"}, {"id": "Bivalirudin_INT_Magnesium salicylate", "text": "Interaction: Bivalirudin AND Magnesium salicylate\nDetails: Magnesium salicylate may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Magnesium salicylate"}, {"id": "Bivalirudin_INT_Salsalate", "text": "Interaction: Bivalirudin AND Salsalate\nDetails: Salsalate may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Salsalate"}, {"id": "Bivalirudin_INT_Choline magnesium trisalicylate", "text": "Interaction: Bivalirudin AND Choline magnesium trisalicylate\nDetails: Choline magnesium trisalicylate may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Choline magnesium trisalicylate"}, {"id": "Bivalirudin_INT_Antipyrine", "text": "Interaction: Bivalirudin AND Antipyrine\nDetails: Antipyrine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Antipyrine"}, {"id": "Bivalirudin_INT_Tiaprofenic acid", "text": "Interaction: Bivalirudin AND Tiaprofenic acid\nDetails: Tiaprofenic acid may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tiaprofenic acid"}, {"id": "Bivalirudin_INT_Etoricoxib", "text": "Interaction: Bivalirudin AND Etoricoxib\nDetails: Etoricoxib may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Etoricoxib"}, {"id": "Bivalirudin_INT_Castanospermine", "text": "Interaction: Bivalirudin AND Castanospermine\nDetails: Castanospermine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Castanospermine"}, {"id": "Bivalirudin_INT_Resveratrol", "text": "Interaction: Bivalirudin AND Resveratrol\nDetails: Resveratrol may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Resveratrol"}, {"id": "Bivalirudin_INT_Oxyphenbutazone", "text": "Interaction: Bivalirudin AND Oxyphenbutazone\nDetails: Oxyphenbutazone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Oxyphenbutazone"}, {"id": "Bivalirudin_INT_Niflumic Acid", "text": "Interaction: Bivalirudin AND Niflumic Acid\nDetails: Niflumic Acid may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Niflumic Acid"}, {"id": "Bivalirudin_INT_Nimesulide", "text": "Interaction: Bivalirudin AND Nimesulide\nDetails: Nimesulide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Nimesulide"}, {"id": "Bivalirudin_INT_Benoxaprofen", "text": "Interaction: Bivalirudin AND Benoxaprofen\nDetails: Benoxaprofen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Benoxaprofen"}, {"id": "Bivalirudin_INT_Metamizole", "text": "Interaction: Bivalirudin AND Metamizole\nDetails: Metamizole may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Metamizole"}, {"id": "Bivalirudin_INT_Zomepirac", "text": "Interaction: Bivalirudin AND Zomepirac\nDetails: Zomepirac may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Zomepirac"}, {"id": "Bivalirudin_INT_Pirfenidone", "text": "Interaction: Bivalirudin AND Pirfenidone\nDetails: Pirfenidone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Pirfenidone"}, {"id": "Bivalirudin_INT_SRT501", "text": "Interaction: Bivalirudin AND SRT501\nDetails: SRT501 may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + SRT501"}, {"id": "Bivalirudin_INT_PTC299", "text": "Interaction: Bivalirudin AND PTC299\nDetails: PTC299 may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + PTC299"}, {"id": "Bivalirudin_INT_Tarenflurbil", "text": "Interaction: Bivalirudin AND Tarenflurbil\nDetails: Tarenflurbil may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tarenflurbil"}, {"id": "Bivalirudin_INT_Apremilast", "text": "Interaction: Bivalirudin AND Apremilast\nDetails: Apremilast may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Apremilast"}, {"id": "Bivalirudin_INT_Andrographolide", "text": "Interaction: Bivalirudin AND Andrographolide\nDetails: Andrographolide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Andrographolide"}, {"id": "Bivalirudin_INT_Icatibant", "text": "Interaction: Bivalirudin AND Icatibant\nDetails: Icatibant may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Icatibant"}, {"id": "Bivalirudin_INT_exisulind", "text": "Interaction: Bivalirudin AND exisulind\nDetails: exisulind may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + exisulind"}, {"id": "Bivalirudin_INT_Lornoxicam", "text": "Interaction: Bivalirudin AND Lornoxicam\nDetails: Lornoxicam may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Lornoxicam"}, {"id": "Bivalirudin_INT_Aceclofenac", "text": "Interaction: Bivalirudin AND Aceclofenac\nDetails: Aceclofenac may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Aceclofenac"}, {"id": "Bivalirudin_INT_Zaltoprofen", "text": "Interaction: Bivalirudin AND Zaltoprofen\nDetails: Zaltoprofen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Zaltoprofen"}, {"id": "Bivalirudin_INT_Seratrodast", "text": "Interaction: Bivalirudin AND Seratrodast\nDetails: Seratrodast may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Seratrodast"}, {"id": "Bivalirudin_INT_Azapropazone", "text": "Interaction: Bivalirudin AND Azapropazone\nDetails: Azapropazone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Azapropazone"}, {"id": "Bivalirudin_INT_Felbinac", "text": "Interaction: Bivalirudin AND Felbinac\nDetails: Felbinac may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Felbinac"}, {"id": "Bivalirudin_INT_Tranilast", "text": "Interaction: Bivalirudin AND Tranilast\nDetails: Tranilast may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tranilast"}, {"id": "Bivalirudin_INT_Ferulic acid", "text": "Interaction: Bivalirudin AND Ferulic acid\nDetails: Ferulic acid may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ferulic acid"}, {"id": "Bivalirudin_INT_Parecoxib", "text": "Interaction: Bivalirudin AND Parecoxib\nDetails: Parecoxib may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Parecoxib"}, {"id": "Bivalirudin_INT_Salicylamide", "text": "Interaction: Bivalirudin AND Salicylamide\nDetails: Salicylamide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Salicylamide"}, {"id": "Bivalirudin_INT_Teriflunomide", "text": "Interaction: Bivalirudin AND Teriflunomide\nDetails: Teriflunomide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Teriflunomide"}, {"id": "Bivalirudin_INT_D-Limonene", "text": "Interaction: Bivalirudin AND D-Limonene\nDetails: D-Limonene may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + D-Limonene"}, {"id": "Bivalirudin_INT_Kebuzone", "text": "Interaction: Bivalirudin AND Kebuzone\nDetails: Kebuzone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Kebuzone"}, {"id": "Bivalirudin_INT_Isoxicam", "text": "Interaction: Bivalirudin AND Isoxicam\nDetails: Isoxicam may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Isoxicam"}, {"id": "Bivalirudin_INT_Indoprofen", "text": "Interaction: Bivalirudin AND Indoprofen\nDetails: Indoprofen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Indoprofen"}, {"id": "Bivalirudin_INT_Ibuproxam", "text": "Interaction: Bivalirudin AND Ibuproxam\nDetails: Ibuproxam may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ibuproxam"}, {"id": "Bivalirudin_INT_Floctafenine", "text": "Interaction: Bivalirudin AND Floctafenine\nDetails: Floctafenine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Floctafenine"}, {"id": "Bivalirudin_INT_Fenbufen", "text": "Interaction: Bivalirudin AND Fenbufen\nDetails: Fenbufen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Fenbufen"}, {"id": "Bivalirudin_INT_Etofenamate", "text": "Interaction: Bivalirudin AND Etofenamate\nDetails: Etofenamate may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Etofenamate"}, {"id": "Bivalirudin_INT_Epirizole", "text": "Interaction: Bivalirudin AND Epirizole\nDetails: Epirizole may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Epirizole"}, {"id": "Bivalirudin_INT_Loxoprofen", "text": "Interaction: Bivalirudin AND Loxoprofen\nDetails: Loxoprofen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Loxoprofen"}, {"id": "Bivalirudin_INT_Droxicam", "text": "Interaction: Bivalirudin AND Droxicam\nDetails: Droxicam may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Droxicam"}, {"id": "Bivalirudin_INT_Tolfenamic Acid", "text": "Interaction: Bivalirudin AND Tolfenamic Acid\nDetails: Tolfenamic Acid may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tolfenamic Acid"}, {"id": "Bivalirudin_INT_Clonixin", "text": "Interaction: Bivalirudin AND Clonixin\nDetails: Clonixin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Clonixin"}, {"id": "Bivalirudin_INT_Propacetamol", "text": "Interaction: Bivalirudin AND Propacetamol\nDetails: Propacetamol may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Propacetamol"}, {"id": "Bivalirudin_INT_Evening primrose oil", "text": "Interaction: Bivalirudin AND Evening primrose oil\nDetails: Evening primrose oil may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Evening primrose oil"}, {"id": "Bivalirudin_INT_Orgotein", "text": "Interaction: Bivalirudin AND Orgotein\nDetails: Orgotein may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Orgotein"}, {"id": "Bivalirudin_INT_Tepoxalin", "text": "Interaction: Bivalirudin AND Tepoxalin\nDetails: Tepoxalin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tepoxalin"}, {"id": "Bivalirudin_INT_Flunixin", "text": "Interaction: Bivalirudin AND Flunixin\nDetails: Flunixin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Flunixin"}, {"id": "Bivalirudin_INT_Curcumin", "text": "Interaction: Bivalirudin AND Curcumin\nDetails: Curcumin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Curcumin"}, {"id": "Bivalirudin_INT_E-6201", "text": "Interaction: Bivalirudin AND E-6201\nDetails: E-6201 may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + E-6201"}, {"id": "Bivalirudin_INT_Anisodamine", "text": "Interaction: Bivalirudin AND Anisodamine\nDetails: Anisodamine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Anisodamine"}, {"id": "Bivalirudin_INT_Duvelisib", "text": "Interaction: Bivalirudin AND Duvelisib\nDetails: Duvelisib may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Duvelisib"}, {"id": "Bivalirudin_INT_Triptolide", "text": "Interaction: Bivalirudin AND Triptolide\nDetails: Triptolide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Triptolide"}, {"id": "Bivalirudin_INT_Semapimod", "text": "Interaction: Bivalirudin AND Semapimod\nDetails: Semapimod may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Semapimod"}, {"id": "Bivalirudin_INT_Bucillamine", "text": "Interaction: Bivalirudin AND Bucillamine\nDetails: Bucillamine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Bucillamine"}, {"id": "Bivalirudin_INT_Lisofylline", "text": "Interaction: Bivalirudin AND Lisofylline\nDetails: Lisofylline may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Lisofylline"}, {"id": "Bivalirudin_INT_Nitroaspirin", "text": "Interaction: Bivalirudin AND Nitroaspirin\nDetails: Nitroaspirin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Nitroaspirin"}, {"id": "Bivalirudin_INT_Nafamostat", "text": "Interaction: Bivalirudin AND Nafamostat\nDetails: Nafamostat may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Nafamostat"}, {"id": "Bivalirudin_INT_Mizoribine", "text": "Interaction: Bivalirudin AND Mizoribine\nDetails: Mizoribine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Mizoribine"}, {"id": "Bivalirudin_INT_Apocynin", "text": "Interaction: Bivalirudin AND Apocynin\nDetails: Apocynin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Apocynin"}, {"id": "Bivalirudin_INT_Higenamine", "text": "Interaction: Bivalirudin AND Higenamine\nDetails: Higenamine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Higenamine"}, {"id": "Bivalirudin_INT_Tinoridine", "text": "Interaction: Bivalirudin AND Tinoridine\nDetails: Tinoridine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tinoridine"}, {"id": "Bivalirudin_INT_Parthenolide", "text": "Interaction: Bivalirudin AND Parthenolide\nDetails: Parthenolide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Parthenolide"}, {"id": "Bivalirudin_INT_Serrapeptase", "text": "Interaction: Bivalirudin AND Serrapeptase\nDetails: Serrapeptase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Serrapeptase"}, {"id": "Bivalirudin_INT_Alclofenac", "text": "Interaction: Bivalirudin AND Alclofenac\nDetails: Alclofenac may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Alclofenac"}, {"id": "Bivalirudin_INT_Fentiazac", "text": "Interaction: Bivalirudin AND Fentiazac\nDetails: Fentiazac may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Fentiazac"}, {"id": "Bivalirudin_INT_Tribenoside", "text": "Interaction: Bivalirudin AND Tribenoside\nDetails: Tribenoside may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tribenoside"}, {"id": "Bivalirudin_INT_Suxibuzone", "text": "Interaction: Bivalirudin AND Suxibuzone\nDetails: Suxibuzone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Suxibuzone"}, {"id": "Bivalirudin_INT_Bumadizone", "text": "Interaction: Bivalirudin AND Bumadizone\nDetails: Bumadizone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Bumadizone"}, {"id": "Bivalirudin_INT_Alminoprofen", "text": "Interaction: Bivalirudin AND Alminoprofen\nDetails: Alminoprofen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Alminoprofen"}, {"id": "Bivalirudin_INT_Flunoxaprofen", "text": "Interaction: Bivalirudin AND Flunoxaprofen\nDetails: Flunoxaprofen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Flunoxaprofen"}, {"id": "Bivalirudin_INT_Bufexamac", "text": "Interaction: Bivalirudin AND Bufexamac\nDetails: Bufexamac may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Bufexamac"}, {"id": "Bivalirudin_INT_Feprazone", "text": "Interaction: Bivalirudin AND Feprazone\nDetails: Feprazone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Feprazone"}, {"id": "Bivalirudin_INT_Difenpiramide", "text": "Interaction: Bivalirudin AND Difenpiramide\nDetails: Difenpiramide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Difenpiramide"}, {"id": "Bivalirudin_INT_Nifenazone", "text": "Interaction: Bivalirudin AND Nifenazone\nDetails: Nifenazone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Nifenazone"}, {"id": "Bivalirudin_INT_Lonazolac", "text": "Interaction: Bivalirudin AND Lonazolac\nDetails: Lonazolac may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Lonazolac"}, {"id": "Bivalirudin_INT_Tenidap", "text": "Interaction: Bivalirudin AND Tenidap\nDetails: Tenidap may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tenidap"}, {"id": "Bivalirudin_INT_Bendazac", "text": "Interaction: Bivalirudin AND Bendazac\nDetails: Bendazac may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Bendazac"}, {"id": "Bivalirudin_INT_Pranoprofen", "text": "Interaction: Bivalirudin AND Pranoprofen\nDetails: Pranoprofen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Pranoprofen"}, {"id": "Bivalirudin_INT_Propyphenazone", "text": "Interaction: Bivalirudin AND Propyphenazone\nDetails: Propyphenazone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Propyphenazone"}, {"id": "Bivalirudin_INT_Proglumetacin", "text": "Interaction: Bivalirudin AND Proglumetacin\nDetails: Proglumetacin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Proglumetacin"}, {"id": "Bivalirudin_INT_Guacetisal", "text": "Interaction: Bivalirudin AND Guacetisal\nDetails: Guacetisal may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Guacetisal"}, {"id": "Bivalirudin_INT_Bevonium", "text": "Interaction: Bivalirudin AND Bevonium\nDetails: Bevonium may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Bevonium"}, {"id": "Bivalirudin_INT_Ethenzamide", "text": "Interaction: Bivalirudin AND Ethenzamide\nDetails: Ethenzamide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ethenzamide"}, {"id": "Bivalirudin_INT_Carbaspirin calcium", "text": "Interaction: Bivalirudin AND Carbaspirin calcium\nDetails: Carbaspirin calcium may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Carbaspirin calcium"}, {"id": "Bivalirudin_INT_Mofebutazone", "text": "Interaction: Bivalirudin AND Mofebutazone\nDetails: Mofebutazone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Mofebutazone"}, {"id": "Bivalirudin_INT_Proquazone", "text": "Interaction: Bivalirudin AND Proquazone\nDetails: Proquazone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Proquazone"}, {"id": "Bivalirudin_INT_Benorilate", "text": "Interaction: Bivalirudin AND Benorilate\nDetails: Benorilate may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Benorilate"}, {"id": "Bivalirudin_INT_Pirprofen", "text": "Interaction: Bivalirudin AND Pirprofen\nDetails: Pirprofen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Pirprofen"}, {"id": "Bivalirudin_INT_Imidazole salicylate", "text": "Interaction: Bivalirudin AND Imidazole salicylate\nDetails: Imidazole salicylate may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Imidazole salicylate"}, {"id": "Bivalirudin_INT_Benzydamine", "text": "Interaction: Bivalirudin AND Benzydamine\nDetails: Benzydamine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Benzydamine"}, {"id": "Bivalirudin_INT_Tipranavir", "text": "Interaction: Bivalirudin AND Tipranavir\nDetails: Tipranavir may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tipranavir"}, {"id": "Bivalirudin_INT_Omega-3 fatty acids", "text": "Interaction: Bivalirudin AND Omega-3 fatty acids\nDetails: Omega-3 fatty acids may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Omega-3 fatty acids"}, {"id": "Bivalirudin_INT_Vitamin E", "text": "Interaction: Bivalirudin AND Vitamin E\nDetails: Vitamin E may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Vitamin E"}, {"id": "Bivalirudin_INT_Tositumomab", "text": "Interaction: Bivalirudin AND Tositumomab\nDetails: The risk or severity of adverse effects can be increased when Bivalirudin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Bivalirudin + Tositumomab"}, {"id": "Bivalirudin_INT_Dabigatran etexilate", "text": "Interaction: Bivalirudin AND Dabigatran etexilate\nDetails: Bivalirudin may increase the anticoagulant activities of Dabigatran etexilate.\nRisk: Monitor closely.", "source": "Bivalirudin + Dabigatran etexilate"}, {"id": "Bivalirudin_INT_Lepirudin", "text": "Interaction: Bivalirudin AND Lepirudin\nDetails: Lepirudin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Lepirudin"}, {"id": "Bivalirudin_INT_Abciximab", "text": "Interaction: Bivalirudin AND Abciximab\nDetails: Bivalirudin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Bivalirudin + Abciximab"}, {"id": "Bivalirudin_INT_Becaplermin", "text": "Interaction: Bivalirudin AND Becaplermin\nDetails: Bivalirudin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Bivalirudin + Becaplermin"}, {"id": "Bivalirudin_INT_Dicoumarol", "text": "Interaction: Bivalirudin AND Dicoumarol\nDetails: Bivalirudin may increase the anticoagulant activities of Dicoumarol.\nRisk: Monitor closely.", "source": "Bivalirudin + Dicoumarol"}, {"id": "Bivalirudin_INT_Argatroban", "text": "Interaction: Bivalirudin AND Argatroban\nDetails: Bivalirudin may increase the anticoagulant activities of Argatroban.\nRisk: Monitor closely.", "source": "Bivalirudin + Argatroban"}, {"id": "Bivalirudin_INT_Ardeparin", "text": "Interaction: Bivalirudin AND Ardeparin\nDetails: Bivalirudin may increase the anticoagulant activities of Ardeparin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ardeparin"}, {"id": "Bivalirudin_INT_Phenindione", "text": "Interaction: Bivalirudin AND Phenindione\nDetails: Bivalirudin may increase the anticoagulant activities of Phenindione.\nRisk: Monitor closely.", "source": "Bivalirudin + Phenindione"}, {"id": "Bivalirudin_INT_Fondaparinux sodium", "text": "Interaction: Bivalirudin AND Fondaparinux sodium\nDetails: Bivalirudin may increase the anticoagulant activities of Fondaparinux sodium.\nRisk: Monitor closely.", "source": "Bivalirudin + Fondaparinux sodium"}, {"id": "Bivalirudin_INT_Warfarin", "text": "Interaction: Bivalirudin AND Warfarin\nDetails: Bivalirudin may increase the anticoagulant activities of Warfarin.\nRisk: Monitor closely.", "source": "Bivalirudin + Warfarin"}, {"id": "Bivalirudin_INT_Phenprocoumon", "text": "Interaction: Bivalirudin AND Phenprocoumon\nDetails: Bivalirudin may increase the anticoagulant activities of Phenprocoumon.\nRisk: Monitor closely.", "source": "Bivalirudin + Phenprocoumon"}, {"id": "Bivalirudin_INT_Edetic Acid", "text": "Interaction: Bivalirudin AND Edetic Acid\nDetails: Bivalirudin may increase the anticoagulant activities of Edetic Acid.\nRisk: Monitor closely.", "source": "Bivalirudin + Edetic Acid"}, {"id": "Bivalirudin_INT_Heparin", "text": "Interaction: Bivalirudin AND Heparin\nDetails: Bivalirudin may increase the anticoagulant activities of Heparin.\nRisk: Monitor closely.", "source": "Bivalirudin + Heparin"}, {"id": "Bivalirudin_INT_Enoxaparin", "text": "Interaction: Bivalirudin AND Enoxaparin\nDetails: Bivalirudin may increase the anticoagulant activities of Enoxaparin.\nRisk: Monitor closely.", "source": "Bivalirudin + Enoxaparin"}, {"id": "Bivalirudin_INT_Acenocoumarol", "text": "Interaction: Bivalirudin AND Acenocoumarol\nDetails: Bivalirudin may increase the anticoagulant activities of Acenocoumarol.\nRisk: Monitor closely.", "source": "Bivalirudin + Acenocoumarol"}, {"id": "Bivalirudin_INT_Citric Acid", "text": "Interaction: Bivalirudin AND Citric Acid\nDetails: Bivalirudin may increase the anticoagulant activities of Citric Acid.\nRisk: Monitor closely.", "source": "Bivalirudin + Citric Acid"}, {"id": "Bivalirudin_INT_Ximelagatran", "text": "Interaction: Bivalirudin AND Ximelagatran\nDetails: Bivalirudin may increase the anticoagulant activities of Ximelagatran.\nRisk: Monitor closely.", "source": "Bivalirudin + Ximelagatran"}, {"id": "Bivalirudin_INT_Ancrod", "text": "Interaction: Bivalirudin AND Ancrod\nDetails: Bivalirudin may increase the anticoagulant activities of Ancrod.\nRisk: Monitor closely.", "source": "Bivalirudin + Ancrod"}, {"id": "Bivalirudin_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Bivalirudin AND Pentaerythritol Tetranitrate\nDetails: Bivalirudin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.\nRisk: Monitor closely.", "source": "Bivalirudin + Pentaerythritol Tetranitrate"}, {"id": "Bivalirudin_INT_Sulodexide", "text": "Interaction: Bivalirudin AND Sulodexide\nDetails: Bivalirudin may increase the anticoagulant activities of Sulodexide.\nRisk: Monitor closely.", "source": "Bivalirudin + Sulodexide"}, {"id": "Bivalirudin_INT_Idraparinux", "text": "Interaction: Bivalirudin AND Idraparinux\nDetails: Bivalirudin may increase the anticoagulant activities of Idraparinux.\nRisk: Monitor closely.", "source": "Bivalirudin + Idraparinux"}, {"id": "Bivalirudin_INT_Otamixaban", "text": "Interaction: Bivalirudin AND Otamixaban\nDetails: Bivalirudin may increase the anticoagulant activities of Otamixaban.\nRisk: Monitor closely.", "source": "Bivalirudin + Otamixaban"}, {"id": "Bivalirudin_INT_Danaparoid", "text": "Interaction: Bivalirudin AND Danaparoid\nDetails: Bivalirudin may increase the anticoagulant activities of Danaparoid.\nRisk: Monitor closely.", "source": "Bivalirudin + Danaparoid"}, {"id": "Bivalirudin_INT_Dalteparin", "text": "Interaction: Bivalirudin AND Dalteparin\nDetails: Bivalirudin may increase the anticoagulant activities of Dalteparin.\nRisk: Monitor closely.", "source": "Bivalirudin + Dalteparin"}, {"id": "Bivalirudin_INT_Ethyl biscoumacetate", "text": "Interaction: Bivalirudin AND Ethyl biscoumacetate\nDetails: Bivalirudin may increase the anticoagulant activities of Ethyl biscoumacetate.\nRisk: Monitor closely.", "source": "Bivalirudin + Ethyl biscoumacetate"}, {"id": "Bivalirudin_INT_Nadroparin", "text": "Interaction: Bivalirudin AND Nadroparin\nDetails: Bivalirudin may increase the anticoagulant activities of Nadroparin.\nRisk: Monitor closely.", "source": "Bivalirudin + Nadroparin"}, {"id": "Bivalirudin_INT_Dextran", "text": "Interaction: Bivalirudin AND Dextran\nDetails: Bivalirudin may increase the anticoagulant activities of Dextran.\nRisk: Monitor closely.", "source": "Bivalirudin + Dextran"}, {"id": "Bivalirudin_INT_Reviparin", "text": "Interaction: Bivalirudin AND Reviparin\nDetails: Bivalirudin may increase the anticoagulant activities of Reviparin.\nRisk: Monitor closely.", "source": "Bivalirudin + Reviparin"}, {"id": "Bivalirudin_INT_Certoparin", "text": "Interaction: Bivalirudin AND Certoparin\nDetails: Bivalirudin may increase the anticoagulant activities of Certoparin.\nRisk: Monitor closely.", "source": "Bivalirudin + Certoparin"}, {"id": "Bivalirudin_INT_Dextran 70", "text": "Interaction: Bivalirudin AND Dextran 70\nDetails: Bivalirudin may increase the anticoagulant activities of Dextran 70.\nRisk: Monitor closely.", "source": "Bivalirudin + Dextran 70"}, {"id": "Bivalirudin_INT_Desirudin", "text": "Interaction: Bivalirudin AND Desirudin\nDetails: Bivalirudin may increase the anticoagulant activities of Desirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Desirudin"}, {"id": "Bivalirudin_INT_Dextran 40", "text": "Interaction: Bivalirudin AND Dextran 40\nDetails: Bivalirudin may increase the anticoagulant activities of Dextran 40.\nRisk: Monitor closely.", "source": "Bivalirudin + Dextran 40"}, {"id": "Bivalirudin_INT_Dextran 75", "text": "Interaction: Bivalirudin AND Dextran 75\nDetails: Bivalirudin may increase the anticoagulant activities of Dextran 75.\nRisk: Monitor closely.", "source": "Bivalirudin + Dextran 75"}, {"id": "Bivalirudin_INT_Protocatechualdehyde", "text": "Interaction: Bivalirudin AND Protocatechualdehyde\nDetails: Bivalirudin may increase the anticoagulant activities of Protocatechualdehyde.\nRisk: Monitor closely.", "source": "Bivalirudin + Protocatechualdehyde"}, {"id": "Bivalirudin_INT_Protein C", "text": "Interaction: Bivalirudin AND Protein C\nDetails: Bivalirudin may increase the anticoagulant activities of Protein C.\nRisk: Monitor closely.", "source": "Bivalirudin + Protein C"}, {"id": "Bivalirudin_INT_Antithrombin III human", "text": "Interaction: Bivalirudin AND Antithrombin III human\nDetails: Bivalirudin may increase the anticoagulant activities of Antithrombin III human.\nRisk: Monitor closely.", "source": "Bivalirudin + Antithrombin III human"}, {"id": "Bivalirudin_INT_Fondaparinux", "text": "Interaction: Bivalirudin AND Fondaparinux\nDetails: Bivalirudin may increase the anticoagulant activities of Fondaparinux.\nRisk: Monitor closely.", "source": "Bivalirudin + Fondaparinux"}, {"id": "Bivalirudin_INT_Letaxaban", "text": "Interaction: Bivalirudin AND Letaxaban\nDetails: Bivalirudin may increase the anticoagulant activities of Letaxaban.\nRisk: Monitor closely.", "source": "Bivalirudin + Letaxaban"}, {"id": "Bivalirudin_INT_Darexaban", "text": "Interaction: Bivalirudin AND Darexaban\nDetails: Bivalirudin may increase the anticoagulant activities of Darexaban.\nRisk: Monitor closely.", "source": "Bivalirudin + Darexaban"}, {"id": "Bivalirudin_INT_Gabexate", "text": "Interaction: Bivalirudin AND Gabexate\nDetails: Bivalirudin may increase the anticoagulant activities of Gabexate.\nRisk: Monitor closely.", "source": "Bivalirudin + Gabexate"}, {"id": "Bivalirudin_INT_Troxerutin", "text": "Interaction: Bivalirudin AND Troxerutin\nDetails: Bivalirudin may increase the anticoagulant activities of Troxerutin.\nRisk: Monitor closely.", "source": "Bivalirudin + Troxerutin"}, {"id": "Bivalirudin_INT_Fluindione", "text": "Interaction: Bivalirudin AND Fluindione\nDetails: Bivalirudin may increase the anticoagulant activities of Fluindione.\nRisk: Monitor closely.", "source": "Bivalirudin + Fluindione"}, {"id": "Bivalirudin_INT_Protein S human", "text": "Interaction: Bivalirudin AND Protein S human\nDetails: Bivalirudin may increase the anticoagulant activities of Protein S human.\nRisk: Monitor closely.", "source": "Bivalirudin + Protein S human"}, {"id": "Bivalirudin_INT_Melagatran", "text": "Interaction: Bivalirudin AND Melagatran\nDetails: Bivalirudin may increase the anticoagulant activities of Melagatran.\nRisk: Monitor closely.", "source": "Bivalirudin + Melagatran"}, {"id": "Bivalirudin_INT_Aminosalicylic Acid", "text": "Interaction: Bivalirudin AND Aminosalicylic Acid\nDetails: Aminosalicylic Acid may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Aminosalicylic Acid"}, {"id": "Bivalirudin_INT_dersalazine", "text": "Interaction: Bivalirudin AND dersalazine\nDetails: dersalazine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + dersalazine"}, {"id": "Bivalirudin_INT_Aloxiprin", "text": "Interaction: Bivalirudin AND Aloxiprin\nDetails: Aloxiprin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Aloxiprin"}, {"id": "Bivalirudin_INT_Hemoglobin crosfumaril", "text": "Interaction: Bivalirudin AND Hemoglobin crosfumaril\nDetails: Hemoglobin crosfumaril may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Hemoglobin crosfumaril"}, {"id": "Bivalirudin_INT_Methyl salicylate", "text": "Interaction: Bivalirudin AND Methyl salicylate\nDetails: Methyl salicylate may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Methyl salicylate"}, {"id": "Bivalirudin_INT_Trolamine salicylate", "text": "Interaction: Bivalirudin AND Trolamine salicylate\nDetails: Trolamine salicylate may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Trolamine salicylate"}, {"id": "Bivalirudin_INT_Alteplase", "text": "Interaction: Bivalirudin AND Alteplase\nDetails: Alteplase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Alteplase"}, {"id": "Bivalirudin_INT_Reteplase", "text": "Interaction: Bivalirudin AND Reteplase\nDetails: Reteplase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Reteplase"}, {"id": "Bivalirudin_INT_Anistreplase", "text": "Interaction: Bivalirudin AND Anistreplase\nDetails: Anistreplase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Anistreplase"}, {"id": "Bivalirudin_INT_Tenecteplase", "text": "Interaction: Bivalirudin AND Tenecteplase\nDetails: Tenecteplase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tenecteplase"}, {"id": "Bivalirudin_INT_Drotrecogin alfa", "text": "Interaction: Bivalirudin AND Drotrecogin alfa\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Drotrecogin alfa"}, {"id": "Bivalirudin_INT_Ticlopidine", "text": "Interaction: Bivalirudin AND Ticlopidine\nDetails: Ticlopidine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ticlopidine"}, {"id": "Bivalirudin_INT_Tirofiban", "text": "Interaction: Bivalirudin AND Tirofiban\nDetails: Tirofiban may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tirofiban"}, {"id": "Bivalirudin_INT_Cilostazol", "text": "Interaction: Bivalirudin AND Cilostazol\nDetails: Cilostazol may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Cilostazol"}, {"id": "Bivalirudin_INT_Defibrotide", "text": "Interaction: Bivalirudin AND Defibrotide\nDetails: Defibrotide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Defibrotide"}, {"id": "Bivalirudin_INT_Tinzaparin", "text": "Interaction: Bivalirudin AND Tinzaparin\nDetails: Tinzaparin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tinzaparin"}, {"id": "Bivalirudin_INT_Brinase", "text": "Interaction: Bivalirudin AND Brinase\nDetails: Brinase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Brinase"}, {"id": "Bivalirudin_INT_Saruplase", "text": "Interaction: Bivalirudin AND Saruplase\nDetails: Saruplase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Saruplase"}, {"id": "Bivalirudin_INT_Streptokinase", "text": "Interaction: Bivalirudin AND Streptokinase\nDetails: Streptokinase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Streptokinase"}, {"id": "Bivalirudin_INT_Anagrelide", "text": "Interaction: Bivalirudin AND Anagrelide\nDetails: Anagrelide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Anagrelide"}, {"id": "Bivalirudin_INT_Rosiglitazone", "text": "Interaction: Bivalirudin AND Rosiglitazone\nDetails: Rosiglitazone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Rosiglitazone"}, {"id": "Bivalirudin_INT_Desmoteplase", "text": "Interaction: Bivalirudin AND Desmoteplase\nDetails: Desmoteplase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Desmoteplase"}, {"id": "Bivalirudin_INT_Fibrinolysin", "text": "Interaction: Bivalirudin AND Fibrinolysin\nDetails: Fibrinolysin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Fibrinolysin"}, {"id": "Bivalirudin_INT_ALX-0081", "text": "Interaction: Bivalirudin AND ALX-0081\nDetails: ALX-0081 may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + ALX-0081"}, {"id": "Bivalirudin_INT_eplivanserine", "text": "Interaction: Bivalirudin AND eplivanserine\nDetails: eplivanserine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + eplivanserine"}, {"id": "Bivalirudin_INT_Astaxanthin", "text": "Interaction: Bivalirudin AND Astaxanthin\nDetails: Astaxanthin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Astaxanthin"}, {"id": "Bivalirudin_INT_Batroxobin", "text": "Interaction: Bivalirudin AND Batroxobin\nDetails: Batroxobin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Batroxobin"}, {"id": "Bivalirudin_INT_Ozagrel", "text": "Interaction: Bivalirudin AND Ozagrel\nDetails: Ozagrel may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ozagrel"}, {"id": "Bivalirudin_INT_Sarpogrelate", "text": "Interaction: Bivalirudin AND Sarpogrelate\nDetails: Sarpogrelate may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Sarpogrelate"}, {"id": "Bivalirudin_INT_Eplivanserin", "text": "Interaction: Bivalirudin AND Eplivanserin\nDetails: Eplivanserin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Eplivanserin"}, {"id": "Bivalirudin_INT_Eptifibatide", "text": "Interaction: Bivalirudin AND Eptifibatide\nDetails: Eptifibatide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Eptifibatide"}, {"id": "Bivalirudin_INT_Treprostinil", "text": "Interaction: Bivalirudin AND Treprostinil\nDetails: Treprostinil may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Treprostinil"}, {"id": "Bivalirudin_INT_Clopidogrel", "text": "Interaction: Bivalirudin AND Clopidogrel\nDetails: Clopidogrel may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Clopidogrel"}, {"id": "Bivalirudin_INT_Dipyridamole", "text": "Interaction: Bivalirudin AND Dipyridamole\nDetails: Dipyridamole may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Dipyridamole"}, {"id": "Bivalirudin_INT_Iloprost", "text": "Interaction: Bivalirudin AND Iloprost\nDetails: Iloprost may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Iloprost"}, {"id": "Bivalirudin_INT_Epoprostenol", "text": "Interaction: Bivalirudin AND Epoprostenol\nDetails: Epoprostenol may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Epoprostenol"}, {"id": "Bivalirudin_INT_Beraprost", "text": "Interaction: Bivalirudin AND Beraprost\nDetails: Beraprost may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Beraprost"}, {"id": "Bivalirudin_INT_Prasugrel", "text": "Interaction: Bivalirudin AND Prasugrel\nDetails: Prasugrel may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Prasugrel"}, {"id": "Bivalirudin_INT_Cangrelor", "text": "Interaction: Bivalirudin AND Cangrelor\nDetails: Cangrelor may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Cangrelor"}, {"id": "Bivalirudin_INT_Triflusal", "text": "Interaction: Bivalirudin AND Triflusal\nDetails: Triflusal may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Triflusal"}, {"id": "Bivalirudin_INT_Ticagrelor", "text": "Interaction: Bivalirudin AND Ticagrelor\nDetails: Ticagrelor may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ticagrelor"}, {"id": "Bivalirudin_INT_Ditazole", "text": "Interaction: Bivalirudin AND Ditazole\nDetails: Ditazole may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ditazole"}, {"id": "Bivalirudin_INT_Bemiparin", "text": "Interaction: Bivalirudin AND Bemiparin\nDetails: Bemiparin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Bemiparin"}, {"id": "Bivalirudin_INT_Parnaparin", "text": "Interaction: Bivalirudin AND Parnaparin\nDetails: Parnaparin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Parnaparin"}, {"id": "Bivalirudin_INT_Selexipag", "text": "Interaction: Bivalirudin AND Selexipag\nDetails: Selexipag may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Selexipag"}, {"id": "Bivalirudin_INT_Indobufen", "text": "Interaction: Bivalirudin AND Indobufen\nDetails: Indobufen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Indobufen"}, {"id": "Bivalirudin_INT_Clorindione", "text": "Interaction: Bivalirudin AND Clorindione\nDetails: Clorindione may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Clorindione"}, {"id": "Bivalirudin_INT_Picotamide", "text": "Interaction: Bivalirudin AND Picotamide\nDetails: Picotamide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Picotamide"}, {"id": "Bivalirudin_INT_Diphenadione", "text": "Interaction: Bivalirudin AND Diphenadione\nDetails: Diphenadione may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Diphenadione"}, {"id": "Bivalirudin_INT_Cloricromen", "text": "Interaction: Bivalirudin AND Cloricromen\nDetails: Cloricromen may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Cloricromen"}, {"id": "Bivalirudin_INT_Tioclomarol", "text": "Interaction: Bivalirudin AND Tioclomarol\nDetails: Tioclomarol may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tioclomarol"}, {"id": "Bivalirudin_INT_Milrinone", "text": "Interaction: Bivalirudin AND Milrinone\nDetails: Milrinone may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Milrinone"}, {"id": "Bivalirudin_INT_Epinastine", "text": "Interaction: Bivalirudin AND Epinastine\nDetails: Epinastine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Epinastine"}, {"id": "Bivalirudin_INT_Alprostadil", "text": "Interaction: Bivalirudin AND Alprostadil\nDetails: Alprostadil may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Alprostadil"}, {"id": "Bivalirudin_INT_Pentoxifylline", "text": "Interaction: Bivalirudin AND Pentoxifylline\nDetails: Pentoxifylline may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Pentoxifylline"}, {"id": "Bivalirudin_INT_Ridogrel", "text": "Interaction: Bivalirudin AND Ridogrel\nDetails: Ridogrel may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ridogrel"}, {"id": "Bivalirudin_INT_Sevoflurane", "text": "Interaction: Bivalirudin AND Sevoflurane\nDetails: Sevoflurane may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Sevoflurane"}, {"id": "Bivalirudin_INT_Tesmilifene", "text": "Interaction: Bivalirudin AND Tesmilifene\nDetails: Tesmilifene may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Tesmilifene"}, {"id": "Bivalirudin_INT_Ibudilast", "text": "Interaction: Bivalirudin AND Ibudilast\nDetails: Ibudilast may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ibudilast"}, {"id": "Bivalirudin_INT_Icosapent ethyl", "text": "Interaction: Bivalirudin AND Icosapent ethyl\nDetails: Icosapent ethyl may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Icosapent ethyl"}, {"id": "Bivalirudin_INT_Ifenprodil", "text": "Interaction: Bivalirudin AND Ifenprodil\nDetails: Ifenprodil may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ifenprodil"}, {"id": "Bivalirudin_INT_Trapidil", "text": "Interaction: Bivalirudin AND Trapidil\nDetails: Trapidil may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Trapidil"}, {"id": "Bivalirudin_INT_Naftopidil", "text": "Interaction: Bivalirudin AND Naftopidil\nDetails: Naftopidil may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Naftopidil"}, {"id": "Bivalirudin_INT_Ifetroban", "text": "Interaction: Bivalirudin AND Ifetroban\nDetails: Ifetroban may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ifetroban"}, {"id": "Bivalirudin_INT_Ketanserin", "text": "Interaction: Bivalirudin AND Ketanserin\nDetails: Ketanserin may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ketanserin"}, {"id": "Bivalirudin_INT_Butylphthalide", "text": "Interaction: Bivalirudin AND Butylphthalide\nDetails: Butylphthalide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Butylphthalide"}, {"id": "Bivalirudin_INT_Hydroxytyrosol", "text": "Interaction: Bivalirudin AND Hydroxytyrosol\nDetails: Hydroxytyrosol may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Hydroxytyrosol"}, {"id": "Bivalirudin_INT_Ramatroban", "text": "Interaction: Bivalirudin AND Ramatroban\nDetails: Ramatroban may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ramatroban"}, {"id": "Bivalirudin_INT_Linsidomine", "text": "Interaction: Bivalirudin AND Linsidomine\nDetails: Linsidomine may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Linsidomine"}, {"id": "Bivalirudin_INT_Buflomedil", "text": "Interaction: Bivalirudin AND Buflomedil\nDetails: Buflomedil may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Buflomedil"}, {"id": "Bivalirudin_INT_Relcovaptan", "text": "Interaction: Bivalirudin AND Relcovaptan\nDetails: Relcovaptan may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Relcovaptan"}, {"id": "Bivalirudin_INT_Ambroxol acefyllinate", "text": "Interaction: Bivalirudin AND Ambroxol acefyllinate\nDetails: The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Ambroxol acefyllinate"}, {"id": "Bivalirudin_INT_Theophylline", "text": "Interaction: Bivalirudin AND Theophylline\nDetails: The serum concentration of Theophylline can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Theophylline"}, {"id": "Bivalirudin_INT_Dyphylline", "text": "Interaction: Bivalirudin AND Dyphylline\nDetails: The serum concentration of Dyphylline can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Dyphylline"}, {"id": "Bivalirudin_INT_Aminophylline", "text": "Interaction: Bivalirudin AND Aminophylline\nDetails: The serum concentration of Aminophylline can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Aminophylline"}, {"id": "Bivalirudin_INT_Valproic Acid", "text": "Interaction: Bivalirudin AND Valproic Acid\nDetails: The serum concentration of Valproic Acid can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Valproic Acid"}, {"id": "Bivalirudin_INT_Zidovudine", "text": "Interaction: Bivalirudin AND Zidovudine\nDetails: The serum concentration of Zidovudine can be decreased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Bivalirudin + Zidovudine"}, {"id": "Leuprolide_GEN", "text": "Drug: Leuprolide\nDescription: Leuprolide belongs to the general class of drugs known as hormones or hormone antagonists. It is a synthetic 9 residue peptide analog of gonadotropin releasing hormone. Leuprolide is used to treat advanced prostate cancer. It is also used to treat uterine fibroids and endometriosis. Leuprolide is al...", "source": "Leuprolide"}, {"id": "Leuprolide_CLIN", "text": "Drug: Leuprolide\nMechanism: Leuprolide binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion....\nToxicity: In rats subcutaneous administration of 250 to 500 times the recommended human dose, expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local irritation at the injection...", "source": "Leuprolide"}, {"id": "Leuprolide_INT_Dofetilide", "text": "Interaction: Leuprolide AND Dofetilide\nDetails: Leuprolide may increase the QTc-prolonging activities of Dofetilide.\nRisk: Monitor closely.", "source": "Leuprolide + Dofetilide"}, {"id": "Leuprolide_INT_Citalopram", "text": "Interaction: Leuprolide AND Citalopram\nDetails: Leuprolide may increase the QTc-prolonging activities of Citalopram.\nRisk: Monitor closely.", "source": "Leuprolide + Citalopram"}, {"id": "Leuprolide_INT_Ziprasidone", "text": "Interaction: Leuprolide AND Ziprasidone\nDetails: Leuprolide may increase the QTc-prolonging activities of Ziprasidone.\nRisk: Monitor closely.", "source": "Leuprolide + Ziprasidone"}, {"id": "Leuprolide_INT_Anagrelide", "text": "Interaction: Leuprolide AND Anagrelide\nDetails: Leuprolide may increase the QTc-prolonging activities of Anagrelide.\nRisk: Monitor closely.", "source": "Leuprolide + Anagrelide"}, {"id": "Leuprolide_INT_Disopyramide", "text": "Interaction: Leuprolide AND Disopyramide\nDetails: Leuprolide may increase the QTc-prolonging activities of Disopyramide.\nRisk: Monitor closely.", "source": "Leuprolide + Disopyramide"}, {"id": "Leuprolide_INT_Ibutilide", "text": "Interaction: Leuprolide AND Ibutilide\nDetails: Leuprolide may increase the QTc-prolonging activities of Ibutilide.\nRisk: Monitor closely.", "source": "Leuprolide + Ibutilide"}, {"id": "Leuprolide_INT_Quinine", "text": "Interaction: Leuprolide AND Quinine\nDetails: Leuprolide may increase the QTc-prolonging activities of Quinine.\nRisk: Monitor closely.", "source": "Leuprolide + Quinine"}, {"id": "Leuprolide_INT_Fluoxetine", "text": "Interaction: Leuprolide AND Fluoxetine\nDetails: Leuprolide may increase the QTc-prolonging activities of Fluoxetine.\nRisk: Monitor closely.", "source": "Leuprolide + Fluoxetine"}, {"id": "Leuprolide_INT_Sotalol", "text": "Interaction: Leuprolide AND Sotalol\nDetails: Leuprolide may increase the QTc-prolonging activities of Sotalol.\nRisk: Monitor closely.", "source": "Leuprolide + Sotalol"}, {"id": "Leuprolide_INT_Toremifene", "text": "Interaction: Leuprolide AND Toremifene\nDetails: Leuprolide may increase the QTc-prolonging activities of Toremifene.\nRisk: Monitor closely.", "source": "Leuprolide + Toremifene"}, {"id": "Leuprolide_INT_Cisapride", "text": "Interaction: Leuprolide AND Cisapride\nDetails: Leuprolide may increase the QTc-prolonging activities of Cisapride.\nRisk: Monitor closely.", "source": "Leuprolide + Cisapride"}, {"id": "Leuprolide_INT_Thioridazine", "text": "Interaction: Leuprolide AND Thioridazine\nDetails: Leuprolide may increase the QTc-prolonging activities of Thioridazine.\nRisk: Monitor closely.", "source": "Leuprolide + Thioridazine"}, {"id": "Leuprolide_INT_Flupentixol", "text": "Interaction: Leuprolide AND Flupentixol\nDetails: Leuprolide may increase the QTc-prolonging activities of Flupentixol.\nRisk: Monitor closely.", "source": "Leuprolide + Flupentixol"}, {"id": "Leuprolide_INT_Quinidine", "text": "Interaction: Leuprolide AND Quinidine\nDetails: Leuprolide may increase the QTc-prolonging activities of Quinidine.\nRisk: Monitor closely.", "source": "Leuprolide + Quinidine"}, {"id": "Leuprolide_INT_Procainamide", "text": "Interaction: Leuprolide AND Procainamide\nDetails: Leuprolide may increase the QTc-prolonging activities of Procainamide.\nRisk: Monitor closely.", "source": "Leuprolide + Procainamide"}, {"id": "Leuprolide_INT_Pimozide", "text": "Interaction: Leuprolide AND Pimozide\nDetails: Leuprolide may increase the QTc-prolonging activities of Pimozide.\nRisk: Monitor closely.", "source": "Leuprolide + Pimozide"}, {"id": "Leuprolide_INT_Amiodarone", "text": "Interaction: Leuprolide AND Amiodarone\nDetails: Leuprolide may increase the QTc-prolonging activities of Amiodarone.\nRisk: Monitor closely.", "source": "Leuprolide + Amiodarone"}, {"id": "Leuprolide_INT_Arsenic trioxide", "text": "Interaction: Leuprolide AND Arsenic trioxide\nDetails: Leuprolide may increase the QTc-prolonging activities of Arsenic trioxide.\nRisk: Monitor closely.", "source": "Leuprolide + Arsenic trioxide"}, {"id": "Leuprolide_INT_Escitalopram", "text": "Interaction: Leuprolide AND Escitalopram\nDetails: Leuprolide may increase the QTc-prolonging activities of Escitalopram.\nRisk: Monitor closely.", "source": "Leuprolide + Escitalopram"}, {"id": "Leuprolide_INT_Domperidone", "text": "Interaction: Leuprolide AND Domperidone\nDetails: Leuprolide may increase the QTc-prolonging activities of Domperidone.\nRisk: Monitor closely.", "source": "Leuprolide + Domperidone"}, {"id": "Leuprolide_INT_Quetiapine", "text": "Interaction: Leuprolide AND Quetiapine\nDetails: Leuprolide may increase the QTc-prolonging activities of Quetiapine.\nRisk: Monitor closely.", "source": "Leuprolide + Quetiapine"}, {"id": "Leuprolide_INT_Paliperidone", "text": "Interaction: Leuprolide AND Paliperidone\nDetails: Leuprolide may increase the QTc-prolonging activities of Paliperidone.\nRisk: Monitor closely.", "source": "Leuprolide + Paliperidone"}, {"id": "Leuprolide_INT_Lopinavir", "text": "Interaction: Leuprolide AND Lopinavir\nDetails: Leuprolide may increase the QTc-prolonging activities of Lopinavir.\nRisk: Monitor closely.", "source": "Leuprolide + Lopinavir"}, {"id": "Leuprolide_INT_Zuclopenthixol", "text": "Interaction: Leuprolide AND Zuclopenthixol\nDetails: Leuprolide may increase the QTc-prolonging activities of Zuclopenthixol.\nRisk: Monitor closely.", "source": "Leuprolide + Zuclopenthixol"}, {"id": "Leuprolide_INT_Tetrabenazine", "text": "Interaction: Leuprolide AND Tetrabenazine\nDetails: Leuprolide may increase the QTc-prolonging activities of Tetrabenazine.\nRisk: Monitor closely.", "source": "Leuprolide + Tetrabenazine"}, {"id": "Leuprolide_INT_Dronedarone", "text": "Interaction: Leuprolide AND Dronedarone\nDetails: Leuprolide may increase the QTc-prolonging activities of Dronedarone.\nRisk: Monitor closely.", "source": "Leuprolide + Dronedarone"}, {"id": "Leuprolide_INT_Nilotinib", "text": "Interaction: Leuprolide AND Nilotinib\nDetails: Leuprolide may increase the QTc-prolonging activities of Nilotinib.\nRisk: Monitor closely.", "source": "Leuprolide + Nilotinib"}, {"id": "Leuprolide_INT_Iloperidone", "text": "Interaction: Leuprolide AND Iloperidone\nDetails: Leuprolide may increase the QTc-prolonging activities of Iloperidone.\nRisk: Monitor closely.", "source": "Leuprolide + Iloperidone"}, {"id": "Leuprolide_INT_Vandetanib", "text": "Interaction: Leuprolide AND Vandetanib\nDetails: Leuprolide may increase the QTc-prolonging activities of Vandetanib.\nRisk: Monitor closely.", "source": "Leuprolide + Vandetanib"}, {"id": "Leuprolide_INT_Asenapine", "text": "Interaction: Leuprolide AND Asenapine\nDetails: Leuprolide may increase the QTc-prolonging activities of Asenapine.\nRisk: Monitor closely.", "source": "Leuprolide + Asenapine"}, {"id": "Leuprolide_INT_Artemether", "text": "Interaction: Leuprolide AND Artemether\nDetails: Leuprolide may increase the QTc-prolonging activities of Artemether.\nRisk: Monitor closely.", "source": "Leuprolide + Artemether"}, {"id": "Leuprolide_INT_Lumefantrine", "text": "Interaction: Leuprolide AND Lumefantrine\nDetails: Leuprolide may increase the QTc-prolonging activities of Lumefantrine.\nRisk: Monitor closely.", "source": "Leuprolide + Lumefantrine"}, {"id": "Leuprolide_INT_Vemurafenib", "text": "Interaction: Leuprolide AND Vemurafenib\nDetails: Leuprolide may increase the QTc-prolonging activities of Vemurafenib.\nRisk: Monitor closely.", "source": "Leuprolide + Vemurafenib"}, {"id": "Leuprolide_INT_Eliglustat", "text": "Interaction: Leuprolide AND Eliglustat\nDetails: Leuprolide may increase the QTc-prolonging activities of Eliglustat.\nRisk: Monitor closely.", "source": "Leuprolide + Eliglustat"}, {"id": "Leuprolide_INT_Capromab pendetide", "text": "Interaction: Leuprolide AND Capromab pendetide\nDetails: Leuprolide may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Leuprolide + Capromab pendetide"}, {"id": "Leuprolide_INT_Mifepristone", "text": "Interaction: Leuprolide AND Mifepristone\nDetails: Mifepristone may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Mifepristone"}, {"id": "Leuprolide_INT_Trastuzumab", "text": "Interaction: Leuprolide AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Trastuzumab"}, {"id": "Leuprolide_INT_Goserelin", "text": "Interaction: Leuprolide AND Goserelin\nDetails: Leuprolide may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Leuprolide + Goserelin"}, {"id": "Leuprolide_INT_Erythromycin", "text": "Interaction: Leuprolide AND Erythromycin\nDetails: Leuprolide may increase the QTc-prolonging activities of Erythromycin.\nRisk: Monitor closely.", "source": "Leuprolide + Erythromycin"}, {"id": "Leuprolide_INT_Azithromycin", "text": "Interaction: Leuprolide AND Azithromycin\nDetails: Leuprolide may increase the QTc-prolonging activities of Azithromycin.\nRisk: Monitor closely.", "source": "Leuprolide + Azithromycin"}, {"id": "Leuprolide_INT_Moxifloxacin", "text": "Interaction: Leuprolide AND Moxifloxacin\nDetails: Leuprolide may increase the QTc-prolonging activities of Moxifloxacin.\nRisk: Monitor closely.", "source": "Leuprolide + Moxifloxacin"}, {"id": "Leuprolide_INT_Sulfisoxazole", "text": "Interaction: Leuprolide AND Sulfisoxazole\nDetails: Leuprolide may increase the QTc-prolonging activities of Sulfisoxazole.\nRisk: Monitor closely.", "source": "Leuprolide + Sulfisoxazole"}, {"id": "Leuprolide_INT_Methadone", "text": "Interaction: Leuprolide AND Methadone\nDetails: Leuprolide may increase the QTc-prolonging activities of Methadone.\nRisk: Monitor closely.", "source": "Leuprolide + Methadone"}, {"id": "Leuprolide_INT_Clozapine", "text": "Interaction: Leuprolide AND Clozapine\nDetails: Leuprolide may increase the QTc-prolonging activities of Clozapine.\nRisk: Monitor closely.", "source": "Leuprolide + Clozapine"}, {"id": "Leuprolide_INT_Promazine", "text": "Interaction: Leuprolide AND Promazine\nDetails: Leuprolide may increase the QTc-prolonging activities of Promazine.\nRisk: Monitor closely.", "source": "Leuprolide + Promazine"}, {"id": "Leuprolide_INT_Droperidol", "text": "Interaction: Leuprolide AND Droperidol\nDetails: Leuprolide may increase the QTc-prolonging activities of Droperidol.\nRisk: Monitor closely.", "source": "Leuprolide + Droperidol"}, {"id": "Leuprolide_INT_Chlorpromazine", "text": "Interaction: Leuprolide AND Chlorpromazine\nDetails: Leuprolide may increase the QTc-prolonging activities of Chlorpromazine.\nRisk: Monitor closely.", "source": "Leuprolide + Chlorpromazine"}, {"id": "Leuprolide_INT_Haloperidol", "text": "Interaction: Leuprolide AND Haloperidol\nDetails: Leuprolide may increase the QTc-prolonging activities of Haloperidol.\nRisk: Monitor closely.", "source": "Leuprolide + Haloperidol"}, {"id": "Leuprolide_INT_Ciprofloxacin", "text": "Interaction: Leuprolide AND Ciprofloxacin\nDetails: Leuprolide may increase the QTc-prolonging activities of Ciprofloxacin.\nRisk: Monitor closely.", "source": "Leuprolide + Ciprofloxacin"}, {"id": "Leuprolide_INT_Perflutren", "text": "Interaction: Leuprolide AND Perflutren\nDetails: Leuprolide may increase the QTc-prolonging activities of Perflutren.\nRisk: Monitor closely.", "source": "Leuprolide + Perflutren"}, {"id": "Leuprolide_INT_Chloroquine", "text": "Interaction: Leuprolide AND Chloroquine\nDetails: Leuprolide may increase the QTc-prolonging activities of Chloroquine.\nRisk: Monitor closely.", "source": "Leuprolide + Chloroquine"}, {"id": "Leuprolide_INT_Pentamidine", "text": "Interaction: Leuprolide AND Pentamidine\nDetails: Leuprolide may increase the QTc-prolonging activities of Pentamidine.\nRisk: Monitor closely.", "source": "Leuprolide + Pentamidine"}, {"id": "Leuprolide_INT_Gadobenic acid", "text": "Interaction: Leuprolide AND Gadobenic acid\nDetails: Leuprolide may increase the QTc-prolonging activities of Gadobenic acid.\nRisk: Monitor closely.", "source": "Leuprolide + Gadobenic acid"}, {"id": "Leuprolide_INT_Dolasetron", "text": "Interaction: Leuprolide AND Dolasetron\nDetails: Leuprolide may increase the QTc-prolonging activities of Dolasetron.\nRisk: Monitor closely.", "source": "Leuprolide + Dolasetron"}, {"id": "Leuprolide_INT_Granisetron", "text": "Interaction: Leuprolide AND Granisetron\nDetails: Leuprolide may increase the QTc-prolonging activities of Granisetron.\nRisk: Monitor closely.", "source": "Leuprolide + Granisetron"}, {"id": "Leuprolide_INT_Ondansetron", "text": "Interaction: Leuprolide AND Ondansetron\nDetails: Leuprolide may increase the QTc-prolonging activities of Ondansetron.\nRisk: Monitor closely.", "source": "Leuprolide + Ondansetron"}, {"id": "Leuprolide_INT_Telithromycin", "text": "Interaction: Leuprolide AND Telithromycin\nDetails: Leuprolide may increase the QTc-prolonging activities of Telithromycin.\nRisk: Monitor closely.", "source": "Leuprolide + Telithromycin"}, {"id": "Leuprolide_INT_Primaquine", "text": "Interaction: Leuprolide AND Primaquine\nDetails: Leuprolide may increase the QTc-prolonging activities of Primaquine.\nRisk: Monitor closely.", "source": "Leuprolide + Primaquine"}, {"id": "Leuprolide_INT_Levofloxacin", "text": "Interaction: Leuprolide AND Levofloxacin\nDetails: Leuprolide may increase the QTc-prolonging activities of Levofloxacin.\nRisk: Monitor closely.", "source": "Leuprolide + Levofloxacin"}, {"id": "Leuprolide_INT_Gemifloxacin", "text": "Interaction: Leuprolide AND Gemifloxacin\nDetails: Leuprolide may increase the QTc-prolonging activities of Gemifloxacin.\nRisk: Monitor closely.", "source": "Leuprolide + Gemifloxacin"}, {"id": "Leuprolide_INT_Ofloxacin", "text": "Interaction: Leuprolide AND Ofloxacin\nDetails: Leuprolide may increase the QTc-prolonging activities of Ofloxacin.\nRisk: Monitor closely.", "source": "Leuprolide + Ofloxacin"}, {"id": "Leuprolide_INT_Propafenone", "text": "Interaction: Leuprolide AND Propafenone\nDetails: Leuprolide may increase the QTc-prolonging activities of Propafenone.\nRisk: Monitor closely.", "source": "Leuprolide + Propafenone"}, {"id": "Leuprolide_INT_Flecainide", "text": "Interaction: Leuprolide AND Flecainide\nDetails: Leuprolide may increase the QTc-prolonging activities of Flecainide.\nRisk: Monitor closely.", "source": "Leuprolide + Flecainide"}, {"id": "Leuprolide_INT_Clarithromycin", "text": "Interaction: Leuprolide AND Clarithromycin\nDetails: Leuprolide may increase the QTc-prolonging activities of Clarithromycin.\nRisk: Monitor closely.", "source": "Leuprolide + Clarithromycin"}, {"id": "Leuprolide_INT_Saquinavir", "text": "Interaction: Leuprolide AND Saquinavir\nDetails: Leuprolide may increase the QTc-prolonging activities of Saquinavir.\nRisk: Monitor closely.", "source": "Leuprolide + Saquinavir"}, {"id": "Leuprolide_INT_Telavancin", "text": "Interaction: Leuprolide AND Telavancin\nDetails: Leuprolide may increase the QTc-prolonging activities of Telavancin.\nRisk: Monitor closely.", "source": "Leuprolide + Telavancin"}, {"id": "Leuprolide_INT_Pazopanib", "text": "Interaction: Leuprolide AND Pazopanib\nDetails: Leuprolide may increase the QTc-prolonging activities of Pazopanib.\nRisk: Monitor closely.", "source": "Leuprolide + Pazopanib"}, {"id": "Leuprolide_INT_Panobinostat", "text": "Interaction: Leuprolide AND Panobinostat\nDetails: Leuprolide may increase the QTc-prolonging activities of Panobinostat.\nRisk: Monitor closely.", "source": "Leuprolide + Panobinostat"}, {"id": "Leuprolide_INT_Crizotinib", "text": "Interaction: Leuprolide AND Crizotinib\nDetails: Leuprolide may increase the QTc-prolonging activities of Crizotinib.\nRisk: Monitor closely.", "source": "Leuprolide + Crizotinib"}, {"id": "Leuprolide_INT_Bedaquiline", "text": "Interaction: Leuprolide AND Bedaquiline\nDetails: Leuprolide may increase the QTc-prolonging activities of Bedaquiline.\nRisk: Monitor closely.", "source": "Leuprolide + Bedaquiline"}, {"id": "Leuprolide_INT_Ceritinib", "text": "Interaction: Leuprolide AND Ceritinib\nDetails: Leuprolide may increase the QTc-prolonging activities of Ceritinib.\nRisk: Monitor closely.", "source": "Leuprolide + Ceritinib"}, {"id": "Leuprolide_INT_Lenvatinib", "text": "Interaction: Leuprolide AND Lenvatinib\nDetails: Leuprolide may increase the QTc-prolonging activities of Lenvatinib.\nRisk: Monitor closely.", "source": "Leuprolide + Lenvatinib"}, {"id": "Leuprolide_INT_Ivabradine", "text": "Interaction: Leuprolide AND Ivabradine\nDetails: Ivabradine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Ivabradine"}, {"id": "Leuprolide_INT_Paclitaxel", "text": "Interaction: Leuprolide AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Paclitaxel"}, {"id": "Leuprolide_INT_Docetaxel", "text": "Interaction: Leuprolide AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Docetaxel"}, {"id": "Leuprolide_INT_Cabazitaxel", "text": "Interaction: Leuprolide AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Cabazitaxel"}, {"id": "Leuprolide_INT_Digoxin", "text": "Interaction: Leuprolide AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Digoxin"}, {"id": "Leuprolide_INT_Acetyldigitoxin", "text": "Interaction: Leuprolide AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Acetyldigitoxin"}, {"id": "Leuprolide_INT_Deslanoside", "text": "Interaction: Leuprolide AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Deslanoside"}, {"id": "Leuprolide_INT_Ouabain", "text": "Interaction: Leuprolide AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Ouabain"}, {"id": "Leuprolide_INT_Digitoxin", "text": "Interaction: Leuprolide AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Digitoxin"}, {"id": "Leuprolide_INT_Cymarin", "text": "Interaction: Leuprolide AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Cymarin"}, {"id": "Leuprolide_INT_Proscillaridin", "text": "Interaction: Leuprolide AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Proscillaridin"}, {"id": "Leuprolide_INT_Metildigoxin", "text": "Interaction: Leuprolide AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Metildigoxin"}, {"id": "Leuprolide_INT_Peruvoside", "text": "Interaction: Leuprolide AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Peruvoside"}, {"id": "Leuprolide_INT_Lanatoside C", "text": "Interaction: Leuprolide AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Lanatoside C"}, {"id": "Leuprolide_INT_Gitoformate", "text": "Interaction: Leuprolide AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Gitoformate"}, {"id": "Leuprolide_INT_Acetyldigoxin", "text": "Interaction: Leuprolide AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Acetyldigoxin"}, {"id": "Leuprolide_INT_Oleandrin", "text": "Interaction: Leuprolide AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Oleandrin"}, {"id": "Leuprolide_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Leuprolide AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Digoxin Immune Fab (Ovine)"}, {"id": "Leuprolide_INT_Bevacizumab", "text": "Interaction: Leuprolide AND Bevacizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Bevacizumab"}, {"id": "Leuprolide_INT_Cyclophosphamide", "text": "Interaction: Leuprolide AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Cyclophosphamide"}, {"id": "Leuprolide_INT_Octreotide", "text": "Interaction: Leuprolide AND Octreotide\nDetails: Octreotide may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Octreotide"}, {"id": "Leuprolide_INT_Oxytocin", "text": "Interaction: Leuprolide AND Oxytocin\nDetails: Oxytocin may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Oxytocin"}, {"id": "Leuprolide_INT_Bortezomib", "text": "Interaction: Leuprolide AND Bortezomib\nDetails: Bortezomib may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Bortezomib"}, {"id": "Leuprolide_INT_Fluconazole", "text": "Interaction: Leuprolide AND Fluconazole\nDetails: Fluconazole may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Fluconazole"}, {"id": "Leuprolide_INT_Nelfinavir", "text": "Interaction: Leuprolide AND Nelfinavir\nDetails: Nelfinavir may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Nelfinavir"}, {"id": "Leuprolide_INT_Ranolazine", "text": "Interaction: Leuprolide AND Ranolazine\nDetails: Ranolazine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Ranolazine"}, {"id": "Leuprolide_INT_Isradipine", "text": "Interaction: Leuprolide AND Isradipine\nDetails: Isradipine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Isradipine"}, {"id": "Leuprolide_INT_Venlafaxine", "text": "Interaction: Leuprolide AND Venlafaxine\nDetails: Venlafaxine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Venlafaxine"}, {"id": "Leuprolide_INT_Atomoxetine", "text": "Interaction: Leuprolide AND Atomoxetine\nDetails: Atomoxetine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Atomoxetine"}, {"id": "Leuprolide_INT_Amitriptyline", "text": "Interaction: Leuprolide AND Amitriptyline\nDetails: Amitriptyline may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Amitriptyline"}, {"id": "Leuprolide_INT_Olanzapine", "text": "Interaction: Leuprolide AND Olanzapine\nDetails: Olanzapine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Olanzapine"}, {"id": "Leuprolide_INT_Protriptyline", "text": "Interaction: Leuprolide AND Protriptyline\nDetails: Protriptyline may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Protriptyline"}, {"id": "Leuprolide_INT_Alfuzosin", "text": "Interaction: Leuprolide AND Alfuzosin\nDetails: Alfuzosin may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Alfuzosin"}, {"id": "Leuprolide_INT_Mefloquine", "text": "Interaction: Leuprolide AND Mefloquine\nDetails: Mefloquine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Mefloquine"}, {"id": "Leuprolide_INT_Mirtazapine", "text": "Interaction: Leuprolide AND Mirtazapine\nDetails: Mirtazapine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Mirtazapine"}, {"id": "Leuprolide_INT_Treprostinil", "text": "Interaction: Leuprolide AND Treprostinil\nDetails: Treprostinil may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Treprostinil"}, {"id": "Leuprolide_INT_Sorafenib", "text": "Interaction: Leuprolide AND Sorafenib\nDetails: Sorafenib may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Sorafenib"}, {"id": "Leuprolide_INT_Trimethoprim", "text": "Interaction: Leuprolide AND Trimethoprim\nDetails: Trimethoprim may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Trimethoprim"}, {"id": "Leuprolide_INT_Imipramine", "text": "Interaction: Leuprolide AND Imipramine\nDetails: Imipramine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Imipramine"}, {"id": "Leuprolide_INT_Ritonavir", "text": "Interaction: Leuprolide AND Ritonavir\nDetails: Ritonavir may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Ritonavir"}, {"id": "Leuprolide_INT_Foscarnet", "text": "Interaction: Leuprolide AND Foscarnet\nDetails: Foscarnet may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Foscarnet"}, {"id": "Leuprolide_INT_Nortriptyline", "text": "Interaction: Leuprolide AND Nortriptyline\nDetails: Nortriptyline may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Nortriptyline"}, {"id": "Leuprolide_INT_Amoxapine", "text": "Interaction: Leuprolide AND Amoxapine\nDetails: Amoxapine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Amoxapine"}, {"id": "Leuprolide_INT_Hydroxyzine", "text": "Interaction: Leuprolide AND Hydroxyzine\nDetails: Hydroxyzine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Hydroxyzine"}, {"id": "Leuprolide_INT_Voriconazole", "text": "Interaction: Leuprolide AND Voriconazole\nDetails: Voriconazole may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Voriconazole"}, {"id": "Leuprolide_INT_Nicardipine", "text": "Interaction: Leuprolide AND Nicardipine\nDetails: Nicardipine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Nicardipine"}, {"id": "Leuprolide_INT_Trazodone", "text": "Interaction: Leuprolide AND Trazodone\nDetails: Trazodone may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Trazodone"}, {"id": "Leuprolide_INT_Galantamine", "text": "Interaction: Leuprolide AND Galantamine\nDetails: Galantamine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Galantamine"}, {"id": "Leuprolide_INT_Tamoxifen", "text": "Interaction: Leuprolide AND Tamoxifen\nDetails: Tamoxifen may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Tamoxifen"}, {"id": "Leuprolide_INT_Moexipril", "text": "Interaction: Leuprolide AND Moexipril\nDetails: Moexipril may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Moexipril"}, {"id": "Leuprolide_INT_Tizanidine", "text": "Interaction: Leuprolide AND Tizanidine\nDetails: Tizanidine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Tizanidine"}, {"id": "Leuprolide_INT_Ibandronate", "text": "Interaction: Leuprolide AND Ibandronate\nDetails: Ibandronate may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Ibandronate"}, {"id": "Leuprolide_INT_Apomorphine", "text": "Interaction: Leuprolide AND Apomorphine\nDetails: Apomorphine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Apomorphine"}, {"id": "Leuprolide_INT_Paroxetine", "text": "Interaction: Leuprolide AND Paroxetine\nDetails: Paroxetine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Paroxetine"}, {"id": "Leuprolide_INT_Trimipramine", "text": "Interaction: Leuprolide AND Trimipramine\nDetails: Trimipramine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Trimipramine"}, {"id": "Leuprolide_INT_Risperidone", "text": "Interaction: Leuprolide AND Risperidone\nDetails: Risperidone may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Risperidone"}, {"id": "Leuprolide_INT_Isoflurane", "text": "Interaction: Leuprolide AND Isoflurane\nDetails: Isoflurane may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Isoflurane"}, {"id": "Leuprolide_INT_Indapamide", "text": "Interaction: Leuprolide AND Indapamide\nDetails: Indapamide may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Indapamide"}, {"id": "Leuprolide_INT_Propofol", "text": "Interaction: Leuprolide AND Propofol\nDetails: Propofol may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Propofol"}, {"id": "Leuprolide_INT_Vardenafil", "text": "Interaction: Leuprolide AND Vardenafil\nDetails: Vardenafil may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Vardenafil"}, {"id": "Leuprolide_INT_Terbutaline", "text": "Interaction: Leuprolide AND Terbutaline\nDetails: Terbutaline may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Terbutaline"}, {"id": "Leuprolide_INT_Amantadine", "text": "Interaction: Leuprolide AND Amantadine\nDetails: Amantadine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Amantadine"}, {"id": "Leuprolide_INT_Metronidazole", "text": "Interaction: Leuprolide AND Metronidazole\nDetails: Metronidazole may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Metronidazole"}, {"id": "Leuprolide_INT_Famotidine", "text": "Interaction: Leuprolide AND Famotidine\nDetails: Famotidine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Famotidine"}, {"id": "Leuprolide_INT_Maprotiline", "text": "Interaction: Leuprolide AND Maprotiline\nDetails: Maprotiline may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Maprotiline"}, {"id": "Leuprolide_INT_Salmeterol", "text": "Interaction: Leuprolide AND Salmeterol\nDetails: Salmeterol may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Salmeterol"}, {"id": "Leuprolide_INT_Felbamate", "text": "Interaction: Leuprolide AND Felbamate\nDetails: Felbamate may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Felbamate"}, {"id": "Leuprolide_INT_Formoterol", "text": "Interaction: Leuprolide AND Formoterol\nDetails: Formoterol may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Formoterol"}, {"id": "Leuprolide_INT_Salbutamol", "text": "Interaction: Leuprolide AND Salbutamol\nDetails: Salbutamol may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Salbutamol"}, {"id": "Leuprolide_INT_Sulfamethoxazole", "text": "Interaction: Leuprolide AND Sulfamethoxazole\nDetails: Sulfamethoxazole may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Sulfamethoxazole"}, {"id": "Leuprolide_INT_Ketoconazole", "text": "Interaction: Leuprolide AND Ketoconazole\nDetails: Ketoconazole may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Ketoconazole"}, {"id": "Leuprolide_INT_Tolterodine", "text": "Interaction: Leuprolide AND Tolterodine\nDetails: Tolterodine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Tolterodine"}, {"id": "Leuprolide_INT_Norfloxacin", "text": "Interaction: Leuprolide AND Norfloxacin\nDetails: Norfloxacin may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Norfloxacin"}, {"id": "Leuprolide_INT_Promethazine", "text": "Interaction: Leuprolide AND Promethazine\nDetails: Promethazine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Promethazine"}, {"id": "Leuprolide_INT_Atazanavir", "text": "Interaction: Leuprolide AND Atazanavir\nDetails: Atazanavir may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Atazanavir"}, {"id": "Leuprolide_INT_Diphenhydramine", "text": "Interaction: Leuprolide AND Diphenhydramine\nDetails: Diphenhydramine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Diphenhydramine"}, {"id": "Leuprolide_INT_Sertraline", "text": "Interaction: Leuprolide AND Sertraline\nDetails: Sertraline may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Sertraline"}, {"id": "Leuprolide_INT_Doxepin", "text": "Interaction: Leuprolide AND Doxepin\nDetails: Doxepin may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Doxepin"}, {"id": "Leuprolide_INT_Desipramine", "text": "Interaction: Leuprolide AND Desipramine\nDetails: Desipramine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Desipramine"}, {"id": "Leuprolide_INT_Itraconazole", "text": "Interaction: Leuprolide AND Itraconazole\nDetails: Itraconazole may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Itraconazole"}, {"id": "Leuprolide_INT_Desflurane", "text": "Interaction: Leuprolide AND Desflurane\nDetails: Desflurane may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Desflurane"}, {"id": "Leuprolide_INT_Metoclopramide", "text": "Interaction: Leuprolide AND Metoclopramide\nDetails: Metoclopramide may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Metoclopramide"}, {"id": "Leuprolide_INT_Sevoflurane", "text": "Interaction: Leuprolide AND Sevoflurane\nDetails: Sevoflurane may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Sevoflurane"}, {"id": "Leuprolide_INT_Aripiprazole", "text": "Interaction: Leuprolide AND Aripiprazole\nDetails: Aripiprazole may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Aripiprazole"}, {"id": "Leuprolide_INT_Clomipramine", "text": "Interaction: Leuprolide AND Clomipramine\nDetails: Clomipramine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Clomipramine"}, {"id": "Leuprolide_INT_Dasatinib", "text": "Interaction: Leuprolide AND Dasatinib\nDetails: Dasatinib may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Dasatinib"}, {"id": "Leuprolide_INT_Lapatinib", "text": "Interaction: Leuprolide AND Lapatinib\nDetails: Lapatinib may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Lapatinib"}, {"id": "Leuprolide_INT_Posaconazole", "text": "Interaction: Leuprolide AND Posaconazole\nDetails: Posaconazole may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Posaconazole"}, {"id": "Leuprolide_INT_Sunitinib", "text": "Interaction: Leuprolide AND Sunitinib\nDetails: Sunitinib may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Sunitinib"}, {"id": "Leuprolide_INT_Arformoterol", "text": "Interaction: Leuprolide AND Arformoterol\nDetails: Arformoterol may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Arformoterol"}, {"id": "Leuprolide_INT_Lithium", "text": "Interaction: Leuprolide AND Lithium\nDetails: Lithium may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Lithium"}, {"id": "Leuprolide_INT_Methotrimeprazine", "text": "Interaction: Leuprolide AND Methotrimeprazine\nDetails: Methotrimeprazine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Methotrimeprazine"}, {"id": "Leuprolide_INT_Solifenacin", "text": "Interaction: Leuprolide AND Solifenacin\nDetails: Solifenacin may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Solifenacin"}, {"id": "Leuprolide_INT_Thiothixene", "text": "Interaction: Leuprolide AND Thiothixene\nDetails: Thiothixene may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Thiothixene"}, {"id": "Leuprolide_INT_Vorinostat", "text": "Interaction: Leuprolide AND Vorinostat\nDetails: Vorinostat may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Vorinostat"}, {"id": "Leuprolide_INT_Ezogabine", "text": "Interaction: Leuprolide AND Ezogabine\nDetails: Ezogabine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Ezogabine"}, {"id": "Leuprolide_INT_Indacaterol", "text": "Interaction: Leuprolide AND Indacaterol\nDetails: Indacaterol may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Indacaterol"}, {"id": "Leuprolide_INT_Pasireotide", "text": "Interaction: Leuprolide AND Pasireotide\nDetails: Pasireotide may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Pasireotide"}, {"id": "Leuprolide_INT_Degarelix", "text": "Interaction: Leuprolide AND Degarelix\nDetails: Degarelix may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Degarelix"}, {"id": "Leuprolide_INT_Buserelin", "text": "Interaction: Leuprolide AND Buserelin\nDetails: Buserelin may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Buserelin"}, {"id": "Leuprolide_INT_Histrelin", "text": "Interaction: Leuprolide AND Histrelin\nDetails: Histrelin may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Histrelin"}, {"id": "Leuprolide_INT_Triptorelin", "text": "Interaction: Leuprolide AND Triptorelin\nDetails: Triptorelin may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Triptorelin"}, {"id": "Leuprolide_INT_Rilpivirine", "text": "Interaction: Leuprolide AND Rilpivirine\nDetails: Rilpivirine may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Rilpivirine"}, {"id": "Leuprolide_INT_Fingolimod", "text": "Interaction: Leuprolide AND Fingolimod\nDetails: Fingolimod may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Fingolimod"}, {"id": "Leuprolide_INT_Eribulin", "text": "Interaction: Leuprolide AND Eribulin\nDetails: Eribulin may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Eribulin"}, {"id": "Leuprolide_INT_Mirabegron", "text": "Interaction: Leuprolide AND Mirabegron\nDetails: Mirabegron may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Mirabegron"}, {"id": "Leuprolide_INT_Dabrafenib", "text": "Interaction: Leuprolide AND Dabrafenib\nDetails: Dabrafenib may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Dabrafenib"}, {"id": "Leuprolide_INT_Olodaterol", "text": "Interaction: Leuprolide AND Olodaterol\nDetails: Olodaterol may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Olodaterol"}, {"id": "Leuprolide_INT_Vilanterol", "text": "Interaction: Leuprolide AND Vilanterol\nDetails: Vilanterol may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Vilanterol"}, {"id": "Leuprolide_INT_Choline C 11", "text": "Interaction: Leuprolide AND Choline C 11\nDetails: The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Choline C 11"}, {"id": "Leuprolide_INT_Insulin Human", "text": "Interaction: Leuprolide AND Insulin Human\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Insulin Human"}, {"id": "Leuprolide_INT_Insulin Lispro", "text": "Interaction: Leuprolide AND Insulin Lispro\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Insulin Lispro"}, {"id": "Leuprolide_INT_Insulin Glargine", "text": "Interaction: Leuprolide AND Insulin Glargine\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Insulin Glargine"}, {"id": "Leuprolide_INT_Insulin Pork", "text": "Interaction: Leuprolide AND Insulin Pork\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Insulin Pork"}, {"id": "Leuprolide_INT_Troglitazone", "text": "Interaction: Leuprolide AND Troglitazone\nDetails: The therapeutic efficacy of Troglitazone can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Troglitazone"}, {"id": "Leuprolide_INT_Glimepiride", "text": "Interaction: Leuprolide AND Glimepiride\nDetails: The therapeutic efficacy of Glimepiride can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Glimepiride"}, {"id": "Leuprolide_INT_Acarbose", "text": "Interaction: Leuprolide AND Acarbose\nDetails: The therapeutic efficacy of Acarbose can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Acarbose"}, {"id": "Leuprolide_INT_Metformin", "text": "Interaction: Leuprolide AND Metformin\nDetails: The therapeutic efficacy of Metformin can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Metformin"}, {"id": "Leuprolide_INT_Rosiglitazone", "text": "Interaction: Leuprolide AND Rosiglitazone\nDetails: The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Rosiglitazone"}, {"id": "Leuprolide_INT_Acetohexamide", "text": "Interaction: Leuprolide AND Acetohexamide\nDetails: The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Acetohexamide"}, {"id": "Leuprolide_INT_Miglustat", "text": "Interaction: Leuprolide AND Miglustat\nDetails: The therapeutic efficacy of Miglustat can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Miglustat"}, {"id": "Leuprolide_INT_Miglitol", "text": "Interaction: Leuprolide AND Miglitol\nDetails: The therapeutic efficacy of Miglitol can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Miglitol"}, {"id": "Leuprolide_INT_Chlorpropamide", "text": "Interaction: Leuprolide AND Chlorpropamide\nDetails: The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Chlorpropamide"}, {"id": "Leuprolide_INT_Nateglinide", "text": "Interaction: Leuprolide AND Nateglinide\nDetails: The therapeutic efficacy of Nateglinide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Nateglinide"}, {"id": "Leuprolide_INT_Tolazamide", "text": "Interaction: Leuprolide AND Tolazamide\nDetails: The therapeutic efficacy of Tolazamide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Tolazamide"}, {"id": "Leuprolide_INT_Repaglinide", "text": "Interaction: Leuprolide AND Repaglinide\nDetails: The therapeutic efficacy of Repaglinide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Repaglinide"}, {"id": "Leuprolide_INT_Phenformin", "text": "Interaction: Leuprolide AND Phenformin\nDetails: The therapeutic efficacy of Phenformin can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Phenformin"}, {"id": "Leuprolide_INT_Glyburide", "text": "Interaction: Leuprolide AND Glyburide\nDetails: The therapeutic efficacy of Glyburide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Glyburide"}, {"id": "Leuprolide_INT_Glipizide", "text": "Interaction: Leuprolide AND Glipizide\nDetails: The therapeutic efficacy of Glipizide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Glipizide"}, {"id": "Leuprolide_INT_Gliclazide", "text": "Interaction: Leuprolide AND Gliclazide\nDetails: The therapeutic efficacy of Gliclazide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Gliclazide"}, {"id": "Leuprolide_INT_Tolbutamide", "text": "Interaction: Leuprolide AND Tolbutamide\nDetails: The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Tolbutamide"}, {"id": "Leuprolide_INT_Pioglitazone", "text": "Interaction: Leuprolide AND Pioglitazone\nDetails: The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Pioglitazone"}, {"id": "Leuprolide_INT_Gliquidone", "text": "Interaction: Leuprolide AND Gliquidone\nDetails: The therapeutic efficacy of Gliquidone can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Gliquidone"}, {"id": "Leuprolide_INT_Mitiglinide", "text": "Interaction: Leuprolide AND Mitiglinide\nDetails: The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Mitiglinide"}, {"id": "Leuprolide_INT_Sitagliptin", "text": "Interaction: Leuprolide AND Sitagliptin\nDetails: The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Sitagliptin"}, {"id": "Leuprolide_INT_Exenatide", "text": "Interaction: Leuprolide AND Exenatide\nDetails: The therapeutic efficacy of Exenatide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Exenatide"}, {"id": "Leuprolide_INT_Pramlintide", "text": "Interaction: Leuprolide AND Pramlintide\nDetails: The therapeutic efficacy of Pramlintide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Pramlintide"}, {"id": "Leuprolide_INT_Insulin Aspart", "text": "Interaction: Leuprolide AND Insulin Aspart\nDetails: The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Insulin Aspart"}, {"id": "Leuprolide_INT_Insulin Detemir", "text": "Interaction: Leuprolide AND Insulin Detemir\nDetails: The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Insulin Detemir"}, {"id": "Leuprolide_INT_Insulin Glulisine", "text": "Interaction: Leuprolide AND Insulin Glulisine\nDetails: The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Insulin Glulisine"}, {"id": "Leuprolide_INT_AICA ribonucleotide", "text": "Interaction: Leuprolide AND AICA ribonucleotide\nDetails: The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + AICA ribonucleotide"}, {"id": "Leuprolide_INT_Castanospermine", "text": "Interaction: Leuprolide AND Castanospermine\nDetails: The therapeutic efficacy of Castanospermine can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Castanospermine"}, {"id": "Leuprolide_INT_Buformin", "text": "Interaction: Leuprolide AND Buformin\nDetails: The therapeutic efficacy of Buformin can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Buformin"}, {"id": "Leuprolide_INT_Vildagliptin", "text": "Interaction: Leuprolide AND Vildagliptin\nDetails: The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Vildagliptin"}, {"id": "Leuprolide_INT_Voglibose", "text": "Interaction: Leuprolide AND Voglibose\nDetails: The therapeutic efficacy of Voglibose can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Voglibose"}, {"id": "Leuprolide_INT_Alogliptin", "text": "Interaction: Leuprolide AND Alogliptin\nDetails: The therapeutic efficacy of Alogliptin can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Alogliptin"}, {"id": "Leuprolide_INT_Sulodexide", "text": "Interaction: Leuprolide AND Sulodexide\nDetails: The therapeutic efficacy of Sulodexide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Sulodexide"}, {"id": "Leuprolide_INT_Saxagliptin", "text": "Interaction: Leuprolide AND Saxagliptin\nDetails: The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Saxagliptin"}, {"id": "Leuprolide_INT_Liraglutide", "text": "Interaction: Leuprolide AND Liraglutide\nDetails: The therapeutic efficacy of Liraglutide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Liraglutide"}, {"id": "Leuprolide_INT_Linagliptin", "text": "Interaction: Leuprolide AND Linagliptin\nDetails: The therapeutic efficacy of Linagliptin can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Linagliptin"}, {"id": "Leuprolide_INT_Canagliflozin", "text": "Interaction: Leuprolide AND Canagliflozin\nDetails: The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Canagliflozin"}, {"id": "Leuprolide_INT_Glibornuride", "text": "Interaction: Leuprolide AND Glibornuride\nDetails: The therapeutic efficacy of Glibornuride can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Glibornuride"}, {"id": "Leuprolide_INT_Empagliflozin", "text": "Interaction: Leuprolide AND Empagliflozin\nDetails: The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Empagliflozin"}, {"id": "Leuprolide_INT_Dulaglutide", "text": "Interaction: Leuprolide AND Dulaglutide\nDetails: The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Dulaglutide"}, {"id": "Leuprolide_INT_Ciglitazone", "text": "Interaction: Leuprolide AND Ciglitazone\nDetails: The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Ciglitazone"}, {"id": "Leuprolide_INT_Allicin", "text": "Interaction: Leuprolide AND Allicin\nDetails: The therapeutic efficacy of Allicin can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Allicin"}, {"id": "Leuprolide_INT_2,4-thiazolidinedione", "text": "Interaction: Leuprolide AND 2,4-thiazolidinedione\nDetails: The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + 2,4-thiazolidinedione"}, {"id": "Leuprolide_INT_Bempedoic acid", "text": "Interaction: Leuprolide AND Bempedoic acid\nDetails: The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Bempedoic acid"}, {"id": "Leuprolide_INT_Gusperimus", "text": "Interaction: Leuprolide AND Gusperimus\nDetails: The therapeutic efficacy of Gusperimus can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Gusperimus"}, {"id": "Leuprolide_INT_Sotagliflozin", "text": "Interaction: Leuprolide AND Sotagliflozin\nDetails: The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Sotagliflozin"}, {"id": "Leuprolide_INT_Balaglitazone", "text": "Interaction: Leuprolide AND Balaglitazone\nDetails: The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Balaglitazone"}, {"id": "Leuprolide_INT_Deoxyspergualin", "text": "Interaction: Leuprolide AND Deoxyspergualin\nDetails: The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Deoxyspergualin"}, {"id": "Leuprolide_INT_Carbutamide", "text": "Interaction: Leuprolide AND Carbutamide\nDetails: The therapeutic efficacy of Carbutamide can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Leuprolide + Carbutamide"}, {"id": "Peginterferon alfa-2a_GEN", "text": "Drug: Peginterferon alfa-2a\nDescription: Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype...", "source": "Peginterferon alfa-2a"}, {"id": "Peginterferon alfa-2a_CLIN", "text": "Drug: Peginterferon alfa-2a\nMechanism: Peginterferon alfa-2a is derived from recombinant human interferon's alfa-2a moeity [FDA Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates th...\nToxicity: Peginterferon alfa-2a may manifest neuropsychiatric complications include suicide, suicidal ideation, homicidal ideation, depression, relapse of drug addiction, and drug overdose [FDA Label]. Hyperten...", "source": "Peginterferon alfa-2a"}, {"id": "Peginterferon alfa-2a_INT_Metamizole", "text": "Interaction: Peginterferon alfa-2a AND Metamizole\nDetails: The risk or severity of myelosuppression can be increased when Metamizole is combined with Peginterferon alfa-2a.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2a + Metamizole"}, {"id": "Peginterferon alfa-2a_INT_Clozapine", "text": "Interaction: Peginterferon alfa-2a AND Clozapine\nDetails: The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Clozapine.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2a + Clozapine"}, {"id": "Peginterferon alfa-2a_INT_Telbivudine", "text": "Interaction: Peginterferon alfa-2a AND Telbivudine\nDetails: The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Telbivudine.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2a + Telbivudine"}, {"id": "Peginterferon alfa-2a_INT_Aldesleukin", "text": "Interaction: Peginterferon alfa-2a AND Aldesleukin\nDetails: The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2a + Aldesleukin"}, {"id": "Peginterferon alfa-2a_INT_Tizanidine", "text": "Interaction: Peginterferon alfa-2a AND Tizanidine\nDetails: The serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2a.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2a + Tizanidine"}, {"id": "Peginterferon alfa-2a_INT_Pegloticase", "text": "Interaction: Peginterferon alfa-2a AND Pegloticase\nDetails: The therapeutic efficacy of Peginterferon alfa-2a can be decreased when used in combination with Pegloticase.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2a + Pegloticase"}, {"id": "Peginterferon alfa-2a_INT_Ambroxol acefyllinate", "text": "Interaction: Peginterferon alfa-2a AND Ambroxol acefyllinate\nDetails: The metabolism of Ambroxol acefyllinate can be decreased when combined with Peginterferon alfa-2a.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2a + Ambroxol acefyllinate"}, {"id": "Peginterferon alfa-2a_INT_Theophylline", "text": "Interaction: Peginterferon alfa-2a AND Theophylline\nDetails: The metabolism of Theophylline can be decreased when combined with Peginterferon alfa-2a.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2a + Theophylline"}, {"id": "Peginterferon alfa-2a_INT_Dyphylline", "text": "Interaction: Peginterferon alfa-2a AND Dyphylline\nDetails: The metabolism of Dyphylline can be decreased when combined with Peginterferon alfa-2a.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2a + Dyphylline"}, {"id": "Peginterferon alfa-2a_INT_Aminophylline", "text": "Interaction: Peginterferon alfa-2a AND Aminophylline\nDetails: The metabolism of Aminophylline can be decreased when combined with Peginterferon alfa-2a.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2a + Aminophylline"}, {"id": "Peginterferon alfa-2a_INT_Methadone", "text": "Interaction: Peginterferon alfa-2a AND Methadone\nDetails: The serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2a.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2a + Methadone"}, {"id": "Peginterferon alfa-2a_INT_Ribavirin", "text": "Interaction: Peginterferon alfa-2a AND Ribavirin\nDetails: The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ribavirin.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2a + Ribavirin"}, {"id": "Peginterferon alfa-2a_INT_Zidovudine", "text": "Interaction: Peginterferon alfa-2a AND Zidovudine\nDetails: The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Zidovudine.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2a + Zidovudine"}, {"id": "Alteplase_GEN", "text": "Drug: Alteplase\nDescription: ...", "source": "Alteplase"}, {"id": "Phylloquinone_GEN", "text": "Drug: Phylloquinone\nDescription: ...", "source": "Phylloquinone"}, {"id": "Calcium_GEN", "text": "Drug: Calcium\nDescription: ...", "source": "Calcium"}, {"id": "Alteplase_GEN", "text": "Drug: Alteplase\nDescription: Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells...", "source": "Alteplase"}, {"id": "Alteplase_CLIN", "text": "Drug: Alteplase\nMechanism: Alteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn ...\nToxicity: ...", "source": "Alteplase"}, {"id": "Alteplase_INT_Aprotinin", "text": "Interaction: Alteplase AND Aprotinin\nDetails: The therapeutic efficacy of Alteplase can be decreased when used in combination with Aprotinin.\nRisk: Monitor closely.", "source": "Alteplase + Aprotinin"}, {"id": "Alteplase_INT_Limaprost", "text": "Interaction: Alteplase AND Limaprost\nDetails: The risk or severity of adverse effects can be increased when Limaprost is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Limaprost"}, {"id": "Alteplase_INT_Dabigatran etexilate", "text": "Interaction: Alteplase AND Dabigatran etexilate\nDetails: Alteplase may increase the anticoagulant activities of Dabigatran etexilate.\nRisk: Monitor closely.", "source": "Alteplase + Dabigatran etexilate"}, {"id": "Alteplase_INT_Nitroglycerin", "text": "Interaction: Alteplase AND Nitroglycerin\nDetails: The serum concentration of Alteplase can be decreased when it is combined with Nitroglycerin.\nRisk: Monitor closely.", "source": "Alteplase + Nitroglycerin"}, {"id": "Alteplase_INT_Lepirudin", "text": "Interaction: Alteplase AND Lepirudin\nDetails: Alteplase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Alteplase + Lepirudin"}, {"id": "Alteplase_INT_Bivalirudin", "text": "Interaction: Alteplase AND Bivalirudin\nDetails: Alteplase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Alteplase + Bivalirudin"}, {"id": "Alteplase_INT_Abciximab", "text": "Interaction: Alteplase AND Abciximab\nDetails: Alteplase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Alteplase + Abciximab"}, {"id": "Alteplase_INT_Becaplermin", "text": "Interaction: Alteplase AND Becaplermin\nDetails: Alteplase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Alteplase + Becaplermin"}, {"id": "Alteplase_INT_Dicoumarol", "text": "Interaction: Alteplase AND Dicoumarol\nDetails: Alteplase may increase the anticoagulant activities of Dicoumarol.\nRisk: Monitor closely.", "source": "Alteplase + Dicoumarol"}, {"id": "Alteplase_INT_Argatroban", "text": "Interaction: Alteplase AND Argatroban\nDetails: Alteplase may increase the anticoagulant activities of Argatroban.\nRisk: Monitor closely.", "source": "Alteplase + Argatroban"}, {"id": "Alteplase_INT_Ardeparin", "text": "Interaction: Alteplase AND Ardeparin\nDetails: Alteplase may increase the anticoagulant activities of Ardeparin.\nRisk: Monitor closely.", "source": "Alteplase + Ardeparin"}, {"id": "Alteplase_INT_Phenindione", "text": "Interaction: Alteplase AND Phenindione\nDetails: Alteplase may increase the anticoagulant activities of Phenindione.\nRisk: Monitor closely.", "source": "Alteplase + Phenindione"}, {"id": "Alteplase_INT_Fondaparinux sodium", "text": "Interaction: Alteplase AND Fondaparinux sodium\nDetails: Alteplase may increase the anticoagulant activities of Fondaparinux sodium.\nRisk: Monitor closely.", "source": "Alteplase + Fondaparinux sodium"}, {"id": "Alteplase_INT_Warfarin", "text": "Interaction: Alteplase AND Warfarin\nDetails: Alteplase may increase the anticoagulant activities of Warfarin.\nRisk: Monitor closely.", "source": "Alteplase + Warfarin"}, {"id": "Alteplase_INT_Pentosan Polysulfate", "text": "Interaction: Alteplase AND Pentosan Polysulfate\nDetails: Alteplase may increase the anticoagulant activities of Pentosan Polysulfate.\nRisk: Monitor closely.", "source": "Alteplase + Pentosan Polysulfate"}, {"id": "Alteplase_INT_Phenprocoumon", "text": "Interaction: Alteplase AND Phenprocoumon\nDetails: Alteplase may increase the anticoagulant activities of Phenprocoumon.\nRisk: Monitor closely.", "source": "Alteplase + Phenprocoumon"}, {"id": "Alteplase_INT_Edetic Acid", "text": "Interaction: Alteplase AND Edetic Acid\nDetails: Alteplase may increase the anticoagulant activities of Edetic Acid.\nRisk: Monitor closely.", "source": "Alteplase + Edetic Acid"}, {"id": "Alteplase_INT_Heparin", "text": "Interaction: Alteplase AND Heparin\nDetails: Alteplase may increase the anticoagulant activities of Heparin.\nRisk: Monitor closely.", "source": "Alteplase + Heparin"}, {"id": "Alteplase_INT_Enoxaparin", "text": "Interaction: Alteplase AND Enoxaparin\nDetails: Alteplase may increase the anticoagulant activities of Enoxaparin.\nRisk: Monitor closely.", "source": "Alteplase + Enoxaparin"}, {"id": "Alteplase_INT_Acenocoumarol", "text": "Interaction: Alteplase AND Acenocoumarol\nDetails: Alteplase may increase the anticoagulant activities of Acenocoumarol.\nRisk: Monitor closely.", "source": "Alteplase + Acenocoumarol"}, {"id": "Alteplase_INT_Citric Acid", "text": "Interaction: Alteplase AND Citric Acid\nDetails: Alteplase may increase the anticoagulant activities of Citric Acid.\nRisk: Monitor closely.", "source": "Alteplase + Citric Acid"}, {"id": "Alteplase_INT_Ximelagatran", "text": "Interaction: Alteplase AND Ximelagatran\nDetails: Alteplase may increase the anticoagulant activities of Ximelagatran.\nRisk: Monitor closely.", "source": "Alteplase + Ximelagatran"}, {"id": "Alteplase_INT_Ancrod", "text": "Interaction: Alteplase AND Ancrod\nDetails: Alteplase may increase the anticoagulant activities of Ancrod.\nRisk: Monitor closely.", "source": "Alteplase + Ancrod"}, {"id": "Alteplase_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Alteplase AND Pentaerythritol Tetranitrate\nDetails: Alteplase may increase the anticoagulant activities of Pentaerythritol Tetranitrate.\nRisk: Monitor closely.", "source": "Alteplase + Pentaerythritol Tetranitrate"}, {"id": "Alteplase_INT_Rivaroxaban", "text": "Interaction: Alteplase AND Rivaroxaban\nDetails: Alteplase may increase the anticoagulant activities of Rivaroxaban.\nRisk: Monitor closely.", "source": "Alteplase + Rivaroxaban"}, {"id": "Alteplase_INT_Sulodexide", "text": "Interaction: Alteplase AND Sulodexide\nDetails: Alteplase may increase the anticoagulant activities of Sulodexide.\nRisk: Monitor closely.", "source": "Alteplase + Sulodexide"}, {"id": "Alteplase_INT_Idraparinux", "text": "Interaction: Alteplase AND Idraparinux\nDetails: Alteplase may increase the anticoagulant activities of Idraparinux.\nRisk: Monitor closely.", "source": "Alteplase + Idraparinux"}, {"id": "Alteplase_INT_Apixaban", "text": "Interaction: Alteplase AND Apixaban\nDetails: Alteplase may increase the anticoagulant activities of Apixaban.\nRisk: Monitor closely.", "source": "Alteplase + Apixaban"}, {"id": "Alteplase_INT_Otamixaban", "text": "Interaction: Alteplase AND Otamixaban\nDetails: Alteplase may increase the anticoagulant activities of Otamixaban.\nRisk: Monitor closely.", "source": "Alteplase + Otamixaban"}, {"id": "Alteplase_INT_Danaparoid", "text": "Interaction: Alteplase AND Danaparoid\nDetails: Alteplase may increase the anticoagulant activities of Danaparoid.\nRisk: Monitor closely.", "source": "Alteplase + Danaparoid"}, {"id": "Alteplase_INT_Dalteparin", "text": "Interaction: Alteplase AND Dalteparin\nDetails: Alteplase may increase the anticoagulant activities of Dalteparin.\nRisk: Monitor closely.", "source": "Alteplase + Dalteparin"}, {"id": "Alteplase_INT_Ferulic acid", "text": "Interaction: Alteplase AND Ferulic acid\nDetails: Alteplase may increase the anticoagulant activities of Ferulic acid.\nRisk: Monitor closely.", "source": "Alteplase + Ferulic acid"}, {"id": "Alteplase_INT_Ethyl biscoumacetate", "text": "Interaction: Alteplase AND Ethyl biscoumacetate\nDetails: Alteplase may increase the anticoagulant activities of Ethyl biscoumacetate.\nRisk: Monitor closely.", "source": "Alteplase + Ethyl biscoumacetate"}, {"id": "Alteplase_INT_Nadroparin", "text": "Interaction: Alteplase AND Nadroparin\nDetails: Alteplase may increase the anticoagulant activities of Nadroparin.\nRisk: Monitor closely.", "source": "Alteplase + Nadroparin"}, {"id": "Alteplase_INT_Edoxaban", "text": "Interaction: Alteplase AND Edoxaban\nDetails: Alteplase may increase the anticoagulant activities of Edoxaban.\nRisk: Monitor closely.", "source": "Alteplase + Edoxaban"}, {"id": "Alteplase_INT_Dextran", "text": "Interaction: Alteplase AND Dextran\nDetails: Alteplase may increase the anticoagulant activities of Dextran.\nRisk: Monitor closely.", "source": "Alteplase + Dextran"}, {"id": "Alteplase_INT_Reviparin", "text": "Interaction: Alteplase AND Reviparin\nDetails: Alteplase may increase the anticoagulant activities of Reviparin.\nRisk: Monitor closely.", "source": "Alteplase + Reviparin"}, {"id": "Alteplase_INT_Certoparin", "text": "Interaction: Alteplase AND Certoparin\nDetails: Alteplase may increase the anticoagulant activities of Certoparin.\nRisk: Monitor closely.", "source": "Alteplase + Certoparin"}, {"id": "Alteplase_INT_Dextran 70", "text": "Interaction: Alteplase AND Dextran 70\nDetails: Alteplase may increase the anticoagulant activities of Dextran 70.\nRisk: Monitor closely.", "source": "Alteplase + Dextran 70"}, {"id": "Alteplase_INT_Desirudin", "text": "Interaction: Alteplase AND Desirudin\nDetails: Alteplase may increase the anticoagulant activities of Desirudin.\nRisk: Monitor closely.", "source": "Alteplase + Desirudin"}, {"id": "Alteplase_INT_Dextran 40", "text": "Interaction: Alteplase AND Dextran 40\nDetails: Alteplase may increase the anticoagulant activities of Dextran 40.\nRisk: Monitor closely.", "source": "Alteplase + Dextran 40"}, {"id": "Alteplase_INT_Dextran 75", "text": "Interaction: Alteplase AND Dextran 75\nDetails: Alteplase may increase the anticoagulant activities of Dextran 75.\nRisk: Monitor closely.", "source": "Alteplase + Dextran 75"}, {"id": "Alteplase_INT_Protocatechualdehyde", "text": "Interaction: Alteplase AND Protocatechualdehyde\nDetails: Alteplase may increase the anticoagulant activities of Protocatechualdehyde.\nRisk: Monitor closely.", "source": "Alteplase + Protocatechualdehyde"}, {"id": "Alteplase_INT_Protein C", "text": "Interaction: Alteplase AND Protein C\nDetails: Alteplase may increase the anticoagulant activities of Protein C.\nRisk: Monitor closely.", "source": "Alteplase + Protein C"}, {"id": "Alteplase_INT_Antithrombin III human", "text": "Interaction: Alteplase AND Antithrombin III human\nDetails: Alteplase may increase the anticoagulant activities of Antithrombin III human.\nRisk: Monitor closely.", "source": "Alteplase + Antithrombin III human"}, {"id": "Alteplase_INT_Fondaparinux", "text": "Interaction: Alteplase AND Fondaparinux\nDetails: Alteplase may increase the anticoagulant activities of Fondaparinux.\nRisk: Monitor closely.", "source": "Alteplase + Fondaparinux"}, {"id": "Alteplase_INT_Letaxaban", "text": "Interaction: Alteplase AND Letaxaban\nDetails: Alteplase may increase the anticoagulant activities of Letaxaban.\nRisk: Monitor closely.", "source": "Alteplase + Letaxaban"}, {"id": "Alteplase_INT_Darexaban", "text": "Interaction: Alteplase AND Darexaban\nDetails: Alteplase may increase the anticoagulant activities of Darexaban.\nRisk: Monitor closely.", "source": "Alteplase + Darexaban"}, {"id": "Alteplase_INT_Nafamostat", "text": "Interaction: Alteplase AND Nafamostat\nDetails: Alteplase may increase the anticoagulant activities of Nafamostat.\nRisk: Monitor closely.", "source": "Alteplase + Nafamostat"}, {"id": "Alteplase_INT_Gabexate", "text": "Interaction: Alteplase AND Gabexate\nDetails: Alteplase may increase the anticoagulant activities of Gabexate.\nRisk: Monitor closely.", "source": "Alteplase + Gabexate"}, {"id": "Alteplase_INT_Troxerutin", "text": "Interaction: Alteplase AND Troxerutin\nDetails: Alteplase may increase the anticoagulant activities of Troxerutin.\nRisk: Monitor closely.", "source": "Alteplase + Troxerutin"}, {"id": "Alteplase_INT_Fluindione", "text": "Interaction: Alteplase AND Fluindione\nDetails: Alteplase may increase the anticoagulant activities of Fluindione.\nRisk: Monitor closely.", "source": "Alteplase + Fluindione"}, {"id": "Alteplase_INT_Protein S human", "text": "Interaction: Alteplase AND Protein S human\nDetails: Alteplase may increase the anticoagulant activities of Protein S human.\nRisk: Monitor closely.", "source": "Alteplase + Protein S human"}, {"id": "Alteplase_INT_Melagatran", "text": "Interaction: Alteplase AND Melagatran\nDetails: Alteplase may increase the anticoagulant activities of Melagatran.\nRisk: Monitor closely.", "source": "Alteplase + Melagatran"}, {"id": "Alteplase_INT_Salicylic acid", "text": "Interaction: Alteplase AND Salicylic acid\nDetails: The risk or severity of adverse effects can be increased when Salicylic acid is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Salicylic acid"}, {"id": "Alteplase_INT_Acetylsalicylic acid", "text": "Interaction: Alteplase AND Acetylsalicylic acid\nDetails: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Acetylsalicylic acid"}, {"id": "Alteplase_INT_Aminosalicylic Acid", "text": "Interaction: Alteplase AND Aminosalicylic Acid\nDetails: The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Aminosalicylic Acid"}, {"id": "Alteplase_INT_Mesalazine", "text": "Interaction: Alteplase AND Mesalazine\nDetails: The risk or severity of adverse effects can be increased when Mesalazine is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Mesalazine"}, {"id": "Alteplase_INT_Diflunisal", "text": "Interaction: Alteplase AND Diflunisal\nDetails: The risk or severity of adverse effects can be increased when Diflunisal is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Diflunisal"}, {"id": "Alteplase_INT_Balsalazide", "text": "Interaction: Alteplase AND Balsalazide\nDetails: The risk or severity of adverse effects can be increased when Balsalazide is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Balsalazide"}, {"id": "Alteplase_INT_Olsalazine", "text": "Interaction: Alteplase AND Olsalazine\nDetails: The risk or severity of adverse effects can be increased when Olsalazine is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Olsalazine"}, {"id": "Alteplase_INT_dersalazine", "text": "Interaction: Alteplase AND dersalazine\nDetails: The risk or severity of adverse effects can be increased when dersalazine is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + dersalazine"}, {"id": "Alteplase_INT_Nitroaspirin", "text": "Interaction: Alteplase AND Nitroaspirin\nDetails: The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Nitroaspirin"}, {"id": "Alteplase_INT_Aloxiprin", "text": "Interaction: Alteplase AND Aloxiprin\nDetails: The risk or severity of adverse effects can be increased when Aloxiprin is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Aloxiprin"}, {"id": "Alteplase_INT_Guacetisal", "text": "Interaction: Alteplase AND Guacetisal\nDetails: The risk or severity of adverse effects can be increased when Guacetisal is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Guacetisal"}, {"id": "Alteplase_INT_Carbaspirin calcium", "text": "Interaction: Alteplase AND Carbaspirin calcium\nDetails: The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Carbaspirin calcium"}, {"id": "Alteplase_INT_Hemoglobin crosfumaril", "text": "Interaction: Alteplase AND Hemoglobin crosfumaril\nDetails: The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Hemoglobin crosfumaril"}, {"id": "Alteplase_INT_Methyl salicylate", "text": "Interaction: Alteplase AND Methyl salicylate\nDetails: The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Methyl salicylate"}, {"id": "Alteplase_INT_Trolamine salicylate", "text": "Interaction: Alteplase AND Trolamine salicylate\nDetails: The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Trolamine salicylate"}, {"id": "Alteplase_INT_Eptifibatide", "text": "Interaction: Alteplase AND Eptifibatide\nDetails: Eptifibatide may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Eptifibatide"}, {"id": "Alteplase_INT_Ticlopidine", "text": "Interaction: Alteplase AND Ticlopidine\nDetails: Ticlopidine may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Ticlopidine"}, {"id": "Alteplase_INT_Tirofiban", "text": "Interaction: Alteplase AND Tirofiban\nDetails: Tirofiban may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Tirofiban"}, {"id": "Alteplase_INT_Dipyridamole", "text": "Interaction: Alteplase AND Dipyridamole\nDetails: Dipyridamole may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Dipyridamole"}, {"id": "Alteplase_INT_Clopidogrel", "text": "Interaction: Alteplase AND Clopidogrel\nDetails: Clopidogrel may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Clopidogrel"}, {"id": "Alteplase_INT_Prasugrel", "text": "Interaction: Alteplase AND Prasugrel\nDetails: Prasugrel may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Prasugrel"}, {"id": "Alteplase_INT_Vorapaxar", "text": "Interaction: Alteplase AND Vorapaxar\nDetails: Vorapaxar may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Vorapaxar"}, {"id": "Alteplase_INT_Milrinone", "text": "Interaction: Alteplase AND Milrinone\nDetails: Milrinone may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Milrinone"}, {"id": "Alteplase_INT_Anagrelide", "text": "Interaction: Alteplase AND Anagrelide\nDetails: Anagrelide may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Anagrelide"}, {"id": "Alteplase_INT_Epinastine", "text": "Interaction: Alteplase AND Epinastine\nDetails: Epinastine may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Epinastine"}, {"id": "Alteplase_INT_Alprostadil", "text": "Interaction: Alteplase AND Alprostadil\nDetails: Alprostadil may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Alprostadil"}, {"id": "Alteplase_INT_Pentoxifylline", "text": "Interaction: Alteplase AND Pentoxifylline\nDetails: Pentoxifylline may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Pentoxifylline"}, {"id": "Alteplase_INT_Azelastine", "text": "Interaction: Alteplase AND Azelastine\nDetails: Azelastine may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Azelastine"}, {"id": "Alteplase_INT_Iloprost", "text": "Interaction: Alteplase AND Iloprost\nDetails: Iloprost may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Iloprost"}, {"id": "Alteplase_INT_Cilostazol", "text": "Interaction: Alteplase AND Cilostazol\nDetails: Cilostazol may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Cilostazol"}, {"id": "Alteplase_INT_Ridogrel", "text": "Interaction: Alteplase AND Ridogrel\nDetails: Ridogrel may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Ridogrel"}, {"id": "Alteplase_INT_Sevoflurane", "text": "Interaction: Alteplase AND Sevoflurane\nDetails: Sevoflurane may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Sevoflurane"}, {"id": "Alteplase_INT_Epoprostenol", "text": "Interaction: Alteplase AND Epoprostenol\nDetails: Epoprostenol may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Epoprostenol"}, {"id": "Alteplase_INT_Resveratrol", "text": "Interaction: Alteplase AND Resveratrol\nDetails: Resveratrol may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Resveratrol"}, {"id": "Alteplase_INT_Nimesulide", "text": "Interaction: Alteplase AND Nimesulide\nDetails: Nimesulide may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Nimesulide"}, {"id": "Alteplase_INT_Tesmilifene", "text": "Interaction: Alteplase AND Tesmilifene\nDetails: Tesmilifene may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Tesmilifene"}, {"id": "Alteplase_INT_Defibrotide", "text": "Interaction: Alteplase AND Defibrotide\nDetails: Defibrotide may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Defibrotide"}, {"id": "Alteplase_INT_SRT501", "text": "Interaction: Alteplase AND SRT501\nDetails: SRT501 may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + SRT501"}, {"id": "Alteplase_INT_Beraprost", "text": "Interaction: Alteplase AND Beraprost\nDetails: Beraprost may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Beraprost"}, {"id": "Alteplase_INT_Ibudilast", "text": "Interaction: Alteplase AND Ibudilast\nDetails: Ibudilast may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Ibudilast"}, {"id": "Alteplase_INT_Andrographolide", "text": "Interaction: Alteplase AND Andrographolide\nDetails: Andrographolide may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Andrographolide"}, {"id": "Alteplase_INT_eplivanserine", "text": "Interaction: Alteplase AND eplivanserine\nDetails: eplivanserine may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + eplivanserine"}, {"id": "Alteplase_INT_Cangrelor", "text": "Interaction: Alteplase AND Cangrelor\nDetails: Cangrelor may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Cangrelor"}, {"id": "Alteplase_INT_Tranilast", "text": "Interaction: Alteplase AND Tranilast\nDetails: Tranilast may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Tranilast"}, {"id": "Alteplase_INT_Triflusal", "text": "Interaction: Alteplase AND Triflusal\nDetails: Triflusal may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Triflusal"}, {"id": "Alteplase_INT_Icosapent ethyl", "text": "Interaction: Alteplase AND Icosapent ethyl\nDetails: Icosapent ethyl may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Icosapent ethyl"}, {"id": "Alteplase_INT_Ifenprodil", "text": "Interaction: Alteplase AND Ifenprodil\nDetails: Ifenprodil may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Ifenprodil"}, {"id": "Alteplase_INT_Trapidil", "text": "Interaction: Alteplase AND Trapidil\nDetails: Trapidil may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Trapidil"}, {"id": "Alteplase_INT_Naftopidil", "text": "Interaction: Alteplase AND Naftopidil\nDetails: Naftopidil may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Naftopidil"}, {"id": "Alteplase_INT_Sarpogrelate", "text": "Interaction: Alteplase AND Sarpogrelate\nDetails: Sarpogrelate may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Sarpogrelate"}, {"id": "Alteplase_INT_Eplivanserin", "text": "Interaction: Alteplase AND Eplivanserin\nDetails: Eplivanserin may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Eplivanserin"}, {"id": "Alteplase_INT_Ifetroban", "text": "Interaction: Alteplase AND Ifetroban\nDetails: Ifetroban may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Ifetroban"}, {"id": "Alteplase_INT_Ketanserin", "text": "Interaction: Alteplase AND Ketanserin\nDetails: Ketanserin may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Ketanserin"}, {"id": "Alteplase_INT_Indobufen", "text": "Interaction: Alteplase AND Indobufen\nDetails: Indobufen may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Indobufen"}, {"id": "Alteplase_INT_Butylphthalide", "text": "Interaction: Alteplase AND Butylphthalide\nDetails: Butylphthalide may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Butylphthalide"}, {"id": "Alteplase_INT_Hydroxytyrosol", "text": "Interaction: Alteplase AND Hydroxytyrosol\nDetails: Hydroxytyrosol may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Hydroxytyrosol"}, {"id": "Alteplase_INT_Ramatroban", "text": "Interaction: Alteplase AND Ramatroban\nDetails: Ramatroban may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Ramatroban"}, {"id": "Alteplase_INT_Picotamide", "text": "Interaction: Alteplase AND Picotamide\nDetails: Picotamide may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Picotamide"}, {"id": "Alteplase_INT_Cloricromen", "text": "Interaction: Alteplase AND Cloricromen\nDetails: Cloricromen may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Cloricromen"}, {"id": "Alteplase_INT_Linsidomine", "text": "Interaction: Alteplase AND Linsidomine\nDetails: Linsidomine may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Linsidomine"}, {"id": "Alteplase_INT_Buflomedil", "text": "Interaction: Alteplase AND Buflomedil\nDetails: Buflomedil may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Buflomedil"}, {"id": "Alteplase_INT_Relcovaptan", "text": "Interaction: Alteplase AND Relcovaptan\nDetails: Relcovaptan may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Relcovaptan"}, {"id": "Alteplase_INT_Ticagrelor", "text": "Interaction: Alteplase AND Ticagrelor\nDetails: Ticagrelor may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Alteplase + Ticagrelor"}, {"id": "Alteplase_INT_Treprostinil", "text": "Interaction: Alteplase AND Treprostinil\nDetails: The risk or severity of adverse effects can be increased when Alteplase is combined with Treprostinil.\nRisk: Monitor closely.", "source": "Alteplase + Treprostinil"}, {"id": "Sermorelin_GEN", "text": "Drug: Sermorelin\nDescription: Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues...", "source": "Sermorelin"}, {"id": "Sermorelin_CLIN", "text": "Drug: Sermorelin\nMechanism: Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion....\nToxicity: ...", "source": "Sermorelin"}, {"id": "Interferon alfa-n1_GEN", "text": "Drug: Interferon alfa-n1\nDescription: Purified, natural (n is for natural) glycosylated human interferon alpha proteins 166 residues...", "source": "Interferon alfa-n1"}, {"id": "Interferon alfa-n1_CLIN", "text": "Drug: Interferon alfa-n1\nMechanism: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselv...\nToxicity: ...", "source": "Interferon alfa-n1"}, {"id": "Interferon alfa-n1_INT_Ambroxol acefyllinate", "text": "Interaction: Interferon alfa-n1 AND Ambroxol acefyllinate\nDetails: The metabolism of Ambroxol acefyllinate can be decreased when combined with Interferon alfa-n1.\nRisk: Monitor closely.", "source": "Interferon alfa-n1 + Ambroxol acefyllinate"}, {"id": "Interferon alfa-n1_INT_Theophylline", "text": "Interaction: Interferon alfa-n1 AND Theophylline\nDetails: The metabolism of Theophylline can be decreased when combined with Interferon alfa-n1.\nRisk: Monitor closely.", "source": "Interferon alfa-n1 + Theophylline"}, {"id": "Interferon alfa-n1_INT_Dyphylline", "text": "Interaction: Interferon alfa-n1 AND Dyphylline\nDetails: The metabolism of Dyphylline can be decreased when combined with Interferon alfa-n1.\nRisk: Monitor closely.", "source": "Interferon alfa-n1 + Dyphylline"}, {"id": "Interferon alfa-n1_INT_Aminophylline", "text": "Interaction: Interferon alfa-n1 AND Aminophylline\nDetails: The metabolism of Aminophylline can be decreased when combined with Interferon alfa-n1.\nRisk: Monitor closely.", "source": "Interferon alfa-n1 + Aminophylline"}, {"id": "Interferon alfa-n1_INT_Zidovudine", "text": "Interaction: Interferon alfa-n1 AND Zidovudine\nDetails: The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Zidovudine.\nRisk: Monitor closely.", "source": "Interferon alfa-n1 + Zidovudine"}, {"id": "Darbepoetin alfa_GEN", "text": "Drug: Darbepoetin alfa\nDescription: Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology....", "source": "Darbepoetin alfa"}, {"id": "Darbepoetin alfa_CLIN", "text": "Drug: Darbepoetin alfa\nMechanism: Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with\r\nprogenitor stem cells to increase red cell production. Binding of erythrop...\nToxicity: ...", "source": "Darbepoetin alfa"}, {"id": "Darbepoetin alfa_INT_Nandrolone phenpropionate", "text": "Interaction: Darbepoetin alfa AND Nandrolone phenpropionate\nDetails: Nandrolone phenpropionate may increase the stimulatory activities of Darbepoetin alfa.\nRisk: Monitor closely.", "source": "Darbepoetin alfa + Nandrolone phenpropionate"}, {"id": "Darbepoetin alfa_INT_Nandrolone decanoate", "text": "Interaction: Darbepoetin alfa AND Nandrolone decanoate\nDetails: Nandrolone decanoate may increase the stimulatory activities of Darbepoetin alfa.\nRisk: Monitor closely.", "source": "Darbepoetin alfa + Nandrolone decanoate"}, {"id": "Darbepoetin alfa_INT_Lenalidomide", "text": "Interaction: Darbepoetin alfa AND Lenalidomide\nDetails: Darbepoetin alfa may increase the thrombogenic activities of Lenalidomide.\nRisk: Monitor closely.", "source": "Darbepoetin alfa + Lenalidomide"}, {"id": "Darbepoetin alfa_INT_Thalidomide", "text": "Interaction: Darbepoetin alfa AND Thalidomide\nDetails: Darbepoetin alfa may increase the thrombogenic activities of Thalidomide.\nRisk: Monitor closely.", "source": "Darbepoetin alfa + Thalidomide"}, {"id": "Urokinase_GEN", "text": "Drug: Urokinase\nDescription: ...", "source": "Urokinase"}, {"id": "Phylloquinone_GEN", "text": "Drug: Phylloquinone\nDescription: ...", "source": "Phylloquinone"}, {"id": "Calcium_GEN", "text": "Drug: Calcium\nDescription: ...", "source": "Calcium"}, {"id": "Urokinase_GEN", "text": "Drug: Urokinase\nDescription: Low molecular weight form of human urokinase, that consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Recombinant urokinase plasminogen activator...", "source": "Urokinase"}, {"id": "Urokinase_CLIN", "text": "Drug: Urokinase\nMechanism: Urokinase acts on the endogenous fibrinolytic system. It cleaves the Arg-Val bond in plasminogen to produce active plasmin. Plasmin degrades fibrin clots as well as fibrinogen and other plasma protein...\nToxicity: ...", "source": "Urokinase"}, {"id": "Urokinase_INT_Lepirudin", "text": "Interaction: Urokinase AND Lepirudin\nDetails: Urokinase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Urokinase + Lepirudin"}, {"id": "Urokinase_INT_Bivalirudin", "text": "Interaction: Urokinase AND Bivalirudin\nDetails: Urokinase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Urokinase + Bivalirudin"}, {"id": "Urokinase_INT_Abciximab", "text": "Interaction: Urokinase AND Abciximab\nDetails: Urokinase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Urokinase + Abciximab"}, {"id": "Urokinase_INT_Becaplermin", "text": "Interaction: Urokinase AND Becaplermin\nDetails: Urokinase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Urokinase + Becaplermin"}, {"id": "Urokinase_INT_Dicoumarol", "text": "Interaction: Urokinase AND Dicoumarol\nDetails: Urokinase may increase the anticoagulant activities of Dicoumarol.\nRisk: Monitor closely.", "source": "Urokinase + Dicoumarol"}, {"id": "Urokinase_INT_Argatroban", "text": "Interaction: Urokinase AND Argatroban\nDetails: Urokinase may increase the anticoagulant activities of Argatroban.\nRisk: Monitor closely.", "source": "Urokinase + Argatroban"}, {"id": "Urokinase_INT_Ardeparin", "text": "Interaction: Urokinase AND Ardeparin\nDetails: Urokinase may increase the anticoagulant activities of Ardeparin.\nRisk: Monitor closely.", "source": "Urokinase + Ardeparin"}, {"id": "Urokinase_INT_Phenindione", "text": "Interaction: Urokinase AND Phenindione\nDetails: Urokinase may increase the anticoagulant activities of Phenindione.\nRisk: Monitor closely.", "source": "Urokinase + Phenindione"}, {"id": "Urokinase_INT_Fondaparinux sodium", "text": "Interaction: Urokinase AND Fondaparinux sodium\nDetails: Urokinase may increase the anticoagulant activities of Fondaparinux sodium.\nRisk: Monitor closely.", "source": "Urokinase + Fondaparinux sodium"}, {"id": "Urokinase_INT_Warfarin", "text": "Interaction: Urokinase AND Warfarin\nDetails: Urokinase may increase the anticoagulant activities of Warfarin.\nRisk: Monitor closely.", "source": "Urokinase + Warfarin"}, {"id": "Urokinase_INT_Pentosan Polysulfate", "text": "Interaction: Urokinase AND Pentosan Polysulfate\nDetails: Urokinase may increase the anticoagulant activities of Pentosan Polysulfate.\nRisk: Monitor closely.", "source": "Urokinase + Pentosan Polysulfate"}, {"id": "Urokinase_INT_Phenprocoumon", "text": "Interaction: Urokinase AND Phenprocoumon\nDetails: Urokinase may increase the anticoagulant activities of Phenprocoumon.\nRisk: Monitor closely.", "source": "Urokinase + Phenprocoumon"}, {"id": "Urokinase_INT_Edetic Acid", "text": "Interaction: Urokinase AND Edetic Acid\nDetails: Urokinase may increase the anticoagulant activities of Edetic Acid.\nRisk: Monitor closely.", "source": "Urokinase + Edetic Acid"}, {"id": "Urokinase_INT_Heparin", "text": "Interaction: Urokinase AND Heparin\nDetails: Urokinase may increase the anticoagulant activities of Heparin.\nRisk: Monitor closely.", "source": "Urokinase + Heparin"}, {"id": "Urokinase_INT_Enoxaparin", "text": "Interaction: Urokinase AND Enoxaparin\nDetails: Urokinase may increase the anticoagulant activities of Enoxaparin.\nRisk: Monitor closely.", "source": "Urokinase + Enoxaparin"}, {"id": "Urokinase_INT_Acenocoumarol", "text": "Interaction: Urokinase AND Acenocoumarol\nDetails: Urokinase may increase the anticoagulant activities of Acenocoumarol.\nRisk: Monitor closely.", "source": "Urokinase + Acenocoumarol"}, {"id": "Urokinase_INT_Citric Acid", "text": "Interaction: Urokinase AND Citric Acid\nDetails: Urokinase may increase the anticoagulant activities of Citric Acid.\nRisk: Monitor closely.", "source": "Urokinase + Citric Acid"}, {"id": "Urokinase_INT_Ximelagatran", "text": "Interaction: Urokinase AND Ximelagatran\nDetails: Urokinase may increase the anticoagulant activities of Ximelagatran.\nRisk: Monitor closely.", "source": "Urokinase + Ximelagatran"}, {"id": "Urokinase_INT_Ancrod", "text": "Interaction: Urokinase AND Ancrod\nDetails: Urokinase may increase the anticoagulant activities of Ancrod.\nRisk: Monitor closely.", "source": "Urokinase + Ancrod"}, {"id": "Urokinase_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Urokinase AND Pentaerythritol Tetranitrate\nDetails: Urokinase may increase the anticoagulant activities of Pentaerythritol Tetranitrate.\nRisk: Monitor closely.", "source": "Urokinase + Pentaerythritol Tetranitrate"}, {"id": "Urokinase_INT_Rivaroxaban", "text": "Interaction: Urokinase AND Rivaroxaban\nDetails: Urokinase may increase the anticoagulant activities of Rivaroxaban.\nRisk: Monitor closely.", "source": "Urokinase + Rivaroxaban"}, {"id": "Urokinase_INT_Sulodexide", "text": "Interaction: Urokinase AND Sulodexide\nDetails: Urokinase may increase the anticoagulant activities of Sulodexide.\nRisk: Monitor closely.", "source": "Urokinase + Sulodexide"}, {"id": "Urokinase_INT_Idraparinux", "text": "Interaction: Urokinase AND Idraparinux\nDetails: Urokinase may increase the anticoagulant activities of Idraparinux.\nRisk: Monitor closely.", "source": "Urokinase + Idraparinux"}, {"id": "Urokinase_INT_Apixaban", "text": "Interaction: Urokinase AND Apixaban\nDetails: Urokinase may increase the anticoagulant activities of Apixaban.\nRisk: Monitor closely.", "source": "Urokinase + Apixaban"}, {"id": "Urokinase_INT_Otamixaban", "text": "Interaction: Urokinase AND Otamixaban\nDetails: Urokinase may increase the anticoagulant activities of Otamixaban.\nRisk: Monitor closely.", "source": "Urokinase + Otamixaban"}, {"id": "Urokinase_INT_Danaparoid", "text": "Interaction: Urokinase AND Danaparoid\nDetails: Urokinase may increase the anticoagulant activities of Danaparoid.\nRisk: Monitor closely.", "source": "Urokinase + Danaparoid"}, {"id": "Urokinase_INT_Dalteparin", "text": "Interaction: Urokinase AND Dalteparin\nDetails: Urokinase may increase the anticoagulant activities of Dalteparin.\nRisk: Monitor closely.", "source": "Urokinase + Dalteparin"}, {"id": "Urokinase_INT_Ferulic acid", "text": "Interaction: Urokinase AND Ferulic acid\nDetails: Urokinase may increase the anticoagulant activities of Ferulic acid.\nRisk: Monitor closely.", "source": "Urokinase + Ferulic acid"}, {"id": "Urokinase_INT_Ethyl biscoumacetate", "text": "Interaction: Urokinase AND Ethyl biscoumacetate\nDetails: Urokinase may increase the anticoagulant activities of Ethyl biscoumacetate.\nRisk: Monitor closely.", "source": "Urokinase + Ethyl biscoumacetate"}, {"id": "Urokinase_INT_Nadroparin", "text": "Interaction: Urokinase AND Nadroparin\nDetails: Urokinase may increase the anticoagulant activities of Nadroparin.\nRisk: Monitor closely.", "source": "Urokinase + Nadroparin"}, {"id": "Urokinase_INT_Edoxaban", "text": "Interaction: Urokinase AND Edoxaban\nDetails: Urokinase may increase the anticoagulant activities of Edoxaban.\nRisk: Monitor closely.", "source": "Urokinase + Edoxaban"}, {"id": "Urokinase_INT_Dextran", "text": "Interaction: Urokinase AND Dextran\nDetails: Urokinase may increase the anticoagulant activities of Dextran.\nRisk: Monitor closely.", "source": "Urokinase + Dextran"}, {"id": "Urokinase_INT_Reviparin", "text": "Interaction: Urokinase AND Reviparin\nDetails: Urokinase may increase the anticoagulant activities of Reviparin.\nRisk: Monitor closely.", "source": "Urokinase + Reviparin"}, {"id": "Urokinase_INT_Certoparin", "text": "Interaction: Urokinase AND Certoparin\nDetails: Urokinase may increase the anticoagulant activities of Certoparin.\nRisk: Monitor closely.", "source": "Urokinase + Certoparin"}, {"id": "Urokinase_INT_Dextran 70", "text": "Interaction: Urokinase AND Dextran 70\nDetails: Urokinase may increase the anticoagulant activities of Dextran 70.\nRisk: Monitor closely.", "source": "Urokinase + Dextran 70"}, {"id": "Urokinase_INT_Desirudin", "text": "Interaction: Urokinase AND Desirudin\nDetails: Urokinase may increase the anticoagulant activities of Desirudin.\nRisk: Monitor closely.", "source": "Urokinase + Desirudin"}, {"id": "Urokinase_INT_Dextran 40", "text": "Interaction: Urokinase AND Dextran 40\nDetails: Urokinase may increase the anticoagulant activities of Dextran 40.\nRisk: Monitor closely.", "source": "Urokinase + Dextran 40"}, {"id": "Urokinase_INT_Dextran 75", "text": "Interaction: Urokinase AND Dextran 75\nDetails: Urokinase may increase the anticoagulant activities of Dextran 75.\nRisk: Monitor closely.", "source": "Urokinase + Dextran 75"}, {"id": "Urokinase_INT_Protocatechualdehyde", "text": "Interaction: Urokinase AND Protocatechualdehyde\nDetails: Urokinase may increase the anticoagulant activities of Protocatechualdehyde.\nRisk: Monitor closely.", "source": "Urokinase + Protocatechualdehyde"}, {"id": "Urokinase_INT_Protein C", "text": "Interaction: Urokinase AND Protein C\nDetails: Urokinase may increase the anticoagulant activities of Protein C.\nRisk: Monitor closely.", "source": "Urokinase + Protein C"}, {"id": "Urokinase_INT_Antithrombin III human", "text": "Interaction: Urokinase AND Antithrombin III human\nDetails: Urokinase may increase the anticoagulant activities of Antithrombin III human.\nRisk: Monitor closely.", "source": "Urokinase + Antithrombin III human"}, {"id": "Urokinase_INT_Fondaparinux", "text": "Interaction: Urokinase AND Fondaparinux\nDetails: Urokinase may increase the anticoagulant activities of Fondaparinux.\nRisk: Monitor closely.", "source": "Urokinase + Fondaparinux"}, {"id": "Urokinase_INT_Letaxaban", "text": "Interaction: Urokinase AND Letaxaban\nDetails: Urokinase may increase the anticoagulant activities of Letaxaban.\nRisk: Monitor closely.", "source": "Urokinase + Letaxaban"}, {"id": "Urokinase_INT_Darexaban", "text": "Interaction: Urokinase AND Darexaban\nDetails: Urokinase may increase the anticoagulant activities of Darexaban.\nRisk: Monitor closely.", "source": "Urokinase + Darexaban"}, {"id": "Urokinase_INT_Nafamostat", "text": "Interaction: Urokinase AND Nafamostat\nDetails: Urokinase may increase the anticoagulant activities of Nafamostat.\nRisk: Monitor closely.", "source": "Urokinase + Nafamostat"}, {"id": "Urokinase_INT_Gabexate", "text": "Interaction: Urokinase AND Gabexate\nDetails: Urokinase may increase the anticoagulant activities of Gabexate.\nRisk: Monitor closely.", "source": "Urokinase + Gabexate"}, {"id": "Urokinase_INT_Troxerutin", "text": "Interaction: Urokinase AND Troxerutin\nDetails: Urokinase may increase the anticoagulant activities of Troxerutin.\nRisk: Monitor closely.", "source": "Urokinase + Troxerutin"}, {"id": "Urokinase_INT_Fluindione", "text": "Interaction: Urokinase AND Fluindione\nDetails: Urokinase may increase the anticoagulant activities of Fluindione.\nRisk: Monitor closely.", "source": "Urokinase + Fluindione"}, {"id": "Urokinase_INT_Protein S human", "text": "Interaction: Urokinase AND Protein S human\nDetails: Urokinase may increase the anticoagulant activities of Protein S human.\nRisk: Monitor closely.", "source": "Urokinase + Protein S human"}, {"id": "Urokinase_INT_Melagatran", "text": "Interaction: Urokinase AND Melagatran\nDetails: Urokinase may increase the anticoagulant activities of Melagatran.\nRisk: Monitor closely.", "source": "Urokinase + Melagatran"}, {"id": "Urokinase_INT_Eptifibatide", "text": "Interaction: Urokinase AND Eptifibatide\nDetails: Eptifibatide may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Eptifibatide"}, {"id": "Urokinase_INT_Ticlopidine", "text": "Interaction: Urokinase AND Ticlopidine\nDetails: Ticlopidine may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Ticlopidine"}, {"id": "Urokinase_INT_Tirofiban", "text": "Interaction: Urokinase AND Tirofiban\nDetails: Tirofiban may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Tirofiban"}, {"id": "Urokinase_INT_Dipyridamole", "text": "Interaction: Urokinase AND Dipyridamole\nDetails: Dipyridamole may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Dipyridamole"}, {"id": "Urokinase_INT_Clopidogrel", "text": "Interaction: Urokinase AND Clopidogrel\nDetails: Clopidogrel may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Clopidogrel"}, {"id": "Urokinase_INT_Acetylsalicylic acid", "text": "Interaction: Urokinase AND Acetylsalicylic acid\nDetails: Acetylsalicylic acid may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Acetylsalicylic acid"}, {"id": "Urokinase_INT_Prasugrel", "text": "Interaction: Urokinase AND Prasugrel\nDetails: Prasugrel may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Prasugrel"}, {"id": "Urokinase_INT_Vorapaxar", "text": "Interaction: Urokinase AND Vorapaxar\nDetails: Vorapaxar may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Vorapaxar"}, {"id": "Urokinase_INT_Milrinone", "text": "Interaction: Urokinase AND Milrinone\nDetails: Milrinone may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Milrinone"}, {"id": "Urokinase_INT_Anagrelide", "text": "Interaction: Urokinase AND Anagrelide\nDetails: Anagrelide may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Anagrelide"}, {"id": "Urokinase_INT_Epinastine", "text": "Interaction: Urokinase AND Epinastine\nDetails: Epinastine may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Epinastine"}, {"id": "Urokinase_INT_Alprostadil", "text": "Interaction: Urokinase AND Alprostadil\nDetails: Alprostadil may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Alprostadil"}, {"id": "Urokinase_INT_Pentoxifylline", "text": "Interaction: Urokinase AND Pentoxifylline\nDetails: Pentoxifylline may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Pentoxifylline"}, {"id": "Urokinase_INT_Azelastine", "text": "Interaction: Urokinase AND Azelastine\nDetails: Azelastine may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Azelastine"}, {"id": "Urokinase_INT_Iloprost", "text": "Interaction: Urokinase AND Iloprost\nDetails: Iloprost may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Iloprost"}, {"id": "Urokinase_INT_Cilostazol", "text": "Interaction: Urokinase AND Cilostazol\nDetails: Cilostazol may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Cilostazol"}, {"id": "Urokinase_INT_Ridogrel", "text": "Interaction: Urokinase AND Ridogrel\nDetails: Ridogrel may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Ridogrel"}, {"id": "Urokinase_INT_Sevoflurane", "text": "Interaction: Urokinase AND Sevoflurane\nDetails: Sevoflurane may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Sevoflurane"}, {"id": "Urokinase_INT_Epoprostenol", "text": "Interaction: Urokinase AND Epoprostenol\nDetails: Epoprostenol may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Epoprostenol"}, {"id": "Urokinase_INT_Resveratrol", "text": "Interaction: Urokinase AND Resveratrol\nDetails: Resveratrol may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Resveratrol"}, {"id": "Urokinase_INT_Nimesulide", "text": "Interaction: Urokinase AND Nimesulide\nDetails: Nimesulide may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Nimesulide"}, {"id": "Urokinase_INT_Tesmilifene", "text": "Interaction: Urokinase AND Tesmilifene\nDetails: Tesmilifene may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Tesmilifene"}, {"id": "Urokinase_INT_Defibrotide", "text": "Interaction: Urokinase AND Defibrotide\nDetails: Defibrotide may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Defibrotide"}, {"id": "Urokinase_INT_SRT501", "text": "Interaction: Urokinase AND SRT501\nDetails: SRT501 may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + SRT501"}, {"id": "Urokinase_INT_Beraprost", "text": "Interaction: Urokinase AND Beraprost\nDetails: Beraprost may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Beraprost"}, {"id": "Urokinase_INT_Ibudilast", "text": "Interaction: Urokinase AND Ibudilast\nDetails: Ibudilast may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Ibudilast"}, {"id": "Urokinase_INT_Andrographolide", "text": "Interaction: Urokinase AND Andrographolide\nDetails: Andrographolide may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Andrographolide"}, {"id": "Urokinase_INT_eplivanserine", "text": "Interaction: Urokinase AND eplivanserine\nDetails: eplivanserine may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + eplivanserine"}, {"id": "Urokinase_INT_Cangrelor", "text": "Interaction: Urokinase AND Cangrelor\nDetails: Cangrelor may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Cangrelor"}, {"id": "Urokinase_INT_Tranilast", "text": "Interaction: Urokinase AND Tranilast\nDetails: Tranilast may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Tranilast"}, {"id": "Urokinase_INT_Triflusal", "text": "Interaction: Urokinase AND Triflusal\nDetails: Triflusal may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Triflusal"}, {"id": "Urokinase_INT_Icosapent ethyl", "text": "Interaction: Urokinase AND Icosapent ethyl\nDetails: Icosapent ethyl may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Icosapent ethyl"}, {"id": "Urokinase_INT_Ifenprodil", "text": "Interaction: Urokinase AND Ifenprodil\nDetails: Ifenprodil may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Ifenprodil"}, {"id": "Urokinase_INT_Trapidil", "text": "Interaction: Urokinase AND Trapidil\nDetails: Trapidil may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Trapidil"}, {"id": "Urokinase_INT_Naftopidil", "text": "Interaction: Urokinase AND Naftopidil\nDetails: Naftopidil may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Naftopidil"}, {"id": "Urokinase_INT_Sarpogrelate", "text": "Interaction: Urokinase AND Sarpogrelate\nDetails: Sarpogrelate may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Sarpogrelate"}, {"id": "Urokinase_INT_Eplivanserin", "text": "Interaction: Urokinase AND Eplivanserin\nDetails: Eplivanserin may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Eplivanserin"}, {"id": "Urokinase_INT_Ifetroban", "text": "Interaction: Urokinase AND Ifetroban\nDetails: Ifetroban may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Ifetroban"}, {"id": "Urokinase_INT_Nitroaspirin", "text": "Interaction: Urokinase AND Nitroaspirin\nDetails: Nitroaspirin may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Nitroaspirin"}, {"id": "Urokinase_INT_Ketanserin", "text": "Interaction: Urokinase AND Ketanserin\nDetails: Ketanserin may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Ketanserin"}, {"id": "Urokinase_INT_Indobufen", "text": "Interaction: Urokinase AND Indobufen\nDetails: Indobufen may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Indobufen"}, {"id": "Urokinase_INT_Butylphthalide", "text": "Interaction: Urokinase AND Butylphthalide\nDetails: Butylphthalide may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Butylphthalide"}, {"id": "Urokinase_INT_Hydroxytyrosol", "text": "Interaction: Urokinase AND Hydroxytyrosol\nDetails: Hydroxytyrosol may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Hydroxytyrosol"}, {"id": "Urokinase_INT_Ramatroban", "text": "Interaction: Urokinase AND Ramatroban\nDetails: Ramatroban may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Ramatroban"}, {"id": "Urokinase_INT_Picotamide", "text": "Interaction: Urokinase AND Picotamide\nDetails: Picotamide may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Picotamide"}, {"id": "Urokinase_INT_Cloricromen", "text": "Interaction: Urokinase AND Cloricromen\nDetails: Cloricromen may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Cloricromen"}, {"id": "Urokinase_INT_Linsidomine", "text": "Interaction: Urokinase AND Linsidomine\nDetails: Linsidomine may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Linsidomine"}, {"id": "Urokinase_INT_Buflomedil", "text": "Interaction: Urokinase AND Buflomedil\nDetails: Buflomedil may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Buflomedil"}, {"id": "Urokinase_INT_Relcovaptan", "text": "Interaction: Urokinase AND Relcovaptan\nDetails: Relcovaptan may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Relcovaptan"}, {"id": "Urokinase_INT_Ticagrelor", "text": "Interaction: Urokinase AND Ticagrelor\nDetails: Ticagrelor may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Ticagrelor"}, {"id": "Urokinase_INT_Aprotinin", "text": "Interaction: Urokinase AND Aprotinin\nDetails: The therapeutic efficacy of Urokinase can be decreased when used in combination with Aprotinin.\nRisk: Monitor closely.", "source": "Urokinase + Aprotinin"}, {"id": "Urokinase_INT_Limaprost", "text": "Interaction: Urokinase AND Limaprost\nDetails: The risk or severity of adverse effects can be increased when Limaprost is combined with Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Limaprost"}, {"id": "Urokinase_INT_Dabigatran etexilate", "text": "Interaction: Urokinase AND Dabigatran etexilate\nDetails: Urokinase may increase the anticoagulant activities of Dabigatran etexilate.\nRisk: Monitor closely.", "source": "Urokinase + Dabigatran etexilate"}, {"id": "Urokinase_INT_Salicylic acid", "text": "Interaction: Urokinase AND Salicylic acid\nDetails: The risk or severity of adverse effects can be increased when Salicylic acid is combined with Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Salicylic acid"}, {"id": "Urokinase_INT_Aminosalicylic Acid", "text": "Interaction: Urokinase AND Aminosalicylic Acid\nDetails: The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Aminosalicylic Acid"}, {"id": "Urokinase_INT_Mesalazine", "text": "Interaction: Urokinase AND Mesalazine\nDetails: The risk or severity of adverse effects can be increased when Mesalazine is combined with Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Mesalazine"}, {"id": "Urokinase_INT_Diflunisal", "text": "Interaction: Urokinase AND Diflunisal\nDetails: The risk or severity of adverse effects can be increased when Diflunisal is combined with Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Diflunisal"}, {"id": "Urokinase_INT_Balsalazide", "text": "Interaction: Urokinase AND Balsalazide\nDetails: The risk or severity of adverse effects can be increased when Balsalazide is combined with Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Balsalazide"}, {"id": "Urokinase_INT_Olsalazine", "text": "Interaction: Urokinase AND Olsalazine\nDetails: The risk or severity of adverse effects can be increased when Olsalazine is combined with Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Olsalazine"}, {"id": "Urokinase_INT_dersalazine", "text": "Interaction: Urokinase AND dersalazine\nDetails: The risk or severity of adverse effects can be increased when dersalazine is combined with Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + dersalazine"}, {"id": "Urokinase_INT_Aloxiprin", "text": "Interaction: Urokinase AND Aloxiprin\nDetails: The risk or severity of adverse effects can be increased when Aloxiprin is combined with Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Aloxiprin"}, {"id": "Urokinase_INT_Guacetisal", "text": "Interaction: Urokinase AND Guacetisal\nDetails: The risk or severity of adverse effects can be increased when Guacetisal is combined with Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Guacetisal"}, {"id": "Urokinase_INT_Carbaspirin calcium", "text": "Interaction: Urokinase AND Carbaspirin calcium\nDetails: The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Carbaspirin calcium"}, {"id": "Urokinase_INT_Hemoglobin crosfumaril", "text": "Interaction: Urokinase AND Hemoglobin crosfumaril\nDetails: The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Hemoglobin crosfumaril"}, {"id": "Urokinase_INT_Methyl salicylate", "text": "Interaction: Urokinase AND Methyl salicylate\nDetails: The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Methyl salicylate"}, {"id": "Urokinase_INT_Trolamine salicylate", "text": "Interaction: Urokinase AND Trolamine salicylate\nDetails: The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Urokinase.\nRisk: Monitor closely.", "source": "Urokinase + Trolamine salicylate"}, {"id": "Urokinase_INT_Treprostinil", "text": "Interaction: Urokinase AND Treprostinil\nDetails: The risk or severity of adverse effects can be increased when Urokinase is combined with Treprostinil.\nRisk: Monitor closely.", "source": "Urokinase + Treprostinil"}, {"id": "Goserelin_GEN", "text": "Drug: Goserelin\nDescription: Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal ...", "source": "Goserelin"}, {"id": "Goserelin_CLIN", "text": "Drug: Goserelin\nMechanism: Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustai...\nToxicity: No experience of overdosage from clinical trials....", "source": "Goserelin"}, {"id": "Goserelin_INT_Dofetilide", "text": "Interaction: Goserelin AND Dofetilide\nDetails: Goserelin may increase the QTc-prolonging activities of Dofetilide.\nRisk: Monitor closely.", "source": "Goserelin + Dofetilide"}, {"id": "Goserelin_INT_Citalopram", "text": "Interaction: Goserelin AND Citalopram\nDetails: Goserelin may increase the QTc-prolonging activities of Citalopram.\nRisk: Monitor closely.", "source": "Goserelin + Citalopram"}, {"id": "Goserelin_INT_Ziprasidone", "text": "Interaction: Goserelin AND Ziprasidone\nDetails: Goserelin may increase the QTc-prolonging activities of Ziprasidone.\nRisk: Monitor closely.", "source": "Goserelin + Ziprasidone"}, {"id": "Goserelin_INT_Anagrelide", "text": "Interaction: Goserelin AND Anagrelide\nDetails: Goserelin may increase the QTc-prolonging activities of Anagrelide.\nRisk: Monitor closely.", "source": "Goserelin + Anagrelide"}, {"id": "Goserelin_INT_Disopyramide", "text": "Interaction: Goserelin AND Disopyramide\nDetails: Goserelin may increase the QTc-prolonging activities of Disopyramide.\nRisk: Monitor closely.", "source": "Goserelin + Disopyramide"}, {"id": "Goserelin_INT_Ibutilide", "text": "Interaction: Goserelin AND Ibutilide\nDetails: Goserelin may increase the QTc-prolonging activities of Ibutilide.\nRisk: Monitor closely.", "source": "Goserelin + Ibutilide"}, {"id": "Goserelin_INT_Quinine", "text": "Interaction: Goserelin AND Quinine\nDetails: Goserelin may increase the QTc-prolonging activities of Quinine.\nRisk: Monitor closely.", "source": "Goserelin + Quinine"}, {"id": "Goserelin_INT_Fluoxetine", "text": "Interaction: Goserelin AND Fluoxetine\nDetails: Goserelin may increase the QTc-prolonging activities of Fluoxetine.\nRisk: Monitor closely.", "source": "Goserelin + Fluoxetine"}, {"id": "Goserelin_INT_Sotalol", "text": "Interaction: Goserelin AND Sotalol\nDetails: Goserelin may increase the QTc-prolonging activities of Sotalol.\nRisk: Monitor closely.", "source": "Goserelin + Sotalol"}, {"id": "Goserelin_INT_Toremifene", "text": "Interaction: Goserelin AND Toremifene\nDetails: Goserelin may increase the QTc-prolonging activities of Toremifene.\nRisk: Monitor closely.", "source": "Goserelin + Toremifene"}, {"id": "Goserelin_INT_Cisapride", "text": "Interaction: Goserelin AND Cisapride\nDetails: Goserelin may increase the QTc-prolonging activities of Cisapride.\nRisk: Monitor closely.", "source": "Goserelin + Cisapride"}, {"id": "Goserelin_INT_Thioridazine", "text": "Interaction: Goserelin AND Thioridazine\nDetails: Goserelin may increase the QTc-prolonging activities of Thioridazine.\nRisk: Monitor closely.", "source": "Goserelin + Thioridazine"}, {"id": "Goserelin_INT_Flupentixol", "text": "Interaction: Goserelin AND Flupentixol\nDetails: Goserelin may increase the QTc-prolonging activities of Flupentixol.\nRisk: Monitor closely.", "source": "Goserelin + Flupentixol"}, {"id": "Goserelin_INT_Quinidine", "text": "Interaction: Goserelin AND Quinidine\nDetails: Goserelin may increase the QTc-prolonging activities of Quinidine.\nRisk: Monitor closely.", "source": "Goserelin + Quinidine"}, {"id": "Goserelin_INT_Procainamide", "text": "Interaction: Goserelin AND Procainamide\nDetails: Goserelin may increase the QTc-prolonging activities of Procainamide.\nRisk: Monitor closely.", "source": "Goserelin + Procainamide"}, {"id": "Goserelin_INT_Pimozide", "text": "Interaction: Goserelin AND Pimozide\nDetails: Goserelin may increase the QTc-prolonging activities of Pimozide.\nRisk: Monitor closely.", "source": "Goserelin + Pimozide"}, {"id": "Goserelin_INT_Amiodarone", "text": "Interaction: Goserelin AND Amiodarone\nDetails: Goserelin may increase the QTc-prolonging activities of Amiodarone.\nRisk: Monitor closely.", "source": "Goserelin + Amiodarone"}, {"id": "Goserelin_INT_Arsenic trioxide", "text": "Interaction: Goserelin AND Arsenic trioxide\nDetails: Goserelin may increase the QTc-prolonging activities of Arsenic trioxide.\nRisk: Monitor closely.", "source": "Goserelin + Arsenic trioxide"}, {"id": "Goserelin_INT_Escitalopram", "text": "Interaction: Goserelin AND Escitalopram\nDetails: Goserelin may increase the QTc-prolonging activities of Escitalopram.\nRisk: Monitor closely.", "source": "Goserelin + Escitalopram"}, {"id": "Goserelin_INT_Domperidone", "text": "Interaction: Goserelin AND Domperidone\nDetails: Goserelin may increase the QTc-prolonging activities of Domperidone.\nRisk: Monitor closely.", "source": "Goserelin + Domperidone"}, {"id": "Goserelin_INT_Quetiapine", "text": "Interaction: Goserelin AND Quetiapine\nDetails: Goserelin may increase the QTc-prolonging activities of Quetiapine.\nRisk: Monitor closely.", "source": "Goserelin + Quetiapine"}, {"id": "Goserelin_INT_Paliperidone", "text": "Interaction: Goserelin AND Paliperidone\nDetails: Goserelin may increase the QTc-prolonging activities of Paliperidone.\nRisk: Monitor closely.", "source": "Goserelin + Paliperidone"}, {"id": "Goserelin_INT_Lopinavir", "text": "Interaction: Goserelin AND Lopinavir\nDetails: Goserelin may increase the QTc-prolonging activities of Lopinavir.\nRisk: Monitor closely.", "source": "Goserelin + Lopinavir"}, {"id": "Goserelin_INT_Zuclopenthixol", "text": "Interaction: Goserelin AND Zuclopenthixol\nDetails: Goserelin may increase the QTc-prolonging activities of Zuclopenthixol.\nRisk: Monitor closely.", "source": "Goserelin + Zuclopenthixol"}, {"id": "Goserelin_INT_Tetrabenazine", "text": "Interaction: Goserelin AND Tetrabenazine\nDetails: Goserelin may increase the QTc-prolonging activities of Tetrabenazine.\nRisk: Monitor closely.", "source": "Goserelin + Tetrabenazine"}, {"id": "Goserelin_INT_Dronedarone", "text": "Interaction: Goserelin AND Dronedarone\nDetails: Goserelin may increase the QTc-prolonging activities of Dronedarone.\nRisk: Monitor closely.", "source": "Goserelin + Dronedarone"}, {"id": "Goserelin_INT_Nilotinib", "text": "Interaction: Goserelin AND Nilotinib\nDetails: Goserelin may increase the QTc-prolonging activities of Nilotinib.\nRisk: Monitor closely.", "source": "Goserelin + Nilotinib"}, {"id": "Goserelin_INT_Iloperidone", "text": "Interaction: Goserelin AND Iloperidone\nDetails: Goserelin may increase the QTc-prolonging activities of Iloperidone.\nRisk: Monitor closely.", "source": "Goserelin + Iloperidone"}, {"id": "Goserelin_INT_Vandetanib", "text": "Interaction: Goserelin AND Vandetanib\nDetails: Goserelin may increase the QTc-prolonging activities of Vandetanib.\nRisk: Monitor closely.", "source": "Goserelin + Vandetanib"}, {"id": "Goserelin_INT_Asenapine", "text": "Interaction: Goserelin AND Asenapine\nDetails: Goserelin may increase the QTc-prolonging activities of Asenapine.\nRisk: Monitor closely.", "source": "Goserelin + Asenapine"}, {"id": "Goserelin_INT_Artemether", "text": "Interaction: Goserelin AND Artemether\nDetails: Goserelin may increase the QTc-prolonging activities of Artemether.\nRisk: Monitor closely.", "source": "Goserelin + Artemether"}, {"id": "Goserelin_INT_Lumefantrine", "text": "Interaction: Goserelin AND Lumefantrine\nDetails: Goserelin may increase the QTc-prolonging activities of Lumefantrine.\nRisk: Monitor closely.", "source": "Goserelin + Lumefantrine"}, {"id": "Goserelin_INT_Vemurafenib", "text": "Interaction: Goserelin AND Vemurafenib\nDetails: Goserelin may increase the QTc-prolonging activities of Vemurafenib.\nRisk: Monitor closely.", "source": "Goserelin + Vemurafenib"}, {"id": "Goserelin_INT_Eliglustat", "text": "Interaction: Goserelin AND Eliglustat\nDetails: Goserelin may increase the QTc-prolonging activities of Eliglustat.\nRisk: Monitor closely.", "source": "Goserelin + Eliglustat"}, {"id": "Goserelin_INT_Capromab pendetide", "text": "Interaction: Goserelin AND Capromab pendetide\nDetails: Goserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Goserelin + Capromab pendetide"}, {"id": "Goserelin_INT_Mifepristone", "text": "Interaction: Goserelin AND Mifepristone\nDetails: Mifepristone may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Mifepristone"}, {"id": "Goserelin_INT_Trastuzumab", "text": "Interaction: Goserelin AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Trastuzumab"}, {"id": "Goserelin_INT_Leuprolide", "text": "Interaction: Goserelin AND Leuprolide\nDetails: Leuprolide may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Leuprolide"}, {"id": "Goserelin_INT_Erythromycin", "text": "Interaction: Goserelin AND Erythromycin\nDetails: Goserelin may increase the QTc-prolonging activities of Erythromycin.\nRisk: Monitor closely.", "source": "Goserelin + Erythromycin"}, {"id": "Goserelin_INT_Azithromycin", "text": "Interaction: Goserelin AND Azithromycin\nDetails: Goserelin may increase the QTc-prolonging activities of Azithromycin.\nRisk: Monitor closely.", "source": "Goserelin + Azithromycin"}, {"id": "Goserelin_INT_Moxifloxacin", "text": "Interaction: Goserelin AND Moxifloxacin\nDetails: Goserelin may increase the QTc-prolonging activities of Moxifloxacin.\nRisk: Monitor closely.", "source": "Goserelin + Moxifloxacin"}, {"id": "Goserelin_INT_Sulfisoxazole", "text": "Interaction: Goserelin AND Sulfisoxazole\nDetails: Goserelin may increase the QTc-prolonging activities of Sulfisoxazole.\nRisk: Monitor closely.", "source": "Goserelin + Sulfisoxazole"}, {"id": "Goserelin_INT_Methadone", "text": "Interaction: Goserelin AND Methadone\nDetails: Goserelin may increase the QTc-prolonging activities of Methadone.\nRisk: Monitor closely.", "source": "Goserelin + Methadone"}, {"id": "Goserelin_INT_Clozapine", "text": "Interaction: Goserelin AND Clozapine\nDetails: Goserelin may increase the QTc-prolonging activities of Clozapine.\nRisk: Monitor closely.", "source": "Goserelin + Clozapine"}, {"id": "Goserelin_INT_Promazine", "text": "Interaction: Goserelin AND Promazine\nDetails: Goserelin may increase the QTc-prolonging activities of Promazine.\nRisk: Monitor closely.", "source": "Goserelin + Promazine"}, {"id": "Goserelin_INT_Droperidol", "text": "Interaction: Goserelin AND Droperidol\nDetails: Goserelin may increase the QTc-prolonging activities of Droperidol.\nRisk: Monitor closely.", "source": "Goserelin + Droperidol"}, {"id": "Goserelin_INT_Chlorpromazine", "text": "Interaction: Goserelin AND Chlorpromazine\nDetails: Goserelin may increase the QTc-prolonging activities of Chlorpromazine.\nRisk: Monitor closely.", "source": "Goserelin + Chlorpromazine"}, {"id": "Goserelin_INT_Haloperidol", "text": "Interaction: Goserelin AND Haloperidol\nDetails: Goserelin may increase the QTc-prolonging activities of Haloperidol.\nRisk: Monitor closely.", "source": "Goserelin + Haloperidol"}, {"id": "Goserelin_INT_Ciprofloxacin", "text": "Interaction: Goserelin AND Ciprofloxacin\nDetails: Goserelin may increase the QTc-prolonging activities of Ciprofloxacin.\nRisk: Monitor closely.", "source": "Goserelin + Ciprofloxacin"}, {"id": "Goserelin_INT_Perflutren", "text": "Interaction: Goserelin AND Perflutren\nDetails: Goserelin may increase the QTc-prolonging activities of Perflutren.\nRisk: Monitor closely.", "source": "Goserelin + Perflutren"}, {"id": "Goserelin_INT_Chloroquine", "text": "Interaction: Goserelin AND Chloroquine\nDetails: Goserelin may increase the QTc-prolonging activities of Chloroquine.\nRisk: Monitor closely.", "source": "Goserelin + Chloroquine"}, {"id": "Goserelin_INT_Pentamidine", "text": "Interaction: Goserelin AND Pentamidine\nDetails: Goserelin may increase the QTc-prolonging activities of Pentamidine.\nRisk: Monitor closely.", "source": "Goserelin + Pentamidine"}, {"id": "Goserelin_INT_Gadobenic acid", "text": "Interaction: Goserelin AND Gadobenic acid\nDetails: Goserelin may increase the QTc-prolonging activities of Gadobenic acid.\nRisk: Monitor closely.", "source": "Goserelin + Gadobenic acid"}, {"id": "Goserelin_INT_Dolasetron", "text": "Interaction: Goserelin AND Dolasetron\nDetails: Goserelin may increase the QTc-prolonging activities of Dolasetron.\nRisk: Monitor closely.", "source": "Goserelin + Dolasetron"}, {"id": "Goserelin_INT_Granisetron", "text": "Interaction: Goserelin AND Granisetron\nDetails: Goserelin may increase the QTc-prolonging activities of Granisetron.\nRisk: Monitor closely.", "source": "Goserelin + Granisetron"}, {"id": "Goserelin_INT_Ondansetron", "text": "Interaction: Goserelin AND Ondansetron\nDetails: Goserelin may increase the QTc-prolonging activities of Ondansetron.\nRisk: Monitor closely.", "source": "Goserelin + Ondansetron"}, {"id": "Goserelin_INT_Telithromycin", "text": "Interaction: Goserelin AND Telithromycin\nDetails: Goserelin may increase the QTc-prolonging activities of Telithromycin.\nRisk: Monitor closely.", "source": "Goserelin + Telithromycin"}, {"id": "Goserelin_INT_Primaquine", "text": "Interaction: Goserelin AND Primaquine\nDetails: Goserelin may increase the QTc-prolonging activities of Primaquine.\nRisk: Monitor closely.", "source": "Goserelin + Primaquine"}, {"id": "Goserelin_INT_Levofloxacin", "text": "Interaction: Goserelin AND Levofloxacin\nDetails: Goserelin may increase the QTc-prolonging activities of Levofloxacin.\nRisk: Monitor closely.", "source": "Goserelin + Levofloxacin"}, {"id": "Goserelin_INT_Gemifloxacin", "text": "Interaction: Goserelin AND Gemifloxacin\nDetails: Goserelin may increase the QTc-prolonging activities of Gemifloxacin.\nRisk: Monitor closely.", "source": "Goserelin + Gemifloxacin"}, {"id": "Goserelin_INT_Ofloxacin", "text": "Interaction: Goserelin AND Ofloxacin\nDetails: Goserelin may increase the QTc-prolonging activities of Ofloxacin.\nRisk: Monitor closely.", "source": "Goserelin + Ofloxacin"}, {"id": "Goserelin_INT_Propafenone", "text": "Interaction: Goserelin AND Propafenone\nDetails: Goserelin may increase the QTc-prolonging activities of Propafenone.\nRisk: Monitor closely.", "source": "Goserelin + Propafenone"}, {"id": "Goserelin_INT_Flecainide", "text": "Interaction: Goserelin AND Flecainide\nDetails: Goserelin may increase the QTc-prolonging activities of Flecainide.\nRisk: Monitor closely.", "source": "Goserelin + Flecainide"}, {"id": "Goserelin_INT_Clarithromycin", "text": "Interaction: Goserelin AND Clarithromycin\nDetails: Goserelin may increase the QTc-prolonging activities of Clarithromycin.\nRisk: Monitor closely.", "source": "Goserelin + Clarithromycin"}, {"id": "Goserelin_INT_Saquinavir", "text": "Interaction: Goserelin AND Saquinavir\nDetails: Goserelin may increase the QTc-prolonging activities of Saquinavir.\nRisk: Monitor closely.", "source": "Goserelin + Saquinavir"}, {"id": "Goserelin_INT_Telavancin", "text": "Interaction: Goserelin AND Telavancin\nDetails: Goserelin may increase the QTc-prolonging activities of Telavancin.\nRisk: Monitor closely.", "source": "Goserelin + Telavancin"}, {"id": "Goserelin_INT_Pazopanib", "text": "Interaction: Goserelin AND Pazopanib\nDetails: Goserelin may increase the QTc-prolonging activities of Pazopanib.\nRisk: Monitor closely.", "source": "Goserelin + Pazopanib"}, {"id": "Goserelin_INT_Panobinostat", "text": "Interaction: Goserelin AND Panobinostat\nDetails: Goserelin may increase the QTc-prolonging activities of Panobinostat.\nRisk: Monitor closely.", "source": "Goserelin + Panobinostat"}, {"id": "Goserelin_INT_Crizotinib", "text": "Interaction: Goserelin AND Crizotinib\nDetails: Goserelin may increase the QTc-prolonging activities of Crizotinib.\nRisk: Monitor closely.", "source": "Goserelin + Crizotinib"}, {"id": "Goserelin_INT_Bedaquiline", "text": "Interaction: Goserelin AND Bedaquiline\nDetails: Goserelin may increase the QTc-prolonging activities of Bedaquiline.\nRisk: Monitor closely.", "source": "Goserelin + Bedaquiline"}, {"id": "Goserelin_INT_Ceritinib", "text": "Interaction: Goserelin AND Ceritinib\nDetails: Goserelin may increase the QTc-prolonging activities of Ceritinib.\nRisk: Monitor closely.", "source": "Goserelin + Ceritinib"}, {"id": "Goserelin_INT_Lenvatinib", "text": "Interaction: Goserelin AND Lenvatinib\nDetails: Goserelin may increase the QTc-prolonging activities of Lenvatinib.\nRisk: Monitor closely.", "source": "Goserelin + Lenvatinib"}, {"id": "Goserelin_INT_Ivabradine", "text": "Interaction: Goserelin AND Ivabradine\nDetails: Ivabradine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Ivabradine"}, {"id": "Goserelin_INT_Paclitaxel", "text": "Interaction: Goserelin AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Paclitaxel"}, {"id": "Goserelin_INT_Docetaxel", "text": "Interaction: Goserelin AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Docetaxel"}, {"id": "Goserelin_INT_Cabazitaxel", "text": "Interaction: Goserelin AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Cabazitaxel"}, {"id": "Goserelin_INT_Digoxin", "text": "Interaction: Goserelin AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Digoxin"}, {"id": "Goserelin_INT_Acetyldigitoxin", "text": "Interaction: Goserelin AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Acetyldigitoxin"}, {"id": "Goserelin_INT_Deslanoside", "text": "Interaction: Goserelin AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Deslanoside"}, {"id": "Goserelin_INT_Ouabain", "text": "Interaction: Goserelin AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Ouabain"}, {"id": "Goserelin_INT_Digitoxin", "text": "Interaction: Goserelin AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Digitoxin"}, {"id": "Goserelin_INT_Cymarin", "text": "Interaction: Goserelin AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Cymarin"}, {"id": "Goserelin_INT_Proscillaridin", "text": "Interaction: Goserelin AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Proscillaridin"}, {"id": "Goserelin_INT_Metildigoxin", "text": "Interaction: Goserelin AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Metildigoxin"}, {"id": "Goserelin_INT_Peruvoside", "text": "Interaction: Goserelin AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Peruvoside"}, {"id": "Goserelin_INT_Lanatoside C", "text": "Interaction: Goserelin AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Lanatoside C"}, {"id": "Goserelin_INT_Gitoformate", "text": "Interaction: Goserelin AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Gitoformate"}, {"id": "Goserelin_INT_Acetyldigoxin", "text": "Interaction: Goserelin AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Acetyldigoxin"}, {"id": "Goserelin_INT_Oleandrin", "text": "Interaction: Goserelin AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Oleandrin"}, {"id": "Goserelin_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Goserelin AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Digoxin Immune Fab (Ovine)"}, {"id": "Goserelin_INT_Bevacizumab", "text": "Interaction: Goserelin AND Bevacizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Bevacizumab"}, {"id": "Goserelin_INT_Cyclophosphamide", "text": "Interaction: Goserelin AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Cyclophosphamide"}, {"id": "Goserelin_INT_Octreotide", "text": "Interaction: Goserelin AND Octreotide\nDetails: Octreotide may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Octreotide"}, {"id": "Goserelin_INT_Oxytocin", "text": "Interaction: Goserelin AND Oxytocin\nDetails: Oxytocin may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Oxytocin"}, {"id": "Goserelin_INT_Bortezomib", "text": "Interaction: Goserelin AND Bortezomib\nDetails: Bortezomib may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Bortezomib"}, {"id": "Goserelin_INT_Fluconazole", "text": "Interaction: Goserelin AND Fluconazole\nDetails: Fluconazole may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Fluconazole"}, {"id": "Goserelin_INT_Nelfinavir", "text": "Interaction: Goserelin AND Nelfinavir\nDetails: Nelfinavir may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Nelfinavir"}, {"id": "Goserelin_INT_Ranolazine", "text": "Interaction: Goserelin AND Ranolazine\nDetails: Ranolazine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Ranolazine"}, {"id": "Goserelin_INT_Isradipine", "text": "Interaction: Goserelin AND Isradipine\nDetails: Isradipine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Isradipine"}, {"id": "Goserelin_INT_Venlafaxine", "text": "Interaction: Goserelin AND Venlafaxine\nDetails: Venlafaxine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Venlafaxine"}, {"id": "Goserelin_INT_Atomoxetine", "text": "Interaction: Goserelin AND Atomoxetine\nDetails: Atomoxetine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Atomoxetine"}, {"id": "Goserelin_INT_Amitriptyline", "text": "Interaction: Goserelin AND Amitriptyline\nDetails: Amitriptyline may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Amitriptyline"}, {"id": "Goserelin_INT_Olanzapine", "text": "Interaction: Goserelin AND Olanzapine\nDetails: Olanzapine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Olanzapine"}, {"id": "Goserelin_INT_Protriptyline", "text": "Interaction: Goserelin AND Protriptyline\nDetails: Protriptyline may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Protriptyline"}, {"id": "Goserelin_INT_Alfuzosin", "text": "Interaction: Goserelin AND Alfuzosin\nDetails: Alfuzosin may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Alfuzosin"}, {"id": "Goserelin_INT_Mefloquine", "text": "Interaction: Goserelin AND Mefloquine\nDetails: Mefloquine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Mefloquine"}, {"id": "Goserelin_INT_Mirtazapine", "text": "Interaction: Goserelin AND Mirtazapine\nDetails: Mirtazapine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Mirtazapine"}, {"id": "Goserelin_INT_Treprostinil", "text": "Interaction: Goserelin AND Treprostinil\nDetails: Treprostinil may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Treprostinil"}, {"id": "Goserelin_INT_Sorafenib", "text": "Interaction: Goserelin AND Sorafenib\nDetails: Sorafenib may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Sorafenib"}, {"id": "Goserelin_INT_Trimethoprim", "text": "Interaction: Goserelin AND Trimethoprim\nDetails: Trimethoprim may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Trimethoprim"}, {"id": "Goserelin_INT_Imipramine", "text": "Interaction: Goserelin AND Imipramine\nDetails: Imipramine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Imipramine"}, {"id": "Goserelin_INT_Ritonavir", "text": "Interaction: Goserelin AND Ritonavir\nDetails: Ritonavir may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Ritonavir"}, {"id": "Goserelin_INT_Foscarnet", "text": "Interaction: Goserelin AND Foscarnet\nDetails: Foscarnet may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Foscarnet"}, {"id": "Goserelin_INT_Nortriptyline", "text": "Interaction: Goserelin AND Nortriptyline\nDetails: Nortriptyline may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Nortriptyline"}, {"id": "Goserelin_INT_Amoxapine", "text": "Interaction: Goserelin AND Amoxapine\nDetails: Amoxapine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Amoxapine"}, {"id": "Goserelin_INT_Hydroxyzine", "text": "Interaction: Goserelin AND Hydroxyzine\nDetails: Hydroxyzine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Hydroxyzine"}, {"id": "Goserelin_INT_Voriconazole", "text": "Interaction: Goserelin AND Voriconazole\nDetails: Voriconazole may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Voriconazole"}, {"id": "Goserelin_INT_Nicardipine", "text": "Interaction: Goserelin AND Nicardipine\nDetails: Nicardipine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Nicardipine"}, {"id": "Goserelin_INT_Trazodone", "text": "Interaction: Goserelin AND Trazodone\nDetails: Trazodone may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Trazodone"}, {"id": "Goserelin_INT_Galantamine", "text": "Interaction: Goserelin AND Galantamine\nDetails: Galantamine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Galantamine"}, {"id": "Goserelin_INT_Tamoxifen", "text": "Interaction: Goserelin AND Tamoxifen\nDetails: Tamoxifen may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Tamoxifen"}, {"id": "Goserelin_INT_Moexipril", "text": "Interaction: Goserelin AND Moexipril\nDetails: Moexipril may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Moexipril"}, {"id": "Goserelin_INT_Tizanidine", "text": "Interaction: Goserelin AND Tizanidine\nDetails: Tizanidine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Tizanidine"}, {"id": "Goserelin_INT_Ibandronate", "text": "Interaction: Goserelin AND Ibandronate\nDetails: Ibandronate may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Ibandronate"}, {"id": "Goserelin_INT_Apomorphine", "text": "Interaction: Goserelin AND Apomorphine\nDetails: Apomorphine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Apomorphine"}, {"id": "Goserelin_INT_Paroxetine", "text": "Interaction: Goserelin AND Paroxetine\nDetails: Paroxetine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Paroxetine"}, {"id": "Goserelin_INT_Trimipramine", "text": "Interaction: Goserelin AND Trimipramine\nDetails: Trimipramine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Trimipramine"}, {"id": "Goserelin_INT_Risperidone", "text": "Interaction: Goserelin AND Risperidone\nDetails: Risperidone may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Risperidone"}, {"id": "Goserelin_INT_Isoflurane", "text": "Interaction: Goserelin AND Isoflurane\nDetails: Isoflurane may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Isoflurane"}, {"id": "Goserelin_INT_Indapamide", "text": "Interaction: Goserelin AND Indapamide\nDetails: Indapamide may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Indapamide"}, {"id": "Goserelin_INT_Propofol", "text": "Interaction: Goserelin AND Propofol\nDetails: Propofol may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Propofol"}, {"id": "Goserelin_INT_Vardenafil", "text": "Interaction: Goserelin AND Vardenafil\nDetails: Vardenafil may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Vardenafil"}, {"id": "Goserelin_INT_Terbutaline", "text": "Interaction: Goserelin AND Terbutaline\nDetails: Terbutaline may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Terbutaline"}, {"id": "Goserelin_INT_Amantadine", "text": "Interaction: Goserelin AND Amantadine\nDetails: Amantadine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Amantadine"}, {"id": "Goserelin_INT_Metronidazole", "text": "Interaction: Goserelin AND Metronidazole\nDetails: Metronidazole may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Metronidazole"}, {"id": "Goserelin_INT_Famotidine", "text": "Interaction: Goserelin AND Famotidine\nDetails: Famotidine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Famotidine"}, {"id": "Goserelin_INT_Maprotiline", "text": "Interaction: Goserelin AND Maprotiline\nDetails: Maprotiline may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Maprotiline"}, {"id": "Goserelin_INT_Salmeterol", "text": "Interaction: Goserelin AND Salmeterol\nDetails: Salmeterol may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Salmeterol"}, {"id": "Goserelin_INT_Felbamate", "text": "Interaction: Goserelin AND Felbamate\nDetails: Felbamate may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Felbamate"}, {"id": "Goserelin_INT_Formoterol", "text": "Interaction: Goserelin AND Formoterol\nDetails: Formoterol may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Formoterol"}, {"id": "Goserelin_INT_Salbutamol", "text": "Interaction: Goserelin AND Salbutamol\nDetails: Salbutamol may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Salbutamol"}, {"id": "Goserelin_INT_Sulfamethoxazole", "text": "Interaction: Goserelin AND Sulfamethoxazole\nDetails: Sulfamethoxazole may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Sulfamethoxazole"}, {"id": "Goserelin_INT_Ketoconazole", "text": "Interaction: Goserelin AND Ketoconazole\nDetails: Ketoconazole may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Ketoconazole"}, {"id": "Goserelin_INT_Tolterodine", "text": "Interaction: Goserelin AND Tolterodine\nDetails: Tolterodine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Tolterodine"}, {"id": "Goserelin_INT_Norfloxacin", "text": "Interaction: Goserelin AND Norfloxacin\nDetails: Norfloxacin may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Norfloxacin"}, {"id": "Goserelin_INT_Promethazine", "text": "Interaction: Goserelin AND Promethazine\nDetails: Promethazine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Promethazine"}, {"id": "Goserelin_INT_Atazanavir", "text": "Interaction: Goserelin AND Atazanavir\nDetails: Atazanavir may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Atazanavir"}, {"id": "Goserelin_INT_Diphenhydramine", "text": "Interaction: Goserelin AND Diphenhydramine\nDetails: Diphenhydramine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Diphenhydramine"}, {"id": "Goserelin_INT_Sertraline", "text": "Interaction: Goserelin AND Sertraline\nDetails: Sertraline may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Sertraline"}, {"id": "Goserelin_INT_Doxepin", "text": "Interaction: Goserelin AND Doxepin\nDetails: Doxepin may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Doxepin"}, {"id": "Goserelin_INT_Desipramine", "text": "Interaction: Goserelin AND Desipramine\nDetails: Desipramine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Desipramine"}, {"id": "Goserelin_INT_Itraconazole", "text": "Interaction: Goserelin AND Itraconazole\nDetails: Itraconazole may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Itraconazole"}, {"id": "Goserelin_INT_Desflurane", "text": "Interaction: Goserelin AND Desflurane\nDetails: Desflurane may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Desflurane"}, {"id": "Goserelin_INT_Metoclopramide", "text": "Interaction: Goserelin AND Metoclopramide\nDetails: Metoclopramide may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Metoclopramide"}, {"id": "Goserelin_INT_Sevoflurane", "text": "Interaction: Goserelin AND Sevoflurane\nDetails: Sevoflurane may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Sevoflurane"}, {"id": "Goserelin_INT_Aripiprazole", "text": "Interaction: Goserelin AND Aripiprazole\nDetails: Aripiprazole may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Aripiprazole"}, {"id": "Goserelin_INT_Clomipramine", "text": "Interaction: Goserelin AND Clomipramine\nDetails: Clomipramine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Clomipramine"}, {"id": "Goserelin_INT_Dasatinib", "text": "Interaction: Goserelin AND Dasatinib\nDetails: Dasatinib may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Dasatinib"}, {"id": "Goserelin_INT_Lapatinib", "text": "Interaction: Goserelin AND Lapatinib\nDetails: Lapatinib may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Lapatinib"}, {"id": "Goserelin_INT_Posaconazole", "text": "Interaction: Goserelin AND Posaconazole\nDetails: Posaconazole may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Posaconazole"}, {"id": "Goserelin_INT_Sunitinib", "text": "Interaction: Goserelin AND Sunitinib\nDetails: Sunitinib may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Sunitinib"}, {"id": "Goserelin_INT_Arformoterol", "text": "Interaction: Goserelin AND Arformoterol\nDetails: Arformoterol may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Arformoterol"}, {"id": "Goserelin_INT_Lithium", "text": "Interaction: Goserelin AND Lithium\nDetails: Lithium may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Lithium"}, {"id": "Goserelin_INT_Methotrimeprazine", "text": "Interaction: Goserelin AND Methotrimeprazine\nDetails: Methotrimeprazine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Methotrimeprazine"}, {"id": "Goserelin_INT_Solifenacin", "text": "Interaction: Goserelin AND Solifenacin\nDetails: Solifenacin may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Solifenacin"}, {"id": "Goserelin_INT_Thiothixene", "text": "Interaction: Goserelin AND Thiothixene\nDetails: Thiothixene may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Thiothixene"}, {"id": "Goserelin_INT_Vorinostat", "text": "Interaction: Goserelin AND Vorinostat\nDetails: Vorinostat may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Vorinostat"}, {"id": "Goserelin_INT_Ezogabine", "text": "Interaction: Goserelin AND Ezogabine\nDetails: Ezogabine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Ezogabine"}, {"id": "Goserelin_INT_Indacaterol", "text": "Interaction: Goserelin AND Indacaterol\nDetails: Indacaterol may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Indacaterol"}, {"id": "Goserelin_INT_Pasireotide", "text": "Interaction: Goserelin AND Pasireotide\nDetails: Pasireotide may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Pasireotide"}, {"id": "Goserelin_INT_Degarelix", "text": "Interaction: Goserelin AND Degarelix\nDetails: Degarelix may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Degarelix"}, {"id": "Goserelin_INT_Buserelin", "text": "Interaction: Goserelin AND Buserelin\nDetails: Buserelin may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Buserelin"}, {"id": "Goserelin_INT_Histrelin", "text": "Interaction: Goserelin AND Histrelin\nDetails: Histrelin may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Histrelin"}, {"id": "Goserelin_INT_Triptorelin", "text": "Interaction: Goserelin AND Triptorelin\nDetails: Triptorelin may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Triptorelin"}, {"id": "Goserelin_INT_Rilpivirine", "text": "Interaction: Goserelin AND Rilpivirine\nDetails: Rilpivirine may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Rilpivirine"}, {"id": "Goserelin_INT_Fingolimod", "text": "Interaction: Goserelin AND Fingolimod\nDetails: Fingolimod may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Fingolimod"}, {"id": "Goserelin_INT_Eribulin", "text": "Interaction: Goserelin AND Eribulin\nDetails: Eribulin may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Eribulin"}, {"id": "Goserelin_INT_Mirabegron", "text": "Interaction: Goserelin AND Mirabegron\nDetails: Mirabegron may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Mirabegron"}, {"id": "Goserelin_INT_Dabrafenib", "text": "Interaction: Goserelin AND Dabrafenib\nDetails: Dabrafenib may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Dabrafenib"}, {"id": "Goserelin_INT_Olodaterol", "text": "Interaction: Goserelin AND Olodaterol\nDetails: Olodaterol may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Olodaterol"}, {"id": "Goserelin_INT_Vilanterol", "text": "Interaction: Goserelin AND Vilanterol\nDetails: Vilanterol may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Vilanterol"}, {"id": "Goserelin_INT_Choline C 11", "text": "Interaction: Goserelin AND Choline C 11\nDetails: The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Choline C 11"}, {"id": "Goserelin_INT_Insulin Human", "text": "Interaction: Goserelin AND Insulin Human\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Insulin Human"}, {"id": "Goserelin_INT_Insulin Lispro", "text": "Interaction: Goserelin AND Insulin Lispro\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Insulin Lispro"}, {"id": "Goserelin_INT_Insulin Glargine", "text": "Interaction: Goserelin AND Insulin Glargine\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Insulin Glargine"}, {"id": "Goserelin_INT_Insulin Pork", "text": "Interaction: Goserelin AND Insulin Pork\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Insulin Pork"}, {"id": "Goserelin_INT_Troglitazone", "text": "Interaction: Goserelin AND Troglitazone\nDetails: The therapeutic efficacy of Troglitazone can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Troglitazone"}, {"id": "Goserelin_INT_Glimepiride", "text": "Interaction: Goserelin AND Glimepiride\nDetails: The therapeutic efficacy of Glimepiride can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Glimepiride"}, {"id": "Goserelin_INT_Acarbose", "text": "Interaction: Goserelin AND Acarbose\nDetails: The therapeutic efficacy of Acarbose can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Acarbose"}, {"id": "Goserelin_INT_Metformin", "text": "Interaction: Goserelin AND Metformin\nDetails: The therapeutic efficacy of Metformin can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Metformin"}, {"id": "Goserelin_INT_Rosiglitazone", "text": "Interaction: Goserelin AND Rosiglitazone\nDetails: The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Rosiglitazone"}, {"id": "Goserelin_INT_Acetohexamide", "text": "Interaction: Goserelin AND Acetohexamide\nDetails: The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Acetohexamide"}, {"id": "Goserelin_INT_Miglustat", "text": "Interaction: Goserelin AND Miglustat\nDetails: The therapeutic efficacy of Miglustat can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Miglustat"}, {"id": "Goserelin_INT_Miglitol", "text": "Interaction: Goserelin AND Miglitol\nDetails: The therapeutic efficacy of Miglitol can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Miglitol"}, {"id": "Goserelin_INT_Chlorpropamide", "text": "Interaction: Goserelin AND Chlorpropamide\nDetails: The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Chlorpropamide"}, {"id": "Goserelin_INT_Nateglinide", "text": "Interaction: Goserelin AND Nateglinide\nDetails: The therapeutic efficacy of Nateglinide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Nateglinide"}, {"id": "Goserelin_INT_Tolazamide", "text": "Interaction: Goserelin AND Tolazamide\nDetails: The therapeutic efficacy of Tolazamide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Tolazamide"}, {"id": "Goserelin_INT_Repaglinide", "text": "Interaction: Goserelin AND Repaglinide\nDetails: The therapeutic efficacy of Repaglinide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Repaglinide"}, {"id": "Goserelin_INT_Phenformin", "text": "Interaction: Goserelin AND Phenformin\nDetails: The therapeutic efficacy of Phenformin can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Phenformin"}, {"id": "Goserelin_INT_Glyburide", "text": "Interaction: Goserelin AND Glyburide\nDetails: The therapeutic efficacy of Glyburide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Glyburide"}, {"id": "Goserelin_INT_Glipizide", "text": "Interaction: Goserelin AND Glipizide\nDetails: The therapeutic efficacy of Glipizide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Glipizide"}, {"id": "Goserelin_INT_Gliclazide", "text": "Interaction: Goserelin AND Gliclazide\nDetails: The therapeutic efficacy of Gliclazide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Gliclazide"}, {"id": "Goserelin_INT_Tolbutamide", "text": "Interaction: Goserelin AND Tolbutamide\nDetails: The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Tolbutamide"}, {"id": "Goserelin_INT_Pioglitazone", "text": "Interaction: Goserelin AND Pioglitazone\nDetails: The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Pioglitazone"}, {"id": "Goserelin_INT_Gliquidone", "text": "Interaction: Goserelin AND Gliquidone\nDetails: The therapeutic efficacy of Gliquidone can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Gliquidone"}, {"id": "Goserelin_INT_Mitiglinide", "text": "Interaction: Goserelin AND Mitiglinide\nDetails: The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Mitiglinide"}, {"id": "Goserelin_INT_Sitagliptin", "text": "Interaction: Goserelin AND Sitagliptin\nDetails: The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Sitagliptin"}, {"id": "Goserelin_INT_Exenatide", "text": "Interaction: Goserelin AND Exenatide\nDetails: The therapeutic efficacy of Exenatide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Exenatide"}, {"id": "Goserelin_INT_Pramlintide", "text": "Interaction: Goserelin AND Pramlintide\nDetails: The therapeutic efficacy of Pramlintide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Pramlintide"}, {"id": "Goserelin_INT_Insulin Aspart", "text": "Interaction: Goserelin AND Insulin Aspart\nDetails: The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Insulin Aspart"}, {"id": "Goserelin_INT_Insulin Detemir", "text": "Interaction: Goserelin AND Insulin Detemir\nDetails: The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Insulin Detemir"}, {"id": "Goserelin_INT_Insulin Glulisine", "text": "Interaction: Goserelin AND Insulin Glulisine\nDetails: The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Insulin Glulisine"}, {"id": "Goserelin_INT_AICA ribonucleotide", "text": "Interaction: Goserelin AND AICA ribonucleotide\nDetails: The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + AICA ribonucleotide"}, {"id": "Goserelin_INT_Castanospermine", "text": "Interaction: Goserelin AND Castanospermine\nDetails: The therapeutic efficacy of Castanospermine can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Castanospermine"}, {"id": "Goserelin_INT_Buformin", "text": "Interaction: Goserelin AND Buformin\nDetails: The therapeutic efficacy of Buformin can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Buformin"}, {"id": "Goserelin_INT_Vildagliptin", "text": "Interaction: Goserelin AND Vildagliptin\nDetails: The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Vildagliptin"}, {"id": "Goserelin_INT_Voglibose", "text": "Interaction: Goserelin AND Voglibose\nDetails: The therapeutic efficacy of Voglibose can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Voglibose"}, {"id": "Goserelin_INT_Alogliptin", "text": "Interaction: Goserelin AND Alogliptin\nDetails: The therapeutic efficacy of Alogliptin can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Alogliptin"}, {"id": "Goserelin_INT_Sulodexide", "text": "Interaction: Goserelin AND Sulodexide\nDetails: The therapeutic efficacy of Sulodexide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Sulodexide"}, {"id": "Goserelin_INT_Saxagliptin", "text": "Interaction: Goserelin AND Saxagliptin\nDetails: The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Saxagliptin"}, {"id": "Goserelin_INT_Liraglutide", "text": "Interaction: Goserelin AND Liraglutide\nDetails: The therapeutic efficacy of Liraglutide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Liraglutide"}, {"id": "Goserelin_INT_Linagliptin", "text": "Interaction: Goserelin AND Linagliptin\nDetails: The therapeutic efficacy of Linagliptin can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Linagliptin"}, {"id": "Goserelin_INT_Canagliflozin", "text": "Interaction: Goserelin AND Canagliflozin\nDetails: The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Canagliflozin"}, {"id": "Goserelin_INT_Glibornuride", "text": "Interaction: Goserelin AND Glibornuride\nDetails: The therapeutic efficacy of Glibornuride can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Glibornuride"}, {"id": "Goserelin_INT_Empagliflozin", "text": "Interaction: Goserelin AND Empagliflozin\nDetails: The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Empagliflozin"}, {"id": "Goserelin_INT_Dulaglutide", "text": "Interaction: Goserelin AND Dulaglutide\nDetails: The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Dulaglutide"}, {"id": "Goserelin_INT_Ciglitazone", "text": "Interaction: Goserelin AND Ciglitazone\nDetails: The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Ciglitazone"}, {"id": "Goserelin_INT_Allicin", "text": "Interaction: Goserelin AND Allicin\nDetails: The therapeutic efficacy of Allicin can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Allicin"}, {"id": "Goserelin_INT_2,4-thiazolidinedione", "text": "Interaction: Goserelin AND 2,4-thiazolidinedione\nDetails: The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + 2,4-thiazolidinedione"}, {"id": "Goserelin_INT_Bempedoic acid", "text": "Interaction: Goserelin AND Bempedoic acid\nDetails: The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Bempedoic acid"}, {"id": "Goserelin_INT_Gusperimus", "text": "Interaction: Goserelin AND Gusperimus\nDetails: The therapeutic efficacy of Gusperimus can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Gusperimus"}, {"id": "Goserelin_INT_Sotagliflozin", "text": "Interaction: Goserelin AND Sotagliflozin\nDetails: The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Sotagliflozin"}, {"id": "Goserelin_INT_Balaglitazone", "text": "Interaction: Goserelin AND Balaglitazone\nDetails: The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Balaglitazone"}, {"id": "Goserelin_INT_Deoxyspergualin", "text": "Interaction: Goserelin AND Deoxyspergualin\nDetails: The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Deoxyspergualin"}, {"id": "Goserelin_INT_Carbutamide", "text": "Interaction: Goserelin AND Carbutamide\nDetails: The therapeutic efficacy of Carbutamide can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Goserelin + Carbutamide"}, {"id": "Reteplase_GEN", "text": "Drug: Reteplase\nDescription: ...", "source": "Reteplase"}, {"id": "Phylloquinone_GEN", "text": "Drug: Phylloquinone\nDescription: ...", "source": "Phylloquinone"}, {"id": "Calcium_GEN", "text": "Drug: Calcium\nDescription: ...", "source": "Calcium"}, {"id": "Reteplase_GEN", "text": "Drug: Reteplase\nDescription: Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a \"third-generation\" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting v...", "source": "Reteplase"}, {"id": "Reteplase_CLIN", "text": "Drug: Reteplase\nMechanism: Reteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn ...\nToxicity: ...", "source": "Reteplase"}, {"id": "Reteplase_INT_Aprotinin", "text": "Interaction: Reteplase AND Aprotinin\nDetails: The therapeutic efficacy of Reteplase can be decreased when used in combination with Aprotinin.\nRisk: Monitor closely.", "source": "Reteplase + Aprotinin"}, {"id": "Reteplase_INT_Limaprost", "text": "Interaction: Reteplase AND Limaprost\nDetails: The risk or severity of adverse effects can be increased when Limaprost is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Limaprost"}, {"id": "Reteplase_INT_Dabigatran etexilate", "text": "Interaction: Reteplase AND Dabigatran etexilate\nDetails: Reteplase may increase the anticoagulant activities of Dabigatran etexilate.\nRisk: Monitor closely.", "source": "Reteplase + Dabigatran etexilate"}, {"id": "Reteplase_INT_Lepirudin", "text": "Interaction: Reteplase AND Lepirudin\nDetails: Reteplase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Reteplase + Lepirudin"}, {"id": "Reteplase_INT_Bivalirudin", "text": "Interaction: Reteplase AND Bivalirudin\nDetails: Reteplase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Reteplase + Bivalirudin"}, {"id": "Reteplase_INT_Abciximab", "text": "Interaction: Reteplase AND Abciximab\nDetails: Reteplase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Reteplase + Abciximab"}, {"id": "Reteplase_INT_Becaplermin", "text": "Interaction: Reteplase AND Becaplermin\nDetails: Reteplase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Reteplase + Becaplermin"}, {"id": "Reteplase_INT_Dicoumarol", "text": "Interaction: Reteplase AND Dicoumarol\nDetails: Reteplase may increase the anticoagulant activities of Dicoumarol.\nRisk: Monitor closely.", "source": "Reteplase + Dicoumarol"}, {"id": "Reteplase_INT_Argatroban", "text": "Interaction: Reteplase AND Argatroban\nDetails: Reteplase may increase the anticoagulant activities of Argatroban.\nRisk: Monitor closely.", "source": "Reteplase + Argatroban"}, {"id": "Reteplase_INT_Ardeparin", "text": "Interaction: Reteplase AND Ardeparin\nDetails: Reteplase may increase the anticoagulant activities of Ardeparin.\nRisk: Monitor closely.", "source": "Reteplase + Ardeparin"}, {"id": "Reteplase_INT_Phenindione", "text": "Interaction: Reteplase AND Phenindione\nDetails: Reteplase may increase the anticoagulant activities of Phenindione.\nRisk: Monitor closely.", "source": "Reteplase + Phenindione"}, {"id": "Reteplase_INT_Fondaparinux sodium", "text": "Interaction: Reteplase AND Fondaparinux sodium\nDetails: Reteplase may increase the anticoagulant activities of Fondaparinux sodium.\nRisk: Monitor closely.", "source": "Reteplase + Fondaparinux sodium"}, {"id": "Reteplase_INT_Warfarin", "text": "Interaction: Reteplase AND Warfarin\nDetails: Reteplase may increase the anticoagulant activities of Warfarin.\nRisk: Monitor closely.", "source": "Reteplase + Warfarin"}, {"id": "Reteplase_INT_Pentosan Polysulfate", "text": "Interaction: Reteplase AND Pentosan Polysulfate\nDetails: Reteplase may increase the anticoagulant activities of Pentosan Polysulfate.\nRisk: Monitor closely.", "source": "Reteplase + Pentosan Polysulfate"}, {"id": "Reteplase_INT_Phenprocoumon", "text": "Interaction: Reteplase AND Phenprocoumon\nDetails: Reteplase may increase the anticoagulant activities of Phenprocoumon.\nRisk: Monitor closely.", "source": "Reteplase + Phenprocoumon"}, {"id": "Reteplase_INT_Edetic Acid", "text": "Interaction: Reteplase AND Edetic Acid\nDetails: Reteplase may increase the anticoagulant activities of Edetic Acid.\nRisk: Monitor closely.", "source": "Reteplase + Edetic Acid"}, {"id": "Reteplase_INT_Heparin", "text": "Interaction: Reteplase AND Heparin\nDetails: Reteplase may increase the anticoagulant activities of Heparin.\nRisk: Monitor closely.", "source": "Reteplase + Heparin"}, {"id": "Reteplase_INT_Enoxaparin", "text": "Interaction: Reteplase AND Enoxaparin\nDetails: Reteplase may increase the anticoagulant activities of Enoxaparin.\nRisk: Monitor closely.", "source": "Reteplase + Enoxaparin"}, {"id": "Reteplase_INT_Acenocoumarol", "text": "Interaction: Reteplase AND Acenocoumarol\nDetails: Reteplase may increase the anticoagulant activities of Acenocoumarol.\nRisk: Monitor closely.", "source": "Reteplase + Acenocoumarol"}, {"id": "Reteplase_INT_Citric Acid", "text": "Interaction: Reteplase AND Citric Acid\nDetails: Reteplase may increase the anticoagulant activities of Citric Acid.\nRisk: Monitor closely.", "source": "Reteplase + Citric Acid"}, {"id": "Reteplase_INT_Ximelagatran", "text": "Interaction: Reteplase AND Ximelagatran\nDetails: Reteplase may increase the anticoagulant activities of Ximelagatran.\nRisk: Monitor closely.", "source": "Reteplase + Ximelagatran"}, {"id": "Reteplase_INT_Ancrod", "text": "Interaction: Reteplase AND Ancrod\nDetails: Reteplase may increase the anticoagulant activities of Ancrod.\nRisk: Monitor closely.", "source": "Reteplase + Ancrod"}, {"id": "Reteplase_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Reteplase AND Pentaerythritol Tetranitrate\nDetails: Reteplase may increase the anticoagulant activities of Pentaerythritol Tetranitrate.\nRisk: Monitor closely.", "source": "Reteplase + Pentaerythritol Tetranitrate"}, {"id": "Reteplase_INT_Rivaroxaban", "text": "Interaction: Reteplase AND Rivaroxaban\nDetails: Reteplase may increase the anticoagulant activities of Rivaroxaban.\nRisk: Monitor closely.", "source": "Reteplase + Rivaroxaban"}, {"id": "Reteplase_INT_Sulodexide", "text": "Interaction: Reteplase AND Sulodexide\nDetails: Reteplase may increase the anticoagulant activities of Sulodexide.\nRisk: Monitor closely.", "source": "Reteplase + Sulodexide"}, {"id": "Reteplase_INT_Idraparinux", "text": "Interaction: Reteplase AND Idraparinux\nDetails: Reteplase may increase the anticoagulant activities of Idraparinux.\nRisk: Monitor closely.", "source": "Reteplase + Idraparinux"}, {"id": "Reteplase_INT_Apixaban", "text": "Interaction: Reteplase AND Apixaban\nDetails: Reteplase may increase the anticoagulant activities of Apixaban.\nRisk: Monitor closely.", "source": "Reteplase + Apixaban"}, {"id": "Reteplase_INT_Otamixaban", "text": "Interaction: Reteplase AND Otamixaban\nDetails: Reteplase may increase the anticoagulant activities of Otamixaban.\nRisk: Monitor closely.", "source": "Reteplase + Otamixaban"}, {"id": "Reteplase_INT_Danaparoid", "text": "Interaction: Reteplase AND Danaparoid\nDetails: Reteplase may increase the anticoagulant activities of Danaparoid.\nRisk: Monitor closely.", "source": "Reteplase + Danaparoid"}, {"id": "Reteplase_INT_Dalteparin", "text": "Interaction: Reteplase AND Dalteparin\nDetails: Reteplase may increase the anticoagulant activities of Dalteparin.\nRisk: Monitor closely.", "source": "Reteplase + Dalteparin"}, {"id": "Reteplase_INT_Ferulic acid", "text": "Interaction: Reteplase AND Ferulic acid\nDetails: Reteplase may increase the anticoagulant activities of Ferulic acid.\nRisk: Monitor closely.", "source": "Reteplase + Ferulic acid"}, {"id": "Reteplase_INT_Ethyl biscoumacetate", "text": "Interaction: Reteplase AND Ethyl biscoumacetate\nDetails: Reteplase may increase the anticoagulant activities of Ethyl biscoumacetate.\nRisk: Monitor closely.", "source": "Reteplase + Ethyl biscoumacetate"}, {"id": "Reteplase_INT_Nadroparin", "text": "Interaction: Reteplase AND Nadroparin\nDetails: Reteplase may increase the anticoagulant activities of Nadroparin.\nRisk: Monitor closely.", "source": "Reteplase + Nadroparin"}, {"id": "Reteplase_INT_Edoxaban", "text": "Interaction: Reteplase AND Edoxaban\nDetails: Reteplase may increase the anticoagulant activities of Edoxaban.\nRisk: Monitor closely.", "source": "Reteplase + Edoxaban"}, {"id": "Reteplase_INT_Dextran", "text": "Interaction: Reteplase AND Dextran\nDetails: Reteplase may increase the anticoagulant activities of Dextran.\nRisk: Monitor closely.", "source": "Reteplase + Dextran"}, {"id": "Reteplase_INT_Reviparin", "text": "Interaction: Reteplase AND Reviparin\nDetails: Reteplase may increase the anticoagulant activities of Reviparin.\nRisk: Monitor closely.", "source": "Reteplase + Reviparin"}, {"id": "Reteplase_INT_Certoparin", "text": "Interaction: Reteplase AND Certoparin\nDetails: Reteplase may increase the anticoagulant activities of Certoparin.\nRisk: Monitor closely.", "source": "Reteplase + Certoparin"}, {"id": "Reteplase_INT_Dextran 70", "text": "Interaction: Reteplase AND Dextran 70\nDetails: Reteplase may increase the anticoagulant activities of Dextran 70.\nRisk: Monitor closely.", "source": "Reteplase + Dextran 70"}, {"id": "Reteplase_INT_Desirudin", "text": "Interaction: Reteplase AND Desirudin\nDetails: Reteplase may increase the anticoagulant activities of Desirudin.\nRisk: Monitor closely.", "source": "Reteplase + Desirudin"}, {"id": "Reteplase_INT_Dextran 40", "text": "Interaction: Reteplase AND Dextran 40\nDetails: Reteplase may increase the anticoagulant activities of Dextran 40.\nRisk: Monitor closely.", "source": "Reteplase + Dextran 40"}, {"id": "Reteplase_INT_Dextran 75", "text": "Interaction: Reteplase AND Dextran 75\nDetails: Reteplase may increase the anticoagulant activities of Dextran 75.\nRisk: Monitor closely.", "source": "Reteplase + Dextran 75"}, {"id": "Reteplase_INT_Protocatechualdehyde", "text": "Interaction: Reteplase AND Protocatechualdehyde\nDetails: Reteplase may increase the anticoagulant activities of Protocatechualdehyde.\nRisk: Monitor closely.", "source": "Reteplase + Protocatechualdehyde"}, {"id": "Reteplase_INT_Protein C", "text": "Interaction: Reteplase AND Protein C\nDetails: Reteplase may increase the anticoagulant activities of Protein C.\nRisk: Monitor closely.", "source": "Reteplase + Protein C"}, {"id": "Reteplase_INT_Antithrombin III human", "text": "Interaction: Reteplase AND Antithrombin III human\nDetails: Reteplase may increase the anticoagulant activities of Antithrombin III human.\nRisk: Monitor closely.", "source": "Reteplase + Antithrombin III human"}, {"id": "Reteplase_INT_Fondaparinux", "text": "Interaction: Reteplase AND Fondaparinux\nDetails: Reteplase may increase the anticoagulant activities of Fondaparinux.\nRisk: Monitor closely.", "source": "Reteplase + Fondaparinux"}, {"id": "Reteplase_INT_Letaxaban", "text": "Interaction: Reteplase AND Letaxaban\nDetails: Reteplase may increase the anticoagulant activities of Letaxaban.\nRisk: Monitor closely.", "source": "Reteplase + Letaxaban"}, {"id": "Reteplase_INT_Darexaban", "text": "Interaction: Reteplase AND Darexaban\nDetails: Reteplase may increase the anticoagulant activities of Darexaban.\nRisk: Monitor closely.", "source": "Reteplase + Darexaban"}, {"id": "Reteplase_INT_Nafamostat", "text": "Interaction: Reteplase AND Nafamostat\nDetails: Reteplase may increase the anticoagulant activities of Nafamostat.\nRisk: Monitor closely.", "source": "Reteplase + Nafamostat"}, {"id": "Reteplase_INT_Gabexate", "text": "Interaction: Reteplase AND Gabexate\nDetails: Reteplase may increase the anticoagulant activities of Gabexate.\nRisk: Monitor closely.", "source": "Reteplase + Gabexate"}, {"id": "Reteplase_INT_Troxerutin", "text": "Interaction: Reteplase AND Troxerutin\nDetails: Reteplase may increase the anticoagulant activities of Troxerutin.\nRisk: Monitor closely.", "source": "Reteplase + Troxerutin"}, {"id": "Reteplase_INT_Fluindione", "text": "Interaction: Reteplase AND Fluindione\nDetails: Reteplase may increase the anticoagulant activities of Fluindione.\nRisk: Monitor closely.", "source": "Reteplase + Fluindione"}, {"id": "Reteplase_INT_Protein S human", "text": "Interaction: Reteplase AND Protein S human\nDetails: Reteplase may increase the anticoagulant activities of Protein S human.\nRisk: Monitor closely.", "source": "Reteplase + Protein S human"}, {"id": "Reteplase_INT_Melagatran", "text": "Interaction: Reteplase AND Melagatran\nDetails: Reteplase may increase the anticoagulant activities of Melagatran.\nRisk: Monitor closely.", "source": "Reteplase + Melagatran"}, {"id": "Reteplase_INT_Salicylic acid", "text": "Interaction: Reteplase AND Salicylic acid\nDetails: The risk or severity of adverse effects can be increased when Salicylic acid is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Salicylic acid"}, {"id": "Reteplase_INT_Acetylsalicylic acid", "text": "Interaction: Reteplase AND Acetylsalicylic acid\nDetails: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Acetylsalicylic acid"}, {"id": "Reteplase_INT_Aminosalicylic Acid", "text": "Interaction: Reteplase AND Aminosalicylic Acid\nDetails: The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Aminosalicylic Acid"}, {"id": "Reteplase_INT_Mesalazine", "text": "Interaction: Reteplase AND Mesalazine\nDetails: The risk or severity of adverse effects can be increased when Mesalazine is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Mesalazine"}, {"id": "Reteplase_INT_Diflunisal", "text": "Interaction: Reteplase AND Diflunisal\nDetails: The risk or severity of adverse effects can be increased when Diflunisal is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Diflunisal"}, {"id": "Reteplase_INT_Balsalazide", "text": "Interaction: Reteplase AND Balsalazide\nDetails: The risk or severity of adverse effects can be increased when Balsalazide is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Balsalazide"}, {"id": "Reteplase_INT_Olsalazine", "text": "Interaction: Reteplase AND Olsalazine\nDetails: The risk or severity of adverse effects can be increased when Olsalazine is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Olsalazine"}, {"id": "Reteplase_INT_dersalazine", "text": "Interaction: Reteplase AND dersalazine\nDetails: The risk or severity of adverse effects can be increased when dersalazine is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + dersalazine"}, {"id": "Reteplase_INT_Nitroaspirin", "text": "Interaction: Reteplase AND Nitroaspirin\nDetails: The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Nitroaspirin"}, {"id": "Reteplase_INT_Aloxiprin", "text": "Interaction: Reteplase AND Aloxiprin\nDetails: The risk or severity of adverse effects can be increased when Aloxiprin is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Aloxiprin"}, {"id": "Reteplase_INT_Guacetisal", "text": "Interaction: Reteplase AND Guacetisal\nDetails: The risk or severity of adverse effects can be increased when Guacetisal is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Guacetisal"}, {"id": "Reteplase_INT_Carbaspirin calcium", "text": "Interaction: Reteplase AND Carbaspirin calcium\nDetails: The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Carbaspirin calcium"}, {"id": "Reteplase_INT_Hemoglobin crosfumaril", "text": "Interaction: Reteplase AND Hemoglobin crosfumaril\nDetails: The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Hemoglobin crosfumaril"}, {"id": "Reteplase_INT_Methyl salicylate", "text": "Interaction: Reteplase AND Methyl salicylate\nDetails: The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Methyl salicylate"}, {"id": "Reteplase_INT_Trolamine salicylate", "text": "Interaction: Reteplase AND Trolamine salicylate\nDetails: The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Trolamine salicylate"}, {"id": "Reteplase_INT_Eptifibatide", "text": "Interaction: Reteplase AND Eptifibatide\nDetails: Eptifibatide may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Eptifibatide"}, {"id": "Reteplase_INT_Ticlopidine", "text": "Interaction: Reteplase AND Ticlopidine\nDetails: Ticlopidine may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Ticlopidine"}, {"id": "Reteplase_INT_Tirofiban", "text": "Interaction: Reteplase AND Tirofiban\nDetails: Tirofiban may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Tirofiban"}, {"id": "Reteplase_INT_Dipyridamole", "text": "Interaction: Reteplase AND Dipyridamole\nDetails: Dipyridamole may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Dipyridamole"}, {"id": "Reteplase_INT_Clopidogrel", "text": "Interaction: Reteplase AND Clopidogrel\nDetails: Clopidogrel may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Clopidogrel"}, {"id": "Reteplase_INT_Prasugrel", "text": "Interaction: Reteplase AND Prasugrel\nDetails: Prasugrel may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Prasugrel"}, {"id": "Reteplase_INT_Vorapaxar", "text": "Interaction: Reteplase AND Vorapaxar\nDetails: Vorapaxar may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Vorapaxar"}, {"id": "Reteplase_INT_Milrinone", "text": "Interaction: Reteplase AND Milrinone\nDetails: Milrinone may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Milrinone"}, {"id": "Reteplase_INT_Anagrelide", "text": "Interaction: Reteplase AND Anagrelide\nDetails: Anagrelide may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Anagrelide"}, {"id": "Reteplase_INT_Epinastine", "text": "Interaction: Reteplase AND Epinastine\nDetails: Epinastine may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Epinastine"}, {"id": "Reteplase_INT_Alprostadil", "text": "Interaction: Reteplase AND Alprostadil\nDetails: Alprostadil may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Alprostadil"}, {"id": "Reteplase_INT_Pentoxifylline", "text": "Interaction: Reteplase AND Pentoxifylline\nDetails: Pentoxifylline may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Pentoxifylline"}, {"id": "Reteplase_INT_Azelastine", "text": "Interaction: Reteplase AND Azelastine\nDetails: Azelastine may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Azelastine"}, {"id": "Reteplase_INT_Iloprost", "text": "Interaction: Reteplase AND Iloprost\nDetails: Iloprost may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Iloprost"}, {"id": "Reteplase_INT_Cilostazol", "text": "Interaction: Reteplase AND Cilostazol\nDetails: Cilostazol may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Cilostazol"}, {"id": "Reteplase_INT_Ridogrel", "text": "Interaction: Reteplase AND Ridogrel\nDetails: Ridogrel may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Ridogrel"}, {"id": "Reteplase_INT_Sevoflurane", "text": "Interaction: Reteplase AND Sevoflurane\nDetails: Sevoflurane may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Sevoflurane"}, {"id": "Reteplase_INT_Epoprostenol", "text": "Interaction: Reteplase AND Epoprostenol\nDetails: Epoprostenol may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Epoprostenol"}, {"id": "Reteplase_INT_Resveratrol", "text": "Interaction: Reteplase AND Resveratrol\nDetails: Resveratrol may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Resveratrol"}, {"id": "Reteplase_INT_Nimesulide", "text": "Interaction: Reteplase AND Nimesulide\nDetails: Nimesulide may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Nimesulide"}, {"id": "Reteplase_INT_Tesmilifene", "text": "Interaction: Reteplase AND Tesmilifene\nDetails: Tesmilifene may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Tesmilifene"}, {"id": "Reteplase_INT_Defibrotide", "text": "Interaction: Reteplase AND Defibrotide\nDetails: Defibrotide may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Defibrotide"}, {"id": "Reteplase_INT_SRT501", "text": "Interaction: Reteplase AND SRT501\nDetails: SRT501 may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + SRT501"}, {"id": "Reteplase_INT_Beraprost", "text": "Interaction: Reteplase AND Beraprost\nDetails: Beraprost may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Beraprost"}, {"id": "Reteplase_INT_Ibudilast", "text": "Interaction: Reteplase AND Ibudilast\nDetails: Ibudilast may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Ibudilast"}, {"id": "Reteplase_INT_Andrographolide", "text": "Interaction: Reteplase AND Andrographolide\nDetails: Andrographolide may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Andrographolide"}, {"id": "Reteplase_INT_eplivanserine", "text": "Interaction: Reteplase AND eplivanserine\nDetails: eplivanserine may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + eplivanserine"}, {"id": "Reteplase_INT_Cangrelor", "text": "Interaction: Reteplase AND Cangrelor\nDetails: Cangrelor may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Cangrelor"}, {"id": "Reteplase_INT_Tranilast", "text": "Interaction: Reteplase AND Tranilast\nDetails: Tranilast may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Tranilast"}, {"id": "Reteplase_INT_Triflusal", "text": "Interaction: Reteplase AND Triflusal\nDetails: Triflusal may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Triflusal"}, {"id": "Reteplase_INT_Icosapent ethyl", "text": "Interaction: Reteplase AND Icosapent ethyl\nDetails: Icosapent ethyl may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Icosapent ethyl"}, {"id": "Reteplase_INT_Ifenprodil", "text": "Interaction: Reteplase AND Ifenprodil\nDetails: Ifenprodil may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Ifenprodil"}, {"id": "Reteplase_INT_Trapidil", "text": "Interaction: Reteplase AND Trapidil\nDetails: Trapidil may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Trapidil"}, {"id": "Reteplase_INT_Naftopidil", "text": "Interaction: Reteplase AND Naftopidil\nDetails: Naftopidil may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Naftopidil"}, {"id": "Reteplase_INT_Sarpogrelate", "text": "Interaction: Reteplase AND Sarpogrelate\nDetails: Sarpogrelate may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Sarpogrelate"}, {"id": "Reteplase_INT_Eplivanserin", "text": "Interaction: Reteplase AND Eplivanserin\nDetails: Eplivanserin may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Eplivanserin"}, {"id": "Reteplase_INT_Ifetroban", "text": "Interaction: Reteplase AND Ifetroban\nDetails: Ifetroban may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Ifetroban"}, {"id": "Reteplase_INT_Ketanserin", "text": "Interaction: Reteplase AND Ketanserin\nDetails: Ketanserin may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Ketanserin"}, {"id": "Reteplase_INT_Indobufen", "text": "Interaction: Reteplase AND Indobufen\nDetails: Indobufen may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Indobufen"}, {"id": "Reteplase_INT_Butylphthalide", "text": "Interaction: Reteplase AND Butylphthalide\nDetails: Butylphthalide may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Butylphthalide"}, {"id": "Reteplase_INT_Hydroxytyrosol", "text": "Interaction: Reteplase AND Hydroxytyrosol\nDetails: Hydroxytyrosol may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Hydroxytyrosol"}, {"id": "Reteplase_INT_Ramatroban", "text": "Interaction: Reteplase AND Ramatroban\nDetails: Ramatroban may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Ramatroban"}, {"id": "Reteplase_INT_Picotamide", "text": "Interaction: Reteplase AND Picotamide\nDetails: Picotamide may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Picotamide"}, {"id": "Reteplase_INT_Cloricromen", "text": "Interaction: Reteplase AND Cloricromen\nDetails: Cloricromen may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Cloricromen"}, {"id": "Reteplase_INT_Linsidomine", "text": "Interaction: Reteplase AND Linsidomine\nDetails: Linsidomine may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Linsidomine"}, {"id": "Reteplase_INT_Buflomedil", "text": "Interaction: Reteplase AND Buflomedil\nDetails: Buflomedil may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Buflomedil"}, {"id": "Reteplase_INT_Relcovaptan", "text": "Interaction: Reteplase AND Relcovaptan\nDetails: Relcovaptan may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Relcovaptan"}, {"id": "Reteplase_INT_Ticagrelor", "text": "Interaction: Reteplase AND Ticagrelor\nDetails: Ticagrelor may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Reteplase + Ticagrelor"}, {"id": "Reteplase_INT_Treprostinil", "text": "Interaction: Reteplase AND Treprostinil\nDetails: The risk or severity of adverse effects can be increased when Reteplase is combined with Treprostinil.\nRisk: Monitor closely.", "source": "Reteplase + Treprostinil"}, {"id": "Erythropoietin_GEN", "text": "Drug: Erythropoietin\nDescription: Erythropoietin is a 165-amino acid erythropoiesis-stimulating glycoprotein manufactured by recombinant DNA technology. It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product contains the i...", "source": "Erythropoietin"}, {"id": "Erythropoietin_CLIN", "text": "Drug: Erythropoietin\nMechanism: Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transduc...\nToxicity: ...", "source": "Erythropoietin"}, {"id": "Erythropoietin_INT_Nandrolone phenpropionate", "text": "Interaction: Erythropoietin AND Nandrolone phenpropionate\nDetails: Nandrolone phenpropionate may increase the stimulatory activities of Erythropoietin.\nRisk: Monitor closely.", "source": "Erythropoietin + Nandrolone phenpropionate"}, {"id": "Erythropoietin_INT_Nandrolone decanoate", "text": "Interaction: Erythropoietin AND Nandrolone decanoate\nDetails: Nandrolone decanoate may increase the stimulatory activities of Erythropoietin.\nRisk: Monitor closely.", "source": "Erythropoietin + Nandrolone decanoate"}, {"id": "Erythropoietin_INT_Lenalidomide", "text": "Interaction: Erythropoietin AND Lenalidomide\nDetails: Erythropoietin may increase the thrombogenic activities of Lenalidomide.\nRisk: Monitor closely.", "source": "Erythropoietin + Lenalidomide"}, {"id": "Erythropoietin_INT_Thalidomide", "text": "Interaction: Erythropoietin AND Thalidomide\nDetails: Erythropoietin may increase the thrombogenic activities of Thalidomide.\nRisk: Monitor closely.", "source": "Erythropoietin + Thalidomide"}, {"id": "Salmon Calcitonin_GEN", "text": "Drug: Salmon Calcitonin\nDescription: Synthetic peptide, 32 residues long formulated as a nasal spray....", "source": "Salmon Calcitonin"}, {"id": "Salmon Calcitonin_CLIN", "text": "Drug: Salmon Calcitonin\nMechanism: Calcitonin binds to the calcitonin receptor (found primarily in osteoclasts) which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater...\nToxicity: Salmon calcitonin was shown to inhibit lactation in animals and is not recommend in nursing mothers. While research in animals have shown a decrease in fetal weight, no studies have yet shown similar ...", "source": "Salmon Calcitonin"}, {"id": "Salmon Calcitonin_INT_Zoledronic acid", "text": "Interaction: Salmon Calcitonin AND Zoledronic acid\nDetails: Salmon Calcitonin may increase the hypocalcemic activities of Zoledronic acid.\nRisk: Monitor closely.", "source": "Salmon Calcitonin + Zoledronic acid"}, {"id": "Salmon Calcitonin_INT_Lithium", "text": "Interaction: Salmon Calcitonin AND Lithium\nDetails: The serum concentration of Lithium can be decreased when it is combined with Salmon Calcitonin.\nRisk: Monitor closely.", "source": "Salmon Calcitonin + Lithium"}, {"id": "Interferon alfa-n3_GEN", "text": "Drug: Interferon alfa-n3\nDescription: Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD)....", "source": "Interferon alfa-n3"}, {"id": "Interferon alfa-n3_CLIN", "text": "Drug: Interferon alfa-n3\nMechanism: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselv...\nToxicity: ...", "source": "Interferon alfa-n3"}, {"id": "Interferon alfa-n3_INT_Metamizole", "text": "Interaction: Interferon alfa-n3 AND Metamizole\nDetails: The risk or severity of myelosuppression can be increased when Metamizole is combined with Interferon alfa-n3.\nRisk: Monitor closely.", "source": "Interferon alfa-n3 + Metamizole"}, {"id": "Interferon alfa-n3_INT_Clozapine", "text": "Interaction: Interferon alfa-n3 AND Clozapine\nDetails: The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Clozapine.\nRisk: Monitor closely.", "source": "Interferon alfa-n3 + Clozapine"}, {"id": "Interferon alfa-n3_INT_Aldesleukin", "text": "Interaction: Interferon alfa-n3 AND Aldesleukin\nDetails: The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Interferon alfa-n3 + Aldesleukin"}, {"id": "Interferon alfa-n3_INT_Ambroxol acefyllinate", "text": "Interaction: Interferon alfa-n3 AND Ambroxol acefyllinate\nDetails: The metabolism of Ambroxol acefyllinate can be decreased when combined with Interferon alfa-n3.\nRisk: Monitor closely.", "source": "Interferon alfa-n3 + Ambroxol acefyllinate"}, {"id": "Interferon alfa-n3_INT_Theophylline", "text": "Interaction: Interferon alfa-n3 AND Theophylline\nDetails: The metabolism of Theophylline can be decreased when combined with Interferon alfa-n3.\nRisk: Monitor closely.", "source": "Interferon alfa-n3 + Theophylline"}, {"id": "Interferon alfa-n3_INT_Dyphylline", "text": "Interaction: Interferon alfa-n3 AND Dyphylline\nDetails: The metabolism of Dyphylline can be decreased when combined with Interferon alfa-n3.\nRisk: Monitor closely.", "source": "Interferon alfa-n3 + Dyphylline"}, {"id": "Interferon alfa-n3_INT_Aminophylline", "text": "Interaction: Interferon alfa-n3 AND Aminophylline\nDetails: The metabolism of Aminophylline can be decreased when combined with Interferon alfa-n3.\nRisk: Monitor closely.", "source": "Interferon alfa-n3 + Aminophylline"}, {"id": "Interferon alfa-n3_INT_Methadone", "text": "Interaction: Interferon alfa-n3 AND Methadone\nDetails: The serum concentration of Methadone can be increased when it is combined with Interferon alfa-n3.\nRisk: Monitor closely.", "source": "Interferon alfa-n3 + Methadone"}, {"id": "Interferon alfa-n3_INT_Ribavirin", "text": "Interaction: Interferon alfa-n3 AND Ribavirin\nDetails: The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ribavirin.\nRisk: Monitor closely.", "source": "Interferon alfa-n3 + Ribavirin"}, {"id": "Interferon alfa-n3_INT_Zidovudine", "text": "Interaction: Interferon alfa-n3 AND Zidovudine\nDetails: The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Zidovudine.\nRisk: Monitor closely.", "source": "Interferon alfa-n3 + Zidovudine"}, {"id": "Pegfilgrastim_GEN", "text": "Drug: Pegfilgrastim\nDescription: PEGylated (at N terminus) form of human G-CSF (Granulocyte colony stimulating factor), 175 residues, produced from E. coli via bacterial fermentation....", "source": "Pegfilgrastim"}, {"id": "Pegfilgrastim_CLIN", "text": "Drug: Pegfilgrastim\nMechanism: Pegfilgrastim binds to the G-CSF receptor. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Pegfilgrastim also stimul...\nToxicity: ...", "source": "Pegfilgrastim"}, {"id": "Pegfilgrastim_INT_Pegloticase", "text": "Interaction: Pegfilgrastim AND Pegloticase\nDetails: The therapeutic efficacy of Pegfilgrastim can be decreased when used in combination with Pegloticase.\nRisk: Monitor closely.", "source": "Pegfilgrastim + Pegloticase"}, {"id": "Sargramostim_GEN", "text": "Drug: Sargramostim\nDescription: Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein....", "source": "Sargramostim"}, {"id": "Sargramostim_CLIN", "text": "Drug: Sargramostim\nMechanism: Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the product...\nToxicity: ...", "source": "Sargramostim"}, {"id": "Sargramostim_INT_Bleomycin", "text": "Interaction: Sargramostim AND Bleomycin\nDetails: The risk or severity of adverse effects can be increased when Sargramostim is combined with Bleomycin.\nRisk: Monitor closely.", "source": "Sargramostim + Bleomycin"}, {"id": "Sargramostim_INT_Cyclophosphamide", "text": "Interaction: Sargramostim AND Cyclophosphamide\nDetails: The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sargramostim.\nRisk: Monitor closely.", "source": "Sargramostim + Cyclophosphamide"}, {"id": "Secretin_GEN", "text": "Drug: Secretin\nDescription: This drug is the synthetic form of natural secretin.  It is prepared using solid phase peptide synthesis.  Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small  intestine\u2019s contents through the control of gastric acid secretion and...", "source": "Secretin"}, {"id": "Secretin_CLIN", "text": "Drug: Secretin\nMechanism: Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of g...\nToxicity: ...", "source": "Secretin"}, {"id": "Secretin_INT_Benzatropine", "text": "Interaction: Secretin AND Benzatropine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Benzatropine.\nRisk: Monitor closely.", "source": "Secretin + Benzatropine"}, {"id": "Secretin_INT_Ipratropium bromide", "text": "Interaction: Secretin AND Ipratropium bromide\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Ipratropium bromide.\nRisk: Monitor closely.", "source": "Secretin + Ipratropium bromide"}, {"id": "Secretin_INT_Trihexyphenidyl", "text": "Interaction: Secretin AND Trihexyphenidyl\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Trihexyphenidyl.\nRisk: Monitor closely.", "source": "Secretin + Trihexyphenidyl"}, {"id": "Secretin_INT_Procyclidine", "text": "Interaction: Secretin AND Procyclidine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Procyclidine.\nRisk: Monitor closely.", "source": "Secretin + Procyclidine"}, {"id": "Secretin_INT_Ethopropazine", "text": "Interaction: Secretin AND Ethopropazine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Ethopropazine.\nRisk: Monitor closely.", "source": "Secretin + Ethopropazine"}, {"id": "Secretin_INT_Atropine", "text": "Interaction: Secretin AND Atropine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Atropine.\nRisk: Monitor closely.", "source": "Secretin + Atropine"}, {"id": "Secretin_INT_Scopolamine", "text": "Interaction: Secretin AND Scopolamine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Scopolamine.\nRisk: Monitor closely.", "source": "Secretin + Scopolamine"}, {"id": "Secretin_INT_Tropicamide", "text": "Interaction: Secretin AND Tropicamide\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Tropicamide.\nRisk: Monitor closely.", "source": "Secretin + Tropicamide"}, {"id": "Secretin_INT_Biperiden", "text": "Interaction: Secretin AND Biperiden\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Biperiden.\nRisk: Monitor closely.", "source": "Secretin + Biperiden"}, {"id": "Secretin_INT_Cyclopentolate", "text": "Interaction: Secretin AND Cyclopentolate\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Cyclopentolate.\nRisk: Monitor closely.", "source": "Secretin + Cyclopentolate"}, {"id": "Secretin_INT_Tiotropium", "text": "Interaction: Secretin AND Tiotropium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Tiotropium.\nRisk: Monitor closely.", "source": "Secretin + Tiotropium"}, {"id": "Secretin_INT_Dexetimide", "text": "Interaction: Secretin AND Dexetimide\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Dexetimide.\nRisk: Monitor closely.", "source": "Secretin + Dexetimide"}, {"id": "Secretin_INT_Bornaprine", "text": "Interaction: Secretin AND Bornaprine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Bornaprine.\nRisk: Monitor closely.", "source": "Secretin + Bornaprine"}, {"id": "Secretin_INT_Phenglutarimide", "text": "Interaction: Secretin AND Phenglutarimide\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Phenglutarimide.\nRisk: Monitor closely.", "source": "Secretin + Phenglutarimide"}, {"id": "Secretin_INT_Propantheline", "text": "Interaction: Secretin AND Propantheline\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Propantheline.\nRisk: Monitor closely.", "source": "Secretin + Propantheline"}, {"id": "Secretin_INT_Dicyclomine", "text": "Interaction: Secretin AND Dicyclomine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Dicyclomine.\nRisk: Monitor closely.", "source": "Secretin + Dicyclomine"}, {"id": "Secretin_INT_Aclidinium", "text": "Interaction: Secretin AND Aclidinium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Aclidinium.\nRisk: Monitor closely.", "source": "Secretin + Aclidinium"}, {"id": "Secretin_INT_Glycopyrronium", "text": "Interaction: Secretin AND Glycopyrronium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Glycopyrronium.\nRisk: Monitor closely.", "source": "Secretin + Glycopyrronium"}, {"id": "Secretin_INT_Trospium", "text": "Interaction: Secretin AND Trospium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Trospium.\nRisk: Monitor closely.", "source": "Secretin + Trospium"}, {"id": "Secretin_INT_Oxyphenonium", "text": "Interaction: Secretin AND Oxyphenonium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Oxyphenonium.\nRisk: Monitor closely.", "source": "Secretin + Oxyphenonium"}, {"id": "Secretin_INT_Hyoscyamine", "text": "Interaction: Secretin AND Hyoscyamine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Hyoscyamine.\nRisk: Monitor closely.", "source": "Secretin + Hyoscyamine"}, {"id": "Secretin_INT_Gallamine Triethiodide", "text": "Interaction: Secretin AND Gallamine Triethiodide\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Gallamine Triethiodide.\nRisk: Monitor closely.", "source": "Secretin + Gallamine Triethiodide"}, {"id": "Secretin_INT_Darifenacin", "text": "Interaction: Secretin AND Darifenacin\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Darifenacin.\nRisk: Monitor closely.", "source": "Secretin + Darifenacin"}, {"id": "Secretin_INT_Anisotropine Methylbromide", "text": "Interaction: Secretin AND Anisotropine Methylbromide\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Anisotropine Methylbromide.\nRisk: Monitor closely.", "source": "Secretin + Anisotropine Methylbromide"}, {"id": "Secretin_INT_Mecamylamine", "text": "Interaction: Secretin AND Mecamylamine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Mecamylamine.\nRisk: Monitor closely.", "source": "Secretin + Mecamylamine"}, {"id": "Secretin_INT_Pirenzepine", "text": "Interaction: Secretin AND Pirenzepine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Pirenzepine.\nRisk: Monitor closely.", "source": "Secretin + Pirenzepine"}, {"id": "Secretin_INT_Atracurium besylate", "text": "Interaction: Secretin AND Atracurium besylate\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Atracurium besylate.\nRisk: Monitor closely.", "source": "Secretin + Atracurium besylate"}, {"id": "Secretin_INT_Quinidine", "text": "Interaction: Secretin AND Quinidine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Quinidine.\nRisk: Monitor closely.", "source": "Secretin + Quinidine"}, {"id": "Secretin_INT_Methantheline", "text": "Interaction: Secretin AND Methantheline\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Methantheline.\nRisk: Monitor closely.", "source": "Secretin + Methantheline"}, {"id": "Secretin_INT_Desloratadine", "text": "Interaction: Secretin AND Desloratadine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Desloratadine.\nRisk: Monitor closely.", "source": "Secretin + Desloratadine"}, {"id": "Secretin_INT_Tolterodine", "text": "Interaction: Secretin AND Tolterodine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Tolterodine.\nRisk: Monitor closely.", "source": "Secretin + Tolterodine"}, {"id": "Secretin_INT_Oxybutynin", "text": "Interaction: Secretin AND Oxybutynin\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Oxybutynin.\nRisk: Monitor closely.", "source": "Secretin + Oxybutynin"}, {"id": "Secretin_INT_Pentolinium", "text": "Interaction: Secretin AND Pentolinium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Pentolinium.\nRisk: Monitor closely.", "source": "Secretin + Pentolinium"}, {"id": "Secretin_INT_Trimethaphan", "text": "Interaction: Secretin AND Trimethaphan\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Trimethaphan.\nRisk: Monitor closely.", "source": "Secretin + Trimethaphan"}, {"id": "Secretin_INT_Orphenadrine", "text": "Interaction: Secretin AND Orphenadrine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Orphenadrine.\nRisk: Monitor closely.", "source": "Secretin + Orphenadrine"}, {"id": "Secretin_INT_Tubocurarine", "text": "Interaction: Secretin AND Tubocurarine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Tubocurarine.\nRisk: Monitor closely.", "source": "Secretin + Tubocurarine"}, {"id": "Secretin_INT_Pancuronium", "text": "Interaction: Secretin AND Pancuronium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Pancuronium.\nRisk: Monitor closely.", "source": "Secretin + Pancuronium"}, {"id": "Secretin_INT_Pipecuronium", "text": "Interaction: Secretin AND Pipecuronium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Pipecuronium.\nRisk: Monitor closely.", "source": "Secretin + Pipecuronium"}, {"id": "Secretin_INT_Vecuronium", "text": "Interaction: Secretin AND Vecuronium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Vecuronium.\nRisk: Monitor closely.", "source": "Secretin + Vecuronium"}, {"id": "Secretin_INT_Solifenacin", "text": "Interaction: Secretin AND Solifenacin\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Solifenacin.\nRisk: Monitor closely.", "source": "Secretin + Solifenacin"}, {"id": "Secretin_INT_Fesoterodine", "text": "Interaction: Secretin AND Fesoterodine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Fesoterodine.\nRisk: Monitor closely.", "source": "Secretin + Fesoterodine"}, {"id": "Secretin_INT_Hexamethonium", "text": "Interaction: Secretin AND Hexamethonium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Hexamethonium.\nRisk: Monitor closely.", "source": "Secretin + Hexamethonium"}, {"id": "Secretin_INT_Chlorphenoxamine", "text": "Interaction: Secretin AND Chlorphenoxamine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Chlorphenoxamine.\nRisk: Monitor closely.", "source": "Secretin + Chlorphenoxamine"}, {"id": "Secretin_INT_Benactyzine", "text": "Interaction: Secretin AND Benactyzine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Benactyzine.\nRisk: Monitor closely.", "source": "Secretin + Benactyzine"}, {"id": "Secretin_INT_Butylscopolamine", "text": "Interaction: Secretin AND Butylscopolamine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Butylscopolamine.\nRisk: Monitor closely.", "source": "Secretin + Butylscopolamine"}, {"id": "Secretin_INT_Propiverine", "text": "Interaction: Secretin AND Propiverine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Propiverine.\nRisk: Monitor closely.", "source": "Secretin + Propiverine"}, {"id": "Secretin_INT_Atracurium", "text": "Interaction: Secretin AND Atracurium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Atracurium.\nRisk: Monitor closely.", "source": "Secretin + Atracurium"}, {"id": "Secretin_INT_Otilonium", "text": "Interaction: Secretin AND Otilonium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Otilonium.\nRisk: Monitor closely.", "source": "Secretin + Otilonium"}, {"id": "Secretin_INT_Emepronium", "text": "Interaction: Secretin AND Emepronium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Emepronium.\nRisk: Monitor closely.", "source": "Secretin + Emepronium"}, {"id": "Secretin_INT_Gallamine", "text": "Interaction: Secretin AND Gallamine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Gallamine.\nRisk: Monitor closely.", "source": "Secretin + Gallamine"}, {"id": "Secretin_INT_Alcuronium", "text": "Interaction: Secretin AND Alcuronium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Alcuronium.\nRisk: Monitor closely.", "source": "Secretin + Alcuronium"}, {"id": "Secretin_INT_Metixene", "text": "Interaction: Secretin AND Metixene\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Metixene.\nRisk: Monitor closely.", "source": "Secretin + Metixene"}, {"id": "Secretin_INT_Homatropine", "text": "Interaction: Secretin AND Homatropine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Homatropine.\nRisk: Monitor closely.", "source": "Secretin + Homatropine"}, {"id": "Secretin_INT_Methscopolamine", "text": "Interaction: Secretin AND Methscopolamine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Methscopolamine.\nRisk: Monitor closely.", "source": "Secretin + Methscopolamine"}, {"id": "Secretin_INT_Oxitropium", "text": "Interaction: Secretin AND Oxitropium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Oxitropium.\nRisk: Monitor closely.", "source": "Secretin + Oxitropium"}, {"id": "Secretin_INT_Tropatepine", "text": "Interaction: Secretin AND Tropatepine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Tropatepine.\nRisk: Monitor closely.", "source": "Secretin + Tropatepine"}, {"id": "Secretin_INT_Mazaticol", "text": "Interaction: Secretin AND Mazaticol\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Mazaticol.\nRisk: Monitor closely.", "source": "Secretin + Mazaticol"}, {"id": "Secretin_INT_Etybenzatropine", "text": "Interaction: Secretin AND Etybenzatropine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Etybenzatropine.\nRisk: Monitor closely.", "source": "Secretin + Etybenzatropine"}, {"id": "Secretin_INT_Etanautine", "text": "Interaction: Secretin AND Etanautine\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Etanautine.\nRisk: Monitor closely.", "source": "Secretin + Etanautine"}, {"id": "Secretin_INT_Methylscopolamine bromide", "text": "Interaction: Secretin AND Methylscopolamine bromide\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Methylscopolamine bromide.\nRisk: Monitor closely.", "source": "Secretin + Methylscopolamine bromide"}, {"id": "Secretin_INT_Umeclidinium", "text": "Interaction: Secretin AND Umeclidinium\nDetails: The therapeutic efficacy of Secretin can be decreased when used in combination with Umeclidinium.\nRisk: Monitor closely.", "source": "Secretin + Umeclidinium"}, {"id": "Peginterferon alfa-2b_GEN", "text": "Drug: Peginterferon alfa-2b\nDescription: Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype...", "source": "Peginterferon alfa-2b"}, {"id": "Peginterferon alfa-2b_CLIN", "text": "Drug: Peginterferon alfa-2b\nMechanism: Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity [FDA Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates th...\nToxicity: Peginterferon alfa-2b may manifest neuropsychiatric complications include suicide, suicidal ideation, homicidal ideation, depression, relapse of drug addiction, and drug overdose [FDA Label]. Hyperten...", "source": "Peginterferon alfa-2b"}, {"id": "Peginterferon alfa-2b_INT_Metamizole", "text": "Interaction: Peginterferon alfa-2b AND Metamizole\nDetails: The risk or severity of myelosuppression can be increased when Metamizole is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Metamizole"}, {"id": "Peginterferon alfa-2b_INT_Telbivudine", "text": "Interaction: Peginterferon alfa-2b AND Telbivudine\nDetails: The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Telbivudine.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Telbivudine"}, {"id": "Peginterferon alfa-2b_INT_Metoprolol", "text": "Interaction: Peginterferon alfa-2b AND Metoprolol\nDetails: The serum concentration of Metoprolol can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Metoprolol"}, {"id": "Peginterferon alfa-2b_INT_Aldesleukin", "text": "Interaction: Peginterferon alfa-2b AND Aldesleukin\nDetails: The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Aldesleukin"}, {"id": "Peginterferon alfa-2b_INT_Tizanidine", "text": "Interaction: Peginterferon alfa-2b AND Tizanidine\nDetails: The serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Tizanidine"}, {"id": "Peginterferon alfa-2b_INT_Pegloticase", "text": "Interaction: Peginterferon alfa-2b AND Pegloticase\nDetails: The therapeutic efficacy of Peginterferon alfa-2b can be decreased when used in combination with Pegloticase.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Pegloticase"}, {"id": "Peginterferon alfa-2b_INT_Ambroxol acefyllinate", "text": "Interaction: Peginterferon alfa-2b AND Ambroxol acefyllinate\nDetails: The metabolism of Ambroxol acefyllinate can be decreased when combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ambroxol acefyllinate"}, {"id": "Peginterferon alfa-2b_INT_Dyphylline", "text": "Interaction: Peginterferon alfa-2b AND Dyphylline\nDetails: The metabolism of Dyphylline can be decreased when combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Dyphylline"}, {"id": "Peginterferon alfa-2b_INT_Methadone", "text": "Interaction: Peginterferon alfa-2b AND Methadone\nDetails: The serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Methadone"}, {"id": "Peginterferon alfa-2b_INT_Ribavirin", "text": "Interaction: Peginterferon alfa-2b AND Ribavirin\nDetails: The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ribavirin.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ribavirin"}, {"id": "Peginterferon alfa-2b_INT_Zidovudine", "text": "Interaction: Peginterferon alfa-2b AND Zidovudine\nDetails: The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Zidovudine.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Zidovudine"}, {"id": "Peginterferon alfa-2b_INT_Fluoxetine", "text": "Interaction: Peginterferon alfa-2b AND Fluoxetine\nDetails: The serum concentration of Fluoxetine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Fluoxetine"}, {"id": "Peginterferon alfa-2b_INT_Fluvoxamine", "text": "Interaction: Peginterferon alfa-2b AND Fluvoxamine\nDetails: The serum concentration of Fluvoxamine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Fluvoxamine"}, {"id": "Peginterferon alfa-2b_INT_Amphetamine", "text": "Interaction: Peginterferon alfa-2b AND Amphetamine\nDetails: The serum concentration of Amphetamine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Amphetamine"}, {"id": "Peginterferon alfa-2b_INT_Cevimeline", "text": "Interaction: Peginterferon alfa-2b AND Cevimeline\nDetails: The serum concentration of Cevimeline can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Cevimeline"}, {"id": "Peginterferon alfa-2b_INT_Tramadol", "text": "Interaction: Peginterferon alfa-2b AND Tramadol\nDetails: The serum concentration of Tramadol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Tramadol"}, {"id": "Peginterferon alfa-2b_INT_Lidocaine", "text": "Interaction: Peginterferon alfa-2b AND Lidocaine\nDetails: The serum concentration of Lidocaine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Lidocaine"}, {"id": "Peginterferon alfa-2b_INT_Venlafaxine", "text": "Interaction: Peginterferon alfa-2b AND Venlafaxine\nDetails: The serum concentration of Venlafaxine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Venlafaxine"}, {"id": "Peginterferon alfa-2b_INT_Atomoxetine", "text": "Interaction: Peginterferon alfa-2b AND Atomoxetine\nDetails: The serum concentration of Atomoxetine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Atomoxetine"}, {"id": "Peginterferon alfa-2b_INT_Morphine", "text": "Interaction: Peginterferon alfa-2b AND Morphine\nDetails: The serum concentration of Morphine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Morphine"}, {"id": "Peginterferon alfa-2b_INT_Codeine", "text": "Interaction: Peginterferon alfa-2b AND Codeine\nDetails: The serum concentration of Codeine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Codeine"}, {"id": "Peginterferon alfa-2b_INT_Ipratropium bromide", "text": "Interaction: Peginterferon alfa-2b AND Ipratropium bromide\nDetails: The serum concentration of Ipratropium bromide can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ipratropium bromide"}, {"id": "Peginterferon alfa-2b_INT_Mirtazapine", "text": "Interaction: Peginterferon alfa-2b AND Mirtazapine\nDetails: The serum concentration of Mirtazapine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Mirtazapine"}, {"id": "Peginterferon alfa-2b_INT_Timolol", "text": "Interaction: Peginterferon alfa-2b AND Timolol\nDetails: The serum concentration of Timolol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Timolol"}, {"id": "Peginterferon alfa-2b_INT_Mexiletine", "text": "Interaction: Peginterferon alfa-2b AND Mexiletine\nDetails: The serum concentration of Mexiletine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Mexiletine"}, {"id": "Peginterferon alfa-2b_INT_Prochlorperazine", "text": "Interaction: Peginterferon alfa-2b AND Prochlorperazine\nDetails: The serum concentration of Prochlorperazine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Prochlorperazine"}, {"id": "Peginterferon alfa-2b_INT_Pethidine", "text": "Interaction: Peginterferon alfa-2b AND Pethidine\nDetails: The serum concentration of Pethidine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Pethidine"}, {"id": "Peginterferon alfa-2b_INT_Duloxetine", "text": "Interaction: Peginterferon alfa-2b AND Duloxetine\nDetails: The serum concentration of Duloxetine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Duloxetine"}, {"id": "Peginterferon alfa-2b_INT_Chlorpromazine", "text": "Interaction: Peginterferon alfa-2b AND Chlorpromazine\nDetails: The serum concentration of Chlorpromazine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Chlorpromazine"}, {"id": "Peginterferon alfa-2b_INT_Darifenacin", "text": "Interaction: Peginterferon alfa-2b AND Darifenacin\nDetails: The serum concentration of Darifenacin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Darifenacin"}, {"id": "Peginterferon alfa-2b_INT_Oxycodone", "text": "Interaction: Peginterferon alfa-2b AND Oxycodone\nDetails: The serum concentration of Oxycodone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Oxycodone"}, {"id": "Peginterferon alfa-2b_INT_Haloperidol", "text": "Interaction: Peginterferon alfa-2b AND Haloperidol\nDetails: The serum concentration of Haloperidol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Haloperidol"}, {"id": "Peginterferon alfa-2b_INT_Ritonavir", "text": "Interaction: Peginterferon alfa-2b AND Ritonavir\nDetails: The serum concentration of Ritonavir can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ritonavir"}, {"id": "Peginterferon alfa-2b_INT_Dextromethorphan", "text": "Interaction: Peginterferon alfa-2b AND Dextromethorphan\nDetails: The serum concentration of Dextromethorphan can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Dextromethorphan"}, {"id": "Peginterferon alfa-2b_INT_Carteolol", "text": "Interaction: Peginterferon alfa-2b AND Carteolol\nDetails: The serum concentration of Carteolol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Carteolol"}, {"id": "Peginterferon alfa-2b_INT_Clonidine", "text": "Interaction: Peginterferon alfa-2b AND Clonidine\nDetails: The serum concentration of Clonidine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Clonidine"}, {"id": "Peginterferon alfa-2b_INT_Bisoprolol", "text": "Interaction: Peginterferon alfa-2b AND Bisoprolol\nDetails: The serum concentration of Bisoprolol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Bisoprolol"}, {"id": "Peginterferon alfa-2b_INT_Fluphenazine", "text": "Interaction: Peginterferon alfa-2b AND Fluphenazine\nDetails: The serum concentration of Fluphenazine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Fluphenazine"}, {"id": "Peginterferon alfa-2b_INT_Trazodone", "text": "Interaction: Peginterferon alfa-2b AND Trazodone\nDetails: The serum concentration of Trazodone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Trazodone"}, {"id": "Peginterferon alfa-2b_INT_Galantamine", "text": "Interaction: Peginterferon alfa-2b AND Galantamine\nDetails: The serum concentration of Galantamine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Galantamine"}, {"id": "Peginterferon alfa-2b_INT_Tamoxifen", "text": "Interaction: Peginterferon alfa-2b AND Tamoxifen\nDetails: The serum concentration of Tamoxifen can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Tamoxifen"}, {"id": "Peginterferon alfa-2b_INT_Thioridazine", "text": "Interaction: Peginterferon alfa-2b AND Thioridazine\nDetails: The serum concentration of Thioridazine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Thioridazine"}, {"id": "Peginterferon alfa-2b_INT_Nicergoline", "text": "Interaction: Peginterferon alfa-2b AND Nicergoline\nDetails: The serum concentration of Nicergoline can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Nicergoline"}, {"id": "Peginterferon alfa-2b_INT_Paroxetine", "text": "Interaction: Peginterferon alfa-2b AND Paroxetine\nDetails: The serum concentration of Paroxetine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Paroxetine"}, {"id": "Peginterferon alfa-2b_INT_Risperidone", "text": "Interaction: Peginterferon alfa-2b AND Risperidone\nDetails: The serum concentration of Risperidone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Risperidone"}, {"id": "Peginterferon alfa-2b_INT_Dolasetron", "text": "Interaction: Peginterferon alfa-2b AND Dolasetron\nDetails: The serum concentration of Dolasetron can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Dolasetron"}, {"id": "Peginterferon alfa-2b_INT_Minaprine", "text": "Interaction: Peginterferon alfa-2b AND Minaprine\nDetails: The serum concentration of Minaprine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Minaprine"}, {"id": "Peginterferon alfa-2b_INT_Donepezil", "text": "Interaction: Peginterferon alfa-2b AND Donepezil\nDetails: The serum concentration of Donepezil can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Donepezil"}, {"id": "Peginterferon alfa-2b_INT_Perphenazine", "text": "Interaction: Peginterferon alfa-2b AND Perphenazine\nDetails: The serum concentration of Perphenazine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Perphenazine"}, {"id": "Peginterferon alfa-2b_INT_Ranitidine", "text": "Interaction: Peginterferon alfa-2b AND Ranitidine\nDetails: The serum concentration of Ranitidine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ranitidine"}, {"id": "Peginterferon alfa-2b_INT_Alprenolol", "text": "Interaction: Peginterferon alfa-2b AND Alprenolol\nDetails: The serum concentration of Alprenolol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Alprenolol"}, {"id": "Peginterferon alfa-2b_INT_Ondansetron", "text": "Interaction: Peginterferon alfa-2b AND Ondansetron\nDetails: The serum concentration of Ondansetron can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ondansetron"}, {"id": "Peginterferon alfa-2b_INT_Phenformin", "text": "Interaction: Peginterferon alfa-2b AND Phenformin\nDetails: The serum concentration of Phenformin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Phenformin"}, {"id": "Peginterferon alfa-2b_INT_Almotriptan", "text": "Interaction: Peginterferon alfa-2b AND Almotriptan\nDetails: The serum concentration of Almotriptan can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Almotriptan"}, {"id": "Peginterferon alfa-2b_INT_Maprotiline", "text": "Interaction: Peginterferon alfa-2b AND Maprotiline\nDetails: The serum concentration of Maprotiline can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Maprotiline"}, {"id": "Peginterferon alfa-2b_INT_Hydrocodone", "text": "Interaction: Peginterferon alfa-2b AND Hydrocodone\nDetails: The serum concentration of Hydrocodone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Hydrocodone"}, {"id": "Peginterferon alfa-2b_INT_Pindolol", "text": "Interaction: Peginterferon alfa-2b AND Pindolol\nDetails: The serum concentration of Pindolol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Pindolol"}, {"id": "Peginterferon alfa-2b_INT_Formoterol", "text": "Interaction: Peginterferon alfa-2b AND Formoterol\nDetails: The serum concentration of Formoterol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Formoterol"}, {"id": "Peginterferon alfa-2b_INT_Procainamide", "text": "Interaction: Peginterferon alfa-2b AND Procainamide\nDetails: The serum concentration of Procainamide can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Procainamide"}, {"id": "Peginterferon alfa-2b_INT_Tolterodine", "text": "Interaction: Peginterferon alfa-2b AND Tolterodine\nDetails: The serum concentration of Tolterodine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Tolterodine"}, {"id": "Peginterferon alfa-2b_INT_Promethazine", "text": "Interaction: Peginterferon alfa-2b AND Promethazine\nDetails: The serum concentration of Promethazine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Promethazine"}, {"id": "Peginterferon alfa-2b_INT_Perhexiline", "text": "Interaction: Peginterferon alfa-2b AND Perhexiline\nDetails: The serum concentration of Perhexiline can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Perhexiline"}, {"id": "Peginterferon alfa-2b_INT_Chlorphenamine", "text": "Interaction: Peginterferon alfa-2b AND Chlorphenamine\nDetails: The serum concentration of Chlorphenamine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Chlorphenamine"}, {"id": "Peginterferon alfa-2b_INT_Carvedilol", "text": "Interaction: Peginterferon alfa-2b AND Carvedilol\nDetails: The serum concentration of Carvedilol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Carvedilol"}, {"id": "Peginterferon alfa-2b_INT_Doxepin", "text": "Interaction: Peginterferon alfa-2b AND Doxepin\nDetails: The serum concentration of Doxepin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Doxepin"}, {"id": "Peginterferon alfa-2b_INT_Desipramine", "text": "Interaction: Peginterferon alfa-2b AND Desipramine\nDetails: The serum concentration of Desipramine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Desipramine"}, {"id": "Peginterferon alfa-2b_INT_Flecainide", "text": "Interaction: Peginterferon alfa-2b AND Flecainide\nDetails: The serum concentration of Flecainide can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Flecainide"}, {"id": "Peginterferon alfa-2b_INT_Captopril", "text": "Interaction: Peginterferon alfa-2b AND Captopril\nDetails: The serum concentration of Captopril can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Captopril"}, {"id": "Peginterferon alfa-2b_INT_Encainide", "text": "Interaction: Peginterferon alfa-2b AND Encainide\nDetails: The serum concentration of Encainide can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Encainide"}, {"id": "Peginterferon alfa-2b_INT_Metoclopramide", "text": "Interaction: Peginterferon alfa-2b AND Metoclopramide\nDetails: The serum concentration of Metoclopramide can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Metoclopramide"}, {"id": "Peginterferon alfa-2b_INT_Clomipramine", "text": "Interaction: Peginterferon alfa-2b AND Clomipramine\nDetails: The serum concentration of Clomipramine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Clomipramine"}, {"id": "Peginterferon alfa-2b_INT_Moclobemide", "text": "Interaction: Peginterferon alfa-2b AND Moclobemide\nDetails: The serum concentration of Moclobemide can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Moclobemide"}, {"id": "Peginterferon alfa-2b_INT_Arformoterol", "text": "Interaction: Peginterferon alfa-2b AND Arformoterol\nDetails: The serum concentration of Arformoterol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Arformoterol"}, {"id": "Peginterferon alfa-2b_INT_Ethylmorphine", "text": "Interaction: Peginterferon alfa-2b AND Ethylmorphine\nDetails: The serum concentration of Ethylmorphine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ethylmorphine"}, {"id": "Peginterferon alfa-2b_INT_Tiotropium", "text": "Interaction: Peginterferon alfa-2b AND Tiotropium\nDetails: The serum concentration of Tiotropium can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Tiotropium"}, {"id": "Peginterferon alfa-2b_INT_Diphenhydramine", "text": "Interaction: Peginterferon alfa-2b AND Diphenhydramine\nDetails: The serum concentration of Diphenhydramine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Diphenhydramine"}, {"id": "Peginterferon alfa-2b_INT_Debrisoquin", "text": "Interaction: Peginterferon alfa-2b AND Debrisoquin\nDetails: The serum concentration of Debrisoquin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Debrisoquin"}, {"id": "Peginterferon alfa-2b_INT_Citalopram", "text": "Interaction: Peginterferon alfa-2b AND Citalopram\nDetails: The serum concentration of Citalopram can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Citalopram"}, {"id": "Peginterferon alfa-2b_INT_Gefitinib", "text": "Interaction: Peginterferon alfa-2b AND Gefitinib\nDetails: The serum concentration of Gefitinib can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Gefitinib"}, {"id": "Peginterferon alfa-2b_INT_Amitriptyline", "text": "Interaction: Peginterferon alfa-2b AND Amitriptyline\nDetails: The serum concentration of Amitriptyline can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Amitriptyline"}, {"id": "Peginterferon alfa-2b_INT_Hydromorphone", "text": "Interaction: Peginterferon alfa-2b AND Hydromorphone\nDetails: The serum concentration of Hydromorphone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Hydromorphone"}, {"id": "Peginterferon alfa-2b_INT_Terfenadine", "text": "Interaction: Peginterferon alfa-2b AND Terfenadine\nDetails: The serum concentration of Terfenadine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Terfenadine"}, {"id": "Peginterferon alfa-2b_INT_Diltiazem", "text": "Interaction: Peginterferon alfa-2b AND Diltiazem\nDetails: The serum concentration of Diltiazem can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Diltiazem"}, {"id": "Peginterferon alfa-2b_INT_Chlorzoxazone", "text": "Interaction: Peginterferon alfa-2b AND Chlorzoxazone\nDetails: The serum concentration of Chlorzoxazone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Chlorzoxazone"}, {"id": "Peginterferon alfa-2b_INT_Clozapine", "text": "Interaction: Peginterferon alfa-2b AND Clozapine\nDetails: The serum concentration of Clozapine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Clozapine"}, {"id": "Peginterferon alfa-2b_INT_Loratadine", "text": "Interaction: Peginterferon alfa-2b AND Loratadine\nDetails: The serum concentration of Loratadine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Loratadine"}, {"id": "Peginterferon alfa-2b_INT_Imipramine", "text": "Interaction: Peginterferon alfa-2b AND Imipramine\nDetails: The serum concentration of Imipramine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Imipramine"}, {"id": "Peginterferon alfa-2b_INT_Quinine", "text": "Interaction: Peginterferon alfa-2b AND Quinine\nDetails: The serum concentration of Quinine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Quinine"}, {"id": "Peginterferon alfa-2b_INT_Mephenytoin", "text": "Interaction: Peginterferon alfa-2b AND Mephenytoin\nDetails: The serum concentration of Mephenytoin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Mephenytoin"}, {"id": "Peginterferon alfa-2b_INT_Nortriptyline", "text": "Interaction: Peginterferon alfa-2b AND Nortriptyline\nDetails: The serum concentration of Nortriptyline can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Nortriptyline"}, {"id": "Peginterferon alfa-2b_INT_Nicardipine", "text": "Interaction: Peginterferon alfa-2b AND Nicardipine\nDetails: The serum concentration of Nicardipine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Nicardipine"}, {"id": "Peginterferon alfa-2b_INT_Delavirdine", "text": "Interaction: Peginterferon alfa-2b AND Delavirdine\nDetails: The serum concentration of Delavirdine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Delavirdine"}, {"id": "Peginterferon alfa-2b_INT_Trimipramine", "text": "Interaction: Peginterferon alfa-2b AND Trimipramine\nDetails: The serum concentration of Trimipramine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Trimipramine"}, {"id": "Peginterferon alfa-2b_INT_Buprenorphine", "text": "Interaction: Peginterferon alfa-2b AND Buprenorphine\nDetails: The serum concentration of Buprenorphine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Buprenorphine"}, {"id": "Peginterferon alfa-2b_INT_Mesoridazine", "text": "Interaction: Peginterferon alfa-2b AND Mesoridazine\nDetails: The serum concentration of Mesoridazine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Mesoridazine"}, {"id": "Peginterferon alfa-2b_INT_Azelastine", "text": "Interaction: Peginterferon alfa-2b AND Azelastine\nDetails: The serum concentration of Azelastine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Azelastine"}, {"id": "Peginterferon alfa-2b_INT_Mequitazine", "text": "Interaction: Peginterferon alfa-2b AND Mequitazine\nDetails: The serum concentration of Mequitazine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Mequitazine"}, {"id": "Peginterferon alfa-2b_INT_Sertraline", "text": "Interaction: Peginterferon alfa-2b AND Sertraline\nDetails: The serum concentration of Sertraline can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Sertraline"}, {"id": "Peginterferon alfa-2b_INT_Nifedipine", "text": "Interaction: Peginterferon alfa-2b AND Nifedipine\nDetails: The serum concentration of Nifedipine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Nifedipine"}, {"id": "Peginterferon alfa-2b_INT_Amiodarone", "text": "Interaction: Peginterferon alfa-2b AND Amiodarone\nDetails: The serum concentration of Amiodarone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Amiodarone"}, {"id": "Peginterferon alfa-2b_INT_Nefazodone", "text": "Interaction: Peginterferon alfa-2b AND Nefazodone\nDetails: The serum concentration of Nefazodone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Nefazodone"}, {"id": "Peginterferon alfa-2b_INT_Bupropion", "text": "Interaction: Peginterferon alfa-2b AND Bupropion\nDetails: The serum concentration of Bupropion can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Bupropion"}, {"id": "Peginterferon alfa-2b_INT_Escitalopram", "text": "Interaction: Peginterferon alfa-2b AND Escitalopram\nDetails: The serum concentration of Escitalopram can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Escitalopram"}, {"id": "Peginterferon alfa-2b_INT_Propafenone", "text": "Interaction: Peginterferon alfa-2b AND Propafenone\nDetails: The serum concentration of Propafenone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Propafenone"}, {"id": "Peginterferon alfa-2b_INT_Dexfenfluramine", "text": "Interaction: Peginterferon alfa-2b AND Dexfenfluramine\nDetails: The serum concentration of Dexfenfluramine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Dexfenfluramine"}, {"id": "Peginterferon alfa-2b_INT_Oxymorphone", "text": "Interaction: Peginterferon alfa-2b AND Oxymorphone\nDetails: The serum concentration of Oxymorphone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Oxymorphone"}, {"id": "Peginterferon alfa-2b_INT_Halofantrine", "text": "Interaction: Peginterferon alfa-2b AND Halofantrine\nDetails: The serum concentration of Halofantrine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Halofantrine"}, {"id": "Peginterferon alfa-2b_INT_Aripiprazole", "text": "Interaction: Peginterferon alfa-2b AND Aripiprazole\nDetails: The serum concentration of Aripiprazole can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Aripiprazole"}, {"id": "Peginterferon alfa-2b_INT_Methotrimeprazine", "text": "Interaction: Peginterferon alfa-2b AND Methotrimeprazine\nDetails: The serum concentration of Methotrimeprazine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Methotrimeprazine"}, {"id": "Peginterferon alfa-2b_INT_Dihydrocodeine", "text": "Interaction: Peginterferon alfa-2b AND Dihydrocodeine\nDetails: The serum concentration of Dihydrocodeine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Dihydrocodeine"}, {"id": "Peginterferon alfa-2b_INT_Palonosetron", "text": "Interaction: Peginterferon alfa-2b AND Palonosetron\nDetails: The serum concentration of Palonosetron can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Palonosetron"}, {"id": "Peginterferon alfa-2b_INT_Nebivolol", "text": "Interaction: Peginterferon alfa-2b AND Nebivolol\nDetails: The serum concentration of Nebivolol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Nebivolol"}, {"id": "Peginterferon alfa-2b_INT_Sertindole", "text": "Interaction: Peginterferon alfa-2b AND Sertindole\nDetails: The serum concentration of Sertindole can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Sertindole"}, {"id": "Peginterferon alfa-2b_INT_Mianserin", "text": "Interaction: Peginterferon alfa-2b AND Mianserin\nDetails: The serum concentration of Mianserin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Mianserin"}, {"id": "Peginterferon alfa-2b_INT_Tesmilifene", "text": "Interaction: Peginterferon alfa-2b AND Tesmilifene\nDetails: The serum concentration of Tesmilifene can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Tesmilifene"}, {"id": "Peginterferon alfa-2b_INT_Zuclopenthixol", "text": "Interaction: Peginterferon alfa-2b AND Zuclopenthixol\nDetails: The serum concentration of Zuclopenthixol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Zuclopenthixol"}, {"id": "Peginterferon alfa-2b_INT_Dextroamphetamine", "text": "Interaction: Peginterferon alfa-2b AND Dextroamphetamine\nDetails: The serum concentration of Dextroamphetamine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Dextroamphetamine"}, {"id": "Peginterferon alfa-2b_INT_Propranolol", "text": "Interaction: Peginterferon alfa-2b AND Propranolol\nDetails: The serum concentration of Propranolol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Propranolol"}, {"id": "Peginterferon alfa-2b_INT_Rotigotine", "text": "Interaction: Peginterferon alfa-2b AND Rotigotine\nDetails: The serum concentration of Rotigotine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Rotigotine"}, {"id": "Peginterferon alfa-2b_INT_Lisuride", "text": "Interaction: Peginterferon alfa-2b AND Lisuride\nDetails: The serum concentration of Lisuride can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Lisuride"}, {"id": "Peginterferon alfa-2b_INT_Fluvastatin", "text": "Interaction: Peginterferon alfa-2b AND Fluvastatin\nDetails: The serum concentration of Fluvastatin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Fluvastatin"}, {"id": "Peginterferon alfa-2b_INT_Imatinib", "text": "Interaction: Peginterferon alfa-2b AND Imatinib\nDetails: The serum concentration of Imatinib can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Imatinib"}, {"id": "Peginterferon alfa-2b_INT_Olanzapine", "text": "Interaction: Peginterferon alfa-2b AND Olanzapine\nDetails: The serum concentration of Olanzapine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Olanzapine"}, {"id": "Peginterferon alfa-2b_INT_Bortezomib", "text": "Interaction: Peginterferon alfa-2b AND Bortezomib\nDetails: The serum concentration of Bortezomib can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Bortezomib"}, {"id": "Peginterferon alfa-2b_INT_Trabectedin", "text": "Interaction: Peginterferon alfa-2b AND Trabectedin\nDetails: The serum concentration of Trabectedin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Trabectedin"}, {"id": "Peginterferon alfa-2b_INT_Cinnarizine", "text": "Interaction: Peginterferon alfa-2b AND Cinnarizine\nDetails: The serum concentration of Cinnarizine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Cinnarizine"}, {"id": "Peginterferon alfa-2b_INT_Flunarizine", "text": "Interaction: Peginterferon alfa-2b AND Flunarizine\nDetails: The serum concentration of Flunarizine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Flunarizine"}, {"id": "Peginterferon alfa-2b_INT_Bufuralol", "text": "Interaction: Peginterferon alfa-2b AND Bufuralol\nDetails: The serum concentration of Bufuralol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Bufuralol"}, {"id": "Peginterferon alfa-2b_INT_4-Methoxyamphetamine", "text": "Interaction: Peginterferon alfa-2b AND 4-Methoxyamphetamine\nDetails: The serum concentration of 4-Methoxyamphetamine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + 4-Methoxyamphetamine"}, {"id": "Peginterferon alfa-2b_INT_Phenacetin", "text": "Interaction: Peginterferon alfa-2b AND Phenacetin\nDetails: The serum concentration of Phenacetin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Phenacetin"}, {"id": "Peginterferon alfa-2b_INT_Sparteine", "text": "Interaction: Peginterferon alfa-2b AND Sparteine\nDetails: The serum concentration of Sparteine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Sparteine"}, {"id": "Peginterferon alfa-2b_INT_Doxorubicin", "text": "Interaction: Peginterferon alfa-2b AND Doxorubicin\nDetails: The serum concentration of Doxorubicin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Doxorubicin"}, {"id": "Peginterferon alfa-2b_INT_Ticlopidine", "text": "Interaction: Peginterferon alfa-2b AND Ticlopidine\nDetails: The serum concentration of Ticlopidine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ticlopidine"}, {"id": "Peginterferon alfa-2b_INT_Amoxapine", "text": "Interaction: Peginterferon alfa-2b AND Amoxapine\nDetails: The serum concentration of Amoxapine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Amoxapine"}, {"id": "Peginterferon alfa-2b_INT_Chloroquine", "text": "Interaction: Peginterferon alfa-2b AND Chloroquine\nDetails: The serum concentration of Chloroquine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Chloroquine"}, {"id": "Peginterferon alfa-2b_INT_Iloperidone", "text": "Interaction: Peginterferon alfa-2b AND Iloperidone\nDetails: The serum concentration of Iloperidone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Iloperidone"}, {"id": "Peginterferon alfa-2b_INT_Methamphetamine", "text": "Interaction: Peginterferon alfa-2b AND Methamphetamine\nDetails: The serum concentration of Methamphetamine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Methamphetamine"}, {"id": "Peginterferon alfa-2b_INT_Pipotiazine", "text": "Interaction: Peginterferon alfa-2b AND Pipotiazine\nDetails: The serum concentration of Pipotiazine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Pipotiazine"}, {"id": "Peginterferon alfa-2b_INT_Protriptyline", "text": "Interaction: Peginterferon alfa-2b AND Protriptyline\nDetails: The serum concentration of Protriptyline can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Protriptyline"}, {"id": "Peginterferon alfa-2b_INT_Tamsulosin", "text": "Interaction: Peginterferon alfa-2b AND Tamsulosin\nDetails: The serum concentration of Tamsulosin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Tamsulosin"}, {"id": "Peginterferon alfa-2b_INT_Tetrabenazine", "text": "Interaction: Peginterferon alfa-2b AND Tetrabenazine\nDetails: The serum concentration of Tetrabenazine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Tetrabenazine"}, {"id": "Peginterferon alfa-2b_INT_Tipranavir", "text": "Interaction: Peginterferon alfa-2b AND Tipranavir\nDetails: The serum concentration of Tipranavir can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Tipranavir"}, {"id": "Peginterferon alfa-2b_INT_Dronedarone", "text": "Interaction: Peginterferon alfa-2b AND Dronedarone\nDetails: The serum concentration of Dronedarone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Dronedarone"}, {"id": "Peginterferon alfa-2b_INT_Aminophenazone", "text": "Interaction: Peginterferon alfa-2b AND Aminophenazone\nDetails: The serum concentration of Aminophenazone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Aminophenazone"}, {"id": "Peginterferon alfa-2b_INT_Nevirapine", "text": "Interaction: Peginterferon alfa-2b AND Nevirapine\nDetails: The serum concentration of Nevirapine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Nevirapine"}, {"id": "Peginterferon alfa-2b_INT_Eletriptan", "text": "Interaction: Peginterferon alfa-2b AND Eletriptan\nDetails: The serum concentration of Eletriptan can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Eletriptan"}, {"id": "Peginterferon alfa-2b_INT_Zolpidem", "text": "Interaction: Peginterferon alfa-2b AND Zolpidem\nDetails: The serum concentration of Zolpidem can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Zolpidem"}, {"id": "Peginterferon alfa-2b_INT_Etoricoxib", "text": "Interaction: Peginterferon alfa-2b AND Etoricoxib\nDetails: The serum concentration of Etoricoxib can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Etoricoxib"}, {"id": "Peginterferon alfa-2b_INT_Sildenafil", "text": "Interaction: Peginterferon alfa-2b AND Sildenafil\nDetails: The serum concentration of Sildenafil can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Sildenafil"}, {"id": "Peginterferon alfa-2b_INT_Acetaminophen", "text": "Interaction: Peginterferon alfa-2b AND Acetaminophen\nDetails: The serum concentration of Acetaminophen can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Acetaminophen"}, {"id": "Peginterferon alfa-2b_INT_Cyclobenzaprine", "text": "Interaction: Peginterferon alfa-2b AND Cyclobenzaprine\nDetails: The serum concentration of Cyclobenzaprine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Cyclobenzaprine"}, {"id": "Peginterferon alfa-2b_INT_Acetylcholine", "text": "Interaction: Peginterferon alfa-2b AND Acetylcholine\nDetails: The serum concentration of Acetylcholine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Acetylcholine"}, {"id": "Peginterferon alfa-2b_INT_Ajmaline", "text": "Interaction: Peginterferon alfa-2b AND Ajmaline\nDetails: The serum concentration of Ajmaline can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ajmaline"}, {"id": "Peginterferon alfa-2b_INT_Amprenavir", "text": "Interaction: Peginterferon alfa-2b AND Amprenavir\nDetails: The serum concentration of Amprenavir can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Amprenavir"}, {"id": "Peginterferon alfa-2b_INT_Amsacrine", "text": "Interaction: Peginterferon alfa-2b AND Amsacrine\nDetails: The serum concentration of Amsacrine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Amsacrine"}, {"id": "Peginterferon alfa-2b_INT_Aprindine", "text": "Interaction: Peginterferon alfa-2b AND Aprindine\nDetails: The serum concentration of Aprindine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Aprindine"}, {"id": "Peginterferon alfa-2b_INT_Artemether", "text": "Interaction: Peginterferon alfa-2b AND Artemether\nDetails: The serum concentration of Artemether can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Artemether"}, {"id": "Peginterferon alfa-2b_INT_Astemizole", "text": "Interaction: Peginterferon alfa-2b AND Astemizole\nDetails: The serum concentration of Astemizole can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Astemizole"}, {"id": "Peginterferon alfa-2b_INT_Benzatropine", "text": "Interaction: Peginterferon alfa-2b AND Benzatropine\nDetails: The serum concentration of Benzatropine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Benzatropine"}, {"id": "Peginterferon alfa-2b_INT_Bepridil", "text": "Interaction: Peginterferon alfa-2b AND Bepridil\nDetails: The serum concentration of Bepridil can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Bepridil"}, {"id": "Peginterferon alfa-2b_INT_Betaxolol", "text": "Interaction: Peginterferon alfa-2b AND Betaxolol\nDetails: The serum concentration of Betaxolol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Betaxolol"}, {"id": "Peginterferon alfa-2b_INT_Brompheniramine", "text": "Interaction: Peginterferon alfa-2b AND Brompheniramine\nDetails: The serum concentration of Brompheniramine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Brompheniramine"}, {"id": "Peginterferon alfa-2b_INT_Bupivacaine", "text": "Interaction: Peginterferon alfa-2b AND Bupivacaine\nDetails: The serum concentration of Bupivacaine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Bupivacaine"}, {"id": "Peginterferon alfa-2b_INT_Buspirone", "text": "Interaction: Peginterferon alfa-2b AND Buspirone\nDetails: The serum concentration of Buspirone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Buspirone"}, {"id": "Peginterferon alfa-2b_INT_Caffeine", "text": "Interaction: Peginterferon alfa-2b AND Caffeine\nDetails: The serum concentration of Caffeine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Caffeine"}, {"id": "Peginterferon alfa-2b_INT_Cephalexin", "text": "Interaction: Peginterferon alfa-2b AND Cephalexin\nDetails: The serum concentration of Cephalexin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Cephalexin"}, {"id": "Peginterferon alfa-2b_INT_Chlordiazepoxide", "text": "Interaction: Peginterferon alfa-2b AND Chlordiazepoxide\nDetails: The serum concentration of Chlordiazepoxide can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Chlordiazepoxide"}, {"id": "Peginterferon alfa-2b_INT_Cyclophosphamide", "text": "Interaction: Peginterferon alfa-2b AND Cyclophosphamide\nDetails: The serum concentration of Cyclophosphamide can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Cyclophosphamide"}, {"id": "Peginterferon alfa-2b_INT_Domperidone", "text": "Interaction: Peginterferon alfa-2b AND Domperidone\nDetails: The serum concentration of Domperidone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Domperidone"}, {"id": "Peginterferon alfa-2b_INT_Dopamine", "text": "Interaction: Peginterferon alfa-2b AND Dopamine\nDetails: The serum concentration of Dopamine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Dopamine"}, {"id": "Peginterferon alfa-2b_INT_Doxazosin", "text": "Interaction: Peginterferon alfa-2b AND Doxazosin\nDetails: The serum concentration of Doxazosin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Doxazosin"}, {"id": "Peginterferon alfa-2b_INT_Epinastine", "text": "Interaction: Peginterferon alfa-2b AND Epinastine\nDetails: The serum concentration of Epinastine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Epinastine"}, {"id": "Peginterferon alfa-2b_INT_Granisetron", "text": "Interaction: Peginterferon alfa-2b AND Granisetron\nDetails: The serum concentration of Granisetron can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Granisetron"}, {"id": "Peginterferon alfa-2b_INT_Halothane", "text": "Interaction: Peginterferon alfa-2b AND Halothane\nDetails: The serum concentration of Halothane can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Halothane"}, {"id": "Peginterferon alfa-2b_INT_Idarubicin", "text": "Interaction: Peginterferon alfa-2b AND Idarubicin\nDetails: The serum concentration of Idarubicin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Idarubicin"}, {"id": "Peginterferon alfa-2b_INT_Labetalol", "text": "Interaction: Peginterferon alfa-2b AND Labetalol\nDetails: The serum concentration of Labetalol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Labetalol"}, {"id": "Peginterferon alfa-2b_INT_Levodopa", "text": "Interaction: Peginterferon alfa-2b AND Levodopa\nDetails: The serum concentration of Levodopa can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Levodopa"}, {"id": "Peginterferon alfa-2b_INT_Lomustine", "text": "Interaction: Peginterferon alfa-2b AND Lomustine\nDetails: The serum concentration of Lomustine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Lomustine"}, {"id": "Peginterferon alfa-2b_INT_Methoxyflurane", "text": "Interaction: Peginterferon alfa-2b AND Methoxyflurane\nDetails: The serum concentration of Methoxyflurane can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Methoxyflurane"}, {"id": "Peginterferon alfa-2b_INT_Methylphenidate", "text": "Interaction: Peginterferon alfa-2b AND Methylphenidate\nDetails: The serum concentration of Methylphenidate can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Methylphenidate"}, {"id": "Peginterferon alfa-2b_INT_Methyprylon", "text": "Interaction: Peginterferon alfa-2b AND Methyprylon\nDetails: The serum concentration of Methyprylon can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Methyprylon"}, {"id": "Peginterferon alfa-2b_INT_Nateglinide", "text": "Interaction: Peginterferon alfa-2b AND Nateglinide\nDetails: The serum concentration of Nateglinide can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Nateglinide"}, {"id": "Peginterferon alfa-2b_INT_Nicotine", "text": "Interaction: Peginterferon alfa-2b AND Nicotine\nDetails: The serum concentration of Nicotine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Nicotine"}, {"id": "Peginterferon alfa-2b_INT_Nitrofural", "text": "Interaction: Peginterferon alfa-2b AND Nitrofural\nDetails: The serum concentration of Nitrofural can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Nitrofural"}, {"id": "Peginterferon alfa-2b_INT_Pentamidine", "text": "Interaction: Peginterferon alfa-2b AND Pentamidine\nDetails: The serum concentration of Pentamidine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Pentamidine"}, {"id": "Peginterferon alfa-2b_INT_Antipyrine", "text": "Interaction: Peginterferon alfa-2b AND Antipyrine\nDetails: The serum concentration of Antipyrine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Antipyrine"}, {"id": "Peginterferon alfa-2b_INT_Piperazine", "text": "Interaction: Peginterferon alfa-2b AND Piperazine\nDetails: The serum concentration of Piperazine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Piperazine"}, {"id": "Peginterferon alfa-2b_INT_Progesterone", "text": "Interaction: Peginterferon alfa-2b AND Progesterone\nDetails: The serum concentration of Progesterone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Progesterone"}, {"id": "Peginterferon alfa-2b_INT_Propofol", "text": "Interaction: Peginterferon alfa-2b AND Propofol\nDetails: The serum concentration of Propofol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Propofol"}, {"id": "Peginterferon alfa-2b_INT_Pseudoephedrine", "text": "Interaction: Peginterferon alfa-2b AND Pseudoephedrine\nDetails: The serum concentration of Pseudoephedrine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Pseudoephedrine"}, {"id": "Peginterferon alfa-2b_INT_Quetiapine", "text": "Interaction: Peginterferon alfa-2b AND Quetiapine\nDetails: The serum concentration of Quetiapine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Quetiapine"}, {"id": "Peginterferon alfa-2b_INT_Remoxipride", "text": "Interaction: Peginterferon alfa-2b AND Remoxipride\nDetails: The serum concentration of Remoxipride can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Remoxipride"}, {"id": "Peginterferon alfa-2b_INT_Ropivacaine", "text": "Interaction: Peginterferon alfa-2b AND Ropivacaine\nDetails: The serum concentration of Ropivacaine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ropivacaine"}, {"id": "Peginterferon alfa-2b_INT_Saquinavir", "text": "Interaction: Peginterferon alfa-2b AND Saquinavir\nDetails: The serum concentration of Saquinavir can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Saquinavir"}, {"id": "Peginterferon alfa-2b_INT_Simvastatin", "text": "Interaction: Peginterferon alfa-2b AND Simvastatin\nDetails: The serum concentration of Simvastatin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Simvastatin"}, {"id": "Peginterferon alfa-2b_INT_Tegaserod", "text": "Interaction: Peginterferon alfa-2b AND Tegaserod\nDetails: The serum concentration of Tegaserod can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Tegaserod"}, {"id": "Peginterferon alfa-2b_INT_Theophylline", "text": "Interaction: Peginterferon alfa-2b AND Theophylline\nDetails: The serum concentration of Theophylline can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Theophylline"}, {"id": "Peginterferon alfa-2b_INT_Vinblastine", "text": "Interaction: Peginterferon alfa-2b AND Vinblastine\nDetails: The serum concentration of Vinblastine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Vinblastine"}, {"id": "Peginterferon alfa-2b_INT_Vinorelbine", "text": "Interaction: Peginterferon alfa-2b AND Vinorelbine\nDetails: The serum concentration of Vinorelbine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Vinorelbine"}, {"id": "Peginterferon alfa-2b_INT_Yohimbine", "text": "Interaction: Peginterferon alfa-2b AND Yohimbine\nDetails: The serum concentration of Yohimbine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Yohimbine"}, {"id": "Peginterferon alfa-2b_INT_Zalcitabine", "text": "Interaction: Peginterferon alfa-2b AND Zalcitabine\nDetails: The serum concentration of Zalcitabine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Zalcitabine"}, {"id": "Peginterferon alfa-2b_INT_Dexmethylphenidate", "text": "Interaction: Peginterferon alfa-2b AND Dexmethylphenidate\nDetails: The serum concentration of Dexmethylphenidate can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Dexmethylphenidate"}, {"id": "Peginterferon alfa-2b_INT_Erlotinib", "text": "Interaction: Peginterferon alfa-2b AND Erlotinib\nDetails: The serum concentration of Erlotinib can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Erlotinib"}, {"id": "Peginterferon alfa-2b_INT_Cilostazol", "text": "Interaction: Peginterferon alfa-2b AND Cilostazol\nDetails: The serum concentration of Cilostazol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Cilostazol"}, {"id": "Peginterferon alfa-2b_INT_Pazopanib", "text": "Interaction: Peginterferon alfa-2b AND Pazopanib\nDetails: The serum concentration of Pazopanib can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Pazopanib"}, {"id": "Peginterferon alfa-2b_INT_Fesoterodine", "text": "Interaction: Peginterferon alfa-2b AND Fesoterodine\nDetails: The serum concentration of Fesoterodine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Fesoterodine"}, {"id": "Peginterferon alfa-2b_INT_Vilazodone", "text": "Interaction: Peginterferon alfa-2b AND Vilazodone\nDetails: The serum concentration of Vilazodone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Vilazodone"}, {"id": "Peginterferon alfa-2b_INT_Loperamide", "text": "Interaction: Peginterferon alfa-2b AND Loperamide\nDetails: The serum concentration of Loperamide can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Loperamide"}, {"id": "Peginterferon alfa-2b_INT_repinotan", "text": "Interaction: Peginterferon alfa-2b AND repinotan\nDetails: The serum concentration of repinotan can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + repinotan"}, {"id": "Peginterferon alfa-2b_INT_Benzyl alcohol", "text": "Interaction: Peginterferon alfa-2b AND Benzyl alcohol\nDetails: The serum concentration of Benzyl alcohol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Benzyl alcohol"}, {"id": "Peginterferon alfa-2b_INT_Clevidipine", "text": "Interaction: Peginterferon alfa-2b AND Clevidipine\nDetails: The serum concentration of Clevidipine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Clevidipine"}, {"id": "Peginterferon alfa-2b_INT_Enclomiphene", "text": "Interaction: Peginterferon alfa-2b AND Enclomiphene\nDetails: The serum concentration of Enclomiphene can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Enclomiphene"}, {"id": "Peginterferon alfa-2b_INT_Tapentadol", "text": "Interaction: Peginterferon alfa-2b AND Tapentadol\nDetails: The serum concentration of Tapentadol can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Tapentadol"}, {"id": "Peginterferon alfa-2b_INT_Fingolimod", "text": "Interaction: Peginterferon alfa-2b AND Fingolimod\nDetails: The serum concentration of Fingolimod can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Fingolimod"}, {"id": "Peginterferon alfa-2b_INT_Lorcaserin", "text": "Interaction: Peginterferon alfa-2b AND Lorcaserin\nDetails: The serum concentration of Lorcaserin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Lorcaserin"}, {"id": "Peginterferon alfa-2b_INT_Mirabegron", "text": "Interaction: Peginterferon alfa-2b AND Mirabegron\nDetails: The serum concentration of Mirabegron can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Mirabegron"}, {"id": "Peginterferon alfa-2b_INT_Ponatinib", "text": "Interaction: Peginterferon alfa-2b AND Ponatinib\nDetails: The serum concentration of Ponatinib can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ponatinib"}, {"id": "Peginterferon alfa-2b_INT_Alogliptin", "text": "Interaction: Peginterferon alfa-2b AND Alogliptin\nDetails: The serum concentration of Alogliptin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Alogliptin"}, {"id": "Peginterferon alfa-2b_INT_Levomilnacipran", "text": "Interaction: Peginterferon alfa-2b AND Levomilnacipran\nDetails: The serum concentration of Levomilnacipran can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Levomilnacipran"}, {"id": "Peginterferon alfa-2b_INT_Dapagliflozin", "text": "Interaction: Peginterferon alfa-2b AND Dapagliflozin\nDetails: The serum concentration of Dapagliflozin can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Dapagliflozin"}, {"id": "Peginterferon alfa-2b_INT_Eliglustat", "text": "Interaction: Peginterferon alfa-2b AND Eliglustat\nDetails: The serum concentration of Eliglustat can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Eliglustat"}, {"id": "Peginterferon alfa-2b_INT_Netupitant", "text": "Interaction: Peginterferon alfa-2b AND Netupitant\nDetails: The serum concentration of Netupitant can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Netupitant"}, {"id": "Peginterferon alfa-2b_INT_Ibrutinib", "text": "Interaction: Peginterferon alfa-2b AND Ibrutinib\nDetails: The serum concentration of Ibrutinib can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ibrutinib"}, {"id": "Peginterferon alfa-2b_INT_Umeclidinium", "text": "Interaction: Peginterferon alfa-2b AND Umeclidinium\nDetails: The serum concentration of Umeclidinium can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Umeclidinium"}, {"id": "Peginterferon alfa-2b_INT_Vortioxetine", "text": "Interaction: Peginterferon alfa-2b AND Vortioxetine\nDetails: The serum concentration of Vortioxetine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Vortioxetine"}, {"id": "Peginterferon alfa-2b_INT_Cariprazine", "text": "Interaction: Peginterferon alfa-2b AND Cariprazine\nDetails: The serum concentration of Cariprazine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Cariprazine"}, {"id": "Peginterferon alfa-2b_INT_Brexpiprazole", "text": "Interaction: Peginterferon alfa-2b AND Brexpiprazole\nDetails: The serum concentration of Brexpiprazole can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Brexpiprazole"}, {"id": "Peginterferon alfa-2b_INT_Esmirtazapine", "text": "Interaction: Peginterferon alfa-2b AND Esmirtazapine\nDetails: The serum concentration of Esmirtazapine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Esmirtazapine"}, {"id": "Peginterferon alfa-2b_INT_Ixazomib", "text": "Interaction: Peginterferon alfa-2b AND Ixazomib\nDetails: The serum concentration of Ixazomib can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ixazomib"}, {"id": "Peginterferon alfa-2b_INT_Dasabuvir", "text": "Interaction: Peginterferon alfa-2b AND Dasabuvir\nDetails: The serum concentration of Dasabuvir can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Dasabuvir"}, {"id": "Peginterferon alfa-2b_INT_Rucaparib", "text": "Interaction: Peginterferon alfa-2b AND Rucaparib\nDetails: The serum concentration of Rucaparib can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Rucaparib"}, {"id": "Peginterferon alfa-2b_INT_Dexchlorpheniramine maleate", "text": "Interaction: Peginterferon alfa-2b AND Dexchlorpheniramine maleate\nDetails: The serum concentration of Dexchlorpheniramine maleate can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Dexchlorpheniramine maleate"}, {"id": "Peginterferon alfa-2b_INT_Deutetrabenazine", "text": "Interaction: Peginterferon alfa-2b AND Deutetrabenazine\nDetails: The serum concentration of Deutetrabenazine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Deutetrabenazine"}, {"id": "Peginterferon alfa-2b_INT_Vernakalant", "text": "Interaction: Peginterferon alfa-2b AND Vernakalant\nDetails: The serum concentration of Vernakalant can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Vernakalant"}, {"id": "Peginterferon alfa-2b_INT_Valbenazine", "text": "Interaction: Peginterferon alfa-2b AND Valbenazine\nDetails: The serum concentration of Valbenazine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Valbenazine"}, {"id": "Peginterferon alfa-2b_INT_Perospirone", "text": "Interaction: Peginterferon alfa-2b AND Perospirone\nDetails: The serum concentration of Perospirone can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Perospirone"}, {"id": "Peginterferon alfa-2b_INT_Rupatadine", "text": "Interaction: Peginterferon alfa-2b AND Rupatadine\nDetails: The serum concentration of Rupatadine can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Rupatadine"}, {"id": "Peginterferon alfa-2b_INT_Enasidenib", "text": "Interaction: Peginterferon alfa-2b AND Enasidenib\nDetails: The serum concentration of Enasidenib can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Enasidenib"}, {"id": "Peginterferon alfa-2b_INT_Letermovir", "text": "Interaction: Peginterferon alfa-2b AND Letermovir\nDetails: The serum concentration of Letermovir can be decreased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Letermovir"}, {"id": "Peginterferon alfa-2b_INT_Anagrelide", "text": "Interaction: Peginterferon alfa-2b AND Anagrelide\nDetails: The serum concentration of Anagrelide can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Anagrelide"}, {"id": "Peginterferon alfa-2b_INT_Carmustine", "text": "Interaction: Peginterferon alfa-2b AND Carmustine\nDetails: The serum concentration of Carmustine can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Carmustine"}, {"id": "Peginterferon alfa-2b_INT_Ropinirole", "text": "Interaction: Peginterferon alfa-2b AND Ropinirole\nDetails: The serum concentration of Ropinirole can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ropinirole"}, {"id": "Peginterferon alfa-2b_INT_Conjugated estrogens", "text": "Interaction: Peginterferon alfa-2b AND Conjugated estrogens\nDetails: The serum concentration of Conjugated estrogens can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Conjugated estrogens"}, {"id": "Peginterferon alfa-2b_INT_Zolmitriptan", "text": "Interaction: Peginterferon alfa-2b AND Zolmitriptan\nDetails: The serum concentration of Zolmitriptan can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Zolmitriptan"}, {"id": "Peginterferon alfa-2b_INT_Grepafloxacin", "text": "Interaction: Peginterferon alfa-2b AND Grepafloxacin\nDetails: The serum concentration of Grepafloxacin can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Grepafloxacin"}, {"id": "Peginterferon alfa-2b_INT_Tacrine", "text": "Interaction: Peginterferon alfa-2b AND Tacrine\nDetails: The serum concentration of Tacrine can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Tacrine"}, {"id": "Peginterferon alfa-2b_INT_Flutamide", "text": "Interaction: Peginterferon alfa-2b AND Flutamide\nDetails: The serum concentration of Flutamide can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Flutamide"}, {"id": "Peginterferon alfa-2b_INT_Fluorouracil", "text": "Interaction: Peginterferon alfa-2b AND Fluorouracil\nDetails: The serum concentration of Fluorouracil can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Fluorouracil"}, {"id": "Peginterferon alfa-2b_INT_Estrone", "text": "Interaction: Peginterferon alfa-2b AND Estrone\nDetails: The serum concentration of Estrone can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Estrone"}, {"id": "Peginterferon alfa-2b_INT_Verapamil", "text": "Interaction: Peginterferon alfa-2b AND Verapamil\nDetails: The serum concentration of Verapamil can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Verapamil"}, {"id": "Peginterferon alfa-2b_INT_Warfarin", "text": "Interaction: Peginterferon alfa-2b AND Warfarin\nDetails: The serum concentration of Warfarin can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Warfarin"}, {"id": "Peginterferon alfa-2b_INT_Riluzole", "text": "Interaction: Peginterferon alfa-2b AND Riluzole\nDetails: The serum concentration of Riluzole can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Riluzole"}, {"id": "Peginterferon alfa-2b_INT_Zileuton", "text": "Interaction: Peginterferon alfa-2b AND Zileuton\nDetails: The serum concentration of Zileuton can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Zileuton"}, {"id": "Peginterferon alfa-2b_INT_Estradiol", "text": "Interaction: Peginterferon alfa-2b AND Estradiol\nDetails: The serum concentration of Estradiol can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Estradiol"}, {"id": "Peginterferon alfa-2b_INT_Diazepam", "text": "Interaction: Peginterferon alfa-2b AND Diazepam\nDetails: The serum concentration of Diazepam can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Diazepam"}, {"id": "Peginterferon alfa-2b_INT_Dacarbazine", "text": "Interaction: Peginterferon alfa-2b AND Dacarbazine\nDetails: The serum concentration of Dacarbazine can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Dacarbazine"}, {"id": "Peginterferon alfa-2b_INT_Lomefloxacin", "text": "Interaction: Peginterferon alfa-2b AND Lomefloxacin\nDetails: The serum concentration of Lomefloxacin can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Lomefloxacin"}, {"id": "Peginterferon alfa-2b_INT_Ramelteon", "text": "Interaction: Peginterferon alfa-2b AND Ramelteon\nDetails: The serum concentration of Ramelteon can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ramelteon"}, {"id": "Peginterferon alfa-2b_INT_Frovatriptan", "text": "Interaction: Peginterferon alfa-2b AND Frovatriptan\nDetails: The serum concentration of Frovatriptan can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Frovatriptan"}, {"id": "Peginterferon alfa-2b_INT_Levobupivacaine", "text": "Interaction: Peginterferon alfa-2b AND Levobupivacaine\nDetails: The serum concentration of Levobupivacaine can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Levobupivacaine"}, {"id": "Peginterferon alfa-2b_INT_Cinacalcet", "text": "Interaction: Peginterferon alfa-2b AND Cinacalcet\nDetails: The serum concentration of Cinacalcet can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Cinacalcet"}, {"id": "Peginterferon alfa-2b_INT_Hesperetin", "text": "Interaction: Peginterferon alfa-2b AND Hesperetin\nDetails: The serum concentration of Hesperetin can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Hesperetin"}, {"id": "Peginterferon alfa-2b_INT_Leflunomide", "text": "Interaction: Peginterferon alfa-2b AND Leflunomide\nDetails: The serum concentration of Leflunomide can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Leflunomide"}, {"id": "Peginterferon alfa-2b_INT_Pimozide", "text": "Interaction: Peginterferon alfa-2b AND Pimozide\nDetails: The serum concentration of Pimozide can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Pimozide"}, {"id": "Peginterferon alfa-2b_INT_Alosetron", "text": "Interaction: Peginterferon alfa-2b AND Alosetron\nDetails: The serum concentration of Alosetron can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Alosetron"}, {"id": "Peginterferon alfa-2b_INT_Rasagiline", "text": "Interaction: Peginterferon alfa-2b AND Rasagiline\nDetails: The serum concentration of Rasagiline can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Rasagiline"}, {"id": "Peginterferon alfa-2b_INT_Pantoprazole", "text": "Interaction: Peginterferon alfa-2b AND Pantoprazole\nDetails: The serum concentration of Pantoprazole can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Pantoprazole"}, {"id": "Peginterferon alfa-2b_INT_Rofecoxib", "text": "Interaction: Peginterferon alfa-2b AND Rofecoxib\nDetails: The serum concentration of Rofecoxib can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Rofecoxib"}, {"id": "Peginterferon alfa-2b_INT_Diclofenac", "text": "Interaction: Peginterferon alfa-2b AND Diclofenac\nDetails: The serum concentration of Diclofenac can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Diclofenac"}, {"id": "Peginterferon alfa-2b_INT_Thiabendazole", "text": "Interaction: Peginterferon alfa-2b AND Thiabendazole\nDetails: The serum concentration of Thiabendazole can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Thiabendazole"}, {"id": "Peginterferon alfa-2b_INT_Telithromycin", "text": "Interaction: Peginterferon alfa-2b AND Telithromycin\nDetails: The serum concentration of Telithromycin can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Telithromycin"}, {"id": "Peginterferon alfa-2b_INT_Acenocoumarol", "text": "Interaction: Peginterferon alfa-2b AND Acenocoumarol\nDetails: The serum concentration of Acenocoumarol can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Acenocoumarol"}, {"id": "Peginterferon alfa-2b_INT_Melatonin", "text": "Interaction: Peginterferon alfa-2b AND Melatonin\nDetails: The serum concentration of Melatonin can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Melatonin"}, {"id": "Peginterferon alfa-2b_INT_Thalidomide", "text": "Interaction: Peginterferon alfa-2b AND Thalidomide\nDetails: The serum concentration of Thalidomide can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Thalidomide"}, {"id": "Peginterferon alfa-2b_INT_Carbamazepine", "text": "Interaction: Peginterferon alfa-2b AND Carbamazepine\nDetails: The serum concentration of Carbamazepine can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Carbamazepine"}, {"id": "Peginterferon alfa-2b_INT_Terbinafine", "text": "Interaction: Peginterferon alfa-2b AND Terbinafine\nDetails: The serum concentration of Terbinafine can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Terbinafine"}, {"id": "Peginterferon alfa-2b_INT_Naproxen", "text": "Interaction: Peginterferon alfa-2b AND Naproxen\nDetails: The serum concentration of Naproxen can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Naproxen"}, {"id": "Peginterferon alfa-2b_INT_Omeprazole", "text": "Interaction: Peginterferon alfa-2b AND Omeprazole\nDetails: The serum concentration of Omeprazole can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Omeprazole"}, {"id": "Peginterferon alfa-2b_INT_Aminophylline", "text": "Interaction: Peginterferon alfa-2b AND Aminophylline\nDetails: The serum concentration of Aminophylline can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Aminophylline"}, {"id": "Peginterferon alfa-2b_INT_Asenapine", "text": "Interaction: Peginterferon alfa-2b AND Asenapine\nDetails: The serum concentration of Asenapine can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Asenapine"}, {"id": "Peginterferon alfa-2b_INT_Estrone sulfate", "text": "Interaction: Peginterferon alfa-2b AND Estrone sulfate\nDetails: The serum concentration of Estrone sulfate can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Estrone sulfate"}, {"id": "Peginterferon alfa-2b_INT_Guanabenz", "text": "Interaction: Peginterferon alfa-2b AND Guanabenz\nDetails: The serum concentration of Guanabenz can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Guanabenz"}, {"id": "Peginterferon alfa-2b_INT_Thiothixene", "text": "Interaction: Peginterferon alfa-2b AND Thiothixene\nDetails: The serum concentration of Thiothixene can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Thiothixene"}, {"id": "Peginterferon alfa-2b_INT_Trifluoperazine", "text": "Interaction: Peginterferon alfa-2b AND Trifluoperazine\nDetails: The serum concentration of Trifluoperazine can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Trifluoperazine"}, {"id": "Peginterferon alfa-2b_INT_Primaquine", "text": "Interaction: Peginterferon alfa-2b AND Primaquine\nDetails: The serum concentration of Primaquine can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Primaquine"}, {"id": "Peginterferon alfa-2b_INT_Clopidogrel", "text": "Interaction: Peginterferon alfa-2b AND Clopidogrel\nDetails: The serum concentration of Clopidogrel can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Clopidogrel"}, {"id": "Peginterferon alfa-2b_INT_Promazine", "text": "Interaction: Peginterferon alfa-2b AND Promazine\nDetails: The serum concentration of Promazine can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Promazine"}, {"id": "Peginterferon alfa-2b_INT_Genistein", "text": "Interaction: Peginterferon alfa-2b AND Genistein\nDetails: The serum concentration of Genistein can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Genistein"}, {"id": "Peginterferon alfa-2b_INT_Resveratrol", "text": "Interaction: Peginterferon alfa-2b AND Resveratrol\nDetails: The serum concentration of Resveratrol can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Resveratrol"}, {"id": "Peginterferon alfa-2b_INT_Albendazole", "text": "Interaction: Peginterferon alfa-2b AND Albendazole\nDetails: The serum concentration of Albendazole can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Albendazole"}, {"id": "Peginterferon alfa-2b_INT_Aprepitant", "text": "Interaction: Peginterferon alfa-2b AND Aprepitant\nDetails: The serum concentration of Aprepitant can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Aprepitant"}, {"id": "Peginterferon alfa-2b_INT_Bromazepam", "text": "Interaction: Peginterferon alfa-2b AND Bromazepam\nDetails: The serum concentration of Bromazepam can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Bromazepam"}, {"id": "Peginterferon alfa-2b_INT_Cisapride", "text": "Interaction: Peginterferon alfa-2b AND Cisapride\nDetails: The serum concentration of Cisapride can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Cisapride"}, {"id": "Peginterferon alfa-2b_INT_Clenbuterol", "text": "Interaction: Peginterferon alfa-2b AND Clenbuterol\nDetails: The serum concentration of Clenbuterol can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Clenbuterol"}, {"id": "Peginterferon alfa-2b_INT_Daunorubicin", "text": "Interaction: Peginterferon alfa-2b AND Daunorubicin\nDetails: The serum concentration of Daunorubicin can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Daunorubicin"}, {"id": "Peginterferon alfa-2b_INT_Dinoprostone", "text": "Interaction: Peginterferon alfa-2b AND Dinoprostone\nDetails: The serum concentration of Dinoprostone can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Dinoprostone"}, {"id": "Peginterferon alfa-2b_INT_Ergotamine", "text": "Interaction: Peginterferon alfa-2b AND Ergotamine\nDetails: The serum concentration of Ergotamine can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ergotamine"}, {"id": "Peginterferon alfa-2b_INT_Ethanol", "text": "Interaction: Peginterferon alfa-2b AND Ethanol\nDetails: The serum concentration of Ethanol can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ethanol"}, {"id": "Peginterferon alfa-2b_INT_Etoposide", "text": "Interaction: Peginterferon alfa-2b AND Etoposide\nDetails: The serum concentration of Etoposide can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Etoposide"}, {"id": "Peginterferon alfa-2b_INT_Flunitrazepam", "text": "Interaction: Peginterferon alfa-2b AND Flunitrazepam\nDetails: The serum concentration of Flunitrazepam can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Flunitrazepam"}, {"id": "Peginterferon alfa-2b_INT_Hexobarbital", "text": "Interaction: Peginterferon alfa-2b AND Hexobarbital\nDetails: The serum concentration of Hexobarbital can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Hexobarbital"}, {"id": "Peginterferon alfa-2b_INT_Imiquimod", "text": "Interaction: Peginterferon alfa-2b AND Imiquimod\nDetails: The serum concentration of Imiquimod can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Imiquimod"}, {"id": "Peginterferon alfa-2b_INT_Lumiracoxib", "text": "Interaction: Peginterferon alfa-2b AND Lumiracoxib\nDetails: The serum concentration of Lumiracoxib can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Lumiracoxib"}, {"id": "Peginterferon alfa-2b_INT_Malathion", "text": "Interaction: Peginterferon alfa-2b AND Malathion\nDetails: The serum concentration of Malathion can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Malathion"}, {"id": "Peginterferon alfa-2b_INT_Menadione", "text": "Interaction: Peginterferon alfa-2b AND Menadione\nDetails: The serum concentration of Menadione can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Menadione"}, {"id": "Peginterferon alfa-2b_INT_Oxaliplatin", "text": "Interaction: Peginterferon alfa-2b AND Oxaliplatin\nDetails: The serum concentration of Oxaliplatin can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Oxaliplatin"}, {"id": "Peginterferon alfa-2b_INT_Pentoxifylline", "text": "Interaction: Peginterferon alfa-2b AND Pentoxifylline\nDetails: The serum concentration of Pentoxifylline can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Pentoxifylline"}, {"id": "Peginterferon alfa-2b_INT_Praziquantel", "text": "Interaction: Peginterferon alfa-2b AND Praziquantel\nDetails: The serum concentration of Praziquantel can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Praziquantel"}, {"id": "Peginterferon alfa-2b_INT_Proguanil", "text": "Interaction: Peginterferon alfa-2b AND Proguanil\nDetails: The serum concentration of Proguanil can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Proguanil"}, {"id": "Peginterferon alfa-2b_INT_Pyrazinamide", "text": "Interaction: Peginterferon alfa-2b AND Pyrazinamide\nDetails: The serum concentration of Pyrazinamide can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Pyrazinamide"}, {"id": "Peginterferon alfa-2b_INT_Rifabutin", "text": "Interaction: Peginterferon alfa-2b AND Rifabutin\nDetails: The serum concentration of Rifabutin can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Rifabutin"}, {"id": "Peginterferon alfa-2b_INT_Selegiline", "text": "Interaction: Peginterferon alfa-2b AND Selegiline\nDetails: The serum concentration of Selegiline can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Selegiline"}, {"id": "Peginterferon alfa-2b_INT_Temafloxacin", "text": "Interaction: Peginterferon alfa-2b AND Temafloxacin\nDetails: The serum concentration of Temafloxacin can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Temafloxacin"}, {"id": "Peginterferon alfa-2b_INT_Theobromine", "text": "Interaction: Peginterferon alfa-2b AND Theobromine\nDetails: The serum concentration of Theobromine can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Theobromine"}, {"id": "Peginterferon alfa-2b_INT_Tolperisone", "text": "Interaction: Peginterferon alfa-2b AND Tolperisone\nDetails: The serum concentration of Tolperisone can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Tolperisone"}, {"id": "Peginterferon alfa-2b_INT_Toremifene", "text": "Interaction: Peginterferon alfa-2b AND Toremifene\nDetails: The serum concentration of Toremifene can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Toremifene"}, {"id": "Peginterferon alfa-2b_INT_Triamterene", "text": "Interaction: Peginterferon alfa-2b AND Triamterene\nDetails: The serum concentration of Triamterene can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Triamterene"}, {"id": "Peginterferon alfa-2b_INT_Ziprasidone", "text": "Interaction: Peginterferon alfa-2b AND Ziprasidone\nDetails: The serum concentration of Ziprasidone can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ziprasidone"}, {"id": "Peginterferon alfa-2b_INT_Oxtriphylline", "text": "Interaction: Peginterferon alfa-2b AND Oxtriphylline\nDetails: The serum concentration of Oxtriphylline can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Oxtriphylline"}, {"id": "Peginterferon alfa-2b_INT_Dasatinib", "text": "Interaction: Peginterferon alfa-2b AND Dasatinib\nDetails: The serum concentration of Dasatinib can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Dasatinib"}, {"id": "Peginterferon alfa-2b_INT_Eltrombopag", "text": "Interaction: Peginterferon alfa-2b AND Eltrombopag\nDetails: The serum concentration of Eltrombopag can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Eltrombopag"}, {"id": "Peginterferon alfa-2b_INT_Rizatriptan", "text": "Interaction: Peginterferon alfa-2b AND Rizatriptan\nDetails: The serum concentration of Rizatriptan can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Rizatriptan"}, {"id": "Peginterferon alfa-2b_INT_muraglitazar", "text": "Interaction: Peginterferon alfa-2b AND muraglitazar\nDetails: The serum concentration of muraglitazar can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + muraglitazar"}, {"id": "Peginterferon alfa-2b_INT_Vadimezan", "text": "Interaction: Peginterferon alfa-2b AND Vadimezan\nDetails: The serum concentration of Vadimezan can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Vadimezan"}, {"id": "Peginterferon alfa-2b_INT_Nabumetone", "text": "Interaction: Peginterferon alfa-2b AND Nabumetone\nDetails: The serum concentration of Nabumetone can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Nabumetone"}, {"id": "Peginterferon alfa-2b_INT_Nitric Oxide", "text": "Interaction: Peginterferon alfa-2b AND Nitric Oxide\nDetails: The serum concentration of Nitric Oxide can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Nitric Oxide"}, {"id": "Peginterferon alfa-2b_INT_Ulipristal", "text": "Interaction: Peginterferon alfa-2b AND Ulipristal\nDetails: The serum concentration of Ulipristal can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Ulipristal"}, {"id": "Peginterferon alfa-2b_INT_Apixaban", "text": "Interaction: Peginterferon alfa-2b AND Apixaban\nDetails: The serum concentration of Apixaban can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Apixaban"}, {"id": "Peginterferon alfa-2b_INT_Axitinib", "text": "Interaction: Peginterferon alfa-2b AND Axitinib\nDetails: The serum concentration of Axitinib can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Axitinib"}, {"id": "Peginterferon alfa-2b_INT_Pomalidomide", "text": "Interaction: Peginterferon alfa-2b AND Pomalidomide\nDetails: The serum concentration of Pomalidomide can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Pomalidomide"}, {"id": "Peginterferon alfa-2b_INT_Bendamustine", "text": "Interaction: Peginterferon alfa-2b AND Bendamustine\nDetails: The serum concentration of Bendamustine can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Bendamustine"}, {"id": "Peginterferon alfa-2b_INT_Icotinib", "text": "Interaction: Peginterferon alfa-2b AND Icotinib\nDetails: The serum concentration of Icotinib can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Icotinib"}, {"id": "Peginterferon alfa-2b_INT_Stiripentol", "text": "Interaction: Peginterferon alfa-2b AND Stiripentol\nDetails: The serum concentration of Stiripentol can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Stiripentol"}, {"id": "Peginterferon alfa-2b_INT_Voxilaprevir", "text": "Interaction: Peginterferon alfa-2b AND Voxilaprevir\nDetails: The serum concentration of Voxilaprevir can be increased when it is combined with Peginterferon alfa-2b.\nRisk: Monitor closely.", "source": "Peginterferon alfa-2b + Voxilaprevir"}, {"id": "Asparaginase_GEN", "text": "Drug: Asparaginase\nDescription: L-asparagine amidohydrolase from E. coli...", "source": "Asparaginase"}, {"id": "Asparaginase_CLIN", "text": "Drug: Asparaginase\nMechanism: Asparaginase converts asparagine to aspartic acid and ammonia. It facilitates production of oxaloacetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produ...\nToxicity: ...", "source": "Asparaginase"}, {"id": "Asparaginase_INT_Trastuzumab", "text": "Interaction: Asparaginase AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Trastuzumab"}, {"id": "Asparaginase_INT_Paclitaxel", "text": "Interaction: Asparaginase AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Paclitaxel"}, {"id": "Asparaginase_INT_Docetaxel", "text": "Interaction: Asparaginase AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Docetaxel"}, {"id": "Asparaginase_INT_Cabazitaxel", "text": "Interaction: Asparaginase AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Cabazitaxel"}, {"id": "Asparaginase_INT_Digoxin", "text": "Interaction: Asparaginase AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Digoxin"}, {"id": "Asparaginase_INT_Acetyldigitoxin", "text": "Interaction: Asparaginase AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Acetyldigitoxin"}, {"id": "Asparaginase_INT_Deslanoside", "text": "Interaction: Asparaginase AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Deslanoside"}, {"id": "Asparaginase_INT_Ouabain", "text": "Interaction: Asparaginase AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Ouabain"}, {"id": "Asparaginase_INT_Digitoxin", "text": "Interaction: Asparaginase AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Digitoxin"}, {"id": "Asparaginase_INT_Cymarin", "text": "Interaction: Asparaginase AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Cymarin"}, {"id": "Asparaginase_INT_Proscillaridin", "text": "Interaction: Asparaginase AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Proscillaridin"}, {"id": "Asparaginase_INT_Metildigoxin", "text": "Interaction: Asparaginase AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Metildigoxin"}, {"id": "Asparaginase_INT_Peruvoside", "text": "Interaction: Asparaginase AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Peruvoside"}, {"id": "Asparaginase_INT_Lanatoside C", "text": "Interaction: Asparaginase AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Lanatoside C"}, {"id": "Asparaginase_INT_Gitoformate", "text": "Interaction: Asparaginase AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Gitoformate"}, {"id": "Asparaginase_INT_Acetyldigoxin", "text": "Interaction: Asparaginase AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Acetyldigoxin"}, {"id": "Asparaginase_INT_Oleandrin", "text": "Interaction: Asparaginase AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Oleandrin"}, {"id": "Asparaginase_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Asparaginase AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Digoxin Immune Fab (Ovine)"}, {"id": "Asparaginase_INT_Bevacizumab", "text": "Interaction: Asparaginase AND Bevacizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Bevacizumab"}, {"id": "Asparaginase_INT_Cyclophosphamide", "text": "Interaction: Asparaginase AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Cyclophosphamide"}, {"id": "Asparaginase_INT_Dexamethasone", "text": "Interaction: Asparaginase AND Dexamethasone\nDetails: The serum concentration of Dexamethasone can be increased when it is combined with Asparaginase.\nRisk: Monitor closely.", "source": "Asparaginase + Dexamethasone"}, {"id": "Thyrotropin Alfa_GEN", "text": "Drug: Thyrotropin Alfa\nDescription: Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed beca...", "source": "Thyrotropin Alfa"}, {"id": "Thyrotropin Alfa_CLIN", "text": "Drug: Thyrotropin Alfa\nMechanism: Thyrotropin Alfa binds to the thyrotropin receptors found on any residual thyroid cells or tissues. This stimulates radioactive iodine uptake for better radiodiagnostic imaging....\nToxicity: No difference in efficacy and toxicity between adult and geriatric patients. No studies in lactating women, pregnant women and pediatrics. Cautionary administration is advised. ...", "source": "Thyrotropin Alfa"}, {"id": "Antihemophilic factor, human recombinant_GEN", "text": "Drug: Antihemophilic factor, human recombinant\nDescription: Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells...", "source": "Antihemophilic factor, human recombinant"}, {"id": "Antihemophilic factor, human recombinant_CLIN", "text": "Drug: Antihemophilic factor, human recombinant\nMechanism: Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correc...\nToxicity: ...", "source": "Antihemophilic factor, human recombinant"}, {"id": "Antihemophilic factor, human recombinant_INT_Emicizumab", "text": "Interaction: Antihemophilic factor, human recombinant AND Emicizumab\nDetails: The risk or severity of hypercoagulability can be increased when Emicizumab is combined with Antihemophilic factor, human recombinant.\nRisk: Monitor closely.", "source": "Antihemophilic factor, human recombinant + Emicizumab"}, {"id": "Anakinra_GEN", "text": "Drug: Anakinra\nDescription: Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor antagonist (IL-1Ra). The difference  between anakinra and the native human IL-1Ra is that anakinra has an extra methionine residue at the amino terminus. It is manufactured by using the E. coli expression system. Anakinra is com...", "source": "Anakinra"}, {"id": "Anakinra_CLIN", "text": "Drug: Anakinra\nMechanism: Anakinra binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption....\nToxicity: Most common adverse reactions (incidence \u2265 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu...", "source": "Anakinra"}, {"id": "Anakinra_INT_Rituximab", "text": "Interaction: Anakinra AND Rituximab\nDetails: The risk or severity of adverse effects can be increased when Anakinra is combined with Rituximab.\nRisk: Monitor closely.", "source": "Anakinra + Rituximab"}, {"id": "Anakinra_INT_Tocilizumab", "text": "Interaction: Anakinra AND Tocilizumab\nDetails: The risk or severity of adverse effects can be increased when Anakinra is combined with Tocilizumab.\nRisk: Monitor closely.", "source": "Anakinra + Tocilizumab"}, {"id": "Anakinra_INT_Afelimomab", "text": "Interaction: Anakinra AND Afelimomab\nDetails: The risk or severity of adverse effects can be increased when Afelimomab is combined with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Afelimomab"}, {"id": "Anakinra_INT_Pirfenidone", "text": "Interaction: Anakinra AND Pirfenidone\nDetails: The risk or severity of adverse effects can be increased when Pirfenidone is combined with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Pirfenidone"}, {"id": "Anakinra_INT_Etanercept", "text": "Interaction: Anakinra AND Etanercept\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Etanercept"}, {"id": "Anakinra_INT_Adalimumab", "text": "Interaction: Anakinra AND Adalimumab\nDetails: The risk or severity of adverse effects can be increased when Adalimumab is combined with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Adalimumab"}, {"id": "Anakinra_INT_Golimumab", "text": "Interaction: Anakinra AND Golimumab\nDetails: The risk or severity of adverse effects can be increased when Golimumab is combined with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Golimumab"}, {"id": "Anakinra_INT_Certolizumab pegol", "text": "Interaction: Anakinra AND Certolizumab pegol\nDetails: The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Certolizumab pegol"}, {"id": "Anakinra_INT_Natalizumab", "text": "Interaction: Anakinra AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Anakinra is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Anakinra + Natalizumab"}, {"id": "Anakinra_INT_Infliximab", "text": "Interaction: Anakinra AND Infliximab\nDetails: The risk or severity of adverse effects can be d when Anakinra is combined with Infliximab.\nRisk: Monitor closely.", "source": "Anakinra + Infliximab"}, {"id": "Anakinra_INT_Pimecrolimus", "text": "Interaction: Anakinra AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Pimecrolimus"}, {"id": "Anakinra_INT_Tacrolimus", "text": "Interaction: Anakinra AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Tacrolimus"}, {"id": "Anakinra_INT_Abatacept", "text": "Interaction: Anakinra AND Abatacept\nDetails: The risk or severity of adverse effects can be increased when Anakinra is combined with Abatacept.\nRisk: Monitor closely.", "source": "Anakinra + Abatacept"}, {"id": "Anakinra_INT_Canakinumab", "text": "Interaction: Anakinra AND Canakinumab\nDetails: The risk or severity of infection can be increased when Anakinra is combined with Canakinumab.\nRisk: Monitor closely.", "source": "Anakinra + Canakinumab"}, {"id": "Anakinra_INT_Tofacitinib", "text": "Interaction: Anakinra AND Tofacitinib\nDetails: The risk or severity of adverse effects can be increased when Anakinra is combined with Tofacitinib.\nRisk: Monitor closely.", "source": "Anakinra + Tofacitinib"}, {"id": "Anakinra_INT_BCG vaccine", "text": "Interaction: Anakinra AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + BCG vaccine"}, {"id": "Anakinra_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Anakinra AND Rabies virus inactivated antigen, A\nDetails: The risk or severity of adverse effects can be increased when Anakinra is combined with Rabies virus inactivated antigen, A.\nRisk: Monitor closely.", "source": "Anakinra + Rabies virus inactivated antigen, A"}, {"id": "Anakinra_INT_Sarilumab", "text": "Interaction: Anakinra AND Sarilumab\nDetails: Sarilumab may increase the immunosuppressive activities of Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Sarilumab"}, {"id": "Anakinra_INT_Leflunomide", "text": "Interaction: Anakinra AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Anakinra is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Anakinra + Leflunomide"}, {"id": "Anakinra_INT_Fingolimod", "text": "Interaction: Anakinra AND Fingolimod\nDetails: Anakinra may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Anakinra + Fingolimod"}, {"id": "Anakinra_INT_Roflumilast", "text": "Interaction: Anakinra AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Roflumilast"}, {"id": "Anakinra_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Anakinra AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Anakinra_INT_Yellow fever vaccine", "text": "Interaction: Anakinra AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Yellow fever vaccine"}, {"id": "Anakinra_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Anakinra AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Anakinra_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Anakinra AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Anakinra_INT_Rotavirus Vaccine", "text": "Interaction: Anakinra AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Rotavirus Vaccine"}, {"id": "Anakinra_INT_G17DT", "text": "Interaction: Anakinra AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + G17DT"}, {"id": "Anakinra_INT_INGN 201", "text": "Interaction: Anakinra AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + INGN 201"}, {"id": "Anakinra_INT_INGN 225", "text": "Interaction: Anakinra AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + INGN 225"}, {"id": "Anakinra_INT_Rindopepimut", "text": "Interaction: Anakinra AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Rindopepimut"}, {"id": "Anakinra_INT_SRP 299", "text": "Interaction: Anakinra AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + SRP 299"}, {"id": "Anakinra_INT_GI-5005", "text": "Interaction: Anakinra AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + GI-5005"}, {"id": "Anakinra_INT_TG4010", "text": "Interaction: Anakinra AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + TG4010"}, {"id": "Anakinra_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Anakinra AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Rabies virus inactivated antigen, A"}, {"id": "Anakinra_INT_Tecemotide", "text": "Interaction: Anakinra AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Tecemotide"}, {"id": "Anakinra_INT_Rubella virus vaccine", "text": "Interaction: Anakinra AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Rubella virus vaccine"}, {"id": "Anakinra_INT_Hepatitis A Vaccine", "text": "Interaction: Anakinra AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Hepatitis A Vaccine"}, {"id": "Anakinra_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Anakinra AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Salmonella typhi ty21a live antigen"}, {"id": "Anakinra_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Anakinra AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Hepatitis B Vaccine (Recombinant)"}, {"id": "Anakinra_INT_Denosumab", "text": "Interaction: Anakinra AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Denosumab"}, {"id": "Anakinra_INT_Sipuleucel-T", "text": "Interaction: Anakinra AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Sipuleucel-T"}, {"id": "Anakinra_INT_Trastuzumab", "text": "Interaction: Anakinra AND Trastuzumab\nDetails: Trastuzumab may increase the neutropenic activities of Anakinra.\nRisk: Monitor closely.", "source": "Anakinra + Trastuzumab"}, {"id": "Gramicidin D_GEN", "text": "Drug: Gramicidin D\nDescription: Gramcidin D is a heterogeneous mixture of three antibiotic compounds, gramicidins A, B and C, making up 80%, 6%, and 14% respectively all of which are obtained from the soil bacterial species Bacillus brevis and called collectively gramicidin D. Gramcidins are 15 residue peptides with alternating D ...", "source": "Gramicidin D"}, {"id": "Gramicidin D_CLIN", "text": "Drug: Gramicidin D\nMechanism: Gramicidin D binds to and inserts itself into bacterial membranes (with a strong preference to gram-positive cell membranes). This results in membrane disruption and permeabilization (it acts as a cha...\nToxicity: ...", "source": "Gramicidin D"}, {"id": "Gramicidin D_INT_Pazopanib", "text": "Interaction: Gramicidin D AND Pazopanib\nDetails: The serum concentration of Pazopanib can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Pazopanib"}, {"id": "Gramicidin D_INT_Silodosin", "text": "Interaction: Gramicidin D AND Silodosin\nDetails: The serum concentration of Silodosin can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Silodosin"}, {"id": "Gramicidin D_INT_Topotecan", "text": "Interaction: Gramicidin D AND Topotecan\nDetails: The serum concentration of Topotecan can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Topotecan"}, {"id": "Gramicidin D_INT_Vincristine", "text": "Interaction: Gramicidin D AND Vincristine\nDetails: The serum concentration of Vincristine can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Vincristine"}, {"id": "Gramicidin D_INT_Bosutinib", "text": "Interaction: Gramicidin D AND Bosutinib\nDetails: The serum concentration of Bosutinib can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Bosutinib"}, {"id": "Gramicidin D_INT_BCG vaccine", "text": "Interaction: Gramicidin D AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + BCG vaccine"}, {"id": "Gramicidin D_INT_Edoxaban", "text": "Interaction: Gramicidin D AND Edoxaban\nDetails: The serum concentration of Edoxaban can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Edoxaban"}, {"id": "Gramicidin D_INT_Doxorubicin", "text": "Interaction: Gramicidin D AND Doxorubicin\nDetails: The serum concentration of Doxorubicin can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Doxorubicin"}, {"id": "Gramicidin D_INT_Picosulfuric acid", "text": "Interaction: Gramicidin D AND Picosulfuric acid\nDetails: The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Picosulfuric acid"}, {"id": "Gramicidin D_INT_Everolimus", "text": "Interaction: Gramicidin D AND Everolimus\nDetails: The serum concentration of Everolimus can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Everolimus"}, {"id": "Gramicidin D_INT_Afatinib", "text": "Interaction: Gramicidin D AND Afatinib\nDetails: The serum concentration of Afatinib can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Afatinib"}, {"id": "Gramicidin D_INT_Colchicine", "text": "Interaction: Gramicidin D AND Colchicine\nDetails: The serum concentration of Colchicine can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Colchicine"}, {"id": "Gramicidin D_INT_Dabigatran etexilate", "text": "Interaction: Gramicidin D AND Dabigatran etexilate\nDetails: The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Dabigatran etexilate"}, {"id": "Gramicidin D_INT_Ledipasvir", "text": "Interaction: Gramicidin D AND Ledipasvir\nDetails: The serum concentration of Ledipasvir can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Ledipasvir"}, {"id": "Gramicidin D_INT_Naloxegol", "text": "Interaction: Gramicidin D AND Naloxegol\nDetails: The serum concentration of Naloxegol can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Naloxegol"}, {"id": "Gramicidin D_INT_Prucalopride", "text": "Interaction: Gramicidin D AND Prucalopride\nDetails: The serum concentration of Prucalopride can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Prucalopride"}, {"id": "Gramicidin D_INT_Ranolazine", "text": "Interaction: Gramicidin D AND Ranolazine\nDetails: The serum concentration of Ranolazine can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Ranolazine"}, {"id": "Gramicidin D_INT_Rifaximin", "text": "Interaction: Gramicidin D AND Rifaximin\nDetails: The serum concentration of Rifaximin can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Rifaximin"}, {"id": "Gramicidin D_INT_Brentuximab vedotin", "text": "Interaction: Gramicidin D AND Brentuximab vedotin\nDetails: The serum concentration of Brentuximab vedotin can be increased when it is combined with Gramicidin D.\nRisk: Monitor closely.", "source": "Gramicidin D + Brentuximab vedotin"}, {"id": "Immune Globulin Human_GEN", "text": "Drug: Immune Globulin Human\nDescription: Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution ...", "source": "Immune Globulin Human"}, {"id": "Immune Globulin Human_CLIN", "text": "Drug: Immune Globulin Human\nMechanism: IVIg interacts with a number of different components of the immune system, including cytokines, complement, Fc receptors and several cell surface immunocompetent molecules. IVIg also impacts different...\nToxicity: ...", "source": "Immune Globulin Human"}, {"id": "Immune Globulin Human_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Immune Globulin Human AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Immune Globulin Human_INT_Yellow fever vaccine", "text": "Interaction: Immune Globulin Human AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + Yellow fever vaccine"}, {"id": "Immune Globulin Human_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Immune Globulin Human AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Immune Globulin Human_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Immune Globulin Human AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Immune Globulin Human_INT_Rotavirus Vaccine", "text": "Interaction: Immune Globulin Human AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + Rotavirus Vaccine"}, {"id": "Immune Globulin Human_INT_G17DT", "text": "Interaction: Immune Globulin Human AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + G17DT"}, {"id": "Immune Globulin Human_INT_INGN 201", "text": "Interaction: Immune Globulin Human AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + INGN 201"}, {"id": "Immune Globulin Human_INT_INGN 225", "text": "Interaction: Immune Globulin Human AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + INGN 225"}, {"id": "Immune Globulin Human_INT_Rindopepimut", "text": "Interaction: Immune Globulin Human AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + Rindopepimut"}, {"id": "Immune Globulin Human_INT_SRP 299", "text": "Interaction: Immune Globulin Human AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + SRP 299"}, {"id": "Immune Globulin Human_INT_GI-5005", "text": "Interaction: Immune Globulin Human AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + GI-5005"}, {"id": "Immune Globulin Human_INT_TG4010", "text": "Interaction: Immune Globulin Human AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + TG4010"}, {"id": "Immune Globulin Human_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Immune Globulin Human AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + Rabies virus inactivated antigen, A"}, {"id": "Immune Globulin Human_INT_Tecemotide", "text": "Interaction: Immune Globulin Human AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + Tecemotide"}, {"id": "Immune Globulin Human_INT_BCG vaccine", "text": "Interaction: Immune Globulin Human AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + BCG vaccine"}, {"id": "Immune Globulin Human_INT_Rubella virus vaccine", "text": "Interaction: Immune Globulin Human AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + Rubella virus vaccine"}, {"id": "Immune Globulin Human_INT_Hepatitis A Vaccine", "text": "Interaction: Immune Globulin Human AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + Hepatitis A Vaccine"}, {"id": "Immune Globulin Human_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Immune Globulin Human AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + Salmonella typhi ty21a live antigen"}, {"id": "Immune Globulin Human_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Immune Globulin Human AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Immune Globulin Human.\nRisk: Monitor closely.", "source": "Immune Globulin Human + Hepatitis B Vaccine (Recombinant)"}, {"id": "Anistreplase_GEN", "text": "Drug: Anistreplase\nDescription: ...", "source": "Anistreplase"}, {"id": "Phylloquinone_GEN", "text": "Drug: Phylloquinone\nDescription: ...", "source": "Phylloquinone"}, {"id": "Calcium_GEN", "text": "Drug: Calcium\nDescription: ...", "source": "Calcium"}, {"id": "Anistreplase_GEN", "text": "Drug: Anistreplase\nDescription: Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokina...", "source": "Anistreplase"}, {"id": "Anistreplase_CLIN", "text": "Drug: Anistreplase\nMechanism: Anistreplase cleaves the Arg/Val bond in plasminogen to form plasmin. This in turn leads to the degradation of blood clots....\nToxicity: ...", "source": "Anistreplase"}, {"id": "Anistreplase_INT_Aprotinin", "text": "Interaction: Anistreplase AND Aprotinin\nDetails: The therapeutic efficacy of Anistreplase can be decreased when used in combination with Aprotinin.\nRisk: Monitor closely.", "source": "Anistreplase + Aprotinin"}, {"id": "Anistreplase_INT_Limaprost", "text": "Interaction: Anistreplase AND Limaprost\nDetails: The risk or severity of adverse effects can be increased when Limaprost is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Limaprost"}, {"id": "Anistreplase_INT_Dabigatran etexilate", "text": "Interaction: Anistreplase AND Dabigatran etexilate\nDetails: Anistreplase may increase the anticoagulant activities of Dabigatran etexilate.\nRisk: Monitor closely.", "source": "Anistreplase + Dabigatran etexilate"}, {"id": "Anistreplase_INT_Lepirudin", "text": "Interaction: Anistreplase AND Lepirudin\nDetails: Anistreplase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Anistreplase + Lepirudin"}, {"id": "Anistreplase_INT_Bivalirudin", "text": "Interaction: Anistreplase AND Bivalirudin\nDetails: Anistreplase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Anistreplase + Bivalirudin"}, {"id": "Anistreplase_INT_Abciximab", "text": "Interaction: Anistreplase AND Abciximab\nDetails: Anistreplase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Anistreplase + Abciximab"}, {"id": "Anistreplase_INT_Becaplermin", "text": "Interaction: Anistreplase AND Becaplermin\nDetails: Anistreplase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Anistreplase + Becaplermin"}, {"id": "Anistreplase_INT_Dicoumarol", "text": "Interaction: Anistreplase AND Dicoumarol\nDetails: Anistreplase may increase the anticoagulant activities of Dicoumarol.\nRisk: Monitor closely.", "source": "Anistreplase + Dicoumarol"}, {"id": "Anistreplase_INT_Argatroban", "text": "Interaction: Anistreplase AND Argatroban\nDetails: Anistreplase may increase the anticoagulant activities of Argatroban.\nRisk: Monitor closely.", "source": "Anistreplase + Argatroban"}, {"id": "Anistreplase_INT_Ardeparin", "text": "Interaction: Anistreplase AND Ardeparin\nDetails: Anistreplase may increase the anticoagulant activities of Ardeparin.\nRisk: Monitor closely.", "source": "Anistreplase + Ardeparin"}, {"id": "Anistreplase_INT_Phenindione", "text": "Interaction: Anistreplase AND Phenindione\nDetails: Anistreplase may increase the anticoagulant activities of Phenindione.\nRisk: Monitor closely.", "source": "Anistreplase + Phenindione"}, {"id": "Anistreplase_INT_Fondaparinux sodium", "text": "Interaction: Anistreplase AND Fondaparinux sodium\nDetails: Anistreplase may increase the anticoagulant activities of Fondaparinux sodium.\nRisk: Monitor closely.", "source": "Anistreplase + Fondaparinux sodium"}, {"id": "Anistreplase_INT_Warfarin", "text": "Interaction: Anistreplase AND Warfarin\nDetails: Anistreplase may increase the anticoagulant activities of Warfarin.\nRisk: Monitor closely.", "source": "Anistreplase + Warfarin"}, {"id": "Anistreplase_INT_Pentosan Polysulfate", "text": "Interaction: Anistreplase AND Pentosan Polysulfate\nDetails: Anistreplase may increase the anticoagulant activities of Pentosan Polysulfate.\nRisk: Monitor closely.", "source": "Anistreplase + Pentosan Polysulfate"}, {"id": "Anistreplase_INT_Phenprocoumon", "text": "Interaction: Anistreplase AND Phenprocoumon\nDetails: Anistreplase may increase the anticoagulant activities of Phenprocoumon.\nRisk: Monitor closely.", "source": "Anistreplase + Phenprocoumon"}, {"id": "Anistreplase_INT_Edetic Acid", "text": "Interaction: Anistreplase AND Edetic Acid\nDetails: Anistreplase may increase the anticoagulant activities of Edetic Acid.\nRisk: Monitor closely.", "source": "Anistreplase + Edetic Acid"}, {"id": "Anistreplase_INT_Heparin", "text": "Interaction: Anistreplase AND Heparin\nDetails: Anistreplase may increase the anticoagulant activities of Heparin.\nRisk: Monitor closely.", "source": "Anistreplase + Heparin"}, {"id": "Anistreplase_INT_Enoxaparin", "text": "Interaction: Anistreplase AND Enoxaparin\nDetails: Anistreplase may increase the anticoagulant activities of Enoxaparin.\nRisk: Monitor closely.", "source": "Anistreplase + Enoxaparin"}, {"id": "Anistreplase_INT_Acenocoumarol", "text": "Interaction: Anistreplase AND Acenocoumarol\nDetails: Anistreplase may increase the anticoagulant activities of Acenocoumarol.\nRisk: Monitor closely.", "source": "Anistreplase + Acenocoumarol"}, {"id": "Anistreplase_INT_Citric Acid", "text": "Interaction: Anistreplase AND Citric Acid\nDetails: Anistreplase may increase the anticoagulant activities of Citric Acid.\nRisk: Monitor closely.", "source": "Anistreplase + Citric Acid"}, {"id": "Anistreplase_INT_Ximelagatran", "text": "Interaction: Anistreplase AND Ximelagatran\nDetails: Anistreplase may increase the anticoagulant activities of Ximelagatran.\nRisk: Monitor closely.", "source": "Anistreplase + Ximelagatran"}, {"id": "Anistreplase_INT_Ancrod", "text": "Interaction: Anistreplase AND Ancrod\nDetails: Anistreplase may increase the anticoagulant activities of Ancrod.\nRisk: Monitor closely.", "source": "Anistreplase + Ancrod"}, {"id": "Anistreplase_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Anistreplase AND Pentaerythritol Tetranitrate\nDetails: Anistreplase may increase the anticoagulant activities of Pentaerythritol Tetranitrate.\nRisk: Monitor closely.", "source": "Anistreplase + Pentaerythritol Tetranitrate"}, {"id": "Anistreplase_INT_Rivaroxaban", "text": "Interaction: Anistreplase AND Rivaroxaban\nDetails: Anistreplase may increase the anticoagulant activities of Rivaroxaban.\nRisk: Monitor closely.", "source": "Anistreplase + Rivaroxaban"}, {"id": "Anistreplase_INT_Sulodexide", "text": "Interaction: Anistreplase AND Sulodexide\nDetails: Anistreplase may increase the anticoagulant activities of Sulodexide.\nRisk: Monitor closely.", "source": "Anistreplase + Sulodexide"}, {"id": "Anistreplase_INT_Idraparinux", "text": "Interaction: Anistreplase AND Idraparinux\nDetails: Anistreplase may increase the anticoagulant activities of Idraparinux.\nRisk: Monitor closely.", "source": "Anistreplase + Idraparinux"}, {"id": "Anistreplase_INT_Apixaban", "text": "Interaction: Anistreplase AND Apixaban\nDetails: Anistreplase may increase the anticoagulant activities of Apixaban.\nRisk: Monitor closely.", "source": "Anistreplase + Apixaban"}, {"id": "Anistreplase_INT_Otamixaban", "text": "Interaction: Anistreplase AND Otamixaban\nDetails: Anistreplase may increase the anticoagulant activities of Otamixaban.\nRisk: Monitor closely.", "source": "Anistreplase + Otamixaban"}, {"id": "Anistreplase_INT_Danaparoid", "text": "Interaction: Anistreplase AND Danaparoid\nDetails: Anistreplase may increase the anticoagulant activities of Danaparoid.\nRisk: Monitor closely.", "source": "Anistreplase + Danaparoid"}, {"id": "Anistreplase_INT_Dalteparin", "text": "Interaction: Anistreplase AND Dalteparin\nDetails: Anistreplase may increase the anticoagulant activities of Dalteparin.\nRisk: Monitor closely.", "source": "Anistreplase + Dalteparin"}, {"id": "Anistreplase_INT_Ferulic acid", "text": "Interaction: Anistreplase AND Ferulic acid\nDetails: Anistreplase may increase the anticoagulant activities of Ferulic acid.\nRisk: Monitor closely.", "source": "Anistreplase + Ferulic acid"}, {"id": "Anistreplase_INT_Ethyl biscoumacetate", "text": "Interaction: Anistreplase AND Ethyl biscoumacetate\nDetails: Anistreplase may increase the anticoagulant activities of Ethyl biscoumacetate.\nRisk: Monitor closely.", "source": "Anistreplase + Ethyl biscoumacetate"}, {"id": "Anistreplase_INT_Nadroparin", "text": "Interaction: Anistreplase AND Nadroparin\nDetails: Anistreplase may increase the anticoagulant activities of Nadroparin.\nRisk: Monitor closely.", "source": "Anistreplase + Nadroparin"}, {"id": "Anistreplase_INT_Edoxaban", "text": "Interaction: Anistreplase AND Edoxaban\nDetails: Anistreplase may increase the anticoagulant activities of Edoxaban.\nRisk: Monitor closely.", "source": "Anistreplase + Edoxaban"}, {"id": "Anistreplase_INT_Dextran", "text": "Interaction: Anistreplase AND Dextran\nDetails: Anistreplase may increase the anticoagulant activities of Dextran.\nRisk: Monitor closely.", "source": "Anistreplase + Dextran"}, {"id": "Anistreplase_INT_Reviparin", "text": "Interaction: Anistreplase AND Reviparin\nDetails: Anistreplase may increase the anticoagulant activities of Reviparin.\nRisk: Monitor closely.", "source": "Anistreplase + Reviparin"}, {"id": "Anistreplase_INT_Certoparin", "text": "Interaction: Anistreplase AND Certoparin\nDetails: Anistreplase may increase the anticoagulant activities of Certoparin.\nRisk: Monitor closely.", "source": "Anistreplase + Certoparin"}, {"id": "Anistreplase_INT_Dextran 70", "text": "Interaction: Anistreplase AND Dextran 70\nDetails: Anistreplase may increase the anticoagulant activities of Dextran 70.\nRisk: Monitor closely.", "source": "Anistreplase + Dextran 70"}, {"id": "Anistreplase_INT_Desirudin", "text": "Interaction: Anistreplase AND Desirudin\nDetails: Anistreplase may increase the anticoagulant activities of Desirudin.\nRisk: Monitor closely.", "source": "Anistreplase + Desirudin"}, {"id": "Anistreplase_INT_Dextran 40", "text": "Interaction: Anistreplase AND Dextran 40\nDetails: Anistreplase may increase the anticoagulant activities of Dextran 40.\nRisk: Monitor closely.", "source": "Anistreplase + Dextran 40"}, {"id": "Anistreplase_INT_Dextran 75", "text": "Interaction: Anistreplase AND Dextran 75\nDetails: Anistreplase may increase the anticoagulant activities of Dextran 75.\nRisk: Monitor closely.", "source": "Anistreplase + Dextran 75"}, {"id": "Anistreplase_INT_Protocatechualdehyde", "text": "Interaction: Anistreplase AND Protocatechualdehyde\nDetails: Anistreplase may increase the anticoagulant activities of Protocatechualdehyde.\nRisk: Monitor closely.", "source": "Anistreplase + Protocatechualdehyde"}, {"id": "Anistreplase_INT_Protein C", "text": "Interaction: Anistreplase AND Protein C\nDetails: Anistreplase may increase the anticoagulant activities of Protein C.\nRisk: Monitor closely.", "source": "Anistreplase + Protein C"}, {"id": "Anistreplase_INT_Antithrombin III human", "text": "Interaction: Anistreplase AND Antithrombin III human\nDetails: Anistreplase may increase the anticoagulant activities of Antithrombin III human.\nRisk: Monitor closely.", "source": "Anistreplase + Antithrombin III human"}, {"id": "Anistreplase_INT_Fondaparinux", "text": "Interaction: Anistreplase AND Fondaparinux\nDetails: Anistreplase may increase the anticoagulant activities of Fondaparinux.\nRisk: Monitor closely.", "source": "Anistreplase + Fondaparinux"}, {"id": "Anistreplase_INT_Letaxaban", "text": "Interaction: Anistreplase AND Letaxaban\nDetails: Anistreplase may increase the anticoagulant activities of Letaxaban.\nRisk: Monitor closely.", "source": "Anistreplase + Letaxaban"}, {"id": "Anistreplase_INT_Darexaban", "text": "Interaction: Anistreplase AND Darexaban\nDetails: Anistreplase may increase the anticoagulant activities of Darexaban.\nRisk: Monitor closely.", "source": "Anistreplase + Darexaban"}, {"id": "Anistreplase_INT_Nafamostat", "text": "Interaction: Anistreplase AND Nafamostat\nDetails: Anistreplase may increase the anticoagulant activities of Nafamostat.\nRisk: Monitor closely.", "source": "Anistreplase + Nafamostat"}, {"id": "Anistreplase_INT_Gabexate", "text": "Interaction: Anistreplase AND Gabexate\nDetails: Anistreplase may increase the anticoagulant activities of Gabexate.\nRisk: Monitor closely.", "source": "Anistreplase + Gabexate"}, {"id": "Anistreplase_INT_Troxerutin", "text": "Interaction: Anistreplase AND Troxerutin\nDetails: Anistreplase may increase the anticoagulant activities of Troxerutin.\nRisk: Monitor closely.", "source": "Anistreplase + Troxerutin"}, {"id": "Anistreplase_INT_Fluindione", "text": "Interaction: Anistreplase AND Fluindione\nDetails: Anistreplase may increase the anticoagulant activities of Fluindione.\nRisk: Monitor closely.", "source": "Anistreplase + Fluindione"}, {"id": "Anistreplase_INT_Protein S human", "text": "Interaction: Anistreplase AND Protein S human\nDetails: Anistreplase may increase the anticoagulant activities of Protein S human.\nRisk: Monitor closely.", "source": "Anistreplase + Protein S human"}, {"id": "Anistreplase_INT_Melagatran", "text": "Interaction: Anistreplase AND Melagatran\nDetails: Anistreplase may increase the anticoagulant activities of Melagatran.\nRisk: Monitor closely.", "source": "Anistreplase + Melagatran"}, {"id": "Anistreplase_INT_Salicylic acid", "text": "Interaction: Anistreplase AND Salicylic acid\nDetails: The risk or severity of adverse effects can be increased when Salicylic acid is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Salicylic acid"}, {"id": "Anistreplase_INT_Acetylsalicylic acid", "text": "Interaction: Anistreplase AND Acetylsalicylic acid\nDetails: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Acetylsalicylic acid"}, {"id": "Anistreplase_INT_Aminosalicylic Acid", "text": "Interaction: Anistreplase AND Aminosalicylic Acid\nDetails: The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Aminosalicylic Acid"}, {"id": "Anistreplase_INT_Mesalazine", "text": "Interaction: Anistreplase AND Mesalazine\nDetails: The risk or severity of adverse effects can be increased when Mesalazine is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Mesalazine"}, {"id": "Anistreplase_INT_Diflunisal", "text": "Interaction: Anistreplase AND Diflunisal\nDetails: The risk or severity of adverse effects can be increased when Diflunisal is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Diflunisal"}, {"id": "Anistreplase_INT_Balsalazide", "text": "Interaction: Anistreplase AND Balsalazide\nDetails: The risk or severity of adverse effects can be increased when Balsalazide is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Balsalazide"}, {"id": "Anistreplase_INT_Olsalazine", "text": "Interaction: Anistreplase AND Olsalazine\nDetails: The risk or severity of adverse effects can be increased when Olsalazine is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Olsalazine"}, {"id": "Anistreplase_INT_dersalazine", "text": "Interaction: Anistreplase AND dersalazine\nDetails: The risk or severity of adverse effects can be increased when dersalazine is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + dersalazine"}, {"id": "Anistreplase_INT_Nitroaspirin", "text": "Interaction: Anistreplase AND Nitroaspirin\nDetails: The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Nitroaspirin"}, {"id": "Anistreplase_INT_Aloxiprin", "text": "Interaction: Anistreplase AND Aloxiprin\nDetails: The risk or severity of adverse effects can be increased when Aloxiprin is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Aloxiprin"}, {"id": "Anistreplase_INT_Guacetisal", "text": "Interaction: Anistreplase AND Guacetisal\nDetails: The risk or severity of adverse effects can be increased when Guacetisal is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Guacetisal"}, {"id": "Anistreplase_INT_Carbaspirin calcium", "text": "Interaction: Anistreplase AND Carbaspirin calcium\nDetails: The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Carbaspirin calcium"}, {"id": "Anistreplase_INT_Hemoglobin crosfumaril", "text": "Interaction: Anistreplase AND Hemoglobin crosfumaril\nDetails: The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Hemoglobin crosfumaril"}, {"id": "Anistreplase_INT_Methyl salicylate", "text": "Interaction: Anistreplase AND Methyl salicylate\nDetails: The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Methyl salicylate"}, {"id": "Anistreplase_INT_Trolamine salicylate", "text": "Interaction: Anistreplase AND Trolamine salicylate\nDetails: The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Trolamine salicylate"}, {"id": "Anistreplase_INT_Eptifibatide", "text": "Interaction: Anistreplase AND Eptifibatide\nDetails: Eptifibatide may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Eptifibatide"}, {"id": "Anistreplase_INT_Ticlopidine", "text": "Interaction: Anistreplase AND Ticlopidine\nDetails: Ticlopidine may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Ticlopidine"}, {"id": "Anistreplase_INT_Tirofiban", "text": "Interaction: Anistreplase AND Tirofiban\nDetails: Tirofiban may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Tirofiban"}, {"id": "Anistreplase_INT_Dipyridamole", "text": "Interaction: Anistreplase AND Dipyridamole\nDetails: Dipyridamole may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Dipyridamole"}, {"id": "Anistreplase_INT_Clopidogrel", "text": "Interaction: Anistreplase AND Clopidogrel\nDetails: Clopidogrel may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Clopidogrel"}, {"id": "Anistreplase_INT_Prasugrel", "text": "Interaction: Anistreplase AND Prasugrel\nDetails: Prasugrel may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Prasugrel"}, {"id": "Anistreplase_INT_Vorapaxar", "text": "Interaction: Anistreplase AND Vorapaxar\nDetails: Vorapaxar may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Vorapaxar"}, {"id": "Anistreplase_INT_Milrinone", "text": "Interaction: Anistreplase AND Milrinone\nDetails: Milrinone may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Milrinone"}, {"id": "Anistreplase_INT_Anagrelide", "text": "Interaction: Anistreplase AND Anagrelide\nDetails: Anagrelide may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Anagrelide"}, {"id": "Anistreplase_INT_Epinastine", "text": "Interaction: Anistreplase AND Epinastine\nDetails: Epinastine may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Epinastine"}, {"id": "Anistreplase_INT_Alprostadil", "text": "Interaction: Anistreplase AND Alprostadil\nDetails: Alprostadil may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Alprostadil"}, {"id": "Anistreplase_INT_Pentoxifylline", "text": "Interaction: Anistreplase AND Pentoxifylline\nDetails: Pentoxifylline may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Pentoxifylline"}, {"id": "Anistreplase_INT_Azelastine", "text": "Interaction: Anistreplase AND Azelastine\nDetails: Azelastine may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Azelastine"}, {"id": "Anistreplase_INT_Iloprost", "text": "Interaction: Anistreplase AND Iloprost\nDetails: Iloprost may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Iloprost"}, {"id": "Anistreplase_INT_Cilostazol", "text": "Interaction: Anistreplase AND Cilostazol\nDetails: Cilostazol may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Cilostazol"}, {"id": "Anistreplase_INT_Ridogrel", "text": "Interaction: Anistreplase AND Ridogrel\nDetails: Ridogrel may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Ridogrel"}, {"id": "Anistreplase_INT_Sevoflurane", "text": "Interaction: Anistreplase AND Sevoflurane\nDetails: Sevoflurane may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Sevoflurane"}, {"id": "Anistreplase_INT_Epoprostenol", "text": "Interaction: Anistreplase AND Epoprostenol\nDetails: Epoprostenol may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Epoprostenol"}, {"id": "Anistreplase_INT_Resveratrol", "text": "Interaction: Anistreplase AND Resveratrol\nDetails: Resveratrol may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Resveratrol"}, {"id": "Anistreplase_INT_Nimesulide", "text": "Interaction: Anistreplase AND Nimesulide\nDetails: Nimesulide may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Nimesulide"}, {"id": "Anistreplase_INT_Tesmilifene", "text": "Interaction: Anistreplase AND Tesmilifene\nDetails: Tesmilifene may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Tesmilifene"}, {"id": "Anistreplase_INT_Defibrotide", "text": "Interaction: Anistreplase AND Defibrotide\nDetails: Defibrotide may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Defibrotide"}, {"id": "Anistreplase_INT_SRT501", "text": "Interaction: Anistreplase AND SRT501\nDetails: SRT501 may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + SRT501"}, {"id": "Anistreplase_INT_Beraprost", "text": "Interaction: Anistreplase AND Beraprost\nDetails: Beraprost may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Beraprost"}, {"id": "Anistreplase_INT_Ibudilast", "text": "Interaction: Anistreplase AND Ibudilast\nDetails: Ibudilast may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Ibudilast"}, {"id": "Anistreplase_INT_Andrographolide", "text": "Interaction: Anistreplase AND Andrographolide\nDetails: Andrographolide may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Andrographolide"}, {"id": "Anistreplase_INT_eplivanserine", "text": "Interaction: Anistreplase AND eplivanserine\nDetails: eplivanserine may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + eplivanserine"}, {"id": "Anistreplase_INT_Cangrelor", "text": "Interaction: Anistreplase AND Cangrelor\nDetails: Cangrelor may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Cangrelor"}, {"id": "Anistreplase_INT_Tranilast", "text": "Interaction: Anistreplase AND Tranilast\nDetails: Tranilast may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Tranilast"}, {"id": "Anistreplase_INT_Triflusal", "text": "Interaction: Anistreplase AND Triflusal\nDetails: Triflusal may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Triflusal"}, {"id": "Anistreplase_INT_Icosapent ethyl", "text": "Interaction: Anistreplase AND Icosapent ethyl\nDetails: Icosapent ethyl may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Icosapent ethyl"}, {"id": "Anistreplase_INT_Ifenprodil", "text": "Interaction: Anistreplase AND Ifenprodil\nDetails: Ifenprodil may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Ifenprodil"}, {"id": "Anistreplase_INT_Trapidil", "text": "Interaction: Anistreplase AND Trapidil\nDetails: Trapidil may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Trapidil"}, {"id": "Anistreplase_INT_Naftopidil", "text": "Interaction: Anistreplase AND Naftopidil\nDetails: Naftopidil may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Naftopidil"}, {"id": "Anistreplase_INT_Sarpogrelate", "text": "Interaction: Anistreplase AND Sarpogrelate\nDetails: Sarpogrelate may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Sarpogrelate"}, {"id": "Anistreplase_INT_Eplivanserin", "text": "Interaction: Anistreplase AND Eplivanserin\nDetails: Eplivanserin may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Eplivanserin"}, {"id": "Anistreplase_INT_Ifetroban", "text": "Interaction: Anistreplase AND Ifetroban\nDetails: Ifetroban may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Ifetroban"}, {"id": "Anistreplase_INT_Ketanserin", "text": "Interaction: Anistreplase AND Ketanserin\nDetails: Ketanserin may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Ketanserin"}, {"id": "Anistreplase_INT_Indobufen", "text": "Interaction: Anistreplase AND Indobufen\nDetails: Indobufen may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Indobufen"}, {"id": "Anistreplase_INT_Butylphthalide", "text": "Interaction: Anistreplase AND Butylphthalide\nDetails: Butylphthalide may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Butylphthalide"}, {"id": "Anistreplase_INT_Hydroxytyrosol", "text": "Interaction: Anistreplase AND Hydroxytyrosol\nDetails: Hydroxytyrosol may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Hydroxytyrosol"}, {"id": "Anistreplase_INT_Ramatroban", "text": "Interaction: Anistreplase AND Ramatroban\nDetails: Ramatroban may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Ramatroban"}, {"id": "Anistreplase_INT_Picotamide", "text": "Interaction: Anistreplase AND Picotamide\nDetails: Picotamide may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Picotamide"}, {"id": "Anistreplase_INT_Cloricromen", "text": "Interaction: Anistreplase AND Cloricromen\nDetails: Cloricromen may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Cloricromen"}, {"id": "Anistreplase_INT_Linsidomine", "text": "Interaction: Anistreplase AND Linsidomine\nDetails: Linsidomine may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Linsidomine"}, {"id": "Anistreplase_INT_Buflomedil", "text": "Interaction: Anistreplase AND Buflomedil\nDetails: Buflomedil may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Buflomedil"}, {"id": "Anistreplase_INT_Relcovaptan", "text": "Interaction: Anistreplase AND Relcovaptan\nDetails: Relcovaptan may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Relcovaptan"}, {"id": "Anistreplase_INT_Ticagrelor", "text": "Interaction: Anistreplase AND Ticagrelor\nDetails: Ticagrelor may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Anistreplase + Ticagrelor"}, {"id": "Anistreplase_INT_Treprostinil", "text": "Interaction: Anistreplase AND Treprostinil\nDetails: The risk or severity of adverse effects can be increased when Anistreplase is combined with Treprostinil.\nRisk: Monitor closely.", "source": "Anistreplase + Treprostinil"}, {"id": "Insulin Human_GEN", "text": "Drug: Insulin Human\nDescription: Insulin human is a 51 residue peptide hormone, composed of two amino acid chains covalently linked by disulfide bonds. The structure is identical to native human insulin. Recombinant insulin is synthesized by recombinant DNA techncology. Inserting the human insulin gene into the Escherichia coli bac...", "source": "Insulin Human"}, {"id": "Insulin Human_CLIN", "text": "Drug: Insulin Human\nMechanism: The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It al...\nToxicity: Hypoglycemia is one of the most frequent adverse events experienced by insulin users. ...", "source": "Insulin Human"}, {"id": "Insulin Human_INT_Rosiglitazone", "text": "Interaction: Insulin Human AND Rosiglitazone\nDetails: The risk or severity of myocardial ischemia can be increased when Insulin Human is combined with Rosiglitazone.\nRisk: Monitor closely.", "source": "Insulin Human + Rosiglitazone"}, {"id": "Insulin Human_INT_Pregabalin", "text": "Interaction: Insulin Human AND Pregabalin\nDetails: The risk or severity of heart failure can be increased when Pregabalin is combined with Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Pregabalin"}, {"id": "Insulin Human_INT_Sitagliptin", "text": "Interaction: Insulin Human AND Sitagliptin\nDetails: Sitagliptin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Sitagliptin"}, {"id": "Insulin Human_INT_Vildagliptin", "text": "Interaction: Insulin Human AND Vildagliptin\nDetails: Vildagliptin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Vildagliptin"}, {"id": "Insulin Human_INT_Alogliptin", "text": "Interaction: Insulin Human AND Alogliptin\nDetails: Alogliptin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Alogliptin"}, {"id": "Insulin Human_INT_Saxagliptin", "text": "Interaction: Insulin Human AND Saxagliptin\nDetails: Saxagliptin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Saxagliptin"}, {"id": "Insulin Human_INT_Atorvastatin", "text": "Interaction: Insulin Human AND Atorvastatin\nDetails: Atorvastatin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Atorvastatin"}, {"id": "Insulin Human_INT_Linagliptin", "text": "Interaction: Insulin Human AND Linagliptin\nDetails: Linagliptin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Linagliptin"}, {"id": "Insulin Human_INT_Exenatide", "text": "Interaction: Insulin Human AND Exenatide\nDetails: Exenatide may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Exenatide"}, {"id": "Insulin Human_INT_Albiglutide", "text": "Interaction: Insulin Human AND Albiglutide\nDetails: Albiglutide may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Albiglutide"}, {"id": "Insulin Human_INT_Dulaglutide", "text": "Interaction: Insulin Human AND Dulaglutide\nDetails: Dulaglutide may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Dulaglutide"}, {"id": "Insulin Human_INT_Canagliflozin", "text": "Interaction: Insulin Human AND Canagliflozin\nDetails: Canagliflozin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Canagliflozin"}, {"id": "Insulin Human_INT_Empagliflozin", "text": "Interaction: Insulin Human AND Empagliflozin\nDetails: Empagliflozin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Empagliflozin"}, {"id": "Insulin Human_INT_Liraglutide", "text": "Interaction: Insulin Human AND Liraglutide\nDetails: Liraglutide may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Liraglutide"}, {"id": "Insulin Human_INT_Metreleptin", "text": "Interaction: Insulin Human AND Metreleptin\nDetails: Metreleptin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Metreleptin"}, {"id": "Insulin Human_INT_Pioglitazone", "text": "Interaction: Insulin Human AND Pioglitazone\nDetails: The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Pioglitazone"}, {"id": "Insulin Human_INT_Pramlintide", "text": "Interaction: Insulin Human AND Pramlintide\nDetails: Pramlintide may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Pramlintide"}, {"id": "Insulin Human_INT_Lipoic Acid", "text": "Interaction: Insulin Human AND Lipoic Acid\nDetails: Lipoic Acid may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Lipoic Acid"}, {"id": "Insulin Human_INT_Edetic Acid", "text": "Interaction: Insulin Human AND Edetic Acid\nDetails: Edetic Acid may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Edetic Acid"}, {"id": "Insulin Human_INT_Insulin Lispro", "text": "Interaction: Insulin Human AND Insulin Lispro\nDetails: Insulin Human may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Human + Insulin Lispro"}, {"id": "Insulin Human_INT_Insulin Glargine", "text": "Interaction: Insulin Human AND Insulin Glargine\nDetails: Insulin Human may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Human + Insulin Glargine"}, {"id": "Insulin Human_INT_Octreotide", "text": "Interaction: Insulin Human AND Octreotide\nDetails: Insulin Human may increase the hypoglycemic activities of Octreotide.\nRisk: Monitor closely.", "source": "Insulin Human + Octreotide"}, {"id": "Insulin Human_INT_Glimepiride", "text": "Interaction: Insulin Human AND Glimepiride\nDetails: Insulin Human may increase the hypoglycemic activities of Glimepiride.\nRisk: Monitor closely.", "source": "Insulin Human + Glimepiride"}, {"id": "Insulin Human_INT_Sulfisoxazole", "text": "Interaction: Insulin Human AND Sulfisoxazole\nDetails: Insulin Human may increase the hypoglycemic activities of Sulfisoxazole.\nRisk: Monitor closely.", "source": "Insulin Human + Sulfisoxazole"}, {"id": "Insulin Human_INT_Disopyramide", "text": "Interaction: Insulin Human AND Disopyramide\nDetails: Insulin Human may increase the hypoglycemic activities of Disopyramide.\nRisk: Monitor closely.", "source": "Insulin Human + Disopyramide"}, {"id": "Insulin Human_INT_Sulfadiazine", "text": "Interaction: Insulin Human AND Sulfadiazine\nDetails: Insulin Human may increase the hypoglycemic activities of Sulfadiazine.\nRisk: Monitor closely.", "source": "Insulin Human + Sulfadiazine"}, {"id": "Insulin Human_INT_Quinine", "text": "Interaction: Insulin Human AND Quinine\nDetails: Insulin Human may increase the hypoglycemic activities of Quinine.\nRisk: Monitor closely.", "source": "Insulin Human + Quinine"}, {"id": "Insulin Human_INT_Chlorpropamide", "text": "Interaction: Insulin Human AND Chlorpropamide\nDetails: Insulin Human may increase the hypoglycemic activities of Chlorpropamide.\nRisk: Monitor closely.", "source": "Insulin Human + Chlorpropamide"}, {"id": "Insulin Human_INT_Nateglinide", "text": "Interaction: Insulin Human AND Nateglinide\nDetails: Insulin Human may increase the hypoglycemic activities of Nateglinide.\nRisk: Monitor closely.", "source": "Insulin Human + Nateglinide"}, {"id": "Insulin Human_INT_Pentamidine", "text": "Interaction: Insulin Human AND Pentamidine\nDetails: Insulin Human may increase the hypoglycemic activities of Pentamidine.\nRisk: Monitor closely.", "source": "Insulin Human + Pentamidine"}, {"id": "Insulin Human_INT_Mifepristone", "text": "Interaction: Insulin Human AND Mifepristone\nDetails: Insulin Human may increase the hypoglycemic activities of Mifepristone.\nRisk: Monitor closely.", "source": "Insulin Human + Mifepristone"}, {"id": "Insulin Human_INT_Tolazamide", "text": "Interaction: Insulin Human AND Tolazamide\nDetails: Insulin Human may increase the hypoglycemic activities of Tolazamide.\nRisk: Monitor closely.", "source": "Insulin Human + Tolazamide"}, {"id": "Insulin Human_INT_Repaglinide", "text": "Interaction: Insulin Human AND Repaglinide\nDetails: Insulin Human may increase the hypoglycemic activities of Repaglinide.\nRisk: Monitor closely.", "source": "Insulin Human + Repaglinide"}, {"id": "Insulin Human_INT_Sulfamethoxazole", "text": "Interaction: Insulin Human AND Sulfamethoxazole\nDetails: Insulin Human may increase the hypoglycemic activities of Sulfamethoxazole.\nRisk: Monitor closely.", "source": "Insulin Human + Sulfamethoxazole"}, {"id": "Insulin Human_INT_Glyburide", "text": "Interaction: Insulin Human AND Glyburide\nDetails: Insulin Human may increase the hypoglycemic activities of Glyburide.\nRisk: Monitor closely.", "source": "Insulin Human + Glyburide"}, {"id": "Insulin Human_INT_Glipizide", "text": "Interaction: Insulin Human AND Glipizide\nDetails: Insulin Human may increase the hypoglycemic activities of Glipizide.\nRisk: Monitor closely.", "source": "Insulin Human + Glipizide"}, {"id": "Insulin Human_INT_Gliclazide", "text": "Interaction: Insulin Human AND Gliclazide\nDetails: Insulin Human may increase the hypoglycemic activities of Gliclazide.\nRisk: Monitor closely.", "source": "Insulin Human + Gliclazide"}, {"id": "Insulin Human_INT_Tolbutamide", "text": "Interaction: Insulin Human AND Tolbutamide\nDetails: Insulin Human may increase the hypoglycemic activities of Tolbutamide.\nRisk: Monitor closely.", "source": "Insulin Human + Tolbutamide"}, {"id": "Insulin Human_INT_Sunitinib", "text": "Interaction: Insulin Human AND Sunitinib\nDetails: Insulin Human may increase the hypoglycemic activities of Sunitinib.\nRisk: Monitor closely.", "source": "Insulin Human + Sunitinib"}, {"id": "Insulin Human_INT_Mecasermin", "text": "Interaction: Insulin Human AND Mecasermin\nDetails: Insulin Human may increase the hypoglycemic activities of Mecasermin.\nRisk: Monitor closely.", "source": "Insulin Human + Mecasermin"}, {"id": "Insulin Human_INT_Insulin Aspart", "text": "Interaction: Insulin Human AND Insulin Aspart\nDetails: Insulin Human may increase the hypoglycemic activities of Insulin Aspart.\nRisk: Monitor closely.", "source": "Insulin Human + Insulin Aspart"}, {"id": "Insulin Human_INT_Insulin Detemir", "text": "Interaction: Insulin Human AND Insulin Detemir\nDetails: Insulin Human may increase the hypoglycemic activities of Insulin Detemir.\nRisk: Monitor closely.", "source": "Insulin Human + Insulin Detemir"}, {"id": "Insulin Human_INT_Insulin Glulisine", "text": "Interaction: Insulin Human AND Insulin Glulisine\nDetails: Insulin Human may increase the hypoglycemic activities of Insulin Glulisine.\nRisk: Monitor closely.", "source": "Insulin Human + Insulin Glulisine"}, {"id": "Insulin Human_INT_Pasireotide", "text": "Interaction: Insulin Human AND Pasireotide\nDetails: Insulin Human may increase the hypoglycemic activities of Pasireotide.\nRisk: Monitor closely.", "source": "Insulin Human + Pasireotide"}, {"id": "Insulin Human_INT_Lanreotide", "text": "Interaction: Insulin Human AND Lanreotide\nDetails: Insulin Human may increase the hypoglycemic activities of Lanreotide.\nRisk: Monitor closely.", "source": "Insulin Human + Lanreotide"}, {"id": "Insulin Human_INT_Tranylcypromine", "text": "Interaction: Insulin Human AND Tranylcypromine\nDetails: Tranylcypromine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Tranylcypromine"}, {"id": "Insulin Human_INT_Phenelzine", "text": "Interaction: Insulin Human AND Phenelzine\nDetails: Phenelzine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Phenelzine"}, {"id": "Insulin Human_INT_Minaprine", "text": "Interaction: Insulin Human AND Minaprine\nDetails: Minaprine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Minaprine"}, {"id": "Insulin Human_INT_Selegiline", "text": "Interaction: Insulin Human AND Selegiline\nDetails: Selegiline may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Selegiline"}, {"id": "Insulin Human_INT_Moclobemide", "text": "Interaction: Insulin Human AND Moclobemide\nDetails: Moclobemide may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Moclobemide"}, {"id": "Insulin Human_INT_Isocarboxazid", "text": "Interaction: Insulin Human AND Isocarboxazid\nDetails: Isocarboxazid may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Isocarboxazid"}, {"id": "Insulin Human_INT_Rasagiline", "text": "Interaction: Insulin Human AND Rasagiline\nDetails: Rasagiline may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Rasagiline"}, {"id": "Insulin Human_INT_Pargyline", "text": "Interaction: Insulin Human AND Pargyline\nDetails: Pargyline may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Pargyline"}, {"id": "Insulin Human_INT_Nialamide", "text": "Interaction: Insulin Human AND Nialamide\nDetails: Nialamide may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Nialamide"}, {"id": "Insulin Human_INT_Pirlindole", "text": "Interaction: Insulin Human AND Pirlindole\nDetails: Pirlindole may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Pirlindole"}, {"id": "Insulin Human_INT_Toloxatone", "text": "Interaction: Insulin Human AND Toloxatone\nDetails: Toloxatone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Toloxatone"}, {"id": "Insulin Human_INT_Iproniazid", "text": "Interaction: Insulin Human AND Iproniazid\nDetails: Iproniazid may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Iproniazid"}, {"id": "Insulin Human_INT_Furazolidone", "text": "Interaction: Insulin Human AND Furazolidone\nDetails: Furazolidone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Furazolidone"}, {"id": "Insulin Human_INT_Trans-2-Phenylcyclopropylamine", "text": "Interaction: Insulin Human AND Trans-2-Phenylcyclopropylamine\nDetails: Trans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Trans-2-Phenylcyclopropylamine"}, {"id": "Insulin Human_INT_7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline", "text": "Interaction: Insulin Human AND 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline\nDetails: 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline"}, {"id": "Insulin Human_INT_Harmaline", "text": "Interaction: Insulin Human AND Harmaline\nDetails: Harmaline may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Harmaline"}, {"id": "Insulin Human_INT_Brofaromine", "text": "Interaction: Insulin Human AND Brofaromine\nDetails: Brofaromine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Brofaromine"}, {"id": "Insulin Human_INT_Amphetamine", "text": "Interaction: Insulin Human AND Amphetamine\nDetails: Amphetamine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Amphetamine"}, {"id": "Insulin Human_INT_Procarbazine", "text": "Interaction: Insulin Human AND Procarbazine\nDetails: Procarbazine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Procarbazine"}, {"id": "Insulin Human_INT_Hydracarbazine", "text": "Interaction: Insulin Human AND Hydracarbazine\nDetails: Hydracarbazine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Hydracarbazine"}, {"id": "Insulin Human_INT_Methylene blue", "text": "Interaction: Insulin Human AND Methylene blue\nDetails: Methylene blue may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Methylene blue"}, {"id": "Insulin Human_INT_Benmoxin", "text": "Interaction: Insulin Human AND Benmoxin\nDetails: Benmoxin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Benmoxin"}, {"id": "Insulin Human_INT_Iproclozide", "text": "Interaction: Insulin Human AND Iproclozide\nDetails: Iproclozide may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Iproclozide"}, {"id": "Insulin Human_INT_Mebanazine", "text": "Interaction: Insulin Human AND Mebanazine\nDetails: Mebanazine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Mebanazine"}, {"id": "Insulin Human_INT_Octamoxin", "text": "Interaction: Insulin Human AND Octamoxin\nDetails: Octamoxin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Octamoxin"}, {"id": "Insulin Human_INT_Pheniprazine", "text": "Interaction: Insulin Human AND Pheniprazine\nDetails: Pheniprazine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Pheniprazine"}, {"id": "Insulin Human_INT_Phenoxypropazine", "text": "Interaction: Insulin Human AND Phenoxypropazine\nDetails: Phenoxypropazine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Phenoxypropazine"}, {"id": "Insulin Human_INT_Pivhydrazine", "text": "Interaction: Insulin Human AND Pivhydrazine\nDetails: Pivhydrazine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Pivhydrazine"}, {"id": "Insulin Human_INT_Safrazine", "text": "Interaction: Insulin Human AND Safrazine\nDetails: Safrazine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Safrazine"}, {"id": "Insulin Human_INT_Caroxazone", "text": "Interaction: Insulin Human AND Caroxazone\nDetails: Caroxazone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Caroxazone"}, {"id": "Insulin Human_INT_Ubidecarenone", "text": "Interaction: Insulin Human AND Ubidecarenone\nDetails: The therapeutic efficacy of Insulin Human can be increased when used in combination with Ubidecarenone.\nRisk: Monitor closely.", "source": "Insulin Human + Ubidecarenone"}, {"id": "Insulin Human_INT_Esmolol", "text": "Interaction: Insulin Human AND Esmolol\nDetails: Esmolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Esmolol"}, {"id": "Insulin Human_INT_Betaxolol", "text": "Interaction: Insulin Human AND Betaxolol\nDetails: Betaxolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Betaxolol"}, {"id": "Insulin Human_INT_Metoprolol", "text": "Interaction: Insulin Human AND Metoprolol\nDetails: Metoprolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Metoprolol"}, {"id": "Insulin Human_INT_Atenolol", "text": "Interaction: Insulin Human AND Atenolol\nDetails: Atenolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Atenolol"}, {"id": "Insulin Human_INT_Timolol", "text": "Interaction: Insulin Human AND Timolol\nDetails: Timolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Timolol"}, {"id": "Insulin Human_INT_Carteolol", "text": "Interaction: Insulin Human AND Carteolol\nDetails: Carteolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Carteolol"}, {"id": "Insulin Human_INT_Propranolol", "text": "Interaction: Insulin Human AND Propranolol\nDetails: Propranolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Propranolol"}, {"id": "Insulin Human_INT_Labetalol", "text": "Interaction: Insulin Human AND Labetalol\nDetails: Labetalol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Labetalol"}, {"id": "Insulin Human_INT_Bisoprolol", "text": "Interaction: Insulin Human AND Bisoprolol\nDetails: Bisoprolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Bisoprolol"}, {"id": "Insulin Human_INT_Pindolol", "text": "Interaction: Insulin Human AND Pindolol\nDetails: Pindolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Pindolol"}, {"id": "Insulin Human_INT_Carvedilol", "text": "Interaction: Insulin Human AND Carvedilol\nDetails: Carvedilol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Carvedilol"}, {"id": "Insulin Human_INT_Acebutolol", "text": "Interaction: Insulin Human AND Acebutolol\nDetails: Acebutolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Acebutolol"}, {"id": "Insulin Human_INT_Nadolol", "text": "Interaction: Insulin Human AND Nadolol\nDetails: Nadolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Nadolol"}, {"id": "Insulin Human_INT_Sotalol", "text": "Interaction: Insulin Human AND Sotalol\nDetails: Sotalol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Sotalol"}, {"id": "Insulin Human_INT_Nebivolol", "text": "Interaction: Insulin Human AND Nebivolol\nDetails: Nebivolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Nebivolol"}, {"id": "Insulin Human_INT_Alprenolol", "text": "Interaction: Insulin Human AND Alprenolol\nDetails: Alprenolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Alprenolol"}, {"id": "Insulin Human_INT_Bevantolol", "text": "Interaction: Insulin Human AND Bevantolol\nDetails: Bevantolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Bevantolol"}, {"id": "Insulin Human_INT_Practolol", "text": "Interaction: Insulin Human AND Practolol\nDetails: Practolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Practolol"}, {"id": "Insulin Human_INT_Penbutolol", "text": "Interaction: Insulin Human AND Penbutolol\nDetails: Penbutolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Penbutolol"}, {"id": "Insulin Human_INT_Oxprenolol", "text": "Interaction: Insulin Human AND Oxprenolol\nDetails: Oxprenolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Oxprenolol"}, {"id": "Insulin Human_INT_Platelet Activating Factor", "text": "Interaction: Insulin Human AND Platelet Activating Factor\nDetails: Platelet Activating Factor may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Platelet Activating Factor"}, {"id": "Insulin Human_INT_Celiprolol", "text": "Interaction: Insulin Human AND Celiprolol\nDetails: Celiprolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Celiprolol"}, {"id": "Insulin Human_INT_Bufuralol", "text": "Interaction: Insulin Human AND Bufuralol\nDetails: Bufuralol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Bufuralol"}, {"id": "Insulin Human_INT_Bopindolol", "text": "Interaction: Insulin Human AND Bopindolol\nDetails: Bopindolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Bopindolol"}, {"id": "Insulin Human_INT_Bupranolol", "text": "Interaction: Insulin Human AND Bupranolol\nDetails: Bupranolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Bupranolol"}, {"id": "Insulin Human_INT_Indenolol", "text": "Interaction: Insulin Human AND Indenolol\nDetails: Indenolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Indenolol"}, {"id": "Insulin Human_INT_Befunolol", "text": "Interaction: Insulin Human AND Befunolol\nDetails: Befunolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Befunolol"}, {"id": "Insulin Human_INT_Arotinolol", "text": "Interaction: Insulin Human AND Arotinolol\nDetails: Arotinolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Arotinolol"}, {"id": "Insulin Human_INT_Talinolol", "text": "Interaction: Insulin Human AND Talinolol\nDetails: Talinolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Talinolol"}, {"id": "Insulin Human_INT_Landiolol", "text": "Interaction: Insulin Human AND Landiolol\nDetails: Landiolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Landiolol"}, {"id": "Insulin Human_INT_Bucindolol", "text": "Interaction: Insulin Human AND Bucindolol\nDetails: Bucindolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Bucindolol"}, {"id": "Insulin Human_INT_Cloranolol", "text": "Interaction: Insulin Human AND Cloranolol\nDetails: Cloranolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Cloranolol"}, {"id": "Insulin Human_INT_Mepindolol", "text": "Interaction: Insulin Human AND Mepindolol\nDetails: Mepindolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Mepindolol"}, {"id": "Insulin Human_INT_Epanolol", "text": "Interaction: Insulin Human AND Epanolol\nDetails: Epanolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Epanolol"}, {"id": "Insulin Human_INT_Tertatolol", "text": "Interaction: Insulin Human AND Tertatolol\nDetails: Tertatolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Tertatolol"}, {"id": "Insulin Human_INT_Grepafloxacin", "text": "Interaction: Insulin Human AND Grepafloxacin\nDetails: Grepafloxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Grepafloxacin"}, {"id": "Insulin Human_INT_Enoxacin", "text": "Interaction: Insulin Human AND Enoxacin\nDetails: Enoxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Enoxacin"}, {"id": "Insulin Human_INT_Pefloxacin", "text": "Interaction: Insulin Human AND Pefloxacin\nDetails: Pefloxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Pefloxacin"}, {"id": "Insulin Human_INT_Trovafloxacin", "text": "Interaction: Insulin Human AND Trovafloxacin\nDetails: Trovafloxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Trovafloxacin"}, {"id": "Insulin Human_INT_Nalidixic Acid", "text": "Interaction: Insulin Human AND Nalidixic Acid\nDetails: Nalidixic Acid may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Nalidixic Acid"}, {"id": "Insulin Human_INT_Rosoxacin", "text": "Interaction: Insulin Human AND Rosoxacin\nDetails: Rosoxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Rosoxacin"}, {"id": "Insulin Human_INT_Cinoxacin", "text": "Interaction: Insulin Human AND Cinoxacin\nDetails: Cinoxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Cinoxacin"}, {"id": "Insulin Human_INT_Gatifloxacin", "text": "Interaction: Insulin Human AND Gatifloxacin\nDetails: Gatifloxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Gatifloxacin"}, {"id": "Insulin Human_INT_Norfloxacin", "text": "Interaction: Insulin Human AND Norfloxacin\nDetails: Norfloxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Norfloxacin"}, {"id": "Insulin Human_INT_Levofloxacin", "text": "Interaction: Insulin Human AND Levofloxacin\nDetails: Levofloxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Levofloxacin"}, {"id": "Insulin Human_INT_Gemifloxacin", "text": "Interaction: Insulin Human AND Gemifloxacin\nDetails: Gemifloxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Gemifloxacin"}, {"id": "Insulin Human_INT_Sparfloxacin", "text": "Interaction: Insulin Human AND Sparfloxacin\nDetails: Sparfloxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Sparfloxacin"}, {"id": "Insulin Human_INT_Temafloxacin", "text": "Interaction: Insulin Human AND Temafloxacin\nDetails: Temafloxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Temafloxacin"}, {"id": "Insulin Human_INT_Fleroxacin", "text": "Interaction: Insulin Human AND Fleroxacin\nDetails: Fleroxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Fleroxacin"}, {"id": "Insulin Human_INT_Garenoxacin", "text": "Interaction: Insulin Human AND Garenoxacin\nDetails: Garenoxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Garenoxacin"}, {"id": "Insulin Human_INT_Nemonoxacin", "text": "Interaction: Insulin Human AND Nemonoxacin\nDetails: Nemonoxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Nemonoxacin"}, {"id": "Insulin Human_INT_Flumequine", "text": "Interaction: Insulin Human AND Flumequine\nDetails: Flumequine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Flumequine"}, {"id": "Insulin Human_INT_Pazufloxacin", "text": "Interaction: Insulin Human AND Pazufloxacin\nDetails: Pazufloxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Pazufloxacin"}, {"id": "Insulin Human_INT_Prulifloxacin", "text": "Interaction: Insulin Human AND Prulifloxacin\nDetails: Prulifloxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Prulifloxacin"}, {"id": "Insulin Human_INT_Sitafloxacin", "text": "Interaction: Insulin Human AND Sitafloxacin\nDetails: Sitafloxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Sitafloxacin"}, {"id": "Insulin Human_INT_Oxolinic acid", "text": "Interaction: Insulin Human AND Oxolinic acid\nDetails: Oxolinic acid may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Oxolinic acid"}, {"id": "Insulin Human_INT_Piromidic acid", "text": "Interaction: Insulin Human AND Piromidic acid\nDetails: Piromidic acid may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Piromidic acid"}, {"id": "Insulin Human_INT_Rufloxacin", "text": "Interaction: Insulin Human AND Rufloxacin\nDetails: Rufloxacin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Rufloxacin"}, {"id": "Insulin Human_INT_Pipemidic acid", "text": "Interaction: Insulin Human AND Pipemidic acid\nDetails: Pipemidic acid may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Pipemidic acid"}, {"id": "Insulin Human_INT_Duloxetine", "text": "Interaction: Insulin Human AND Duloxetine\nDetails: Duloxetine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Duloxetine"}, {"id": "Insulin Human_INT_Nefazodone", "text": "Interaction: Insulin Human AND Nefazodone\nDetails: Nefazodone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Nefazodone"}, {"id": "Insulin Human_INT_Desvenlafaxine", "text": "Interaction: Insulin Human AND Desvenlafaxine\nDetails: Desvenlafaxine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Desvenlafaxine"}, {"id": "Insulin Human_INT_Milnacipran", "text": "Interaction: Insulin Human AND Milnacipran\nDetails: Milnacipran may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Milnacipran"}, {"id": "Insulin Human_INT_Venlafaxine", "text": "Interaction: Insulin Human AND Venlafaxine\nDetails: Venlafaxine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Venlafaxine"}, {"id": "Insulin Human_INT_Levomilnacipran", "text": "Interaction: Insulin Human AND Levomilnacipran\nDetails: Levomilnacipran may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Levomilnacipran"}, {"id": "Insulin Human_INT_Dapoxetine", "text": "Interaction: Insulin Human AND Dapoxetine\nDetails: Dapoxetine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Dapoxetine"}, {"id": "Insulin Human_INT_Indalpine", "text": "Interaction: Insulin Human AND Indalpine\nDetails: Indalpine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Indalpine"}, {"id": "Insulin Human_INT_Fluvoxamine", "text": "Interaction: Insulin Human AND Fluvoxamine\nDetails: Fluvoxamine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Fluvoxamine"}, {"id": "Insulin Human_INT_Citalopram", "text": "Interaction: Insulin Human AND Citalopram\nDetails: Citalopram may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Citalopram"}, {"id": "Insulin Human_INT_Fluoxetine", "text": "Interaction: Insulin Human AND Fluoxetine\nDetails: Fluoxetine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Fluoxetine"}, {"id": "Insulin Human_INT_Paroxetine", "text": "Interaction: Insulin Human AND Paroxetine\nDetails: Paroxetine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Paroxetine"}, {"id": "Insulin Human_INT_Sertraline", "text": "Interaction: Insulin Human AND Sertraline\nDetails: Sertraline may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Sertraline"}, {"id": "Insulin Human_INT_Escitalopram", "text": "Interaction: Insulin Human AND Escitalopram\nDetails: Escitalopram may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Escitalopram"}, {"id": "Insulin Human_INT_Zimelidine", "text": "Interaction: Insulin Human AND Zimelidine\nDetails: Zimelidine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Zimelidine"}, {"id": "Insulin Human_INT_Etoperidone", "text": "Interaction: Insulin Human AND Etoperidone\nDetails: Etoperidone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Etoperidone"}, {"id": "Insulin Human_INT_Alaproclate", "text": "Interaction: Insulin Human AND Alaproclate\nDetails: Alaproclate may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Alaproclate"}, {"id": "Insulin Human_INT_Methyclothiazide", "text": "Interaction: Insulin Human AND Methyclothiazide\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Methyclothiazide.\nRisk: Monitor closely.", "source": "Insulin Human + Methyclothiazide"}, {"id": "Insulin Human_INT_Chlorothiazide", "text": "Interaction: Insulin Human AND Chlorothiazide\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Chlorothiazide.\nRisk: Monitor closely.", "source": "Insulin Human + Chlorothiazide"}, {"id": "Insulin Human_INT_Hydrochlorothiazide", "text": "Interaction: Insulin Human AND Hydrochlorothiazide\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Hydrochlorothiazide.\nRisk: Monitor closely.", "source": "Insulin Human + Hydrochlorothiazide"}, {"id": "Insulin Human_INT_Chlorthalidone", "text": "Interaction: Insulin Human AND Chlorthalidone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Chlorthalidone.\nRisk: Monitor closely.", "source": "Insulin Human + Chlorthalidone"}, {"id": "Insulin Human_INT_Bendroflumethiazide", "text": "Interaction: Insulin Human AND Bendroflumethiazide\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Bendroflumethiazide.\nRisk: Monitor closely.", "source": "Insulin Human + Bendroflumethiazide"}, {"id": "Insulin Human_INT_Metolazone", "text": "Interaction: Insulin Human AND Metolazone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Metolazone.\nRisk: Monitor closely.", "source": "Insulin Human + Metolazone"}, {"id": "Insulin Human_INT_Hydroflumethiazide", "text": "Interaction: Insulin Human AND Hydroflumethiazide\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Hydroflumethiazide.\nRisk: Monitor closely.", "source": "Insulin Human + Hydroflumethiazide"}, {"id": "Insulin Human_INT_Indapamide", "text": "Interaction: Insulin Human AND Indapamide\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Indapamide.\nRisk: Monitor closely.", "source": "Insulin Human + Indapamide"}, {"id": "Insulin Human_INT_Trichlormethiazide", "text": "Interaction: Insulin Human AND Trichlormethiazide\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Trichlormethiazide.\nRisk: Monitor closely.", "source": "Insulin Human + Trichlormethiazide"}, {"id": "Insulin Human_INT_Polythiazide", "text": "Interaction: Insulin Human AND Polythiazide\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Polythiazide.\nRisk: Monitor closely.", "source": "Insulin Human + Polythiazide"}, {"id": "Insulin Human_INT_Quinethazone", "text": "Interaction: Insulin Human AND Quinethazone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Quinethazone.\nRisk: Monitor closely.", "source": "Insulin Human + Quinethazone"}, {"id": "Insulin Human_INT_Cyclopenthiazide", "text": "Interaction: Insulin Human AND Cyclopenthiazide\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Cyclopenthiazide.\nRisk: Monitor closely.", "source": "Insulin Human + Cyclopenthiazide"}, {"id": "Insulin Human_INT_Leuprolide", "text": "Interaction: Insulin Human AND Leuprolide\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Insulin Human + Leuprolide"}, {"id": "Insulin Human_INT_Goserelin", "text": "Interaction: Insulin Human AND Goserelin\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Insulin Human + Goserelin"}, {"id": "Insulin Human_INT_Torasemide", "text": "Interaction: Insulin Human AND Torasemide\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Torasemide.\nRisk: Monitor closely.", "source": "Insulin Human + Torasemide"}, {"id": "Insulin Human_INT_Nelfinavir", "text": "Interaction: Insulin Human AND Nelfinavir\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Nelfinavir.\nRisk: Monitor closely.", "source": "Insulin Human + Nelfinavir"}, {"id": "Insulin Human_INT_Indinavir", "text": "Interaction: Insulin Human AND Indinavir\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Indinavir.\nRisk: Monitor closely.", "source": "Insulin Human + Indinavir"}, {"id": "Insulin Human_INT_Ziprasidone", "text": "Interaction: Insulin Human AND Ziprasidone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Ziprasidone.\nRisk: Monitor closely.", "source": "Insulin Human + Ziprasidone"}, {"id": "Insulin Human_INT_Etonogestrel", "text": "Interaction: Insulin Human AND Etonogestrel\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Etonogestrel.\nRisk: Monitor closely.", "source": "Insulin Human + Etonogestrel"}, {"id": "Insulin Human_INT_Desogestrel", "text": "Interaction: Insulin Human AND Desogestrel\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Desogestrel.\nRisk: Monitor closely.", "source": "Insulin Human + Desogestrel"}, {"id": "Insulin Human_INT_Olanzapine", "text": "Interaction: Insulin Human AND Olanzapine\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Olanzapine.\nRisk: Monitor closely.", "source": "Insulin Human + Olanzapine"}, {"id": "Insulin Human_INT_Megestrol acetate", "text": "Interaction: Insulin Human AND Megestrol acetate\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Megestrol acetate.\nRisk: Monitor closely.", "source": "Insulin Human + Megestrol acetate"}, {"id": "Insulin Human_INT_Clozapine", "text": "Interaction: Insulin Human AND Clozapine\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Clozapine.\nRisk: Monitor closely.", "source": "Insulin Human + Clozapine"}, {"id": "Insulin Human_INT_Levonorgestrel", "text": "Interaction: Insulin Human AND Levonorgestrel\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Levonorgestrel.\nRisk: Monitor closely.", "source": "Insulin Human + Levonorgestrel"}, {"id": "Insulin Human_INT_Progesterone", "text": "Interaction: Insulin Human AND Progesterone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Progesterone.\nRisk: Monitor closely.", "source": "Insulin Human + Progesterone"}, {"id": "Insulin Human_INT_Betamethasone", "text": "Interaction: Insulin Human AND Betamethasone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Betamethasone.\nRisk: Monitor closely.", "source": "Insulin Human + Betamethasone"}, {"id": "Insulin Human_INT_Ritonavir", "text": "Interaction: Insulin Human AND Ritonavir\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Ritonavir.\nRisk: Monitor closely.", "source": "Insulin Human + Ritonavir"}, {"id": "Insulin Human_INT_Piperazine", "text": "Interaction: Insulin Human AND Piperazine\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Piperazine.\nRisk: Monitor closely.", "source": "Insulin Human + Piperazine"}, {"id": "Insulin Human_INT_Medroxyprogesterone acetate", "text": "Interaction: Insulin Human AND Medroxyprogesterone acetate\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Medroxyprogesterone acetate.\nRisk: Monitor closely.", "source": "Insulin Human + Medroxyprogesterone acetate"}, {"id": "Insulin Human_INT_Triamcinolone", "text": "Interaction: Insulin Human AND Triamcinolone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Triamcinolone.\nRisk: Monitor closely.", "source": "Insulin Human + Triamcinolone"}, {"id": "Insulin Human_INT_Niacin", "text": "Interaction: Insulin Human AND Niacin\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Niacin.\nRisk: Monitor closely.", "source": "Insulin Human + Niacin"}, {"id": "Insulin Human_INT_Prednisone", "text": "Interaction: Insulin Human AND Prednisone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Prednisone.\nRisk: Monitor closely.", "source": "Insulin Human + Prednisone"}, {"id": "Insulin Human_INT_Epinephrine", "text": "Interaction: Insulin Human AND Epinephrine\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Epinephrine.\nRisk: Monitor closely.", "source": "Insulin Human + Epinephrine"}, {"id": "Insulin Human_INT_Fludrocortisone", "text": "Interaction: Insulin Human AND Fludrocortisone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Fludrocortisone.\nRisk: Monitor closely.", "source": "Insulin Human + Fludrocortisone"}, {"id": "Insulin Human_INT_Furosemide", "text": "Interaction: Insulin Human AND Furosemide\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Furosemide.\nRisk: Monitor closely.", "source": "Insulin Human + Furosemide"}, {"id": "Insulin Human_INT_Norethisterone", "text": "Interaction: Insulin Human AND Norethisterone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Norethisterone.\nRisk: Monitor closely.", "source": "Insulin Human + Norethisterone"}, {"id": "Insulin Human_INT_Risperidone", "text": "Interaction: Insulin Human AND Risperidone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Risperidone.\nRisk: Monitor closely.", "source": "Insulin Human + Risperidone"}, {"id": "Insulin Human_INT_Hydrocortisone", "text": "Interaction: Insulin Human AND Hydrocortisone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Hydrocortisone.\nRisk: Monitor closely.", "source": "Insulin Human + Hydrocortisone"}, {"id": "Insulin Human_INT_Estradiol", "text": "Interaction: Insulin Human AND Estradiol\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Estradiol.\nRisk: Monitor closely.", "source": "Insulin Human + Estradiol"}, {"id": "Insulin Human_INT_Ethynodiol diacetate", "text": "Interaction: Insulin Human AND Ethynodiol diacetate\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Ethynodiol diacetate.\nRisk: Monitor closely.", "source": "Insulin Human + Ethynodiol diacetate"}, {"id": "Insulin Human_INT_Prednisolone", "text": "Interaction: Insulin Human AND Prednisolone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Prednisolone.\nRisk: Monitor closely.", "source": "Insulin Human + Prednisolone"}, {"id": "Insulin Human_INT_Tacrolimus", "text": "Interaction: Insulin Human AND Tacrolimus\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Tacrolimus.\nRisk: Monitor closely.", "source": "Insulin Human + Tacrolimus"}, {"id": "Insulin Human_INT_Sirolimus", "text": "Interaction: Insulin Human AND Sirolimus\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Sirolimus.\nRisk: Monitor closely.", "source": "Insulin Human + Sirolimus"}, {"id": "Insulin Human_INT_Bumetanide", "text": "Interaction: Insulin Human AND Bumetanide\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Bumetanide.\nRisk: Monitor closely.", "source": "Insulin Human + Bumetanide"}, {"id": "Insulin Human_INT_Etacrynic acid", "text": "Interaction: Insulin Human AND Etacrynic acid\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Etacrynic acid.\nRisk: Monitor closely.", "source": "Insulin Human + Etacrynic acid"}, {"id": "Insulin Human_INT_Tipranavir", "text": "Interaction: Insulin Human AND Tipranavir\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Tipranavir.\nRisk: Monitor closely.", "source": "Insulin Human + Tipranavir"}, {"id": "Insulin Human_INT_Norgestimate", "text": "Interaction: Insulin Human AND Norgestimate\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Norgestimate.\nRisk: Monitor closely.", "source": "Insulin Human + Norgestimate"}, {"id": "Insulin Human_INT_Methylprednisolone", "text": "Interaction: Insulin Human AND Methylprednisolone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Methylprednisolone.\nRisk: Monitor closely.", "source": "Insulin Human + Methylprednisolone"}, {"id": "Insulin Human_INT_Ethinyl Estradiol", "text": "Interaction: Insulin Human AND Ethinyl Estradiol\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Ethinyl Estradiol.\nRisk: Monitor closely.", "source": "Insulin Human + Ethinyl Estradiol"}, {"id": "Insulin Human_INT_Atazanavir", "text": "Interaction: Insulin Human AND Atazanavir\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Atazanavir.\nRisk: Monitor closely.", "source": "Insulin Human + Atazanavir"}, {"id": "Insulin Human_INT_Diazoxide", "text": "Interaction: Insulin Human AND Diazoxide\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Diazoxide.\nRisk: Monitor closely.", "source": "Insulin Human + Diazoxide"}, {"id": "Insulin Human_INT_Arsenic trioxide", "text": "Interaction: Insulin Human AND Arsenic trioxide\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Arsenic trioxide.\nRisk: Monitor closely.", "source": "Insulin Human + Arsenic trioxide"}, {"id": "Insulin Human_INT_Quetiapine", "text": "Interaction: Insulin Human AND Quetiapine\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Quetiapine.\nRisk: Monitor closely.", "source": "Insulin Human + Quetiapine"}, {"id": "Insulin Human_INT_Saquinavir", "text": "Interaction: Insulin Human AND Saquinavir\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Saquinavir.\nRisk: Monitor closely.", "source": "Insulin Human + Saquinavir"}, {"id": "Insulin Human_INT_Dexamethasone", "text": "Interaction: Insulin Human AND Dexamethasone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Dexamethasone.\nRisk: Monitor closely.", "source": "Insulin Human + Dexamethasone"}, {"id": "Insulin Human_INT_Aripiprazole", "text": "Interaction: Insulin Human AND Aripiprazole\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Aripiprazole.\nRisk: Monitor closely.", "source": "Insulin Human + Aripiprazole"}, {"id": "Insulin Human_INT_Darunavir", "text": "Interaction: Insulin Human AND Darunavir\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Darunavir.\nRisk: Monitor closely.", "source": "Insulin Human + Darunavir"}, {"id": "Insulin Human_INT_Paliperidone", "text": "Interaction: Insulin Human AND Paliperidone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Paliperidone.\nRisk: Monitor closely.", "source": "Insulin Human + Paliperidone"}, {"id": "Insulin Human_INT_Corticotropin", "text": "Interaction: Insulin Human AND Corticotropin\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Corticotropin.\nRisk: Monitor closely.", "source": "Insulin Human + Corticotropin"}, {"id": "Insulin Human_INT_Fosamprenavir", "text": "Interaction: Insulin Human AND Fosamprenavir\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Fosamprenavir.\nRisk: Monitor closely.", "source": "Insulin Human + Fosamprenavir"}, {"id": "Insulin Human_INT_Mestranol", "text": "Interaction: Insulin Human AND Mestranol\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Mestranol.\nRisk: Monitor closely.", "source": "Insulin Human + Mestranol"}, {"id": "Insulin Human_INT_Cortisone acetate", "text": "Interaction: Insulin Human AND Cortisone acetate\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Cortisone acetate.\nRisk: Monitor closely.", "source": "Insulin Human + Cortisone acetate"}, {"id": "Insulin Human_INT_Drospirenone", "text": "Interaction: Insulin Human AND Drospirenone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Drospirenone.\nRisk: Monitor closely.", "source": "Insulin Human + Drospirenone"}, {"id": "Insulin Human_INT_Methotrimeprazine", "text": "Interaction: Insulin Human AND Methotrimeprazine\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Methotrimeprazine.\nRisk: Monitor closely.", "source": "Insulin Human + Methotrimeprazine"}, {"id": "Insulin Human_INT_Danazol", "text": "Interaction: Insulin Human AND Danazol\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Danazol.\nRisk: Monitor closely.", "source": "Insulin Human + Danazol"}, {"id": "Insulin Human_INT_Everolimus", "text": "Interaction: Insulin Human AND Everolimus\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Everolimus.\nRisk: Monitor closely.", "source": "Insulin Human + Everolimus"}, {"id": "Insulin Human_INT_Lopinavir", "text": "Interaction: Insulin Human AND Lopinavir\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Lopinavir.\nRisk: Monitor closely.", "source": "Insulin Human + Lopinavir"}, {"id": "Insulin Human_INT_Pipotiazine", "text": "Interaction: Insulin Human AND Pipotiazine\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Pipotiazine.\nRisk: Monitor closely.", "source": "Insulin Human + Pipotiazine"}, {"id": "Insulin Human_INT_Vorinostat", "text": "Interaction: Insulin Human AND Vorinostat\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Vorinostat.\nRisk: Monitor closely.", "source": "Insulin Human + Vorinostat"}, {"id": "Insulin Human_INT_Estrone sulfate", "text": "Interaction: Insulin Human AND Estrone sulfate\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Estrone sulfate.\nRisk: Monitor closely.", "source": "Insulin Human + Estrone sulfate"}, {"id": "Insulin Human_INT_Cyproterone acetate", "text": "Interaction: Insulin Human AND Cyproterone acetate\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Cyproterone acetate.\nRisk: Monitor closely.", "source": "Insulin Human + Cyproterone acetate"}, {"id": "Insulin Human_INT_Nilotinib", "text": "Interaction: Insulin Human AND Nilotinib\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Nilotinib.\nRisk: Monitor closely.", "source": "Insulin Human + Nilotinib"}, {"id": "Insulin Human_INT_Iloperidone", "text": "Interaction: Insulin Human AND Iloperidone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Iloperidone.\nRisk: Monitor closely.", "source": "Insulin Human + Iloperidone"}, {"id": "Insulin Human_INT_Asenapine", "text": "Interaction: Insulin Human AND Asenapine\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Asenapine.\nRisk: Monitor closely.", "source": "Insulin Human + Asenapine"}, {"id": "Insulin Human_INT_Temsirolimus", "text": "Interaction: Insulin Human AND Temsirolimus\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Temsirolimus.\nRisk: Monitor closely.", "source": "Insulin Human + Temsirolimus"}, {"id": "Insulin Human_INT_Buserelin", "text": "Interaction: Insulin Human AND Buserelin\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Buserelin.\nRisk: Monitor closely.", "source": "Insulin Human + Buserelin"}, {"id": "Insulin Human_INT_Histrelin", "text": "Interaction: Insulin Human AND Histrelin\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Histrelin.\nRisk: Monitor closely.", "source": "Insulin Human + Histrelin"}, {"id": "Insulin Human_INT_Hydroxyprogesterone caproate", "text": "Interaction: Insulin Human AND Hydroxyprogesterone caproate\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Hydroxyprogesterone caproate.\nRisk: Monitor closely.", "source": "Insulin Human + Hydroxyprogesterone caproate"}, {"id": "Insulin Human_INT_Triptorelin", "text": "Interaction: Insulin Human AND Triptorelin\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Triptorelin.\nRisk: Monitor closely.", "source": "Insulin Human + Triptorelin"}, {"id": "Insulin Human_INT_Lurasidone", "text": "Interaction: Insulin Human AND Lurasidone\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Lurasidone.\nRisk: Monitor closely.", "source": "Insulin Human + Lurasidone"}, {"id": "Insulin Human_INT_Dabrafenib", "text": "Interaction: Insulin Human AND Dabrafenib\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Dabrafenib.\nRisk: Monitor closely.", "source": "Insulin Human + Dabrafenib"}, {"id": "Insulin Human_INT_Articaine", "text": "Interaction: Insulin Human AND Articaine\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Articaine.\nRisk: Monitor closely.", "source": "Insulin Human + Articaine"}, {"id": "Insulin Human_INT_Ceritinib", "text": "Interaction: Insulin Human AND Ceritinib\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Ceritinib.\nRisk: Monitor closely.", "source": "Insulin Human + Ceritinib"}, {"id": "Insulin Human_INT_Dienogest", "text": "Interaction: Insulin Human AND Dienogest\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Dienogest.\nRisk: Monitor closely.", "source": "Insulin Human + Dienogest"}, {"id": "Insulin Human_INT_Brexpiprazole", "text": "Interaction: Insulin Human AND Brexpiprazole\nDetails: The therapeutic efficacy of Insulin Human can be decreased when used in combination with Brexpiprazole.\nRisk: Monitor closely.", "source": "Insulin Human + Brexpiprazole"}, {"id": "Insulin Human_INT_Testosterone", "text": "Interaction: Insulin Human AND Testosterone\nDetails: Testosterone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Testosterone"}, {"id": "Insulin Human_INT_Dihydrotestosterone", "text": "Interaction: Insulin Human AND Dihydrotestosterone\nDetails: Dihydrotestosterone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Dihydrotestosterone"}, {"id": "Insulin Human_INT_Fluoxymesterone", "text": "Interaction: Insulin Human AND Fluoxymesterone\nDetails: Fluoxymesterone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Fluoxymesterone"}, {"id": "Insulin Human_INT_Testosterone Propionate", "text": "Interaction: Insulin Human AND Testosterone Propionate\nDetails: Testosterone Propionate may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Testosterone Propionate"}, {"id": "Insulin Human_INT_Methyltestosterone", "text": "Interaction: Insulin Human AND Methyltestosterone\nDetails: Methyltestosterone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Methyltestosterone"}, {"id": "Insulin Human_INT_Oxandrolone", "text": "Interaction: Insulin Human AND Oxandrolone\nDetails: Oxandrolone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Oxandrolone"}, {"id": "Insulin Human_INT_Oxymetholone", "text": "Interaction: Insulin Human AND Oxymetholone\nDetails: Oxymetholone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Oxymetholone"}, {"id": "Insulin Human_INT_Stanozolol", "text": "Interaction: Insulin Human AND Stanozolol\nDetails: Stanozolol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Stanozolol"}, {"id": "Insulin Human_INT_GLPG-0492", "text": "Interaction: Insulin Human AND GLPG-0492\nDetails: GLPG-0492 may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + GLPG-0492"}, {"id": "Insulin Human_INT_Nandrolone", "text": "Interaction: Insulin Human AND Nandrolone\nDetails: Nandrolone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Nandrolone"}, {"id": "Insulin Human_INT_Mesterolone", "text": "Interaction: Insulin Human AND Mesterolone\nDetails: Mesterolone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Mesterolone"}, {"id": "Insulin Human_INT_Nandrolone decanoate", "text": "Interaction: Insulin Human AND Nandrolone decanoate\nDetails: Nandrolone decanoate may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Nandrolone decanoate"}, {"id": "Insulin Human_INT_Pegvisomant", "text": "Interaction: Insulin Human AND Pegvisomant\nDetails: Pegvisomant may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Pegvisomant"}, {"id": "Insulin Human_INT_Insulin Pork", "text": "Interaction: Insulin Human AND Insulin Pork\nDetails: Insulin Pork may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Insulin Pork"}, {"id": "Insulin Human_INT_Troglitazone", "text": "Interaction: Insulin Human AND Troglitazone\nDetails: Troglitazone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Troglitazone"}, {"id": "Insulin Human_INT_Acarbose", "text": "Interaction: Insulin Human AND Acarbose\nDetails: Acarbose may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Acarbose"}, {"id": "Insulin Human_INT_Metformin", "text": "Interaction: Insulin Human AND Metformin\nDetails: Metformin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Metformin"}, {"id": "Insulin Human_INT_Rosiglitazone", "text": "Interaction: Insulin Human AND Rosiglitazone\nDetails: Rosiglitazone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Rosiglitazone"}, {"id": "Insulin Human_INT_Acetohexamide", "text": "Interaction: Insulin Human AND Acetohexamide\nDetails: Acetohexamide may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Acetohexamide"}, {"id": "Insulin Human_INT_Miglustat", "text": "Interaction: Insulin Human AND Miglustat\nDetails: Miglustat may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Miglustat"}, {"id": "Insulin Human_INT_Miglitol", "text": "Interaction: Insulin Human AND Miglitol\nDetails: Miglitol may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Miglitol"}, {"id": "Insulin Human_INT_Phenformin", "text": "Interaction: Insulin Human AND Phenformin\nDetails: Phenformin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Phenformin"}, {"id": "Insulin Human_INT_Gliquidone", "text": "Interaction: Insulin Human AND Gliquidone\nDetails: Gliquidone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Gliquidone"}, {"id": "Insulin Human_INT_Mitiglinide", "text": "Interaction: Insulin Human AND Mitiglinide\nDetails: Mitiglinide may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Mitiglinide"}, {"id": "Insulin Human_INT_AICA ribonucleotide", "text": "Interaction: Insulin Human AND AICA ribonucleotide\nDetails: AICA ribonucleotide may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + AICA ribonucleotide"}, {"id": "Insulin Human_INT_Castanospermine", "text": "Interaction: Insulin Human AND Castanospermine\nDetails: Castanospermine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Castanospermine"}, {"id": "Insulin Human_INT_Buformin", "text": "Interaction: Insulin Human AND Buformin\nDetails: Buformin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Buformin"}, {"id": "Insulin Human_INT_Voglibose", "text": "Interaction: Insulin Human AND Voglibose\nDetails: Voglibose may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Voglibose"}, {"id": "Insulin Human_INT_Sulodexide", "text": "Interaction: Insulin Human AND Sulodexide\nDetails: Sulodexide may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Sulodexide"}, {"id": "Insulin Human_INT_Glibornuride", "text": "Interaction: Insulin Human AND Glibornuride\nDetails: Glibornuride may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Glibornuride"}, {"id": "Insulin Human_INT_Ciglitazone", "text": "Interaction: Insulin Human AND Ciglitazone\nDetails: Ciglitazone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Ciglitazone"}, {"id": "Insulin Human_INT_Allicin", "text": "Interaction: Insulin Human AND Allicin\nDetails: Allicin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Allicin"}, {"id": "Insulin Human_INT_2,4-thiazolidinedione", "text": "Interaction: Insulin Human AND 2,4-thiazolidinedione\nDetails: 2,4-thiazolidinedione may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + 2,4-thiazolidinedione"}, {"id": "Insulin Human_INT_Bempedoic acid", "text": "Interaction: Insulin Human AND Bempedoic acid\nDetails: Bempedoic acid may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Bempedoic acid"}, {"id": "Insulin Human_INT_Gusperimus", "text": "Interaction: Insulin Human AND Gusperimus\nDetails: Gusperimus may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Gusperimus"}, {"id": "Insulin Human_INT_Sotagliflozin", "text": "Interaction: Insulin Human AND Sotagliflozin\nDetails: Sotagliflozin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Sotagliflozin"}, {"id": "Insulin Human_INT_Balaglitazone", "text": "Interaction: Insulin Human AND Balaglitazone\nDetails: Balaglitazone may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Balaglitazone"}, {"id": "Insulin Human_INT_Deoxyspergualin", "text": "Interaction: Insulin Human AND Deoxyspergualin\nDetails: Deoxyspergualin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Deoxyspergualin"}, {"id": "Insulin Human_INT_Carbutamide", "text": "Interaction: Insulin Human AND Carbutamide\nDetails: Carbutamide may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Carbutamide"}, {"id": "Insulin Human_INT_Salicylic acid", "text": "Interaction: Insulin Human AND Salicylic acid\nDetails: Salicylic acid may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Salicylic acid"}, {"id": "Insulin Human_INT_Acetylsalicylic acid", "text": "Interaction: Insulin Human AND Acetylsalicylic acid\nDetails: Acetylsalicylic acid may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Acetylsalicylic acid"}, {"id": "Insulin Human_INT_Aminosalicylic Acid", "text": "Interaction: Insulin Human AND Aminosalicylic Acid\nDetails: Aminosalicylic Acid may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Aminosalicylic Acid"}, {"id": "Insulin Human_INT_Mesalazine", "text": "Interaction: Insulin Human AND Mesalazine\nDetails: Mesalazine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Mesalazine"}, {"id": "Insulin Human_INT_Diflunisal", "text": "Interaction: Insulin Human AND Diflunisal\nDetails: Diflunisal may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Diflunisal"}, {"id": "Insulin Human_INT_Balsalazide", "text": "Interaction: Insulin Human AND Balsalazide\nDetails: Balsalazide may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Balsalazide"}, {"id": "Insulin Human_INT_Olsalazine", "text": "Interaction: Insulin Human AND Olsalazine\nDetails: Olsalazine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Olsalazine"}, {"id": "Insulin Human_INT_dersalazine", "text": "Interaction: Insulin Human AND dersalazine\nDetails: dersalazine may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + dersalazine"}, {"id": "Insulin Human_INT_Nitroaspirin", "text": "Interaction: Insulin Human AND Nitroaspirin\nDetails: Nitroaspirin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Nitroaspirin"}, {"id": "Insulin Human_INT_Aloxiprin", "text": "Interaction: Insulin Human AND Aloxiprin\nDetails: Aloxiprin may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Aloxiprin"}, {"id": "Insulin Human_INT_Guacetisal", "text": "Interaction: Insulin Human AND Guacetisal\nDetails: Guacetisal may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Guacetisal"}, {"id": "Insulin Human_INT_Carbaspirin calcium", "text": "Interaction: Insulin Human AND Carbaspirin calcium\nDetails: Carbaspirin calcium may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Carbaspirin calcium"}, {"id": "Insulin Human_INT_Hemoglobin crosfumaril", "text": "Interaction: Insulin Human AND Hemoglobin crosfumaril\nDetails: Hemoglobin crosfumaril may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Hemoglobin crosfumaril"}, {"id": "Insulin Human_INT_Methyl salicylate", "text": "Interaction: Insulin Human AND Methyl salicylate\nDetails: Methyl salicylate may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Methyl salicylate"}, {"id": "Insulin Human_INT_Trolamine salicylate", "text": "Interaction: Insulin Human AND Trolamine salicylate\nDetails: Trolamine salicylate may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Human + Trolamine salicylate"}, {"id": "Tenecteplase_GEN", "text": "Drug: Tenecteplase\nDescription: ...", "source": "Tenecteplase"}, {"id": "Phylloquinone_GEN", "text": "Drug: Phylloquinone\nDescription: ...", "source": "Phylloquinone"}, {"id": "Calcium_GEN", "text": "Drug: Calcium\nDescription: ...", "source": "Calcium"}, {"id": "Tenecteplase_GEN", "text": "Drug: Tenecteplase\nDescription: Tissue plasminogen activator (tPA). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both wit...", "source": "Tenecteplase"}, {"id": "Tenecteplase_CLIN", "text": "Drug: Tenecteplase\nMechanism: Tenecteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in tu...\nToxicity: ...", "source": "Tenecteplase"}, {"id": "Tenecteplase_INT_Aprotinin", "text": "Interaction: Tenecteplase AND Aprotinin\nDetails: The therapeutic efficacy of Tenecteplase can be decreased when used in combination with Aprotinin.\nRisk: Monitor closely.", "source": "Tenecteplase + Aprotinin"}, {"id": "Tenecteplase_INT_Limaprost", "text": "Interaction: Tenecteplase AND Limaprost\nDetails: The risk or severity of adverse effects can be increased when Limaprost is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Limaprost"}, {"id": "Tenecteplase_INT_Dabigatran etexilate", "text": "Interaction: Tenecteplase AND Dabigatran etexilate\nDetails: Tenecteplase may increase the anticoagulant activities of Dabigatran etexilate.\nRisk: Monitor closely.", "source": "Tenecteplase + Dabigatran etexilate"}, {"id": "Tenecteplase_INT_Lepirudin", "text": "Interaction: Tenecteplase AND Lepirudin\nDetails: Tenecteplase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Tenecteplase + Lepirudin"}, {"id": "Tenecteplase_INT_Bivalirudin", "text": "Interaction: Tenecteplase AND Bivalirudin\nDetails: Tenecteplase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Tenecteplase + Bivalirudin"}, {"id": "Tenecteplase_INT_Abciximab", "text": "Interaction: Tenecteplase AND Abciximab\nDetails: Tenecteplase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Tenecteplase + Abciximab"}, {"id": "Tenecteplase_INT_Becaplermin", "text": "Interaction: Tenecteplase AND Becaplermin\nDetails: Tenecteplase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Tenecteplase + Becaplermin"}, {"id": "Tenecteplase_INT_Dicoumarol", "text": "Interaction: Tenecteplase AND Dicoumarol\nDetails: Tenecteplase may increase the anticoagulant activities of Dicoumarol.\nRisk: Monitor closely.", "source": "Tenecteplase + Dicoumarol"}, {"id": "Tenecteplase_INT_Argatroban", "text": "Interaction: Tenecteplase AND Argatroban\nDetails: Tenecteplase may increase the anticoagulant activities of Argatroban.\nRisk: Monitor closely.", "source": "Tenecteplase + Argatroban"}, {"id": "Tenecteplase_INT_Ardeparin", "text": "Interaction: Tenecteplase AND Ardeparin\nDetails: Tenecteplase may increase the anticoagulant activities of Ardeparin.\nRisk: Monitor closely.", "source": "Tenecteplase + Ardeparin"}, {"id": "Tenecteplase_INT_Phenindione", "text": "Interaction: Tenecteplase AND Phenindione\nDetails: Tenecteplase may increase the anticoagulant activities of Phenindione.\nRisk: Monitor closely.", "source": "Tenecteplase + Phenindione"}, {"id": "Tenecteplase_INT_Fondaparinux sodium", "text": "Interaction: Tenecteplase AND Fondaparinux sodium\nDetails: Tenecteplase may increase the anticoagulant activities of Fondaparinux sodium.\nRisk: Monitor closely.", "source": "Tenecteplase + Fondaparinux sodium"}, {"id": "Tenecteplase_INT_Warfarin", "text": "Interaction: Tenecteplase AND Warfarin\nDetails: Tenecteplase may increase the anticoagulant activities of Warfarin.\nRisk: Monitor closely.", "source": "Tenecteplase + Warfarin"}, {"id": "Tenecteplase_INT_Pentosan Polysulfate", "text": "Interaction: Tenecteplase AND Pentosan Polysulfate\nDetails: Tenecteplase may increase the anticoagulant activities of Pentosan Polysulfate.\nRisk: Monitor closely.", "source": "Tenecteplase + Pentosan Polysulfate"}, {"id": "Tenecteplase_INT_Phenprocoumon", "text": "Interaction: Tenecteplase AND Phenprocoumon\nDetails: Tenecteplase may increase the anticoagulant activities of Phenprocoumon.\nRisk: Monitor closely.", "source": "Tenecteplase + Phenprocoumon"}, {"id": "Tenecteplase_INT_Edetic Acid", "text": "Interaction: Tenecteplase AND Edetic Acid\nDetails: Tenecteplase may increase the anticoagulant activities of Edetic Acid.\nRisk: Monitor closely.", "source": "Tenecteplase + Edetic Acid"}, {"id": "Tenecteplase_INT_Heparin", "text": "Interaction: Tenecteplase AND Heparin\nDetails: Tenecteplase may increase the anticoagulant activities of Heparin.\nRisk: Monitor closely.", "source": "Tenecteplase + Heparin"}, {"id": "Tenecteplase_INT_Enoxaparin", "text": "Interaction: Tenecteplase AND Enoxaparin\nDetails: Tenecteplase may increase the anticoagulant activities of Enoxaparin.\nRisk: Monitor closely.", "source": "Tenecteplase + Enoxaparin"}, {"id": "Tenecteplase_INT_Acenocoumarol", "text": "Interaction: Tenecteplase AND Acenocoumarol\nDetails: Tenecteplase may increase the anticoagulant activities of Acenocoumarol.\nRisk: Monitor closely.", "source": "Tenecteplase + Acenocoumarol"}, {"id": "Tenecteplase_INT_Citric Acid", "text": "Interaction: Tenecteplase AND Citric Acid\nDetails: Tenecteplase may increase the anticoagulant activities of Citric Acid.\nRisk: Monitor closely.", "source": "Tenecteplase + Citric Acid"}, {"id": "Tenecteplase_INT_Ximelagatran", "text": "Interaction: Tenecteplase AND Ximelagatran\nDetails: Tenecteplase may increase the anticoagulant activities of Ximelagatran.\nRisk: Monitor closely.", "source": "Tenecteplase + Ximelagatran"}, {"id": "Tenecteplase_INT_Ancrod", "text": "Interaction: Tenecteplase AND Ancrod\nDetails: Tenecteplase may increase the anticoagulant activities of Ancrod.\nRisk: Monitor closely.", "source": "Tenecteplase + Ancrod"}, {"id": "Tenecteplase_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Tenecteplase AND Pentaerythritol Tetranitrate\nDetails: Tenecteplase may increase the anticoagulant activities of Pentaerythritol Tetranitrate.\nRisk: Monitor closely.", "source": "Tenecteplase + Pentaerythritol Tetranitrate"}, {"id": "Tenecteplase_INT_Rivaroxaban", "text": "Interaction: Tenecteplase AND Rivaroxaban\nDetails: Tenecteplase may increase the anticoagulant activities of Rivaroxaban.\nRisk: Monitor closely.", "source": "Tenecteplase + Rivaroxaban"}, {"id": "Tenecteplase_INT_Sulodexide", "text": "Interaction: Tenecteplase AND Sulodexide\nDetails: Tenecteplase may increase the anticoagulant activities of Sulodexide.\nRisk: Monitor closely.", "source": "Tenecteplase + Sulodexide"}, {"id": "Tenecteplase_INT_Idraparinux", "text": "Interaction: Tenecteplase AND Idraparinux\nDetails: Tenecteplase may increase the anticoagulant activities of Idraparinux.\nRisk: Monitor closely.", "source": "Tenecteplase + Idraparinux"}, {"id": "Tenecteplase_INT_Apixaban", "text": "Interaction: Tenecteplase AND Apixaban\nDetails: Tenecteplase may increase the anticoagulant activities of Apixaban.\nRisk: Monitor closely.", "source": "Tenecteplase + Apixaban"}, {"id": "Tenecteplase_INT_Otamixaban", "text": "Interaction: Tenecteplase AND Otamixaban\nDetails: Tenecteplase may increase the anticoagulant activities of Otamixaban.\nRisk: Monitor closely.", "source": "Tenecteplase + Otamixaban"}, {"id": "Tenecteplase_INT_Danaparoid", "text": "Interaction: Tenecteplase AND Danaparoid\nDetails: Tenecteplase may increase the anticoagulant activities of Danaparoid.\nRisk: Monitor closely.", "source": "Tenecteplase + Danaparoid"}, {"id": "Tenecteplase_INT_Dalteparin", "text": "Interaction: Tenecteplase AND Dalteparin\nDetails: Tenecteplase may increase the anticoagulant activities of Dalteparin.\nRisk: Monitor closely.", "source": "Tenecteplase + Dalteparin"}, {"id": "Tenecteplase_INT_Ferulic acid", "text": "Interaction: Tenecteplase AND Ferulic acid\nDetails: Tenecteplase may increase the anticoagulant activities of Ferulic acid.\nRisk: Monitor closely.", "source": "Tenecteplase + Ferulic acid"}, {"id": "Tenecteplase_INT_Ethyl biscoumacetate", "text": "Interaction: Tenecteplase AND Ethyl biscoumacetate\nDetails: Tenecteplase may increase the anticoagulant activities of Ethyl biscoumacetate.\nRisk: Monitor closely.", "source": "Tenecteplase + Ethyl biscoumacetate"}, {"id": "Tenecteplase_INT_Nadroparin", "text": "Interaction: Tenecteplase AND Nadroparin\nDetails: Tenecteplase may increase the anticoagulant activities of Nadroparin.\nRisk: Monitor closely.", "source": "Tenecteplase + Nadroparin"}, {"id": "Tenecteplase_INT_Edoxaban", "text": "Interaction: Tenecteplase AND Edoxaban\nDetails: Tenecteplase may increase the anticoagulant activities of Edoxaban.\nRisk: Monitor closely.", "source": "Tenecteplase + Edoxaban"}, {"id": "Tenecteplase_INT_Dextran", "text": "Interaction: Tenecteplase AND Dextran\nDetails: Tenecteplase may increase the anticoagulant activities of Dextran.\nRisk: Monitor closely.", "source": "Tenecteplase + Dextran"}, {"id": "Tenecteplase_INT_Reviparin", "text": "Interaction: Tenecteplase AND Reviparin\nDetails: Tenecteplase may increase the anticoagulant activities of Reviparin.\nRisk: Monitor closely.", "source": "Tenecteplase + Reviparin"}, {"id": "Tenecteplase_INT_Certoparin", "text": "Interaction: Tenecteplase AND Certoparin\nDetails: Tenecteplase may increase the anticoagulant activities of Certoparin.\nRisk: Monitor closely.", "source": "Tenecteplase + Certoparin"}, {"id": "Tenecteplase_INT_Dextran 70", "text": "Interaction: Tenecteplase AND Dextran 70\nDetails: Tenecteplase may increase the anticoagulant activities of Dextran 70.\nRisk: Monitor closely.", "source": "Tenecteplase + Dextran 70"}, {"id": "Tenecteplase_INT_Desirudin", "text": "Interaction: Tenecteplase AND Desirudin\nDetails: Tenecteplase may increase the anticoagulant activities of Desirudin.\nRisk: Monitor closely.", "source": "Tenecteplase + Desirudin"}, {"id": "Tenecteplase_INT_Dextran 40", "text": "Interaction: Tenecteplase AND Dextran 40\nDetails: Tenecteplase may increase the anticoagulant activities of Dextran 40.\nRisk: Monitor closely.", "source": "Tenecteplase + Dextran 40"}, {"id": "Tenecteplase_INT_Dextran 75", "text": "Interaction: Tenecteplase AND Dextran 75\nDetails: Tenecteplase may increase the anticoagulant activities of Dextran 75.\nRisk: Monitor closely.", "source": "Tenecteplase + Dextran 75"}, {"id": "Tenecteplase_INT_Protocatechualdehyde", "text": "Interaction: Tenecteplase AND Protocatechualdehyde\nDetails: Tenecteplase may increase the anticoagulant activities of Protocatechualdehyde.\nRisk: Monitor closely.", "source": "Tenecteplase + Protocatechualdehyde"}, {"id": "Tenecteplase_INT_Protein C", "text": "Interaction: Tenecteplase AND Protein C\nDetails: Tenecteplase may increase the anticoagulant activities of Protein C.\nRisk: Monitor closely.", "source": "Tenecteplase + Protein C"}, {"id": "Tenecteplase_INT_Antithrombin III human", "text": "Interaction: Tenecteplase AND Antithrombin III human\nDetails: Tenecteplase may increase the anticoagulant activities of Antithrombin III human.\nRisk: Monitor closely.", "source": "Tenecteplase + Antithrombin III human"}, {"id": "Tenecteplase_INT_Fondaparinux", "text": "Interaction: Tenecteplase AND Fondaparinux\nDetails: Tenecteplase may increase the anticoagulant activities of Fondaparinux.\nRisk: Monitor closely.", "source": "Tenecteplase + Fondaparinux"}, {"id": "Tenecteplase_INT_Letaxaban", "text": "Interaction: Tenecteplase AND Letaxaban\nDetails: Tenecteplase may increase the anticoagulant activities of Letaxaban.\nRisk: Monitor closely.", "source": "Tenecteplase + Letaxaban"}, {"id": "Tenecteplase_INT_Darexaban", "text": "Interaction: Tenecteplase AND Darexaban\nDetails: Tenecteplase may increase the anticoagulant activities of Darexaban.\nRisk: Monitor closely.", "source": "Tenecteplase + Darexaban"}, {"id": "Tenecteplase_INT_Nafamostat", "text": "Interaction: Tenecteplase AND Nafamostat\nDetails: Tenecteplase may increase the anticoagulant activities of Nafamostat.\nRisk: Monitor closely.", "source": "Tenecteplase + Nafamostat"}, {"id": "Tenecteplase_INT_Gabexate", "text": "Interaction: Tenecteplase AND Gabexate\nDetails: Tenecteplase may increase the anticoagulant activities of Gabexate.\nRisk: Monitor closely.", "source": "Tenecteplase + Gabexate"}, {"id": "Tenecteplase_INT_Troxerutin", "text": "Interaction: Tenecteplase AND Troxerutin\nDetails: Tenecteplase may increase the anticoagulant activities of Troxerutin.\nRisk: Monitor closely.", "source": "Tenecteplase + Troxerutin"}, {"id": "Tenecteplase_INT_Fluindione", "text": "Interaction: Tenecteplase AND Fluindione\nDetails: Tenecteplase may increase the anticoagulant activities of Fluindione.\nRisk: Monitor closely.", "source": "Tenecteplase + Fluindione"}, {"id": "Tenecteplase_INT_Protein S human", "text": "Interaction: Tenecteplase AND Protein S human\nDetails: Tenecteplase may increase the anticoagulant activities of Protein S human.\nRisk: Monitor closely.", "source": "Tenecteplase + Protein S human"}, {"id": "Tenecteplase_INT_Melagatran", "text": "Interaction: Tenecteplase AND Melagatran\nDetails: Tenecteplase may increase the anticoagulant activities of Melagatran.\nRisk: Monitor closely.", "source": "Tenecteplase + Melagatran"}, {"id": "Tenecteplase_INT_Salicylic acid", "text": "Interaction: Tenecteplase AND Salicylic acid\nDetails: The risk or severity of adverse effects can be increased when Salicylic acid is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Salicylic acid"}, {"id": "Tenecteplase_INT_Acetylsalicylic acid", "text": "Interaction: Tenecteplase AND Acetylsalicylic acid\nDetails: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Acetylsalicylic acid"}, {"id": "Tenecteplase_INT_Aminosalicylic Acid", "text": "Interaction: Tenecteplase AND Aminosalicylic Acid\nDetails: The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Aminosalicylic Acid"}, {"id": "Tenecteplase_INT_Mesalazine", "text": "Interaction: Tenecteplase AND Mesalazine\nDetails: The risk or severity of adverse effects can be increased when Mesalazine is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Mesalazine"}, {"id": "Tenecteplase_INT_Diflunisal", "text": "Interaction: Tenecteplase AND Diflunisal\nDetails: The risk or severity of adverse effects can be increased when Diflunisal is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Diflunisal"}, {"id": "Tenecteplase_INT_Balsalazide", "text": "Interaction: Tenecteplase AND Balsalazide\nDetails: The risk or severity of adverse effects can be increased when Balsalazide is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Balsalazide"}, {"id": "Tenecteplase_INT_Olsalazine", "text": "Interaction: Tenecteplase AND Olsalazine\nDetails: The risk or severity of adverse effects can be increased when Olsalazine is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Olsalazine"}, {"id": "Tenecteplase_INT_dersalazine", "text": "Interaction: Tenecteplase AND dersalazine\nDetails: The risk or severity of adverse effects can be increased when dersalazine is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + dersalazine"}, {"id": "Tenecteplase_INT_Nitroaspirin", "text": "Interaction: Tenecteplase AND Nitroaspirin\nDetails: The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Nitroaspirin"}, {"id": "Tenecteplase_INT_Aloxiprin", "text": "Interaction: Tenecteplase AND Aloxiprin\nDetails: The risk or severity of adverse effects can be increased when Aloxiprin is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Aloxiprin"}, {"id": "Tenecteplase_INT_Guacetisal", "text": "Interaction: Tenecteplase AND Guacetisal\nDetails: The risk or severity of adverse effects can be increased when Guacetisal is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Guacetisal"}, {"id": "Tenecteplase_INT_Carbaspirin calcium", "text": "Interaction: Tenecteplase AND Carbaspirin calcium\nDetails: The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Carbaspirin calcium"}, {"id": "Tenecteplase_INT_Hemoglobin crosfumaril", "text": "Interaction: Tenecteplase AND Hemoglobin crosfumaril\nDetails: The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Hemoglobin crosfumaril"}, {"id": "Tenecteplase_INT_Methyl salicylate", "text": "Interaction: Tenecteplase AND Methyl salicylate\nDetails: The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Methyl salicylate"}, {"id": "Tenecteplase_INT_Trolamine salicylate", "text": "Interaction: Tenecteplase AND Trolamine salicylate\nDetails: The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Trolamine salicylate"}, {"id": "Tenecteplase_INT_Eptifibatide", "text": "Interaction: Tenecteplase AND Eptifibatide\nDetails: Eptifibatide may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Eptifibatide"}, {"id": "Tenecteplase_INT_Ticlopidine", "text": "Interaction: Tenecteplase AND Ticlopidine\nDetails: Ticlopidine may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Ticlopidine"}, {"id": "Tenecteplase_INT_Tirofiban", "text": "Interaction: Tenecteplase AND Tirofiban\nDetails: Tirofiban may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Tirofiban"}, {"id": "Tenecteplase_INT_Dipyridamole", "text": "Interaction: Tenecteplase AND Dipyridamole\nDetails: Dipyridamole may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Dipyridamole"}, {"id": "Tenecteplase_INT_Clopidogrel", "text": "Interaction: Tenecteplase AND Clopidogrel\nDetails: Clopidogrel may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Clopidogrel"}, {"id": "Tenecteplase_INT_Prasugrel", "text": "Interaction: Tenecteplase AND Prasugrel\nDetails: Prasugrel may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Prasugrel"}, {"id": "Tenecteplase_INT_Vorapaxar", "text": "Interaction: Tenecteplase AND Vorapaxar\nDetails: Vorapaxar may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Vorapaxar"}, {"id": "Tenecteplase_INT_Milrinone", "text": "Interaction: Tenecteplase AND Milrinone\nDetails: Milrinone may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Milrinone"}, {"id": "Tenecteplase_INT_Anagrelide", "text": "Interaction: Tenecteplase AND Anagrelide\nDetails: Anagrelide may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Anagrelide"}, {"id": "Tenecteplase_INT_Epinastine", "text": "Interaction: Tenecteplase AND Epinastine\nDetails: Epinastine may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Epinastine"}, {"id": "Tenecteplase_INT_Alprostadil", "text": "Interaction: Tenecteplase AND Alprostadil\nDetails: Alprostadil may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Alprostadil"}, {"id": "Tenecteplase_INT_Pentoxifylline", "text": "Interaction: Tenecteplase AND Pentoxifylline\nDetails: Pentoxifylline may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Pentoxifylline"}, {"id": "Tenecteplase_INT_Azelastine", "text": "Interaction: Tenecteplase AND Azelastine\nDetails: Azelastine may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Azelastine"}, {"id": "Tenecteplase_INT_Iloprost", "text": "Interaction: Tenecteplase AND Iloprost\nDetails: Iloprost may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Iloprost"}, {"id": "Tenecteplase_INT_Cilostazol", "text": "Interaction: Tenecteplase AND Cilostazol\nDetails: Cilostazol may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Cilostazol"}, {"id": "Tenecteplase_INT_Ridogrel", "text": "Interaction: Tenecteplase AND Ridogrel\nDetails: Ridogrel may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Ridogrel"}, {"id": "Tenecteplase_INT_Sevoflurane", "text": "Interaction: Tenecteplase AND Sevoflurane\nDetails: Sevoflurane may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Sevoflurane"}, {"id": "Tenecteplase_INT_Epoprostenol", "text": "Interaction: Tenecteplase AND Epoprostenol\nDetails: Epoprostenol may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Epoprostenol"}, {"id": "Tenecteplase_INT_Resveratrol", "text": "Interaction: Tenecteplase AND Resveratrol\nDetails: Resveratrol may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Resveratrol"}, {"id": "Tenecteplase_INT_Nimesulide", "text": "Interaction: Tenecteplase AND Nimesulide\nDetails: Nimesulide may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Nimesulide"}, {"id": "Tenecteplase_INT_Tesmilifene", "text": "Interaction: Tenecteplase AND Tesmilifene\nDetails: Tesmilifene may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Tesmilifene"}, {"id": "Tenecteplase_INT_Defibrotide", "text": "Interaction: Tenecteplase AND Defibrotide\nDetails: Defibrotide may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Defibrotide"}, {"id": "Tenecteplase_INT_SRT501", "text": "Interaction: Tenecteplase AND SRT501\nDetails: SRT501 may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + SRT501"}, {"id": "Tenecteplase_INT_Beraprost", "text": "Interaction: Tenecteplase AND Beraprost\nDetails: Beraprost may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Beraprost"}, {"id": "Tenecteplase_INT_Ibudilast", "text": "Interaction: Tenecteplase AND Ibudilast\nDetails: Ibudilast may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Ibudilast"}, {"id": "Tenecteplase_INT_Andrographolide", "text": "Interaction: Tenecteplase AND Andrographolide\nDetails: Andrographolide may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Andrographolide"}, {"id": "Tenecteplase_INT_eplivanserine", "text": "Interaction: Tenecteplase AND eplivanserine\nDetails: eplivanserine may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + eplivanserine"}, {"id": "Tenecteplase_INT_Cangrelor", "text": "Interaction: Tenecteplase AND Cangrelor\nDetails: Cangrelor may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Cangrelor"}, {"id": "Tenecteplase_INT_Tranilast", "text": "Interaction: Tenecteplase AND Tranilast\nDetails: Tranilast may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Tranilast"}, {"id": "Tenecteplase_INT_Triflusal", "text": "Interaction: Tenecteplase AND Triflusal\nDetails: Triflusal may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Triflusal"}, {"id": "Tenecteplase_INT_Icosapent ethyl", "text": "Interaction: Tenecteplase AND Icosapent ethyl\nDetails: Icosapent ethyl may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Icosapent ethyl"}, {"id": "Tenecteplase_INT_Ifenprodil", "text": "Interaction: Tenecteplase AND Ifenprodil\nDetails: Ifenprodil may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Ifenprodil"}, {"id": "Tenecteplase_INT_Trapidil", "text": "Interaction: Tenecteplase AND Trapidil\nDetails: Trapidil may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Trapidil"}, {"id": "Tenecteplase_INT_Naftopidil", "text": "Interaction: Tenecteplase AND Naftopidil\nDetails: Naftopidil may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Naftopidil"}, {"id": "Tenecteplase_INT_Sarpogrelate", "text": "Interaction: Tenecteplase AND Sarpogrelate\nDetails: Sarpogrelate may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Sarpogrelate"}, {"id": "Tenecteplase_INT_Eplivanserin", "text": "Interaction: Tenecteplase AND Eplivanserin\nDetails: Eplivanserin may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Eplivanserin"}, {"id": "Tenecteplase_INT_Ifetroban", "text": "Interaction: Tenecteplase AND Ifetroban\nDetails: Ifetroban may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Ifetroban"}, {"id": "Tenecteplase_INT_Ketanserin", "text": "Interaction: Tenecteplase AND Ketanserin\nDetails: Ketanserin may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Ketanserin"}, {"id": "Tenecteplase_INT_Indobufen", "text": "Interaction: Tenecteplase AND Indobufen\nDetails: Indobufen may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Indobufen"}, {"id": "Tenecteplase_INT_Butylphthalide", "text": "Interaction: Tenecteplase AND Butylphthalide\nDetails: Butylphthalide may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Butylphthalide"}, {"id": "Tenecteplase_INT_Hydroxytyrosol", "text": "Interaction: Tenecteplase AND Hydroxytyrosol\nDetails: Hydroxytyrosol may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Hydroxytyrosol"}, {"id": "Tenecteplase_INT_Ramatroban", "text": "Interaction: Tenecteplase AND Ramatroban\nDetails: Ramatroban may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Ramatroban"}, {"id": "Tenecteplase_INT_Picotamide", "text": "Interaction: Tenecteplase AND Picotamide\nDetails: Picotamide may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Picotamide"}, {"id": "Tenecteplase_INT_Cloricromen", "text": "Interaction: Tenecteplase AND Cloricromen\nDetails: Cloricromen may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Cloricromen"}, {"id": "Tenecteplase_INT_Linsidomine", "text": "Interaction: Tenecteplase AND Linsidomine\nDetails: Linsidomine may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Linsidomine"}, {"id": "Tenecteplase_INT_Buflomedil", "text": "Interaction: Tenecteplase AND Buflomedil\nDetails: Buflomedil may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Buflomedil"}, {"id": "Tenecteplase_INT_Relcovaptan", "text": "Interaction: Tenecteplase AND Relcovaptan\nDetails: Relcovaptan may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Relcovaptan"}, {"id": "Tenecteplase_INT_Ticagrelor", "text": "Interaction: Tenecteplase AND Ticagrelor\nDetails: Ticagrelor may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Tenecteplase + Ticagrelor"}, {"id": "Tenecteplase_INT_Treprostinil", "text": "Interaction: Tenecteplase AND Treprostinil\nDetails: The risk or severity of adverse effects can be increased when Tenecteplase is combined with Treprostinil.\nRisk: Monitor closely.", "source": "Tenecteplase + Treprostinil"}, {"id": "Menotropins_GEN", "text": "Drug: Menotropins\nDescription: Menotropins contains follicle stimulating hormone (FSH) and luteinizing hormone (LH) purified from the urine of postmenopausal women.  It is used as a fertility medication that is injected either subcutaneously or intramuscularly. It is composed of LH with 2 subunits, alpha = 92 residues, beta = 121...", "source": "Menotropins"}, {"id": "Menotropins_CLIN", "text": "Drug: Menotropins\nMechanism: Being a combination drug, Menotropins bind to the follicle stimulating hormone receptor (FSH), which results in ovulation in the absence of sufficient endogenous luteinizing hormone (LH). It also bind...\nToxicity: ...", "source": "Menotropins"}, {"id": "Interferon gamma-1b_GEN", "text": "Drug: Interferon gamma-1b\nDescription: Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatog...", "source": "Interferon gamma-1b"}, {"id": "Interferon gamma-1b_CLIN", "text": "Drug: Interferon gamma-1b\nMechanism: Binds directly to the type II interferon gamma receptor IFNGR1, leading to a complex of IFNGR1 and IFNGR2. This activates JAK1 and JAK2 kinases which form a STAT1 docking site. This leads to STAT1 pho...\nToxicity: ...", "source": "Interferon gamma-1b"}, {"id": "Interferon gamma-1b_INT_Tizanidine", "text": "Interaction: Interferon gamma-1b AND Tizanidine\nDetails: The serum concentration of Tizanidine can be increased when it is combined with Interferon gamma-1b.\nRisk: Monitor closely.", "source": "Interferon gamma-1b + Tizanidine"}, {"id": "Interferon gamma-1b_INT_Ambroxol acefyllinate", "text": "Interaction: Interferon gamma-1b AND Ambroxol acefyllinate\nDetails: The metabolism of Ambroxol acefyllinate can be decreased when combined with Interferon gamma-1b.\nRisk: Monitor closely.", "source": "Interferon gamma-1b + Ambroxol acefyllinate"}, {"id": "Interferon gamma-1b_INT_Theophylline", "text": "Interaction: Interferon gamma-1b AND Theophylline\nDetails: The metabolism of Theophylline can be decreased when combined with Interferon gamma-1b.\nRisk: Monitor closely.", "source": "Interferon gamma-1b + Theophylline"}, {"id": "Interferon gamma-1b_INT_Dyphylline", "text": "Interaction: Interferon gamma-1b AND Dyphylline\nDetails: The metabolism of Dyphylline can be decreased when combined with Interferon gamma-1b.\nRisk: Monitor closely.", "source": "Interferon gamma-1b + Dyphylline"}, {"id": "Interferon gamma-1b_INT_Aminophylline", "text": "Interaction: Interferon gamma-1b AND Aminophylline\nDetails: The metabolism of Aminophylline can be decreased when combined with Interferon gamma-1b.\nRisk: Monitor closely.", "source": "Interferon gamma-1b + Aminophylline"}, {"id": "Interferon gamma-1b_INT_Zidovudine", "text": "Interaction: Interferon gamma-1b AND Zidovudine\nDetails: The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Zidovudine.\nRisk: Monitor closely.", "source": "Interferon gamma-1b + Zidovudine"}, {"id": "Interferon Alfa-2a, Recombinant_GEN", "text": "Drug: Interferon Alfa-2a, Recombinant\nDescription: Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplasti...", "source": "Interferon Alfa-2a, Recombinant"}, {"id": "Interferon Alfa-2a, Recombinant_CLIN", "text": "Drug: Interferon Alfa-2a, Recombinant\nMechanism: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselv...\nToxicity: Interferon alfa-2 may cause serious adverse effects such as anemia; autoimmune diseases, including vasculitis, arthritis, hemolytic anemia, and erythematosus syndrome; cardiotoxicity; hepatotoxicity; ...", "source": "Interferon Alfa-2a, Recombinant"}, {"id": "Interferon Alfa-2a, Recombinant_INT_Aldesleukin", "text": "Interaction: Interferon Alfa-2a, Recombinant AND Aldesleukin\nDetails: The risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Interferon Alfa-2a, Recombinant + Aldesleukin"}, {"id": "Interferon Alfa-2a, Recombinant_INT_Ambroxol acefyllinate", "text": "Interaction: Interferon Alfa-2a, Recombinant AND Ambroxol acefyllinate\nDetails: The metabolism of Ambroxol acefyllinate can be decreased when combined with Interferon Alfa-2a, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2a, Recombinant + Ambroxol acefyllinate"}, {"id": "Interferon Alfa-2a, Recombinant_INT_Theophylline", "text": "Interaction: Interferon Alfa-2a, Recombinant AND Theophylline\nDetails: The metabolism of Theophylline can be decreased when combined with Interferon Alfa-2a, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2a, Recombinant + Theophylline"}, {"id": "Interferon Alfa-2a, Recombinant_INT_Dyphylline", "text": "Interaction: Interferon Alfa-2a, Recombinant AND Dyphylline\nDetails: The metabolism of Dyphylline can be decreased when combined with Interferon Alfa-2a, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2a, Recombinant + Dyphylline"}, {"id": "Interferon Alfa-2a, Recombinant_INT_Aminophylline", "text": "Interaction: Interferon Alfa-2a, Recombinant AND Aminophylline\nDetails: The metabolism of Aminophylline can be decreased when combined with Interferon Alfa-2a, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2a, Recombinant + Aminophylline"}, {"id": "Interferon Alfa-2a, Recombinant_INT_Methadone", "text": "Interaction: Interferon Alfa-2a, Recombinant AND Methadone\nDetails: The serum concentration of Methadone can be increased when it is combined with Interferon Alfa-2a, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2a, Recombinant + Methadone"}, {"id": "Interferon Alfa-2a, Recombinant_INT_Ribavirin", "text": "Interaction: Interferon Alfa-2a, Recombinant AND Ribavirin\nDetails: The risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Ribavirin.\nRisk: Monitor closely.", "source": "Interferon Alfa-2a, Recombinant + Ribavirin"}, {"id": "Interferon Alfa-2a, Recombinant_INT_Zidovudine", "text": "Interaction: Interferon Alfa-2a, Recombinant AND Zidovudine\nDetails: The risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Zidovudine.\nRisk: Monitor closely.", "source": "Interferon Alfa-2a, Recombinant + Zidovudine"}, {"id": "Desmopressin_GEN", "text": "Drug: Desmopressin\nDescription: Desmopressin is a chemical that is similar to Antidiuretic Hormone (ADH) which is found naturally in the body. It increases urine concentration and decreases urine production. Desmopressin is used to prevent and control excessive thirst, urination, and dehydration caused by injury, surgery, and cert...", "source": "Desmopressin"}, {"id": "Desmopressin_CLIN", "text": "Drug: Desmopressin\nMechanism: Desmopressin emulates the actions of endogenous human ADH (refer to Pharmacology section above). Desmpressin is a structural analogue of ADH modified by  deamination of 1-cysteine and substitution of ...\nToxicity: Overdose may lead to increased duration of action and lead to symptoms such as fluid retention, headaches, abdominal cramps, nausea, and facial flushing. Adverse effects include headache, nausea, abdo...", "source": "Desmopressin"}, {"id": "Desmopressin_INT_Tolvaptan", "text": "Interaction: Desmopressin AND Tolvaptan\nDetails: The therapeutic efficacy of Desmopressin can be decreased when used in combination with Tolvaptan.\nRisk: Monitor closely.", "source": "Desmopressin + Tolvaptan"}, {"id": "Desmopressin_INT_Amitriptyline", "text": "Interaction: Desmopressin AND Amitriptyline\nDetails: The risk or severity of adverse effects can be increased when Amitriptyline is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Amitriptyline"}, {"id": "Desmopressin_INT_Protriptyline", "text": "Interaction: Desmopressin AND Protriptyline\nDetails: The risk or severity of adverse effects can be increased when Protriptyline is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Protriptyline"}, {"id": "Desmopressin_INT_Imipramine", "text": "Interaction: Desmopressin AND Imipramine\nDetails: The risk or severity of adverse effects can be increased when Imipramine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Imipramine"}, {"id": "Desmopressin_INT_Nortriptyline", "text": "Interaction: Desmopressin AND Nortriptyline\nDetails: The risk or severity of adverse effects can be increased when Nortriptyline is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Nortriptyline"}, {"id": "Desmopressin_INT_Trimipramine", "text": "Interaction: Desmopressin AND Trimipramine\nDetails: The risk or severity of adverse effects can be increased when Trimipramine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Trimipramine"}, {"id": "Desmopressin_INT_Doxepin", "text": "Interaction: Desmopressin AND Doxepin\nDetails: The risk or severity of adverse effects can be increased when Doxepin is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Doxepin"}, {"id": "Desmopressin_INT_Desipramine", "text": "Interaction: Desmopressin AND Desipramine\nDetails: The risk or severity of adverse effects can be increased when Desipramine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Desipramine"}, {"id": "Desmopressin_INT_Clomipramine", "text": "Interaction: Desmopressin AND Clomipramine\nDetails: The risk or severity of adverse effects can be increased when Clomipramine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Clomipramine"}, {"id": "Desmopressin_INT_Mirtazapine", "text": "Interaction: Desmopressin AND Mirtazapine\nDetails: The risk or severity of adverse effects can be increased when Mirtazapine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Mirtazapine"}, {"id": "Desmopressin_INT_Cyclobenzaprine", "text": "Interaction: Desmopressin AND Cyclobenzaprine\nDetails: The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Cyclobenzaprine"}, {"id": "Desmopressin_INT_Amineptine", "text": "Interaction: Desmopressin AND Amineptine\nDetails: The risk or severity of adverse effects can be increased when Amineptine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Amineptine"}, {"id": "Desmopressin_INT_Esmirtazapine", "text": "Interaction: Desmopressin AND Esmirtazapine\nDetails: The risk or severity of adverse effects can be increased when Esmirtazapine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Esmirtazapine"}, {"id": "Desmopressin_INT_Dosulepin", "text": "Interaction: Desmopressin AND Dosulepin\nDetails: The risk or severity of adverse effects can be increased when Dosulepin is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Dosulepin"}, {"id": "Desmopressin_INT_Tianeptine", "text": "Interaction: Desmopressin AND Tianeptine\nDetails: The risk or severity of adverse effects can be increased when Tianeptine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Tianeptine"}, {"id": "Desmopressin_INT_Opipramol", "text": "Interaction: Desmopressin AND Opipramol\nDetails: The risk or severity of adverse effects can be increased when Opipramol is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Opipramol"}, {"id": "Desmopressin_INT_Dibenzepin", "text": "Interaction: Desmopressin AND Dibenzepin\nDetails: The risk or severity of adverse effects can be increased when Dibenzepin is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Dibenzepin"}, {"id": "Desmopressin_INT_Lofepramine", "text": "Interaction: Desmopressin AND Lofepramine\nDetails: The risk or severity of adverse effects can be increased when Lofepramine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Lofepramine"}, {"id": "Desmopressin_INT_Iprindole", "text": "Interaction: Desmopressin AND Iprindole\nDetails: The risk or severity of adverse effects can be increased when Iprindole is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Iprindole"}, {"id": "Desmopressin_INT_Amoxapine", "text": "Interaction: Desmopressin AND Amoxapine\nDetails: The risk or severity of adverse effects can be increased when Amoxapine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Amoxapine"}, {"id": "Desmopressin_INT_Ketorolac", "text": "Interaction: Desmopressin AND Ketorolac\nDetails: The risk or severity of adverse effects can be increased when Ketorolac is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Ketorolac"}, {"id": "Desmopressin_INT_Diclofenac", "text": "Interaction: Desmopressin AND Diclofenac\nDetails: The risk or severity of adverse effects can be increased when Diclofenac is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Diclofenac"}, {"id": "Desmopressin_INT_Flurbiprofen", "text": "Interaction: Desmopressin AND Flurbiprofen\nDetails: The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Flurbiprofen"}, {"id": "Desmopressin_INT_Bromfenac", "text": "Interaction: Desmopressin AND Bromfenac\nDetails: The risk or severity of adverse effects can be increased when Bromfenac is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Bromfenac"}, {"id": "Desmopressin_INT_Nepafenac", "text": "Interaction: Desmopressin AND Nepafenac\nDetails: The risk or severity of adverse effects can be increased when Nepafenac is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Nepafenac"}, {"id": "Desmopressin_INT_Etanercept", "text": "Interaction: Desmopressin AND Etanercept\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Etanercept"}, {"id": "Desmopressin_INT_Masoprocol", "text": "Interaction: Desmopressin AND Masoprocol\nDetails: The risk or severity of adverse effects can be increased when Masoprocol is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Masoprocol"}, {"id": "Desmopressin_INT_Adapalene", "text": "Interaction: Desmopressin AND Adapalene\nDetails: The risk or severity of adverse effects can be increased when Adapalene is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Adapalene"}, {"id": "Desmopressin_INT_Mesalazine", "text": "Interaction: Desmopressin AND Mesalazine\nDetails: The risk or severity of adverse effects can be increased when Mesalazine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Mesalazine"}, {"id": "Desmopressin_INT_Indomethacin", "text": "Interaction: Desmopressin AND Indomethacin\nDetails: The risk or severity of adverse effects can be increased when Indomethacin is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Indomethacin"}, {"id": "Desmopressin_INT_Pimecrolimus", "text": "Interaction: Desmopressin AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Pimecrolimus"}, {"id": "Desmopressin_INT_Nabumetone", "text": "Interaction: Desmopressin AND Nabumetone\nDetails: The risk or severity of adverse effects can be increased when Nabumetone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Nabumetone"}, {"id": "Desmopressin_INT_Tenoxicam", "text": "Interaction: Desmopressin AND Tenoxicam\nDetails: The risk or severity of adverse effects can be increased when Tenoxicam is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Tenoxicam"}, {"id": "Desmopressin_INT_Celecoxib", "text": "Interaction: Desmopressin AND Celecoxib\nDetails: The risk or severity of adverse effects can be increased when Celecoxib is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Celecoxib"}, {"id": "Desmopressin_INT_Tolmetin", "text": "Interaction: Desmopressin AND Tolmetin\nDetails: The risk or severity of adverse effects can be increased when Tolmetin is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Tolmetin"}, {"id": "Desmopressin_INT_Rofecoxib", "text": "Interaction: Desmopressin AND Rofecoxib\nDetails: The risk or severity of adverse effects can be increased when Rofecoxib is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Rofecoxib"}, {"id": "Desmopressin_INT_Piroxicam", "text": "Interaction: Desmopressin AND Piroxicam\nDetails: The risk or severity of adverse effects can be increased when Piroxicam is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Piroxicam"}, {"id": "Desmopressin_INT_Fenoprofen", "text": "Interaction: Desmopressin AND Fenoprofen\nDetails: The risk or severity of adverse effects can be increased when Fenoprofen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Fenoprofen"}, {"id": "Desmopressin_INT_Valdecoxib", "text": "Interaction: Desmopressin AND Valdecoxib\nDetails: The risk or severity of adverse effects can be increased when Valdecoxib is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Valdecoxib"}, {"id": "Desmopressin_INT_Sulindac", "text": "Interaction: Desmopressin AND Sulindac\nDetails: The risk or severity of adverse effects can be increased when Sulindac is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Sulindac"}, {"id": "Desmopressin_INT_Chloroquine", "text": "Interaction: Desmopressin AND Chloroquine\nDetails: The risk or severity of adverse effects can be increased when Chloroquine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Chloroquine"}, {"id": "Desmopressin_INT_Mycophenolate mofetil", "text": "Interaction: Desmopressin AND Mycophenolate mofetil\nDetails: The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Mycophenolate mofetil"}, {"id": "Desmopressin_INT_Naftifine", "text": "Interaction: Desmopressin AND Naftifine\nDetails: The risk or severity of adverse effects can be increased when Naftifine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Naftifine"}, {"id": "Desmopressin_INT_Zileuton", "text": "Interaction: Desmopressin AND Zileuton\nDetails: The risk or severity of adverse effects can be increased when Zileuton is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Zileuton"}, {"id": "Desmopressin_INT_Etodolac", "text": "Interaction: Desmopressin AND Etodolac\nDetails: The risk or severity of adverse effects can be increased when Etodolac is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Etodolac"}, {"id": "Desmopressin_INT_Olopatadine", "text": "Interaction: Desmopressin AND Olopatadine\nDetails: The risk or severity of adverse effects can be increased when Olopatadine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Olopatadine"}, {"id": "Desmopressin_INT_Mefenamic acid", "text": "Interaction: Desmopressin AND Mefenamic acid\nDetails: The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Mefenamic acid"}, {"id": "Desmopressin_INT_Naproxen", "text": "Interaction: Desmopressin AND Naproxen\nDetails: The risk or severity of adverse effects can be increased when Naproxen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Naproxen"}, {"id": "Desmopressin_INT_Sulfasalazine", "text": "Interaction: Desmopressin AND Sulfasalazine\nDetails: The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Sulfasalazine"}, {"id": "Desmopressin_INT_Phenylbutazone", "text": "Interaction: Desmopressin AND Phenylbutazone\nDetails: The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Phenylbutazone"}, {"id": "Desmopressin_INT_Meloxicam", "text": "Interaction: Desmopressin AND Meloxicam\nDetails: The risk or severity of adverse effects can be increased when Meloxicam is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Meloxicam"}, {"id": "Desmopressin_INT_Carprofen", "text": "Interaction: Desmopressin AND Carprofen\nDetails: The risk or severity of adverse effects can be increased when Carprofen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Carprofen"}, {"id": "Desmopressin_INT_Diflunisal", "text": "Interaction: Desmopressin AND Diflunisal\nDetails: The risk or severity of adverse effects can be increased when Diflunisal is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Diflunisal"}, {"id": "Desmopressin_INT_Suprofen", "text": "Interaction: Desmopressin AND Suprofen\nDetails: The risk or severity of adverse effects can be increased when Suprofen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Suprofen"}, {"id": "Desmopressin_INT_Salicylic acid", "text": "Interaction: Desmopressin AND Salicylic acid\nDetails: The risk or severity of adverse effects can be increased when Salicylic acid is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Salicylic acid"}, {"id": "Desmopressin_INT_Meclofenamic acid", "text": "Interaction: Desmopressin AND Meclofenamic acid\nDetails: The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Meclofenamic acid"}, {"id": "Desmopressin_INT_Acetylsalicylic acid", "text": "Interaction: Desmopressin AND Acetylsalicylic acid\nDetails: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Acetylsalicylic acid"}, {"id": "Desmopressin_INT_Azelastine", "text": "Interaction: Desmopressin AND Azelastine\nDetails: The risk or severity of adverse effects can be increased when Azelastine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Azelastine"}, {"id": "Desmopressin_INT_Oxaprozin", "text": "Interaction: Desmopressin AND Oxaprozin\nDetails: The risk or severity of adverse effects can be increased when Oxaprozin is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Oxaprozin"}, {"id": "Desmopressin_INT_Ketoprofen", "text": "Interaction: Desmopressin AND Ketoprofen\nDetails: The risk or severity of adverse effects can be increased when Ketoprofen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Ketoprofen"}, {"id": "Desmopressin_INT_Balsalazide", "text": "Interaction: Desmopressin AND Balsalazide\nDetails: The risk or severity of adverse effects can be increased when Balsalazide is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Balsalazide"}, {"id": "Desmopressin_INT_Mycophenolic acid", "text": "Interaction: Desmopressin AND Mycophenolic acid\nDetails: The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Mycophenolic acid"}, {"id": "Desmopressin_INT_Ibuprofen", "text": "Interaction: Desmopressin AND Ibuprofen\nDetails: The risk or severity of adverse effects can be increased when Ibuprofen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Ibuprofen"}, {"id": "Desmopressin_INT_Leflunomide", "text": "Interaction: Desmopressin AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Leflunomide is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Leflunomide"}, {"id": "Desmopressin_INT_Olsalazine", "text": "Interaction: Desmopressin AND Olsalazine\nDetails: The risk or severity of adverse effects can be increased when Olsalazine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Olsalazine"}, {"id": "Desmopressin_INT_Lumiracoxib", "text": "Interaction: Desmopressin AND Lumiracoxib\nDetails: The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Lumiracoxib"}, {"id": "Desmopressin_INT_Magnesium salicylate", "text": "Interaction: Desmopressin AND Magnesium salicylate\nDetails: The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Magnesium salicylate"}, {"id": "Desmopressin_INT_Salsalate", "text": "Interaction: Desmopressin AND Salsalate\nDetails: The risk or severity of adverse effects can be increased when Salsalate is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Salsalate"}, {"id": "Desmopressin_INT_Choline magnesium trisalicylate", "text": "Interaction: Desmopressin AND Choline magnesium trisalicylate\nDetails: The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Choline magnesium trisalicylate"}, {"id": "Desmopressin_INT_Antipyrine", "text": "Interaction: Desmopressin AND Antipyrine\nDetails: The risk or severity of adverse effects can be increased when Antipyrine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Antipyrine"}, {"id": "Desmopressin_INT_Tiaprofenic acid", "text": "Interaction: Desmopressin AND Tiaprofenic acid\nDetails: The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Tiaprofenic acid"}, {"id": "Desmopressin_INT_Etoricoxib", "text": "Interaction: Desmopressin AND Etoricoxib\nDetails: The risk or severity of adverse effects can be increased when Etoricoxib is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Etoricoxib"}, {"id": "Desmopressin_INT_Castanospermine", "text": "Interaction: Desmopressin AND Castanospermine\nDetails: The risk or severity of adverse effects can be increased when Castanospermine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Castanospermine"}, {"id": "Desmopressin_INT_Resveratrol", "text": "Interaction: Desmopressin AND Resveratrol\nDetails: The risk or severity of adverse effects can be increased when Resveratrol is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Resveratrol"}, {"id": "Desmopressin_INT_Oxyphenbutazone", "text": "Interaction: Desmopressin AND Oxyphenbutazone\nDetails: The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Oxyphenbutazone"}, {"id": "Desmopressin_INT_Niflumic Acid", "text": "Interaction: Desmopressin AND Niflumic Acid\nDetails: The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Niflumic Acid"}, {"id": "Desmopressin_INT_Nimesulide", "text": "Interaction: Desmopressin AND Nimesulide\nDetails: The risk or severity of adverse effects can be increased when Nimesulide is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Nimesulide"}, {"id": "Desmopressin_INT_Benoxaprofen", "text": "Interaction: Desmopressin AND Benoxaprofen\nDetails: The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Benoxaprofen"}, {"id": "Desmopressin_INT_Metamizole", "text": "Interaction: Desmopressin AND Metamizole\nDetails: The risk or severity of adverse effects can be increased when Metamizole is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Metamizole"}, {"id": "Desmopressin_INT_Zomepirac", "text": "Interaction: Desmopressin AND Zomepirac\nDetails: The risk or severity of adverse effects can be increased when Zomepirac is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Zomepirac"}, {"id": "Desmopressin_INT_Pirfenidone", "text": "Interaction: Desmopressin AND Pirfenidone\nDetails: The risk or severity of adverse effects can be increased when Pirfenidone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Pirfenidone"}, {"id": "Desmopressin_INT_SRT501", "text": "Interaction: Desmopressin AND SRT501\nDetails: The risk or severity of adverse effects can be increased when SRT501 is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + SRT501"}, {"id": "Desmopressin_INT_PTC299", "text": "Interaction: Desmopressin AND PTC299\nDetails: The risk or severity of adverse effects can be increased when PTC299 is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + PTC299"}, {"id": "Desmopressin_INT_Tarenflurbil", "text": "Interaction: Desmopressin AND Tarenflurbil\nDetails: The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Tarenflurbil"}, {"id": "Desmopressin_INT_Apremilast", "text": "Interaction: Desmopressin AND Apremilast\nDetails: The risk or severity of adverse effects can be increased when Apremilast is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Apremilast"}, {"id": "Desmopressin_INT_Andrographolide", "text": "Interaction: Desmopressin AND Andrographolide\nDetails: The risk or severity of adverse effects can be increased when Andrographolide is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Andrographolide"}, {"id": "Desmopressin_INT_Icatibant", "text": "Interaction: Desmopressin AND Icatibant\nDetails: The risk or severity of adverse effects can be increased when Icatibant is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Icatibant"}, {"id": "Desmopressin_INT_exisulind", "text": "Interaction: Desmopressin AND exisulind\nDetails: The risk or severity of adverse effects can be increased when exisulind is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + exisulind"}, {"id": "Desmopressin_INT_Lornoxicam", "text": "Interaction: Desmopressin AND Lornoxicam\nDetails: The risk or severity of adverse effects can be increased when Lornoxicam is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Lornoxicam"}, {"id": "Desmopressin_INT_Aceclofenac", "text": "Interaction: Desmopressin AND Aceclofenac\nDetails: The risk or severity of adverse effects can be increased when Aceclofenac is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Aceclofenac"}, {"id": "Desmopressin_INT_Zaltoprofen", "text": "Interaction: Desmopressin AND Zaltoprofen\nDetails: The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Zaltoprofen"}, {"id": "Desmopressin_INT_Seratrodast", "text": "Interaction: Desmopressin AND Seratrodast\nDetails: The risk or severity of adverse effects can be increased when Seratrodast is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Seratrodast"}, {"id": "Desmopressin_INT_Azapropazone", "text": "Interaction: Desmopressin AND Azapropazone\nDetails: The risk or severity of adverse effects can be increased when Azapropazone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Azapropazone"}, {"id": "Desmopressin_INT_Felbinac", "text": "Interaction: Desmopressin AND Felbinac\nDetails: The risk or severity of adverse effects can be increased when Felbinac is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Felbinac"}, {"id": "Desmopressin_INT_Tranilast", "text": "Interaction: Desmopressin AND Tranilast\nDetails: The risk or severity of adverse effects can be increased when Tranilast is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Tranilast"}, {"id": "Desmopressin_INT_Ferulic acid", "text": "Interaction: Desmopressin AND Ferulic acid\nDetails: The risk or severity of adverse effects can be increased when Ferulic acid is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Ferulic acid"}, {"id": "Desmopressin_INT_Parecoxib", "text": "Interaction: Desmopressin AND Parecoxib\nDetails: The risk or severity of adverse effects can be increased when Parecoxib is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Parecoxib"}, {"id": "Desmopressin_INT_Salicylamide", "text": "Interaction: Desmopressin AND Salicylamide\nDetails: The risk or severity of adverse effects can be increased when Salicylamide is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Salicylamide"}, {"id": "Desmopressin_INT_Teriflunomide", "text": "Interaction: Desmopressin AND Teriflunomide\nDetails: The risk or severity of adverse effects can be increased when Teriflunomide is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Teriflunomide"}, {"id": "Desmopressin_INT_D-Limonene", "text": "Interaction: Desmopressin AND D-Limonene\nDetails: The risk or severity of adverse effects can be increased when D-Limonene is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + D-Limonene"}, {"id": "Desmopressin_INT_Kebuzone", "text": "Interaction: Desmopressin AND Kebuzone\nDetails: The risk or severity of adverse effects can be increased when Kebuzone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Kebuzone"}, {"id": "Desmopressin_INT_Isoxicam", "text": "Interaction: Desmopressin AND Isoxicam\nDetails: The risk or severity of adverse effects can be increased when Isoxicam is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Isoxicam"}, {"id": "Desmopressin_INT_Indoprofen", "text": "Interaction: Desmopressin AND Indoprofen\nDetails: The risk or severity of adverse effects can be increased when Indoprofen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Indoprofen"}, {"id": "Desmopressin_INT_Ibuproxam", "text": "Interaction: Desmopressin AND Ibuproxam\nDetails: The risk or severity of adverse effects can be increased when Ibuproxam is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Ibuproxam"}, {"id": "Desmopressin_INT_Floctafenine", "text": "Interaction: Desmopressin AND Floctafenine\nDetails: The risk or severity of adverse effects can be increased when Floctafenine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Floctafenine"}, {"id": "Desmopressin_INT_Fenbufen", "text": "Interaction: Desmopressin AND Fenbufen\nDetails: The risk or severity of adverse effects can be increased when Fenbufen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Fenbufen"}, {"id": "Desmopressin_INT_Etofenamate", "text": "Interaction: Desmopressin AND Etofenamate\nDetails: The risk or severity of adverse effects can be increased when Etofenamate is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Etofenamate"}, {"id": "Desmopressin_INT_Epirizole", "text": "Interaction: Desmopressin AND Epirizole\nDetails: The risk or severity of adverse effects can be increased when Epirizole is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Epirizole"}, {"id": "Desmopressin_INT_Loxoprofen", "text": "Interaction: Desmopressin AND Loxoprofen\nDetails: The risk or severity of adverse effects can be increased when Loxoprofen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Loxoprofen"}, {"id": "Desmopressin_INT_Droxicam", "text": "Interaction: Desmopressin AND Droxicam\nDetails: The risk or severity of adverse effects can be increased when Droxicam is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Droxicam"}, {"id": "Desmopressin_INT_Tolfenamic Acid", "text": "Interaction: Desmopressin AND Tolfenamic Acid\nDetails: The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Tolfenamic Acid"}, {"id": "Desmopressin_INT_Clonixin", "text": "Interaction: Desmopressin AND Clonixin\nDetails: The risk or severity of adverse effects can be increased when Clonixin is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Clonixin"}, {"id": "Desmopressin_INT_Propacetamol", "text": "Interaction: Desmopressin AND Propacetamol\nDetails: The risk or severity of adverse effects can be increased when Propacetamol is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Propacetamol"}, {"id": "Desmopressin_INT_Evening primrose oil", "text": "Interaction: Desmopressin AND Evening primrose oil\nDetails: The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Evening primrose oil"}, {"id": "Desmopressin_INT_Orgotein", "text": "Interaction: Desmopressin AND Orgotein\nDetails: The risk or severity of adverse effects can be increased when Orgotein is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Orgotein"}, {"id": "Desmopressin_INT_Tepoxalin", "text": "Interaction: Desmopressin AND Tepoxalin\nDetails: The risk or severity of adverse effects can be increased when Tepoxalin is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Tepoxalin"}, {"id": "Desmopressin_INT_Flunixin", "text": "Interaction: Desmopressin AND Flunixin\nDetails: The risk or severity of adverse effects can be increased when Flunixin is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Flunixin"}, {"id": "Desmopressin_INT_Curcumin", "text": "Interaction: Desmopressin AND Curcumin\nDetails: The risk or severity of adverse effects can be increased when Curcumin is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Curcumin"}, {"id": "Desmopressin_INT_E-6201", "text": "Interaction: Desmopressin AND E-6201\nDetails: The risk or severity of adverse effects can be increased when E-6201 is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + E-6201"}, {"id": "Desmopressin_INT_Anisodamine", "text": "Interaction: Desmopressin AND Anisodamine\nDetails: The risk or severity of adverse effects can be increased when Anisodamine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Anisodamine"}, {"id": "Desmopressin_INT_Duvelisib", "text": "Interaction: Desmopressin AND Duvelisib\nDetails: The risk or severity of adverse effects can be increased when Duvelisib is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Duvelisib"}, {"id": "Desmopressin_INT_Triptolide", "text": "Interaction: Desmopressin AND Triptolide\nDetails: The risk or severity of adverse effects can be increased when Triptolide is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Triptolide"}, {"id": "Desmopressin_INT_Semapimod", "text": "Interaction: Desmopressin AND Semapimod\nDetails: The risk or severity of adverse effects can be increased when Semapimod is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Semapimod"}, {"id": "Desmopressin_INT_Bucillamine", "text": "Interaction: Desmopressin AND Bucillamine\nDetails: The risk or severity of adverse effects can be increased when Bucillamine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Bucillamine"}, {"id": "Desmopressin_INT_Lisofylline", "text": "Interaction: Desmopressin AND Lisofylline\nDetails: The risk or severity of adverse effects can be increased when Lisofylline is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Lisofylline"}, {"id": "Desmopressin_INT_Nitroaspirin", "text": "Interaction: Desmopressin AND Nitroaspirin\nDetails: The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Nitroaspirin"}, {"id": "Desmopressin_INT_Indobufen", "text": "Interaction: Desmopressin AND Indobufen\nDetails: The risk or severity of adverse effects can be increased when Indobufen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Indobufen"}, {"id": "Desmopressin_INT_Nafamostat", "text": "Interaction: Desmopressin AND Nafamostat\nDetails: The risk or severity of adverse effects can be increased when Nafamostat is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Nafamostat"}, {"id": "Desmopressin_INT_Mizoribine", "text": "Interaction: Desmopressin AND Mizoribine\nDetails: The risk or severity of adverse effects can be increased when Mizoribine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Mizoribine"}, {"id": "Desmopressin_INT_Apocynin", "text": "Interaction: Desmopressin AND Apocynin\nDetails: The risk or severity of adverse effects can be increased when Apocynin is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Apocynin"}, {"id": "Desmopressin_INT_Higenamine", "text": "Interaction: Desmopressin AND Higenamine\nDetails: The risk or severity of adverse effects can be increased when Higenamine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Higenamine"}, {"id": "Desmopressin_INT_Tinoridine", "text": "Interaction: Desmopressin AND Tinoridine\nDetails: The risk or severity of adverse effects can be increased when Tinoridine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Tinoridine"}, {"id": "Desmopressin_INT_Parthenolide", "text": "Interaction: Desmopressin AND Parthenolide\nDetails: The risk or severity of adverse effects can be increased when Parthenolide is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Parthenolide"}, {"id": "Desmopressin_INT_Serrapeptase", "text": "Interaction: Desmopressin AND Serrapeptase\nDetails: The risk or severity of adverse effects can be increased when Serrapeptase is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Serrapeptase"}, {"id": "Desmopressin_INT_Alclofenac", "text": "Interaction: Desmopressin AND Alclofenac\nDetails: The risk or severity of adverse effects can be increased when Alclofenac is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Alclofenac"}, {"id": "Desmopressin_INT_Fentiazac", "text": "Interaction: Desmopressin AND Fentiazac\nDetails: The risk or severity of adverse effects can be increased when Fentiazac is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Fentiazac"}, {"id": "Desmopressin_INT_Tribenoside", "text": "Interaction: Desmopressin AND Tribenoside\nDetails: The risk or severity of adverse effects can be increased when Tribenoside is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Tribenoside"}, {"id": "Desmopressin_INT_Suxibuzone", "text": "Interaction: Desmopressin AND Suxibuzone\nDetails: The risk or severity of adverse effects can be increased when Suxibuzone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Suxibuzone"}, {"id": "Desmopressin_INT_Bumadizone", "text": "Interaction: Desmopressin AND Bumadizone\nDetails: The risk or severity of adverse effects can be increased when Bumadizone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Bumadizone"}, {"id": "Desmopressin_INT_Alminoprofen", "text": "Interaction: Desmopressin AND Alminoprofen\nDetails: The risk or severity of adverse effects can be increased when Alminoprofen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Alminoprofen"}, {"id": "Desmopressin_INT_Flunoxaprofen", "text": "Interaction: Desmopressin AND Flunoxaprofen\nDetails: The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Flunoxaprofen"}, {"id": "Desmopressin_INT_Bufexamac", "text": "Interaction: Desmopressin AND Bufexamac\nDetails: The risk or severity of adverse effects can be increased when Bufexamac is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Bufexamac"}, {"id": "Desmopressin_INT_Feprazone", "text": "Interaction: Desmopressin AND Feprazone\nDetails: The risk or severity of adverse effects can be increased when Feprazone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Feprazone"}, {"id": "Desmopressin_INT_Difenpiramide", "text": "Interaction: Desmopressin AND Difenpiramide\nDetails: The risk or severity of adverse effects can be increased when Difenpiramide is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Difenpiramide"}, {"id": "Desmopressin_INT_Nifenazone", "text": "Interaction: Desmopressin AND Nifenazone\nDetails: The risk or severity of adverse effects can be increased when Nifenazone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Nifenazone"}, {"id": "Desmopressin_INT_Lonazolac", "text": "Interaction: Desmopressin AND Lonazolac\nDetails: The risk or severity of adverse effects can be increased when Lonazolac is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Lonazolac"}, {"id": "Desmopressin_INT_Tenidap", "text": "Interaction: Desmopressin AND Tenidap\nDetails: The risk or severity of adverse effects can be increased when Tenidap is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Tenidap"}, {"id": "Desmopressin_INT_Bendazac", "text": "Interaction: Desmopressin AND Bendazac\nDetails: The risk or severity of adverse effects can be increased when Bendazac is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Bendazac"}, {"id": "Desmopressin_INT_Pranoprofen", "text": "Interaction: Desmopressin AND Pranoprofen\nDetails: The risk or severity of adverse effects can be increased when Pranoprofen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Pranoprofen"}, {"id": "Desmopressin_INT_Propyphenazone", "text": "Interaction: Desmopressin AND Propyphenazone\nDetails: The risk or severity of adverse effects can be increased when Propyphenazone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Propyphenazone"}, {"id": "Desmopressin_INT_Proglumetacin", "text": "Interaction: Desmopressin AND Proglumetacin\nDetails: The risk or severity of adverse effects can be increased when Proglumetacin is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Proglumetacin"}, {"id": "Desmopressin_INT_Guacetisal", "text": "Interaction: Desmopressin AND Guacetisal\nDetails: The risk or severity of adverse effects can be increased when Guacetisal is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Guacetisal"}, {"id": "Desmopressin_INT_Bevonium", "text": "Interaction: Desmopressin AND Bevonium\nDetails: The risk or severity of adverse effects can be increased when Bevonium is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Bevonium"}, {"id": "Desmopressin_INT_Ethenzamide", "text": "Interaction: Desmopressin AND Ethenzamide\nDetails: The risk or severity of adverse effects can be increased when Ethenzamide is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Ethenzamide"}, {"id": "Desmopressin_INT_Carbaspirin calcium", "text": "Interaction: Desmopressin AND Carbaspirin calcium\nDetails: The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Carbaspirin calcium"}, {"id": "Desmopressin_INT_Mofebutazone", "text": "Interaction: Desmopressin AND Mofebutazone\nDetails: The risk or severity of adverse effects can be increased when Mofebutazone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Mofebutazone"}, {"id": "Desmopressin_INT_Proquazone", "text": "Interaction: Desmopressin AND Proquazone\nDetails: The risk or severity of adverse effects can be increased when Proquazone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Proquazone"}, {"id": "Desmopressin_INT_Benorilate", "text": "Interaction: Desmopressin AND Benorilate\nDetails: The risk or severity of adverse effects can be increased when Benorilate is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Benorilate"}, {"id": "Desmopressin_INT_Pirprofen", "text": "Interaction: Desmopressin AND Pirprofen\nDetails: The risk or severity of adverse effects can be increased when Pirprofen is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Pirprofen"}, {"id": "Desmopressin_INT_Acemetacin", "text": "Interaction: Desmopressin AND Acemetacin\nDetails: The risk or severity of adverse effects can be increased when Acemetacin is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Acemetacin"}, {"id": "Desmopressin_INT_Imidazole salicylate", "text": "Interaction: Desmopressin AND Imidazole salicylate\nDetails: The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Imidazole salicylate"}, {"id": "Desmopressin_INT_Benzydamine", "text": "Interaction: Desmopressin AND Benzydamine\nDetails: The risk or severity of adverse effects can be increased when Benzydamine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Benzydamine"}, {"id": "Desmopressin_INT_Tramadol", "text": "Interaction: Desmopressin AND Tramadol\nDetails: The risk or severity of adverse effects can be increased when Tramadol is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Tramadol"}, {"id": "Desmopressin_INT_Morphine", "text": "Interaction: Desmopressin AND Morphine\nDetails: The risk or severity of adverse effects can be increased when Morphine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Morphine"}, {"id": "Desmopressin_INT_Hydromorphone", "text": "Interaction: Desmopressin AND Hydromorphone\nDetails: The risk or severity of adverse effects can be increased when Hydromorphone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Hydromorphone"}, {"id": "Desmopressin_INT_Methadone", "text": "Interaction: Desmopressin AND Methadone\nDetails: The risk or severity of adverse effects can be increased when Methadone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Methadone"}, {"id": "Desmopressin_INT_Pethidine", "text": "Interaction: Desmopressin AND Pethidine\nDetails: The risk or severity of adverse effects can be increased when Pethidine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Pethidine"}, {"id": "Desmopressin_INT_Oxycodone", "text": "Interaction: Desmopressin AND Oxycodone\nDetails: The risk or severity of adverse effects can be increased when Oxycodone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Oxycodone"}, {"id": "Desmopressin_INT_Butorphanol", "text": "Interaction: Desmopressin AND Butorphanol\nDetails: The risk or severity of adverse effects can be increased when Butorphanol is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Butorphanol"}, {"id": "Desmopressin_INT_Dextropropoxyphene", "text": "Interaction: Desmopressin AND Dextropropoxyphene\nDetails: The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Dextropropoxyphene"}, {"id": "Desmopressin_INT_Pentazocine", "text": "Interaction: Desmopressin AND Pentazocine\nDetails: The risk or severity of adverse effects can be increased when Pentazocine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Pentazocine"}, {"id": "Desmopressin_INT_Fentanyl", "text": "Interaction: Desmopressin AND Fentanyl\nDetails: The risk or severity of adverse effects can be increased when Fentanyl is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Fentanyl"}, {"id": "Desmopressin_INT_Nalbuphine", "text": "Interaction: Desmopressin AND Nalbuphine\nDetails: The risk or severity of adverse effects can be increased when Nalbuphine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Nalbuphine"}, {"id": "Desmopressin_INT_Buprenorphine", "text": "Interaction: Desmopressin AND Buprenorphine\nDetails: The risk or severity of adverse effects can be increased when Buprenorphine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Buprenorphine"}, {"id": "Desmopressin_INT_Dezocine", "text": "Interaction: Desmopressin AND Dezocine\nDetails: The risk or severity of adverse effects can be increased when Dezocine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Dezocine"}, {"id": "Desmopressin_INT_Dextromoramide", "text": "Interaction: Desmopressin AND Dextromoramide\nDetails: The risk or severity of adverse effects can be increased when Dextromoramide is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Dextromoramide"}, {"id": "Desmopressin_INT_Dihydrocodeine", "text": "Interaction: Desmopressin AND Dihydrocodeine\nDetails: The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Dihydrocodeine"}, {"id": "Desmopressin_INT_Ketobemidone", "text": "Interaction: Desmopressin AND Ketobemidone\nDetails: The risk or severity of adverse effects can be increased when Ketobemidone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Ketobemidone"}, {"id": "Desmopressin_INT_Piritramide", "text": "Interaction: Desmopressin AND Piritramide\nDetails: The risk or severity of adverse effects can be increased when Piritramide is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Piritramide"}, {"id": "Desmopressin_INT_Meptazinol", "text": "Interaction: Desmopressin AND Meptazinol\nDetails: The risk or severity of adverse effects can be increased when Meptazinol is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Meptazinol"}, {"id": "Desmopressin_INT_Phenazocine", "text": "Interaction: Desmopressin AND Phenazocine\nDetails: The risk or severity of adverse effects can be increased when Phenazocine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Phenazocine"}, {"id": "Desmopressin_INT_Tilidine", "text": "Interaction: Desmopressin AND Tilidine\nDetails: The risk or severity of adverse effects can be increased when Tilidine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Tilidine"}, {"id": "Desmopressin_INT_Codeine", "text": "Interaction: Desmopressin AND Codeine\nDetails: The risk or severity of adverse effects can be increased when Codeine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Codeine"}, {"id": "Desmopressin_INT_Sufentanil", "text": "Interaction: Desmopressin AND Sufentanil\nDetails: The risk or severity of adverse effects can be increased when Sufentanil is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Sufentanil"}, {"id": "Desmopressin_INT_Alfentanil", "text": "Interaction: Desmopressin AND Alfentanil\nDetails: The risk or severity of adverse effects can be increased when Alfentanil is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Alfentanil"}, {"id": "Desmopressin_INT_Levorphanol", "text": "Interaction: Desmopressin AND Levorphanol\nDetails: The risk or severity of adverse effects can be increased when Levorphanol is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Levorphanol"}, {"id": "Desmopressin_INT_Remifentanil", "text": "Interaction: Desmopressin AND Remifentanil\nDetails: The risk or severity of adverse effects can be increased when Remifentanil is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Remifentanil"}, {"id": "Desmopressin_INT_Hydrocodone", "text": "Interaction: Desmopressin AND Hydrocodone\nDetails: The risk or severity of adverse effects can be increased when Hydrocodone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Hydrocodone"}, {"id": "Desmopressin_INT_Diphenoxylate", "text": "Interaction: Desmopressin AND Diphenoxylate\nDetails: The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Diphenoxylate"}, {"id": "Desmopressin_INT_Oxymorphone", "text": "Interaction: Desmopressin AND Oxymorphone\nDetails: The risk or severity of adverse effects can be increased when Oxymorphone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Oxymorphone"}, {"id": "Desmopressin_INT_Levomethadyl Acetate", "text": "Interaction: Desmopressin AND Levomethadyl Acetate\nDetails: The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Levomethadyl Acetate"}, {"id": "Desmopressin_INT_Methadyl Acetate", "text": "Interaction: Desmopressin AND Methadyl Acetate\nDetails: The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Methadyl Acetate"}, {"id": "Desmopressin_INT_Dihydroetorphine", "text": "Interaction: Desmopressin AND Dihydroetorphine\nDetails: The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Dihydroetorphine"}, {"id": "Desmopressin_INT_Heroin", "text": "Interaction: Desmopressin AND Heroin\nDetails: The risk or severity of adverse effects can be increased when Heroin is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Heroin"}, {"id": "Desmopressin_INT_Ethylmorphine", "text": "Interaction: Desmopressin AND Ethylmorphine\nDetails: The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Ethylmorphine"}, {"id": "Desmopressin_INT_Etorphine", "text": "Interaction: Desmopressin AND Etorphine\nDetails: The risk or severity of adverse effects can be increased when Etorphine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Etorphine"}, {"id": "Desmopressin_INT_Carfentanil", "text": "Interaction: Desmopressin AND Carfentanil\nDetails: The risk or severity of adverse effects can be increased when Carfentanil is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Carfentanil"}, {"id": "Desmopressin_INT_Alphacetylmethadol", "text": "Interaction: Desmopressin AND Alphacetylmethadol\nDetails: The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Alphacetylmethadol"}, {"id": "Desmopressin_INT_Dihydromorphine", "text": "Interaction: Desmopressin AND Dihydromorphine\nDetails: The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Dihydromorphine"}, {"id": "Desmopressin_INT_DPDPE", "text": "Interaction: Desmopressin AND DPDPE\nDetails: The risk or severity of adverse effects can be increased when DPDPE is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + DPDPE"}, {"id": "Desmopressin_INT_Lofentanil", "text": "Interaction: Desmopressin AND Lofentanil\nDetails: The risk or severity of adverse effects can be increased when Lofentanil is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Lofentanil"}, {"id": "Desmopressin_INT_Opium", "text": "Interaction: Desmopressin AND Opium\nDetails: The risk or severity of adverse effects can be increased when Opium is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Opium"}, {"id": "Desmopressin_INT_Normethadone", "text": "Interaction: Desmopressin AND Normethadone\nDetails: The risk or severity of adverse effects can be increased when Normethadone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Normethadone"}, {"id": "Desmopressin_INT_Alphaprodine", "text": "Interaction: Desmopressin AND Alphaprodine\nDetails: The risk or severity of adverse effects can be increased when Alphaprodine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Alphaprodine"}, {"id": "Desmopressin_INT_Phenoperidine", "text": "Interaction: Desmopressin AND Phenoperidine\nDetails: The risk or severity of adverse effects can be increased when Phenoperidine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Phenoperidine"}, {"id": "Desmopressin_INT_Bezitramide", "text": "Interaction: Desmopressin AND Bezitramide\nDetails: The risk or severity of adverse effects can be increased when Bezitramide is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Bezitramide"}, {"id": "Desmopressin_INT_Tapentadol", "text": "Interaction: Desmopressin AND Tapentadol\nDetails: The risk or severity of adverse effects can be increased when Tapentadol is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Tapentadol"}, {"id": "Desmopressin_INT_Nicomorphine", "text": "Interaction: Desmopressin AND Nicomorphine\nDetails: The risk or severity of adverse effects can be increased when Nicomorphine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Nicomorphine"}, {"id": "Desmopressin_INT_Duloxetine", "text": "Interaction: Desmopressin AND Duloxetine\nDetails: The risk or severity of adverse effects can be increased when Duloxetine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Duloxetine"}, {"id": "Desmopressin_INT_Nefazodone", "text": "Interaction: Desmopressin AND Nefazodone\nDetails: The risk or severity of adverse effects can be increased when Nefazodone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Nefazodone"}, {"id": "Desmopressin_INT_Desvenlafaxine", "text": "Interaction: Desmopressin AND Desvenlafaxine\nDetails: The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Desvenlafaxine"}, {"id": "Desmopressin_INT_Milnacipran", "text": "Interaction: Desmopressin AND Milnacipran\nDetails: The risk or severity of adverse effects can be increased when Milnacipran is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Milnacipran"}, {"id": "Desmopressin_INT_Venlafaxine", "text": "Interaction: Desmopressin AND Venlafaxine\nDetails: The risk or severity of adverse effects can be increased when Venlafaxine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Venlafaxine"}, {"id": "Desmopressin_INT_Levomilnacipran", "text": "Interaction: Desmopressin AND Levomilnacipran\nDetails: The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Levomilnacipran"}, {"id": "Desmopressin_INT_Dapoxetine", "text": "Interaction: Desmopressin AND Dapoxetine\nDetails: The risk or severity of adverse effects can be increased when Dapoxetine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Dapoxetine"}, {"id": "Desmopressin_INT_Indalpine", "text": "Interaction: Desmopressin AND Indalpine\nDetails: The risk or severity of adverse effects can be increased when Indalpine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Indalpine"}, {"id": "Desmopressin_INT_Fluvoxamine", "text": "Interaction: Desmopressin AND Fluvoxamine\nDetails: The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Fluvoxamine"}, {"id": "Desmopressin_INT_Citalopram", "text": "Interaction: Desmopressin AND Citalopram\nDetails: The risk or severity of adverse effects can be increased when Citalopram is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Citalopram"}, {"id": "Desmopressin_INT_Fluoxetine", "text": "Interaction: Desmopressin AND Fluoxetine\nDetails: The risk or severity of adverse effects can be increased when Fluoxetine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Fluoxetine"}, {"id": "Desmopressin_INT_Paroxetine", "text": "Interaction: Desmopressin AND Paroxetine\nDetails: The risk or severity of adverse effects can be increased when Paroxetine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Paroxetine"}, {"id": "Desmopressin_INT_Sertraline", "text": "Interaction: Desmopressin AND Sertraline\nDetails: The risk or severity of adverse effects can be increased when Sertraline is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Sertraline"}, {"id": "Desmopressin_INT_Escitalopram", "text": "Interaction: Desmopressin AND Escitalopram\nDetails: The risk or severity of adverse effects can be increased when Escitalopram is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Escitalopram"}, {"id": "Desmopressin_INT_Zimelidine", "text": "Interaction: Desmopressin AND Zimelidine\nDetails: The risk or severity of adverse effects can be increased when Zimelidine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Zimelidine"}, {"id": "Desmopressin_INT_Etoperidone", "text": "Interaction: Desmopressin AND Etoperidone\nDetails: The risk or severity of adverse effects can be increased when Etoperidone is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Etoperidone"}, {"id": "Desmopressin_INT_Alaproclate", "text": "Interaction: Desmopressin AND Alaproclate\nDetails: The risk or severity of adverse effects can be increased when Alaproclate is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Alaproclate"}, {"id": "Desmopressin_INT_Carbamazepine", "text": "Interaction: Desmopressin AND Carbamazepine\nDetails: The risk or severity of adverse effects can be increased when Carbamazepine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Carbamazepine"}, {"id": "Desmopressin_INT_Chlorpromazine", "text": "Interaction: Desmopressin AND Chlorpromazine\nDetails: The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Chlorpromazine"}, {"id": "Desmopressin_INT_Demeclocycline", "text": "Interaction: Desmopressin AND Demeclocycline\nDetails: The therapeutic efficacy of Desmopressin can be decreased when used in combination with Demeclocycline.\nRisk: Monitor closely.", "source": "Desmopressin + Demeclocycline"}, {"id": "Desmopressin_INT_Lamotrigine", "text": "Interaction: Desmopressin AND Lamotrigine\nDetails: The risk or severity of adverse effects can be increased when Lamotrigine is combined with Desmopressin.\nRisk: Monitor closely.", "source": "Desmopressin + Lamotrigine"}, {"id": "Desmopressin_INT_Lithium", "text": "Interaction: Desmopressin AND Lithium\nDetails: The therapeutic efficacy of Desmopressin can be decreased when used in combination with Lithium.\nRisk: Monitor closely.", "source": "Desmopressin + Lithium"}, {"id": "Coagulation factor VIIa Recombinant Human_GEN", "text": "Drug: Coagulation factor VIIa Recombinant Human\nDescription: Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is ca...", "source": "Coagulation factor VIIa Recombinant Human"}, {"id": "Coagulation factor VIIa Recombinant Human_CLIN", "text": "Drug: Coagulation factor VIIa Recombinant Human\nMechanism: NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin....\nToxicity: ...", "source": "Coagulation factor VIIa Recombinant Human"}, {"id": "Oprelvekin_GEN", "text": "Drug: Oprelvekin\nDescription: Oprelvekin, the active ingredient in Neumega\u00ae is recombinant Interleukin eleven, which is produced in Escherichia coli (E. coli) by recombinant DNA technology. The protein has a molecular mass of approximately 19,000 daltons, and is non-glycosylated. The polypeptide is 177 amino acids in length (the...", "source": "Oprelvekin"}, {"id": "Oprelvekin_CLIN", "text": "Drug: Oprelvekin\nMechanism: Oprelvekin binds to the interleukin 11 receptor which leads to a cascade of signal transduction events. IL-11 is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoie...\nToxicity: ...", "source": "Oprelvekin"}, {"id": "Oprelvekin_INT_Trastuzumab", "text": "Interaction: Oprelvekin AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Trastuzumab"}, {"id": "Oprelvekin_INT_Paclitaxel", "text": "Interaction: Oprelvekin AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Paclitaxel"}, {"id": "Oprelvekin_INT_Docetaxel", "text": "Interaction: Oprelvekin AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Docetaxel"}, {"id": "Oprelvekin_INT_Cabazitaxel", "text": "Interaction: Oprelvekin AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Cabazitaxel"}, {"id": "Oprelvekin_INT_Digoxin", "text": "Interaction: Oprelvekin AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Digoxin"}, {"id": "Oprelvekin_INT_Acetyldigitoxin", "text": "Interaction: Oprelvekin AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Acetyldigitoxin"}, {"id": "Oprelvekin_INT_Deslanoside", "text": "Interaction: Oprelvekin AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Deslanoside"}, {"id": "Oprelvekin_INT_Ouabain", "text": "Interaction: Oprelvekin AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Ouabain"}, {"id": "Oprelvekin_INT_Digitoxin", "text": "Interaction: Oprelvekin AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Digitoxin"}, {"id": "Oprelvekin_INT_Cymarin", "text": "Interaction: Oprelvekin AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Cymarin"}, {"id": "Oprelvekin_INT_Proscillaridin", "text": "Interaction: Oprelvekin AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Proscillaridin"}, {"id": "Oprelvekin_INT_Metildigoxin", "text": "Interaction: Oprelvekin AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Metildigoxin"}, {"id": "Oprelvekin_INT_Peruvoside", "text": "Interaction: Oprelvekin AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Peruvoside"}, {"id": "Oprelvekin_INT_Lanatoside C", "text": "Interaction: Oprelvekin AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Lanatoside C"}, {"id": "Oprelvekin_INT_Gitoformate", "text": "Interaction: Oprelvekin AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Gitoformate"}, {"id": "Oprelvekin_INT_Acetyldigoxin", "text": "Interaction: Oprelvekin AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Acetyldigoxin"}, {"id": "Oprelvekin_INT_Oleandrin", "text": "Interaction: Oprelvekin AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Oleandrin"}, {"id": "Oprelvekin_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Oprelvekin AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Digoxin Immune Fab (Ovine)"}, {"id": "Oprelvekin_INT_Bevacizumab", "text": "Interaction: Oprelvekin AND Bevacizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Bevacizumab"}, {"id": "Oprelvekin_INT_Cyclophosphamide", "text": "Interaction: Oprelvekin AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Oprelvekin + Cyclophosphamide"}, {"id": "Palifermin_GEN", "text": "Drug: Palifermin\nDescription: Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli....", "source": "Palifermin"}, {"id": "Palifermin_CLIN", "text": "Drug: Palifermin\nMechanism: Kepivance binds to the human keratinocyte growth factor (KGF) receptor found on buccal cell surfaces. The binding activates a Ras-MapK (Map kinase) signaling pathway which leads to the transcriptional...\nToxicity: ...", "source": "Palifermin"}, {"id": "Palifermin_INT_Bemiparin", "text": "Interaction: Palifermin AND Bemiparin\nDetails: The serum concentration of Palifermin can be increased when it is combined with Bemiparin.\nRisk: Monitor closely.", "source": "Palifermin + Bemiparin"}, {"id": "Palifermin_INT_Nadroparin", "text": "Interaction: Palifermin AND Nadroparin\nDetails: The serum concentration of Palifermin can be increased when it is combined with Nadroparin.\nRisk: Monitor closely.", "source": "Palifermin + Nadroparin"}, {"id": "Palifermin_INT_Reviparin", "text": "Interaction: Palifermin AND Reviparin\nDetails: The serum concentration of Palifermin can be increased when it is combined with Reviparin.\nRisk: Monitor closely.", "source": "Palifermin + Reviparin"}, {"id": "Palifermin_INT_Tinzaparin", "text": "Interaction: Palifermin AND Tinzaparin\nDetails: The serum concentration of Palifermin can be increased when it is combined with Tinzaparin.\nRisk: Monitor closely.", "source": "Palifermin + Tinzaparin"}, {"id": "Palifermin_INT_Enoxaparin", "text": "Interaction: Palifermin AND Enoxaparin\nDetails: The serum concentration of Palifermin can be increased when it is combined with Enoxaparin.\nRisk: Monitor closely.", "source": "Palifermin + Enoxaparin"}, {"id": "Palifermin_INT_Parnaparin", "text": "Interaction: Palifermin AND Parnaparin\nDetails: The serum concentration of Palifermin can be increased when it is combined with Parnaparin.\nRisk: Monitor closely.", "source": "Palifermin + Parnaparin"}, {"id": "Palifermin_INT_Certoparin", "text": "Interaction: Palifermin AND Certoparin\nDetails: The serum concentration of Palifermin can be increased when it is combined with Certoparin.\nRisk: Monitor closely.", "source": "Palifermin + Certoparin"}, {"id": "Palifermin_INT_Dalteparin", "text": "Interaction: Palifermin AND Dalteparin\nDetails: The serum concentration of Palifermin can be increased when it is combined with Dalteparin.\nRisk: Monitor closely.", "source": "Palifermin + Dalteparin"}, {"id": "Palifermin_INT_Ardeparin", "text": "Interaction: Palifermin AND Ardeparin\nDetails: The serum concentration of Palifermin can be increased when it is combined with Ardeparin.\nRisk: Monitor closely.", "source": "Palifermin + Ardeparin"}, {"id": "Palifermin_INT_Heparin", "text": "Interaction: Palifermin AND Heparin\nDetails: The serum concentration of Palifermin can be increased when it is combined with Heparin.\nRisk: Monitor closely.", "source": "Palifermin + Heparin"}, {"id": "Glucagon recombinant_GEN", "text": "Drug: Glucagon recombinant\nDescription: 29 residue peptide hormone. Glucagon is synthesized in a special non- pathogenic laboratory strain of Escherichia coli bacteria that has been genetically altered by the addition of the gene for glucagons...", "source": "Glucagon recombinant"}, {"id": "Glucagon recombinant_CLIN", "text": "Drug: Glucagon recombinant\nMechanism: Glucagon binds the glucagon receptor, a G protein-coupled receptor located in the plasma membrane, which then initiates a dual signaling pathway using both adenylate cyclase activation and increased i...\nToxicity: ...", "source": "Glucagon recombinant"}, {"id": "Glucagon recombinant_INT_Benzatropine", "text": "Interaction: Glucagon recombinant AND Benzatropine\nDetails: The risk or severity of adverse effects can be increased when Benzatropine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Benzatropine"}, {"id": "Glucagon recombinant_INT_Ipratropium bromide", "text": "Interaction: Glucagon recombinant AND Ipratropium bromide\nDetails: The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Ipratropium bromide"}, {"id": "Glucagon recombinant_INT_Trihexyphenidyl", "text": "Interaction: Glucagon recombinant AND Trihexyphenidyl\nDetails: The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Trihexyphenidyl"}, {"id": "Glucagon recombinant_INT_Procyclidine", "text": "Interaction: Glucagon recombinant AND Procyclidine\nDetails: The risk or severity of adverse effects can be increased when Procyclidine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Procyclidine"}, {"id": "Glucagon recombinant_INT_Ethopropazine", "text": "Interaction: Glucagon recombinant AND Ethopropazine\nDetails: The risk or severity of adverse effects can be increased when Ethopropazine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Ethopropazine"}, {"id": "Glucagon recombinant_INT_Atropine", "text": "Interaction: Glucagon recombinant AND Atropine\nDetails: The risk or severity of adverse effects can be increased when Atropine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Atropine"}, {"id": "Glucagon recombinant_INT_Scopolamine", "text": "Interaction: Glucagon recombinant AND Scopolamine\nDetails: The risk or severity of adverse effects can be increased when Scopolamine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Scopolamine"}, {"id": "Glucagon recombinant_INT_Tropicamide", "text": "Interaction: Glucagon recombinant AND Tropicamide\nDetails: The risk or severity of adverse effects can be increased when Tropicamide is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Tropicamide"}, {"id": "Glucagon recombinant_INT_Biperiden", "text": "Interaction: Glucagon recombinant AND Biperiden\nDetails: The risk or severity of adverse effects can be increased when Biperiden is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Biperiden"}, {"id": "Glucagon recombinant_INT_Cyclopentolate", "text": "Interaction: Glucagon recombinant AND Cyclopentolate\nDetails: The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Cyclopentolate"}, {"id": "Glucagon recombinant_INT_Tiotropium", "text": "Interaction: Glucagon recombinant AND Tiotropium\nDetails: The risk or severity of adverse effects can be increased when Tiotropium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Tiotropium"}, {"id": "Glucagon recombinant_INT_Dexetimide", "text": "Interaction: Glucagon recombinant AND Dexetimide\nDetails: The risk or severity of adverse effects can be increased when Dexetimide is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Dexetimide"}, {"id": "Glucagon recombinant_INT_Bornaprine", "text": "Interaction: Glucagon recombinant AND Bornaprine\nDetails: The risk or severity of adverse effects can be increased when Bornaprine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Bornaprine"}, {"id": "Glucagon recombinant_INT_Phenglutarimide", "text": "Interaction: Glucagon recombinant AND Phenglutarimide\nDetails: The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Phenglutarimide"}, {"id": "Glucagon recombinant_INT_Propantheline", "text": "Interaction: Glucagon recombinant AND Propantheline\nDetails: The risk or severity of adverse effects can be increased when Propantheline is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Propantheline"}, {"id": "Glucagon recombinant_INT_Dicyclomine", "text": "Interaction: Glucagon recombinant AND Dicyclomine\nDetails: The risk or severity of adverse effects can be increased when Dicyclomine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Dicyclomine"}, {"id": "Glucagon recombinant_INT_Aclidinium", "text": "Interaction: Glucagon recombinant AND Aclidinium\nDetails: The risk or severity of adverse effects can be increased when Aclidinium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Aclidinium"}, {"id": "Glucagon recombinant_INT_Glycopyrronium", "text": "Interaction: Glucagon recombinant AND Glycopyrronium\nDetails: The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Glycopyrronium"}, {"id": "Glucagon recombinant_INT_Trospium", "text": "Interaction: Glucagon recombinant AND Trospium\nDetails: The risk or severity of adverse effects can be increased when Trospium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Trospium"}, {"id": "Glucagon recombinant_INT_Oxyphenonium", "text": "Interaction: Glucagon recombinant AND Oxyphenonium\nDetails: The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Oxyphenonium"}, {"id": "Glucagon recombinant_INT_Hyoscyamine", "text": "Interaction: Glucagon recombinant AND Hyoscyamine\nDetails: The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Hyoscyamine"}, {"id": "Glucagon recombinant_INT_Gallamine Triethiodide", "text": "Interaction: Glucagon recombinant AND Gallamine Triethiodide\nDetails: The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Gallamine Triethiodide"}, {"id": "Glucagon recombinant_INT_Darifenacin", "text": "Interaction: Glucagon recombinant AND Darifenacin\nDetails: The risk or severity of adverse effects can be increased when Darifenacin is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Darifenacin"}, {"id": "Glucagon recombinant_INT_Anisotropine Methylbromide", "text": "Interaction: Glucagon recombinant AND Anisotropine Methylbromide\nDetails: The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Anisotropine Methylbromide"}, {"id": "Glucagon recombinant_INT_Mecamylamine", "text": "Interaction: Glucagon recombinant AND Mecamylamine\nDetails: The risk or severity of adverse effects can be increased when Mecamylamine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Mecamylamine"}, {"id": "Glucagon recombinant_INT_Pirenzepine", "text": "Interaction: Glucagon recombinant AND Pirenzepine\nDetails: The risk or severity of adverse effects can be increased when Pirenzepine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Pirenzepine"}, {"id": "Glucagon recombinant_INT_Atracurium besylate", "text": "Interaction: Glucagon recombinant AND Atracurium besylate\nDetails: The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Atracurium besylate"}, {"id": "Glucagon recombinant_INT_Quinidine", "text": "Interaction: Glucagon recombinant AND Quinidine\nDetails: The risk or severity of adverse effects can be increased when Quinidine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Quinidine"}, {"id": "Glucagon recombinant_INT_Methantheline", "text": "Interaction: Glucagon recombinant AND Methantheline\nDetails: The risk or severity of adverse effects can be increased when Methantheline is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Methantheline"}, {"id": "Glucagon recombinant_INT_Desloratadine", "text": "Interaction: Glucagon recombinant AND Desloratadine\nDetails: The risk or severity of adverse effects can be increased when Desloratadine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Desloratadine"}, {"id": "Glucagon recombinant_INT_Tolterodine", "text": "Interaction: Glucagon recombinant AND Tolterodine\nDetails: The risk or severity of adverse effects can be increased when Tolterodine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Tolterodine"}, {"id": "Glucagon recombinant_INT_Oxybutynin", "text": "Interaction: Glucagon recombinant AND Oxybutynin\nDetails: The risk or severity of adverse effects can be increased when Oxybutynin is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Oxybutynin"}, {"id": "Glucagon recombinant_INT_Pentolinium", "text": "Interaction: Glucagon recombinant AND Pentolinium\nDetails: The risk or severity of adverse effects can be increased when Pentolinium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Pentolinium"}, {"id": "Glucagon recombinant_INT_Trimethaphan", "text": "Interaction: Glucagon recombinant AND Trimethaphan\nDetails: The risk or severity of adverse effects can be increased when Trimethaphan is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Trimethaphan"}, {"id": "Glucagon recombinant_INT_Orphenadrine", "text": "Interaction: Glucagon recombinant AND Orphenadrine\nDetails: The risk or severity of adverse effects can be increased when Orphenadrine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Orphenadrine"}, {"id": "Glucagon recombinant_INT_Tubocurarine", "text": "Interaction: Glucagon recombinant AND Tubocurarine\nDetails: The risk or severity of adverse effects can be increased when Tubocurarine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Tubocurarine"}, {"id": "Glucagon recombinant_INT_Pancuronium", "text": "Interaction: Glucagon recombinant AND Pancuronium\nDetails: The risk or severity of adverse effects can be increased when Pancuronium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Pancuronium"}, {"id": "Glucagon recombinant_INT_Pipecuronium", "text": "Interaction: Glucagon recombinant AND Pipecuronium\nDetails: The risk or severity of adverse effects can be increased when Pipecuronium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Pipecuronium"}, {"id": "Glucagon recombinant_INT_Vecuronium", "text": "Interaction: Glucagon recombinant AND Vecuronium\nDetails: The risk or severity of adverse effects can be increased when Vecuronium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Vecuronium"}, {"id": "Glucagon recombinant_INT_Solifenacin", "text": "Interaction: Glucagon recombinant AND Solifenacin\nDetails: The risk or severity of adverse effects can be increased when Solifenacin is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Solifenacin"}, {"id": "Glucagon recombinant_INT_Fesoterodine", "text": "Interaction: Glucagon recombinant AND Fesoterodine\nDetails: The risk or severity of adverse effects can be increased when Fesoterodine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Fesoterodine"}, {"id": "Glucagon recombinant_INT_Hexamethonium", "text": "Interaction: Glucagon recombinant AND Hexamethonium\nDetails: The risk or severity of adverse effects can be increased when Hexamethonium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Hexamethonium"}, {"id": "Glucagon recombinant_INT_Chlorphenoxamine", "text": "Interaction: Glucagon recombinant AND Chlorphenoxamine\nDetails: The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Chlorphenoxamine"}, {"id": "Glucagon recombinant_INT_Benactyzine", "text": "Interaction: Glucagon recombinant AND Benactyzine\nDetails: The risk or severity of adverse effects can be increased when Benactyzine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Benactyzine"}, {"id": "Glucagon recombinant_INT_Butylscopolamine", "text": "Interaction: Glucagon recombinant AND Butylscopolamine\nDetails: The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Butylscopolamine"}, {"id": "Glucagon recombinant_INT_Propiverine", "text": "Interaction: Glucagon recombinant AND Propiverine\nDetails: The risk or severity of adverse effects can be increased when Propiverine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Propiverine"}, {"id": "Glucagon recombinant_INT_Atracurium", "text": "Interaction: Glucagon recombinant AND Atracurium\nDetails: The risk or severity of adverse effects can be increased when Atracurium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Atracurium"}, {"id": "Glucagon recombinant_INT_Otilonium", "text": "Interaction: Glucagon recombinant AND Otilonium\nDetails: The risk or severity of adverse effects can be increased when Otilonium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Otilonium"}, {"id": "Glucagon recombinant_INT_Emepronium", "text": "Interaction: Glucagon recombinant AND Emepronium\nDetails: The risk or severity of adverse effects can be increased when Emepronium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Emepronium"}, {"id": "Glucagon recombinant_INT_Gallamine", "text": "Interaction: Glucagon recombinant AND Gallamine\nDetails: The risk or severity of adverse effects can be increased when Gallamine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Gallamine"}, {"id": "Glucagon recombinant_INT_Alcuronium", "text": "Interaction: Glucagon recombinant AND Alcuronium\nDetails: The risk or severity of adverse effects can be increased when Alcuronium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Alcuronium"}, {"id": "Glucagon recombinant_INT_Metixene", "text": "Interaction: Glucagon recombinant AND Metixene\nDetails: The risk or severity of adverse effects can be increased when Metixene is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Metixene"}, {"id": "Glucagon recombinant_INT_Homatropine", "text": "Interaction: Glucagon recombinant AND Homatropine\nDetails: The risk or severity of adverse effects can be increased when Homatropine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Homatropine"}, {"id": "Glucagon recombinant_INT_Methscopolamine", "text": "Interaction: Glucagon recombinant AND Methscopolamine\nDetails: The risk or severity of adverse effects can be increased when Methscopolamine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Methscopolamine"}, {"id": "Glucagon recombinant_INT_Oxitropium", "text": "Interaction: Glucagon recombinant AND Oxitropium\nDetails: The risk or severity of adverse effects can be increased when Oxitropium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Oxitropium"}, {"id": "Glucagon recombinant_INT_Tropatepine", "text": "Interaction: Glucagon recombinant AND Tropatepine\nDetails: The risk or severity of adverse effects can be increased when Tropatepine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Tropatepine"}, {"id": "Glucagon recombinant_INT_Mazaticol", "text": "Interaction: Glucagon recombinant AND Mazaticol\nDetails: The risk or severity of adverse effects can be increased when Mazaticol is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Mazaticol"}, {"id": "Glucagon recombinant_INT_Etybenzatropine", "text": "Interaction: Glucagon recombinant AND Etybenzatropine\nDetails: The risk or severity of adverse effects can be increased when Etybenzatropine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Etybenzatropine"}, {"id": "Glucagon recombinant_INT_Etanautine", "text": "Interaction: Glucagon recombinant AND Etanautine\nDetails: The risk or severity of adverse effects can be increased when Etanautine is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Etanautine"}, {"id": "Glucagon recombinant_INT_Methylscopolamine bromide", "text": "Interaction: Glucagon recombinant AND Methylscopolamine bromide\nDetails: The risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Methylscopolamine bromide"}, {"id": "Glucagon recombinant_INT_Umeclidinium", "text": "Interaction: Glucagon recombinant AND Umeclidinium\nDetails: The risk or severity of adverse effects can be increased when Umeclidinium is combined with Glucagon recombinant.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Umeclidinium"}, {"id": "Glucagon recombinant_INT_Indomethacin", "text": "Interaction: Glucagon recombinant AND Indomethacin\nDetails: The therapeutic efficacy of Glucagon recombinant can be decreased when used in combination with Indomethacin.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Indomethacin"}, {"id": "Glucagon recombinant_INT_Warfarin", "text": "Interaction: Glucagon recombinant AND Warfarin\nDetails: Glucagon recombinant may increase the anticoagulant activities of Warfarin.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Warfarin"}, {"id": "Glucagon recombinant_INT_Dicoumarol", "text": "Interaction: Glucagon recombinant AND Dicoumarol\nDetails: Glucagon recombinant may increase the anticoagulant activities of Dicoumarol.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Dicoumarol"}, {"id": "Glucagon recombinant_INT_Phenindione", "text": "Interaction: Glucagon recombinant AND Phenindione\nDetails: Glucagon recombinant may increase the anticoagulant activities of Phenindione.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Phenindione"}, {"id": "Glucagon recombinant_INT_Phenprocoumon", "text": "Interaction: Glucagon recombinant AND Phenprocoumon\nDetails: Glucagon recombinant may increase the anticoagulant activities of Phenprocoumon.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Phenprocoumon"}, {"id": "Glucagon recombinant_INT_Acenocoumarol", "text": "Interaction: Glucagon recombinant AND Acenocoumarol\nDetails: Glucagon recombinant may increase the anticoagulant activities of Acenocoumarol.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Acenocoumarol"}, {"id": "Glucagon recombinant_INT_Ethyl biscoumacetate", "text": "Interaction: Glucagon recombinant AND Ethyl biscoumacetate\nDetails: Glucagon recombinant may increase the anticoagulant activities of Ethyl biscoumacetate.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Ethyl biscoumacetate"}, {"id": "Glucagon recombinant_INT_Fluindione", "text": "Interaction: Glucagon recombinant AND Fluindione\nDetails: Glucagon recombinant may increase the anticoagulant activities of Fluindione.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Fluindione"}, {"id": "Glucagon recombinant_INT_Clorindione", "text": "Interaction: Glucagon recombinant AND Clorindione\nDetails: Glucagon recombinant may increase the anticoagulant activities of Clorindione.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Clorindione"}, {"id": "Glucagon recombinant_INT_Diphenadione", "text": "Interaction: Glucagon recombinant AND Diphenadione\nDetails: Glucagon recombinant may increase the anticoagulant activities of Diphenadione.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Diphenadione"}, {"id": "Glucagon recombinant_INT_Tioclomarol", "text": "Interaction: Glucagon recombinant AND Tioclomarol\nDetails: Glucagon recombinant may increase the anticoagulant activities of Tioclomarol.\nRisk: Monitor closely.", "source": "Glucagon recombinant + Tioclomarol"}, {"id": "Aldesleukin_GEN", "text": "Drug: Aldesleukin\nDescription: Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human...", "source": "Aldesleukin"}, {"id": "Aldesleukin_CLIN", "text": "Drug: Aldesleukin\nMechanism: Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation o...\nToxicity: ...", "source": "Aldesleukin"}, {"id": "Aldesleukin_INT_Pravastatin", "text": "Interaction: Aldesleukin AND Pravastatin\nDetails: The serum concentration of Pravastatin can be increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Pravastatin"}, {"id": "Aldesleukin_INT_Lovastatin", "text": "Interaction: Aldesleukin AND Lovastatin\nDetails: The serum concentration of Lovastatin can be increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Lovastatin"}, {"id": "Aldesleukin_INT_Cerivastatin", "text": "Interaction: Aldesleukin AND Cerivastatin\nDetails: The serum concentration of Cerivastatin can be increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Cerivastatin"}, {"id": "Aldesleukin_INT_Simvastatin", "text": "Interaction: Aldesleukin AND Simvastatin\nDetails: The serum concentration of Simvastatin can be increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Simvastatin"}, {"id": "Aldesleukin_INT_Fluvastatin", "text": "Interaction: Aldesleukin AND Fluvastatin\nDetails: The serum concentration of Fluvastatin can be increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Fluvastatin"}, {"id": "Aldesleukin_INT_Rosuvastatin", "text": "Interaction: Aldesleukin AND Rosuvastatin\nDetails: The serum concentration of Rosuvastatin can be increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Rosuvastatin"}, {"id": "Aldesleukin_INT_Pitavastatin", "text": "Interaction: Aldesleukin AND Pitavastatin\nDetails: The serum concentration of Pitavastatin can be increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Pitavastatin"}, {"id": "Aldesleukin_INT_Mevastatin", "text": "Interaction: Aldesleukin AND Mevastatin\nDetails: The serum concentration of Mevastatin can be increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Mevastatin"}, {"id": "Aldesleukin_INT_Ubidecarenone", "text": "Interaction: Aldesleukin AND Ubidecarenone\nDetails: The serum concentration of Ubidecarenone can be increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Ubidecarenone"}, {"id": "Aldesleukin_INT_Methysergide", "text": "Interaction: Aldesleukin AND Methysergide\nDetails: The risk or severity of adverse effects can be increased when Methysergide is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Methysergide"}, {"id": "Aldesleukin_INT_Dihydroergotamine", "text": "Interaction: Aldesleukin AND Dihydroergotamine\nDetails: The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Dihydroergotamine"}, {"id": "Aldesleukin_INT_Lisuride", "text": "Interaction: Aldesleukin AND Lisuride\nDetails: The risk or severity of adverse effects can be increased when Lisuride is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Lisuride"}, {"id": "Aldesleukin_INT_Ergotamine", "text": "Interaction: Aldesleukin AND Ergotamine\nDetails: The risk or severity of adverse effects can be increased when Ergotamine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Ergotamine"}, {"id": "Aldesleukin_INT_Nicergoline", "text": "Interaction: Aldesleukin AND Nicergoline\nDetails: The risk or severity of adverse effects can be increased when Nicergoline is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Nicergoline"}, {"id": "Aldesleukin_INT_Ergonovine", "text": "Interaction: Aldesleukin AND Ergonovine\nDetails: The risk or severity of adverse effects can be increased when Ergonovine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Ergonovine"}, {"id": "Aldesleukin_INT_Dihydroergocristine", "text": "Interaction: Aldesleukin AND Dihydroergocristine\nDetails: The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Dihydroergocristine"}, {"id": "Aldesleukin_INT_Methylergometrine", "text": "Interaction: Aldesleukin AND Methylergometrine\nDetails: The risk or severity of adverse effects can be increased when Methylergometrine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Methylergometrine"}, {"id": "Aldesleukin_INT_Cabergoline", "text": "Interaction: Aldesleukin AND Cabergoline\nDetails: The risk or severity of adverse effects can be increased when Cabergoline is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Cabergoline"}, {"id": "Aldesleukin_INT_Pergolide", "text": "Interaction: Aldesleukin AND Pergolide\nDetails: The risk or severity of adverse effects can be increased when Pergolide is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Pergolide"}, {"id": "Aldesleukin_INT_Lysergic Acid Diethylamide", "text": "Interaction: Aldesleukin AND Lysergic Acid Diethylamide\nDetails: The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Lysergic Acid Diethylamide"}, {"id": "Aldesleukin_INT_Dihydroergocornine", "text": "Interaction: Aldesleukin AND Dihydroergocornine\nDetails: The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Dihydroergocornine"}, {"id": "Aldesleukin_INT_Dihydroergocryptine", "text": "Interaction: Aldesleukin AND Dihydroergocryptine\nDetails: The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Dihydroergocryptine"}, {"id": "Aldesleukin_INT_Terguride", "text": "Interaction: Aldesleukin AND Terguride\nDetails: The risk or severity of adverse effects can be increased when Terguride is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Terguride"}, {"id": "Aldesleukin_INT_Metergoline", "text": "Interaction: Aldesleukin AND Metergoline\nDetails: The risk or severity of adverse effects can be increased when Metergoline is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Metergoline"}, {"id": "Aldesleukin_INT_Metamizole", "text": "Interaction: Aldesleukin AND Metamizole\nDetails: The risk or severity of myelosuppression can be increased when Metamizole is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Metamizole"}, {"id": "Aldesleukin_INT_Bosutinib", "text": "Interaction: Aldesleukin AND Bosutinib\nDetails: The serum concentration of Bosutinib can be increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Bosutinib"}, {"id": "Aldesleukin_INT_Ibrutinib", "text": "Interaction: Aldesleukin AND Ibrutinib\nDetails: The serum concentration of Ibrutinib can be increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Ibrutinib"}, {"id": "Aldesleukin_INT_Tolvaptan", "text": "Interaction: Aldesleukin AND Tolvaptan\nDetails: The serum concentration of Tolvaptan can be increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Tolvaptan"}, {"id": "Aldesleukin_INT_Clozapine", "text": "Interaction: Aldesleukin AND Clozapine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clozapine.\nRisk: Monitor closely.", "source": "Aldesleukin + Clozapine"}, {"id": "Aldesleukin_INT_Fluorometholone", "text": "Interaction: Aldesleukin AND Fluorometholone\nDetails: Fluorometholone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Fluorometholone"}, {"id": "Aldesleukin_INT_Beclomethasone dipropionate", "text": "Interaction: Aldesleukin AND Beclomethasone dipropionate\nDetails: Beclomethasone dipropionate may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Beclomethasone dipropionate"}, {"id": "Aldesleukin_INT_Betamethasone", "text": "Interaction: Aldesleukin AND Betamethasone\nDetails: Betamethasone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Betamethasone"}, {"id": "Aldesleukin_INT_Triamcinolone", "text": "Interaction: Aldesleukin AND Triamcinolone\nDetails: Triamcinolone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Triamcinolone"}, {"id": "Aldesleukin_INT_Hydrocortisone", "text": "Interaction: Aldesleukin AND Hydrocortisone\nDetails: Hydrocortisone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Hydrocortisone"}, {"id": "Aldesleukin_INT_Prednisolone", "text": "Interaction: Aldesleukin AND Prednisolone\nDetails: Prednisolone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Prednisolone"}, {"id": "Aldesleukin_INT_Fluocinonide", "text": "Interaction: Aldesleukin AND Fluocinonide\nDetails: Fluocinonide may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Fluocinonide"}, {"id": "Aldesleukin_INT_Budesonide", "text": "Interaction: Aldesleukin AND Budesonide\nDetails: Budesonide may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Budesonide"}, {"id": "Aldesleukin_INT_Dexamethasone", "text": "Interaction: Aldesleukin AND Dexamethasone\nDetails: Dexamethasone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Dexamethasone"}, {"id": "Aldesleukin_INT_Ciclesonide", "text": "Interaction: Aldesleukin AND Ciclesonide\nDetails: Ciclesonide may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Ciclesonide"}, {"id": "Aldesleukin_INT_Tixocortol", "text": "Interaction: Aldesleukin AND Tixocortol\nDetails: Tixocortol may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Tixocortol"}, {"id": "Aldesleukin_INT_Fluocinolone Acetonide", "text": "Interaction: Aldesleukin AND Fluocinolone Acetonide\nDetails: Fluocinolone Acetonide may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Fluocinolone Acetonide"}, {"id": "Aldesleukin_INT_Diflorasone", "text": "Interaction: Aldesleukin AND Diflorasone\nDetails: Diflorasone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Diflorasone"}, {"id": "Aldesleukin_INT_Alclometasone", "text": "Interaction: Aldesleukin AND Alclometasone\nDetails: Alclometasone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Alclometasone"}, {"id": "Aldesleukin_INT_Amcinonide", "text": "Interaction: Aldesleukin AND Amcinonide\nDetails: Amcinonide may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Amcinonide"}, {"id": "Aldesleukin_INT_Desoximetasone", "text": "Interaction: Aldesleukin AND Desoximetasone\nDetails: Desoximetasone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Desoximetasone"}, {"id": "Aldesleukin_INT_Clocortolone", "text": "Interaction: Aldesleukin AND Clocortolone\nDetails: Clocortolone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Clocortolone"}, {"id": "Aldesleukin_INT_Flurandrenolide", "text": "Interaction: Aldesleukin AND Flurandrenolide\nDetails: Flurandrenolide may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Flurandrenolide"}, {"id": "Aldesleukin_INT_Rimexolone", "text": "Interaction: Aldesleukin AND Rimexolone\nDetails: Rimexolone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Rimexolone"}, {"id": "Aldesleukin_INT_Methylprednisolone", "text": "Interaction: Aldesleukin AND Methylprednisolone\nDetails: Methylprednisolone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Methylprednisolone"}, {"id": "Aldesleukin_INT_Clobetasol propionate", "text": "Interaction: Aldesleukin AND Clobetasol propionate\nDetails: Clobetasol propionate may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Clobetasol propionate"}, {"id": "Aldesleukin_INT_Prednicarbate", "text": "Interaction: Aldesleukin AND Prednicarbate\nDetails: Prednicarbate may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Prednicarbate"}, {"id": "Aldesleukin_INT_Cortisone acetate", "text": "Interaction: Aldesleukin AND Cortisone acetate\nDetails: Cortisone acetate may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Cortisone acetate"}, {"id": "Aldesleukin_INT_Flunisolide", "text": "Interaction: Aldesleukin AND Flunisolide\nDetails: Flunisolide may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Flunisolide"}, {"id": "Aldesleukin_INT_Fluticasone propionate", "text": "Interaction: Aldesleukin AND Fluticasone propionate\nDetails: Fluticasone propionate may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Fluticasone propionate"}, {"id": "Aldesleukin_INT_Mometasone", "text": "Interaction: Aldesleukin AND Mometasone\nDetails: Mometasone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Mometasone"}, {"id": "Aldesleukin_INT_Loteprednol", "text": "Interaction: Aldesleukin AND Loteprednol\nDetails: Loteprednol may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Loteprednol"}, {"id": "Aldesleukin_INT_Fluticasone furoate", "text": "Interaction: Aldesleukin AND Fluticasone furoate\nDetails: Fluticasone furoate may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Fluticasone furoate"}, {"id": "Aldesleukin_INT_Difluprednate", "text": "Interaction: Aldesleukin AND Difluprednate\nDetails: Difluprednate may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Difluprednate"}, {"id": "Aldesleukin_INT_Medrysone", "text": "Interaction: Aldesleukin AND Medrysone\nDetails: Medrysone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Medrysone"}, {"id": "Aldesleukin_INT_Prednisone", "text": "Interaction: Aldesleukin AND Prednisone\nDetails: Prednisone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Prednisone"}, {"id": "Aldesleukin_INT_Estrone", "text": "Interaction: Aldesleukin AND Estrone\nDetails: Estrone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Estrone"}, {"id": "Aldesleukin_INT_Flumethasone", "text": "Interaction: Aldesleukin AND Flumethasone\nDetails: Flumethasone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Flumethasone"}, {"id": "Aldesleukin_INT_Fludrocortisone", "text": "Interaction: Aldesleukin AND Fludrocortisone\nDetails: Fludrocortisone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Fludrocortisone"}, {"id": "Aldesleukin_INT_Desoxycorticosterone Pivalate", "text": "Interaction: Aldesleukin AND Desoxycorticosterone Pivalate\nDetails: Desoxycorticosterone Pivalate may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Desoxycorticosterone Pivalate"}, {"id": "Aldesleukin_INT_Paramethasone", "text": "Interaction: Aldesleukin AND Paramethasone\nDetails: Paramethasone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Paramethasone"}, {"id": "Aldesleukin_INT_19-norandrostenedione", "text": "Interaction: Aldesleukin AND 19-norandrostenedione\nDetails: 19-norandrostenedione may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + 19-norandrostenedione"}, {"id": "Aldesleukin_INT_5-androstenedione", "text": "Interaction: Aldesleukin AND 5-androstenedione\nDetails: 5-androstenedione may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + 5-androstenedione"}, {"id": "Aldesleukin_INT_Androstenedione", "text": "Interaction: Aldesleukin AND Androstenedione\nDetails: Androstenedione may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Androstenedione"}, {"id": "Aldesleukin_INT_Prasterone", "text": "Interaction: Aldesleukin AND Prasterone\nDetails: Prasterone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Prasterone"}, {"id": "Aldesleukin_INT_Equilin", "text": "Interaction: Aldesleukin AND Equilin\nDetails: Equilin may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Equilin"}, {"id": "Aldesleukin_INT_Pregnenolone", "text": "Interaction: Aldesleukin AND Pregnenolone\nDetails: Pregnenolone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Pregnenolone"}, {"id": "Aldesleukin_INT_Equilenin", "text": "Interaction: Aldesleukin AND Equilenin\nDetails: Equilenin may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Equilenin"}, {"id": "Aldesleukin_INT_Estrone sulfate", "text": "Interaction: Aldesleukin AND Estrone sulfate\nDetails: Estrone sulfate may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Estrone sulfate"}, {"id": "Aldesleukin_INT_Aldosterone", "text": "Interaction: Aldesleukin AND Aldosterone\nDetails: Aldosterone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Aldosterone"}, {"id": "Aldesleukin_INT_Corticosterone", "text": "Interaction: Aldesleukin AND Corticosterone\nDetails: Corticosterone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Corticosterone"}, {"id": "Aldesleukin_INT_Oleoyl-estrone", "text": "Interaction: Aldesleukin AND Oleoyl-estrone\nDetails: Oleoyl-estrone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Oleoyl-estrone"}, {"id": "Aldesleukin_INT_16-Bromoepiandrosterone", "text": "Interaction: Aldesleukin AND 16-Bromoepiandrosterone\nDetails: 16-Bromoepiandrosterone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + 16-Bromoepiandrosterone"}, {"id": "Aldesleukin_INT_HE3286", "text": "Interaction: Aldesleukin AND HE3286\nDetails: HE3286 may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + HE3286"}, {"id": "Aldesleukin_INT_anecortave acetate", "text": "Interaction: Aldesleukin AND anecortave acetate\nDetails: anecortave acetate may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + anecortave acetate"}, {"id": "Aldesleukin_INT_ME-609", "text": "Interaction: Aldesleukin AND ME-609\nDetails: ME-609 may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + ME-609"}, {"id": "Aldesleukin_INT_NCX 1022", "text": "Interaction: Aldesleukin AND NCX 1022\nDetails: NCX 1022 may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + NCX 1022"}, {"id": "Aldesleukin_INT_Prasterone sulfate", "text": "Interaction: Aldesleukin AND Prasterone sulfate\nDetails: Prasterone sulfate may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Prasterone sulfate"}, {"id": "Aldesleukin_INT_Istaroxime", "text": "Interaction: Aldesleukin AND Istaroxime\nDetails: Istaroxime may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Istaroxime"}, {"id": "Aldesleukin_INT_fluasterone", "text": "Interaction: Aldesleukin AND fluasterone\nDetails: fluasterone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + fluasterone"}, {"id": "Aldesleukin_INT_Desoxycorticosterone acetate", "text": "Interaction: Aldesleukin AND Desoxycorticosterone acetate\nDetails: Desoxycorticosterone acetate may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Desoxycorticosterone acetate"}, {"id": "Aldesleukin_INT_Formestane", "text": "Interaction: Aldesleukin AND Formestane\nDetails: Formestane may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Formestane"}, {"id": "Aldesleukin_INT_Fluprednidene", "text": "Interaction: Aldesleukin AND Fluprednidene\nDetails: Fluprednidene may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Fluprednidene"}, {"id": "Aldesleukin_INT_Fluocortolone", "text": "Interaction: Aldesleukin AND Fluocortolone\nDetails: Fluocortolone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Fluocortolone"}, {"id": "Aldesleukin_INT_Difluocortolone", "text": "Interaction: Aldesleukin AND Difluocortolone\nDetails: Difluocortolone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Difluocortolone"}, {"id": "Aldesleukin_INT_Fluprednisolone", "text": "Interaction: Aldesleukin AND Fluprednisolone\nDetails: Fluprednisolone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Fluprednisolone"}, {"id": "Aldesleukin_INT_Dexamethasone isonicotinate", "text": "Interaction: Aldesleukin AND Dexamethasone isonicotinate\nDetails: Dexamethasone isonicotinate may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Dexamethasone isonicotinate"}, {"id": "Aldesleukin_INT_Melengestrol", "text": "Interaction: Aldesleukin AND Melengestrol\nDetails: Melengestrol may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Melengestrol"}, {"id": "Aldesleukin_INT_Clobetasol", "text": "Interaction: Aldesleukin AND Clobetasol\nDetails: Clobetasol may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Clobetasol"}, {"id": "Aldesleukin_INT_Anecortave", "text": "Interaction: Aldesleukin AND Anecortave\nDetails: Anecortave may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Anecortave"}, {"id": "Aldesleukin_INT_Atamestane", "text": "Interaction: Aldesleukin AND Atamestane\nDetails: Atamestane may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Atamestane"}, {"id": "Aldesleukin_INT_Cortexolone 17\u03b1-propionate", "text": "Interaction: Aldesleukin AND Cortexolone 17\u03b1-propionate\nDetails: Cortexolone 17\u03b1-propionate may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Cortexolone 17\u03b1-propionate"}, {"id": "Aldesleukin_INT_Clobetasone", "text": "Interaction: Aldesleukin AND Clobetasone\nDetails: Clobetasone may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Clobetasone"}, {"id": "Aldesleukin_INT_Ulobetasol", "text": "Interaction: Aldesleukin AND Ulobetasol\nDetails: Ulobetasol may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Ulobetasol"}, {"id": "Aldesleukin_INT_Desonide", "text": "Interaction: Aldesleukin AND Desonide\nDetails: Desonide may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Desonide"}, {"id": "Aldesleukin_INT_Halcinonide", "text": "Interaction: Aldesleukin AND Halcinonide\nDetails: Halcinonide may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Halcinonide"}, {"id": "Aldesleukin_INT_Deflazacort", "text": "Interaction: Aldesleukin AND Deflazacort\nDetails: Deflazacort may decrease the antineoplastic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Deflazacort"}, {"id": "Aldesleukin_INT_Atorvastatin", "text": "Interaction: Aldesleukin AND Atorvastatin\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Atorvastatin.\nRisk: Monitor closely.", "source": "Aldesleukin + Atorvastatin"}, {"id": "Aldesleukin_INT_Trastuzumab", "text": "Interaction: Aldesleukin AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Trastuzumab"}, {"id": "Aldesleukin_INT_Interferon Alfa-2a, Recombinant", "text": "Interaction: Aldesleukin AND Interferon Alfa-2a, Recombinant\nDetails: The risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Interferon Alfa-2a, Recombinant"}, {"id": "Aldesleukin_INT_Interferon Alfa-2b, Recombinant", "text": "Interaction: Aldesleukin AND Interferon Alfa-2b, Recombinant\nDetails: The risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Interferon Alfa-2b, Recombinant"}, {"id": "Aldesleukin_INT_Interferon alfacon-1", "text": "Interaction: Aldesleukin AND Interferon alfacon-1\nDetails: The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Interferon alfacon-1"}, {"id": "Aldesleukin_INT_Interferon alfa-n3", "text": "Interaction: Aldesleukin AND Interferon alfa-n3\nDetails: The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Interferon alfa-n3"}, {"id": "Aldesleukin_INT_Peginterferon alfa-2a", "text": "Interaction: Aldesleukin AND Peginterferon alfa-2a\nDetails: The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Peginterferon alfa-2a"}, {"id": "Aldesleukin_INT_Peginterferon alfa-2b", "text": "Interaction: Aldesleukin AND Peginterferon alfa-2b\nDetails: The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Peginterferon alfa-2b"}, {"id": "Aldesleukin_INT_Paclitaxel", "text": "Interaction: Aldesleukin AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Paclitaxel"}, {"id": "Aldesleukin_INT_Docetaxel", "text": "Interaction: Aldesleukin AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Docetaxel"}, {"id": "Aldesleukin_INT_Cabazitaxel", "text": "Interaction: Aldesleukin AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Cabazitaxel"}, {"id": "Aldesleukin_INT_Digoxin", "text": "Interaction: Aldesleukin AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Digoxin"}, {"id": "Aldesleukin_INT_Acetyldigitoxin", "text": "Interaction: Aldesleukin AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Acetyldigitoxin"}, {"id": "Aldesleukin_INT_Deslanoside", "text": "Interaction: Aldesleukin AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Deslanoside"}, {"id": "Aldesleukin_INT_Ouabain", "text": "Interaction: Aldesleukin AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Ouabain"}, {"id": "Aldesleukin_INT_Digitoxin", "text": "Interaction: Aldesleukin AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Digitoxin"}, {"id": "Aldesleukin_INT_Cymarin", "text": "Interaction: Aldesleukin AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Cymarin"}, {"id": "Aldesleukin_INT_Proscillaridin", "text": "Interaction: Aldesleukin AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Proscillaridin"}, {"id": "Aldesleukin_INT_Metildigoxin", "text": "Interaction: Aldesleukin AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Metildigoxin"}, {"id": "Aldesleukin_INT_Peruvoside", "text": "Interaction: Aldesleukin AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Peruvoside"}, {"id": "Aldesleukin_INT_Lanatoside C", "text": "Interaction: Aldesleukin AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Lanatoside C"}, {"id": "Aldesleukin_INT_Gitoformate", "text": "Interaction: Aldesleukin AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Gitoformate"}, {"id": "Aldesleukin_INT_Acetyldigoxin", "text": "Interaction: Aldesleukin AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Acetyldigoxin"}, {"id": "Aldesleukin_INT_Oleandrin", "text": "Interaction: Aldesleukin AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Oleandrin"}, {"id": "Aldesleukin_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Aldesleukin AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Digoxin Immune Fab (Ovine)"}, {"id": "Aldesleukin_INT_Diatrizoate", "text": "Interaction: Aldesleukin AND Diatrizoate\nDetails: The risk of a hypersensitivity reaction to Diatrizoate is increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Diatrizoate"}, {"id": "Aldesleukin_INT_Ethiodized oil", "text": "Interaction: Aldesleukin AND Ethiodized oil\nDetails: The risk of a hypersensitivity reaction to Ethiodized oil is increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Ethiodized oil"}, {"id": "Aldesleukin_INT_Iodixanol", "text": "Interaction: Aldesleukin AND Iodixanol\nDetails: The risk of a hypersensitivity reaction to Iodixanol is increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Iodixanol"}, {"id": "Aldesleukin_INT_Iohexol", "text": "Interaction: Aldesleukin AND Iohexol\nDetails: The risk of a hypersensitivity reaction to Iohexol is increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Iohexol"}, {"id": "Aldesleukin_INT_Iodipamide", "text": "Interaction: Aldesleukin AND Iodipamide\nDetails: The risk of a hypersensitivity reaction to Iodipamide is increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Iodipamide"}, {"id": "Aldesleukin_INT_Iopamidol", "text": "Interaction: Aldesleukin AND Iopamidol\nDetails: The risk of a hypersensitivity reaction to Iopamidol is increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Iopamidol"}, {"id": "Aldesleukin_INT_Ioversol", "text": "Interaction: Aldesleukin AND Ioversol\nDetails: The risk of a hypersensitivity reaction to Ioversol is increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Ioversol"}, {"id": "Aldesleukin_INT_Ioxilan", "text": "Interaction: Aldesleukin AND Ioxilan\nDetails: The risk of a hypersensitivity reaction to Ioxilan is increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Ioxilan"}, {"id": "Aldesleukin_INT_Iopromide", "text": "Interaction: Aldesleukin AND Iopromide\nDetails: The risk of a hypersensitivity reaction to Iopromide is increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Iopromide"}, {"id": "Aldesleukin_INT_Bevacizumab", "text": "Interaction: Aldesleukin AND Bevacizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Bevacizumab"}, {"id": "Aldesleukin_INT_Cyclophosphamide", "text": "Interaction: Aldesleukin AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Cyclophosphamide"}, {"id": "Aldesleukin_INT_Amifostine", "text": "Interaction: Aldesleukin AND Amifostine\nDetails: The risk or severity of adverse effects can be increased when Amifostine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Amifostine"}, {"id": "Aldesleukin_INT_Amiodarone", "text": "Interaction: Aldesleukin AND Amiodarone\nDetails: The risk or severity of adverse effects can be increased when Amiodarone is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Amiodarone"}, {"id": "Aldesleukin_INT_Amphotericin B", "text": "Interaction: Aldesleukin AND Amphotericin B\nDetails: The risk or severity of adverse effects can be increased when Amphotericin B is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Amphotericin B"}, {"id": "Aldesleukin_INT_Apomorphine", "text": "Interaction: Aldesleukin AND Apomorphine\nDetails: The risk or severity of adverse effects can be increased when Apomorphine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Apomorphine"}, {"id": "Aldesleukin_INT_Arotinolol", "text": "Interaction: Aldesleukin AND Arotinolol\nDetails: The risk or severity of adverse effects can be increased when Arotinolol is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Arotinolol"}, {"id": "Aldesleukin_INT_Arsenic trioxide", "text": "Interaction: Aldesleukin AND Arsenic trioxide\nDetails: The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Arsenic trioxide"}, {"id": "Aldesleukin_INT_Barnidipine", "text": "Interaction: Aldesleukin AND Barnidipine\nDetails: The risk or severity of adverse effects can be increased when Barnidipine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Barnidipine"}, {"id": "Aldesleukin_INT_Bepridil", "text": "Interaction: Aldesleukin AND Bepridil\nDetails: The risk or severity of adverse effects can be increased when Bepridil is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Bepridil"}, {"id": "Aldesleukin_INT_Bortezomib", "text": "Interaction: Aldesleukin AND Bortezomib\nDetails: The risk or severity of adverse effects can be increased when Bortezomib is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Bortezomib"}, {"id": "Aldesleukin_INT_Bromocriptine", "text": "Interaction: Aldesleukin AND Bromocriptine\nDetails: The risk or severity of adverse effects can be increased when Bromocriptine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Bromocriptine"}, {"id": "Aldesleukin_INT_Bupivacaine", "text": "Interaction: Aldesleukin AND Bupivacaine\nDetails: The risk or severity of adverse effects can be increased when Bupivacaine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Bupivacaine"}, {"id": "Aldesleukin_INT_Carbetocin", "text": "Interaction: Aldesleukin AND Carbetocin\nDetails: The risk or severity of adverse effects can be increased when Carbetocin is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Carbetocin"}, {"id": "Aldesleukin_INT_Chlorpromazine", "text": "Interaction: Aldesleukin AND Chlorpromazine\nDetails: The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Chlorpromazine"}, {"id": "Aldesleukin_INT_Cilnidipine", "text": "Interaction: Aldesleukin AND Cilnidipine\nDetails: The risk or severity of adverse effects can be increased when Cilnidipine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Cilnidipine"}, {"id": "Aldesleukin_INT_Clofarabine", "text": "Interaction: Aldesleukin AND Clofarabine\nDetails: The risk or severity of adverse effects can be increased when Clofarabine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Clofarabine"}, {"id": "Aldesleukin_INT_Clomipramine", "text": "Interaction: Aldesleukin AND Clomipramine\nDetails: The risk or severity of adverse effects can be increased when Clomipramine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Clomipramine"}, {"id": "Aldesleukin_INT_Conivaptan", "text": "Interaction: Aldesleukin AND Conivaptan\nDetails: The risk or severity of adverse effects can be increased when Conivaptan is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Conivaptan"}, {"id": "Aldesleukin_INT_Desflurane", "text": "Interaction: Aldesleukin AND Desflurane\nDetails: The risk or severity of adverse effects can be increased when Desflurane is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Desflurane"}, {"id": "Aldesleukin_INT_Efonidipine", "text": "Interaction: Aldesleukin AND Efonidipine\nDetails: The risk or severity of adverse effects can be increased when Efonidipine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Efonidipine"}, {"id": "Aldesleukin_INT_Enalaprilat", "text": "Interaction: Aldesleukin AND Enalaprilat\nDetails: The risk or severity of adverse effects can be increased when Enalaprilat is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Enalaprilat"}, {"id": "Aldesleukin_INT_Epoprostenol", "text": "Interaction: Aldesleukin AND Epoprostenol\nDetails: The risk or severity of adverse effects can be increased when Epoprostenol is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Epoprostenol"}, {"id": "Aldesleukin_INT_Fenoldopam", "text": "Interaction: Aldesleukin AND Fenoldopam\nDetails: The risk or severity of adverse effects can be increased when Fenoldopam is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Fenoldopam"}, {"id": "Aldesleukin_INT_Fimasartan", "text": "Interaction: Aldesleukin AND Fimasartan\nDetails: The risk or severity of adverse effects can be increased when Fimasartan is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Fimasartan"}, {"id": "Aldesleukin_INT_Halothane", "text": "Interaction: Aldesleukin AND Halothane\nDetails: The risk or severity of adverse effects can be increased when Halothane is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Halothane"}, {"id": "Aldesleukin_INT_Hydroflumethiazide", "text": "Interaction: Aldesleukin AND Hydroflumethiazide\nDetails: The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Hydroflumethiazide"}, {"id": "Aldesleukin_INT_Iloprost", "text": "Interaction: Aldesleukin AND Iloprost\nDetails: The risk or severity of adverse effects can be increased when Iloprost is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Iloprost"}, {"id": "Aldesleukin_INT_Imidapril", "text": "Interaction: Aldesleukin AND Imidapril\nDetails: The risk or severity of adverse effects can be increased when Imidapril is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Imidapril"}, {"id": "Aldesleukin_INT_Imipramine", "text": "Interaction: Aldesleukin AND Imipramine\nDetails: The risk or severity of adverse effects can be increased when Imipramine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Imipramine"}, {"id": "Aldesleukin_INT_Indoramin", "text": "Interaction: Aldesleukin AND Indoramin\nDetails: The risk or severity of adverse effects can be increased when Indoramin is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Indoramin"}, {"id": "Aldesleukin_INT_Isocarboxazid", "text": "Interaction: Aldesleukin AND Isocarboxazid\nDetails: The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Isocarboxazid"}, {"id": "Aldesleukin_INT_Isoflurane", "text": "Interaction: Aldesleukin AND Isoflurane\nDetails: The risk or severity of adverse effects can be increased when Isoflurane is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Isoflurane"}, {"id": "Aldesleukin_INT_Lacidipine", "text": "Interaction: Aldesleukin AND Lacidipine\nDetails: The risk or severity of adverse effects can be increased when Lacidipine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Lacidipine"}, {"id": "Aldesleukin_INT_Lercanidipine", "text": "Interaction: Aldesleukin AND Lercanidipine\nDetails: The risk or severity of adverse effects can be increased when Lercanidipine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Lercanidipine"}, {"id": "Aldesleukin_INT_Levobupivacaine", "text": "Interaction: Aldesleukin AND Levobupivacaine\nDetails: The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Levobupivacaine"}, {"id": "Aldesleukin_INT_Levosimendan", "text": "Interaction: Aldesleukin AND Levosimendan\nDetails: The risk or severity of adverse effects can be increased when Levosimendan is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Levosimendan"}, {"id": "Aldesleukin_INT_Lofexidine", "text": "Interaction: Aldesleukin AND Lofexidine\nDetails: The risk or severity of adverse effects can be increased when Lofexidine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Lofexidine"}, {"id": "Aldesleukin_INT_Morphine", "text": "Interaction: Aldesleukin AND Morphine\nDetails: The risk or severity of adverse effects can be increased when Morphine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Morphine"}, {"id": "Aldesleukin_INT_Moxonidine", "text": "Interaction: Aldesleukin AND Moxonidine\nDetails: The risk or severity of adverse effects can be increased when Moxonidine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Moxonidine"}, {"id": "Aldesleukin_INT_Nabilone", "text": "Interaction: Aldesleukin AND Nabilone\nDetails: The risk or severity of adverse effects can be increased when Nabilone is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Nabilone"}, {"id": "Aldesleukin_INT_Nilvadipine", "text": "Interaction: Aldesleukin AND Nilvadipine\nDetails: The risk or severity of adverse effects can be increased when Nilvadipine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Nilvadipine"}, {"id": "Aldesleukin_INT_Nitrendipine", "text": "Interaction: Aldesleukin AND Nitrendipine\nDetails: The risk or severity of adverse effects can be increased when Nitrendipine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Nitrendipine"}, {"id": "Aldesleukin_INT_Nitric Oxide", "text": "Interaction: Aldesleukin AND Nitric Oxide\nDetails: The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Nitric Oxide"}, {"id": "Aldesleukin_INT_Obinutuzumab", "text": "Interaction: Aldesleukin AND Obinutuzumab\nDetails: The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Obinutuzumab"}, {"id": "Aldesleukin_INT_Oxprenolol", "text": "Interaction: Aldesleukin AND Oxprenolol\nDetails: The risk or severity of adverse effects can be increased when Oxprenolol is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Oxprenolol"}, {"id": "Aldesleukin_INT_Phenelzine", "text": "Interaction: Aldesleukin AND Phenelzine\nDetails: The risk or severity of adverse effects can be increased when Phenelzine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Phenelzine"}, {"id": "Aldesleukin_INT_Phenoxybenzamine", "text": "Interaction: Aldesleukin AND Phenoxybenzamine\nDetails: The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Phenoxybenzamine"}, {"id": "Aldesleukin_INT_Phentolamine", "text": "Interaction: Aldesleukin AND Phentolamine\nDetails: The risk or severity of adverse effects can be increased when Phentolamine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Phentolamine"}, {"id": "Aldesleukin_INT_Pipamperone", "text": "Interaction: Aldesleukin AND Pipamperone\nDetails: The risk or severity of adverse effects can be increased when Pipamperone is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Pipamperone"}, {"id": "Aldesleukin_INT_Pramipexole", "text": "Interaction: Aldesleukin AND Pramipexole\nDetails: The risk or severity of adverse effects can be increased when Pramipexole is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Pramipexole"}, {"id": "Aldesleukin_INT_Propofol", "text": "Interaction: Aldesleukin AND Propofol\nDetails: The risk or severity of adverse effects can be increased when Propofol is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Propofol"}, {"id": "Aldesleukin_INT_Rasagiline", "text": "Interaction: Aldesleukin AND Rasagiline\nDetails: The risk or severity of adverse effects can be increased when Rasagiline is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Rasagiline"}, {"id": "Aldesleukin_INT_Remifentanil", "text": "Interaction: Aldesleukin AND Remifentanil\nDetails: The risk or severity of adverse effects can be increased when Remifentanil is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Remifentanil"}, {"id": "Aldesleukin_INT_Ropinirole", "text": "Interaction: Aldesleukin AND Ropinirole\nDetails: The risk or severity of adverse effects can be increased when Ropinirole is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Ropinirole"}, {"id": "Aldesleukin_INT_Ropivacaine", "text": "Interaction: Aldesleukin AND Ropivacaine\nDetails: The risk or severity of adverse effects can be increased when Ropivacaine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Ropivacaine"}, {"id": "Aldesleukin_INT_Rotigotine", "text": "Interaction: Aldesleukin AND Rotigotine\nDetails: The risk or severity of adverse effects can be increased when Rotigotine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Rotigotine"}, {"id": "Aldesleukin_INT_Sacubitril", "text": "Interaction: Aldesleukin AND Sacubitril\nDetails: The risk or severity of adverse effects can be increased when Sacubitril is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Sacubitril"}, {"id": "Aldesleukin_INT_Selegiline", "text": "Interaction: Aldesleukin AND Selegiline\nDetails: The risk or severity of adverse effects can be increased when Selegiline is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Selegiline"}, {"id": "Aldesleukin_INT_Sevoflurane", "text": "Interaction: Aldesleukin AND Sevoflurane\nDetails: The risk or severity of adverse effects can be increased when Sevoflurane is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Sevoflurane"}, {"id": "Aldesleukin_INT_Sodium Nitrite", "text": "Interaction: Aldesleukin AND Sodium Nitrite\nDetails: The risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Sodium Nitrite"}, {"id": "Aldesleukin_INT_Streptokinase", "text": "Interaction: Aldesleukin AND Streptokinase\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Streptokinase"}, {"id": "Aldesleukin_INT_Sufentanil", "text": "Interaction: Aldesleukin AND Sufentanil\nDetails: The risk or severity of adverse effects can be increased when Sufentanil is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Sufentanil"}, {"id": "Aldesleukin_INT_Tamsulosin", "text": "Interaction: Aldesleukin AND Tamsulosin\nDetails: The risk or severity of adverse effects can be increased when Tamsulosin is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Tamsulosin"}, {"id": "Aldesleukin_INT_Thalidomide", "text": "Interaction: Aldesleukin AND Thalidomide\nDetails: The risk or severity of adverse effects can be increased when Thalidomide is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Thalidomide"}, {"id": "Aldesleukin_INT_Thioridazine", "text": "Interaction: Aldesleukin AND Thioridazine\nDetails: The risk or severity of adverse effects can be increased when Thioridazine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Thioridazine"}, {"id": "Aldesleukin_INT_Tolazoline", "text": "Interaction: Aldesleukin AND Tolazoline\nDetails: The risk or severity of adverse effects can be increased when Tolazoline is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Tolazoline"}, {"id": "Aldesleukin_INT_Tolcapone", "text": "Interaction: Aldesleukin AND Tolcapone\nDetails: The risk or severity of adverse effects can be increased when Tolcapone is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Tolcapone"}, {"id": "Aldesleukin_INT_Tranylcypromine", "text": "Interaction: Aldesleukin AND Tranylcypromine\nDetails: The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Tranylcypromine"}, {"id": "Aldesleukin_INT_Tretinoin", "text": "Interaction: Aldesleukin AND Tretinoin\nDetails: The risk or severity of adverse effects can be increased when Tretinoin is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Tretinoin"}, {"id": "Aldesleukin_INT_Valsartan", "text": "Interaction: Aldesleukin AND Valsartan\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Valsartan.\nRisk: Monitor closely.", "source": "Aldesleukin + Valsartan"}, {"id": "Aldesleukin_INT_Ramipril", "text": "Interaction: Aldesleukin AND Ramipril\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ramipril.\nRisk: Monitor closely.", "source": "Aldesleukin + Ramipril"}, {"id": "Aldesleukin_INT_Esmolol", "text": "Interaction: Aldesleukin AND Esmolol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Esmolol.\nRisk: Monitor closely.", "source": "Aldesleukin + Esmolol"}, {"id": "Aldesleukin_INT_Betaxolol", "text": "Interaction: Aldesleukin AND Betaxolol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Betaxolol.\nRisk: Monitor closely.", "source": "Aldesleukin + Betaxolol"}, {"id": "Aldesleukin_INT_Reserpine", "text": "Interaction: Aldesleukin AND Reserpine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Reserpine.\nRisk: Monitor closely.", "source": "Aldesleukin + Reserpine"}, {"id": "Aldesleukin_INT_Torasemide", "text": "Interaction: Aldesleukin AND Torasemide\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Torasemide.\nRisk: Monitor closely.", "source": "Aldesleukin + Torasemide"}, {"id": "Aldesleukin_INT_Methyclothiazide", "text": "Interaction: Aldesleukin AND Methyclothiazide\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyclothiazide.\nRisk: Monitor closely.", "source": "Aldesleukin + Methyclothiazide"}, {"id": "Aldesleukin_INT_Metoprolol", "text": "Interaction: Aldesleukin AND Metoprolol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Metoprolol.\nRisk: Monitor closely.", "source": "Aldesleukin + Metoprolol"}, {"id": "Aldesleukin_INT_Isradipine", "text": "Interaction: Aldesleukin AND Isradipine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isradipine.\nRisk: Monitor closely.", "source": "Aldesleukin + Isradipine"}, {"id": "Aldesleukin_INT_Olmesartan", "text": "Interaction: Aldesleukin AND Olmesartan\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Olmesartan.\nRisk: Monitor closely.", "source": "Aldesleukin + Olmesartan"}, {"id": "Aldesleukin_INT_Chlorthalidone", "text": "Interaction: Aldesleukin AND Chlorthalidone\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorthalidone.\nRisk: Monitor closely.", "source": "Aldesleukin + Chlorthalidone"}, {"id": "Aldesleukin_INT_Nitroprusside", "text": "Interaction: Aldesleukin AND Nitroprusside\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroprusside.\nRisk: Monitor closely.", "source": "Aldesleukin + Nitroprusside"}, {"id": "Aldesleukin_INT_Atenolol", "text": "Interaction: Aldesleukin AND Atenolol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Atenolol.\nRisk: Monitor closely.", "source": "Aldesleukin + Atenolol"}, {"id": "Aldesleukin_INT_Diltiazem", "text": "Interaction: Aldesleukin AND Diltiazem\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Diltiazem.\nRisk: Monitor closely.", "source": "Aldesleukin + Diltiazem"}, {"id": "Aldesleukin_INT_Minoxidil", "text": "Interaction: Aldesleukin AND Minoxidil\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Minoxidil.\nRisk: Monitor closely.", "source": "Aldesleukin + Minoxidil"}, {"id": "Aldesleukin_INT_Timolol", "text": "Interaction: Aldesleukin AND Timolol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Timolol.\nRisk: Monitor closely.", "source": "Aldesleukin + Timolol"}, {"id": "Aldesleukin_INT_Amlodipine", "text": "Interaction: Aldesleukin AND Amlodipine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amlodipine.\nRisk: Monitor closely.", "source": "Aldesleukin + Amlodipine"}, {"id": "Aldesleukin_INT_Triamterene", "text": "Interaction: Aldesleukin AND Triamterene\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Triamterene.\nRisk: Monitor closely.", "source": "Aldesleukin + Triamterene"}, {"id": "Aldesleukin_INT_Nimodipine", "text": "Interaction: Aldesleukin AND Nimodipine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nimodipine.\nRisk: Monitor closely.", "source": "Aldesleukin + Nimodipine"}, {"id": "Aldesleukin_INT_Nisoldipine", "text": "Interaction: Aldesleukin AND Nisoldipine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nisoldipine.\nRisk: Monitor closely.", "source": "Aldesleukin + Nisoldipine"}, {"id": "Aldesleukin_INT_Spironolactone", "text": "Interaction: Aldesleukin AND Spironolactone\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Spironolactone.\nRisk: Monitor closely.", "source": "Aldesleukin + Spironolactone"}, {"id": "Aldesleukin_INT_Bendroflumethiazide", "text": "Interaction: Aldesleukin AND Bendroflumethiazide\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bendroflumethiazide.\nRisk: Monitor closely.", "source": "Aldesleukin + Bendroflumethiazide"}, {"id": "Aldesleukin_INT_Prazosin", "text": "Interaction: Aldesleukin AND Prazosin\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Prazosin.\nRisk: Monitor closely.", "source": "Aldesleukin + Prazosin"}, {"id": "Aldesleukin_INT_Brimonidine", "text": "Interaction: Aldesleukin AND Brimonidine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Brimonidine.\nRisk: Monitor closely.", "source": "Aldesleukin + Brimonidine"}, {"id": "Aldesleukin_INT_Sotalol", "text": "Interaction: Aldesleukin AND Sotalol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sotalol.\nRisk: Monitor closely.", "source": "Aldesleukin + Sotalol"}, {"id": "Aldesleukin_INT_Fosinopril", "text": "Interaction: Aldesleukin AND Fosinopril\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fosinopril.\nRisk: Monitor closely.", "source": "Aldesleukin + Fosinopril"}, {"id": "Aldesleukin_INT_Trandolapril", "text": "Interaction: Aldesleukin AND Trandolapril\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Trandolapril.\nRisk: Monitor closely.", "source": "Aldesleukin + Trandolapril"}, {"id": "Aldesleukin_INT_Carteolol", "text": "Interaction: Aldesleukin AND Carteolol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carteolol.\nRisk: Monitor closely.", "source": "Aldesleukin + Carteolol"}, {"id": "Aldesleukin_INT_Metolazone", "text": "Interaction: Aldesleukin AND Metolazone\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Metolazone.\nRisk: Monitor closely.", "source": "Aldesleukin + Metolazone"}, {"id": "Aldesleukin_INT_Benazepril", "text": "Interaction: Aldesleukin AND Benazepril\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Benazepril.\nRisk: Monitor closely.", "source": "Aldesleukin + Benazepril"}, {"id": "Aldesleukin_INT_Propranolol", "text": "Interaction: Aldesleukin AND Propranolol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Propranolol.\nRisk: Monitor closely.", "source": "Aldesleukin + Propranolol"}, {"id": "Aldesleukin_INT_Clonidine", "text": "Interaction: Aldesleukin AND Clonidine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clonidine.\nRisk: Monitor closely.", "source": "Aldesleukin + Clonidine"}, {"id": "Aldesleukin_INT_Enalapril", "text": "Interaction: Aldesleukin AND Enalapril\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Enalapril.\nRisk: Monitor closely.", "source": "Aldesleukin + Enalapril"}, {"id": "Aldesleukin_INT_Doxazosin", "text": "Interaction: Aldesleukin AND Doxazosin\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Doxazosin.\nRisk: Monitor closely.", "source": "Aldesleukin + Doxazosin"}, {"id": "Aldesleukin_INT_Amiloride", "text": "Interaction: Aldesleukin AND Amiloride\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amiloride.\nRisk: Monitor closely.", "source": "Aldesleukin + Amiloride"}, {"id": "Aldesleukin_INT_Labetalol", "text": "Interaction: Aldesleukin AND Labetalol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Labetalol.\nRisk: Monitor closely.", "source": "Aldesleukin + Labetalol"}, {"id": "Aldesleukin_INT_Bisoprolol", "text": "Interaction: Aldesleukin AND Bisoprolol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bisoprolol.\nRisk: Monitor closely.", "source": "Aldesleukin + Bisoprolol"}, {"id": "Aldesleukin_INT_Nicardipine", "text": "Interaction: Aldesleukin AND Nicardipine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nicardipine.\nRisk: Monitor closely.", "source": "Aldesleukin + Nicardipine"}, {"id": "Aldesleukin_INT_Dexmedetomidine", "text": "Interaction: Aldesleukin AND Dexmedetomidine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexmedetomidine.\nRisk: Monitor closely.", "source": "Aldesleukin + Dexmedetomidine"}, {"id": "Aldesleukin_INT_Mecamylamine", "text": "Interaction: Aldesleukin AND Mecamylamine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mecamylamine.\nRisk: Monitor closely.", "source": "Aldesleukin + Mecamylamine"}, {"id": "Aldesleukin_INT_Verapamil", "text": "Interaction: Aldesleukin AND Verapamil\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Verapamil.\nRisk: Monitor closely.", "source": "Aldesleukin + Verapamil"}, {"id": "Aldesleukin_INT_Losartan", "text": "Interaction: Aldesleukin AND Losartan\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Losartan.\nRisk: Monitor closely.", "source": "Aldesleukin + Losartan"}, {"id": "Aldesleukin_INT_Moexipril", "text": "Interaction: Aldesleukin AND Moexipril\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Moexipril.\nRisk: Monitor closely.", "source": "Aldesleukin + Moexipril"}, {"id": "Aldesleukin_INT_Furosemide", "text": "Interaction: Aldesleukin AND Furosemide\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Furosemide.\nRisk: Monitor closely.", "source": "Aldesleukin + Furosemide"}, {"id": "Aldesleukin_INT_Tizanidine", "text": "Interaction: Aldesleukin AND Tizanidine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tizanidine.\nRisk: Monitor closely.", "source": "Aldesleukin + Tizanidine"}, {"id": "Aldesleukin_INT_Eplerenone", "text": "Interaction: Aldesleukin AND Eplerenone\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Eplerenone.\nRisk: Monitor closely.", "source": "Aldesleukin + Eplerenone"}, {"id": "Aldesleukin_INT_Methazolamide", "text": "Interaction: Aldesleukin AND Methazolamide\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methazolamide.\nRisk: Monitor closely.", "source": "Aldesleukin + Methazolamide"}, {"id": "Aldesleukin_INT_Lisinopril", "text": "Interaction: Aldesleukin AND Lisinopril\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lisinopril.\nRisk: Monitor closely.", "source": "Aldesleukin + Lisinopril"}, {"id": "Aldesleukin_INT_Nitroglycerin", "text": "Interaction: Aldesleukin AND Nitroglycerin\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroglycerin.\nRisk: Monitor closely.", "source": "Aldesleukin + Nitroglycerin"}, {"id": "Aldesleukin_INT_Mannitol", "text": "Interaction: Aldesleukin AND Mannitol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mannitol.\nRisk: Monitor closely.", "source": "Aldesleukin + Mannitol"}, {"id": "Aldesleukin_INT_Perindopril", "text": "Interaction: Aldesleukin AND Perindopril\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Perindopril.\nRisk: Monitor closely.", "source": "Aldesleukin + Perindopril"}, {"id": "Aldesleukin_INT_Candesartan cilexetil", "text": "Interaction: Aldesleukin AND Candesartan cilexetil\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Candesartan cilexetil.\nRisk: Monitor closely.", "source": "Aldesleukin + Candesartan cilexetil"}, {"id": "Aldesleukin_INT_Indapamide", "text": "Interaction: Aldesleukin AND Indapamide\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Indapamide.\nRisk: Monitor closely.", "source": "Aldesleukin + Indapamide"}, {"id": "Aldesleukin_INT_Eprosartan", "text": "Interaction: Aldesleukin AND Eprosartan\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Eprosartan.\nRisk: Monitor closely.", "source": "Aldesleukin + Eprosartan"}, {"id": "Aldesleukin_INT_Chlorothiazide", "text": "Interaction: Aldesleukin AND Chlorothiazide\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorothiazide.\nRisk: Monitor closely.", "source": "Aldesleukin + Chlorothiazide"}, {"id": "Aldesleukin_INT_Quinapril", "text": "Interaction: Aldesleukin AND Quinapril\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Quinapril.\nRisk: Monitor closely.", "source": "Aldesleukin + Quinapril"}, {"id": "Aldesleukin_INT_Isosorbide Dinitrate", "text": "Interaction: Aldesleukin AND Isosorbide Dinitrate\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Dinitrate.\nRisk: Monitor closely.", "source": "Aldesleukin + Isosorbide Dinitrate"}, {"id": "Aldesleukin_INT_Bumetanide", "text": "Interaction: Aldesleukin AND Bumetanide\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bumetanide.\nRisk: Monitor closely.", "source": "Aldesleukin + Bumetanide"}, {"id": "Aldesleukin_INT_Etacrynic acid", "text": "Interaction: Aldesleukin AND Etacrynic acid\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Etacrynic acid.\nRisk: Monitor closely.", "source": "Aldesleukin + Etacrynic acid"}, {"id": "Aldesleukin_INT_Pindolol", "text": "Interaction: Aldesleukin AND Pindolol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pindolol.\nRisk: Monitor closely.", "source": "Aldesleukin + Pindolol"}, {"id": "Aldesleukin_INT_Apraclonidine", "text": "Interaction: Aldesleukin AND Apraclonidine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Apraclonidine.\nRisk: Monitor closely.", "source": "Aldesleukin + Apraclonidine"}, {"id": "Aldesleukin_INT_Telmisartan", "text": "Interaction: Aldesleukin AND Telmisartan\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Telmisartan.\nRisk: Monitor closely.", "source": "Aldesleukin + Telmisartan"}, {"id": "Aldesleukin_INT_Methyldopa", "text": "Interaction: Aldesleukin AND Methyldopa\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyldopa.\nRisk: Monitor closely.", "source": "Aldesleukin + Methyldopa"}, {"id": "Aldesleukin_INT_Dipyridamole", "text": "Interaction: Aldesleukin AND Dipyridamole\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dipyridamole.\nRisk: Monitor closely.", "source": "Aldesleukin + Dipyridamole"}, {"id": "Aldesleukin_INT_Hydrochlorothiazide", "text": "Interaction: Aldesleukin AND Hydrochlorothiazide\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydrochlorothiazide.\nRisk: Monitor closely.", "source": "Aldesleukin + Hydrochlorothiazide"}, {"id": "Aldesleukin_INT_Guanfacine", "text": "Interaction: Aldesleukin AND Guanfacine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Guanfacine.\nRisk: Monitor closely.", "source": "Aldesleukin + Guanfacine"}, {"id": "Aldesleukin_INT_Isosorbide Mononitrate", "text": "Interaction: Aldesleukin AND Isosorbide Mononitrate\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Mononitrate.\nRisk: Monitor closely.", "source": "Aldesleukin + Isosorbide Mononitrate"}, {"id": "Aldesleukin_INT_Felodipine", "text": "Interaction: Aldesleukin AND Felodipine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Felodipine.\nRisk: Monitor closely.", "source": "Aldesleukin + Felodipine"}, {"id": "Aldesleukin_INT_Irbesartan", "text": "Interaction: Aldesleukin AND Irbesartan\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Irbesartan.\nRisk: Monitor closely.", "source": "Aldesleukin + Irbesartan"}, {"id": "Aldesleukin_INT_Papaverine", "text": "Interaction: Aldesleukin AND Papaverine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Papaverine.\nRisk: Monitor closely.", "source": "Aldesleukin + Papaverine"}, {"id": "Aldesleukin_INT_Nifedipine", "text": "Interaction: Aldesleukin AND Nifedipine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nifedipine.\nRisk: Monitor closely.", "source": "Aldesleukin + Nifedipine"}, {"id": "Aldesleukin_INT_Carvedilol", "text": "Interaction: Aldesleukin AND Carvedilol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carvedilol.\nRisk: Monitor closely.", "source": "Aldesleukin + Carvedilol"}, {"id": "Aldesleukin_INT_Diclofenamide", "text": "Interaction: Aldesleukin AND Diclofenamide\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Diclofenamide.\nRisk: Monitor closely.", "source": "Aldesleukin + Diclofenamide"}, {"id": "Aldesleukin_INT_Bretylium", "text": "Interaction: Aldesleukin AND Bretylium\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bretylium.\nRisk: Monitor closely.", "source": "Aldesleukin + Bretylium"}, {"id": "Aldesleukin_INT_Terazosin", "text": "Interaction: Aldesleukin AND Terazosin\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Terazosin.\nRisk: Monitor closely.", "source": "Aldesleukin + Terazosin"}, {"id": "Aldesleukin_INT_Acebutolol", "text": "Interaction: Aldesleukin AND Acebutolol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Acebutolol.\nRisk: Monitor closely.", "source": "Aldesleukin + Acebutolol"}, {"id": "Aldesleukin_INT_Captopril", "text": "Interaction: Aldesleukin AND Captopril\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Captopril.\nRisk: Monitor closely.", "source": "Aldesleukin + Captopril"}, {"id": "Aldesleukin_INT_Nadolol", "text": "Interaction: Aldesleukin AND Nadolol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nadolol.\nRisk: Monitor closely.", "source": "Aldesleukin + Nadolol"}, {"id": "Aldesleukin_INT_Levobunolol", "text": "Interaction: Aldesleukin AND Levobunolol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Levobunolol.\nRisk: Monitor closely.", "source": "Aldesleukin + Levobunolol"}, {"id": "Aldesleukin_INT_Metipranolol", "text": "Interaction: Aldesleukin AND Metipranolol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Metipranolol.\nRisk: Monitor closely.", "source": "Aldesleukin + Metipranolol"}, {"id": "Aldesleukin_INT_Quetiapine", "text": "Interaction: Aldesleukin AND Quetiapine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Quetiapine.\nRisk: Monitor closely.", "source": "Aldesleukin + Quetiapine"}, {"id": "Aldesleukin_INT_Hydralazine", "text": "Interaction: Aldesleukin AND Hydralazine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydralazine.\nRisk: Monitor closely.", "source": "Aldesleukin + Hydralazine"}, {"id": "Aldesleukin_INT_Cilazapril", "text": "Interaction: Aldesleukin AND Cilazapril\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilazapril.\nRisk: Monitor closely.", "source": "Aldesleukin + Cilazapril"}, {"id": "Aldesleukin_INT_Penbutolol", "text": "Interaction: Aldesleukin AND Penbutolol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Penbutolol.\nRisk: Monitor closely.", "source": "Aldesleukin + Penbutolol"}, {"id": "Aldesleukin_INT_Amyl Nitrite", "text": "Interaction: Aldesleukin AND Amyl Nitrite\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amyl Nitrite.\nRisk: Monitor closely.", "source": "Aldesleukin + Amyl Nitrite"}, {"id": "Aldesleukin_INT_Nebivolol", "text": "Interaction: Aldesleukin AND Nebivolol\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nebivolol.\nRisk: Monitor closely.", "source": "Aldesleukin + Nebivolol"}, {"id": "Aldesleukin_INT_Nesiritide", "text": "Interaction: Aldesleukin AND Nesiritide\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nesiritide.\nRisk: Monitor closely.", "source": "Aldesleukin + Nesiritide"}, {"id": "Aldesleukin_INT_Clevidipine", "text": "Interaction: Aldesleukin AND Clevidipine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clevidipine.\nRisk: Monitor closely.", "source": "Aldesleukin + Clevidipine"}, {"id": "Aldesleukin_INT_Dapagliflozin", "text": "Interaction: Aldesleukin AND Dapagliflozin\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dapagliflozin.\nRisk: Monitor closely.", "source": "Aldesleukin + Dapagliflozin"}, {"id": "Aldesleukin_INT_Azilsartan medoxomil", "text": "Interaction: Aldesleukin AND Azilsartan medoxomil\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Azilsartan medoxomil.\nRisk: Monitor closely.", "source": "Aldesleukin + Azilsartan medoxomil"}, {"id": "Aldesleukin_INT_Canagliflozin", "text": "Interaction: Aldesleukin AND Canagliflozin\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Canagliflozin.\nRisk: Monitor closely.", "source": "Aldesleukin + Canagliflozin"}, {"id": "Aldesleukin_INT_Riociguat", "text": "Interaction: Aldesleukin AND Riociguat\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Riociguat.\nRisk: Monitor closely.", "source": "Aldesleukin + Riociguat"}, {"id": "Aldesleukin_INT_Isoxsuprine", "text": "Interaction: Aldesleukin AND Isoxsuprine\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isoxsuprine.\nRisk: Monitor closely.", "source": "Aldesleukin + Isoxsuprine"}, {"id": "Aldesleukin_INT_Aliskiren", "text": "Interaction: Aldesleukin AND Aliskiren\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Aliskiren.\nRisk: Monitor closely.", "source": "Aldesleukin + Aliskiren"}, {"id": "Aldesleukin_INT_Empagliflozin", "text": "Interaction: Aldesleukin AND Empagliflozin\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Empagliflozin.\nRisk: Monitor closely.", "source": "Aldesleukin + Empagliflozin"}, {"id": "Aldesleukin_INT_Dinutuximab", "text": "Interaction: Aldesleukin AND Dinutuximab\nDetails: The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dinutuximab.\nRisk: Monitor closely.", "source": "Aldesleukin + Dinutuximab"}, {"id": "Aldesleukin_INT_Aripiprazole", "text": "Interaction: Aldesleukin AND Aripiprazole\nDetails: Aripiprazole may increase the hypotensive activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Aripiprazole"}, {"id": "Aldesleukin_INT_Nicorandil", "text": "Interaction: Aldesleukin AND Nicorandil\nDetails: Nicorandil may increase the hypotensive activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Nicorandil"}, {"id": "Aldesleukin_INT_Methohexital", "text": "Interaction: Aldesleukin AND Methohexital\nDetails: Methohexital may increase the hypotensive activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Methohexital"}, {"id": "Aldesleukin_INT_Primidone", "text": "Interaction: Aldesleukin AND Primidone\nDetails: Primidone may increase the hypotensive activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Primidone"}, {"id": "Aldesleukin_INT_Phenobarbital", "text": "Interaction: Aldesleukin AND Phenobarbital\nDetails: Phenobarbital may increase the hypotensive activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Phenobarbital"}, {"id": "Aldesleukin_INT_Pentobarbital", "text": "Interaction: Aldesleukin AND Pentobarbital\nDetails: Pentobarbital may increase the hypotensive activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Pentobarbital"}, {"id": "Aldesleukin_INT_Secobarbital", "text": "Interaction: Aldesleukin AND Secobarbital\nDetails: Secobarbital may increase the hypotensive activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Secobarbital"}, {"id": "Aldesleukin_INT_Thiopental", "text": "Interaction: Aldesleukin AND Thiopental\nDetails: Thiopental may increase the hypotensive activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Thiopental"}, {"id": "Aldesleukin_INT_Methylphenobarbital", "text": "Interaction: Aldesleukin AND Methylphenobarbital\nDetails: Methylphenobarbital may increase the hypotensive activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Methylphenobarbital"}, {"id": "Aldesleukin_INT_Thiamylal", "text": "Interaction: Aldesleukin AND Thiamylal\nDetails: Thiamylal may increase the hypotensive activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Thiamylal"}, {"id": "Aldesleukin_INT_Amobarbital", "text": "Interaction: Aldesleukin AND Amobarbital\nDetails: Amobarbital may increase the hypotensive activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Amobarbital"}, {"id": "Aldesleukin_INT_Hexobarbital", "text": "Interaction: Aldesleukin AND Hexobarbital\nDetails: Hexobarbital may increase the hypotensive activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Hexobarbital"}, {"id": "Aldesleukin_INT_Barbital", "text": "Interaction: Aldesleukin AND Barbital\nDetails: Barbital may increase the hypotensive activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Barbital"}, {"id": "Aldesleukin_INT_Barbexaclone", "text": "Interaction: Aldesleukin AND Barbexaclone\nDetails: Barbexaclone may increase the hypotensive activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Barbexaclone"}, {"id": "Aldesleukin_INT_Rilpivirine", "text": "Interaction: Aldesleukin AND Rilpivirine\nDetails: The serum concentration of Rilpivirine can be increased when it is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Aldesleukin + Rilpivirine"}, {"id": "Aldesleukin_INT_Duloxetine", "text": "Interaction: Aldesleukin AND Duloxetine\nDetails: Aldesleukin may increase the orthostatic hypotensive activities of Duloxetine.\nRisk: Monitor closely.", "source": "Aldesleukin + Duloxetine"}, {"id": "Aldesleukin_INT_Levodopa", "text": "Interaction: Aldesleukin AND Levodopa\nDetails: Aldesleukin may increase the orthostatic hypotensive activities of Levodopa.\nRisk: Monitor closely.", "source": "Aldesleukin + Levodopa"}, {"id": "Aldesleukin_INT_Risperidone", "text": "Interaction: Aldesleukin AND Risperidone\nDetails: Aldesleukin may increase the hypotensive activities of Risperidone.\nRisk: Monitor closely.", "source": "Aldesleukin + Risperidone"}, {"id": "Botulinum Toxin Type B_GEN", "text": "Drug: Botulinum Toxin Type B\nDescription: Neurotoxin produced by fermentation of clostridium botulinum type B. The protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitatio...", "source": "Botulinum Toxin Type B"}, {"id": "Botulinum Toxin Type B_CLIN", "text": "Drug: Botulinum Toxin Type B\nMechanism: Botulinum Toxin Type B binds to and cleaves the synaptic Vesicle Associated Membrane Protein (VAMP, also known as synaptobrevin) which is a component of the protein complex responsible for docking and...\nToxicity: One unit of Botulinum Toxin Type B corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice....", "source": "Botulinum Toxin Type B"}, {"id": "Botulinum Toxin Type B_INT_Botulinum Toxin Type A", "text": "Interaction: Botulinum Toxin Type B AND Botulinum Toxin Type A\nDetails: Botulinum Toxin Type A may increase the adverse neuromuscular activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Botulinum Toxin Type A"}, {"id": "Botulinum Toxin Type B_INT_Succinylcholine", "text": "Interaction: Botulinum Toxin Type B AND Succinylcholine\nDetails: Succinylcholine may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Succinylcholine"}, {"id": "Botulinum Toxin Type B_INT_Cisatracurium besylate", "text": "Interaction: Botulinum Toxin Type B AND Cisatracurium besylate\nDetails: Cisatracurium besylate may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Cisatracurium besylate"}, {"id": "Botulinum Toxin Type B_INT_Rocuronium", "text": "Interaction: Botulinum Toxin Type B AND Rocuronium\nDetails: Rocuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Rocuronium"}, {"id": "Botulinum Toxin Type B_INT_Atracurium besylate", "text": "Interaction: Botulinum Toxin Type B AND Atracurium besylate\nDetails: Atracurium besylate may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Atracurium besylate"}, {"id": "Botulinum Toxin Type B_INT_Pancuronium", "text": "Interaction: Botulinum Toxin Type B AND Pancuronium\nDetails: Pancuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Pancuronium"}, {"id": "Botulinum Toxin Type B_INT_Vecuronium", "text": "Interaction: Botulinum Toxin Type B AND Vecuronium\nDetails: Vecuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Vecuronium"}, {"id": "Botulinum Toxin Type B_INT_Metocurine Iodide", "text": "Interaction: Botulinum Toxin Type B AND Metocurine Iodide\nDetails: Metocurine Iodide may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Metocurine Iodide"}, {"id": "Botulinum Toxin Type B_INT_Gallamine Triethiodide", "text": "Interaction: Botulinum Toxin Type B AND Gallamine Triethiodide\nDetails: Gallamine Triethiodide may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Gallamine Triethiodide"}, {"id": "Botulinum Toxin Type B_INT_Doxacurium chloride", "text": "Interaction: Botulinum Toxin Type B AND Doxacurium chloride\nDetails: Doxacurium chloride may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Doxacurium chloride"}, {"id": "Botulinum Toxin Type B_INT_Tubocurarine", "text": "Interaction: Botulinum Toxin Type B AND Tubocurarine\nDetails: Tubocurarine may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Tubocurarine"}, {"id": "Botulinum Toxin Type B_INT_Mivacurium", "text": "Interaction: Botulinum Toxin Type B AND Mivacurium\nDetails: Mivacurium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Mivacurium"}, {"id": "Botulinum Toxin Type B_INT_Decamethonium", "text": "Interaction: Botulinum Toxin Type B AND Decamethonium\nDetails: Decamethonium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Decamethonium"}, {"id": "Botulinum Toxin Type B_INT_Metocurine", "text": "Interaction: Botulinum Toxin Type B AND Metocurine\nDetails: Metocurine may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Metocurine"}, {"id": "Botulinum Toxin Type B_INT_Pipecuronium", "text": "Interaction: Botulinum Toxin Type B AND Pipecuronium\nDetails: Pipecuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Pipecuronium"}, {"id": "Botulinum Toxin Type B_INT_Domoic Acid", "text": "Interaction: Botulinum Toxin Type B AND Domoic Acid\nDetails: Domoic Acid may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Domoic Acid"}, {"id": "Botulinum Toxin Type B_INT_Rapacuronium", "text": "Interaction: Botulinum Toxin Type B AND Rapacuronium\nDetails: Rapacuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Rapacuronium"}, {"id": "Botulinum Toxin Type B_INT_Pyrantel", "text": "Interaction: Botulinum Toxin Type B AND Pyrantel\nDetails: Pyrantel may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Pyrantel"}, {"id": "Botulinum Toxin Type B_INT_Neosaxitoxin", "text": "Interaction: Botulinum Toxin Type B AND Neosaxitoxin\nDetails: Neosaxitoxin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Neosaxitoxin"}, {"id": "Botulinum Toxin Type B_INT_Atracurium", "text": "Interaction: Botulinum Toxin Type B AND Atracurium\nDetails: Atracurium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Atracurium"}, {"id": "Botulinum Toxin Type B_INT_Cisatracurium", "text": "Interaction: Botulinum Toxin Type B AND Cisatracurium\nDetails: Cisatracurium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Cisatracurium"}, {"id": "Botulinum Toxin Type B_INT_Gallamine", "text": "Interaction: Botulinum Toxin Type B AND Gallamine\nDetails: Gallamine may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Gallamine"}, {"id": "Botulinum Toxin Type B_INT_Alcuronium", "text": "Interaction: Botulinum Toxin Type B AND Alcuronium\nDetails: Alcuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Alcuronium"}, {"id": "Botulinum Toxin Type B_INT_Benzatropine", "text": "Interaction: Botulinum Toxin Type B AND Benzatropine\nDetails: Benzatropine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Benzatropine"}, {"id": "Botulinum Toxin Type B_INT_Ipratropium bromide", "text": "Interaction: Botulinum Toxin Type B AND Ipratropium bromide\nDetails: Ipratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Ipratropium bromide"}, {"id": "Botulinum Toxin Type B_INT_Trihexyphenidyl", "text": "Interaction: Botulinum Toxin Type B AND Trihexyphenidyl\nDetails: Trihexyphenidyl may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Trihexyphenidyl"}, {"id": "Botulinum Toxin Type B_INT_Procyclidine", "text": "Interaction: Botulinum Toxin Type B AND Procyclidine\nDetails: Procyclidine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Procyclidine"}, {"id": "Botulinum Toxin Type B_INT_Ethopropazine", "text": "Interaction: Botulinum Toxin Type B AND Ethopropazine\nDetails: Ethopropazine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Ethopropazine"}, {"id": "Botulinum Toxin Type B_INT_Atropine", "text": "Interaction: Botulinum Toxin Type B AND Atropine\nDetails: Atropine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Atropine"}, {"id": "Botulinum Toxin Type B_INT_Scopolamine", "text": "Interaction: Botulinum Toxin Type B AND Scopolamine\nDetails: Scopolamine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Scopolamine"}, {"id": "Botulinum Toxin Type B_INT_Tropicamide", "text": "Interaction: Botulinum Toxin Type B AND Tropicamide\nDetails: Tropicamide may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Tropicamide"}, {"id": "Botulinum Toxin Type B_INT_Biperiden", "text": "Interaction: Botulinum Toxin Type B AND Biperiden\nDetails: Biperiden may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Biperiden"}, {"id": "Botulinum Toxin Type B_INT_Cyclopentolate", "text": "Interaction: Botulinum Toxin Type B AND Cyclopentolate\nDetails: Cyclopentolate may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Cyclopentolate"}, {"id": "Botulinum Toxin Type B_INT_Tiotropium", "text": "Interaction: Botulinum Toxin Type B AND Tiotropium\nDetails: Tiotropium may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Tiotropium"}, {"id": "Botulinum Toxin Type B_INT_Dexetimide", "text": "Interaction: Botulinum Toxin Type B AND Dexetimide\nDetails: Dexetimide may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Dexetimide"}, {"id": "Botulinum Toxin Type B_INT_Bornaprine", "text": "Interaction: Botulinum Toxin Type B AND Bornaprine\nDetails: Bornaprine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Bornaprine"}, {"id": "Botulinum Toxin Type B_INT_Phenglutarimide", "text": "Interaction: Botulinum Toxin Type B AND Phenglutarimide\nDetails: Phenglutarimide may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Phenglutarimide"}, {"id": "Botulinum Toxin Type B_INT_Propantheline", "text": "Interaction: Botulinum Toxin Type B AND Propantheline\nDetails: Propantheline may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Propantheline"}, {"id": "Botulinum Toxin Type B_INT_Dicyclomine", "text": "Interaction: Botulinum Toxin Type B AND Dicyclomine\nDetails: Dicyclomine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Dicyclomine"}, {"id": "Botulinum Toxin Type B_INT_Aclidinium", "text": "Interaction: Botulinum Toxin Type B AND Aclidinium\nDetails: Aclidinium may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Aclidinium"}, {"id": "Botulinum Toxin Type B_INT_Glycopyrronium", "text": "Interaction: Botulinum Toxin Type B AND Glycopyrronium\nDetails: Glycopyrronium may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Glycopyrronium"}, {"id": "Botulinum Toxin Type B_INT_Trospium", "text": "Interaction: Botulinum Toxin Type B AND Trospium\nDetails: Trospium may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Trospium"}, {"id": "Botulinum Toxin Type B_INT_Oxyphenonium", "text": "Interaction: Botulinum Toxin Type B AND Oxyphenonium\nDetails: Oxyphenonium may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Oxyphenonium"}, {"id": "Botulinum Toxin Type B_INT_Hyoscyamine", "text": "Interaction: Botulinum Toxin Type B AND Hyoscyamine\nDetails: Hyoscyamine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Hyoscyamine"}, {"id": "Botulinum Toxin Type B_INT_Darifenacin", "text": "Interaction: Botulinum Toxin Type B AND Darifenacin\nDetails: Darifenacin may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Darifenacin"}, {"id": "Botulinum Toxin Type B_INT_Anisotropine Methylbromide", "text": "Interaction: Botulinum Toxin Type B AND Anisotropine Methylbromide\nDetails: Anisotropine Methylbromide may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Anisotropine Methylbromide"}, {"id": "Botulinum Toxin Type B_INT_Mecamylamine", "text": "Interaction: Botulinum Toxin Type B AND Mecamylamine\nDetails: Mecamylamine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Mecamylamine"}, {"id": "Botulinum Toxin Type B_INT_Pirenzepine", "text": "Interaction: Botulinum Toxin Type B AND Pirenzepine\nDetails: Pirenzepine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Pirenzepine"}, {"id": "Botulinum Toxin Type B_INT_Quinidine", "text": "Interaction: Botulinum Toxin Type B AND Quinidine\nDetails: Quinidine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Quinidine"}, {"id": "Botulinum Toxin Type B_INT_Methantheline", "text": "Interaction: Botulinum Toxin Type B AND Methantheline\nDetails: Methantheline may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Methantheline"}, {"id": "Botulinum Toxin Type B_INT_Desloratadine", "text": "Interaction: Botulinum Toxin Type B AND Desloratadine\nDetails: Desloratadine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Desloratadine"}, {"id": "Botulinum Toxin Type B_INT_Tolterodine", "text": "Interaction: Botulinum Toxin Type B AND Tolterodine\nDetails: Tolterodine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Tolterodine"}, {"id": "Botulinum Toxin Type B_INT_Oxybutynin", "text": "Interaction: Botulinum Toxin Type B AND Oxybutynin\nDetails: Oxybutynin may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Oxybutynin"}, {"id": "Botulinum Toxin Type B_INT_Pentolinium", "text": "Interaction: Botulinum Toxin Type B AND Pentolinium\nDetails: Pentolinium may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Pentolinium"}, {"id": "Botulinum Toxin Type B_INT_Trimethaphan", "text": "Interaction: Botulinum Toxin Type B AND Trimethaphan\nDetails: Trimethaphan may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Trimethaphan"}, {"id": "Botulinum Toxin Type B_INT_Orphenadrine", "text": "Interaction: Botulinum Toxin Type B AND Orphenadrine\nDetails: Orphenadrine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Orphenadrine"}, {"id": "Botulinum Toxin Type B_INT_Solifenacin", "text": "Interaction: Botulinum Toxin Type B AND Solifenacin\nDetails: Solifenacin may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Solifenacin"}, {"id": "Botulinum Toxin Type B_INT_Fesoterodine", "text": "Interaction: Botulinum Toxin Type B AND Fesoterodine\nDetails: Fesoterodine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Fesoterodine"}, {"id": "Botulinum Toxin Type B_INT_Hexamethonium", "text": "Interaction: Botulinum Toxin Type B AND Hexamethonium\nDetails: Hexamethonium may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Hexamethonium"}, {"id": "Botulinum Toxin Type B_INT_Chlorphenoxamine", "text": "Interaction: Botulinum Toxin Type B AND Chlorphenoxamine\nDetails: Chlorphenoxamine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Chlorphenoxamine"}, {"id": "Botulinum Toxin Type B_INT_Benactyzine", "text": "Interaction: Botulinum Toxin Type B AND Benactyzine\nDetails: Benactyzine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Benactyzine"}, {"id": "Botulinum Toxin Type B_INT_Butylscopolamine", "text": "Interaction: Botulinum Toxin Type B AND Butylscopolamine\nDetails: Butylscopolamine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Butylscopolamine"}, {"id": "Botulinum Toxin Type B_INT_Propiverine", "text": "Interaction: Botulinum Toxin Type B AND Propiverine\nDetails: Propiverine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Propiverine"}, {"id": "Botulinum Toxin Type B_INT_Otilonium", "text": "Interaction: Botulinum Toxin Type B AND Otilonium\nDetails: Otilonium may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Otilonium"}, {"id": "Botulinum Toxin Type B_INT_Emepronium", "text": "Interaction: Botulinum Toxin Type B AND Emepronium\nDetails: Emepronium may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Emepronium"}, {"id": "Botulinum Toxin Type B_INT_Metixene", "text": "Interaction: Botulinum Toxin Type B AND Metixene\nDetails: Metixene may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Metixene"}, {"id": "Botulinum Toxin Type B_INT_Homatropine", "text": "Interaction: Botulinum Toxin Type B AND Homatropine\nDetails: Homatropine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Homatropine"}, {"id": "Botulinum Toxin Type B_INT_Methscopolamine", "text": "Interaction: Botulinum Toxin Type B AND Methscopolamine\nDetails: Methscopolamine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Methscopolamine"}, {"id": "Botulinum Toxin Type B_INT_Oxitropium", "text": "Interaction: Botulinum Toxin Type B AND Oxitropium\nDetails: Oxitropium may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Oxitropium"}, {"id": "Botulinum Toxin Type B_INT_Tropatepine", "text": "Interaction: Botulinum Toxin Type B AND Tropatepine\nDetails: Tropatepine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Tropatepine"}, {"id": "Botulinum Toxin Type B_INT_Mazaticol", "text": "Interaction: Botulinum Toxin Type B AND Mazaticol\nDetails: Mazaticol may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Mazaticol"}, {"id": "Botulinum Toxin Type B_INT_Etybenzatropine", "text": "Interaction: Botulinum Toxin Type B AND Etybenzatropine\nDetails: Etybenzatropine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Etybenzatropine"}, {"id": "Botulinum Toxin Type B_INT_Etanautine", "text": "Interaction: Botulinum Toxin Type B AND Etanautine\nDetails: Etanautine may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Etanautine"}, {"id": "Botulinum Toxin Type B_INT_Methylscopolamine bromide", "text": "Interaction: Botulinum Toxin Type B AND Methylscopolamine bromide\nDetails: Methylscopolamine bromide may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Methylscopolamine bromide"}, {"id": "Botulinum Toxin Type B_INT_Umeclidinium", "text": "Interaction: Botulinum Toxin Type B AND Umeclidinium\nDetails: Umeclidinium may increase the anticholinergic activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Umeclidinium"}, {"id": "Botulinum Toxin Type B_INT_Amikacin", "text": "Interaction: Botulinum Toxin Type B AND Amikacin\nDetails: Amikacin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Amikacin"}, {"id": "Botulinum Toxin Type B_INT_Tobramycin", "text": "Interaction: Botulinum Toxin Type B AND Tobramycin\nDetails: Tobramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Tobramycin"}, {"id": "Botulinum Toxin Type B_INT_Gentamicin", "text": "Interaction: Botulinum Toxin Type B AND Gentamicin\nDetails: Gentamicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Gentamicin"}, {"id": "Botulinum Toxin Type B_INT_Neomycin", "text": "Interaction: Botulinum Toxin Type B AND Neomycin\nDetails: Neomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Neomycin"}, {"id": "Botulinum Toxin Type B_INT_Streptomycin", "text": "Interaction: Botulinum Toxin Type B AND Streptomycin\nDetails: Streptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Streptomycin"}, {"id": "Botulinum Toxin Type B_INT_Valrubicin", "text": "Interaction: Botulinum Toxin Type B AND Valrubicin\nDetails: Valrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Valrubicin"}, {"id": "Botulinum Toxin Type B_INT_Streptozocin", "text": "Interaction: Botulinum Toxin Type B AND Streptozocin\nDetails: Streptozocin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Streptozocin"}, {"id": "Botulinum Toxin Type B_INT_Epirubicin", "text": "Interaction: Botulinum Toxin Type B AND Epirubicin\nDetails: Epirubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Epirubicin"}, {"id": "Botulinum Toxin Type B_INT_Framycetin", "text": "Interaction: Botulinum Toxin Type B AND Framycetin\nDetails: Framycetin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Framycetin"}, {"id": "Botulinum Toxin Type B_INT_Daunorubicin", "text": "Interaction: Botulinum Toxin Type B AND Daunorubicin\nDetails: Daunorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Daunorubicin"}, {"id": "Botulinum Toxin Type B_INT_Spectinomycin", "text": "Interaction: Botulinum Toxin Type B AND Spectinomycin\nDetails: Spectinomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Spectinomycin"}, {"id": "Botulinum Toxin Type B_INT_Netilmicin", "text": "Interaction: Botulinum Toxin Type B AND Netilmicin\nDetails: Netilmicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Netilmicin"}, {"id": "Botulinum Toxin Type B_INT_Doxorubicin", "text": "Interaction: Botulinum Toxin Type B AND Doxorubicin\nDetails: Doxorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Doxorubicin"}, {"id": "Botulinum Toxin Type B_INT_Kanamycin", "text": "Interaction: Botulinum Toxin Type B AND Kanamycin\nDetails: Kanamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Kanamycin"}, {"id": "Botulinum Toxin Type B_INT_Idarubicin", "text": "Interaction: Botulinum Toxin Type B AND Idarubicin\nDetails: Idarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Idarubicin"}, {"id": "Botulinum Toxin Type B_INT_Paromomycin", "text": "Interaction: Botulinum Toxin Type B AND Paromomycin\nDetails: Paromomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Paromomycin"}, {"id": "Botulinum Toxin Type B_INT_Metrizamide", "text": "Interaction: Botulinum Toxin Type B AND Metrizamide\nDetails: Metrizamide may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Metrizamide"}, {"id": "Botulinum Toxin Type B_INT_Ribostamycin", "text": "Interaction: Botulinum Toxin Type B AND Ribostamycin\nDetails: Ribostamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Ribostamycin"}, {"id": "Botulinum Toxin Type B_INT_Geneticin", "text": "Interaction: Botulinum Toxin Type B AND Geneticin\nDetails: Geneticin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Geneticin"}, {"id": "Botulinum Toxin Type B_INT_Apramycin", "text": "Interaction: Botulinum Toxin Type B AND Apramycin\nDetails: Apramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Apramycin"}, {"id": "Botulinum Toxin Type B_INT_GENTAMICIN C1A", "text": "Interaction: Botulinum Toxin Type B AND GENTAMICIN C1A\nDetails: GENTAMICIN C1A may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + GENTAMICIN C1A"}, {"id": "Botulinum Toxin Type B_INT_Neamine", "text": "Interaction: Botulinum Toxin Type B AND Neamine\nDetails: Neamine may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Neamine"}, {"id": "Botulinum Toxin Type B_INT_SP1049C", "text": "Interaction: Botulinum Toxin Type B AND SP1049C\nDetails: SP1049C may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + SP1049C"}, {"id": "Botulinum Toxin Type B_INT_INNO-206", "text": "Interaction: Botulinum Toxin Type B AND INNO-206\nDetails: INNO-206 may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + INNO-206"}, {"id": "Botulinum Toxin Type B_INT_Amrubicin", "text": "Interaction: Botulinum Toxin Type B AND Amrubicin\nDetails: Amrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Amrubicin"}, {"id": "Botulinum Toxin Type B_INT_annamycin", "text": "Interaction: Botulinum Toxin Type B AND annamycin\nDetails: annamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + annamycin"}, {"id": "Botulinum Toxin Type B_INT_Arbekacin", "text": "Interaction: Botulinum Toxin Type B AND Arbekacin\nDetails: Arbekacin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Arbekacin"}, {"id": "Botulinum Toxin Type B_INT_Plicamycin", "text": "Interaction: Botulinum Toxin Type B AND Plicamycin\nDetails: Plicamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Plicamycin"}, {"id": "Botulinum Toxin Type B_INT_Puromycin", "text": "Interaction: Botulinum Toxin Type B AND Puromycin\nDetails: Puromycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Puromycin"}, {"id": "Botulinum Toxin Type B_INT_Dihydrostreptomycin", "text": "Interaction: Botulinum Toxin Type B AND Dihydrostreptomycin\nDetails: Dihydrostreptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Dihydrostreptomycin"}, {"id": "Botulinum Toxin Type B_INT_Hygromycin B", "text": "Interaction: Botulinum Toxin Type B AND Hygromycin B\nDetails: Hygromycin B may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Hygromycin B"}, {"id": "Botulinum Toxin Type B_INT_Pirarubicin", "text": "Interaction: Botulinum Toxin Type B AND Pirarubicin\nDetails: Pirarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Pirarubicin"}, {"id": "Botulinum Toxin Type B_INT_Aclarubicin", "text": "Interaction: Botulinum Toxin Type B AND Aclarubicin\nDetails: Aclarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Aclarubicin"}, {"id": "Botulinum Toxin Type B_INT_Zorubicin", "text": "Interaction: Botulinum Toxin Type B AND Zorubicin\nDetails: Zorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Zorubicin"}, {"id": "Botulinum Toxin Type B_INT_Sabarubicin", "text": "Interaction: Botulinum Toxin Type B AND Sabarubicin\nDetails: Sabarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Sabarubicin"}, {"id": "Botulinum Toxin Type B_INT_Sisomicin", "text": "Interaction: Botulinum Toxin Type B AND Sisomicin\nDetails: Sisomicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Sisomicin"}, {"id": "Botulinum Toxin Type B_INT_Plazomicin", "text": "Interaction: Botulinum Toxin Type B AND Plazomicin\nDetails: Plazomicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Plazomicin"}, {"id": "Botulinum Toxin Type B_INT_Zoptarelin doxorubicin", "text": "Interaction: Botulinum Toxin Type B AND Zoptarelin doxorubicin\nDetails: Zoptarelin doxorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Zoptarelin doxorubicin"}, {"id": "Botulinum Toxin Type B_INT_GPX-150", "text": "Interaction: Botulinum Toxin Type B AND GPX-150\nDetails: GPX-150 may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + GPX-150"}, {"id": "Botulinum Toxin Type B_INT_Dibekacin", "text": "Interaction: Botulinum Toxin Type B AND Dibekacin\nDetails: Dibekacin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Dibekacin"}, {"id": "Botulinum Toxin Type B_INT_Micronomicin", "text": "Interaction: Botulinum Toxin Type B AND Micronomicin\nDetails: Micronomicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Micronomicin"}, {"id": "Botulinum Toxin Type B_INT_Isepamicin", "text": "Interaction: Botulinum Toxin Type B AND Isepamicin\nDetails: Isepamicin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Isepamicin"}, {"id": "Botulinum Toxin Type B_INT_Bekanamycin", "text": "Interaction: Botulinum Toxin Type B AND Bekanamycin\nDetails: Bekanamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type B + Bekanamycin"}, {"id": "Omalizumab_GEN", "text": "Drug: Omalizumab\nDescription: A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin....", "source": "Omalizumab"}, {"id": "Omalizumab_CLIN", "text": "Drug: Omalizumab\nMechanism: Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils....\nToxicity: ...", "source": "Omalizumab"}, {"id": "Omalizumab_INT_Belimumab", "text": "Interaction: Omalizumab AND Belimumab\nDetails: The risk or severity of adverse effects can be increased when Omalizumab is combined with Belimumab.\nRisk: Monitor closely.", "source": "Omalizumab + Belimumab"}, {"id": "Omalizumab_INT_Amoxapine", "text": "Interaction: Omalizumab AND Amoxapine\nDetails: The therapeutic efficacy of Omalizumab can be decreased when used in combination with Amoxapine.\nRisk: Monitor closely.", "source": "Omalizumab + Amoxapine"}, {"id": "Omalizumab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Omalizumab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Omalizumab_INT_Yellow fever vaccine", "text": "Interaction: Omalizumab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + Yellow fever vaccine"}, {"id": "Omalizumab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Omalizumab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Omalizumab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Omalizumab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Omalizumab_INT_Rotavirus Vaccine", "text": "Interaction: Omalizumab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + Rotavirus Vaccine"}, {"id": "Omalizumab_INT_G17DT", "text": "Interaction: Omalizumab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + G17DT"}, {"id": "Omalizumab_INT_INGN 201", "text": "Interaction: Omalizumab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + INGN 201"}, {"id": "Omalizumab_INT_INGN 225", "text": "Interaction: Omalizumab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + INGN 225"}, {"id": "Omalizumab_INT_Rindopepimut", "text": "Interaction: Omalizumab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + Rindopepimut"}, {"id": "Omalizumab_INT_SRP 299", "text": "Interaction: Omalizumab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + SRP 299"}, {"id": "Omalizumab_INT_GI-5005", "text": "Interaction: Omalizumab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + GI-5005"}, {"id": "Omalizumab_INT_TG4010", "text": "Interaction: Omalizumab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + TG4010"}, {"id": "Omalizumab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Omalizumab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + Rabies virus inactivated antigen, A"}, {"id": "Omalizumab_INT_Tecemotide", "text": "Interaction: Omalizumab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + Tecemotide"}, {"id": "Omalizumab_INT_BCG vaccine", "text": "Interaction: Omalizumab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + BCG vaccine"}, {"id": "Omalizumab_INT_Rubella virus vaccine", "text": "Interaction: Omalizumab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + Rubella virus vaccine"}, {"id": "Omalizumab_INT_Hepatitis A Vaccine", "text": "Interaction: Omalizumab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + Hepatitis A Vaccine"}, {"id": "Omalizumab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Omalizumab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + Salmonella typhi ty21a live antigen"}, {"id": "Omalizumab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Omalizumab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Omalizumab.\nRisk: Monitor closely.", "source": "Omalizumab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Lutropin alfa_GEN", "text": "Drug: Lutropin alfa\nDescription: Lutropin alfa is a recombinant human luteinizing hormone produced in yeast with 2 subunits, alpha = 92 residues, beta = 121 residues. It is a heterodimeric glycoprotein. Each monomeric unit is a glycoprotein molecule. In females, an acute rise of LH (\"LH surge\") triggers ovulation and the developmen...", "source": "Lutropin alfa"}, {"id": "Lutropin alfa_CLIN", "text": "Drug: Lutropin alfa\nMechanism: Luteinizing hormone binds to a receptor shared with the human chorionic gonadotropin hormone (hCG) on the ovarian theca (and granulosa) cells and testicular Leydig cells. This LH/CG transmembrane rece...\nToxicity: Lutropin alfa is not indicated for people under 16 and over 60, pregnant and lactating women, patients with uncontrolled thyroid and adrenal failure, patients with active, untreated tumours of the hyp...", "source": "Lutropin alfa"}, {"id": "Lyme disease vaccine (recombinant OspA)_GEN", "text": "Drug: Lyme disease vaccine (recombinant OspA)\nDescription: Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli. Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with ...", "source": "Lyme disease vaccine (recombinant OspA)"}, {"id": "Lyme disease vaccine (recombinant OspA)_CLIN", "text": "Drug: Lyme disease vaccine (recombinant OspA)\nMechanism: OspA lipoprotein, an outer surface protein of the bacteria Borrelia burgdorferi sensu stricto ZS7, is used to stimulate the production of specific antibodies against B. burgdorferi. It is used as a va...\nToxicity: ...", "source": "Lyme disease vaccine (recombinant OspA)"}, {"id": "Insulin Lispro_GEN", "text": "Drug: Insulin Lispro\nDescription: Insulin lispro is a recombinant human insulin analogue produced in a specialized laboratory strain of Escherischia coli. Plasmid DNA transfected into the bacteria encodes for an analogue of human insulin that has a lysine at residuce B28 and proline at B29; these residues are reversed in endogenous ...", "source": "Insulin Lispro"}, {"id": "Insulin Lispro_CLIN", "text": "Drug: Insulin Lispro\nMechanism: Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit ...\nToxicity: Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms...", "source": "Insulin Lispro"}, {"id": "Insulin Lispro_INT_Pregabalin", "text": "Interaction: Insulin Lispro AND Pregabalin\nDetails: The risk or severity of heart failure can be increased when Pregabalin is combined with Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Pregabalin"}, {"id": "Insulin Lispro_INT_Lipoic Acid", "text": "Interaction: Insulin Lispro AND Lipoic Acid\nDetails: Lipoic Acid may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Lipoic Acid"}, {"id": "Insulin Lispro_INT_Insulin Human", "text": "Interaction: Insulin Lispro AND Insulin Human\nDetails: Insulin Human may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Insulin Human"}, {"id": "Insulin Lispro_INT_Insulin Glargine", "text": "Interaction: Insulin Lispro AND Insulin Glargine\nDetails: Insulin Lispro may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Lispro + Insulin Glargine"}, {"id": "Insulin Lispro_INT_Octreotide", "text": "Interaction: Insulin Lispro AND Octreotide\nDetails: Insulin Lispro may increase the hypoglycemic activities of Octreotide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Octreotide"}, {"id": "Insulin Lispro_INT_Glimepiride", "text": "Interaction: Insulin Lispro AND Glimepiride\nDetails: Insulin Lispro may increase the hypoglycemic activities of Glimepiride.\nRisk: Monitor closely.", "source": "Insulin Lispro + Glimepiride"}, {"id": "Insulin Lispro_INT_Sulfisoxazole", "text": "Interaction: Insulin Lispro AND Sulfisoxazole\nDetails: Insulin Lispro may increase the hypoglycemic activities of Sulfisoxazole.\nRisk: Monitor closely.", "source": "Insulin Lispro + Sulfisoxazole"}, {"id": "Insulin Lispro_INT_Disopyramide", "text": "Interaction: Insulin Lispro AND Disopyramide\nDetails: Insulin Lispro may increase the hypoglycemic activities of Disopyramide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Disopyramide"}, {"id": "Insulin Lispro_INT_Sulfadiazine", "text": "Interaction: Insulin Lispro AND Sulfadiazine\nDetails: Insulin Lispro may increase the hypoglycemic activities of Sulfadiazine.\nRisk: Monitor closely.", "source": "Insulin Lispro + Sulfadiazine"}, {"id": "Insulin Lispro_INT_Quinine", "text": "Interaction: Insulin Lispro AND Quinine\nDetails: Insulin Lispro may increase the hypoglycemic activities of Quinine.\nRisk: Monitor closely.", "source": "Insulin Lispro + Quinine"}, {"id": "Insulin Lispro_INT_Chlorpropamide", "text": "Interaction: Insulin Lispro AND Chlorpropamide\nDetails: Insulin Lispro may increase the hypoglycemic activities of Chlorpropamide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Chlorpropamide"}, {"id": "Insulin Lispro_INT_Nateglinide", "text": "Interaction: Insulin Lispro AND Nateglinide\nDetails: Insulin Lispro may increase the hypoglycemic activities of Nateglinide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Nateglinide"}, {"id": "Insulin Lispro_INT_Pentamidine", "text": "Interaction: Insulin Lispro AND Pentamidine\nDetails: Insulin Lispro may increase the hypoglycemic activities of Pentamidine.\nRisk: Monitor closely.", "source": "Insulin Lispro + Pentamidine"}, {"id": "Insulin Lispro_INT_Mifepristone", "text": "Interaction: Insulin Lispro AND Mifepristone\nDetails: Insulin Lispro may increase the hypoglycemic activities of Mifepristone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Mifepristone"}, {"id": "Insulin Lispro_INT_Tolazamide", "text": "Interaction: Insulin Lispro AND Tolazamide\nDetails: Insulin Lispro may increase the hypoglycemic activities of Tolazamide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Tolazamide"}, {"id": "Insulin Lispro_INT_Repaglinide", "text": "Interaction: Insulin Lispro AND Repaglinide\nDetails: Insulin Lispro may increase the hypoglycemic activities of Repaglinide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Repaglinide"}, {"id": "Insulin Lispro_INT_Sulfamethoxazole", "text": "Interaction: Insulin Lispro AND Sulfamethoxazole\nDetails: Insulin Lispro may increase the hypoglycemic activities of Sulfamethoxazole.\nRisk: Monitor closely.", "source": "Insulin Lispro + Sulfamethoxazole"}, {"id": "Insulin Lispro_INT_Glyburide", "text": "Interaction: Insulin Lispro AND Glyburide\nDetails: Insulin Lispro may increase the hypoglycemic activities of Glyburide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Glyburide"}, {"id": "Insulin Lispro_INT_Glipizide", "text": "Interaction: Insulin Lispro AND Glipizide\nDetails: Insulin Lispro may increase the hypoglycemic activities of Glipizide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Glipizide"}, {"id": "Insulin Lispro_INT_Gliclazide", "text": "Interaction: Insulin Lispro AND Gliclazide\nDetails: Insulin Lispro may increase the hypoglycemic activities of Gliclazide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Gliclazide"}, {"id": "Insulin Lispro_INT_Tolbutamide", "text": "Interaction: Insulin Lispro AND Tolbutamide\nDetails: Insulin Lispro may increase the hypoglycemic activities of Tolbutamide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Tolbutamide"}, {"id": "Insulin Lispro_INT_Sunitinib", "text": "Interaction: Insulin Lispro AND Sunitinib\nDetails: Insulin Lispro may increase the hypoglycemic activities of Sunitinib.\nRisk: Monitor closely.", "source": "Insulin Lispro + Sunitinib"}, {"id": "Insulin Lispro_INT_Mecasermin", "text": "Interaction: Insulin Lispro AND Mecasermin\nDetails: Insulin Lispro may increase the hypoglycemic activities of Mecasermin.\nRisk: Monitor closely.", "source": "Insulin Lispro + Mecasermin"}, {"id": "Insulin Lispro_INT_Insulin Aspart", "text": "Interaction: Insulin Lispro AND Insulin Aspart\nDetails: Insulin Lispro may increase the hypoglycemic activities of Insulin Aspart.\nRisk: Monitor closely.", "source": "Insulin Lispro + Insulin Aspart"}, {"id": "Insulin Lispro_INT_Insulin Detemir", "text": "Interaction: Insulin Lispro AND Insulin Detemir\nDetails: Insulin Lispro may increase the hypoglycemic activities of Insulin Detemir.\nRisk: Monitor closely.", "source": "Insulin Lispro + Insulin Detemir"}, {"id": "Insulin Lispro_INT_Insulin Glulisine", "text": "Interaction: Insulin Lispro AND Insulin Glulisine\nDetails: Insulin Lispro may increase the hypoglycemic activities of Insulin Glulisine.\nRisk: Monitor closely.", "source": "Insulin Lispro + Insulin Glulisine"}, {"id": "Insulin Lispro_INT_Pasireotide", "text": "Interaction: Insulin Lispro AND Pasireotide\nDetails: Insulin Lispro may increase the hypoglycemic activities of Pasireotide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Pasireotide"}, {"id": "Insulin Lispro_INT_Lanreotide", "text": "Interaction: Insulin Lispro AND Lanreotide\nDetails: Insulin Lispro may increase the hypoglycemic activities of Lanreotide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Lanreotide"}, {"id": "Insulin Lispro_INT_Tranylcypromine", "text": "Interaction: Insulin Lispro AND Tranylcypromine\nDetails: Tranylcypromine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Tranylcypromine"}, {"id": "Insulin Lispro_INT_Phenelzine", "text": "Interaction: Insulin Lispro AND Phenelzine\nDetails: Phenelzine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Phenelzine"}, {"id": "Insulin Lispro_INT_Minaprine", "text": "Interaction: Insulin Lispro AND Minaprine\nDetails: Minaprine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Minaprine"}, {"id": "Insulin Lispro_INT_Selegiline", "text": "Interaction: Insulin Lispro AND Selegiline\nDetails: Selegiline may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Selegiline"}, {"id": "Insulin Lispro_INT_Moclobemide", "text": "Interaction: Insulin Lispro AND Moclobemide\nDetails: Moclobemide may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Moclobemide"}, {"id": "Insulin Lispro_INT_Isocarboxazid", "text": "Interaction: Insulin Lispro AND Isocarboxazid\nDetails: Isocarboxazid may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Isocarboxazid"}, {"id": "Insulin Lispro_INT_Rasagiline", "text": "Interaction: Insulin Lispro AND Rasagiline\nDetails: Rasagiline may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Rasagiline"}, {"id": "Insulin Lispro_INT_Pargyline", "text": "Interaction: Insulin Lispro AND Pargyline\nDetails: Pargyline may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Pargyline"}, {"id": "Insulin Lispro_INT_Nialamide", "text": "Interaction: Insulin Lispro AND Nialamide\nDetails: Nialamide may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Nialamide"}, {"id": "Insulin Lispro_INT_Pirlindole", "text": "Interaction: Insulin Lispro AND Pirlindole\nDetails: Pirlindole may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Pirlindole"}, {"id": "Insulin Lispro_INT_Toloxatone", "text": "Interaction: Insulin Lispro AND Toloxatone\nDetails: Toloxatone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Toloxatone"}, {"id": "Insulin Lispro_INT_Iproniazid", "text": "Interaction: Insulin Lispro AND Iproniazid\nDetails: Iproniazid may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Iproniazid"}, {"id": "Insulin Lispro_INT_Furazolidone", "text": "Interaction: Insulin Lispro AND Furazolidone\nDetails: Furazolidone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Furazolidone"}, {"id": "Insulin Lispro_INT_Trans-2-Phenylcyclopropylamine", "text": "Interaction: Insulin Lispro AND Trans-2-Phenylcyclopropylamine\nDetails: Trans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Trans-2-Phenylcyclopropylamine"}, {"id": "Insulin Lispro_INT_7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline", "text": "Interaction: Insulin Lispro AND 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline\nDetails: 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline"}, {"id": "Insulin Lispro_INT_Harmaline", "text": "Interaction: Insulin Lispro AND Harmaline\nDetails: Harmaline may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Harmaline"}, {"id": "Insulin Lispro_INT_Brofaromine", "text": "Interaction: Insulin Lispro AND Brofaromine\nDetails: Brofaromine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Brofaromine"}, {"id": "Insulin Lispro_INT_Amphetamine", "text": "Interaction: Insulin Lispro AND Amphetamine\nDetails: Amphetamine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Amphetamine"}, {"id": "Insulin Lispro_INT_Procarbazine", "text": "Interaction: Insulin Lispro AND Procarbazine\nDetails: Procarbazine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Procarbazine"}, {"id": "Insulin Lispro_INT_Hydracarbazine", "text": "Interaction: Insulin Lispro AND Hydracarbazine\nDetails: Hydracarbazine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Hydracarbazine"}, {"id": "Insulin Lispro_INT_Methylene blue", "text": "Interaction: Insulin Lispro AND Methylene blue\nDetails: Methylene blue may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Methylene blue"}, {"id": "Insulin Lispro_INT_Benmoxin", "text": "Interaction: Insulin Lispro AND Benmoxin\nDetails: Benmoxin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Benmoxin"}, {"id": "Insulin Lispro_INT_Iproclozide", "text": "Interaction: Insulin Lispro AND Iproclozide\nDetails: Iproclozide may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Iproclozide"}, {"id": "Insulin Lispro_INT_Mebanazine", "text": "Interaction: Insulin Lispro AND Mebanazine\nDetails: Mebanazine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Mebanazine"}, {"id": "Insulin Lispro_INT_Octamoxin", "text": "Interaction: Insulin Lispro AND Octamoxin\nDetails: Octamoxin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Octamoxin"}, {"id": "Insulin Lispro_INT_Pheniprazine", "text": "Interaction: Insulin Lispro AND Pheniprazine\nDetails: Pheniprazine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Pheniprazine"}, {"id": "Insulin Lispro_INT_Phenoxypropazine", "text": "Interaction: Insulin Lispro AND Phenoxypropazine\nDetails: Phenoxypropazine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Phenoxypropazine"}, {"id": "Insulin Lispro_INT_Pivhydrazine", "text": "Interaction: Insulin Lispro AND Pivhydrazine\nDetails: Pivhydrazine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Pivhydrazine"}, {"id": "Insulin Lispro_INT_Safrazine", "text": "Interaction: Insulin Lispro AND Safrazine\nDetails: Safrazine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Safrazine"}, {"id": "Insulin Lispro_INT_Caroxazone", "text": "Interaction: Insulin Lispro AND Caroxazone\nDetails: Caroxazone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Caroxazone"}, {"id": "Insulin Lispro_INT_Ubidecarenone", "text": "Interaction: Insulin Lispro AND Ubidecarenone\nDetails: The therapeutic efficacy of Insulin Lispro can be increased when used in combination with Ubidecarenone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Ubidecarenone"}, {"id": "Insulin Lispro_INT_Grepafloxacin", "text": "Interaction: Insulin Lispro AND Grepafloxacin\nDetails: Grepafloxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Grepafloxacin"}, {"id": "Insulin Lispro_INT_Enoxacin", "text": "Interaction: Insulin Lispro AND Enoxacin\nDetails: Enoxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Enoxacin"}, {"id": "Insulin Lispro_INT_Pefloxacin", "text": "Interaction: Insulin Lispro AND Pefloxacin\nDetails: Pefloxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Pefloxacin"}, {"id": "Insulin Lispro_INT_Trovafloxacin", "text": "Interaction: Insulin Lispro AND Trovafloxacin\nDetails: Trovafloxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Trovafloxacin"}, {"id": "Insulin Lispro_INT_Nalidixic Acid", "text": "Interaction: Insulin Lispro AND Nalidixic Acid\nDetails: Nalidixic Acid may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Nalidixic Acid"}, {"id": "Insulin Lispro_INT_Rosoxacin", "text": "Interaction: Insulin Lispro AND Rosoxacin\nDetails: Rosoxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Rosoxacin"}, {"id": "Insulin Lispro_INT_Cinoxacin", "text": "Interaction: Insulin Lispro AND Cinoxacin\nDetails: Cinoxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Cinoxacin"}, {"id": "Insulin Lispro_INT_Gatifloxacin", "text": "Interaction: Insulin Lispro AND Gatifloxacin\nDetails: Gatifloxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Gatifloxacin"}, {"id": "Insulin Lispro_INT_Norfloxacin", "text": "Interaction: Insulin Lispro AND Norfloxacin\nDetails: Norfloxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Norfloxacin"}, {"id": "Insulin Lispro_INT_Levofloxacin", "text": "Interaction: Insulin Lispro AND Levofloxacin\nDetails: Levofloxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Levofloxacin"}, {"id": "Insulin Lispro_INT_Gemifloxacin", "text": "Interaction: Insulin Lispro AND Gemifloxacin\nDetails: Gemifloxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Gemifloxacin"}, {"id": "Insulin Lispro_INT_Sparfloxacin", "text": "Interaction: Insulin Lispro AND Sparfloxacin\nDetails: Sparfloxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Sparfloxacin"}, {"id": "Insulin Lispro_INT_Temafloxacin", "text": "Interaction: Insulin Lispro AND Temafloxacin\nDetails: Temafloxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Temafloxacin"}, {"id": "Insulin Lispro_INT_Fleroxacin", "text": "Interaction: Insulin Lispro AND Fleroxacin\nDetails: Fleroxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Fleroxacin"}, {"id": "Insulin Lispro_INT_Garenoxacin", "text": "Interaction: Insulin Lispro AND Garenoxacin\nDetails: Garenoxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Garenoxacin"}, {"id": "Insulin Lispro_INT_Nemonoxacin", "text": "Interaction: Insulin Lispro AND Nemonoxacin\nDetails: Nemonoxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Nemonoxacin"}, {"id": "Insulin Lispro_INT_Flumequine", "text": "Interaction: Insulin Lispro AND Flumequine\nDetails: Flumequine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Flumequine"}, {"id": "Insulin Lispro_INT_Pazufloxacin", "text": "Interaction: Insulin Lispro AND Pazufloxacin\nDetails: Pazufloxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Pazufloxacin"}, {"id": "Insulin Lispro_INT_Prulifloxacin", "text": "Interaction: Insulin Lispro AND Prulifloxacin\nDetails: Prulifloxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Prulifloxacin"}, {"id": "Insulin Lispro_INT_Sitafloxacin", "text": "Interaction: Insulin Lispro AND Sitafloxacin\nDetails: Sitafloxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Sitafloxacin"}, {"id": "Insulin Lispro_INT_Oxolinic acid", "text": "Interaction: Insulin Lispro AND Oxolinic acid\nDetails: Oxolinic acid may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Oxolinic acid"}, {"id": "Insulin Lispro_INT_Piromidic acid", "text": "Interaction: Insulin Lispro AND Piromidic acid\nDetails: Piromidic acid may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Piromidic acid"}, {"id": "Insulin Lispro_INT_Rufloxacin", "text": "Interaction: Insulin Lispro AND Rufloxacin\nDetails: Rufloxacin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Rufloxacin"}, {"id": "Insulin Lispro_INT_Pipemidic acid", "text": "Interaction: Insulin Lispro AND Pipemidic acid\nDetails: Pipemidic acid may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Pipemidic acid"}, {"id": "Insulin Lispro_INT_Duloxetine", "text": "Interaction: Insulin Lispro AND Duloxetine\nDetails: Duloxetine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Duloxetine"}, {"id": "Insulin Lispro_INT_Nefazodone", "text": "Interaction: Insulin Lispro AND Nefazodone\nDetails: Nefazodone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Nefazodone"}, {"id": "Insulin Lispro_INT_Desvenlafaxine", "text": "Interaction: Insulin Lispro AND Desvenlafaxine\nDetails: Desvenlafaxine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Desvenlafaxine"}, {"id": "Insulin Lispro_INT_Milnacipran", "text": "Interaction: Insulin Lispro AND Milnacipran\nDetails: Milnacipran may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Milnacipran"}, {"id": "Insulin Lispro_INT_Venlafaxine", "text": "Interaction: Insulin Lispro AND Venlafaxine\nDetails: Venlafaxine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Venlafaxine"}, {"id": "Insulin Lispro_INT_Levomilnacipran", "text": "Interaction: Insulin Lispro AND Levomilnacipran\nDetails: Levomilnacipran may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Levomilnacipran"}, {"id": "Insulin Lispro_INT_Dapoxetine", "text": "Interaction: Insulin Lispro AND Dapoxetine\nDetails: Dapoxetine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Dapoxetine"}, {"id": "Insulin Lispro_INT_Indalpine", "text": "Interaction: Insulin Lispro AND Indalpine\nDetails: Indalpine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Indalpine"}, {"id": "Insulin Lispro_INT_Fluvoxamine", "text": "Interaction: Insulin Lispro AND Fluvoxamine\nDetails: Fluvoxamine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Fluvoxamine"}, {"id": "Insulin Lispro_INT_Citalopram", "text": "Interaction: Insulin Lispro AND Citalopram\nDetails: Citalopram may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Citalopram"}, {"id": "Insulin Lispro_INT_Fluoxetine", "text": "Interaction: Insulin Lispro AND Fluoxetine\nDetails: Fluoxetine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Fluoxetine"}, {"id": "Insulin Lispro_INT_Paroxetine", "text": "Interaction: Insulin Lispro AND Paroxetine\nDetails: Paroxetine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Paroxetine"}, {"id": "Insulin Lispro_INT_Sertraline", "text": "Interaction: Insulin Lispro AND Sertraline\nDetails: Sertraline may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Sertraline"}, {"id": "Insulin Lispro_INT_Escitalopram", "text": "Interaction: Insulin Lispro AND Escitalopram\nDetails: Escitalopram may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Escitalopram"}, {"id": "Insulin Lispro_INT_Zimelidine", "text": "Interaction: Insulin Lispro AND Zimelidine\nDetails: Zimelidine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Zimelidine"}, {"id": "Insulin Lispro_INT_Etoperidone", "text": "Interaction: Insulin Lispro AND Etoperidone\nDetails: Etoperidone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Etoperidone"}, {"id": "Insulin Lispro_INT_Alaproclate", "text": "Interaction: Insulin Lispro AND Alaproclate\nDetails: Alaproclate may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Alaproclate"}, {"id": "Insulin Lispro_INT_Methyclothiazide", "text": "Interaction: Insulin Lispro AND Methyclothiazide\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methyclothiazide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Methyclothiazide"}, {"id": "Insulin Lispro_INT_Chlorothiazide", "text": "Interaction: Insulin Lispro AND Chlorothiazide\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Chlorothiazide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Chlorothiazide"}, {"id": "Insulin Lispro_INT_Hydrochlorothiazide", "text": "Interaction: Insulin Lispro AND Hydrochlorothiazide\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrochlorothiazide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Hydrochlorothiazide"}, {"id": "Insulin Lispro_INT_Chlorthalidone", "text": "Interaction: Insulin Lispro AND Chlorthalidone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Chlorthalidone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Chlorthalidone"}, {"id": "Insulin Lispro_INT_Bendroflumethiazide", "text": "Interaction: Insulin Lispro AND Bendroflumethiazide\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Bendroflumethiazide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Bendroflumethiazide"}, {"id": "Insulin Lispro_INT_Metolazone", "text": "Interaction: Insulin Lispro AND Metolazone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Metolazone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Metolazone"}, {"id": "Insulin Lispro_INT_Hydroflumethiazide", "text": "Interaction: Insulin Lispro AND Hydroflumethiazide\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydroflumethiazide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Hydroflumethiazide"}, {"id": "Insulin Lispro_INT_Indapamide", "text": "Interaction: Insulin Lispro AND Indapamide\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Indapamide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Indapamide"}, {"id": "Insulin Lispro_INT_Trichlormethiazide", "text": "Interaction: Insulin Lispro AND Trichlormethiazide\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Trichlormethiazide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Trichlormethiazide"}, {"id": "Insulin Lispro_INT_Polythiazide", "text": "Interaction: Insulin Lispro AND Polythiazide\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Polythiazide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Polythiazide"}, {"id": "Insulin Lispro_INT_Quinethazone", "text": "Interaction: Insulin Lispro AND Quinethazone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Quinethazone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Quinethazone"}, {"id": "Insulin Lispro_INT_Cyclopenthiazide", "text": "Interaction: Insulin Lispro AND Cyclopenthiazide\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Cyclopenthiazide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Cyclopenthiazide"}, {"id": "Insulin Lispro_INT_Leuprolide", "text": "Interaction: Insulin Lispro AND Leuprolide\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Leuprolide"}, {"id": "Insulin Lispro_INT_Goserelin", "text": "Interaction: Insulin Lispro AND Goserelin\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Insulin Lispro + Goserelin"}, {"id": "Insulin Lispro_INT_Torasemide", "text": "Interaction: Insulin Lispro AND Torasemide\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Torasemide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Torasemide"}, {"id": "Insulin Lispro_INT_Nelfinavir", "text": "Interaction: Insulin Lispro AND Nelfinavir\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Nelfinavir.\nRisk: Monitor closely.", "source": "Insulin Lispro + Nelfinavir"}, {"id": "Insulin Lispro_INT_Indinavir", "text": "Interaction: Insulin Lispro AND Indinavir\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Indinavir.\nRisk: Monitor closely.", "source": "Insulin Lispro + Indinavir"}, {"id": "Insulin Lispro_INT_Ziprasidone", "text": "Interaction: Insulin Lispro AND Ziprasidone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ziprasidone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Ziprasidone"}, {"id": "Insulin Lispro_INT_Etonogestrel", "text": "Interaction: Insulin Lispro AND Etonogestrel\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Etonogestrel.\nRisk: Monitor closely.", "source": "Insulin Lispro + Etonogestrel"}, {"id": "Insulin Lispro_INT_Desogestrel", "text": "Interaction: Insulin Lispro AND Desogestrel\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Desogestrel.\nRisk: Monitor closely.", "source": "Insulin Lispro + Desogestrel"}, {"id": "Insulin Lispro_INT_Olanzapine", "text": "Interaction: Insulin Lispro AND Olanzapine\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Olanzapine.\nRisk: Monitor closely.", "source": "Insulin Lispro + Olanzapine"}, {"id": "Insulin Lispro_INT_Megestrol acetate", "text": "Interaction: Insulin Lispro AND Megestrol acetate\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Megestrol acetate.\nRisk: Monitor closely.", "source": "Insulin Lispro + Megestrol acetate"}, {"id": "Insulin Lispro_INT_Clozapine", "text": "Interaction: Insulin Lispro AND Clozapine\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Clozapine.\nRisk: Monitor closely.", "source": "Insulin Lispro + Clozapine"}, {"id": "Insulin Lispro_INT_Levonorgestrel", "text": "Interaction: Insulin Lispro AND Levonorgestrel\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Levonorgestrel.\nRisk: Monitor closely.", "source": "Insulin Lispro + Levonorgestrel"}, {"id": "Insulin Lispro_INT_Progesterone", "text": "Interaction: Insulin Lispro AND Progesterone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Progesterone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Progesterone"}, {"id": "Insulin Lispro_INT_Betamethasone", "text": "Interaction: Insulin Lispro AND Betamethasone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Betamethasone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Betamethasone"}, {"id": "Insulin Lispro_INT_Ritonavir", "text": "Interaction: Insulin Lispro AND Ritonavir\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ritonavir.\nRisk: Monitor closely.", "source": "Insulin Lispro + Ritonavir"}, {"id": "Insulin Lispro_INT_Piperazine", "text": "Interaction: Insulin Lispro AND Piperazine\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Piperazine.\nRisk: Monitor closely.", "source": "Insulin Lispro + Piperazine"}, {"id": "Insulin Lispro_INT_Medroxyprogesterone acetate", "text": "Interaction: Insulin Lispro AND Medroxyprogesterone acetate\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Medroxyprogesterone acetate.\nRisk: Monitor closely.", "source": "Insulin Lispro + Medroxyprogesterone acetate"}, {"id": "Insulin Lispro_INT_Triamcinolone", "text": "Interaction: Insulin Lispro AND Triamcinolone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Triamcinolone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Triamcinolone"}, {"id": "Insulin Lispro_INT_Niacin", "text": "Interaction: Insulin Lispro AND Niacin\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Niacin.\nRisk: Monitor closely.", "source": "Insulin Lispro + Niacin"}, {"id": "Insulin Lispro_INT_Prednisone", "text": "Interaction: Insulin Lispro AND Prednisone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Prednisone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Prednisone"}, {"id": "Insulin Lispro_INT_Epinephrine", "text": "Interaction: Insulin Lispro AND Epinephrine\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Epinephrine.\nRisk: Monitor closely.", "source": "Insulin Lispro + Epinephrine"}, {"id": "Insulin Lispro_INT_Fludrocortisone", "text": "Interaction: Insulin Lispro AND Fludrocortisone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Fludrocortisone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Fludrocortisone"}, {"id": "Insulin Lispro_INT_Furosemide", "text": "Interaction: Insulin Lispro AND Furosemide\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Furosemide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Furosemide"}, {"id": "Insulin Lispro_INT_Norethisterone", "text": "Interaction: Insulin Lispro AND Norethisterone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Norethisterone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Norethisterone"}, {"id": "Insulin Lispro_INT_Risperidone", "text": "Interaction: Insulin Lispro AND Risperidone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Risperidone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Risperidone"}, {"id": "Insulin Lispro_INT_Hydrocortisone", "text": "Interaction: Insulin Lispro AND Hydrocortisone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydrocortisone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Hydrocortisone"}, {"id": "Insulin Lispro_INT_Estradiol", "text": "Interaction: Insulin Lispro AND Estradiol\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Estradiol.\nRisk: Monitor closely.", "source": "Insulin Lispro + Estradiol"}, {"id": "Insulin Lispro_INT_Ethynodiol diacetate", "text": "Interaction: Insulin Lispro AND Ethynodiol diacetate\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ethynodiol diacetate.\nRisk: Monitor closely.", "source": "Insulin Lispro + Ethynodiol diacetate"}, {"id": "Insulin Lispro_INT_Prednisolone", "text": "Interaction: Insulin Lispro AND Prednisolone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Prednisolone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Prednisolone"}, {"id": "Insulin Lispro_INT_Tacrolimus", "text": "Interaction: Insulin Lispro AND Tacrolimus\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Tacrolimus.\nRisk: Monitor closely.", "source": "Insulin Lispro + Tacrolimus"}, {"id": "Insulin Lispro_INT_Sirolimus", "text": "Interaction: Insulin Lispro AND Sirolimus\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Sirolimus.\nRisk: Monitor closely.", "source": "Insulin Lispro + Sirolimus"}, {"id": "Insulin Lispro_INT_Bumetanide", "text": "Interaction: Insulin Lispro AND Bumetanide\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Bumetanide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Bumetanide"}, {"id": "Insulin Lispro_INT_Etacrynic acid", "text": "Interaction: Insulin Lispro AND Etacrynic acid\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Etacrynic acid.\nRisk: Monitor closely.", "source": "Insulin Lispro + Etacrynic acid"}, {"id": "Insulin Lispro_INT_Tipranavir", "text": "Interaction: Insulin Lispro AND Tipranavir\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Tipranavir.\nRisk: Monitor closely.", "source": "Insulin Lispro + Tipranavir"}, {"id": "Insulin Lispro_INT_Norgestimate", "text": "Interaction: Insulin Lispro AND Norgestimate\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Norgestimate.\nRisk: Monitor closely.", "source": "Insulin Lispro + Norgestimate"}, {"id": "Insulin Lispro_INT_Methylprednisolone", "text": "Interaction: Insulin Lispro AND Methylprednisolone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methylprednisolone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Methylprednisolone"}, {"id": "Insulin Lispro_INT_Ethinyl Estradiol", "text": "Interaction: Insulin Lispro AND Ethinyl Estradiol\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ethinyl Estradiol.\nRisk: Monitor closely.", "source": "Insulin Lispro + Ethinyl Estradiol"}, {"id": "Insulin Lispro_INT_Atazanavir", "text": "Interaction: Insulin Lispro AND Atazanavir\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Atazanavir.\nRisk: Monitor closely.", "source": "Insulin Lispro + Atazanavir"}, {"id": "Insulin Lispro_INT_Diazoxide", "text": "Interaction: Insulin Lispro AND Diazoxide\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Diazoxide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Diazoxide"}, {"id": "Insulin Lispro_INT_Arsenic trioxide", "text": "Interaction: Insulin Lispro AND Arsenic trioxide\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Arsenic trioxide.\nRisk: Monitor closely.", "source": "Insulin Lispro + Arsenic trioxide"}, {"id": "Insulin Lispro_INT_Quetiapine", "text": "Interaction: Insulin Lispro AND Quetiapine\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Quetiapine.\nRisk: Monitor closely.", "source": "Insulin Lispro + Quetiapine"}, {"id": "Insulin Lispro_INT_Saquinavir", "text": "Interaction: Insulin Lispro AND Saquinavir\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Saquinavir.\nRisk: Monitor closely.", "source": "Insulin Lispro + Saquinavir"}, {"id": "Insulin Lispro_INT_Dexamethasone", "text": "Interaction: Insulin Lispro AND Dexamethasone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dexamethasone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Dexamethasone"}, {"id": "Insulin Lispro_INT_Aripiprazole", "text": "Interaction: Insulin Lispro AND Aripiprazole\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Aripiprazole.\nRisk: Monitor closely.", "source": "Insulin Lispro + Aripiprazole"}, {"id": "Insulin Lispro_INT_Darunavir", "text": "Interaction: Insulin Lispro AND Darunavir\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Darunavir.\nRisk: Monitor closely.", "source": "Insulin Lispro + Darunavir"}, {"id": "Insulin Lispro_INT_Paliperidone", "text": "Interaction: Insulin Lispro AND Paliperidone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Paliperidone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Paliperidone"}, {"id": "Insulin Lispro_INT_Corticotropin", "text": "Interaction: Insulin Lispro AND Corticotropin\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Corticotropin.\nRisk: Monitor closely.", "source": "Insulin Lispro + Corticotropin"}, {"id": "Insulin Lispro_INT_Fosamprenavir", "text": "Interaction: Insulin Lispro AND Fosamprenavir\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Fosamprenavir.\nRisk: Monitor closely.", "source": "Insulin Lispro + Fosamprenavir"}, {"id": "Insulin Lispro_INT_Mestranol", "text": "Interaction: Insulin Lispro AND Mestranol\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Mestranol.\nRisk: Monitor closely.", "source": "Insulin Lispro + Mestranol"}, {"id": "Insulin Lispro_INT_Cortisone acetate", "text": "Interaction: Insulin Lispro AND Cortisone acetate\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Cortisone acetate.\nRisk: Monitor closely.", "source": "Insulin Lispro + Cortisone acetate"}, {"id": "Insulin Lispro_INT_Drospirenone", "text": "Interaction: Insulin Lispro AND Drospirenone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Drospirenone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Drospirenone"}, {"id": "Insulin Lispro_INT_Methotrimeprazine", "text": "Interaction: Insulin Lispro AND Methotrimeprazine\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Methotrimeprazine.\nRisk: Monitor closely.", "source": "Insulin Lispro + Methotrimeprazine"}, {"id": "Insulin Lispro_INT_Danazol", "text": "Interaction: Insulin Lispro AND Danazol\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Danazol.\nRisk: Monitor closely.", "source": "Insulin Lispro + Danazol"}, {"id": "Insulin Lispro_INT_Everolimus", "text": "Interaction: Insulin Lispro AND Everolimus\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Everolimus.\nRisk: Monitor closely.", "source": "Insulin Lispro + Everolimus"}, {"id": "Insulin Lispro_INT_Lopinavir", "text": "Interaction: Insulin Lispro AND Lopinavir\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lopinavir.\nRisk: Monitor closely.", "source": "Insulin Lispro + Lopinavir"}, {"id": "Insulin Lispro_INT_Pipotiazine", "text": "Interaction: Insulin Lispro AND Pipotiazine\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Pipotiazine.\nRisk: Monitor closely.", "source": "Insulin Lispro + Pipotiazine"}, {"id": "Insulin Lispro_INT_Vorinostat", "text": "Interaction: Insulin Lispro AND Vorinostat\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Vorinostat.\nRisk: Monitor closely.", "source": "Insulin Lispro + Vorinostat"}, {"id": "Insulin Lispro_INT_Estrone sulfate", "text": "Interaction: Insulin Lispro AND Estrone sulfate\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Estrone sulfate.\nRisk: Monitor closely.", "source": "Insulin Lispro + Estrone sulfate"}, {"id": "Insulin Lispro_INT_Cyproterone acetate", "text": "Interaction: Insulin Lispro AND Cyproterone acetate\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Cyproterone acetate.\nRisk: Monitor closely.", "source": "Insulin Lispro + Cyproterone acetate"}, {"id": "Insulin Lispro_INT_Nilotinib", "text": "Interaction: Insulin Lispro AND Nilotinib\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Nilotinib.\nRisk: Monitor closely.", "source": "Insulin Lispro + Nilotinib"}, {"id": "Insulin Lispro_INT_Iloperidone", "text": "Interaction: Insulin Lispro AND Iloperidone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Iloperidone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Iloperidone"}, {"id": "Insulin Lispro_INT_Asenapine", "text": "Interaction: Insulin Lispro AND Asenapine\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Asenapine.\nRisk: Monitor closely.", "source": "Insulin Lispro + Asenapine"}, {"id": "Insulin Lispro_INT_Temsirolimus", "text": "Interaction: Insulin Lispro AND Temsirolimus\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Temsirolimus.\nRisk: Monitor closely.", "source": "Insulin Lispro + Temsirolimus"}, {"id": "Insulin Lispro_INT_Buserelin", "text": "Interaction: Insulin Lispro AND Buserelin\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Buserelin.\nRisk: Monitor closely.", "source": "Insulin Lispro + Buserelin"}, {"id": "Insulin Lispro_INT_Histrelin", "text": "Interaction: Insulin Lispro AND Histrelin\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Histrelin.\nRisk: Monitor closely.", "source": "Insulin Lispro + Histrelin"}, {"id": "Insulin Lispro_INT_Hydroxyprogesterone caproate", "text": "Interaction: Insulin Lispro AND Hydroxyprogesterone caproate\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydroxyprogesterone caproate.\nRisk: Monitor closely.", "source": "Insulin Lispro + Hydroxyprogesterone caproate"}, {"id": "Insulin Lispro_INT_Triptorelin", "text": "Interaction: Insulin Lispro AND Triptorelin\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Triptorelin.\nRisk: Monitor closely.", "source": "Insulin Lispro + Triptorelin"}, {"id": "Insulin Lispro_INT_Lurasidone", "text": "Interaction: Insulin Lispro AND Lurasidone\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lurasidone.\nRisk: Monitor closely.", "source": "Insulin Lispro + Lurasidone"}, {"id": "Insulin Lispro_INT_Dabrafenib", "text": "Interaction: Insulin Lispro AND Dabrafenib\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dabrafenib.\nRisk: Monitor closely.", "source": "Insulin Lispro + Dabrafenib"}, {"id": "Insulin Lispro_INT_Articaine", "text": "Interaction: Insulin Lispro AND Articaine\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Articaine.\nRisk: Monitor closely.", "source": "Insulin Lispro + Articaine"}, {"id": "Insulin Lispro_INT_Ceritinib", "text": "Interaction: Insulin Lispro AND Ceritinib\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Ceritinib.\nRisk: Monitor closely.", "source": "Insulin Lispro + Ceritinib"}, {"id": "Insulin Lispro_INT_Dienogest", "text": "Interaction: Insulin Lispro AND Dienogest\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Dienogest.\nRisk: Monitor closely.", "source": "Insulin Lispro + Dienogest"}, {"id": "Insulin Lispro_INT_Brexpiprazole", "text": "Interaction: Insulin Lispro AND Brexpiprazole\nDetails: The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Brexpiprazole.\nRisk: Monitor closely.", "source": "Insulin Lispro + Brexpiprazole"}, {"id": "Insulin Lispro_INT_Testosterone", "text": "Interaction: Insulin Lispro AND Testosterone\nDetails: Testosterone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Testosterone"}, {"id": "Insulin Lispro_INT_Dihydrotestosterone", "text": "Interaction: Insulin Lispro AND Dihydrotestosterone\nDetails: Dihydrotestosterone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Dihydrotestosterone"}, {"id": "Insulin Lispro_INT_Fluoxymesterone", "text": "Interaction: Insulin Lispro AND Fluoxymesterone\nDetails: Fluoxymesterone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Fluoxymesterone"}, {"id": "Insulin Lispro_INT_Testosterone Propionate", "text": "Interaction: Insulin Lispro AND Testosterone Propionate\nDetails: Testosterone Propionate may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Testosterone Propionate"}, {"id": "Insulin Lispro_INT_Methyltestosterone", "text": "Interaction: Insulin Lispro AND Methyltestosterone\nDetails: Methyltestosterone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Methyltestosterone"}, {"id": "Insulin Lispro_INT_Oxandrolone", "text": "Interaction: Insulin Lispro AND Oxandrolone\nDetails: Oxandrolone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Oxandrolone"}, {"id": "Insulin Lispro_INT_Oxymetholone", "text": "Interaction: Insulin Lispro AND Oxymetholone\nDetails: Oxymetholone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Oxymetholone"}, {"id": "Insulin Lispro_INT_Stanozolol", "text": "Interaction: Insulin Lispro AND Stanozolol\nDetails: Stanozolol may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Stanozolol"}, {"id": "Insulin Lispro_INT_GLPG-0492", "text": "Interaction: Insulin Lispro AND GLPG-0492\nDetails: GLPG-0492 may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + GLPG-0492"}, {"id": "Insulin Lispro_INT_Nandrolone", "text": "Interaction: Insulin Lispro AND Nandrolone\nDetails: Nandrolone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Nandrolone"}, {"id": "Insulin Lispro_INT_Mesterolone", "text": "Interaction: Insulin Lispro AND Mesterolone\nDetails: Mesterolone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Mesterolone"}, {"id": "Insulin Lispro_INT_Nandrolone decanoate", "text": "Interaction: Insulin Lispro AND Nandrolone decanoate\nDetails: Nandrolone decanoate may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Nandrolone decanoate"}, {"id": "Insulin Lispro_INT_Pegvisomant", "text": "Interaction: Insulin Lispro AND Pegvisomant\nDetails: Pegvisomant may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Pegvisomant"}, {"id": "Insulin Lispro_INT_Insulin Pork", "text": "Interaction: Insulin Lispro AND Insulin Pork\nDetails: Insulin Pork may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Insulin Pork"}, {"id": "Insulin Lispro_INT_Troglitazone", "text": "Interaction: Insulin Lispro AND Troglitazone\nDetails: Troglitazone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Troglitazone"}, {"id": "Insulin Lispro_INT_Acarbose", "text": "Interaction: Insulin Lispro AND Acarbose\nDetails: Acarbose may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Acarbose"}, {"id": "Insulin Lispro_INT_Metformin", "text": "Interaction: Insulin Lispro AND Metformin\nDetails: Metformin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Metformin"}, {"id": "Insulin Lispro_INT_Rosiglitazone", "text": "Interaction: Insulin Lispro AND Rosiglitazone\nDetails: Rosiglitazone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Rosiglitazone"}, {"id": "Insulin Lispro_INT_Acetohexamide", "text": "Interaction: Insulin Lispro AND Acetohexamide\nDetails: Acetohexamide may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Acetohexamide"}, {"id": "Insulin Lispro_INT_Miglustat", "text": "Interaction: Insulin Lispro AND Miglustat\nDetails: Miglustat may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Miglustat"}, {"id": "Insulin Lispro_INT_Miglitol", "text": "Interaction: Insulin Lispro AND Miglitol\nDetails: Miglitol may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Miglitol"}, {"id": "Insulin Lispro_INT_Phenformin", "text": "Interaction: Insulin Lispro AND Phenformin\nDetails: Phenformin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Phenformin"}, {"id": "Insulin Lispro_INT_Pioglitazone", "text": "Interaction: Insulin Lispro AND Pioglitazone\nDetails: Pioglitazone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Pioglitazone"}, {"id": "Insulin Lispro_INT_Gliquidone", "text": "Interaction: Insulin Lispro AND Gliquidone\nDetails: Gliquidone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Gliquidone"}, {"id": "Insulin Lispro_INT_Mitiglinide", "text": "Interaction: Insulin Lispro AND Mitiglinide\nDetails: Mitiglinide may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Mitiglinide"}, {"id": "Insulin Lispro_INT_Sitagliptin", "text": "Interaction: Insulin Lispro AND Sitagliptin\nDetails: Sitagliptin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Sitagliptin"}, {"id": "Insulin Lispro_INT_Exenatide", "text": "Interaction: Insulin Lispro AND Exenatide\nDetails: Exenatide may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Exenatide"}, {"id": "Insulin Lispro_INT_Pramlintide", "text": "Interaction: Insulin Lispro AND Pramlintide\nDetails: Pramlintide may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Pramlintide"}, {"id": "Insulin Lispro_INT_AICA ribonucleotide", "text": "Interaction: Insulin Lispro AND AICA ribonucleotide\nDetails: AICA ribonucleotide may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + AICA ribonucleotide"}, {"id": "Insulin Lispro_INT_Castanospermine", "text": "Interaction: Insulin Lispro AND Castanospermine\nDetails: Castanospermine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Castanospermine"}, {"id": "Insulin Lispro_INT_Buformin", "text": "Interaction: Insulin Lispro AND Buformin\nDetails: Buformin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Buformin"}, {"id": "Insulin Lispro_INT_Vildagliptin", "text": "Interaction: Insulin Lispro AND Vildagliptin\nDetails: Vildagliptin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Vildagliptin"}, {"id": "Insulin Lispro_INT_Voglibose", "text": "Interaction: Insulin Lispro AND Voglibose\nDetails: Voglibose may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Voglibose"}, {"id": "Insulin Lispro_INT_Alogliptin", "text": "Interaction: Insulin Lispro AND Alogliptin\nDetails: Alogliptin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Alogliptin"}, {"id": "Insulin Lispro_INT_Sulodexide", "text": "Interaction: Insulin Lispro AND Sulodexide\nDetails: Sulodexide may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Sulodexide"}, {"id": "Insulin Lispro_INT_Saxagliptin", "text": "Interaction: Insulin Lispro AND Saxagliptin\nDetails: Saxagliptin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Saxagliptin"}, {"id": "Insulin Lispro_INT_Liraglutide", "text": "Interaction: Insulin Lispro AND Liraglutide\nDetails: Liraglutide may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Liraglutide"}, {"id": "Insulin Lispro_INT_Linagliptin", "text": "Interaction: Insulin Lispro AND Linagliptin\nDetails: Linagliptin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Linagliptin"}, {"id": "Insulin Lispro_INT_Canagliflozin", "text": "Interaction: Insulin Lispro AND Canagliflozin\nDetails: Canagliflozin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Canagliflozin"}, {"id": "Insulin Lispro_INT_Glibornuride", "text": "Interaction: Insulin Lispro AND Glibornuride\nDetails: Glibornuride may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Glibornuride"}, {"id": "Insulin Lispro_INT_Empagliflozin", "text": "Interaction: Insulin Lispro AND Empagliflozin\nDetails: Empagliflozin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Empagliflozin"}, {"id": "Insulin Lispro_INT_Dulaglutide", "text": "Interaction: Insulin Lispro AND Dulaglutide\nDetails: Dulaglutide may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Dulaglutide"}, {"id": "Insulin Lispro_INT_Ciglitazone", "text": "Interaction: Insulin Lispro AND Ciglitazone\nDetails: Ciglitazone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Ciglitazone"}, {"id": "Insulin Lispro_INT_Allicin", "text": "Interaction: Insulin Lispro AND Allicin\nDetails: Allicin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Allicin"}, {"id": "Insulin Lispro_INT_2,4-thiazolidinedione", "text": "Interaction: Insulin Lispro AND 2,4-thiazolidinedione\nDetails: 2,4-thiazolidinedione may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + 2,4-thiazolidinedione"}, {"id": "Insulin Lispro_INT_Bempedoic acid", "text": "Interaction: Insulin Lispro AND Bempedoic acid\nDetails: Bempedoic acid may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Bempedoic acid"}, {"id": "Insulin Lispro_INT_Gusperimus", "text": "Interaction: Insulin Lispro AND Gusperimus\nDetails: Gusperimus may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Gusperimus"}, {"id": "Insulin Lispro_INT_Sotagliflozin", "text": "Interaction: Insulin Lispro AND Sotagliflozin\nDetails: Sotagliflozin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Sotagliflozin"}, {"id": "Insulin Lispro_INT_Balaglitazone", "text": "Interaction: Insulin Lispro AND Balaglitazone\nDetails: Balaglitazone may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Balaglitazone"}, {"id": "Insulin Lispro_INT_Deoxyspergualin", "text": "Interaction: Insulin Lispro AND Deoxyspergualin\nDetails: Deoxyspergualin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Deoxyspergualin"}, {"id": "Insulin Lispro_INT_Carbutamide", "text": "Interaction: Insulin Lispro AND Carbutamide\nDetails: Carbutamide may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Carbutamide"}, {"id": "Insulin Lispro_INT_Salicylic acid", "text": "Interaction: Insulin Lispro AND Salicylic acid\nDetails: Salicylic acid may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Salicylic acid"}, {"id": "Insulin Lispro_INT_Acetylsalicylic acid", "text": "Interaction: Insulin Lispro AND Acetylsalicylic acid\nDetails: Acetylsalicylic acid may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Acetylsalicylic acid"}, {"id": "Insulin Lispro_INT_Aminosalicylic Acid", "text": "Interaction: Insulin Lispro AND Aminosalicylic Acid\nDetails: Aminosalicylic Acid may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Aminosalicylic Acid"}, {"id": "Insulin Lispro_INT_Mesalazine", "text": "Interaction: Insulin Lispro AND Mesalazine\nDetails: Mesalazine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Mesalazine"}, {"id": "Insulin Lispro_INT_Diflunisal", "text": "Interaction: Insulin Lispro AND Diflunisal\nDetails: Diflunisal may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Diflunisal"}, {"id": "Insulin Lispro_INT_Balsalazide", "text": "Interaction: Insulin Lispro AND Balsalazide\nDetails: Balsalazide may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Balsalazide"}, {"id": "Insulin Lispro_INT_Olsalazine", "text": "Interaction: Insulin Lispro AND Olsalazine\nDetails: Olsalazine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Olsalazine"}, {"id": "Insulin Lispro_INT_dersalazine", "text": "Interaction: Insulin Lispro AND dersalazine\nDetails: dersalazine may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + dersalazine"}, {"id": "Insulin Lispro_INT_Nitroaspirin", "text": "Interaction: Insulin Lispro AND Nitroaspirin\nDetails: Nitroaspirin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Nitroaspirin"}, {"id": "Insulin Lispro_INT_Aloxiprin", "text": "Interaction: Insulin Lispro AND Aloxiprin\nDetails: Aloxiprin may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Aloxiprin"}, {"id": "Insulin Lispro_INT_Guacetisal", "text": "Interaction: Insulin Lispro AND Guacetisal\nDetails: Guacetisal may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Guacetisal"}, {"id": "Insulin Lispro_INT_Carbaspirin calcium", "text": "Interaction: Insulin Lispro AND Carbaspirin calcium\nDetails: Carbaspirin calcium may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Carbaspirin calcium"}, {"id": "Insulin Lispro_INT_Hemoglobin crosfumaril", "text": "Interaction: Insulin Lispro AND Hemoglobin crosfumaril\nDetails: Hemoglobin crosfumaril may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Hemoglobin crosfumaril"}, {"id": "Insulin Lispro_INT_Methyl salicylate", "text": "Interaction: Insulin Lispro AND Methyl salicylate\nDetails: Methyl salicylate may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Methyl salicylate"}, {"id": "Insulin Lispro_INT_Trolamine salicylate", "text": "Interaction: Insulin Lispro AND Trolamine salicylate\nDetails: Trolamine salicylate may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Lispro + Trolamine salicylate"}, {"id": "Insulin Glargine_GEN", "text": "Drug: Insulin Glargine\nDescription: Insulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. It is an analogue of human insulin made by replacing the asparagine residue at position A21 of the A-chain with glycine and adding two arginines t...", "source": "Insulin Glargine"}, {"id": "Insulin Glargine_CLIN", "text": "Drug: Insulin Glargine\nMechanism: Insulin glargine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subuni...\nToxicity: Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms...", "source": "Insulin Glargine"}, {"id": "Insulin Glargine_INT_Pregabalin", "text": "Interaction: Insulin Glargine AND Pregabalin\nDetails: The risk or severity of heart failure can be increased when Pregabalin is combined with Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Pregabalin"}, {"id": "Insulin Glargine_INT_Lipoic Acid", "text": "Interaction: Insulin Glargine AND Lipoic Acid\nDetails: Lipoic Acid may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Lipoic Acid"}, {"id": "Insulin Glargine_INT_Insulin Human", "text": "Interaction: Insulin Glargine AND Insulin Human\nDetails: Insulin Human may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Insulin Human"}, {"id": "Insulin Glargine_INT_Insulin Lispro", "text": "Interaction: Insulin Glargine AND Insulin Lispro\nDetails: Insulin Lispro may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Insulin Lispro"}, {"id": "Insulin Glargine_INT_Octreotide", "text": "Interaction: Insulin Glargine AND Octreotide\nDetails: Insulin Glargine may increase the hypoglycemic activities of Octreotide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Octreotide"}, {"id": "Insulin Glargine_INT_Glimepiride", "text": "Interaction: Insulin Glargine AND Glimepiride\nDetails: Insulin Glargine may increase the hypoglycemic activities of Glimepiride.\nRisk: Monitor closely.", "source": "Insulin Glargine + Glimepiride"}, {"id": "Insulin Glargine_INT_Sulfisoxazole", "text": "Interaction: Insulin Glargine AND Sulfisoxazole\nDetails: Insulin Glargine may increase the hypoglycemic activities of Sulfisoxazole.\nRisk: Monitor closely.", "source": "Insulin Glargine + Sulfisoxazole"}, {"id": "Insulin Glargine_INT_Disopyramide", "text": "Interaction: Insulin Glargine AND Disopyramide\nDetails: Insulin Glargine may increase the hypoglycemic activities of Disopyramide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Disopyramide"}, {"id": "Insulin Glargine_INT_Sulfadiazine", "text": "Interaction: Insulin Glargine AND Sulfadiazine\nDetails: Insulin Glargine may increase the hypoglycemic activities of Sulfadiazine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Sulfadiazine"}, {"id": "Insulin Glargine_INT_Quinine", "text": "Interaction: Insulin Glargine AND Quinine\nDetails: Insulin Glargine may increase the hypoglycemic activities of Quinine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Quinine"}, {"id": "Insulin Glargine_INT_Chlorpropamide", "text": "Interaction: Insulin Glargine AND Chlorpropamide\nDetails: Insulin Glargine may increase the hypoglycemic activities of Chlorpropamide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Chlorpropamide"}, {"id": "Insulin Glargine_INT_Nateglinide", "text": "Interaction: Insulin Glargine AND Nateglinide\nDetails: Insulin Glargine may increase the hypoglycemic activities of Nateglinide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Nateglinide"}, {"id": "Insulin Glargine_INT_Pentamidine", "text": "Interaction: Insulin Glargine AND Pentamidine\nDetails: Insulin Glargine may increase the hypoglycemic activities of Pentamidine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Pentamidine"}, {"id": "Insulin Glargine_INT_Mifepristone", "text": "Interaction: Insulin Glargine AND Mifepristone\nDetails: Insulin Glargine may increase the hypoglycemic activities of Mifepristone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Mifepristone"}, {"id": "Insulin Glargine_INT_Tolazamide", "text": "Interaction: Insulin Glargine AND Tolazamide\nDetails: Insulin Glargine may increase the hypoglycemic activities of Tolazamide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Tolazamide"}, {"id": "Insulin Glargine_INT_Repaglinide", "text": "Interaction: Insulin Glargine AND Repaglinide\nDetails: Insulin Glargine may increase the hypoglycemic activities of Repaglinide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Repaglinide"}, {"id": "Insulin Glargine_INT_Sulfamethoxazole", "text": "Interaction: Insulin Glargine AND Sulfamethoxazole\nDetails: Insulin Glargine may increase the hypoglycemic activities of Sulfamethoxazole.\nRisk: Monitor closely.", "source": "Insulin Glargine + Sulfamethoxazole"}, {"id": "Insulin Glargine_INT_Glyburide", "text": "Interaction: Insulin Glargine AND Glyburide\nDetails: Insulin Glargine may increase the hypoglycemic activities of Glyburide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Glyburide"}, {"id": "Insulin Glargine_INT_Glipizide", "text": "Interaction: Insulin Glargine AND Glipizide\nDetails: Insulin Glargine may increase the hypoglycemic activities of Glipizide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Glipizide"}, {"id": "Insulin Glargine_INT_Gliclazide", "text": "Interaction: Insulin Glargine AND Gliclazide\nDetails: Insulin Glargine may increase the hypoglycemic activities of Gliclazide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Gliclazide"}, {"id": "Insulin Glargine_INT_Tolbutamide", "text": "Interaction: Insulin Glargine AND Tolbutamide\nDetails: Insulin Glargine may increase the hypoglycemic activities of Tolbutamide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Tolbutamide"}, {"id": "Insulin Glargine_INT_Sunitinib", "text": "Interaction: Insulin Glargine AND Sunitinib\nDetails: Insulin Glargine may increase the hypoglycemic activities of Sunitinib.\nRisk: Monitor closely.", "source": "Insulin Glargine + Sunitinib"}, {"id": "Insulin Glargine_INT_Mecasermin", "text": "Interaction: Insulin Glargine AND Mecasermin\nDetails: Insulin Glargine may increase the hypoglycemic activities of Mecasermin.\nRisk: Monitor closely.", "source": "Insulin Glargine + Mecasermin"}, {"id": "Insulin Glargine_INT_Insulin Aspart", "text": "Interaction: Insulin Glargine AND Insulin Aspart\nDetails: Insulin Glargine may increase the hypoglycemic activities of Insulin Aspart.\nRisk: Monitor closely.", "source": "Insulin Glargine + Insulin Aspart"}, {"id": "Insulin Glargine_INT_Insulin Detemir", "text": "Interaction: Insulin Glargine AND Insulin Detemir\nDetails: Insulin Glargine may increase the hypoglycemic activities of Insulin Detemir.\nRisk: Monitor closely.", "source": "Insulin Glargine + Insulin Detemir"}, {"id": "Insulin Glargine_INT_Insulin Glulisine", "text": "Interaction: Insulin Glargine AND Insulin Glulisine\nDetails: Insulin Glargine may increase the hypoglycemic activities of Insulin Glulisine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Insulin Glulisine"}, {"id": "Insulin Glargine_INT_Pasireotide", "text": "Interaction: Insulin Glargine AND Pasireotide\nDetails: Insulin Glargine may increase the hypoglycemic activities of Pasireotide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Pasireotide"}, {"id": "Insulin Glargine_INT_Lanreotide", "text": "Interaction: Insulin Glargine AND Lanreotide\nDetails: Insulin Glargine may increase the hypoglycemic activities of Lanreotide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Lanreotide"}, {"id": "Insulin Glargine_INT_Tranylcypromine", "text": "Interaction: Insulin Glargine AND Tranylcypromine\nDetails: Tranylcypromine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Tranylcypromine"}, {"id": "Insulin Glargine_INT_Phenelzine", "text": "Interaction: Insulin Glargine AND Phenelzine\nDetails: Phenelzine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Phenelzine"}, {"id": "Insulin Glargine_INT_Minaprine", "text": "Interaction: Insulin Glargine AND Minaprine\nDetails: Minaprine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Minaprine"}, {"id": "Insulin Glargine_INT_Selegiline", "text": "Interaction: Insulin Glargine AND Selegiline\nDetails: Selegiline may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Selegiline"}, {"id": "Insulin Glargine_INT_Moclobemide", "text": "Interaction: Insulin Glargine AND Moclobemide\nDetails: Moclobemide may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Moclobemide"}, {"id": "Insulin Glargine_INT_Isocarboxazid", "text": "Interaction: Insulin Glargine AND Isocarboxazid\nDetails: Isocarboxazid may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Isocarboxazid"}, {"id": "Insulin Glargine_INT_Rasagiline", "text": "Interaction: Insulin Glargine AND Rasagiline\nDetails: Rasagiline may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Rasagiline"}, {"id": "Insulin Glargine_INT_Pargyline", "text": "Interaction: Insulin Glargine AND Pargyline\nDetails: Pargyline may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Pargyline"}, {"id": "Insulin Glargine_INT_Nialamide", "text": "Interaction: Insulin Glargine AND Nialamide\nDetails: Nialamide may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Nialamide"}, {"id": "Insulin Glargine_INT_Pirlindole", "text": "Interaction: Insulin Glargine AND Pirlindole\nDetails: Pirlindole may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Pirlindole"}, {"id": "Insulin Glargine_INT_Toloxatone", "text": "Interaction: Insulin Glargine AND Toloxatone\nDetails: Toloxatone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Toloxatone"}, {"id": "Insulin Glargine_INT_Iproniazid", "text": "Interaction: Insulin Glargine AND Iproniazid\nDetails: Iproniazid may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Iproniazid"}, {"id": "Insulin Glargine_INT_Furazolidone", "text": "Interaction: Insulin Glargine AND Furazolidone\nDetails: Furazolidone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Furazolidone"}, {"id": "Insulin Glargine_INT_Trans-2-Phenylcyclopropylamine", "text": "Interaction: Insulin Glargine AND Trans-2-Phenylcyclopropylamine\nDetails: Trans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Trans-2-Phenylcyclopropylamine"}, {"id": "Insulin Glargine_INT_7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline", "text": "Interaction: Insulin Glargine AND 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline\nDetails: 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline"}, {"id": "Insulin Glargine_INT_Harmaline", "text": "Interaction: Insulin Glargine AND Harmaline\nDetails: Harmaline may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Harmaline"}, {"id": "Insulin Glargine_INT_Brofaromine", "text": "Interaction: Insulin Glargine AND Brofaromine\nDetails: Brofaromine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Brofaromine"}, {"id": "Insulin Glargine_INT_Amphetamine", "text": "Interaction: Insulin Glargine AND Amphetamine\nDetails: Amphetamine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Amphetamine"}, {"id": "Insulin Glargine_INT_Procarbazine", "text": "Interaction: Insulin Glargine AND Procarbazine\nDetails: Procarbazine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Procarbazine"}, {"id": "Insulin Glargine_INT_Hydracarbazine", "text": "Interaction: Insulin Glargine AND Hydracarbazine\nDetails: Hydracarbazine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Hydracarbazine"}, {"id": "Insulin Glargine_INT_Methylene blue", "text": "Interaction: Insulin Glargine AND Methylene blue\nDetails: Methylene blue may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Methylene blue"}, {"id": "Insulin Glargine_INT_Benmoxin", "text": "Interaction: Insulin Glargine AND Benmoxin\nDetails: Benmoxin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Benmoxin"}, {"id": "Insulin Glargine_INT_Iproclozide", "text": "Interaction: Insulin Glargine AND Iproclozide\nDetails: Iproclozide may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Iproclozide"}, {"id": "Insulin Glargine_INT_Mebanazine", "text": "Interaction: Insulin Glargine AND Mebanazine\nDetails: Mebanazine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Mebanazine"}, {"id": "Insulin Glargine_INT_Octamoxin", "text": "Interaction: Insulin Glargine AND Octamoxin\nDetails: Octamoxin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Octamoxin"}, {"id": "Insulin Glargine_INT_Pheniprazine", "text": "Interaction: Insulin Glargine AND Pheniprazine\nDetails: Pheniprazine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Pheniprazine"}, {"id": "Insulin Glargine_INT_Phenoxypropazine", "text": "Interaction: Insulin Glargine AND Phenoxypropazine\nDetails: Phenoxypropazine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Phenoxypropazine"}, {"id": "Insulin Glargine_INT_Pivhydrazine", "text": "Interaction: Insulin Glargine AND Pivhydrazine\nDetails: Pivhydrazine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Pivhydrazine"}, {"id": "Insulin Glargine_INT_Safrazine", "text": "Interaction: Insulin Glargine AND Safrazine\nDetails: Safrazine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Safrazine"}, {"id": "Insulin Glargine_INT_Caroxazone", "text": "Interaction: Insulin Glargine AND Caroxazone\nDetails: Caroxazone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Caroxazone"}, {"id": "Insulin Glargine_INT_Ubidecarenone", "text": "Interaction: Insulin Glargine AND Ubidecarenone\nDetails: The therapeutic efficacy of Insulin Glargine can be increased when used in combination with Ubidecarenone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Ubidecarenone"}, {"id": "Insulin Glargine_INT_Grepafloxacin", "text": "Interaction: Insulin Glargine AND Grepafloxacin\nDetails: Grepafloxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Grepafloxacin"}, {"id": "Insulin Glargine_INT_Enoxacin", "text": "Interaction: Insulin Glargine AND Enoxacin\nDetails: Enoxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Enoxacin"}, {"id": "Insulin Glargine_INT_Pefloxacin", "text": "Interaction: Insulin Glargine AND Pefloxacin\nDetails: Pefloxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Pefloxacin"}, {"id": "Insulin Glargine_INT_Trovafloxacin", "text": "Interaction: Insulin Glargine AND Trovafloxacin\nDetails: Trovafloxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Trovafloxacin"}, {"id": "Insulin Glargine_INT_Nalidixic Acid", "text": "Interaction: Insulin Glargine AND Nalidixic Acid\nDetails: Nalidixic Acid may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Nalidixic Acid"}, {"id": "Insulin Glargine_INT_Rosoxacin", "text": "Interaction: Insulin Glargine AND Rosoxacin\nDetails: Rosoxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Rosoxacin"}, {"id": "Insulin Glargine_INT_Cinoxacin", "text": "Interaction: Insulin Glargine AND Cinoxacin\nDetails: Cinoxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Cinoxacin"}, {"id": "Insulin Glargine_INT_Gatifloxacin", "text": "Interaction: Insulin Glargine AND Gatifloxacin\nDetails: Gatifloxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Gatifloxacin"}, {"id": "Insulin Glargine_INT_Norfloxacin", "text": "Interaction: Insulin Glargine AND Norfloxacin\nDetails: Norfloxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Norfloxacin"}, {"id": "Insulin Glargine_INT_Levofloxacin", "text": "Interaction: Insulin Glargine AND Levofloxacin\nDetails: Levofloxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Levofloxacin"}, {"id": "Insulin Glargine_INT_Gemifloxacin", "text": "Interaction: Insulin Glargine AND Gemifloxacin\nDetails: Gemifloxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Gemifloxacin"}, {"id": "Insulin Glargine_INT_Sparfloxacin", "text": "Interaction: Insulin Glargine AND Sparfloxacin\nDetails: Sparfloxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Sparfloxacin"}, {"id": "Insulin Glargine_INT_Temafloxacin", "text": "Interaction: Insulin Glargine AND Temafloxacin\nDetails: Temafloxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Temafloxacin"}, {"id": "Insulin Glargine_INT_Fleroxacin", "text": "Interaction: Insulin Glargine AND Fleroxacin\nDetails: Fleroxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Fleroxacin"}, {"id": "Insulin Glargine_INT_Garenoxacin", "text": "Interaction: Insulin Glargine AND Garenoxacin\nDetails: Garenoxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Garenoxacin"}, {"id": "Insulin Glargine_INT_Nemonoxacin", "text": "Interaction: Insulin Glargine AND Nemonoxacin\nDetails: Nemonoxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Nemonoxacin"}, {"id": "Insulin Glargine_INT_Flumequine", "text": "Interaction: Insulin Glargine AND Flumequine\nDetails: Flumequine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Flumequine"}, {"id": "Insulin Glargine_INT_Pazufloxacin", "text": "Interaction: Insulin Glargine AND Pazufloxacin\nDetails: Pazufloxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Pazufloxacin"}, {"id": "Insulin Glargine_INT_Prulifloxacin", "text": "Interaction: Insulin Glargine AND Prulifloxacin\nDetails: Prulifloxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Prulifloxacin"}, {"id": "Insulin Glargine_INT_Sitafloxacin", "text": "Interaction: Insulin Glargine AND Sitafloxacin\nDetails: Sitafloxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Sitafloxacin"}, {"id": "Insulin Glargine_INT_Oxolinic acid", "text": "Interaction: Insulin Glargine AND Oxolinic acid\nDetails: Oxolinic acid may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Oxolinic acid"}, {"id": "Insulin Glargine_INT_Piromidic acid", "text": "Interaction: Insulin Glargine AND Piromidic acid\nDetails: Piromidic acid may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Piromidic acid"}, {"id": "Insulin Glargine_INT_Rufloxacin", "text": "Interaction: Insulin Glargine AND Rufloxacin\nDetails: Rufloxacin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Rufloxacin"}, {"id": "Insulin Glargine_INT_Pipemidic acid", "text": "Interaction: Insulin Glargine AND Pipemidic acid\nDetails: Pipemidic acid may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Pipemidic acid"}, {"id": "Insulin Glargine_INT_Duloxetine", "text": "Interaction: Insulin Glargine AND Duloxetine\nDetails: Duloxetine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Duloxetine"}, {"id": "Insulin Glargine_INT_Nefazodone", "text": "Interaction: Insulin Glargine AND Nefazodone\nDetails: Nefazodone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Nefazodone"}, {"id": "Insulin Glargine_INT_Desvenlafaxine", "text": "Interaction: Insulin Glargine AND Desvenlafaxine\nDetails: Desvenlafaxine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Desvenlafaxine"}, {"id": "Insulin Glargine_INT_Milnacipran", "text": "Interaction: Insulin Glargine AND Milnacipran\nDetails: Milnacipran may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Milnacipran"}, {"id": "Insulin Glargine_INT_Venlafaxine", "text": "Interaction: Insulin Glargine AND Venlafaxine\nDetails: Venlafaxine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Venlafaxine"}, {"id": "Insulin Glargine_INT_Levomilnacipran", "text": "Interaction: Insulin Glargine AND Levomilnacipran\nDetails: Levomilnacipran may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Levomilnacipran"}, {"id": "Insulin Glargine_INT_Dapoxetine", "text": "Interaction: Insulin Glargine AND Dapoxetine\nDetails: Dapoxetine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Dapoxetine"}, {"id": "Insulin Glargine_INT_Indalpine", "text": "Interaction: Insulin Glargine AND Indalpine\nDetails: Indalpine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Indalpine"}, {"id": "Insulin Glargine_INT_Fluvoxamine", "text": "Interaction: Insulin Glargine AND Fluvoxamine\nDetails: Fluvoxamine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Fluvoxamine"}, {"id": "Insulin Glargine_INT_Citalopram", "text": "Interaction: Insulin Glargine AND Citalopram\nDetails: Citalopram may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Citalopram"}, {"id": "Insulin Glargine_INT_Fluoxetine", "text": "Interaction: Insulin Glargine AND Fluoxetine\nDetails: Fluoxetine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Fluoxetine"}, {"id": "Insulin Glargine_INT_Paroxetine", "text": "Interaction: Insulin Glargine AND Paroxetine\nDetails: Paroxetine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Paroxetine"}, {"id": "Insulin Glargine_INT_Sertraline", "text": "Interaction: Insulin Glargine AND Sertraline\nDetails: Sertraline may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Sertraline"}, {"id": "Insulin Glargine_INT_Escitalopram", "text": "Interaction: Insulin Glargine AND Escitalopram\nDetails: Escitalopram may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Escitalopram"}, {"id": "Insulin Glargine_INT_Zimelidine", "text": "Interaction: Insulin Glargine AND Zimelidine\nDetails: Zimelidine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Zimelidine"}, {"id": "Insulin Glargine_INT_Etoperidone", "text": "Interaction: Insulin Glargine AND Etoperidone\nDetails: Etoperidone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Etoperidone"}, {"id": "Insulin Glargine_INT_Alaproclate", "text": "Interaction: Insulin Glargine AND Alaproclate\nDetails: Alaproclate may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Alaproclate"}, {"id": "Insulin Glargine_INT_Methyclothiazide", "text": "Interaction: Insulin Glargine AND Methyclothiazide\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methyclothiazide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Methyclothiazide"}, {"id": "Insulin Glargine_INT_Chlorothiazide", "text": "Interaction: Insulin Glargine AND Chlorothiazide\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Chlorothiazide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Chlorothiazide"}, {"id": "Insulin Glargine_INT_Hydrochlorothiazide", "text": "Interaction: Insulin Glargine AND Hydrochlorothiazide\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydrochlorothiazide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Hydrochlorothiazide"}, {"id": "Insulin Glargine_INT_Chlorthalidone", "text": "Interaction: Insulin Glargine AND Chlorthalidone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Chlorthalidone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Chlorthalidone"}, {"id": "Insulin Glargine_INT_Bendroflumethiazide", "text": "Interaction: Insulin Glargine AND Bendroflumethiazide\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Bendroflumethiazide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Bendroflumethiazide"}, {"id": "Insulin Glargine_INT_Metolazone", "text": "Interaction: Insulin Glargine AND Metolazone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Metolazone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Metolazone"}, {"id": "Insulin Glargine_INT_Hydroflumethiazide", "text": "Interaction: Insulin Glargine AND Hydroflumethiazide\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydroflumethiazide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Hydroflumethiazide"}, {"id": "Insulin Glargine_INT_Indapamide", "text": "Interaction: Insulin Glargine AND Indapamide\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Indapamide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Indapamide"}, {"id": "Insulin Glargine_INT_Trichlormethiazide", "text": "Interaction: Insulin Glargine AND Trichlormethiazide\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Trichlormethiazide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Trichlormethiazide"}, {"id": "Insulin Glargine_INT_Polythiazide", "text": "Interaction: Insulin Glargine AND Polythiazide\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Polythiazide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Polythiazide"}, {"id": "Insulin Glargine_INT_Quinethazone", "text": "Interaction: Insulin Glargine AND Quinethazone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Quinethazone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Quinethazone"}, {"id": "Insulin Glargine_INT_Cyclopenthiazide", "text": "Interaction: Insulin Glargine AND Cyclopenthiazide\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Cyclopenthiazide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Cyclopenthiazide"}, {"id": "Insulin Glargine_INT_Leuprolide", "text": "Interaction: Insulin Glargine AND Leuprolide\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Leuprolide"}, {"id": "Insulin Glargine_INT_Goserelin", "text": "Interaction: Insulin Glargine AND Goserelin\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Insulin Glargine + Goserelin"}, {"id": "Insulin Glargine_INT_Torasemide", "text": "Interaction: Insulin Glargine AND Torasemide\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Torasemide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Torasemide"}, {"id": "Insulin Glargine_INT_Nelfinavir", "text": "Interaction: Insulin Glargine AND Nelfinavir\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Nelfinavir.\nRisk: Monitor closely.", "source": "Insulin Glargine + Nelfinavir"}, {"id": "Insulin Glargine_INT_Indinavir", "text": "Interaction: Insulin Glargine AND Indinavir\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Indinavir.\nRisk: Monitor closely.", "source": "Insulin Glargine + Indinavir"}, {"id": "Insulin Glargine_INT_Ziprasidone", "text": "Interaction: Insulin Glargine AND Ziprasidone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ziprasidone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Ziprasidone"}, {"id": "Insulin Glargine_INT_Etonogestrel", "text": "Interaction: Insulin Glargine AND Etonogestrel\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Etonogestrel.\nRisk: Monitor closely.", "source": "Insulin Glargine + Etonogestrel"}, {"id": "Insulin Glargine_INT_Desogestrel", "text": "Interaction: Insulin Glargine AND Desogestrel\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Desogestrel.\nRisk: Monitor closely.", "source": "Insulin Glargine + Desogestrel"}, {"id": "Insulin Glargine_INT_Olanzapine", "text": "Interaction: Insulin Glargine AND Olanzapine\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Olanzapine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Olanzapine"}, {"id": "Insulin Glargine_INT_Megestrol acetate", "text": "Interaction: Insulin Glargine AND Megestrol acetate\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Megestrol acetate.\nRisk: Monitor closely.", "source": "Insulin Glargine + Megestrol acetate"}, {"id": "Insulin Glargine_INT_Clozapine", "text": "Interaction: Insulin Glargine AND Clozapine\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Clozapine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Clozapine"}, {"id": "Insulin Glargine_INT_Levonorgestrel", "text": "Interaction: Insulin Glargine AND Levonorgestrel\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Levonorgestrel.\nRisk: Monitor closely.", "source": "Insulin Glargine + Levonorgestrel"}, {"id": "Insulin Glargine_INT_Progesterone", "text": "Interaction: Insulin Glargine AND Progesterone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Progesterone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Progesterone"}, {"id": "Insulin Glargine_INT_Betamethasone", "text": "Interaction: Insulin Glargine AND Betamethasone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Betamethasone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Betamethasone"}, {"id": "Insulin Glargine_INT_Ritonavir", "text": "Interaction: Insulin Glargine AND Ritonavir\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ritonavir.\nRisk: Monitor closely.", "source": "Insulin Glargine + Ritonavir"}, {"id": "Insulin Glargine_INT_Piperazine", "text": "Interaction: Insulin Glargine AND Piperazine\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Piperazine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Piperazine"}, {"id": "Insulin Glargine_INT_Medroxyprogesterone acetate", "text": "Interaction: Insulin Glargine AND Medroxyprogesterone acetate\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Medroxyprogesterone acetate.\nRisk: Monitor closely.", "source": "Insulin Glargine + Medroxyprogesterone acetate"}, {"id": "Insulin Glargine_INT_Triamcinolone", "text": "Interaction: Insulin Glargine AND Triamcinolone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Triamcinolone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Triamcinolone"}, {"id": "Insulin Glargine_INT_Niacin", "text": "Interaction: Insulin Glargine AND Niacin\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Niacin.\nRisk: Monitor closely.", "source": "Insulin Glargine + Niacin"}, {"id": "Insulin Glargine_INT_Prednisone", "text": "Interaction: Insulin Glargine AND Prednisone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Prednisone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Prednisone"}, {"id": "Insulin Glargine_INT_Epinephrine", "text": "Interaction: Insulin Glargine AND Epinephrine\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Epinephrine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Epinephrine"}, {"id": "Insulin Glargine_INT_Fludrocortisone", "text": "Interaction: Insulin Glargine AND Fludrocortisone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Fludrocortisone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Fludrocortisone"}, {"id": "Insulin Glargine_INT_Furosemide", "text": "Interaction: Insulin Glargine AND Furosemide\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Furosemide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Furosemide"}, {"id": "Insulin Glargine_INT_Norethisterone", "text": "Interaction: Insulin Glargine AND Norethisterone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Norethisterone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Norethisterone"}, {"id": "Insulin Glargine_INT_Risperidone", "text": "Interaction: Insulin Glargine AND Risperidone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Risperidone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Risperidone"}, {"id": "Insulin Glargine_INT_Hydrocortisone", "text": "Interaction: Insulin Glargine AND Hydrocortisone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydrocortisone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Hydrocortisone"}, {"id": "Insulin Glargine_INT_Estradiol", "text": "Interaction: Insulin Glargine AND Estradiol\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Estradiol.\nRisk: Monitor closely.", "source": "Insulin Glargine + Estradiol"}, {"id": "Insulin Glargine_INT_Ethynodiol diacetate", "text": "Interaction: Insulin Glargine AND Ethynodiol diacetate\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ethynodiol diacetate.\nRisk: Monitor closely.", "source": "Insulin Glargine + Ethynodiol diacetate"}, {"id": "Insulin Glargine_INT_Prednisolone", "text": "Interaction: Insulin Glargine AND Prednisolone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Prednisolone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Prednisolone"}, {"id": "Insulin Glargine_INT_Tacrolimus", "text": "Interaction: Insulin Glargine AND Tacrolimus\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Tacrolimus.\nRisk: Monitor closely.", "source": "Insulin Glargine + Tacrolimus"}, {"id": "Insulin Glargine_INT_Sirolimus", "text": "Interaction: Insulin Glargine AND Sirolimus\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Sirolimus.\nRisk: Monitor closely.", "source": "Insulin Glargine + Sirolimus"}, {"id": "Insulin Glargine_INT_Bumetanide", "text": "Interaction: Insulin Glargine AND Bumetanide\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Bumetanide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Bumetanide"}, {"id": "Insulin Glargine_INT_Etacrynic acid", "text": "Interaction: Insulin Glargine AND Etacrynic acid\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Etacrynic acid.\nRisk: Monitor closely.", "source": "Insulin Glargine + Etacrynic acid"}, {"id": "Insulin Glargine_INT_Tipranavir", "text": "Interaction: Insulin Glargine AND Tipranavir\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Tipranavir.\nRisk: Monitor closely.", "source": "Insulin Glargine + Tipranavir"}, {"id": "Insulin Glargine_INT_Norgestimate", "text": "Interaction: Insulin Glargine AND Norgestimate\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Norgestimate.\nRisk: Monitor closely.", "source": "Insulin Glargine + Norgestimate"}, {"id": "Insulin Glargine_INT_Methylprednisolone", "text": "Interaction: Insulin Glargine AND Methylprednisolone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methylprednisolone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Methylprednisolone"}, {"id": "Insulin Glargine_INT_Ethinyl Estradiol", "text": "Interaction: Insulin Glargine AND Ethinyl Estradiol\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ethinyl Estradiol.\nRisk: Monitor closely.", "source": "Insulin Glargine + Ethinyl Estradiol"}, {"id": "Insulin Glargine_INT_Atazanavir", "text": "Interaction: Insulin Glargine AND Atazanavir\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Atazanavir.\nRisk: Monitor closely.", "source": "Insulin Glargine + Atazanavir"}, {"id": "Insulin Glargine_INT_Diazoxide", "text": "Interaction: Insulin Glargine AND Diazoxide\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Diazoxide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Diazoxide"}, {"id": "Insulin Glargine_INT_Arsenic trioxide", "text": "Interaction: Insulin Glargine AND Arsenic trioxide\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Arsenic trioxide.\nRisk: Monitor closely.", "source": "Insulin Glargine + Arsenic trioxide"}, {"id": "Insulin Glargine_INT_Quetiapine", "text": "Interaction: Insulin Glargine AND Quetiapine\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Quetiapine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Quetiapine"}, {"id": "Insulin Glargine_INT_Saquinavir", "text": "Interaction: Insulin Glargine AND Saquinavir\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Saquinavir.\nRisk: Monitor closely.", "source": "Insulin Glargine + Saquinavir"}, {"id": "Insulin Glargine_INT_Dexamethasone", "text": "Interaction: Insulin Glargine AND Dexamethasone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Dexamethasone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Dexamethasone"}, {"id": "Insulin Glargine_INT_Aripiprazole", "text": "Interaction: Insulin Glargine AND Aripiprazole\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Aripiprazole.\nRisk: Monitor closely.", "source": "Insulin Glargine + Aripiprazole"}, {"id": "Insulin Glargine_INT_Darunavir", "text": "Interaction: Insulin Glargine AND Darunavir\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Darunavir.\nRisk: Monitor closely.", "source": "Insulin Glargine + Darunavir"}, {"id": "Insulin Glargine_INT_Paliperidone", "text": "Interaction: Insulin Glargine AND Paliperidone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Paliperidone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Paliperidone"}, {"id": "Insulin Glargine_INT_Corticotropin", "text": "Interaction: Insulin Glargine AND Corticotropin\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Corticotropin.\nRisk: Monitor closely.", "source": "Insulin Glargine + Corticotropin"}, {"id": "Insulin Glargine_INT_Fosamprenavir", "text": "Interaction: Insulin Glargine AND Fosamprenavir\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Fosamprenavir.\nRisk: Monitor closely.", "source": "Insulin Glargine + Fosamprenavir"}, {"id": "Insulin Glargine_INT_Mestranol", "text": "Interaction: Insulin Glargine AND Mestranol\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Mestranol.\nRisk: Monitor closely.", "source": "Insulin Glargine + Mestranol"}, {"id": "Insulin Glargine_INT_Cortisone acetate", "text": "Interaction: Insulin Glargine AND Cortisone acetate\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Cortisone acetate.\nRisk: Monitor closely.", "source": "Insulin Glargine + Cortisone acetate"}, {"id": "Insulin Glargine_INT_Drospirenone", "text": "Interaction: Insulin Glargine AND Drospirenone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Drospirenone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Drospirenone"}, {"id": "Insulin Glargine_INT_Methotrimeprazine", "text": "Interaction: Insulin Glargine AND Methotrimeprazine\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methotrimeprazine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Methotrimeprazine"}, {"id": "Insulin Glargine_INT_Danazol", "text": "Interaction: Insulin Glargine AND Danazol\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Danazol.\nRisk: Monitor closely.", "source": "Insulin Glargine + Danazol"}, {"id": "Insulin Glargine_INT_Everolimus", "text": "Interaction: Insulin Glargine AND Everolimus\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Everolimus.\nRisk: Monitor closely.", "source": "Insulin Glargine + Everolimus"}, {"id": "Insulin Glargine_INT_Lopinavir", "text": "Interaction: Insulin Glargine AND Lopinavir\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Lopinavir.\nRisk: Monitor closely.", "source": "Insulin Glargine + Lopinavir"}, {"id": "Insulin Glargine_INT_Pipotiazine", "text": "Interaction: Insulin Glargine AND Pipotiazine\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Pipotiazine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Pipotiazine"}, {"id": "Insulin Glargine_INT_Vorinostat", "text": "Interaction: Insulin Glargine AND Vorinostat\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Vorinostat.\nRisk: Monitor closely.", "source": "Insulin Glargine + Vorinostat"}, {"id": "Insulin Glargine_INT_Estrone sulfate", "text": "Interaction: Insulin Glargine AND Estrone sulfate\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Estrone sulfate.\nRisk: Monitor closely.", "source": "Insulin Glargine + Estrone sulfate"}, {"id": "Insulin Glargine_INT_Cyproterone acetate", "text": "Interaction: Insulin Glargine AND Cyproterone acetate\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Cyproterone acetate.\nRisk: Monitor closely.", "source": "Insulin Glargine + Cyproterone acetate"}, {"id": "Insulin Glargine_INT_Nilotinib", "text": "Interaction: Insulin Glargine AND Nilotinib\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Nilotinib.\nRisk: Monitor closely.", "source": "Insulin Glargine + Nilotinib"}, {"id": "Insulin Glargine_INT_Iloperidone", "text": "Interaction: Insulin Glargine AND Iloperidone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Iloperidone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Iloperidone"}, {"id": "Insulin Glargine_INT_Asenapine", "text": "Interaction: Insulin Glargine AND Asenapine\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Asenapine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Asenapine"}, {"id": "Insulin Glargine_INT_Temsirolimus", "text": "Interaction: Insulin Glargine AND Temsirolimus\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Temsirolimus.\nRisk: Monitor closely.", "source": "Insulin Glargine + Temsirolimus"}, {"id": "Insulin Glargine_INT_Buserelin", "text": "Interaction: Insulin Glargine AND Buserelin\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Buserelin.\nRisk: Monitor closely.", "source": "Insulin Glargine + Buserelin"}, {"id": "Insulin Glargine_INT_Histrelin", "text": "Interaction: Insulin Glargine AND Histrelin\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Histrelin.\nRisk: Monitor closely.", "source": "Insulin Glargine + Histrelin"}, {"id": "Insulin Glargine_INT_Hydroxyprogesterone caproate", "text": "Interaction: Insulin Glargine AND Hydroxyprogesterone caproate\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydroxyprogesterone caproate.\nRisk: Monitor closely.", "source": "Insulin Glargine + Hydroxyprogesterone caproate"}, {"id": "Insulin Glargine_INT_Triptorelin", "text": "Interaction: Insulin Glargine AND Triptorelin\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Triptorelin.\nRisk: Monitor closely.", "source": "Insulin Glargine + Triptorelin"}, {"id": "Insulin Glargine_INT_Lurasidone", "text": "Interaction: Insulin Glargine AND Lurasidone\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Lurasidone.\nRisk: Monitor closely.", "source": "Insulin Glargine + Lurasidone"}, {"id": "Insulin Glargine_INT_Dabrafenib", "text": "Interaction: Insulin Glargine AND Dabrafenib\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Dabrafenib.\nRisk: Monitor closely.", "source": "Insulin Glargine + Dabrafenib"}, {"id": "Insulin Glargine_INT_Articaine", "text": "Interaction: Insulin Glargine AND Articaine\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Articaine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Articaine"}, {"id": "Insulin Glargine_INT_Ceritinib", "text": "Interaction: Insulin Glargine AND Ceritinib\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Ceritinib.\nRisk: Monitor closely.", "source": "Insulin Glargine + Ceritinib"}, {"id": "Insulin Glargine_INT_Dienogest", "text": "Interaction: Insulin Glargine AND Dienogest\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Dienogest.\nRisk: Monitor closely.", "source": "Insulin Glargine + Dienogest"}, {"id": "Insulin Glargine_INT_Brexpiprazole", "text": "Interaction: Insulin Glargine AND Brexpiprazole\nDetails: The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Brexpiprazole.\nRisk: Monitor closely.", "source": "Insulin Glargine + Brexpiprazole"}, {"id": "Insulin Glargine_INT_Testosterone", "text": "Interaction: Insulin Glargine AND Testosterone\nDetails: Testosterone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Testosterone"}, {"id": "Insulin Glargine_INT_Dihydrotestosterone", "text": "Interaction: Insulin Glargine AND Dihydrotestosterone\nDetails: Dihydrotestosterone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Dihydrotestosterone"}, {"id": "Insulin Glargine_INT_Fluoxymesterone", "text": "Interaction: Insulin Glargine AND Fluoxymesterone\nDetails: Fluoxymesterone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Fluoxymesterone"}, {"id": "Insulin Glargine_INT_Testosterone Propionate", "text": "Interaction: Insulin Glargine AND Testosterone Propionate\nDetails: Testosterone Propionate may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Testosterone Propionate"}, {"id": "Insulin Glargine_INT_Methyltestosterone", "text": "Interaction: Insulin Glargine AND Methyltestosterone\nDetails: Methyltestosterone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Methyltestosterone"}, {"id": "Insulin Glargine_INT_Oxandrolone", "text": "Interaction: Insulin Glargine AND Oxandrolone\nDetails: Oxandrolone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Oxandrolone"}, {"id": "Insulin Glargine_INT_Oxymetholone", "text": "Interaction: Insulin Glargine AND Oxymetholone\nDetails: Oxymetholone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Oxymetholone"}, {"id": "Insulin Glargine_INT_Stanozolol", "text": "Interaction: Insulin Glargine AND Stanozolol\nDetails: Stanozolol may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Stanozolol"}, {"id": "Insulin Glargine_INT_GLPG-0492", "text": "Interaction: Insulin Glargine AND GLPG-0492\nDetails: GLPG-0492 may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + GLPG-0492"}, {"id": "Insulin Glargine_INT_Nandrolone", "text": "Interaction: Insulin Glargine AND Nandrolone\nDetails: Nandrolone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Nandrolone"}, {"id": "Insulin Glargine_INT_Mesterolone", "text": "Interaction: Insulin Glargine AND Mesterolone\nDetails: Mesterolone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Mesterolone"}, {"id": "Insulin Glargine_INT_Nandrolone decanoate", "text": "Interaction: Insulin Glargine AND Nandrolone decanoate\nDetails: Nandrolone decanoate may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Nandrolone decanoate"}, {"id": "Insulin Glargine_INT_Pegvisomant", "text": "Interaction: Insulin Glargine AND Pegvisomant\nDetails: Pegvisomant may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Pegvisomant"}, {"id": "Insulin Glargine_INT_Insulin Pork", "text": "Interaction: Insulin Glargine AND Insulin Pork\nDetails: Insulin Pork may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Insulin Pork"}, {"id": "Insulin Glargine_INT_Troglitazone", "text": "Interaction: Insulin Glargine AND Troglitazone\nDetails: Troglitazone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Troglitazone"}, {"id": "Insulin Glargine_INT_Acarbose", "text": "Interaction: Insulin Glargine AND Acarbose\nDetails: Acarbose may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Acarbose"}, {"id": "Insulin Glargine_INT_Metformin", "text": "Interaction: Insulin Glargine AND Metformin\nDetails: Metformin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Metformin"}, {"id": "Insulin Glargine_INT_Rosiglitazone", "text": "Interaction: Insulin Glargine AND Rosiglitazone\nDetails: Rosiglitazone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Rosiglitazone"}, {"id": "Insulin Glargine_INT_Acetohexamide", "text": "Interaction: Insulin Glargine AND Acetohexamide\nDetails: Acetohexamide may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Acetohexamide"}, {"id": "Insulin Glargine_INT_Miglustat", "text": "Interaction: Insulin Glargine AND Miglustat\nDetails: Miglustat may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Miglustat"}, {"id": "Insulin Glargine_INT_Miglitol", "text": "Interaction: Insulin Glargine AND Miglitol\nDetails: Miglitol may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Miglitol"}, {"id": "Insulin Glargine_INT_Phenformin", "text": "Interaction: Insulin Glargine AND Phenformin\nDetails: Phenformin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Phenformin"}, {"id": "Insulin Glargine_INT_Pioglitazone", "text": "Interaction: Insulin Glargine AND Pioglitazone\nDetails: Pioglitazone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Pioglitazone"}, {"id": "Insulin Glargine_INT_Gliquidone", "text": "Interaction: Insulin Glargine AND Gliquidone\nDetails: Gliquidone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Gliquidone"}, {"id": "Insulin Glargine_INT_Mitiglinide", "text": "Interaction: Insulin Glargine AND Mitiglinide\nDetails: Mitiglinide may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Mitiglinide"}, {"id": "Insulin Glargine_INT_Sitagliptin", "text": "Interaction: Insulin Glargine AND Sitagliptin\nDetails: Sitagliptin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Sitagliptin"}, {"id": "Insulin Glargine_INT_Exenatide", "text": "Interaction: Insulin Glargine AND Exenatide\nDetails: Exenatide may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Exenatide"}, {"id": "Insulin Glargine_INT_Pramlintide", "text": "Interaction: Insulin Glargine AND Pramlintide\nDetails: Pramlintide may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Pramlintide"}, {"id": "Insulin Glargine_INT_AICA ribonucleotide", "text": "Interaction: Insulin Glargine AND AICA ribonucleotide\nDetails: AICA ribonucleotide may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + AICA ribonucleotide"}, {"id": "Insulin Glargine_INT_Castanospermine", "text": "Interaction: Insulin Glargine AND Castanospermine\nDetails: Castanospermine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Castanospermine"}, {"id": "Insulin Glargine_INT_Buformin", "text": "Interaction: Insulin Glargine AND Buformin\nDetails: Buformin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Buformin"}, {"id": "Insulin Glargine_INT_Vildagliptin", "text": "Interaction: Insulin Glargine AND Vildagliptin\nDetails: Vildagliptin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Vildagliptin"}, {"id": "Insulin Glargine_INT_Voglibose", "text": "Interaction: Insulin Glargine AND Voglibose\nDetails: Voglibose may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Voglibose"}, {"id": "Insulin Glargine_INT_Alogliptin", "text": "Interaction: Insulin Glargine AND Alogliptin\nDetails: Alogliptin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Alogliptin"}, {"id": "Insulin Glargine_INT_Sulodexide", "text": "Interaction: Insulin Glargine AND Sulodexide\nDetails: Sulodexide may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Sulodexide"}, {"id": "Insulin Glargine_INT_Saxagliptin", "text": "Interaction: Insulin Glargine AND Saxagliptin\nDetails: Saxagliptin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Saxagliptin"}, {"id": "Insulin Glargine_INT_Liraglutide", "text": "Interaction: Insulin Glargine AND Liraglutide\nDetails: Liraglutide may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Liraglutide"}, {"id": "Insulin Glargine_INT_Linagliptin", "text": "Interaction: Insulin Glargine AND Linagliptin\nDetails: Linagliptin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Linagliptin"}, {"id": "Insulin Glargine_INT_Canagliflozin", "text": "Interaction: Insulin Glargine AND Canagliflozin\nDetails: Canagliflozin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Canagliflozin"}, {"id": "Insulin Glargine_INT_Glibornuride", "text": "Interaction: Insulin Glargine AND Glibornuride\nDetails: Glibornuride may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Glibornuride"}, {"id": "Insulin Glargine_INT_Empagliflozin", "text": "Interaction: Insulin Glargine AND Empagliflozin\nDetails: Empagliflozin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Empagliflozin"}, {"id": "Insulin Glargine_INT_Dulaglutide", "text": "Interaction: Insulin Glargine AND Dulaglutide\nDetails: Dulaglutide may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Dulaglutide"}, {"id": "Insulin Glargine_INT_Ciglitazone", "text": "Interaction: Insulin Glargine AND Ciglitazone\nDetails: Ciglitazone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Ciglitazone"}, {"id": "Insulin Glargine_INT_Allicin", "text": "Interaction: Insulin Glargine AND Allicin\nDetails: Allicin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Allicin"}, {"id": "Insulin Glargine_INT_2,4-thiazolidinedione", "text": "Interaction: Insulin Glargine AND 2,4-thiazolidinedione\nDetails: 2,4-thiazolidinedione may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + 2,4-thiazolidinedione"}, {"id": "Insulin Glargine_INT_Bempedoic acid", "text": "Interaction: Insulin Glargine AND Bempedoic acid\nDetails: Bempedoic acid may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Bempedoic acid"}, {"id": "Insulin Glargine_INT_Gusperimus", "text": "Interaction: Insulin Glargine AND Gusperimus\nDetails: Gusperimus may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Gusperimus"}, {"id": "Insulin Glargine_INT_Sotagliflozin", "text": "Interaction: Insulin Glargine AND Sotagliflozin\nDetails: Sotagliflozin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Sotagliflozin"}, {"id": "Insulin Glargine_INT_Balaglitazone", "text": "Interaction: Insulin Glargine AND Balaglitazone\nDetails: Balaglitazone may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Balaglitazone"}, {"id": "Insulin Glargine_INT_Deoxyspergualin", "text": "Interaction: Insulin Glargine AND Deoxyspergualin\nDetails: Deoxyspergualin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Deoxyspergualin"}, {"id": "Insulin Glargine_INT_Carbutamide", "text": "Interaction: Insulin Glargine AND Carbutamide\nDetails: Carbutamide may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Carbutamide"}, {"id": "Insulin Glargine_INT_Salicylic acid", "text": "Interaction: Insulin Glargine AND Salicylic acid\nDetails: Salicylic acid may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Salicylic acid"}, {"id": "Insulin Glargine_INT_Acetylsalicylic acid", "text": "Interaction: Insulin Glargine AND Acetylsalicylic acid\nDetails: Acetylsalicylic acid may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Acetylsalicylic acid"}, {"id": "Insulin Glargine_INT_Aminosalicylic Acid", "text": "Interaction: Insulin Glargine AND Aminosalicylic Acid\nDetails: Aminosalicylic Acid may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Aminosalicylic Acid"}, {"id": "Insulin Glargine_INT_Mesalazine", "text": "Interaction: Insulin Glargine AND Mesalazine\nDetails: Mesalazine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Mesalazine"}, {"id": "Insulin Glargine_INT_Diflunisal", "text": "Interaction: Insulin Glargine AND Diflunisal\nDetails: Diflunisal may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Diflunisal"}, {"id": "Insulin Glargine_INT_Balsalazide", "text": "Interaction: Insulin Glargine AND Balsalazide\nDetails: Balsalazide may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Balsalazide"}, {"id": "Insulin Glargine_INT_Olsalazine", "text": "Interaction: Insulin Glargine AND Olsalazine\nDetails: Olsalazine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Olsalazine"}, {"id": "Insulin Glargine_INT_dersalazine", "text": "Interaction: Insulin Glargine AND dersalazine\nDetails: dersalazine may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + dersalazine"}, {"id": "Insulin Glargine_INT_Nitroaspirin", "text": "Interaction: Insulin Glargine AND Nitroaspirin\nDetails: Nitroaspirin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Nitroaspirin"}, {"id": "Insulin Glargine_INT_Aloxiprin", "text": "Interaction: Insulin Glargine AND Aloxiprin\nDetails: Aloxiprin may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Aloxiprin"}, {"id": "Insulin Glargine_INT_Guacetisal", "text": "Interaction: Insulin Glargine AND Guacetisal\nDetails: Guacetisal may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Guacetisal"}, {"id": "Insulin Glargine_INT_Carbaspirin calcium", "text": "Interaction: Insulin Glargine AND Carbaspirin calcium\nDetails: Carbaspirin calcium may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Carbaspirin calcium"}, {"id": "Insulin Glargine_INT_Hemoglobin crosfumaril", "text": "Interaction: Insulin Glargine AND Hemoglobin crosfumaril\nDetails: Hemoglobin crosfumaril may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Hemoglobin crosfumaril"}, {"id": "Insulin Glargine_INT_Methyl salicylate", "text": "Interaction: Insulin Glargine AND Methyl salicylate\nDetails: Methyl salicylate may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Methyl salicylate"}, {"id": "Insulin Glargine_INT_Trolamine salicylate", "text": "Interaction: Insulin Glargine AND Trolamine salicylate\nDetails: Trolamine salicylate may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Glargine + Trolamine salicylate"}, {"id": "Collagenase clostridium histolyticum_GEN", "text": "Drug: Collagenase clostridium histolyticum\nDescription: Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum that dismantles collagen. It is used as a powder-and-solvent injection kit for the treatment of Dupuytren's contracture, a condition where the fingers bend towards the palm and cannot be fully straig...", "source": "Collagenase clostridium histolyticum"}, {"id": "Collagenase clostridium histolyticum_CLIN", "text": "Drug: Collagenase clostridium histolyticum\nMechanism: Collagenase is a protease that is specific to collagen. The triple helical region of interstitial collagens is highly resistant to most cell proteinases. However, during remodeling of the connective t...\nToxicity: ...", "source": "Collagenase clostridium histolyticum"}, {"id": "Collagenase clostridium histolyticum_INT_Lepirudin", "text": "Interaction: Collagenase clostridium histolyticum AND Lepirudin\nDetails: The risk or severity of adverse effects can be increased when Lepirudin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Lepirudin"}, {"id": "Collagenase clostridium histolyticum_INT_Bivalirudin", "text": "Interaction: Collagenase clostridium histolyticum AND Bivalirudin\nDetails: The risk or severity of adverse effects can be increased when Bivalirudin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Bivalirudin"}, {"id": "Collagenase clostridium histolyticum_INT_Abciximab", "text": "Interaction: Collagenase clostridium histolyticum AND Abciximab\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Abciximab"}, {"id": "Collagenase clostridium histolyticum_INT_Becaplermin", "text": "Interaction: Collagenase clostridium histolyticum AND Becaplermin\nDetails: The risk or severity of adverse effects can be increased when Becaplermin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Becaplermin"}, {"id": "Collagenase clostridium histolyticum_INT_Dicoumarol", "text": "Interaction: Collagenase clostridium histolyticum AND Dicoumarol\nDetails: The risk or severity of adverse effects can be increased when Dicoumarol is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Dicoumarol"}, {"id": "Collagenase clostridium histolyticum_INT_Argatroban", "text": "Interaction: Collagenase clostridium histolyticum AND Argatroban\nDetails: The risk or severity of adverse effects can be increased when Argatroban is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Argatroban"}, {"id": "Collagenase clostridium histolyticum_INT_Ardeparin", "text": "Interaction: Collagenase clostridium histolyticum AND Ardeparin\nDetails: The risk or severity of adverse effects can be increased when Ardeparin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Ardeparin"}, {"id": "Collagenase clostridium histolyticum_INT_Phenindione", "text": "Interaction: Collagenase clostridium histolyticum AND Phenindione\nDetails: The risk or severity of adverse effects can be increased when Phenindione is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Phenindione"}, {"id": "Collagenase clostridium histolyticum_INT_Fondaparinux sodium", "text": "Interaction: Collagenase clostridium histolyticum AND Fondaparinux sodium\nDetails: The risk or severity of adverse effects can be increased when Fondaparinux sodium is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Fondaparinux sodium"}, {"id": "Collagenase clostridium histolyticum_INT_Warfarin", "text": "Interaction: Collagenase clostridium histolyticum AND Warfarin\nDetails: The risk or severity of adverse effects can be increased when Warfarin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Warfarin"}, {"id": "Collagenase clostridium histolyticum_INT_Pentosan Polysulfate", "text": "Interaction: Collagenase clostridium histolyticum AND Pentosan Polysulfate\nDetails: The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Pentosan Polysulfate"}, {"id": "Collagenase clostridium histolyticum_INT_Phenprocoumon", "text": "Interaction: Collagenase clostridium histolyticum AND Phenprocoumon\nDetails: The risk or severity of adverse effects can be increased when Phenprocoumon is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Phenprocoumon"}, {"id": "Collagenase clostridium histolyticum_INT_Edetic Acid", "text": "Interaction: Collagenase clostridium histolyticum AND Edetic Acid\nDetails: The risk or severity of adverse effects can be increased when Edetic Acid is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Edetic Acid"}, {"id": "Collagenase clostridium histolyticum_INT_Heparin", "text": "Interaction: Collagenase clostridium histolyticum AND Heparin\nDetails: The risk or severity of adverse effects can be increased when Heparin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Heparin"}, {"id": "Collagenase clostridium histolyticum_INT_Enoxaparin", "text": "Interaction: Collagenase clostridium histolyticum AND Enoxaparin\nDetails: The risk or severity of adverse effects can be increased when Enoxaparin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Enoxaparin"}, {"id": "Collagenase clostridium histolyticum_INT_Acenocoumarol", "text": "Interaction: Collagenase clostridium histolyticum AND Acenocoumarol\nDetails: The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Acenocoumarol"}, {"id": "Collagenase clostridium histolyticum_INT_Citric Acid", "text": "Interaction: Collagenase clostridium histolyticum AND Citric Acid\nDetails: The risk or severity of adverse effects can be increased when Citric Acid is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Citric Acid"}, {"id": "Collagenase clostridium histolyticum_INT_Ximelagatran", "text": "Interaction: Collagenase clostridium histolyticum AND Ximelagatran\nDetails: The risk or severity of adverse effects can be increased when Ximelagatran is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Ximelagatran"}, {"id": "Collagenase clostridium histolyticum_INT_Ancrod", "text": "Interaction: Collagenase clostridium histolyticum AND Ancrod\nDetails: The risk or severity of adverse effects can be increased when Ancrod is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Ancrod"}, {"id": "Collagenase clostridium histolyticum_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Collagenase clostridium histolyticum AND Pentaerythritol Tetranitrate\nDetails: The risk or severity of adverse effects can be increased when Pentaerythritol Tetranitrate is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Pentaerythritol Tetranitrate"}, {"id": "Collagenase clostridium histolyticum_INT_Rivaroxaban", "text": "Interaction: Collagenase clostridium histolyticum AND Rivaroxaban\nDetails: The risk or severity of adverse effects can be increased when Rivaroxaban is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Rivaroxaban"}, {"id": "Collagenase clostridium histolyticum_INT_Sulodexide", "text": "Interaction: Collagenase clostridium histolyticum AND Sulodexide\nDetails: The risk or severity of adverse effects can be increased when Sulodexide is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Sulodexide"}, {"id": "Collagenase clostridium histolyticum_INT_Idraparinux", "text": "Interaction: Collagenase clostridium histolyticum AND Idraparinux\nDetails: The risk or severity of adverse effects can be increased when Idraparinux is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Idraparinux"}, {"id": "Collagenase clostridium histolyticum_INT_Apixaban", "text": "Interaction: Collagenase clostridium histolyticum AND Apixaban\nDetails: The risk or severity of adverse effects can be increased when Apixaban is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Apixaban"}, {"id": "Collagenase clostridium histolyticum_INT_Otamixaban", "text": "Interaction: Collagenase clostridium histolyticum AND Otamixaban\nDetails: The risk or severity of adverse effects can be increased when Otamixaban is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Otamixaban"}, {"id": "Collagenase clostridium histolyticum_INT_Dabigatran etexilate", "text": "Interaction: Collagenase clostridium histolyticum AND Dabigatran etexilate\nDetails: The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Dabigatran etexilate"}, {"id": "Collagenase clostridium histolyticum_INT_Danaparoid", "text": "Interaction: Collagenase clostridium histolyticum AND Danaparoid\nDetails: The risk or severity of adverse effects can be increased when Danaparoid is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Danaparoid"}, {"id": "Collagenase clostridium histolyticum_INT_Dalteparin", "text": "Interaction: Collagenase clostridium histolyticum AND Dalteparin\nDetails: The risk or severity of adverse effects can be increased when Dalteparin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Dalteparin"}, {"id": "Collagenase clostridium histolyticum_INT_Ferulic acid", "text": "Interaction: Collagenase clostridium histolyticum AND Ferulic acid\nDetails: The risk or severity of adverse effects can be increased when Ferulic acid is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Ferulic acid"}, {"id": "Collagenase clostridium histolyticum_INT_Ethyl biscoumacetate", "text": "Interaction: Collagenase clostridium histolyticum AND Ethyl biscoumacetate\nDetails: The risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Ethyl biscoumacetate"}, {"id": "Collagenase clostridium histolyticum_INT_Nadroparin", "text": "Interaction: Collagenase clostridium histolyticum AND Nadroparin\nDetails: The risk or severity of adverse effects can be increased when Nadroparin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Nadroparin"}, {"id": "Collagenase clostridium histolyticum_INT_Edoxaban", "text": "Interaction: Collagenase clostridium histolyticum AND Edoxaban\nDetails: The risk or severity of adverse effects can be increased when Edoxaban is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Edoxaban"}, {"id": "Collagenase clostridium histolyticum_INT_Dextran", "text": "Interaction: Collagenase clostridium histolyticum AND Dextran\nDetails: The risk or severity of adverse effects can be increased when Dextran is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Dextran"}, {"id": "Collagenase clostridium histolyticum_INT_Reviparin", "text": "Interaction: Collagenase clostridium histolyticum AND Reviparin\nDetails: The risk or severity of adverse effects can be increased when Reviparin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Reviparin"}, {"id": "Collagenase clostridium histolyticum_INT_Certoparin", "text": "Interaction: Collagenase clostridium histolyticum AND Certoparin\nDetails: The risk or severity of adverse effects can be increased when Certoparin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Certoparin"}, {"id": "Collagenase clostridium histolyticum_INT_Dextran 70", "text": "Interaction: Collagenase clostridium histolyticum AND Dextran 70\nDetails: The risk or severity of adverse effects can be increased when Dextran 70 is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Dextran 70"}, {"id": "Collagenase clostridium histolyticum_INT_Desirudin", "text": "Interaction: Collagenase clostridium histolyticum AND Desirudin\nDetails: The risk or severity of adverse effects can be increased when Desirudin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Desirudin"}, {"id": "Collagenase clostridium histolyticum_INT_Dextran 40", "text": "Interaction: Collagenase clostridium histolyticum AND Dextran 40\nDetails: The risk or severity of adverse effects can be increased when Dextran 40 is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Dextran 40"}, {"id": "Collagenase clostridium histolyticum_INT_Dextran 75", "text": "Interaction: Collagenase clostridium histolyticum AND Dextran 75\nDetails: The risk or severity of adverse effects can be increased when Dextran 75 is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Dextran 75"}, {"id": "Collagenase clostridium histolyticum_INT_Protocatechualdehyde", "text": "Interaction: Collagenase clostridium histolyticum AND Protocatechualdehyde\nDetails: The risk or severity of adverse effects can be increased when Protocatechualdehyde is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Protocatechualdehyde"}, {"id": "Collagenase clostridium histolyticum_INT_Protein C", "text": "Interaction: Collagenase clostridium histolyticum AND Protein C\nDetails: The risk or severity of adverse effects can be increased when Protein C is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Protein C"}, {"id": "Collagenase clostridium histolyticum_INT_Antithrombin III human", "text": "Interaction: Collagenase clostridium histolyticum AND Antithrombin III human\nDetails: The risk or severity of adverse effects can be increased when Antithrombin III human is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Antithrombin III human"}, {"id": "Collagenase clostridium histolyticum_INT_Fondaparinux", "text": "Interaction: Collagenase clostridium histolyticum AND Fondaparinux\nDetails: The risk or severity of adverse effects can be increased when Fondaparinux is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Fondaparinux"}, {"id": "Collagenase clostridium histolyticum_INT_Letaxaban", "text": "Interaction: Collagenase clostridium histolyticum AND Letaxaban\nDetails: The risk or severity of adverse effects can be increased when Letaxaban is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Letaxaban"}, {"id": "Collagenase clostridium histolyticum_INT_Darexaban", "text": "Interaction: Collagenase clostridium histolyticum AND Darexaban\nDetails: The risk or severity of adverse effects can be increased when Darexaban is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Darexaban"}, {"id": "Collagenase clostridium histolyticum_INT_Nafamostat", "text": "Interaction: Collagenase clostridium histolyticum AND Nafamostat\nDetails: The risk or severity of adverse effects can be increased when Nafamostat is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Nafamostat"}, {"id": "Collagenase clostridium histolyticum_INT_Gabexate", "text": "Interaction: Collagenase clostridium histolyticum AND Gabexate\nDetails: The risk or severity of adverse effects can be increased when Gabexate is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Gabexate"}, {"id": "Collagenase clostridium histolyticum_INT_Troxerutin", "text": "Interaction: Collagenase clostridium histolyticum AND Troxerutin\nDetails: The risk or severity of adverse effects can be increased when Troxerutin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Troxerutin"}, {"id": "Collagenase clostridium histolyticum_INT_Fluindione", "text": "Interaction: Collagenase clostridium histolyticum AND Fluindione\nDetails: The risk or severity of adverse effects can be increased when Fluindione is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Fluindione"}, {"id": "Collagenase clostridium histolyticum_INT_Protein S human", "text": "Interaction: Collagenase clostridium histolyticum AND Protein S human\nDetails: The risk or severity of adverse effects can be increased when Protein S human is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Protein S human"}, {"id": "Collagenase clostridium histolyticum_INT_Melagatran", "text": "Interaction: Collagenase clostridium histolyticum AND Melagatran\nDetails: The risk or severity of adverse effects can be increased when Melagatran is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Melagatran"}, {"id": "Collagenase clostridium histolyticum_INT_Eptifibatide", "text": "Interaction: Collagenase clostridium histolyticum AND Eptifibatide\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Eptifibatide"}, {"id": "Collagenase clostridium histolyticum_INT_Ticlopidine", "text": "Interaction: Collagenase clostridium histolyticum AND Ticlopidine\nDetails: The risk or severity of adverse effects can be increased when Ticlopidine is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Ticlopidine"}, {"id": "Collagenase clostridium histolyticum_INT_Tirofiban", "text": "Interaction: Collagenase clostridium histolyticum AND Tirofiban\nDetails: The risk or severity of adverse effects can be increased when Tirofiban is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Tirofiban"}, {"id": "Collagenase clostridium histolyticum_INT_Dipyridamole", "text": "Interaction: Collagenase clostridium histolyticum AND Dipyridamole\nDetails: The risk or severity of adverse effects can be increased when Dipyridamole is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Dipyridamole"}, {"id": "Collagenase clostridium histolyticum_INT_Clopidogrel", "text": "Interaction: Collagenase clostridium histolyticum AND Clopidogrel\nDetails: The risk or severity of adverse effects can be increased when Clopidogrel is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Clopidogrel"}, {"id": "Collagenase clostridium histolyticum_INT_Acetylsalicylic acid", "text": "Interaction: Collagenase clostridium histolyticum AND Acetylsalicylic acid\nDetails: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Acetylsalicylic acid"}, {"id": "Collagenase clostridium histolyticum_INT_Prasugrel", "text": "Interaction: Collagenase clostridium histolyticum AND Prasugrel\nDetails: The risk or severity of adverse effects can be increased when Prasugrel is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Prasugrel"}, {"id": "Collagenase clostridium histolyticum_INT_Vorapaxar", "text": "Interaction: Collagenase clostridium histolyticum AND Vorapaxar\nDetails: The risk or severity of adverse effects can be increased when Vorapaxar is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Vorapaxar"}, {"id": "Collagenase clostridium histolyticum_INT_Milrinone", "text": "Interaction: Collagenase clostridium histolyticum AND Milrinone\nDetails: The risk or severity of adverse effects can be increased when Milrinone is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Milrinone"}, {"id": "Collagenase clostridium histolyticum_INT_Anagrelide", "text": "Interaction: Collagenase clostridium histolyticum AND Anagrelide\nDetails: The risk or severity of adverse effects can be increased when Anagrelide is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Anagrelide"}, {"id": "Collagenase clostridium histolyticum_INT_Epinastine", "text": "Interaction: Collagenase clostridium histolyticum AND Epinastine\nDetails: The risk or severity of adverse effects can be increased when Epinastine is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Epinastine"}, {"id": "Collagenase clostridium histolyticum_INT_Alprostadil", "text": "Interaction: Collagenase clostridium histolyticum AND Alprostadil\nDetails: The risk or severity of adverse effects can be increased when Alprostadil is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Alprostadil"}, {"id": "Collagenase clostridium histolyticum_INT_Pentoxifylline", "text": "Interaction: Collagenase clostridium histolyticum AND Pentoxifylline\nDetails: The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Pentoxifylline"}, {"id": "Collagenase clostridium histolyticum_INT_Azelastine", "text": "Interaction: Collagenase clostridium histolyticum AND Azelastine\nDetails: The risk or severity of adverse effects can be increased when Azelastine is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Azelastine"}, {"id": "Collagenase clostridium histolyticum_INT_Iloprost", "text": "Interaction: Collagenase clostridium histolyticum AND Iloprost\nDetails: The risk or severity of adverse effects can be increased when Iloprost is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Iloprost"}, {"id": "Collagenase clostridium histolyticum_INT_Cilostazol", "text": "Interaction: Collagenase clostridium histolyticum AND Cilostazol\nDetails: The risk or severity of adverse effects can be increased when Cilostazol is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Cilostazol"}, {"id": "Collagenase clostridium histolyticum_INT_Ridogrel", "text": "Interaction: Collagenase clostridium histolyticum AND Ridogrel\nDetails: The risk or severity of adverse effects can be increased when Ridogrel is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Ridogrel"}, {"id": "Collagenase clostridium histolyticum_INT_Sevoflurane", "text": "Interaction: Collagenase clostridium histolyticum AND Sevoflurane\nDetails: The risk or severity of adverse effects can be increased when Sevoflurane is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Sevoflurane"}, {"id": "Collagenase clostridium histolyticum_INT_Epoprostenol", "text": "Interaction: Collagenase clostridium histolyticum AND Epoprostenol\nDetails: The risk or severity of adverse effects can be increased when Epoprostenol is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Epoprostenol"}, {"id": "Collagenase clostridium histolyticum_INT_Resveratrol", "text": "Interaction: Collagenase clostridium histolyticum AND Resveratrol\nDetails: The risk or severity of adverse effects can be increased when Resveratrol is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Resveratrol"}, {"id": "Collagenase clostridium histolyticum_INT_Nimesulide", "text": "Interaction: Collagenase clostridium histolyticum AND Nimesulide\nDetails: The risk or severity of adverse effects can be increased when Nimesulide is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Nimesulide"}, {"id": "Collagenase clostridium histolyticum_INT_Tesmilifene", "text": "Interaction: Collagenase clostridium histolyticum AND Tesmilifene\nDetails: The risk or severity of adverse effects can be increased when Tesmilifene is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Tesmilifene"}, {"id": "Collagenase clostridium histolyticum_INT_Defibrotide", "text": "Interaction: Collagenase clostridium histolyticum AND Defibrotide\nDetails: The risk or severity of adverse effects can be increased when Defibrotide is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Defibrotide"}, {"id": "Collagenase clostridium histolyticum_INT_SRT501", "text": "Interaction: Collagenase clostridium histolyticum AND SRT501\nDetails: The risk or severity of adverse effects can be increased when SRT501 is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + SRT501"}, {"id": "Collagenase clostridium histolyticum_INT_Beraprost", "text": "Interaction: Collagenase clostridium histolyticum AND Beraprost\nDetails: The risk or severity of adverse effects can be increased when Beraprost is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Beraprost"}, {"id": "Collagenase clostridium histolyticum_INT_Ibudilast", "text": "Interaction: Collagenase clostridium histolyticum AND Ibudilast\nDetails: The risk or severity of adverse effects can be increased when Ibudilast is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Ibudilast"}, {"id": "Collagenase clostridium histolyticum_INT_Andrographolide", "text": "Interaction: Collagenase clostridium histolyticum AND Andrographolide\nDetails: The risk or severity of adverse effects can be increased when Andrographolide is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Andrographolide"}, {"id": "Collagenase clostridium histolyticum_INT_eplivanserine", "text": "Interaction: Collagenase clostridium histolyticum AND eplivanserine\nDetails: The risk or severity of adverse effects can be increased when eplivanserine is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + eplivanserine"}, {"id": "Collagenase clostridium histolyticum_INT_Cangrelor", "text": "Interaction: Collagenase clostridium histolyticum AND Cangrelor\nDetails: The risk or severity of adverse effects can be increased when Cangrelor is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Cangrelor"}, {"id": "Collagenase clostridium histolyticum_INT_Tranilast", "text": "Interaction: Collagenase clostridium histolyticum AND Tranilast\nDetails: The risk or severity of adverse effects can be increased when Tranilast is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Tranilast"}, {"id": "Collagenase clostridium histolyticum_INT_Triflusal", "text": "Interaction: Collagenase clostridium histolyticum AND Triflusal\nDetails: The risk or severity of adverse effects can be increased when Triflusal is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Triflusal"}, {"id": "Collagenase clostridium histolyticum_INT_Icosapent ethyl", "text": "Interaction: Collagenase clostridium histolyticum AND Icosapent ethyl\nDetails: The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Icosapent ethyl"}, {"id": "Collagenase clostridium histolyticum_INT_Ifenprodil", "text": "Interaction: Collagenase clostridium histolyticum AND Ifenprodil\nDetails: The risk or severity of adverse effects can be increased when Ifenprodil is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Ifenprodil"}, {"id": "Collagenase clostridium histolyticum_INT_Trapidil", "text": "Interaction: Collagenase clostridium histolyticum AND Trapidil\nDetails: The risk or severity of adverse effects can be increased when Trapidil is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Trapidil"}, {"id": "Collagenase clostridium histolyticum_INT_Naftopidil", "text": "Interaction: Collagenase clostridium histolyticum AND Naftopidil\nDetails: The risk or severity of adverse effects can be increased when Naftopidil is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Naftopidil"}, {"id": "Collagenase clostridium histolyticum_INT_Sarpogrelate", "text": "Interaction: Collagenase clostridium histolyticum AND Sarpogrelate\nDetails: The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Sarpogrelate"}, {"id": "Collagenase clostridium histolyticum_INT_Eplivanserin", "text": "Interaction: Collagenase clostridium histolyticum AND Eplivanserin\nDetails: The risk or severity of adverse effects can be increased when Eplivanserin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Eplivanserin"}, {"id": "Collagenase clostridium histolyticum_INT_Ifetroban", "text": "Interaction: Collagenase clostridium histolyticum AND Ifetroban\nDetails: The risk or severity of adverse effects can be increased when Ifetroban is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Ifetroban"}, {"id": "Collagenase clostridium histolyticum_INT_Nitroaspirin", "text": "Interaction: Collagenase clostridium histolyticum AND Nitroaspirin\nDetails: The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Nitroaspirin"}, {"id": "Collagenase clostridium histolyticum_INT_Ketanserin", "text": "Interaction: Collagenase clostridium histolyticum AND Ketanserin\nDetails: The risk or severity of adverse effects can be increased when Ketanserin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Ketanserin"}, {"id": "Collagenase clostridium histolyticum_INT_Indobufen", "text": "Interaction: Collagenase clostridium histolyticum AND Indobufen\nDetails: The risk or severity of adverse effects can be increased when Indobufen is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Indobufen"}, {"id": "Collagenase clostridium histolyticum_INT_Butylphthalide", "text": "Interaction: Collagenase clostridium histolyticum AND Butylphthalide\nDetails: The risk or severity of adverse effects can be increased when Butylphthalide is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Butylphthalide"}, {"id": "Collagenase clostridium histolyticum_INT_Hydroxytyrosol", "text": "Interaction: Collagenase clostridium histolyticum AND Hydroxytyrosol\nDetails: The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Hydroxytyrosol"}, {"id": "Collagenase clostridium histolyticum_INT_Ramatroban", "text": "Interaction: Collagenase clostridium histolyticum AND Ramatroban\nDetails: The risk or severity of adverse effects can be increased when Ramatroban is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Ramatroban"}, {"id": "Collagenase clostridium histolyticum_INT_Picotamide", "text": "Interaction: Collagenase clostridium histolyticum AND Picotamide\nDetails: The risk or severity of adverse effects can be increased when Picotamide is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Picotamide"}, {"id": "Collagenase clostridium histolyticum_INT_Cloricromen", "text": "Interaction: Collagenase clostridium histolyticum AND Cloricromen\nDetails: The risk or severity of adverse effects can be increased when Cloricromen is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Cloricromen"}, {"id": "Collagenase clostridium histolyticum_INT_Linsidomine", "text": "Interaction: Collagenase clostridium histolyticum AND Linsidomine\nDetails: The risk or severity of adverse effects can be increased when Linsidomine is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Linsidomine"}, {"id": "Collagenase clostridium histolyticum_INT_Buflomedil", "text": "Interaction: Collagenase clostridium histolyticum AND Buflomedil\nDetails: The risk or severity of adverse effects can be increased when Buflomedil is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Buflomedil"}, {"id": "Collagenase clostridium histolyticum_INT_Relcovaptan", "text": "Interaction: Collagenase clostridium histolyticum AND Relcovaptan\nDetails: The risk or severity of adverse effects can be increased when Relcovaptan is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Relcovaptan"}, {"id": "Collagenase clostridium histolyticum_INT_Ticagrelor", "text": "Interaction: Collagenase clostridium histolyticum AND Ticagrelor\nDetails: The risk or severity of adverse effects can be increased when Ticagrelor is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Collagenase clostridium histolyticum + Ticagrelor"}, {"id": "Rasburicase_GEN", "text": "Drug: Rasburicase\nDescription: Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified <i>Saccharomyces cerevisiae</i> strain. The cDNA coding for rasburicase was cloned from a strain of <i>Aspergillus flavus</i>....", "source": "Rasburicase"}, {"id": "Rasburicase_CLIN", "text": "Drug: Rasburicase\nMechanism: Rasburicase catalyzes enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin)....\nToxicity: ...", "source": "Rasburicase"}, {"id": "Rasburicase_INT_Sarilumab", "text": "Interaction: Rasburicase AND Sarilumab\nDetails: Sarilumab may increase the immunosuppressive activities of Rasburicase.\nRisk: Monitor closely.", "source": "Rasburicase + Sarilumab"}, {"id": "Cetrorelix_GEN", "text": "Drug: Cetrorelix\nDescription: Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH). GnRH controls another hormone that is called luteinizing hormone (LH), which is the hormone that starts ovulation during the menstrual cycle. When undergoing hormone treatment sometimes premature ovula...", "source": "Cetrorelix"}, {"id": "Cetrorelix_CLIN", "text": "Drug: Cetrorelix\nMechanism: Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary c...\nToxicity: ...", "source": "Cetrorelix"}, {"id": "Adalimumab_GEN", "text": "Drug: Adalimumab\nDescription: Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons....", "source": "Adalimumab"}, {"id": "Adalimumab_CLIN", "text": "Drug: Adalimumab\nMechanism: Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement....\nToxicity: ...", "source": "Adalimumab"}, {"id": "Adalimumab_INT_Etanercept", "text": "Interaction: Adalimumab AND Etanercept\nDetails: The risk or severity of adverse effects can be increased when Adalimumab is combined with Etanercept.\nRisk: Monitor closely.", "source": "Adalimumab + Etanercept"}, {"id": "Adalimumab_INT_Golimumab", "text": "Interaction: Adalimumab AND Golimumab\nDetails: The risk or severity of adverse effects can be increased when Adalimumab is combined with Golimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Golimumab"}, {"id": "Adalimumab_INT_Rituximab", "text": "Interaction: Adalimumab AND Rituximab\nDetails: The risk or severity of adverse effects can be increased when Adalimumab is combined with Rituximab.\nRisk: Monitor closely.", "source": "Adalimumab + Rituximab"}, {"id": "Adalimumab_INT_Abatacept", "text": "Interaction: Adalimumab AND Abatacept\nDetails: The risk or severity of infection can be increased when Adalimumab is combined with Abatacept.\nRisk: Monitor closely.", "source": "Adalimumab + Abatacept"}, {"id": "Adalimumab_INT_Anakinra", "text": "Interaction: Adalimumab AND Anakinra\nDetails: The risk or severity of adverse effects can be increased when Adalimumab is combined with Anakinra.\nRisk: Monitor closely.", "source": "Adalimumab + Anakinra"}, {"id": "Adalimumab_INT_Canakinumab", "text": "Interaction: Adalimumab AND Canakinumab\nDetails: The risk or severity of adverse effects can be increased when Adalimumab is combined with Canakinumab.\nRisk: Monitor closely.", "source": "Adalimumab + Canakinumab"}, {"id": "Adalimumab_INT_Certolizumab pegol", "text": "Interaction: Adalimumab AND Certolizumab pegol\nDetails: Adalimumab may increase the immunosuppressive activities of Certolizumab pegol.\nRisk: Monitor closely.", "source": "Adalimumab + Certolizumab pegol"}, {"id": "Adalimumab_INT_Natalizumab", "text": "Interaction: Adalimumab AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Adalimumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Adalimumab + Natalizumab"}, {"id": "Adalimumab_INT_Pimecrolimus", "text": "Interaction: Adalimumab AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Pimecrolimus"}, {"id": "Adalimumab_INT_Rilonacept", "text": "Interaction: Adalimumab AND Rilonacept\nDetails: The risk or severity of adverse effects can be increased when Adalimumab is combined with Rilonacept.\nRisk: Monitor closely.", "source": "Adalimumab + Rilonacept"}, {"id": "Adalimumab_INT_Tocilizumab", "text": "Interaction: Adalimumab AND Tocilizumab\nDetails: Tocilizumab may increase the immunosuppressive activities of Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Tocilizumab"}, {"id": "Adalimumab_INT_Tofacitinib", "text": "Interaction: Adalimumab AND Tofacitinib\nDetails: The risk or severity of adverse effects can be increased when Adalimumab is combined with Tofacitinib.\nRisk: Monitor closely.", "source": "Adalimumab + Tofacitinib"}, {"id": "Adalimumab_INT_Vedolizumab", "text": "Interaction: Adalimumab AND Vedolizumab\nDetails: The risk or severity of infection can be increased when Adalimumab is combined with Vedolizumab.\nRisk: Monitor closely.", "source": "Adalimumab + Vedolizumab"}, {"id": "Adalimumab_INT_Tacrolimus", "text": "Interaction: Adalimumab AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Tacrolimus"}, {"id": "Adalimumab_INT_Belimumab", "text": "Interaction: Adalimumab AND Belimumab\nDetails: The risk or severity of adverse effects can be increased when Adalimumab is combined with Belimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Belimumab"}, {"id": "Adalimumab_INT_Infliximab", "text": "Interaction: Adalimumab AND Infliximab\nDetails: Adalimumab may increase the immunosuppressive activities of Infliximab.\nRisk: Monitor closely.", "source": "Adalimumab + Infliximab"}, {"id": "Adalimumab_INT_BCG vaccine", "text": "Interaction: Adalimumab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + BCG vaccine"}, {"id": "Adalimumab_INT_Sarilumab", "text": "Interaction: Adalimumab AND Sarilumab\nDetails: Sarilumab may increase the immunosuppressive activities of Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Sarilumab"}, {"id": "Adalimumab_INT_Leflunomide", "text": "Interaction: Adalimumab AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Adalimumab is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Adalimumab + Leflunomide"}, {"id": "Adalimumab_INT_Fingolimod", "text": "Interaction: Adalimumab AND Fingolimod\nDetails: Adalimumab may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Adalimumab + Fingolimod"}, {"id": "Adalimumab_INT_Roflumilast", "text": "Interaction: Adalimumab AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Roflumilast"}, {"id": "Adalimumab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Adalimumab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Adalimumab_INT_Yellow fever vaccine", "text": "Interaction: Adalimumab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Yellow fever vaccine"}, {"id": "Adalimumab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Adalimumab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Adalimumab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Adalimumab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Adalimumab_INT_Rotavirus Vaccine", "text": "Interaction: Adalimumab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Rotavirus Vaccine"}, {"id": "Adalimumab_INT_G17DT", "text": "Interaction: Adalimumab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + G17DT"}, {"id": "Adalimumab_INT_INGN 201", "text": "Interaction: Adalimumab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + INGN 201"}, {"id": "Adalimumab_INT_INGN 225", "text": "Interaction: Adalimumab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + INGN 225"}, {"id": "Adalimumab_INT_Rindopepimut", "text": "Interaction: Adalimumab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Rindopepimut"}, {"id": "Adalimumab_INT_SRP 299", "text": "Interaction: Adalimumab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + SRP 299"}, {"id": "Adalimumab_INT_GI-5005", "text": "Interaction: Adalimumab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + GI-5005"}, {"id": "Adalimumab_INT_TG4010", "text": "Interaction: Adalimumab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + TG4010"}, {"id": "Adalimumab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Adalimumab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Rabies virus inactivated antigen, A"}, {"id": "Adalimumab_INT_Tecemotide", "text": "Interaction: Adalimumab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Tecemotide"}, {"id": "Adalimumab_INT_Rubella virus vaccine", "text": "Interaction: Adalimumab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Rubella virus vaccine"}, {"id": "Adalimumab_INT_Hepatitis A Vaccine", "text": "Interaction: Adalimumab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Hepatitis A Vaccine"}, {"id": "Adalimumab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Adalimumab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Salmonella typhi ty21a live antigen"}, {"id": "Adalimumab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Adalimumab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Adalimumab_INT_Ambroxol acefyllinate", "text": "Interaction: Adalimumab AND Ambroxol acefyllinate\nDetails: The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Ambroxol acefyllinate"}, {"id": "Adalimumab_INT_Theophylline", "text": "Interaction: Adalimumab AND Theophylline\nDetails: The serum concentration of Theophylline can be decreased when it is combined with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Theophylline"}, {"id": "Adalimumab_INT_Dyphylline", "text": "Interaction: Adalimumab AND Dyphylline\nDetails: The serum concentration of Dyphylline can be decreased when it is combined with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Dyphylline"}, {"id": "Adalimumab_INT_Aminophylline", "text": "Interaction: Adalimumab AND Aminophylline\nDetails: The serum concentration of Aminophylline can be decreased when it is combined with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Aminophylline"}, {"id": "Adalimumab_INT_Denosumab", "text": "Interaction: Adalimumab AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Denosumab"}, {"id": "Adalimumab_INT_Sipuleucel-T", "text": "Interaction: Adalimumab AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Sipuleucel-T"}, {"id": "Adalimumab_INT_Trastuzumab", "text": "Interaction: Adalimumab AND Trastuzumab\nDetails: Trastuzumab may increase the neutropenic activities of Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Trastuzumab"}, {"id": "Adalimumab_INT_Warfarin", "text": "Interaction: Adalimumab AND Warfarin\nDetails: The serum concentration of Warfarin can be decreased when it is combined with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Warfarin"}, {"id": "Adalimumab_INT_Cyclosporine", "text": "Interaction: Adalimumab AND Cyclosporine\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.\nRisk: Monitor closely.", "source": "Adalimumab + Cyclosporine"}, {"id": "Somatotropin_GEN", "text": "Drug: Somatotropin\nDescription: Recombinant human growth hormone (somatotropin) 191 residues, MW 22.1 kD, synthesized in E. coli...", "source": "Somatotropin"}, {"id": "Somatotropin_CLIN", "text": "Drug: Somatotropin\nMechanism: hGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and ...\nToxicity: ...", "source": "Somatotropin"}, {"id": "Somatotropin_INT_Prednisone", "text": "Interaction: Somatotropin AND Prednisone\nDetails: The therapeutic efficacy of Prednisone can be decreased when used in combination with Somatotropin.\nRisk: Monitor closely.", "source": "Somatotropin + Prednisone"}, {"id": "Somatotropin_INT_Diethylstilbestrol", "text": "Interaction: Somatotropin AND Diethylstilbestrol\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Diethylstilbestrol.\nRisk: Monitor closely.", "source": "Somatotropin + Diethylstilbestrol"}, {"id": "Somatotropin_INT_Chlorotrianisene", "text": "Interaction: Somatotropin AND Chlorotrianisene\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Chlorotrianisene.\nRisk: Monitor closely.", "source": "Somatotropin + Chlorotrianisene"}, {"id": "Somatotropin_INT_Conjugated estrogens", "text": "Interaction: Somatotropin AND Conjugated estrogens\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Conjugated estrogens.\nRisk: Monitor closely.", "source": "Somatotropin + Conjugated estrogens"}, {"id": "Somatotropin_INT_Estrone", "text": "Interaction: Somatotropin AND Estrone\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Estrone.\nRisk: Monitor closely.", "source": "Somatotropin + Estrone"}, {"id": "Somatotropin_INT_Estradiol", "text": "Interaction: Somatotropin AND Estradiol\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Estradiol.\nRisk: Monitor closely.", "source": "Somatotropin + Estradiol"}, {"id": "Somatotropin_INT_Dienestrol", "text": "Interaction: Somatotropin AND Dienestrol\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Dienestrol.\nRisk: Monitor closely.", "source": "Somatotropin + Dienestrol"}, {"id": "Somatotropin_INT_Ethinyl Estradiol", "text": "Interaction: Somatotropin AND Ethinyl Estradiol\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Ethinyl Estradiol.\nRisk: Monitor closely.", "source": "Somatotropin + Ethinyl Estradiol"}, {"id": "Somatotropin_INT_Polyestradiol phosphate", "text": "Interaction: Somatotropin AND Polyestradiol phosphate\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Polyestradiol phosphate.\nRisk: Monitor closely.", "source": "Somatotropin + Polyestradiol phosphate"}, {"id": "Somatotropin_INT_Mestranol", "text": "Interaction: Somatotropin AND Mestranol\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Mestranol.\nRisk: Monitor closely.", "source": "Somatotropin + Mestranol"}, {"id": "Somatotropin_INT_Genistein", "text": "Interaction: Somatotropin AND Genistein\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Genistein.\nRisk: Monitor closely.", "source": "Somatotropin + Genistein"}, {"id": "Somatotropin_INT_Quinestrol", "text": "Interaction: Somatotropin AND Quinestrol\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Quinestrol.\nRisk: Monitor closely.", "source": "Somatotropin + Quinestrol"}, {"id": "Somatotropin_INT_Hexestrol", "text": "Interaction: Somatotropin AND Hexestrol\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Hexestrol.\nRisk: Monitor closely.", "source": "Somatotropin + Hexestrol"}, {"id": "Somatotropin_INT_Synthetic Conjugated Estrogens, A", "text": "Interaction: Somatotropin AND Synthetic Conjugated Estrogens, A\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Synthetic Conjugated Estrogens, A.\nRisk: Monitor closely.", "source": "Somatotropin + Synthetic Conjugated Estrogens, A"}, {"id": "Somatotropin_INT_Synthetic Conjugated Estrogens, B", "text": "Interaction: Somatotropin AND Synthetic Conjugated Estrogens, B\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Synthetic Conjugated Estrogens, B.\nRisk: Monitor closely.", "source": "Somatotropin + Synthetic Conjugated Estrogens, B"}, {"id": "Somatotropin_INT_Zeranol", "text": "Interaction: Somatotropin AND Zeranol\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Zeranol.\nRisk: Monitor closely.", "source": "Somatotropin + Zeranol"}, {"id": "Somatotropin_INT_Equol", "text": "Interaction: Somatotropin AND Equol\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Equol.\nRisk: Monitor closely.", "source": "Somatotropin + Equol"}, {"id": "Somatotropin_INT_Secoisolariciresinol", "text": "Interaction: Somatotropin AND Secoisolariciresinol\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Secoisolariciresinol.\nRisk: Monitor closely.", "source": "Somatotropin + Secoisolariciresinol"}, {"id": "Somatotropin_INT_Daidzein", "text": "Interaction: Somatotropin AND Daidzein\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Daidzein.\nRisk: Monitor closely.", "source": "Somatotropin + Daidzein"}, {"id": "Somatotropin_INT_Epimestrol", "text": "Interaction: Somatotropin AND Epimestrol\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Epimestrol.\nRisk: Monitor closely.", "source": "Somatotropin + Epimestrol"}, {"id": "Somatotropin_INT_Estriol", "text": "Interaction: Somatotropin AND Estriol\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Estriol.\nRisk: Monitor closely.", "source": "Somatotropin + Estriol"}, {"id": "Somatotropin_INT_Tibolone", "text": "Interaction: Somatotropin AND Tibolone\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Tibolone.\nRisk: Monitor closely.", "source": "Somatotropin + Tibolone"}, {"id": "Somatotropin_INT_Promestriene", "text": "Interaction: Somatotropin AND Promestriene\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Promestriene.\nRisk: Monitor closely.", "source": "Somatotropin + Promestriene"}, {"id": "Somatotropin_INT_Methallenestril", "text": "Interaction: Somatotropin AND Methallenestril\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Methallenestril.\nRisk: Monitor closely.", "source": "Somatotropin + Methallenestril"}, {"id": "Somatotropin_INT_Moxestrol", "text": "Interaction: Somatotropin AND Moxestrol\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Moxestrol.\nRisk: Monitor closely.", "source": "Somatotropin + Moxestrol"}, {"id": "Somatotropin_INT_Estrogens, esterified", "text": "Interaction: Somatotropin AND Estrogens, esterified\nDetails: The therapeutic efficacy of Somatotropin can be decreased when used in combination with Estrogens, esterified.\nRisk: Monitor closely.", "source": "Somatotropin + Estrogens, esterified"}, {"id": "Somatotropin_INT_Cortisone acetate", "text": "Interaction: Somatotropin AND Cortisone acetate\nDetails: The therapeutic efficacy of Cortisone acetate can be decreased when used in combination with Somatotropin.\nRisk: Monitor closely.", "source": "Somatotropin + Cortisone acetate"}, {"id": "Imiglucerase_GEN", "text": "Drug: Imiglucerase\nDescription: Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar resi...", "source": "Imiglucerase"}, {"id": "Imiglucerase_CLIN", "text": "Drug: Imiglucerase\nMechanism: Imiglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids....\nToxicity: ...", "source": "Imiglucerase"}, {"id": "Abciximab_GEN", "text": "Drug: Abciximab\nDescription: ...", "source": "Abciximab"}, {"id": "Abciximab_GEN", "text": "Drug: Abciximab\nDescription: Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also bind...", "source": "Abciximab"}, {"id": "Abciximab_CLIN", "text": "Drug: Abciximab\nMechanism: Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. Thi...\nToxicity: ...", "source": "Abciximab"}, {"id": "Abciximab_INT_Dextran", "text": "Interaction: Abciximab AND Dextran\nDetails: Dextran may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Dextran"}, {"id": "Abciximab_INT_Acemetacin", "text": "Interaction: Abciximab AND Acemetacin\nDetails: The risk or severity of bleeding can be increased when Abciximab is combined with Acemetacin.\nRisk: Monitor closely.", "source": "Abciximab + Acemetacin"}, {"id": "Abciximab_INT_Edoxaban", "text": "Interaction: Abciximab AND Edoxaban\nDetails: Edoxaban may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Edoxaban"}, {"id": "Abciximab_INT_Urokinase", "text": "Interaction: Abciximab AND Urokinase\nDetails: Urokinase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Urokinase"}, {"id": "Abciximab_INT_Vorapaxar", "text": "Interaction: Abciximab AND Vorapaxar\nDetails: The risk or severity of adverse effects can be increased when Vorapaxar is combined with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Vorapaxar"}, {"id": "Abciximab_INT_Hemin", "text": "Interaction: Abciximab AND Hemin\nDetails: Hemin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Hemin"}, {"id": "Abciximab_INT_Diethylstilbestrol", "text": "Interaction: Abciximab AND Diethylstilbestrol\nDetails: Diethylstilbestrol may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Diethylstilbestrol"}, {"id": "Abciximab_INT_Chlorotrianisene", "text": "Interaction: Abciximab AND Chlorotrianisene\nDetails: Chlorotrianisene may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Chlorotrianisene"}, {"id": "Abciximab_INT_Conjugated estrogens", "text": "Interaction: Abciximab AND Conjugated estrogens\nDetails: Conjugated estrogens may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Conjugated estrogens"}, {"id": "Abciximab_INT_Estrone", "text": "Interaction: Abciximab AND Estrone\nDetails: Estrone may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Estrone"}, {"id": "Abciximab_INT_Estradiol", "text": "Interaction: Abciximab AND Estradiol\nDetails: Estradiol may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Estradiol"}, {"id": "Abciximab_INT_Dienestrol", "text": "Interaction: Abciximab AND Dienestrol\nDetails: Dienestrol may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Dienestrol"}, {"id": "Abciximab_INT_Ethinyl Estradiol", "text": "Interaction: Abciximab AND Ethinyl Estradiol\nDetails: Ethinyl Estradiol may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ethinyl Estradiol"}, {"id": "Abciximab_INT_Polyestradiol phosphate", "text": "Interaction: Abciximab AND Polyestradiol phosphate\nDetails: Polyestradiol phosphate may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Polyestradiol phosphate"}, {"id": "Abciximab_INT_Mestranol", "text": "Interaction: Abciximab AND Mestranol\nDetails: Mestranol may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Mestranol"}, {"id": "Abciximab_INT_Genistein", "text": "Interaction: Abciximab AND Genistein\nDetails: Genistein may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Genistein"}, {"id": "Abciximab_INT_Quinestrol", "text": "Interaction: Abciximab AND Quinestrol\nDetails: Quinestrol may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Quinestrol"}, {"id": "Abciximab_INT_Hexestrol", "text": "Interaction: Abciximab AND Hexestrol\nDetails: Hexestrol may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Hexestrol"}, {"id": "Abciximab_INT_Synthetic Conjugated Estrogens, A", "text": "Interaction: Abciximab AND Synthetic Conjugated Estrogens, A\nDetails: Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Synthetic Conjugated Estrogens, A"}, {"id": "Abciximab_INT_Synthetic Conjugated Estrogens, B", "text": "Interaction: Abciximab AND Synthetic Conjugated Estrogens, B\nDetails: Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Synthetic Conjugated Estrogens, B"}, {"id": "Abciximab_INT_Zeranol", "text": "Interaction: Abciximab AND Zeranol\nDetails: Zeranol may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Zeranol"}, {"id": "Abciximab_INT_Equol", "text": "Interaction: Abciximab AND Equol\nDetails: Equol may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Equol"}, {"id": "Abciximab_INT_Secoisolariciresinol", "text": "Interaction: Abciximab AND Secoisolariciresinol\nDetails: Secoisolariciresinol may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Secoisolariciresinol"}, {"id": "Abciximab_INT_Daidzein", "text": "Interaction: Abciximab AND Daidzein\nDetails: Daidzein may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Daidzein"}, {"id": "Abciximab_INT_Epimestrol", "text": "Interaction: Abciximab AND Epimestrol\nDetails: Epimestrol may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Epimestrol"}, {"id": "Abciximab_INT_Estriol", "text": "Interaction: Abciximab AND Estriol\nDetails: Estriol may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Estriol"}, {"id": "Abciximab_INT_Promestriene", "text": "Interaction: Abciximab AND Promestriene\nDetails: Promestriene may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Promestriene"}, {"id": "Abciximab_INT_Methallenestril", "text": "Interaction: Abciximab AND Methallenestril\nDetails: Methallenestril may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Methallenestril"}, {"id": "Abciximab_INT_Moxestrol", "text": "Interaction: Abciximab AND Moxestrol\nDetails: Moxestrol may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Moxestrol"}, {"id": "Abciximab_INT_Estrogens, esterified", "text": "Interaction: Abciximab AND Estrogens, esterified\nDetails: Estrogens, esterified may decrease the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Estrogens, esterified"}, {"id": "Abciximab_INT_Omacetaxine mepesuccinate", "text": "Interaction: Abciximab AND Omacetaxine mepesuccinate\nDetails: The risk or severity of bleeding can be increased when Abciximab is combined with Omacetaxine mepesuccinate.\nRisk: Monitor closely.", "source": "Abciximab + Omacetaxine mepesuccinate"}, {"id": "Abciximab_INT_Aprotinin", "text": "Interaction: Abciximab AND Aprotinin\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Aprotinin.\nRisk: Monitor closely.", "source": "Abciximab + Aprotinin"}, {"id": "Abciximab_INT_Allylestrenol", "text": "Interaction: Abciximab AND Allylestrenol\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Allylestrenol.\nRisk: Monitor closely.", "source": "Abciximab + Allylestrenol"}, {"id": "Abciximab_INT_Etonogestrel", "text": "Interaction: Abciximab AND Etonogestrel\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Etonogestrel.\nRisk: Monitor closely.", "source": "Abciximab + Etonogestrel"}, {"id": "Abciximab_INT_Medroxyprogesterone acetate", "text": "Interaction: Abciximab AND Medroxyprogesterone acetate\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Medroxyprogesterone acetate.\nRisk: Monitor closely.", "source": "Abciximab + Medroxyprogesterone acetate"}, {"id": "Abciximab_INT_Dienogest", "text": "Interaction: Abciximab AND Dienogest\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Dienogest.\nRisk: Monitor closely.", "source": "Abciximab + Dienogest"}, {"id": "Abciximab_INT_Progesterone", "text": "Interaction: Abciximab AND Progesterone\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Progesterone.\nRisk: Monitor closely.", "source": "Abciximab + Progesterone"}, {"id": "Abciximab_INT_Norethisterone", "text": "Interaction: Abciximab AND Norethisterone\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Norethisterone.\nRisk: Monitor closely.", "source": "Abciximab + Norethisterone"}, {"id": "Abciximab_INT_Hydroxyprogesterone caproate", "text": "Interaction: Abciximab AND Hydroxyprogesterone caproate\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Hydroxyprogesterone caproate.\nRisk: Monitor closely.", "source": "Abciximab + Hydroxyprogesterone caproate"}, {"id": "Abciximab_INT_Desogestrel", "text": "Interaction: Abciximab AND Desogestrel\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Desogestrel.\nRisk: Monitor closely.", "source": "Abciximab + Desogestrel"}, {"id": "Abciximab_INT_Dydrogesterone", "text": "Interaction: Abciximab AND Dydrogesterone\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Dydrogesterone.\nRisk: Monitor closely.", "source": "Abciximab + Dydrogesterone"}, {"id": "Abciximab_INT_Gestodene", "text": "Interaction: Abciximab AND Gestodene\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Gestodene.\nRisk: Monitor closely.", "source": "Abciximab + Gestodene"}, {"id": "Abciximab_INT_Altrenogest", "text": "Interaction: Abciximab AND Altrenogest\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Altrenogest.\nRisk: Monitor closely.", "source": "Abciximab + Altrenogest"}, {"id": "Abciximab_INT_Gestrinone", "text": "Interaction: Abciximab AND Gestrinone\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Gestrinone.\nRisk: Monitor closely.", "source": "Abciximab + Gestrinone"}, {"id": "Abciximab_INT_Medrogestone", "text": "Interaction: Abciximab AND Medrogestone\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Medrogestone.\nRisk: Monitor closely.", "source": "Abciximab + Medrogestone"}, {"id": "Abciximab_INT_Nomegestrol", "text": "Interaction: Abciximab AND Nomegestrol\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Nomegestrol.\nRisk: Monitor closely.", "source": "Abciximab + Nomegestrol"}, {"id": "Abciximab_INT_Gestonorone", "text": "Interaction: Abciximab AND Gestonorone\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Gestonorone.\nRisk: Monitor closely.", "source": "Abciximab + Gestonorone"}, {"id": "Abciximab_INT_Methylestrenolone", "text": "Interaction: Abciximab AND Methylestrenolone\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Methylestrenolone.\nRisk: Monitor closely.", "source": "Abciximab + Methylestrenolone"}, {"id": "Abciximab_INT_Norgestrienone", "text": "Interaction: Abciximab AND Norgestrienone\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Norgestrienone.\nRisk: Monitor closely.", "source": "Abciximab + Norgestrienone"}, {"id": "Abciximab_INT_Promegestone", "text": "Interaction: Abciximab AND Promegestone\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Promegestone.\nRisk: Monitor closely.", "source": "Abciximab + Promegestone"}, {"id": "Abciximab_INT_Demegestone", "text": "Interaction: Abciximab AND Demegestone\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Demegestone.\nRisk: Monitor closely.", "source": "Abciximab + Demegestone"}, {"id": "Abciximab_INT_Megestrol acetate", "text": "Interaction: Abciximab AND Megestrol acetate\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Megestrol acetate.\nRisk: Monitor closely.", "source": "Abciximab + Megestrol acetate"}, {"id": "Abciximab_INT_Levonorgestrel", "text": "Interaction: Abciximab AND Levonorgestrel\nDetails: The therapeutic efficacy of Abciximab can be decreased when used in combination with Levonorgestrel.\nRisk: Monitor closely.", "source": "Abciximab + Levonorgestrel"}, {"id": "Abciximab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Abciximab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Abciximab_INT_Yellow fever vaccine", "text": "Interaction: Abciximab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Yellow fever vaccine"}, {"id": "Abciximab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Abciximab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Abciximab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Abciximab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Abciximab_INT_Rotavirus Vaccine", "text": "Interaction: Abciximab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Rotavirus Vaccine"}, {"id": "Abciximab_INT_G17DT", "text": "Interaction: Abciximab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + G17DT"}, {"id": "Abciximab_INT_INGN 201", "text": "Interaction: Abciximab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + INGN 201"}, {"id": "Abciximab_INT_INGN 225", "text": "Interaction: Abciximab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + INGN 225"}, {"id": "Abciximab_INT_Rindopepimut", "text": "Interaction: Abciximab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Rindopepimut"}, {"id": "Abciximab_INT_SRP 299", "text": "Interaction: Abciximab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + SRP 299"}, {"id": "Abciximab_INT_GI-5005", "text": "Interaction: Abciximab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + GI-5005"}, {"id": "Abciximab_INT_TG4010", "text": "Interaction: Abciximab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + TG4010"}, {"id": "Abciximab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Abciximab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Rabies virus inactivated antigen, A"}, {"id": "Abciximab_INT_Tecemotide", "text": "Interaction: Abciximab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tecemotide"}, {"id": "Abciximab_INT_BCG vaccine", "text": "Interaction: Abciximab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + BCG vaccine"}, {"id": "Abciximab_INT_Rubella virus vaccine", "text": "Interaction: Abciximab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Rubella virus vaccine"}, {"id": "Abciximab_INT_Hepatitis A Vaccine", "text": "Interaction: Abciximab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Hepatitis A Vaccine"}, {"id": "Abciximab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Abciximab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Salmonella typhi ty21a live antigen"}, {"id": "Abciximab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Abciximab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Abciximab_INT_Rivaroxaban", "text": "Interaction: Abciximab AND Rivaroxaban\nDetails: Abciximab may increase the anticoagulant activities of Rivaroxaban.\nRisk: Monitor closely.", "source": "Abciximab + Rivaroxaban"}, {"id": "Abciximab_INT_Apixaban", "text": "Interaction: Abciximab AND Apixaban\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Apixaban.\nRisk: Monitor closely.", "source": "Abciximab + Apixaban"}, {"id": "Abciximab_INT_Dabigatran etexilate", "text": "Interaction: Abciximab AND Dabigatran etexilate\nDetails: Abciximab may increase the anticoagulant activities of Dabigatran etexilate.\nRisk: Monitor closely.", "source": "Abciximab + Dabigatran etexilate"}, {"id": "Abciximab_INT_Pentosan Polysulfate", "text": "Interaction: Abciximab AND Pentosan Polysulfate\nDetails: Pentosan Polysulfate may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Pentosan Polysulfate"}, {"id": "Abciximab_INT_Salicylic acid", "text": "Interaction: Abciximab AND Salicylic acid\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Salicylic acid.\nRisk: Monitor closely.", "source": "Abciximab + Salicylic acid"}, {"id": "Abciximab_INT_Acetylsalicylic acid", "text": "Interaction: Abciximab AND Acetylsalicylic acid\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Acetylsalicylic acid.\nRisk: Monitor closely.", "source": "Abciximab + Acetylsalicylic acid"}, {"id": "Abciximab_INT_Aminosalicylic Acid", "text": "Interaction: Abciximab AND Aminosalicylic Acid\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Aminosalicylic Acid.\nRisk: Monitor closely.", "source": "Abciximab + Aminosalicylic Acid"}, {"id": "Abciximab_INT_Mesalazine", "text": "Interaction: Abciximab AND Mesalazine\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Mesalazine.\nRisk: Monitor closely.", "source": "Abciximab + Mesalazine"}, {"id": "Abciximab_INT_Diflunisal", "text": "Interaction: Abciximab AND Diflunisal\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Diflunisal.\nRisk: Monitor closely.", "source": "Abciximab + Diflunisal"}, {"id": "Abciximab_INT_dersalazine", "text": "Interaction: Abciximab AND dersalazine\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with dersalazine.\nRisk: Monitor closely.", "source": "Abciximab + dersalazine"}, {"id": "Abciximab_INT_Nitroaspirin", "text": "Interaction: Abciximab AND Nitroaspirin\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Nitroaspirin.\nRisk: Monitor closely.", "source": "Abciximab + Nitroaspirin"}, {"id": "Abciximab_INT_Aloxiprin", "text": "Interaction: Abciximab AND Aloxiprin\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Aloxiprin.\nRisk: Monitor closely.", "source": "Abciximab + Aloxiprin"}, {"id": "Abciximab_INT_Guacetisal", "text": "Interaction: Abciximab AND Guacetisal\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Guacetisal.\nRisk: Monitor closely.", "source": "Abciximab + Guacetisal"}, {"id": "Abciximab_INT_Carbaspirin calcium", "text": "Interaction: Abciximab AND Carbaspirin calcium\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Carbaspirin calcium.\nRisk: Monitor closely.", "source": "Abciximab + Carbaspirin calcium"}, {"id": "Abciximab_INT_Hemoglobin crosfumaril", "text": "Interaction: Abciximab AND Hemoglobin crosfumaril\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Hemoglobin crosfumaril.\nRisk: Monitor closely.", "source": "Abciximab + Hemoglobin crosfumaril"}, {"id": "Abciximab_INT_Methyl salicylate", "text": "Interaction: Abciximab AND Methyl salicylate\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Methyl salicylate.\nRisk: Monitor closely.", "source": "Abciximab + Methyl salicylate"}, {"id": "Abciximab_INT_Trolamine salicylate", "text": "Interaction: Abciximab AND Trolamine salicylate\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Trolamine salicylate.\nRisk: Monitor closely.", "source": "Abciximab + Trolamine salicylate"}, {"id": "Abciximab_INT_Treprostinil", "text": "Interaction: Abciximab AND Treprostinil\nDetails: Treprostinil may increase the antiplatelet activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Treprostinil"}, {"id": "Abciximab_INT_Iloprost", "text": "Interaction: Abciximab AND Iloprost\nDetails: Iloprost may increase the antiplatelet activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Iloprost"}, {"id": "Abciximab_INT_Epoprostenol", "text": "Interaction: Abciximab AND Epoprostenol\nDetails: Epoprostenol may increase the antiplatelet activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Epoprostenol"}, {"id": "Abciximab_INT_Dasatinib", "text": "Interaction: Abciximab AND Dasatinib\nDetails: Dasatinib may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Dasatinib"}, {"id": "Abciximab_INT_Deferasirox", "text": "Interaction: Abciximab AND Deferasirox\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Deferasirox.\nRisk: Monitor closely.", "source": "Abciximab + Deferasirox"}, {"id": "Abciximab_INT_Deoxycholic Acid", "text": "Interaction: Abciximab AND Deoxycholic Acid\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Deoxycholic Acid.\nRisk: Monitor closely.", "source": "Abciximab + Deoxycholic Acid"}, {"id": "Abciximab_INT_Ibritumomab tiuxetan", "text": "Interaction: Abciximab AND Ibritumomab tiuxetan\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Abciximab + Ibritumomab tiuxetan"}, {"id": "Abciximab_INT_Ibrutinib", "text": "Interaction: Abciximab AND Ibrutinib\nDetails: The risk or severity of adverse effects can be increased when Ibrutinib is combined with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ibrutinib"}, {"id": "Abciximab_INT_Nintedanib", "text": "Interaction: Abciximab AND Nintedanib\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Nintedanib.\nRisk: Monitor closely.", "source": "Abciximab + Nintedanib"}, {"id": "Abciximab_INT_Obinutuzumab", "text": "Interaction: Abciximab AND Obinutuzumab\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Obinutuzumab.\nRisk: Monitor closely.", "source": "Abciximab + Obinutuzumab"}, {"id": "Abciximab_INT_Collagenase clostridium histolyticum", "text": "Interaction: Abciximab AND Collagenase clostridium histolyticum\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Abciximab + Collagenase clostridium histolyticum"}, {"id": "Abciximab_INT_Sugammadex", "text": "Interaction: Abciximab AND Sugammadex\nDetails: Sugammadex may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Sugammadex"}, {"id": "Abciximab_INT_Limaprost", "text": "Interaction: Abciximab AND Limaprost\nDetails: The risk or severity of adverse effects can be increased when Limaprost is combined with Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Limaprost"}, {"id": "Abciximab_INT_Tibolone", "text": "Interaction: Abciximab AND Tibolone\nDetails: Tibolone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tibolone"}, {"id": "Abciximab_INT_Ketorolac", "text": "Interaction: Abciximab AND Ketorolac\nDetails: Ketorolac may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ketorolac"}, {"id": "Abciximab_INT_Diclofenac", "text": "Interaction: Abciximab AND Diclofenac\nDetails: Diclofenac may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Diclofenac"}, {"id": "Abciximab_INT_Flurbiprofen", "text": "Interaction: Abciximab AND Flurbiprofen\nDetails: Flurbiprofen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Flurbiprofen"}, {"id": "Abciximab_INT_Bromfenac", "text": "Interaction: Abciximab AND Bromfenac\nDetails: Bromfenac may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Bromfenac"}, {"id": "Abciximab_INT_Nepafenac", "text": "Interaction: Abciximab AND Nepafenac\nDetails: Nepafenac may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Nepafenac"}, {"id": "Abciximab_INT_Etanercept", "text": "Interaction: Abciximab AND Etanercept\nDetails: Etanercept may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Etanercept"}, {"id": "Abciximab_INT_Masoprocol", "text": "Interaction: Abciximab AND Masoprocol\nDetails: Masoprocol may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Masoprocol"}, {"id": "Abciximab_INT_Adapalene", "text": "Interaction: Abciximab AND Adapalene\nDetails: Adapalene may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Adapalene"}, {"id": "Abciximab_INT_Indomethacin", "text": "Interaction: Abciximab AND Indomethacin\nDetails: Indomethacin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Indomethacin"}, {"id": "Abciximab_INT_Pimecrolimus", "text": "Interaction: Abciximab AND Pimecrolimus\nDetails: Pimecrolimus may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Pimecrolimus"}, {"id": "Abciximab_INT_Nabumetone", "text": "Interaction: Abciximab AND Nabumetone\nDetails: Nabumetone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Nabumetone"}, {"id": "Abciximab_INT_Tenoxicam", "text": "Interaction: Abciximab AND Tenoxicam\nDetails: Tenoxicam may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tenoxicam"}, {"id": "Abciximab_INT_Celecoxib", "text": "Interaction: Abciximab AND Celecoxib\nDetails: Celecoxib may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Celecoxib"}, {"id": "Abciximab_INT_Tolmetin", "text": "Interaction: Abciximab AND Tolmetin\nDetails: Tolmetin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tolmetin"}, {"id": "Abciximab_INT_Rofecoxib", "text": "Interaction: Abciximab AND Rofecoxib\nDetails: Rofecoxib may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Rofecoxib"}, {"id": "Abciximab_INT_Piroxicam", "text": "Interaction: Abciximab AND Piroxicam\nDetails: Piroxicam may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Piroxicam"}, {"id": "Abciximab_INT_Fenoprofen", "text": "Interaction: Abciximab AND Fenoprofen\nDetails: Fenoprofen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Fenoprofen"}, {"id": "Abciximab_INT_Valdecoxib", "text": "Interaction: Abciximab AND Valdecoxib\nDetails: Valdecoxib may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Valdecoxib"}, {"id": "Abciximab_INT_Sulindac", "text": "Interaction: Abciximab AND Sulindac\nDetails: Sulindac may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Sulindac"}, {"id": "Abciximab_INT_Chloroquine", "text": "Interaction: Abciximab AND Chloroquine\nDetails: Chloroquine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Chloroquine"}, {"id": "Abciximab_INT_Mycophenolate mofetil", "text": "Interaction: Abciximab AND Mycophenolate mofetil\nDetails: Mycophenolate mofetil may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Mycophenolate mofetil"}, {"id": "Abciximab_INT_Naftifine", "text": "Interaction: Abciximab AND Naftifine\nDetails: Naftifine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Naftifine"}, {"id": "Abciximab_INT_Zileuton", "text": "Interaction: Abciximab AND Zileuton\nDetails: Zileuton may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Zileuton"}, {"id": "Abciximab_INT_Etodolac", "text": "Interaction: Abciximab AND Etodolac\nDetails: Etodolac may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Etodolac"}, {"id": "Abciximab_INT_Olopatadine", "text": "Interaction: Abciximab AND Olopatadine\nDetails: Olopatadine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Olopatadine"}, {"id": "Abciximab_INT_Mefenamic acid", "text": "Interaction: Abciximab AND Mefenamic acid\nDetails: Mefenamic acid may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Mefenamic acid"}, {"id": "Abciximab_INT_Naproxen", "text": "Interaction: Abciximab AND Naproxen\nDetails: Naproxen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Naproxen"}, {"id": "Abciximab_INT_Sulfasalazine", "text": "Interaction: Abciximab AND Sulfasalazine\nDetails: Sulfasalazine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Sulfasalazine"}, {"id": "Abciximab_INT_Phenylbutazone", "text": "Interaction: Abciximab AND Phenylbutazone\nDetails: Phenylbutazone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Phenylbutazone"}, {"id": "Abciximab_INT_Meloxicam", "text": "Interaction: Abciximab AND Meloxicam\nDetails: Meloxicam may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Meloxicam"}, {"id": "Abciximab_INT_Carprofen", "text": "Interaction: Abciximab AND Carprofen\nDetails: Carprofen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Carprofen"}, {"id": "Abciximab_INT_Suprofen", "text": "Interaction: Abciximab AND Suprofen\nDetails: Suprofen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Suprofen"}, {"id": "Abciximab_INT_Meclofenamic acid", "text": "Interaction: Abciximab AND Meclofenamic acid\nDetails: Meclofenamic acid may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Meclofenamic acid"}, {"id": "Abciximab_INT_Azelastine", "text": "Interaction: Abciximab AND Azelastine\nDetails: Azelastine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Azelastine"}, {"id": "Abciximab_INT_Oxaprozin", "text": "Interaction: Abciximab AND Oxaprozin\nDetails: Oxaprozin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Oxaprozin"}, {"id": "Abciximab_INT_Ketoprofen", "text": "Interaction: Abciximab AND Ketoprofen\nDetails: Ketoprofen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ketoprofen"}, {"id": "Abciximab_INT_Balsalazide", "text": "Interaction: Abciximab AND Balsalazide\nDetails: Balsalazide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Balsalazide"}, {"id": "Abciximab_INT_Mycophenolic acid", "text": "Interaction: Abciximab AND Mycophenolic acid\nDetails: Mycophenolic acid may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Mycophenolic acid"}, {"id": "Abciximab_INT_Ibuprofen", "text": "Interaction: Abciximab AND Ibuprofen\nDetails: Ibuprofen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ibuprofen"}, {"id": "Abciximab_INT_Leflunomide", "text": "Interaction: Abciximab AND Leflunomide\nDetails: Leflunomide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Leflunomide"}, {"id": "Abciximab_INT_Olsalazine", "text": "Interaction: Abciximab AND Olsalazine\nDetails: Olsalazine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Olsalazine"}, {"id": "Abciximab_INT_Lumiracoxib", "text": "Interaction: Abciximab AND Lumiracoxib\nDetails: Lumiracoxib may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Lumiracoxib"}, {"id": "Abciximab_INT_Magnesium salicylate", "text": "Interaction: Abciximab AND Magnesium salicylate\nDetails: Magnesium salicylate may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Magnesium salicylate"}, {"id": "Abciximab_INT_Salsalate", "text": "Interaction: Abciximab AND Salsalate\nDetails: Salsalate may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Salsalate"}, {"id": "Abciximab_INT_Choline magnesium trisalicylate", "text": "Interaction: Abciximab AND Choline magnesium trisalicylate\nDetails: Choline magnesium trisalicylate may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Choline magnesium trisalicylate"}, {"id": "Abciximab_INT_Antipyrine", "text": "Interaction: Abciximab AND Antipyrine\nDetails: Antipyrine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Antipyrine"}, {"id": "Abciximab_INT_Tiaprofenic acid", "text": "Interaction: Abciximab AND Tiaprofenic acid\nDetails: Tiaprofenic acid may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tiaprofenic acid"}, {"id": "Abciximab_INT_Etoricoxib", "text": "Interaction: Abciximab AND Etoricoxib\nDetails: Etoricoxib may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Etoricoxib"}, {"id": "Abciximab_INT_Castanospermine", "text": "Interaction: Abciximab AND Castanospermine\nDetails: Castanospermine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Castanospermine"}, {"id": "Abciximab_INT_Resveratrol", "text": "Interaction: Abciximab AND Resveratrol\nDetails: Resveratrol may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Resveratrol"}, {"id": "Abciximab_INT_Oxyphenbutazone", "text": "Interaction: Abciximab AND Oxyphenbutazone\nDetails: Oxyphenbutazone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Oxyphenbutazone"}, {"id": "Abciximab_INT_Niflumic Acid", "text": "Interaction: Abciximab AND Niflumic Acid\nDetails: Niflumic Acid may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Niflumic Acid"}, {"id": "Abciximab_INT_Nimesulide", "text": "Interaction: Abciximab AND Nimesulide\nDetails: Nimesulide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Nimesulide"}, {"id": "Abciximab_INT_Benoxaprofen", "text": "Interaction: Abciximab AND Benoxaprofen\nDetails: Benoxaprofen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Benoxaprofen"}, {"id": "Abciximab_INT_Metamizole", "text": "Interaction: Abciximab AND Metamizole\nDetails: Metamizole may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Metamizole"}, {"id": "Abciximab_INT_Zomepirac", "text": "Interaction: Abciximab AND Zomepirac\nDetails: Zomepirac may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Zomepirac"}, {"id": "Abciximab_INT_Pirfenidone", "text": "Interaction: Abciximab AND Pirfenidone\nDetails: Pirfenidone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Pirfenidone"}, {"id": "Abciximab_INT_SRT501", "text": "Interaction: Abciximab AND SRT501\nDetails: SRT501 may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + SRT501"}, {"id": "Abciximab_INT_PTC299", "text": "Interaction: Abciximab AND PTC299\nDetails: PTC299 may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + PTC299"}, {"id": "Abciximab_INT_Tarenflurbil", "text": "Interaction: Abciximab AND Tarenflurbil\nDetails: Tarenflurbil may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tarenflurbil"}, {"id": "Abciximab_INT_Apremilast", "text": "Interaction: Abciximab AND Apremilast\nDetails: Apremilast may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Apremilast"}, {"id": "Abciximab_INT_Andrographolide", "text": "Interaction: Abciximab AND Andrographolide\nDetails: Andrographolide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Andrographolide"}, {"id": "Abciximab_INT_Icatibant", "text": "Interaction: Abciximab AND Icatibant\nDetails: Icatibant may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Icatibant"}, {"id": "Abciximab_INT_exisulind", "text": "Interaction: Abciximab AND exisulind\nDetails: exisulind may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + exisulind"}, {"id": "Abciximab_INT_Lornoxicam", "text": "Interaction: Abciximab AND Lornoxicam\nDetails: Lornoxicam may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Lornoxicam"}, {"id": "Abciximab_INT_Aceclofenac", "text": "Interaction: Abciximab AND Aceclofenac\nDetails: Aceclofenac may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Aceclofenac"}, {"id": "Abciximab_INT_Zaltoprofen", "text": "Interaction: Abciximab AND Zaltoprofen\nDetails: Zaltoprofen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Zaltoprofen"}, {"id": "Abciximab_INT_Seratrodast", "text": "Interaction: Abciximab AND Seratrodast\nDetails: Seratrodast may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Seratrodast"}, {"id": "Abciximab_INT_Azapropazone", "text": "Interaction: Abciximab AND Azapropazone\nDetails: Azapropazone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Azapropazone"}, {"id": "Abciximab_INT_Felbinac", "text": "Interaction: Abciximab AND Felbinac\nDetails: Felbinac may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Felbinac"}, {"id": "Abciximab_INT_Tranilast", "text": "Interaction: Abciximab AND Tranilast\nDetails: Tranilast may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tranilast"}, {"id": "Abciximab_INT_Ferulic acid", "text": "Interaction: Abciximab AND Ferulic acid\nDetails: Ferulic acid may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ferulic acid"}, {"id": "Abciximab_INT_Parecoxib", "text": "Interaction: Abciximab AND Parecoxib\nDetails: Parecoxib may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Parecoxib"}, {"id": "Abciximab_INT_Salicylamide", "text": "Interaction: Abciximab AND Salicylamide\nDetails: Salicylamide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Salicylamide"}, {"id": "Abciximab_INT_Teriflunomide", "text": "Interaction: Abciximab AND Teriflunomide\nDetails: Teriflunomide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Teriflunomide"}, {"id": "Abciximab_INT_D-Limonene", "text": "Interaction: Abciximab AND D-Limonene\nDetails: D-Limonene may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + D-Limonene"}, {"id": "Abciximab_INT_Kebuzone", "text": "Interaction: Abciximab AND Kebuzone\nDetails: Kebuzone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Kebuzone"}, {"id": "Abciximab_INT_Isoxicam", "text": "Interaction: Abciximab AND Isoxicam\nDetails: Isoxicam may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Isoxicam"}, {"id": "Abciximab_INT_Indoprofen", "text": "Interaction: Abciximab AND Indoprofen\nDetails: Indoprofen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Indoprofen"}, {"id": "Abciximab_INT_Ibuproxam", "text": "Interaction: Abciximab AND Ibuproxam\nDetails: Ibuproxam may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ibuproxam"}, {"id": "Abciximab_INT_Floctafenine", "text": "Interaction: Abciximab AND Floctafenine\nDetails: Floctafenine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Floctafenine"}, {"id": "Abciximab_INT_Fenbufen", "text": "Interaction: Abciximab AND Fenbufen\nDetails: Fenbufen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Fenbufen"}, {"id": "Abciximab_INT_Etofenamate", "text": "Interaction: Abciximab AND Etofenamate\nDetails: Etofenamate may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Etofenamate"}, {"id": "Abciximab_INT_Epirizole", "text": "Interaction: Abciximab AND Epirizole\nDetails: Epirizole may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Epirizole"}, {"id": "Abciximab_INT_Loxoprofen", "text": "Interaction: Abciximab AND Loxoprofen\nDetails: Loxoprofen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Loxoprofen"}, {"id": "Abciximab_INT_Droxicam", "text": "Interaction: Abciximab AND Droxicam\nDetails: Droxicam may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Droxicam"}, {"id": "Abciximab_INT_Tolfenamic Acid", "text": "Interaction: Abciximab AND Tolfenamic Acid\nDetails: Tolfenamic Acid may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tolfenamic Acid"}, {"id": "Abciximab_INT_Clonixin", "text": "Interaction: Abciximab AND Clonixin\nDetails: Clonixin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Clonixin"}, {"id": "Abciximab_INT_Propacetamol", "text": "Interaction: Abciximab AND Propacetamol\nDetails: Propacetamol may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Propacetamol"}, {"id": "Abciximab_INT_Evening primrose oil", "text": "Interaction: Abciximab AND Evening primrose oil\nDetails: Evening primrose oil may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Evening primrose oil"}, {"id": "Abciximab_INT_Orgotein", "text": "Interaction: Abciximab AND Orgotein\nDetails: Orgotein may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Orgotein"}, {"id": "Abciximab_INT_Tepoxalin", "text": "Interaction: Abciximab AND Tepoxalin\nDetails: Tepoxalin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tepoxalin"}, {"id": "Abciximab_INT_Flunixin", "text": "Interaction: Abciximab AND Flunixin\nDetails: Flunixin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Flunixin"}, {"id": "Abciximab_INT_Curcumin", "text": "Interaction: Abciximab AND Curcumin\nDetails: Curcumin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Curcumin"}, {"id": "Abciximab_INT_E-6201", "text": "Interaction: Abciximab AND E-6201\nDetails: E-6201 may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + E-6201"}, {"id": "Abciximab_INT_Anisodamine", "text": "Interaction: Abciximab AND Anisodamine\nDetails: Anisodamine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Anisodamine"}, {"id": "Abciximab_INT_Duvelisib", "text": "Interaction: Abciximab AND Duvelisib\nDetails: Duvelisib may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Duvelisib"}, {"id": "Abciximab_INT_Triptolide", "text": "Interaction: Abciximab AND Triptolide\nDetails: Triptolide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Triptolide"}, {"id": "Abciximab_INT_Semapimod", "text": "Interaction: Abciximab AND Semapimod\nDetails: Semapimod may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Semapimod"}, {"id": "Abciximab_INT_Bucillamine", "text": "Interaction: Abciximab AND Bucillamine\nDetails: Bucillamine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Bucillamine"}, {"id": "Abciximab_INT_Lisofylline", "text": "Interaction: Abciximab AND Lisofylline\nDetails: Lisofylline may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Lisofylline"}, {"id": "Abciximab_INT_Nafamostat", "text": "Interaction: Abciximab AND Nafamostat\nDetails: Nafamostat may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Nafamostat"}, {"id": "Abciximab_INT_Mizoribine", "text": "Interaction: Abciximab AND Mizoribine\nDetails: Mizoribine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Mizoribine"}, {"id": "Abciximab_INT_Apocynin", "text": "Interaction: Abciximab AND Apocynin\nDetails: Apocynin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Apocynin"}, {"id": "Abciximab_INT_Higenamine", "text": "Interaction: Abciximab AND Higenamine\nDetails: Higenamine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Higenamine"}, {"id": "Abciximab_INT_Tinoridine", "text": "Interaction: Abciximab AND Tinoridine\nDetails: Tinoridine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tinoridine"}, {"id": "Abciximab_INT_Parthenolide", "text": "Interaction: Abciximab AND Parthenolide\nDetails: Parthenolide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Parthenolide"}, {"id": "Abciximab_INT_Serrapeptase", "text": "Interaction: Abciximab AND Serrapeptase\nDetails: Serrapeptase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Serrapeptase"}, {"id": "Abciximab_INT_Alclofenac", "text": "Interaction: Abciximab AND Alclofenac\nDetails: Alclofenac may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Alclofenac"}, {"id": "Abciximab_INT_Fentiazac", "text": "Interaction: Abciximab AND Fentiazac\nDetails: Fentiazac may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Fentiazac"}, {"id": "Abciximab_INT_Tribenoside", "text": "Interaction: Abciximab AND Tribenoside\nDetails: Tribenoside may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tribenoside"}, {"id": "Abciximab_INT_Suxibuzone", "text": "Interaction: Abciximab AND Suxibuzone\nDetails: Suxibuzone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Suxibuzone"}, {"id": "Abciximab_INT_Bumadizone", "text": "Interaction: Abciximab AND Bumadizone\nDetails: Bumadizone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Bumadizone"}, {"id": "Abciximab_INT_Alminoprofen", "text": "Interaction: Abciximab AND Alminoprofen\nDetails: Alminoprofen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Alminoprofen"}, {"id": "Abciximab_INT_Flunoxaprofen", "text": "Interaction: Abciximab AND Flunoxaprofen\nDetails: Flunoxaprofen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Flunoxaprofen"}, {"id": "Abciximab_INT_Bufexamac", "text": "Interaction: Abciximab AND Bufexamac\nDetails: Bufexamac may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Bufexamac"}, {"id": "Abciximab_INT_Feprazone", "text": "Interaction: Abciximab AND Feprazone\nDetails: Feprazone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Feprazone"}, {"id": "Abciximab_INT_Difenpiramide", "text": "Interaction: Abciximab AND Difenpiramide\nDetails: Difenpiramide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Difenpiramide"}, {"id": "Abciximab_INT_Nifenazone", "text": "Interaction: Abciximab AND Nifenazone\nDetails: Nifenazone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Nifenazone"}, {"id": "Abciximab_INT_Lonazolac", "text": "Interaction: Abciximab AND Lonazolac\nDetails: Lonazolac may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Lonazolac"}, {"id": "Abciximab_INT_Tenidap", "text": "Interaction: Abciximab AND Tenidap\nDetails: Tenidap may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tenidap"}, {"id": "Abciximab_INT_Bendazac", "text": "Interaction: Abciximab AND Bendazac\nDetails: Bendazac may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Bendazac"}, {"id": "Abciximab_INT_Pranoprofen", "text": "Interaction: Abciximab AND Pranoprofen\nDetails: Pranoprofen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Pranoprofen"}, {"id": "Abciximab_INT_Propyphenazone", "text": "Interaction: Abciximab AND Propyphenazone\nDetails: Propyphenazone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Propyphenazone"}, {"id": "Abciximab_INT_Proglumetacin", "text": "Interaction: Abciximab AND Proglumetacin\nDetails: Proglumetacin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Proglumetacin"}, {"id": "Abciximab_INT_Bevonium", "text": "Interaction: Abciximab AND Bevonium\nDetails: Bevonium may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Bevonium"}, {"id": "Abciximab_INT_Ethenzamide", "text": "Interaction: Abciximab AND Ethenzamide\nDetails: Ethenzamide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ethenzamide"}, {"id": "Abciximab_INT_Mofebutazone", "text": "Interaction: Abciximab AND Mofebutazone\nDetails: Mofebutazone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Mofebutazone"}, {"id": "Abciximab_INT_Proquazone", "text": "Interaction: Abciximab AND Proquazone\nDetails: Proquazone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Proquazone"}, {"id": "Abciximab_INT_Benorilate", "text": "Interaction: Abciximab AND Benorilate\nDetails: Benorilate may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Benorilate"}, {"id": "Abciximab_INT_Pirprofen", "text": "Interaction: Abciximab AND Pirprofen\nDetails: Pirprofen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Pirprofen"}, {"id": "Abciximab_INT_Imidazole salicylate", "text": "Interaction: Abciximab AND Imidazole salicylate\nDetails: Imidazole salicylate may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Imidazole salicylate"}, {"id": "Abciximab_INT_Benzydamine", "text": "Interaction: Abciximab AND Benzydamine\nDetails: Benzydamine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Benzydamine"}, {"id": "Abciximab_INT_Tipranavir", "text": "Interaction: Abciximab AND Tipranavir\nDetails: Tipranavir may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tipranavir"}, {"id": "Abciximab_INT_Omega-3 fatty acids", "text": "Interaction: Abciximab AND Omega-3 fatty acids\nDetails: Omega-3 fatty acids may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Omega-3 fatty acids"}, {"id": "Abciximab_INT_Vitamin E", "text": "Interaction: Abciximab AND Vitamin E\nDetails: Vitamin E may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Vitamin E"}, {"id": "Abciximab_INT_Tositumomab", "text": "Interaction: Abciximab AND Tositumomab\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Abciximab + Tositumomab"}, {"id": "Abciximab_INT_Lepirudin", "text": "Interaction: Abciximab AND Lepirudin\nDetails: Lepirudin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Lepirudin"}, {"id": "Abciximab_INT_Bivalirudin", "text": "Interaction: Abciximab AND Bivalirudin\nDetails: Bivalirudin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Bivalirudin"}, {"id": "Abciximab_INT_Becaplermin", "text": "Interaction: Abciximab AND Becaplermin\nDetails: Abciximab may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Abciximab + Becaplermin"}, {"id": "Abciximab_INT_Dicoumarol", "text": "Interaction: Abciximab AND Dicoumarol\nDetails: Abciximab may increase the anticoagulant activities of Dicoumarol.\nRisk: Monitor closely.", "source": "Abciximab + Dicoumarol"}, {"id": "Abciximab_INT_Argatroban", "text": "Interaction: Abciximab AND Argatroban\nDetails: Abciximab may increase the anticoagulant activities of Argatroban.\nRisk: Monitor closely.", "source": "Abciximab + Argatroban"}, {"id": "Abciximab_INT_Ardeparin", "text": "Interaction: Abciximab AND Ardeparin\nDetails: Abciximab may increase the anticoagulant activities of Ardeparin.\nRisk: Monitor closely.", "source": "Abciximab + Ardeparin"}, {"id": "Abciximab_INT_Phenindione", "text": "Interaction: Abciximab AND Phenindione\nDetails: Abciximab may increase the anticoagulant activities of Phenindione.\nRisk: Monitor closely.", "source": "Abciximab + Phenindione"}, {"id": "Abciximab_INT_Fondaparinux sodium", "text": "Interaction: Abciximab AND Fondaparinux sodium\nDetails: Abciximab may increase the anticoagulant activities of Fondaparinux sodium.\nRisk: Monitor closely.", "source": "Abciximab + Fondaparinux sodium"}, {"id": "Abciximab_INT_Warfarin", "text": "Interaction: Abciximab AND Warfarin\nDetails: Abciximab may increase the anticoagulant activities of Warfarin.\nRisk: Monitor closely.", "source": "Abciximab + Warfarin"}, {"id": "Abciximab_INT_Phenprocoumon", "text": "Interaction: Abciximab AND Phenprocoumon\nDetails: Abciximab may increase the anticoagulant activities of Phenprocoumon.\nRisk: Monitor closely.", "source": "Abciximab + Phenprocoumon"}, {"id": "Abciximab_INT_Edetic Acid", "text": "Interaction: Abciximab AND Edetic Acid\nDetails: Abciximab may increase the anticoagulant activities of Edetic Acid.\nRisk: Monitor closely.", "source": "Abciximab + Edetic Acid"}, {"id": "Abciximab_INT_Heparin", "text": "Interaction: Abciximab AND Heparin\nDetails: Abciximab may increase the anticoagulant activities of Heparin.\nRisk: Monitor closely.", "source": "Abciximab + Heparin"}, {"id": "Abciximab_INT_Enoxaparin", "text": "Interaction: Abciximab AND Enoxaparin\nDetails: Abciximab may increase the anticoagulant activities of Enoxaparin.\nRisk: Monitor closely.", "source": "Abciximab + Enoxaparin"}, {"id": "Abciximab_INT_Acenocoumarol", "text": "Interaction: Abciximab AND Acenocoumarol\nDetails: Abciximab may increase the anticoagulant activities of Acenocoumarol.\nRisk: Monitor closely.", "source": "Abciximab + Acenocoumarol"}, {"id": "Abciximab_INT_Citric Acid", "text": "Interaction: Abciximab AND Citric Acid\nDetails: Abciximab may increase the anticoagulant activities of Citric Acid.\nRisk: Monitor closely.", "source": "Abciximab + Citric Acid"}, {"id": "Abciximab_INT_Ximelagatran", "text": "Interaction: Abciximab AND Ximelagatran\nDetails: Abciximab may increase the anticoagulant activities of Ximelagatran.\nRisk: Monitor closely.", "source": "Abciximab + Ximelagatran"}, {"id": "Abciximab_INT_Ancrod", "text": "Interaction: Abciximab AND Ancrod\nDetails: Abciximab may increase the anticoagulant activities of Ancrod.\nRisk: Monitor closely.", "source": "Abciximab + Ancrod"}, {"id": "Abciximab_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Abciximab AND Pentaerythritol Tetranitrate\nDetails: Abciximab may increase the anticoagulant activities of Pentaerythritol Tetranitrate.\nRisk: Monitor closely.", "source": "Abciximab + Pentaerythritol Tetranitrate"}, {"id": "Abciximab_INT_Sulodexide", "text": "Interaction: Abciximab AND Sulodexide\nDetails: Abciximab may increase the anticoagulant activities of Sulodexide.\nRisk: Monitor closely.", "source": "Abciximab + Sulodexide"}, {"id": "Abciximab_INT_Idraparinux", "text": "Interaction: Abciximab AND Idraparinux\nDetails: Abciximab may increase the anticoagulant activities of Idraparinux.\nRisk: Monitor closely.", "source": "Abciximab + Idraparinux"}, {"id": "Abciximab_INT_Otamixaban", "text": "Interaction: Abciximab AND Otamixaban\nDetails: Abciximab may increase the anticoagulant activities of Otamixaban.\nRisk: Monitor closely.", "source": "Abciximab + Otamixaban"}, {"id": "Abciximab_INT_Danaparoid", "text": "Interaction: Abciximab AND Danaparoid\nDetails: Abciximab may increase the anticoagulant activities of Danaparoid.\nRisk: Monitor closely.", "source": "Abciximab + Danaparoid"}, {"id": "Abciximab_INT_Dalteparin", "text": "Interaction: Abciximab AND Dalteparin\nDetails: Abciximab may increase the anticoagulant activities of Dalteparin.\nRisk: Monitor closely.", "source": "Abciximab + Dalteparin"}, {"id": "Abciximab_INT_Ethyl biscoumacetate", "text": "Interaction: Abciximab AND Ethyl biscoumacetate\nDetails: Abciximab may increase the anticoagulant activities of Ethyl biscoumacetate.\nRisk: Monitor closely.", "source": "Abciximab + Ethyl biscoumacetate"}, {"id": "Abciximab_INT_Nadroparin", "text": "Interaction: Abciximab AND Nadroparin\nDetails: Abciximab may increase the anticoagulant activities of Nadroparin.\nRisk: Monitor closely.", "source": "Abciximab + Nadroparin"}, {"id": "Abciximab_INT_Reviparin", "text": "Interaction: Abciximab AND Reviparin\nDetails: Abciximab may increase the anticoagulant activities of Reviparin.\nRisk: Monitor closely.", "source": "Abciximab + Reviparin"}, {"id": "Abciximab_INT_Certoparin", "text": "Interaction: Abciximab AND Certoparin\nDetails: Abciximab may increase the anticoagulant activities of Certoparin.\nRisk: Monitor closely.", "source": "Abciximab + Certoparin"}, {"id": "Abciximab_INT_Dextran 70", "text": "Interaction: Abciximab AND Dextran 70\nDetails: Abciximab may increase the anticoagulant activities of Dextran 70.\nRisk: Monitor closely.", "source": "Abciximab + Dextran 70"}, {"id": "Abciximab_INT_Desirudin", "text": "Interaction: Abciximab AND Desirudin\nDetails: Abciximab may increase the anticoagulant activities of Desirudin.\nRisk: Monitor closely.", "source": "Abciximab + Desirudin"}, {"id": "Abciximab_INT_Dextran 40", "text": "Interaction: Abciximab AND Dextran 40\nDetails: Abciximab may increase the anticoagulant activities of Dextran 40.\nRisk: Monitor closely.", "source": "Abciximab + Dextran 40"}, {"id": "Abciximab_INT_Dextran 75", "text": "Interaction: Abciximab AND Dextran 75\nDetails: Abciximab may increase the anticoagulant activities of Dextran 75.\nRisk: Monitor closely.", "source": "Abciximab + Dextran 75"}, {"id": "Abciximab_INT_Protocatechualdehyde", "text": "Interaction: Abciximab AND Protocatechualdehyde\nDetails: Abciximab may increase the anticoagulant activities of Protocatechualdehyde.\nRisk: Monitor closely.", "source": "Abciximab + Protocatechualdehyde"}, {"id": "Abciximab_INT_Protein C", "text": "Interaction: Abciximab AND Protein C\nDetails: Abciximab may increase the anticoagulant activities of Protein C.\nRisk: Monitor closely.", "source": "Abciximab + Protein C"}, {"id": "Abciximab_INT_Antithrombin III human", "text": "Interaction: Abciximab AND Antithrombin III human\nDetails: Abciximab may increase the anticoagulant activities of Antithrombin III human.\nRisk: Monitor closely.", "source": "Abciximab + Antithrombin III human"}, {"id": "Abciximab_INT_Fondaparinux", "text": "Interaction: Abciximab AND Fondaparinux\nDetails: Abciximab may increase the anticoagulant activities of Fondaparinux.\nRisk: Monitor closely.", "source": "Abciximab + Fondaparinux"}, {"id": "Abciximab_INT_Letaxaban", "text": "Interaction: Abciximab AND Letaxaban\nDetails: Abciximab may increase the anticoagulant activities of Letaxaban.\nRisk: Monitor closely.", "source": "Abciximab + Letaxaban"}, {"id": "Abciximab_INT_Darexaban", "text": "Interaction: Abciximab AND Darexaban\nDetails: Abciximab may increase the anticoagulant activities of Darexaban.\nRisk: Monitor closely.", "source": "Abciximab + Darexaban"}, {"id": "Abciximab_INT_Gabexate", "text": "Interaction: Abciximab AND Gabexate\nDetails: Abciximab may increase the anticoagulant activities of Gabexate.\nRisk: Monitor closely.", "source": "Abciximab + Gabexate"}, {"id": "Abciximab_INT_Troxerutin", "text": "Interaction: Abciximab AND Troxerutin\nDetails: Abciximab may increase the anticoagulant activities of Troxerutin.\nRisk: Monitor closely.", "source": "Abciximab + Troxerutin"}, {"id": "Abciximab_INT_Fluindione", "text": "Interaction: Abciximab AND Fluindione\nDetails: Abciximab may increase the anticoagulant activities of Fluindione.\nRisk: Monitor closely.", "source": "Abciximab + Fluindione"}, {"id": "Abciximab_INT_Protein S human", "text": "Interaction: Abciximab AND Protein S human\nDetails: Abciximab may increase the anticoagulant activities of Protein S human.\nRisk: Monitor closely.", "source": "Abciximab + Protein S human"}, {"id": "Abciximab_INT_Melagatran", "text": "Interaction: Abciximab AND Melagatran\nDetails: Abciximab may increase the anticoagulant activities of Melagatran.\nRisk: Monitor closely.", "source": "Abciximab + Melagatran"}, {"id": "Abciximab_INT_Alteplase", "text": "Interaction: Abciximab AND Alteplase\nDetails: Alteplase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Alteplase"}, {"id": "Abciximab_INT_Reteplase", "text": "Interaction: Abciximab AND Reteplase\nDetails: Reteplase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Reteplase"}, {"id": "Abciximab_INT_Anistreplase", "text": "Interaction: Abciximab AND Anistreplase\nDetails: Anistreplase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Anistreplase"}, {"id": "Abciximab_INT_Tenecteplase", "text": "Interaction: Abciximab AND Tenecteplase\nDetails: Tenecteplase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tenecteplase"}, {"id": "Abciximab_INT_Drotrecogin alfa", "text": "Interaction: Abciximab AND Drotrecogin alfa\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Drotrecogin alfa"}, {"id": "Abciximab_INT_Ticlopidine", "text": "Interaction: Abciximab AND Ticlopidine\nDetails: Ticlopidine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ticlopidine"}, {"id": "Abciximab_INT_Tirofiban", "text": "Interaction: Abciximab AND Tirofiban\nDetails: Tirofiban may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tirofiban"}, {"id": "Abciximab_INT_Cilostazol", "text": "Interaction: Abciximab AND Cilostazol\nDetails: Cilostazol may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Cilostazol"}, {"id": "Abciximab_INT_Defibrotide", "text": "Interaction: Abciximab AND Defibrotide\nDetails: Defibrotide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Defibrotide"}, {"id": "Abciximab_INT_Tinzaparin", "text": "Interaction: Abciximab AND Tinzaparin\nDetails: Tinzaparin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tinzaparin"}, {"id": "Abciximab_INT_Brinase", "text": "Interaction: Abciximab AND Brinase\nDetails: Brinase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Brinase"}, {"id": "Abciximab_INT_Saruplase", "text": "Interaction: Abciximab AND Saruplase\nDetails: Saruplase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Saruplase"}, {"id": "Abciximab_INT_Streptokinase", "text": "Interaction: Abciximab AND Streptokinase\nDetails: Streptokinase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Streptokinase"}, {"id": "Abciximab_INT_Anagrelide", "text": "Interaction: Abciximab AND Anagrelide\nDetails: Anagrelide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Anagrelide"}, {"id": "Abciximab_INT_Rosiglitazone", "text": "Interaction: Abciximab AND Rosiglitazone\nDetails: Rosiglitazone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Rosiglitazone"}, {"id": "Abciximab_INT_Desmoteplase", "text": "Interaction: Abciximab AND Desmoteplase\nDetails: Desmoteplase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Desmoteplase"}, {"id": "Abciximab_INT_Fibrinolysin", "text": "Interaction: Abciximab AND Fibrinolysin\nDetails: Fibrinolysin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Fibrinolysin"}, {"id": "Abciximab_INT_ALX-0081", "text": "Interaction: Abciximab AND ALX-0081\nDetails: ALX-0081 may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + ALX-0081"}, {"id": "Abciximab_INT_eplivanserine", "text": "Interaction: Abciximab AND eplivanserine\nDetails: eplivanserine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + eplivanserine"}, {"id": "Abciximab_INT_Astaxanthin", "text": "Interaction: Abciximab AND Astaxanthin\nDetails: Astaxanthin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Astaxanthin"}, {"id": "Abciximab_INT_Batroxobin", "text": "Interaction: Abciximab AND Batroxobin\nDetails: Batroxobin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Batroxobin"}, {"id": "Abciximab_INT_Ozagrel", "text": "Interaction: Abciximab AND Ozagrel\nDetails: Ozagrel may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ozagrel"}, {"id": "Abciximab_INT_Sarpogrelate", "text": "Interaction: Abciximab AND Sarpogrelate\nDetails: Sarpogrelate may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Sarpogrelate"}, {"id": "Abciximab_INT_Eplivanserin", "text": "Interaction: Abciximab AND Eplivanserin\nDetails: Eplivanserin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Eplivanserin"}, {"id": "Abciximab_INT_Eptifibatide", "text": "Interaction: Abciximab AND Eptifibatide\nDetails: Eptifibatide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Eptifibatide"}, {"id": "Abciximab_INT_Clopidogrel", "text": "Interaction: Abciximab AND Clopidogrel\nDetails: Clopidogrel may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Clopidogrel"}, {"id": "Abciximab_INT_Dipyridamole", "text": "Interaction: Abciximab AND Dipyridamole\nDetails: Dipyridamole may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Dipyridamole"}, {"id": "Abciximab_INT_Beraprost", "text": "Interaction: Abciximab AND Beraprost\nDetails: Beraprost may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Beraprost"}, {"id": "Abciximab_INT_Prasugrel", "text": "Interaction: Abciximab AND Prasugrel\nDetails: Prasugrel may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Prasugrel"}, {"id": "Abciximab_INT_Cangrelor", "text": "Interaction: Abciximab AND Cangrelor\nDetails: Cangrelor may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Cangrelor"}, {"id": "Abciximab_INT_Triflusal", "text": "Interaction: Abciximab AND Triflusal\nDetails: Triflusal may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Triflusal"}, {"id": "Abciximab_INT_Ticagrelor", "text": "Interaction: Abciximab AND Ticagrelor\nDetails: Ticagrelor may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ticagrelor"}, {"id": "Abciximab_INT_Ditazole", "text": "Interaction: Abciximab AND Ditazole\nDetails: Ditazole may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ditazole"}, {"id": "Abciximab_INT_Bemiparin", "text": "Interaction: Abciximab AND Bemiparin\nDetails: Bemiparin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Bemiparin"}, {"id": "Abciximab_INT_Parnaparin", "text": "Interaction: Abciximab AND Parnaparin\nDetails: Parnaparin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Parnaparin"}, {"id": "Abciximab_INT_Selexipag", "text": "Interaction: Abciximab AND Selexipag\nDetails: Selexipag may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Selexipag"}, {"id": "Abciximab_INT_Indobufen", "text": "Interaction: Abciximab AND Indobufen\nDetails: Indobufen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Indobufen"}, {"id": "Abciximab_INT_Clorindione", "text": "Interaction: Abciximab AND Clorindione\nDetails: Clorindione may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Clorindione"}, {"id": "Abciximab_INT_Picotamide", "text": "Interaction: Abciximab AND Picotamide\nDetails: Picotamide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Picotamide"}, {"id": "Abciximab_INT_Diphenadione", "text": "Interaction: Abciximab AND Diphenadione\nDetails: Diphenadione may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Diphenadione"}, {"id": "Abciximab_INT_Cloricromen", "text": "Interaction: Abciximab AND Cloricromen\nDetails: Cloricromen may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Cloricromen"}, {"id": "Abciximab_INT_Tioclomarol", "text": "Interaction: Abciximab AND Tioclomarol\nDetails: Tioclomarol may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tioclomarol"}, {"id": "Abciximab_INT_Milrinone", "text": "Interaction: Abciximab AND Milrinone\nDetails: Milrinone may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Milrinone"}, {"id": "Abciximab_INT_Epinastine", "text": "Interaction: Abciximab AND Epinastine\nDetails: Epinastine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Epinastine"}, {"id": "Abciximab_INT_Alprostadil", "text": "Interaction: Abciximab AND Alprostadil\nDetails: Alprostadil may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Alprostadil"}, {"id": "Abciximab_INT_Ridogrel", "text": "Interaction: Abciximab AND Ridogrel\nDetails: Ridogrel may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ridogrel"}, {"id": "Abciximab_INT_Sevoflurane", "text": "Interaction: Abciximab AND Sevoflurane\nDetails: Sevoflurane may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Sevoflurane"}, {"id": "Abciximab_INT_Tesmilifene", "text": "Interaction: Abciximab AND Tesmilifene\nDetails: Tesmilifene may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Tesmilifene"}, {"id": "Abciximab_INT_Ibudilast", "text": "Interaction: Abciximab AND Ibudilast\nDetails: Ibudilast may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ibudilast"}, {"id": "Abciximab_INT_Icosapent ethyl", "text": "Interaction: Abciximab AND Icosapent ethyl\nDetails: Icosapent ethyl may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Icosapent ethyl"}, {"id": "Abciximab_INT_Ifenprodil", "text": "Interaction: Abciximab AND Ifenprodil\nDetails: Ifenprodil may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ifenprodil"}, {"id": "Abciximab_INT_Trapidil", "text": "Interaction: Abciximab AND Trapidil\nDetails: Trapidil may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Trapidil"}, {"id": "Abciximab_INT_Naftopidil", "text": "Interaction: Abciximab AND Naftopidil\nDetails: Naftopidil may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Naftopidil"}, {"id": "Abciximab_INT_Ifetroban", "text": "Interaction: Abciximab AND Ifetroban\nDetails: Ifetroban may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ifetroban"}, {"id": "Abciximab_INT_Ketanserin", "text": "Interaction: Abciximab AND Ketanserin\nDetails: Ketanserin may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ketanserin"}, {"id": "Abciximab_INT_Butylphthalide", "text": "Interaction: Abciximab AND Butylphthalide\nDetails: Butylphthalide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Butylphthalide"}, {"id": "Abciximab_INT_Hydroxytyrosol", "text": "Interaction: Abciximab AND Hydroxytyrosol\nDetails: Hydroxytyrosol may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Hydroxytyrosol"}, {"id": "Abciximab_INT_Ramatroban", "text": "Interaction: Abciximab AND Ramatroban\nDetails: Ramatroban may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Ramatroban"}, {"id": "Abciximab_INT_Linsidomine", "text": "Interaction: Abciximab AND Linsidomine\nDetails: Linsidomine may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Linsidomine"}, {"id": "Abciximab_INT_Buflomedil", "text": "Interaction: Abciximab AND Buflomedil\nDetails: Buflomedil may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Buflomedil"}, {"id": "Abciximab_INT_Relcovaptan", "text": "Interaction: Abciximab AND Relcovaptan\nDetails: Relcovaptan may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Relcovaptan"}, {"id": "Abciximab_INT_Glucosamine", "text": "Interaction: Abciximab AND Glucosamine\nDetails: Glucosamine may increase the antiplatelet activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Glucosamine"}, {"id": "Abciximab_INT_Pentoxifylline", "text": "Interaction: Abciximab AND Pentoxifylline\nDetails: Pentoxifylline may increase the antiplatelet activities of Abciximab.\nRisk: Monitor closely.", "source": "Abciximab + Pentoxifylline"}, {"id": "Drotrecogin alfa_GEN", "text": "Drug: Drotrecogin alfa\nDescription: Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a majo...", "source": "Drotrecogin alfa"}, {"id": "Drotrecogin alfa_CLIN", "text": "Drug: Drotrecogin alfa\nMechanism: Activated protein C combines with protein S on platelet surfaces and then degrades factor Va and factor VIIIa, thereby reducing blood coagulability....\nToxicity: ...", "source": "Drotrecogin alfa"}, {"id": "Drotrecogin alfa_INT_Aprotinin", "text": "Interaction: Drotrecogin alfa AND Aprotinin\nDetails: The therapeutic efficacy of Drotrecogin alfa can be decreased when used in combination with Aprotinin.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Aprotinin"}, {"id": "Drotrecogin alfa_INT_Limaprost", "text": "Interaction: Drotrecogin alfa AND Limaprost\nDetails: The risk or severity of adverse effects can be increased when Limaprost is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Limaprost"}, {"id": "Drotrecogin alfa_INT_Dabigatran etexilate", "text": "Interaction: Drotrecogin alfa AND Dabigatran etexilate\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Dabigatran etexilate.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Dabigatran etexilate"}, {"id": "Drotrecogin alfa_INT_Lepirudin", "text": "Interaction: Drotrecogin alfa AND Lepirudin\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Lepirudin"}, {"id": "Drotrecogin alfa_INT_Bivalirudin", "text": "Interaction: Drotrecogin alfa AND Bivalirudin\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Bivalirudin"}, {"id": "Drotrecogin alfa_INT_Abciximab", "text": "Interaction: Drotrecogin alfa AND Abciximab\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Abciximab"}, {"id": "Drotrecogin alfa_INT_Becaplermin", "text": "Interaction: Drotrecogin alfa AND Becaplermin\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Becaplermin"}, {"id": "Drotrecogin alfa_INT_Dicoumarol", "text": "Interaction: Drotrecogin alfa AND Dicoumarol\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Dicoumarol.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Dicoumarol"}, {"id": "Drotrecogin alfa_INT_Argatroban", "text": "Interaction: Drotrecogin alfa AND Argatroban\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Argatroban.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Argatroban"}, {"id": "Drotrecogin alfa_INT_Ardeparin", "text": "Interaction: Drotrecogin alfa AND Ardeparin\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Ardeparin.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Ardeparin"}, {"id": "Drotrecogin alfa_INT_Phenindione", "text": "Interaction: Drotrecogin alfa AND Phenindione\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Phenindione.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Phenindione"}, {"id": "Drotrecogin alfa_INT_Fondaparinux sodium", "text": "Interaction: Drotrecogin alfa AND Fondaparinux sodium\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Fondaparinux sodium.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Fondaparinux sodium"}, {"id": "Drotrecogin alfa_INT_Warfarin", "text": "Interaction: Drotrecogin alfa AND Warfarin\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Warfarin.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Warfarin"}, {"id": "Drotrecogin alfa_INT_Pentosan Polysulfate", "text": "Interaction: Drotrecogin alfa AND Pentosan Polysulfate\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Pentosan Polysulfate.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Pentosan Polysulfate"}, {"id": "Drotrecogin alfa_INT_Phenprocoumon", "text": "Interaction: Drotrecogin alfa AND Phenprocoumon\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Phenprocoumon.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Phenprocoumon"}, {"id": "Drotrecogin alfa_INT_Edetic Acid", "text": "Interaction: Drotrecogin alfa AND Edetic Acid\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Edetic Acid.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Edetic Acid"}, {"id": "Drotrecogin alfa_INT_Heparin", "text": "Interaction: Drotrecogin alfa AND Heparin\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Heparin.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Heparin"}, {"id": "Drotrecogin alfa_INT_Enoxaparin", "text": "Interaction: Drotrecogin alfa AND Enoxaparin\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Enoxaparin.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Enoxaparin"}, {"id": "Drotrecogin alfa_INT_Acenocoumarol", "text": "Interaction: Drotrecogin alfa AND Acenocoumarol\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Acenocoumarol.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Acenocoumarol"}, {"id": "Drotrecogin alfa_INT_Citric Acid", "text": "Interaction: Drotrecogin alfa AND Citric Acid\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Citric Acid.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Citric Acid"}, {"id": "Drotrecogin alfa_INT_Ximelagatran", "text": "Interaction: Drotrecogin alfa AND Ximelagatran\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Ximelagatran.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Ximelagatran"}, {"id": "Drotrecogin alfa_INT_Ancrod", "text": "Interaction: Drotrecogin alfa AND Ancrod\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Ancrod.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Ancrod"}, {"id": "Drotrecogin alfa_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Drotrecogin alfa AND Pentaerythritol Tetranitrate\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Pentaerythritol Tetranitrate.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Pentaerythritol Tetranitrate"}, {"id": "Drotrecogin alfa_INT_Rivaroxaban", "text": "Interaction: Drotrecogin alfa AND Rivaroxaban\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Rivaroxaban.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Rivaroxaban"}, {"id": "Drotrecogin alfa_INT_Sulodexide", "text": "Interaction: Drotrecogin alfa AND Sulodexide\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Sulodexide.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Sulodexide"}, {"id": "Drotrecogin alfa_INT_Idraparinux", "text": "Interaction: Drotrecogin alfa AND Idraparinux\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Idraparinux.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Idraparinux"}, {"id": "Drotrecogin alfa_INT_Apixaban", "text": "Interaction: Drotrecogin alfa AND Apixaban\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Apixaban.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Apixaban"}, {"id": "Drotrecogin alfa_INT_Otamixaban", "text": "Interaction: Drotrecogin alfa AND Otamixaban\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Otamixaban.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Otamixaban"}, {"id": "Drotrecogin alfa_INT_Danaparoid", "text": "Interaction: Drotrecogin alfa AND Danaparoid\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Danaparoid.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Danaparoid"}, {"id": "Drotrecogin alfa_INT_Dalteparin", "text": "Interaction: Drotrecogin alfa AND Dalteparin\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Dalteparin.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Dalteparin"}, {"id": "Drotrecogin alfa_INT_Ferulic acid", "text": "Interaction: Drotrecogin alfa AND Ferulic acid\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Ferulic acid.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Ferulic acid"}, {"id": "Drotrecogin alfa_INT_Ethyl biscoumacetate", "text": "Interaction: Drotrecogin alfa AND Ethyl biscoumacetate\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Ethyl biscoumacetate.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Ethyl biscoumacetate"}, {"id": "Drotrecogin alfa_INT_Nadroparin", "text": "Interaction: Drotrecogin alfa AND Nadroparin\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Nadroparin.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Nadroparin"}, {"id": "Drotrecogin alfa_INT_Edoxaban", "text": "Interaction: Drotrecogin alfa AND Edoxaban\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Edoxaban.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Edoxaban"}, {"id": "Drotrecogin alfa_INT_Dextran", "text": "Interaction: Drotrecogin alfa AND Dextran\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Dextran.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Dextran"}, {"id": "Drotrecogin alfa_INT_Reviparin", "text": "Interaction: Drotrecogin alfa AND Reviparin\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Reviparin.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Reviparin"}, {"id": "Drotrecogin alfa_INT_Certoparin", "text": "Interaction: Drotrecogin alfa AND Certoparin\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Certoparin.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Certoparin"}, {"id": "Drotrecogin alfa_INT_Dextran 70", "text": "Interaction: Drotrecogin alfa AND Dextran 70\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Dextran 70.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Dextran 70"}, {"id": "Drotrecogin alfa_INT_Desirudin", "text": "Interaction: Drotrecogin alfa AND Desirudin\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Desirudin.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Desirudin"}, {"id": "Drotrecogin alfa_INT_Dextran 40", "text": "Interaction: Drotrecogin alfa AND Dextran 40\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Dextran 40.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Dextran 40"}, {"id": "Drotrecogin alfa_INT_Dextran 75", "text": "Interaction: Drotrecogin alfa AND Dextran 75\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Dextran 75.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Dextran 75"}, {"id": "Drotrecogin alfa_INT_Protocatechualdehyde", "text": "Interaction: Drotrecogin alfa AND Protocatechualdehyde\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Protocatechualdehyde.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Protocatechualdehyde"}, {"id": "Drotrecogin alfa_INT_Protein C", "text": "Interaction: Drotrecogin alfa AND Protein C\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Protein C.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Protein C"}, {"id": "Drotrecogin alfa_INT_Antithrombin III human", "text": "Interaction: Drotrecogin alfa AND Antithrombin III human\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Antithrombin III human.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Antithrombin III human"}, {"id": "Drotrecogin alfa_INT_Fondaparinux", "text": "Interaction: Drotrecogin alfa AND Fondaparinux\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Fondaparinux.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Fondaparinux"}, {"id": "Drotrecogin alfa_INT_Letaxaban", "text": "Interaction: Drotrecogin alfa AND Letaxaban\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Letaxaban.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Letaxaban"}, {"id": "Drotrecogin alfa_INT_Darexaban", "text": "Interaction: Drotrecogin alfa AND Darexaban\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Darexaban.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Darexaban"}, {"id": "Drotrecogin alfa_INT_Nafamostat", "text": "Interaction: Drotrecogin alfa AND Nafamostat\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Nafamostat.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Nafamostat"}, {"id": "Drotrecogin alfa_INT_Gabexate", "text": "Interaction: Drotrecogin alfa AND Gabexate\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Gabexate.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Gabexate"}, {"id": "Drotrecogin alfa_INT_Troxerutin", "text": "Interaction: Drotrecogin alfa AND Troxerutin\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Troxerutin.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Troxerutin"}, {"id": "Drotrecogin alfa_INT_Fluindione", "text": "Interaction: Drotrecogin alfa AND Fluindione\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Fluindione.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Fluindione"}, {"id": "Drotrecogin alfa_INT_Protein S human", "text": "Interaction: Drotrecogin alfa AND Protein S human\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Protein S human.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Protein S human"}, {"id": "Drotrecogin alfa_INT_Melagatran", "text": "Interaction: Drotrecogin alfa AND Melagatran\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Melagatran.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Melagatran"}, {"id": "Drotrecogin alfa_INT_Salicylic acid", "text": "Interaction: Drotrecogin alfa AND Salicylic acid\nDetails: The risk or severity of adverse effects can be increased when Salicylic acid is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Salicylic acid"}, {"id": "Drotrecogin alfa_INT_Acetylsalicylic acid", "text": "Interaction: Drotrecogin alfa AND Acetylsalicylic acid\nDetails: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Acetylsalicylic acid"}, {"id": "Drotrecogin alfa_INT_Aminosalicylic Acid", "text": "Interaction: Drotrecogin alfa AND Aminosalicylic Acid\nDetails: The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Aminosalicylic Acid"}, {"id": "Drotrecogin alfa_INT_Mesalazine", "text": "Interaction: Drotrecogin alfa AND Mesalazine\nDetails: The risk or severity of adverse effects can be increased when Mesalazine is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Mesalazine"}, {"id": "Drotrecogin alfa_INT_Diflunisal", "text": "Interaction: Drotrecogin alfa AND Diflunisal\nDetails: The risk or severity of adverse effects can be increased when Diflunisal is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Diflunisal"}, {"id": "Drotrecogin alfa_INT_Balsalazide", "text": "Interaction: Drotrecogin alfa AND Balsalazide\nDetails: The risk or severity of adverse effects can be increased when Balsalazide is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Balsalazide"}, {"id": "Drotrecogin alfa_INT_Olsalazine", "text": "Interaction: Drotrecogin alfa AND Olsalazine\nDetails: The risk or severity of adverse effects can be increased when Olsalazine is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Olsalazine"}, {"id": "Drotrecogin alfa_INT_dersalazine", "text": "Interaction: Drotrecogin alfa AND dersalazine\nDetails: The risk or severity of adverse effects can be increased when dersalazine is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + dersalazine"}, {"id": "Drotrecogin alfa_INT_Nitroaspirin", "text": "Interaction: Drotrecogin alfa AND Nitroaspirin\nDetails: The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Nitroaspirin"}, {"id": "Drotrecogin alfa_INT_Aloxiprin", "text": "Interaction: Drotrecogin alfa AND Aloxiprin\nDetails: The risk or severity of adverse effects can be increased when Aloxiprin is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Aloxiprin"}, {"id": "Drotrecogin alfa_INT_Guacetisal", "text": "Interaction: Drotrecogin alfa AND Guacetisal\nDetails: The risk or severity of adverse effects can be increased when Guacetisal is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Guacetisal"}, {"id": "Drotrecogin alfa_INT_Carbaspirin calcium", "text": "Interaction: Drotrecogin alfa AND Carbaspirin calcium\nDetails: The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Carbaspirin calcium"}, {"id": "Drotrecogin alfa_INT_Hemoglobin crosfumaril", "text": "Interaction: Drotrecogin alfa AND Hemoglobin crosfumaril\nDetails: The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Hemoglobin crosfumaril"}, {"id": "Drotrecogin alfa_INT_Methyl salicylate", "text": "Interaction: Drotrecogin alfa AND Methyl salicylate\nDetails: The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Methyl salicylate"}, {"id": "Drotrecogin alfa_INT_Trolamine salicylate", "text": "Interaction: Drotrecogin alfa AND Trolamine salicylate\nDetails: The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Trolamine salicylate"}, {"id": "Drotrecogin alfa_INT_Eptifibatide", "text": "Interaction: Drotrecogin alfa AND Eptifibatide\nDetails: Eptifibatide may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Eptifibatide"}, {"id": "Drotrecogin alfa_INT_Ticlopidine", "text": "Interaction: Drotrecogin alfa AND Ticlopidine\nDetails: Ticlopidine may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Ticlopidine"}, {"id": "Drotrecogin alfa_INT_Tirofiban", "text": "Interaction: Drotrecogin alfa AND Tirofiban\nDetails: Tirofiban may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Tirofiban"}, {"id": "Drotrecogin alfa_INT_Dipyridamole", "text": "Interaction: Drotrecogin alfa AND Dipyridamole\nDetails: Dipyridamole may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Dipyridamole"}, {"id": "Drotrecogin alfa_INT_Clopidogrel", "text": "Interaction: Drotrecogin alfa AND Clopidogrel\nDetails: Clopidogrel may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Clopidogrel"}, {"id": "Drotrecogin alfa_INT_Prasugrel", "text": "Interaction: Drotrecogin alfa AND Prasugrel\nDetails: Prasugrel may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Prasugrel"}, {"id": "Drotrecogin alfa_INT_Vorapaxar", "text": "Interaction: Drotrecogin alfa AND Vorapaxar\nDetails: Vorapaxar may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Vorapaxar"}, {"id": "Drotrecogin alfa_INT_Milrinone", "text": "Interaction: Drotrecogin alfa AND Milrinone\nDetails: Milrinone may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Milrinone"}, {"id": "Drotrecogin alfa_INT_Anagrelide", "text": "Interaction: Drotrecogin alfa AND Anagrelide\nDetails: Anagrelide may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Anagrelide"}, {"id": "Drotrecogin alfa_INT_Epinastine", "text": "Interaction: Drotrecogin alfa AND Epinastine\nDetails: Epinastine may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Epinastine"}, {"id": "Drotrecogin alfa_INT_Alprostadil", "text": "Interaction: Drotrecogin alfa AND Alprostadil\nDetails: Alprostadil may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Alprostadil"}, {"id": "Drotrecogin alfa_INT_Pentoxifylline", "text": "Interaction: Drotrecogin alfa AND Pentoxifylline\nDetails: Pentoxifylline may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Pentoxifylline"}, {"id": "Drotrecogin alfa_INT_Azelastine", "text": "Interaction: Drotrecogin alfa AND Azelastine\nDetails: Azelastine may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Azelastine"}, {"id": "Drotrecogin alfa_INT_Iloprost", "text": "Interaction: Drotrecogin alfa AND Iloprost\nDetails: Iloprost may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Iloprost"}, {"id": "Drotrecogin alfa_INT_Cilostazol", "text": "Interaction: Drotrecogin alfa AND Cilostazol\nDetails: Cilostazol may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Cilostazol"}, {"id": "Drotrecogin alfa_INT_Ridogrel", "text": "Interaction: Drotrecogin alfa AND Ridogrel\nDetails: Ridogrel may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Ridogrel"}, {"id": "Drotrecogin alfa_INT_Sevoflurane", "text": "Interaction: Drotrecogin alfa AND Sevoflurane\nDetails: Sevoflurane may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Sevoflurane"}, {"id": "Drotrecogin alfa_INT_Epoprostenol", "text": "Interaction: Drotrecogin alfa AND Epoprostenol\nDetails: Epoprostenol may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Epoprostenol"}, {"id": "Drotrecogin alfa_INT_Resveratrol", "text": "Interaction: Drotrecogin alfa AND Resveratrol\nDetails: Resveratrol may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Resveratrol"}, {"id": "Drotrecogin alfa_INT_Nimesulide", "text": "Interaction: Drotrecogin alfa AND Nimesulide\nDetails: Nimesulide may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Nimesulide"}, {"id": "Drotrecogin alfa_INT_Tesmilifene", "text": "Interaction: Drotrecogin alfa AND Tesmilifene\nDetails: Tesmilifene may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Tesmilifene"}, {"id": "Drotrecogin alfa_INT_Defibrotide", "text": "Interaction: Drotrecogin alfa AND Defibrotide\nDetails: Defibrotide may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Defibrotide"}, {"id": "Drotrecogin alfa_INT_SRT501", "text": "Interaction: Drotrecogin alfa AND SRT501\nDetails: SRT501 may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + SRT501"}, {"id": "Drotrecogin alfa_INT_Beraprost", "text": "Interaction: Drotrecogin alfa AND Beraprost\nDetails: Beraprost may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Beraprost"}, {"id": "Drotrecogin alfa_INT_Ibudilast", "text": "Interaction: Drotrecogin alfa AND Ibudilast\nDetails: Ibudilast may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Ibudilast"}, {"id": "Drotrecogin alfa_INT_Andrographolide", "text": "Interaction: Drotrecogin alfa AND Andrographolide\nDetails: Andrographolide may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Andrographolide"}, {"id": "Drotrecogin alfa_INT_eplivanserine", "text": "Interaction: Drotrecogin alfa AND eplivanserine\nDetails: eplivanserine may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + eplivanserine"}, {"id": "Drotrecogin alfa_INT_Cangrelor", "text": "Interaction: Drotrecogin alfa AND Cangrelor\nDetails: Cangrelor may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Cangrelor"}, {"id": "Drotrecogin alfa_INT_Tranilast", "text": "Interaction: Drotrecogin alfa AND Tranilast\nDetails: Tranilast may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Tranilast"}, {"id": "Drotrecogin alfa_INT_Triflusal", "text": "Interaction: Drotrecogin alfa AND Triflusal\nDetails: Triflusal may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Triflusal"}, {"id": "Drotrecogin alfa_INT_Icosapent ethyl", "text": "Interaction: Drotrecogin alfa AND Icosapent ethyl\nDetails: Icosapent ethyl may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Icosapent ethyl"}, {"id": "Drotrecogin alfa_INT_Ifenprodil", "text": "Interaction: Drotrecogin alfa AND Ifenprodil\nDetails: Ifenprodil may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Ifenprodil"}, {"id": "Drotrecogin alfa_INT_Trapidil", "text": "Interaction: Drotrecogin alfa AND Trapidil\nDetails: Trapidil may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Trapidil"}, {"id": "Drotrecogin alfa_INT_Naftopidil", "text": "Interaction: Drotrecogin alfa AND Naftopidil\nDetails: Naftopidil may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Naftopidil"}, {"id": "Drotrecogin alfa_INT_Sarpogrelate", "text": "Interaction: Drotrecogin alfa AND Sarpogrelate\nDetails: Sarpogrelate may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Sarpogrelate"}, {"id": "Drotrecogin alfa_INT_Eplivanserin", "text": "Interaction: Drotrecogin alfa AND Eplivanserin\nDetails: Eplivanserin may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Eplivanserin"}, {"id": "Drotrecogin alfa_INT_Ifetroban", "text": "Interaction: Drotrecogin alfa AND Ifetroban\nDetails: Ifetroban may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Ifetroban"}, {"id": "Drotrecogin alfa_INT_Ketanserin", "text": "Interaction: Drotrecogin alfa AND Ketanserin\nDetails: Ketanserin may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Ketanserin"}, {"id": "Drotrecogin alfa_INT_Indobufen", "text": "Interaction: Drotrecogin alfa AND Indobufen\nDetails: Indobufen may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Indobufen"}, {"id": "Drotrecogin alfa_INT_Butylphthalide", "text": "Interaction: Drotrecogin alfa AND Butylphthalide\nDetails: Butylphthalide may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Butylphthalide"}, {"id": "Drotrecogin alfa_INT_Hydroxytyrosol", "text": "Interaction: Drotrecogin alfa AND Hydroxytyrosol\nDetails: Hydroxytyrosol may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Hydroxytyrosol"}, {"id": "Drotrecogin alfa_INT_Ramatroban", "text": "Interaction: Drotrecogin alfa AND Ramatroban\nDetails: Ramatroban may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Ramatroban"}, {"id": "Drotrecogin alfa_INT_Picotamide", "text": "Interaction: Drotrecogin alfa AND Picotamide\nDetails: Picotamide may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Picotamide"}, {"id": "Drotrecogin alfa_INT_Cloricromen", "text": "Interaction: Drotrecogin alfa AND Cloricromen\nDetails: Cloricromen may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Cloricromen"}, {"id": "Drotrecogin alfa_INT_Linsidomine", "text": "Interaction: Drotrecogin alfa AND Linsidomine\nDetails: Linsidomine may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Linsidomine"}, {"id": "Drotrecogin alfa_INT_Buflomedil", "text": "Interaction: Drotrecogin alfa AND Buflomedil\nDetails: Buflomedil may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Buflomedil"}, {"id": "Drotrecogin alfa_INT_Relcovaptan", "text": "Interaction: Drotrecogin alfa AND Relcovaptan\nDetails: Relcovaptan may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Relcovaptan"}, {"id": "Drotrecogin alfa_INT_Ticagrelor", "text": "Interaction: Drotrecogin alfa AND Ticagrelor\nDetails: Ticagrelor may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Ticagrelor"}, {"id": "Drotrecogin alfa_INT_Treprostinil", "text": "Interaction: Drotrecogin alfa AND Treprostinil\nDetails: The risk or severity of adverse effects can be increased when Drotrecogin alfa is combined with Treprostinil.\nRisk: Monitor closely.", "source": "Drotrecogin alfa + Treprostinil"}, {"id": "Gemtuzumab ozogamicin_GEN", "text": "Drug: Gemtuzumab ozogamicin\nDescription: Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with ...", "source": "Gemtuzumab ozogamicin"}, {"id": "Gemtuzumab ozogamicin_CLIN", "text": "Drug: Gemtuzumab ozogamicin\nMechanism: Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that i...\nToxicity: The most frequently reported toxicities are myelosuppression and hepatic veno-occlusive disorder....", "source": "Gemtuzumab ozogamicin"}, {"id": "Gemtuzumab ozogamicin_INT_Metamizole", "text": "Interaction: Gemtuzumab ozogamicin AND Metamizole\nDetails: The risk or severity of myelosuppression can be increased when Metamizole is combined with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Metamizole"}, {"id": "Gemtuzumab ozogamicin_INT_Natalizumab", "text": "Interaction: Gemtuzumab ozogamicin AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Natalizumab"}, {"id": "Gemtuzumab ozogamicin_INT_Pimecrolimus", "text": "Interaction: Gemtuzumab ozogamicin AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Pimecrolimus"}, {"id": "Gemtuzumab ozogamicin_INT_Tofacitinib", "text": "Interaction: Gemtuzumab ozogamicin AND Tofacitinib\nDetails: Gemtuzumab ozogamicin may increase the immunosuppressive activities of Tofacitinib.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Tofacitinib"}, {"id": "Gemtuzumab ozogamicin_INT_Tacrolimus", "text": "Interaction: Gemtuzumab ozogamicin AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Tacrolimus"}, {"id": "Gemtuzumab ozogamicin_INT_Clozapine", "text": "Interaction: Gemtuzumab ozogamicin AND Clozapine\nDetails: The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Clozapine.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Clozapine"}, {"id": "Gemtuzumab ozogamicin_INT_Belimumab", "text": "Interaction: Gemtuzumab ozogamicin AND Belimumab\nDetails: The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belimumab.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Belimumab"}, {"id": "Gemtuzumab ozogamicin_INT_BCG vaccine", "text": "Interaction: Gemtuzumab ozogamicin AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + BCG vaccine"}, {"id": "Gemtuzumab ozogamicin_INT_Trastuzumab", "text": "Interaction: Gemtuzumab ozogamicin AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Trastuzumab"}, {"id": "Gemtuzumab ozogamicin_INT_Leflunomide", "text": "Interaction: Gemtuzumab ozogamicin AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Leflunomide"}, {"id": "Gemtuzumab ozogamicin_INT_Fingolimod", "text": "Interaction: Gemtuzumab ozogamicin AND Fingolimod\nDetails: Gemtuzumab ozogamicin may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Fingolimod"}, {"id": "Gemtuzumab ozogamicin_INT_Roflumilast", "text": "Interaction: Gemtuzumab ozogamicin AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Roflumilast"}, {"id": "Gemtuzumab ozogamicin_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Gemtuzumab ozogamicin AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Gemtuzumab ozogamicin_INT_Yellow fever vaccine", "text": "Interaction: Gemtuzumab ozogamicin AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Yellow fever vaccine"}, {"id": "Gemtuzumab ozogamicin_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Gemtuzumab ozogamicin AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Gemtuzumab ozogamicin_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Gemtuzumab ozogamicin AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Gemtuzumab ozogamicin_INT_Rotavirus Vaccine", "text": "Interaction: Gemtuzumab ozogamicin AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Rotavirus Vaccine"}, {"id": "Gemtuzumab ozogamicin_INT_G17DT", "text": "Interaction: Gemtuzumab ozogamicin AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + G17DT"}, {"id": "Gemtuzumab ozogamicin_INT_INGN 201", "text": "Interaction: Gemtuzumab ozogamicin AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + INGN 201"}, {"id": "Gemtuzumab ozogamicin_INT_INGN 225", "text": "Interaction: Gemtuzumab ozogamicin AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + INGN 225"}, {"id": "Gemtuzumab ozogamicin_INT_Rindopepimut", "text": "Interaction: Gemtuzumab ozogamicin AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Rindopepimut"}, {"id": "Gemtuzumab ozogamicin_INT_SRP 299", "text": "Interaction: Gemtuzumab ozogamicin AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + SRP 299"}, {"id": "Gemtuzumab ozogamicin_INT_GI-5005", "text": "Interaction: Gemtuzumab ozogamicin AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + GI-5005"}, {"id": "Gemtuzumab ozogamicin_INT_TG4010", "text": "Interaction: Gemtuzumab ozogamicin AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + TG4010"}, {"id": "Gemtuzumab ozogamicin_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Gemtuzumab ozogamicin AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Rabies virus inactivated antigen, A"}, {"id": "Gemtuzumab ozogamicin_INT_Tecemotide", "text": "Interaction: Gemtuzumab ozogamicin AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Tecemotide"}, {"id": "Gemtuzumab ozogamicin_INT_Rubella virus vaccine", "text": "Interaction: Gemtuzumab ozogamicin AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Rubella virus vaccine"}, {"id": "Gemtuzumab ozogamicin_INT_Hepatitis A Vaccine", "text": "Interaction: Gemtuzumab ozogamicin AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Hepatitis A Vaccine"}, {"id": "Gemtuzumab ozogamicin_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Gemtuzumab ozogamicin AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Salmonella typhi ty21a live antigen"}, {"id": "Gemtuzumab ozogamicin_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Gemtuzumab ozogamicin AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Hepatitis B Vaccine (Recombinant)"}, {"id": "Gemtuzumab ozogamicin_INT_Paclitaxel", "text": "Interaction: Gemtuzumab ozogamicin AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Paclitaxel"}, {"id": "Gemtuzumab ozogamicin_INT_Docetaxel", "text": "Interaction: Gemtuzumab ozogamicin AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Docetaxel"}, {"id": "Gemtuzumab ozogamicin_INT_Cabazitaxel", "text": "Interaction: Gemtuzumab ozogamicin AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Cabazitaxel"}, {"id": "Gemtuzumab ozogamicin_INT_Digoxin", "text": "Interaction: Gemtuzumab ozogamicin AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Digoxin"}, {"id": "Gemtuzumab ozogamicin_INT_Acetyldigitoxin", "text": "Interaction: Gemtuzumab ozogamicin AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Acetyldigitoxin"}, {"id": "Gemtuzumab ozogamicin_INT_Deslanoside", "text": "Interaction: Gemtuzumab ozogamicin AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Deslanoside"}, {"id": "Gemtuzumab ozogamicin_INT_Ouabain", "text": "Interaction: Gemtuzumab ozogamicin AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Ouabain"}, {"id": "Gemtuzumab ozogamicin_INT_Digitoxin", "text": "Interaction: Gemtuzumab ozogamicin AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Digitoxin"}, {"id": "Gemtuzumab ozogamicin_INT_Cymarin", "text": "Interaction: Gemtuzumab ozogamicin AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Cymarin"}, {"id": "Gemtuzumab ozogamicin_INT_Proscillaridin", "text": "Interaction: Gemtuzumab ozogamicin AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Proscillaridin"}, {"id": "Gemtuzumab ozogamicin_INT_Metildigoxin", "text": "Interaction: Gemtuzumab ozogamicin AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Metildigoxin"}, {"id": "Gemtuzumab ozogamicin_INT_Peruvoside", "text": "Interaction: Gemtuzumab ozogamicin AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Peruvoside"}, {"id": "Gemtuzumab ozogamicin_INT_Lanatoside C", "text": "Interaction: Gemtuzumab ozogamicin AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Lanatoside C"}, {"id": "Gemtuzumab ozogamicin_INT_Gitoformate", "text": "Interaction: Gemtuzumab ozogamicin AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Gitoformate"}, {"id": "Gemtuzumab ozogamicin_INT_Acetyldigoxin", "text": "Interaction: Gemtuzumab ozogamicin AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Acetyldigoxin"}, {"id": "Gemtuzumab ozogamicin_INT_Oleandrin", "text": "Interaction: Gemtuzumab ozogamicin AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Oleandrin"}, {"id": "Gemtuzumab ozogamicin_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Gemtuzumab ozogamicin AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Digoxin Immune Fab (Ovine)"}, {"id": "Gemtuzumab ozogamicin_INT_Bevacizumab", "text": "Interaction: Gemtuzumab ozogamicin AND Bevacizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Bevacizumab"}, {"id": "Gemtuzumab ozogamicin_INT_Cyclophosphamide", "text": "Interaction: Gemtuzumab ozogamicin AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Cyclophosphamide"}, {"id": "Gemtuzumab ozogamicin_INT_Denosumab", "text": "Interaction: Gemtuzumab ozogamicin AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Denosumab"}, {"id": "Gemtuzumab ozogamicin_INT_Sipuleucel-T", "text": "Interaction: Gemtuzumab ozogamicin AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Gemtuzumab ozogamicin + Sipuleucel-T"}, {"id": "Indium In-111 satumomab pendetide_GEN", "text": "Drug: Indium In-111 satumomab pendetide\nDescription: Tumor associated glycoprotein (TAG) 72 (B72.3) monoclonal antibody conjugated with Indium 111 for radioimaging colon tumors. Satumomab Pendetide (trade name: OncoScint\u00ae) is no longer commercially available....", "source": "Indium In-111 satumomab pendetide"}, {"id": "Indium In-111 satumomab pendetide_CLIN", "text": "Drug: Indium In-111 satumomab pendetide\nMechanism: Satumomab Pendetide is a monoclonal antibody which is attached to the chelator pentetic acid (DTPA) linked to the tripeptide  glycine  (G) \u2013 L-tyrosine (Y) \u2013 L-lysine (K), which chelates Indium 111. S...\nToxicity: ...", "source": "Indium In-111 satumomab pendetide"}, {"id": "Indium In-111 satumomab pendetide_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Indium In-111 satumomab pendetide AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Indium In-111 satumomab pendetide_INT_Yellow fever vaccine", "text": "Interaction: Indium In-111 satumomab pendetide AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + Yellow fever vaccine"}, {"id": "Indium In-111 satumomab pendetide_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Indium In-111 satumomab pendetide AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Indium In-111 satumomab pendetide_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Indium In-111 satumomab pendetide AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Indium In-111 satumomab pendetide_INT_Rotavirus Vaccine", "text": "Interaction: Indium In-111 satumomab pendetide AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + Rotavirus Vaccine"}, {"id": "Indium In-111 satumomab pendetide_INT_G17DT", "text": "Interaction: Indium In-111 satumomab pendetide AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + G17DT"}, {"id": "Indium In-111 satumomab pendetide_INT_INGN 201", "text": "Interaction: Indium In-111 satumomab pendetide AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + INGN 201"}, {"id": "Indium In-111 satumomab pendetide_INT_INGN 225", "text": "Interaction: Indium In-111 satumomab pendetide AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + INGN 225"}, {"id": "Indium In-111 satumomab pendetide_INT_Rindopepimut", "text": "Interaction: Indium In-111 satumomab pendetide AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + Rindopepimut"}, {"id": "Indium In-111 satumomab pendetide_INT_SRP 299", "text": "Interaction: Indium In-111 satumomab pendetide AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + SRP 299"}, {"id": "Indium In-111 satumomab pendetide_INT_GI-5005", "text": "Interaction: Indium In-111 satumomab pendetide AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + GI-5005"}, {"id": "Indium In-111 satumomab pendetide_INT_TG4010", "text": "Interaction: Indium In-111 satumomab pendetide AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + TG4010"}, {"id": "Indium In-111 satumomab pendetide_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Indium In-111 satumomab pendetide AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + Rabies virus inactivated antigen, A"}, {"id": "Indium In-111 satumomab pendetide_INT_Tecemotide", "text": "Interaction: Indium In-111 satumomab pendetide AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + Tecemotide"}, {"id": "Indium In-111 satumomab pendetide_INT_BCG vaccine", "text": "Interaction: Indium In-111 satumomab pendetide AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + BCG vaccine"}, {"id": "Indium In-111 satumomab pendetide_INT_Rubella virus vaccine", "text": "Interaction: Indium In-111 satumomab pendetide AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + Rubella virus vaccine"}, {"id": "Indium In-111 satumomab pendetide_INT_Hepatitis A Vaccine", "text": "Interaction: Indium In-111 satumomab pendetide AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + Hepatitis A Vaccine"}, {"id": "Indium In-111 satumomab pendetide_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Indium In-111 satumomab pendetide AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + Salmonella typhi ty21a live antigen"}, {"id": "Indium In-111 satumomab pendetide_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Indium In-111 satumomab pendetide AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Indium In-111 satumomab pendetide.\nRisk: Monitor closely.", "source": "Indium In-111 satumomab pendetide + Hepatitis B Vaccine (Recombinant)"}, {"id": "Alpha-1-proteinase inhibitor_GEN", "text": "Drug: Alpha-1-proteinase inhibitor\nDescription: Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation....", "source": "Alpha-1-proteinase inhibitor"}, {"id": "Alpha-1-proteinase inhibitor_CLIN", "text": "Drug: Alpha-1-proteinase inhibitor\nMechanism: Alpha-1 proteinase inhibitor is a serine protease inhibitor (Serpin). Its primary mechanism is inhibiting the action of the serine protease called elastase (also plasmin and thrombin) in the lungs. Th...\nToxicity: ...", "source": "Alpha-1-proteinase inhibitor"}, {"id": "Alpha-1-proteinase inhibitor_INT_St. John's Wort", "text": "Interaction: Alpha-1-proteinase inhibitor AND St. John's Wort\nDetails: The metabolism of Alpha-1-proteinase inhibitor can be increased when combined with St. John&#39;s Wort.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + St. John's Wort"}, {"id": "Alpha-1-proteinase inhibitor_INT_Alfuzosin", "text": "Interaction: Alpha-1-proteinase inhibitor AND Alfuzosin\nDetails: The serum concentration of Alfuzosin can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Alfuzosin"}, {"id": "Alpha-1-proteinase inhibitor_INT_Lovastatin", "text": "Interaction: Alpha-1-proteinase inhibitor AND Lovastatin\nDetails: The serum concentration of Lovastatin can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Lovastatin"}, {"id": "Alpha-1-proteinase inhibitor_INT_Midazolam", "text": "Interaction: Alpha-1-proteinase inhibitor AND Midazolam\nDetails: The serum concentration of Midazolam can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Midazolam"}, {"id": "Alpha-1-proteinase inhibitor_INT_Simvastatin", "text": "Interaction: Alpha-1-proteinase inhibitor AND Simvastatin\nDetails: The serum concentration of Simvastatin can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Simvastatin"}, {"id": "Alpha-1-proteinase inhibitor_INT_Tipranavir", "text": "Interaction: Alpha-1-proteinase inhibitor AND Tipranavir\nDetails: The serum concentration of Alpha-1-proteinase inhibitor can be decreased when it is combined with Tipranavir.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Tipranavir"}, {"id": "Alpha-1-proteinase inhibitor_INT_Cabergoline", "text": "Interaction: Alpha-1-proteinase inhibitor AND Cabergoline\nDetails: The serum concentration of Cabergoline can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Cabergoline"}, {"id": "Alpha-1-proteinase inhibitor_INT_Bromocriptine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Bromocriptine\nDetails: The serum concentration of Bromocriptine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Bromocriptine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Methylergometrine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Methylergometrine\nDetails: The serum concentration of Methylergometrine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Methylergometrine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Dihydroergotamine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Dihydroergotamine\nDetails: The serum concentration of Dihydroergotamine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Dihydroergotamine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Ergotamine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Ergotamine\nDetails: The serum concentration of Ergotamine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Ergotamine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Ergoloid mesylate", "text": "Interaction: Alpha-1-proteinase inhibitor AND Ergoloid mesylate\nDetails: The serum concentration of Ergoloid mesylate can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Ergoloid mesylate"}, {"id": "Alpha-1-proteinase inhibitor_INT_Ergonovine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Ergonovine\nDetails: The serum concentration of Ergonovine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Ergonovine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Triazolam", "text": "Interaction: Alpha-1-proteinase inhibitor AND Triazolam\nDetails: The serum concentration of Triazolam can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Triazolam"}, {"id": "Alpha-1-proteinase inhibitor_INT_Ethinyl Estradiol", "text": "Interaction: Alpha-1-proteinase inhibitor AND Ethinyl Estradiol\nDetails: The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Ethinyl Estradiol"}, {"id": "Alpha-1-proteinase inhibitor_INT_Mestranol", "text": "Interaction: Alpha-1-proteinase inhibitor AND Mestranol\nDetails: The serum concentration of Mestranol can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Mestranol"}, {"id": "Alpha-1-proteinase inhibitor_INT_Estradiol", "text": "Interaction: Alpha-1-proteinase inhibitor AND Estradiol\nDetails: The serum concentration of Estradiol can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Estradiol"}, {"id": "Alpha-1-proteinase inhibitor_INT_Estrone sulfate", "text": "Interaction: Alpha-1-proteinase inhibitor AND Estrone sulfate\nDetails: The serum concentration of Estrone sulfate can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Estrone sulfate"}, {"id": "Alpha-1-proteinase inhibitor_INT_Synthetic Conjugated Estrogens, A", "text": "Interaction: Alpha-1-proteinase inhibitor AND Synthetic Conjugated Estrogens, A\nDetails: The serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Synthetic Conjugated Estrogens, A"}, {"id": "Alpha-1-proteinase inhibitor_INT_Estrogens, esterified", "text": "Interaction: Alpha-1-proteinase inhibitor AND Estrogens, esterified\nDetails: The serum concentration of Estrogens, esterified can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Estrogens, esterified"}, {"id": "Alpha-1-proteinase inhibitor_INT_Chlorotrianisene", "text": "Interaction: Alpha-1-proteinase inhibitor AND Chlorotrianisene\nDetails: The serum concentration of Chlorotrianisene can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Chlorotrianisene"}, {"id": "Alpha-1-proteinase inhibitor_INT_Conjugated estrogens", "text": "Interaction: Alpha-1-proteinase inhibitor AND Conjugated estrogens\nDetails: The serum concentration of Conjugated estrogens can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Conjugated estrogens"}, {"id": "Alpha-1-proteinase inhibitor_INT_Estramustine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Estramustine\nDetails: The serum concentration of Estramustine can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Estramustine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Dienestrol", "text": "Interaction: Alpha-1-proteinase inhibitor AND Dienestrol\nDetails: The serum concentration of Dienestrol can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Dienestrol"}, {"id": "Alpha-1-proteinase inhibitor_INT_Diethylstilbestrol", "text": "Interaction: Alpha-1-proteinase inhibitor AND Diethylstilbestrol\nDetails: The serum concentration of Diethylstilbestrol can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Diethylstilbestrol"}, {"id": "Alpha-1-proteinase inhibitor_INT_Hexestrol", "text": "Interaction: Alpha-1-proteinase inhibitor AND Hexestrol\nDetails: The serum concentration of Hexestrol can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Hexestrol"}, {"id": "Alpha-1-proteinase inhibitor_INT_Methallenestril", "text": "Interaction: Alpha-1-proteinase inhibitor AND Methallenestril\nDetails: The serum concentration of Methallenestril can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Methallenestril"}, {"id": "Alpha-1-proteinase inhibitor_INT_Cyclosporine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Cyclosporine\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Cyclosporine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Garlic", "text": "Interaction: Alpha-1-proteinase inhibitor AND Garlic\nDetails: The serum concentration of Alpha-1-proteinase inhibitor can be decreased when it is combined with Garlic.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Garlic"}, {"id": "Alpha-1-proteinase inhibitor_INT_Tacrolimus", "text": "Interaction: Alpha-1-proteinase inhibitor AND Tacrolimus\nDetails: The metabolism of Tacrolimus can be decreased when combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Tacrolimus"}, {"id": "Alpha-1-proteinase inhibitor_INT_Pethidine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Pethidine\nDetails: The risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Pethidine.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Pethidine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Alprazolam", "text": "Interaction: Alpha-1-proteinase inhibitor AND Alprazolam\nDetails: The serum concentration of Alprazolam can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Alprazolam"}, {"id": "Alpha-1-proteinase inhibitor_INT_Atorvastatin", "text": "Interaction: Alpha-1-proteinase inhibitor AND Atorvastatin\nDetails: The serum concentration of Atorvastatin can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Atorvastatin"}, {"id": "Alpha-1-proteinase inhibitor_INT_Boceprevir", "text": "Interaction: Alpha-1-proteinase inhibitor AND Boceprevir\nDetails: The serum concentration of Alpha-1-proteinase inhibitor can be decreased when it is combined with Boceprevir.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Boceprevir"}, {"id": "Alpha-1-proteinase inhibitor_INT_Carbamazepine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Carbamazepine\nDetails: The metabolism of Alpha-1-proteinase inhibitor can be increased when combined with Carbamazepine.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Carbamazepine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Clarithromycin", "text": "Interaction: Alpha-1-proteinase inhibitor AND Clarithromycin\nDetails: The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Clarithromycin"}, {"id": "Alpha-1-proteinase inhibitor_INT_Delavirdine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Delavirdine\nDetails: The serum concentration of Delavirdine can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Delavirdine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Nefazodone", "text": "Interaction: Alpha-1-proteinase inhibitor AND Nefazodone\nDetails: The serum concentration of Nefazodone can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Nefazodone"}, {"id": "Alpha-1-proteinase inhibitor_INT_Riociguat", "text": "Interaction: Alpha-1-proteinase inhibitor AND Riociguat\nDetails: The serum concentration of Riociguat can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Riociguat"}, {"id": "Alpha-1-proteinase inhibitor_INT_Rosuvastatin", "text": "Interaction: Alpha-1-proteinase inhibitor AND Rosuvastatin\nDetails: The serum concentration of Rosuvastatin can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Rosuvastatin"}, {"id": "Alpha-1-proteinase inhibitor_INT_Sildenafil", "text": "Interaction: Alpha-1-proteinase inhibitor AND Sildenafil\nDetails: The serum concentration of Sildenafil can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Sildenafil"}, {"id": "Alpha-1-proteinase inhibitor_INT_Temsirolimus", "text": "Interaction: Alpha-1-proteinase inhibitor AND Temsirolimus\nDetails: The risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Temsirolimus.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Temsirolimus"}, {"id": "Alpha-1-proteinase inhibitor_INT_Diltiazem", "text": "Interaction: Alpha-1-proteinase inhibitor AND Diltiazem\nDetails: The metabolism of Diltiazem can be decreased when combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Diltiazem"}, {"id": "Alpha-1-proteinase inhibitor_INT_Verapamil", "text": "Interaction: Alpha-1-proteinase inhibitor AND Verapamil\nDetails: The metabolism of Verapamil can be decreased when combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Verapamil"}, {"id": "Alpha-1-proteinase inhibitor_INT_Amitriptyline", "text": "Interaction: Alpha-1-proteinase inhibitor AND Amitriptyline\nDetails: The serum concentration of Amitriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Amitriptyline"}, {"id": "Alpha-1-proteinase inhibitor_INT_Protriptyline", "text": "Interaction: Alpha-1-proteinase inhibitor AND Protriptyline\nDetails: The serum concentration of Protriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Protriptyline"}, {"id": "Alpha-1-proteinase inhibitor_INT_Imipramine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Imipramine\nDetails: The serum concentration of Imipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Imipramine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Nortriptyline", "text": "Interaction: Alpha-1-proteinase inhibitor AND Nortriptyline\nDetails: The serum concentration of Nortriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Nortriptyline"}, {"id": "Alpha-1-proteinase inhibitor_INT_Trimipramine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Trimipramine\nDetails: The serum concentration of Trimipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Trimipramine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Doxepin", "text": "Interaction: Alpha-1-proteinase inhibitor AND Doxepin\nDetails: The serum concentration of Doxepin can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Doxepin"}, {"id": "Alpha-1-proteinase inhibitor_INT_Desipramine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Desipramine\nDetails: The serum concentration of Desipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Desipramine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Clomipramine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Clomipramine\nDetails: The serum concentration of Clomipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Clomipramine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Mirtazapine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Mirtazapine\nDetails: The serum concentration of Mirtazapine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Mirtazapine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Cyclobenzaprine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Cyclobenzaprine\nDetails: The serum concentration of Cyclobenzaprine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Cyclobenzaprine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Amineptine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Amineptine\nDetails: The serum concentration of Amineptine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Amineptine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Esmirtazapine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Esmirtazapine\nDetails: The serum concentration of Esmirtazapine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Esmirtazapine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Dosulepin", "text": "Interaction: Alpha-1-proteinase inhibitor AND Dosulepin\nDetails: The serum concentration of Dosulepin can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Dosulepin"}, {"id": "Alpha-1-proteinase inhibitor_INT_Tianeptine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Tianeptine\nDetails: The serum concentration of Tianeptine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Tianeptine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Opipramol", "text": "Interaction: Alpha-1-proteinase inhibitor AND Opipramol\nDetails: The serum concentration of Opipramol can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Opipramol"}, {"id": "Alpha-1-proteinase inhibitor_INT_Dibenzepin", "text": "Interaction: Alpha-1-proteinase inhibitor AND Dibenzepin\nDetails: The serum concentration of Dibenzepin can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Dibenzepin"}, {"id": "Alpha-1-proteinase inhibitor_INT_Lofepramine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Lofepramine\nDetails: The serum concentration of Lofepramine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Lofepramine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Iprindole", "text": "Interaction: Alpha-1-proteinase inhibitor AND Iprindole\nDetails: The serum concentration of Iprindole can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Iprindole"}, {"id": "Alpha-1-proteinase inhibitor_INT_Amoxapine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Amoxapine\nDetails: The serum concentration of Amoxapine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Amoxapine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Abacavir", "text": "Interaction: Alpha-1-proteinase inhibitor AND Abacavir\nDetails: The serum concentration of Abacavir can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Abacavir"}, {"id": "Alpha-1-proteinase inhibitor_INT_Cyclophosphamide", "text": "Interaction: Alpha-1-proteinase inhibitor AND Cyclophosphamide\nDetails: The risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Cyclophosphamide.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Cyclophosphamide"}, {"id": "Alpha-1-proteinase inhibitor_INT_Digoxin", "text": "Interaction: Alpha-1-proteinase inhibitor AND Digoxin\nDetails: The serum concentration of Digoxin can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Digoxin"}, {"id": "Alpha-1-proteinase inhibitor_INT_Enfuvirtide", "text": "Interaction: Alpha-1-proteinase inhibitor AND Enfuvirtide\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Enfuvirtide"}, {"id": "Alpha-1-proteinase inhibitor_INT_Etravirine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Etravirine\nDetails: The serum concentration of Etravirine can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Etravirine"}, {"id": "Alpha-1-proteinase inhibitor_INT_Fibrinogen Human", "text": "Interaction: Alpha-1-proteinase inhibitor AND Fibrinogen Human\nDetails: The risk or severity of adverse effects can be increased when Alpha-1-proteinase inhibitor is combined with Fibrinogen Human.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Fibrinogen Human"}, {"id": "Alpha-1-proteinase inhibitor_INT_Tretinoin", "text": "Interaction: Alpha-1-proteinase inhibitor AND Tretinoin\nDetails: Tretinoin may increase the thrombogenic activities of Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Tretinoin"}, {"id": "Alpha-1-proteinase inhibitor_INT_Ambroxol acefyllinate", "text": "Interaction: Alpha-1-proteinase inhibitor AND Ambroxol acefyllinate\nDetails: The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Ambroxol acefyllinate"}, {"id": "Alpha-1-proteinase inhibitor_INT_Theophylline", "text": "Interaction: Alpha-1-proteinase inhibitor AND Theophylline\nDetails: The serum concentration of Theophylline can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Theophylline"}, {"id": "Alpha-1-proteinase inhibitor_INT_Dyphylline", "text": "Interaction: Alpha-1-proteinase inhibitor AND Dyphylline\nDetails: The serum concentration of Dyphylline can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Dyphylline"}, {"id": "Alpha-1-proteinase inhibitor_INT_Aminophylline", "text": "Interaction: Alpha-1-proteinase inhibitor AND Aminophylline\nDetails: The serum concentration of Aminophylline can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Aminophylline"}, {"id": "Alpha-1-proteinase inhibitor_INT_Valproic Acid", "text": "Interaction: Alpha-1-proteinase inhibitor AND Valproic Acid\nDetails: The serum concentration of Valproic Acid can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Valproic Acid"}, {"id": "Alpha-1-proteinase inhibitor_INT_Zidovudine", "text": "Interaction: Alpha-1-proteinase inhibitor AND Zidovudine\nDetails: The serum concentration of Zidovudine can be decreased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Alpha-1-proteinase inhibitor + Zidovudine"}, {"id": "Pegaspargase_GEN", "text": "Drug: Pegaspargase\nDescription: Pegylated L-asparagine amidohydrolase from E. coli. Pegylation substantially (by a factor of 4) extends the protein half life....", "source": "Pegaspargase"}, {"id": "Pegaspargase_CLIN", "text": "Drug: Pegaspargase\nMechanism: Pegaspargase, more effective than asparaginase, converts asparagine to aspartic acid and ammonia. It facilitates production of oxaloacetate which is needed for general cellular metabolism. Some malign...\nToxicity: Adverse effects that occur more than 10% of the time include hepatotoxicity as it is known to increase serum transaminases (ALT, AST). Also known to induce hypersensitivity reactions including anaphyl...", "source": "Pegaspargase"}, {"id": "Pegaspargase_INT_Natalizumab", "text": "Interaction: Pegaspargase AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Pegaspargase is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Pegaspargase + Natalizumab"}, {"id": "Pegaspargase_INT_Pimecrolimus", "text": "Interaction: Pegaspargase AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Pimecrolimus"}, {"id": "Pegaspargase_INT_Tofacitinib", "text": "Interaction: Pegaspargase AND Tofacitinib\nDetails: Pegaspargase may increase the immunosuppressive activities of Tofacitinib.\nRisk: Monitor closely.", "source": "Pegaspargase + Tofacitinib"}, {"id": "Pegaspargase_INT_Tacrolimus", "text": "Interaction: Pegaspargase AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Tacrolimus"}, {"id": "Pegaspargase_INT_BCG vaccine", "text": "Interaction: Pegaspargase AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + BCG vaccine"}, {"id": "Pegaspargase_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Pegaspargase AND Rabies virus inactivated antigen, A\nDetails: The risk or severity of adverse effects can be increased when Pegaspargase is combined with Rabies virus inactivated antigen, A.\nRisk: Monitor closely.", "source": "Pegaspargase + Rabies virus inactivated antigen, A"}, {"id": "Pegaspargase_INT_Trastuzumab", "text": "Interaction: Pegaspargase AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Trastuzumab"}, {"id": "Pegaspargase_INT_Leflunomide", "text": "Interaction: Pegaspargase AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Pegaspargase is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Pegaspargase + Leflunomide"}, {"id": "Pegaspargase_INT_Fingolimod", "text": "Interaction: Pegaspargase AND Fingolimod\nDetails: Pegaspargase may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Pegaspargase + Fingolimod"}, {"id": "Pegaspargase_INT_Roflumilast", "text": "Interaction: Pegaspargase AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Roflumilast"}, {"id": "Pegaspargase_INT_Paclitaxel", "text": "Interaction: Pegaspargase AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Paclitaxel"}, {"id": "Pegaspargase_INT_Docetaxel", "text": "Interaction: Pegaspargase AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Docetaxel"}, {"id": "Pegaspargase_INT_Cabazitaxel", "text": "Interaction: Pegaspargase AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Cabazitaxel"}, {"id": "Pegaspargase_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Pegaspargase AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Pegaspargase_INT_Yellow fever vaccine", "text": "Interaction: Pegaspargase AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Yellow fever vaccine"}, {"id": "Pegaspargase_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Pegaspargase AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Pegaspargase_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Pegaspargase AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Pegaspargase_INT_Rotavirus Vaccine", "text": "Interaction: Pegaspargase AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Rotavirus Vaccine"}, {"id": "Pegaspargase_INT_G17DT", "text": "Interaction: Pegaspargase AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + G17DT"}, {"id": "Pegaspargase_INT_INGN 201", "text": "Interaction: Pegaspargase AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + INGN 201"}, {"id": "Pegaspargase_INT_INGN 225", "text": "Interaction: Pegaspargase AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + INGN 225"}, {"id": "Pegaspargase_INT_Rindopepimut", "text": "Interaction: Pegaspargase AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Rindopepimut"}, {"id": "Pegaspargase_INT_SRP 299", "text": "Interaction: Pegaspargase AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + SRP 299"}, {"id": "Pegaspargase_INT_GI-5005", "text": "Interaction: Pegaspargase AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + GI-5005"}, {"id": "Pegaspargase_INT_TG4010", "text": "Interaction: Pegaspargase AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + TG4010"}, {"id": "Pegaspargase_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Pegaspargase AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Rabies virus inactivated antigen, A"}, {"id": "Pegaspargase_INT_Tecemotide", "text": "Interaction: Pegaspargase AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Tecemotide"}, {"id": "Pegaspargase_INT_Rubella virus vaccine", "text": "Interaction: Pegaspargase AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Rubella virus vaccine"}, {"id": "Pegaspargase_INT_Hepatitis A Vaccine", "text": "Interaction: Pegaspargase AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Hepatitis A Vaccine"}, {"id": "Pegaspargase_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Pegaspargase AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Salmonella typhi ty21a live antigen"}, {"id": "Pegaspargase_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Pegaspargase AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Hepatitis B Vaccine (Recombinant)"}, {"id": "Pegaspargase_INT_Digoxin", "text": "Interaction: Pegaspargase AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Digoxin"}, {"id": "Pegaspargase_INT_Acetyldigitoxin", "text": "Interaction: Pegaspargase AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Acetyldigitoxin"}, {"id": "Pegaspargase_INT_Deslanoside", "text": "Interaction: Pegaspargase AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Deslanoside"}, {"id": "Pegaspargase_INT_Ouabain", "text": "Interaction: Pegaspargase AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Ouabain"}, {"id": "Pegaspargase_INT_Digitoxin", "text": "Interaction: Pegaspargase AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Digitoxin"}, {"id": "Pegaspargase_INT_Cymarin", "text": "Interaction: Pegaspargase AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Cymarin"}, {"id": "Pegaspargase_INT_Proscillaridin", "text": "Interaction: Pegaspargase AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Proscillaridin"}, {"id": "Pegaspargase_INT_Metildigoxin", "text": "Interaction: Pegaspargase AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Metildigoxin"}, {"id": "Pegaspargase_INT_Peruvoside", "text": "Interaction: Pegaspargase AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Peruvoside"}, {"id": "Pegaspargase_INT_Lanatoside C", "text": "Interaction: Pegaspargase AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Lanatoside C"}, {"id": "Pegaspargase_INT_Gitoformate", "text": "Interaction: Pegaspargase AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Gitoformate"}, {"id": "Pegaspargase_INT_Acetyldigoxin", "text": "Interaction: Pegaspargase AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Acetyldigoxin"}, {"id": "Pegaspargase_INT_Oleandrin", "text": "Interaction: Pegaspargase AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Oleandrin"}, {"id": "Pegaspargase_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Pegaspargase AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Digoxin Immune Fab (Ovine)"}, {"id": "Pegaspargase_INT_Bevacizumab", "text": "Interaction: Pegaspargase AND Bevacizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Bevacizumab"}, {"id": "Pegaspargase_INT_Cyclophosphamide", "text": "Interaction: Pegaspargase AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Cyclophosphamide"}, {"id": "Pegaspargase_INT_Pegloticase", "text": "Interaction: Pegaspargase AND Pegloticase\nDetails: The therapeutic efficacy of Pegaspargase can be decreased when used in combination with Pegloticase.\nRisk: Monitor closely.", "source": "Pegaspargase + Pegloticase"}, {"id": "Pegaspargase_INT_Denosumab", "text": "Interaction: Pegaspargase AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Denosumab"}, {"id": "Pegaspargase_INT_Sipuleucel-T", "text": "Interaction: Pegaspargase AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pegaspargase.\nRisk: Monitor closely.", "source": "Pegaspargase + Sipuleucel-T"}, {"id": "Interferon beta-1a_GEN", "text": "Drug: Interferon beta-1a\nDescription: Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta....", "source": "Interferon beta-1a"}, {"id": "Interferon beta-1a_CLIN", "text": "Drug: Interferon beta-1a\nMechanism: Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselve...\nToxicity: ...", "source": "Interferon beta-1a"}, {"id": "Interferon beta-1a_INT_Trastuzumab", "text": "Interaction: Interferon beta-1a AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Trastuzumab"}, {"id": "Interferon beta-1a_INT_Paclitaxel", "text": "Interaction: Interferon beta-1a AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Paclitaxel"}, {"id": "Interferon beta-1a_INT_Docetaxel", "text": "Interaction: Interferon beta-1a AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Docetaxel"}, {"id": "Interferon beta-1a_INT_Cabazitaxel", "text": "Interaction: Interferon beta-1a AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Cabazitaxel"}, {"id": "Interferon beta-1a_INT_Digoxin", "text": "Interaction: Interferon beta-1a AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Digoxin"}, {"id": "Interferon beta-1a_INT_Acetyldigitoxin", "text": "Interaction: Interferon beta-1a AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Acetyldigitoxin"}, {"id": "Interferon beta-1a_INT_Deslanoside", "text": "Interaction: Interferon beta-1a AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Deslanoside"}, {"id": "Interferon beta-1a_INT_Ouabain", "text": "Interaction: Interferon beta-1a AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Ouabain"}, {"id": "Interferon beta-1a_INT_Digitoxin", "text": "Interaction: Interferon beta-1a AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Digitoxin"}, {"id": "Interferon beta-1a_INT_Cymarin", "text": "Interaction: Interferon beta-1a AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Cymarin"}, {"id": "Interferon beta-1a_INT_Proscillaridin", "text": "Interaction: Interferon beta-1a AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Proscillaridin"}, {"id": "Interferon beta-1a_INT_Metildigoxin", "text": "Interaction: Interferon beta-1a AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Metildigoxin"}, {"id": "Interferon beta-1a_INT_Peruvoside", "text": "Interaction: Interferon beta-1a AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Peruvoside"}, {"id": "Interferon beta-1a_INT_Lanatoside C", "text": "Interaction: Interferon beta-1a AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Lanatoside C"}, {"id": "Interferon beta-1a_INT_Gitoformate", "text": "Interaction: Interferon beta-1a AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Gitoformate"}, {"id": "Interferon beta-1a_INT_Acetyldigoxin", "text": "Interaction: Interferon beta-1a AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Acetyldigoxin"}, {"id": "Interferon beta-1a_INT_Oleandrin", "text": "Interaction: Interferon beta-1a AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Oleandrin"}, {"id": "Interferon beta-1a_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Interferon beta-1a AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Digoxin Immune Fab (Ovine)"}, {"id": "Interferon beta-1a_INT_Bevacizumab", "text": "Interaction: Interferon beta-1a AND Bevacizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Bevacizumab"}, {"id": "Interferon beta-1a_INT_Cyclophosphamide", "text": "Interaction: Interferon beta-1a AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Cyclophosphamide"}, {"id": "Interferon beta-1a_INT_Ambroxol acefyllinate", "text": "Interaction: Interferon beta-1a AND Ambroxol acefyllinate\nDetails: The metabolism of Ambroxol acefyllinate can be decreased when combined with Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Ambroxol acefyllinate"}, {"id": "Interferon beta-1a_INT_Theophylline", "text": "Interaction: Interferon beta-1a AND Theophylline\nDetails: The metabolism of Theophylline can be decreased when combined with Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Theophylline"}, {"id": "Interferon beta-1a_INT_Dyphylline", "text": "Interaction: Interferon beta-1a AND Dyphylline\nDetails: The metabolism of Dyphylline can be decreased when combined with Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Dyphylline"}, {"id": "Interferon beta-1a_INT_Aminophylline", "text": "Interaction: Interferon beta-1a AND Aminophylline\nDetails: The metabolism of Aminophylline can be decreased when combined with Interferon beta-1a.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Aminophylline"}, {"id": "Interferon beta-1a_INT_Zidovudine", "text": "Interaction: Interferon beta-1a AND Zidovudine\nDetails: The risk or severity of adverse effects can be increased when Interferon beta-1a is combined with Zidovudine.\nRisk: Monitor closely.", "source": "Interferon beta-1a + Zidovudine"}, {"id": "Pegademase bovine_GEN", "text": "Drug: Pegademase bovine\nDescription: Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life....", "source": "Pegademase bovine"}, {"id": "Pegademase bovine_CLIN", "text": "Drug: Pegademase bovine\nMechanism: Pegademase converts adenosine (toxic) to inosine (less toxic) by deamination. It also converts 2'-deoxyadenosine to 2'-deoxyinosine via deamination....\nToxicity: ...", "source": "Pegademase bovine"}, {"id": "Pegademase bovine_INT_Pentostatin", "text": "Interaction: Pegademase bovine AND Pentostatin\nDetails: The therapeutic efficacy of Pentostatin can be decreased when used in combination with Pegademase bovine.\nRisk: Monitor closely.", "source": "Pegademase bovine + Pentostatin"}, {"id": "Pegademase bovine_INT_Pegloticase", "text": "Interaction: Pegademase bovine AND Pegloticase\nDetails: The therapeutic efficacy of Pegademase bovine can be decreased when used in combination with Pegloticase.\nRisk: Monitor closely.", "source": "Pegademase bovine + Pegloticase"}, {"id": "Human Serum Albumin_GEN", "text": "Drug: Human Serum Albumin\nDescription: Human serum albumin isolated from expired blood plasma. In the iodonated form ( I 131), it is used as a diagnostic radiopharmaceutical for intravenous imaging....", "source": "Human Serum Albumin"}, {"id": "Human Serum Albumin_CLIN", "text": "Drug: Human Serum Albumin\nMechanism: Serum albumin acts as a high molecular weight, very soluble osmolyte. Serum albumin also acts as a protein drug carrier in plasma, and transports hemin, steroids, thyroid hormones and fatty acids. It ...\nToxicity: ...", "source": "Human Serum Albumin"}, {"id": "Eptifibatide_GEN", "text": "Drug: Eptifibatide\nDescription: ...", "source": "Eptifibatide"}, {"id": "Eptifibatide_GEN", "text": "Drug: Eptifibatide\nDescription: Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation....", "source": "Eptifibatide"}, {"id": "Eptifibatide_CLIN", "text": "Drug: Eptifibatide\nMechanism: Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand facto...\nToxicity: Eptifibatide was not lethal to rats, rabbits, or monkeys when administered by continuous intravenous infusion for 90 minutes at a total dose of 45 mg/kg (about 2 to 5 times the recommended maximum dai...", "source": "Eptifibatide"}, {"id": "Eptifibatide_INT_Urokinase", "text": "Interaction: Eptifibatide AND Urokinase\nDetails: Eptifibatide may increase the anticoagulant activities of Urokinase.\nRisk: Monitor closely.", "source": "Eptifibatide + Urokinase"}, {"id": "Eptifibatide_INT_Aprotinin", "text": "Interaction: Eptifibatide AND Aprotinin\nDetails: The therapeutic efficacy of Eptifibatide can be decreased when used in combination with Aprotinin.\nRisk: Monitor closely.", "source": "Eptifibatide + Aprotinin"}, {"id": "Eptifibatide_INT_Rivaroxaban", "text": "Interaction: Eptifibatide AND Rivaroxaban\nDetails: Eptifibatide may increase the anticoagulant activities of Rivaroxaban.\nRisk: Monitor closely.", "source": "Eptifibatide + Rivaroxaban"}, {"id": "Eptifibatide_INT_Apixaban", "text": "Interaction: Eptifibatide AND Apixaban\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Apixaban.\nRisk: Monitor closely.", "source": "Eptifibatide + Apixaban"}, {"id": "Eptifibatide_INT_Dabigatran etexilate", "text": "Interaction: Eptifibatide AND Dabigatran etexilate\nDetails: Eptifibatide may increase the anticoagulant activities of Dabigatran etexilate.\nRisk: Monitor closely.", "source": "Eptifibatide + Dabigatran etexilate"}, {"id": "Eptifibatide_INT_Salicylic acid", "text": "Interaction: Eptifibatide AND Salicylic acid\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Salicylic acid.\nRisk: Monitor closely.", "source": "Eptifibatide + Salicylic acid"}, {"id": "Eptifibatide_INT_Acetylsalicylic acid", "text": "Interaction: Eptifibatide AND Acetylsalicylic acid\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Acetylsalicylic acid.\nRisk: Monitor closely.", "source": "Eptifibatide + Acetylsalicylic acid"}, {"id": "Eptifibatide_INT_Aminosalicylic Acid", "text": "Interaction: Eptifibatide AND Aminosalicylic Acid\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Aminosalicylic Acid.\nRisk: Monitor closely.", "source": "Eptifibatide + Aminosalicylic Acid"}, {"id": "Eptifibatide_INT_Mesalazine", "text": "Interaction: Eptifibatide AND Mesalazine\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Mesalazine.\nRisk: Monitor closely.", "source": "Eptifibatide + Mesalazine"}, {"id": "Eptifibatide_INT_Diflunisal", "text": "Interaction: Eptifibatide AND Diflunisal\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Diflunisal.\nRisk: Monitor closely.", "source": "Eptifibatide + Diflunisal"}, {"id": "Eptifibatide_INT_Balsalazide", "text": "Interaction: Eptifibatide AND Balsalazide\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Balsalazide.\nRisk: Monitor closely.", "source": "Eptifibatide + Balsalazide"}, {"id": "Eptifibatide_INT_Olsalazine", "text": "Interaction: Eptifibatide AND Olsalazine\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Olsalazine.\nRisk: Monitor closely.", "source": "Eptifibatide + Olsalazine"}, {"id": "Eptifibatide_INT_dersalazine", "text": "Interaction: Eptifibatide AND dersalazine\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with dersalazine.\nRisk: Monitor closely.", "source": "Eptifibatide + dersalazine"}, {"id": "Eptifibatide_INT_Nitroaspirin", "text": "Interaction: Eptifibatide AND Nitroaspirin\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Nitroaspirin.\nRisk: Monitor closely.", "source": "Eptifibatide + Nitroaspirin"}, {"id": "Eptifibatide_INT_Aloxiprin", "text": "Interaction: Eptifibatide AND Aloxiprin\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Aloxiprin.\nRisk: Monitor closely.", "source": "Eptifibatide + Aloxiprin"}, {"id": "Eptifibatide_INT_Guacetisal", "text": "Interaction: Eptifibatide AND Guacetisal\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Guacetisal.\nRisk: Monitor closely.", "source": "Eptifibatide + Guacetisal"}, {"id": "Eptifibatide_INT_Carbaspirin calcium", "text": "Interaction: Eptifibatide AND Carbaspirin calcium\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Carbaspirin calcium.\nRisk: Monitor closely.", "source": "Eptifibatide + Carbaspirin calcium"}, {"id": "Eptifibatide_INT_Hemoglobin crosfumaril", "text": "Interaction: Eptifibatide AND Hemoglobin crosfumaril\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Hemoglobin crosfumaril.\nRisk: Monitor closely.", "source": "Eptifibatide + Hemoglobin crosfumaril"}, {"id": "Eptifibatide_INT_Methyl salicylate", "text": "Interaction: Eptifibatide AND Methyl salicylate\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Methyl salicylate.\nRisk: Monitor closely.", "source": "Eptifibatide + Methyl salicylate"}, {"id": "Eptifibatide_INT_Trolamine salicylate", "text": "Interaction: Eptifibatide AND Trolamine salicylate\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Trolamine salicylate.\nRisk: Monitor closely.", "source": "Eptifibatide + Trolamine salicylate"}, {"id": "Eptifibatide_INT_Pentosan Polysulfate", "text": "Interaction: Eptifibatide AND Pentosan Polysulfate\nDetails: The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Pentosan Polysulfate"}, {"id": "Eptifibatide_INT_Treprostinil", "text": "Interaction: Eptifibatide AND Treprostinil\nDetails: Treprostinil may increase the antiplatelet activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Treprostinil"}, {"id": "Eptifibatide_INT_Iloprost", "text": "Interaction: Eptifibatide AND Iloprost\nDetails: Iloprost may increase the antiplatelet activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Iloprost"}, {"id": "Eptifibatide_INT_Epoprostenol", "text": "Interaction: Eptifibatide AND Epoprostenol\nDetails: Epoprostenol may increase the antiplatelet activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Epoprostenol"}, {"id": "Eptifibatide_INT_Limaprost", "text": "Interaction: Eptifibatide AND Limaprost\nDetails: The risk or severity of adverse effects can be increased when Limaprost is combined with Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Limaprost"}, {"id": "Eptifibatide_INT_Collagenase clostridium histolyticum", "text": "Interaction: Eptifibatide AND Collagenase clostridium histolyticum\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Eptifibatide + Collagenase clostridium histolyticum"}, {"id": "Eptifibatide_INT_Omega-3 fatty acids", "text": "Interaction: Eptifibatide AND Omega-3 fatty acids\nDetails: Omega-3 fatty acids may increase the antiplatelet activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Omega-3 fatty acids"}, {"id": "Eptifibatide_INT_Tositumomab", "text": "Interaction: Eptifibatide AND Tositumomab\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Eptifibatide + Tositumomab"}, {"id": "Eptifibatide_INT_Lepirudin", "text": "Interaction: Eptifibatide AND Lepirudin\nDetails: Eptifibatide may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Eptifibatide + Lepirudin"}, {"id": "Eptifibatide_INT_Bivalirudin", "text": "Interaction: Eptifibatide AND Bivalirudin\nDetails: Eptifibatide may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Eptifibatide + Bivalirudin"}, {"id": "Eptifibatide_INT_Abciximab", "text": "Interaction: Eptifibatide AND Abciximab\nDetails: Eptifibatide may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Eptifibatide + Abciximab"}, {"id": "Eptifibatide_INT_Becaplermin", "text": "Interaction: Eptifibatide AND Becaplermin\nDetails: Eptifibatide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Eptifibatide + Becaplermin"}, {"id": "Eptifibatide_INT_Dicoumarol", "text": "Interaction: Eptifibatide AND Dicoumarol\nDetails: Eptifibatide may increase the anticoagulant activities of Dicoumarol.\nRisk: Monitor closely.", "source": "Eptifibatide + Dicoumarol"}, {"id": "Eptifibatide_INT_Argatroban", "text": "Interaction: Eptifibatide AND Argatroban\nDetails: Eptifibatide may increase the anticoagulant activities of Argatroban.\nRisk: Monitor closely.", "source": "Eptifibatide + Argatroban"}, {"id": "Eptifibatide_INT_Ardeparin", "text": "Interaction: Eptifibatide AND Ardeparin\nDetails: Eptifibatide may increase the anticoagulant activities of Ardeparin.\nRisk: Monitor closely.", "source": "Eptifibatide + Ardeparin"}, {"id": "Eptifibatide_INT_Phenindione", "text": "Interaction: Eptifibatide AND Phenindione\nDetails: Eptifibatide may increase the anticoagulant activities of Phenindione.\nRisk: Monitor closely.", "source": "Eptifibatide + Phenindione"}, {"id": "Eptifibatide_INT_Fondaparinux sodium", "text": "Interaction: Eptifibatide AND Fondaparinux sodium\nDetails: Eptifibatide may increase the anticoagulant activities of Fondaparinux sodium.\nRisk: Monitor closely.", "source": "Eptifibatide + Fondaparinux sodium"}, {"id": "Eptifibatide_INT_Warfarin", "text": "Interaction: Eptifibatide AND Warfarin\nDetails: Eptifibatide may increase the anticoagulant activities of Warfarin.\nRisk: Monitor closely.", "source": "Eptifibatide + Warfarin"}, {"id": "Eptifibatide_INT_Phenprocoumon", "text": "Interaction: Eptifibatide AND Phenprocoumon\nDetails: Eptifibatide may increase the anticoagulant activities of Phenprocoumon.\nRisk: Monitor closely.", "source": "Eptifibatide + Phenprocoumon"}, {"id": "Eptifibatide_INT_Edetic Acid", "text": "Interaction: Eptifibatide AND Edetic Acid\nDetails: Eptifibatide may increase the anticoagulant activities of Edetic Acid.\nRisk: Monitor closely.", "source": "Eptifibatide + Edetic Acid"}, {"id": "Eptifibatide_INT_Heparin", "text": "Interaction: Eptifibatide AND Heparin\nDetails: Eptifibatide may increase the anticoagulant activities of Heparin.\nRisk: Monitor closely.", "source": "Eptifibatide + Heparin"}, {"id": "Eptifibatide_INT_Enoxaparin", "text": "Interaction: Eptifibatide AND Enoxaparin\nDetails: Eptifibatide may increase the anticoagulant activities of Enoxaparin.\nRisk: Monitor closely.", "source": "Eptifibatide + Enoxaparin"}, {"id": "Eptifibatide_INT_Acenocoumarol", "text": "Interaction: Eptifibatide AND Acenocoumarol\nDetails: Eptifibatide may increase the anticoagulant activities of Acenocoumarol.\nRisk: Monitor closely.", "source": "Eptifibatide + Acenocoumarol"}, {"id": "Eptifibatide_INT_Citric Acid", "text": "Interaction: Eptifibatide AND Citric Acid\nDetails: Eptifibatide may increase the anticoagulant activities of Citric Acid.\nRisk: Monitor closely.", "source": "Eptifibatide + Citric Acid"}, {"id": "Eptifibatide_INT_Ximelagatran", "text": "Interaction: Eptifibatide AND Ximelagatran\nDetails: Eptifibatide may increase the anticoagulant activities of Ximelagatran.\nRisk: Monitor closely.", "source": "Eptifibatide + Ximelagatran"}, {"id": "Eptifibatide_INT_Ancrod", "text": "Interaction: Eptifibatide AND Ancrod\nDetails: Eptifibatide may increase the anticoagulant activities of Ancrod.\nRisk: Monitor closely.", "source": "Eptifibatide + Ancrod"}, {"id": "Eptifibatide_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Eptifibatide AND Pentaerythritol Tetranitrate\nDetails: Eptifibatide may increase the anticoagulant activities of Pentaerythritol Tetranitrate.\nRisk: Monitor closely.", "source": "Eptifibatide + Pentaerythritol Tetranitrate"}, {"id": "Eptifibatide_INT_Sulodexide", "text": "Interaction: Eptifibatide AND Sulodexide\nDetails: Eptifibatide may increase the anticoagulant activities of Sulodexide.\nRisk: Monitor closely.", "source": "Eptifibatide + Sulodexide"}, {"id": "Eptifibatide_INT_Idraparinux", "text": "Interaction: Eptifibatide AND Idraparinux\nDetails: Eptifibatide may increase the anticoagulant activities of Idraparinux.\nRisk: Monitor closely.", "source": "Eptifibatide + Idraparinux"}, {"id": "Eptifibatide_INT_Otamixaban", "text": "Interaction: Eptifibatide AND Otamixaban\nDetails: Eptifibatide may increase the anticoagulant activities of Otamixaban.\nRisk: Monitor closely.", "source": "Eptifibatide + Otamixaban"}, {"id": "Eptifibatide_INT_Danaparoid", "text": "Interaction: Eptifibatide AND Danaparoid\nDetails: Eptifibatide may increase the anticoagulant activities of Danaparoid.\nRisk: Monitor closely.", "source": "Eptifibatide + Danaparoid"}, {"id": "Eptifibatide_INT_Dalteparin", "text": "Interaction: Eptifibatide AND Dalteparin\nDetails: Eptifibatide may increase the anticoagulant activities of Dalteparin.\nRisk: Monitor closely.", "source": "Eptifibatide + Dalteparin"}, {"id": "Eptifibatide_INT_Ferulic acid", "text": "Interaction: Eptifibatide AND Ferulic acid\nDetails: Eptifibatide may increase the anticoagulant activities of Ferulic acid.\nRisk: Monitor closely.", "source": "Eptifibatide + Ferulic acid"}, {"id": "Eptifibatide_INT_Ethyl biscoumacetate", "text": "Interaction: Eptifibatide AND Ethyl biscoumacetate\nDetails: Eptifibatide may increase the anticoagulant activities of Ethyl biscoumacetate.\nRisk: Monitor closely.", "source": "Eptifibatide + Ethyl biscoumacetate"}, {"id": "Eptifibatide_INT_Nadroparin", "text": "Interaction: Eptifibatide AND Nadroparin\nDetails: Eptifibatide may increase the anticoagulant activities of Nadroparin.\nRisk: Monitor closely.", "source": "Eptifibatide + Nadroparin"}, {"id": "Eptifibatide_INT_Edoxaban", "text": "Interaction: Eptifibatide AND Edoxaban\nDetails: Eptifibatide may increase the anticoagulant activities of Edoxaban.\nRisk: Monitor closely.", "source": "Eptifibatide + Edoxaban"}, {"id": "Eptifibatide_INT_Dextran", "text": "Interaction: Eptifibatide AND Dextran\nDetails: Eptifibatide may increase the anticoagulant activities of Dextran.\nRisk: Monitor closely.", "source": "Eptifibatide + Dextran"}, {"id": "Eptifibatide_INT_Reviparin", "text": "Interaction: Eptifibatide AND Reviparin\nDetails: Eptifibatide may increase the anticoagulant activities of Reviparin.\nRisk: Monitor closely.", "source": "Eptifibatide + Reviparin"}, {"id": "Eptifibatide_INT_Certoparin", "text": "Interaction: Eptifibatide AND Certoparin\nDetails: Eptifibatide may increase the anticoagulant activities of Certoparin.\nRisk: Monitor closely.", "source": "Eptifibatide + Certoparin"}, {"id": "Eptifibatide_INT_Dextran 70", "text": "Interaction: Eptifibatide AND Dextran 70\nDetails: Eptifibatide may increase the anticoagulant activities of Dextran 70.\nRisk: Monitor closely.", "source": "Eptifibatide + Dextran 70"}, {"id": "Eptifibatide_INT_Desirudin", "text": "Interaction: Eptifibatide AND Desirudin\nDetails: Eptifibatide may increase the anticoagulant activities of Desirudin.\nRisk: Monitor closely.", "source": "Eptifibatide + Desirudin"}, {"id": "Eptifibatide_INT_Dextran 40", "text": "Interaction: Eptifibatide AND Dextran 40\nDetails: Eptifibatide may increase the anticoagulant activities of Dextran 40.\nRisk: Monitor closely.", "source": "Eptifibatide + Dextran 40"}, {"id": "Eptifibatide_INT_Dextran 75", "text": "Interaction: Eptifibatide AND Dextran 75\nDetails: Eptifibatide may increase the anticoagulant activities of Dextran 75.\nRisk: Monitor closely.", "source": "Eptifibatide + Dextran 75"}, {"id": "Eptifibatide_INT_Protocatechualdehyde", "text": "Interaction: Eptifibatide AND Protocatechualdehyde\nDetails: Eptifibatide may increase the anticoagulant activities of Protocatechualdehyde.\nRisk: Monitor closely.", "source": "Eptifibatide + Protocatechualdehyde"}, {"id": "Eptifibatide_INT_Protein C", "text": "Interaction: Eptifibatide AND Protein C\nDetails: Eptifibatide may increase the anticoagulant activities of Protein C.\nRisk: Monitor closely.", "source": "Eptifibatide + Protein C"}, {"id": "Eptifibatide_INT_Antithrombin III human", "text": "Interaction: Eptifibatide AND Antithrombin III human\nDetails: Eptifibatide may increase the anticoagulant activities of Antithrombin III human.\nRisk: Monitor closely.", "source": "Eptifibatide + Antithrombin III human"}, {"id": "Eptifibatide_INT_Fondaparinux", "text": "Interaction: Eptifibatide AND Fondaparinux\nDetails: Eptifibatide may increase the anticoagulant activities of Fondaparinux.\nRisk: Monitor closely.", "source": "Eptifibatide + Fondaparinux"}, {"id": "Eptifibatide_INT_Letaxaban", "text": "Interaction: Eptifibatide AND Letaxaban\nDetails: Eptifibatide may increase the anticoagulant activities of Letaxaban.\nRisk: Monitor closely.", "source": "Eptifibatide + Letaxaban"}, {"id": "Eptifibatide_INT_Darexaban", "text": "Interaction: Eptifibatide AND Darexaban\nDetails: Eptifibatide may increase the anticoagulant activities of Darexaban.\nRisk: Monitor closely.", "source": "Eptifibatide + Darexaban"}, {"id": "Eptifibatide_INT_Nafamostat", "text": "Interaction: Eptifibatide AND Nafamostat\nDetails: Eptifibatide may increase the anticoagulant activities of Nafamostat.\nRisk: Monitor closely.", "source": "Eptifibatide + Nafamostat"}, {"id": "Eptifibatide_INT_Gabexate", "text": "Interaction: Eptifibatide AND Gabexate\nDetails: Eptifibatide may increase the anticoagulant activities of Gabexate.\nRisk: Monitor closely.", "source": "Eptifibatide + Gabexate"}, {"id": "Eptifibatide_INT_Troxerutin", "text": "Interaction: Eptifibatide AND Troxerutin\nDetails: Eptifibatide may increase the anticoagulant activities of Troxerutin.\nRisk: Monitor closely.", "source": "Eptifibatide + Troxerutin"}, {"id": "Eptifibatide_INT_Fluindione", "text": "Interaction: Eptifibatide AND Fluindione\nDetails: Eptifibatide may increase the anticoagulant activities of Fluindione.\nRisk: Monitor closely.", "source": "Eptifibatide + Fluindione"}, {"id": "Eptifibatide_INT_Protein S human", "text": "Interaction: Eptifibatide AND Protein S human\nDetails: Eptifibatide may increase the anticoagulant activities of Protein S human.\nRisk: Monitor closely.", "source": "Eptifibatide + Protein S human"}, {"id": "Eptifibatide_INT_Melagatran", "text": "Interaction: Eptifibatide AND Melagatran\nDetails: Eptifibatide may increase the anticoagulant activities of Melagatran.\nRisk: Monitor closely.", "source": "Eptifibatide + Melagatran"}, {"id": "Eptifibatide_INT_Deoxycholic Acid", "text": "Interaction: Eptifibatide AND Deoxycholic Acid\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Deoxycholic Acid.\nRisk: Monitor closely.", "source": "Eptifibatide + Deoxycholic Acid"}, {"id": "Eptifibatide_INT_Alteplase", "text": "Interaction: Eptifibatide AND Alteplase\nDetails: Eptifibatide may increase the anticoagulant activities of Alteplase.\nRisk: Monitor closely.", "source": "Eptifibatide + Alteplase"}, {"id": "Eptifibatide_INT_Reteplase", "text": "Interaction: Eptifibatide AND Reteplase\nDetails: Eptifibatide may increase the anticoagulant activities of Reteplase.\nRisk: Monitor closely.", "source": "Eptifibatide + Reteplase"}, {"id": "Eptifibatide_INT_Anistreplase", "text": "Interaction: Eptifibatide AND Anistreplase\nDetails: Eptifibatide may increase the anticoagulant activities of Anistreplase.\nRisk: Monitor closely.", "source": "Eptifibatide + Anistreplase"}, {"id": "Eptifibatide_INT_Tenecteplase", "text": "Interaction: Eptifibatide AND Tenecteplase\nDetails: Eptifibatide may increase the anticoagulant activities of Tenecteplase.\nRisk: Monitor closely.", "source": "Eptifibatide + Tenecteplase"}, {"id": "Eptifibatide_INT_Drotrecogin alfa", "text": "Interaction: Eptifibatide AND Drotrecogin alfa\nDetails: Eptifibatide may increase the anticoagulant activities of Drotrecogin alfa.\nRisk: Monitor closely.", "source": "Eptifibatide + Drotrecogin alfa"}, {"id": "Eptifibatide_INT_Ticlopidine", "text": "Interaction: Eptifibatide AND Ticlopidine\nDetails: Eptifibatide may increase the anticoagulant activities of Ticlopidine.\nRisk: Monitor closely.", "source": "Eptifibatide + Ticlopidine"}, {"id": "Eptifibatide_INT_Tirofiban", "text": "Interaction: Eptifibatide AND Tirofiban\nDetails: Eptifibatide may increase the anticoagulant activities of Tirofiban.\nRisk: Monitor closely.", "source": "Eptifibatide + Tirofiban"}, {"id": "Eptifibatide_INT_Cilostazol", "text": "Interaction: Eptifibatide AND Cilostazol\nDetails: Eptifibatide may increase the anticoagulant activities of Cilostazol.\nRisk: Monitor closely.", "source": "Eptifibatide + Cilostazol"}, {"id": "Eptifibatide_INT_Defibrotide", "text": "Interaction: Eptifibatide AND Defibrotide\nDetails: Eptifibatide may increase the anticoagulant activities of Defibrotide.\nRisk: Monitor closely.", "source": "Eptifibatide + Defibrotide"}, {"id": "Eptifibatide_INT_Tinzaparin", "text": "Interaction: Eptifibatide AND Tinzaparin\nDetails: Eptifibatide may increase the anticoagulant activities of Tinzaparin.\nRisk: Monitor closely.", "source": "Eptifibatide + Tinzaparin"}, {"id": "Eptifibatide_INT_Brinase", "text": "Interaction: Eptifibatide AND Brinase\nDetails: Eptifibatide may increase the anticoagulant activities of Brinase.\nRisk: Monitor closely.", "source": "Eptifibatide + Brinase"}, {"id": "Eptifibatide_INT_Saruplase", "text": "Interaction: Eptifibatide AND Saruplase\nDetails: Eptifibatide may increase the anticoagulant activities of Saruplase.\nRisk: Monitor closely.", "source": "Eptifibatide + Saruplase"}, {"id": "Eptifibatide_INT_Streptokinase", "text": "Interaction: Eptifibatide AND Streptokinase\nDetails: Eptifibatide may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Eptifibatide + Streptokinase"}, {"id": "Eptifibatide_INT_Anagrelide", "text": "Interaction: Eptifibatide AND Anagrelide\nDetails: Eptifibatide may increase the anticoagulant activities of Anagrelide.\nRisk: Monitor closely.", "source": "Eptifibatide + Anagrelide"}, {"id": "Eptifibatide_INT_Rosiglitazone", "text": "Interaction: Eptifibatide AND Rosiglitazone\nDetails: Eptifibatide may increase the anticoagulant activities of Rosiglitazone.\nRisk: Monitor closely.", "source": "Eptifibatide + Rosiglitazone"}, {"id": "Eptifibatide_INT_Desmoteplase", "text": "Interaction: Eptifibatide AND Desmoteplase\nDetails: Eptifibatide may increase the anticoagulant activities of Desmoteplase.\nRisk: Monitor closely.", "source": "Eptifibatide + Desmoteplase"}, {"id": "Eptifibatide_INT_Fibrinolysin", "text": "Interaction: Eptifibatide AND Fibrinolysin\nDetails: Eptifibatide may increase the anticoagulant activities of Fibrinolysin.\nRisk: Monitor closely.", "source": "Eptifibatide + Fibrinolysin"}, {"id": "Eptifibatide_INT_ALX-0081", "text": "Interaction: Eptifibatide AND ALX-0081\nDetails: Eptifibatide may increase the anticoagulant activities of ALX-0081.\nRisk: Monitor closely.", "source": "Eptifibatide + ALX-0081"}, {"id": "Eptifibatide_INT_eplivanserine", "text": "Interaction: Eptifibatide AND eplivanserine\nDetails: Eptifibatide may increase the anticoagulant activities of eplivanserine.\nRisk: Monitor closely.", "source": "Eptifibatide + eplivanserine"}, {"id": "Eptifibatide_INT_Astaxanthin", "text": "Interaction: Eptifibatide AND Astaxanthin\nDetails: Eptifibatide may increase the anticoagulant activities of Astaxanthin.\nRisk: Monitor closely.", "source": "Eptifibatide + Astaxanthin"}, {"id": "Eptifibatide_INT_Batroxobin", "text": "Interaction: Eptifibatide AND Batroxobin\nDetails: Eptifibatide may increase the anticoagulant activities of Batroxobin.\nRisk: Monitor closely.", "source": "Eptifibatide + Batroxobin"}, {"id": "Eptifibatide_INT_Ozagrel", "text": "Interaction: Eptifibatide AND Ozagrel\nDetails: Eptifibatide may increase the anticoagulant activities of Ozagrel.\nRisk: Monitor closely.", "source": "Eptifibatide + Ozagrel"}, {"id": "Eptifibatide_INT_Sarpogrelate", "text": "Interaction: Eptifibatide AND Sarpogrelate\nDetails: Eptifibatide may increase the anticoagulant activities of Sarpogrelate.\nRisk: Monitor closely.", "source": "Eptifibatide + Sarpogrelate"}, {"id": "Eptifibatide_INT_Eplivanserin", "text": "Interaction: Eptifibatide AND Eplivanserin\nDetails: Eptifibatide may increase the anticoagulant activities of Eplivanserin.\nRisk: Monitor closely.", "source": "Eptifibatide + Eplivanserin"}, {"id": "Eptifibatide_INT_Higenamine", "text": "Interaction: Eptifibatide AND Higenamine\nDetails: Eptifibatide may increase the anticoagulant activities of Higenamine.\nRisk: Monitor closely.", "source": "Eptifibatide + Higenamine"}, {"id": "Eptifibatide_INT_Clopidogrel", "text": "Interaction: Eptifibatide AND Clopidogrel\nDetails: Eptifibatide may increase the anticoagulant activities of Clopidogrel.\nRisk: Monitor closely.", "source": "Eptifibatide + Clopidogrel"}, {"id": "Eptifibatide_INT_Dipyridamole", "text": "Interaction: Eptifibatide AND Dipyridamole\nDetails: Eptifibatide may increase the anticoagulant activities of Dipyridamole.\nRisk: Monitor closely.", "source": "Eptifibatide + Dipyridamole"}, {"id": "Eptifibatide_INT_Beraprost", "text": "Interaction: Eptifibatide AND Beraprost\nDetails: Eptifibatide may increase the anticoagulant activities of Beraprost.\nRisk: Monitor closely.", "source": "Eptifibatide + Beraprost"}, {"id": "Eptifibatide_INT_Prasugrel", "text": "Interaction: Eptifibatide AND Prasugrel\nDetails: Eptifibatide may increase the anticoagulant activities of Prasugrel.\nRisk: Monitor closely.", "source": "Eptifibatide + Prasugrel"}, {"id": "Eptifibatide_INT_Cangrelor", "text": "Interaction: Eptifibatide AND Cangrelor\nDetails: Eptifibatide may increase the anticoagulant activities of Cangrelor.\nRisk: Monitor closely.", "source": "Eptifibatide + Cangrelor"}, {"id": "Eptifibatide_INT_Triflusal", "text": "Interaction: Eptifibatide AND Triflusal\nDetails: Eptifibatide may increase the anticoagulant activities of Triflusal.\nRisk: Monitor closely.", "source": "Eptifibatide + Triflusal"}, {"id": "Eptifibatide_INT_Ticagrelor", "text": "Interaction: Eptifibatide AND Ticagrelor\nDetails: Eptifibatide may increase the anticoagulant activities of Ticagrelor.\nRisk: Monitor closely.", "source": "Eptifibatide + Ticagrelor"}, {"id": "Eptifibatide_INT_Ditazole", "text": "Interaction: Eptifibatide AND Ditazole\nDetails: Eptifibatide may increase the anticoagulant activities of Ditazole.\nRisk: Monitor closely.", "source": "Eptifibatide + Ditazole"}, {"id": "Eptifibatide_INT_Vorapaxar", "text": "Interaction: Eptifibatide AND Vorapaxar\nDetails: Eptifibatide may increase the anticoagulant activities of Vorapaxar.\nRisk: Monitor closely.", "source": "Eptifibatide + Vorapaxar"}, {"id": "Eptifibatide_INT_Bemiparin", "text": "Interaction: Eptifibatide AND Bemiparin\nDetails: Eptifibatide may increase the anticoagulant activities of Bemiparin.\nRisk: Monitor closely.", "source": "Eptifibatide + Bemiparin"}, {"id": "Eptifibatide_INT_Parnaparin", "text": "Interaction: Eptifibatide AND Parnaparin\nDetails: Eptifibatide may increase the anticoagulant activities of Parnaparin.\nRisk: Monitor closely.", "source": "Eptifibatide + Parnaparin"}, {"id": "Eptifibatide_INT_Selexipag", "text": "Interaction: Eptifibatide AND Selexipag\nDetails: Eptifibatide may increase the anticoagulant activities of Selexipag.\nRisk: Monitor closely.", "source": "Eptifibatide + Selexipag"}, {"id": "Eptifibatide_INT_Indobufen", "text": "Interaction: Eptifibatide AND Indobufen\nDetails: Eptifibatide may increase the anticoagulant activities of Indobufen.\nRisk: Monitor closely.", "source": "Eptifibatide + Indobufen"}, {"id": "Eptifibatide_INT_Clorindione", "text": "Interaction: Eptifibatide AND Clorindione\nDetails: Eptifibatide may increase the anticoagulant activities of Clorindione.\nRisk: Monitor closely.", "source": "Eptifibatide + Clorindione"}, {"id": "Eptifibatide_INT_Picotamide", "text": "Interaction: Eptifibatide AND Picotamide\nDetails: Eptifibatide may increase the anticoagulant activities of Picotamide.\nRisk: Monitor closely.", "source": "Eptifibatide + Picotamide"}, {"id": "Eptifibatide_INT_Diphenadione", "text": "Interaction: Eptifibatide AND Diphenadione\nDetails: Eptifibatide may increase the anticoagulant activities of Diphenadione.\nRisk: Monitor closely.", "source": "Eptifibatide + Diphenadione"}, {"id": "Eptifibatide_INT_Cloricromen", "text": "Interaction: Eptifibatide AND Cloricromen\nDetails: Eptifibatide may increase the anticoagulant activities of Cloricromen.\nRisk: Monitor closely.", "source": "Eptifibatide + Cloricromen"}, {"id": "Eptifibatide_INT_Tioclomarol", "text": "Interaction: Eptifibatide AND Tioclomarol\nDetails: Eptifibatide may increase the anticoagulant activities of Tioclomarol.\nRisk: Monitor closely.", "source": "Eptifibatide + Tioclomarol"}, {"id": "Eptifibatide_INT_Milrinone", "text": "Interaction: Eptifibatide AND Milrinone\nDetails: Milrinone may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Milrinone"}, {"id": "Eptifibatide_INT_Epinastine", "text": "Interaction: Eptifibatide AND Epinastine\nDetails: Epinastine may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Epinastine"}, {"id": "Eptifibatide_INT_Alprostadil", "text": "Interaction: Eptifibatide AND Alprostadil\nDetails: Alprostadil may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Alprostadil"}, {"id": "Eptifibatide_INT_Azelastine", "text": "Interaction: Eptifibatide AND Azelastine\nDetails: Azelastine may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Azelastine"}, {"id": "Eptifibatide_INT_Ridogrel", "text": "Interaction: Eptifibatide AND Ridogrel\nDetails: Ridogrel may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Ridogrel"}, {"id": "Eptifibatide_INT_Sevoflurane", "text": "Interaction: Eptifibatide AND Sevoflurane\nDetails: Sevoflurane may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Sevoflurane"}, {"id": "Eptifibatide_INT_Resveratrol", "text": "Interaction: Eptifibatide AND Resveratrol\nDetails: Resveratrol may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Resveratrol"}, {"id": "Eptifibatide_INT_Nimesulide", "text": "Interaction: Eptifibatide AND Nimesulide\nDetails: Nimesulide may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Nimesulide"}, {"id": "Eptifibatide_INT_Tesmilifene", "text": "Interaction: Eptifibatide AND Tesmilifene\nDetails: Tesmilifene may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Tesmilifene"}, {"id": "Eptifibatide_INT_SRT501", "text": "Interaction: Eptifibatide AND SRT501\nDetails: SRT501 may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + SRT501"}, {"id": "Eptifibatide_INT_Ibudilast", "text": "Interaction: Eptifibatide AND Ibudilast\nDetails: Ibudilast may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Ibudilast"}, {"id": "Eptifibatide_INT_Andrographolide", "text": "Interaction: Eptifibatide AND Andrographolide\nDetails: Andrographolide may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Andrographolide"}, {"id": "Eptifibatide_INT_Tranilast", "text": "Interaction: Eptifibatide AND Tranilast\nDetails: Tranilast may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Tranilast"}, {"id": "Eptifibatide_INT_Icosapent ethyl", "text": "Interaction: Eptifibatide AND Icosapent ethyl\nDetails: Icosapent ethyl may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Icosapent ethyl"}, {"id": "Eptifibatide_INT_Ifenprodil", "text": "Interaction: Eptifibatide AND Ifenprodil\nDetails: Ifenprodil may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Ifenprodil"}, {"id": "Eptifibatide_INT_Trapidil", "text": "Interaction: Eptifibatide AND Trapidil\nDetails: Trapidil may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Trapidil"}, {"id": "Eptifibatide_INT_Naftopidil", "text": "Interaction: Eptifibatide AND Naftopidil\nDetails: Naftopidil may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Naftopidil"}, {"id": "Eptifibatide_INT_Ifetroban", "text": "Interaction: Eptifibatide AND Ifetroban\nDetails: Ifetroban may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Ifetroban"}, {"id": "Eptifibatide_INT_Ketanserin", "text": "Interaction: Eptifibatide AND Ketanserin\nDetails: Ketanserin may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Ketanserin"}, {"id": "Eptifibatide_INT_Butylphthalide", "text": "Interaction: Eptifibatide AND Butylphthalide\nDetails: Butylphthalide may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Butylphthalide"}, {"id": "Eptifibatide_INT_Hydroxytyrosol", "text": "Interaction: Eptifibatide AND Hydroxytyrosol\nDetails: Hydroxytyrosol may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Hydroxytyrosol"}, {"id": "Eptifibatide_INT_Ramatroban", "text": "Interaction: Eptifibatide AND Ramatroban\nDetails: Ramatroban may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Ramatroban"}, {"id": "Eptifibatide_INT_Linsidomine", "text": "Interaction: Eptifibatide AND Linsidomine\nDetails: Linsidomine may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Linsidomine"}, {"id": "Eptifibatide_INT_Buflomedil", "text": "Interaction: Eptifibatide AND Buflomedil\nDetails: Buflomedil may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Buflomedil"}, {"id": "Eptifibatide_INT_Relcovaptan", "text": "Interaction: Eptifibatide AND Relcovaptan\nDetails: Relcovaptan may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Relcovaptan"}, {"id": "Eptifibatide_INT_Dasatinib", "text": "Interaction: Eptifibatide AND Dasatinib\nDetails: Dasatinib may increase the anticoagulant activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Dasatinib"}, {"id": "Eptifibatide_INT_Glucosamine", "text": "Interaction: Eptifibatide AND Glucosamine\nDetails: Glucosamine may increase the antiplatelet activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Glucosamine"}, {"id": "Eptifibatide_INT_Ibritumomab tiuxetan", "text": "Interaction: Eptifibatide AND Ibritumomab tiuxetan\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Eptifibatide + Ibritumomab tiuxetan"}, {"id": "Eptifibatide_INT_Ibrutinib", "text": "Interaction: Eptifibatide AND Ibrutinib\nDetails: The risk or severity of adverse effects can be increased when Ibrutinib is combined with Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Ibrutinib"}, {"id": "Eptifibatide_INT_Obinutuzumab", "text": "Interaction: Eptifibatide AND Obinutuzumab\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Obinutuzumab.\nRisk: Monitor closely.", "source": "Eptifibatide + Obinutuzumab"}, {"id": "Eptifibatide_INT_Pentoxifylline", "text": "Interaction: Eptifibatide AND Pentoxifylline\nDetails: Pentoxifylline may increase the antiplatelet activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Pentoxifylline"}, {"id": "Eptifibatide_INT_Tipranavir", "text": "Interaction: Eptifibatide AND Tipranavir\nDetails: Tipranavir may increase the antiplatelet activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Tipranavir"}, {"id": "Eptifibatide_INT_Vitamin E", "text": "Interaction: Eptifibatide AND Vitamin E\nDetails: Vitamin E may increase the antiplatelet activities of Eptifibatide.\nRisk: Monitor closely.", "source": "Eptifibatide + Vitamin E"}, {"id": "Infliximab_GEN", "text": "Drug: Infliximab\nDescription: Infliximab is a tumor necrosis factor (TNF-alpha or TNF-\u03b1) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions [A31469]. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF...", "source": "Infliximab"}, {"id": "Infliximab_CLIN", "text": "Drug: Infliximab\nMechanism: Infliximab is a IgG1\u03ba monoclonal antibody that binds to soluble and transmembrane forms of TNF-\u03b1 with high affinity to disrupt the pro-inflammatory cascade signalling. Binding of the antibody to TNF-\u03b1...\nToxicity: In an acute toxicity animal study, the NOAEL of intravenous infliximab in rats was 50 mg/kg. In a repeated dose animal study, the NOAEL values of intravenous infliximab was 50 mg/kg in rats at 2 weeks...", "source": "Infliximab"}, {"id": "Infliximab_INT_Rituximab", "text": "Interaction: Infliximab AND Rituximab\nDetails: The risk or severity of adverse effects can be increased when Infliximab is combined with Rituximab.\nRisk: Monitor closely.", "source": "Infliximab + Rituximab"}, {"id": "Infliximab_INT_Canakinumab", "text": "Interaction: Infliximab AND Canakinumab\nDetails: The risk or severity of adverse effects can be increased when Infliximab is combined with Canakinumab.\nRisk: Monitor closely.", "source": "Infliximab + Canakinumab"}, {"id": "Infliximab_INT_Certolizumab pegol", "text": "Interaction: Infliximab AND Certolizumab pegol\nDetails: Infliximab may increase the immunosuppressive activities of Certolizumab pegol.\nRisk: Monitor closely.", "source": "Infliximab + Certolizumab pegol"}, {"id": "Infliximab_INT_Etanercept", "text": "Interaction: Infliximab AND Etanercept\nDetails: Etanercept may increase the immunosuppressive activities of Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Etanercept"}, {"id": "Infliximab_INT_Natalizumab", "text": "Interaction: Infliximab AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Infliximab + Natalizumab"}, {"id": "Infliximab_INT_Anakinra", "text": "Interaction: Infliximab AND Anakinra\nDetails: The risk or severity of adverse effects can be d when Anakinra is combined with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Anakinra"}, {"id": "Infliximab_INT_Pimecrolimus", "text": "Interaction: Infliximab AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Pimecrolimus"}, {"id": "Infliximab_INT_Abatacept", "text": "Interaction: Infliximab AND Abatacept\nDetails: The risk or severity of adverse effects can be d when Abatacept is combined with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Abatacept"}, {"id": "Infliximab_INT_Rilonacept", "text": "Interaction: Infliximab AND Rilonacept\nDetails: The risk or severity of adverse effects can be increased when Infliximab is combined with Rilonacept.\nRisk: Monitor closely.", "source": "Infliximab + Rilonacept"}, {"id": "Infliximab_INT_Tocilizumab", "text": "Interaction: Infliximab AND Tocilizumab\nDetails: The risk or severity of adverse effects can be d when Tocilizumab is combined with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Tocilizumab"}, {"id": "Infliximab_INT_Tofacitinib", "text": "Interaction: Infliximab AND Tofacitinib\nDetails: The risk or severity of adverse effects can be increased when Infliximab is combined with Tofacitinib.\nRisk: Monitor closely.", "source": "Infliximab + Tofacitinib"}, {"id": "Infliximab_INT_Vedolizumab", "text": "Interaction: Infliximab AND Vedolizumab\nDetails: The risk or severity of infection can be increased when Infliximab is combined with Vedolizumab.\nRisk: Monitor closely.", "source": "Infliximab + Vedolizumab"}, {"id": "Infliximab_INT_Tacrolimus", "text": "Interaction: Infliximab AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Tacrolimus"}, {"id": "Infliximab_INT_Belimumab", "text": "Interaction: Infliximab AND Belimumab\nDetails: The risk or severity of adverse effects can be increased when Infliximab is combined with Belimumab.\nRisk: Monitor closely.", "source": "Infliximab + Belimumab"}, {"id": "Infliximab_INT_Adalimumab", "text": "Interaction: Infliximab AND Adalimumab\nDetails: Adalimumab may increase the immunosuppressive activities of Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Adalimumab"}, {"id": "Infliximab_INT_Golimumab", "text": "Interaction: Infliximab AND Golimumab\nDetails: Golimumab may increase the immunosuppressive activities of Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Golimumab"}, {"id": "Infliximab_INT_Ustekinumab", "text": "Interaction: Infliximab AND Ustekinumab\nDetails: Ustekinumab may increase the immunosuppressive activities of Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Ustekinumab"}, {"id": "Infliximab_INT_BCG vaccine", "text": "Interaction: Infliximab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + BCG vaccine"}, {"id": "Infliximab_INT_Sarilumab", "text": "Interaction: Infliximab AND Sarilumab\nDetails: Sarilumab may increase the immunosuppressive activities of Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Sarilumab"}, {"id": "Infliximab_INT_Leflunomide", "text": "Interaction: Infliximab AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Infliximab is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Infliximab + Leflunomide"}, {"id": "Infliximab_INT_Fingolimod", "text": "Interaction: Infliximab AND Fingolimod\nDetails: Infliximab may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Infliximab + Fingolimod"}, {"id": "Infliximab_INT_Roflumilast", "text": "Interaction: Infliximab AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Roflumilast"}, {"id": "Infliximab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Infliximab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Infliximab_INT_Yellow fever vaccine", "text": "Interaction: Infliximab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Yellow fever vaccine"}, {"id": "Infliximab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Infliximab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Infliximab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Infliximab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Infliximab_INT_Rotavirus Vaccine", "text": "Interaction: Infliximab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Rotavirus Vaccine"}, {"id": "Infliximab_INT_G17DT", "text": "Interaction: Infliximab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + G17DT"}, {"id": "Infliximab_INT_INGN 201", "text": "Interaction: Infliximab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + INGN 201"}, {"id": "Infliximab_INT_INGN 225", "text": "Interaction: Infliximab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + INGN 225"}, {"id": "Infliximab_INT_Rindopepimut", "text": "Interaction: Infliximab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Rindopepimut"}, {"id": "Infliximab_INT_SRP 299", "text": "Interaction: Infliximab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + SRP 299"}, {"id": "Infliximab_INT_GI-5005", "text": "Interaction: Infliximab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + GI-5005"}, {"id": "Infliximab_INT_TG4010", "text": "Interaction: Infliximab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + TG4010"}, {"id": "Infliximab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Infliximab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Rabies virus inactivated antigen, A"}, {"id": "Infliximab_INT_Tecemotide", "text": "Interaction: Infliximab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Tecemotide"}, {"id": "Infliximab_INT_Rubella virus vaccine", "text": "Interaction: Infliximab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Rubella virus vaccine"}, {"id": "Infliximab_INT_Hepatitis A Vaccine", "text": "Interaction: Infliximab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Hepatitis A Vaccine"}, {"id": "Infliximab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Infliximab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Salmonella typhi ty21a live antigen"}, {"id": "Infliximab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Infliximab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Infliximab_INT_Denosumab", "text": "Interaction: Infliximab AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Denosumab"}, {"id": "Infliximab_INT_Sipuleucel-T", "text": "Interaction: Infliximab AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Sipuleucel-T"}, {"id": "Infliximab_INT_Trastuzumab", "text": "Interaction: Infliximab AND Trastuzumab\nDetails: Trastuzumab may increase the neutropenic activities of Infliximab.\nRisk: Monitor closely.", "source": "Infliximab + Trastuzumab"}, {"id": "Follitropin_GEN", "text": "Drug: Follitropin\nDescription: Follitropin is a human follicle stimulating hormone (FSH) preparation of recombinant DNA origin, which consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and 111 amino acids. The alpha subunit is glyco...", "source": "Follitropin"}, {"id": "Follitropin_CLIN", "text": "Drug: Follitropin\nMechanism: Follitropin is a recombinant form of endogenous follicle stimulating hormone (FSH). FSH binds to the follicle stimulating hormone receptor which is a G-coupled transmembrane receptor. Binding of the F...\nToxicity: Headaches, ovarian cysts, nausea and upper respiratory tract infections occurred in more than 10% of women in clinical trials. In men, the most serious adverse events reported were testicular surgery ...", "source": "Follitropin"}, {"id": "Vasopressin_GEN", "text": "Drug: Vasopressin\nDescription: Antidiuretic hormone, also known as vasopressin, is a nine amino acid peptide secreted from the posterior pituitary. Antidiuretic hormone binds to receptors in the distal or collecting tubules of the kidney and promotes reabsorbtion of water back into the circulation...", "source": "Vasopressin"}, {"id": "Vasopressin_CLIN", "text": "Drug: Vasopressin\nMechanism: Vasopressin acts on three different receptors, vasopressin receptor V1a (which initiates vasoconstriction, liver gluconeogenesis, platelet aggregation and release of factor VIII), vasopressin receptor...\nToxicity: ...", "source": "Vasopressin"}, {"id": "Interferon beta-1b_GEN", "text": "Drug: Interferon beta-1b\nDescription: Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD...", "source": "Interferon beta-1b"}, {"id": "Interferon beta-1b_CLIN", "text": "Drug: Interferon beta-1b\nMechanism: Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate ...\nToxicity: ...", "source": "Interferon beta-1b"}, {"id": "Interferon beta-1b_INT_Ambroxol acefyllinate", "text": "Interaction: Interferon beta-1b AND Ambroxol acefyllinate\nDetails: The metabolism of Ambroxol acefyllinate can be decreased when combined with Interferon beta-1b.\nRisk: Monitor closely.", "source": "Interferon beta-1b + Ambroxol acefyllinate"}, {"id": "Interferon beta-1b_INT_Theophylline", "text": "Interaction: Interferon beta-1b AND Theophylline\nDetails: The metabolism of Theophylline can be decreased when combined with Interferon beta-1b.\nRisk: Monitor closely.", "source": "Interferon beta-1b + Theophylline"}, {"id": "Interferon beta-1b_INT_Dyphylline", "text": "Interaction: Interferon beta-1b AND Dyphylline\nDetails: The metabolism of Dyphylline can be decreased when combined with Interferon beta-1b.\nRisk: Monitor closely.", "source": "Interferon beta-1b + Dyphylline"}, {"id": "Interferon beta-1b_INT_Aminophylline", "text": "Interaction: Interferon beta-1b AND Aminophylline\nDetails: The metabolism of Aminophylline can be decreased when combined with Interferon beta-1b.\nRisk: Monitor closely.", "source": "Interferon beta-1b + Aminophylline"}, {"id": "Interferon beta-1b_INT_Zidovudine", "text": "Interaction: Interferon beta-1b AND Zidovudine\nDetails: The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Zidovudine.\nRisk: Monitor closely.", "source": "Interferon beta-1b + Zidovudine"}, {"id": "Interferon alfacon-1_GEN", "text": "Drug: Interferon alfacon-1\nDescription: Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position...", "source": "Interferon alfacon-1"}, {"id": "Interferon alfacon-1_CLIN", "text": "Drug: Interferon alfacon-1\nMechanism: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselv...\nToxicity: Reproductive toxicity studies in pregnant rhesus monkeys and golden Syrian hamsters demonstrated an increase in fetal loss in hamsters treated with Interferon alfacon-1 at doses of > 150 mcg/kg/day, a...", "source": "Interferon alfacon-1"}, {"id": "Interferon alfacon-1_INT_Metamizole", "text": "Interaction: Interferon alfacon-1 AND Metamizole\nDetails: The risk or severity of myelosuppression can be increased when Metamizole is combined with Interferon alfacon-1.\nRisk: Monitor closely.", "source": "Interferon alfacon-1 + Metamizole"}, {"id": "Interferon alfacon-1_INT_Clozapine", "text": "Interaction: Interferon alfacon-1 AND Clozapine\nDetails: The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Clozapine.\nRisk: Monitor closely.", "source": "Interferon alfacon-1 + Clozapine"}, {"id": "Interferon alfacon-1_INT_Aldesleukin", "text": "Interaction: Interferon alfacon-1 AND Aldesleukin\nDetails: The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Interferon alfacon-1 + Aldesleukin"}, {"id": "Interferon alfacon-1_INT_Ambroxol acefyllinate", "text": "Interaction: Interferon alfacon-1 AND Ambroxol acefyllinate\nDetails: The metabolism of Ambroxol acefyllinate can be decreased when combined with Interferon alfacon-1.\nRisk: Monitor closely.", "source": "Interferon alfacon-1 + Ambroxol acefyllinate"}, {"id": "Interferon alfacon-1_INT_Theophylline", "text": "Interaction: Interferon alfacon-1 AND Theophylline\nDetails: The metabolism of Theophylline can be decreased when combined with Interferon alfacon-1.\nRisk: Monitor closely.", "source": "Interferon alfacon-1 + Theophylline"}, {"id": "Interferon alfacon-1_INT_Dyphylline", "text": "Interaction: Interferon alfacon-1 AND Dyphylline\nDetails: The metabolism of Dyphylline can be decreased when combined with Interferon alfacon-1.\nRisk: Monitor closely.", "source": "Interferon alfacon-1 + Dyphylline"}, {"id": "Interferon alfacon-1_INT_Aminophylline", "text": "Interaction: Interferon alfacon-1 AND Aminophylline\nDetails: The metabolism of Aminophylline can be decreased when combined with Interferon alfacon-1.\nRisk: Monitor closely.", "source": "Interferon alfacon-1 + Aminophylline"}, {"id": "Interferon alfacon-1_INT_Methadone", "text": "Interaction: Interferon alfacon-1 AND Methadone\nDetails: The serum concentration of Methadone can be increased when it is combined with Interferon alfacon-1.\nRisk: Monitor closely.", "source": "Interferon alfacon-1 + Methadone"}, {"id": "Interferon alfacon-1_INT_Ribavirin", "text": "Interaction: Interferon alfacon-1 AND Ribavirin\nDetails: The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ribavirin.\nRisk: Monitor closely.", "source": "Interferon alfacon-1 + Ribavirin"}, {"id": "Interferon alfacon-1_INT_Zidovudine", "text": "Interaction: Interferon alfacon-1 AND Zidovudine\nDetails: The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Zidovudine.\nRisk: Monitor closely.", "source": "Interferon alfacon-1 + Zidovudine"}, {"id": "Hyaluronidase_GEN", "text": "Drug: Hyaluronidase\nDescription: Highly purified sheep hyaluronidase for administration by injection into the vitreous of the eye....", "source": "Hyaluronidase"}, {"id": "Hyaluronidase_CLIN", "text": "Drug: Hyaluronidase\nMechanism: Hyaluronidase is a spreading or diffusing substance. It increase the permeability of connective tissue through the hydrolysis of hyaluronic acid. Hyaluronidase hydrolyzes hyaluronic acid by splitting ...\nToxicity: ...", "source": "Hyaluronidase"}, {"id": "Hyaluronidase_INT_Lorazepam", "text": "Interaction: Hyaluronidase AND Lorazepam\nDetails: The therapeutic efficacy of Lorazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Lorazepam"}, {"id": "Hyaluronidase_INT_Temazepam", "text": "Interaction: Hyaluronidase AND Temazepam\nDetails: The therapeutic efficacy of Temazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Temazepam"}, {"id": "Hyaluronidase_INT_Alprazolam", "text": "Interaction: Hyaluronidase AND Alprazolam\nDetails: The therapeutic efficacy of Alprazolam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Alprazolam"}, {"id": "Hyaluronidase_INT_Chlordiazepoxide", "text": "Interaction: Hyaluronidase AND Chlordiazepoxide\nDetails: The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Chlordiazepoxide"}, {"id": "Hyaluronidase_INT_Clorazepate", "text": "Interaction: Hyaluronidase AND Clorazepate\nDetails: The therapeutic efficacy of Clorazepate can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Clorazepate"}, {"id": "Hyaluronidase_INT_Midazolam", "text": "Interaction: Hyaluronidase AND Midazolam\nDetails: The therapeutic efficacy of Midazolam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Midazolam"}, {"id": "Hyaluronidase_INT_Flurazepam", "text": "Interaction: Hyaluronidase AND Flurazepam\nDetails: The therapeutic efficacy of Flurazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Flurazepam"}, {"id": "Hyaluronidase_INT_Diazepam", "text": "Interaction: Hyaluronidase AND Diazepam\nDetails: The therapeutic efficacy of Diazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Diazepam"}, {"id": "Hyaluronidase_INT_Oxazepam", "text": "Interaction: Hyaluronidase AND Oxazepam\nDetails: The therapeutic efficacy of Oxazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Oxazepam"}, {"id": "Hyaluronidase_INT_Triazolam", "text": "Interaction: Hyaluronidase AND Triazolam\nDetails: The therapeutic efficacy of Triazolam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Triazolam"}, {"id": "Hyaluronidase_INT_Clonazepam", "text": "Interaction: Hyaluronidase AND Clonazepam\nDetails: The therapeutic efficacy of Clonazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Clonazepam"}, {"id": "Hyaluronidase_INT_Estazolam", "text": "Interaction: Hyaluronidase AND Estazolam\nDetails: The therapeutic efficacy of Estazolam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Estazolam"}, {"id": "Hyaluronidase_INT_Bromazepam", "text": "Interaction: Hyaluronidase AND Bromazepam\nDetails: The therapeutic efficacy of Bromazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Bromazepam"}, {"id": "Hyaluronidase_INT_Nitrazepam", "text": "Interaction: Hyaluronidase AND Nitrazepam\nDetails: The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Nitrazepam"}, {"id": "Hyaluronidase_INT_Clobazam", "text": "Interaction: Hyaluronidase AND Clobazam\nDetails: The therapeutic efficacy of Clobazam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Clobazam"}, {"id": "Hyaluronidase_INT_Pirenzepine", "text": "Interaction: Hyaluronidase AND Pirenzepine\nDetails: The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Pirenzepine"}, {"id": "Hyaluronidase_INT_Flumazenil", "text": "Interaction: Hyaluronidase AND Flumazenil\nDetails: The therapeutic efficacy of Flumazenil can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Flumazenil"}, {"id": "Hyaluronidase_INT_Camazepam", "text": "Interaction: Hyaluronidase AND Camazepam\nDetails: The therapeutic efficacy of Camazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Camazepam"}, {"id": "Hyaluronidase_INT_Delorazepam", "text": "Interaction: Hyaluronidase AND Delorazepam\nDetails: The therapeutic efficacy of Delorazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Delorazepam"}, {"id": "Hyaluronidase_INT_Flunitrazepam", "text": "Interaction: Hyaluronidase AND Flunitrazepam\nDetails: The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Flunitrazepam"}, {"id": "Hyaluronidase_INT_Fludiazepam", "text": "Interaction: Hyaluronidase AND Fludiazepam\nDetails: The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Fludiazepam"}, {"id": "Hyaluronidase_INT_Prazepam", "text": "Interaction: Hyaluronidase AND Prazepam\nDetails: The therapeutic efficacy of Prazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Prazepam"}, {"id": "Hyaluronidase_INT_Etizolam", "text": "Interaction: Hyaluronidase AND Etizolam\nDetails: The therapeutic efficacy of Etizolam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Etizolam"}, {"id": "Hyaluronidase_INT_SJG-136", "text": "Interaction: Hyaluronidase AND SJG-136\nDetails: The therapeutic efficacy of SJG-136 can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + SJG-136"}, {"id": "Hyaluronidase_INT_BMS-906024", "text": "Interaction: Hyaluronidase AND BMS-906024\nDetails: The therapeutic efficacy of BMS-906024 can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + BMS-906024"}, {"id": "Hyaluronidase_INT_Netazepide", "text": "Interaction: Hyaluronidase AND Netazepide\nDetails: The therapeutic efficacy of Netazepide can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Netazepide"}, {"id": "Hyaluronidase_INT_PF-477736", "text": "Interaction: Hyaluronidase AND PF-477736\nDetails: The therapeutic efficacy of PF-477736 can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + PF-477736"}, {"id": "Hyaluronidase_INT_CE-326597", "text": "Interaction: Hyaluronidase AND CE-326597\nDetails: The therapeutic efficacy of CE-326597 can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + CE-326597"}, {"id": "Hyaluronidase_INT_Medazepam", "text": "Interaction: Hyaluronidase AND Medazepam\nDetails: The therapeutic efficacy of Medazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Medazepam"}, {"id": "Hyaluronidase_INT_Doxefazepam", "text": "Interaction: Hyaluronidase AND Doxefazepam\nDetails: The therapeutic efficacy of Doxefazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Doxefazepam"}, {"id": "Hyaluronidase_INT_Lormetazepam", "text": "Interaction: Hyaluronidase AND Lormetazepam\nDetails: The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Lormetazepam"}, {"id": "Hyaluronidase_INT_Quazepam", "text": "Interaction: Hyaluronidase AND Quazepam\nDetails: The therapeutic efficacy of Quazepam can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Quazepam"}, {"id": "Hyaluronidase_INT_Furosemide", "text": "Interaction: Hyaluronidase AND Furosemide\nDetails: The therapeutic efficacy of Furosemide can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Furosemide"}, {"id": "Hyaluronidase_INT_Phenytoin", "text": "Interaction: Hyaluronidase AND Phenytoin\nDetails: The therapeutic efficacy of Phenytoin can be decreased when used in combination with Hyaluronidase.\nRisk: Monitor closely.", "source": "Hyaluronidase + Phenytoin"}, {"id": "Hyaluronidase_INT_Diethylstilbestrol", "text": "Interaction: Hyaluronidase AND Diethylstilbestrol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diethylstilbestrol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Diethylstilbestrol"}, {"id": "Hyaluronidase_INT_Chlorotrianisene", "text": "Interaction: Hyaluronidase AND Chlorotrianisene\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorotrianisene.\nRisk: Monitor closely.", "source": "Hyaluronidase + Chlorotrianisene"}, {"id": "Hyaluronidase_INT_Conjugated estrogens", "text": "Interaction: Hyaluronidase AND Conjugated estrogens\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Conjugated estrogens.\nRisk: Monitor closely.", "source": "Hyaluronidase + Conjugated estrogens"}, {"id": "Hyaluronidase_INT_Estrone", "text": "Interaction: Hyaluronidase AND Estrone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estrone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Estrone"}, {"id": "Hyaluronidase_INT_Estradiol", "text": "Interaction: Hyaluronidase AND Estradiol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estradiol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Estradiol"}, {"id": "Hyaluronidase_INT_Dienestrol", "text": "Interaction: Hyaluronidase AND Dienestrol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dienestrol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Dienestrol"}, {"id": "Hyaluronidase_INT_Ethinyl Estradiol", "text": "Interaction: Hyaluronidase AND Ethinyl Estradiol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ethinyl Estradiol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Ethinyl Estradiol"}, {"id": "Hyaluronidase_INT_Polyestradiol phosphate", "text": "Interaction: Hyaluronidase AND Polyestradiol phosphate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Polyestradiol phosphate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Polyestradiol phosphate"}, {"id": "Hyaluronidase_INT_Mestranol", "text": "Interaction: Hyaluronidase AND Mestranol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mestranol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Mestranol"}, {"id": "Hyaluronidase_INT_Genistein", "text": "Interaction: Hyaluronidase AND Genistein\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Genistein.\nRisk: Monitor closely.", "source": "Hyaluronidase + Genistein"}, {"id": "Hyaluronidase_INT_Quinestrol", "text": "Interaction: Hyaluronidase AND Quinestrol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Quinestrol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Quinestrol"}, {"id": "Hyaluronidase_INT_Hexestrol", "text": "Interaction: Hyaluronidase AND Hexestrol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hexestrol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Hexestrol"}, {"id": "Hyaluronidase_INT_Synthetic Conjugated Estrogens, A", "text": "Interaction: Hyaluronidase AND Synthetic Conjugated Estrogens, A\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Synthetic Conjugated Estrogens, A.\nRisk: Monitor closely.", "source": "Hyaluronidase + Synthetic Conjugated Estrogens, A"}, {"id": "Hyaluronidase_INT_Synthetic Conjugated Estrogens, B", "text": "Interaction: Hyaluronidase AND Synthetic Conjugated Estrogens, B\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Synthetic Conjugated Estrogens, B.\nRisk: Monitor closely.", "source": "Hyaluronidase + Synthetic Conjugated Estrogens, B"}, {"id": "Hyaluronidase_INT_Zeranol", "text": "Interaction: Hyaluronidase AND Zeranol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Zeranol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Zeranol"}, {"id": "Hyaluronidase_INT_Equol", "text": "Interaction: Hyaluronidase AND Equol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Equol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Equol"}, {"id": "Hyaluronidase_INT_Secoisolariciresinol", "text": "Interaction: Hyaluronidase AND Secoisolariciresinol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Secoisolariciresinol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Secoisolariciresinol"}, {"id": "Hyaluronidase_INT_Daidzein", "text": "Interaction: Hyaluronidase AND Daidzein\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Daidzein.\nRisk: Monitor closely.", "source": "Hyaluronidase + Daidzein"}, {"id": "Hyaluronidase_INT_Epimestrol", "text": "Interaction: Hyaluronidase AND Epimestrol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Epimestrol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Epimestrol"}, {"id": "Hyaluronidase_INT_Estriol", "text": "Interaction: Hyaluronidase AND Estriol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estriol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Estriol"}, {"id": "Hyaluronidase_INT_Tibolone", "text": "Interaction: Hyaluronidase AND Tibolone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tibolone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Tibolone"}, {"id": "Hyaluronidase_INT_Promestriene", "text": "Interaction: Hyaluronidase AND Promestriene\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Promestriene.\nRisk: Monitor closely.", "source": "Hyaluronidase + Promestriene"}, {"id": "Hyaluronidase_INT_Methallenestril", "text": "Interaction: Hyaluronidase AND Methallenestril\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methallenestril.\nRisk: Monitor closely.", "source": "Hyaluronidase + Methallenestril"}, {"id": "Hyaluronidase_INT_Moxestrol", "text": "Interaction: Hyaluronidase AND Moxestrol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Moxestrol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Moxestrol"}, {"id": "Hyaluronidase_INT_Estrogens, esterified", "text": "Interaction: Hyaluronidase AND Estrogens, esterified\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estrogens, esterified.\nRisk: Monitor closely.", "source": "Hyaluronidase + Estrogens, esterified"}, {"id": "Hyaluronidase_INT_Salicylic acid", "text": "Interaction: Hyaluronidase AND Salicylic acid\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Salicylic acid.\nRisk: Monitor closely.", "source": "Hyaluronidase + Salicylic acid"}, {"id": "Hyaluronidase_INT_Acetylsalicylic acid", "text": "Interaction: Hyaluronidase AND Acetylsalicylic acid\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Acetylsalicylic acid.\nRisk: Monitor closely.", "source": "Hyaluronidase + Acetylsalicylic acid"}, {"id": "Hyaluronidase_INT_Aminosalicylic Acid", "text": "Interaction: Hyaluronidase AND Aminosalicylic Acid\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aminosalicylic Acid.\nRisk: Monitor closely.", "source": "Hyaluronidase + Aminosalicylic Acid"}, {"id": "Hyaluronidase_INT_Mesalazine", "text": "Interaction: Hyaluronidase AND Mesalazine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mesalazine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Mesalazine"}, {"id": "Hyaluronidase_INT_Diflunisal", "text": "Interaction: Hyaluronidase AND Diflunisal\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diflunisal.\nRisk: Monitor closely.", "source": "Hyaluronidase + Diflunisal"}, {"id": "Hyaluronidase_INT_Balsalazide", "text": "Interaction: Hyaluronidase AND Balsalazide\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Balsalazide.\nRisk: Monitor closely.", "source": "Hyaluronidase + Balsalazide"}, {"id": "Hyaluronidase_INT_Olsalazine", "text": "Interaction: Hyaluronidase AND Olsalazine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Olsalazine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Olsalazine"}, {"id": "Hyaluronidase_INT_dersalazine", "text": "Interaction: Hyaluronidase AND dersalazine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with dersalazine.\nRisk: Monitor closely.", "source": "Hyaluronidase + dersalazine"}, {"id": "Hyaluronidase_INT_Nitroaspirin", "text": "Interaction: Hyaluronidase AND Nitroaspirin\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Nitroaspirin.\nRisk: Monitor closely.", "source": "Hyaluronidase + Nitroaspirin"}, {"id": "Hyaluronidase_INT_Aloxiprin", "text": "Interaction: Hyaluronidase AND Aloxiprin\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aloxiprin.\nRisk: Monitor closely.", "source": "Hyaluronidase + Aloxiprin"}, {"id": "Hyaluronidase_INT_Guacetisal", "text": "Interaction: Hyaluronidase AND Guacetisal\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Guacetisal.\nRisk: Monitor closely.", "source": "Hyaluronidase + Guacetisal"}, {"id": "Hyaluronidase_INT_Carbaspirin calcium", "text": "Interaction: Hyaluronidase AND Carbaspirin calcium\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Carbaspirin calcium.\nRisk: Monitor closely.", "source": "Hyaluronidase + Carbaspirin calcium"}, {"id": "Hyaluronidase_INT_Hemoglobin crosfumaril", "text": "Interaction: Hyaluronidase AND Hemoglobin crosfumaril\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hemoglobin crosfumaril.\nRisk: Monitor closely.", "source": "Hyaluronidase + Hemoglobin crosfumaril"}, {"id": "Hyaluronidase_INT_Methyl salicylate", "text": "Interaction: Hyaluronidase AND Methyl salicylate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methyl salicylate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Methyl salicylate"}, {"id": "Hyaluronidase_INT_Trolamine salicylate", "text": "Interaction: Hyaluronidase AND Trolamine salicylate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Trolamine salicylate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Trolamine salicylate"}, {"id": "Hyaluronidase_INT_Hydroxyzine", "text": "Interaction: Hyaluronidase AND Hydroxyzine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydroxyzine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Hydroxyzine"}, {"id": "Hyaluronidase_INT_Meclizine", "text": "Interaction: Hyaluronidase AND Meclizine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Meclizine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Meclizine"}, {"id": "Hyaluronidase_INT_Dimenhydrinate", "text": "Interaction: Hyaluronidase AND Dimenhydrinate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimenhydrinate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Dimenhydrinate"}, {"id": "Hyaluronidase_INT_Clemastine", "text": "Interaction: Hyaluronidase AND Clemastine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clemastine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Clemastine"}, {"id": "Hyaluronidase_INT_Cetirizine", "text": "Interaction: Hyaluronidase AND Cetirizine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cetirizine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Cetirizine"}, {"id": "Hyaluronidase_INT_Terfenadine", "text": "Interaction: Hyaluronidase AND Terfenadine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Terfenadine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Terfenadine"}, {"id": "Hyaluronidase_INT_Buclizine", "text": "Interaction: Hyaluronidase AND Buclizine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Buclizine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Buclizine"}, {"id": "Hyaluronidase_INT_Doxylamine", "text": "Interaction: Hyaluronidase AND Doxylamine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Doxylamine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Doxylamine"}, {"id": "Hyaluronidase_INT_Mirtazapine", "text": "Interaction: Hyaluronidase AND Mirtazapine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mirtazapine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Mirtazapine"}, {"id": "Hyaluronidase_INT_Ethopropazine", "text": "Interaction: Hyaluronidase AND Ethopropazine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ethopropazine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Ethopropazine"}, {"id": "Hyaluronidase_INT_Dexbrompheniramine", "text": "Interaction: Hyaluronidase AND Dexbrompheniramine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexbrompheniramine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Dexbrompheniramine"}, {"id": "Hyaluronidase_INT_Triprolidine", "text": "Interaction: Hyaluronidase AND Triprolidine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Triprolidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Triprolidine"}, {"id": "Hyaluronidase_INT_Cyproheptadine", "text": "Interaction: Hyaluronidase AND Cyproheptadine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cyproheptadine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Cyproheptadine"}, {"id": "Hyaluronidase_INT_Loratadine", "text": "Interaction: Hyaluronidase AND Loratadine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Loratadine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Loratadine"}, {"id": "Hyaluronidase_INT_Cimetidine", "text": "Interaction: Hyaluronidase AND Cimetidine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cimetidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Cimetidine"}, {"id": "Hyaluronidase_INT_Cinnarizine", "text": "Interaction: Hyaluronidase AND Cinnarizine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cinnarizine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Cinnarizine"}, {"id": "Hyaluronidase_INT_Nizatidine", "text": "Interaction: Hyaluronidase AND Nizatidine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Nizatidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Nizatidine"}, {"id": "Hyaluronidase_INT_Astemizole", "text": "Interaction: Hyaluronidase AND Astemizole\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Astemizole.\nRisk: Monitor closely.", "source": "Hyaluronidase + Astemizole"}, {"id": "Hyaluronidase_INT_Azatadine", "text": "Interaction: Hyaluronidase AND Azatadine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Azatadine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Azatadine"}, {"id": "Hyaluronidase_INT_Carbinoxamine", "text": "Interaction: Hyaluronidase AND Carbinoxamine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Carbinoxamine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Carbinoxamine"}, {"id": "Hyaluronidase_INT_Epinastine", "text": "Interaction: Hyaluronidase AND Epinastine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Epinastine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Epinastine"}, {"id": "Hyaluronidase_INT_Olopatadine", "text": "Interaction: Hyaluronidase AND Olopatadine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Olopatadine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Olopatadine"}, {"id": "Hyaluronidase_INT_Tripelennamine", "text": "Interaction: Hyaluronidase AND Tripelennamine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tripelennamine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Tripelennamine"}, {"id": "Hyaluronidase_INT_Brompheniramine", "text": "Interaction: Hyaluronidase AND Brompheniramine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Brompheniramine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Brompheniramine"}, {"id": "Hyaluronidase_INT_Ranitidine", "text": "Interaction: Hyaluronidase AND Ranitidine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ranitidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Ranitidine"}, {"id": "Hyaluronidase_INT_Pemirolast", "text": "Interaction: Hyaluronidase AND Pemirolast\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Pemirolast.\nRisk: Monitor closely.", "source": "Hyaluronidase + Pemirolast"}, {"id": "Hyaluronidase_INT_Ketotifen", "text": "Interaction: Hyaluronidase AND Ketotifen\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ketotifen.\nRisk: Monitor closely.", "source": "Hyaluronidase + Ketotifen"}, {"id": "Hyaluronidase_INT_Famotidine", "text": "Interaction: Hyaluronidase AND Famotidine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Famotidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Famotidine"}, {"id": "Hyaluronidase_INT_Fexofenadine", "text": "Interaction: Hyaluronidase AND Fexofenadine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fexofenadine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Fexofenadine"}, {"id": "Hyaluronidase_INT_Desloratadine", "text": "Interaction: Hyaluronidase AND Desloratadine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desloratadine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Desloratadine"}, {"id": "Hyaluronidase_INT_Azelastine", "text": "Interaction: Hyaluronidase AND Azelastine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Azelastine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Azelastine"}, {"id": "Hyaluronidase_INT_Promethazine", "text": "Interaction: Hyaluronidase AND Promethazine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Promethazine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Promethazine"}, {"id": "Hyaluronidase_INT_Mequitazine", "text": "Interaction: Hyaluronidase AND Mequitazine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mequitazine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Mequitazine"}, {"id": "Hyaluronidase_INT_Diphenhydramine", "text": "Interaction: Hyaluronidase AND Diphenhydramine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diphenhydramine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Diphenhydramine"}, {"id": "Hyaluronidase_INT_Emedastine", "text": "Interaction: Hyaluronidase AND Emedastine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Emedastine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Emedastine"}, {"id": "Hyaluronidase_INT_Levocabastine", "text": "Interaction: Hyaluronidase AND Levocabastine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Levocabastine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Levocabastine"}, {"id": "Hyaluronidase_INT_Chlorphenamine", "text": "Interaction: Hyaluronidase AND Chlorphenamine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorphenamine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Chlorphenamine"}, {"id": "Hyaluronidase_INT_Doxepin", "text": "Interaction: Hyaluronidase AND Doxepin\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Doxepin.\nRisk: Monitor closely.", "source": "Hyaluronidase + Doxepin"}, {"id": "Hyaluronidase_INT_Cyclizine", "text": "Interaction: Hyaluronidase AND Cyclizine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cyclizine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Cyclizine"}, {"id": "Hyaluronidase_INT_Alimemazine", "text": "Interaction: Hyaluronidase AND Alimemazine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Alimemazine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Alimemazine"}, {"id": "Hyaluronidase_INT_Phenindamine", "text": "Interaction: Hyaluronidase AND Phenindamine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Phenindamine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Phenindamine"}, {"id": "Hyaluronidase_INT_Pheniramine", "text": "Interaction: Hyaluronidase AND Pheniramine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Pheniramine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Pheniramine"}, {"id": "Hyaluronidase_INT_Butyric Acid", "text": "Interaction: Hyaluronidase AND Butyric Acid\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Butyric Acid.\nRisk: Monitor closely.", "source": "Hyaluronidase + Butyric Acid"}, {"id": "Hyaluronidase_INT_Methapyrilene", "text": "Interaction: Hyaluronidase AND Methapyrilene\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methapyrilene.\nRisk: Monitor closely.", "source": "Hyaluronidase + Methapyrilene"}, {"id": "Hyaluronidase_INT_Flunarizine", "text": "Interaction: Hyaluronidase AND Flunarizine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flunarizine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Flunarizine"}, {"id": "Hyaluronidase_INT_Tesmilifene", "text": "Interaction: Hyaluronidase AND Tesmilifene\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tesmilifene.\nRisk: Monitor closely.", "source": "Hyaluronidase + Tesmilifene"}, {"id": "Hyaluronidase_INT_Mianserin", "text": "Interaction: Hyaluronidase AND Mianserin\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mianserin.\nRisk: Monitor closely.", "source": "Hyaluronidase + Mianserin"}, {"id": "Hyaluronidase_INT_Levocetirizine", "text": "Interaction: Hyaluronidase AND Levocetirizine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Levocetirizine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Levocetirizine"}, {"id": "Hyaluronidase_INT_Esmirtazapine", "text": "Interaction: Hyaluronidase AND Esmirtazapine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Esmirtazapine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Esmirtazapine"}, {"id": "Hyaluronidase_INT_Mepyramine", "text": "Interaction: Hyaluronidase AND Mepyramine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mepyramine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Mepyramine"}, {"id": "Hyaluronidase_INT_Alcaftadine", "text": "Interaction: Hyaluronidase AND Alcaftadine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Alcaftadine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Alcaftadine"}, {"id": "Hyaluronidase_INT_Lodoxamide", "text": "Interaction: Hyaluronidase AND Lodoxamide\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Lodoxamide.\nRisk: Monitor closely.", "source": "Hyaluronidase + Lodoxamide"}, {"id": "Hyaluronidase_INT_Tranilast", "text": "Interaction: Hyaluronidase AND Tranilast\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tranilast.\nRisk: Monitor closely.", "source": "Hyaluronidase + Tranilast"}, {"id": "Hyaluronidase_INT_Antazoline", "text": "Interaction: Hyaluronidase AND Antazoline\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Antazoline.\nRisk: Monitor closely.", "source": "Hyaluronidase + Antazoline"}, {"id": "Hyaluronidase_INT_Chloropyramine", "text": "Interaction: Hyaluronidase AND Chloropyramine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chloropyramine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Chloropyramine"}, {"id": "Hyaluronidase_INT_Dimetindene", "text": "Interaction: Hyaluronidase AND Dimetindene\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimetindene.\nRisk: Monitor closely.", "source": "Hyaluronidase + Dimetindene"}, {"id": "Hyaluronidase_INT_Isothipendyl", "text": "Interaction: Hyaluronidase AND Isothipendyl\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Isothipendyl.\nRisk: Monitor closely.", "source": "Hyaluronidase + Isothipendyl"}, {"id": "Hyaluronidase_INT_Metiamide", "text": "Interaction: Hyaluronidase AND Metiamide\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Metiamide.\nRisk: Monitor closely.", "source": "Hyaluronidase + Metiamide"}, {"id": "Hyaluronidase_INT_Roxatidine acetate", "text": "Interaction: Hyaluronidase AND Roxatidine acetate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Roxatidine acetate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Roxatidine acetate"}, {"id": "Hyaluronidase_INT_Dimetotiazine", "text": "Interaction: Hyaluronidase AND Dimetotiazine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dimetotiazine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Dimetotiazine"}, {"id": "Hyaluronidase_INT_Chlorphenoxamine", "text": "Interaction: Hyaluronidase AND Chlorphenoxamine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Chlorphenoxamine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Chlorphenoxamine"}, {"id": "Hyaluronidase_INT_Acrivastine", "text": "Interaction: Hyaluronidase AND Acrivastine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Acrivastine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Acrivastine"}, {"id": "Hyaluronidase_INT_Dexchlorpheniramine maleate", "text": "Interaction: Hyaluronidase AND Dexchlorpheniramine maleate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexchlorpheniramine maleate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Dexchlorpheniramine maleate"}, {"id": "Hyaluronidase_INT_Thonzylamine", "text": "Interaction: Hyaluronidase AND Thonzylamine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Thonzylamine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Thonzylamine"}, {"id": "Hyaluronidase_INT_Ebastine", "text": "Interaction: Hyaluronidase AND Ebastine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ebastine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Ebastine"}, {"id": "Hyaluronidase_INT_Ozagrel", "text": "Interaction: Hyaluronidase AND Ozagrel\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ozagrel.\nRisk: Monitor closely.", "source": "Hyaluronidase + Ozagrel"}, {"id": "Hyaluronidase_INT_Mizolastine", "text": "Interaction: Hyaluronidase AND Mizolastine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mizolastine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Mizolastine"}, {"id": "Hyaluronidase_INT_Lafutidine", "text": "Interaction: Hyaluronidase AND Lafutidine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Lafutidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Lafutidine"}, {"id": "Hyaluronidase_INT_Oxatomide", "text": "Interaction: Hyaluronidase AND Oxatomide\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Oxatomide.\nRisk: Monitor closely.", "source": "Hyaluronidase + Oxatomide"}, {"id": "Hyaluronidase_INT_Lavoltidine", "text": "Interaction: Hyaluronidase AND Lavoltidine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Lavoltidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Lavoltidine"}, {"id": "Hyaluronidase_INT_Bamipine", "text": "Interaction: Hyaluronidase AND Bamipine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Bamipine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Bamipine"}, {"id": "Hyaluronidase_INT_Dexchlorpheniramine", "text": "Interaction: Hyaluronidase AND Dexchlorpheniramine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexchlorpheniramine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Dexchlorpheniramine"}, {"id": "Hyaluronidase_INT_Tritoqualine", "text": "Interaction: Hyaluronidase AND Tritoqualine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tritoqualine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Tritoqualine"}, {"id": "Hyaluronidase_INT_Quifenadine", "text": "Interaction: Hyaluronidase AND Quifenadine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Quifenadine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Quifenadine"}, {"id": "Hyaluronidase_INT_Benzatropine", "text": "Interaction: Hyaluronidase AND Benzatropine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Benzatropine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Benzatropine"}, {"id": "Hyaluronidase_INT_Prochlorperazine", "text": "Interaction: Hyaluronidase AND Prochlorperazine\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prochlorperazine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Prochlorperazine"}, {"id": "Hyaluronidase_INT_Midodrine", "text": "Interaction: Hyaluronidase AND Midodrine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Midodrine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Midodrine"}, {"id": "Hyaluronidase_INT_Brimonidine", "text": "Interaction: Hyaluronidase AND Brimonidine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Brimonidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Brimonidine"}, {"id": "Hyaluronidase_INT_Epinephrine", "text": "Interaction: Hyaluronidase AND Epinephrine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Epinephrine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Epinephrine"}, {"id": "Hyaluronidase_INT_Apraclonidine", "text": "Interaction: Hyaluronidase AND Apraclonidine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Apraclonidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Apraclonidine"}, {"id": "Hyaluronidase_INT_Phenylephrine", "text": "Interaction: Hyaluronidase AND Phenylephrine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Phenylephrine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Phenylephrine"}, {"id": "Hyaluronidase_INT_Norepinephrine", "text": "Interaction: Hyaluronidase AND Norepinephrine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Norepinephrine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Norepinephrine"}, {"id": "Hyaluronidase_INT_Phenylpropanolamine", "text": "Interaction: Hyaluronidase AND Phenylpropanolamine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Phenylpropanolamine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Phenylpropanolamine"}, {"id": "Hyaluronidase_INT_Clonidine", "text": "Interaction: Hyaluronidase AND Clonidine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Clonidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Clonidine"}, {"id": "Hyaluronidase_INT_Metaraminol", "text": "Interaction: Hyaluronidase AND Metaraminol\nDetails: Hyaluronidase may increase the vasoconstricting activities of Metaraminol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Metaraminol"}, {"id": "Hyaluronidase_INT_Guanabenz", "text": "Interaction: Hyaluronidase AND Guanabenz\nDetails: Hyaluronidase may increase the vasoconstricting activities of Guanabenz.\nRisk: Monitor closely.", "source": "Hyaluronidase + Guanabenz"}, {"id": "Hyaluronidase_INT_Dexmedetomidine", "text": "Interaction: Hyaluronidase AND Dexmedetomidine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Dexmedetomidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Dexmedetomidine"}, {"id": "Hyaluronidase_INT_Ergotamine", "text": "Interaction: Hyaluronidase AND Ergotamine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Ergotamine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Ergotamine"}, {"id": "Hyaluronidase_INT_Tizanidine", "text": "Interaction: Hyaluronidase AND Tizanidine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Tizanidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Tizanidine"}, {"id": "Hyaluronidase_INT_Methoxamine", "text": "Interaction: Hyaluronidase AND Methoxamine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Methoxamine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Methoxamine"}, {"id": "Hyaluronidase_INT_Oxymetazoline", "text": "Interaction: Hyaluronidase AND Oxymetazoline\nDetails: Hyaluronidase may increase the vasoconstricting activities of Oxymetazoline.\nRisk: Monitor closely.", "source": "Hyaluronidase + Oxymetazoline"}, {"id": "Hyaluronidase_INT_Methyldopa", "text": "Interaction: Hyaluronidase AND Methyldopa\nDetails: Hyaluronidase may increase the vasoconstricting activities of Methyldopa.\nRisk: Monitor closely.", "source": "Hyaluronidase + Methyldopa"}, {"id": "Hyaluronidase_INT_Guanfacine", "text": "Interaction: Hyaluronidase AND Guanfacine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Guanfacine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Guanfacine"}, {"id": "Hyaluronidase_INT_Mephentermine", "text": "Interaction: Hyaluronidase AND Mephentermine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Mephentermine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Mephentermine"}, {"id": "Hyaluronidase_INT_Lofexidine", "text": "Interaction: Hyaluronidase AND Lofexidine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Lofexidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Lofexidine"}, {"id": "Hyaluronidase_INT_Xylometazoline", "text": "Interaction: Hyaluronidase AND Xylometazoline\nDetails: Hyaluronidase may increase the vasoconstricting activities of Xylometazoline.\nRisk: Monitor closely.", "source": "Hyaluronidase + Xylometazoline"}, {"id": "Hyaluronidase_INT_Naphazoline", "text": "Interaction: Hyaluronidase AND Naphazoline\nDetails: Hyaluronidase may increase the vasoconstricting activities of Naphazoline.\nRisk: Monitor closely.", "source": "Hyaluronidase + Naphazoline"}, {"id": "Hyaluronidase_INT_Adrafinil", "text": "Interaction: Hyaluronidase AND Adrafinil\nDetails: Hyaluronidase may increase the vasoconstricting activities of Adrafinil.\nRisk: Monitor closely.", "source": "Hyaluronidase + Adrafinil"}, {"id": "Hyaluronidase_INT_Etilefrine", "text": "Interaction: Hyaluronidase AND Etilefrine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Etilefrine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Etilefrine"}, {"id": "Hyaluronidase_INT_Cirazoline", "text": "Interaction: Hyaluronidase AND Cirazoline\nDetails: Hyaluronidase may increase the vasoconstricting activities of Cirazoline.\nRisk: Monitor closely.", "source": "Hyaluronidase + Cirazoline"}, {"id": "Hyaluronidase_INT_Synephrine", "text": "Interaction: Hyaluronidase AND Synephrine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Synephrine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Synephrine"}, {"id": "Hyaluronidase_INT_Racepinephrine", "text": "Interaction: Hyaluronidase AND Racepinephrine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Racepinephrine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Racepinephrine"}, {"id": "Hyaluronidase_INT_Amitraz", "text": "Interaction: Hyaluronidase AND Amitraz\nDetails: Hyaluronidase may increase the vasoconstricting activities of Amitraz.\nRisk: Monitor closely.", "source": "Hyaluronidase + Amitraz"}, {"id": "Hyaluronidase_INT_Medetomidine", "text": "Interaction: Hyaluronidase AND Medetomidine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Medetomidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Medetomidine"}, {"id": "Hyaluronidase_INT_Xylazine", "text": "Interaction: Hyaluronidase AND Xylazine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Xylazine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Xylazine"}, {"id": "Hyaluronidase_INT_Romifidine", "text": "Interaction: Hyaluronidase AND Romifidine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Romifidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Romifidine"}, {"id": "Hyaluronidase_INT_Detomidine", "text": "Interaction: Hyaluronidase AND Detomidine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Detomidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Detomidine"}, {"id": "Hyaluronidase_INT_Rilmenidine", "text": "Interaction: Hyaluronidase AND Rilmenidine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Rilmenidine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Rilmenidine"}, {"id": "Hyaluronidase_INT_Anisodamine", "text": "Interaction: Hyaluronidase AND Anisodamine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Anisodamine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Anisodamine"}, {"id": "Hyaluronidase_INT_Octopamine", "text": "Interaction: Hyaluronidase AND Octopamine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Octopamine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Octopamine"}, {"id": "Hyaluronidase_INT_Norfenefrine", "text": "Interaction: Hyaluronidase AND Norfenefrine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Norfenefrine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Norfenefrine"}, {"id": "Hyaluronidase_INT_Pseudoephedrine", "text": "Interaction: Hyaluronidase AND Pseudoephedrine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Pseudoephedrine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Pseudoephedrine"}, {"id": "Hyaluronidase_INT_Ephedrine", "text": "Interaction: Hyaluronidase AND Ephedrine\nDetails: Hyaluronidase may increase the vasoconstricting activities of Ephedrine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Ephedrine"}, {"id": "Hyaluronidase_INT_Dopamine", "text": "Interaction: Hyaluronidase AND Dopamine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dopamine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Dopamine"}, {"id": "Hyaluronidase_INT_Fluorometholone", "text": "Interaction: Hyaluronidase AND Fluorometholone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluorometholone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Fluorometholone"}, {"id": "Hyaluronidase_INT_Beclomethasone dipropionate", "text": "Interaction: Hyaluronidase AND Beclomethasone dipropionate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Beclomethasone dipropionate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Beclomethasone dipropionate"}, {"id": "Hyaluronidase_INT_Betamethasone", "text": "Interaction: Hyaluronidase AND Betamethasone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Betamethasone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Betamethasone"}, {"id": "Hyaluronidase_INT_Triamcinolone", "text": "Interaction: Hyaluronidase AND Triamcinolone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Triamcinolone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Triamcinolone"}, {"id": "Hyaluronidase_INT_Hydrocortisone", "text": "Interaction: Hyaluronidase AND Hydrocortisone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydrocortisone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Hydrocortisone"}, {"id": "Hyaluronidase_INT_Prednisolone", "text": "Interaction: Hyaluronidase AND Prednisolone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednisolone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Prednisolone"}, {"id": "Hyaluronidase_INT_Fluocinonide", "text": "Interaction: Hyaluronidase AND Fluocinonide\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluocinonide.\nRisk: Monitor closely.", "source": "Hyaluronidase + Fluocinonide"}, {"id": "Hyaluronidase_INT_Budesonide", "text": "Interaction: Hyaluronidase AND Budesonide\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Budesonide.\nRisk: Monitor closely.", "source": "Hyaluronidase + Budesonide"}, {"id": "Hyaluronidase_INT_Dexamethasone", "text": "Interaction: Hyaluronidase AND Dexamethasone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexamethasone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Dexamethasone"}, {"id": "Hyaluronidase_INT_Ciclesonide", "text": "Interaction: Hyaluronidase AND Ciclesonide\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ciclesonide.\nRisk: Monitor closely.", "source": "Hyaluronidase + Ciclesonide"}, {"id": "Hyaluronidase_INT_Tixocortol", "text": "Interaction: Hyaluronidase AND Tixocortol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tixocortol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Tixocortol"}, {"id": "Hyaluronidase_INT_Fluocinolone Acetonide", "text": "Interaction: Hyaluronidase AND Fluocinolone Acetonide\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluocinolone Acetonide.\nRisk: Monitor closely.", "source": "Hyaluronidase + Fluocinolone Acetonide"}, {"id": "Hyaluronidase_INT_Diflorasone", "text": "Interaction: Hyaluronidase AND Diflorasone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Diflorasone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Diflorasone"}, {"id": "Hyaluronidase_INT_Alclometasone", "text": "Interaction: Hyaluronidase AND Alclometasone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Alclometasone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Alclometasone"}, {"id": "Hyaluronidase_INT_Amcinonide", "text": "Interaction: Hyaluronidase AND Amcinonide\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Amcinonide.\nRisk: Monitor closely.", "source": "Hyaluronidase + Amcinonide"}, {"id": "Hyaluronidase_INT_Desoximetasone", "text": "Interaction: Hyaluronidase AND Desoximetasone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desoximetasone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Desoximetasone"}, {"id": "Hyaluronidase_INT_Clocortolone", "text": "Interaction: Hyaluronidase AND Clocortolone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clocortolone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Clocortolone"}, {"id": "Hyaluronidase_INT_Flurandrenolide", "text": "Interaction: Hyaluronidase AND Flurandrenolide\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flurandrenolide.\nRisk: Monitor closely.", "source": "Hyaluronidase + Flurandrenolide"}, {"id": "Hyaluronidase_INT_Rimexolone", "text": "Interaction: Hyaluronidase AND Rimexolone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Rimexolone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Rimexolone"}, {"id": "Hyaluronidase_INT_Methylprednisolone", "text": "Interaction: Hyaluronidase AND Methylprednisolone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methylprednisolone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Methylprednisolone"}, {"id": "Hyaluronidase_INT_Clobetasol propionate", "text": "Interaction: Hyaluronidase AND Clobetasol propionate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clobetasol propionate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Clobetasol propionate"}, {"id": "Hyaluronidase_INT_Prednicarbate", "text": "Interaction: Hyaluronidase AND Prednicarbate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednicarbate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Prednicarbate"}, {"id": "Hyaluronidase_INT_Cortisone acetate", "text": "Interaction: Hyaluronidase AND Cortisone acetate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cortisone acetate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Cortisone acetate"}, {"id": "Hyaluronidase_INT_Flunisolide", "text": "Interaction: Hyaluronidase AND Flunisolide\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flunisolide.\nRisk: Monitor closely.", "source": "Hyaluronidase + Flunisolide"}, {"id": "Hyaluronidase_INT_Fluticasone propionate", "text": "Interaction: Hyaluronidase AND Fluticasone propionate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluticasone propionate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Fluticasone propionate"}, {"id": "Hyaluronidase_INT_Mometasone", "text": "Interaction: Hyaluronidase AND Mometasone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mometasone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Mometasone"}, {"id": "Hyaluronidase_INT_Loteprednol", "text": "Interaction: Hyaluronidase AND Loteprednol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Loteprednol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Loteprednol"}, {"id": "Hyaluronidase_INT_Fluticasone furoate", "text": "Interaction: Hyaluronidase AND Fluticasone furoate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluticasone furoate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Fluticasone furoate"}, {"id": "Hyaluronidase_INT_Difluprednate", "text": "Interaction: Hyaluronidase AND Difluprednate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Difluprednate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Difluprednate"}, {"id": "Hyaluronidase_INT_Medrysone", "text": "Interaction: Hyaluronidase AND Medrysone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Medrysone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Medrysone"}, {"id": "Hyaluronidase_INT_Prednisone", "text": "Interaction: Hyaluronidase AND Prednisone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednisone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Prednisone"}, {"id": "Hyaluronidase_INT_Flumethasone", "text": "Interaction: Hyaluronidase AND Flumethasone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Flumethasone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Flumethasone"}, {"id": "Hyaluronidase_INT_Fludrocortisone", "text": "Interaction: Hyaluronidase AND Fludrocortisone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fludrocortisone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Fludrocortisone"}, {"id": "Hyaluronidase_INT_Desoxycorticosterone Pivalate", "text": "Interaction: Hyaluronidase AND Desoxycorticosterone Pivalate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desoxycorticosterone Pivalate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Desoxycorticosterone Pivalate"}, {"id": "Hyaluronidase_INT_Paramethasone", "text": "Interaction: Hyaluronidase AND Paramethasone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Paramethasone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Paramethasone"}, {"id": "Hyaluronidase_INT_19-norandrostenedione", "text": "Interaction: Hyaluronidase AND 19-norandrostenedione\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with 19-norandrostenedione.\nRisk: Monitor closely.", "source": "Hyaluronidase + 19-norandrostenedione"}, {"id": "Hyaluronidase_INT_5-androstenedione", "text": "Interaction: Hyaluronidase AND 5-androstenedione\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with 5-androstenedione.\nRisk: Monitor closely.", "source": "Hyaluronidase + 5-androstenedione"}, {"id": "Hyaluronidase_INT_Androstenedione", "text": "Interaction: Hyaluronidase AND Androstenedione\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Androstenedione.\nRisk: Monitor closely.", "source": "Hyaluronidase + Androstenedione"}, {"id": "Hyaluronidase_INT_Prasterone", "text": "Interaction: Hyaluronidase AND Prasterone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prasterone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Prasterone"}, {"id": "Hyaluronidase_INT_Equilin", "text": "Interaction: Hyaluronidase AND Equilin\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Equilin.\nRisk: Monitor closely.", "source": "Hyaluronidase + Equilin"}, {"id": "Hyaluronidase_INT_Pregnenolone", "text": "Interaction: Hyaluronidase AND Pregnenolone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Pregnenolone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Pregnenolone"}, {"id": "Hyaluronidase_INT_Equilenin", "text": "Interaction: Hyaluronidase AND Equilenin\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Equilenin.\nRisk: Monitor closely.", "source": "Hyaluronidase + Equilenin"}, {"id": "Hyaluronidase_INT_Estrone sulfate", "text": "Interaction: Hyaluronidase AND Estrone sulfate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estrone sulfate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Estrone sulfate"}, {"id": "Hyaluronidase_INT_Aldosterone", "text": "Interaction: Hyaluronidase AND Aldosterone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aldosterone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Aldosterone"}, {"id": "Hyaluronidase_INT_Corticosterone", "text": "Interaction: Hyaluronidase AND Corticosterone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Corticosterone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Corticosterone"}, {"id": "Hyaluronidase_INT_Oleoyl-estrone", "text": "Interaction: Hyaluronidase AND Oleoyl-estrone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Oleoyl-estrone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Oleoyl-estrone"}, {"id": "Hyaluronidase_INT_16-Bromoepiandrosterone", "text": "Interaction: Hyaluronidase AND 16-Bromoepiandrosterone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with 16-Bromoepiandrosterone.\nRisk: Monitor closely.", "source": "Hyaluronidase + 16-Bromoepiandrosterone"}, {"id": "Hyaluronidase_INT_HE3286", "text": "Interaction: Hyaluronidase AND HE3286\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with HE3286.\nRisk: Monitor closely.", "source": "Hyaluronidase + HE3286"}, {"id": "Hyaluronidase_INT_anecortave acetate", "text": "Interaction: Hyaluronidase AND anecortave acetate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with anecortave acetate.\nRisk: Monitor closely.", "source": "Hyaluronidase + anecortave acetate"}, {"id": "Hyaluronidase_INT_ME-609", "text": "Interaction: Hyaluronidase AND ME-609\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with ME-609.\nRisk: Monitor closely.", "source": "Hyaluronidase + ME-609"}, {"id": "Hyaluronidase_INT_NCX 1022", "text": "Interaction: Hyaluronidase AND NCX 1022\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with NCX 1022.\nRisk: Monitor closely.", "source": "Hyaluronidase + NCX 1022"}, {"id": "Hyaluronidase_INT_Prasterone sulfate", "text": "Interaction: Hyaluronidase AND Prasterone sulfate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prasterone sulfate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Prasterone sulfate"}, {"id": "Hyaluronidase_INT_Istaroxime", "text": "Interaction: Hyaluronidase AND Istaroxime\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Istaroxime.\nRisk: Monitor closely.", "source": "Hyaluronidase + Istaroxime"}, {"id": "Hyaluronidase_INT_fluasterone", "text": "Interaction: Hyaluronidase AND fluasterone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with fluasterone.\nRisk: Monitor closely.", "source": "Hyaluronidase + fluasterone"}, {"id": "Hyaluronidase_INT_Desoxycorticosterone acetate", "text": "Interaction: Hyaluronidase AND Desoxycorticosterone acetate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desoxycorticosterone acetate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Desoxycorticosterone acetate"}, {"id": "Hyaluronidase_INT_Formestane", "text": "Interaction: Hyaluronidase AND Formestane\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Formestane.\nRisk: Monitor closely.", "source": "Hyaluronidase + Formestane"}, {"id": "Hyaluronidase_INT_Fluprednidene", "text": "Interaction: Hyaluronidase AND Fluprednidene\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluprednidene.\nRisk: Monitor closely.", "source": "Hyaluronidase + Fluprednidene"}, {"id": "Hyaluronidase_INT_Fluocortolone", "text": "Interaction: Hyaluronidase AND Fluocortolone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluocortolone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Fluocortolone"}, {"id": "Hyaluronidase_INT_Difluocortolone", "text": "Interaction: Hyaluronidase AND Difluocortolone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Difluocortolone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Difluocortolone"}, {"id": "Hyaluronidase_INT_Fluprednisolone", "text": "Interaction: Hyaluronidase AND Fluprednisolone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluprednisolone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Fluprednisolone"}, {"id": "Hyaluronidase_INT_Dexamethasone isonicotinate", "text": "Interaction: Hyaluronidase AND Dexamethasone isonicotinate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Dexamethasone isonicotinate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Dexamethasone isonicotinate"}, {"id": "Hyaluronidase_INT_Melengestrol", "text": "Interaction: Hyaluronidase AND Melengestrol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Melengestrol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Melengestrol"}, {"id": "Hyaluronidase_INT_Clobetasol", "text": "Interaction: Hyaluronidase AND Clobetasol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clobetasol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Clobetasol"}, {"id": "Hyaluronidase_INT_Anecortave", "text": "Interaction: Hyaluronidase AND Anecortave\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Anecortave.\nRisk: Monitor closely.", "source": "Hyaluronidase + Anecortave"}, {"id": "Hyaluronidase_INT_Atamestane", "text": "Interaction: Hyaluronidase AND Atamestane\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Atamestane.\nRisk: Monitor closely.", "source": "Hyaluronidase + Atamestane"}, {"id": "Hyaluronidase_INT_Cortexolone 17\u03b1-propionate", "text": "Interaction: Hyaluronidase AND Cortexolone 17\u03b1-propionate\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Cortexolone 17\u03b1-propionate.\nRisk: Monitor closely.", "source": "Hyaluronidase + Cortexolone 17\u03b1-propionate"}, {"id": "Hyaluronidase_INT_Clobetasone", "text": "Interaction: Hyaluronidase AND Clobetasone\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Clobetasone.\nRisk: Monitor closely.", "source": "Hyaluronidase + Clobetasone"}, {"id": "Hyaluronidase_INT_Ulobetasol", "text": "Interaction: Hyaluronidase AND Ulobetasol\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ulobetasol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Ulobetasol"}, {"id": "Hyaluronidase_INT_Desonide", "text": "Interaction: Hyaluronidase AND Desonide\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Desonide.\nRisk: Monitor closely.", "source": "Hyaluronidase + Desonide"}, {"id": "Hyaluronidase_INT_Halcinonide", "text": "Interaction: Hyaluronidase AND Halcinonide\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Halcinonide.\nRisk: Monitor closely.", "source": "Hyaluronidase + Halcinonide"}, {"id": "Hyaluronidase_INT_Deflazacort", "text": "Interaction: Hyaluronidase AND Deflazacort\nDetails: The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Deflazacort.\nRisk: Monitor closely.", "source": "Hyaluronidase + Deflazacort"}, {"id": "Hyaluronidase_INT_Lidocaine", "text": "Interaction: Hyaluronidase AND Lidocaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Lidocaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Lidocaine"}, {"id": "Hyaluronidase_INT_Ropivacaine", "text": "Interaction: Hyaluronidase AND Ropivacaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Ropivacaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Ropivacaine"}, {"id": "Hyaluronidase_INT_Bupivacaine", "text": "Interaction: Hyaluronidase AND Bupivacaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Bupivacaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Bupivacaine"}, {"id": "Hyaluronidase_INT_Dyclonine", "text": "Interaction: Hyaluronidase AND Dyclonine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dyclonine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Dyclonine"}, {"id": "Hyaluronidase_INT_Procaine", "text": "Interaction: Hyaluronidase AND Procaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Procaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Procaine"}, {"id": "Hyaluronidase_INT_Prilocaine", "text": "Interaction: Hyaluronidase AND Prilocaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Prilocaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Prilocaine"}, {"id": "Hyaluronidase_INT_Proparacaine", "text": "Interaction: Hyaluronidase AND Proparacaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Proparacaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Proparacaine"}, {"id": "Hyaluronidase_INT_Mepivacaine", "text": "Interaction: Hyaluronidase AND Mepivacaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Mepivacaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Mepivacaine"}, {"id": "Hyaluronidase_INT_Levobupivacaine", "text": "Interaction: Hyaluronidase AND Levobupivacaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Levobupivacaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Levobupivacaine"}, {"id": "Hyaluronidase_INT_Benzocaine", "text": "Interaction: Hyaluronidase AND Benzocaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Benzocaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Benzocaine"}, {"id": "Hyaluronidase_INT_Chloroprocaine", "text": "Interaction: Hyaluronidase AND Chloroprocaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Chloroprocaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Chloroprocaine"}, {"id": "Hyaluronidase_INT_Etidocaine", "text": "Interaction: Hyaluronidase AND Etidocaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Etidocaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Etidocaine"}, {"id": "Hyaluronidase_INT_Articaine", "text": "Interaction: Hyaluronidase AND Articaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Articaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Articaine"}, {"id": "Hyaluronidase_INT_Tetracaine", "text": "Interaction: Hyaluronidase AND Tetracaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Tetracaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Tetracaine"}, {"id": "Hyaluronidase_INT_Oxethazaine", "text": "Interaction: Hyaluronidase AND Oxethazaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Oxethazaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Oxethazaine"}, {"id": "Hyaluronidase_INT_Ethyl chloride", "text": "Interaction: Hyaluronidase AND Ethyl chloride\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Ethyl chloride.\nRisk: Monitor closely.", "source": "Hyaluronidase + Ethyl chloride"}, {"id": "Hyaluronidase_INT_Oxybuprocaine", "text": "Interaction: Hyaluronidase AND Oxybuprocaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Oxybuprocaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Oxybuprocaine"}, {"id": "Hyaluronidase_INT_Phenol", "text": "Interaction: Hyaluronidase AND Phenol\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Phenol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Phenol"}, {"id": "Hyaluronidase_INT_Cinchocaine", "text": "Interaction: Hyaluronidase AND Cinchocaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Cinchocaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Cinchocaine"}, {"id": "Hyaluronidase_INT_Cocaine", "text": "Interaction: Hyaluronidase AND Cocaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Cocaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Cocaine"}, {"id": "Hyaluronidase_INT_Tetrodotoxin", "text": "Interaction: Hyaluronidase AND Tetrodotoxin\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Tetrodotoxin.\nRisk: Monitor closely.", "source": "Hyaluronidase + Tetrodotoxin"}, {"id": "Hyaluronidase_INT_Canertinib", "text": "Interaction: Hyaluronidase AND Canertinib\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Canertinib.\nRisk: Monitor closely.", "source": "Hyaluronidase + Canertinib"}, {"id": "Hyaluronidase_INT_PSD502", "text": "Interaction: Hyaluronidase AND PSD502\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with PSD502.\nRisk: Monitor closely.", "source": "Hyaluronidase + PSD502"}, {"id": "Hyaluronidase_INT_Benzyl alcohol", "text": "Interaction: Hyaluronidase AND Benzyl alcohol\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Benzyl alcohol.\nRisk: Monitor closely.", "source": "Hyaluronidase + Benzyl alcohol"}, {"id": "Hyaluronidase_INT_Propoxycaine", "text": "Interaction: Hyaluronidase AND Propoxycaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Propoxycaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Propoxycaine"}, {"id": "Hyaluronidase_INT_Pramocaine", "text": "Interaction: Hyaluronidase AND Pramocaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Pramocaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Pramocaine"}, {"id": "Hyaluronidase_INT_Butamben", "text": "Interaction: Hyaluronidase AND Butamben\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Butamben.\nRisk: Monitor closely.", "source": "Hyaluronidase + Butamben"}, {"id": "Hyaluronidase_INT_Butacaine", "text": "Interaction: Hyaluronidase AND Butacaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Butacaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Butacaine"}, {"id": "Hyaluronidase_INT_Quinisocaine", "text": "Interaction: Hyaluronidase AND Quinisocaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Quinisocaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Quinisocaine"}, {"id": "Hyaluronidase_INT_Capsaicin", "text": "Interaction: Hyaluronidase AND Capsaicin\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Capsaicin.\nRisk: Monitor closely.", "source": "Hyaluronidase + Capsaicin"}, {"id": "Hyaluronidase_INT_Butanilicaine", "text": "Interaction: Hyaluronidase AND Butanilicaine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Butanilicaine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Butanilicaine"}, {"id": "Hyaluronidase_INT_Metabutethamine", "text": "Interaction: Hyaluronidase AND Metabutethamine\nDetails: The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Metabutethamine.\nRisk: Monitor closely.", "source": "Hyaluronidase + Metabutethamine"}, {"id": "Insulin Pork_GEN", "text": "Drug: Insulin Pork\nDescription: Insulin isolated from pig pancreas. Composed of alpha and beta chains, processed from pro-insulin. Forms a hexameric structure....", "source": "Insulin Pork"}, {"id": "Insulin Pork_CLIN", "text": "Drug: Insulin Pork\nMechanism: Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR s...\nToxicity: ...", "source": "Insulin Pork"}, {"id": "Insulin Pork_INT_Rosiglitazone", "text": "Interaction: Insulin Pork AND Rosiglitazone\nDetails: The risk or severity of myocardial ischemia can be increased when Insulin Pork is combined with Rosiglitazone.\nRisk: Monitor closely.", "source": "Insulin Pork + Rosiglitazone"}, {"id": "Insulin Pork_INT_Pregabalin", "text": "Interaction: Insulin Pork AND Pregabalin\nDetails: The risk or severity of heart failure can be increased when Pregabalin is combined with Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Pregabalin"}, {"id": "Insulin Pork_INT_Sitagliptin", "text": "Interaction: Insulin Pork AND Sitagliptin\nDetails: Sitagliptin may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Sitagliptin"}, {"id": "Insulin Pork_INT_Vildagliptin", "text": "Interaction: Insulin Pork AND Vildagliptin\nDetails: Vildagliptin may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Vildagliptin"}, {"id": "Insulin Pork_INT_Alogliptin", "text": "Interaction: Insulin Pork AND Alogliptin\nDetails: Alogliptin may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Alogliptin"}, {"id": "Insulin Pork_INT_Saxagliptin", "text": "Interaction: Insulin Pork AND Saxagliptin\nDetails: Saxagliptin may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Saxagliptin"}, {"id": "Insulin Pork_INT_Atorvastatin", "text": "Interaction: Insulin Pork AND Atorvastatin\nDetails: Atorvastatin may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Atorvastatin"}, {"id": "Insulin Pork_INT_Linagliptin", "text": "Interaction: Insulin Pork AND Linagliptin\nDetails: Linagliptin may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Linagliptin"}, {"id": "Insulin Pork_INT_Exenatide", "text": "Interaction: Insulin Pork AND Exenatide\nDetails: Exenatide may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Exenatide"}, {"id": "Insulin Pork_INT_Albiglutide", "text": "Interaction: Insulin Pork AND Albiglutide\nDetails: Albiglutide may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Albiglutide"}, {"id": "Insulin Pork_INT_Dulaglutide", "text": "Interaction: Insulin Pork AND Dulaglutide\nDetails: Dulaglutide may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Dulaglutide"}, {"id": "Insulin Pork_INT_Canagliflozin", "text": "Interaction: Insulin Pork AND Canagliflozin\nDetails: Canagliflozin may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Canagliflozin"}, {"id": "Insulin Pork_INT_Empagliflozin", "text": "Interaction: Insulin Pork AND Empagliflozin\nDetails: Empagliflozin may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Empagliflozin"}, {"id": "Insulin Pork_INT_Liraglutide", "text": "Interaction: Insulin Pork AND Liraglutide\nDetails: Liraglutide may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Liraglutide"}, {"id": "Insulin Pork_INT_Metreleptin", "text": "Interaction: Insulin Pork AND Metreleptin\nDetails: Metreleptin may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Metreleptin"}, {"id": "Insulin Pork_INT_Pioglitazone", "text": "Interaction: Insulin Pork AND Pioglitazone\nDetails: The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Pioglitazone"}, {"id": "Insulin Pork_INT_Pramlintide", "text": "Interaction: Insulin Pork AND Pramlintide\nDetails: Pramlintide may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Pramlintide"}, {"id": "Insulin Pork_INT_Lipoic Acid", "text": "Interaction: Insulin Pork AND Lipoic Acid\nDetails: Lipoic Acid may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Lipoic Acid"}, {"id": "Insulin Pork_INT_Edetic Acid", "text": "Interaction: Insulin Pork AND Edetic Acid\nDetails: Edetic Acid may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Edetic Acid"}, {"id": "Insulin Pork_INT_Ubidecarenone", "text": "Interaction: Insulin Pork AND Ubidecarenone\nDetails: The therapeutic efficacy of Insulin Pork can be increased when used in combination with Ubidecarenone.\nRisk: Monitor closely.", "source": "Insulin Pork + Ubidecarenone"}, {"id": "Insulin Pork_INT_Esmolol", "text": "Interaction: Insulin Pork AND Esmolol\nDetails: Esmolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Esmolol"}, {"id": "Insulin Pork_INT_Betaxolol", "text": "Interaction: Insulin Pork AND Betaxolol\nDetails: Betaxolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Betaxolol"}, {"id": "Insulin Pork_INT_Metoprolol", "text": "Interaction: Insulin Pork AND Metoprolol\nDetails: Metoprolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Metoprolol"}, {"id": "Insulin Pork_INT_Atenolol", "text": "Interaction: Insulin Pork AND Atenolol\nDetails: Atenolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Atenolol"}, {"id": "Insulin Pork_INT_Timolol", "text": "Interaction: Insulin Pork AND Timolol\nDetails: Timolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Timolol"}, {"id": "Insulin Pork_INT_Carteolol", "text": "Interaction: Insulin Pork AND Carteolol\nDetails: Carteolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Carteolol"}, {"id": "Insulin Pork_INT_Propranolol", "text": "Interaction: Insulin Pork AND Propranolol\nDetails: Propranolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Propranolol"}, {"id": "Insulin Pork_INT_Labetalol", "text": "Interaction: Insulin Pork AND Labetalol\nDetails: Labetalol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Labetalol"}, {"id": "Insulin Pork_INT_Bisoprolol", "text": "Interaction: Insulin Pork AND Bisoprolol\nDetails: Bisoprolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Bisoprolol"}, {"id": "Insulin Pork_INT_Pindolol", "text": "Interaction: Insulin Pork AND Pindolol\nDetails: Pindolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Pindolol"}, {"id": "Insulin Pork_INT_Carvedilol", "text": "Interaction: Insulin Pork AND Carvedilol\nDetails: Carvedilol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Carvedilol"}, {"id": "Insulin Pork_INT_Acebutolol", "text": "Interaction: Insulin Pork AND Acebutolol\nDetails: Acebutolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Acebutolol"}, {"id": "Insulin Pork_INT_Nadolol", "text": "Interaction: Insulin Pork AND Nadolol\nDetails: Nadolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Nadolol"}, {"id": "Insulin Pork_INT_Sotalol", "text": "Interaction: Insulin Pork AND Sotalol\nDetails: Sotalol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Sotalol"}, {"id": "Insulin Pork_INT_Nebivolol", "text": "Interaction: Insulin Pork AND Nebivolol\nDetails: Nebivolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Nebivolol"}, {"id": "Insulin Pork_INT_Alprenolol", "text": "Interaction: Insulin Pork AND Alprenolol\nDetails: Alprenolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Alprenolol"}, {"id": "Insulin Pork_INT_Bevantolol", "text": "Interaction: Insulin Pork AND Bevantolol\nDetails: Bevantolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Bevantolol"}, {"id": "Insulin Pork_INT_Practolol", "text": "Interaction: Insulin Pork AND Practolol\nDetails: Practolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Practolol"}, {"id": "Insulin Pork_INT_Penbutolol", "text": "Interaction: Insulin Pork AND Penbutolol\nDetails: Penbutolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Penbutolol"}, {"id": "Insulin Pork_INT_Oxprenolol", "text": "Interaction: Insulin Pork AND Oxprenolol\nDetails: Oxprenolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Oxprenolol"}, {"id": "Insulin Pork_INT_Platelet Activating Factor", "text": "Interaction: Insulin Pork AND Platelet Activating Factor\nDetails: Platelet Activating Factor may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Platelet Activating Factor"}, {"id": "Insulin Pork_INT_Celiprolol", "text": "Interaction: Insulin Pork AND Celiprolol\nDetails: Celiprolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Celiprolol"}, {"id": "Insulin Pork_INT_Bufuralol", "text": "Interaction: Insulin Pork AND Bufuralol\nDetails: Bufuralol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Bufuralol"}, {"id": "Insulin Pork_INT_Bopindolol", "text": "Interaction: Insulin Pork AND Bopindolol\nDetails: Bopindolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Bopindolol"}, {"id": "Insulin Pork_INT_Bupranolol", "text": "Interaction: Insulin Pork AND Bupranolol\nDetails: Bupranolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Bupranolol"}, {"id": "Insulin Pork_INT_Indenolol", "text": "Interaction: Insulin Pork AND Indenolol\nDetails: Indenolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Indenolol"}, {"id": "Insulin Pork_INT_Befunolol", "text": "Interaction: Insulin Pork AND Befunolol\nDetails: Befunolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Befunolol"}, {"id": "Insulin Pork_INT_Arotinolol", "text": "Interaction: Insulin Pork AND Arotinolol\nDetails: Arotinolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Arotinolol"}, {"id": "Insulin Pork_INT_Talinolol", "text": "Interaction: Insulin Pork AND Talinolol\nDetails: Talinolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Talinolol"}, {"id": "Insulin Pork_INT_Landiolol", "text": "Interaction: Insulin Pork AND Landiolol\nDetails: Landiolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Landiolol"}, {"id": "Insulin Pork_INT_Bucindolol", "text": "Interaction: Insulin Pork AND Bucindolol\nDetails: Bucindolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Bucindolol"}, {"id": "Insulin Pork_INT_Cloranolol", "text": "Interaction: Insulin Pork AND Cloranolol\nDetails: Cloranolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Cloranolol"}, {"id": "Insulin Pork_INT_Mepindolol", "text": "Interaction: Insulin Pork AND Mepindolol\nDetails: Mepindolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Mepindolol"}, {"id": "Insulin Pork_INT_Epanolol", "text": "Interaction: Insulin Pork AND Epanolol\nDetails: Epanolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Epanolol"}, {"id": "Insulin Pork_INT_Tertatolol", "text": "Interaction: Insulin Pork AND Tertatolol\nDetails: Tertatolol may increase the hypoglycemic activities of Insulin Pork.\nRisk: Monitor closely.", "source": "Insulin Pork + Tertatolol"}, {"id": "Insulin Pork_INT_Methyclothiazide", "text": "Interaction: Insulin Pork AND Methyclothiazide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methyclothiazide.\nRisk: Monitor closely.", "source": "Insulin Pork + Methyclothiazide"}, {"id": "Insulin Pork_INT_Chlorothiazide", "text": "Interaction: Insulin Pork AND Chlorothiazide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Chlorothiazide.\nRisk: Monitor closely.", "source": "Insulin Pork + Chlorothiazide"}, {"id": "Insulin Pork_INT_Hydrochlorothiazide", "text": "Interaction: Insulin Pork AND Hydrochlorothiazide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydrochlorothiazide.\nRisk: Monitor closely.", "source": "Insulin Pork + Hydrochlorothiazide"}, {"id": "Insulin Pork_INT_Chlorthalidone", "text": "Interaction: Insulin Pork AND Chlorthalidone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Chlorthalidone.\nRisk: Monitor closely.", "source": "Insulin Pork + Chlorthalidone"}, {"id": "Insulin Pork_INT_Bendroflumethiazide", "text": "Interaction: Insulin Pork AND Bendroflumethiazide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Bendroflumethiazide.\nRisk: Monitor closely.", "source": "Insulin Pork + Bendroflumethiazide"}, {"id": "Insulin Pork_INT_Metolazone", "text": "Interaction: Insulin Pork AND Metolazone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Metolazone.\nRisk: Monitor closely.", "source": "Insulin Pork + Metolazone"}, {"id": "Insulin Pork_INT_Hydroflumethiazide", "text": "Interaction: Insulin Pork AND Hydroflumethiazide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydroflumethiazide.\nRisk: Monitor closely.", "source": "Insulin Pork + Hydroflumethiazide"}, {"id": "Insulin Pork_INT_Indapamide", "text": "Interaction: Insulin Pork AND Indapamide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Indapamide.\nRisk: Monitor closely.", "source": "Insulin Pork + Indapamide"}, {"id": "Insulin Pork_INT_Trichlormethiazide", "text": "Interaction: Insulin Pork AND Trichlormethiazide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Trichlormethiazide.\nRisk: Monitor closely.", "source": "Insulin Pork + Trichlormethiazide"}, {"id": "Insulin Pork_INT_Polythiazide", "text": "Interaction: Insulin Pork AND Polythiazide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Polythiazide.\nRisk: Monitor closely.", "source": "Insulin Pork + Polythiazide"}, {"id": "Insulin Pork_INT_Quinethazone", "text": "Interaction: Insulin Pork AND Quinethazone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Quinethazone.\nRisk: Monitor closely.", "source": "Insulin Pork + Quinethazone"}, {"id": "Insulin Pork_INT_Cyclopenthiazide", "text": "Interaction: Insulin Pork AND Cyclopenthiazide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Cyclopenthiazide.\nRisk: Monitor closely.", "source": "Insulin Pork + Cyclopenthiazide"}, {"id": "Insulin Pork_INT_Leuprolide", "text": "Interaction: Insulin Pork AND Leuprolide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Leuprolide.\nRisk: Monitor closely.", "source": "Insulin Pork + Leuprolide"}, {"id": "Insulin Pork_INT_Goserelin", "text": "Interaction: Insulin Pork AND Goserelin\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Goserelin.\nRisk: Monitor closely.", "source": "Insulin Pork + Goserelin"}, {"id": "Insulin Pork_INT_Octreotide", "text": "Interaction: Insulin Pork AND Octreotide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Insulin Pork + Octreotide"}, {"id": "Insulin Pork_INT_Torasemide", "text": "Interaction: Insulin Pork AND Torasemide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Torasemide.\nRisk: Monitor closely.", "source": "Insulin Pork + Torasemide"}, {"id": "Insulin Pork_INT_Nelfinavir", "text": "Interaction: Insulin Pork AND Nelfinavir\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Nelfinavir.\nRisk: Monitor closely.", "source": "Insulin Pork + Nelfinavir"}, {"id": "Insulin Pork_INT_Indinavir", "text": "Interaction: Insulin Pork AND Indinavir\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Indinavir.\nRisk: Monitor closely.", "source": "Insulin Pork + Indinavir"}, {"id": "Insulin Pork_INT_Ziprasidone", "text": "Interaction: Insulin Pork AND Ziprasidone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ziprasidone.\nRisk: Monitor closely.", "source": "Insulin Pork + Ziprasidone"}, {"id": "Insulin Pork_INT_Etonogestrel", "text": "Interaction: Insulin Pork AND Etonogestrel\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Etonogestrel.\nRisk: Monitor closely.", "source": "Insulin Pork + Etonogestrel"}, {"id": "Insulin Pork_INT_Desogestrel", "text": "Interaction: Insulin Pork AND Desogestrel\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Desogestrel.\nRisk: Monitor closely.", "source": "Insulin Pork + Desogestrel"}, {"id": "Insulin Pork_INT_Olanzapine", "text": "Interaction: Insulin Pork AND Olanzapine\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Olanzapine.\nRisk: Monitor closely.", "source": "Insulin Pork + Olanzapine"}, {"id": "Insulin Pork_INT_Megestrol acetate", "text": "Interaction: Insulin Pork AND Megestrol acetate\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Megestrol acetate.\nRisk: Monitor closely.", "source": "Insulin Pork + Megestrol acetate"}, {"id": "Insulin Pork_INT_Clozapine", "text": "Interaction: Insulin Pork AND Clozapine\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Clozapine.\nRisk: Monitor closely.", "source": "Insulin Pork + Clozapine"}, {"id": "Insulin Pork_INT_Levonorgestrel", "text": "Interaction: Insulin Pork AND Levonorgestrel\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Levonorgestrel.\nRisk: Monitor closely.", "source": "Insulin Pork + Levonorgestrel"}, {"id": "Insulin Pork_INT_Progesterone", "text": "Interaction: Insulin Pork AND Progesterone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Progesterone.\nRisk: Monitor closely.", "source": "Insulin Pork + Progesterone"}, {"id": "Insulin Pork_INT_Betamethasone", "text": "Interaction: Insulin Pork AND Betamethasone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Betamethasone.\nRisk: Monitor closely.", "source": "Insulin Pork + Betamethasone"}, {"id": "Insulin Pork_INT_Ritonavir", "text": "Interaction: Insulin Pork AND Ritonavir\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ritonavir.\nRisk: Monitor closely.", "source": "Insulin Pork + Ritonavir"}, {"id": "Insulin Pork_INT_Piperazine", "text": "Interaction: Insulin Pork AND Piperazine\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Piperazine.\nRisk: Monitor closely.", "source": "Insulin Pork + Piperazine"}, {"id": "Insulin Pork_INT_Medroxyprogesterone acetate", "text": "Interaction: Insulin Pork AND Medroxyprogesterone acetate\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Medroxyprogesterone acetate.\nRisk: Monitor closely.", "source": "Insulin Pork + Medroxyprogesterone acetate"}, {"id": "Insulin Pork_INT_Triamcinolone", "text": "Interaction: Insulin Pork AND Triamcinolone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Triamcinolone.\nRisk: Monitor closely.", "source": "Insulin Pork + Triamcinolone"}, {"id": "Insulin Pork_INT_Niacin", "text": "Interaction: Insulin Pork AND Niacin\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Niacin.\nRisk: Monitor closely.", "source": "Insulin Pork + Niacin"}, {"id": "Insulin Pork_INT_Prednisone", "text": "Interaction: Insulin Pork AND Prednisone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Prednisone.\nRisk: Monitor closely.", "source": "Insulin Pork + Prednisone"}, {"id": "Insulin Pork_INT_Epinephrine", "text": "Interaction: Insulin Pork AND Epinephrine\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Epinephrine.\nRisk: Monitor closely.", "source": "Insulin Pork + Epinephrine"}, {"id": "Insulin Pork_INT_Fludrocortisone", "text": "Interaction: Insulin Pork AND Fludrocortisone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Fludrocortisone.\nRisk: Monitor closely.", "source": "Insulin Pork + Fludrocortisone"}, {"id": "Insulin Pork_INT_Furosemide", "text": "Interaction: Insulin Pork AND Furosemide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Furosemide.\nRisk: Monitor closely.", "source": "Insulin Pork + Furosemide"}, {"id": "Insulin Pork_INT_Norethisterone", "text": "Interaction: Insulin Pork AND Norethisterone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Norethisterone.\nRisk: Monitor closely.", "source": "Insulin Pork + Norethisterone"}, {"id": "Insulin Pork_INT_Risperidone", "text": "Interaction: Insulin Pork AND Risperidone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Risperidone.\nRisk: Monitor closely.", "source": "Insulin Pork + Risperidone"}, {"id": "Insulin Pork_INT_Pentamidine", "text": "Interaction: Insulin Pork AND Pentamidine\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Pentamidine.\nRisk: Monitor closely.", "source": "Insulin Pork + Pentamidine"}, {"id": "Insulin Pork_INT_Hydrocortisone", "text": "Interaction: Insulin Pork AND Hydrocortisone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydrocortisone.\nRisk: Monitor closely.", "source": "Insulin Pork + Hydrocortisone"}, {"id": "Insulin Pork_INT_Estradiol", "text": "Interaction: Insulin Pork AND Estradiol\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Estradiol.\nRisk: Monitor closely.", "source": "Insulin Pork + Estradiol"}, {"id": "Insulin Pork_INT_Ethynodiol diacetate", "text": "Interaction: Insulin Pork AND Ethynodiol diacetate\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ethynodiol diacetate.\nRisk: Monitor closely.", "source": "Insulin Pork + Ethynodiol diacetate"}, {"id": "Insulin Pork_INT_Prednisolone", "text": "Interaction: Insulin Pork AND Prednisolone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Prednisolone.\nRisk: Monitor closely.", "source": "Insulin Pork + Prednisolone"}, {"id": "Insulin Pork_INT_Tacrolimus", "text": "Interaction: Insulin Pork AND Tacrolimus\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Tacrolimus.\nRisk: Monitor closely.", "source": "Insulin Pork + Tacrolimus"}, {"id": "Insulin Pork_INT_Sirolimus", "text": "Interaction: Insulin Pork AND Sirolimus\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Sirolimus.\nRisk: Monitor closely.", "source": "Insulin Pork + Sirolimus"}, {"id": "Insulin Pork_INT_Bumetanide", "text": "Interaction: Insulin Pork AND Bumetanide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Bumetanide.\nRisk: Monitor closely.", "source": "Insulin Pork + Bumetanide"}, {"id": "Insulin Pork_INT_Etacrynic acid", "text": "Interaction: Insulin Pork AND Etacrynic acid\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Etacrynic acid.\nRisk: Monitor closely.", "source": "Insulin Pork + Etacrynic acid"}, {"id": "Insulin Pork_INT_Tipranavir", "text": "Interaction: Insulin Pork AND Tipranavir\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Tipranavir.\nRisk: Monitor closely.", "source": "Insulin Pork + Tipranavir"}, {"id": "Insulin Pork_INT_Norgestimate", "text": "Interaction: Insulin Pork AND Norgestimate\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Norgestimate.\nRisk: Monitor closely.", "source": "Insulin Pork + Norgestimate"}, {"id": "Insulin Pork_INT_Methylprednisolone", "text": "Interaction: Insulin Pork AND Methylprednisolone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methylprednisolone.\nRisk: Monitor closely.", "source": "Insulin Pork + Methylprednisolone"}, {"id": "Insulin Pork_INT_Ethinyl Estradiol", "text": "Interaction: Insulin Pork AND Ethinyl Estradiol\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ethinyl Estradiol.\nRisk: Monitor closely.", "source": "Insulin Pork + Ethinyl Estradiol"}, {"id": "Insulin Pork_INT_Atazanavir", "text": "Interaction: Insulin Pork AND Atazanavir\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Atazanavir.\nRisk: Monitor closely.", "source": "Insulin Pork + Atazanavir"}, {"id": "Insulin Pork_INT_Diazoxide", "text": "Interaction: Insulin Pork AND Diazoxide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Diazoxide.\nRisk: Monitor closely.", "source": "Insulin Pork + Diazoxide"}, {"id": "Insulin Pork_INT_Arsenic trioxide", "text": "Interaction: Insulin Pork AND Arsenic trioxide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Arsenic trioxide.\nRisk: Monitor closely.", "source": "Insulin Pork + Arsenic trioxide"}, {"id": "Insulin Pork_INT_Quetiapine", "text": "Interaction: Insulin Pork AND Quetiapine\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Quetiapine.\nRisk: Monitor closely.", "source": "Insulin Pork + Quetiapine"}, {"id": "Insulin Pork_INT_Saquinavir", "text": "Interaction: Insulin Pork AND Saquinavir\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Saquinavir.\nRisk: Monitor closely.", "source": "Insulin Pork + Saquinavir"}, {"id": "Insulin Pork_INT_Dexamethasone", "text": "Interaction: Insulin Pork AND Dexamethasone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Dexamethasone.\nRisk: Monitor closely.", "source": "Insulin Pork + Dexamethasone"}, {"id": "Insulin Pork_INT_Aripiprazole", "text": "Interaction: Insulin Pork AND Aripiprazole\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Aripiprazole.\nRisk: Monitor closely.", "source": "Insulin Pork + Aripiprazole"}, {"id": "Insulin Pork_INT_Darunavir", "text": "Interaction: Insulin Pork AND Darunavir\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Darunavir.\nRisk: Monitor closely.", "source": "Insulin Pork + Darunavir"}, {"id": "Insulin Pork_INT_Paliperidone", "text": "Interaction: Insulin Pork AND Paliperidone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Paliperidone.\nRisk: Monitor closely.", "source": "Insulin Pork + Paliperidone"}, {"id": "Insulin Pork_INT_Corticotropin", "text": "Interaction: Insulin Pork AND Corticotropin\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Corticotropin.\nRisk: Monitor closely.", "source": "Insulin Pork + Corticotropin"}, {"id": "Insulin Pork_INT_Fosamprenavir", "text": "Interaction: Insulin Pork AND Fosamprenavir\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Fosamprenavir.\nRisk: Monitor closely.", "source": "Insulin Pork + Fosamprenavir"}, {"id": "Insulin Pork_INT_Mestranol", "text": "Interaction: Insulin Pork AND Mestranol\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Mestranol.\nRisk: Monitor closely.", "source": "Insulin Pork + Mestranol"}, {"id": "Insulin Pork_INT_Cortisone acetate", "text": "Interaction: Insulin Pork AND Cortisone acetate\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Cortisone acetate.\nRisk: Monitor closely.", "source": "Insulin Pork + Cortisone acetate"}, {"id": "Insulin Pork_INT_Drospirenone", "text": "Interaction: Insulin Pork AND Drospirenone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Drospirenone.\nRisk: Monitor closely.", "source": "Insulin Pork + Drospirenone"}, {"id": "Insulin Pork_INT_Methotrimeprazine", "text": "Interaction: Insulin Pork AND Methotrimeprazine\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methotrimeprazine.\nRisk: Monitor closely.", "source": "Insulin Pork + Methotrimeprazine"}, {"id": "Insulin Pork_INT_Danazol", "text": "Interaction: Insulin Pork AND Danazol\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Danazol.\nRisk: Monitor closely.", "source": "Insulin Pork + Danazol"}, {"id": "Insulin Pork_INT_Everolimus", "text": "Interaction: Insulin Pork AND Everolimus\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Everolimus.\nRisk: Monitor closely.", "source": "Insulin Pork + Everolimus"}, {"id": "Insulin Pork_INT_Lopinavir", "text": "Interaction: Insulin Pork AND Lopinavir\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lopinavir.\nRisk: Monitor closely.", "source": "Insulin Pork + Lopinavir"}, {"id": "Insulin Pork_INT_Pipotiazine", "text": "Interaction: Insulin Pork AND Pipotiazine\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Pipotiazine.\nRisk: Monitor closely.", "source": "Insulin Pork + Pipotiazine"}, {"id": "Insulin Pork_INT_Vorinostat", "text": "Interaction: Insulin Pork AND Vorinostat\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Vorinostat.\nRisk: Monitor closely.", "source": "Insulin Pork + Vorinostat"}, {"id": "Insulin Pork_INT_Estrone sulfate", "text": "Interaction: Insulin Pork AND Estrone sulfate\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Estrone sulfate.\nRisk: Monitor closely.", "source": "Insulin Pork + Estrone sulfate"}, {"id": "Insulin Pork_INT_Cyproterone acetate", "text": "Interaction: Insulin Pork AND Cyproterone acetate\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Cyproterone acetate.\nRisk: Monitor closely.", "source": "Insulin Pork + Cyproterone acetate"}, {"id": "Insulin Pork_INT_Nilotinib", "text": "Interaction: Insulin Pork AND Nilotinib\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Nilotinib.\nRisk: Monitor closely.", "source": "Insulin Pork + Nilotinib"}, {"id": "Insulin Pork_INT_Iloperidone", "text": "Interaction: Insulin Pork AND Iloperidone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Iloperidone.\nRisk: Monitor closely.", "source": "Insulin Pork + Iloperidone"}, {"id": "Insulin Pork_INT_Asenapine", "text": "Interaction: Insulin Pork AND Asenapine\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Asenapine.\nRisk: Monitor closely.", "source": "Insulin Pork + Asenapine"}, {"id": "Insulin Pork_INT_Temsirolimus", "text": "Interaction: Insulin Pork AND Temsirolimus\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Temsirolimus.\nRisk: Monitor closely.", "source": "Insulin Pork + Temsirolimus"}, {"id": "Insulin Pork_INT_Pasireotide", "text": "Interaction: Insulin Pork AND Pasireotide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Pasireotide.\nRisk: Monitor closely.", "source": "Insulin Pork + Pasireotide"}, {"id": "Insulin Pork_INT_Buserelin", "text": "Interaction: Insulin Pork AND Buserelin\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Buserelin.\nRisk: Monitor closely.", "source": "Insulin Pork + Buserelin"}, {"id": "Insulin Pork_INT_Histrelin", "text": "Interaction: Insulin Pork AND Histrelin\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Histrelin.\nRisk: Monitor closely.", "source": "Insulin Pork + Histrelin"}, {"id": "Insulin Pork_INT_Hydroxyprogesterone caproate", "text": "Interaction: Insulin Pork AND Hydroxyprogesterone caproate\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydroxyprogesterone caproate.\nRisk: Monitor closely.", "source": "Insulin Pork + Hydroxyprogesterone caproate"}, {"id": "Insulin Pork_INT_Lanreotide", "text": "Interaction: Insulin Pork AND Lanreotide\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lanreotide.\nRisk: Monitor closely.", "source": "Insulin Pork + Lanreotide"}, {"id": "Insulin Pork_INT_Triptorelin", "text": "Interaction: Insulin Pork AND Triptorelin\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Triptorelin.\nRisk: Monitor closely.", "source": "Insulin Pork + Triptorelin"}, {"id": "Insulin Pork_INT_Lurasidone", "text": "Interaction: Insulin Pork AND Lurasidone\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lurasidone.\nRisk: Monitor closely.", "source": "Insulin Pork + Lurasidone"}, {"id": "Insulin Pork_INT_Dabrafenib", "text": "Interaction: Insulin Pork AND Dabrafenib\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Dabrafenib.\nRisk: Monitor closely.", "source": "Insulin Pork + Dabrafenib"}, {"id": "Insulin Pork_INT_Articaine", "text": "Interaction: Insulin Pork AND Articaine\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Articaine.\nRisk: Monitor closely.", "source": "Insulin Pork + Articaine"}, {"id": "Insulin Pork_INT_Ceritinib", "text": "Interaction: Insulin Pork AND Ceritinib\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Ceritinib.\nRisk: Monitor closely.", "source": "Insulin Pork + Ceritinib"}, {"id": "Insulin Pork_INT_Dienogest", "text": "Interaction: Insulin Pork AND Dienogest\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Dienogest.\nRisk: Monitor closely.", "source": "Insulin Pork + Dienogest"}, {"id": "Insulin Pork_INT_Brexpiprazole", "text": "Interaction: Insulin Pork AND Brexpiprazole\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Brexpiprazole.\nRisk: Monitor closely.", "source": "Insulin Pork + Brexpiprazole"}, {"id": "Insulin Pork_INT_Insulin Human", "text": "Interaction: Insulin Pork AND Insulin Human\nDetails: Insulin Pork may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Insulin Pork + Insulin Human"}, {"id": "Insulin Pork_INT_Insulin Lispro", "text": "Interaction: Insulin Pork AND Insulin Lispro\nDetails: Insulin Pork may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Insulin Pork + Insulin Lispro"}, {"id": "Insulin Pork_INT_Insulin Glargine", "text": "Interaction: Insulin Pork AND Insulin Glargine\nDetails: Insulin Pork may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Insulin Pork + Insulin Glargine"}, {"id": "Insulin Pork_INT_Glimepiride", "text": "Interaction: Insulin Pork AND Glimepiride\nDetails: Insulin Pork may increase the hypoglycemic activities of Glimepiride.\nRisk: Monitor closely.", "source": "Insulin Pork + Glimepiride"}, {"id": "Insulin Pork_INT_Sulfisoxazole", "text": "Interaction: Insulin Pork AND Sulfisoxazole\nDetails: Insulin Pork may increase the hypoglycemic activities of Sulfisoxazole.\nRisk: Monitor closely.", "source": "Insulin Pork + Sulfisoxazole"}, {"id": "Insulin Pork_INT_Disopyramide", "text": "Interaction: Insulin Pork AND Disopyramide\nDetails: Insulin Pork may increase the hypoglycemic activities of Disopyramide.\nRisk: Monitor closely.", "source": "Insulin Pork + Disopyramide"}, {"id": "Insulin Pork_INT_Sulfadiazine", "text": "Interaction: Insulin Pork AND Sulfadiazine\nDetails: Insulin Pork may increase the hypoglycemic activities of Sulfadiazine.\nRisk: Monitor closely.", "source": "Insulin Pork + Sulfadiazine"}, {"id": "Insulin Pork_INT_Quinine", "text": "Interaction: Insulin Pork AND Quinine\nDetails: Insulin Pork may increase the hypoglycemic activities of Quinine.\nRisk: Monitor closely.", "source": "Insulin Pork + Quinine"}, {"id": "Insulin Pork_INT_Chlorpropamide", "text": "Interaction: Insulin Pork AND Chlorpropamide\nDetails: Insulin Pork may increase the hypoglycemic activities of Chlorpropamide.\nRisk: Monitor closely.", "source": "Insulin Pork + Chlorpropamide"}, {"id": "Insulin Pork_INT_Nateglinide", "text": "Interaction: Insulin Pork AND Nateglinide\nDetails: Insulin Pork may increase the hypoglycemic activities of Nateglinide.\nRisk: Monitor closely.", "source": "Insulin Pork + Nateglinide"}, {"id": "Insulin Pork_INT_Mifepristone", "text": "Interaction: Insulin Pork AND Mifepristone\nDetails: Insulin Pork may increase the hypoglycemic activities of Mifepristone.\nRisk: Monitor closely.", "source": "Insulin Pork + Mifepristone"}, {"id": "Insulin Pork_INT_Tolazamide", "text": "Interaction: Insulin Pork AND Tolazamide\nDetails: Insulin Pork may increase the hypoglycemic activities of Tolazamide.\nRisk: Monitor closely.", "source": "Insulin Pork + Tolazamide"}, {"id": "Insulin Pork_INT_Repaglinide", "text": "Interaction: Insulin Pork AND Repaglinide\nDetails: Insulin Pork may increase the hypoglycemic activities of Repaglinide.\nRisk: Monitor closely.", "source": "Insulin Pork + Repaglinide"}, {"id": "Insulin Pork_INT_Sulfamethoxazole", "text": "Interaction: Insulin Pork AND Sulfamethoxazole\nDetails: Insulin Pork may increase the hypoglycemic activities of Sulfamethoxazole.\nRisk: Monitor closely.", "source": "Insulin Pork + Sulfamethoxazole"}, {"id": "Insulin Pork_INT_Glyburide", "text": "Interaction: Insulin Pork AND Glyburide\nDetails: Insulin Pork may increase the hypoglycemic activities of Glyburide.\nRisk: Monitor closely.", "source": "Insulin Pork + Glyburide"}, {"id": "Insulin Pork_INT_Glipizide", "text": "Interaction: Insulin Pork AND Glipizide\nDetails: Insulin Pork may increase the hypoglycemic activities of Glipizide.\nRisk: Monitor closely.", "source": "Insulin Pork + Glipizide"}, {"id": "Insulin Pork_INT_Gliclazide", "text": "Interaction: Insulin Pork AND Gliclazide\nDetails: Insulin Pork may increase the hypoglycemic activities of Gliclazide.\nRisk: Monitor closely.", "source": "Insulin Pork + Gliclazide"}, {"id": "Insulin Pork_INT_Tolbutamide", "text": "Interaction: Insulin Pork AND Tolbutamide\nDetails: Insulin Pork may increase the hypoglycemic activities of Tolbutamide.\nRisk: Monitor closely.", "source": "Insulin Pork + Tolbutamide"}, {"id": "Insulin Pork_INT_Sunitinib", "text": "Interaction: Insulin Pork AND Sunitinib\nDetails: Insulin Pork may increase the hypoglycemic activities of Sunitinib.\nRisk: Monitor closely.", "source": "Insulin Pork + Sunitinib"}, {"id": "Insulin Pork_INT_Mecasermin", "text": "Interaction: Insulin Pork AND Mecasermin\nDetails: Insulin Pork may increase the hypoglycemic activities of Mecasermin.\nRisk: Monitor closely.", "source": "Insulin Pork + Mecasermin"}, {"id": "Insulin Pork_INT_Insulin Aspart", "text": "Interaction: Insulin Pork AND Insulin Aspart\nDetails: Insulin Pork may increase the hypoglycemic activities of Insulin Aspart.\nRisk: Monitor closely.", "source": "Insulin Pork + Insulin Aspart"}, {"id": "Insulin Pork_INT_Insulin Detemir", "text": "Interaction: Insulin Pork AND Insulin Detemir\nDetails: Insulin Pork may increase the hypoglycemic activities of Insulin Detemir.\nRisk: Monitor closely.", "source": "Insulin Pork + Insulin Detemir"}, {"id": "Insulin Pork_INT_Insulin Glulisine", "text": "Interaction: Insulin Pork AND Insulin Glulisine\nDetails: Insulin Pork may increase the hypoglycemic activities of Insulin Glulisine.\nRisk: Monitor closely.", "source": "Insulin Pork + Insulin Glulisine"}, {"id": "Trastuzumab_GEN", "text": "Drug: Trastuzumab\nDescription: ...", "source": "Trastuzumab"}, {"id": "Trastuzumab_GEN", "text": "Drug: Trastuzumab\nDescription: A recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein. Produced in CHO cell culture.\r\n\r\nIn December 2017, FDA approved Ogivri (trastuzumab-d...", "source": "Trastuzumab"}, {"id": "Trastuzumab_CLIN", "text": "Drug: Trastuzumab\nMechanism: Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of ...\nToxicity: Administration of trastuzumab can result in ventricular dysfunction and congestive heart failure. Risk of cardiotocity is especially elevated in patients recieving concurrent anthracycline or cyclopho...", "source": "Trastuzumab"}, {"id": "Trastuzumab_INT_Cetuximab", "text": "Interaction: Trastuzumab AND Cetuximab\nDetails: Trastuzumab may increase the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Trastuzumab + Cetuximab"}, {"id": "Trastuzumab_INT_Denileukin diftitox", "text": "Interaction: Trastuzumab AND Denileukin diftitox\nDetails: Trastuzumab may increase the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Trastuzumab + Denileukin diftitox"}, {"id": "Trastuzumab_INT_Asparaginase", "text": "Interaction: Trastuzumab AND Asparaginase\nDetails: Trastuzumab may increase the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Trastuzumab + Asparaginase"}, {"id": "Trastuzumab_INT_Pegaspargase", "text": "Interaction: Trastuzumab AND Pegaspargase\nDetails: Trastuzumab may increase the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Trastuzumab + Pegaspargase"}, {"id": "Trastuzumab_INT_Rituximab", "text": "Interaction: Trastuzumab AND Rituximab\nDetails: Trastuzumab may increase the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Trastuzumab + Rituximab"}, {"id": "Trastuzumab_INT_Bevacizumab", "text": "Interaction: Trastuzumab AND Bevacizumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Bevacizumab"}, {"id": "Trastuzumab_INT_Bortezomib", "text": "Interaction: Trastuzumab AND Bortezomib\nDetails: Trastuzumab may increase the cardiotoxic activities of Bortezomib.\nRisk: Monitor closely.", "source": "Trastuzumab + Bortezomib"}, {"id": "Trastuzumab_INT_Pipobroman", "text": "Interaction: Trastuzumab AND Pipobroman\nDetails: Trastuzumab may increase the cardiotoxic activities of Pipobroman.\nRisk: Monitor closely.", "source": "Trastuzumab + Pipobroman"}, {"id": "Trastuzumab_INT_Cladribine", "text": "Interaction: Trastuzumab AND Cladribine\nDetails: Trastuzumab may increase the cardiotoxic activities of Cladribine.\nRisk: Monitor closely.", "source": "Trastuzumab + Cladribine"}, {"id": "Trastuzumab_INT_Carmustine", "text": "Interaction: Trastuzumab AND Carmustine\nDetails: Trastuzumab may increase the cardiotoxic activities of Carmustine.\nRisk: Monitor closely.", "source": "Trastuzumab + Carmustine"}, {"id": "Trastuzumab_INT_Amsacrine", "text": "Interaction: Trastuzumab AND Amsacrine\nDetails: Trastuzumab may increase the cardiotoxic activities of Amsacrine.\nRisk: Monitor closely.", "source": "Trastuzumab + Amsacrine"}, {"id": "Trastuzumab_INT_Bleomycin", "text": "Interaction: Trastuzumab AND Bleomycin\nDetails: Trastuzumab may increase the cardiotoxic activities of Bleomycin.\nRisk: Monitor closely.", "source": "Trastuzumab + Bleomycin"}, {"id": "Trastuzumab_INT_Chlorambucil", "text": "Interaction: Trastuzumab AND Chlorambucil\nDetails: Trastuzumab may increase the cardiotoxic activities of Chlorambucil.\nRisk: Monitor closely.", "source": "Trastuzumab + Chlorambucil"}, {"id": "Trastuzumab_INT_Raltitrexed", "text": "Interaction: Trastuzumab AND Raltitrexed\nDetails: Trastuzumab may increase the cardiotoxic activities of Raltitrexed.\nRisk: Monitor closely.", "source": "Trastuzumab + Raltitrexed"}, {"id": "Trastuzumab_INT_Mitomycin", "text": "Interaction: Trastuzumab AND Mitomycin\nDetails: Trastuzumab may increase the cardiotoxic activities of Mitomycin.\nRisk: Monitor closely.", "source": "Trastuzumab + Mitomycin"}, {"id": "Trastuzumab_INT_Bexarotene", "text": "Interaction: Trastuzumab AND Bexarotene\nDetails: Trastuzumab may increase the cardiotoxic activities of Bexarotene.\nRisk: Monitor closely.", "source": "Trastuzumab + Bexarotene"}, {"id": "Trastuzumab_INT_Vindesine", "text": "Interaction: Trastuzumab AND Vindesine\nDetails: Trastuzumab may increase the cardiotoxic activities of Vindesine.\nRisk: Monitor closely.", "source": "Trastuzumab + Vindesine"}, {"id": "Trastuzumab_INT_Gefitinib", "text": "Interaction: Trastuzumab AND Gefitinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Gefitinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Gefitinib"}, {"id": "Trastuzumab_INT_Tioguanine", "text": "Interaction: Trastuzumab AND Tioguanine\nDetails: Trastuzumab may increase the cardiotoxic activities of Tioguanine.\nRisk: Monitor closely.", "source": "Trastuzumab + Tioguanine"}, {"id": "Trastuzumab_INT_Vinorelbine", "text": "Interaction: Trastuzumab AND Vinorelbine\nDetails: Trastuzumab may increase the cardiotoxic activities of Vinorelbine.\nRisk: Monitor closely.", "source": "Trastuzumab + Vinorelbine"}, {"id": "Trastuzumab_INT_Valrubicin", "text": "Interaction: Trastuzumab AND Valrubicin\nDetails: Trastuzumab may increase the cardiotoxic activities of Valrubicin.\nRisk: Monitor closely.", "source": "Trastuzumab + Valrubicin"}, {"id": "Trastuzumab_INT_Sorafenib", "text": "Interaction: Trastuzumab AND Sorafenib\nDetails: Trastuzumab may increase the cardiotoxic activities of Sorafenib.\nRisk: Monitor closely.", "source": "Trastuzumab + Sorafenib"}, {"id": "Trastuzumab_INT_Streptozocin", "text": "Interaction: Trastuzumab AND Streptozocin\nDetails: Trastuzumab may increase the cardiotoxic activities of Streptozocin.\nRisk: Monitor closely.", "source": "Trastuzumab + Streptozocin"}, {"id": "Trastuzumab_INT_Gemcitabine", "text": "Interaction: Trastuzumab AND Gemcitabine\nDetails: Trastuzumab may increase the cardiotoxic activities of Gemcitabine.\nRisk: Monitor closely.", "source": "Trastuzumab + Gemcitabine"}, {"id": "Trastuzumab_INT_Teniposide", "text": "Interaction: Trastuzumab AND Teniposide\nDetails: Trastuzumab may increase the cardiotoxic activities of Teniposide.\nRisk: Monitor closely.", "source": "Trastuzumab + Teniposide"}, {"id": "Trastuzumab_INT_Epirubicin", "text": "Interaction: Trastuzumab AND Epirubicin\nDetails: Trastuzumab may increase the cardiotoxic activities of Epirubicin.\nRisk: Monitor closely.", "source": "Trastuzumab + Epirubicin"}, {"id": "Trastuzumab_INT_Altretamine", "text": "Interaction: Trastuzumab AND Altretamine\nDetails: Trastuzumab may increase the cardiotoxic activities of Altretamine.\nRisk: Monitor closely.", "source": "Trastuzumab + Altretamine"}, {"id": "Trastuzumab_INT_Cisplatin", "text": "Interaction: Trastuzumab AND Cisplatin\nDetails: Trastuzumab may increase the cardiotoxic activities of Cisplatin.\nRisk: Monitor closely.", "source": "Trastuzumab + Cisplatin"}, {"id": "Trastuzumab_INT_Alitretinoin", "text": "Interaction: Trastuzumab AND Alitretinoin\nDetails: Trastuzumab may increase the cardiotoxic activities of Alitretinoin.\nRisk: Monitor closely.", "source": "Trastuzumab + Alitretinoin"}, {"id": "Trastuzumab_INT_Oxaliplatin", "text": "Interaction: Trastuzumab AND Oxaliplatin\nDetails: Trastuzumab may increase the cardiotoxic activities of Oxaliplatin.\nRisk: Monitor closely.", "source": "Trastuzumab + Oxaliplatin"}, {"id": "Trastuzumab_INT_Erlotinib", "text": "Interaction: Trastuzumab AND Erlotinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Erlotinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Erlotinib"}, {"id": "Trastuzumab_INT_Cyclophosphamide", "text": "Interaction: Trastuzumab AND Cyclophosphamide\nDetails: Trastuzumab may increase the cardiotoxic activities of Cyclophosphamide.\nRisk: Monitor closely.", "source": "Trastuzumab + Cyclophosphamide"}, {"id": "Trastuzumab_INT_Vincristine", "text": "Interaction: Trastuzumab AND Vincristine\nDetails: Trastuzumab may increase the cardiotoxic activities of Vincristine.\nRisk: Monitor closely.", "source": "Trastuzumab + Vincristine"}, {"id": "Trastuzumab_INT_Fluorouracil", "text": "Interaction: Trastuzumab AND Fluorouracil\nDetails: Trastuzumab may increase the cardiotoxic activities of Fluorouracil.\nRisk: Monitor closely.", "source": "Trastuzumab + Fluorouracil"}, {"id": "Trastuzumab_INT_Pentostatin", "text": "Interaction: Trastuzumab AND Pentostatin\nDetails: Trastuzumab may increase the cardiotoxic activities of Pentostatin.\nRisk: Monitor closely.", "source": "Trastuzumab + Pentostatin"}, {"id": "Trastuzumab_INT_Methotrexate", "text": "Interaction: Trastuzumab AND Methotrexate\nDetails: Trastuzumab may increase the cardiotoxic activities of Methotrexate.\nRisk: Monitor closely.", "source": "Trastuzumab + Methotrexate"}, {"id": "Trastuzumab_INT_Vinblastine", "text": "Interaction: Trastuzumab AND Vinblastine\nDetails: Trastuzumab may increase the cardiotoxic activities of Vinblastine.\nRisk: Monitor closely.", "source": "Trastuzumab + Vinblastine"}, {"id": "Trastuzumab_INT_Imatinib", "text": "Interaction: Trastuzumab AND Imatinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Imatinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Imatinib"}, {"id": "Trastuzumab_INT_Clofarabine", "text": "Interaction: Trastuzumab AND Clofarabine\nDetails: Trastuzumab may increase the cardiotoxic activities of Clofarabine.\nRisk: Monitor closely.", "source": "Trastuzumab + Clofarabine"}, {"id": "Trastuzumab_INT_Pemetrexed", "text": "Interaction: Trastuzumab AND Pemetrexed\nDetails: Trastuzumab may increase the cardiotoxic activities of Pemetrexed.\nRisk: Monitor closely.", "source": "Trastuzumab + Pemetrexed"}, {"id": "Trastuzumab_INT_Mitotane", "text": "Interaction: Trastuzumab AND Mitotane\nDetails: Trastuzumab may increase the cardiotoxic activities of Mitotane.\nRisk: Monitor closely.", "source": "Trastuzumab + Mitotane"}, {"id": "Trastuzumab_INT_Daunorubicin", "text": "Interaction: Trastuzumab AND Daunorubicin\nDetails: Trastuzumab may increase the cardiotoxic activities of Daunorubicin.\nRisk: Monitor closely.", "source": "Trastuzumab + Daunorubicin"}, {"id": "Trastuzumab_INT_Porfimer sodium", "text": "Interaction: Trastuzumab AND Porfimer sodium\nDetails: Trastuzumab may increase the cardiotoxic activities of Porfimer sodium.\nRisk: Monitor closely.", "source": "Trastuzumab + Porfimer sodium"}, {"id": "Trastuzumab_INT_Irinotecan", "text": "Interaction: Trastuzumab AND Irinotecan\nDetails: Trastuzumab may increase the cardiotoxic activities of Irinotecan.\nRisk: Monitor closely.", "source": "Trastuzumab + Irinotecan"}, {"id": "Trastuzumab_INT_Etoposide", "text": "Interaction: Trastuzumab AND Etoposide\nDetails: Trastuzumab may increase the cardiotoxic activities of Etoposide.\nRisk: Monitor closely.", "source": "Trastuzumab + Etoposide"}, {"id": "Trastuzumab_INT_Dacarbazine", "text": "Interaction: Trastuzumab AND Dacarbazine\nDetails: Trastuzumab may increase the cardiotoxic activities of Dacarbazine.\nRisk: Monitor closely.", "source": "Trastuzumab + Dacarbazine"}, {"id": "Trastuzumab_INT_Temozolomide", "text": "Interaction: Trastuzumab AND Temozolomide\nDetails: Trastuzumab may increase the cardiotoxic activities of Temozolomide.\nRisk: Monitor closely.", "source": "Trastuzumab + Temozolomide"}, {"id": "Trastuzumab_INT_Mechlorethamine", "text": "Interaction: Trastuzumab AND Mechlorethamine\nDetails: Trastuzumab may increase the cardiotoxic activities of Mechlorethamine.\nRisk: Monitor closely.", "source": "Trastuzumab + Mechlorethamine"}, {"id": "Trastuzumab_INT_Azacitidine", "text": "Interaction: Trastuzumab AND Azacitidine\nDetails: Trastuzumab may increase the cardiotoxic activities of Azacitidine.\nRisk: Monitor closely.", "source": "Trastuzumab + Azacitidine"}, {"id": "Trastuzumab_INT_Carboplatin", "text": "Interaction: Trastuzumab AND Carboplatin\nDetails: Trastuzumab may increase the cardiotoxic activities of Carboplatin.\nRisk: Monitor closely.", "source": "Trastuzumab + Carboplatin"}, {"id": "Trastuzumab_INT_Dactinomycin", "text": "Interaction: Trastuzumab AND Dactinomycin\nDetails: Trastuzumab may increase the cardiotoxic activities of Dactinomycin.\nRisk: Monitor closely.", "source": "Trastuzumab + Dactinomycin"}, {"id": "Trastuzumab_INT_Cytarabine", "text": "Interaction: Trastuzumab AND Cytarabine\nDetails: Trastuzumab may increase the cardiotoxic activities of Cytarabine.\nRisk: Monitor closely.", "source": "Trastuzumab + Cytarabine"}, {"id": "Trastuzumab_INT_Doxorubicin", "text": "Interaction: Trastuzumab AND Doxorubicin\nDetails: Trastuzumab may increase the cardiotoxic activities of Doxorubicin.\nRisk: Monitor closely.", "source": "Trastuzumab + Doxorubicin"}, {"id": "Trastuzumab_INT_Hydroxyurea", "text": "Interaction: Trastuzumab AND Hydroxyurea\nDetails: Trastuzumab may increase the cardiotoxic activities of Hydroxyurea.\nRisk: Monitor closely.", "source": "Trastuzumab + Hydroxyurea"}, {"id": "Trastuzumab_INT_Busulfan", "text": "Interaction: Trastuzumab AND Busulfan\nDetails: Trastuzumab may increase the cardiotoxic activities of Busulfan.\nRisk: Monitor closely.", "source": "Trastuzumab + Busulfan"}, {"id": "Trastuzumab_INT_Topotecan", "text": "Interaction: Trastuzumab AND Topotecan\nDetails: Trastuzumab may increase the cardiotoxic activities of Topotecan.\nRisk: Monitor closely.", "source": "Trastuzumab + Topotecan"}, {"id": "Trastuzumab_INT_Mercaptopurine", "text": "Interaction: Trastuzumab AND Mercaptopurine\nDetails: Trastuzumab may increase the cardiotoxic activities of Mercaptopurine.\nRisk: Monitor closely.", "source": "Trastuzumab + Mercaptopurine"}, {"id": "Trastuzumab_INT_Melphalan", "text": "Interaction: Trastuzumab AND Melphalan\nDetails: Trastuzumab may increase the cardiotoxic activities of Melphalan.\nRisk: Monitor closely.", "source": "Trastuzumab + Melphalan"}, {"id": "Trastuzumab_INT_Fludarabine", "text": "Interaction: Trastuzumab AND Fludarabine\nDetails: Trastuzumab may increase the cardiotoxic activities of Fludarabine.\nRisk: Monitor closely.", "source": "Trastuzumab + Fludarabine"}, {"id": "Trastuzumab_INT_Capecitabine", "text": "Interaction: Trastuzumab AND Capecitabine\nDetails: Trastuzumab may increase the cardiotoxic activities of Capecitabine.\nRisk: Monitor closely.", "source": "Trastuzumab + Capecitabine"}, {"id": "Trastuzumab_INT_Procarbazine", "text": "Interaction: Trastuzumab AND Procarbazine\nDetails: Trastuzumab may increase the cardiotoxic activities of Procarbazine.\nRisk: Monitor closely.", "source": "Trastuzumab + Procarbazine"}, {"id": "Trastuzumab_INT_Arsenic trioxide", "text": "Interaction: Trastuzumab AND Arsenic trioxide\nDetails: Trastuzumab may increase the cardiotoxic activities of Arsenic trioxide.\nRisk: Monitor closely.", "source": "Trastuzumab + Arsenic trioxide"}, {"id": "Trastuzumab_INT_Idarubicin", "text": "Interaction: Trastuzumab AND Idarubicin\nDetails: Trastuzumab may increase the cardiotoxic activities of Idarubicin.\nRisk: Monitor closely.", "source": "Trastuzumab + Idarubicin"}, {"id": "Trastuzumab_INT_Ifosfamide", "text": "Interaction: Trastuzumab AND Ifosfamide\nDetails: Trastuzumab may increase the cardiotoxic activities of Ifosfamide.\nRisk: Monitor closely.", "source": "Trastuzumab + Ifosfamide"}, {"id": "Trastuzumab_INT_Estramustine", "text": "Interaction: Trastuzumab AND Estramustine\nDetails: Trastuzumab may increase the cardiotoxic activities of Estramustine.\nRisk: Monitor closely.", "source": "Trastuzumab + Estramustine"}, {"id": "Trastuzumab_INT_Mitoxantrone", "text": "Interaction: Trastuzumab AND Mitoxantrone\nDetails: Trastuzumab may increase the cardiotoxic activities of Mitoxantrone.\nRisk: Monitor closely.", "source": "Trastuzumab + Mitoxantrone"}, {"id": "Trastuzumab_INT_Lomustine", "text": "Interaction: Trastuzumab AND Lomustine\nDetails: Trastuzumab may increase the cardiotoxic activities of Lomustine.\nRisk: Monitor closely.", "source": "Trastuzumab + Lomustine"}, {"id": "Trastuzumab_INT_Paclitaxel", "text": "Interaction: Trastuzumab AND Paclitaxel\nDetails: Trastuzumab may increase the cardiotoxic activities of Paclitaxel.\nRisk: Monitor closely.", "source": "Trastuzumab + Paclitaxel"}, {"id": "Trastuzumab_INT_Docetaxel", "text": "Interaction: Trastuzumab AND Docetaxel\nDetails: Trastuzumab may increase the cardiotoxic activities of Docetaxel.\nRisk: Monitor closely.", "source": "Trastuzumab + Docetaxel"}, {"id": "Trastuzumab_INT_Dasatinib", "text": "Interaction: Trastuzumab AND Dasatinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Dasatinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Dasatinib"}, {"id": "Trastuzumab_INT_Lapatinib", "text": "Interaction: Trastuzumab AND Lapatinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Lapatinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Lapatinib"}, {"id": "Trastuzumab_INT_Decitabine", "text": "Interaction: Trastuzumab AND Decitabine\nDetails: Trastuzumab may increase the cardiotoxic activities of Decitabine.\nRisk: Monitor closely.", "source": "Trastuzumab + Decitabine"}, {"id": "Trastuzumab_INT_Sunitinib", "text": "Interaction: Trastuzumab AND Sunitinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Sunitinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Sunitinib"}, {"id": "Trastuzumab_INT_Panitumumab", "text": "Interaction: Trastuzumab AND Panitumumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Panitumumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Panitumumab"}, {"id": "Trastuzumab_INT_Vorinostat", "text": "Interaction: Trastuzumab AND Vorinostat\nDetails: Trastuzumab may increase the cardiotoxic activities of Vorinostat.\nRisk: Monitor closely.", "source": "Trastuzumab + Vorinostat"}, {"id": "Trastuzumab_INT_Fotemustine", "text": "Interaction: Trastuzumab AND Fotemustine\nDetails: Trastuzumab may increase the cardiotoxic activities of Fotemustine.\nRisk: Monitor closely.", "source": "Trastuzumab + Fotemustine"}, {"id": "Trastuzumab_INT_Thiotepa", "text": "Interaction: Trastuzumab AND Thiotepa\nDetails: Trastuzumab may increase the cardiotoxic activities of Thiotepa.\nRisk: Monitor closely.", "source": "Trastuzumab + Thiotepa"}, {"id": "Trastuzumab_INT_Omacetaxine mepesuccinate", "text": "Interaction: Trastuzumab AND Omacetaxine mepesuccinate\nDetails: Trastuzumab may increase the cardiotoxic activities of Omacetaxine mepesuccinate.\nRisk: Monitor closely.", "source": "Trastuzumab + Omacetaxine mepesuccinate"}, {"id": "Trastuzumab_INT_Satraplatin", "text": "Interaction: Trastuzumab AND Satraplatin\nDetails: Trastuzumab may increase the cardiotoxic activities of Satraplatin.\nRisk: Monitor closely.", "source": "Trastuzumab + Satraplatin"}, {"id": "Trastuzumab_INT_Belinostat", "text": "Interaction: Trastuzumab AND Belinostat\nDetails: Trastuzumab may increase the cardiotoxic activities of Belinostat.\nRisk: Monitor closely.", "source": "Trastuzumab + Belinostat"}, {"id": "Trastuzumab_INT_Trabectedin", "text": "Interaction: Trastuzumab AND Trabectedin\nDetails: Trastuzumab may increase the cardiotoxic activities of Trabectedin.\nRisk: Monitor closely.", "source": "Trastuzumab + Trabectedin"}, {"id": "Trastuzumab_INT_Ramucirumab", "text": "Interaction: Trastuzumab AND Ramucirumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Ramucirumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Ramucirumab"}, {"id": "Trastuzumab_INT_Trastuzumab emtansine", "text": "Interaction: Trastuzumab AND Trastuzumab emtansine\nDetails: Trastuzumab may increase the cardiotoxic activities of Trastuzumab emtansine.\nRisk: Monitor closely.", "source": "Trastuzumab + Trastuzumab emtansine"}, {"id": "Trastuzumab_INT_Romidepsin", "text": "Interaction: Trastuzumab AND Romidepsin\nDetails: Trastuzumab may increase the cardiotoxic activities of Romidepsin.\nRisk: Monitor closely.", "source": "Trastuzumab + Romidepsin"}, {"id": "Trastuzumab_INT_Pixantrone", "text": "Interaction: Trastuzumab AND Pixantrone\nDetails: Trastuzumab may increase the cardiotoxic activities of Pixantrone.\nRisk: Monitor closely.", "source": "Trastuzumab + Pixantrone"}, {"id": "Trastuzumab_INT_Amrubicin", "text": "Interaction: Trastuzumab AND Amrubicin\nDetails: Trastuzumab may increase the cardiotoxic activities of Amrubicin.\nRisk: Monitor closely.", "source": "Trastuzumab + Amrubicin"}, {"id": "Trastuzumab_INT_Lonidamine", "text": "Interaction: Trastuzumab AND Lonidamine\nDetails: Trastuzumab may increase the cardiotoxic activities of Lonidamine.\nRisk: Monitor closely.", "source": "Trastuzumab + Lonidamine"}, {"id": "Trastuzumab_INT_Temsirolimus", "text": "Interaction: Trastuzumab AND Temsirolimus\nDetails: Trastuzumab may increase the cardiotoxic activities of Temsirolimus.\nRisk: Monitor closely.", "source": "Trastuzumab + Temsirolimus"}, {"id": "Trastuzumab_INT_Pertuzumab", "text": "Interaction: Trastuzumab AND Pertuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Pertuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Pertuzumab"}, {"id": "Trastuzumab_INT_Panobinostat", "text": "Interaction: Trastuzumab AND Panobinostat\nDetails: Trastuzumab may increase the cardiotoxic activities of Panobinostat.\nRisk: Monitor closely.", "source": "Trastuzumab + Panobinostat"}, {"id": "Trastuzumab_INT_Bendamustine", "text": "Interaction: Trastuzumab AND Bendamustine\nDetails: Trastuzumab may increase the cardiotoxic activities of Bendamustine.\nRisk: Monitor closely.", "source": "Trastuzumab + Bendamustine"}, {"id": "Trastuzumab_INT_Plicamycin", "text": "Interaction: Trastuzumab AND Plicamycin\nDetails: Trastuzumab may increase the cardiotoxic activities of Plicamycin.\nRisk: Monitor closely.", "source": "Trastuzumab + Plicamycin"}, {"id": "Trastuzumab_INT_Ponatinib", "text": "Interaction: Trastuzumab AND Ponatinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Ponatinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Ponatinib"}, {"id": "Trastuzumab_INT_Trametinib", "text": "Interaction: Trastuzumab AND Trametinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Trametinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Trametinib"}, {"id": "Trastuzumab_INT_Dabrafenib", "text": "Interaction: Trastuzumab AND Dabrafenib\nDetails: Trastuzumab may increase the cardiotoxic activities of Dabrafenib.\nRisk: Monitor closely.", "source": "Trastuzumab + Dabrafenib"}, {"id": "Trastuzumab_INT_Obinutuzumab", "text": "Interaction: Trastuzumab AND Obinutuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Obinutuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Obinutuzumab"}, {"id": "Trastuzumab_INT_Carmofur", "text": "Interaction: Trastuzumab AND Carmofur\nDetails: Trastuzumab may increase the cardiotoxic activities of Carmofur.\nRisk: Monitor closely.", "source": "Trastuzumab + Carmofur"}, {"id": "Trastuzumab_INT_Miltefosine", "text": "Interaction: Trastuzumab AND Miltefosine\nDetails: Trastuzumab may increase the cardiotoxic activities of Miltefosine.\nRisk: Monitor closely.", "source": "Trastuzumab + Miltefosine"}, {"id": "Trastuzumab_INT_Nivolumab", "text": "Interaction: Trastuzumab AND Nivolumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Nivolumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Nivolumab"}, {"id": "Trastuzumab_INT_Pembrolizumab", "text": "Interaction: Trastuzumab AND Pembrolizumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Pembrolizumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Pembrolizumab"}, {"id": "Trastuzumab_INT_Blinatumomab", "text": "Interaction: Trastuzumab AND Blinatumomab\nDetails: Trastuzumab may increase the cardiotoxic activities of Blinatumomab.\nRisk: Monitor closely.", "source": "Trastuzumab + Blinatumomab"}, {"id": "Trastuzumab_INT_Idelalisib", "text": "Interaction: Trastuzumab AND Idelalisib\nDetails: Trastuzumab may increase the cardiotoxic activities of Idelalisib.\nRisk: Monitor closely.", "source": "Trastuzumab + Idelalisib"}, {"id": "Trastuzumab_INT_Ceritinib", "text": "Interaction: Trastuzumab AND Ceritinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Ceritinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Ceritinib"}, {"id": "Trastuzumab_INT_Palbociclib", "text": "Interaction: Trastuzumab AND Palbociclib\nDetails: Trastuzumab may increase the cardiotoxic activities of Palbociclib.\nRisk: Monitor closely.", "source": "Trastuzumab + Palbociclib"}, {"id": "Trastuzumab_INT_Olaparib", "text": "Interaction: Trastuzumab AND Olaparib\nDetails: Trastuzumab may increase the cardiotoxic activities of Olaparib.\nRisk: Monitor closely.", "source": "Trastuzumab + Olaparib"}, {"id": "Trastuzumab_INT_Lenvatinib", "text": "Interaction: Trastuzumab AND Lenvatinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Lenvatinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Lenvatinib"}, {"id": "Trastuzumab_INT_Nintedanib", "text": "Interaction: Trastuzumab AND Nintedanib\nDetails: Trastuzumab may increase the cardiotoxic activities of Nintedanib.\nRisk: Monitor closely.", "source": "Trastuzumab + Nintedanib"}, {"id": "Trastuzumab_INT_Tegafur", "text": "Interaction: Trastuzumab AND Tegafur\nDetails: Trastuzumab may increase the cardiotoxic activities of Tegafur.\nRisk: Monitor closely.", "source": "Trastuzumab + Tegafur"}, {"id": "Trastuzumab_INT_Ixazomib", "text": "Interaction: Trastuzumab AND Ixazomib\nDetails: Trastuzumab may increase the cardiotoxic activities of Ixazomib.\nRisk: Monitor closely.", "source": "Trastuzumab + Ixazomib"}, {"id": "Trastuzumab_INT_Pirarubicin", "text": "Interaction: Trastuzumab AND Pirarubicin\nDetails: Trastuzumab may increase the cardiotoxic activities of Pirarubicin.\nRisk: Monitor closely.", "source": "Trastuzumab + Pirarubicin"}, {"id": "Trastuzumab_INT_Aclarubicin", "text": "Interaction: Trastuzumab AND Aclarubicin\nDetails: Trastuzumab may increase the cardiotoxic activities of Aclarubicin.\nRisk: Monitor closely.", "source": "Trastuzumab + Aclarubicin"}, {"id": "Trastuzumab_INT_Zorubicin", "text": "Interaction: Trastuzumab AND Zorubicin\nDetails: Trastuzumab may increase the cardiotoxic activities of Zorubicin.\nRisk: Monitor closely.", "source": "Trastuzumab + Zorubicin"}, {"id": "Trastuzumab_INT_Temoporfin", "text": "Interaction: Trastuzumab AND Temoporfin\nDetails: Trastuzumab may increase the cardiotoxic activities of Temoporfin.\nRisk: Monitor closely.", "source": "Trastuzumab + Temoporfin"}, {"id": "Trastuzumab_INT_Prednimustine", "text": "Interaction: Trastuzumab AND Prednimustine\nDetails: Trastuzumab may increase the cardiotoxic activities of Prednimustine.\nRisk: Monitor closely.", "source": "Trastuzumab + Prednimustine"}, {"id": "Trastuzumab_INT_Trofosfamide", "text": "Interaction: Trastuzumab AND Trofosfamide\nDetails: Trastuzumab may increase the cardiotoxic activities of Trofosfamide.\nRisk: Monitor closely.", "source": "Trastuzumab + Trofosfamide"}, {"id": "Trastuzumab_INT_Mitoguazone", "text": "Interaction: Trastuzumab AND Mitoguazone\nDetails: Trastuzumab may increase the cardiotoxic activities of Mitoguazone.\nRisk: Monitor closely.", "source": "Trastuzumab + Mitoguazone"}, {"id": "Trastuzumab_INT_Nimustine", "text": "Interaction: Trastuzumab AND Nimustine\nDetails: Trastuzumab may increase the cardiotoxic activities of Nimustine.\nRisk: Monitor closely.", "source": "Trastuzumab + Nimustine"}, {"id": "Trastuzumab_INT_Treosulfan", "text": "Interaction: Trastuzumab AND Treosulfan\nDetails: Trastuzumab may increase the cardiotoxic activities of Treosulfan.\nRisk: Monitor closely.", "source": "Trastuzumab + Treosulfan"}, {"id": "Trastuzumab_INT_Cediranib", "text": "Interaction: Trastuzumab AND Cediranib\nDetails: Trastuzumab may increase the cardiotoxic activities of Cediranib.\nRisk: Monitor closely.", "source": "Trastuzumab + Cediranib"}, {"id": "Trastuzumab_INT_Gemtuzumab ozogamicin", "text": "Interaction: Trastuzumab AND Gemtuzumab ozogamicin\nDetails: Trastuzumab may increase the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Trastuzumab + Gemtuzumab ozogamicin"}, {"id": "Trastuzumab_INT_Tiazofurine", "text": "Interaction: Trastuzumab AND Tiazofurine\nDetails: Trastuzumab may increase the cardiotoxic activities of Tiazofurine.\nRisk: Monitor closely.", "source": "Trastuzumab + Tiazofurine"}, {"id": "Trastuzumab_INT_Triaziquone", "text": "Interaction: Trastuzumab AND Triaziquone\nDetails: Trastuzumab may increase the cardiotoxic activities of Triaziquone.\nRisk: Monitor closely.", "source": "Trastuzumab + Triaziquone"}, {"id": "Trastuzumab_INT_Demecolcine", "text": "Interaction: Trastuzumab AND Demecolcine\nDetails: Trastuzumab may increase the cardiotoxic activities of Demecolcine.\nRisk: Monitor closely.", "source": "Trastuzumab + Demecolcine"}, {"id": "Trastuzumab_INT_Etoglucid", "text": "Interaction: Trastuzumab AND Etoglucid\nDetails: Trastuzumab may increase the cardiotoxic activities of Etoglucid.\nRisk: Monitor closely.", "source": "Trastuzumab + Etoglucid"}, {"id": "Trastuzumab_INT_Mitobronitol", "text": "Interaction: Trastuzumab AND Mitobronitol\nDetails: Trastuzumab may increase the cardiotoxic activities of Mitobronitol.\nRisk: Monitor closely.", "source": "Trastuzumab + Mitobronitol"}, {"id": "Trastuzumab_INT_Semustine", "text": "Interaction: Trastuzumab AND Semustine\nDetails: Trastuzumab may increase the cardiotoxic activities of Semustine.\nRisk: Monitor closely.", "source": "Trastuzumab + Semustine"}, {"id": "Trastuzumab_INT_Carboquone", "text": "Interaction: Trastuzumab AND Carboquone\nDetails: Trastuzumab may increase the cardiotoxic activities of Carboquone.\nRisk: Monitor closely.", "source": "Trastuzumab + Carboquone"}, {"id": "Trastuzumab_INT_Ranimustine", "text": "Interaction: Trastuzumab AND Ranimustine\nDetails: Trastuzumab may increase the cardiotoxic activities of Ranimustine.\nRisk: Monitor closely.", "source": "Trastuzumab + Ranimustine"}, {"id": "Trastuzumab_INT_Leuprolide", "text": "Interaction: Trastuzumab AND Leuprolide\nDetails: Trastuzumab may increase the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Trastuzumab + Leuprolide"}, {"id": "Trastuzumab_INT_Aldesleukin", "text": "Interaction: Trastuzumab AND Aldesleukin\nDetails: Trastuzumab may increase the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Trastuzumab + Aldesleukin"}, {"id": "Trastuzumab_INT_Alemtuzumab", "text": "Interaction: Trastuzumab AND Alemtuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Alemtuzumab"}, {"id": "Trastuzumab_INT_Megestrol acetate", "text": "Interaction: Trastuzumab AND Megestrol acetate\nDetails: Trastuzumab may increase the cardiotoxic activities of Megestrol acetate.\nRisk: Monitor closely.", "source": "Trastuzumab + Megestrol acetate"}, {"id": "Trastuzumab_INT_Lenalidomide", "text": "Interaction: Trastuzumab AND Lenalidomide\nDetails: Trastuzumab may increase the cardiotoxic activities of Lenalidomide.\nRisk: Monitor closely.", "source": "Trastuzumab + Lenalidomide"}, {"id": "Trastuzumab_INT_Flutamide", "text": "Interaction: Trastuzumab AND Flutamide\nDetails: Trastuzumab may increase the cardiotoxic activities of Flutamide.\nRisk: Monitor closely.", "source": "Trastuzumab + Flutamide"}, {"id": "Trastuzumab_INT_Nilutamide", "text": "Interaction: Trastuzumab AND Nilutamide\nDetails: Trastuzumab may increase the cardiotoxic activities of Nilutamide.\nRisk: Monitor closely.", "source": "Trastuzumab + Nilutamide"}, {"id": "Trastuzumab_INT_Tamoxifen", "text": "Interaction: Trastuzumab AND Tamoxifen\nDetails: Trastuzumab may increase the cardiotoxic activities of Tamoxifen.\nRisk: Monitor closely.", "source": "Trastuzumab + Tamoxifen"}, {"id": "Trastuzumab_INT_Tretinoin", "text": "Interaction: Trastuzumab AND Tretinoin\nDetails: Trastuzumab may increase the cardiotoxic activities of Tretinoin.\nRisk: Monitor closely.", "source": "Trastuzumab + Tretinoin"}, {"id": "Trastuzumab_INT_Fulvestrant", "text": "Interaction: Trastuzumab AND Fulvestrant\nDetails: Trastuzumab may increase the cardiotoxic activities of Fulvestrant.\nRisk: Monitor closely.", "source": "Trastuzumab + Fulvestrant"}, {"id": "Trastuzumab_INT_Exemestane", "text": "Interaction: Trastuzumab AND Exemestane\nDetails: Trastuzumab may increase the cardiotoxic activities of Exemestane.\nRisk: Monitor closely.", "source": "Trastuzumab + Exemestane"}, {"id": "Trastuzumab_INT_Letrozole", "text": "Interaction: Trastuzumab AND Letrozole\nDetails: Trastuzumab may increase the cardiotoxic activities of Letrozole.\nRisk: Monitor closely.", "source": "Trastuzumab + Letrozole"}, {"id": "Trastuzumab_INT_Bicalutamide", "text": "Interaction: Trastuzumab AND Bicalutamide\nDetails: Trastuzumab may increase the cardiotoxic activities of Bicalutamide.\nRisk: Monitor closely.", "source": "Trastuzumab + Bicalutamide"}, {"id": "Trastuzumab_INT_Anastrozole", "text": "Interaction: Trastuzumab AND Anastrozole\nDetails: Trastuzumab may increase the cardiotoxic activities of Anastrozole.\nRisk: Monitor closely.", "source": "Trastuzumab + Anastrozole"}, {"id": "Trastuzumab_INT_Everolimus", "text": "Interaction: Trastuzumab AND Everolimus\nDetails: Trastuzumab may increase the cardiotoxic activities of Everolimus.\nRisk: Monitor closely.", "source": "Trastuzumab + Everolimus"}, {"id": "Trastuzumab_INT_Nelarabine", "text": "Interaction: Trastuzumab AND Nelarabine\nDetails: Trastuzumab may increase the cardiotoxic activities of Nelarabine.\nRisk: Monitor closely.", "source": "Trastuzumab + Nelarabine"}, {"id": "Trastuzumab_INT_Nilotinib", "text": "Interaction: Trastuzumab AND Nilotinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Nilotinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Nilotinib"}, {"id": "Trastuzumab_INT_Vandetanib", "text": "Interaction: Trastuzumab AND Vandetanib\nDetails: Trastuzumab may increase the cardiotoxic activities of Vandetanib.\nRisk: Monitor closely.", "source": "Trastuzumab + Vandetanib"}, {"id": "Trastuzumab_INT_Ipilimumab", "text": "Interaction: Trastuzumab AND Ipilimumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Ipilimumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Ipilimumab"}, {"id": "Trastuzumab_INT_Pazopanib", "text": "Interaction: Trastuzumab AND Pazopanib\nDetails: Trastuzumab may increase the cardiotoxic activities of Pazopanib.\nRisk: Monitor closely.", "source": "Trastuzumab + Pazopanib"}, {"id": "Trastuzumab_INT_Catumaxomab", "text": "Interaction: Trastuzumab AND Catumaxomab\nDetails: Trastuzumab may increase the cardiotoxic activities of Catumaxomab.\nRisk: Monitor closely.", "source": "Trastuzumab + Catumaxomab"}, {"id": "Trastuzumab_INT_Bosutinib", "text": "Interaction: Trastuzumab AND Bosutinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Bosutinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Bosutinib"}, {"id": "Trastuzumab_INT_Axitinib", "text": "Interaction: Trastuzumab AND Axitinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Axitinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Axitinib"}, {"id": "Trastuzumab_INT_Ofatumumab", "text": "Interaction: Trastuzumab AND Ofatumumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Ofatumumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Ofatumumab"}, {"id": "Trastuzumab_INT_Cabazitaxel", "text": "Interaction: Trastuzumab AND Cabazitaxel\nDetails: Trastuzumab may increase the cardiotoxic activities of Cabazitaxel.\nRisk: Monitor closely.", "source": "Trastuzumab + Cabazitaxel"}, {"id": "Trastuzumab_INT_Vismodegib", "text": "Interaction: Trastuzumab AND Vismodegib\nDetails: Trastuzumab may increase the cardiotoxic activities of Vismodegib.\nRisk: Monitor closely.", "source": "Trastuzumab + Vismodegib"}, {"id": "Trastuzumab_INT_Crizotinib", "text": "Interaction: Trastuzumab AND Crizotinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Crizotinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Crizotinib"}, {"id": "Trastuzumab_INT_Brentuximab vedotin", "text": "Interaction: Trastuzumab AND Brentuximab vedotin\nDetails: Trastuzumab may increase the cardiotoxic activities of Brentuximab vedotin.\nRisk: Monitor closely.", "source": "Trastuzumab + Brentuximab vedotin"}, {"id": "Trastuzumab_INT_Eribulin", "text": "Interaction: Trastuzumab AND Eribulin\nDetails: Trastuzumab may increase the cardiotoxic activities of Eribulin.\nRisk: Monitor closely.", "source": "Trastuzumab + Eribulin"}, {"id": "Trastuzumab_INT_Ruxolitinib", "text": "Interaction: Trastuzumab AND Ruxolitinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Ruxolitinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Ruxolitinib"}, {"id": "Trastuzumab_INT_Vemurafenib", "text": "Interaction: Trastuzumab AND Vemurafenib\nDetails: Trastuzumab may increase the cardiotoxic activities of Vemurafenib.\nRisk: Monitor closely.", "source": "Trastuzumab + Vemurafenib"}, {"id": "Trastuzumab_INT_Carfilzomib", "text": "Interaction: Trastuzumab AND Carfilzomib\nDetails: Trastuzumab may increase the cardiotoxic activities of Carfilzomib.\nRisk: Monitor closely.", "source": "Trastuzumab + Carfilzomib"}, {"id": "Trastuzumab_INT_Regorafenib", "text": "Interaction: Trastuzumab AND Regorafenib\nDetails: Trastuzumab may increase the cardiotoxic activities of Regorafenib.\nRisk: Monitor closely.", "source": "Trastuzumab + Regorafenib"}, {"id": "Trastuzumab_INT_Afatinib", "text": "Interaction: Trastuzumab AND Afatinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Afatinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Afatinib"}, {"id": "Trastuzumab_INT_Ibrutinib", "text": "Interaction: Trastuzumab AND Ibrutinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Ibrutinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Ibrutinib"}, {"id": "Trastuzumab_INT_Necitumumab", "text": "Interaction: Trastuzumab AND Necitumumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Necitumumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Necitumumab"}, {"id": "Trastuzumab_INT_Abiraterone", "text": "Interaction: Trastuzumab AND Abiraterone\nDetails: Trastuzumab may increase the cardiotoxic activities of Abiraterone.\nRisk: Monitor closely.", "source": "Trastuzumab + Abiraterone"}, {"id": "Trastuzumab_INT_Midostaurin", "text": "Interaction: Trastuzumab AND Midostaurin\nDetails: Trastuzumab may increase the cardiotoxic activities of Midostaurin.\nRisk: Monitor closely.", "source": "Trastuzumab + Midostaurin"}, {"id": "Trastuzumab_INT_Triptorelin", "text": "Interaction: Trastuzumab AND Triptorelin\nDetails: Trastuzumab may increase the cardiotoxic activities of Triptorelin.\nRisk: Monitor closely.", "source": "Trastuzumab + Triptorelin"}, {"id": "Trastuzumab_INT_Pomalidomide", "text": "Interaction: Trastuzumab AND Pomalidomide\nDetails: Trastuzumab may increase the cardiotoxic activities of Pomalidomide.\nRisk: Monitor closely.", "source": "Trastuzumab + Pomalidomide"}, {"id": "Trastuzumab_INT_Osimertinib", "text": "Interaction: Trastuzumab AND Osimertinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Osimertinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Osimertinib"}, {"id": "Trastuzumab_INT_Daratumumab", "text": "Interaction: Trastuzumab AND Daratumumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Daratumumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Daratumumab"}, {"id": "Trastuzumab_INT_Goserelin", "text": "Interaction: Trastuzumab AND Goserelin\nDetails: Trastuzumab may increase the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Trastuzumab + Goserelin"}, {"id": "Trastuzumab_INT_Oprelvekin", "text": "Interaction: Trastuzumab AND Oprelvekin\nDetails: Trastuzumab may increase the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Trastuzumab + Oprelvekin"}, {"id": "Trastuzumab_INT_Interferon beta-1a", "text": "Interaction: Trastuzumab AND Interferon beta-1a\nDetails: Trastuzumab may increase the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Trastuzumab + Interferon beta-1a"}, {"id": "Trastuzumab_INT_Tositumomab", "text": "Interaction: Trastuzumab AND Tositumomab\nDetails: Trastuzumab may increase the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Trastuzumab + Tositumomab"}, {"id": "Trastuzumab_INT_Octreotide", "text": "Interaction: Trastuzumab AND Octreotide\nDetails: Trastuzumab may increase the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Trastuzumab + Octreotide"}, {"id": "Trastuzumab_INT_Vitamin A", "text": "Interaction: Trastuzumab AND Vitamin A\nDetails: Trastuzumab may increase the cardiotoxic activities of Vitamin A.\nRisk: Monitor closely.", "source": "Trastuzumab + Vitamin A"}, {"id": "Trastuzumab_INT_Moxifloxacin", "text": "Interaction: Trastuzumab AND Moxifloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Moxifloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Moxifloxacin"}, {"id": "Trastuzumab_INT_Cabergoline", "text": "Interaction: Trastuzumab AND Cabergoline\nDetails: Trastuzumab may increase the cardiotoxic activities of Cabergoline.\nRisk: Monitor closely.", "source": "Trastuzumab + Cabergoline"}, {"id": "Trastuzumab_INT_Diethylstilbestrol", "text": "Interaction: Trastuzumab AND Diethylstilbestrol\nDetails: Trastuzumab may increase the cardiotoxic activities of Diethylstilbestrol.\nRisk: Monitor closely.", "source": "Trastuzumab + Diethylstilbestrol"}, {"id": "Trastuzumab_INT_Chlorotrianisene", "text": "Interaction: Trastuzumab AND Chlorotrianisene\nDetails: Trastuzumab may increase the cardiotoxic activities of Chlorotrianisene.\nRisk: Monitor closely.", "source": "Trastuzumab + Chlorotrianisene"}, {"id": "Trastuzumab_INT_Pamidronate", "text": "Interaction: Trastuzumab AND Pamidronate\nDetails: Trastuzumab may increase the cardiotoxic activities of Pamidronate.\nRisk: Monitor closely.", "source": "Trastuzumab + Pamidronate"}, {"id": "Trastuzumab_INT_Floxuridine", "text": "Interaction: Trastuzumab AND Floxuridine\nDetails: Trastuzumab may increase the cardiotoxic activities of Floxuridine.\nRisk: Monitor closely.", "source": "Trastuzumab + Floxuridine"}, {"id": "Trastuzumab_INT_Aminoglutethimide", "text": "Interaction: Trastuzumab AND Aminoglutethimide\nDetails: Trastuzumab may increase the cardiotoxic activities of Aminoglutethimide.\nRisk: Monitor closely.", "source": "Trastuzumab + Aminoglutethimide"}, {"id": "Trastuzumab_INT_Grepafloxacin", "text": "Interaction: Trastuzumab AND Grepafloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Grepafloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Grepafloxacin"}, {"id": "Trastuzumab_INT_Dexrazoxane", "text": "Interaction: Trastuzumab AND Dexrazoxane\nDetails: Trastuzumab may increase the cardiotoxic activities of Dexrazoxane.\nRisk: Monitor closely.", "source": "Trastuzumab + Dexrazoxane"}, {"id": "Trastuzumab_INT_Verteporfin", "text": "Interaction: Trastuzumab AND Verteporfin\nDetails: Trastuzumab may increase the cardiotoxic activities of Verteporfin.\nRisk: Monitor closely.", "source": "Trastuzumab + Verteporfin"}, {"id": "Trastuzumab_INT_Enoxacin", "text": "Interaction: Trastuzumab AND Enoxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Enoxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Enoxacin"}, {"id": "Trastuzumab_INT_Pefloxacin", "text": "Interaction: Trastuzumab AND Pefloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Pefloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Pefloxacin"}, {"id": "Trastuzumab_INT_Albendazole", "text": "Interaction: Trastuzumab AND Albendazole\nDetails: Trastuzumab may increase the cardiotoxic activities of Albendazole.\nRisk: Monitor closely.", "source": "Trastuzumab + Albendazole"}, {"id": "Trastuzumab_INT_Ciprofloxacin", "text": "Interaction: Trastuzumab AND Ciprofloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Ciprofloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Ciprofloxacin"}, {"id": "Trastuzumab_INT_Toremifene", "text": "Interaction: Trastuzumab AND Toremifene\nDetails: Trastuzumab may increase the cardiotoxic activities of Toremifene.\nRisk: Monitor closely.", "source": "Trastuzumab + Toremifene"}, {"id": "Trastuzumab_INT_Azelaic Acid", "text": "Interaction: Trastuzumab AND Azelaic Acid\nDetails: Trastuzumab may increase the cardiotoxic activities of Azelaic Acid.\nRisk: Monitor closely.", "source": "Trastuzumab + Azelaic Acid"}, {"id": "Trastuzumab_INT_Medroxyprogesterone acetate", "text": "Interaction: Trastuzumab AND Medroxyprogesterone acetate\nDetails: Trastuzumab may increase the cardiotoxic activities of Medroxyprogesterone acetate.\nRisk: Monitor closely.", "source": "Trastuzumab + Medroxyprogesterone acetate"}, {"id": "Trastuzumab_INT_Sulindac", "text": "Interaction: Trastuzumab AND Sulindac\nDetails: Trastuzumab may increase the cardiotoxic activities of Sulindac.\nRisk: Monitor closely.", "source": "Trastuzumab + Sulindac"}, {"id": "Trastuzumab_INT_Prednisone", "text": "Interaction: Trastuzumab AND Prednisone\nDetails: Trastuzumab may increase the cardiotoxic activities of Prednisone.\nRisk: Monitor closely.", "source": "Trastuzumab + Prednisone"}, {"id": "Trastuzumab_INT_Mebendazole", "text": "Interaction: Trastuzumab AND Mebendazole\nDetails: Trastuzumab may increase the cardiotoxic activities of Mebendazole.\nRisk: Monitor closely.", "source": "Trastuzumab + Mebendazole"}, {"id": "Trastuzumab_INT_Trovafloxacin", "text": "Interaction: Trastuzumab AND Trovafloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Trovafloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Trovafloxacin"}, {"id": "Trastuzumab_INT_Imiquimod", "text": "Interaction: Trastuzumab AND Imiquimod\nDetails: Trastuzumab may increase the cardiotoxic activities of Imiquimod.\nRisk: Monitor closely.", "source": "Trastuzumab + Imiquimod"}, {"id": "Trastuzumab_INT_Nalidixic Acid", "text": "Interaction: Trastuzumab AND Nalidixic Acid\nDetails: Trastuzumab may increase the cardiotoxic activities of Nalidixic Acid.\nRisk: Monitor closely.", "source": "Trastuzumab + Nalidixic Acid"}, {"id": "Trastuzumab_INT_Uracil mustard", "text": "Interaction: Trastuzumab AND Uracil mustard\nDetails: Trastuzumab may increase the cardiotoxic activities of Uracil mustard.\nRisk: Monitor closely.", "source": "Trastuzumab + Uracil mustard"}, {"id": "Trastuzumab_INT_Cinoxacin", "text": "Interaction: Trastuzumab AND Cinoxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Cinoxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Cinoxacin"}, {"id": "Trastuzumab_INT_Prednisolone", "text": "Interaction: Trastuzumab AND Prednisolone\nDetails: Trastuzumab may increase the cardiotoxic activities of Prednisolone.\nRisk: Monitor closely.", "source": "Trastuzumab + Prednisolone"}, {"id": "Trastuzumab_INT_Sirolimus", "text": "Interaction: Trastuzumab AND Sirolimus\nDetails: Trastuzumab may increase the cardiotoxic activities of Sirolimus.\nRisk: Monitor closely.", "source": "Trastuzumab + Sirolimus"}, {"id": "Trastuzumab_INT_Testolactone", "text": "Interaction: Trastuzumab AND Testolactone\nDetails: Trastuzumab may increase the cardiotoxic activities of Testolactone.\nRisk: Monitor closely.", "source": "Trastuzumab + Testolactone"}, {"id": "Trastuzumab_INT_Methylprednisolone", "text": "Interaction: Trastuzumab AND Methylprednisolone\nDetails: Trastuzumab may increase the cardiotoxic activities of Methylprednisolone.\nRisk: Monitor closely.", "source": "Trastuzumab + Methylprednisolone"}, {"id": "Trastuzumab_INT_Ethiodized oil", "text": "Interaction: Trastuzumab AND Ethiodized oil\nDetails: Trastuzumab may increase the cardiotoxic activities of Ethiodized oil.\nRisk: Monitor closely.", "source": "Trastuzumab + Ethiodized oil"}, {"id": "Trastuzumab_INT_Lomefloxacin", "text": "Interaction: Trastuzumab AND Lomefloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Lomefloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Lomefloxacin"}, {"id": "Trastuzumab_INT_Azathioprine", "text": "Interaction: Trastuzumab AND Azathioprine\nDetails: Trastuzumab may increase the cardiotoxic activities of Azathioprine.\nRisk: Monitor closely.", "source": "Trastuzumab + Azathioprine"}, {"id": "Trastuzumab_INT_Mycophenolic acid", "text": "Interaction: Trastuzumab AND Mycophenolic acid\nDetails: Trastuzumab may increase the cardiotoxic activities of Mycophenolic acid.\nRisk: Monitor closely.", "source": "Trastuzumab + Mycophenolic acid"}, {"id": "Trastuzumab_INT_Thalidomide", "text": "Interaction: Trastuzumab AND Thalidomide\nDetails: Trastuzumab may increase the cardiotoxic activities of Thalidomide.\nRisk: Monitor closely.", "source": "Trastuzumab + Thalidomide"}, {"id": "Trastuzumab_INT_Gatifloxacin", "text": "Interaction: Trastuzumab AND Gatifloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Gatifloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Gatifloxacin"}, {"id": "Trastuzumab_INT_Norfloxacin", "text": "Interaction: Trastuzumab AND Norfloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Norfloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Norfloxacin"}, {"id": "Trastuzumab_INT_Leflunomide", "text": "Interaction: Trastuzumab AND Leflunomide\nDetails: Trastuzumab may increase the cardiotoxic activities of Leflunomide.\nRisk: Monitor closely.", "source": "Trastuzumab + Leflunomide"}, {"id": "Trastuzumab_INT_Quinacrine", "text": "Interaction: Trastuzumab AND Quinacrine\nDetails: Trastuzumab may increase the cardiotoxic activities of Quinacrine.\nRisk: Monitor closely.", "source": "Trastuzumab + Quinacrine"}, {"id": "Trastuzumab_INT_Trilostane", "text": "Interaction: Trastuzumab AND Trilostane\nDetails: Trastuzumab may increase the cardiotoxic activities of Trilostane.\nRisk: Monitor closely.", "source": "Trastuzumab + Trilostane"}, {"id": "Trastuzumab_INT_Levofloxacin", "text": "Interaction: Trastuzumab AND Levofloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Levofloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Levofloxacin"}, {"id": "Trastuzumab_INT_Gemifloxacin", "text": "Interaction: Trastuzumab AND Gemifloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Gemifloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Gemifloxacin"}, {"id": "Trastuzumab_INT_Trimetrexate", "text": "Interaction: Trastuzumab AND Trimetrexate\nDetails: Trastuzumab may increase the cardiotoxic activities of Trimetrexate.\nRisk: Monitor closely.", "source": "Trastuzumab + Trimetrexate"}, {"id": "Trastuzumab_INT_Ofloxacin", "text": "Interaction: Trastuzumab AND Ofloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Ofloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Ofloxacin"}, {"id": "Trastuzumab_INT_Podofilox", "text": "Interaction: Trastuzumab AND Podofilox\nDetails: Trastuzumab may increase the cardiotoxic activities of Podofilox.\nRisk: Monitor closely.", "source": "Trastuzumab + Podofilox"}, {"id": "Trastuzumab_INT_Sparfloxacin", "text": "Interaction: Trastuzumab AND Sparfloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Sparfloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Sparfloxacin"}, {"id": "Trastuzumab_INT_Dexamethasone", "text": "Interaction: Trastuzumab AND Dexamethasone\nDetails: Trastuzumab may increase the cardiotoxic activities of Dexamethasone.\nRisk: Monitor closely.", "source": "Trastuzumab + Dexamethasone"}, {"id": "Trastuzumab_INT_Ranibizumab", "text": "Interaction: Trastuzumab AND Ranibizumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Ranibizumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Ranibizumab"}, {"id": "Trastuzumab_INT_Colchicine", "text": "Interaction: Trastuzumab AND Colchicine\nDetails: Trastuzumab may increase the cardiotoxic activities of Colchicine.\nRisk: Monitor closely.", "source": "Trastuzumab + Colchicine"}, {"id": "Trastuzumab_INT_Temafloxacin", "text": "Interaction: Trastuzumab AND Temafloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Temafloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Temafloxacin"}, {"id": "Trastuzumab_INT_Genistein", "text": "Interaction: Trastuzumab AND Genistein\nDetails: Trastuzumab may increase the cardiotoxic activities of Genistein.\nRisk: Monitor closely.", "source": "Trastuzumab + Genistein"}, {"id": "Trastuzumab_INT_8-azaguanine", "text": "Interaction: Trastuzumab AND 8-azaguanine\nDetails: Trastuzumab may increase the cardiotoxic activities of 8-azaguanine.\nRisk: Monitor closely.", "source": "Trastuzumab + 8-azaguanine"}, {"id": "Trastuzumab_INT_7-Hydroxystaurosporine", "text": "Interaction: Trastuzumab AND 7-Hydroxystaurosporine\nDetails: Trastuzumab may increase the cardiotoxic activities of 7-Hydroxystaurosporine.\nRisk: Monitor closely.", "source": "Trastuzumab + 7-Hydroxystaurosporine"}, {"id": "Trastuzumab_INT_Hadacidin", "text": "Interaction: Trastuzumab AND Hadacidin\nDetails: Trastuzumab may increase the cardiotoxic activities of Hadacidin.\nRisk: Monitor closely.", "source": "Trastuzumab + Hadacidin"}, {"id": "Trastuzumab_INT_Formycin", "text": "Interaction: Trastuzumab AND Formycin\nDetails: Trastuzumab may increase the cardiotoxic activities of Formycin.\nRisk: Monitor closely.", "source": "Trastuzumab + Formycin"}, {"id": "Trastuzumab_INT_Calcipotriol", "text": "Interaction: Trastuzumab AND Calcipotriol\nDetails: Trastuzumab may increase the cardiotoxic activities of Calcipotriol.\nRisk: Monitor closely.", "source": "Trastuzumab + Calcipotriol"}, {"id": "Trastuzumab_INT_2-Methoxyestradiol", "text": "Interaction: Trastuzumab AND 2-Methoxyestradiol\nDetails: Trastuzumab may increase the cardiotoxic activities of 2-Methoxyestradiol.\nRisk: Monitor closely.", "source": "Trastuzumab + 2-Methoxyestradiol"}, {"id": "Trastuzumab_INT_Geldanamycin", "text": "Interaction: Trastuzumab AND Geldanamycin\nDetails: Trastuzumab may increase the cardiotoxic activities of Geldanamycin.\nRisk: Monitor closely.", "source": "Trastuzumab + Geldanamycin"}, {"id": "Trastuzumab_INT_Fumagillin", "text": "Interaction: Trastuzumab AND Fumagillin\nDetails: Trastuzumab may increase the cardiotoxic activities of Fumagillin.\nRisk: Monitor closely.", "source": "Trastuzumab + Fumagillin"}, {"id": "Trastuzumab_INT_Resveratrol", "text": "Interaction: Trastuzumab AND Resveratrol\nDetails: Trastuzumab may increase the cardiotoxic activities of Resveratrol.\nRisk: Monitor closely.", "source": "Trastuzumab + Resveratrol"}, {"id": "Trastuzumab_INT_Arotinoid acid", "text": "Interaction: Trastuzumab AND Arotinoid acid\nDetails: Trastuzumab may increase the cardiotoxic activities of Arotinoid acid.\nRisk: Monitor closely.", "source": "Trastuzumab + Arotinoid acid"}, {"id": "Trastuzumab_INT_Arsanilic acid", "text": "Interaction: Trastuzumab AND Arsanilic acid\nDetails: Trastuzumab may increase the cardiotoxic activities of Arsanilic acid.\nRisk: Monitor closely.", "source": "Trastuzumab + Arsanilic acid"}, {"id": "Trastuzumab_INT_Patupilone", "text": "Interaction: Trastuzumab AND Patupilone\nDetails: Trastuzumab may increase the cardiotoxic activities of Patupilone.\nRisk: Monitor closely.", "source": "Trastuzumab + Patupilone"}, {"id": "Trastuzumab_INT_3-Methoxybenzamide", "text": "Interaction: Trastuzumab AND 3-Methoxybenzamide\nDetails: Trastuzumab may increase the cardiotoxic activities of 3-Methoxybenzamide.\nRisk: Monitor closely.", "source": "Trastuzumab + 3-Methoxybenzamide"}, {"id": "Trastuzumab_INT_Tubercidin", "text": "Interaction: Trastuzumab AND Tubercidin\nDetails: Trastuzumab may increase the cardiotoxic activities of Tubercidin.\nRisk: Monitor closely.", "source": "Trastuzumab + Tubercidin"}, {"id": "Trastuzumab_INT_Ubenimex", "text": "Interaction: Trastuzumab AND Ubenimex\nDetails: Trastuzumab may increase the cardiotoxic activities of Ubenimex.\nRisk: Monitor closely.", "source": "Trastuzumab + Ubenimex"}, {"id": "Trastuzumab_INT_Sparfosic acid", "text": "Interaction: Trastuzumab AND Sparfosic acid\nDetails: Trastuzumab may increase the cardiotoxic activities of Sparfosic acid.\nRisk: Monitor closely.", "source": "Trastuzumab + Sparfosic acid"}, {"id": "Trastuzumab_INT_Alvocidib", "text": "Interaction: Trastuzumab AND Alvocidib\nDetails: Trastuzumab may increase the cardiotoxic activities of Alvocidib.\nRisk: Monitor closely.", "source": "Trastuzumab + Alvocidib"}, {"id": "Trastuzumab_INT_2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide", "text": "Interaction: Trastuzumab AND 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide\nDetails: Trastuzumab may increase the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.\nRisk: Monitor closely.", "source": "Trastuzumab + 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide"}, {"id": "Trastuzumab_INT_Rhodamine 6G", "text": "Interaction: Trastuzumab AND Rhodamine 6G\nDetails: Trastuzumab may increase the cardiotoxic activities of Rhodamine 6G.\nRisk: Monitor closely.", "source": "Trastuzumab + Rhodamine 6G"}, {"id": "Trastuzumab_INT_Batimastat", "text": "Interaction: Trastuzumab AND Batimastat\nDetails: Trastuzumab may increase the cardiotoxic activities of Batimastat.\nRisk: Monitor closely.", "source": "Trastuzumab + Batimastat"}, {"id": "Trastuzumab_INT_3,4-Dihydroxybenzoic Acid", "text": "Interaction: Trastuzumab AND 3,4-Dihydroxybenzoic Acid\nDetails: Trastuzumab may increase the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.\nRisk: Monitor closely.", "source": "Trastuzumab + 3,4-Dihydroxybenzoic Acid"}, {"id": "Trastuzumab_INT_Sparsomycin", "text": "Interaction: Trastuzumab AND Sparsomycin\nDetails: Trastuzumab may increase the cardiotoxic activities of Sparsomycin.\nRisk: Monitor closely.", "source": "Trastuzumab + Sparsomycin"}, {"id": "Trastuzumab_INT_Tretazicar", "text": "Interaction: Trastuzumab AND Tretazicar\nDetails: Trastuzumab may increase the cardiotoxic activities of Tretazicar.\nRisk: Monitor closely.", "source": "Trastuzumab + Tretazicar"}, {"id": "Trastuzumab_INT_Seocalcitol", "text": "Interaction: Trastuzumab AND Seocalcitol\nDetails: Trastuzumab may increase the cardiotoxic activities of Seocalcitol.\nRisk: Monitor closely.", "source": "Trastuzumab + Seocalcitol"}, {"id": "Trastuzumab_INT_Nebularine", "text": "Interaction: Trastuzumab AND Nebularine\nDetails: Trastuzumab may increase the cardiotoxic activities of Nebularine.\nRisk: Monitor closely.", "source": "Trastuzumab + Nebularine"}, {"id": "Trastuzumab_INT_Afimoxifene", "text": "Interaction: Trastuzumab AND Afimoxifene\nDetails: Trastuzumab may increase the cardiotoxic activities of Afimoxifene.\nRisk: Monitor closely.", "source": "Trastuzumab + Afimoxifene"}, {"id": "Trastuzumab_INT_Cholesterol", "text": "Interaction: Trastuzumab AND Cholesterol\nDetails: Trastuzumab may increase the cardiotoxic activities of Cholesterol.\nRisk: Monitor closely.", "source": "Trastuzumab + Cholesterol"}, {"id": "Trastuzumab_INT_Fleroxacin", "text": "Interaction: Trastuzumab AND Fleroxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Fleroxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Fleroxacin"}, {"id": "Trastuzumab_INT_Metoprine", "text": "Interaction: Trastuzumab AND Metoprine\nDetails: Trastuzumab may increase the cardiotoxic activities of Metoprine.\nRisk: Monitor closely.", "source": "Trastuzumab + Metoprine"}, {"id": "Trastuzumab_INT_Camptothecin", "text": "Interaction: Trastuzumab AND Camptothecin\nDetails: Trastuzumab may increase the cardiotoxic activities of Camptothecin.\nRisk: Monitor closely.", "source": "Trastuzumab + Camptothecin"}, {"id": "Trastuzumab_INT_Suramin", "text": "Interaction: Trastuzumab AND Suramin\nDetails: Trastuzumab may increase the cardiotoxic activities of Suramin.\nRisk: Monitor closely.", "source": "Trastuzumab + Suramin"}, {"id": "Trastuzumab_INT_Ethyl carbamate", "text": "Interaction: Trastuzumab AND Ethyl carbamate\nDetails: Trastuzumab may increase the cardiotoxic activities of Ethyl carbamate.\nRisk: Monitor closely.", "source": "Trastuzumab + Ethyl carbamate"}, {"id": "Trastuzumab_INT_Cyproterone acetate", "text": "Interaction: Trastuzumab AND Cyproterone acetate\nDetails: Trastuzumab may increase the cardiotoxic activities of Cyproterone acetate.\nRisk: Monitor closely.", "source": "Trastuzumab + Cyproterone acetate"}, {"id": "Trastuzumab_INT_Tirapazamine", "text": "Interaction: Trastuzumab AND Tirapazamine\nDetails: Trastuzumab may increase the cardiotoxic activities of Tirapazamine.\nRisk: Monitor closely.", "source": "Trastuzumab + Tirapazamine"}, {"id": "Trastuzumab_INT_Halofuginone", "text": "Interaction: Trastuzumab AND Halofuginone\nDetails: Trastuzumab may increase the cardiotoxic activities of Halofuginone.\nRisk: Monitor closely.", "source": "Trastuzumab + Halofuginone"}, {"id": "Trastuzumab_INT_Vapreotide", "text": "Interaction: Trastuzumab AND Vapreotide\nDetails: Trastuzumab may increase the cardiotoxic activities of Vapreotide.\nRisk: Monitor closely.", "source": "Trastuzumab + Vapreotide"}, {"id": "Trastuzumab_INT_Thymalfasin", "text": "Interaction: Trastuzumab AND Thymalfasin\nDetails: Trastuzumab may increase the cardiotoxic activities of Thymalfasin.\nRisk: Monitor closely.", "source": "Trastuzumab + Thymalfasin"}, {"id": "Trastuzumab_INT_Ranpirnase", "text": "Interaction: Trastuzumab AND Ranpirnase\nDetails: Trastuzumab may increase the cardiotoxic activities of Ranpirnase.\nRisk: Monitor closely.", "source": "Trastuzumab + Ranpirnase"}, {"id": "Trastuzumab_INT_Pirfenidone", "text": "Interaction: Trastuzumab AND Pirfenidone\nDetails: Trastuzumab may increase the cardiotoxic activities of Pirfenidone.\nRisk: Monitor closely.", "source": "Trastuzumab + Pirfenidone"}, {"id": "Trastuzumab_INT_Tipifarnib", "text": "Interaction: Trastuzumab AND Tipifarnib\nDetails: Trastuzumab may increase the cardiotoxic activities of Tipifarnib.\nRisk: Monitor closely.", "source": "Trastuzumab + Tipifarnib"}, {"id": "Trastuzumab_INT_Troxacitabine", "text": "Interaction: Trastuzumab AND Troxacitabine\nDetails: Trastuzumab may increase the cardiotoxic activities of Troxacitabine.\nRisk: Monitor closely.", "source": "Trastuzumab + Troxacitabine"}, {"id": "Trastuzumab_INT_Amonafide", "text": "Interaction: Trastuzumab AND Amonafide\nDetails: Trastuzumab may increase the cardiotoxic activities of Amonafide.\nRisk: Monitor closely.", "source": "Trastuzumab + Amonafide"}, {"id": "Trastuzumab_INT_SRT501", "text": "Interaction: Trastuzumab AND SRT501\nDetails: Trastuzumab may increase the cardiotoxic activities of SRT501.\nRisk: Monitor closely.", "source": "Trastuzumab + SRT501"}, {"id": "Trastuzumab_INT_Fenretinide", "text": "Interaction: Trastuzumab AND Fenretinide\nDetails: Trastuzumab may increase the cardiotoxic activities of Fenretinide.\nRisk: Monitor closely.", "source": "Trastuzumab + Fenretinide"}, {"id": "Trastuzumab_INT_Tiomolibdate ion", "text": "Interaction: Trastuzumab AND Tiomolibdate ion\nDetails: Trastuzumab may increase the cardiotoxic activities of Tiomolibdate ion.\nRisk: Monitor closely.", "source": "Trastuzumab + Tiomolibdate ion"}, {"id": "Trastuzumab_INT_Elsamitrucin", "text": "Interaction: Trastuzumab AND Elsamitrucin\nDetails: Trastuzumab may increase the cardiotoxic activities of Elsamitrucin.\nRisk: Monitor closely.", "source": "Trastuzumab + Elsamitrucin"}, {"id": "Trastuzumab_INT_Gallium nitrate", "text": "Interaction: Trastuzumab AND Gallium nitrate\nDetails: Trastuzumab may increase the cardiotoxic activities of Gallium nitrate.\nRisk: Monitor closely.", "source": "Trastuzumab + Gallium nitrate"}, {"id": "Trastuzumab_INT_Ecabet", "text": "Interaction: Trastuzumab AND Ecabet\nDetails: Trastuzumab may increase the cardiotoxic activities of Ecabet.\nRisk: Monitor closely.", "source": "Trastuzumab + Ecabet"}, {"id": "Trastuzumab_INT_Canertinib", "text": "Interaction: Trastuzumab AND Canertinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Canertinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Canertinib"}, {"id": "Trastuzumab_INT_motexafin gadolinium", "text": "Interaction: Trastuzumab AND motexafin gadolinium\nDetails: Trastuzumab may increase the cardiotoxic activities of motexafin gadolinium.\nRisk: Monitor closely.", "source": "Trastuzumab + motexafin gadolinium"}, {"id": "Trastuzumab_INT_Alanosine", "text": "Interaction: Trastuzumab AND Alanosine\nDetails: Trastuzumab may increase the cardiotoxic activities of Alanosine.\nRisk: Monitor closely.", "source": "Trastuzumab + Alanosine"}, {"id": "Trastuzumab_INT_Palifosfamide", "text": "Interaction: Trastuzumab AND Palifosfamide\nDetails: Trastuzumab may increase the cardiotoxic activities of Palifosfamide.\nRisk: Monitor closely.", "source": "Trastuzumab + Palifosfamide"}, {"id": "Trastuzumab_INT_AP 12009", "text": "Interaction: Trastuzumab AND AP 12009\nDetails: Trastuzumab may increase the cardiotoxic activities of AP 12009.\nRisk: Monitor closely.", "source": "Trastuzumab + AP 12009"}, {"id": "Trastuzumab_INT_Oglufanide", "text": "Interaction: Trastuzumab AND Oglufanide\nDetails: Trastuzumab may increase the cardiotoxic activities of Oglufanide.\nRisk: Monitor closely.", "source": "Trastuzumab + Oglufanide"}, {"id": "Trastuzumab_INT_Irofulven", "text": "Interaction: Trastuzumab AND Irofulven\nDetails: Trastuzumab may increase the cardiotoxic activities of Irofulven.\nRisk: Monitor closely.", "source": "Trastuzumab + Irofulven"}, {"id": "Trastuzumab_INT_KOS-1584", "text": "Interaction: Trastuzumab AND KOS-1584\nDetails: Trastuzumab may increase the cardiotoxic activities of KOS-1584.\nRisk: Monitor closely.", "source": "Trastuzumab + KOS-1584"}, {"id": "Trastuzumab_INT_BSI-201", "text": "Interaction: Trastuzumab AND BSI-201\nDetails: Trastuzumab may increase the cardiotoxic activities of BSI-201.\nRisk: Monitor closely.", "source": "Trastuzumab + BSI-201"}, {"id": "Trastuzumab_INT_Rubitecan", "text": "Interaction: Trastuzumab AND Rubitecan\nDetails: Trastuzumab may increase the cardiotoxic activities of Rubitecan.\nRisk: Monitor closely.", "source": "Trastuzumab + Rubitecan"}, {"id": "Trastuzumab_INT_Garenoxacin", "text": "Interaction: Trastuzumab AND Garenoxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Garenoxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Garenoxacin"}, {"id": "Trastuzumab_INT_Plevitrexed", "text": "Interaction: Trastuzumab AND Plevitrexed\nDetails: Trastuzumab may increase the cardiotoxic activities of Plevitrexed.\nRisk: Monitor closely.", "source": "Trastuzumab + Plevitrexed"}, {"id": "Trastuzumab_INT_Seliciclib", "text": "Interaction: Trastuzumab AND Seliciclib\nDetails: Trastuzumab may increase the cardiotoxic activities of Seliciclib.\nRisk: Monitor closely.", "source": "Trastuzumab + Seliciclib"}, {"id": "Trastuzumab_INT_Vadimezan", "text": "Interaction: Trastuzumab AND Vadimezan\nDetails: Trastuzumab may increase the cardiotoxic activities of Vadimezan.\nRisk: Monitor closely.", "source": "Trastuzumab + Vadimezan"}, {"id": "Trastuzumab_INT_Eflornithine", "text": "Interaction: Trastuzumab AND Eflornithine\nDetails: Trastuzumab may increase the cardiotoxic activities of Eflornithine.\nRisk: Monitor closely.", "source": "Trastuzumab + Eflornithine"}, {"id": "Trastuzumab_INT_exisulind", "text": "Interaction: Trastuzumab AND exisulind\nDetails: Trastuzumab may increase the cardiotoxic activities of exisulind.\nRisk: Monitor closely.", "source": "Trastuzumab + exisulind"}, {"id": "Trastuzumab_INT_Maxacalcitol", "text": "Interaction: Trastuzumab AND Maxacalcitol\nDetails: Trastuzumab may increase the cardiotoxic activities of Maxacalcitol.\nRisk: Monitor closely.", "source": "Trastuzumab + Maxacalcitol"}, {"id": "Trastuzumab_INT_AP24534", "text": "Interaction: Trastuzumab AND AP24534\nDetails: Trastuzumab may increase the cardiotoxic activities of AP24534.\nRisk: Monitor closely.", "source": "Trastuzumab + AP24534"}, {"id": "Trastuzumab_INT_annamycin", "text": "Interaction: Trastuzumab AND annamycin\nDetails: Trastuzumab may increase the cardiotoxic activities of annamycin.\nRisk: Monitor closely.", "source": "Trastuzumab + annamycin"}, {"id": "Trastuzumab_INT_Endostatin", "text": "Interaction: Trastuzumab AND Endostatin\nDetails: Trastuzumab may increase the cardiotoxic activities of Endostatin.\nRisk: Monitor closely.", "source": "Trastuzumab + Endostatin"}, {"id": "Trastuzumab_INT_Tezacitabine", "text": "Interaction: Trastuzumab AND Tezacitabine\nDetails: Trastuzumab may increase the cardiotoxic activities of Tezacitabine.\nRisk: Monitor closely.", "source": "Trastuzumab + Tezacitabine"}, {"id": "Trastuzumab_INT_Semaxanib", "text": "Interaction: Trastuzumab AND Semaxanib\nDetails: Trastuzumab may increase the cardiotoxic activities of Semaxanib.\nRisk: Monitor closely.", "source": "Trastuzumab + Semaxanib"}, {"id": "Trastuzumab_INT_diethylnorspermine", "text": "Interaction: Trastuzumab AND diethylnorspermine\nDetails: Trastuzumab may increase the cardiotoxic activities of diethylnorspermine.\nRisk: Monitor closely.", "source": "Trastuzumab + diethylnorspermine"}, {"id": "Trastuzumab_INT_squalamine", "text": "Interaction: Trastuzumab AND squalamine\nDetails: Trastuzumab may increase the cardiotoxic activities of squalamine.\nRisk: Monitor closely.", "source": "Trastuzumab + squalamine"}, {"id": "Trastuzumab_INT_porfiromycin", "text": "Interaction: Trastuzumab AND porfiromycin\nDetails: Trastuzumab may increase the cardiotoxic activities of porfiromycin.\nRisk: Monitor closely.", "source": "Trastuzumab + porfiromycin"}, {"id": "Trastuzumab_INT_MLN576", "text": "Interaction: Trastuzumab AND MLN576\nDetails: Trastuzumab may increase the cardiotoxic activities of MLN576.\nRisk: Monitor closely.", "source": "Trastuzumab + MLN576"}, {"id": "Trastuzumab_INT_Iobenguane", "text": "Interaction: Trastuzumab AND Iobenguane\nDetails: Trastuzumab may increase the cardiotoxic activities of Iobenguane.\nRisk: Monitor closely.", "source": "Trastuzumab + Iobenguane"}, {"id": "Trastuzumab_INT_Methyltestosterone", "text": "Interaction: Trastuzumab AND Methyltestosterone\nDetails: Trastuzumab may increase the cardiotoxic activities of Methyltestosterone.\nRisk: Monitor closely.", "source": "Trastuzumab + Methyltestosterone"}, {"id": "Trastuzumab_INT_Ginsenoside C", "text": "Interaction: Trastuzumab AND Ginsenoside C\nDetails: Trastuzumab may increase the cardiotoxic activities of Ginsenoside C.\nRisk: Monitor closely.", "source": "Trastuzumab + Ginsenoside C"}, {"id": "Trastuzumab_INT_Besifloxacin", "text": "Interaction: Trastuzumab AND Besifloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Besifloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Besifloxacin"}, {"id": "Trastuzumab_INT_Hydroxyprogesterone caproate", "text": "Interaction: Trastuzumab AND Hydroxyprogesterone caproate\nDetails: Trastuzumab may increase the cardiotoxic activities of Hydroxyprogesterone caproate.\nRisk: Monitor closely.", "source": "Trastuzumab + Hydroxyprogesterone caproate"}, {"id": "Trastuzumab_INT_Lanreotide", "text": "Interaction: Trastuzumab AND Lanreotide\nDetails: Trastuzumab may increase the cardiotoxic activities of Lanreotide.\nRisk: Monitor closely.", "source": "Trastuzumab + Lanreotide"}, {"id": "Trastuzumab_INT_Phenylbutyric acid", "text": "Interaction: Trastuzumab AND Phenylbutyric acid\nDetails: Trastuzumab may increase the cardiotoxic activities of Phenylbutyric acid.\nRisk: Monitor closely.", "source": "Trastuzumab + Phenylbutyric acid"}, {"id": "Trastuzumab_INT_Veliparib", "text": "Interaction: Trastuzumab AND Veliparib\nDetails: Trastuzumab may increase the cardiotoxic activities of Veliparib.\nRisk: Monitor closely.", "source": "Trastuzumab + Veliparib"}, {"id": "Trastuzumab_INT_Hexestrol", "text": "Interaction: Trastuzumab AND Hexestrol\nDetails: Trastuzumab may increase the cardiotoxic activities of Hexestrol.\nRisk: Monitor closely.", "source": "Trastuzumab + Hexestrol"}, {"id": "Trastuzumab_INT_nocodazole", "text": "Interaction: Trastuzumab AND nocodazole\nDetails: Trastuzumab may increase the cardiotoxic activities of nocodazole.\nRisk: Monitor closely.", "source": "Trastuzumab + nocodazole"}, {"id": "Trastuzumab_INT_Puromycin", "text": "Interaction: Trastuzumab AND Puromycin\nDetails: Trastuzumab may increase the cardiotoxic activities of Puromycin.\nRisk: Monitor closely.", "source": "Trastuzumab + Puromycin"}, {"id": "Trastuzumab_INT_GS 0573", "text": "Interaction: Trastuzumab AND GS 0573\nDetails: Trastuzumab may increase the cardiotoxic activities of GS 0573.\nRisk: Monitor closely.", "source": "Trastuzumab + GS 0573"}, {"id": "Trastuzumab_INT_Formestane", "text": "Interaction: Trastuzumab AND Formestane\nDetails: Trastuzumab may increase the cardiotoxic activities of Formestane.\nRisk: Monitor closely.", "source": "Trastuzumab + Formestane"}, {"id": "Trastuzumab_INT_Radium Ra 223 Dichloride", "text": "Interaction: Trastuzumab AND Radium Ra 223 Dichloride\nDetails: Trastuzumab may increase the cardiotoxic activities of Radium Ra 223 Dichloride.\nRisk: Monitor closely.", "source": "Trastuzumab + Radium Ra 223 Dichloride"}, {"id": "Trastuzumab_INT_Flumequine", "text": "Interaction: Trastuzumab AND Flumequine\nDetails: Trastuzumab may increase the cardiotoxic activities of Flumequine.\nRisk: Monitor closely.", "source": "Trastuzumab + Flumequine"}, {"id": "Trastuzumab_INT_Siltuximab", "text": "Interaction: Trastuzumab AND Siltuximab\nDetails: Trastuzumab may increase the cardiotoxic activities of Siltuximab.\nRisk: Monitor closely.", "source": "Trastuzumab + Siltuximab"}, {"id": "Trastuzumab_INT_Tibolone", "text": "Interaction: Trastuzumab AND Tibolone\nDetails: Trastuzumab may increase the cardiotoxic activities of Tibolone.\nRisk: Monitor closely.", "source": "Trastuzumab + Tibolone"}, {"id": "Trastuzumab_INT_Podophyllin", "text": "Interaction: Trastuzumab AND Podophyllin\nDetails: Trastuzumab may increase the cardiotoxic activities of Podophyllin.\nRisk: Monitor closely.", "source": "Trastuzumab + Podophyllin"}, {"id": "Trastuzumab_INT_Dienogest", "text": "Interaction: Trastuzumab AND Dienogest\nDetails: Trastuzumab may increase the cardiotoxic activities of Dienogest.\nRisk: Monitor closely.", "source": "Trastuzumab + Dienogest"}, {"id": "Trastuzumab_INT_Medrogestone", "text": "Interaction: Trastuzumab AND Medrogestone\nDetails: Trastuzumab may increase the cardiotoxic activities of Medrogestone.\nRisk: Monitor closely.", "source": "Trastuzumab + Medrogestone"}, {"id": "Trastuzumab_INT_Niguldipine", "text": "Interaction: Trastuzumab AND Niguldipine\nDetails: Trastuzumab may increase the cardiotoxic activities of Niguldipine.\nRisk: Monitor closely.", "source": "Trastuzumab + Niguldipine"}, {"id": "Trastuzumab_INT_Pirlindole", "text": "Interaction: Trastuzumab AND Pirlindole\nDetails: Trastuzumab may increase the cardiotoxic activities of Pirlindole.\nRisk: Monitor closely.", "source": "Trastuzumab + Pirlindole"}, {"id": "Trastuzumab_INT_Phenylacetic acid", "text": "Interaction: Trastuzumab AND Phenylacetic acid\nDetails: Trastuzumab may increase the cardiotoxic activities of Phenylacetic acid.\nRisk: Monitor closely.", "source": "Trastuzumab + Phenylacetic acid"}, {"id": "Trastuzumab_INT_Alatrofloxacin", "text": "Interaction: Trastuzumab AND Alatrofloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Alatrofloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Alatrofloxacin"}, {"id": "Trastuzumab_INT_Isosorbide", "text": "Interaction: Trastuzumab AND Isosorbide\nDetails: Trastuzumab may increase the cardiotoxic activities of Isosorbide.\nRisk: Monitor closely.", "source": "Trastuzumab + Isosorbide"}, {"id": "Trastuzumab_INT_Mequinol", "text": "Interaction: Trastuzumab AND Mequinol\nDetails: Trastuzumab may increase the cardiotoxic activities of Mequinol.\nRisk: Monitor closely.", "source": "Trastuzumab + Mequinol"}, {"id": "Trastuzumab_INT_Lycopene", "text": "Interaction: Trastuzumab AND Lycopene\nDetails: Trastuzumab may increase the cardiotoxic activities of Lycopene.\nRisk: Monitor closely.", "source": "Trastuzumab + Lycopene"}, {"id": "Trastuzumab_INT_Roquinimex", "text": "Interaction: Trastuzumab AND Roquinimex\nDetails: Trastuzumab may increase the cardiotoxic activities of Roquinimex.\nRisk: Monitor closely.", "source": "Trastuzumab + Roquinimex"}, {"id": "Trastuzumab_INT_Enrofloxacin", "text": "Interaction: Trastuzumab AND Enrofloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Enrofloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Enrofloxacin"}, {"id": "Trastuzumab_INT_Rabusertib", "text": "Interaction: Trastuzumab AND Rabusertib\nDetails: Trastuzumab may increase the cardiotoxic activities of Rabusertib.\nRisk: Monitor closely.", "source": "Trastuzumab + Rabusertib"}, {"id": "Trastuzumab_INT_Curcumin", "text": "Interaction: Trastuzumab AND Curcumin\nDetails: Trastuzumab may increase the cardiotoxic activities of Curcumin.\nRisk: Monitor closely.", "source": "Trastuzumab + Curcumin"}, {"id": "Trastuzumab_INT_2-chloroethyl-3-sarcosinamide-1-nitrosourea", "text": "Interaction: Trastuzumab AND 2-chloroethyl-3-sarcosinamide-1-nitrosourea\nDetails: Trastuzumab may increase the cardiotoxic activities of 2-chloroethyl-3-sarcosinamide-1-nitrosourea.\nRisk: Monitor closely.", "source": "Trastuzumab + 2-chloroethyl-3-sarcosinamide-1-nitrosourea"}, {"id": "Trastuzumab_INT_Misonidazole", "text": "Interaction: Trastuzumab AND Misonidazole\nDetails: Trastuzumab may increase the cardiotoxic activities of Misonidazole.\nRisk: Monitor closely.", "source": "Trastuzumab + Misonidazole"}, {"id": "Trastuzumab_INT_Bryostatin 1", "text": "Interaction: Trastuzumab AND Bryostatin 1\nDetails: Trastuzumab may increase the cardiotoxic activities of Bryostatin 1.\nRisk: Monitor closely.", "source": "Trastuzumab + Bryostatin 1"}, {"id": "Trastuzumab_INT_Talazoparib", "text": "Interaction: Trastuzumab AND Talazoparib\nDetails: Trastuzumab may increase the cardiotoxic activities of Talazoparib.\nRisk: Monitor closely.", "source": "Trastuzumab + Talazoparib"}, {"id": "Trastuzumab_INT_Tremelimumab", "text": "Interaction: Trastuzumab AND Tremelimumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Tremelimumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Tremelimumab"}, {"id": "Trastuzumab_INT_Pazufloxacin", "text": "Interaction: Trastuzumab AND Pazufloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Pazufloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Pazufloxacin"}, {"id": "Trastuzumab_INT_Niraparib", "text": "Interaction: Trastuzumab AND Niraparib\nDetails: Trastuzumab may increase the cardiotoxic activities of Niraparib.\nRisk: Monitor closely.", "source": "Trastuzumab + Niraparib"}, {"id": "Trastuzumab_INT_Saracatinib", "text": "Interaction: Trastuzumab AND Saracatinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Saracatinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Saracatinib"}, {"id": "Trastuzumab_INT_Talaporfin", "text": "Interaction: Trastuzumab AND Talaporfin\nDetails: Trastuzumab may increase the cardiotoxic activities of Talaporfin.\nRisk: Monitor closely.", "source": "Trastuzumab + Talaporfin"}, {"id": "Trastuzumab_INT_Crenolanib", "text": "Interaction: Trastuzumab AND Crenolanib\nDetails: Trastuzumab may increase the cardiotoxic activities of Crenolanib.\nRisk: Monitor closely.", "source": "Trastuzumab + Crenolanib"}, {"id": "Trastuzumab_INT_Entinostat", "text": "Interaction: Trastuzumab AND Entinostat\nDetails: Trastuzumab may increase the cardiotoxic activities of Entinostat.\nRisk: Monitor closely.", "source": "Trastuzumab + Entinostat"}, {"id": "Trastuzumab_INT_3,3'-diindolylmethane", "text": "Interaction: Trastuzumab AND 3,3'-diindolylmethane\nDetails: Trastuzumab may increase the cardiotoxic activities of 3,3&#39;-diindolylmethane.\nRisk: Monitor closely.", "source": "Trastuzumab + 3,3'-diindolylmethane"}, {"id": "Trastuzumab_INT_Acridine Carboxamide", "text": "Interaction: Trastuzumab AND Acridine Carboxamide\nDetails: Trastuzumab may increase the cardiotoxic activities of Acridine Carboxamide.\nRisk: Monitor closely.", "source": "Trastuzumab + Acridine Carboxamide"}, {"id": "Trastuzumab_INT_Infigratinib", "text": "Interaction: Trastuzumab AND Infigratinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Infigratinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Infigratinib"}, {"id": "Trastuzumab_INT_Prulifloxacin", "text": "Interaction: Trastuzumab AND Prulifloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Prulifloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Prulifloxacin"}, {"id": "Trastuzumab_INT_Efatutazone", "text": "Interaction: Trastuzumab AND Efatutazone\nDetails: Trastuzumab may increase the cardiotoxic activities of Efatutazone.\nRisk: Monitor closely.", "source": "Trastuzumab + Efatutazone"}, {"id": "Trastuzumab_INT_6-O-benzylguanine", "text": "Interaction: Trastuzumab AND 6-O-benzylguanine\nDetails: Trastuzumab may increase the cardiotoxic activities of 6-O-benzylguanine.\nRisk: Monitor closely.", "source": "Trastuzumab + 6-O-benzylguanine"}, {"id": "Trastuzumab_INT_Carboxyamidotriazole", "text": "Interaction: Trastuzumab AND Carboxyamidotriazole\nDetails: Trastuzumab may increase the cardiotoxic activities of Carboxyamidotriazole.\nRisk: Monitor closely.", "source": "Trastuzumab + Carboxyamidotriazole"}, {"id": "Trastuzumab_INT_Triptolide", "text": "Interaction: Trastuzumab AND Triptolide\nDetails: Trastuzumab may increase the cardiotoxic activities of Triptolide.\nRisk: Monitor closely.", "source": "Trastuzumab + Triptolide"}, {"id": "Trastuzumab_INT_Broxuridine", "text": "Interaction: Trastuzumab AND Broxuridine\nDetails: Trastuzumab may increase the cardiotoxic activities of Broxuridine.\nRisk: Monitor closely.", "source": "Trastuzumab + Broxuridine"}, {"id": "Trastuzumab_INT_Trebananib", "text": "Interaction: Trastuzumab AND Trebananib\nDetails: Trastuzumab may increase the cardiotoxic activities of Trebananib.\nRisk: Monitor closely.", "source": "Trastuzumab + Trebananib"}, {"id": "Trastuzumab_INT_Anecortave", "text": "Interaction: Trastuzumab AND Anecortave\nDetails: Trastuzumab may increase the cardiotoxic activities of Anecortave.\nRisk: Monitor closely.", "source": "Trastuzumab + Anecortave"}, {"id": "Trastuzumab_INT_Vesnarinone", "text": "Interaction: Trastuzumab AND Vesnarinone\nDetails: Trastuzumab may increase the cardiotoxic activities of Vesnarinone.\nRisk: Monitor closely.", "source": "Trastuzumab + Vesnarinone"}, {"id": "Trastuzumab_INT_Mafosfamide", "text": "Interaction: Trastuzumab AND Mafosfamide\nDetails: Trastuzumab may increase the cardiotoxic activities of Mafosfamide.\nRisk: Monitor closely.", "source": "Trastuzumab + Mafosfamide"}, {"id": "Trastuzumab_INT_LCL-161", "text": "Interaction: Trastuzumab AND LCL-161\nDetails: Trastuzumab may increase the cardiotoxic activities of LCL-161.\nRisk: Monitor closely.", "source": "Trastuzumab + LCL-161"}, {"id": "Trastuzumab_INT_Taselisib", "text": "Interaction: Trastuzumab AND Taselisib\nDetails: Trastuzumab may increase the cardiotoxic activities of Taselisib.\nRisk: Monitor closely.", "source": "Trastuzumab + Taselisib"}, {"id": "Trastuzumab_INT_Zuretinol acetate", "text": "Interaction: Trastuzumab AND Zuretinol acetate\nDetails: Trastuzumab may increase the cardiotoxic activities of Zuretinol acetate.\nRisk: Monitor closely.", "source": "Trastuzumab + Zuretinol acetate"}, {"id": "Trastuzumab_INT_Epigallocatechin Gallate", "text": "Interaction: Trastuzumab AND Epigallocatechin Gallate\nDetails: Trastuzumab may increase the cardiotoxic activities of Epigallocatechin Gallate.\nRisk: Monitor closely.", "source": "Trastuzumab + Epigallocatechin Gallate"}, {"id": "Trastuzumab_INT_Namitecan", "text": "Interaction: Trastuzumab AND Namitecan\nDetails: Trastuzumab may increase the cardiotoxic activities of Namitecan.\nRisk: Monitor closely.", "source": "Trastuzumab + Namitecan"}, {"id": "Trastuzumab_INT_Duligotuzumab", "text": "Interaction: Trastuzumab AND Duligotuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Duligotuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Duligotuzumab"}, {"id": "Trastuzumab_INT_Cordycepin", "text": "Interaction: Trastuzumab AND Cordycepin\nDetails: Trastuzumab may increase the cardiotoxic activities of Cordycepin.\nRisk: Monitor closely.", "source": "Trastuzumab + Cordycepin"}, {"id": "Trastuzumab_INT_Binetrakin", "text": "Interaction: Trastuzumab AND Binetrakin\nDetails: Trastuzumab may increase the cardiotoxic activities of Binetrakin.\nRisk: Monitor closely.", "source": "Trastuzumab + Binetrakin"}, {"id": "Trastuzumab_INT_Exatecan", "text": "Interaction: Trastuzumab AND Exatecan\nDetails: Trastuzumab may increase the cardiotoxic activities of Exatecan.\nRisk: Monitor closely.", "source": "Trastuzumab + Exatecan"}, {"id": "Trastuzumab_INT_Lurtotecan", "text": "Interaction: Trastuzumab AND Lurtotecan\nDetails: Trastuzumab may increase the cardiotoxic activities of Lurtotecan.\nRisk: Monitor closely.", "source": "Trastuzumab + Lurtotecan"}, {"id": "Trastuzumab_INT_KRN-7000", "text": "Interaction: Trastuzumab AND KRN-7000\nDetails: Trastuzumab may increase the cardiotoxic activities of KRN-7000.\nRisk: Monitor closely.", "source": "Trastuzumab + KRN-7000"}, {"id": "Trastuzumab_INT_Epofolate", "text": "Interaction: Trastuzumab AND Epofolate\nDetails: Trastuzumab may increase the cardiotoxic activities of Epofolate.\nRisk: Monitor closely.", "source": "Trastuzumab + Epofolate"}, {"id": "Trastuzumab_INT_OBP-801", "text": "Interaction: Trastuzumab AND OBP-801\nDetails: Trastuzumab may increase the cardiotoxic activities of OBP-801.\nRisk: Monitor closely.", "source": "Trastuzumab + OBP-801"}, {"id": "Trastuzumab_INT_Rucaparib", "text": "Interaction: Trastuzumab AND Rucaparib\nDetails: Trastuzumab may increase the cardiotoxic activities of Rucaparib.\nRisk: Monitor closely.", "source": "Trastuzumab + Rucaparib"}, {"id": "Trastuzumab_INT_Navitoclax", "text": "Interaction: Trastuzumab AND Navitoclax\nDetails: Trastuzumab may increase the cardiotoxic activities of Navitoclax.\nRisk: Monitor closely.", "source": "Trastuzumab + Navitoclax"}, {"id": "Trastuzumab_INT_Bizelesin", "text": "Interaction: Trastuzumab AND Bizelesin\nDetails: Trastuzumab may increase the cardiotoxic activities of Bizelesin.\nRisk: Monitor closely.", "source": "Trastuzumab + Bizelesin"}, {"id": "Trastuzumab_INT_Indirubin", "text": "Interaction: Trastuzumab AND Indirubin\nDetails: Trastuzumab may increase the cardiotoxic activities of Indirubin.\nRisk: Monitor closely.", "source": "Trastuzumab + Indirubin"}, {"id": "Trastuzumab_INT_Merestinib", "text": "Interaction: Trastuzumab AND Merestinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Merestinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Merestinib"}, {"id": "Trastuzumab_INT_10-hydroxycamptothecin", "text": "Interaction: Trastuzumab AND 10-hydroxycamptothecin\nDetails: Trastuzumab may increase the cardiotoxic activities of 10-hydroxycamptothecin.\nRisk: Monitor closely.", "source": "Trastuzumab + 10-hydroxycamptothecin"}, {"id": "Trastuzumab_INT_Sulforaphane", "text": "Interaction: Trastuzumab AND Sulforaphane\nDetails: Trastuzumab may increase the cardiotoxic activities of Sulforaphane.\nRisk: Monitor closely.", "source": "Trastuzumab + Sulforaphane"}, {"id": "Trastuzumab_INT_Nadifloxacin", "text": "Interaction: Trastuzumab AND Nadifloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Nadifloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Nadifloxacin"}, {"id": "Trastuzumab_INT_Belotecan", "text": "Interaction: Trastuzumab AND Belotecan\nDetails: Trastuzumab may increase the cardiotoxic activities of Belotecan.\nRisk: Monitor closely.", "source": "Trastuzumab + Belotecan"}, {"id": "Trastuzumab_INT_Taurolidine", "text": "Interaction: Trastuzumab AND Taurolidine\nDetails: Trastuzumab may increase the cardiotoxic activities of Taurolidine.\nRisk: Monitor closely.", "source": "Trastuzumab + Taurolidine"}, {"id": "Trastuzumab_INT_9-aminocamptothecin", "text": "Interaction: Trastuzumab AND 9-aminocamptothecin\nDetails: Trastuzumab may increase the cardiotoxic activities of 9-aminocamptothecin.\nRisk: Monitor closely.", "source": "Trastuzumab + 9-aminocamptothecin"}, {"id": "Trastuzumab_INT_Molgramostim", "text": "Interaction: Trastuzumab AND Molgramostim\nDetails: Trastuzumab may increase the cardiotoxic activities of Molgramostim.\nRisk: Monitor closely.", "source": "Trastuzumab + Molgramostim"}, {"id": "Trastuzumab_INT_Oltipraz", "text": "Interaction: Trastuzumab AND Oltipraz\nDetails: Trastuzumab may increase the cardiotoxic activities of Oltipraz.\nRisk: Monitor closely.", "source": "Trastuzumab + Oltipraz"}, {"id": "Trastuzumab_INT_Pyrazoloacridine", "text": "Interaction: Trastuzumab AND Pyrazoloacridine\nDetails: Trastuzumab may increase the cardiotoxic activities of Pyrazoloacridine.\nRisk: Monitor closely.", "source": "Trastuzumab + Pyrazoloacridine"}, {"id": "Trastuzumab_INT_Fosbretabulin", "text": "Interaction: Trastuzumab AND Fosbretabulin\nDetails: Trastuzumab may increase the cardiotoxic activities of Fosbretabulin.\nRisk: Monitor closely.", "source": "Trastuzumab + Fosbretabulin"}, {"id": "Trastuzumab_INT_Apaziquone", "text": "Interaction: Trastuzumab AND Apaziquone\nDetails: Trastuzumab may increase the cardiotoxic activities of Apaziquone.\nRisk: Monitor closely.", "source": "Trastuzumab + Apaziquone"}, {"id": "Trastuzumab_INT_Combretastatin", "text": "Interaction: Trastuzumab AND Combretastatin\nDetails: Trastuzumab may increase the cardiotoxic activities of Combretastatin.\nRisk: Monitor closely.", "source": "Trastuzumab + Combretastatin"}, {"id": "Trastuzumab_INT_Mizoribine", "text": "Interaction: Trastuzumab AND Mizoribine\nDetails: Trastuzumab may increase the cardiotoxic activities of Mizoribine.\nRisk: Monitor closely.", "source": "Trastuzumab + Mizoribine"}, {"id": "Trastuzumab_INT_Onapristone", "text": "Interaction: Trastuzumab AND Onapristone\nDetails: Trastuzumab may increase the cardiotoxic activities of Onapristone.\nRisk: Monitor closely.", "source": "Trastuzumab + Onapristone"}, {"id": "Trastuzumab_INT_Soblidotin", "text": "Interaction: Trastuzumab AND Soblidotin\nDetails: Trastuzumab may increase the cardiotoxic activities of Soblidotin.\nRisk: Monitor closely.", "source": "Trastuzumab + Soblidotin"}, {"id": "Trastuzumab_INT_Salirasib", "text": "Interaction: Trastuzumab AND Salirasib\nDetails: Trastuzumab may increase the cardiotoxic activities of Salirasib.\nRisk: Monitor closely.", "source": "Trastuzumab + Salirasib"}, {"id": "Trastuzumab_INT_Gusperimus", "text": "Interaction: Trastuzumab AND Gusperimus\nDetails: Trastuzumab may increase the cardiotoxic activities of Gusperimus.\nRisk: Monitor closely.", "source": "Trastuzumab + Gusperimus"}, {"id": "Trastuzumab_INT_Phenethyl Isothiocyanate", "text": "Interaction: Trastuzumab AND Phenethyl Isothiocyanate\nDetails: Trastuzumab may increase the cardiotoxic activities of Phenethyl Isothiocyanate.\nRisk: Monitor closely.", "source": "Trastuzumab + Phenethyl Isothiocyanate"}, {"id": "Trastuzumab_INT_Methylselenocysteine", "text": "Interaction: Trastuzumab AND Methylselenocysteine\nDetails: Trastuzumab may increase the cardiotoxic activities of Methylselenocysteine.\nRisk: Monitor closely.", "source": "Trastuzumab + Methylselenocysteine"}, {"id": "Trastuzumab_INT_Dolastatin 10", "text": "Interaction: Trastuzumab AND Dolastatin 10\nDetails: Trastuzumab may increase the cardiotoxic activities of Dolastatin 10.\nRisk: Monitor closely.", "source": "Trastuzumab + Dolastatin 10"}, {"id": "Trastuzumab_INT_Etanidazole", "text": "Interaction: Trastuzumab AND Etanidazole\nDetails: Trastuzumab may increase the cardiotoxic activities of Etanidazole.\nRisk: Monitor closely.", "source": "Trastuzumab + Etanidazole"}, {"id": "Trastuzumab_INT_Lometrexol", "text": "Interaction: Trastuzumab AND Lometrexol\nDetails: Trastuzumab may increase the cardiotoxic activities of Lometrexol.\nRisk: Monitor closely.", "source": "Trastuzumab + Lometrexol"}, {"id": "Trastuzumab_INT_Buthionine Sulfoximine", "text": "Interaction: Trastuzumab AND Buthionine Sulfoximine\nDetails: Trastuzumab may increase the cardiotoxic activities of Buthionine Sulfoximine.\nRisk: Monitor closely.", "source": "Trastuzumab + Buthionine Sulfoximine"}, {"id": "Trastuzumab_INT_Dianhydrogalactitol", "text": "Interaction: Trastuzumab AND Dianhydrogalactitol\nDetails: Trastuzumab may increase the cardiotoxic activities of Dianhydrogalactitol.\nRisk: Monitor closely.", "source": "Trastuzumab + Dianhydrogalactitol"}, {"id": "Trastuzumab_INT_Indole-3-carbinol", "text": "Interaction: Trastuzumab AND Indole-3-carbinol\nDetails: Trastuzumab may increase the cardiotoxic activities of Indole-3-carbinol.\nRisk: Monitor closely.", "source": "Trastuzumab + Indole-3-carbinol"}, {"id": "Trastuzumab_INT_Fiacitabine", "text": "Interaction: Trastuzumab AND Fiacitabine\nDetails: Trastuzumab may increase the cardiotoxic activities of Fiacitabine.\nRisk: Monitor closely.", "source": "Trastuzumab + Fiacitabine"}, {"id": "Trastuzumab_INT_Nolatrexed", "text": "Interaction: Trastuzumab AND Nolatrexed\nDetails: Trastuzumab may increase the cardiotoxic activities of Nolatrexed.\nRisk: Monitor closely.", "source": "Trastuzumab + Nolatrexed"}, {"id": "Trastuzumab_INT_Mitolactol", "text": "Interaction: Trastuzumab AND Mitolactol\nDetails: Trastuzumab may increase the cardiotoxic activities of Mitolactol.\nRisk: Monitor closely.", "source": "Trastuzumab + Mitolactol"}, {"id": "Trastuzumab_INT_Pinometostat", "text": "Interaction: Trastuzumab AND Pinometostat\nDetails: Trastuzumab may increase the cardiotoxic activities of Pinometostat.\nRisk: Monitor closely.", "source": "Trastuzumab + Pinometostat"}, {"id": "Trastuzumab_INT_Doxifluridine", "text": "Interaction: Trastuzumab AND Doxifluridine\nDetails: Trastuzumab may increase the cardiotoxic activities of Doxifluridine.\nRisk: Monitor closely.", "source": "Trastuzumab + Doxifluridine"}, {"id": "Trastuzumab_INT_Didox", "text": "Interaction: Trastuzumab AND Didox\nDetails: Trastuzumab may increase the cardiotoxic activities of Didox.\nRisk: Monitor closely.", "source": "Trastuzumab + Didox"}, {"id": "Trastuzumab_INT_Penclomedine", "text": "Interaction: Trastuzumab AND Penclomedine\nDetails: Trastuzumab may increase the cardiotoxic activities of Penclomedine.\nRisk: Monitor closely.", "source": "Trastuzumab + Penclomedine"}, {"id": "Trastuzumab_INT_Deoxyspergualin", "text": "Interaction: Trastuzumab AND Deoxyspergualin\nDetails: Trastuzumab may increase the cardiotoxic activities of Deoxyspergualin.\nRisk: Monitor closely.", "source": "Trastuzumab + Deoxyspergualin"}, {"id": "Trastuzumab_INT_Acteoside", "text": "Interaction: Trastuzumab AND Acteoside\nDetails: Trastuzumab may increase the cardiotoxic activities of Acteoside.\nRisk: Monitor closely.", "source": "Trastuzumab + Acteoside"}, {"id": "Trastuzumab_INT_Hypericin", "text": "Interaction: Trastuzumab AND Hypericin\nDetails: Trastuzumab may increase the cardiotoxic activities of Hypericin.\nRisk: Monitor closely.", "source": "Trastuzumab + Hypericin"}, {"id": "Trastuzumab_INT_Irsogladine", "text": "Interaction: Trastuzumab AND Irsogladine\nDetails: Trastuzumab may increase the cardiotoxic activities of Irsogladine.\nRisk: Monitor closely.", "source": "Trastuzumab + Irsogladine"}, {"id": "Trastuzumab_INT_Liarozole", "text": "Interaction: Trastuzumab AND Liarozole\nDetails: Trastuzumab may increase the cardiotoxic activities of Liarozole.\nRisk: Monitor closely.", "source": "Trastuzumab + Liarozole"}, {"id": "Trastuzumab_INT_Sizofiran", "text": "Interaction: Trastuzumab AND Sizofiran\nDetails: Trastuzumab may increase the cardiotoxic activities of Sizofiran.\nRisk: Monitor closely.", "source": "Trastuzumab + Sizofiran"}, {"id": "Trastuzumab_INT_Nedaplatin", "text": "Interaction: Trastuzumab AND Nedaplatin\nDetails: Trastuzumab may increase the cardiotoxic activities of Nedaplatin.\nRisk: Monitor closely.", "source": "Trastuzumab + Nedaplatin"}, {"id": "Trastuzumab_INT_Sitafloxacin", "text": "Interaction: Trastuzumab AND Sitafloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Sitafloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Sitafloxacin"}, {"id": "Trastuzumab_INT_Lentinan", "text": "Interaction: Trastuzumab AND Lentinan\nDetails: Trastuzumab may increase the cardiotoxic activities of Lentinan.\nRisk: Monitor closely.", "source": "Trastuzumab + Lentinan"}, {"id": "Trastuzumab_INT_Oxolinic acid", "text": "Interaction: Trastuzumab AND Oxolinic acid\nDetails: Trastuzumab may increase the cardiotoxic activities of Oxolinic acid.\nRisk: Monitor closely.", "source": "Trastuzumab + Oxolinic acid"}, {"id": "Trastuzumab_INT_Vorozole", "text": "Interaction: Trastuzumab AND Vorozole\nDetails: Trastuzumab may increase the cardiotoxic activities of Vorozole.\nRisk: Monitor closely.", "source": "Trastuzumab + Vorozole"}, {"id": "Trastuzumab_INT_Rufloxacin", "text": "Interaction: Trastuzumab AND Rufloxacin\nDetails: Trastuzumab may increase the cardiotoxic activities of Rufloxacin.\nRisk: Monitor closely.", "source": "Trastuzumab + Rufloxacin"}, {"id": "Trastuzumab_INT_Iniparib", "text": "Interaction: Trastuzumab AND Iniparib\nDetails: Trastuzumab may increase the cardiotoxic activities of Iniparib.\nRisk: Monitor closely.", "source": "Trastuzumab + Iniparib"}, {"id": "Trastuzumab_INT_Coumermycin A1", "text": "Interaction: Trastuzumab AND Coumermycin A1\nDetails: Trastuzumab may increase the cardiotoxic activities of Coumermycin A1.\nRisk: Monitor closely.", "source": "Trastuzumab + Coumermycin A1"}, {"id": "Trastuzumab_INT_Toyocamycin", "text": "Interaction: Trastuzumab AND Toyocamycin\nDetails: Trastuzumab may increase the cardiotoxic activities of Toyocamycin.\nRisk: Monitor closely.", "source": "Trastuzumab + Toyocamycin"}, {"id": "Trastuzumab_INT_Masoprocol", "text": "Interaction: Trastuzumab AND Masoprocol\nDetails: Trastuzumab may increase the cardiotoxic activities of Masoprocol.\nRisk: Monitor closely.", "source": "Trastuzumab + Masoprocol"}, {"id": "Trastuzumab_INT_Anagrelide", "text": "Interaction: Trastuzumab AND Anagrelide\nDetails: Trastuzumab may increase the cardiotoxic activities of Anagrelide.\nRisk: Monitor closely.", "source": "Trastuzumab + Anagrelide"}, {"id": "Trastuzumab_INT_Trifluridine", "text": "Interaction: Trastuzumab AND Trifluridine\nDetails: Trastuzumab may increase the cardiotoxic activities of Trifluridine.\nRisk: Monitor closely.", "source": "Trastuzumab + Trifluridine"}, {"id": "Trastuzumab_INT_Aminolevulinic acid", "text": "Interaction: Trastuzumab AND Aminolevulinic acid\nDetails: Trastuzumab may increase the cardiotoxic activities of Aminolevulinic acid.\nRisk: Monitor closely.", "source": "Trastuzumab + Aminolevulinic acid"}, {"id": "Trastuzumab_INT_Methyl aminolevulinate", "text": "Interaction: Trastuzumab AND Methyl aminolevulinate\nDetails: Trastuzumab may increase the cardiotoxic activities of Methyl aminolevulinate.\nRisk: Monitor closely.", "source": "Trastuzumab + Methyl aminolevulinate"}, {"id": "Trastuzumab_INT_Ixabepilone", "text": "Interaction: Trastuzumab AND Ixabepilone\nDetails: Trastuzumab may increase the cardiotoxic activities of Ixabepilone.\nRisk: Monitor closely.", "source": "Trastuzumab + Ixabepilone"}, {"id": "Trastuzumab_INT_EG009", "text": "Interaction: Trastuzumab AND EG009\nDetails: Trastuzumab may increase the cardiotoxic activities of EG009.\nRisk: Monitor closely.", "source": "Trastuzumab + EG009"}, {"id": "Trastuzumab_INT_Vintafolide", "text": "Interaction: Trastuzumab AND Vintafolide\nDetails: Trastuzumab may increase the cardiotoxic activities of Vintafolide.\nRisk: Monitor closely.", "source": "Trastuzumab + Vintafolide"}, {"id": "Trastuzumab_INT_Ridaforolimus", "text": "Interaction: Trastuzumab AND Ridaforolimus\nDetails: Trastuzumab may increase the cardiotoxic activities of Ridaforolimus.\nRisk: Monitor closely.", "source": "Trastuzumab + Ridaforolimus"}, {"id": "Trastuzumab_INT_Pralatrexate", "text": "Interaction: Trastuzumab AND Pralatrexate\nDetails: Trastuzumab may increase the cardiotoxic activities of Pralatrexate.\nRisk: Monitor closely.", "source": "Trastuzumab + Pralatrexate"}, {"id": "Trastuzumab_INT_Efaproxiral", "text": "Interaction: Trastuzumab AND Efaproxiral\nDetails: Trastuzumab may increase the cardiotoxic activities of Efaproxiral.\nRisk: Monitor closely.", "source": "Trastuzumab + Efaproxiral"}, {"id": "Trastuzumab_INT_Cabozantinib", "text": "Interaction: Trastuzumab AND Cabozantinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Cabozantinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Cabozantinib"}, {"id": "Trastuzumab_INT_Dinutuximab", "text": "Interaction: Trastuzumab AND Dinutuximab\nDetails: Trastuzumab may increase the cardiotoxic activities of Dinutuximab.\nRisk: Monitor closely.", "source": "Trastuzumab + Dinutuximab"}, {"id": "Trastuzumab_INT_Sonidegib", "text": "Interaction: Trastuzumab AND Sonidegib\nDetails: Trastuzumab may increase the cardiotoxic activities of Sonidegib.\nRisk: Monitor closely.", "source": "Trastuzumab + Sonidegib"}, {"id": "Trastuzumab_INT_Masitinib", "text": "Interaction: Trastuzumab AND Masitinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Masitinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Masitinib"}, {"id": "Trastuzumab_INT_Vinflunine", "text": "Interaction: Trastuzumab AND Vinflunine\nDetails: Trastuzumab may increase the cardiotoxic activities of Vinflunine.\nRisk: Monitor closely.", "source": "Trastuzumab + Vinflunine"}, {"id": "Trastuzumab_INT_Tivozanib", "text": "Interaction: Trastuzumab AND Tivozanib\nDetails: Trastuzumab may increase the cardiotoxic activities of Tivozanib.\nRisk: Monitor closely.", "source": "Trastuzumab + Tivozanib"}, {"id": "Trastuzumab_INT_Mannosulfan", "text": "Interaction: Trastuzumab AND Mannosulfan\nDetails: Trastuzumab may increase the cardiotoxic activities of Mannosulfan.\nRisk: Monitor closely.", "source": "Trastuzumab + Mannosulfan"}, {"id": "Trastuzumab_INT_Edrecolomab", "text": "Interaction: Trastuzumab AND Edrecolomab\nDetails: Trastuzumab may increase the cardiotoxic activities of Edrecolomab.\nRisk: Monitor closely.", "source": "Trastuzumab + Edrecolomab"}, {"id": "Trastuzumab_INT_Paclitaxel poliglumex", "text": "Interaction: Trastuzumab AND Paclitaxel poliglumex\nDetails: Trastuzumab may increase the cardiotoxic activities of Paclitaxel poliglumex.\nRisk: Monitor closely.", "source": "Trastuzumab + Paclitaxel poliglumex"}, {"id": "Trastuzumab_INT_Oblimersen", "text": "Interaction: Trastuzumab AND Oblimersen\nDetails: Trastuzumab may increase the cardiotoxic activities of Oblimersen.\nRisk: Monitor closely.", "source": "Trastuzumab + Oblimersen"}, {"id": "Trastuzumab_INT_Interferon Alfa-2b, Recombinant", "text": "Interaction: Trastuzumab AND Interferon Alfa-2b, Recombinant\nDetails: Trastuzumab may increase the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Trastuzumab + Interferon Alfa-2b, Recombinant"}, {"id": "Trastuzumab_INT_Mycophenolate mofetil", "text": "Interaction: Trastuzumab AND Mycophenolate mofetil\nDetails: Trastuzumab may increase the cardiotoxic activities of Mycophenolate mofetil.\nRisk: Monitor closely.", "source": "Trastuzumab + Mycophenolate mofetil"}, {"id": "Trastuzumab_INT_Cobimetinib", "text": "Interaction: Trastuzumab AND Cobimetinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Cobimetinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Cobimetinib"}, {"id": "Trastuzumab_INT_Elotuzumab", "text": "Interaction: Trastuzumab AND Elotuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Elotuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Elotuzumab"}, {"id": "Trastuzumab_INT_Degarelix", "text": "Interaction: Trastuzumab AND Degarelix\nDetails: Trastuzumab may increase the cardiotoxic activities of Degarelix.\nRisk: Monitor closely.", "source": "Trastuzumab + Degarelix"}, {"id": "Trastuzumab_INT_Buserelin", "text": "Interaction: Trastuzumab AND Buserelin\nDetails: Trastuzumab may increase the cardiotoxic activities of Buserelin.\nRisk: Monitor closely.", "source": "Trastuzumab + Buserelin"}, {"id": "Trastuzumab_INT_Aflibercept", "text": "Interaction: Trastuzumab AND Aflibercept\nDetails: Trastuzumab may increase the cardiotoxic activities of Aflibercept.\nRisk: Monitor closely.", "source": "Trastuzumab + Aflibercept"}, {"id": "Trastuzumab_INT_Enzalutamide", "text": "Interaction: Trastuzumab AND Enzalutamide\nDetails: Trastuzumab may increase the cardiotoxic activities of Enzalutamide.\nRisk: Monitor closely.", "source": "Trastuzumab + Enzalutamide"}, {"id": "Trastuzumab_INT_Alectinib", "text": "Interaction: Trastuzumab AND Alectinib\nDetails: Trastuzumab may increase the cardiotoxic activities of Alectinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Alectinib"}, {"id": "Trastuzumab_INT_Venetoclax", "text": "Interaction: Trastuzumab AND Venetoclax\nDetails: Trastuzumab may increase the cardiotoxic activities of Venetoclax.\nRisk: Monitor closely.", "source": "Trastuzumab + Venetoclax"}, {"id": "Trastuzumab_INT_Atezolizumab", "text": "Interaction: Trastuzumab AND Atezolizumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Atezolizumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Atezolizumab"}, {"id": "Trastuzumab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Trastuzumab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Trastuzumab_INT_Yellow fever vaccine", "text": "Interaction: Trastuzumab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Yellow fever vaccine"}, {"id": "Trastuzumab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Trastuzumab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Trastuzumab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Trastuzumab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Trastuzumab_INT_Rotavirus Vaccine", "text": "Interaction: Trastuzumab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Rotavirus Vaccine"}, {"id": "Trastuzumab_INT_G17DT", "text": "Interaction: Trastuzumab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + G17DT"}, {"id": "Trastuzumab_INT_INGN 201", "text": "Interaction: Trastuzumab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + INGN 201"}, {"id": "Trastuzumab_INT_INGN 225", "text": "Interaction: Trastuzumab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + INGN 225"}, {"id": "Trastuzumab_INT_Rindopepimut", "text": "Interaction: Trastuzumab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Rindopepimut"}, {"id": "Trastuzumab_INT_SRP 299", "text": "Interaction: Trastuzumab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + SRP 299"}, {"id": "Trastuzumab_INT_GI-5005", "text": "Interaction: Trastuzumab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + GI-5005"}, {"id": "Trastuzumab_INT_TG4010", "text": "Interaction: Trastuzumab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + TG4010"}, {"id": "Trastuzumab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Trastuzumab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Rabies virus inactivated antigen, A"}, {"id": "Trastuzumab_INT_Tecemotide", "text": "Interaction: Trastuzumab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Tecemotide"}, {"id": "Trastuzumab_INT_BCG vaccine", "text": "Interaction: Trastuzumab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + BCG vaccine"}, {"id": "Trastuzumab_INT_Rubella virus vaccine", "text": "Interaction: Trastuzumab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Rubella virus vaccine"}, {"id": "Trastuzumab_INT_Hepatitis A Vaccine", "text": "Interaction: Trastuzumab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Hepatitis A Vaccine"}, {"id": "Trastuzumab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Trastuzumab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Salmonella typhi ty21a live antigen"}, {"id": "Trastuzumab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Trastuzumab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Trastuzumab_INT_Digoxin", "text": "Interaction: Trastuzumab AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Digoxin"}, {"id": "Trastuzumab_INT_Acetyldigitoxin", "text": "Interaction: Trastuzumab AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Acetyldigitoxin"}, {"id": "Trastuzumab_INT_Deslanoside", "text": "Interaction: Trastuzumab AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Deslanoside"}, {"id": "Trastuzumab_INT_Ouabain", "text": "Interaction: Trastuzumab AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Ouabain"}, {"id": "Trastuzumab_INT_Digitoxin", "text": "Interaction: Trastuzumab AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Digitoxin"}, {"id": "Trastuzumab_INT_Cymarin", "text": "Interaction: Trastuzumab AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Cymarin"}, {"id": "Trastuzumab_INT_Proscillaridin", "text": "Interaction: Trastuzumab AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Proscillaridin"}, {"id": "Trastuzumab_INT_Metildigoxin", "text": "Interaction: Trastuzumab AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Metildigoxin"}, {"id": "Trastuzumab_INT_Peruvoside", "text": "Interaction: Trastuzumab AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Peruvoside"}, {"id": "Trastuzumab_INT_Lanatoside C", "text": "Interaction: Trastuzumab AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Lanatoside C"}, {"id": "Trastuzumab_INT_Gitoformate", "text": "Interaction: Trastuzumab AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Gitoformate"}, {"id": "Trastuzumab_INT_Acetyldigoxin", "text": "Interaction: Trastuzumab AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Acetyldigoxin"}, {"id": "Trastuzumab_INT_Oleandrin", "text": "Interaction: Trastuzumab AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Oleandrin"}, {"id": "Trastuzumab_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Trastuzumab AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Digoxin Immune Fab (Ovine)"}, {"id": "Trastuzumab_INT_Paclitaxel", "text": "Interaction: Trastuzumab AND Paclitaxel\nDetails: The serum concentration of Paclitaxel can be decreased when it is combined with Trastuzumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Paclitaxel"}, {"id": "Trastuzumab_INT_Etanercept", "text": "Interaction: Trastuzumab AND Etanercept\nDetails: Trastuzumab may increase the neutropenic activities of Etanercept.\nRisk: Monitor closely.", "source": "Trastuzumab + Etanercept"}, {"id": "Trastuzumab_INT_Basiliximab", "text": "Interaction: Trastuzumab AND Basiliximab\nDetails: Trastuzumab may increase the neutropenic activities of Basiliximab.\nRisk: Monitor closely.", "source": "Trastuzumab + Basiliximab"}, {"id": "Trastuzumab_INT_Muromonab", "text": "Interaction: Trastuzumab AND Muromonab\nDetails: Trastuzumab may increase the neutropenic activities of Muromonab.\nRisk: Monitor closely.", "source": "Trastuzumab + Muromonab"}, {"id": "Trastuzumab_INT_Cyclosporine", "text": "Interaction: Trastuzumab AND Cyclosporine\nDetails: Trastuzumab may increase the neutropenic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Trastuzumab + Cyclosporine"}, {"id": "Trastuzumab_INT_Daclizumab", "text": "Interaction: Trastuzumab AND Daclizumab\nDetails: Trastuzumab may increase the neutropenic activities of Daclizumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Daclizumab"}, {"id": "Trastuzumab_INT_Triamcinolone", "text": "Interaction: Trastuzumab AND Triamcinolone\nDetails: Trastuzumab may increase the neutropenic activities of Triamcinolone.\nRisk: Monitor closely.", "source": "Trastuzumab + Triamcinolone"}, {"id": "Trastuzumab_INT_Tacrolimus", "text": "Interaction: Trastuzumab AND Tacrolimus\nDetails: Trastuzumab may increase the neutropenic activities of Tacrolimus.\nRisk: Monitor closely.", "source": "Trastuzumab + Tacrolimus"}, {"id": "Trastuzumab_INT_Abatacept", "text": "Interaction: Trastuzumab AND Abatacept\nDetails: Trastuzumab may increase the neutropenic activities of Abatacept.\nRisk: Monitor closely.", "source": "Trastuzumab + Abatacept"}, {"id": "Trastuzumab_INT_Belatacept", "text": "Interaction: Trastuzumab AND Belatacept\nDetails: Trastuzumab may increase the neutropenic activities of Belatacept.\nRisk: Monitor closely.", "source": "Trastuzumab + Belatacept"}, {"id": "Trastuzumab_INT_Fingolimod", "text": "Interaction: Trastuzumab AND Fingolimod\nDetails: Trastuzumab may increase the neutropenic activities of Fingolimod.\nRisk: Monitor closely.", "source": "Trastuzumab + Fingolimod"}, {"id": "Trastuzumab_INT_Belimumab", "text": "Interaction: Trastuzumab AND Belimumab\nDetails: Trastuzumab may increase the neutropenic activities of Belimumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Belimumab"}, {"id": "Trastuzumab_INT_Teriflunomide", "text": "Interaction: Trastuzumab AND Teriflunomide\nDetails: Trastuzumab may increase the neutropenic activities of Teriflunomide.\nRisk: Monitor closely.", "source": "Trastuzumab + Teriflunomide"}, {"id": "Trastuzumab_INT_Certolizumab pegol", "text": "Interaction: Trastuzumab AND Certolizumab pegol\nDetails: Trastuzumab may increase the neutropenic activities of Certolizumab pegol.\nRisk: Monitor closely.", "source": "Trastuzumab + Certolizumab pegol"}, {"id": "Trastuzumab_INT_Anakinra", "text": "Interaction: Trastuzumab AND Anakinra\nDetails: Trastuzumab may increase the neutropenic activities of Anakinra.\nRisk: Monitor closely.", "source": "Trastuzumab + Anakinra"}, {"id": "Trastuzumab_INT_Adalimumab", "text": "Interaction: Trastuzumab AND Adalimumab\nDetails: Trastuzumab may increase the neutropenic activities of Adalimumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Adalimumab"}, {"id": "Trastuzumab_INT_Infliximab", "text": "Interaction: Trastuzumab AND Infliximab\nDetails: Trastuzumab may increase the neutropenic activities of Infliximab.\nRisk: Monitor closely.", "source": "Trastuzumab + Infliximab"}, {"id": "Trastuzumab_INT_Natalizumab", "text": "Interaction: Trastuzumab AND Natalizumab\nDetails: Trastuzumab may increase the neutropenic activities of Natalizumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Natalizumab"}, {"id": "Trastuzumab_INT_Eculizumab", "text": "Interaction: Trastuzumab AND Eculizumab\nDetails: Trastuzumab may increase the neutropenic activities of Eculizumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Eculizumab"}, {"id": "Trastuzumab_INT_Ustekinumab", "text": "Interaction: Trastuzumab AND Ustekinumab\nDetails: Trastuzumab may increase the neutropenic activities of Ustekinumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Ustekinumab"}, {"id": "Trastuzumab_INT_Canakinumab", "text": "Interaction: Trastuzumab AND Canakinumab\nDetails: Trastuzumab may increase the neutropenic activities of Canakinumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Canakinumab"}, {"id": "Trastuzumab_INT_Tocilizumab", "text": "Interaction: Trastuzumab AND Tocilizumab\nDetails: Trastuzumab may increase the neutropenic activities of Tocilizumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Tocilizumab"}, {"id": "Trastuzumab_INT_Rilonacept", "text": "Interaction: Trastuzumab AND Rilonacept\nDetails: Trastuzumab may increase the neutropenic activities of Rilonacept.\nRisk: Monitor closely.", "source": "Trastuzumab + Rilonacept"}, {"id": "Trastuzumab_INT_Golimumab", "text": "Interaction: Trastuzumab AND Golimumab\nDetails: Trastuzumab may increase the neutropenic activities of Golimumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Golimumab"}, {"id": "Trastuzumab_INT_Tofacitinib", "text": "Interaction: Trastuzumab AND Tofacitinib\nDetails: Trastuzumab may increase the neutropenic activities of Tofacitinib.\nRisk: Monitor closely.", "source": "Trastuzumab + Tofacitinib"}, {"id": "Trastuzumab_INT_Secukinumab", "text": "Interaction: Trastuzumab AND Secukinumab\nDetails: Trastuzumab may increase the neutropenic activities of Secukinumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Secukinumab"}, {"id": "Trastuzumab_INT_Vedolizumab", "text": "Interaction: Trastuzumab AND Vedolizumab\nDetails: Trastuzumab may increase the neutropenic activities of Vedolizumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Vedolizumab"}, {"id": "Trastuzumab_INT_Voclosporin", "text": "Interaction: Trastuzumab AND Voclosporin\nDetails: Trastuzumab may increase the neutropenic activities of Voclosporin.\nRisk: Monitor closely.", "source": "Trastuzumab + Voclosporin"}, {"id": "Trastuzumab_INT_Antithymocyte immunoglobulin (rabbit)", "text": "Interaction: Trastuzumab AND Antithymocyte immunoglobulin (rabbit)\nDetails: Trastuzumab may increase the neutropenic activities of Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Trastuzumab + Antithymocyte immunoglobulin (rabbit)"}, {"id": "Trastuzumab_INT_Antilymphocyte immunoglobulin (horse)", "text": "Interaction: Trastuzumab AND Antilymphocyte immunoglobulin (horse)\nDetails: Trastuzumab may increase the neutropenic activities of Antilymphocyte immunoglobulin (horse).\nRisk: Monitor closely.", "source": "Trastuzumab + Antilymphocyte immunoglobulin (horse)"}, {"id": "Trastuzumab_INT_Mepolizumab", "text": "Interaction: Trastuzumab AND Mepolizumab\nDetails: Trastuzumab may increase the neutropenic activities of Mepolizumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Mepolizumab"}, {"id": "Trastuzumab_INT_Glatiramer Acetate", "text": "Interaction: Trastuzumab AND Glatiramer Acetate\nDetails: Trastuzumab may increase the neutropenic activities of Glatiramer Acetate.\nRisk: Monitor closely.", "source": "Trastuzumab + Glatiramer Acetate"}, {"id": "Trastuzumab_INT_Glimepiride", "text": "Interaction: Trastuzumab AND Glimepiride\nDetails: Trastuzumab may increase the neutropenic activities of Glimepiride.\nRisk: Monitor closely.", "source": "Trastuzumab + Glimepiride"}, {"id": "Trastuzumab_INT_Pimecrolimus", "text": "Interaction: Trastuzumab AND Pimecrolimus\nDetails: Trastuzumab may increase the neutropenic activities of Pimecrolimus.\nRisk: Monitor closely.", "source": "Trastuzumab + Pimecrolimus"}, {"id": "Trastuzumab_INT_Stepronin", "text": "Interaction: Trastuzumab AND Stepronin\nDetails: Trastuzumab may increase the neutropenic activities of Stepronin.\nRisk: Monitor closely.", "source": "Trastuzumab + Stepronin"}, {"id": "Trastuzumab_INT_Castanospermine", "text": "Interaction: Trastuzumab AND Castanospermine\nDetails: Trastuzumab may increase the neutropenic activities of Castanospermine.\nRisk: Monitor closely.", "source": "Trastuzumab + Castanospermine"}, {"id": "Trastuzumab_INT_2-Methoxyethanol", "text": "Interaction: Trastuzumab AND 2-Methoxyethanol\nDetails: Trastuzumab may increase the neutropenic activities of 2-Methoxyethanol.\nRisk: Monitor closely.", "source": "Trastuzumab + 2-Methoxyethanol"}, {"id": "Trastuzumab_INT_Icatibant", "text": "Interaction: Trastuzumab AND Icatibant\nDetails: Trastuzumab may increase the neutropenic activities of Icatibant.\nRisk: Monitor closely.", "source": "Trastuzumab + Icatibant"}, {"id": "Trastuzumab_INT_Alicaforsen", "text": "Interaction: Trastuzumab AND Alicaforsen\nDetails: Trastuzumab may increase the neutropenic activities of Alicaforsen.\nRisk: Monitor closely.", "source": "Trastuzumab + Alicaforsen"}, {"id": "Trastuzumab_INT_Human C1-esterase inhibitor", "text": "Interaction: Trastuzumab AND Human C1-esterase inhibitor\nDetails: Trastuzumab may increase the neutropenic activities of Human C1-esterase inhibitor.\nRisk: Monitor closely.", "source": "Trastuzumab + Human C1-esterase inhibitor"}, {"id": "Trastuzumab_INT_Dimethyl fumarate", "text": "Interaction: Trastuzumab AND Dimethyl fumarate\nDetails: Trastuzumab may increase the neutropenic activities of Dimethyl fumarate.\nRisk: Monitor closely.", "source": "Trastuzumab + Dimethyl fumarate"}, {"id": "Trastuzumab_INT_Tepoxalin", "text": "Interaction: Trastuzumab AND Tepoxalin\nDetails: Trastuzumab may increase the neutropenic activities of Tepoxalin.\nRisk: Monitor closely.", "source": "Trastuzumab + Tepoxalin"}, {"id": "Trastuzumab_INT_Deflazacort", "text": "Interaction: Trastuzumab AND Deflazacort\nDetails: Trastuzumab may increase the neutropenic activities of Deflazacort.\nRisk: Monitor closely.", "source": "Trastuzumab + Deflazacort"}, {"id": "Trastuzumab_INT_Benznidazole", "text": "Interaction: Trastuzumab AND Benznidazole\nDetails: Trastuzumab may increase the neutropenic activities of Benznidazole.\nRisk: Monitor closely.", "source": "Trastuzumab + Benznidazole"}, {"id": "Trastuzumab_INT_Semapimod", "text": "Interaction: Trastuzumab AND Semapimod\nDetails: Trastuzumab may increase the neutropenic activities of Semapimod.\nRisk: Monitor closely.", "source": "Trastuzumab + Semapimod"}, {"id": "Trastuzumab_INT_Lisofylline", "text": "Interaction: Trastuzumab AND Lisofylline\nDetails: Trastuzumab may increase the neutropenic activities of Lisofylline.\nRisk: Monitor closely.", "source": "Trastuzumab + Lisofylline"}, {"id": "Trastuzumab_INT_Nafamostat", "text": "Interaction: Trastuzumab AND Nafamostat\nDetails: Trastuzumab may increase the neutropenic activities of Nafamostat.\nRisk: Monitor closely.", "source": "Trastuzumab + Nafamostat"}, {"id": "Trastuzumab_INT_Paquinimod", "text": "Interaction: Trastuzumab AND Paquinimod\nDetails: Trastuzumab may increase the neutropenic activities of Paquinimod.\nRisk: Monitor closely.", "source": "Trastuzumab + Paquinimod"}, {"id": "Trastuzumab_INT_Adefovir", "text": "Interaction: Trastuzumab AND Adefovir\nDetails: Trastuzumab may increase the neutropenic activities of Adefovir.\nRisk: Monitor closely.", "source": "Trastuzumab + Adefovir"}, {"id": "Trastuzumab_INT_Alefacept", "text": "Interaction: Trastuzumab AND Alefacept\nDetails: Trastuzumab may increase the neutropenic activities of Alefacept.\nRisk: Monitor closely.", "source": "Trastuzumab + Alefacept"}, {"id": "Trastuzumab_INT_Efalizumab", "text": "Interaction: Trastuzumab AND Efalizumab\nDetails: Trastuzumab may increase the neutropenic activities of Efalizumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Efalizumab"}, {"id": "Trastuzumab_INT_Afelimomab", "text": "Interaction: Trastuzumab AND Afelimomab\nDetails: Trastuzumab may increase the neutropenic activities of Afelimomab.\nRisk: Monitor closely.", "source": "Trastuzumab + Afelimomab"}, {"id": "Trastuzumab_INT_Briakinumab", "text": "Interaction: Trastuzumab AND Briakinumab\nDetails: Trastuzumab may increase the neutropenic activities of Briakinumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Briakinumab"}, {"id": "Trastuzumab_INT_Apremilast", "text": "Interaction: Trastuzumab AND Apremilast\nDetails: Trastuzumab may increase the neutropenic activities of Apremilast.\nRisk: Monitor closely.", "source": "Trastuzumab + Apremilast"}, {"id": "Trastuzumab_INT_Abetimus", "text": "Interaction: Trastuzumab AND Abetimus\nDetails: Trastuzumab may increase the neutropenic activities of Abetimus.\nRisk: Monitor closely.", "source": "Trastuzumab + Abetimus"}, {"id": "Trastuzumab_INT_Brodalumab", "text": "Interaction: Trastuzumab AND Brodalumab\nDetails: Trastuzumab may increase the neutropenic activities of Brodalumab.\nRisk: Monitor closely.", "source": "Trastuzumab + Brodalumab"}, {"id": "Trastuzumab_INT_Begelomab", "text": "Interaction: Trastuzumab AND Begelomab\nDetails: Trastuzumab may increase the neutropenic activities of Begelomab.\nRisk: Monitor closely.", "source": "Trastuzumab + Begelomab"}, {"id": "Trastuzumab_INT_Ibritumomab tiuxetan", "text": "Interaction: Trastuzumab AND Ibritumomab tiuxetan\nDetails: Trastuzumab may increase the neutropenic activities of Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Trastuzumab + Ibritumomab tiuxetan"}, {"id": "Trastuzumab_INT_L-Phenylalanine", "text": "Interaction: Trastuzumab AND L-Phenylalanine\nDetails: Trastuzumab may increase the neutropenic activities of L-Phenylalanine.\nRisk: Monitor closely.", "source": "Trastuzumab + L-Phenylalanine"}, {"id": "Trastuzumab_INT_Betamethasone", "text": "Interaction: Trastuzumab AND Betamethasone\nDetails: Trastuzumab may increase the neutropenic activities of Betamethasone.\nRisk: Monitor closely.", "source": "Trastuzumab + Betamethasone"}, {"id": "Trastuzumab_INT_Fludrocortisone", "text": "Interaction: Trastuzumab AND Fludrocortisone\nDetails: Trastuzumab may increase the neutropenic activities of Fludrocortisone.\nRisk: Monitor closely.", "source": "Trastuzumab + Fludrocortisone"}, {"id": "Trastuzumab_INT_Hydrocortisone", "text": "Interaction: Trastuzumab AND Hydrocortisone\nDetails: Trastuzumab may increase the neutropenic activities of Hydrocortisone.\nRisk: Monitor closely.", "source": "Trastuzumab + Hydrocortisone"}, {"id": "Trastuzumab_INT_Budesonide", "text": "Interaction: Trastuzumab AND Budesonide\nDetails: Trastuzumab may increase the neutropenic activities of Budesonide.\nRisk: Monitor closely.", "source": "Trastuzumab + Budesonide"}, {"id": "Trastuzumab_INT_Corticotropin", "text": "Interaction: Trastuzumab AND Corticotropin\nDetails: Trastuzumab may increase the neutropenic activities of Corticotropin.\nRisk: Monitor closely.", "source": "Trastuzumab + Corticotropin"}, {"id": "Trastuzumab_INT_Cortisone acetate", "text": "Interaction: Trastuzumab AND Cortisone acetate\nDetails: Trastuzumab may increase the neutropenic activities of Cortisone acetate.\nRisk: Monitor closely.", "source": "Trastuzumab + Cortisone acetate"}, {"id": "Trastuzumab_INT_Vilanterol", "text": "Interaction: Trastuzumab AND Vilanterol\nDetails: Trastuzumab may increase the neutropenic activities of Vilanterol.\nRisk: Monitor closely.", "source": "Trastuzumab + Vilanterol"}, {"id": "Rituximab_GEN", "text": "Drug: Rituximab\nDescription: Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human consta...", "source": "Rituximab"}, {"id": "Rituximab_CLIN", "text": "Drug: Rituximab\nMechanism: The Fab regions of rituximab binds to the CD20 antigen on B lymphocytes, while the Fc domain recruits antibodies and complements to mediate cell lysis....\nToxicity: ...", "source": "Rituximab"}, {"id": "Rituximab_INT_Adalimumab", "text": "Interaction: Rituximab AND Adalimumab\nDetails: The risk or severity of adverse effects can be increased when Adalimumab is combined with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Adalimumab"}, {"id": "Rituximab_INT_Anakinra", "text": "Interaction: Rituximab AND Anakinra\nDetails: The risk or severity of adverse effects can be increased when Anakinra is combined with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Anakinra"}, {"id": "Rituximab_INT_Etanercept", "text": "Interaction: Rituximab AND Etanercept\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Etanercept"}, {"id": "Rituximab_INT_Golimumab", "text": "Interaction: Rituximab AND Golimumab\nDetails: The risk or severity of adverse effects can be increased when Golimumab is combined with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Golimumab"}, {"id": "Rituximab_INT_Infliximab", "text": "Interaction: Rituximab AND Infliximab\nDetails: The risk or severity of adverse effects can be increased when Infliximab is combined with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Infliximab"}, {"id": "Rituximab_INT_Tocilizumab", "text": "Interaction: Rituximab AND Tocilizumab\nDetails: The risk or severity of adverse effects can be increased when Rituximab is combined with Tocilizumab.\nRisk: Monitor closely.", "source": "Rituximab + Tocilizumab"}, {"id": "Rituximab_INT_Metamizole", "text": "Interaction: Rituximab AND Metamizole\nDetails: The risk or severity of myelosuppression can be increased when Metamizole is combined with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Metamizole"}, {"id": "Rituximab_INT_Natalizumab", "text": "Interaction: Rituximab AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Rituximab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Rituximab + Natalizumab"}, {"id": "Rituximab_INT_Pimecrolimus", "text": "Interaction: Rituximab AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Pimecrolimus"}, {"id": "Rituximab_INT_Tacrolimus", "text": "Interaction: Rituximab AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Tacrolimus"}, {"id": "Rituximab_INT_Clozapine", "text": "Interaction: Rituximab AND Clozapine\nDetails: The risk or severity of adverse effects can be increased when Rituximab is combined with Clozapine.\nRisk: Monitor closely.", "source": "Rituximab + Clozapine"}, {"id": "Rituximab_INT_Belimumab", "text": "Interaction: Rituximab AND Belimumab\nDetails: The risk or severity of adverse effects can be increased when Rituximab is combined with Belimumab.\nRisk: Monitor closely.", "source": "Rituximab + Belimumab"}, {"id": "Rituximab_INT_Abatacept", "text": "Interaction: Rituximab AND Abatacept\nDetails: The risk or severity of adverse effects can be increased when Rituximab is combined with Abatacept.\nRisk: Monitor closely.", "source": "Rituximab + Abatacept"}, {"id": "Rituximab_INT_Certolizumab pegol", "text": "Interaction: Rituximab AND Certolizumab pegol\nDetails: Rituximab may increase the immunosuppressive activities of Certolizumab pegol.\nRisk: Monitor closely.", "source": "Rituximab + Certolizumab pegol"}, {"id": "Rituximab_INT_Tofacitinib", "text": "Interaction: Rituximab AND Tofacitinib\nDetails: The risk or severity of adverse effects can be increased when Rituximab is combined with Tofacitinib.\nRisk: Monitor closely.", "source": "Rituximab + Tofacitinib"}, {"id": "Rituximab_INT_BCG vaccine", "text": "Interaction: Rituximab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + BCG vaccine"}, {"id": "Rituximab_INT_Sarilumab", "text": "Interaction: Rituximab AND Sarilumab\nDetails: Sarilumab may increase the immunosuppressive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Sarilumab"}, {"id": "Rituximab_INT_Trastuzumab", "text": "Interaction: Rituximab AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Trastuzumab"}, {"id": "Rituximab_INT_Leflunomide", "text": "Interaction: Rituximab AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Rituximab is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Rituximab + Leflunomide"}, {"id": "Rituximab_INT_Fingolimod", "text": "Interaction: Rituximab AND Fingolimod\nDetails: Rituximab may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Rituximab + Fingolimod"}, {"id": "Rituximab_INT_Roflumilast", "text": "Interaction: Rituximab AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Roflumilast"}, {"id": "Rituximab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Rituximab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Rituximab_INT_Yellow fever vaccine", "text": "Interaction: Rituximab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Yellow fever vaccine"}, {"id": "Rituximab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Rituximab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Rituximab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Rituximab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Rituximab_INT_Rotavirus Vaccine", "text": "Interaction: Rituximab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Rotavirus Vaccine"}, {"id": "Rituximab_INT_G17DT", "text": "Interaction: Rituximab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + G17DT"}, {"id": "Rituximab_INT_INGN 201", "text": "Interaction: Rituximab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + INGN 201"}, {"id": "Rituximab_INT_INGN 225", "text": "Interaction: Rituximab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + INGN 225"}, {"id": "Rituximab_INT_Rindopepimut", "text": "Interaction: Rituximab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Rindopepimut"}, {"id": "Rituximab_INT_SRP 299", "text": "Interaction: Rituximab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + SRP 299"}, {"id": "Rituximab_INT_GI-5005", "text": "Interaction: Rituximab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + GI-5005"}, {"id": "Rituximab_INT_TG4010", "text": "Interaction: Rituximab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + TG4010"}, {"id": "Rituximab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Rituximab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Rabies virus inactivated antigen, A"}, {"id": "Rituximab_INT_Tecemotide", "text": "Interaction: Rituximab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Tecemotide"}, {"id": "Rituximab_INT_Rubella virus vaccine", "text": "Interaction: Rituximab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Rubella virus vaccine"}, {"id": "Rituximab_INT_Hepatitis A Vaccine", "text": "Interaction: Rituximab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Hepatitis A Vaccine"}, {"id": "Rituximab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Rituximab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Salmonella typhi ty21a live antigen"}, {"id": "Rituximab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Rituximab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Rituximab_INT_Paclitaxel", "text": "Interaction: Rituximab AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Paclitaxel"}, {"id": "Rituximab_INT_Docetaxel", "text": "Interaction: Rituximab AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Docetaxel"}, {"id": "Rituximab_INT_Cabazitaxel", "text": "Interaction: Rituximab AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Cabazitaxel"}, {"id": "Rituximab_INT_Reserpine", "text": "Interaction: Rituximab AND Reserpine\nDetails: Reserpine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Reserpine"}, {"id": "Rituximab_INT_Bethanidine", "text": "Interaction: Rituximab AND Bethanidine\nDetails: Bethanidine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Bethanidine"}, {"id": "Rituximab_INT_Nitroprusside", "text": "Interaction: Rituximab AND Nitroprusside\nDetails: Nitroprusside may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Nitroprusside"}, {"id": "Rituximab_INT_Minoxidil", "text": "Interaction: Rituximab AND Minoxidil\nDetails: Minoxidil may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Minoxidil"}, {"id": "Rituximab_INT_Prazosin", "text": "Interaction: Rituximab AND Prazosin\nDetails: Prazosin may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Prazosin"}, {"id": "Rituximab_INT_Bosentan", "text": "Interaction: Rituximab AND Bosentan\nDetails: Bosentan may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Bosentan"}, {"id": "Rituximab_INT_Clonidine", "text": "Interaction: Rituximab AND Clonidine\nDetails: Clonidine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Clonidine"}, {"id": "Rituximab_INT_Doxazosin", "text": "Interaction: Rituximab AND Doxazosin\nDetails: Doxazosin may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Doxazosin"}, {"id": "Rituximab_INT_Mecamylamine", "text": "Interaction: Rituximab AND Mecamylamine\nDetails: Mecamylamine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Mecamylamine"}, {"id": "Rituximab_INT_Guanfacine", "text": "Interaction: Rituximab AND Guanfacine\nDetails: Guanfacine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Guanfacine"}, {"id": "Rituximab_INT_Trimethaphan", "text": "Interaction: Rituximab AND Trimethaphan\nDetails: Trimethaphan may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Trimethaphan"}, {"id": "Rituximab_INT_Hydralazine", "text": "Interaction: Rituximab AND Hydralazine\nDetails: Hydralazine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Hydralazine"}, {"id": "Rituximab_INT_Pargyline", "text": "Interaction: Rituximab AND Pargyline\nDetails: Pargyline may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Pargyline"}, {"id": "Rituximab_INT_Debrisoquin", "text": "Interaction: Rituximab AND Debrisoquin\nDetails: Debrisoquin may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Debrisoquin"}, {"id": "Rituximab_INT_Pinacidil", "text": "Interaction: Rituximab AND Pinacidil\nDetails: Pinacidil may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Pinacidil"}, {"id": "Rituximab_INT_Indoramin", "text": "Interaction: Rituximab AND Indoramin\nDetails: Indoramin may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Indoramin"}, {"id": "Rituximab_INT_Trimazosin", "text": "Interaction: Rituximab AND Trimazosin\nDetails: Trimazosin may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Trimazosin"}, {"id": "Rituximab_INT_Moxonidine", "text": "Interaction: Rituximab AND Moxonidine\nDetails: Moxonidine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Moxonidine"}, {"id": "Rituximab_INT_Rilmenidine", "text": "Interaction: Rituximab AND Rilmenidine\nDetails: Rilmenidine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Rilmenidine"}, {"id": "Rituximab_INT_Ketanserin", "text": "Interaction: Rituximab AND Ketanserin\nDetails: Ketanserin may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Ketanserin"}, {"id": "Rituximab_INT_Dihydralazine", "text": "Interaction: Rituximab AND Dihydralazine\nDetails: Dihydralazine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Dihydralazine"}, {"id": "Rituximab_INT_Urapidil", "text": "Interaction: Rituximab AND Urapidil\nDetails: Urapidil may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Urapidil"}, {"id": "Rituximab_INT_Endralazine", "text": "Interaction: Rituximab AND Endralazine\nDetails: Endralazine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Endralazine"}, {"id": "Rituximab_INT_Cadralazine", "text": "Interaction: Rituximab AND Cadralazine\nDetails: Cadralazine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Cadralazine"}, {"id": "Rituximab_INT_Bietaserpine", "text": "Interaction: Rituximab AND Bietaserpine\nDetails: Bietaserpine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Bietaserpine"}, {"id": "Rituximab_INT_Valsartan", "text": "Interaction: Rituximab AND Valsartan\nDetails: Valsartan may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Valsartan"}, {"id": "Rituximab_INT_Ramipril", "text": "Interaction: Rituximab AND Ramipril\nDetails: Ramipril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Ramipril"}, {"id": "Rituximab_INT_Betaxolol", "text": "Interaction: Rituximab AND Betaxolol\nDetails: Betaxolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Betaxolol"}, {"id": "Rituximab_INT_Remikiren", "text": "Interaction: Rituximab AND Remikiren\nDetails: Remikiren may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Remikiren"}, {"id": "Rituximab_INT_Torasemide", "text": "Interaction: Rituximab AND Torasemide\nDetails: Torasemide may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Torasemide"}, {"id": "Rituximab_INT_Guanadrel", "text": "Interaction: Rituximab AND Guanadrel\nDetails: Guanadrel may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Guanadrel"}, {"id": "Rituximab_INT_Metoprolol", "text": "Interaction: Rituximab AND Metoprolol\nDetails: Metoprolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Metoprolol"}, {"id": "Rituximab_INT_Isradipine", "text": "Interaction: Rituximab AND Isradipine\nDetails: Isradipine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Isradipine"}, {"id": "Rituximab_INT_Olmesartan", "text": "Interaction: Rituximab AND Olmesartan\nDetails: Olmesartan may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Olmesartan"}, {"id": "Rituximab_INT_Travoprost", "text": "Interaction: Rituximab AND Travoprost\nDetails: Travoprost may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Travoprost"}, {"id": "Rituximab_INT_Chlorthalidone", "text": "Interaction: Rituximab AND Chlorthalidone\nDetails: Chlorthalidone may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Chlorthalidone"}, {"id": "Rituximab_INT_Atenolol", "text": "Interaction: Rituximab AND Atenolol\nDetails: Atenolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Atenolol"}, {"id": "Rituximab_INT_Diltiazem", "text": "Interaction: Rituximab AND Diltiazem\nDetails: Diltiazem may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Diltiazem"}, {"id": "Rituximab_INT_Timolol", "text": "Interaction: Rituximab AND Timolol\nDetails: Timolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Timolol"}, {"id": "Rituximab_INT_Treprostinil", "text": "Interaction: Rituximab AND Treprostinil\nDetails: Treprostinil may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Treprostinil"}, {"id": "Rituximab_INT_Amlodipine", "text": "Interaction: Rituximab AND Amlodipine\nDetails: Amlodipine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Amlodipine"}, {"id": "Rituximab_INT_Nimodipine", "text": "Interaction: Rituximab AND Nimodipine\nDetails: Nimodipine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Nimodipine"}, {"id": "Rituximab_INT_Nisoldipine", "text": "Interaction: Rituximab AND Nisoldipine\nDetails: Nisoldipine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Nisoldipine"}, {"id": "Rituximab_INT_Bendroflumethiazide", "text": "Interaction: Rituximab AND Bendroflumethiazide\nDetails: Bendroflumethiazide may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Bendroflumethiazide"}, {"id": "Rituximab_INT_Brimonidine", "text": "Interaction: Rituximab AND Brimonidine\nDetails: Brimonidine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Brimonidine"}, {"id": "Rituximab_INT_Fosinopril", "text": "Interaction: Rituximab AND Fosinopril\nDetails: Fosinopril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Fosinopril"}, {"id": "Rituximab_INT_Trandolapril", "text": "Interaction: Rituximab AND Trandolapril\nDetails: Trandolapril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Trandolapril"}, {"id": "Rituximab_INT_Carteolol", "text": "Interaction: Rituximab AND Carteolol\nDetails: Carteolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Carteolol"}, {"id": "Rituximab_INT_Metolazone", "text": "Interaction: Rituximab AND Metolazone\nDetails: Metolazone may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Metolazone"}, {"id": "Rituximab_INT_Lercanidipine", "text": "Interaction: Rituximab AND Lercanidipine\nDetails: Lercanidipine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Lercanidipine"}, {"id": "Rituximab_INT_Benazepril", "text": "Interaction: Rituximab AND Benazepril\nDetails: Benazepril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Benazepril"}, {"id": "Rituximab_INT_Propranolol", "text": "Interaction: Rituximab AND Propranolol\nDetails: Propranolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Propranolol"}, {"id": "Rituximab_INT_Enalapril", "text": "Interaction: Rituximab AND Enalapril\nDetails: Enalapril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Enalapril"}, {"id": "Rituximab_INT_Labetalol", "text": "Interaction: Rituximab AND Labetalol\nDetails: Labetalol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Labetalol"}, {"id": "Rituximab_INT_Cyclothiazide", "text": "Interaction: Rituximab AND Cyclothiazide\nDetails: Cyclothiazide may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Cyclothiazide"}, {"id": "Rituximab_INT_Bisoprolol", "text": "Interaction: Rituximab AND Bisoprolol\nDetails: Bisoprolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Bisoprolol"}, {"id": "Rituximab_INT_Candoxatril", "text": "Interaction: Rituximab AND Candoxatril\nDetails: Candoxatril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Candoxatril"}, {"id": "Rituximab_INT_Nicardipine", "text": "Interaction: Rituximab AND Nicardipine\nDetails: Nicardipine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Nicardipine"}, {"id": "Rituximab_INT_Guanabenz", "text": "Interaction: Rituximab AND Guanabenz\nDetails: Guanabenz may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Guanabenz"}, {"id": "Rituximab_INT_Latanoprost", "text": "Interaction: Rituximab AND Latanoprost\nDetails: Latanoprost may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Latanoprost"}, {"id": "Rituximab_INT_Losartan", "text": "Interaction: Rituximab AND Losartan\nDetails: Losartan may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Losartan"}, {"id": "Rituximab_INT_Moexipril", "text": "Interaction: Rituximab AND Moexipril\nDetails: Moexipril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Moexipril"}, {"id": "Rituximab_INT_Phentolamine", "text": "Interaction: Rituximab AND Phentolamine\nDetails: Phentolamine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Phentolamine"}, {"id": "Rituximab_INT_Lisinopril", "text": "Interaction: Rituximab AND Lisinopril\nDetails: Lisinopril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Lisinopril"}, {"id": "Rituximab_INT_Hydroflumethiazide", "text": "Interaction: Rituximab AND Hydroflumethiazide\nDetails: Hydroflumethiazide may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Hydroflumethiazide"}, {"id": "Rituximab_INT_Cryptenamine", "text": "Interaction: Rituximab AND Cryptenamine\nDetails: Cryptenamine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Cryptenamine"}, {"id": "Rituximab_INT_Perindopril", "text": "Interaction: Rituximab AND Perindopril\nDetails: Perindopril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Perindopril"}, {"id": "Rituximab_INT_Candesartan cilexetil", "text": "Interaction: Rituximab AND Candesartan cilexetil\nDetails: Candesartan cilexetil may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Candesartan cilexetil"}, {"id": "Rituximab_INT_Tolazoline", "text": "Interaction: Rituximab AND Tolazoline\nDetails: Tolazoline may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Tolazoline"}, {"id": "Rituximab_INT_Fenoldopam", "text": "Interaction: Rituximab AND Fenoldopam\nDetails: Fenoldopam may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Fenoldopam"}, {"id": "Rituximab_INT_Indapamide", "text": "Interaction: Rituximab AND Indapamide\nDetails: Indapamide may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Indapamide"}, {"id": "Rituximab_INT_Alprenolol", "text": "Interaction: Rituximab AND Alprenolol\nDetails: Alprenolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Alprenolol"}, {"id": "Rituximab_INT_Dorzolamide", "text": "Interaction: Rituximab AND Dorzolamide\nDetails: Dorzolamide may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Dorzolamide"}, {"id": "Rituximab_INT_Eprosartan", "text": "Interaction: Rituximab AND Eprosartan\nDetails: Eprosartan may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Eprosartan"}, {"id": "Rituximab_INT_Chlorothiazide", "text": "Interaction: Rituximab AND Chlorothiazide\nDetails: Chlorothiazide may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Chlorothiazide"}, {"id": "Rituximab_INT_Quinapril", "text": "Interaction: Rituximab AND Quinapril\nDetails: Quinapril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Quinapril"}, {"id": "Rituximab_INT_Omapatrilat", "text": "Interaction: Rituximab AND Omapatrilat\nDetails: Omapatrilat may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Omapatrilat"}, {"id": "Rituximab_INT_Bimatoprost", "text": "Interaction: Rituximab AND Bimatoprost\nDetails: Bimatoprost may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Bimatoprost"}, {"id": "Rituximab_INT_Phenoxybenzamine", "text": "Interaction: Rituximab AND Phenoxybenzamine\nDetails: Phenoxybenzamine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Phenoxybenzamine"}, {"id": "Rituximab_INT_Pindolol", "text": "Interaction: Rituximab AND Pindolol\nDetails: Pindolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Pindolol"}, {"id": "Rituximab_INT_Telmisartan", "text": "Interaction: Rituximab AND Telmisartan\nDetails: Telmisartan may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Telmisartan"}, {"id": "Rituximab_INT_Methyldopa", "text": "Interaction: Rituximab AND Methyldopa\nDetails: Methyldopa may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Methyldopa"}, {"id": "Rituximab_INT_Hydrochlorothiazide", "text": "Interaction: Rituximab AND Hydrochlorothiazide\nDetails: Hydrochlorothiazide may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Hydrochlorothiazide"}, {"id": "Rituximab_INT_Trichlormethiazide", "text": "Interaction: Rituximab AND Trichlormethiazide\nDetails: Trichlormethiazide may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Trichlormethiazide"}, {"id": "Rituximab_INT_Felodipine", "text": "Interaction: Rituximab AND Felodipine\nDetails: Felodipine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Felodipine"}, {"id": "Rituximab_INT_Irbesartan", "text": "Interaction: Rituximab AND Irbesartan\nDetails: Irbesartan may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Irbesartan"}, {"id": "Rituximab_INT_Nitrendipine", "text": "Interaction: Rituximab AND Nitrendipine\nDetails: Nitrendipine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Nitrendipine"}, {"id": "Rituximab_INT_Pentolinium", "text": "Interaction: Rituximab AND Pentolinium\nDetails: Pentolinium may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Pentolinium"}, {"id": "Rituximab_INT_Diazoxide", "text": "Interaction: Rituximab AND Diazoxide\nDetails: Diazoxide may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Diazoxide"}, {"id": "Rituximab_INT_Carvedilol", "text": "Interaction: Rituximab AND Carvedilol\nDetails: Carvedilol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Carvedilol"}, {"id": "Rituximab_INT_Bretylium", "text": "Interaction: Rituximab AND Bretylium\nDetails: Bretylium may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Bretylium"}, {"id": "Rituximab_INT_Guanethidine", "text": "Interaction: Rituximab AND Guanethidine\nDetails: Guanethidine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Guanethidine"}, {"id": "Rituximab_INT_Acebutolol", "text": "Interaction: Rituximab AND Acebutolol\nDetails: Acebutolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Acebutolol"}, {"id": "Rituximab_INT_Captopril", "text": "Interaction: Rituximab AND Captopril\nDetails: Captopril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Captopril"}, {"id": "Rituximab_INT_Nadolol", "text": "Interaction: Rituximab AND Nadolol\nDetails: Nadolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Nadolol"}, {"id": "Rituximab_INT_Metipranolol", "text": "Interaction: Rituximab AND Metipranolol\nDetails: Metipranolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Metipranolol"}, {"id": "Rituximab_INT_Epoprostenol", "text": "Interaction: Rituximab AND Epoprostenol\nDetails: Epoprostenol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Epoprostenol"}, {"id": "Rituximab_INT_Bepridil", "text": "Interaction: Rituximab AND Bepridil\nDetails: Bepridil may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Bepridil"}, {"id": "Rituximab_INT_Polythiazide", "text": "Interaction: Rituximab AND Polythiazide\nDetails: Polythiazide may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Polythiazide"}, {"id": "Rituximab_INT_Cilazapril", "text": "Interaction: Rituximab AND Cilazapril\nDetails: Cilazapril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Cilazapril"}, {"id": "Rituximab_INT_Saprisartan", "text": "Interaction: Rituximab AND Saprisartan\nDetails: Saprisartan may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Saprisartan"}, {"id": "Rituximab_INT_Spirapril", "text": "Interaction: Rituximab AND Spirapril\nDetails: Spirapril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Spirapril"}, {"id": "Rituximab_INT_Penbutolol", "text": "Interaction: Rituximab AND Penbutolol\nDetails: Penbutolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Penbutolol"}, {"id": "Rituximab_INT_Mibefradil", "text": "Interaction: Rituximab AND Mibefradil\nDetails: Mibefradil may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Mibefradil"}, {"id": "Rituximab_INT_Oxprenolol", "text": "Interaction: Rituximab AND Oxprenolol\nDetails: Oxprenolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Oxprenolol"}, {"id": "Rituximab_INT_Platelet Activating Factor", "text": "Interaction: Rituximab AND Platelet Activating Factor\nDetails: Platelet Activating Factor may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Platelet Activating Factor"}, {"id": "Rituximab_INT_Terlipressin", "text": "Interaction: Rituximab AND Terlipressin\nDetails: Terlipressin may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Terlipressin"}, {"id": "Rituximab_INT_Ticrynafen", "text": "Interaction: Rituximab AND Ticrynafen\nDetails: Ticrynafen may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Ticrynafen"}, {"id": "Rituximab_INT_Celiprolol", "text": "Interaction: Rituximab AND Celiprolol\nDetails: Celiprolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Celiprolol"}, {"id": "Rituximab_INT_Nebivolol", "text": "Interaction: Rituximab AND Nebivolol\nDetails: Nebivolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Nebivolol"}, {"id": "Rituximab_INT_Lofexidine", "text": "Interaction: Rituximab AND Lofexidine\nDetails: Lofexidine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Lofexidine"}, {"id": "Rituximab_INT_diethylnorspermine", "text": "Interaction: Rituximab AND diethylnorspermine\nDetails: diethylnorspermine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + diethylnorspermine"}, {"id": "Rituximab_INT_Xylometazoline", "text": "Interaction: Rituximab AND Xylometazoline\nDetails: Xylometazoline may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Xylometazoline"}, {"id": "Rituximab_INT_Nilvadipine", "text": "Interaction: Rituximab AND Nilvadipine\nDetails: Nilvadipine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Nilvadipine"}, {"id": "Rituximab_INT_Unoprostone", "text": "Interaction: Rituximab AND Unoprostone\nDetails: Unoprostone may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Unoprostone"}, {"id": "Rituximab_INT_Ferulic acid", "text": "Interaction: Rituximab AND Ferulic acid\nDetails: Ferulic acid may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Ferulic acid"}, {"id": "Rituximab_INT_Bupranolol", "text": "Interaction: Rituximab AND Bupranolol\nDetails: Bupranolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Bupranolol"}, {"id": "Rituximab_INT_Temocapril", "text": "Interaction: Rituximab AND Temocapril\nDetails: Temocapril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Temocapril"}, {"id": "Rituximab_INT_Indenolol", "text": "Interaction: Rituximab AND Indenolol\nDetails: Indenolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Indenolol"}, {"id": "Rituximab_INT_Hexamethonium", "text": "Interaction: Rituximab AND Hexamethonium\nDetails: Hexamethonium may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Hexamethonium"}, {"id": "Rituximab_INT_Aliskiren", "text": "Interaction: Rituximab AND Aliskiren\nDetails: Aliskiren may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Aliskiren"}, {"id": "Rituximab_INT_Tibolone", "text": "Interaction: Rituximab AND Tibolone\nDetails: Tibolone may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Tibolone"}, {"id": "Rituximab_INT_Nicorandil", "text": "Interaction: Rituximab AND Nicorandil\nDetails: Nicorandil may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Nicorandil"}, {"id": "Rituximab_INT_Efonidipine", "text": "Interaction: Rituximab AND Efonidipine\nDetails: Efonidipine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Efonidipine"}, {"id": "Rituximab_INT_Lacidipine", "text": "Interaction: Rituximab AND Lacidipine\nDetails: Lacidipine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Lacidipine"}, {"id": "Rituximab_INT_Manidipine", "text": "Interaction: Rituximab AND Manidipine\nDetails: Manidipine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Manidipine"}, {"id": "Rituximab_INT_Niguldipine", "text": "Interaction: Rituximab AND Niguldipine\nDetails: Niguldipine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Niguldipine"}, {"id": "Rituximab_INT_Enalaprilat", "text": "Interaction: Rituximab AND Enalaprilat\nDetails: Enalaprilat may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Enalaprilat"}, {"id": "Rituximab_INT_Selexipag", "text": "Interaction: Rituximab AND Selexipag\nDetails: Selexipag may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Selexipag"}, {"id": "Rituximab_INT_Talinolol", "text": "Interaction: Rituximab AND Talinolol\nDetails: Talinolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Talinolol"}, {"id": "Rituximab_INT_Imidapril", "text": "Interaction: Rituximab AND Imidapril\nDetails: Imidapril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Imidapril"}, {"id": "Rituximab_INT_BQ-123", "text": "Interaction: Rituximab AND BQ-123\nDetails: BQ-123 may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + BQ-123"}, {"id": "Rituximab_INT_Naftopidil", "text": "Interaction: Rituximab AND Naftopidil\nDetails: Naftopidil may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Naftopidil"}, {"id": "Rituximab_INT_Tetrahydropalmatine", "text": "Interaction: Rituximab AND Tetrahydropalmatine\nDetails: Tetrahydropalmatine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Tetrahydropalmatine"}, {"id": "Rituximab_INT_Vinpocetine", "text": "Interaction: Rituximab AND Vinpocetine\nDetails: Vinpocetine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Vinpocetine"}, {"id": "Rituximab_INT_Cicletanine", "text": "Interaction: Rituximab AND Cicletanine\nDetails: Cicletanine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Cicletanine"}, {"id": "Rituximab_INT_Cafedrine", "text": "Interaction: Rituximab AND Cafedrine\nDetails: Cafedrine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Cafedrine"}, {"id": "Rituximab_INT_Theodrenaline", "text": "Interaction: Rituximab AND Theodrenaline\nDetails: Theodrenaline may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Theodrenaline"}, {"id": "Rituximab_INT_Zofenopril", "text": "Interaction: Rituximab AND Zofenopril\nDetails: Zofenopril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Zofenopril"}, {"id": "Rituximab_INT_Delapril", "text": "Interaction: Rituximab AND Delapril\nDetails: Delapril may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Delapril"}, {"id": "Rituximab_INT_Vincamine", "text": "Interaction: Rituximab AND Vincamine\nDetails: Vincamine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Vincamine"}, {"id": "Rituximab_INT_Linsidomine", "text": "Interaction: Rituximab AND Linsidomine\nDetails: Linsidomine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Linsidomine"}, {"id": "Rituximab_INT_Cloranolol", "text": "Interaction: Rituximab AND Cloranolol\nDetails: Cloranolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Cloranolol"}, {"id": "Rituximab_INT_Cyclopenthiazide", "text": "Interaction: Rituximab AND Cyclopenthiazide\nDetails: Cyclopenthiazide may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Cyclopenthiazide"}, {"id": "Rituximab_INT_Epanolol", "text": "Interaction: Rituximab AND Epanolol\nDetails: Epanolol may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Epanolol"}, {"id": "Rituximab_INT_Muzolimine", "text": "Interaction: Rituximab AND Muzolimine\nDetails: Muzolimine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Muzolimine"}, {"id": "Rituximab_INT_Xipamide", "text": "Interaction: Rituximab AND Xipamide\nDetails: Xipamide may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Xipamide"}, {"id": "Rituximab_INT_Candesartan", "text": "Interaction: Rituximab AND Candesartan\nDetails: Candesartan may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Candesartan"}, {"id": "Rituximab_INT_Metyrosine", "text": "Interaction: Rituximab AND Metyrosine\nDetails: Metyrosine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Metyrosine"}, {"id": "Rituximab_INT_Deserpidine", "text": "Interaction: Rituximab AND Deserpidine\nDetails: Deserpidine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Deserpidine"}, {"id": "Rituximab_INT_Rescinnamine", "text": "Interaction: Rituximab AND Rescinnamine\nDetails: Rescinnamine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Rescinnamine"}, {"id": "Rituximab_INT_Sitaxentan", "text": "Interaction: Rituximab AND Sitaxentan\nDetails: Sitaxentan may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Sitaxentan"}, {"id": "Rituximab_INT_Ambrisentan", "text": "Interaction: Rituximab AND Ambrisentan\nDetails: Ambrisentan may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Ambrisentan"}, {"id": "Rituximab_INT_Riociguat", "text": "Interaction: Rituximab AND Riociguat\nDetails: Riociguat may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Riociguat"}, {"id": "Rituximab_INT_Macitentan", "text": "Interaction: Rituximab AND Macitentan\nDetails: Macitentan may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Macitentan"}, {"id": "Rituximab_INT_Guanoxan", "text": "Interaction: Rituximab AND Guanoxan\nDetails: Guanoxan may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Guanoxan"}, {"id": "Rituximab_INT_Guanoxabenz", "text": "Interaction: Rituximab AND Guanoxabenz\nDetails: Guanoxabenz may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Guanoxabenz"}, {"id": "Rituximab_INT_Tolonidine", "text": "Interaction: Rituximab AND Tolonidine\nDetails: Tolonidine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Tolonidine"}, {"id": "Rituximab_INT_Guanazodine", "text": "Interaction: Rituximab AND Guanazodine\nDetails: Guanazodine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Guanazodine"}, {"id": "Rituximab_INT_Methoserpidine", "text": "Interaction: Rituximab AND Methoserpidine\nDetails: Methoserpidine may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Methoserpidine"}, {"id": "Rituximab_INT_Guanoclor", "text": "Interaction: Rituximab AND Guanoclor\nDetails: Guanoclor may increase the hypotensive activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Guanoclor"}, {"id": "Rituximab_INT_Digoxin", "text": "Interaction: Rituximab AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Digoxin"}, {"id": "Rituximab_INT_Acetyldigitoxin", "text": "Interaction: Rituximab AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Acetyldigitoxin"}, {"id": "Rituximab_INT_Deslanoside", "text": "Interaction: Rituximab AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Deslanoside"}, {"id": "Rituximab_INT_Ouabain", "text": "Interaction: Rituximab AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Ouabain"}, {"id": "Rituximab_INT_Digitoxin", "text": "Interaction: Rituximab AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Digitoxin"}, {"id": "Rituximab_INT_Cymarin", "text": "Interaction: Rituximab AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Cymarin"}, {"id": "Rituximab_INT_Proscillaridin", "text": "Interaction: Rituximab AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Proscillaridin"}, {"id": "Rituximab_INT_Metildigoxin", "text": "Interaction: Rituximab AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Metildigoxin"}, {"id": "Rituximab_INT_Peruvoside", "text": "Interaction: Rituximab AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Peruvoside"}, {"id": "Rituximab_INT_Lanatoside C", "text": "Interaction: Rituximab AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Lanatoside C"}, {"id": "Rituximab_INT_Gitoformate", "text": "Interaction: Rituximab AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Gitoformate"}, {"id": "Rituximab_INT_Acetyldigoxin", "text": "Interaction: Rituximab AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Acetyldigoxin"}, {"id": "Rituximab_INT_Oleandrin", "text": "Interaction: Rituximab AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Oleandrin"}, {"id": "Rituximab_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Rituximab AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Digoxin Immune Fab (Ovine)"}, {"id": "Rituximab_INT_Bevacizumab", "text": "Interaction: Rituximab AND Bevacizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Bevacizumab"}, {"id": "Rituximab_INT_Cyclophosphamide", "text": "Interaction: Rituximab AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Cyclophosphamide"}, {"id": "Rituximab_INT_Denosumab", "text": "Interaction: Rituximab AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Denosumab"}, {"id": "Rituximab_INT_Sipuleucel-T", "text": "Interaction: Rituximab AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Rituximab.\nRisk: Monitor closely.", "source": "Rituximab + Sipuleucel-T"}, {"id": "Basiliximab_GEN", "text": "Drug: Basiliximab\nDescription: A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein ob...", "source": "Basiliximab"}, {"id": "Basiliximab_CLIN", "text": "Drug: Basiliximab\nMechanism: Basiliximab binds with high-affinity to the alpha-subunit (CD25) of the high-affinity IL-2 receptor. This inhibits IL-2 binding, which inhibits T-cell activation and prevents the body from mounting an...\nToxicity: ...", "source": "Basiliximab"}, {"id": "Basiliximab_INT_Natalizumab", "text": "Interaction: Basiliximab AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Basiliximab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Basiliximab + Natalizumab"}, {"id": "Basiliximab_INT_Pimecrolimus", "text": "Interaction: Basiliximab AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Pimecrolimus"}, {"id": "Basiliximab_INT_Tofacitinib", "text": "Interaction: Basiliximab AND Tofacitinib\nDetails: Basiliximab may increase the immunosuppressive activities of Tofacitinib.\nRisk: Monitor closely.", "source": "Basiliximab + Tofacitinib"}, {"id": "Basiliximab_INT_Tacrolimus", "text": "Interaction: Basiliximab AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Tacrolimus"}, {"id": "Basiliximab_INT_BCG vaccine", "text": "Interaction: Basiliximab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + BCG vaccine"}, {"id": "Basiliximab_INT_Leflunomide", "text": "Interaction: Basiliximab AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Basiliximab is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Basiliximab + Leflunomide"}, {"id": "Basiliximab_INT_Fingolimod", "text": "Interaction: Basiliximab AND Fingolimod\nDetails: Basiliximab may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Basiliximab + Fingolimod"}, {"id": "Basiliximab_INT_Roflumilast", "text": "Interaction: Basiliximab AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Roflumilast"}, {"id": "Basiliximab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Basiliximab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Basiliximab_INT_Yellow fever vaccine", "text": "Interaction: Basiliximab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Yellow fever vaccine"}, {"id": "Basiliximab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Basiliximab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Basiliximab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Basiliximab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Basiliximab_INT_Rotavirus Vaccine", "text": "Interaction: Basiliximab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Rotavirus Vaccine"}, {"id": "Basiliximab_INT_G17DT", "text": "Interaction: Basiliximab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + G17DT"}, {"id": "Basiliximab_INT_INGN 201", "text": "Interaction: Basiliximab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + INGN 201"}, {"id": "Basiliximab_INT_INGN 225", "text": "Interaction: Basiliximab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + INGN 225"}, {"id": "Basiliximab_INT_Rindopepimut", "text": "Interaction: Basiliximab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Rindopepimut"}, {"id": "Basiliximab_INT_SRP 299", "text": "Interaction: Basiliximab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + SRP 299"}, {"id": "Basiliximab_INT_GI-5005", "text": "Interaction: Basiliximab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + GI-5005"}, {"id": "Basiliximab_INT_TG4010", "text": "Interaction: Basiliximab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + TG4010"}, {"id": "Basiliximab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Basiliximab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Rabies virus inactivated antigen, A"}, {"id": "Basiliximab_INT_Tecemotide", "text": "Interaction: Basiliximab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Tecemotide"}, {"id": "Basiliximab_INT_Rubella virus vaccine", "text": "Interaction: Basiliximab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Rubella virus vaccine"}, {"id": "Basiliximab_INT_Hepatitis A Vaccine", "text": "Interaction: Basiliximab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Hepatitis A Vaccine"}, {"id": "Basiliximab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Basiliximab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Salmonella typhi ty21a live antigen"}, {"id": "Basiliximab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Basiliximab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Basiliximab_INT_Denosumab", "text": "Interaction: Basiliximab AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Denosumab"}, {"id": "Basiliximab_INT_Sipuleucel-T", "text": "Interaction: Basiliximab AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Sipuleucel-T"}, {"id": "Basiliximab_INT_Trastuzumab", "text": "Interaction: Basiliximab AND Trastuzumab\nDetails: Trastuzumab may increase the neutropenic activities of Basiliximab.\nRisk: Monitor closely.", "source": "Basiliximab + Trastuzumab"}, {"id": "Muromonab_GEN", "text": "Drug: Muromonab\nDescription: Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric im...", "source": "Muromonab"}, {"id": "Muromonab_CLIN", "text": "Drug: Muromonab\nMechanism: Muromonab binds to the T-cell surface glycoprotein CD3 epsilon chain. It appears to kill CD-3 positive cells by inducing Fc mediated apoptosis, antibody mediated cytotoxicity and complement-dependent ...\nToxicity: ...", "source": "Muromonab"}, {"id": "Muromonab_INT_Natalizumab", "text": "Interaction: Muromonab AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Muromonab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Muromonab + Natalizumab"}, {"id": "Muromonab_INT_Pimecrolimus", "text": "Interaction: Muromonab AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Pimecrolimus"}, {"id": "Muromonab_INT_Tofacitinib", "text": "Interaction: Muromonab AND Tofacitinib\nDetails: Muromonab may increase the immunosuppressive activities of Tofacitinib.\nRisk: Monitor closely.", "source": "Muromonab + Tofacitinib"}, {"id": "Muromonab_INT_Tacrolimus", "text": "Interaction: Muromonab AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Tacrolimus"}, {"id": "Muromonab_INT_Belimumab", "text": "Interaction: Muromonab AND Belimumab\nDetails: The risk or severity of adverse effects can be increased when Muromonab is combined with Belimumab.\nRisk: Monitor closely.", "source": "Muromonab + Belimumab"}, {"id": "Muromonab_INT_BCG vaccine", "text": "Interaction: Muromonab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + BCG vaccine"}, {"id": "Muromonab_INT_Leflunomide", "text": "Interaction: Muromonab AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Muromonab is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Muromonab + Leflunomide"}, {"id": "Muromonab_INT_Fingolimod", "text": "Interaction: Muromonab AND Fingolimod\nDetails: Muromonab may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Muromonab + Fingolimod"}, {"id": "Muromonab_INT_Roflumilast", "text": "Interaction: Muromonab AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Roflumilast"}, {"id": "Muromonab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Muromonab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Muromonab_INT_Yellow fever vaccine", "text": "Interaction: Muromonab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Yellow fever vaccine"}, {"id": "Muromonab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Muromonab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Muromonab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Muromonab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Muromonab_INT_Rotavirus Vaccine", "text": "Interaction: Muromonab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Rotavirus Vaccine"}, {"id": "Muromonab_INT_G17DT", "text": "Interaction: Muromonab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + G17DT"}, {"id": "Muromonab_INT_INGN 201", "text": "Interaction: Muromonab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + INGN 201"}, {"id": "Muromonab_INT_INGN 225", "text": "Interaction: Muromonab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + INGN 225"}, {"id": "Muromonab_INT_Rindopepimut", "text": "Interaction: Muromonab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Rindopepimut"}, {"id": "Muromonab_INT_SRP 299", "text": "Interaction: Muromonab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + SRP 299"}, {"id": "Muromonab_INT_GI-5005", "text": "Interaction: Muromonab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + GI-5005"}, {"id": "Muromonab_INT_TG4010", "text": "Interaction: Muromonab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + TG4010"}, {"id": "Muromonab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Muromonab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Rabies virus inactivated antigen, A"}, {"id": "Muromonab_INT_Tecemotide", "text": "Interaction: Muromonab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Tecemotide"}, {"id": "Muromonab_INT_Rubella virus vaccine", "text": "Interaction: Muromonab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Rubella virus vaccine"}, {"id": "Muromonab_INT_Hepatitis A Vaccine", "text": "Interaction: Muromonab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Hepatitis A Vaccine"}, {"id": "Muromonab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Muromonab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Salmonella typhi ty21a live antigen"}, {"id": "Muromonab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Muromonab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Muromonab_INT_Denosumab", "text": "Interaction: Muromonab AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Denosumab"}, {"id": "Muromonab_INT_Sipuleucel-T", "text": "Interaction: Muromonab AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Sipuleucel-T"}, {"id": "Muromonab_INT_Trastuzumab", "text": "Interaction: Muromonab AND Trastuzumab\nDetails: Trastuzumab may increase the neutropenic activities of Muromonab.\nRisk: Monitor closely.", "source": "Muromonab + Trastuzumab"}, {"id": "Digoxin Immune Fab (Ovine)_GEN", "text": "Drug: Digoxin Immune Fab (Ovine)\nDescription: Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin....", "source": "Digoxin Immune Fab (Ovine)"}, {"id": "Digoxin Immune Fab (Ovine)_CLIN", "text": "Drug: Digoxin Immune Fab (Ovine)\nMechanism: Binds excess digoxin or digitoxin molecules circulating in the blood....\nToxicity: ...", "source": "Digoxin Immune Fab (Ovine)"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Amiodarone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Amiodarone\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Amiodarone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Amiodarone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Itraconazole", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Itraconazole\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Itraconazole.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Itraconazole"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Quinidine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Quinidine\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Quinidine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Quinidine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Clarithromycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Clarithromycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Clarithromycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Clarithromycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Erythromycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Erythromycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Erythromycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Erythromycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Telithromycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Telithromycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Telithromycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Telithromycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Azithromycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Azithromycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Azithromycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Azithromycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Spiramycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Spiramycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Spiramycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Spiramycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Carbomycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Carbomycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Carbomycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Carbomycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Josamycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Josamycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Josamycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Josamycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Kitasamycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Kitasamycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Kitasamycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Kitasamycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Oleandomycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Oleandomycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Oleandomycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Oleandomycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Solithromycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Solithromycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Solithromycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Solithromycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tylosin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tylosin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Tylosin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tylosin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Succinylcholine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Succinylcholine\nDetails: Succinylcholine may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Succinylcholine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cisatracurium besylate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cisatracurium besylate\nDetails: Cisatracurium besylate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cisatracurium besylate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Rocuronium", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Rocuronium\nDetails: Rocuronium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Rocuronium"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Atracurium besylate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Atracurium besylate\nDetails: Atracurium besylate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Atracurium besylate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pancuronium", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pancuronium\nDetails: Pancuronium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pancuronium"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vecuronium", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vecuronium\nDetails: Vecuronium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vecuronium"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Metocurine Iodide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Metocurine Iodide\nDetails: Metocurine Iodide may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Metocurine Iodide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Gallamine Triethiodide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Gallamine Triethiodide\nDetails: Gallamine Triethiodide may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Gallamine Triethiodide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Doxacurium chloride", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Doxacurium chloride\nDetails: Doxacurium chloride may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Doxacurium chloride"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tubocurarine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tubocurarine\nDetails: Tubocurarine may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tubocurarine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mivacurium", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mivacurium\nDetails: Mivacurium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mivacurium"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Decamethonium", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Decamethonium\nDetails: Decamethonium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Decamethonium"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Metocurine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Metocurine\nDetails: Metocurine may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Metocurine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pipecuronium", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pipecuronium\nDetails: Pipecuronium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pipecuronium"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Domoic Acid", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Domoic Acid\nDetails: Domoic Acid may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Domoic Acid"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Rapacuronium", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Rapacuronium\nDetails: Rapacuronium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Rapacuronium"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pyrantel", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pyrantel\nDetails: Pyrantel may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pyrantel"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Neosaxitoxin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Neosaxitoxin\nDetails: Neosaxitoxin may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Neosaxitoxin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Atracurium", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Atracurium\nDetails: Atracurium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Atracurium"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cisatracurium", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cisatracurium\nDetails: Cisatracurium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cisatracurium"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Gallamine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Gallamine\nDetails: Gallamine may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Gallamine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Alcuronium", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Alcuronium\nDetails: Alcuronium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Alcuronium"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cetuximab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cetuximab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cetuximab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Denileukin diftitox", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Denileukin diftitox\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Denileukin diftitox"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Asparaginase", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Asparaginase\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Asparaginase"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pegaspargase", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pegaspargase\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pegaspargase"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Trastuzumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Trastuzumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Trastuzumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Trastuzumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Rituximab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Rituximab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Rituximab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bevacizumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bevacizumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bevacizumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bortezomib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bortezomib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Bortezomib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bortezomib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pipobroman", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pipobroman\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pipobroman.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pipobroman"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cladribine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cladribine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cladribine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cladribine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Carmustine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Carmustine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Carmustine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Carmustine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Amsacrine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Amsacrine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Amsacrine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Amsacrine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bleomycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bleomycin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Bleomycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bleomycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Chlorambucil", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Chlorambucil\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Chlorambucil.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Chlorambucil"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Raltitrexed", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Raltitrexed\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Raltitrexed.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Raltitrexed"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mitomycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mitomycin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mitomycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mitomycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bexarotene", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bexarotene\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Bexarotene.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bexarotene"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vindesine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vindesine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vindesine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vindesine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Gefitinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Gefitinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Gefitinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Gefitinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tioguanine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tioguanine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tioguanine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tioguanine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vinorelbine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vinorelbine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vinorelbine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vinorelbine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Valrubicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Valrubicin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Valrubicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Valrubicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Sorafenib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Sorafenib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Sorafenib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Sorafenib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Streptozocin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Streptozocin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Streptozocin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Streptozocin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Gemcitabine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Gemcitabine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Gemcitabine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Gemcitabine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Teniposide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Teniposide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Teniposide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Teniposide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Epirubicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Epirubicin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Epirubicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Epirubicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Altretamine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Altretamine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Altretamine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Altretamine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cisplatin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cisplatin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cisplatin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cisplatin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Alitretinoin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Alitretinoin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Alitretinoin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Alitretinoin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Oxaliplatin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Oxaliplatin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Oxaliplatin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Oxaliplatin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Erlotinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Erlotinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Erlotinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Erlotinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cyclophosphamide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cyclophosphamide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cyclophosphamide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cyclophosphamide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vincristine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vincristine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vincristine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vincristine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Fluorouracil", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Fluorouracil\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Fluorouracil.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Fluorouracil"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pentostatin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pentostatin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pentostatin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pentostatin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Methotrexate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Methotrexate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Methotrexate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Methotrexate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vinblastine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vinblastine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vinblastine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vinblastine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Imatinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Imatinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Imatinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Imatinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Clofarabine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Clofarabine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Clofarabine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Clofarabine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pemetrexed", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pemetrexed\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pemetrexed.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pemetrexed"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mitotane", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mitotane\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mitotane.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mitotane"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Daunorubicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Daunorubicin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Daunorubicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Daunorubicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Porfimer sodium", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Porfimer sodium\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Porfimer sodium.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Porfimer sodium"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Irinotecan", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Irinotecan\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Irinotecan.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Irinotecan"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Etoposide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Etoposide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Etoposide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Etoposide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Dacarbazine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Dacarbazine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Dacarbazine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Dacarbazine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Temozolomide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Temozolomide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Temozolomide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Temozolomide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mechlorethamine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mechlorethamine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mechlorethamine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mechlorethamine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Azacitidine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Azacitidine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Azacitidine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Azacitidine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Carboplatin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Carboplatin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Carboplatin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Carboplatin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Dactinomycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Dactinomycin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Dactinomycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Dactinomycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cytarabine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cytarabine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cytarabine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cytarabine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Doxorubicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Doxorubicin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Doxorubicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Doxorubicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Hydroxyurea", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Hydroxyurea\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Hydroxyurea.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Hydroxyurea"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Busulfan", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Busulfan\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Busulfan.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Busulfan"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Topotecan", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Topotecan\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Topotecan.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Topotecan"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mercaptopurine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mercaptopurine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mercaptopurine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mercaptopurine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Melphalan", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Melphalan\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Melphalan.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Melphalan"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Fludarabine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Fludarabine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Fludarabine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Fludarabine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Capecitabine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Capecitabine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Capecitabine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Capecitabine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Procarbazine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Procarbazine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Procarbazine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Procarbazine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Arsenic trioxide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Arsenic trioxide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Arsenic trioxide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Arsenic trioxide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Idarubicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Idarubicin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Idarubicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Idarubicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ifosfamide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ifosfamide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ifosfamide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ifosfamide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Estramustine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Estramustine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Estramustine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Estramustine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mitoxantrone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mitoxantrone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mitoxantrone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mitoxantrone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Lomustine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Lomustine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lomustine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Lomustine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Paclitaxel", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Paclitaxel\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Paclitaxel.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Paclitaxel"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Docetaxel", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Docetaxel\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Docetaxel.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Docetaxel"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Dasatinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Dasatinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Dasatinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Dasatinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Lapatinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Lapatinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lapatinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Lapatinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Decitabine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Decitabine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Decitabine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Decitabine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Sunitinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Sunitinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Sunitinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Sunitinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Panitumumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Panitumumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Panitumumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Panitumumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vorinostat", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vorinostat\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vorinostat.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vorinostat"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Fotemustine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Fotemustine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Fotemustine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Fotemustine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Thiotepa", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Thiotepa\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Thiotepa.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Thiotepa"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Omacetaxine mepesuccinate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Omacetaxine mepesuccinate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Omacetaxine mepesuccinate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Satraplatin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Satraplatin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Satraplatin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Satraplatin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Belinostat", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Belinostat\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Belinostat.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Belinostat"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Trabectedin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Trabectedin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Trabectedin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Trabectedin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ramucirumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ramucirumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ramucirumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ramucirumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Trastuzumab emtansine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Trastuzumab emtansine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Trastuzumab emtansine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Trastuzumab emtansine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Romidepsin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Romidepsin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Romidepsin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Romidepsin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pixantrone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pixantrone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pixantrone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pixantrone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Amrubicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Amrubicin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Amrubicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Amrubicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Lonidamine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Lonidamine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lonidamine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Lonidamine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Temsirolimus", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Temsirolimus\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Temsirolimus.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Temsirolimus"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pertuzumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pertuzumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pertuzumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pertuzumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Panobinostat", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Panobinostat\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Panobinostat.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Panobinostat"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bendamustine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bendamustine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Bendamustine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bendamustine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Plicamycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Plicamycin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Plicamycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Plicamycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ponatinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ponatinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ponatinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ponatinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Trametinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Trametinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Trametinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Trametinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Dabrafenib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Dabrafenib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Dabrafenib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Dabrafenib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Obinutuzumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Obinutuzumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Obinutuzumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Obinutuzumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Carmofur", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Carmofur\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Carmofur.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Carmofur"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Miltefosine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Miltefosine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Miltefosine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Miltefosine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Nivolumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Nivolumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nivolumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Nivolumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pembrolizumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pembrolizumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pembrolizumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pembrolizumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Blinatumomab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Blinatumomab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Blinatumomab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Blinatumomab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Idelalisib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Idelalisib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Idelalisib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Idelalisib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ceritinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ceritinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ceritinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ceritinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Palbociclib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Palbociclib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Palbociclib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Palbociclib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Olaparib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Olaparib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Olaparib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Olaparib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Lenvatinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Lenvatinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lenvatinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Lenvatinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Nintedanib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Nintedanib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nintedanib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Nintedanib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tegafur", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tegafur\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tegafur.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tegafur"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ixazomib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ixazomib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ixazomib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ixazomib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pirarubicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pirarubicin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pirarubicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pirarubicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Aclarubicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Aclarubicin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Aclarubicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Aclarubicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Zorubicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Zorubicin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Zorubicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Zorubicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Temoporfin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Temoporfin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Temoporfin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Temoporfin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Prednimustine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Prednimustine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Prednimustine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Prednimustine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Trofosfamide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Trofosfamide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Trofosfamide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Trofosfamide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mitoguazone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mitoguazone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mitoguazone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mitoguazone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Nimustine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Nimustine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nimustine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Nimustine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Treosulfan", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Treosulfan\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Treosulfan.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Treosulfan"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cediranib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cediranib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cediranib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cediranib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Gemtuzumab ozogamicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Gemtuzumab ozogamicin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Gemtuzumab ozogamicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tiazofurine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tiazofurine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tiazofurine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tiazofurine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Triaziquone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Triaziquone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Triaziquone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Triaziquone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Demecolcine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Demecolcine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Demecolcine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Demecolcine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Etoglucid", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Etoglucid\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Etoglucid.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Etoglucid"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mitobronitol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mitobronitol\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mitobronitol.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mitobronitol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Semustine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Semustine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Semustine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Semustine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Carboquone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Carboquone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Carboquone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Carboquone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ranimustine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ranimustine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ranimustine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ranimustine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Leuprolide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Leuprolide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Leuprolide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Aldesleukin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Aldesleukin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Aldesleukin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Alemtuzumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Alemtuzumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Alemtuzumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Megestrol acetate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Megestrol acetate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Megestrol acetate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Megestrol acetate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Lenalidomide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Lenalidomide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lenalidomide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Lenalidomide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Flutamide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Flutamide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Flutamide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Flutamide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Nilutamide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Nilutamide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nilutamide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Nilutamide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tamoxifen", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tamoxifen\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tamoxifen.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tamoxifen"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tretinoin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tretinoin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tretinoin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tretinoin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Fulvestrant", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Fulvestrant\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Fulvestrant.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Fulvestrant"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Exemestane", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Exemestane\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Exemestane.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Exemestane"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Letrozole", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Letrozole\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Letrozole.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Letrozole"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bicalutamide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bicalutamide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Bicalutamide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bicalutamide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Anastrozole", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Anastrozole\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Anastrozole.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Anastrozole"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Everolimus", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Everolimus\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Everolimus.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Everolimus"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Nelarabine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Nelarabine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nelarabine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Nelarabine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Nilotinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Nilotinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nilotinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Nilotinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vandetanib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vandetanib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vandetanib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vandetanib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ipilimumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ipilimumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ipilimumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ipilimumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pazopanib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pazopanib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pazopanib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pazopanib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Catumaxomab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Catumaxomab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Catumaxomab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Catumaxomab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bosutinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bosutinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Bosutinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bosutinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Axitinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Axitinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Axitinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Axitinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ofatumumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ofatumumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ofatumumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ofatumumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cabazitaxel", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cabazitaxel\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cabazitaxel.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cabazitaxel"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vismodegib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vismodegib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vismodegib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vismodegib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Crizotinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Crizotinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Crizotinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Crizotinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Brentuximab vedotin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Brentuximab vedotin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Brentuximab vedotin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Brentuximab vedotin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Eribulin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Eribulin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Eribulin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Eribulin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ruxolitinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ruxolitinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ruxolitinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ruxolitinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vemurafenib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vemurafenib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vemurafenib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vemurafenib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Carfilzomib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Carfilzomib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Carfilzomib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Carfilzomib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Regorafenib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Regorafenib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Regorafenib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Regorafenib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Afatinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Afatinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Afatinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Afatinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ibrutinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ibrutinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ibrutinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ibrutinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Necitumumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Necitumumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Necitumumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Necitumumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Abiraterone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Abiraterone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Abiraterone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Abiraterone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Midostaurin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Midostaurin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Midostaurin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Midostaurin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Triptorelin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Triptorelin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Triptorelin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Triptorelin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pomalidomide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pomalidomide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pomalidomide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pomalidomide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Osimertinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Osimertinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Osimertinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Osimertinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Daratumumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Daratumumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Daratumumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Daratumumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Goserelin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Goserelin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Goserelin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Oprelvekin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Oprelvekin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Oprelvekin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Interferon beta-1a", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Interferon beta-1a\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Interferon beta-1a"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tositumomab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tositumomab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tositumomab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Octreotide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Octreotide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Octreotide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vitamin A", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vitamin A\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vitamin A.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vitamin A"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Moxifloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Moxifloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Moxifloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Moxifloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cabergoline", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cabergoline\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cabergoline.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cabergoline"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Diethylstilbestrol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Diethylstilbestrol\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Diethylstilbestrol.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Diethylstilbestrol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Chlorotrianisene", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Chlorotrianisene\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Chlorotrianisene.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Chlorotrianisene"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pamidronate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pamidronate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pamidronate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pamidronate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Floxuridine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Floxuridine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Floxuridine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Floxuridine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Aminoglutethimide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Aminoglutethimide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Aminoglutethimide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Aminoglutethimide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Grepafloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Grepafloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Grepafloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Grepafloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Dexrazoxane", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Dexrazoxane\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Dexrazoxane.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Dexrazoxane"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Verteporfin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Verteporfin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Verteporfin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Verteporfin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Enoxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Enoxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Enoxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Enoxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pefloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pefloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pefloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pefloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Albendazole", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Albendazole\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Albendazole.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Albendazole"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ciprofloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ciprofloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ciprofloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ciprofloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Toremifene", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Toremifene\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Toremifene.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Toremifene"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Azelaic Acid", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Azelaic Acid\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Azelaic Acid.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Azelaic Acid"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Medroxyprogesterone acetate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Medroxyprogesterone acetate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Medroxyprogesterone acetate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Medroxyprogesterone acetate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Sulindac", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Sulindac\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Sulindac.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Sulindac"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Prednisone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Prednisone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Prednisone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Prednisone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mebendazole", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mebendazole\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mebendazole.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mebendazole"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Trovafloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Trovafloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Trovafloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Trovafloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Imiquimod", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Imiquimod\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Imiquimod.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Imiquimod"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Nalidixic Acid", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Nalidixic Acid\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nalidixic Acid.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Nalidixic Acid"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Uracil mustard", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Uracil mustard\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Uracil mustard.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Uracil mustard"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cinoxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cinoxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cinoxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cinoxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Prednisolone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Prednisolone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Prednisolone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Prednisolone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Sirolimus", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Sirolimus\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Sirolimus.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Sirolimus"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Testolactone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Testolactone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Testolactone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Testolactone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Methylprednisolone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Methylprednisolone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Methylprednisolone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Methylprednisolone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ethiodized oil", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ethiodized oil\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ethiodized oil.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ethiodized oil"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Lomefloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Lomefloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lomefloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Lomefloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Azathioprine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Azathioprine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Azathioprine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Azathioprine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mycophenolic acid", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mycophenolic acid\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mycophenolic acid.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mycophenolic acid"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Thalidomide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Thalidomide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Thalidomide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Thalidomide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Gatifloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Gatifloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Gatifloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Gatifloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Norfloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Norfloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Norfloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Norfloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Leflunomide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Leflunomide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Leflunomide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Leflunomide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Quinacrine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Quinacrine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Quinacrine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Quinacrine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Trilostane", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Trilostane\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Trilostane.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Trilostane"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Levofloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Levofloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Levofloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Levofloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Gemifloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Gemifloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Gemifloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Gemifloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Trimetrexate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Trimetrexate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Trimetrexate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Trimetrexate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ofloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ofloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ofloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ofloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Podofilox", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Podofilox\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Podofilox.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Podofilox"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Sparfloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Sparfloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Sparfloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Sparfloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Dexamethasone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Dexamethasone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Dexamethasone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Dexamethasone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ranibizumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ranibizumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ranibizumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ranibizumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Colchicine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Colchicine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Colchicine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Colchicine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Temafloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Temafloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Temafloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Temafloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Genistein", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Genistein\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Genistein.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Genistein"}, {"id": "Digoxin Immune Fab (Ovine)_INT_8-azaguanine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND 8-azaguanine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of 8-azaguanine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + 8-azaguanine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_7-Hydroxystaurosporine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND 7-Hydroxystaurosporine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + 7-Hydroxystaurosporine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Hadacidin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Hadacidin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Hadacidin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Hadacidin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Formycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Formycin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Formycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Formycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Calcipotriol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Calcipotriol\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Calcipotriol.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Calcipotriol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_2-Methoxyestradiol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND 2-Methoxyestradiol\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of 2-Methoxyestradiol.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + 2-Methoxyestradiol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Geldanamycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Geldanamycin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Geldanamycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Geldanamycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Fumagillin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Fumagillin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Fumagillin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Fumagillin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Resveratrol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Resveratrol\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Resveratrol.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Resveratrol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Arotinoid acid", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Arotinoid acid\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Arotinoid acid.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Arotinoid acid"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Arsanilic acid", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Arsanilic acid\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Arsanilic acid.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Arsanilic acid"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Patupilone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Patupilone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Patupilone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Patupilone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_3-Methoxybenzamide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND 3-Methoxybenzamide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of 3-Methoxybenzamide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + 3-Methoxybenzamide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tubercidin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tubercidin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tubercidin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tubercidin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ubenimex", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ubenimex\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ubenimex.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ubenimex"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Sparfosic acid", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Sparfosic acid\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Sparfosic acid.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Sparfosic acid"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Alvocidib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Alvocidib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Alvocidib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Alvocidib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Rhodamine 6G", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Rhodamine 6G\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Rhodamine 6G.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Rhodamine 6G"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Batimastat", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Batimastat\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Batimastat.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Batimastat"}, {"id": "Digoxin Immune Fab (Ovine)_INT_3,4-Dihydroxybenzoic Acid", "text": "Interaction: Digoxin Immune Fab (Ovine) AND 3,4-Dihydroxybenzoic Acid\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + 3,4-Dihydroxybenzoic Acid"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Sparsomycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Sparsomycin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Sparsomycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Sparsomycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tretazicar", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tretazicar\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tretazicar.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tretazicar"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Seocalcitol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Seocalcitol\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Seocalcitol.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Seocalcitol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Nebularine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Nebularine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nebularine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Nebularine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Afimoxifene", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Afimoxifene\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Afimoxifene.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Afimoxifene"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cholesterol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cholesterol\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cholesterol.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cholesterol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Fleroxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Fleroxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Fleroxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Fleroxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Metoprine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Metoprine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Metoprine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Metoprine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Camptothecin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Camptothecin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Camptothecin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Camptothecin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Suramin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Suramin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Suramin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Suramin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ethyl carbamate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ethyl carbamate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ethyl carbamate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ethyl carbamate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cyproterone acetate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cyproterone acetate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cyproterone acetate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cyproterone acetate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tirapazamine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tirapazamine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tirapazamine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tirapazamine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Halofuginone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Halofuginone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Halofuginone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Halofuginone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vapreotide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vapreotide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vapreotide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vapreotide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Thymalfasin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Thymalfasin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Thymalfasin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Thymalfasin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ranpirnase", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ranpirnase\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ranpirnase.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ranpirnase"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pirfenidone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pirfenidone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pirfenidone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pirfenidone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tipifarnib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tipifarnib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tipifarnib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tipifarnib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Troxacitabine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Troxacitabine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Troxacitabine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Troxacitabine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Amonafide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Amonafide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Amonafide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Amonafide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_SRT501", "text": "Interaction: Digoxin Immune Fab (Ovine) AND SRT501\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of SRT501.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + SRT501"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Fenretinide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Fenretinide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Fenretinide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Fenretinide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tiomolibdate ion", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tiomolibdate ion\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tiomolibdate ion.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tiomolibdate ion"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Elsamitrucin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Elsamitrucin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Elsamitrucin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Elsamitrucin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Gallium nitrate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Gallium nitrate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Gallium nitrate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Gallium nitrate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ecabet", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ecabet\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ecabet.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ecabet"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Canertinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Canertinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Canertinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Canertinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_motexafin gadolinium", "text": "Interaction: Digoxin Immune Fab (Ovine) AND motexafin gadolinium\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of motexafin gadolinium.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + motexafin gadolinium"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Alanosine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Alanosine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Alanosine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Alanosine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Palifosfamide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Palifosfamide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Palifosfamide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Palifosfamide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_AP 12009", "text": "Interaction: Digoxin Immune Fab (Ovine) AND AP 12009\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of AP 12009.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + AP 12009"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Oglufanide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Oglufanide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Oglufanide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Oglufanide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Irofulven", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Irofulven\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Irofulven.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Irofulven"}, {"id": "Digoxin Immune Fab (Ovine)_INT_KOS-1584", "text": "Interaction: Digoxin Immune Fab (Ovine) AND KOS-1584\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of KOS-1584.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + KOS-1584"}, {"id": "Digoxin Immune Fab (Ovine)_INT_BSI-201", "text": "Interaction: Digoxin Immune Fab (Ovine) AND BSI-201\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of BSI-201.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + BSI-201"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Rubitecan", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Rubitecan\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Rubitecan.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Rubitecan"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Garenoxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Garenoxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Garenoxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Garenoxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Plevitrexed", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Plevitrexed\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Plevitrexed.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Plevitrexed"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Seliciclib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Seliciclib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Seliciclib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Seliciclib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vadimezan", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vadimezan\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vadimezan.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vadimezan"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Eflornithine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Eflornithine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Eflornithine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Eflornithine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_exisulind", "text": "Interaction: Digoxin Immune Fab (Ovine) AND exisulind\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of exisulind.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + exisulind"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Maxacalcitol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Maxacalcitol\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Maxacalcitol.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Maxacalcitol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_AP24534", "text": "Interaction: Digoxin Immune Fab (Ovine) AND AP24534\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of AP24534.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + AP24534"}, {"id": "Digoxin Immune Fab (Ovine)_INT_annamycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND annamycin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of annamycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + annamycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Endostatin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Endostatin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Endostatin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Endostatin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tezacitabine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tezacitabine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tezacitabine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tezacitabine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Semaxanib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Semaxanib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Semaxanib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Semaxanib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_diethylnorspermine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND diethylnorspermine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of diethylnorspermine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + diethylnorspermine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_squalamine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND squalamine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of squalamine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + squalamine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_porfiromycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND porfiromycin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of porfiromycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + porfiromycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_MLN576", "text": "Interaction: Digoxin Immune Fab (Ovine) AND MLN576\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of MLN576.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + MLN576"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Iobenguane", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Iobenguane\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Iobenguane.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Iobenguane"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Methyltestosterone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Methyltestosterone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Methyltestosterone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Methyltestosterone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ginsenoside C", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ginsenoside C\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ginsenoside C.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ginsenoside C"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Besifloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Besifloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Besifloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Besifloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Hydroxyprogesterone caproate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Hydroxyprogesterone caproate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Hydroxyprogesterone caproate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Lanreotide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Lanreotide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lanreotide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Lanreotide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Phenylbutyric acid", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Phenylbutyric acid\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Phenylbutyric acid.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Phenylbutyric acid"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Veliparib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Veliparib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Veliparib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Veliparib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Hexestrol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Hexestrol\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Hexestrol.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Hexestrol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_nocodazole", "text": "Interaction: Digoxin Immune Fab (Ovine) AND nocodazole\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of nocodazole.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + nocodazole"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Puromycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Puromycin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Puromycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Puromycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_GS 0573", "text": "Interaction: Digoxin Immune Fab (Ovine) AND GS 0573\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of GS 0573.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + GS 0573"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Formestane", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Formestane\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Formestane.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Formestane"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Radium Ra 223 Dichloride", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Radium Ra 223 Dichloride\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Radium Ra 223 Dichloride"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Flumequine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Flumequine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Flumequine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Flumequine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Siltuximab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Siltuximab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Siltuximab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Siltuximab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tibolone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tibolone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tibolone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tibolone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Podophyllin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Podophyllin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Podophyllin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Podophyllin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Dienogest", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Dienogest\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Dienogest.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Dienogest"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Medrogestone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Medrogestone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Medrogestone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Medrogestone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Niguldipine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Niguldipine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Niguldipine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Niguldipine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pirlindole", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pirlindole\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pirlindole.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pirlindole"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Phenylacetic acid", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Phenylacetic acid\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Phenylacetic acid.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Phenylacetic acid"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Alatrofloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Alatrofloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Alatrofloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Alatrofloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Isosorbide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Isosorbide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Isosorbide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Isosorbide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mequinol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mequinol\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mequinol.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mequinol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Lycopene", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Lycopene\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lycopene.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Lycopene"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Roquinimex", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Roquinimex\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Roquinimex.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Roquinimex"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Enrofloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Enrofloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Enrofloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Enrofloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Rabusertib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Rabusertib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Rabusertib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Rabusertib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Curcumin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Curcumin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Curcumin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Curcumin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_2-chloroethyl-3-sarcosinamide-1-nitrosourea", "text": "Interaction: Digoxin Immune Fab (Ovine) AND 2-chloroethyl-3-sarcosinamide-1-nitrosourea\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of 2-chloroethyl-3-sarcosinamide-1-nitrosourea.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + 2-chloroethyl-3-sarcosinamide-1-nitrosourea"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Misonidazole", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Misonidazole\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Misonidazole.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Misonidazole"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bryostatin 1", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bryostatin 1\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Bryostatin 1.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bryostatin 1"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Talazoparib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Talazoparib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Talazoparib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Talazoparib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tremelimumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tremelimumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tremelimumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tremelimumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pazufloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pazufloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pazufloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pazufloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Niraparib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Niraparib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Niraparib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Niraparib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Saracatinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Saracatinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Saracatinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Saracatinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Talaporfin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Talaporfin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Talaporfin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Talaporfin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Crenolanib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Crenolanib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Crenolanib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Crenolanib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Entinostat", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Entinostat\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Entinostat.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Entinostat"}, {"id": "Digoxin Immune Fab (Ovine)_INT_3,3'-diindolylmethane", "text": "Interaction: Digoxin Immune Fab (Ovine) AND 3,3'-diindolylmethane\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of 3,3&#39;-diindolylmethane.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + 3,3'-diindolylmethane"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Acridine Carboxamide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Acridine Carboxamide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Acridine Carboxamide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Acridine Carboxamide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Infigratinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Infigratinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Infigratinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Infigratinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Prulifloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Prulifloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Prulifloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Prulifloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Efatutazone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Efatutazone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Efatutazone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Efatutazone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_6-O-benzylguanine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND 6-O-benzylguanine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of 6-O-benzylguanine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + 6-O-benzylguanine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Carboxyamidotriazole", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Carboxyamidotriazole\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Carboxyamidotriazole.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Carboxyamidotriazole"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Triptolide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Triptolide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Triptolide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Triptolide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Broxuridine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Broxuridine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Broxuridine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Broxuridine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Trebananib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Trebananib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Trebananib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Trebananib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Anecortave", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Anecortave\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Anecortave.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Anecortave"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vesnarinone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vesnarinone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vesnarinone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vesnarinone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mafosfamide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mafosfamide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mafosfamide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mafosfamide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_LCL-161", "text": "Interaction: Digoxin Immune Fab (Ovine) AND LCL-161\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of LCL-161.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + LCL-161"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Taselisib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Taselisib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Taselisib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Taselisib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Zuretinol acetate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Zuretinol acetate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Zuretinol acetate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Zuretinol acetate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Epigallocatechin Gallate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Epigallocatechin Gallate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Epigallocatechin Gallate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Epigallocatechin Gallate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Namitecan", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Namitecan\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Namitecan.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Namitecan"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Duligotuzumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Duligotuzumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Duligotuzumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Duligotuzumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cordycepin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cordycepin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cordycepin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cordycepin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Binetrakin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Binetrakin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Binetrakin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Binetrakin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Exatecan", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Exatecan\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Exatecan.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Exatecan"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Lurtotecan", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Lurtotecan\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lurtotecan.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Lurtotecan"}, {"id": "Digoxin Immune Fab (Ovine)_INT_KRN-7000", "text": "Interaction: Digoxin Immune Fab (Ovine) AND KRN-7000\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of KRN-7000.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + KRN-7000"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Epofolate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Epofolate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Epofolate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Epofolate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_OBP-801", "text": "Interaction: Digoxin Immune Fab (Ovine) AND OBP-801\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of OBP-801.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + OBP-801"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Rucaparib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Rucaparib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Rucaparib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Rucaparib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Navitoclax", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Navitoclax\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Navitoclax.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Navitoclax"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bizelesin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bizelesin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Bizelesin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bizelesin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Indirubin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Indirubin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Indirubin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Indirubin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Merestinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Merestinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Merestinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Merestinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_10-hydroxycamptothecin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND 10-hydroxycamptothecin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of 10-hydroxycamptothecin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + 10-hydroxycamptothecin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Sulforaphane", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Sulforaphane\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Sulforaphane.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Sulforaphane"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Nadifloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Nadifloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nadifloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Nadifloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Belotecan", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Belotecan\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Belotecan.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Belotecan"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Taurolidine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Taurolidine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Taurolidine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Taurolidine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_9-aminocamptothecin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND 9-aminocamptothecin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of 9-aminocamptothecin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + 9-aminocamptothecin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Molgramostim", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Molgramostim\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Molgramostim.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Molgramostim"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Oltipraz", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Oltipraz\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Oltipraz.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Oltipraz"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pyrazoloacridine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pyrazoloacridine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pyrazoloacridine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pyrazoloacridine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Fosbretabulin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Fosbretabulin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Fosbretabulin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Fosbretabulin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Apaziquone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Apaziquone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Apaziquone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Apaziquone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Combretastatin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Combretastatin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Combretastatin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Combretastatin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mizoribine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mizoribine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mizoribine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mizoribine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Onapristone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Onapristone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Onapristone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Onapristone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Soblidotin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Soblidotin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Soblidotin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Soblidotin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Salirasib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Salirasib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Salirasib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Salirasib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Gusperimus", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Gusperimus\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Gusperimus.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Gusperimus"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Phenethyl Isothiocyanate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Phenethyl Isothiocyanate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Phenethyl Isothiocyanate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Phenethyl Isothiocyanate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Methylselenocysteine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Methylselenocysteine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Methylselenocysteine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Methylselenocysteine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Dolastatin 10", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Dolastatin 10\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Dolastatin 10.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Dolastatin 10"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Etanidazole", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Etanidazole\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Etanidazole.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Etanidazole"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Lometrexol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Lometrexol\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lometrexol.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Lometrexol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Buthionine Sulfoximine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Buthionine Sulfoximine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Buthionine Sulfoximine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Buthionine Sulfoximine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Dianhydrogalactitol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Dianhydrogalactitol\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Dianhydrogalactitol.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Dianhydrogalactitol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Indole-3-carbinol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Indole-3-carbinol\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Indole-3-carbinol.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Indole-3-carbinol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Fiacitabine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Fiacitabine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Fiacitabine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Fiacitabine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Nolatrexed", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Nolatrexed\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nolatrexed.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Nolatrexed"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mitolactol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mitolactol\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mitolactol.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mitolactol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pinometostat", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pinometostat\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pinometostat.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pinometostat"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Doxifluridine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Doxifluridine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Doxifluridine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Doxifluridine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Didox", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Didox\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Didox.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Didox"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Penclomedine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Penclomedine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Penclomedine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Penclomedine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Deoxyspergualin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Deoxyspergualin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Deoxyspergualin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Deoxyspergualin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Acteoside", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Acteoside\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Acteoside.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Acteoside"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Hypericin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Hypericin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Hypericin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Hypericin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Irsogladine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Irsogladine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Irsogladine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Irsogladine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Liarozole", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Liarozole\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Liarozole.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Liarozole"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Sizofiran", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Sizofiran\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Sizofiran.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Sizofiran"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Nedaplatin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Nedaplatin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nedaplatin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Nedaplatin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Sitafloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Sitafloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Sitafloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Sitafloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Lentinan", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Lentinan\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Lentinan.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Lentinan"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Oxolinic acid", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Oxolinic acid\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Oxolinic acid.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Oxolinic acid"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vorozole", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vorozole\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vorozole.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vorozole"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Rufloxacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Rufloxacin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Rufloxacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Rufloxacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Iniparib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Iniparib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Iniparib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Iniparib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Coumermycin A1", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Coumermycin A1\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Coumermycin A1.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Coumermycin A1"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Toyocamycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Toyocamycin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Toyocamycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Toyocamycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Masoprocol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Masoprocol\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Masoprocol.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Masoprocol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Anagrelide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Anagrelide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Anagrelide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Anagrelide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Trifluridine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Trifluridine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Trifluridine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Trifluridine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Aminolevulinic acid", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Aminolevulinic acid\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Aminolevulinic acid.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Aminolevulinic acid"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Methyl aminolevulinate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Methyl aminolevulinate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Methyl aminolevulinate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Methyl aminolevulinate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ixabepilone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ixabepilone\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ixabepilone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ixabepilone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_EG009", "text": "Interaction: Digoxin Immune Fab (Ovine) AND EG009\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of EG009.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + EG009"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vintafolide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vintafolide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vintafolide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vintafolide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ridaforolimus", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ridaforolimus\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ridaforolimus.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ridaforolimus"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pralatrexate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pralatrexate\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pralatrexate.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pralatrexate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Efaproxiral", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Efaproxiral\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Efaproxiral.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Efaproxiral"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cabozantinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cabozantinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cabozantinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cabozantinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Dinutuximab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Dinutuximab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Dinutuximab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Dinutuximab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Sonidegib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Sonidegib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Sonidegib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Sonidegib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Masitinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Masitinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Masitinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Masitinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Vinflunine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Vinflunine\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Vinflunine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Vinflunine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tivozanib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tivozanib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tivozanib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tivozanib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mannosulfan", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mannosulfan\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mannosulfan.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mannosulfan"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Edrecolomab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Edrecolomab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Edrecolomab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Edrecolomab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Paclitaxel poliglumex", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Paclitaxel poliglumex\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Paclitaxel poliglumex.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Paclitaxel poliglumex"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Oblimersen", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Oblimersen\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Oblimersen.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Oblimersen"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Interferon Alfa-2b, Recombinant", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Interferon Alfa-2b, Recombinant\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Interferon Alfa-2b, Recombinant"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mycophenolate mofetil", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mycophenolate mofetil\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mycophenolate mofetil.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mycophenolate mofetil"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cobimetinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cobimetinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Cobimetinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cobimetinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Elotuzumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Elotuzumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Elotuzumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Elotuzumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Degarelix", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Degarelix\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Degarelix.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Degarelix"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Buserelin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Buserelin\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Buserelin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Buserelin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Aflibercept", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Aflibercept\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Aflibercept.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Aflibercept"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Enzalutamide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Enzalutamide\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Enzalutamide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Enzalutamide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Alectinib", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Alectinib\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Alectinib.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Alectinib"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Venetoclax", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Venetoclax\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Venetoclax.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Venetoclax"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Atezolizumab", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Atezolizumab\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Atezolizumab.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Atezolizumab"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Torasemide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Torasemide\nDetails: The risk or severity of adverse effects can be increased when Torasemide is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Torasemide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Furosemide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Furosemide\nDetails: The risk or severity of adverse effects can be increased when Furosemide is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Furosemide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bumetanide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bumetanide\nDetails: The risk or severity of adverse effects can be increased when Bumetanide is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bumetanide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Etacrynic acid", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Etacrynic acid\nDetails: The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Etacrynic acid"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Piretanide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Piretanide\nDetails: The risk or severity of adverse effects can be increased when Piretanide is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Piretanide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Propylthiouracil", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Propylthiouracil\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Propylthiouracil.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Propylthiouracil"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Methimazole", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Methimazole\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Methimazole.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Methimazole"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Carbimazole", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Carbimazole\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Carbimazole.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Carbimazole"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Methylthiouracil", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Methylthiouracil\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Methylthiouracil.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Methylthiouracil"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Potassium Iodide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Potassium Iodide\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Potassium Iodide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Potassium Iodide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Methyclothiazide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Methyclothiazide\nDetails: The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Methyclothiazide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Chlorothiazide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Chlorothiazide\nDetails: The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Chlorothiazide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Hydrochlorothiazide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Hydrochlorothiazide\nDetails: The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Hydrochlorothiazide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Chlorthalidone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Chlorthalidone\nDetails: The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Chlorthalidone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bendroflumethiazide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bendroflumethiazide\nDetails: The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bendroflumethiazide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Metolazone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Metolazone\nDetails: The risk or severity of adverse effects can be increased when Metolazone is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Metolazone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Hydroflumethiazide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Hydroflumethiazide\nDetails: The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Hydroflumethiazide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Indapamide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Indapamide\nDetails: The risk or severity of adverse effects can be increased when Indapamide is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Indapamide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Trichlormethiazide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Trichlormethiazide\nDetails: The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Trichlormethiazide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Polythiazide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Polythiazide\nDetails: The risk or severity of adverse effects can be increased when Polythiazide is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Polythiazide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Quinethazone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Quinethazone\nDetails: The risk or severity of adverse effects can be increased when Quinethazone is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Quinethazone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cyclopenthiazide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cyclopenthiazide\nDetails: The risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cyclopenthiazide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mesalazine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mesalazine\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Mesalazine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mesalazine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Balsalazide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Balsalazide\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Balsalazide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Balsalazide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Olsalazine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Olsalazine\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Olsalazine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Olsalazine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tolevamer", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tolevamer\nDetails: The risk or severity of adverse effects can be increased when Tolevamer is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tolevamer"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Sulpiride", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Sulpiride\nDetails: The risk or severity of adverse effects can be increased when Sulpiride is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Sulpiride"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Parathyroid hormone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Parathyroid hormone\nDetails: The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Parathyroid hormone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Chloroquine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Chloroquine\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Chloroquine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Chloroquine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Amodiaquine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Amodiaquine\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Amodiaquine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Amodiaquine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Primaquine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Primaquine\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Primaquine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Primaquine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Hydroxychloroquine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Hydroxychloroquine\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Hydroxychloroquine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Hydroxychloroquine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Calcium Gluceptate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Calcium Gluceptate\nDetails: Calcium Gluceptate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Calcium Gluceptate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Calcium glubionate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Calcium glubionate\nDetails: Calcium glubionate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Calcium glubionate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Calcium gluconate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Calcium gluconate\nDetails: Calcium gluconate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Calcium gluconate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Casein", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Casein\nDetails: Casein may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Casein"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Calcium Citrate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Calcium Citrate\nDetails: Calcium Citrate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Calcium Citrate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Calcium Phosphate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Calcium Phosphate\nDetails: Calcium Phosphate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Calcium Phosphate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Calcium lactate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Calcium lactate\nDetails: Calcium lactate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Calcium lactate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Calcium lactate gluconate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Calcium lactate gluconate\nDetails: Calcium lactate gluconate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Calcium lactate gluconate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Calcium pangamate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Calcium pangamate\nDetails: Calcium pangamate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Calcium pangamate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Calcium laevulate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Calcium laevulate\nDetails: Calcium laevulate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Calcium laevulate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Calcium Acetate", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Calcium Acetate\nDetails: Calcium Acetate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Calcium Acetate"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Calcium Chloride", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Calcium Chloride\nDetails: Calcium Chloride may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Calcium Chloride"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Doxercalciferol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Doxercalciferol\nDetails: Doxercalciferol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Doxercalciferol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Paricalcitol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Paricalcitol\nDetails: Paricalcitol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Paricalcitol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Calcidiol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Calcidiol\nDetails: Calcidiol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Calcidiol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ergocalciferol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ergocalciferol\nDetails: Ergocalciferol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ergocalciferol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Dihydrotachysterol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Dihydrotachysterol\nDetails: Dihydrotachysterol may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Dihydrotachysterol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Amphotericin B", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Amphotericin B\nDetails: The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Amphotericin B"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Diltiazem", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Diltiazem\nDetails: Diltiazem may increase the atrioventricular blocking (AV block) activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Diltiazem"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Verapamil", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Verapamil\nDetails: Verapamil may increase the atrioventricular blocking (AV block) activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Verapamil"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Clonidine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Clonidine\nDetails: Clonidine may increase the atrioventricular blocking (AV block) activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Clonidine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Edrophonium", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Edrophonium\nDetails: Edrophonium may increase the atrioventricular blocking (AV block) activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Edrophonium"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Kaolin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Kaolin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Kaolin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Kaolin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Midodrine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Midodrine\nDetails: Digoxin Immune Fab (Ovine) may increase the bradycardic activities of Midodrine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Midodrine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Colestipol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Colestipol\nDetails: Colestipol can cause a decrease in the absorption of Digoxin Immune Fab (Ovine) resulting in a reduced serum concentration and potentially a decrease in efficacy.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Colestipol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Colesevelam", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Colesevelam\nDetails: Colesevelam can cause a decrease in the absorption of Digoxin Immune Fab (Ovine) resulting in a reduced serum concentration and potentially a decrease in efficacy.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Colesevelam"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cholestyramine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cholestyramine\nDetails: Cholestyramine can cause a decrease in the absorption of Digoxin Immune Fab (Ovine) resulting in a reduced serum concentration and potentially a decrease in efficacy.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cholestyramine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Propafenone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Propafenone\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Propafenone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Propafenone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Reserpine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Reserpine\nDetails: The risk or severity of adverse effects can be increased when Reserpine is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Reserpine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Triamterene", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Triamterene\nDetails: The therapeutic efficacy of Digoxin Immune Fab (Ovine) can be decreased when used in combination with Triamterene.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Triamterene"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Amiloride", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Amiloride\nDetails: The therapeutic efficacy of Digoxin Immune Fab (Ovine) can be decreased when used in combination with Amiloride.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Amiloride"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Spironolactone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Spironolactone\nDetails: The therapeutic efficacy of Digoxin Immune Fab (Ovine) can be decreased when used in combination with Spironolactone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Spironolactone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Eplerenone", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Eplerenone\nDetails: The therapeutic efficacy of Digoxin Immune Fab (Ovine) can be decreased when used in combination with Eplerenone.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Eplerenone"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Amikacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Amikacin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Amikacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Amikacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tobramycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tobramycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Tobramycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tobramycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Gentamicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Gentamicin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Gentamicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Gentamicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Neomycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Neomycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Neomycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Neomycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Streptomycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Streptomycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Streptomycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Streptomycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Framycetin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Framycetin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Framycetin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Framycetin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Spectinomycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Spectinomycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Spectinomycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Spectinomycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Netilmicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Netilmicin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Netilmicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Netilmicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Kanamycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Kanamycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Kanamycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Kanamycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Paromomycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Paromomycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Paromomycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Paromomycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Metrizamide", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Metrizamide\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Metrizamide.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Metrizamide"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Ribostamycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Ribostamycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Ribostamycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Ribostamycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Geneticin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Geneticin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Geneticin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Geneticin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Apramycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Apramycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Apramycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Apramycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_GENTAMICIN C1A", "text": "Interaction: Digoxin Immune Fab (Ovine) AND GENTAMICIN C1A\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with GENTAMICIN C1A.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + GENTAMICIN C1A"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Neamine", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Neamine\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Neamine.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Neamine"}, {"id": "Digoxin Immune Fab (Ovine)_INT_SP1049C", "text": "Interaction: Digoxin Immune Fab (Ovine) AND SP1049C\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with SP1049C.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + SP1049C"}, {"id": "Digoxin Immune Fab (Ovine)_INT_INNO-206", "text": "Interaction: Digoxin Immune Fab (Ovine) AND INNO-206\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with INNO-206.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + INNO-206"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Arbekacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Arbekacin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Arbekacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Arbekacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Dihydrostreptomycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Dihydrostreptomycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Dihydrostreptomycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Dihydrostreptomycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Hygromycin B", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Hygromycin B\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Hygromycin B.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Hygromycin B"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Sabarubicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Sabarubicin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Sabarubicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Sabarubicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Sisomicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Sisomicin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Sisomicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Sisomicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Plazomicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Plazomicin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Plazomicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Plazomicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Zoptarelin doxorubicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Zoptarelin doxorubicin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Zoptarelin doxorubicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Zoptarelin doxorubicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_GPX-150", "text": "Interaction: Digoxin Immune Fab (Ovine) AND GPX-150\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with GPX-150.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + GPX-150"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Dibekacin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Dibekacin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Dibekacin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Dibekacin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Micronomicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Micronomicin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Micronomicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Micronomicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Isepamicin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Isepamicin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Isepamicin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Isepamicin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bekanamycin", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bekanamycin\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Bekanamycin.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bekanamycin"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Esmolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Esmolol\nDetails: Esmolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Esmolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Betaxolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Betaxolol\nDetails: Betaxolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Betaxolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Metoprolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Metoprolol\nDetails: Metoprolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Metoprolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Atenolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Atenolol\nDetails: Atenolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Atenolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Timolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Timolol\nDetails: Timolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Timolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Carteolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Carteolol\nDetails: Carteolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Carteolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Propranolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Propranolol\nDetails: Propranolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Propranolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Labetalol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Labetalol\nDetails: Labetalol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Labetalol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bisoprolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bisoprolol\nDetails: Bisoprolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bisoprolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Pindolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Pindolol\nDetails: Pindolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Pindolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Carvedilol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Carvedilol\nDetails: Carvedilol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Carvedilol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Acebutolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Acebutolol\nDetails: Acebutolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Acebutolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Nadolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Nadolol\nDetails: Nadolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Nadolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Levobunolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Levobunolol\nDetails: Levobunolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Levobunolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Metipranolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Metipranolol\nDetails: Metipranolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Metipranolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Sotalol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Sotalol\nDetails: Sotalol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Sotalol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Nebivolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Nebivolol\nDetails: Nebivolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Nebivolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Alprenolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Alprenolol\nDetails: Alprenolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Alprenolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bevantolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bevantolol\nDetails: Bevantolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bevantolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Practolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Practolol\nDetails: Practolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Practolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Penbutolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Penbutolol\nDetails: Penbutolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Penbutolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Oxprenolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Oxprenolol\nDetails: Oxprenolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Oxprenolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Platelet Activating Factor", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Platelet Activating Factor\nDetails: Platelet Activating Factor may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Platelet Activating Factor"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Celiprolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Celiprolol\nDetails: Celiprolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Celiprolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bufuralol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bufuralol\nDetails: Bufuralol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bufuralol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bopindolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bopindolol\nDetails: Bopindolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bopindolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bupranolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bupranolol\nDetails: Bupranolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bupranolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Indenolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Indenolol\nDetails: Indenolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Indenolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Befunolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Befunolol\nDetails: Befunolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Befunolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Arotinolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Arotinolol\nDetails: Arotinolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Arotinolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Talinolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Talinolol\nDetails: Talinolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Talinolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Landiolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Landiolol\nDetails: Landiolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Landiolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Bucindolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Bucindolol\nDetails: Bucindolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Bucindolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Cloranolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Cloranolol\nDetails: Cloranolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Cloranolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Mepindolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Mepindolol\nDetails: Mepindolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Mepindolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Epanolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Epanolol\nDetails: Epanolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Epanolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Tertatolol", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Tertatolol\nDetails: Tertatolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Tertatolol"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Telmisartan", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Telmisartan\nDetails: The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Telmisartan.\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Telmisartan"}, {"id": "Digoxin Immune Fab (Ovine)_INT_Licorice", "text": "Interaction: Digoxin Immune Fab (Ovine) AND Licorice\nDetails: The risk or severity of adverse effects can be increased when Licorice is combined with Digoxin Immune Fab (Ovine).\nRisk: Monitor closely.", "source": "Digoxin Immune Fab (Ovine) + Licorice"}, {"id": "Ibritumomab tiuxetan_GEN", "text": "Drug: Ibritumomab tiuxetan\nDescription: Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each...", "source": "Ibritumomab tiuxetan"}, {"id": "Ibritumomab tiuxetan_CLIN", "text": "Drug: Ibritumomab tiuxetan\nMechanism: The Fab segment of the antibody targets the CD20 epitope on B-cells, allowing the radioactive yttrium to destroy the cell via production of beta particles....\nToxicity: ...", "source": "Ibritumomab tiuxetan"}, {"id": "Ibritumomab tiuxetan_INT_Metamizole", "text": "Interaction: Ibritumomab tiuxetan AND Metamizole\nDetails: The risk or severity of myelosuppression can be increased when Metamizole is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Metamizole"}, {"id": "Ibritumomab tiuxetan_INT_Natalizumab", "text": "Interaction: Ibritumomab tiuxetan AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Natalizumab"}, {"id": "Ibritumomab tiuxetan_INT_Pimecrolimus", "text": "Interaction: Ibritumomab tiuxetan AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Pimecrolimus"}, {"id": "Ibritumomab tiuxetan_INT_Tofacitinib", "text": "Interaction: Ibritumomab tiuxetan AND Tofacitinib\nDetails: Ibritumomab tiuxetan may increase the immunosuppressive activities of Tofacitinib.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Tofacitinib"}, {"id": "Ibritumomab tiuxetan_INT_Tacrolimus", "text": "Interaction: Ibritumomab tiuxetan AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Tacrolimus"}, {"id": "Ibritumomab tiuxetan_INT_Clozapine", "text": "Interaction: Ibritumomab tiuxetan AND Clozapine\nDetails: The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Clozapine.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Clozapine"}, {"id": "Ibritumomab tiuxetan_INT_BCG vaccine", "text": "Interaction: Ibritumomab tiuxetan AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + BCG vaccine"}, {"id": "Ibritumomab tiuxetan_INT_Leflunomide", "text": "Interaction: Ibritumomab tiuxetan AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Leflunomide"}, {"id": "Ibritumomab tiuxetan_INT_Fingolimod", "text": "Interaction: Ibritumomab tiuxetan AND Fingolimod\nDetails: Ibritumomab tiuxetan may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Fingolimod"}, {"id": "Ibritumomab tiuxetan_INT_Roflumilast", "text": "Interaction: Ibritumomab tiuxetan AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Roflumilast"}, {"id": "Ibritumomab tiuxetan_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Ibritumomab tiuxetan AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Ibritumomab tiuxetan_INT_Yellow fever vaccine", "text": "Interaction: Ibritumomab tiuxetan AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Yellow fever vaccine"}, {"id": "Ibritumomab tiuxetan_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Ibritumomab tiuxetan AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Ibritumomab tiuxetan_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Ibritumomab tiuxetan AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Ibritumomab tiuxetan_INT_Rotavirus Vaccine", "text": "Interaction: Ibritumomab tiuxetan AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Rotavirus Vaccine"}, {"id": "Ibritumomab tiuxetan_INT_G17DT", "text": "Interaction: Ibritumomab tiuxetan AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + G17DT"}, {"id": "Ibritumomab tiuxetan_INT_INGN 201", "text": "Interaction: Ibritumomab tiuxetan AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + INGN 201"}, {"id": "Ibritumomab tiuxetan_INT_INGN 225", "text": "Interaction: Ibritumomab tiuxetan AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + INGN 225"}, {"id": "Ibritumomab tiuxetan_INT_Rindopepimut", "text": "Interaction: Ibritumomab tiuxetan AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Rindopepimut"}, {"id": "Ibritumomab tiuxetan_INT_SRP 299", "text": "Interaction: Ibritumomab tiuxetan AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + SRP 299"}, {"id": "Ibritumomab tiuxetan_INT_GI-5005", "text": "Interaction: Ibritumomab tiuxetan AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + GI-5005"}, {"id": "Ibritumomab tiuxetan_INT_TG4010", "text": "Interaction: Ibritumomab tiuxetan AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + TG4010"}, {"id": "Ibritumomab tiuxetan_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Ibritumomab tiuxetan AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Rabies virus inactivated antigen, A"}, {"id": "Ibritumomab tiuxetan_INT_Tecemotide", "text": "Interaction: Ibritumomab tiuxetan AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Tecemotide"}, {"id": "Ibritumomab tiuxetan_INT_Rubella virus vaccine", "text": "Interaction: Ibritumomab tiuxetan AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Rubella virus vaccine"}, {"id": "Ibritumomab tiuxetan_INT_Hepatitis A Vaccine", "text": "Interaction: Ibritumomab tiuxetan AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Hepatitis A Vaccine"}, {"id": "Ibritumomab tiuxetan_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Ibritumomab tiuxetan AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Salmonella typhi ty21a live antigen"}, {"id": "Ibritumomab tiuxetan_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Ibritumomab tiuxetan AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Hepatitis B Vaccine (Recombinant)"}, {"id": "Ibritumomab tiuxetan_INT_Denosumab", "text": "Interaction: Ibritumomab tiuxetan AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Denosumab"}, {"id": "Ibritumomab tiuxetan_INT_Sipuleucel-T", "text": "Interaction: Ibritumomab tiuxetan AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Sipuleucel-T"}, {"id": "Ibritumomab tiuxetan_INT_Trastuzumab", "text": "Interaction: Ibritumomab tiuxetan AND Trastuzumab\nDetails: Trastuzumab may increase the neutropenic activities of Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Trastuzumab"}, {"id": "Ibritumomab tiuxetan_INT_Lepirudin", "text": "Interaction: Ibritumomab tiuxetan AND Lepirudin\nDetails: The risk or severity of adverse effects can be increased when Lepirudin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Lepirudin"}, {"id": "Ibritumomab tiuxetan_INT_Bivalirudin", "text": "Interaction: Ibritumomab tiuxetan AND Bivalirudin\nDetails: The risk or severity of adverse effects can be increased when Bivalirudin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Bivalirudin"}, {"id": "Ibritumomab tiuxetan_INT_Abciximab", "text": "Interaction: Ibritumomab tiuxetan AND Abciximab\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Abciximab"}, {"id": "Ibritumomab tiuxetan_INT_Becaplermin", "text": "Interaction: Ibritumomab tiuxetan AND Becaplermin\nDetails: The risk or severity of adverse effects can be increased when Becaplermin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Becaplermin"}, {"id": "Ibritumomab tiuxetan_INT_Dicoumarol", "text": "Interaction: Ibritumomab tiuxetan AND Dicoumarol\nDetails: The risk or severity of adverse effects can be increased when Dicoumarol is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Dicoumarol"}, {"id": "Ibritumomab tiuxetan_INT_Argatroban", "text": "Interaction: Ibritumomab tiuxetan AND Argatroban\nDetails: The risk or severity of adverse effects can be increased when Argatroban is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Argatroban"}, {"id": "Ibritumomab tiuxetan_INT_Ardeparin", "text": "Interaction: Ibritumomab tiuxetan AND Ardeparin\nDetails: The risk or severity of adverse effects can be increased when Ardeparin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Ardeparin"}, {"id": "Ibritumomab tiuxetan_INT_Phenindione", "text": "Interaction: Ibritumomab tiuxetan AND Phenindione\nDetails: The risk or severity of adverse effects can be increased when Phenindione is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Phenindione"}, {"id": "Ibritumomab tiuxetan_INT_Fondaparinux sodium", "text": "Interaction: Ibritumomab tiuxetan AND Fondaparinux sodium\nDetails: The risk or severity of adverse effects can be increased when Fondaparinux sodium is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Fondaparinux sodium"}, {"id": "Ibritumomab tiuxetan_INT_Warfarin", "text": "Interaction: Ibritumomab tiuxetan AND Warfarin\nDetails: The risk or severity of adverse effects can be increased when Warfarin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Warfarin"}, {"id": "Ibritumomab tiuxetan_INT_Pentosan Polysulfate", "text": "Interaction: Ibritumomab tiuxetan AND Pentosan Polysulfate\nDetails: The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Pentosan Polysulfate"}, {"id": "Ibritumomab tiuxetan_INT_Phenprocoumon", "text": "Interaction: Ibritumomab tiuxetan AND Phenprocoumon\nDetails: The risk or severity of adverse effects can be increased when Phenprocoumon is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Phenprocoumon"}, {"id": "Ibritumomab tiuxetan_INT_Edetic Acid", "text": "Interaction: Ibritumomab tiuxetan AND Edetic Acid\nDetails: The risk or severity of adverse effects can be increased when Edetic Acid is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Edetic Acid"}, {"id": "Ibritumomab tiuxetan_INT_Heparin", "text": "Interaction: Ibritumomab tiuxetan AND Heparin\nDetails: The risk or severity of adverse effects can be increased when Heparin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Heparin"}, {"id": "Ibritumomab tiuxetan_INT_Enoxaparin", "text": "Interaction: Ibritumomab tiuxetan AND Enoxaparin\nDetails: The risk or severity of adverse effects can be increased when Enoxaparin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Enoxaparin"}, {"id": "Ibritumomab tiuxetan_INT_Acenocoumarol", "text": "Interaction: Ibritumomab tiuxetan AND Acenocoumarol\nDetails: The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Acenocoumarol"}, {"id": "Ibritumomab tiuxetan_INT_Citric Acid", "text": "Interaction: Ibritumomab tiuxetan AND Citric Acid\nDetails: The risk or severity of adverse effects can be increased when Citric Acid is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Citric Acid"}, {"id": "Ibritumomab tiuxetan_INT_Ximelagatran", "text": "Interaction: Ibritumomab tiuxetan AND Ximelagatran\nDetails: The risk or severity of adverse effects can be increased when Ximelagatran is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Ximelagatran"}, {"id": "Ibritumomab tiuxetan_INT_Ancrod", "text": "Interaction: Ibritumomab tiuxetan AND Ancrod\nDetails: The risk or severity of adverse effects can be increased when Ancrod is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Ancrod"}, {"id": "Ibritumomab tiuxetan_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Ibritumomab tiuxetan AND Pentaerythritol Tetranitrate\nDetails: The risk or severity of adverse effects can be increased when Pentaerythritol Tetranitrate is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Pentaerythritol Tetranitrate"}, {"id": "Ibritumomab tiuxetan_INT_Rivaroxaban", "text": "Interaction: Ibritumomab tiuxetan AND Rivaroxaban\nDetails: The risk or severity of adverse effects can be increased when Rivaroxaban is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Rivaroxaban"}, {"id": "Ibritumomab tiuxetan_INT_Sulodexide", "text": "Interaction: Ibritumomab tiuxetan AND Sulodexide\nDetails: The risk or severity of adverse effects can be increased when Sulodexide is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Sulodexide"}, {"id": "Ibritumomab tiuxetan_INT_Idraparinux", "text": "Interaction: Ibritumomab tiuxetan AND Idraparinux\nDetails: The risk or severity of adverse effects can be increased when Idraparinux is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Idraparinux"}, {"id": "Ibritumomab tiuxetan_INT_Apixaban", "text": "Interaction: Ibritumomab tiuxetan AND Apixaban\nDetails: The risk or severity of adverse effects can be increased when Apixaban is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Apixaban"}, {"id": "Ibritumomab tiuxetan_INT_Otamixaban", "text": "Interaction: Ibritumomab tiuxetan AND Otamixaban\nDetails: The risk or severity of adverse effects can be increased when Otamixaban is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Otamixaban"}, {"id": "Ibritumomab tiuxetan_INT_Dabigatran etexilate", "text": "Interaction: Ibritumomab tiuxetan AND Dabigatran etexilate\nDetails: The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Dabigatran etexilate"}, {"id": "Ibritumomab tiuxetan_INT_Danaparoid", "text": "Interaction: Ibritumomab tiuxetan AND Danaparoid\nDetails: The risk or severity of adverse effects can be increased when Danaparoid is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Danaparoid"}, {"id": "Ibritumomab tiuxetan_INT_Dalteparin", "text": "Interaction: Ibritumomab tiuxetan AND Dalteparin\nDetails: The risk or severity of adverse effects can be increased when Dalteparin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Dalteparin"}, {"id": "Ibritumomab tiuxetan_INT_Ferulic acid", "text": "Interaction: Ibritumomab tiuxetan AND Ferulic acid\nDetails: The risk or severity of adverse effects can be increased when Ferulic acid is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Ferulic acid"}, {"id": "Ibritumomab tiuxetan_INT_Ethyl biscoumacetate", "text": "Interaction: Ibritumomab tiuxetan AND Ethyl biscoumacetate\nDetails: The risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Ethyl biscoumacetate"}, {"id": "Ibritumomab tiuxetan_INT_Nadroparin", "text": "Interaction: Ibritumomab tiuxetan AND Nadroparin\nDetails: The risk or severity of adverse effects can be increased when Nadroparin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Nadroparin"}, {"id": "Ibritumomab tiuxetan_INT_Edoxaban", "text": "Interaction: Ibritumomab tiuxetan AND Edoxaban\nDetails: The risk or severity of adverse effects can be increased when Edoxaban is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Edoxaban"}, {"id": "Ibritumomab tiuxetan_INT_Dextran", "text": "Interaction: Ibritumomab tiuxetan AND Dextran\nDetails: The risk or severity of adverse effects can be increased when Dextran is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Dextran"}, {"id": "Ibritumomab tiuxetan_INT_Reviparin", "text": "Interaction: Ibritumomab tiuxetan AND Reviparin\nDetails: The risk or severity of adverse effects can be increased when Reviparin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Reviparin"}, {"id": "Ibritumomab tiuxetan_INT_Certoparin", "text": "Interaction: Ibritumomab tiuxetan AND Certoparin\nDetails: The risk or severity of adverse effects can be increased when Certoparin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Certoparin"}, {"id": "Ibritumomab tiuxetan_INT_Dextran 70", "text": "Interaction: Ibritumomab tiuxetan AND Dextran 70\nDetails: The risk or severity of adverse effects can be increased when Dextran 70 is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Dextran 70"}, {"id": "Ibritumomab tiuxetan_INT_Desirudin", "text": "Interaction: Ibritumomab tiuxetan AND Desirudin\nDetails: The risk or severity of adverse effects can be increased when Desirudin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Desirudin"}, {"id": "Ibritumomab tiuxetan_INT_Dextran 40", "text": "Interaction: Ibritumomab tiuxetan AND Dextran 40\nDetails: The risk or severity of adverse effects can be increased when Dextran 40 is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Dextran 40"}, {"id": "Ibritumomab tiuxetan_INT_Dextran 75", "text": "Interaction: Ibritumomab tiuxetan AND Dextran 75\nDetails: The risk or severity of adverse effects can be increased when Dextran 75 is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Dextran 75"}, {"id": "Ibritumomab tiuxetan_INT_Protocatechualdehyde", "text": "Interaction: Ibritumomab tiuxetan AND Protocatechualdehyde\nDetails: The risk or severity of adverse effects can be increased when Protocatechualdehyde is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Protocatechualdehyde"}, {"id": "Ibritumomab tiuxetan_INT_Protein C", "text": "Interaction: Ibritumomab tiuxetan AND Protein C\nDetails: The risk or severity of adverse effects can be increased when Protein C is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Protein C"}, {"id": "Ibritumomab tiuxetan_INT_Antithrombin III human", "text": "Interaction: Ibritumomab tiuxetan AND Antithrombin III human\nDetails: The risk or severity of adverse effects can be increased when Antithrombin III human is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Antithrombin III human"}, {"id": "Ibritumomab tiuxetan_INT_Fondaparinux", "text": "Interaction: Ibritumomab tiuxetan AND Fondaparinux\nDetails: The risk or severity of adverse effects can be increased when Fondaparinux is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Fondaparinux"}, {"id": "Ibritumomab tiuxetan_INT_Letaxaban", "text": "Interaction: Ibritumomab tiuxetan AND Letaxaban\nDetails: The risk or severity of adverse effects can be increased when Letaxaban is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Letaxaban"}, {"id": "Ibritumomab tiuxetan_INT_Darexaban", "text": "Interaction: Ibritumomab tiuxetan AND Darexaban\nDetails: The risk or severity of adverse effects can be increased when Darexaban is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Darexaban"}, {"id": "Ibritumomab tiuxetan_INT_Nafamostat", "text": "Interaction: Ibritumomab tiuxetan AND Nafamostat\nDetails: The risk or severity of adverse effects can be increased when Nafamostat is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Nafamostat"}, {"id": "Ibritumomab tiuxetan_INT_Gabexate", "text": "Interaction: Ibritumomab tiuxetan AND Gabexate\nDetails: The risk or severity of adverse effects can be increased when Gabexate is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Gabexate"}, {"id": "Ibritumomab tiuxetan_INT_Troxerutin", "text": "Interaction: Ibritumomab tiuxetan AND Troxerutin\nDetails: The risk or severity of adverse effects can be increased when Troxerutin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Troxerutin"}, {"id": "Ibritumomab tiuxetan_INT_Fluindione", "text": "Interaction: Ibritumomab tiuxetan AND Fluindione\nDetails: The risk or severity of adverse effects can be increased when Fluindione is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Fluindione"}, {"id": "Ibritumomab tiuxetan_INT_Protein S human", "text": "Interaction: Ibritumomab tiuxetan AND Protein S human\nDetails: The risk or severity of adverse effects can be increased when Protein S human is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Protein S human"}, {"id": "Ibritumomab tiuxetan_INT_Melagatran", "text": "Interaction: Ibritumomab tiuxetan AND Melagatran\nDetails: The risk or severity of adverse effects can be increased when Melagatran is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Melagatran"}, {"id": "Ibritumomab tiuxetan_INT_Eptifibatide", "text": "Interaction: Ibritumomab tiuxetan AND Eptifibatide\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Eptifibatide"}, {"id": "Ibritumomab tiuxetan_INT_Ticlopidine", "text": "Interaction: Ibritumomab tiuxetan AND Ticlopidine\nDetails: The risk or severity of adverse effects can be increased when Ticlopidine is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Ticlopidine"}, {"id": "Ibritumomab tiuxetan_INT_Tirofiban", "text": "Interaction: Ibritumomab tiuxetan AND Tirofiban\nDetails: The risk or severity of adverse effects can be increased when Tirofiban is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Tirofiban"}, {"id": "Ibritumomab tiuxetan_INT_Dipyridamole", "text": "Interaction: Ibritumomab tiuxetan AND Dipyridamole\nDetails: The risk or severity of adverse effects can be increased when Dipyridamole is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Dipyridamole"}, {"id": "Ibritumomab tiuxetan_INT_Clopidogrel", "text": "Interaction: Ibritumomab tiuxetan AND Clopidogrel\nDetails: The risk or severity of adverse effects can be increased when Clopidogrel is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Clopidogrel"}, {"id": "Ibritumomab tiuxetan_INT_Acetylsalicylic acid", "text": "Interaction: Ibritumomab tiuxetan AND Acetylsalicylic acid\nDetails: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Acetylsalicylic acid"}, {"id": "Ibritumomab tiuxetan_INT_Prasugrel", "text": "Interaction: Ibritumomab tiuxetan AND Prasugrel\nDetails: The risk or severity of adverse effects can be increased when Prasugrel is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Prasugrel"}, {"id": "Ibritumomab tiuxetan_INT_Vorapaxar", "text": "Interaction: Ibritumomab tiuxetan AND Vorapaxar\nDetails: The risk or severity of adverse effects can be increased when Vorapaxar is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Vorapaxar"}, {"id": "Ibritumomab tiuxetan_INT_Milrinone", "text": "Interaction: Ibritumomab tiuxetan AND Milrinone\nDetails: The risk or severity of adverse effects can be increased when Milrinone is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Milrinone"}, {"id": "Ibritumomab tiuxetan_INT_Anagrelide", "text": "Interaction: Ibritumomab tiuxetan AND Anagrelide\nDetails: The risk or severity of adverse effects can be increased when Anagrelide is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Anagrelide"}, {"id": "Ibritumomab tiuxetan_INT_Epinastine", "text": "Interaction: Ibritumomab tiuxetan AND Epinastine\nDetails: The risk or severity of adverse effects can be increased when Epinastine is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Epinastine"}, {"id": "Ibritumomab tiuxetan_INT_Alprostadil", "text": "Interaction: Ibritumomab tiuxetan AND Alprostadil\nDetails: The risk or severity of adverse effects can be increased when Alprostadil is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Alprostadil"}, {"id": "Ibritumomab tiuxetan_INT_Pentoxifylline", "text": "Interaction: Ibritumomab tiuxetan AND Pentoxifylline\nDetails: The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Pentoxifylline"}, {"id": "Ibritumomab tiuxetan_INT_Azelastine", "text": "Interaction: Ibritumomab tiuxetan AND Azelastine\nDetails: The risk or severity of adverse effects can be increased when Azelastine is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Azelastine"}, {"id": "Ibritumomab tiuxetan_INT_Iloprost", "text": "Interaction: Ibritumomab tiuxetan AND Iloprost\nDetails: The risk or severity of adverse effects can be increased when Iloprost is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Iloprost"}, {"id": "Ibritumomab tiuxetan_INT_Cilostazol", "text": "Interaction: Ibritumomab tiuxetan AND Cilostazol\nDetails: The risk or severity of adverse effects can be increased when Cilostazol is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Cilostazol"}, {"id": "Ibritumomab tiuxetan_INT_Ridogrel", "text": "Interaction: Ibritumomab tiuxetan AND Ridogrel\nDetails: The risk or severity of adverse effects can be increased when Ridogrel is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Ridogrel"}, {"id": "Ibritumomab tiuxetan_INT_Sevoflurane", "text": "Interaction: Ibritumomab tiuxetan AND Sevoflurane\nDetails: The risk or severity of adverse effects can be increased when Sevoflurane is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Sevoflurane"}, {"id": "Ibritumomab tiuxetan_INT_Epoprostenol", "text": "Interaction: Ibritumomab tiuxetan AND Epoprostenol\nDetails: The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Epoprostenol"}, {"id": "Ibritumomab tiuxetan_INT_Resveratrol", "text": "Interaction: Ibritumomab tiuxetan AND Resveratrol\nDetails: The risk or severity of adverse effects can be increased when Resveratrol is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Resveratrol"}, {"id": "Ibritumomab tiuxetan_INT_Nimesulide", "text": "Interaction: Ibritumomab tiuxetan AND Nimesulide\nDetails: The risk or severity of adverse effects can be increased when Nimesulide is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Nimesulide"}, {"id": "Ibritumomab tiuxetan_INT_Tesmilifene", "text": "Interaction: Ibritumomab tiuxetan AND Tesmilifene\nDetails: The risk or severity of adverse effects can be increased when Tesmilifene is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Tesmilifene"}, {"id": "Ibritumomab tiuxetan_INT_Defibrotide", "text": "Interaction: Ibritumomab tiuxetan AND Defibrotide\nDetails: The risk or severity of adverse effects can be increased when Defibrotide is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Defibrotide"}, {"id": "Ibritumomab tiuxetan_INT_SRT501", "text": "Interaction: Ibritumomab tiuxetan AND SRT501\nDetails: The risk or severity of adverse effects can be increased when SRT501 is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + SRT501"}, {"id": "Ibritumomab tiuxetan_INT_Beraprost", "text": "Interaction: Ibritumomab tiuxetan AND Beraprost\nDetails: The risk or severity of adverse effects can be increased when Beraprost is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Beraprost"}, {"id": "Ibritumomab tiuxetan_INT_Ibudilast", "text": "Interaction: Ibritumomab tiuxetan AND Ibudilast\nDetails: The risk or severity of adverse effects can be increased when Ibudilast is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Ibudilast"}, {"id": "Ibritumomab tiuxetan_INT_Andrographolide", "text": "Interaction: Ibritumomab tiuxetan AND Andrographolide\nDetails: The risk or severity of adverse effects can be increased when Andrographolide is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Andrographolide"}, {"id": "Ibritumomab tiuxetan_INT_eplivanserine", "text": "Interaction: Ibritumomab tiuxetan AND eplivanserine\nDetails: The risk or severity of adverse effects can be increased when eplivanserine is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + eplivanserine"}, {"id": "Ibritumomab tiuxetan_INT_Cangrelor", "text": "Interaction: Ibritumomab tiuxetan AND Cangrelor\nDetails: The risk or severity of adverse effects can be increased when Cangrelor is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Cangrelor"}, {"id": "Ibritumomab tiuxetan_INT_Tranilast", "text": "Interaction: Ibritumomab tiuxetan AND Tranilast\nDetails: The risk or severity of adverse effects can be increased when Tranilast is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Tranilast"}, {"id": "Ibritumomab tiuxetan_INT_Triflusal", "text": "Interaction: Ibritumomab tiuxetan AND Triflusal\nDetails: The risk or severity of adverse effects can be increased when Triflusal is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Triflusal"}, {"id": "Ibritumomab tiuxetan_INT_Icosapent ethyl", "text": "Interaction: Ibritumomab tiuxetan AND Icosapent ethyl\nDetails: The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Icosapent ethyl"}, {"id": "Ibritumomab tiuxetan_INT_Ifenprodil", "text": "Interaction: Ibritumomab tiuxetan AND Ifenprodil\nDetails: The risk or severity of adverse effects can be increased when Ifenprodil is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Ifenprodil"}, {"id": "Ibritumomab tiuxetan_INT_Trapidil", "text": "Interaction: Ibritumomab tiuxetan AND Trapidil\nDetails: The risk or severity of adverse effects can be increased when Trapidil is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Trapidil"}, {"id": "Ibritumomab tiuxetan_INT_Naftopidil", "text": "Interaction: Ibritumomab tiuxetan AND Naftopidil\nDetails: The risk or severity of adverse effects can be increased when Naftopidil is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Naftopidil"}, {"id": "Ibritumomab tiuxetan_INT_Sarpogrelate", "text": "Interaction: Ibritumomab tiuxetan AND Sarpogrelate\nDetails: The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Sarpogrelate"}, {"id": "Ibritumomab tiuxetan_INT_Eplivanserin", "text": "Interaction: Ibritumomab tiuxetan AND Eplivanserin\nDetails: The risk or severity of adverse effects can be increased when Eplivanserin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Eplivanserin"}, {"id": "Ibritumomab tiuxetan_INT_Ifetroban", "text": "Interaction: Ibritumomab tiuxetan AND Ifetroban\nDetails: The risk or severity of adverse effects can be increased when Ifetroban is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Ifetroban"}, {"id": "Ibritumomab tiuxetan_INT_Nitroaspirin", "text": "Interaction: Ibritumomab tiuxetan AND Nitroaspirin\nDetails: The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Nitroaspirin"}, {"id": "Ibritumomab tiuxetan_INT_Ketanserin", "text": "Interaction: Ibritumomab tiuxetan AND Ketanserin\nDetails: The risk or severity of adverse effects can be increased when Ketanserin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Ketanserin"}, {"id": "Ibritumomab tiuxetan_INT_Indobufen", "text": "Interaction: Ibritumomab tiuxetan AND Indobufen\nDetails: The risk or severity of adverse effects can be increased when Indobufen is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Indobufen"}, {"id": "Ibritumomab tiuxetan_INT_Butylphthalide", "text": "Interaction: Ibritumomab tiuxetan AND Butylphthalide\nDetails: The risk or severity of adverse effects can be increased when Butylphthalide is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Butylphthalide"}, {"id": "Ibritumomab tiuxetan_INT_Hydroxytyrosol", "text": "Interaction: Ibritumomab tiuxetan AND Hydroxytyrosol\nDetails: The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Hydroxytyrosol"}, {"id": "Ibritumomab tiuxetan_INT_Ramatroban", "text": "Interaction: Ibritumomab tiuxetan AND Ramatroban\nDetails: The risk or severity of adverse effects can be increased when Ramatroban is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Ramatroban"}, {"id": "Ibritumomab tiuxetan_INT_Picotamide", "text": "Interaction: Ibritumomab tiuxetan AND Picotamide\nDetails: The risk or severity of adverse effects can be increased when Picotamide is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Picotamide"}, {"id": "Ibritumomab tiuxetan_INT_Cloricromen", "text": "Interaction: Ibritumomab tiuxetan AND Cloricromen\nDetails: The risk or severity of adverse effects can be increased when Cloricromen is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Cloricromen"}, {"id": "Ibritumomab tiuxetan_INT_Linsidomine", "text": "Interaction: Ibritumomab tiuxetan AND Linsidomine\nDetails: The risk or severity of adverse effects can be increased when Linsidomine is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Linsidomine"}, {"id": "Ibritumomab tiuxetan_INT_Buflomedil", "text": "Interaction: Ibritumomab tiuxetan AND Buflomedil\nDetails: The risk or severity of adverse effects can be increased when Buflomedil is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Buflomedil"}, {"id": "Ibritumomab tiuxetan_INT_Relcovaptan", "text": "Interaction: Ibritumomab tiuxetan AND Relcovaptan\nDetails: The risk or severity of adverse effects can be increased when Relcovaptan is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Relcovaptan"}, {"id": "Ibritumomab tiuxetan_INT_Ticagrelor", "text": "Interaction: Ibritumomab tiuxetan AND Ticagrelor\nDetails: The risk or severity of adverse effects can be increased when Ticagrelor is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Ibritumomab tiuxetan + Ticagrelor"}, {"id": "Daptomycin_GEN", "text": "Drug: Daptomycin\nDescription: Daptomycin is a lipopeptide antibiotic that kills susceptible gram positive bacteria by disrupting their membrane potential. It is a naturally-occurring compound found in the soil bacterium <i>Streptomyces roseosporus</i>. Antibiotics are used in the treatment of infections caused by bacteria. They ...", "source": "Daptomycin"}, {"id": "Daptomycin_CLIN", "text": "Drug: Daptomycin\nMechanism: Daptomycin appears to bind or insert into the outer membrane of gram positive bacteria. The binding and integration of daptomycin into the cell membrane is calcium dependent. Calcium ions cause a conf...\nToxicity: ...", "source": "Daptomycin"}, {"id": "Daptomycin_INT_BCG vaccine", "text": "Interaction: Daptomycin AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Daptomycin.\nRisk: Monitor closely.", "source": "Daptomycin + BCG vaccine"}, {"id": "Daptomycin_INT_Picosulfuric acid", "text": "Interaction: Daptomycin AND Picosulfuric acid\nDetails: The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Daptomycin.\nRisk: Monitor closely.", "source": "Daptomycin + Picosulfuric acid"}, {"id": "Daptomycin_INT_Pravastatin", "text": "Interaction: Daptomycin AND Pravastatin\nDetails: The risk or severity of adverse effects can be increased when Pravastatin is combined with Daptomycin.\nRisk: Monitor closely.", "source": "Daptomycin + Pravastatin"}, {"id": "Daptomycin_INT_Lovastatin", "text": "Interaction: Daptomycin AND Lovastatin\nDetails: The risk or severity of adverse effects can be increased when Lovastatin is combined with Daptomycin.\nRisk: Monitor closely.", "source": "Daptomycin + Lovastatin"}, {"id": "Daptomycin_INT_Cerivastatin", "text": "Interaction: Daptomycin AND Cerivastatin\nDetails: The risk or severity of adverse effects can be increased when Cerivastatin is combined with Daptomycin.\nRisk: Monitor closely.", "source": "Daptomycin + Cerivastatin"}, {"id": "Daptomycin_INT_Simvastatin", "text": "Interaction: Daptomycin AND Simvastatin\nDetails: The risk or severity of adverse effects can be increased when Simvastatin is combined with Daptomycin.\nRisk: Monitor closely.", "source": "Daptomycin + Simvastatin"}, {"id": "Daptomycin_INT_Atorvastatin", "text": "Interaction: Daptomycin AND Atorvastatin\nDetails: The risk or severity of adverse effects can be increased when Atorvastatin is combined with Daptomycin.\nRisk: Monitor closely.", "source": "Daptomycin + Atorvastatin"}, {"id": "Daptomycin_INT_Fluvastatin", "text": "Interaction: Daptomycin AND Fluvastatin\nDetails: The risk or severity of adverse effects can be increased when Fluvastatin is combined with Daptomycin.\nRisk: Monitor closely.", "source": "Daptomycin + Fluvastatin"}, {"id": "Daptomycin_INT_Rosuvastatin", "text": "Interaction: Daptomycin AND Rosuvastatin\nDetails: The risk or severity of adverse effects can be increased when Rosuvastatin is combined with Daptomycin.\nRisk: Monitor closely.", "source": "Daptomycin + Rosuvastatin"}, {"id": "Daptomycin_INT_Pitavastatin", "text": "Interaction: Daptomycin AND Pitavastatin\nDetails: The risk or severity of adverse effects can be increased when Pitavastatin is combined with Daptomycin.\nRisk: Monitor closely.", "source": "Daptomycin + Pitavastatin"}, {"id": "Daptomycin_INT_Mevastatin", "text": "Interaction: Daptomycin AND Mevastatin\nDetails: The risk or severity of adverse effects can be increased when Mevastatin is combined with Daptomycin.\nRisk: Monitor closely.", "source": "Daptomycin + Mevastatin"}, {"id": "Daptomycin_INT_Ubidecarenone", "text": "Interaction: Daptomycin AND Ubidecarenone\nDetails: The risk or severity of adverse effects can be increased when Ubidecarenone is combined with Daptomycin.\nRisk: Monitor closely.", "source": "Daptomycin + Ubidecarenone"}, {"id": "Tositumomab_GEN", "text": "Drug: Tositumomab\nDescription: Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine)....", "source": "Tositumomab"}, {"id": "Tositumomab_CLIN", "text": "Drug: Tositumomab\nMechanism: Binds to the CD20 antigen which is found on mature B lymphocytes. The antibody binding appears to induce apoptosis, complement-dependent cytotoxicity and cell death through ionizing radiation....\nToxicity: ...", "source": "Tositumomab"}, {"id": "Tositumomab_INT_Metamizole", "text": "Interaction: Tositumomab AND Metamizole\nDetails: The risk or severity of myelosuppression can be increased when Metamizole is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Metamizole"}, {"id": "Tositumomab_INT_Natalizumab", "text": "Interaction: Tositumomab AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Tositumomab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Tositumomab + Natalizumab"}, {"id": "Tositumomab_INT_Pimecrolimus", "text": "Interaction: Tositumomab AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Pimecrolimus"}, {"id": "Tositumomab_INT_Tofacitinib", "text": "Interaction: Tositumomab AND Tofacitinib\nDetails: Tositumomab may increase the immunosuppressive activities of Tofacitinib.\nRisk: Monitor closely.", "source": "Tositumomab + Tofacitinib"}, {"id": "Tositumomab_INT_Tacrolimus", "text": "Interaction: Tositumomab AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Tacrolimus"}, {"id": "Tositumomab_INT_Clozapine", "text": "Interaction: Tositumomab AND Clozapine\nDetails: The risk or severity of adverse effects can be increased when Tositumomab is combined with Clozapine.\nRisk: Monitor closely.", "source": "Tositumomab + Clozapine"}, {"id": "Tositumomab_INT_Metamizole", "text": "Interaction: Tositumomab AND Metamizole\nDetails: The risk or severity of adverse effects can be increased when Metamizole is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Metamizole"}, {"id": "Tositumomab_INT_BCG vaccine", "text": "Interaction: Tositumomab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + BCG vaccine"}, {"id": "Tositumomab_INT_Trastuzumab", "text": "Interaction: Tositumomab AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Trastuzumab"}, {"id": "Tositumomab_INT_Leflunomide", "text": "Interaction: Tositumomab AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Tositumomab is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Tositumomab + Leflunomide"}, {"id": "Tositumomab_INT_Fingolimod", "text": "Interaction: Tositumomab AND Fingolimod\nDetails: Tositumomab may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Tositumomab + Fingolimod"}, {"id": "Tositumomab_INT_Roflumilast", "text": "Interaction: Tositumomab AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Roflumilast"}, {"id": "Tositumomab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Tositumomab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Tositumomab_INT_Yellow fever vaccine", "text": "Interaction: Tositumomab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Yellow fever vaccine"}, {"id": "Tositumomab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Tositumomab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Tositumomab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Tositumomab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Tositumomab_INT_Rotavirus Vaccine", "text": "Interaction: Tositumomab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Rotavirus Vaccine"}, {"id": "Tositumomab_INT_G17DT", "text": "Interaction: Tositumomab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + G17DT"}, {"id": "Tositumomab_INT_INGN 201", "text": "Interaction: Tositumomab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + INGN 201"}, {"id": "Tositumomab_INT_INGN 225", "text": "Interaction: Tositumomab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + INGN 225"}, {"id": "Tositumomab_INT_Rindopepimut", "text": "Interaction: Tositumomab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Rindopepimut"}, {"id": "Tositumomab_INT_SRP 299", "text": "Interaction: Tositumomab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + SRP 299"}, {"id": "Tositumomab_INT_GI-5005", "text": "Interaction: Tositumomab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + GI-5005"}, {"id": "Tositumomab_INT_TG4010", "text": "Interaction: Tositumomab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + TG4010"}, {"id": "Tositumomab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Tositumomab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Rabies virus inactivated antigen, A"}, {"id": "Tositumomab_INT_Tecemotide", "text": "Interaction: Tositumomab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Tecemotide"}, {"id": "Tositumomab_INT_Rubella virus vaccine", "text": "Interaction: Tositumomab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Rubella virus vaccine"}, {"id": "Tositumomab_INT_Hepatitis A Vaccine", "text": "Interaction: Tositumomab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Hepatitis A Vaccine"}, {"id": "Tositumomab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Tositumomab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Salmonella typhi ty21a live antigen"}, {"id": "Tositumomab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Tositumomab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Tositumomab_INT_Paclitaxel", "text": "Interaction: Tositumomab AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Paclitaxel"}, {"id": "Tositumomab_INT_Docetaxel", "text": "Interaction: Tositumomab AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Docetaxel"}, {"id": "Tositumomab_INT_Cabazitaxel", "text": "Interaction: Tositumomab AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Cabazitaxel"}, {"id": "Tositumomab_INT_Digoxin", "text": "Interaction: Tositumomab AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Digoxin"}, {"id": "Tositumomab_INT_Acetyldigitoxin", "text": "Interaction: Tositumomab AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Acetyldigitoxin"}, {"id": "Tositumomab_INT_Deslanoside", "text": "Interaction: Tositumomab AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Deslanoside"}, {"id": "Tositumomab_INT_Ouabain", "text": "Interaction: Tositumomab AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Ouabain"}, {"id": "Tositumomab_INT_Digitoxin", "text": "Interaction: Tositumomab AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Digitoxin"}, {"id": "Tositumomab_INT_Cymarin", "text": "Interaction: Tositumomab AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Cymarin"}, {"id": "Tositumomab_INT_Proscillaridin", "text": "Interaction: Tositumomab AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Proscillaridin"}, {"id": "Tositumomab_INT_Metildigoxin", "text": "Interaction: Tositumomab AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Metildigoxin"}, {"id": "Tositumomab_INT_Peruvoside", "text": "Interaction: Tositumomab AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Peruvoside"}, {"id": "Tositumomab_INT_Lanatoside C", "text": "Interaction: Tositumomab AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Lanatoside C"}, {"id": "Tositumomab_INT_Gitoformate", "text": "Interaction: Tositumomab AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Gitoformate"}, {"id": "Tositumomab_INT_Acetyldigoxin", "text": "Interaction: Tositumomab AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Acetyldigoxin"}, {"id": "Tositumomab_INT_Oleandrin", "text": "Interaction: Tositumomab AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Oleandrin"}, {"id": "Tositumomab_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Tositumomab AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Digoxin Immune Fab (Ovine)"}, {"id": "Tositumomab_INT_Bevacizumab", "text": "Interaction: Tositumomab AND Bevacizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Bevacizumab"}, {"id": "Tositumomab_INT_Cyclophosphamide", "text": "Interaction: Tositumomab AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Cyclophosphamide"}, {"id": "Tositumomab_INT_Denosumab", "text": "Interaction: Tositumomab AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Denosumab"}, {"id": "Tositumomab_INT_Sipuleucel-T", "text": "Interaction: Tositumomab AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Sipuleucel-T"}, {"id": "Tositumomab_INT_Lepirudin", "text": "Interaction: Tositumomab AND Lepirudin\nDetails: The risk or severity of adverse effects can be increased when Lepirudin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Lepirudin"}, {"id": "Tositumomab_INT_Bivalirudin", "text": "Interaction: Tositumomab AND Bivalirudin\nDetails: The risk or severity of adverse effects can be increased when Bivalirudin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Bivalirudin"}, {"id": "Tositumomab_INT_Abciximab", "text": "Interaction: Tositumomab AND Abciximab\nDetails: The risk or severity of adverse effects can be increased when Abciximab is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Abciximab"}, {"id": "Tositumomab_INT_Becaplermin", "text": "Interaction: Tositumomab AND Becaplermin\nDetails: The risk or severity of adverse effects can be increased when Becaplermin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Becaplermin"}, {"id": "Tositumomab_INT_Dicoumarol", "text": "Interaction: Tositumomab AND Dicoumarol\nDetails: The risk or severity of adverse effects can be increased when Dicoumarol is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Dicoumarol"}, {"id": "Tositumomab_INT_Argatroban", "text": "Interaction: Tositumomab AND Argatroban\nDetails: The risk or severity of adverse effects can be increased when Argatroban is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Argatroban"}, {"id": "Tositumomab_INT_Ardeparin", "text": "Interaction: Tositumomab AND Ardeparin\nDetails: The risk or severity of adverse effects can be increased when Ardeparin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Ardeparin"}, {"id": "Tositumomab_INT_Phenindione", "text": "Interaction: Tositumomab AND Phenindione\nDetails: The risk or severity of adverse effects can be increased when Phenindione is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Phenindione"}, {"id": "Tositumomab_INT_Fondaparinux sodium", "text": "Interaction: Tositumomab AND Fondaparinux sodium\nDetails: The risk or severity of adverse effects can be increased when Fondaparinux sodium is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Fondaparinux sodium"}, {"id": "Tositumomab_INT_Warfarin", "text": "Interaction: Tositumomab AND Warfarin\nDetails: The risk or severity of adverse effects can be increased when Warfarin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Warfarin"}, {"id": "Tositumomab_INT_Pentosan Polysulfate", "text": "Interaction: Tositumomab AND Pentosan Polysulfate\nDetails: The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Pentosan Polysulfate"}, {"id": "Tositumomab_INT_Phenprocoumon", "text": "Interaction: Tositumomab AND Phenprocoumon\nDetails: The risk or severity of adverse effects can be increased when Phenprocoumon is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Phenprocoumon"}, {"id": "Tositumomab_INT_Edetic Acid", "text": "Interaction: Tositumomab AND Edetic Acid\nDetails: The risk or severity of adverse effects can be increased when Edetic Acid is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Edetic Acid"}, {"id": "Tositumomab_INT_Heparin", "text": "Interaction: Tositumomab AND Heparin\nDetails: The risk or severity of adverse effects can be increased when Heparin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Heparin"}, {"id": "Tositumomab_INT_Enoxaparin", "text": "Interaction: Tositumomab AND Enoxaparin\nDetails: The risk or severity of adverse effects can be increased when Enoxaparin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Enoxaparin"}, {"id": "Tositumomab_INT_Acenocoumarol", "text": "Interaction: Tositumomab AND Acenocoumarol\nDetails: The risk or severity of adverse effects can be increased when Acenocoumarol is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Acenocoumarol"}, {"id": "Tositumomab_INT_Citric Acid", "text": "Interaction: Tositumomab AND Citric Acid\nDetails: The risk or severity of adverse effects can be increased when Citric Acid is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Citric Acid"}, {"id": "Tositumomab_INT_Ximelagatran", "text": "Interaction: Tositumomab AND Ximelagatran\nDetails: The risk or severity of adverse effects can be increased when Ximelagatran is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Ximelagatran"}, {"id": "Tositumomab_INT_Ancrod", "text": "Interaction: Tositumomab AND Ancrod\nDetails: The risk or severity of adverse effects can be increased when Ancrod is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Ancrod"}, {"id": "Tositumomab_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Tositumomab AND Pentaerythritol Tetranitrate\nDetails: The risk or severity of adverse effects can be increased when Pentaerythritol Tetranitrate is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Pentaerythritol Tetranitrate"}, {"id": "Tositumomab_INT_Rivaroxaban", "text": "Interaction: Tositumomab AND Rivaroxaban\nDetails: The risk or severity of adverse effects can be increased when Rivaroxaban is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Rivaroxaban"}, {"id": "Tositumomab_INT_Sulodexide", "text": "Interaction: Tositumomab AND Sulodexide\nDetails: The risk or severity of adverse effects can be increased when Sulodexide is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Sulodexide"}, {"id": "Tositumomab_INT_Idraparinux", "text": "Interaction: Tositumomab AND Idraparinux\nDetails: The risk or severity of adverse effects can be increased when Idraparinux is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Idraparinux"}, {"id": "Tositumomab_INT_Apixaban", "text": "Interaction: Tositumomab AND Apixaban\nDetails: The risk or severity of adverse effects can be increased when Apixaban is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Apixaban"}, {"id": "Tositumomab_INT_Otamixaban", "text": "Interaction: Tositumomab AND Otamixaban\nDetails: The risk or severity of adverse effects can be increased when Otamixaban is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Otamixaban"}, {"id": "Tositumomab_INT_Dabigatran etexilate", "text": "Interaction: Tositumomab AND Dabigatran etexilate\nDetails: The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Dabigatran etexilate"}, {"id": "Tositumomab_INT_Danaparoid", "text": "Interaction: Tositumomab AND Danaparoid\nDetails: The risk or severity of adverse effects can be increased when Danaparoid is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Danaparoid"}, {"id": "Tositumomab_INT_Dalteparin", "text": "Interaction: Tositumomab AND Dalteparin\nDetails: The risk or severity of adverse effects can be increased when Dalteparin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Dalteparin"}, {"id": "Tositumomab_INT_Ferulic acid", "text": "Interaction: Tositumomab AND Ferulic acid\nDetails: The risk or severity of adverse effects can be increased when Ferulic acid is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Ferulic acid"}, {"id": "Tositumomab_INT_Ethyl biscoumacetate", "text": "Interaction: Tositumomab AND Ethyl biscoumacetate\nDetails: The risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Ethyl biscoumacetate"}, {"id": "Tositumomab_INT_Nadroparin", "text": "Interaction: Tositumomab AND Nadroparin\nDetails: The risk or severity of adverse effects can be increased when Nadroparin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Nadroparin"}, {"id": "Tositumomab_INT_Edoxaban", "text": "Interaction: Tositumomab AND Edoxaban\nDetails: The risk or severity of adverse effects can be increased when Edoxaban is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Edoxaban"}, {"id": "Tositumomab_INT_Dextran", "text": "Interaction: Tositumomab AND Dextran\nDetails: The risk or severity of adverse effects can be increased when Dextran is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Dextran"}, {"id": "Tositumomab_INT_Reviparin", "text": "Interaction: Tositumomab AND Reviparin\nDetails: The risk or severity of adverse effects can be increased when Reviparin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Reviparin"}, {"id": "Tositumomab_INT_Certoparin", "text": "Interaction: Tositumomab AND Certoparin\nDetails: The risk or severity of adverse effects can be increased when Certoparin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Certoparin"}, {"id": "Tositumomab_INT_Dextran 70", "text": "Interaction: Tositumomab AND Dextran 70\nDetails: The risk or severity of adverse effects can be increased when Dextran 70 is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Dextran 70"}, {"id": "Tositumomab_INT_Desirudin", "text": "Interaction: Tositumomab AND Desirudin\nDetails: The risk or severity of adverse effects can be increased when Desirudin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Desirudin"}, {"id": "Tositumomab_INT_Dextran 40", "text": "Interaction: Tositumomab AND Dextran 40\nDetails: The risk or severity of adverse effects can be increased when Dextran 40 is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Dextran 40"}, {"id": "Tositumomab_INT_Dextran 75", "text": "Interaction: Tositumomab AND Dextran 75\nDetails: The risk or severity of adverse effects can be increased when Dextran 75 is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Dextran 75"}, {"id": "Tositumomab_INT_Protocatechualdehyde", "text": "Interaction: Tositumomab AND Protocatechualdehyde\nDetails: The risk or severity of adverse effects can be increased when Protocatechualdehyde is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Protocatechualdehyde"}, {"id": "Tositumomab_INT_Protein C", "text": "Interaction: Tositumomab AND Protein C\nDetails: The risk or severity of adverse effects can be increased when Protein C is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Protein C"}, {"id": "Tositumomab_INT_Antithrombin III human", "text": "Interaction: Tositumomab AND Antithrombin III human\nDetails: The risk or severity of adverse effects can be increased when Antithrombin III human is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Antithrombin III human"}, {"id": "Tositumomab_INT_Fondaparinux", "text": "Interaction: Tositumomab AND Fondaparinux\nDetails: The risk or severity of adverse effects can be increased when Fondaparinux is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Fondaparinux"}, {"id": "Tositumomab_INT_Letaxaban", "text": "Interaction: Tositumomab AND Letaxaban\nDetails: The risk or severity of adverse effects can be increased when Letaxaban is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Letaxaban"}, {"id": "Tositumomab_INT_Darexaban", "text": "Interaction: Tositumomab AND Darexaban\nDetails: The risk or severity of adverse effects can be increased when Darexaban is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Darexaban"}, {"id": "Tositumomab_INT_Nafamostat", "text": "Interaction: Tositumomab AND Nafamostat\nDetails: The risk or severity of adverse effects can be increased when Nafamostat is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Nafamostat"}, {"id": "Tositumomab_INT_Gabexate", "text": "Interaction: Tositumomab AND Gabexate\nDetails: The risk or severity of adverse effects can be increased when Gabexate is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Gabexate"}, {"id": "Tositumomab_INT_Troxerutin", "text": "Interaction: Tositumomab AND Troxerutin\nDetails: The risk or severity of adverse effects can be increased when Troxerutin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Troxerutin"}, {"id": "Tositumomab_INT_Fluindione", "text": "Interaction: Tositumomab AND Fluindione\nDetails: The risk or severity of adverse effects can be increased when Fluindione is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Fluindione"}, {"id": "Tositumomab_INT_Protein S human", "text": "Interaction: Tositumomab AND Protein S human\nDetails: The risk or severity of adverse effects can be increased when Protein S human is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Protein S human"}, {"id": "Tositumomab_INT_Melagatran", "text": "Interaction: Tositumomab AND Melagatran\nDetails: The risk or severity of adverse effects can be increased when Melagatran is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Melagatran"}, {"id": "Tositumomab_INT_Eptifibatide", "text": "Interaction: Tositumomab AND Eptifibatide\nDetails: The risk or severity of adverse effects can be increased when Eptifibatide is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Eptifibatide"}, {"id": "Tositumomab_INT_Ticlopidine", "text": "Interaction: Tositumomab AND Ticlopidine\nDetails: The risk or severity of adverse effects can be increased when Ticlopidine is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Ticlopidine"}, {"id": "Tositumomab_INT_Tirofiban", "text": "Interaction: Tositumomab AND Tirofiban\nDetails: The risk or severity of adverse effects can be increased when Tirofiban is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Tirofiban"}, {"id": "Tositumomab_INT_Dipyridamole", "text": "Interaction: Tositumomab AND Dipyridamole\nDetails: The risk or severity of adverse effects can be increased when Dipyridamole is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Dipyridamole"}, {"id": "Tositumomab_INT_Clopidogrel", "text": "Interaction: Tositumomab AND Clopidogrel\nDetails: The risk or severity of adverse effects can be increased when Clopidogrel is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Clopidogrel"}, {"id": "Tositumomab_INT_Acetylsalicylic acid", "text": "Interaction: Tositumomab AND Acetylsalicylic acid\nDetails: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Acetylsalicylic acid"}, {"id": "Tositumomab_INT_Prasugrel", "text": "Interaction: Tositumomab AND Prasugrel\nDetails: The risk or severity of adverse effects can be increased when Prasugrel is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Prasugrel"}, {"id": "Tositumomab_INT_Vorapaxar", "text": "Interaction: Tositumomab AND Vorapaxar\nDetails: The risk or severity of adverse effects can be increased when Vorapaxar is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Vorapaxar"}, {"id": "Tositumomab_INT_Milrinone", "text": "Interaction: Tositumomab AND Milrinone\nDetails: The risk or severity of adverse effects can be increased when Milrinone is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Milrinone"}, {"id": "Tositumomab_INT_Anagrelide", "text": "Interaction: Tositumomab AND Anagrelide\nDetails: The risk or severity of adverse effects can be increased when Anagrelide is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Anagrelide"}, {"id": "Tositumomab_INT_Epinastine", "text": "Interaction: Tositumomab AND Epinastine\nDetails: The risk or severity of adverse effects can be increased when Epinastine is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Epinastine"}, {"id": "Tositumomab_INT_Alprostadil", "text": "Interaction: Tositumomab AND Alprostadil\nDetails: The risk or severity of adverse effects can be increased when Alprostadil is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Alprostadil"}, {"id": "Tositumomab_INT_Pentoxifylline", "text": "Interaction: Tositumomab AND Pentoxifylline\nDetails: The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Pentoxifylline"}, {"id": "Tositumomab_INT_Azelastine", "text": "Interaction: Tositumomab AND Azelastine\nDetails: The risk or severity of adverse effects can be increased when Azelastine is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Azelastine"}, {"id": "Tositumomab_INT_Iloprost", "text": "Interaction: Tositumomab AND Iloprost\nDetails: The risk or severity of adverse effects can be increased when Iloprost is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Iloprost"}, {"id": "Tositumomab_INT_Cilostazol", "text": "Interaction: Tositumomab AND Cilostazol\nDetails: The risk or severity of adverse effects can be increased when Cilostazol is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Cilostazol"}, {"id": "Tositumomab_INT_Ridogrel", "text": "Interaction: Tositumomab AND Ridogrel\nDetails: The risk or severity of adverse effects can be increased when Ridogrel is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Ridogrel"}, {"id": "Tositumomab_INT_Sevoflurane", "text": "Interaction: Tositumomab AND Sevoflurane\nDetails: The risk or severity of adverse effects can be increased when Sevoflurane is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Sevoflurane"}, {"id": "Tositumomab_INT_Epoprostenol", "text": "Interaction: Tositumomab AND Epoprostenol\nDetails: The risk or severity of adverse effects can be increased when Epoprostenol is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Epoprostenol"}, {"id": "Tositumomab_INT_Resveratrol", "text": "Interaction: Tositumomab AND Resveratrol\nDetails: The risk or severity of adverse effects can be increased when Resveratrol is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Resveratrol"}, {"id": "Tositumomab_INT_Nimesulide", "text": "Interaction: Tositumomab AND Nimesulide\nDetails: The risk or severity of adverse effects can be increased when Nimesulide is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Nimesulide"}, {"id": "Tositumomab_INT_Tesmilifene", "text": "Interaction: Tositumomab AND Tesmilifene\nDetails: The risk or severity of adverse effects can be increased when Tesmilifene is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Tesmilifene"}, {"id": "Tositumomab_INT_Defibrotide", "text": "Interaction: Tositumomab AND Defibrotide\nDetails: The risk or severity of adverse effects can be increased when Defibrotide is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Defibrotide"}, {"id": "Tositumomab_INT_SRT501", "text": "Interaction: Tositumomab AND SRT501\nDetails: The risk or severity of adverse effects can be increased when SRT501 is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + SRT501"}, {"id": "Tositumomab_INT_Beraprost", "text": "Interaction: Tositumomab AND Beraprost\nDetails: The risk or severity of adverse effects can be increased when Beraprost is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Beraprost"}, {"id": "Tositumomab_INT_Ibudilast", "text": "Interaction: Tositumomab AND Ibudilast\nDetails: The risk or severity of adverse effects can be increased when Ibudilast is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Ibudilast"}, {"id": "Tositumomab_INT_Andrographolide", "text": "Interaction: Tositumomab AND Andrographolide\nDetails: The risk or severity of adverse effects can be increased when Andrographolide is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Andrographolide"}, {"id": "Tositumomab_INT_eplivanserine", "text": "Interaction: Tositumomab AND eplivanserine\nDetails: The risk or severity of adverse effects can be increased when eplivanserine is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + eplivanserine"}, {"id": "Tositumomab_INT_Cangrelor", "text": "Interaction: Tositumomab AND Cangrelor\nDetails: The risk or severity of adverse effects can be increased when Cangrelor is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Cangrelor"}, {"id": "Tositumomab_INT_Tranilast", "text": "Interaction: Tositumomab AND Tranilast\nDetails: The risk or severity of adverse effects can be increased when Tranilast is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Tranilast"}, {"id": "Tositumomab_INT_Triflusal", "text": "Interaction: Tositumomab AND Triflusal\nDetails: The risk or severity of adverse effects can be increased when Triflusal is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Triflusal"}, {"id": "Tositumomab_INT_Icosapent ethyl", "text": "Interaction: Tositumomab AND Icosapent ethyl\nDetails: The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Icosapent ethyl"}, {"id": "Tositumomab_INT_Ifenprodil", "text": "Interaction: Tositumomab AND Ifenprodil\nDetails: The risk or severity of adverse effects can be increased when Ifenprodil is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Ifenprodil"}, {"id": "Tositumomab_INT_Trapidil", "text": "Interaction: Tositumomab AND Trapidil\nDetails: The risk or severity of adverse effects can be increased when Trapidil is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Trapidil"}, {"id": "Tositumomab_INT_Naftopidil", "text": "Interaction: Tositumomab AND Naftopidil\nDetails: The risk or severity of adverse effects can be increased when Naftopidil is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Naftopidil"}, {"id": "Tositumomab_INT_Sarpogrelate", "text": "Interaction: Tositumomab AND Sarpogrelate\nDetails: The risk or severity of adverse effects can be increased when Sarpogrelate is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Sarpogrelate"}, {"id": "Tositumomab_INT_Eplivanserin", "text": "Interaction: Tositumomab AND Eplivanserin\nDetails: The risk or severity of adverse effects can be increased when Eplivanserin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Eplivanserin"}, {"id": "Tositumomab_INT_Ifetroban", "text": "Interaction: Tositumomab AND Ifetroban\nDetails: The risk or severity of adverse effects can be increased when Ifetroban is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Ifetroban"}, {"id": "Tositumomab_INT_Nitroaspirin", "text": "Interaction: Tositumomab AND Nitroaspirin\nDetails: The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Nitroaspirin"}, {"id": "Tositumomab_INT_Ketanserin", "text": "Interaction: Tositumomab AND Ketanserin\nDetails: The risk or severity of adverse effects can be increased when Ketanserin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Ketanserin"}, {"id": "Tositumomab_INT_Indobufen", "text": "Interaction: Tositumomab AND Indobufen\nDetails: The risk or severity of adverse effects can be increased when Indobufen is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Indobufen"}, {"id": "Tositumomab_INT_Butylphthalide", "text": "Interaction: Tositumomab AND Butylphthalide\nDetails: The risk or severity of adverse effects can be increased when Butylphthalide is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Butylphthalide"}, {"id": "Tositumomab_INT_Hydroxytyrosol", "text": "Interaction: Tositumomab AND Hydroxytyrosol\nDetails: The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Hydroxytyrosol"}, {"id": "Tositumomab_INT_Ramatroban", "text": "Interaction: Tositumomab AND Ramatroban\nDetails: The risk or severity of adverse effects can be increased when Ramatroban is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Ramatroban"}, {"id": "Tositumomab_INT_Picotamide", "text": "Interaction: Tositumomab AND Picotamide\nDetails: The risk or severity of adverse effects can be increased when Picotamide is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Picotamide"}, {"id": "Tositumomab_INT_Cloricromen", "text": "Interaction: Tositumomab AND Cloricromen\nDetails: The risk or severity of adverse effects can be increased when Cloricromen is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Cloricromen"}, {"id": "Tositumomab_INT_Linsidomine", "text": "Interaction: Tositumomab AND Linsidomine\nDetails: The risk or severity of adverse effects can be increased when Linsidomine is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Linsidomine"}, {"id": "Tositumomab_INT_Buflomedil", "text": "Interaction: Tositumomab AND Buflomedil\nDetails: The risk or severity of adverse effects can be increased when Buflomedil is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Buflomedil"}, {"id": "Tositumomab_INT_Relcovaptan", "text": "Interaction: Tositumomab AND Relcovaptan\nDetails: The risk or severity of adverse effects can be increased when Relcovaptan is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Relcovaptan"}, {"id": "Tositumomab_INT_Ticagrelor", "text": "Interaction: Tositumomab AND Ticagrelor\nDetails: The risk or severity of adverse effects can be increased when Ticagrelor is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Tositumomab + Ticagrelor"}, {"id": "Pegvisomant_GEN", "text": "Drug: Pegvisomant\nDescription: Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly.  Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is...", "source": "Pegvisomant"}, {"id": "Pegvisomant_CLIN", "text": "Drug: Pegvisomant\nMechanism: Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels....\nToxicity: ...", "source": "Pegvisomant"}, {"id": "Pegvisomant_INT_Rilpivirine", "text": "Interaction: Pegvisomant AND Rilpivirine\nDetails: The serum concentration of Rilpivirine can be decreased when it is combined with Pegvisomant.\nRisk: Monitor closely.", "source": "Pegvisomant + Rilpivirine"}, {"id": "Pegvisomant_INT_Aripiprazole", "text": "Interaction: Pegvisomant AND Aripiprazole\nDetails: The serum concentration of Aripiprazole can be decreased when it is combined with Pegvisomant.\nRisk: Monitor closely.", "source": "Pegvisomant + Aripiprazole"}, {"id": "Pegvisomant_INT_Cilostazol", "text": "Interaction: Pegvisomant AND Cilostazol\nDetails: The serum concentration of Cilostazol can be increased when it is combined with Pegvisomant.\nRisk: Monitor closely.", "source": "Pegvisomant + Cilostazol"}, {"id": "Pegvisomant_INT_Tramadol", "text": "Interaction: Pegvisomant AND Tramadol\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tramadol.\nRisk: Monitor closely.", "source": "Pegvisomant + Tramadol"}, {"id": "Pegvisomant_INT_Morphine", "text": "Interaction: Pegvisomant AND Morphine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Morphine.\nRisk: Monitor closely.", "source": "Pegvisomant + Morphine"}, {"id": "Pegvisomant_INT_Hydromorphone", "text": "Interaction: Pegvisomant AND Hydromorphone\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydromorphone.\nRisk: Monitor closely.", "source": "Pegvisomant + Hydromorphone"}, {"id": "Pegvisomant_INT_Methadone", "text": "Interaction: Pegvisomant AND Methadone\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadone.\nRisk: Monitor closely.", "source": "Pegvisomant + Methadone"}, {"id": "Pegvisomant_INT_Pethidine", "text": "Interaction: Pegvisomant AND Pethidine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pethidine.\nRisk: Monitor closely.", "source": "Pegvisomant + Pethidine"}, {"id": "Pegvisomant_INT_Oxycodone", "text": "Interaction: Pegvisomant AND Oxycodone\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxycodone.\nRisk: Monitor closely.", "source": "Pegvisomant + Oxycodone"}, {"id": "Pegvisomant_INT_Butorphanol", "text": "Interaction: Pegvisomant AND Butorphanol\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Butorphanol.\nRisk: Monitor closely.", "source": "Pegvisomant + Butorphanol"}, {"id": "Pegvisomant_INT_Dextropropoxyphene", "text": "Interaction: Pegvisomant AND Dextropropoxyphene\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextropropoxyphene.\nRisk: Monitor closely.", "source": "Pegvisomant + Dextropropoxyphene"}, {"id": "Pegvisomant_INT_Pentazocine", "text": "Interaction: Pegvisomant AND Pentazocine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pentazocine.\nRisk: Monitor closely.", "source": "Pegvisomant + Pentazocine"}, {"id": "Pegvisomant_INT_Fentanyl", "text": "Interaction: Pegvisomant AND Fentanyl\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fentanyl.\nRisk: Monitor closely.", "source": "Pegvisomant + Fentanyl"}, {"id": "Pegvisomant_INT_Nalbuphine", "text": "Interaction: Pegvisomant AND Nalbuphine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Nalbuphine.\nRisk: Monitor closely.", "source": "Pegvisomant + Nalbuphine"}, {"id": "Pegvisomant_INT_Buprenorphine", "text": "Interaction: Pegvisomant AND Buprenorphine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Buprenorphine.\nRisk: Monitor closely.", "source": "Pegvisomant + Buprenorphine"}, {"id": "Pegvisomant_INT_Dezocine", "text": "Interaction: Pegvisomant AND Dezocine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dezocine.\nRisk: Monitor closely.", "source": "Pegvisomant + Dezocine"}, {"id": "Pegvisomant_INT_Dextromoramide", "text": "Interaction: Pegvisomant AND Dextromoramide\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dextromoramide.\nRisk: Monitor closely.", "source": "Pegvisomant + Dextromoramide"}, {"id": "Pegvisomant_INT_Dihydrocodeine", "text": "Interaction: Pegvisomant AND Dihydrocodeine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydrocodeine.\nRisk: Monitor closely.", "source": "Pegvisomant + Dihydrocodeine"}, {"id": "Pegvisomant_INT_Ketobemidone", "text": "Interaction: Pegvisomant AND Ketobemidone\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ketobemidone.\nRisk: Monitor closely.", "source": "Pegvisomant + Ketobemidone"}, {"id": "Pegvisomant_INT_Piritramide", "text": "Interaction: Pegvisomant AND Piritramide\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Piritramide.\nRisk: Monitor closely.", "source": "Pegvisomant + Piritramide"}, {"id": "Pegvisomant_INT_Meptazinol", "text": "Interaction: Pegvisomant AND Meptazinol\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Meptazinol.\nRisk: Monitor closely.", "source": "Pegvisomant + Meptazinol"}, {"id": "Pegvisomant_INT_Phenazocine", "text": "Interaction: Pegvisomant AND Phenazocine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Phenazocine.\nRisk: Monitor closely.", "source": "Pegvisomant + Phenazocine"}, {"id": "Pegvisomant_INT_Tilidine", "text": "Interaction: Pegvisomant AND Tilidine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tilidine.\nRisk: Monitor closely.", "source": "Pegvisomant + Tilidine"}, {"id": "Pegvisomant_INT_Codeine", "text": "Interaction: Pegvisomant AND Codeine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Codeine.\nRisk: Monitor closely.", "source": "Pegvisomant + Codeine"}, {"id": "Pegvisomant_INT_Sufentanil", "text": "Interaction: Pegvisomant AND Sufentanil\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Sufentanil.\nRisk: Monitor closely.", "source": "Pegvisomant + Sufentanil"}, {"id": "Pegvisomant_INT_Alfentanil", "text": "Interaction: Pegvisomant AND Alfentanil\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alfentanil.\nRisk: Monitor closely.", "source": "Pegvisomant + Alfentanil"}, {"id": "Pegvisomant_INT_Levorphanol", "text": "Interaction: Pegvisomant AND Levorphanol\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levorphanol.\nRisk: Monitor closely.", "source": "Pegvisomant + Levorphanol"}, {"id": "Pegvisomant_INT_Remifentanil", "text": "Interaction: Pegvisomant AND Remifentanil\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Remifentanil.\nRisk: Monitor closely.", "source": "Pegvisomant + Remifentanil"}, {"id": "Pegvisomant_INT_Hydrocodone", "text": "Interaction: Pegvisomant AND Hydrocodone\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocodone.\nRisk: Monitor closely.", "source": "Pegvisomant + Hydrocodone"}, {"id": "Pegvisomant_INT_Diphenoxylate", "text": "Interaction: Pegvisomant AND Diphenoxylate\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Diphenoxylate.\nRisk: Monitor closely.", "source": "Pegvisomant + Diphenoxylate"}, {"id": "Pegvisomant_INT_Oxymorphone", "text": "Interaction: Pegvisomant AND Oxymorphone\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Oxymorphone.\nRisk: Monitor closely.", "source": "Pegvisomant + Oxymorphone"}, {"id": "Pegvisomant_INT_Levomethadyl Acetate", "text": "Interaction: Pegvisomant AND Levomethadyl Acetate\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Levomethadyl Acetate.\nRisk: Monitor closely.", "source": "Pegvisomant + Levomethadyl Acetate"}, {"id": "Pegvisomant_INT_Methadyl Acetate", "text": "Interaction: Pegvisomant AND Methadyl Acetate\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadyl Acetate.\nRisk: Monitor closely.", "source": "Pegvisomant + Methadyl Acetate"}, {"id": "Pegvisomant_INT_Dihydroetorphine", "text": "Interaction: Pegvisomant AND Dihydroetorphine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydroetorphine.\nRisk: Monitor closely.", "source": "Pegvisomant + Dihydroetorphine"}, {"id": "Pegvisomant_INT_Heroin", "text": "Interaction: Pegvisomant AND Heroin\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Heroin.\nRisk: Monitor closely.", "source": "Pegvisomant + Heroin"}, {"id": "Pegvisomant_INT_Ethylmorphine", "text": "Interaction: Pegvisomant AND Ethylmorphine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Ethylmorphine.\nRisk: Monitor closely.", "source": "Pegvisomant + Ethylmorphine"}, {"id": "Pegvisomant_INT_Etorphine", "text": "Interaction: Pegvisomant AND Etorphine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Etorphine.\nRisk: Monitor closely.", "source": "Pegvisomant + Etorphine"}, {"id": "Pegvisomant_INT_Carfentanil", "text": "Interaction: Pegvisomant AND Carfentanil\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Carfentanil.\nRisk: Monitor closely.", "source": "Pegvisomant + Carfentanil"}, {"id": "Pegvisomant_INT_Alphacetylmethadol", "text": "Interaction: Pegvisomant AND Alphacetylmethadol\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alphacetylmethadol.\nRisk: Monitor closely.", "source": "Pegvisomant + Alphacetylmethadol"}, {"id": "Pegvisomant_INT_Dihydromorphine", "text": "Interaction: Pegvisomant AND Dihydromorphine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Dihydromorphine.\nRisk: Monitor closely.", "source": "Pegvisomant + Dihydromorphine"}, {"id": "Pegvisomant_INT_DPDPE", "text": "Interaction: Pegvisomant AND DPDPE\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with DPDPE.\nRisk: Monitor closely.", "source": "Pegvisomant + DPDPE"}, {"id": "Pegvisomant_INT_Lofentanil", "text": "Interaction: Pegvisomant AND Lofentanil\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Lofentanil.\nRisk: Monitor closely.", "source": "Pegvisomant + Lofentanil"}, {"id": "Pegvisomant_INT_Opium", "text": "Interaction: Pegvisomant AND Opium\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Opium.\nRisk: Monitor closely.", "source": "Pegvisomant + Opium"}, {"id": "Pegvisomant_INT_Normethadone", "text": "Interaction: Pegvisomant AND Normethadone\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Normethadone.\nRisk: Monitor closely.", "source": "Pegvisomant + Normethadone"}, {"id": "Pegvisomant_INT_Alphaprodine", "text": "Interaction: Pegvisomant AND Alphaprodine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Alphaprodine.\nRisk: Monitor closely.", "source": "Pegvisomant + Alphaprodine"}, {"id": "Pegvisomant_INT_Phenoperidine", "text": "Interaction: Pegvisomant AND Phenoperidine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Phenoperidine.\nRisk: Monitor closely.", "source": "Pegvisomant + Phenoperidine"}, {"id": "Pegvisomant_INT_Bezitramide", "text": "Interaction: Pegvisomant AND Bezitramide\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Bezitramide.\nRisk: Monitor closely.", "source": "Pegvisomant + Bezitramide"}, {"id": "Pegvisomant_INT_Tapentadol", "text": "Interaction: Pegvisomant AND Tapentadol\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tapentadol.\nRisk: Monitor closely.", "source": "Pegvisomant + Tapentadol"}, {"id": "Pegvisomant_INT_Nicomorphine", "text": "Interaction: Pegvisomant AND Nicomorphine\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Nicomorphine.\nRisk: Monitor closely.", "source": "Pegvisomant + Nicomorphine"}, {"id": "Pegvisomant_INT_Octreotide", "text": "Interaction: Pegvisomant AND Octreotide\nDetails: The risk or severity of adverse effects can be increased when Octreotide is combined with Pegvisomant.\nRisk: Monitor closely.", "source": "Pegvisomant + Octreotide"}, {"id": "Pegvisomant_INT_Pasireotide", "text": "Interaction: Pegvisomant AND Pasireotide\nDetails: The risk or severity of adverse effects can be increased when Pasireotide is combined with Pegvisomant.\nRisk: Monitor closely.", "source": "Pegvisomant + Pasireotide"}, {"id": "Pegvisomant_INT_Lanreotide", "text": "Interaction: Pegvisomant AND Lanreotide\nDetails: The risk or severity of adverse effects can be increased when Lanreotide is combined with Pegvisomant.\nRisk: Monitor closely.", "source": "Pegvisomant + Lanreotide"}, {"id": "Pegvisomant_INT_Vapreotide", "text": "Interaction: Pegvisomant AND Vapreotide\nDetails: The risk or severity of adverse effects can be increased when Vapreotide is combined with Pegvisomant.\nRisk: Monitor closely.", "source": "Pegvisomant + Vapreotide"}, {"id": "Pegvisomant_INT_Somatostatin", "text": "Interaction: Pegvisomant AND Somatostatin\nDetails: The risk or severity of adverse effects can be increased when Somatostatin is combined with Pegvisomant.\nRisk: Monitor closely.", "source": "Pegvisomant + Somatostatin"}, {"id": "Pegvisomant_INT_Pegloticase", "text": "Interaction: Pegvisomant AND Pegloticase\nDetails: The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegloticase.\nRisk: Monitor closely.", "source": "Pegvisomant + Pegloticase"}, {"id": "Pegvisomant_INT_Saxagliptin", "text": "Interaction: Pegvisomant AND Saxagliptin\nDetails: The serum concentration of Saxagliptin can be decreased when it is combined with Pegvisomant.\nRisk: Monitor closely.", "source": "Pegvisomant + Saxagliptin"}, {"id": "Pegvisomant_INT_Insulin Human", "text": "Interaction: Pegvisomant AND Insulin Human\nDetails: Pegvisomant may increase the hypoglycemic activities of Insulin Human.\nRisk: Monitor closely.", "source": "Pegvisomant + Insulin Human"}, {"id": "Pegvisomant_INT_Insulin Lispro", "text": "Interaction: Pegvisomant AND Insulin Lispro\nDetails: Pegvisomant may increase the hypoglycemic activities of Insulin Lispro.\nRisk: Monitor closely.", "source": "Pegvisomant + Insulin Lispro"}, {"id": "Pegvisomant_INT_Insulin Glargine", "text": "Interaction: Pegvisomant AND Insulin Glargine\nDetails: Pegvisomant may increase the hypoglycemic activities of Insulin Glargine.\nRisk: Monitor closely.", "source": "Pegvisomant + Insulin Glargine"}, {"id": "Pegvisomant_INT_Glimepiride", "text": "Interaction: Pegvisomant AND Glimepiride\nDetails: Pegvisomant may increase the hypoglycemic activities of Glimepiride.\nRisk: Monitor closely.", "source": "Pegvisomant + Glimepiride"}, {"id": "Pegvisomant_INT_Sulfisoxazole", "text": "Interaction: Pegvisomant AND Sulfisoxazole\nDetails: Pegvisomant may increase the hypoglycemic activities of Sulfisoxazole.\nRisk: Monitor closely.", "source": "Pegvisomant + Sulfisoxazole"}, {"id": "Pegvisomant_INT_Disopyramide", "text": "Interaction: Pegvisomant AND Disopyramide\nDetails: Pegvisomant may increase the hypoglycemic activities of Disopyramide.\nRisk: Monitor closely.", "source": "Pegvisomant + Disopyramide"}, {"id": "Pegvisomant_INT_Acarbose", "text": "Interaction: Pegvisomant AND Acarbose\nDetails: Pegvisomant may increase the hypoglycemic activities of Acarbose.\nRisk: Monitor closely.", "source": "Pegvisomant + Acarbose"}, {"id": "Pegvisomant_INT_Metformin", "text": "Interaction: Pegvisomant AND Metformin\nDetails: Pegvisomant may increase the hypoglycemic activities of Metformin.\nRisk: Monitor closely.", "source": "Pegvisomant + Metformin"}, {"id": "Pegvisomant_INT_Sulfadiazine", "text": "Interaction: Pegvisomant AND Sulfadiazine\nDetails: Pegvisomant may increase the hypoglycemic activities of Sulfadiazine.\nRisk: Monitor closely.", "source": "Pegvisomant + Sulfadiazine"}, {"id": "Pegvisomant_INT_Rosiglitazone", "text": "Interaction: Pegvisomant AND Rosiglitazone\nDetails: Pegvisomant may increase the hypoglycemic activities of Rosiglitazone.\nRisk: Monitor closely.", "source": "Pegvisomant + Rosiglitazone"}, {"id": "Pegvisomant_INT_Quinine", "text": "Interaction: Pegvisomant AND Quinine\nDetails: Pegvisomant may increase the hypoglycemic activities of Quinine.\nRisk: Monitor closely.", "source": "Pegvisomant + Quinine"}, {"id": "Pegvisomant_INT_Miglitol", "text": "Interaction: Pegvisomant AND Miglitol\nDetails: Pegvisomant may increase the hypoglycemic activities of Miglitol.\nRisk: Monitor closely.", "source": "Pegvisomant + Miglitol"}, {"id": "Pegvisomant_INT_Chlorpropamide", "text": "Interaction: Pegvisomant AND Chlorpropamide\nDetails: Pegvisomant may increase the hypoglycemic activities of Chlorpropamide.\nRisk: Monitor closely.", "source": "Pegvisomant + Chlorpropamide"}, {"id": "Pegvisomant_INT_Nateglinide", "text": "Interaction: Pegvisomant AND Nateglinide\nDetails: Pegvisomant may increase the hypoglycemic activities of Nateglinide.\nRisk: Monitor closely.", "source": "Pegvisomant + Nateglinide"}, {"id": "Pegvisomant_INT_Pentamidine", "text": "Interaction: Pegvisomant AND Pentamidine\nDetails: Pegvisomant may increase the hypoglycemic activities of Pentamidine.\nRisk: Monitor closely.", "source": "Pegvisomant + Pentamidine"}, {"id": "Pegvisomant_INT_Mifepristone", "text": "Interaction: Pegvisomant AND Mifepristone\nDetails: Pegvisomant may increase the hypoglycemic activities of Mifepristone.\nRisk: Monitor closely.", "source": "Pegvisomant + Mifepristone"}, {"id": "Pegvisomant_INT_Tolazamide", "text": "Interaction: Pegvisomant AND Tolazamide\nDetails: Pegvisomant may increase the hypoglycemic activities of Tolazamide.\nRisk: Monitor closely.", "source": "Pegvisomant + Tolazamide"}, {"id": "Pegvisomant_INT_Repaglinide", "text": "Interaction: Pegvisomant AND Repaglinide\nDetails: Pegvisomant may increase the hypoglycemic activities of Repaglinide.\nRisk: Monitor closely.", "source": "Pegvisomant + Repaglinide"}, {"id": "Pegvisomant_INT_Sulfamethoxazole", "text": "Interaction: Pegvisomant AND Sulfamethoxazole\nDetails: Pegvisomant may increase the hypoglycemic activities of Sulfamethoxazole.\nRisk: Monitor closely.", "source": "Pegvisomant + Sulfamethoxazole"}, {"id": "Pegvisomant_INT_Glyburide", "text": "Interaction: Pegvisomant AND Glyburide\nDetails: Pegvisomant may increase the hypoglycemic activities of Glyburide.\nRisk: Monitor closely.", "source": "Pegvisomant + Glyburide"}, {"id": "Pegvisomant_INT_Glipizide", "text": "Interaction: Pegvisomant AND Glipizide\nDetails: Pegvisomant may increase the hypoglycemic activities of Glipizide.\nRisk: Monitor closely.", "source": "Pegvisomant + Glipizide"}, {"id": "Pegvisomant_INT_Gliclazide", "text": "Interaction: Pegvisomant AND Gliclazide\nDetails: Pegvisomant may increase the hypoglycemic activities of Gliclazide.\nRisk: Monitor closely.", "source": "Pegvisomant + Gliclazide"}, {"id": "Pegvisomant_INT_Tolbutamide", "text": "Interaction: Pegvisomant AND Tolbutamide\nDetails: Pegvisomant may increase the hypoglycemic activities of Tolbutamide.\nRisk: Monitor closely.", "source": "Pegvisomant + Tolbutamide"}, {"id": "Pegvisomant_INT_Pioglitazone", "text": "Interaction: Pegvisomant AND Pioglitazone\nDetails: Pegvisomant may increase the hypoglycemic activities of Pioglitazone.\nRisk: Monitor closely.", "source": "Pegvisomant + Pioglitazone"}, {"id": "Pegvisomant_INT_Bromocriptine", "text": "Interaction: Pegvisomant AND Bromocriptine\nDetails: Pegvisomant may increase the hypoglycemic activities of Bromocriptine.\nRisk: Monitor closely.", "source": "Pegvisomant + Bromocriptine"}, {"id": "Pegvisomant_INT_Sitagliptin", "text": "Interaction: Pegvisomant AND Sitagliptin\nDetails: Pegvisomant may increase the hypoglycemic activities of Sitagliptin.\nRisk: Monitor closely.", "source": "Pegvisomant + Sitagliptin"}, {"id": "Pegvisomant_INT_Sunitinib", "text": "Interaction: Pegvisomant AND Sunitinib\nDetails: Pegvisomant may increase the hypoglycemic activities of Sunitinib.\nRisk: Monitor closely.", "source": "Pegvisomant + Sunitinib"}, {"id": "Pegvisomant_INT_Exenatide", "text": "Interaction: Pegvisomant AND Exenatide\nDetails: Pegvisomant may increase the hypoglycemic activities of Exenatide.\nRisk: Monitor closely.", "source": "Pegvisomant + Exenatide"}, {"id": "Pegvisomant_INT_Mecasermin", "text": "Interaction: Pegvisomant AND Mecasermin\nDetails: Pegvisomant may increase the hypoglycemic activities of Mecasermin.\nRisk: Monitor closely.", "source": "Pegvisomant + Mecasermin"}, {"id": "Pegvisomant_INT_Pramlintide", "text": "Interaction: Pegvisomant AND Pramlintide\nDetails: Pegvisomant may increase the hypoglycemic activities of Pramlintide.\nRisk: Monitor closely.", "source": "Pegvisomant + Pramlintide"}, {"id": "Pegvisomant_INT_Insulin Aspart", "text": "Interaction: Pegvisomant AND Insulin Aspart\nDetails: Pegvisomant may increase the hypoglycemic activities of Insulin Aspart.\nRisk: Monitor closely.", "source": "Pegvisomant + Insulin Aspart"}, {"id": "Pegvisomant_INT_Insulin Detemir", "text": "Interaction: Pegvisomant AND Insulin Detemir\nDetails: Pegvisomant may increase the hypoglycemic activities of Insulin Detemir.\nRisk: Monitor closely.", "source": "Pegvisomant + Insulin Detemir"}, {"id": "Pegvisomant_INT_Insulin Glulisine", "text": "Interaction: Pegvisomant AND Insulin Glulisine\nDetails: Pegvisomant may increase the hypoglycemic activities of Insulin Glulisine.\nRisk: Monitor closely.", "source": "Pegvisomant + Insulin Glulisine"}, {"id": "Pegvisomant_INT_Alogliptin", "text": "Interaction: Pegvisomant AND Alogliptin\nDetails: Pegvisomant may increase the hypoglycemic activities of Alogliptin.\nRisk: Monitor closely.", "source": "Pegvisomant + Alogliptin"}, {"id": "Pegvisomant_INT_Dapagliflozin", "text": "Interaction: Pegvisomant AND Dapagliflozin\nDetails: Pegvisomant may increase the hypoglycemic activities of Dapagliflozin.\nRisk: Monitor closely.", "source": "Pegvisomant + Dapagliflozin"}, {"id": "Pegvisomant_INT_Liraglutide", "text": "Interaction: Pegvisomant AND Liraglutide\nDetails: Pegvisomant may increase the hypoglycemic activities of Liraglutide.\nRisk: Monitor closely.", "source": "Pegvisomant + Liraglutide"}, {"id": "Pegvisomant_INT_Canagliflozin", "text": "Interaction: Pegvisomant AND Canagliflozin\nDetails: Pegvisomant may increase the hypoglycemic activities of Canagliflozin.\nRisk: Monitor closely.", "source": "Pegvisomant + Canagliflozin"}, {"id": "Pegvisomant_INT_Empagliflozin", "text": "Interaction: Pegvisomant AND Empagliflozin\nDetails: Pegvisomant may increase the hypoglycemic activities of Empagliflozin.\nRisk: Monitor closely.", "source": "Pegvisomant + Empagliflozin"}, {"id": "Pegvisomant_INT_Albiglutide", "text": "Interaction: Pegvisomant AND Albiglutide\nDetails: Pegvisomant may increase the hypoglycemic activities of Albiglutide.\nRisk: Monitor closely.", "source": "Pegvisomant + Albiglutide"}, {"id": "Pegvisomant_INT_Dulaglutide", "text": "Interaction: Pegvisomant AND Dulaglutide\nDetails: Pegvisomant may increase the hypoglycemic activities of Dulaglutide.\nRisk: Monitor closely.", "source": "Pegvisomant + Dulaglutide"}, {"id": "Botulinum Toxin Type A_GEN", "text": "Drug: Botulinum Toxin Type A\nDescription: Purified botulinum toxin from Clostridium botulinum, purified from culture via dialysis and acid precipitation....", "source": "Botulinum Toxin Type A"}, {"id": "Botulinum Toxin Type A_CLIN", "text": "Drug: Botulinum Toxin Type A\nMechanism: Botulinum Toxin Type A blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine...\nToxicity: Based on toxicological studies, it has been estimated that the human LD50 \r\nby injection is approximately 2800 Units, equivalent to 28 individual vials of BOTOX (Botulinum Toxin Type A) Purified Neuro...", "source": "Botulinum Toxin Type A"}, {"id": "Botulinum Toxin Type A_INT_Botulinum Toxin Type B", "text": "Interaction: Botulinum Toxin Type A AND Botulinum Toxin Type B\nDetails: Botulinum Toxin Type A may increase the adverse neuromuscular activities of Botulinum Toxin Type B.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Botulinum Toxin Type B"}, {"id": "Botulinum Toxin Type A_INT_Succinylcholine", "text": "Interaction: Botulinum Toxin Type A AND Succinylcholine\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Succinylcholine.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Succinylcholine"}, {"id": "Botulinum Toxin Type A_INT_Cisatracurium besylate", "text": "Interaction: Botulinum Toxin Type A AND Cisatracurium besylate\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Cisatracurium besylate.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Cisatracurium besylate"}, {"id": "Botulinum Toxin Type A_INT_Rocuronium", "text": "Interaction: Botulinum Toxin Type A AND Rocuronium\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Rocuronium.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Rocuronium"}, {"id": "Botulinum Toxin Type A_INT_Atracurium besylate", "text": "Interaction: Botulinum Toxin Type A AND Atracurium besylate\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Atracurium besylate.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Atracurium besylate"}, {"id": "Botulinum Toxin Type A_INT_Pancuronium", "text": "Interaction: Botulinum Toxin Type A AND Pancuronium\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Pancuronium.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Pancuronium"}, {"id": "Botulinum Toxin Type A_INT_Vecuronium", "text": "Interaction: Botulinum Toxin Type A AND Vecuronium\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Vecuronium.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Vecuronium"}, {"id": "Botulinum Toxin Type A_INT_Metocurine Iodide", "text": "Interaction: Botulinum Toxin Type A AND Metocurine Iodide\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Metocurine Iodide.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Metocurine Iodide"}, {"id": "Botulinum Toxin Type A_INT_Gallamine Triethiodide", "text": "Interaction: Botulinum Toxin Type A AND Gallamine Triethiodide\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Gallamine Triethiodide.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Gallamine Triethiodide"}, {"id": "Botulinum Toxin Type A_INT_Doxacurium chloride", "text": "Interaction: Botulinum Toxin Type A AND Doxacurium chloride\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Doxacurium chloride.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Doxacurium chloride"}, {"id": "Botulinum Toxin Type A_INT_Tubocurarine", "text": "Interaction: Botulinum Toxin Type A AND Tubocurarine\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Tubocurarine.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Tubocurarine"}, {"id": "Botulinum Toxin Type A_INT_Mivacurium", "text": "Interaction: Botulinum Toxin Type A AND Mivacurium\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Mivacurium.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Mivacurium"}, {"id": "Botulinum Toxin Type A_INT_Decamethonium", "text": "Interaction: Botulinum Toxin Type A AND Decamethonium\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Decamethonium.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Decamethonium"}, {"id": "Botulinum Toxin Type A_INT_Metocurine", "text": "Interaction: Botulinum Toxin Type A AND Metocurine\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Metocurine.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Metocurine"}, {"id": "Botulinum Toxin Type A_INT_Pipecuronium", "text": "Interaction: Botulinum Toxin Type A AND Pipecuronium\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Pipecuronium.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Pipecuronium"}, {"id": "Botulinum Toxin Type A_INT_Domoic Acid", "text": "Interaction: Botulinum Toxin Type A AND Domoic Acid\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Domoic Acid.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Domoic Acid"}, {"id": "Botulinum Toxin Type A_INT_Rapacuronium", "text": "Interaction: Botulinum Toxin Type A AND Rapacuronium\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Rapacuronium.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Rapacuronium"}, {"id": "Botulinum Toxin Type A_INT_Pyrantel", "text": "Interaction: Botulinum Toxin Type A AND Pyrantel\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Pyrantel.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Pyrantel"}, {"id": "Botulinum Toxin Type A_INT_Neosaxitoxin", "text": "Interaction: Botulinum Toxin Type A AND Neosaxitoxin\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Neosaxitoxin.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Neosaxitoxin"}, {"id": "Botulinum Toxin Type A_INT_Atracurium", "text": "Interaction: Botulinum Toxin Type A AND Atracurium\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Atracurium.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Atracurium"}, {"id": "Botulinum Toxin Type A_INT_Cisatracurium", "text": "Interaction: Botulinum Toxin Type A AND Cisatracurium\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Cisatracurium.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Cisatracurium"}, {"id": "Botulinum Toxin Type A_INT_Gallamine", "text": "Interaction: Botulinum Toxin Type A AND Gallamine\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Gallamine.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Gallamine"}, {"id": "Botulinum Toxin Type A_INT_Alcuronium", "text": "Interaction: Botulinum Toxin Type A AND Alcuronium\nDetails: Botulinum Toxin Type A may increase the neuromuscular blocking activities of Alcuronium.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Alcuronium"}, {"id": "Botulinum Toxin Type A_INT_Benzatropine", "text": "Interaction: Botulinum Toxin Type A AND Benzatropine\nDetails: Benzatropine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Benzatropine"}, {"id": "Botulinum Toxin Type A_INT_Ipratropium bromide", "text": "Interaction: Botulinum Toxin Type A AND Ipratropium bromide\nDetails: Ipratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Ipratropium bromide"}, {"id": "Botulinum Toxin Type A_INT_Trihexyphenidyl", "text": "Interaction: Botulinum Toxin Type A AND Trihexyphenidyl\nDetails: Trihexyphenidyl may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Trihexyphenidyl"}, {"id": "Botulinum Toxin Type A_INT_Procyclidine", "text": "Interaction: Botulinum Toxin Type A AND Procyclidine\nDetails: Procyclidine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Procyclidine"}, {"id": "Botulinum Toxin Type A_INT_Ethopropazine", "text": "Interaction: Botulinum Toxin Type A AND Ethopropazine\nDetails: Ethopropazine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Ethopropazine"}, {"id": "Botulinum Toxin Type A_INT_Atropine", "text": "Interaction: Botulinum Toxin Type A AND Atropine\nDetails: Atropine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Atropine"}, {"id": "Botulinum Toxin Type A_INT_Scopolamine", "text": "Interaction: Botulinum Toxin Type A AND Scopolamine\nDetails: Scopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Scopolamine"}, {"id": "Botulinum Toxin Type A_INT_Tropicamide", "text": "Interaction: Botulinum Toxin Type A AND Tropicamide\nDetails: Tropicamide may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Tropicamide"}, {"id": "Botulinum Toxin Type A_INT_Biperiden", "text": "Interaction: Botulinum Toxin Type A AND Biperiden\nDetails: Biperiden may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Biperiden"}, {"id": "Botulinum Toxin Type A_INT_Cyclopentolate", "text": "Interaction: Botulinum Toxin Type A AND Cyclopentolate\nDetails: Cyclopentolate may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Cyclopentolate"}, {"id": "Botulinum Toxin Type A_INT_Tiotropium", "text": "Interaction: Botulinum Toxin Type A AND Tiotropium\nDetails: Tiotropium may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Tiotropium"}, {"id": "Botulinum Toxin Type A_INT_Dexetimide", "text": "Interaction: Botulinum Toxin Type A AND Dexetimide\nDetails: Dexetimide may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Dexetimide"}, {"id": "Botulinum Toxin Type A_INT_Bornaprine", "text": "Interaction: Botulinum Toxin Type A AND Bornaprine\nDetails: Bornaprine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Bornaprine"}, {"id": "Botulinum Toxin Type A_INT_Phenglutarimide", "text": "Interaction: Botulinum Toxin Type A AND Phenglutarimide\nDetails: Phenglutarimide may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Phenglutarimide"}, {"id": "Botulinum Toxin Type A_INT_Propantheline", "text": "Interaction: Botulinum Toxin Type A AND Propantheline\nDetails: Propantheline may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Propantheline"}, {"id": "Botulinum Toxin Type A_INT_Dicyclomine", "text": "Interaction: Botulinum Toxin Type A AND Dicyclomine\nDetails: Dicyclomine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Dicyclomine"}, {"id": "Botulinum Toxin Type A_INT_Aclidinium", "text": "Interaction: Botulinum Toxin Type A AND Aclidinium\nDetails: Aclidinium may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Aclidinium"}, {"id": "Botulinum Toxin Type A_INT_Glycopyrronium", "text": "Interaction: Botulinum Toxin Type A AND Glycopyrronium\nDetails: Glycopyrronium may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Glycopyrronium"}, {"id": "Botulinum Toxin Type A_INT_Trospium", "text": "Interaction: Botulinum Toxin Type A AND Trospium\nDetails: Trospium may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Trospium"}, {"id": "Botulinum Toxin Type A_INT_Oxyphenonium", "text": "Interaction: Botulinum Toxin Type A AND Oxyphenonium\nDetails: Oxyphenonium may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Oxyphenonium"}, {"id": "Botulinum Toxin Type A_INT_Hyoscyamine", "text": "Interaction: Botulinum Toxin Type A AND Hyoscyamine\nDetails: Hyoscyamine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Hyoscyamine"}, {"id": "Botulinum Toxin Type A_INT_Darifenacin", "text": "Interaction: Botulinum Toxin Type A AND Darifenacin\nDetails: Darifenacin may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Darifenacin"}, {"id": "Botulinum Toxin Type A_INT_Anisotropine Methylbromide", "text": "Interaction: Botulinum Toxin Type A AND Anisotropine Methylbromide\nDetails: Anisotropine Methylbromide may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Anisotropine Methylbromide"}, {"id": "Botulinum Toxin Type A_INT_Mecamylamine", "text": "Interaction: Botulinum Toxin Type A AND Mecamylamine\nDetails: Mecamylamine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Mecamylamine"}, {"id": "Botulinum Toxin Type A_INT_Pirenzepine", "text": "Interaction: Botulinum Toxin Type A AND Pirenzepine\nDetails: Pirenzepine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Pirenzepine"}, {"id": "Botulinum Toxin Type A_INT_Quinidine", "text": "Interaction: Botulinum Toxin Type A AND Quinidine\nDetails: Quinidine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Quinidine"}, {"id": "Botulinum Toxin Type A_INT_Methantheline", "text": "Interaction: Botulinum Toxin Type A AND Methantheline\nDetails: Methantheline may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Methantheline"}, {"id": "Botulinum Toxin Type A_INT_Desloratadine", "text": "Interaction: Botulinum Toxin Type A AND Desloratadine\nDetails: Desloratadine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Desloratadine"}, {"id": "Botulinum Toxin Type A_INT_Tolterodine", "text": "Interaction: Botulinum Toxin Type A AND Tolterodine\nDetails: Tolterodine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Tolterodine"}, {"id": "Botulinum Toxin Type A_INT_Oxybutynin", "text": "Interaction: Botulinum Toxin Type A AND Oxybutynin\nDetails: Oxybutynin may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Oxybutynin"}, {"id": "Botulinum Toxin Type A_INT_Pentolinium", "text": "Interaction: Botulinum Toxin Type A AND Pentolinium\nDetails: Pentolinium may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Pentolinium"}, {"id": "Botulinum Toxin Type A_INT_Trimethaphan", "text": "Interaction: Botulinum Toxin Type A AND Trimethaphan\nDetails: Trimethaphan may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Trimethaphan"}, {"id": "Botulinum Toxin Type A_INT_Orphenadrine", "text": "Interaction: Botulinum Toxin Type A AND Orphenadrine\nDetails: Orphenadrine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Orphenadrine"}, {"id": "Botulinum Toxin Type A_INT_Solifenacin", "text": "Interaction: Botulinum Toxin Type A AND Solifenacin\nDetails: Solifenacin may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Solifenacin"}, {"id": "Botulinum Toxin Type A_INT_Fesoterodine", "text": "Interaction: Botulinum Toxin Type A AND Fesoterodine\nDetails: Fesoterodine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Fesoterodine"}, {"id": "Botulinum Toxin Type A_INT_Hexamethonium", "text": "Interaction: Botulinum Toxin Type A AND Hexamethonium\nDetails: Hexamethonium may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Hexamethonium"}, {"id": "Botulinum Toxin Type A_INT_Chlorphenoxamine", "text": "Interaction: Botulinum Toxin Type A AND Chlorphenoxamine\nDetails: Chlorphenoxamine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Chlorphenoxamine"}, {"id": "Botulinum Toxin Type A_INT_Benactyzine", "text": "Interaction: Botulinum Toxin Type A AND Benactyzine\nDetails: Benactyzine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Benactyzine"}, {"id": "Botulinum Toxin Type A_INT_Butylscopolamine", "text": "Interaction: Botulinum Toxin Type A AND Butylscopolamine\nDetails: Butylscopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Butylscopolamine"}, {"id": "Botulinum Toxin Type A_INT_Propiverine", "text": "Interaction: Botulinum Toxin Type A AND Propiverine\nDetails: Propiverine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Propiverine"}, {"id": "Botulinum Toxin Type A_INT_Otilonium", "text": "Interaction: Botulinum Toxin Type A AND Otilonium\nDetails: Otilonium may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Otilonium"}, {"id": "Botulinum Toxin Type A_INT_Emepronium", "text": "Interaction: Botulinum Toxin Type A AND Emepronium\nDetails: Emepronium may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Emepronium"}, {"id": "Botulinum Toxin Type A_INT_Metixene", "text": "Interaction: Botulinum Toxin Type A AND Metixene\nDetails: Metixene may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Metixene"}, {"id": "Botulinum Toxin Type A_INT_Homatropine", "text": "Interaction: Botulinum Toxin Type A AND Homatropine\nDetails: Homatropine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Homatropine"}, {"id": "Botulinum Toxin Type A_INT_Methscopolamine", "text": "Interaction: Botulinum Toxin Type A AND Methscopolamine\nDetails: Methscopolamine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Methscopolamine"}, {"id": "Botulinum Toxin Type A_INT_Oxitropium", "text": "Interaction: Botulinum Toxin Type A AND Oxitropium\nDetails: Oxitropium may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Oxitropium"}, {"id": "Botulinum Toxin Type A_INT_Tropatepine", "text": "Interaction: Botulinum Toxin Type A AND Tropatepine\nDetails: Tropatepine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Tropatepine"}, {"id": "Botulinum Toxin Type A_INT_Mazaticol", "text": "Interaction: Botulinum Toxin Type A AND Mazaticol\nDetails: Mazaticol may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Mazaticol"}, {"id": "Botulinum Toxin Type A_INT_Etybenzatropine", "text": "Interaction: Botulinum Toxin Type A AND Etybenzatropine\nDetails: Etybenzatropine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Etybenzatropine"}, {"id": "Botulinum Toxin Type A_INT_Etanautine", "text": "Interaction: Botulinum Toxin Type A AND Etanautine\nDetails: Etanautine may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Etanautine"}, {"id": "Botulinum Toxin Type A_INT_Methylscopolamine bromide", "text": "Interaction: Botulinum Toxin Type A AND Methylscopolamine bromide\nDetails: Methylscopolamine bromide may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Methylscopolamine bromide"}, {"id": "Botulinum Toxin Type A_INT_Umeclidinium", "text": "Interaction: Botulinum Toxin Type A AND Umeclidinium\nDetails: Umeclidinium may increase the anticholinergic activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Umeclidinium"}, {"id": "Botulinum Toxin Type A_INT_Amikacin", "text": "Interaction: Botulinum Toxin Type A AND Amikacin\nDetails: Amikacin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Amikacin"}, {"id": "Botulinum Toxin Type A_INT_Tobramycin", "text": "Interaction: Botulinum Toxin Type A AND Tobramycin\nDetails: Tobramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Tobramycin"}, {"id": "Botulinum Toxin Type A_INT_Gentamicin", "text": "Interaction: Botulinum Toxin Type A AND Gentamicin\nDetails: Gentamicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Gentamicin"}, {"id": "Botulinum Toxin Type A_INT_Neomycin", "text": "Interaction: Botulinum Toxin Type A AND Neomycin\nDetails: Neomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Neomycin"}, {"id": "Botulinum Toxin Type A_INT_Streptomycin", "text": "Interaction: Botulinum Toxin Type A AND Streptomycin\nDetails: Streptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Streptomycin"}, {"id": "Botulinum Toxin Type A_INT_Valrubicin", "text": "Interaction: Botulinum Toxin Type A AND Valrubicin\nDetails: Valrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Valrubicin"}, {"id": "Botulinum Toxin Type A_INT_Streptozocin", "text": "Interaction: Botulinum Toxin Type A AND Streptozocin\nDetails: Streptozocin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Streptozocin"}, {"id": "Botulinum Toxin Type A_INT_Epirubicin", "text": "Interaction: Botulinum Toxin Type A AND Epirubicin\nDetails: Epirubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Epirubicin"}, {"id": "Botulinum Toxin Type A_INT_Framycetin", "text": "Interaction: Botulinum Toxin Type A AND Framycetin\nDetails: Framycetin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Framycetin"}, {"id": "Botulinum Toxin Type A_INT_Daunorubicin", "text": "Interaction: Botulinum Toxin Type A AND Daunorubicin\nDetails: Daunorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Daunorubicin"}, {"id": "Botulinum Toxin Type A_INT_Spectinomycin", "text": "Interaction: Botulinum Toxin Type A AND Spectinomycin\nDetails: Spectinomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Spectinomycin"}, {"id": "Botulinum Toxin Type A_INT_Netilmicin", "text": "Interaction: Botulinum Toxin Type A AND Netilmicin\nDetails: Netilmicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Netilmicin"}, {"id": "Botulinum Toxin Type A_INT_Doxorubicin", "text": "Interaction: Botulinum Toxin Type A AND Doxorubicin\nDetails: Doxorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Doxorubicin"}, {"id": "Botulinum Toxin Type A_INT_Kanamycin", "text": "Interaction: Botulinum Toxin Type A AND Kanamycin\nDetails: Kanamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Kanamycin"}, {"id": "Botulinum Toxin Type A_INT_Idarubicin", "text": "Interaction: Botulinum Toxin Type A AND Idarubicin\nDetails: Idarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Idarubicin"}, {"id": "Botulinum Toxin Type A_INT_Paromomycin", "text": "Interaction: Botulinum Toxin Type A AND Paromomycin\nDetails: Paromomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Paromomycin"}, {"id": "Botulinum Toxin Type A_INT_Metrizamide", "text": "Interaction: Botulinum Toxin Type A AND Metrizamide\nDetails: Metrizamide may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Metrizamide"}, {"id": "Botulinum Toxin Type A_INT_Ribostamycin", "text": "Interaction: Botulinum Toxin Type A AND Ribostamycin\nDetails: Ribostamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Ribostamycin"}, {"id": "Botulinum Toxin Type A_INT_Geneticin", "text": "Interaction: Botulinum Toxin Type A AND Geneticin\nDetails: Geneticin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Geneticin"}, {"id": "Botulinum Toxin Type A_INT_Apramycin", "text": "Interaction: Botulinum Toxin Type A AND Apramycin\nDetails: Apramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Apramycin"}, {"id": "Botulinum Toxin Type A_INT_GENTAMICIN C1A", "text": "Interaction: Botulinum Toxin Type A AND GENTAMICIN C1A\nDetails: GENTAMICIN C1A may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + GENTAMICIN C1A"}, {"id": "Botulinum Toxin Type A_INT_Neamine", "text": "Interaction: Botulinum Toxin Type A AND Neamine\nDetails: Neamine may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Neamine"}, {"id": "Botulinum Toxin Type A_INT_SP1049C", "text": "Interaction: Botulinum Toxin Type A AND SP1049C\nDetails: SP1049C may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + SP1049C"}, {"id": "Botulinum Toxin Type A_INT_INNO-206", "text": "Interaction: Botulinum Toxin Type A AND INNO-206\nDetails: INNO-206 may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + INNO-206"}, {"id": "Botulinum Toxin Type A_INT_Amrubicin", "text": "Interaction: Botulinum Toxin Type A AND Amrubicin\nDetails: Amrubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Amrubicin"}, {"id": "Botulinum Toxin Type A_INT_annamycin", "text": "Interaction: Botulinum Toxin Type A AND annamycin\nDetails: annamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + annamycin"}, {"id": "Botulinum Toxin Type A_INT_Arbekacin", "text": "Interaction: Botulinum Toxin Type A AND Arbekacin\nDetails: Arbekacin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Arbekacin"}, {"id": "Botulinum Toxin Type A_INT_Plicamycin", "text": "Interaction: Botulinum Toxin Type A AND Plicamycin\nDetails: Plicamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Plicamycin"}, {"id": "Botulinum Toxin Type A_INT_Puromycin", "text": "Interaction: Botulinum Toxin Type A AND Puromycin\nDetails: Puromycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Puromycin"}, {"id": "Botulinum Toxin Type A_INT_Dihydrostreptomycin", "text": "Interaction: Botulinum Toxin Type A AND Dihydrostreptomycin\nDetails: Dihydrostreptomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Dihydrostreptomycin"}, {"id": "Botulinum Toxin Type A_INT_Hygromycin B", "text": "Interaction: Botulinum Toxin Type A AND Hygromycin B\nDetails: Hygromycin B may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Hygromycin B"}, {"id": "Botulinum Toxin Type A_INT_Pirarubicin", "text": "Interaction: Botulinum Toxin Type A AND Pirarubicin\nDetails: Pirarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Pirarubicin"}, {"id": "Botulinum Toxin Type A_INT_Aclarubicin", "text": "Interaction: Botulinum Toxin Type A AND Aclarubicin\nDetails: Aclarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Aclarubicin"}, {"id": "Botulinum Toxin Type A_INT_Zorubicin", "text": "Interaction: Botulinum Toxin Type A AND Zorubicin\nDetails: Zorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Zorubicin"}, {"id": "Botulinum Toxin Type A_INT_Sabarubicin", "text": "Interaction: Botulinum Toxin Type A AND Sabarubicin\nDetails: Sabarubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Sabarubicin"}, {"id": "Botulinum Toxin Type A_INT_Sisomicin", "text": "Interaction: Botulinum Toxin Type A AND Sisomicin\nDetails: Sisomicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Sisomicin"}, {"id": "Botulinum Toxin Type A_INT_Plazomicin", "text": "Interaction: Botulinum Toxin Type A AND Plazomicin\nDetails: Plazomicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Plazomicin"}, {"id": "Botulinum Toxin Type A_INT_Zoptarelin doxorubicin", "text": "Interaction: Botulinum Toxin Type A AND Zoptarelin doxorubicin\nDetails: Zoptarelin doxorubicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Zoptarelin doxorubicin"}, {"id": "Botulinum Toxin Type A_INT_GPX-150", "text": "Interaction: Botulinum Toxin Type A AND GPX-150\nDetails: GPX-150 may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + GPX-150"}, {"id": "Botulinum Toxin Type A_INT_Dibekacin", "text": "Interaction: Botulinum Toxin Type A AND Dibekacin\nDetails: Dibekacin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Dibekacin"}, {"id": "Botulinum Toxin Type A_INT_Micronomicin", "text": "Interaction: Botulinum Toxin Type A AND Micronomicin\nDetails: Micronomicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Micronomicin"}, {"id": "Botulinum Toxin Type A_INT_Isepamicin", "text": "Interaction: Botulinum Toxin Type A AND Isepamicin\nDetails: Isepamicin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Isepamicin"}, {"id": "Botulinum Toxin Type A_INT_Bekanamycin", "text": "Interaction: Botulinum Toxin Type A AND Bekanamycin\nDetails: Bekanamycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.\nRisk: Monitor closely.", "source": "Botulinum Toxin Type A + Bekanamycin"}, {"id": "Pancrelipase_GEN", "text": "Drug: Pancrelipase\nDescription: Pancrelipase is an enzyme mixture isolated from porcine or bovine pancreas, sometimes called pancreatin. It contains 3 enzymes: amylase, lipase, and a protease (chymotrypsin). Pancrelipase is marketed under several brand names such as Ultresa\u2122 and Viokace\u2122....", "source": "Pancrelipase"}, {"id": "Pancrelipase_CLIN", "text": "Drug: Pancrelipase\nMechanism: The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease ...\nToxicity: Overdose symptoms may include diarrhea or stomach upset. The most common adverse reactions seen are ear, neck, and abdominal pain; headache, nasal congestion, and beta-hemolytic streptococcal infectio...", "source": "Pancrelipase"}, {"id": "Pancrelipase_INT_Iron Dextran", "text": "Interaction: Pancrelipase AND Iron Dextran\nDetails: Pancrelipase can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.\nRisk: Monitor closely.", "source": "Pancrelipase + Iron Dextran"}, {"id": "Pancrelipase_INT_Iron", "text": "Interaction: Pancrelipase AND Iron\nDetails: Pancrelipase can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.\nRisk: Monitor closely.", "source": "Pancrelipase + Iron"}, {"id": "Pancrelipase_INT_Iron saccharate", "text": "Interaction: Pancrelipase AND Iron saccharate\nDetails: Pancrelipase can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.\nRisk: Monitor closely.", "source": "Pancrelipase + Iron saccharate"}, {"id": "Pancrelipase_INT_Ferric Carboxymaltose", "text": "Interaction: Pancrelipase AND Ferric Carboxymaltose\nDetails: Pancrelipase can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.\nRisk: Monitor closely.", "source": "Pancrelipase + Ferric Carboxymaltose"}, {"id": "Pancrelipase_INT_Ferric pyrophosphate", "text": "Interaction: Pancrelipase AND Ferric pyrophosphate\nDetails: Pancrelipase can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.\nRisk: Monitor closely.", "source": "Pancrelipase + Ferric pyrophosphate"}, {"id": "Pancrelipase_INT_Ferric Citrate", "text": "Interaction: Pancrelipase AND Ferric Citrate\nDetails: Pancrelipase can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.\nRisk: Monitor closely.", "source": "Pancrelipase + Ferric Citrate"}, {"id": "Streptokinase_GEN", "text": "Drug: Streptokinase\nDescription: ...", "source": "Streptokinase"}, {"id": "Phylloquinone_GEN", "text": "Drug: Phylloquinone\nDescription: ...", "source": "Phylloquinone"}, {"id": "Calcium_GEN", "text": "Drug: Calcium\nDescription: ...", "source": "Calcium"}, {"id": "Streptokinase_GEN", "text": "Drug: Streptokinase\nDescription: Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci....", "source": "Streptokinase"}, {"id": "Streptokinase_CLIN", "text": "Drug: Streptokinase\nMechanism: Plasminogen is an inactive molecule that becomes activated to plasmin when the Arg/Val bond is cleaved. Plasmin breaks down fibrin clots created by the blood clotting cascade. Streptokinase forms a hi...\nToxicity: ...", "source": "Streptokinase"}, {"id": "Streptokinase_INT_Warfarin", "text": "Interaction: Streptokinase AND Warfarin\nDetails: The risk or severity of hemorrhage can be increased when Streptokinase is combined with Warfarin.\nRisk: Monitor closely.", "source": "Streptokinase + Warfarin"}, {"id": "Streptokinase_INT_Dicoumarol", "text": "Interaction: Streptokinase AND Dicoumarol\nDetails: The risk or severity of hemorrhage can be increased when Streptokinase is combined with Dicoumarol.\nRisk: Monitor closely.", "source": "Streptokinase + Dicoumarol"}, {"id": "Streptokinase_INT_Phenindione", "text": "Interaction: Streptokinase AND Phenindione\nDetails: The risk or severity of hemorrhage can be increased when Streptokinase is combined with Phenindione.\nRisk: Monitor closely.", "source": "Streptokinase + Phenindione"}, {"id": "Streptokinase_INT_Phenprocoumon", "text": "Interaction: Streptokinase AND Phenprocoumon\nDetails: The risk or severity of hemorrhage can be increased when Streptokinase is combined with Phenprocoumon.\nRisk: Monitor closely.", "source": "Streptokinase + Phenprocoumon"}, {"id": "Streptokinase_INT_Acenocoumarol", "text": "Interaction: Streptokinase AND Acenocoumarol\nDetails: The risk or severity of hemorrhage can be increased when Streptokinase is combined with Acenocoumarol.\nRisk: Monitor closely.", "source": "Streptokinase + Acenocoumarol"}, {"id": "Streptokinase_INT_Ethyl biscoumacetate", "text": "Interaction: Streptokinase AND Ethyl biscoumacetate\nDetails: The risk or severity of hemorrhage can be increased when Streptokinase is combined with Ethyl biscoumacetate.\nRisk: Monitor closely.", "source": "Streptokinase + Ethyl biscoumacetate"}, {"id": "Streptokinase_INT_Fluindione", "text": "Interaction: Streptokinase AND Fluindione\nDetails: The risk or severity of hemorrhage can be increased when Streptokinase is combined with Fluindione.\nRisk: Monitor closely.", "source": "Streptokinase + Fluindione"}, {"id": "Streptokinase_INT_Clorindione", "text": "Interaction: Streptokinase AND Clorindione\nDetails: The risk or severity of hemorrhage can be increased when Streptokinase is combined with Clorindione.\nRisk: Monitor closely.", "source": "Streptokinase + Clorindione"}, {"id": "Streptokinase_INT_Diphenadione", "text": "Interaction: Streptokinase AND Diphenadione\nDetails: The risk or severity of hemorrhage can be increased when Streptokinase is combined with Diphenadione.\nRisk: Monitor closely.", "source": "Streptokinase + Diphenadione"}, {"id": "Streptokinase_INT_Tioclomarol", "text": "Interaction: Streptokinase AND Tioclomarol\nDetails: The risk or severity of hemorrhage can be increased when Streptokinase is combined with Tioclomarol.\nRisk: Monitor closely.", "source": "Streptokinase + Tioclomarol"}, {"id": "Streptokinase_INT_Heparin", "text": "Interaction: Streptokinase AND Heparin\nDetails: Streptokinase may increase the anticoagulant activities of Heparin.\nRisk: Monitor closely.", "source": "Streptokinase + Heparin"}, {"id": "Streptokinase_INT_Aprotinin", "text": "Interaction: Streptokinase AND Aprotinin\nDetails: The therapeutic efficacy of Streptokinase can be decreased when used in combination with Aprotinin.\nRisk: Monitor closely.", "source": "Streptokinase + Aprotinin"}, {"id": "Streptokinase_INT_Amifostine", "text": "Interaction: Streptokinase AND Amifostine\nDetails: The risk or severity of adverse effects can be increased when Amifostine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Amifostine"}, {"id": "Streptokinase_INT_Amiodarone", "text": "Interaction: Streptokinase AND Amiodarone\nDetails: The risk or severity of adverse effects can be increased when Amiodarone is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Amiodarone"}, {"id": "Streptokinase_INT_Amphotericin B", "text": "Interaction: Streptokinase AND Amphotericin B\nDetails: The risk or severity of adverse effects can be increased when Amphotericin B is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Amphotericin B"}, {"id": "Streptokinase_INT_Apomorphine", "text": "Interaction: Streptokinase AND Apomorphine\nDetails: The risk or severity of adverse effects can be increased when Apomorphine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Apomorphine"}, {"id": "Streptokinase_INT_Arotinolol", "text": "Interaction: Streptokinase AND Arotinolol\nDetails: The risk or severity of adverse effects can be increased when Arotinolol is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Arotinolol"}, {"id": "Streptokinase_INT_Arsenic trioxide", "text": "Interaction: Streptokinase AND Arsenic trioxide\nDetails: The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Arsenic trioxide"}, {"id": "Streptokinase_INT_Barnidipine", "text": "Interaction: Streptokinase AND Barnidipine\nDetails: The risk or severity of adverse effects can be increased when Barnidipine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Barnidipine"}, {"id": "Streptokinase_INT_Bepridil", "text": "Interaction: Streptokinase AND Bepridil\nDetails: The risk or severity of adverse effects can be increased when Bepridil is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Bepridil"}, {"id": "Streptokinase_INT_Bortezomib", "text": "Interaction: Streptokinase AND Bortezomib\nDetails: The risk or severity of adverse effects can be increased when Bortezomib is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Bortezomib"}, {"id": "Streptokinase_INT_Bromocriptine", "text": "Interaction: Streptokinase AND Bromocriptine\nDetails: The risk or severity of adverse effects can be increased when Bromocriptine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Bromocriptine"}, {"id": "Streptokinase_INT_Bupivacaine", "text": "Interaction: Streptokinase AND Bupivacaine\nDetails: The risk or severity of adverse effects can be increased when Bupivacaine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Bupivacaine"}, {"id": "Streptokinase_INT_Carbetocin", "text": "Interaction: Streptokinase AND Carbetocin\nDetails: The risk or severity of adverse effects can be increased when Carbetocin is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Carbetocin"}, {"id": "Streptokinase_INT_Chlorpromazine", "text": "Interaction: Streptokinase AND Chlorpromazine\nDetails: The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Chlorpromazine"}, {"id": "Streptokinase_INT_Cilnidipine", "text": "Interaction: Streptokinase AND Cilnidipine\nDetails: The risk or severity of adverse effects can be increased when Cilnidipine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Cilnidipine"}, {"id": "Streptokinase_INT_Clofarabine", "text": "Interaction: Streptokinase AND Clofarabine\nDetails: The risk or severity of adverse effects can be increased when Clofarabine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Clofarabine"}, {"id": "Streptokinase_INT_Clomipramine", "text": "Interaction: Streptokinase AND Clomipramine\nDetails: The risk or severity of adverse effects can be increased when Clomipramine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Clomipramine"}, {"id": "Streptokinase_INT_Clozapine", "text": "Interaction: Streptokinase AND Clozapine\nDetails: The risk or severity of adverse effects can be increased when Clozapine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Clozapine"}, {"id": "Streptokinase_INT_Conivaptan", "text": "Interaction: Streptokinase AND Conivaptan\nDetails: The risk or severity of adverse effects can be increased when Conivaptan is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Conivaptan"}, {"id": "Streptokinase_INT_Desflurane", "text": "Interaction: Streptokinase AND Desflurane\nDetails: The risk or severity of adverse effects can be increased when Desflurane is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Desflurane"}, {"id": "Streptokinase_INT_Efonidipine", "text": "Interaction: Streptokinase AND Efonidipine\nDetails: The risk or severity of adverse effects can be increased when Efonidipine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Efonidipine"}, {"id": "Streptokinase_INT_Enalaprilat", "text": "Interaction: Streptokinase AND Enalaprilat\nDetails: The risk or severity of adverse effects can be increased when Enalaprilat is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Enalaprilat"}, {"id": "Streptokinase_INT_Epoprostenol", "text": "Interaction: Streptokinase AND Epoprostenol\nDetails: The risk or severity of adverse effects can be increased when Epoprostenol is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Epoprostenol"}, {"id": "Streptokinase_INT_Fenoldopam", "text": "Interaction: Streptokinase AND Fenoldopam\nDetails: The risk or severity of adverse effects can be increased when Fenoldopam is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Fenoldopam"}, {"id": "Streptokinase_INT_Fimasartan", "text": "Interaction: Streptokinase AND Fimasartan\nDetails: The risk or severity of adverse effects can be increased when Fimasartan is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Fimasartan"}, {"id": "Streptokinase_INT_Halothane", "text": "Interaction: Streptokinase AND Halothane\nDetails: The risk or severity of adverse effects can be increased when Halothane is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Halothane"}, {"id": "Streptokinase_INT_Hydroflumethiazide", "text": "Interaction: Streptokinase AND Hydroflumethiazide\nDetails: The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Hydroflumethiazide"}, {"id": "Streptokinase_INT_Iloprost", "text": "Interaction: Streptokinase AND Iloprost\nDetails: The risk or severity of adverse effects can be increased when Iloprost is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Iloprost"}, {"id": "Streptokinase_INT_Imidapril", "text": "Interaction: Streptokinase AND Imidapril\nDetails: The risk or severity of adverse effects can be increased when Imidapril is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Imidapril"}, {"id": "Streptokinase_INT_Imipramine", "text": "Interaction: Streptokinase AND Imipramine\nDetails: The risk or severity of adverse effects can be increased when Imipramine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Imipramine"}, {"id": "Streptokinase_INT_Indoramin", "text": "Interaction: Streptokinase AND Indoramin\nDetails: The risk or severity of adverse effects can be increased when Indoramin is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Indoramin"}, {"id": "Streptokinase_INT_Isocarboxazid", "text": "Interaction: Streptokinase AND Isocarboxazid\nDetails: The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Isocarboxazid"}, {"id": "Streptokinase_INT_Isoflurane", "text": "Interaction: Streptokinase AND Isoflurane\nDetails: The risk or severity of adverse effects can be increased when Isoflurane is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Isoflurane"}, {"id": "Streptokinase_INT_Lacidipine", "text": "Interaction: Streptokinase AND Lacidipine\nDetails: The risk or severity of adverse effects can be increased when Lacidipine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Lacidipine"}, {"id": "Streptokinase_INT_Lercanidipine", "text": "Interaction: Streptokinase AND Lercanidipine\nDetails: The risk or severity of adverse effects can be increased when Lercanidipine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Lercanidipine"}, {"id": "Streptokinase_INT_Levobupivacaine", "text": "Interaction: Streptokinase AND Levobupivacaine\nDetails: The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Levobupivacaine"}, {"id": "Streptokinase_INT_Levosimendan", "text": "Interaction: Streptokinase AND Levosimendan\nDetails: The risk or severity of adverse effects can be increased when Levosimendan is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Levosimendan"}, {"id": "Streptokinase_INT_Lofexidine", "text": "Interaction: Streptokinase AND Lofexidine\nDetails: The risk or severity of adverse effects can be increased when Lofexidine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Lofexidine"}, {"id": "Streptokinase_INT_Morphine", "text": "Interaction: Streptokinase AND Morphine\nDetails: The risk or severity of adverse effects can be increased when Morphine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Morphine"}, {"id": "Streptokinase_INT_Moxonidine", "text": "Interaction: Streptokinase AND Moxonidine\nDetails: The risk or severity of adverse effects can be increased when Moxonidine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Moxonidine"}, {"id": "Streptokinase_INT_Nabilone", "text": "Interaction: Streptokinase AND Nabilone\nDetails: The risk or severity of adverse effects can be increased when Nabilone is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Nabilone"}, {"id": "Streptokinase_INT_Nilvadipine", "text": "Interaction: Streptokinase AND Nilvadipine\nDetails: The risk or severity of adverse effects can be increased when Nilvadipine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Nilvadipine"}, {"id": "Streptokinase_INT_Nitrendipine", "text": "Interaction: Streptokinase AND Nitrendipine\nDetails: The risk or severity of adverse effects can be increased when Nitrendipine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Nitrendipine"}, {"id": "Streptokinase_INT_Nitric Oxide", "text": "Interaction: Streptokinase AND Nitric Oxide\nDetails: The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Nitric Oxide"}, {"id": "Streptokinase_INT_Obinutuzumab", "text": "Interaction: Streptokinase AND Obinutuzumab\nDetails: The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Obinutuzumab"}, {"id": "Streptokinase_INT_Oxprenolol", "text": "Interaction: Streptokinase AND Oxprenolol\nDetails: The risk or severity of adverse effects can be increased when Oxprenolol is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Oxprenolol"}, {"id": "Streptokinase_INT_Paclitaxel", "text": "Interaction: Streptokinase AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Paclitaxel"}, {"id": "Streptokinase_INT_Phenelzine", "text": "Interaction: Streptokinase AND Phenelzine\nDetails: The risk or severity of adverse effects can be increased when Phenelzine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Phenelzine"}, {"id": "Streptokinase_INT_Phenoxybenzamine", "text": "Interaction: Streptokinase AND Phenoxybenzamine\nDetails: The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Phenoxybenzamine"}, {"id": "Streptokinase_INT_Phentolamine", "text": "Interaction: Streptokinase AND Phentolamine\nDetails: The risk or severity of adverse effects can be increased when Phentolamine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Phentolamine"}, {"id": "Streptokinase_INT_Pipamperone", "text": "Interaction: Streptokinase AND Pipamperone\nDetails: The risk or severity of adverse effects can be increased when Pipamperone is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Pipamperone"}, {"id": "Streptokinase_INT_Pramipexole", "text": "Interaction: Streptokinase AND Pramipexole\nDetails: The risk or severity of adverse effects can be increased when Pramipexole is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Pramipexole"}, {"id": "Streptokinase_INT_Propofol", "text": "Interaction: Streptokinase AND Propofol\nDetails: The risk or severity of adverse effects can be increased when Propofol is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Propofol"}, {"id": "Streptokinase_INT_Rasagiline", "text": "Interaction: Streptokinase AND Rasagiline\nDetails: The risk or severity of adverse effects can be increased when Rasagiline is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Rasagiline"}, {"id": "Streptokinase_INT_Remifentanil", "text": "Interaction: Streptokinase AND Remifentanil\nDetails: The risk or severity of adverse effects can be increased when Remifentanil is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Remifentanil"}, {"id": "Streptokinase_INT_Ropinirole", "text": "Interaction: Streptokinase AND Ropinirole\nDetails: The risk or severity of adverse effects can be increased when Ropinirole is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Ropinirole"}, {"id": "Streptokinase_INT_Ropivacaine", "text": "Interaction: Streptokinase AND Ropivacaine\nDetails: The risk or severity of adverse effects can be increased when Ropivacaine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Ropivacaine"}, {"id": "Streptokinase_INT_Rotigotine", "text": "Interaction: Streptokinase AND Rotigotine\nDetails: The risk or severity of adverse effects can be increased when Rotigotine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Rotigotine"}, {"id": "Streptokinase_INT_Sacubitril", "text": "Interaction: Streptokinase AND Sacubitril\nDetails: The risk or severity of adverse effects can be increased when Sacubitril is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Sacubitril"}, {"id": "Streptokinase_INT_Selegiline", "text": "Interaction: Streptokinase AND Selegiline\nDetails: The risk or severity of adverse effects can be increased when Selegiline is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Selegiline"}, {"id": "Streptokinase_INT_Sevoflurane", "text": "Interaction: Streptokinase AND Sevoflurane\nDetails: The risk or severity of adverse effects can be increased when Sevoflurane is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Sevoflurane"}, {"id": "Streptokinase_INT_Sodium Nitrite", "text": "Interaction: Streptokinase AND Sodium Nitrite\nDetails: The risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Sodium Nitrite"}, {"id": "Streptokinase_INT_Sufentanil", "text": "Interaction: Streptokinase AND Sufentanil\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Sufentanil.\nRisk: Monitor closely.", "source": "Streptokinase + Sufentanil"}, {"id": "Streptokinase_INT_Tamsulosin", "text": "Interaction: Streptokinase AND Tamsulosin\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Tamsulosin.\nRisk: Monitor closely.", "source": "Streptokinase + Tamsulosin"}, {"id": "Streptokinase_INT_Thalidomide", "text": "Interaction: Streptokinase AND Thalidomide\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Thalidomide.\nRisk: Monitor closely.", "source": "Streptokinase + Thalidomide"}, {"id": "Streptokinase_INT_Thioridazine", "text": "Interaction: Streptokinase AND Thioridazine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Thioridazine.\nRisk: Monitor closely.", "source": "Streptokinase + Thioridazine"}, {"id": "Streptokinase_INT_Tolazoline", "text": "Interaction: Streptokinase AND Tolazoline\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Tolazoline.\nRisk: Monitor closely.", "source": "Streptokinase + Tolazoline"}, {"id": "Streptokinase_INT_Tolcapone", "text": "Interaction: Streptokinase AND Tolcapone\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Tolcapone.\nRisk: Monitor closely.", "source": "Streptokinase + Tolcapone"}, {"id": "Streptokinase_INT_Tranylcypromine", "text": "Interaction: Streptokinase AND Tranylcypromine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Tranylcypromine.\nRisk: Monitor closely.", "source": "Streptokinase + Tranylcypromine"}, {"id": "Streptokinase_INT_Tretinoin", "text": "Interaction: Streptokinase AND Tretinoin\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Tretinoin.\nRisk: Monitor closely.", "source": "Streptokinase + Tretinoin"}, {"id": "Streptokinase_INT_Aldesleukin", "text": "Interaction: Streptokinase AND Aldesleukin\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Streptokinase + Aldesleukin"}, {"id": "Streptokinase_INT_Valsartan", "text": "Interaction: Streptokinase AND Valsartan\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Valsartan.\nRisk: Monitor closely.", "source": "Streptokinase + Valsartan"}, {"id": "Streptokinase_INT_Ramipril", "text": "Interaction: Streptokinase AND Ramipril\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Ramipril.\nRisk: Monitor closely.", "source": "Streptokinase + Ramipril"}, {"id": "Streptokinase_INT_Esmolol", "text": "Interaction: Streptokinase AND Esmolol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Esmolol.\nRisk: Monitor closely.", "source": "Streptokinase + Esmolol"}, {"id": "Streptokinase_INT_Betaxolol", "text": "Interaction: Streptokinase AND Betaxolol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Betaxolol.\nRisk: Monitor closely.", "source": "Streptokinase + Betaxolol"}, {"id": "Streptokinase_INT_Reserpine", "text": "Interaction: Streptokinase AND Reserpine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Reserpine.\nRisk: Monitor closely.", "source": "Streptokinase + Reserpine"}, {"id": "Streptokinase_INT_Torasemide", "text": "Interaction: Streptokinase AND Torasemide\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Torasemide.\nRisk: Monitor closely.", "source": "Streptokinase + Torasemide"}, {"id": "Streptokinase_INT_Methyclothiazide", "text": "Interaction: Streptokinase AND Methyclothiazide\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Methyclothiazide.\nRisk: Monitor closely.", "source": "Streptokinase + Methyclothiazide"}, {"id": "Streptokinase_INT_Metoprolol", "text": "Interaction: Streptokinase AND Metoprolol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Metoprolol.\nRisk: Monitor closely.", "source": "Streptokinase + Metoprolol"}, {"id": "Streptokinase_INT_Isradipine", "text": "Interaction: Streptokinase AND Isradipine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Isradipine.\nRisk: Monitor closely.", "source": "Streptokinase + Isradipine"}, {"id": "Streptokinase_INT_Olmesartan", "text": "Interaction: Streptokinase AND Olmesartan\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Olmesartan.\nRisk: Monitor closely.", "source": "Streptokinase + Olmesartan"}, {"id": "Streptokinase_INT_Chlorthalidone", "text": "Interaction: Streptokinase AND Chlorthalidone\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Chlorthalidone.\nRisk: Monitor closely.", "source": "Streptokinase + Chlorthalidone"}, {"id": "Streptokinase_INT_Nitroprusside", "text": "Interaction: Streptokinase AND Nitroprusside\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitroprusside.\nRisk: Monitor closely.", "source": "Streptokinase + Nitroprusside"}, {"id": "Streptokinase_INT_Atenolol", "text": "Interaction: Streptokinase AND Atenolol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Atenolol.\nRisk: Monitor closely.", "source": "Streptokinase + Atenolol"}, {"id": "Streptokinase_INT_Diltiazem", "text": "Interaction: Streptokinase AND Diltiazem\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Diltiazem.\nRisk: Monitor closely.", "source": "Streptokinase + Diltiazem"}, {"id": "Streptokinase_INT_Minoxidil", "text": "Interaction: Streptokinase AND Minoxidil\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Minoxidil.\nRisk: Monitor closely.", "source": "Streptokinase + Minoxidil"}, {"id": "Streptokinase_INT_Timolol", "text": "Interaction: Streptokinase AND Timolol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Timolol.\nRisk: Monitor closely.", "source": "Streptokinase + Timolol"}, {"id": "Streptokinase_INT_Amlodipine", "text": "Interaction: Streptokinase AND Amlodipine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Amlodipine.\nRisk: Monitor closely.", "source": "Streptokinase + Amlodipine"}, {"id": "Streptokinase_INT_Triamterene", "text": "Interaction: Streptokinase AND Triamterene\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Triamterene.\nRisk: Monitor closely.", "source": "Streptokinase + Triamterene"}, {"id": "Streptokinase_INT_Nimodipine", "text": "Interaction: Streptokinase AND Nimodipine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Nimodipine.\nRisk: Monitor closely.", "source": "Streptokinase + Nimodipine"}, {"id": "Streptokinase_INT_Nisoldipine", "text": "Interaction: Streptokinase AND Nisoldipine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Nisoldipine.\nRisk: Monitor closely.", "source": "Streptokinase + Nisoldipine"}, {"id": "Streptokinase_INT_Spironolactone", "text": "Interaction: Streptokinase AND Spironolactone\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Spironolactone.\nRisk: Monitor closely.", "source": "Streptokinase + Spironolactone"}, {"id": "Streptokinase_INT_Bendroflumethiazide", "text": "Interaction: Streptokinase AND Bendroflumethiazide\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Bendroflumethiazide.\nRisk: Monitor closely.", "source": "Streptokinase + Bendroflumethiazide"}, {"id": "Streptokinase_INT_Prazosin", "text": "Interaction: Streptokinase AND Prazosin\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Prazosin.\nRisk: Monitor closely.", "source": "Streptokinase + Prazosin"}, {"id": "Streptokinase_INT_Brimonidine", "text": "Interaction: Streptokinase AND Brimonidine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Brimonidine.\nRisk: Monitor closely.", "source": "Streptokinase + Brimonidine"}, {"id": "Streptokinase_INT_Sotalol", "text": "Interaction: Streptokinase AND Sotalol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Sotalol.\nRisk: Monitor closely.", "source": "Streptokinase + Sotalol"}, {"id": "Streptokinase_INT_Fosinopril", "text": "Interaction: Streptokinase AND Fosinopril\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Fosinopril.\nRisk: Monitor closely.", "source": "Streptokinase + Fosinopril"}, {"id": "Streptokinase_INT_Trandolapril", "text": "Interaction: Streptokinase AND Trandolapril\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Trandolapril.\nRisk: Monitor closely.", "source": "Streptokinase + Trandolapril"}, {"id": "Streptokinase_INT_Carteolol", "text": "Interaction: Streptokinase AND Carteolol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Carteolol.\nRisk: Monitor closely.", "source": "Streptokinase + Carteolol"}, {"id": "Streptokinase_INT_Metolazone", "text": "Interaction: Streptokinase AND Metolazone\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Metolazone.\nRisk: Monitor closely.", "source": "Streptokinase + Metolazone"}, {"id": "Streptokinase_INT_Benazepril", "text": "Interaction: Streptokinase AND Benazepril\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Benazepril.\nRisk: Monitor closely.", "source": "Streptokinase + Benazepril"}, {"id": "Streptokinase_INT_Propranolol", "text": "Interaction: Streptokinase AND Propranolol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Propranolol.\nRisk: Monitor closely.", "source": "Streptokinase + Propranolol"}, {"id": "Streptokinase_INT_Clonidine", "text": "Interaction: Streptokinase AND Clonidine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Clonidine.\nRisk: Monitor closely.", "source": "Streptokinase + Clonidine"}, {"id": "Streptokinase_INT_Enalapril", "text": "Interaction: Streptokinase AND Enalapril\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Enalapril.\nRisk: Monitor closely.", "source": "Streptokinase + Enalapril"}, {"id": "Streptokinase_INT_Doxazosin", "text": "Interaction: Streptokinase AND Doxazosin\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Doxazosin.\nRisk: Monitor closely.", "source": "Streptokinase + Doxazosin"}, {"id": "Streptokinase_INT_Amiloride", "text": "Interaction: Streptokinase AND Amiloride\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Amiloride.\nRisk: Monitor closely.", "source": "Streptokinase + Amiloride"}, {"id": "Streptokinase_INT_Labetalol", "text": "Interaction: Streptokinase AND Labetalol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Labetalol.\nRisk: Monitor closely.", "source": "Streptokinase + Labetalol"}, {"id": "Streptokinase_INT_Bisoprolol", "text": "Interaction: Streptokinase AND Bisoprolol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Bisoprolol.\nRisk: Monitor closely.", "source": "Streptokinase + Bisoprolol"}, {"id": "Streptokinase_INT_Nicardipine", "text": "Interaction: Streptokinase AND Nicardipine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Nicardipine.\nRisk: Monitor closely.", "source": "Streptokinase + Nicardipine"}, {"id": "Streptokinase_INT_Dexmedetomidine", "text": "Interaction: Streptokinase AND Dexmedetomidine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Dexmedetomidine.\nRisk: Monitor closely.", "source": "Streptokinase + Dexmedetomidine"}, {"id": "Streptokinase_INT_Mecamylamine", "text": "Interaction: Streptokinase AND Mecamylamine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Mecamylamine.\nRisk: Monitor closely.", "source": "Streptokinase + Mecamylamine"}, {"id": "Streptokinase_INT_Verapamil", "text": "Interaction: Streptokinase AND Verapamil\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Verapamil.\nRisk: Monitor closely.", "source": "Streptokinase + Verapamil"}, {"id": "Streptokinase_INT_Losartan", "text": "Interaction: Streptokinase AND Losartan\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Losartan.\nRisk: Monitor closely.", "source": "Streptokinase + Losartan"}, {"id": "Streptokinase_INT_Moexipril", "text": "Interaction: Streptokinase AND Moexipril\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Moexipril.\nRisk: Monitor closely.", "source": "Streptokinase + Moexipril"}, {"id": "Streptokinase_INT_Furosemide", "text": "Interaction: Streptokinase AND Furosemide\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Furosemide.\nRisk: Monitor closely.", "source": "Streptokinase + Furosemide"}, {"id": "Streptokinase_INT_Tizanidine", "text": "Interaction: Streptokinase AND Tizanidine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Tizanidine.\nRisk: Monitor closely.", "source": "Streptokinase + Tizanidine"}, {"id": "Streptokinase_INT_Eplerenone", "text": "Interaction: Streptokinase AND Eplerenone\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Eplerenone.\nRisk: Monitor closely.", "source": "Streptokinase + Eplerenone"}, {"id": "Streptokinase_INT_Methazolamide", "text": "Interaction: Streptokinase AND Methazolamide\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Methazolamide.\nRisk: Monitor closely.", "source": "Streptokinase + Methazolamide"}, {"id": "Streptokinase_INT_Lisinopril", "text": "Interaction: Streptokinase AND Lisinopril\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Lisinopril.\nRisk: Monitor closely.", "source": "Streptokinase + Lisinopril"}, {"id": "Streptokinase_INT_Nitroglycerin", "text": "Interaction: Streptokinase AND Nitroglycerin\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Nitroglycerin.\nRisk: Monitor closely.", "source": "Streptokinase + Nitroglycerin"}, {"id": "Streptokinase_INT_Mannitol", "text": "Interaction: Streptokinase AND Mannitol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Mannitol.\nRisk: Monitor closely.", "source": "Streptokinase + Mannitol"}, {"id": "Streptokinase_INT_Perindopril", "text": "Interaction: Streptokinase AND Perindopril\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Perindopril.\nRisk: Monitor closely.", "source": "Streptokinase + Perindopril"}, {"id": "Streptokinase_INT_Candesartan cilexetil", "text": "Interaction: Streptokinase AND Candesartan cilexetil\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Candesartan cilexetil.\nRisk: Monitor closely.", "source": "Streptokinase + Candesartan cilexetil"}, {"id": "Streptokinase_INT_Indapamide", "text": "Interaction: Streptokinase AND Indapamide\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Indapamide.\nRisk: Monitor closely.", "source": "Streptokinase + Indapamide"}, {"id": "Streptokinase_INT_Eprosartan", "text": "Interaction: Streptokinase AND Eprosartan\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Eprosartan.\nRisk: Monitor closely.", "source": "Streptokinase + Eprosartan"}, {"id": "Streptokinase_INT_Chlorothiazide", "text": "Interaction: Streptokinase AND Chlorothiazide\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Chlorothiazide.\nRisk: Monitor closely.", "source": "Streptokinase + Chlorothiazide"}, {"id": "Streptokinase_INT_Quinapril", "text": "Interaction: Streptokinase AND Quinapril\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Quinapril.\nRisk: Monitor closely.", "source": "Streptokinase + Quinapril"}, {"id": "Streptokinase_INT_Isosorbide Dinitrate", "text": "Interaction: Streptokinase AND Isosorbide Dinitrate\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Isosorbide Dinitrate.\nRisk: Monitor closely.", "source": "Streptokinase + Isosorbide Dinitrate"}, {"id": "Streptokinase_INT_Bumetanide", "text": "Interaction: Streptokinase AND Bumetanide\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Bumetanide.\nRisk: Monitor closely.", "source": "Streptokinase + Bumetanide"}, {"id": "Streptokinase_INT_Etacrynic acid", "text": "Interaction: Streptokinase AND Etacrynic acid\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Etacrynic acid.\nRisk: Monitor closely.", "source": "Streptokinase + Etacrynic acid"}, {"id": "Streptokinase_INT_Pindolol", "text": "Interaction: Streptokinase AND Pindolol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Pindolol.\nRisk: Monitor closely.", "source": "Streptokinase + Pindolol"}, {"id": "Streptokinase_INT_Apraclonidine", "text": "Interaction: Streptokinase AND Apraclonidine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Apraclonidine.\nRisk: Monitor closely.", "source": "Streptokinase + Apraclonidine"}, {"id": "Streptokinase_INT_Telmisartan", "text": "Interaction: Streptokinase AND Telmisartan\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Telmisartan.\nRisk: Monitor closely.", "source": "Streptokinase + Telmisartan"}, {"id": "Streptokinase_INT_Methyldopa", "text": "Interaction: Streptokinase AND Methyldopa\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Methyldopa.\nRisk: Monitor closely.", "source": "Streptokinase + Methyldopa"}, {"id": "Streptokinase_INT_Dipyridamole", "text": "Interaction: Streptokinase AND Dipyridamole\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Dipyridamole.\nRisk: Monitor closely.", "source": "Streptokinase + Dipyridamole"}, {"id": "Streptokinase_INT_Hydrochlorothiazide", "text": "Interaction: Streptokinase AND Hydrochlorothiazide\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Hydrochlorothiazide.\nRisk: Monitor closely.", "source": "Streptokinase + Hydrochlorothiazide"}, {"id": "Streptokinase_INT_Guanfacine", "text": "Interaction: Streptokinase AND Guanfacine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Guanfacine.\nRisk: Monitor closely.", "source": "Streptokinase + Guanfacine"}, {"id": "Streptokinase_INT_Isosorbide Mononitrate", "text": "Interaction: Streptokinase AND Isosorbide Mononitrate\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Isosorbide Mononitrate.\nRisk: Monitor closely.", "source": "Streptokinase + Isosorbide Mononitrate"}, {"id": "Streptokinase_INT_Felodipine", "text": "Interaction: Streptokinase AND Felodipine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Felodipine.\nRisk: Monitor closely.", "source": "Streptokinase + Felodipine"}, {"id": "Streptokinase_INT_Irbesartan", "text": "Interaction: Streptokinase AND Irbesartan\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Irbesartan.\nRisk: Monitor closely.", "source": "Streptokinase + Irbesartan"}, {"id": "Streptokinase_INT_Papaverine", "text": "Interaction: Streptokinase AND Papaverine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Papaverine.\nRisk: Monitor closely.", "source": "Streptokinase + Papaverine"}, {"id": "Streptokinase_INT_Nifedipine", "text": "Interaction: Streptokinase AND Nifedipine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Nifedipine.\nRisk: Monitor closely.", "source": "Streptokinase + Nifedipine"}, {"id": "Streptokinase_INT_Carvedilol", "text": "Interaction: Streptokinase AND Carvedilol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Carvedilol.\nRisk: Monitor closely.", "source": "Streptokinase + Carvedilol"}, {"id": "Streptokinase_INT_Diclofenamide", "text": "Interaction: Streptokinase AND Diclofenamide\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Diclofenamide.\nRisk: Monitor closely.", "source": "Streptokinase + Diclofenamide"}, {"id": "Streptokinase_INT_Bretylium", "text": "Interaction: Streptokinase AND Bretylium\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Bretylium.\nRisk: Monitor closely.", "source": "Streptokinase + Bretylium"}, {"id": "Streptokinase_INT_Terazosin", "text": "Interaction: Streptokinase AND Terazosin\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Terazosin.\nRisk: Monitor closely.", "source": "Streptokinase + Terazosin"}, {"id": "Streptokinase_INT_Acebutolol", "text": "Interaction: Streptokinase AND Acebutolol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Acebutolol.\nRisk: Monitor closely.", "source": "Streptokinase + Acebutolol"}, {"id": "Streptokinase_INT_Captopril", "text": "Interaction: Streptokinase AND Captopril\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Captopril.\nRisk: Monitor closely.", "source": "Streptokinase + Captopril"}, {"id": "Streptokinase_INT_Nadolol", "text": "Interaction: Streptokinase AND Nadolol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Nadolol.\nRisk: Monitor closely.", "source": "Streptokinase + Nadolol"}, {"id": "Streptokinase_INT_Levobunolol", "text": "Interaction: Streptokinase AND Levobunolol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Levobunolol.\nRisk: Monitor closely.", "source": "Streptokinase + Levobunolol"}, {"id": "Streptokinase_INT_Metipranolol", "text": "Interaction: Streptokinase AND Metipranolol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Metipranolol.\nRisk: Monitor closely.", "source": "Streptokinase + Metipranolol"}, {"id": "Streptokinase_INT_Quetiapine", "text": "Interaction: Streptokinase AND Quetiapine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Quetiapine.\nRisk: Monitor closely.", "source": "Streptokinase + Quetiapine"}, {"id": "Streptokinase_INT_Hydralazine", "text": "Interaction: Streptokinase AND Hydralazine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Hydralazine.\nRisk: Monitor closely.", "source": "Streptokinase + Hydralazine"}, {"id": "Streptokinase_INT_Cilazapril", "text": "Interaction: Streptokinase AND Cilazapril\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Cilazapril.\nRisk: Monitor closely.", "source": "Streptokinase + Cilazapril"}, {"id": "Streptokinase_INT_Penbutolol", "text": "Interaction: Streptokinase AND Penbutolol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Penbutolol.\nRisk: Monitor closely.", "source": "Streptokinase + Penbutolol"}, {"id": "Streptokinase_INT_Amyl Nitrite", "text": "Interaction: Streptokinase AND Amyl Nitrite\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Amyl Nitrite.\nRisk: Monitor closely.", "source": "Streptokinase + Amyl Nitrite"}, {"id": "Streptokinase_INT_Nebivolol", "text": "Interaction: Streptokinase AND Nebivolol\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Nebivolol.\nRisk: Monitor closely.", "source": "Streptokinase + Nebivolol"}, {"id": "Streptokinase_INT_Nesiritide", "text": "Interaction: Streptokinase AND Nesiritide\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Nesiritide.\nRisk: Monitor closely.", "source": "Streptokinase + Nesiritide"}, {"id": "Streptokinase_INT_Clevidipine", "text": "Interaction: Streptokinase AND Clevidipine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Clevidipine.\nRisk: Monitor closely.", "source": "Streptokinase + Clevidipine"}, {"id": "Streptokinase_INT_Dapagliflozin", "text": "Interaction: Streptokinase AND Dapagliflozin\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Dapagliflozin.\nRisk: Monitor closely.", "source": "Streptokinase + Dapagliflozin"}, {"id": "Streptokinase_INT_Azilsartan medoxomil", "text": "Interaction: Streptokinase AND Azilsartan medoxomil\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Azilsartan medoxomil.\nRisk: Monitor closely.", "source": "Streptokinase + Azilsartan medoxomil"}, {"id": "Streptokinase_INT_Canagliflozin", "text": "Interaction: Streptokinase AND Canagliflozin\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Canagliflozin.\nRisk: Monitor closely.", "source": "Streptokinase + Canagliflozin"}, {"id": "Streptokinase_INT_Riociguat", "text": "Interaction: Streptokinase AND Riociguat\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Riociguat.\nRisk: Monitor closely.", "source": "Streptokinase + Riociguat"}, {"id": "Streptokinase_INT_Isoxsuprine", "text": "Interaction: Streptokinase AND Isoxsuprine\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Isoxsuprine.\nRisk: Monitor closely.", "source": "Streptokinase + Isoxsuprine"}, {"id": "Streptokinase_INT_Aliskiren", "text": "Interaction: Streptokinase AND Aliskiren\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Aliskiren.\nRisk: Monitor closely.", "source": "Streptokinase + Aliskiren"}, {"id": "Streptokinase_INT_Empagliflozin", "text": "Interaction: Streptokinase AND Empagliflozin\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Empagliflozin.\nRisk: Monitor closely.", "source": "Streptokinase + Empagliflozin"}, {"id": "Streptokinase_INT_Dinutuximab", "text": "Interaction: Streptokinase AND Dinutuximab\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Dinutuximab.\nRisk: Monitor closely.", "source": "Streptokinase + Dinutuximab"}, {"id": "Streptokinase_INT_Aripiprazole", "text": "Interaction: Streptokinase AND Aripiprazole\nDetails: Aripiprazole may increase the hypotensive activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Aripiprazole"}, {"id": "Streptokinase_INT_Nicorandil", "text": "Interaction: Streptokinase AND Nicorandil\nDetails: Nicorandil may increase the hypotensive activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Nicorandil"}, {"id": "Streptokinase_INT_Limaprost", "text": "Interaction: Streptokinase AND Limaprost\nDetails: The risk or severity of adverse effects can be increased when Limaprost is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Limaprost"}, {"id": "Streptokinase_INT_Dabigatran etexilate", "text": "Interaction: Streptokinase AND Dabigatran etexilate\nDetails: Streptokinase may increase the anticoagulant activities of Dabigatran etexilate.\nRisk: Monitor closely.", "source": "Streptokinase + Dabigatran etexilate"}, {"id": "Streptokinase_INT_Lepirudin", "text": "Interaction: Streptokinase AND Lepirudin\nDetails: Streptokinase may increase the anticoagulant activities of Lepirudin.\nRisk: Monitor closely.", "source": "Streptokinase + Lepirudin"}, {"id": "Streptokinase_INT_Bivalirudin", "text": "Interaction: Streptokinase AND Bivalirudin\nDetails: Streptokinase may increase the anticoagulant activities of Bivalirudin.\nRisk: Monitor closely.", "source": "Streptokinase + Bivalirudin"}, {"id": "Streptokinase_INT_Abciximab", "text": "Interaction: Streptokinase AND Abciximab\nDetails: Streptokinase may increase the anticoagulant activities of Abciximab.\nRisk: Monitor closely.", "source": "Streptokinase + Abciximab"}, {"id": "Streptokinase_INT_Becaplermin", "text": "Interaction: Streptokinase AND Becaplermin\nDetails: Streptokinase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Streptokinase + Becaplermin"}, {"id": "Streptokinase_INT_Argatroban", "text": "Interaction: Streptokinase AND Argatroban\nDetails: Streptokinase may increase the anticoagulant activities of Argatroban.\nRisk: Monitor closely.", "source": "Streptokinase + Argatroban"}, {"id": "Streptokinase_INT_Ardeparin", "text": "Interaction: Streptokinase AND Ardeparin\nDetails: Streptokinase may increase the anticoagulant activities of Ardeparin.\nRisk: Monitor closely.", "source": "Streptokinase + Ardeparin"}, {"id": "Streptokinase_INT_Fondaparinux sodium", "text": "Interaction: Streptokinase AND Fondaparinux sodium\nDetails: Streptokinase may increase the anticoagulant activities of Fondaparinux sodium.\nRisk: Monitor closely.", "source": "Streptokinase + Fondaparinux sodium"}, {"id": "Streptokinase_INT_Pentosan Polysulfate", "text": "Interaction: Streptokinase AND Pentosan Polysulfate\nDetails: Streptokinase may increase the anticoagulant activities of Pentosan Polysulfate.\nRisk: Monitor closely.", "source": "Streptokinase + Pentosan Polysulfate"}, {"id": "Streptokinase_INT_Edetic Acid", "text": "Interaction: Streptokinase AND Edetic Acid\nDetails: Streptokinase may increase the anticoagulant activities of Edetic Acid.\nRisk: Monitor closely.", "source": "Streptokinase + Edetic Acid"}, {"id": "Streptokinase_INT_Enoxaparin", "text": "Interaction: Streptokinase AND Enoxaparin\nDetails: Streptokinase may increase the anticoagulant activities of Enoxaparin.\nRisk: Monitor closely.", "source": "Streptokinase + Enoxaparin"}, {"id": "Streptokinase_INT_Citric Acid", "text": "Interaction: Streptokinase AND Citric Acid\nDetails: Streptokinase may increase the anticoagulant activities of Citric Acid.\nRisk: Monitor closely.", "source": "Streptokinase + Citric Acid"}, {"id": "Streptokinase_INT_Ximelagatran", "text": "Interaction: Streptokinase AND Ximelagatran\nDetails: Streptokinase may increase the anticoagulant activities of Ximelagatran.\nRisk: Monitor closely.", "source": "Streptokinase + Ximelagatran"}, {"id": "Streptokinase_INT_Ancrod", "text": "Interaction: Streptokinase AND Ancrod\nDetails: Streptokinase may increase the anticoagulant activities of Ancrod.\nRisk: Monitor closely.", "source": "Streptokinase + Ancrod"}, {"id": "Streptokinase_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Streptokinase AND Pentaerythritol Tetranitrate\nDetails: Streptokinase may increase the anticoagulant activities of Pentaerythritol Tetranitrate.\nRisk: Monitor closely.", "source": "Streptokinase + Pentaerythritol Tetranitrate"}, {"id": "Streptokinase_INT_Rivaroxaban", "text": "Interaction: Streptokinase AND Rivaroxaban\nDetails: Streptokinase may increase the anticoagulant activities of Rivaroxaban.\nRisk: Monitor closely.", "source": "Streptokinase + Rivaroxaban"}, {"id": "Streptokinase_INT_Sulodexide", "text": "Interaction: Streptokinase AND Sulodexide\nDetails: Streptokinase may increase the anticoagulant activities of Sulodexide.\nRisk: Monitor closely.", "source": "Streptokinase + Sulodexide"}, {"id": "Streptokinase_INT_Idraparinux", "text": "Interaction: Streptokinase AND Idraparinux\nDetails: Streptokinase may increase the anticoagulant activities of Idraparinux.\nRisk: Monitor closely.", "source": "Streptokinase + Idraparinux"}, {"id": "Streptokinase_INT_Apixaban", "text": "Interaction: Streptokinase AND Apixaban\nDetails: Streptokinase may increase the anticoagulant activities of Apixaban.\nRisk: Monitor closely.", "source": "Streptokinase + Apixaban"}, {"id": "Streptokinase_INT_Otamixaban", "text": "Interaction: Streptokinase AND Otamixaban\nDetails: Streptokinase may increase the anticoagulant activities of Otamixaban.\nRisk: Monitor closely.", "source": "Streptokinase + Otamixaban"}, {"id": "Streptokinase_INT_Danaparoid", "text": "Interaction: Streptokinase AND Danaparoid\nDetails: Streptokinase may increase the anticoagulant activities of Danaparoid.\nRisk: Monitor closely.", "source": "Streptokinase + Danaparoid"}, {"id": "Streptokinase_INT_Dalteparin", "text": "Interaction: Streptokinase AND Dalteparin\nDetails: Streptokinase may increase the anticoagulant activities of Dalteparin.\nRisk: Monitor closely.", "source": "Streptokinase + Dalteparin"}, {"id": "Streptokinase_INT_Ferulic acid", "text": "Interaction: Streptokinase AND Ferulic acid\nDetails: Streptokinase may increase the anticoagulant activities of Ferulic acid.\nRisk: Monitor closely.", "source": "Streptokinase + Ferulic acid"}, {"id": "Streptokinase_INT_Nadroparin", "text": "Interaction: Streptokinase AND Nadroparin\nDetails: Streptokinase may increase the anticoagulant activities of Nadroparin.\nRisk: Monitor closely.", "source": "Streptokinase + Nadroparin"}, {"id": "Streptokinase_INT_Edoxaban", "text": "Interaction: Streptokinase AND Edoxaban\nDetails: Streptokinase may increase the anticoagulant activities of Edoxaban.\nRisk: Monitor closely.", "source": "Streptokinase + Edoxaban"}, {"id": "Streptokinase_INT_Dextran", "text": "Interaction: Streptokinase AND Dextran\nDetails: Streptokinase may increase the anticoagulant activities of Dextran.\nRisk: Monitor closely.", "source": "Streptokinase + Dextran"}, {"id": "Streptokinase_INT_Reviparin", "text": "Interaction: Streptokinase AND Reviparin\nDetails: Streptokinase may increase the anticoagulant activities of Reviparin.\nRisk: Monitor closely.", "source": "Streptokinase + Reviparin"}, {"id": "Streptokinase_INT_Certoparin", "text": "Interaction: Streptokinase AND Certoparin\nDetails: Streptokinase may increase the anticoagulant activities of Certoparin.\nRisk: Monitor closely.", "source": "Streptokinase + Certoparin"}, {"id": "Streptokinase_INT_Dextran 70", "text": "Interaction: Streptokinase AND Dextran 70\nDetails: Streptokinase may increase the anticoagulant activities of Dextran 70.\nRisk: Monitor closely.", "source": "Streptokinase + Dextran 70"}, {"id": "Streptokinase_INT_Desirudin", "text": "Interaction: Streptokinase AND Desirudin\nDetails: Streptokinase may increase the anticoagulant activities of Desirudin.\nRisk: Monitor closely.", "source": "Streptokinase + Desirudin"}, {"id": "Streptokinase_INT_Dextran 40", "text": "Interaction: Streptokinase AND Dextran 40\nDetails: Streptokinase may increase the anticoagulant activities of Dextran 40.\nRisk: Monitor closely.", "source": "Streptokinase + Dextran 40"}, {"id": "Streptokinase_INT_Dextran 75", "text": "Interaction: Streptokinase AND Dextran 75\nDetails: Streptokinase may increase the anticoagulant activities of Dextran 75.\nRisk: Monitor closely.", "source": "Streptokinase + Dextran 75"}, {"id": "Streptokinase_INT_Protocatechualdehyde", "text": "Interaction: Streptokinase AND Protocatechualdehyde\nDetails: Streptokinase may increase the anticoagulant activities of Protocatechualdehyde.\nRisk: Monitor closely.", "source": "Streptokinase + Protocatechualdehyde"}, {"id": "Streptokinase_INT_Protein C", "text": "Interaction: Streptokinase AND Protein C\nDetails: Streptokinase may increase the anticoagulant activities of Protein C.\nRisk: Monitor closely.", "source": "Streptokinase + Protein C"}, {"id": "Streptokinase_INT_Antithrombin III human", "text": "Interaction: Streptokinase AND Antithrombin III human\nDetails: Streptokinase may increase the anticoagulant activities of Antithrombin III human.\nRisk: Monitor closely.", "source": "Streptokinase + Antithrombin III human"}, {"id": "Streptokinase_INT_Fondaparinux", "text": "Interaction: Streptokinase AND Fondaparinux\nDetails: Streptokinase may increase the anticoagulant activities of Fondaparinux.\nRisk: Monitor closely.", "source": "Streptokinase + Fondaparinux"}, {"id": "Streptokinase_INT_Letaxaban", "text": "Interaction: Streptokinase AND Letaxaban\nDetails: Streptokinase may increase the anticoagulant activities of Letaxaban.\nRisk: Monitor closely.", "source": "Streptokinase + Letaxaban"}, {"id": "Streptokinase_INT_Darexaban", "text": "Interaction: Streptokinase AND Darexaban\nDetails: Streptokinase may increase the anticoagulant activities of Darexaban.\nRisk: Monitor closely.", "source": "Streptokinase + Darexaban"}, {"id": "Streptokinase_INT_Nafamostat", "text": "Interaction: Streptokinase AND Nafamostat\nDetails: Streptokinase may increase the anticoagulant activities of Nafamostat.\nRisk: Monitor closely.", "source": "Streptokinase + Nafamostat"}, {"id": "Streptokinase_INT_Gabexate", "text": "Interaction: Streptokinase AND Gabexate\nDetails: Streptokinase may increase the anticoagulant activities of Gabexate.\nRisk: Monitor closely.", "source": "Streptokinase + Gabexate"}, {"id": "Streptokinase_INT_Troxerutin", "text": "Interaction: Streptokinase AND Troxerutin\nDetails: Streptokinase may increase the anticoagulant activities of Troxerutin.\nRisk: Monitor closely.", "source": "Streptokinase + Troxerutin"}, {"id": "Streptokinase_INT_Protein S human", "text": "Interaction: Streptokinase AND Protein S human\nDetails: Streptokinase may increase the anticoagulant activities of Protein S human.\nRisk: Monitor closely.", "source": "Streptokinase + Protein S human"}, {"id": "Streptokinase_INT_Melagatran", "text": "Interaction: Streptokinase AND Melagatran\nDetails: Streptokinase may increase the anticoagulant activities of Melagatran.\nRisk: Monitor closely.", "source": "Streptokinase + Melagatran"}, {"id": "Streptokinase_INT_Salicylic acid", "text": "Interaction: Streptokinase AND Salicylic acid\nDetails: The risk or severity of adverse effects can be increased when Salicylic acid is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Salicylic acid"}, {"id": "Streptokinase_INT_Acetylsalicylic acid", "text": "Interaction: Streptokinase AND Acetylsalicylic acid\nDetails: The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Acetylsalicylic acid"}, {"id": "Streptokinase_INT_Aminosalicylic Acid", "text": "Interaction: Streptokinase AND Aminosalicylic Acid\nDetails: The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Aminosalicylic Acid"}, {"id": "Streptokinase_INT_Mesalazine", "text": "Interaction: Streptokinase AND Mesalazine\nDetails: The risk or severity of adverse effects can be increased when Mesalazine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Mesalazine"}, {"id": "Streptokinase_INT_Diflunisal", "text": "Interaction: Streptokinase AND Diflunisal\nDetails: The risk or severity of adverse effects can be increased when Diflunisal is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Diflunisal"}, {"id": "Streptokinase_INT_Balsalazide", "text": "Interaction: Streptokinase AND Balsalazide\nDetails: The risk or severity of adverse effects can be increased when Balsalazide is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Balsalazide"}, {"id": "Streptokinase_INT_Olsalazine", "text": "Interaction: Streptokinase AND Olsalazine\nDetails: The risk or severity of adverse effects can be increased when Olsalazine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Olsalazine"}, {"id": "Streptokinase_INT_dersalazine", "text": "Interaction: Streptokinase AND dersalazine\nDetails: The risk or severity of adverse effects can be increased when dersalazine is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + dersalazine"}, {"id": "Streptokinase_INT_Nitroaspirin", "text": "Interaction: Streptokinase AND Nitroaspirin\nDetails: The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Nitroaspirin"}, {"id": "Streptokinase_INT_Aloxiprin", "text": "Interaction: Streptokinase AND Aloxiprin\nDetails: The risk or severity of adverse effects can be increased when Aloxiprin is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Aloxiprin"}, {"id": "Streptokinase_INT_Guacetisal", "text": "Interaction: Streptokinase AND Guacetisal\nDetails: The risk or severity of adverse effects can be increased when Guacetisal is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Guacetisal"}, {"id": "Streptokinase_INT_Carbaspirin calcium", "text": "Interaction: Streptokinase AND Carbaspirin calcium\nDetails: The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Carbaspirin calcium"}, {"id": "Streptokinase_INT_Hemoglobin crosfumaril", "text": "Interaction: Streptokinase AND Hemoglobin crosfumaril\nDetails: The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Hemoglobin crosfumaril"}, {"id": "Streptokinase_INT_Methyl salicylate", "text": "Interaction: Streptokinase AND Methyl salicylate\nDetails: The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Methyl salicylate"}, {"id": "Streptokinase_INT_Trolamine salicylate", "text": "Interaction: Streptokinase AND Trolamine salicylate\nDetails: The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Trolamine salicylate"}, {"id": "Streptokinase_INT_Methohexital", "text": "Interaction: Streptokinase AND Methohexital\nDetails: Methohexital may increase the hypotensive activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Methohexital"}, {"id": "Streptokinase_INT_Primidone", "text": "Interaction: Streptokinase AND Primidone\nDetails: Primidone may increase the hypotensive activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Primidone"}, {"id": "Streptokinase_INT_Phenobarbital", "text": "Interaction: Streptokinase AND Phenobarbital\nDetails: Phenobarbital may increase the hypotensive activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Phenobarbital"}, {"id": "Streptokinase_INT_Pentobarbital", "text": "Interaction: Streptokinase AND Pentobarbital\nDetails: Pentobarbital may increase the hypotensive activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Pentobarbital"}, {"id": "Streptokinase_INT_Secobarbital", "text": "Interaction: Streptokinase AND Secobarbital\nDetails: Secobarbital may increase the hypotensive activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Secobarbital"}, {"id": "Streptokinase_INT_Thiopental", "text": "Interaction: Streptokinase AND Thiopental\nDetails: Thiopental may increase the hypotensive activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Thiopental"}, {"id": "Streptokinase_INT_Methylphenobarbital", "text": "Interaction: Streptokinase AND Methylphenobarbital\nDetails: Methylphenobarbital may increase the hypotensive activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Methylphenobarbital"}, {"id": "Streptokinase_INT_Thiamylal", "text": "Interaction: Streptokinase AND Thiamylal\nDetails: Thiamylal may increase the hypotensive activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Thiamylal"}, {"id": "Streptokinase_INT_Amobarbital", "text": "Interaction: Streptokinase AND Amobarbital\nDetails: Amobarbital may increase the hypotensive activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Amobarbital"}, {"id": "Streptokinase_INT_Hexobarbital", "text": "Interaction: Streptokinase AND Hexobarbital\nDetails: Hexobarbital may increase the hypotensive activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Hexobarbital"}, {"id": "Streptokinase_INT_Barbital", "text": "Interaction: Streptokinase AND Barbital\nDetails: Barbital may increase the hypotensive activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Barbital"}, {"id": "Streptokinase_INT_Barbexaclone", "text": "Interaction: Streptokinase AND Barbexaclone\nDetails: Barbexaclone may increase the hypotensive activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Barbexaclone"}, {"id": "Streptokinase_INT_Eptifibatide", "text": "Interaction: Streptokinase AND Eptifibatide\nDetails: Eptifibatide may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Eptifibatide"}, {"id": "Streptokinase_INT_Ticlopidine", "text": "Interaction: Streptokinase AND Ticlopidine\nDetails: Ticlopidine may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Ticlopidine"}, {"id": "Streptokinase_INT_Tirofiban", "text": "Interaction: Streptokinase AND Tirofiban\nDetails: Tirofiban may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Tirofiban"}, {"id": "Streptokinase_INT_Clopidogrel", "text": "Interaction: Streptokinase AND Clopidogrel\nDetails: Clopidogrel may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Clopidogrel"}, {"id": "Streptokinase_INT_Prasugrel", "text": "Interaction: Streptokinase AND Prasugrel\nDetails: Prasugrel may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Prasugrel"}, {"id": "Streptokinase_INT_Vorapaxar", "text": "Interaction: Streptokinase AND Vorapaxar\nDetails: Vorapaxar may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Vorapaxar"}, {"id": "Streptokinase_INT_Milrinone", "text": "Interaction: Streptokinase AND Milrinone\nDetails: Milrinone may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Milrinone"}, {"id": "Streptokinase_INT_Anagrelide", "text": "Interaction: Streptokinase AND Anagrelide\nDetails: Anagrelide may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Anagrelide"}, {"id": "Streptokinase_INT_Epinastine", "text": "Interaction: Streptokinase AND Epinastine\nDetails: Epinastine may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Epinastine"}, {"id": "Streptokinase_INT_Alprostadil", "text": "Interaction: Streptokinase AND Alprostadil\nDetails: Alprostadil may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Alprostadil"}, {"id": "Streptokinase_INT_Pentoxifylline", "text": "Interaction: Streptokinase AND Pentoxifylline\nDetails: Pentoxifylline may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Pentoxifylline"}, {"id": "Streptokinase_INT_Azelastine", "text": "Interaction: Streptokinase AND Azelastine\nDetails: Azelastine may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Azelastine"}, {"id": "Streptokinase_INT_Cilostazol", "text": "Interaction: Streptokinase AND Cilostazol\nDetails: Cilostazol may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Cilostazol"}, {"id": "Streptokinase_INT_Ridogrel", "text": "Interaction: Streptokinase AND Ridogrel\nDetails: Ridogrel may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Ridogrel"}, {"id": "Streptokinase_INT_Resveratrol", "text": "Interaction: Streptokinase AND Resveratrol\nDetails: Resveratrol may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Resveratrol"}, {"id": "Streptokinase_INT_Nimesulide", "text": "Interaction: Streptokinase AND Nimesulide\nDetails: Nimesulide may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Nimesulide"}, {"id": "Streptokinase_INT_Tesmilifene", "text": "Interaction: Streptokinase AND Tesmilifene\nDetails: Tesmilifene may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Tesmilifene"}, {"id": "Streptokinase_INT_Defibrotide", "text": "Interaction: Streptokinase AND Defibrotide\nDetails: Defibrotide may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Defibrotide"}, {"id": "Streptokinase_INT_SRT501", "text": "Interaction: Streptokinase AND SRT501\nDetails: SRT501 may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + SRT501"}, {"id": "Streptokinase_INT_Beraprost", "text": "Interaction: Streptokinase AND Beraprost\nDetails: Beraprost may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Beraprost"}, {"id": "Streptokinase_INT_Ibudilast", "text": "Interaction: Streptokinase AND Ibudilast\nDetails: Ibudilast may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Ibudilast"}, {"id": "Streptokinase_INT_Andrographolide", "text": "Interaction: Streptokinase AND Andrographolide\nDetails: Andrographolide may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Andrographolide"}, {"id": "Streptokinase_INT_eplivanserine", "text": "Interaction: Streptokinase AND eplivanserine\nDetails: eplivanserine may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + eplivanserine"}, {"id": "Streptokinase_INT_Cangrelor", "text": "Interaction: Streptokinase AND Cangrelor\nDetails: Cangrelor may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Cangrelor"}, {"id": "Streptokinase_INT_Tranilast", "text": "Interaction: Streptokinase AND Tranilast\nDetails: Tranilast may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Tranilast"}, {"id": "Streptokinase_INT_Triflusal", "text": "Interaction: Streptokinase AND Triflusal\nDetails: Triflusal may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Triflusal"}, {"id": "Streptokinase_INT_Icosapent ethyl", "text": "Interaction: Streptokinase AND Icosapent ethyl\nDetails: Icosapent ethyl may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Icosapent ethyl"}, {"id": "Streptokinase_INT_Ifenprodil", "text": "Interaction: Streptokinase AND Ifenprodil\nDetails: Ifenprodil may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Ifenprodil"}, {"id": "Streptokinase_INT_Trapidil", "text": "Interaction: Streptokinase AND Trapidil\nDetails: Trapidil may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Trapidil"}, {"id": "Streptokinase_INT_Naftopidil", "text": "Interaction: Streptokinase AND Naftopidil\nDetails: Naftopidil may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Naftopidil"}, {"id": "Streptokinase_INT_Sarpogrelate", "text": "Interaction: Streptokinase AND Sarpogrelate\nDetails: Sarpogrelate may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Sarpogrelate"}, {"id": "Streptokinase_INT_Eplivanserin", "text": "Interaction: Streptokinase AND Eplivanserin\nDetails: Eplivanserin may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Eplivanserin"}, {"id": "Streptokinase_INT_Ifetroban", "text": "Interaction: Streptokinase AND Ifetroban\nDetails: Ifetroban may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Ifetroban"}, {"id": "Streptokinase_INT_Ketanserin", "text": "Interaction: Streptokinase AND Ketanserin\nDetails: Ketanserin may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Ketanserin"}, {"id": "Streptokinase_INT_Indobufen", "text": "Interaction: Streptokinase AND Indobufen\nDetails: Indobufen may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Indobufen"}, {"id": "Streptokinase_INT_Butylphthalide", "text": "Interaction: Streptokinase AND Butylphthalide\nDetails: Butylphthalide may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Butylphthalide"}, {"id": "Streptokinase_INT_Hydroxytyrosol", "text": "Interaction: Streptokinase AND Hydroxytyrosol\nDetails: Hydroxytyrosol may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Hydroxytyrosol"}, {"id": "Streptokinase_INT_Ramatroban", "text": "Interaction: Streptokinase AND Ramatroban\nDetails: Ramatroban may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Ramatroban"}, {"id": "Streptokinase_INT_Picotamide", "text": "Interaction: Streptokinase AND Picotamide\nDetails: Picotamide may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Picotamide"}, {"id": "Streptokinase_INT_Cloricromen", "text": "Interaction: Streptokinase AND Cloricromen\nDetails: Cloricromen may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Cloricromen"}, {"id": "Streptokinase_INT_Linsidomine", "text": "Interaction: Streptokinase AND Linsidomine\nDetails: Linsidomine may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Linsidomine"}, {"id": "Streptokinase_INT_Buflomedil", "text": "Interaction: Streptokinase AND Buflomedil\nDetails: Buflomedil may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Buflomedil"}, {"id": "Streptokinase_INT_Relcovaptan", "text": "Interaction: Streptokinase AND Relcovaptan\nDetails: Relcovaptan may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Relcovaptan"}, {"id": "Streptokinase_INT_Ticagrelor", "text": "Interaction: Streptokinase AND Ticagrelor\nDetails: Ticagrelor may increase the anticoagulant activities of Streptokinase.\nRisk: Monitor closely.", "source": "Streptokinase + Ticagrelor"}, {"id": "Streptokinase_INT_Duloxetine", "text": "Interaction: Streptokinase AND Duloxetine\nDetails: Streptokinase may increase the orthostatic hypotensive activities of Duloxetine.\nRisk: Monitor closely.", "source": "Streptokinase + Duloxetine"}, {"id": "Streptokinase_INT_Levodopa", "text": "Interaction: Streptokinase AND Levodopa\nDetails: Streptokinase may increase the orthostatic hypotensive activities of Levodopa.\nRisk: Monitor closely.", "source": "Streptokinase + Levodopa"}, {"id": "Streptokinase_INT_Risperidone", "text": "Interaction: Streptokinase AND Risperidone\nDetails: Streptokinase may increase the hypotensive activities of Risperidone.\nRisk: Monitor closely.", "source": "Streptokinase + Risperidone"}, {"id": "Streptokinase_INT_Treprostinil", "text": "Interaction: Streptokinase AND Treprostinil\nDetails: The risk or severity of adverse effects can be increased when Streptokinase is combined with Treprostinil.\nRisk: Monitor closely.", "source": "Streptokinase + Treprostinil"}, {"id": "Alemtuzumab_GEN", "text": "Drug: Alemtuzumab\nDescription: Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions,...", "source": "Alemtuzumab"}, {"id": "Alemtuzumab_CLIN", "text": "Drug: Alemtuzumab\nMechanism: Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells....\nToxicity: ...", "source": "Alemtuzumab"}, {"id": "Alemtuzumab_INT_Metamizole", "text": "Interaction: Alemtuzumab AND Metamizole\nDetails: The risk or severity of myelosuppression can be increased when Metamizole is combined with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Metamizole"}, {"id": "Alemtuzumab_INT_Natalizumab", "text": "Interaction: Alemtuzumab AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Natalizumab"}, {"id": "Alemtuzumab_INT_Pimecrolimus", "text": "Interaction: Alemtuzumab AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Pimecrolimus"}, {"id": "Alemtuzumab_INT_Tofacitinib", "text": "Interaction: Alemtuzumab AND Tofacitinib\nDetails: Alemtuzumab may increase the immunosuppressive activities of Tofacitinib.\nRisk: Monitor closely.", "source": "Alemtuzumab + Tofacitinib"}, {"id": "Alemtuzumab_INT_Tacrolimus", "text": "Interaction: Alemtuzumab AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Tacrolimus"}, {"id": "Alemtuzumab_INT_Clozapine", "text": "Interaction: Alemtuzumab AND Clozapine\nDetails: The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clozapine.\nRisk: Monitor closely.", "source": "Alemtuzumab + Clozapine"}, {"id": "Alemtuzumab_INT_Belimumab", "text": "Interaction: Alemtuzumab AND Belimumab\nDetails: The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belimumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Belimumab"}, {"id": "Alemtuzumab_INT_BCG vaccine", "text": "Interaction: Alemtuzumab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + BCG vaccine"}, {"id": "Alemtuzumab_INT_Trastuzumab", "text": "Interaction: Alemtuzumab AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Trastuzumab"}, {"id": "Alemtuzumab_INT_Leflunomide", "text": "Interaction: Alemtuzumab AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Alemtuzumab + Leflunomide"}, {"id": "Alemtuzumab_INT_Fingolimod", "text": "Interaction: Alemtuzumab AND Fingolimod\nDetails: Alemtuzumab may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Alemtuzumab + Fingolimod"}, {"id": "Alemtuzumab_INT_Roflumilast", "text": "Interaction: Alemtuzumab AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Roflumilast"}, {"id": "Alemtuzumab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Alemtuzumab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Alemtuzumab_INT_Yellow fever vaccine", "text": "Interaction: Alemtuzumab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Yellow fever vaccine"}, {"id": "Alemtuzumab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Alemtuzumab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Alemtuzumab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Alemtuzumab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Alemtuzumab_INT_Rotavirus Vaccine", "text": "Interaction: Alemtuzumab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Rotavirus Vaccine"}, {"id": "Alemtuzumab_INT_G17DT", "text": "Interaction: Alemtuzumab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + G17DT"}, {"id": "Alemtuzumab_INT_INGN 201", "text": "Interaction: Alemtuzumab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + INGN 201"}, {"id": "Alemtuzumab_INT_INGN 225", "text": "Interaction: Alemtuzumab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + INGN 225"}, {"id": "Alemtuzumab_INT_Rindopepimut", "text": "Interaction: Alemtuzumab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Rindopepimut"}, {"id": "Alemtuzumab_INT_SRP 299", "text": "Interaction: Alemtuzumab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + SRP 299"}, {"id": "Alemtuzumab_INT_GI-5005", "text": "Interaction: Alemtuzumab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + GI-5005"}, {"id": "Alemtuzumab_INT_TG4010", "text": "Interaction: Alemtuzumab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + TG4010"}, {"id": "Alemtuzumab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Alemtuzumab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Rabies virus inactivated antigen, A"}, {"id": "Alemtuzumab_INT_Tecemotide", "text": "Interaction: Alemtuzumab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Tecemotide"}, {"id": "Alemtuzumab_INT_Rubella virus vaccine", "text": "Interaction: Alemtuzumab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Rubella virus vaccine"}, {"id": "Alemtuzumab_INT_Hepatitis A Vaccine", "text": "Interaction: Alemtuzumab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Hepatitis A Vaccine"}, {"id": "Alemtuzumab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Alemtuzumab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Salmonella typhi ty21a live antigen"}, {"id": "Alemtuzumab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Alemtuzumab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Alemtuzumab_INT_Paclitaxel", "text": "Interaction: Alemtuzumab AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Paclitaxel"}, {"id": "Alemtuzumab_INT_Docetaxel", "text": "Interaction: Alemtuzumab AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Docetaxel"}, {"id": "Alemtuzumab_INT_Cabazitaxel", "text": "Interaction: Alemtuzumab AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Cabazitaxel"}, {"id": "Alemtuzumab_INT_Digoxin", "text": "Interaction: Alemtuzumab AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Digoxin"}, {"id": "Alemtuzumab_INT_Acetyldigitoxin", "text": "Interaction: Alemtuzumab AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Acetyldigitoxin"}, {"id": "Alemtuzumab_INT_Deslanoside", "text": "Interaction: Alemtuzumab AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Deslanoside"}, {"id": "Alemtuzumab_INT_Ouabain", "text": "Interaction: Alemtuzumab AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Ouabain"}, {"id": "Alemtuzumab_INT_Digitoxin", "text": "Interaction: Alemtuzumab AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Digitoxin"}, {"id": "Alemtuzumab_INT_Cymarin", "text": "Interaction: Alemtuzumab AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Cymarin"}, {"id": "Alemtuzumab_INT_Proscillaridin", "text": "Interaction: Alemtuzumab AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Proscillaridin"}, {"id": "Alemtuzumab_INT_Metildigoxin", "text": "Interaction: Alemtuzumab AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Metildigoxin"}, {"id": "Alemtuzumab_INT_Peruvoside", "text": "Interaction: Alemtuzumab AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Peruvoside"}, {"id": "Alemtuzumab_INT_Lanatoside C", "text": "Interaction: Alemtuzumab AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Lanatoside C"}, {"id": "Alemtuzumab_INT_Gitoformate", "text": "Interaction: Alemtuzumab AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Gitoformate"}, {"id": "Alemtuzumab_INT_Acetyldigoxin", "text": "Interaction: Alemtuzumab AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Acetyldigoxin"}, {"id": "Alemtuzumab_INT_Oleandrin", "text": "Interaction: Alemtuzumab AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Oleandrin"}, {"id": "Alemtuzumab_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Alemtuzumab AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Digoxin Immune Fab (Ovine)"}, {"id": "Alemtuzumab_INT_Bevacizumab", "text": "Interaction: Alemtuzumab AND Bevacizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Bevacizumab"}, {"id": "Alemtuzumab_INT_Cyclophosphamide", "text": "Interaction: Alemtuzumab AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Cyclophosphamide"}, {"id": "Alemtuzumab_INT_Denosumab", "text": "Interaction: Alemtuzumab AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Denosumab"}, {"id": "Alemtuzumab_INT_Sipuleucel-T", "text": "Interaction: Alemtuzumab AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alemtuzumab.\nRisk: Monitor closely.", "source": "Alemtuzumab + Sipuleucel-T"}, {"id": "Alglucerase_GEN", "text": "Drug: Alglucerase\nDescription: Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar resi...", "source": "Alglucerase"}, {"id": "Alglucerase_CLIN", "text": "Drug: Alglucerase\nMechanism: Alglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids....\nToxicity: ...", "source": "Alglucerase"}, {"id": "Capromab pendetide_GEN", "text": "Drug: Capromab pendetide\nDescription: Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA \u2013 also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA. Pendetide acts as a chelating agent f...", "source": "Capromab pendetide"}, {"id": "Capromab pendetide_CLIN", "text": "Drug: Capromab pendetide\nMechanism: Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors....\nToxicity: ...", "source": "Capromab pendetide"}, {"id": "Capromab pendetide_INT_Fluorometholone", "text": "Interaction: Capromab pendetide AND Fluorometholone\nDetails: Fluorometholone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Fluorometholone"}, {"id": "Capromab pendetide_INT_Beclomethasone dipropionate", "text": "Interaction: Capromab pendetide AND Beclomethasone dipropionate\nDetails: Beclomethasone dipropionate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Beclomethasone dipropionate"}, {"id": "Capromab pendetide_INT_Betamethasone", "text": "Interaction: Capromab pendetide AND Betamethasone\nDetails: Betamethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Betamethasone"}, {"id": "Capromab pendetide_INT_Triamcinolone", "text": "Interaction: Capromab pendetide AND Triamcinolone\nDetails: Triamcinolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Triamcinolone"}, {"id": "Capromab pendetide_INT_Hydrocortisone", "text": "Interaction: Capromab pendetide AND Hydrocortisone\nDetails: Hydrocortisone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Hydrocortisone"}, {"id": "Capromab pendetide_INT_Prednisolone", "text": "Interaction: Capromab pendetide AND Prednisolone\nDetails: Prednisolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Prednisolone"}, {"id": "Capromab pendetide_INT_Fluocinonide", "text": "Interaction: Capromab pendetide AND Fluocinonide\nDetails: Fluocinonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Fluocinonide"}, {"id": "Capromab pendetide_INT_Budesonide", "text": "Interaction: Capromab pendetide AND Budesonide\nDetails: Budesonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Budesonide"}, {"id": "Capromab pendetide_INT_Dexamethasone", "text": "Interaction: Capromab pendetide AND Dexamethasone\nDetails: Dexamethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Dexamethasone"}, {"id": "Capromab pendetide_INT_Ciclesonide", "text": "Interaction: Capromab pendetide AND Ciclesonide\nDetails: Ciclesonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Ciclesonide"}, {"id": "Capromab pendetide_INT_Tixocortol", "text": "Interaction: Capromab pendetide AND Tixocortol\nDetails: Tixocortol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Tixocortol"}, {"id": "Capromab pendetide_INT_Fluocinolone Acetonide", "text": "Interaction: Capromab pendetide AND Fluocinolone Acetonide\nDetails: Fluocinolone Acetonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Fluocinolone Acetonide"}, {"id": "Capromab pendetide_INT_Diflorasone", "text": "Interaction: Capromab pendetide AND Diflorasone\nDetails: Diflorasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Diflorasone"}, {"id": "Capromab pendetide_INT_Alclometasone", "text": "Interaction: Capromab pendetide AND Alclometasone\nDetails: Alclometasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Alclometasone"}, {"id": "Capromab pendetide_INT_Amcinonide", "text": "Interaction: Capromab pendetide AND Amcinonide\nDetails: Amcinonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Amcinonide"}, {"id": "Capromab pendetide_INT_Desoximetasone", "text": "Interaction: Capromab pendetide AND Desoximetasone\nDetails: Desoximetasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Desoximetasone"}, {"id": "Capromab pendetide_INT_Clocortolone", "text": "Interaction: Capromab pendetide AND Clocortolone\nDetails: Clocortolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Clocortolone"}, {"id": "Capromab pendetide_INT_Flurandrenolide", "text": "Interaction: Capromab pendetide AND Flurandrenolide\nDetails: Flurandrenolide may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Flurandrenolide"}, {"id": "Capromab pendetide_INT_Rimexolone", "text": "Interaction: Capromab pendetide AND Rimexolone\nDetails: Rimexolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Rimexolone"}, {"id": "Capromab pendetide_INT_Methylprednisolone", "text": "Interaction: Capromab pendetide AND Methylprednisolone\nDetails: Methylprednisolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Methylprednisolone"}, {"id": "Capromab pendetide_INT_Clobetasol propionate", "text": "Interaction: Capromab pendetide AND Clobetasol propionate\nDetails: Clobetasol propionate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Clobetasol propionate"}, {"id": "Capromab pendetide_INT_Prednicarbate", "text": "Interaction: Capromab pendetide AND Prednicarbate\nDetails: Prednicarbate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Prednicarbate"}, {"id": "Capromab pendetide_INT_Cortisone acetate", "text": "Interaction: Capromab pendetide AND Cortisone acetate\nDetails: Cortisone acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Cortisone acetate"}, {"id": "Capromab pendetide_INT_Flunisolide", "text": "Interaction: Capromab pendetide AND Flunisolide\nDetails: Flunisolide may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Flunisolide"}, {"id": "Capromab pendetide_INT_Fluticasone propionate", "text": "Interaction: Capromab pendetide AND Fluticasone propionate\nDetails: Fluticasone propionate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Fluticasone propionate"}, {"id": "Capromab pendetide_INT_Mometasone", "text": "Interaction: Capromab pendetide AND Mometasone\nDetails: Mometasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Mometasone"}, {"id": "Capromab pendetide_INT_Loteprednol", "text": "Interaction: Capromab pendetide AND Loteprednol\nDetails: Loteprednol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Loteprednol"}, {"id": "Capromab pendetide_INT_Fluticasone furoate", "text": "Interaction: Capromab pendetide AND Fluticasone furoate\nDetails: Fluticasone furoate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Fluticasone furoate"}, {"id": "Capromab pendetide_INT_Difluprednate", "text": "Interaction: Capromab pendetide AND Difluprednate\nDetails: Difluprednate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Difluprednate"}, {"id": "Capromab pendetide_INT_Medrysone", "text": "Interaction: Capromab pendetide AND Medrysone\nDetails: Medrysone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Medrysone"}, {"id": "Capromab pendetide_INT_Prednisone", "text": "Interaction: Capromab pendetide AND Prednisone\nDetails: Prednisone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Prednisone"}, {"id": "Capromab pendetide_INT_Estrone", "text": "Interaction: Capromab pendetide AND Estrone\nDetails: Estrone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Estrone"}, {"id": "Capromab pendetide_INT_Flumethasone", "text": "Interaction: Capromab pendetide AND Flumethasone\nDetails: Flumethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Flumethasone"}, {"id": "Capromab pendetide_INT_Fludrocortisone", "text": "Interaction: Capromab pendetide AND Fludrocortisone\nDetails: Fludrocortisone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Fludrocortisone"}, {"id": "Capromab pendetide_INT_Desoxycorticosterone Pivalate", "text": "Interaction: Capromab pendetide AND Desoxycorticosterone Pivalate\nDetails: Desoxycorticosterone Pivalate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Desoxycorticosterone Pivalate"}, {"id": "Capromab pendetide_INT_Paramethasone", "text": "Interaction: Capromab pendetide AND Paramethasone\nDetails: Paramethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Paramethasone"}, {"id": "Capromab pendetide_INT_19-norandrostenedione", "text": "Interaction: Capromab pendetide AND 19-norandrostenedione\nDetails: 19-norandrostenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + 19-norandrostenedione"}, {"id": "Capromab pendetide_INT_5-androstenedione", "text": "Interaction: Capromab pendetide AND 5-androstenedione\nDetails: 5-androstenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + 5-androstenedione"}, {"id": "Capromab pendetide_INT_Androstenedione", "text": "Interaction: Capromab pendetide AND Androstenedione\nDetails: Androstenedione may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Androstenedione"}, {"id": "Capromab pendetide_INT_Prasterone", "text": "Interaction: Capromab pendetide AND Prasterone\nDetails: Prasterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Prasterone"}, {"id": "Capromab pendetide_INT_Equilin", "text": "Interaction: Capromab pendetide AND Equilin\nDetails: Equilin may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Equilin"}, {"id": "Capromab pendetide_INT_Pregnenolone", "text": "Interaction: Capromab pendetide AND Pregnenolone\nDetails: Pregnenolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Pregnenolone"}, {"id": "Capromab pendetide_INT_Equilenin", "text": "Interaction: Capromab pendetide AND Equilenin\nDetails: Equilenin may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Equilenin"}, {"id": "Capromab pendetide_INT_Estrone sulfate", "text": "Interaction: Capromab pendetide AND Estrone sulfate\nDetails: Estrone sulfate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Estrone sulfate"}, {"id": "Capromab pendetide_INT_Aldosterone", "text": "Interaction: Capromab pendetide AND Aldosterone\nDetails: Aldosterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Aldosterone"}, {"id": "Capromab pendetide_INT_Corticosterone", "text": "Interaction: Capromab pendetide AND Corticosterone\nDetails: Corticosterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Corticosterone"}, {"id": "Capromab pendetide_INT_Oleoyl-estrone", "text": "Interaction: Capromab pendetide AND Oleoyl-estrone\nDetails: Oleoyl-estrone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Oleoyl-estrone"}, {"id": "Capromab pendetide_INT_16-Bromoepiandrosterone", "text": "Interaction: Capromab pendetide AND 16-Bromoepiandrosterone\nDetails: 16-Bromoepiandrosterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + 16-Bromoepiandrosterone"}, {"id": "Capromab pendetide_INT_HE3286", "text": "Interaction: Capromab pendetide AND HE3286\nDetails: HE3286 may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + HE3286"}, {"id": "Capromab pendetide_INT_anecortave acetate", "text": "Interaction: Capromab pendetide AND anecortave acetate\nDetails: anecortave acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + anecortave acetate"}, {"id": "Capromab pendetide_INT_ME-609", "text": "Interaction: Capromab pendetide AND ME-609\nDetails: ME-609 may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + ME-609"}, {"id": "Capromab pendetide_INT_NCX 1022", "text": "Interaction: Capromab pendetide AND NCX 1022\nDetails: NCX 1022 may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + NCX 1022"}, {"id": "Capromab pendetide_INT_Prasterone sulfate", "text": "Interaction: Capromab pendetide AND Prasterone sulfate\nDetails: Prasterone sulfate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Prasterone sulfate"}, {"id": "Capromab pendetide_INT_Istaroxime", "text": "Interaction: Capromab pendetide AND Istaroxime\nDetails: Istaroxime may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Istaroxime"}, {"id": "Capromab pendetide_INT_fluasterone", "text": "Interaction: Capromab pendetide AND fluasterone\nDetails: fluasterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + fluasterone"}, {"id": "Capromab pendetide_INT_Desoxycorticosterone acetate", "text": "Interaction: Capromab pendetide AND Desoxycorticosterone acetate\nDetails: Desoxycorticosterone acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Desoxycorticosterone acetate"}, {"id": "Capromab pendetide_INT_Formestane", "text": "Interaction: Capromab pendetide AND Formestane\nDetails: Formestane may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Formestane"}, {"id": "Capromab pendetide_INT_Fluprednidene", "text": "Interaction: Capromab pendetide AND Fluprednidene\nDetails: Fluprednidene may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Fluprednidene"}, {"id": "Capromab pendetide_INT_Fluocortolone", "text": "Interaction: Capromab pendetide AND Fluocortolone\nDetails: Fluocortolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Fluocortolone"}, {"id": "Capromab pendetide_INT_Difluocortolone", "text": "Interaction: Capromab pendetide AND Difluocortolone\nDetails: Difluocortolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Difluocortolone"}, {"id": "Capromab pendetide_INT_Fluprednisolone", "text": "Interaction: Capromab pendetide AND Fluprednisolone\nDetails: Fluprednisolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Fluprednisolone"}, {"id": "Capromab pendetide_INT_Dexamethasone isonicotinate", "text": "Interaction: Capromab pendetide AND Dexamethasone isonicotinate\nDetails: Dexamethasone isonicotinate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Dexamethasone isonicotinate"}, {"id": "Capromab pendetide_INT_Melengestrol", "text": "Interaction: Capromab pendetide AND Melengestrol\nDetails: Melengestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Melengestrol"}, {"id": "Capromab pendetide_INT_Clobetasol", "text": "Interaction: Capromab pendetide AND Clobetasol\nDetails: Clobetasol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Clobetasol"}, {"id": "Capromab pendetide_INT_Anecortave", "text": "Interaction: Capromab pendetide AND Anecortave\nDetails: Anecortave may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Anecortave"}, {"id": "Capromab pendetide_INT_Atamestane", "text": "Interaction: Capromab pendetide AND Atamestane\nDetails: Atamestane may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Atamestane"}, {"id": "Capromab pendetide_INT_Cortexolone 17\u03b1-propionate", "text": "Interaction: Capromab pendetide AND Cortexolone 17\u03b1-propionate\nDetails: Cortexolone 17\u03b1-propionate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Cortexolone 17\u03b1-propionate"}, {"id": "Capromab pendetide_INT_Clobetasone", "text": "Interaction: Capromab pendetide AND Clobetasone\nDetails: Clobetasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Clobetasone"}, {"id": "Capromab pendetide_INT_Ulobetasol", "text": "Interaction: Capromab pendetide AND Ulobetasol\nDetails: Ulobetasol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Ulobetasol"}, {"id": "Capromab pendetide_INT_Desonide", "text": "Interaction: Capromab pendetide AND Desonide\nDetails: Desonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Desonide"}, {"id": "Capromab pendetide_INT_Halcinonide", "text": "Interaction: Capromab pendetide AND Halcinonide\nDetails: Halcinonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Halcinonide"}, {"id": "Capromab pendetide_INT_Deflazacort", "text": "Interaction: Capromab pendetide AND Deflazacort\nDetails: Deflazacort may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Deflazacort"}, {"id": "Capromab pendetide_INT_Leuprolide", "text": "Interaction: Capromab pendetide AND Leuprolide\nDetails: Leuprolide may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Leuprolide"}, {"id": "Capromab pendetide_INT_Goserelin", "text": "Interaction: Capromab pendetide AND Goserelin\nDetails: Goserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Goserelin"}, {"id": "Capromab pendetide_INT_Buserelin", "text": "Interaction: Capromab pendetide AND Buserelin\nDetails: Buserelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Buserelin"}, {"id": "Capromab pendetide_INT_Triptorelin", "text": "Interaction: Capromab pendetide AND Triptorelin\nDetails: Triptorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Triptorelin"}, {"id": "Capromab pendetide_INT_Nafarelin", "text": "Interaction: Capromab pendetide AND Nafarelin\nDetails: Nafarelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Nafarelin"}, {"id": "Capromab pendetide_INT_Deslorelin", "text": "Interaction: Capromab pendetide AND Deslorelin\nDetails: Deslorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Deslorelin"}, {"id": "Capromab pendetide_INT_Histrelin", "text": "Interaction: Capromab pendetide AND Histrelin\nDetails: Histrelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Histrelin"}, {"id": "Capromab pendetide_INT_Danazol", "text": "Interaction: Capromab pendetide AND Danazol\nDetails: Danazol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Danazol"}, {"id": "Capromab pendetide_INT_Gestrinone", "text": "Interaction: Capromab pendetide AND Gestrinone\nDetails: Gestrinone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Gestrinone"}, {"id": "Capromab pendetide_INT_Diethylstilbestrol", "text": "Interaction: Capromab pendetide AND Diethylstilbestrol\nDetails: Diethylstilbestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Diethylstilbestrol"}, {"id": "Capromab pendetide_INT_Chlorotrianisene", "text": "Interaction: Capromab pendetide AND Chlorotrianisene\nDetails: Chlorotrianisene may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Chlorotrianisene"}, {"id": "Capromab pendetide_INT_Conjugated estrogens", "text": "Interaction: Capromab pendetide AND Conjugated estrogens\nDetails: Conjugated estrogens may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Conjugated estrogens"}, {"id": "Capromab pendetide_INT_Estradiol", "text": "Interaction: Capromab pendetide AND Estradiol\nDetails: Estradiol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Estradiol"}, {"id": "Capromab pendetide_INT_Dienestrol", "text": "Interaction: Capromab pendetide AND Dienestrol\nDetails: Dienestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Dienestrol"}, {"id": "Capromab pendetide_INT_Ethinyl Estradiol", "text": "Interaction: Capromab pendetide AND Ethinyl Estradiol\nDetails: Ethinyl Estradiol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Ethinyl Estradiol"}, {"id": "Capromab pendetide_INT_Polyestradiol phosphate", "text": "Interaction: Capromab pendetide AND Polyestradiol phosphate\nDetails: Polyestradiol phosphate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Polyestradiol phosphate"}, {"id": "Capromab pendetide_INT_Mestranol", "text": "Interaction: Capromab pendetide AND Mestranol\nDetails: Mestranol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Mestranol"}, {"id": "Capromab pendetide_INT_Genistein", "text": "Interaction: Capromab pendetide AND Genistein\nDetails: Genistein may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Genistein"}, {"id": "Capromab pendetide_INT_Quinestrol", "text": "Interaction: Capromab pendetide AND Quinestrol\nDetails: Quinestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Quinestrol"}, {"id": "Capromab pendetide_INT_Hexestrol", "text": "Interaction: Capromab pendetide AND Hexestrol\nDetails: Hexestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Hexestrol"}, {"id": "Capromab pendetide_INT_Synthetic Conjugated Estrogens, A", "text": "Interaction: Capromab pendetide AND Synthetic Conjugated Estrogens, A\nDetails: Synthetic Conjugated Estrogens, A may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Synthetic Conjugated Estrogens, A"}, {"id": "Capromab pendetide_INT_Synthetic Conjugated Estrogens, B", "text": "Interaction: Capromab pendetide AND Synthetic Conjugated Estrogens, B\nDetails: Synthetic Conjugated Estrogens, B may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Synthetic Conjugated Estrogens, B"}, {"id": "Capromab pendetide_INT_Zeranol", "text": "Interaction: Capromab pendetide AND Zeranol\nDetails: Zeranol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Zeranol"}, {"id": "Capromab pendetide_INT_Equol", "text": "Interaction: Capromab pendetide AND Equol\nDetails: Equol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Equol"}, {"id": "Capromab pendetide_INT_Secoisolariciresinol", "text": "Interaction: Capromab pendetide AND Secoisolariciresinol\nDetails: Secoisolariciresinol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Secoisolariciresinol"}, {"id": "Capromab pendetide_INT_Daidzein", "text": "Interaction: Capromab pendetide AND Daidzein\nDetails: Daidzein may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Daidzein"}, {"id": "Capromab pendetide_INT_Epimestrol", "text": "Interaction: Capromab pendetide AND Epimestrol\nDetails: Epimestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Epimestrol"}, {"id": "Capromab pendetide_INT_Estriol", "text": "Interaction: Capromab pendetide AND Estriol\nDetails: Estriol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Estriol"}, {"id": "Capromab pendetide_INT_Tibolone", "text": "Interaction: Capromab pendetide AND Tibolone\nDetails: Tibolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Tibolone"}, {"id": "Capromab pendetide_INT_Promestriene", "text": "Interaction: Capromab pendetide AND Promestriene\nDetails: Promestriene may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Promestriene"}, {"id": "Capromab pendetide_INT_Methallenestril", "text": "Interaction: Capromab pendetide AND Methallenestril\nDetails: Methallenestril may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Methallenestril"}, {"id": "Capromab pendetide_INT_Moxestrol", "text": "Interaction: Capromab pendetide AND Moxestrol\nDetails: Moxestrol may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Moxestrol"}, {"id": "Capromab pendetide_INT_Estrogens, esterified", "text": "Interaction: Capromab pendetide AND Estrogens, esterified\nDetails: Estrogens, esterified may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Estrogens, esterified"}, {"id": "Capromab pendetide_INT_Cyproterone acetate", "text": "Interaction: Capromab pendetide AND Cyproterone acetate\nDetails: Cyproterone acetate may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Cyproterone acetate"}, {"id": "Capromab pendetide_INT_Flutamide", "text": "Interaction: Capromab pendetide AND Flutamide\nDetails: Flutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Flutamide"}, {"id": "Capromab pendetide_INT_Nilutamide", "text": "Interaction: Capromab pendetide AND Nilutamide\nDetails: Nilutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Nilutamide"}, {"id": "Capromab pendetide_INT_Bicalutamide", "text": "Interaction: Capromab pendetide AND Bicalutamide\nDetails: Bicalutamide may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Bicalutamide"}, {"id": "Capromab pendetide_INT_Liarozole", "text": "Interaction: Capromab pendetide AND Liarozole\nDetails: Liarozole may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Liarozole"}, {"id": "Capromab pendetide_INT_Chlormadinone", "text": "Interaction: Capromab pendetide AND Chlormadinone\nDetails: Chlormadinone may decrease effectiveness of Capromab pendetide as a diagnostic agent.\nRisk: Monitor closely.", "source": "Capromab pendetide + Chlormadinone"}, {"id": "Capromab pendetide_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Capromab pendetide AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Capromab pendetide_INT_Yellow fever vaccine", "text": "Interaction: Capromab pendetide AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + Yellow fever vaccine"}, {"id": "Capromab pendetide_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Capromab pendetide AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Capromab pendetide_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Capromab pendetide AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Capromab pendetide_INT_Rotavirus Vaccine", "text": "Interaction: Capromab pendetide AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + Rotavirus Vaccine"}, {"id": "Capromab pendetide_INT_G17DT", "text": "Interaction: Capromab pendetide AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + G17DT"}, {"id": "Capromab pendetide_INT_INGN 201", "text": "Interaction: Capromab pendetide AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + INGN 201"}, {"id": "Capromab pendetide_INT_INGN 225", "text": "Interaction: Capromab pendetide AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + INGN 225"}, {"id": "Capromab pendetide_INT_Rindopepimut", "text": "Interaction: Capromab pendetide AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + Rindopepimut"}, {"id": "Capromab pendetide_INT_SRP 299", "text": "Interaction: Capromab pendetide AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + SRP 299"}, {"id": "Capromab pendetide_INT_GI-5005", "text": "Interaction: Capromab pendetide AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + GI-5005"}, {"id": "Capromab pendetide_INT_TG4010", "text": "Interaction: Capromab pendetide AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + TG4010"}, {"id": "Capromab pendetide_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Capromab pendetide AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + Rabies virus inactivated antigen, A"}, {"id": "Capromab pendetide_INT_Tecemotide", "text": "Interaction: Capromab pendetide AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + Tecemotide"}, {"id": "Capromab pendetide_INT_BCG vaccine", "text": "Interaction: Capromab pendetide AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + BCG vaccine"}, {"id": "Capromab pendetide_INT_Rubella virus vaccine", "text": "Interaction: Capromab pendetide AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + Rubella virus vaccine"}, {"id": "Capromab pendetide_INT_Hepatitis A Vaccine", "text": "Interaction: Capromab pendetide AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + Hepatitis A Vaccine"}, {"id": "Capromab pendetide_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Capromab pendetide AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + Salmonella typhi ty21a live antigen"}, {"id": "Capromab pendetide_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Capromab pendetide AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Capromab pendetide.\nRisk: Monitor closely.", "source": "Capromab pendetide + Hepatitis B Vaccine (Recombinant)"}, {"id": "Laronidase_GEN", "text": "Drug: Laronidase\nDescription: Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleo...", "source": "Laronidase"}, {"id": "Laronidase_CLIN", "text": "Drug: Laronidase\nMechanism: Laronidase catalyses the hydrolysis of terminal alpha-L-iduronic acid residues of dermatan sulfate and heparin sulfate....\nToxicity: ...", "source": "Laronidase"}, {"id": "Cyclosporine_GEN", "text": "Drug: Cyclosporine\nDescription: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. Cyclosporine is produced as a metabolite by the fungus species Cordyceps militaris. ...", "source": "Cyclosporine"}, {"id": "Cyclosporine_CLIN", "text": "Drug: Cyclosporine\nMechanism: Cyclosporine binds to cyclophilin. The complex then inhibits calcineurin which is normally responsible for activating transcription of interleukin 2. Cyclosporine also inhibits lymphokine production a...\nToxicity: The oral LD<sub>50</sub> is 2329 mg/kg in mice, 1480 mg/kg in rats, and > 1000 mg/kg in rabbits. The I.V. LD<sub>50</sub> is 148 mg/kg in mice, 104 mg/kg in rats, and 46 mg/kg in rabbits....", "source": "Cyclosporine"}, {"id": "Cyclosporine_INT_Dronedarone", "text": "Interaction: Cyclosporine AND Dronedarone\nDetails: The serum concentration of Dronedarone can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dronedarone"}, {"id": "Cyclosporine_INT_Enzalutamide", "text": "Interaction: Cyclosporine AND Enzalutamide\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Enzalutamide.\nRisk: Monitor closely.", "source": "Cyclosporine + Enzalutamide"}, {"id": "Cyclosporine_INT_Eplerenone", "text": "Interaction: Cyclosporine AND Eplerenone\nDetails: Eplerenone may increase the hyperkalemic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Eplerenone"}, {"id": "Cyclosporine_INT_Thioridazine", "text": "Interaction: Cyclosporine AND Thioridazine\nDetails: The serum concentration of Thioridazine can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Thioridazine"}, {"id": "Cyclosporine_INT_Ubidecarenone", "text": "Interaction: Cyclosporine AND Ubidecarenone\nDetails: The serum concentration of Ubidecarenone can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ubidecarenone"}, {"id": "Cyclosporine_INT_Foscarnet", "text": "Interaction: Cyclosporine AND Foscarnet\nDetails: Foscarnet may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Foscarnet"}, {"id": "Cyclosporine_INT_Methysergide", "text": "Interaction: Cyclosporine AND Methysergide\nDetails: The risk or severity of adverse effects can be increased when Methysergide is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Methysergide"}, {"id": "Cyclosporine_INT_Nicergoline", "text": "Interaction: Cyclosporine AND Nicergoline\nDetails: The risk or severity of adverse effects can be increased when Nicergoline is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nicergoline"}, {"id": "Cyclosporine_INT_Dihydroergocristine", "text": "Interaction: Cyclosporine AND Dihydroergocristine\nDetails: The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dihydroergocristine"}, {"id": "Cyclosporine_INT_Methylergometrine", "text": "Interaction: Cyclosporine AND Methylergometrine\nDetails: The risk or severity of adverse effects can be increased when Methylergometrine is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Methylergometrine"}, {"id": "Cyclosporine_INT_Lysergic Acid Diethylamide", "text": "Interaction: Cyclosporine AND Lysergic Acid Diethylamide\nDetails: The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lysergic Acid Diethylamide"}, {"id": "Cyclosporine_INT_Dihydroergocornine", "text": "Interaction: Cyclosporine AND Dihydroergocornine\nDetails: The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dihydroergocornine"}, {"id": "Cyclosporine_INT_Dihydroergocryptine", "text": "Interaction: Cyclosporine AND Dihydroergocryptine\nDetails: The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dihydroergocryptine"}, {"id": "Cyclosporine_INT_Terguride", "text": "Interaction: Cyclosporine AND Terguride\nDetails: The risk or severity of adverse effects can be increased when Terguride is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Terguride"}, {"id": "Cyclosporine_INT_Metergoline", "text": "Interaction: Cyclosporine AND Metergoline\nDetails: The risk or severity of adverse effects can be increased when Metergoline is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Metergoline"}, {"id": "Cyclosporine_INT_Lercanidipine", "text": "Interaction: Cyclosporine AND Lercanidipine\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Lercanidipine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lercanidipine"}, {"id": "Cyclosporine_INT_Lovastatin", "text": "Interaction: Cyclosporine AND Lovastatin\nDetails: The serum concentration of Lovastatin can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lovastatin"}, {"id": "Cyclosporine_INT_Mifepristone", "text": "Interaction: Cyclosporine AND Mifepristone\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Mifepristone.\nRisk: Monitor closely.", "source": "Cyclosporine + Mifepristone"}, {"id": "Cyclosporine_INT_Amodiaquine", "text": "Interaction: Cyclosporine AND Amodiaquine\nDetails: The serum concentration of Amodiaquine can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Amodiaquine"}, {"id": "Cyclosporine_INT_Pitavastatin", "text": "Interaction: Cyclosporine AND Pitavastatin\nDetails: The serum concentration of Pitavastatin can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pitavastatin"}, {"id": "Cyclosporine_INT_Silodosin", "text": "Interaction: Cyclosporine AND Silodosin\nDetails: The serum concentration of Silodosin can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Silodosin"}, {"id": "Cyclosporine_INT_Simeprevir", "text": "Interaction: Cyclosporine AND Simeprevir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Simeprevir.\nRisk: Monitor closely.", "source": "Cyclosporine + Simeprevir"}, {"id": "Cyclosporine_INT_Simvastatin", "text": "Interaction: Cyclosporine AND Simvastatin\nDetails: The serum concentration of Simvastatin can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Simvastatin"}, {"id": "Cyclosporine_INT_Sitaxentan", "text": "Interaction: Cyclosporine AND Sitaxentan\nDetails: The serum concentration of Sitaxentan can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sitaxentan"}, {"id": "Cyclosporine_INT_Bosutinib", "text": "Interaction: Cyclosporine AND Bosutinib\nDetails: The serum concentration of Bosutinib can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bosutinib"}, {"id": "Cyclosporine_INT_Cisapride", "text": "Interaction: Cyclosporine AND Cisapride\nDetails: The serum concentration of Cisapride can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cisapride"}, {"id": "Cyclosporine_INT_Domperidone", "text": "Interaction: Cyclosporine AND Domperidone\nDetails: The serum concentration of Domperidone can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Domperidone"}, {"id": "Cyclosporine_INT_Flibanserin", "text": "Interaction: Cyclosporine AND Flibanserin\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Flibanserin.\nRisk: Monitor closely.", "source": "Cyclosporine + Flibanserin"}, {"id": "Cyclosporine_INT_Ibrutinib", "text": "Interaction: Cyclosporine AND Ibrutinib\nDetails: The serum concentration of Ibrutinib can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ibrutinib"}, {"id": "Cyclosporine_INT_Ivabradine", "text": "Interaction: Cyclosporine AND Ivabradine\nDetails: The serum concentration of Ivabradine can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ivabradine"}, {"id": "Cyclosporine_INT_Lomitapide", "text": "Interaction: Cyclosporine AND Lomitapide\nDetails: The serum concentration of Lomitapide can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lomitapide"}, {"id": "Cyclosporine_INT_Progesterone", "text": "Interaction: Cyclosporine AND Progesterone\nDetails: The absorption of Progesterone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Progesterone"}, {"id": "Cyclosporine_INT_Olaparib", "text": "Interaction: Cyclosporine AND Olaparib\nDetails: The serum concentration of Olaparib can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Olaparib"}, {"id": "Cyclosporine_INT_Vincristine", "text": "Interaction: Cyclosporine AND Vincristine\nDetails: The serum concentration of Vincristine can be decreased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Vincristine"}, {"id": "Cyclosporine_INT_Pimozide", "text": "Interaction: Cyclosporine AND Pimozide\nDetails: The serum concentration of Pimozide can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pimozide"}, {"id": "Cyclosporine_INT_Quinidine", "text": "Interaction: Cyclosporine AND Quinidine\nDetails: The serum concentration of Quinidine can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Quinidine"}, {"id": "Cyclosporine_INT_Ranolazine", "text": "Interaction: Cyclosporine AND Ranolazine\nDetails: The serum concentration of Ranolazine can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ranolazine"}, {"id": "Cyclosporine_INT_Natalizumab", "text": "Interaction: Cyclosporine AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Cyclosporine + Natalizumab"}, {"id": "Cyclosporine_INT_Tofacitinib", "text": "Interaction: Cyclosporine AND Tofacitinib\nDetails: Cyclosporine may increase the immunosuppressive activities of Tofacitinib.\nRisk: Monitor closely.", "source": "Cyclosporine + Tofacitinib"}, {"id": "Cyclosporine_INT_Tolvaptan", "text": "Interaction: Cyclosporine AND Tolvaptan\nDetails: The serum concentration of Tolvaptan can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tolvaptan"}, {"id": "Cyclosporine_INT_Fusidic Acid", "text": "Interaction: Cyclosporine AND Fusidic Acid\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Fusidic Acid.\nRisk: Monitor closely.", "source": "Cyclosporine + Fusidic Acid"}, {"id": "Cyclosporine_INT_Tacrolimus", "text": "Interaction: Cyclosporine AND Tacrolimus\nDetails: Tacrolimus may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tacrolimus"}, {"id": "Cyclosporine_INT_Ledipasvir", "text": "Interaction: Cyclosporine AND Ledipasvir\nDetails: The serum concentration of Ledipasvir can be decreased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ledipasvir"}, {"id": "Cyclosporine_INT_Cobimetinib", "text": "Interaction: Cyclosporine AND Cobimetinib\nDetails: The serum concentration of Cobimetinib can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cobimetinib"}, {"id": "Cyclosporine_INT_Aliskiren", "text": "Interaction: Cyclosporine AND Aliskiren\nDetails: The serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Aliskiren"}, {"id": "Cyclosporine_INT_BCG vaccine", "text": "Interaction: Cyclosporine AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + BCG vaccine"}, {"id": "Cyclosporine_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Cyclosporine AND Rabies virus inactivated antigen, A\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Rabies virus inactivated antigen, A.\nRisk: Monitor closely.", "source": "Cyclosporine + Rabies virus inactivated antigen, A"}, {"id": "Cyclosporine_INT_Atorvastatin", "text": "Interaction: Cyclosporine AND Atorvastatin\nDetails: The serum concentration of Atorvastatin can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Atorvastatin"}, {"id": "Cyclosporine_INT_Bosentan", "text": "Interaction: Cyclosporine AND Bosentan\nDetails: The serum concentration of Bosentan can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bosentan"}, {"id": "Cyclosporine_INT_Triamterene", "text": "Interaction: Cyclosporine AND Triamterene\nDetails: The risk or severity of hyperkalemia can be increased when Triamterene is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Triamterene"}, {"id": "Cyclosporine_INT_Amiloride", "text": "Interaction: Cyclosporine AND Amiloride\nDetails: The risk or severity of hyperkalemia can be increased when Amiloride is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Amiloride"}, {"id": "Cyclosporine_INT_Spironolactone", "text": "Interaction: Cyclosporine AND Spironolactone\nDetails: The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Spironolactone"}, {"id": "Cyclosporine_INT_Cholic Acid", "text": "Interaction: Cyclosporine AND Cholic Acid\nDetails: Cyclosporine may decrease the excretion rate of Cholic Acid which could result in a higher serum level.\nRisk: Monitor closely.", "source": "Cyclosporine + Cholic Acid"}, {"id": "Cyclosporine_INT_Conivaptan", "text": "Interaction: Cyclosporine AND Conivaptan\nDetails: The serum concentration of Conivaptan can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Conivaptan"}, {"id": "Cyclosporine_INT_Sofosbuvir", "text": "Interaction: Cyclosporine AND Sofosbuvir\nDetails: The serum concentration of Sofosbuvir can be decreased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sofosbuvir"}, {"id": "Cyclosporine_INT_Crizotinib", "text": "Interaction: Cyclosporine AND Crizotinib\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Crizotinib.\nRisk: Monitor closely.", "source": "Cyclosporine + Crizotinib"}, {"id": "Cyclosporine_INT_Budesonide", "text": "Interaction: Cyclosporine AND Budesonide\nDetails: The serum concentration of Budesonide can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Budesonide"}, {"id": "Cyclosporine_INT_Edoxaban", "text": "Interaction: Cyclosporine AND Edoxaban\nDetails: The serum concentration of Edoxaban can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Edoxaban"}, {"id": "Cyclosporine_INT_Metoprolol", "text": "Interaction: Cyclosporine AND Metoprolol\nDetails: The serum concentration of Metoprolol can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Metoprolol"}, {"id": "Cyclosporine_INT_Efavirenz", "text": "Interaction: Cyclosporine AND Efavirenz\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Efavirenz.\nRisk: Monitor closely.", "source": "Cyclosporine + Efavirenz"}, {"id": "Cyclosporine_INT_Etoposide", "text": "Interaction: Cyclosporine AND Etoposide\nDetails: The metabolism of Etoposide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Etoposide"}, {"id": "Cyclosporine_INT_Everolimus", "text": "Interaction: Cyclosporine AND Everolimus\nDetails: The serum concentration of Everolimus can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Everolimus"}, {"id": "Cyclosporine_INT_Ezetimibe", "text": "Interaction: Cyclosporine AND Ezetimibe\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Ezetimibe.\nRisk: Monitor closely.", "source": "Cyclosporine + Ezetimibe"}, {"id": "Cyclosporine_INT_Fluvastatin", "text": "Interaction: Cyclosporine AND Fluvastatin\nDetails: The serum concentration of Fluvastatin can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Fluvastatin"}, {"id": "Cyclosporine_INT_Fosphenytoin", "text": "Interaction: Cyclosporine AND Fosphenytoin\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Fosphenytoin.\nRisk: Monitor closely.", "source": "Cyclosporine + Fosphenytoin"}, {"id": "Cyclosporine_INT_Methotrexate", "text": "Interaction: Cyclosporine AND Methotrexate\nDetails: The serum concentration of Methotrexate can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Methotrexate"}, {"id": "Cyclosporine_INT_Sarilumab", "text": "Interaction: Cyclosporine AND Sarilumab\nDetails: Sarilumab may increase the immunosuppressive activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sarilumab"}, {"id": "Cyclosporine_INT_Mitotane", "text": "Interaction: Cyclosporine AND Mitotane\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Mitotane.\nRisk: Monitor closely.", "source": "Cyclosporine + Mitotane"}, {"id": "Cyclosporine_INT_Mitoxantrone", "text": "Interaction: Cyclosporine AND Mitoxantrone\nDetails: The serum concentration of Mitoxantrone can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mitoxantrone"}, {"id": "Cyclosporine_INT_Orlistat", "text": "Interaction: Cyclosporine AND Orlistat\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Orlistat.\nRisk: Monitor closely.", "source": "Cyclosporine + Orlistat"}, {"id": "Cyclosporine_INT_Phenytoin", "text": "Interaction: Cyclosporine AND Phenytoin\nDetails: The metabolism of Cyclosporine can be increased when combined with Phenytoin.\nRisk: Monitor closely.", "source": "Cyclosporine + Phenytoin"}, {"id": "Cyclosporine_INT_Pazopanib", "text": "Interaction: Cyclosporine AND Pazopanib\nDetails: The serum concentration of Pazopanib can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pazopanib"}, {"id": "Cyclosporine_INT_Pravastatin", "text": "Interaction: Cyclosporine AND Pravastatin\nDetails: The serum concentration of Pravastatin can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pravastatin"}, {"id": "Cyclosporine_INT_Vemurafenib", "text": "Interaction: Cyclosporine AND Vemurafenib\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Vemurafenib.\nRisk: Monitor closely.", "source": "Cyclosporine + Vemurafenib"}, {"id": "Cyclosporine_INT_Mycophenolic acid", "text": "Interaction: Cyclosporine AND Mycophenolic acid\nDetails: The serum concentration of Mycophenolic acid can be decreased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mycophenolic acid"}, {"id": "Cyclosporine_INT_Topotecan", "text": "Interaction: Cyclosporine AND Topotecan\nDetails: The serum concentration of Topotecan can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Topotecan"}, {"id": "Cyclosporine_INT_Nelfinavir", "text": "Interaction: Cyclosporine AND Nelfinavir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Nelfinavir.\nRisk: Monitor closely.", "source": "Cyclosporine + Nelfinavir"}, {"id": "Cyclosporine_INT_Indinavir", "text": "Interaction: Cyclosporine AND Indinavir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Indinavir.\nRisk: Monitor closely.", "source": "Cyclosporine + Indinavir"}, {"id": "Cyclosporine_INT_Amprenavir", "text": "Interaction: Cyclosporine AND Amprenavir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Amprenavir.\nRisk: Monitor closely.", "source": "Cyclosporine + Amprenavir"}, {"id": "Cyclosporine_INT_Atazanavir", "text": "Interaction: Cyclosporine AND Atazanavir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Atazanavir.\nRisk: Monitor closely.", "source": "Cyclosporine + Atazanavir"}, {"id": "Cyclosporine_INT_Saquinavir", "text": "Interaction: Cyclosporine AND Saquinavir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Saquinavir.\nRisk: Monitor closely.", "source": "Cyclosporine + Saquinavir"}, {"id": "Cyclosporine_INT_Darunavir", "text": "Interaction: Cyclosporine AND Darunavir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Darunavir.\nRisk: Monitor closely.", "source": "Cyclosporine + Darunavir"}, {"id": "Cyclosporine_INT_Fosamprenavir", "text": "Interaction: Cyclosporine AND Fosamprenavir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Fosamprenavir.\nRisk: Monitor closely.", "source": "Cyclosporine + Fosamprenavir"}, {"id": "Cyclosporine_INT_Tipranavir", "text": "Interaction: Cyclosporine AND Tipranavir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Tipranavir.\nRisk: Monitor closely.", "source": "Cyclosporine + Tipranavir"}, {"id": "Cyclosporine_INT_Lepirudin", "text": "Interaction: Cyclosporine AND Lepirudin\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Cyclosporine + Lepirudin"}, {"id": "Cyclosporine_INT_Bivalirudin", "text": "Interaction: Cyclosporine AND Bivalirudin\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Cyclosporine + Bivalirudin"}, {"id": "Cyclosporine_INT_Alpha-1-proteinase inhibitor", "text": "Interaction: Cyclosporine AND Alpha-1-proteinase inhibitor\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Cyclosporine + Alpha-1-proteinase inhibitor"}, {"id": "Cyclosporine_INT_Ramipril", "text": "Interaction: Cyclosporine AND Ramipril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Ramipril.\nRisk: Monitor closely.", "source": "Cyclosporine + Ramipril"}, {"id": "Cyclosporine_INT_Remikiren", "text": "Interaction: Cyclosporine AND Remikiren\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Remikiren.\nRisk: Monitor closely.", "source": "Cyclosporine + Remikiren"}, {"id": "Cyclosporine_INT_Argatroban", "text": "Interaction: Cyclosporine AND Argatroban\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Argatroban.\nRisk: Monitor closely.", "source": "Cyclosporine + Argatroban"}, {"id": "Cyclosporine_INT_Fosinopril", "text": "Interaction: Cyclosporine AND Fosinopril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Fosinopril.\nRisk: Monitor closely.", "source": "Cyclosporine + Fosinopril"}, {"id": "Cyclosporine_INT_Trandolapril", "text": "Interaction: Cyclosporine AND Trandolapril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Trandolapril.\nRisk: Monitor closely.", "source": "Cyclosporine + Trandolapril"}, {"id": "Cyclosporine_INT_Benazepril", "text": "Interaction: Cyclosporine AND Benazepril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Benazepril.\nRisk: Monitor closely.", "source": "Cyclosporine + Benazepril"}, {"id": "Cyclosporine_INT_Enalapril", "text": "Interaction: Cyclosporine AND Enalapril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Enalapril.\nRisk: Monitor closely.", "source": "Cyclosporine + Enalapril"}, {"id": "Cyclosporine_INT_Candoxatril", "text": "Interaction: Cyclosporine AND Candoxatril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Candoxatril.\nRisk: Monitor closely.", "source": "Cyclosporine + Candoxatril"}, {"id": "Cyclosporine_INT_Isoflurophate", "text": "Interaction: Cyclosporine AND Isoflurophate\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Isoflurophate.\nRisk: Monitor closely.", "source": "Cyclosporine + Isoflurophate"}, {"id": "Cyclosporine_INT_Moexipril", "text": "Interaction: Cyclosporine AND Moexipril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Moexipril.\nRisk: Monitor closely.", "source": "Cyclosporine + Moexipril"}, {"id": "Cyclosporine_INT_Lisinopril", "text": "Interaction: Cyclosporine AND Lisinopril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Lisinopril.\nRisk: Monitor closely.", "source": "Cyclosporine + Lisinopril"}, {"id": "Cyclosporine_INT_Perindopril", "text": "Interaction: Cyclosporine AND Perindopril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Perindopril.\nRisk: Monitor closely.", "source": "Cyclosporine + Perindopril"}, {"id": "Cyclosporine_INT_Quinapril", "text": "Interaction: Cyclosporine AND Quinapril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Quinapril.\nRisk: Monitor closely.", "source": "Cyclosporine + Quinapril"}, {"id": "Cyclosporine_INT_Omapatrilat", "text": "Interaction: Cyclosporine AND Omapatrilat\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Omapatrilat.\nRisk: Monitor closely.", "source": "Cyclosporine + Omapatrilat"}, {"id": "Cyclosporine_INT_Captopril", "text": "Interaction: Cyclosporine AND Captopril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Captopril.\nRisk: Monitor closely.", "source": "Cyclosporine + Captopril"}, {"id": "Cyclosporine_INT_Sitagliptin", "text": "Interaction: Cyclosporine AND Sitagliptin\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Sitagliptin.\nRisk: Monitor closely.", "source": "Cyclosporine + Sitagliptin"}, {"id": "Cyclosporine_INT_Cilazapril", "text": "Interaction: Cyclosporine AND Cilazapril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Cilazapril.\nRisk: Monitor closely.", "source": "Cyclosporine + Cilazapril"}, {"id": "Cyclosporine_INT_Spirapril", "text": "Interaction: Cyclosporine AND Spirapril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Spirapril.\nRisk: Monitor closely.", "source": "Cyclosporine + Spirapril"}, {"id": "Cyclosporine_INT_Cilastatin", "text": "Interaction: Cyclosporine AND Cilastatin\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Cilastatin.\nRisk: Monitor closely.", "source": "Cyclosporine + Cilastatin"}, {"id": "Cyclosporine_INT_Lopinavir", "text": "Interaction: Cyclosporine AND Lopinavir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Lopinavir.\nRisk: Monitor closely.", "source": "Cyclosporine + Lopinavir"}, {"id": "Cyclosporine_INT_Chymostatin", "text": "Interaction: Cyclosporine AND Chymostatin\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Chymostatin.\nRisk: Monitor closely.", "source": "Cyclosporine + Chymostatin"}, {"id": "Cyclosporine_INT_GM6001", "text": "Interaction: Cyclosporine AND GM6001\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with GM6001.\nRisk: Monitor closely.", "source": "Cyclosporine + GM6001"}, {"id": "Cyclosporine_INT_1,10-Phenanthroline", "text": "Interaction: Cyclosporine AND 1,10-Phenanthroline\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with 1,10-Phenanthroline.\nRisk: Monitor closely.", "source": "Cyclosporine + 1,10-Phenanthroline"}, {"id": "Cyclosporine_INT_Geldanamycin", "text": "Interaction: Cyclosporine AND Geldanamycin\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Geldanamycin.\nRisk: Monitor closely.", "source": "Cyclosporine + Geldanamycin"}, {"id": "Cyclosporine_INT_Phosphoramidon", "text": "Interaction: Cyclosporine AND Phosphoramidon\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Phosphoramidon.\nRisk: Monitor closely.", "source": "Cyclosporine + Phosphoramidon"}, {"id": "Cyclosporine_INT_N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline", "text": "Interaction: Cyclosporine AND N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.\nRisk: Monitor closely.", "source": "Cyclosporine + N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline"}, {"id": "Cyclosporine_INT_Benzamidine", "text": "Interaction: Cyclosporine AND Benzamidine\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Benzamidine.\nRisk: Monitor closely.", "source": "Cyclosporine + Benzamidine"}, {"id": "Cyclosporine_INT_Enalkiren", "text": "Interaction: Cyclosporine AND Enalkiren\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Enalkiren.\nRisk: Monitor closely.", "source": "Cyclosporine + Enalkiren"}, {"id": "Cyclosporine_INT_Ubenimex", "text": "Interaction: Cyclosporine AND Ubenimex\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Ubenimex.\nRisk: Monitor closely.", "source": "Cyclosporine + Ubenimex"}, {"id": "Cyclosporine_INT_Batimastat", "text": "Interaction: Cyclosporine AND Batimastat\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Batimastat.\nRisk: Monitor closely.", "source": "Cyclosporine + Batimastat"}, {"id": "Cyclosporine_INT_3,4-Dichloroisocoumarin", "text": "Interaction: Cyclosporine AND 3,4-Dichloroisocoumarin\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with 3,4-Dichloroisocoumarin.\nRisk: Monitor closely.", "source": "Cyclosporine + 3,4-Dichloroisocoumarin"}, {"id": "Cyclosporine_INT_Cholesterol", "text": "Interaction: Cyclosporine AND Cholesterol\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Cholesterol.\nRisk: Monitor closely.", "source": "Cyclosporine + Cholesterol"}, {"id": "Cyclosporine_INT_Vildagliptin", "text": "Interaction: Cyclosporine AND Vildagliptin\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Vildagliptin.\nRisk: Monitor closely.", "source": "Cyclosporine + Vildagliptin"}, {"id": "Cyclosporine_INT_Ximelagatran", "text": "Interaction: Cyclosporine AND Ximelagatran\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Ximelagatran.\nRisk: Monitor closely.", "source": "Cyclosporine + Ximelagatran"}, {"id": "Cyclosporine_INT_Prinomastat", "text": "Interaction: Cyclosporine AND Prinomastat\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Prinomastat.\nRisk: Monitor closely.", "source": "Cyclosporine + Prinomastat"}, {"id": "Cyclosporine_INT_Elafin", "text": "Interaction: Cyclosporine AND Elafin\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Elafin.\nRisk: Monitor closely.", "source": "Cyclosporine + Elafin"}, {"id": "Cyclosporine_INT_Ecabet", "text": "Interaction: Cyclosporine AND Ecabet\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Ecabet.\nRisk: Monitor closely.", "source": "Cyclosporine + Ecabet"}, {"id": "Cyclosporine_INT_Alogliptin", "text": "Interaction: Cyclosporine AND Alogliptin\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Alogliptin.\nRisk: Monitor closely.", "source": "Cyclosporine + Alogliptin"}, {"id": "Cyclosporine_INT_Rivaroxaban", "text": "Interaction: Cyclosporine AND Rivaroxaban\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Rivaroxaban.\nRisk: Monitor closely.", "source": "Cyclosporine + Rivaroxaban"}, {"id": "Cyclosporine_INT_Saxagliptin", "text": "Interaction: Cyclosporine AND Saxagliptin\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Saxagliptin.\nRisk: Monitor closely.", "source": "Cyclosporine + Saxagliptin"}, {"id": "Cyclosporine_INT_Idraparinux", "text": "Interaction: Cyclosporine AND Idraparinux\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Idraparinux.\nRisk: Monitor closely.", "source": "Cyclosporine + Idraparinux"}, {"id": "Cyclosporine_INT_Apixaban", "text": "Interaction: Cyclosporine AND Apixaban\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Apixaban.\nRisk: Monitor closely.", "source": "Cyclosporine + Apixaban"}, {"id": "Cyclosporine_INT_Otamixaban", "text": "Interaction: Cyclosporine AND Otamixaban\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Otamixaban.\nRisk: Monitor closely.", "source": "Cyclosporine + Otamixaban"}, {"id": "Cyclosporine_INT_Aprotinin", "text": "Interaction: Cyclosporine AND Aprotinin\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Aprotinin.\nRisk: Monitor closely.", "source": "Cyclosporine + Aprotinin"}, {"id": "Cyclosporine_INT_Dabigatran etexilate", "text": "Interaction: Cyclosporine AND Dabigatran etexilate\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Dabigatran etexilate.\nRisk: Monitor closely.", "source": "Cyclosporine + Dabigatran etexilate"}, {"id": "Cyclosporine_INT_4-(2-Aminoethyl)Benzenesulfonyl Fluoride", "text": "Interaction: Cyclosporine AND 4-(2-Aminoethyl)Benzenesulfonyl Fluoride\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.\nRisk: Monitor closely.", "source": "Cyclosporine + 4-(2-Aminoethyl)Benzenesulfonyl Fluoride"}, {"id": "Cyclosporine_INT_Z-Val-Ala-Asp fluoromethyl ketone", "text": "Interaction: Cyclosporine AND Z-Val-Ala-Asp fluoromethyl ketone\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.\nRisk: Monitor closely.", "source": "Cyclosporine + Z-Val-Ala-Asp fluoromethyl ketone"}, {"id": "Cyclosporine_INT_Thiorphan", "text": "Interaction: Cyclosporine AND Thiorphan\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Thiorphan.\nRisk: Monitor closely.", "source": "Cyclosporine + Thiorphan"}, {"id": "Cyclosporine_INT_Temocapril", "text": "Interaction: Cyclosporine AND Temocapril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Temocapril.\nRisk: Monitor closely.", "source": "Cyclosporine + Temocapril"}, {"id": "Cyclosporine_INT_Enalaprilat", "text": "Interaction: Cyclosporine AND Enalaprilat\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Enalaprilat.\nRisk: Monitor closely.", "source": "Cyclosporine + Enalaprilat"}, {"id": "Cyclosporine_INT_Ixazomib", "text": "Interaction: Cyclosporine AND Ixazomib\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Ixazomib.\nRisk: Monitor closely.", "source": "Cyclosporine + Ixazomib"}, {"id": "Cyclosporine_INT_Antithrombin III human", "text": "Interaction: Cyclosporine AND Antithrombin III human\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Antithrombin III human.\nRisk: Monitor closely.", "source": "Cyclosporine + Antithrombin III human"}, {"id": "Cyclosporine_INT_Candoxatrilat", "text": "Interaction: Cyclosporine AND Candoxatrilat\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Candoxatrilat.\nRisk: Monitor closely.", "source": "Cyclosporine + Candoxatrilat"}, {"id": "Cyclosporine_INT_Racecadotril", "text": "Interaction: Cyclosporine AND Racecadotril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Racecadotril.\nRisk: Monitor closely.", "source": "Cyclosporine + Racecadotril"}, {"id": "Cyclosporine_INT_Imidapril", "text": "Interaction: Cyclosporine AND Imidapril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Imidapril.\nRisk: Monitor closely.", "source": "Cyclosporine + Imidapril"}, {"id": "Cyclosporine_INT_Delanzomib", "text": "Interaction: Cyclosporine AND Delanzomib\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Delanzomib.\nRisk: Monitor closely.", "source": "Cyclosporine + Delanzomib"}, {"id": "Cyclosporine_INT_Letaxaban", "text": "Interaction: Cyclosporine AND Letaxaban\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Letaxaban.\nRisk: Monitor closely.", "source": "Cyclosporine + Letaxaban"}, {"id": "Cyclosporine_INT_Ulinastatin", "text": "Interaction: Cyclosporine AND Ulinastatin\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Ulinastatin.\nRisk: Monitor closely.", "source": "Cyclosporine + Ulinastatin"}, {"id": "Cyclosporine_INT_Epigallocatechin Gallate", "text": "Interaction: Cyclosporine AND Epigallocatechin Gallate\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Epigallocatechin Gallate.\nRisk: Monitor closely.", "source": "Cyclosporine + Epigallocatechin Gallate"}, {"id": "Cyclosporine_INT_S-3304", "text": "Interaction: Cyclosporine AND S-3304\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with S-3304.\nRisk: Monitor closely.", "source": "Cyclosporine + S-3304"}, {"id": "Cyclosporine_INT_Darexaban", "text": "Interaction: Cyclosporine AND Darexaban\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Darexaban.\nRisk: Monitor closely.", "source": "Cyclosporine + Darexaban"}, {"id": "Cyclosporine_INT_Nitroaspirin", "text": "Interaction: Cyclosporine AND Nitroaspirin\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Nitroaspirin.\nRisk: Monitor closely.", "source": "Cyclosporine + Nitroaspirin"}, {"id": "Cyclosporine_INT_Nafamostat", "text": "Interaction: Cyclosporine AND Nafamostat\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Nafamostat.\nRisk: Monitor closely.", "source": "Cyclosporine + Nafamostat"}, {"id": "Cyclosporine_INT_Gabexate", "text": "Interaction: Cyclosporine AND Gabexate\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Gabexate.\nRisk: Monitor closely.", "source": "Cyclosporine + Gabexate"}, {"id": "Cyclosporine_INT_Sivelestat", "text": "Interaction: Cyclosporine AND Sivelestat\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Sivelestat.\nRisk: Monitor closely.", "source": "Cyclosporine + Sivelestat"}, {"id": "Cyclosporine_INT_Zofenopril", "text": "Interaction: Cyclosporine AND Zofenopril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Zofenopril.\nRisk: Monitor closely.", "source": "Cyclosporine + Zofenopril"}, {"id": "Cyclosporine_INT_Delapril", "text": "Interaction: Cyclosporine AND Delapril\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Delapril.\nRisk: Monitor closely.", "source": "Cyclosporine + Delapril"}, {"id": "Cyclosporine_INT_Melagatran", "text": "Interaction: Cyclosporine AND Melagatran\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Melagatran.\nRisk: Monitor closely.", "source": "Cyclosporine + Melagatran"}, {"id": "Cyclosporine_INT_Camostat", "text": "Interaction: Cyclosporine AND Camostat\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Camostat.\nRisk: Monitor closely.", "source": "Cyclosporine + Camostat"}, {"id": "Cyclosporine_INT_Asunaprevir", "text": "Interaction: Cyclosporine AND Asunaprevir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Asunaprevir.\nRisk: Monitor closely.", "source": "Cyclosporine + Asunaprevir"}, {"id": "Cyclosporine_INT_Faldaprevir", "text": "Interaction: Cyclosporine AND Faldaprevir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Faldaprevir.\nRisk: Monitor closely.", "source": "Cyclosporine + Faldaprevir"}, {"id": "Cyclosporine_INT_Ritonavir", "text": "Interaction: Cyclosporine AND Ritonavir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Ritonavir.\nRisk: Monitor closely.", "source": "Cyclosporine + Ritonavir"}, {"id": "Cyclosporine_INT_Rosuvastatin", "text": "Interaction: Cyclosporine AND Rosuvastatin\nDetails: The serum concentration of Rosuvastatin can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rosuvastatin"}, {"id": "Cyclosporine_INT_Sirolimus", "text": "Interaction: Cyclosporine AND Sirolimus\nDetails: The risk or severity of adverse effects can be increased when Sirolimus is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sirolimus"}, {"id": "Cyclosporine_INT_Stiripentol", "text": "Interaction: Cyclosporine AND Stiripentol\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Stiripentol.\nRisk: Monitor closely.", "source": "Cyclosporine + Stiripentol"}, {"id": "Cyclosporine_INT_Telaprevir", "text": "Interaction: Cyclosporine AND Telaprevir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Telaprevir.\nRisk: Monitor closely.", "source": "Cyclosporine + Telaprevir"}, {"id": "Cyclosporine_INT_Temsirolimus", "text": "Interaction: Cyclosporine AND Temsirolimus\nDetails: The risk or severity of adverse effects can be increased when Temsirolimus is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Temsirolimus"}, {"id": "Cyclosporine_INT_Buspirone", "text": "Interaction: Cyclosporine AND Buspirone\nDetails: The metabolism of Buspirone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Buspirone"}, {"id": "Cyclosporine_INT_Cilostazol", "text": "Interaction: Cyclosporine AND Cilostazol\nDetails: The serum concentration of Cilostazol can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cilostazol"}, {"id": "Cyclosporine_INT_Methohexital", "text": "Interaction: Cyclosporine AND Methohexital\nDetails: The metabolism of Cyclosporine can be increased when combined with Methohexital.\nRisk: Monitor closely.", "source": "Cyclosporine + Methohexital"}, {"id": "Cyclosporine_INT_Primidone", "text": "Interaction: Cyclosporine AND Primidone\nDetails: The metabolism of Cyclosporine can be increased when combined with Primidone.\nRisk: Monitor closely.", "source": "Cyclosporine + Primidone"}, {"id": "Cyclosporine_INT_Phenobarbital", "text": "Interaction: Cyclosporine AND Phenobarbital\nDetails: The metabolism of Cyclosporine can be increased when combined with Phenobarbital.\nRisk: Monitor closely.", "source": "Cyclosporine + Phenobarbital"}, {"id": "Cyclosporine_INT_Pentobarbital", "text": "Interaction: Cyclosporine AND Pentobarbital\nDetails: The metabolism of Cyclosporine can be increased when combined with Pentobarbital.\nRisk: Monitor closely.", "source": "Cyclosporine + Pentobarbital"}, {"id": "Cyclosporine_INT_Secobarbital", "text": "Interaction: Cyclosporine AND Secobarbital\nDetails: The metabolism of Cyclosporine can be increased when combined with Secobarbital.\nRisk: Monitor closely.", "source": "Cyclosporine + Secobarbital"}, {"id": "Cyclosporine_INT_Thiopental", "text": "Interaction: Cyclosporine AND Thiopental\nDetails: The metabolism of Cyclosporine can be increased when combined with Thiopental.\nRisk: Monitor closely.", "source": "Cyclosporine + Thiopental"}, {"id": "Cyclosporine_INT_Methylphenobarbital", "text": "Interaction: Cyclosporine AND Methylphenobarbital\nDetails: The metabolism of Cyclosporine can be increased when combined with Methylphenobarbital.\nRisk: Monitor closely.", "source": "Cyclosporine + Methylphenobarbital"}, {"id": "Cyclosporine_INT_Thiamylal", "text": "Interaction: Cyclosporine AND Thiamylal\nDetails: The metabolism of Cyclosporine can be increased when combined with Thiamylal.\nRisk: Monitor closely.", "source": "Cyclosporine + Thiamylal"}, {"id": "Cyclosporine_INT_Amobarbital", "text": "Interaction: Cyclosporine AND Amobarbital\nDetails: The metabolism of Cyclosporine can be increased when combined with Amobarbital.\nRisk: Monitor closely.", "source": "Cyclosporine + Amobarbital"}, {"id": "Cyclosporine_INT_Hexobarbital", "text": "Interaction: Cyclosporine AND Hexobarbital\nDetails: The metabolism of Cyclosporine can be increased when combined with Hexobarbital.\nRisk: Monitor closely.", "source": "Cyclosporine + Hexobarbital"}, {"id": "Cyclosporine_INT_Barbital", "text": "Interaction: Cyclosporine AND Barbital\nDetails: The metabolism of Cyclosporine can be increased when combined with Barbital.\nRisk: Monitor closely.", "source": "Cyclosporine + Barbital"}, {"id": "Cyclosporine_INT_Barbexaclone", "text": "Interaction: Cyclosporine AND Barbexaclone\nDetails: The metabolism of Cyclosporine can be increased when combined with Barbexaclone.\nRisk: Monitor closely.", "source": "Cyclosporine + Barbexaclone"}, {"id": "Cyclosporine_INT_Colchicine", "text": "Interaction: Cyclosporine AND Colchicine\nDetails: The serum concentration of Colchicine can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Colchicine"}, {"id": "Cyclosporine_INT_Dapoxetine", "text": "Interaction: Cyclosporine AND Dapoxetine\nDetails: The serum concentration of Dapoxetine can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dapoxetine"}, {"id": "Cyclosporine_INT_Didanosine", "text": "Interaction: Cyclosporine AND Didanosine\nDetails: Didanosine can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.\nRisk: Monitor closely.", "source": "Cyclosporine + Didanosine"}, {"id": "Cyclosporine_INT_Oxiconazole", "text": "Interaction: Cyclosporine AND Oxiconazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Oxiconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Oxiconazole"}, {"id": "Cyclosporine_INT_Terconazole", "text": "Interaction: Cyclosporine AND Terconazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Terconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Terconazole"}, {"id": "Cyclosporine_INT_Clotrimazole", "text": "Interaction: Cyclosporine AND Clotrimazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Clotrimazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Clotrimazole"}, {"id": "Cyclosporine_INT_Anidulafungin", "text": "Interaction: Cyclosporine AND Anidulafungin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Anidulafungin.\nRisk: Monitor closely.", "source": "Cyclosporine + Anidulafungin"}, {"id": "Cyclosporine_INT_Tolnaftate", "text": "Interaction: Cyclosporine AND Tolnaftate\nDetails: The metabolism of Cyclosporine can be decreased when combined with Tolnaftate.\nRisk: Monitor closely.", "source": "Cyclosporine + Tolnaftate"}, {"id": "Cyclosporine_INT_Voriconazole", "text": "Interaction: Cyclosporine AND Voriconazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Voriconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Voriconazole"}, {"id": "Cyclosporine_INT_Butoconazole", "text": "Interaction: Cyclosporine AND Butoconazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Butoconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Butoconazole"}, {"id": "Cyclosporine_INT_Nystatin", "text": "Interaction: Cyclosporine AND Nystatin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Nystatin.\nRisk: Monitor closely.", "source": "Cyclosporine + Nystatin"}, {"id": "Cyclosporine_INT_Naftifine", "text": "Interaction: Cyclosporine AND Naftifine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Naftifine.\nRisk: Monitor closely.", "source": "Cyclosporine + Naftifine"}, {"id": "Cyclosporine_INT_Pentamidine", "text": "Interaction: Cyclosporine AND Pentamidine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Pentamidine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pentamidine"}, {"id": "Cyclosporine_INT_Haloprogin", "text": "Interaction: Cyclosporine AND Haloprogin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Haloprogin.\nRisk: Monitor closely.", "source": "Cyclosporine + Haloprogin"}, {"id": "Cyclosporine_INT_Natamycin", "text": "Interaction: Cyclosporine AND Natamycin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Natamycin.\nRisk: Monitor closely.", "source": "Cyclosporine + Natamycin"}, {"id": "Cyclosporine_INT_Terbinafine", "text": "Interaction: Cyclosporine AND Terbinafine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Terbinafine.\nRisk: Monitor closely.", "source": "Cyclosporine + Terbinafine"}, {"id": "Cyclosporine_INT_Salicylic acid", "text": "Interaction: Cyclosporine AND Salicylic acid\nDetails: The metabolism of Cyclosporine can be decreased when combined with Salicylic acid.\nRisk: Monitor closely.", "source": "Cyclosporine + Salicylic acid"}, {"id": "Cyclosporine_INT_Tioconazole", "text": "Interaction: Cyclosporine AND Tioconazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Tioconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Tioconazole"}, {"id": "Cyclosporine_INT_Ketoconazole", "text": "Interaction: Cyclosporine AND Ketoconazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Ketoconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Ketoconazole"}, {"id": "Cyclosporine_INT_Cerulenin", "text": "Interaction: Cyclosporine AND Cerulenin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Cerulenin.\nRisk: Monitor closely.", "source": "Cyclosporine + Cerulenin"}, {"id": "Cyclosporine_INT_Butenafine", "text": "Interaction: Cyclosporine AND Butenafine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Butenafine.\nRisk: Monitor closely.", "source": "Cyclosporine + Butenafine"}, {"id": "Cyclosporine_INT_Flucytosine", "text": "Interaction: Cyclosporine AND Flucytosine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Flucytosine.\nRisk: Monitor closely.", "source": "Cyclosporine + Flucytosine"}, {"id": "Cyclosporine_INT_Miconazole", "text": "Interaction: Cyclosporine AND Miconazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Miconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Miconazole"}, {"id": "Cyclosporine_INT_Econazole", "text": "Interaction: Cyclosporine AND Econazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Econazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Econazole"}, {"id": "Cyclosporine_INT_Micafungin", "text": "Interaction: Cyclosporine AND Micafungin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Micafungin.\nRisk: Monitor closely.", "source": "Cyclosporine + Micafungin"}, {"id": "Cyclosporine_INT_Candicidin", "text": "Interaction: Cyclosporine AND Candicidin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Candicidin.\nRisk: Monitor closely.", "source": "Cyclosporine + Candicidin"}, {"id": "Cyclosporine_INT_Sertaconazole", "text": "Interaction: Cyclosporine AND Sertaconazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Sertaconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Sertaconazole"}, {"id": "Cyclosporine_INT_Trimetrexate", "text": "Interaction: Cyclosporine AND Trimetrexate\nDetails: The metabolism of Cyclosporine can be decreased when combined with Trimetrexate.\nRisk: Monitor closely.", "source": "Cyclosporine + Trimetrexate"}, {"id": "Cyclosporine_INT_Itraconazole", "text": "Interaction: Cyclosporine AND Itraconazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Itraconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Itraconazole"}, {"id": "Cyclosporine_INT_Ciclopirox", "text": "Interaction: Cyclosporine AND Ciclopirox\nDetails: The metabolism of Cyclosporine can be decreased when combined with Ciclopirox.\nRisk: Monitor closely.", "source": "Cyclosporine + Ciclopirox"}, {"id": "Cyclosporine_INT_Chloroxine", "text": "Interaction: Cyclosporine AND Chloroxine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Chloroxine.\nRisk: Monitor closely.", "source": "Cyclosporine + Chloroxine"}, {"id": "Cyclosporine_INT_Posaconazole", "text": "Interaction: Cyclosporine AND Posaconazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Posaconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Posaconazole"}, {"id": "Cyclosporine_INT_Nitroxoline", "text": "Interaction: Cyclosporine AND Nitroxoline\nDetails: The metabolism of Cyclosporine can be decreased when combined with Nitroxoline.\nRisk: Monitor closely.", "source": "Cyclosporine + Nitroxoline"}, {"id": "Cyclosporine_INT_Sinefungin", "text": "Interaction: Cyclosporine AND Sinefungin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Sinefungin.\nRisk: Monitor closely.", "source": "Cyclosporine + Sinefungin"}, {"id": "Cyclosporine_INT_Thymol", "text": "Interaction: Cyclosporine AND Thymol\nDetails: The metabolism of Cyclosporine can be decreased when combined with Thymol.\nRisk: Monitor closely.", "source": "Cyclosporine + Thymol"}, {"id": "Cyclosporine_INT_Capric acid", "text": "Interaction: Cyclosporine AND Capric acid\nDetails: The metabolism of Cyclosporine can be decreased when combined with Capric acid.\nRisk: Monitor closely.", "source": "Cyclosporine + Capric acid"}, {"id": "Cyclosporine_INT_Radicicol", "text": "Interaction: Cyclosporine AND Radicicol\nDetails: The metabolism of Cyclosporine can be decreased when combined with Radicicol.\nRisk: Monitor closely.", "source": "Cyclosporine + Radicicol"}, {"id": "Cyclosporine_INT_Benzoic Acid", "text": "Interaction: Cyclosporine AND Benzoic Acid\nDetails: The metabolism of Cyclosporine can be decreased when combined with Benzoic Acid.\nRisk: Monitor closely.", "source": "Cyclosporine + Benzoic Acid"}, {"id": "Cyclosporine_INT_Salicylhydroxamic Acid", "text": "Interaction: Cyclosporine AND Salicylhydroxamic Acid\nDetails: The metabolism of Cyclosporine can be decreased when combined with Salicylhydroxamic Acid.\nRisk: Monitor closely.", "source": "Cyclosporine + Salicylhydroxamic Acid"}, {"id": "Cyclosporine_INT_Glyphosate", "text": "Interaction: Cyclosporine AND Glyphosate\nDetails: The metabolism of Cyclosporine can be decreased when combined with Glyphosate.\nRisk: Monitor closely.", "source": "Cyclosporine + Glyphosate"}, {"id": "Cyclosporine_INT_Myxothiazol", "text": "Interaction: Cyclosporine AND Myxothiazol\nDetails: The metabolism of Cyclosporine can be decreased when combined with Myxothiazol.\nRisk: Monitor closely.", "source": "Cyclosporine + Myxothiazol"}, {"id": "Cyclosporine_INT_2-HYDROXY-1,4-NAPHTHOQUINONE", "text": "Interaction: Cyclosporine AND 2-HYDROXY-1,4-NAPHTHOQUINONE\nDetails: The metabolism of Cyclosporine can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.\nRisk: Monitor closely.", "source": "Cyclosporine + 2-HYDROXY-1,4-NAPHTHOQUINONE"}, {"id": "Cyclosporine_INT_Bifonazole", "text": "Interaction: Cyclosporine AND Bifonazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Bifonazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Bifonazole"}, {"id": "Cyclosporine_INT_pafuramidine", "text": "Interaction: Cyclosporine AND pafuramidine\nDetails: The metabolism of Cyclosporine can be decreased when combined with pafuramidine.\nRisk: Monitor closely.", "source": "Cyclosporine + pafuramidine"}, {"id": "Cyclosporine_INT_Mevastatin", "text": "Interaction: Cyclosporine AND Mevastatin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Mevastatin.\nRisk: Monitor closely.", "source": "Cyclosporine + Mevastatin"}, {"id": "Cyclosporine_INT_Artemether", "text": "Interaction: Cyclosporine AND Artemether\nDetails: The metabolism of Cyclosporine can be decreased when combined with Artemether.\nRisk: Monitor closely.", "source": "Cyclosporine + Artemether"}, {"id": "Cyclosporine_INT_Bafilomycin A1", "text": "Interaction: Cyclosporine AND Bafilomycin A1\nDetails: The metabolism of Cyclosporine can be decreased when combined with Bafilomycin A1.\nRisk: Monitor closely.", "source": "Cyclosporine + Bafilomycin A1"}, {"id": "Cyclosporine_INT_Sulconazole", "text": "Interaction: Cyclosporine AND Sulconazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Sulconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Sulconazole"}, {"id": "Cyclosporine_INT_Brefeldin A", "text": "Interaction: Cyclosporine AND Brefeldin A\nDetails: The metabolism of Cyclosporine can be decreased when combined with Brefeldin A.\nRisk: Monitor closely.", "source": "Cyclosporine + Brefeldin A"}, {"id": "Cyclosporine_INT_Isoconazole", "text": "Interaction: Cyclosporine AND Isoconazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Isoconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Isoconazole"}, {"id": "Cyclosporine_INT_Hexetidine", "text": "Interaction: Cyclosporine AND Hexetidine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Hexetidine.\nRisk: Monitor closely.", "source": "Cyclosporine + Hexetidine"}, {"id": "Cyclosporine_INT_Miltefosine", "text": "Interaction: Cyclosporine AND Miltefosine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Miltefosine.\nRisk: Monitor closely.", "source": "Cyclosporine + Miltefosine"}, {"id": "Cyclosporine_INT_Efinaconazole", "text": "Interaction: Cyclosporine AND Efinaconazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Efinaconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Efinaconazole"}, {"id": "Cyclosporine_INT_Tavaborole", "text": "Interaction: Cyclosporine AND Tavaborole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Tavaborole.\nRisk: Monitor closely.", "source": "Cyclosporine + Tavaborole"}, {"id": "Cyclosporine_INT_Amorolfine", "text": "Interaction: Cyclosporine AND Amorolfine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Amorolfine.\nRisk: Monitor closely.", "source": "Cyclosporine + Amorolfine"}, {"id": "Cyclosporine_INT_Dichlorophene", "text": "Interaction: Cyclosporine AND Dichlorophene\nDetails: The metabolism of Cyclosporine can be decreased when combined with Dichlorophene.\nRisk: Monitor closely.", "source": "Cyclosporine + Dichlorophene"}, {"id": "Cyclosporine_INT_Monensin", "text": "Interaction: Cyclosporine AND Monensin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Monensin.\nRisk: Monitor closely.", "source": "Cyclosporine + Monensin"}, {"id": "Cyclosporine_INT_2-mercaptobenzothiazole", "text": "Interaction: Cyclosporine AND 2-mercaptobenzothiazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with 2-mercaptobenzothiazole.\nRisk: Monitor closely.", "source": "Cyclosporine + 2-mercaptobenzothiazole"}, {"id": "Cyclosporine_INT_Cordycepin", "text": "Interaction: Cyclosporine AND Cordycepin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Cordycepin.\nRisk: Monitor closely.", "source": "Cyclosporine + Cordycepin"}, {"id": "Cyclosporine_INT_Nikkomycin Z", "text": "Interaction: Cyclosporine AND Nikkomycin Z\nDetails: The metabolism of Cyclosporine can be decreased when combined with Nikkomycin Z.\nRisk: Monitor closely.", "source": "Cyclosporine + Nikkomycin Z"}, {"id": "Cyclosporine_INT_Hachimycin", "text": "Interaction: Cyclosporine AND Hachimycin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Hachimycin.\nRisk: Monitor closely.", "source": "Cyclosporine + Hachimycin"}, {"id": "Cyclosporine_INT_Tolciclate", "text": "Interaction: Cyclosporine AND Tolciclate\nDetails: The metabolism of Cyclosporine can be decreased when combined with Tolciclate.\nRisk: Monitor closely.", "source": "Cyclosporine + Tolciclate"}, {"id": "Cyclosporine_INT_Flutrimazole", "text": "Interaction: Cyclosporine AND Flutrimazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Flutrimazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Flutrimazole"}, {"id": "Cyclosporine_INT_Fenticonazole", "text": "Interaction: Cyclosporine AND Fenticonazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Fenticonazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Fenticonazole"}, {"id": "Cyclosporine_INT_Pyrrolnitrin", "text": "Interaction: Cyclosporine AND Pyrrolnitrin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Pyrrolnitrin.\nRisk: Monitor closely.", "source": "Cyclosporine + Pyrrolnitrin"}, {"id": "Cyclosporine_INT_Mepartricin", "text": "Interaction: Cyclosporine AND Mepartricin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Mepartricin.\nRisk: Monitor closely.", "source": "Cyclosporine + Mepartricin"}, {"id": "Cyclosporine_INT_Omoconazole", "text": "Interaction: Cyclosporine AND Omoconazole\nDetails: The metabolism of Cyclosporine can be decreased when combined with Omoconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Omoconazole"}, {"id": "Cyclosporine_INT_Nifuratel", "text": "Interaction: Cyclosporine AND Nifuratel\nDetails: The metabolism of Cyclosporine can be decreased when combined with Nifuratel.\nRisk: Monitor closely.", "source": "Cyclosporine + Nifuratel"}, {"id": "Cyclosporine_INT_Eletriptan", "text": "Interaction: Cyclosporine AND Eletriptan\nDetails: The serum concentration of Eletriptan can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Eletriptan"}, {"id": "Cyclosporine_INT_Eliglustat", "text": "Interaction: Cyclosporine AND Eliglustat\nDetails: The serum concentration of Eliglustat can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Eliglustat"}, {"id": "Cyclosporine_INT_Etravirine", "text": "Interaction: Cyclosporine AND Etravirine\nDetails: The serum concentration of Etravirine can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Etravirine"}, {"id": "Cyclosporine_INT_Fentanyl", "text": "Interaction: Cyclosporine AND Fentanyl\nDetails: The serum concentration of Fentanyl can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Fentanyl"}, {"id": "Cyclosporine_INT_Halofantrine", "text": "Interaction: Cyclosporine AND Halofantrine\nDetails: The serum concentration of Halofantrine can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Halofantrine"}, {"id": "Cyclosporine_INT_Aripiprazole", "text": "Interaction: Cyclosporine AND Aripiprazole\nDetails: The serum concentration of Aripiprazole can be decreased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Aripiprazole"}, {"id": "Cyclosporine_INT_Ivacaftor", "text": "Interaction: Cyclosporine AND Ivacaftor\nDetails: The serum concentration of Ivacaftor can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ivacaftor"}, {"id": "Cyclosporine_INT_Nevirapine", "text": "Interaction: Cyclosporine AND Nevirapine\nDetails: The metabolism of Cyclosporine can be increased when combined with Nevirapine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nevirapine"}, {"id": "Cyclosporine_INT_Nefazodone", "text": "Interaction: Cyclosporine AND Nefazodone\nDetails: The metabolism of Cyclosporine can be decreased when combined with Nefazodone.\nRisk: Monitor closely.", "source": "Cyclosporine + Nefazodone"}, {"id": "Cyclosporine_INT_Idelalisib", "text": "Interaction: Cyclosporine AND Idelalisib\nDetails: The metabolism of Cyclosporine can be decreased when combined with Idelalisib.\nRisk: Monitor closely.", "source": "Cyclosporine + Idelalisib"}, {"id": "Cyclosporine_INT_Cobicistat", "text": "Interaction: Cyclosporine AND Cobicistat\nDetails: The metabolism of Cyclosporine can be decreased when combined with Cobicistat.\nRisk: Monitor closely.", "source": "Cyclosporine + Cobicistat"}, {"id": "Cyclosporine_INT_Lurasidone", "text": "Interaction: Cyclosporine AND Lurasidone\nDetails: The serum concentration of Lurasidone can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lurasidone"}, {"id": "Cyclosporine_INT_Afatinib", "text": "Interaction: Cyclosporine AND Afatinib\nDetails: The serum concentration of Afatinib can be decreased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Afatinib"}, {"id": "Cyclosporine_INT_Rifabutin", "text": "Interaction: Cyclosporine AND Rifabutin\nDetails: The metabolism of Cyclosporine can be increased when combined with Rifabutin.\nRisk: Monitor closely.", "source": "Cyclosporine + Rifabutin"}, {"id": "Cyclosporine_INT_Rifampicin", "text": "Interaction: Cyclosporine AND Rifampicin\nDetails: The metabolism of Cyclosporine can be increased when combined with Rifampicin.\nRisk: Monitor closely.", "source": "Cyclosporine + Rifampicin"}, {"id": "Cyclosporine_INT_Rifapentine", "text": "Interaction: Cyclosporine AND Rifapentine\nDetails: The metabolism of Cyclosporine can be increased when combined with Rifapentine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rifapentine"}, {"id": "Cyclosporine_INT_Docetaxel", "text": "Interaction: Cyclosporine AND Docetaxel\nDetails: The metabolism of Docetaxel can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Docetaxel"}, {"id": "Cyclosporine_INT_Oxycodone", "text": "Interaction: Cyclosporine AND Oxycodone\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Oxycodone.\nRisk: Monitor closely.", "source": "Cyclosporine + Oxycodone"}, {"id": "Cyclosporine_INT_Testosterone", "text": "Interaction: Cyclosporine AND Testosterone\nDetails: Testosterone may increase the hepatotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Testosterone"}, {"id": "Cyclosporine_INT_Dihydrotestosterone", "text": "Interaction: Cyclosporine AND Dihydrotestosterone\nDetails: Dihydrotestosterone may increase the hepatotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dihydrotestosterone"}, {"id": "Cyclosporine_INT_Fluoxymesterone", "text": "Interaction: Cyclosporine AND Fluoxymesterone\nDetails: Fluoxymesterone may increase the hepatotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Fluoxymesterone"}, {"id": "Cyclosporine_INT_Testosterone Propionate", "text": "Interaction: Cyclosporine AND Testosterone Propionate\nDetails: Testosterone Propionate may increase the hepatotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Testosterone Propionate"}, {"id": "Cyclosporine_INT_Danazol", "text": "Interaction: Cyclosporine AND Danazol\nDetails: Danazol may increase the hepatotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Danazol"}, {"id": "Cyclosporine_INT_Methyltestosterone", "text": "Interaction: Cyclosporine AND Methyltestosterone\nDetails: Methyltestosterone may increase the hepatotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Methyltestosterone"}, {"id": "Cyclosporine_INT_Oxandrolone", "text": "Interaction: Cyclosporine AND Oxandrolone\nDetails: Oxandrolone may increase the hepatotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Oxandrolone"}, {"id": "Cyclosporine_INT_Oxymetholone", "text": "Interaction: Cyclosporine AND Oxymetholone\nDetails: Oxymetholone may increase the hepatotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Oxymetholone"}, {"id": "Cyclosporine_INT_Stanozolol", "text": "Interaction: Cyclosporine AND Stanozolol\nDetails: Stanozolol may increase the hepatotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Stanozolol"}, {"id": "Cyclosporine_INT_GLPG-0492", "text": "Interaction: Cyclosporine AND GLPG-0492\nDetails: GLPG-0492 may increase the hepatotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + GLPG-0492"}, {"id": "Cyclosporine_INT_Nandrolone", "text": "Interaction: Cyclosporine AND Nandrolone\nDetails: Nandrolone may increase the hepatotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nandrolone"}, {"id": "Cyclosporine_INT_Mesterolone", "text": "Interaction: Cyclosporine AND Mesterolone\nDetails: Mesterolone may increase the hepatotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mesterolone"}, {"id": "Cyclosporine_INT_Nandrolone decanoate", "text": "Interaction: Cyclosporine AND Nandrolone decanoate\nDetails: Nandrolone decanoate may increase the hepatotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nandrolone decanoate"}, {"id": "Cyclosporine_INT_Leflunomide", "text": "Interaction: Cyclosporine AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Cyclosporine + Leflunomide"}, {"id": "Cyclosporine_INT_Solifenacin", "text": "Interaction: Cyclosporine AND Solifenacin\nDetails: The metabolism of Solifenacin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Solifenacin"}, {"id": "Cyclosporine_INT_Fingolimod", "text": "Interaction: Cyclosporine AND Fingolimod\nDetails: Cyclosporine may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Cyclosporine + Fingolimod"}, {"id": "Cyclosporine_INT_Roflumilast", "text": "Interaction: Cyclosporine AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Roflumilast"}, {"id": "Cyclosporine_INT_Sonidegib", "text": "Interaction: Cyclosporine AND Sonidegib\nDetails: The serum concentration of Sonidegib can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sonidegib"}, {"id": "Cyclosporine_INT_Sunitinib", "text": "Interaction: Cyclosporine AND Sunitinib\nDetails: The metabolism of Sunitinib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sunitinib"}, {"id": "Cyclosporine_INT_Suvorexant", "text": "Interaction: Cyclosporine AND Suvorexant\nDetails: The serum concentration of Suvorexant can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Suvorexant"}, {"id": "Cyclosporine_INT_Ulipristal", "text": "Interaction: Cyclosporine AND Ulipristal\nDetails: The serum concentration of Ulipristal can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ulipristal"}, {"id": "Cyclosporine_INT_Zolpidem", "text": "Interaction: Cyclosporine AND Zolpidem\nDetails: The serum concentration of Zolpidem can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Zolpidem"}, {"id": "Cyclosporine_INT_Zopiclone", "text": "Interaction: Cyclosporine AND Zopiclone\nDetails: The serum concentration of Zopiclone can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Zopiclone"}, {"id": "Cyclosporine_INT_Avanafil", "text": "Interaction: Cyclosporine AND Avanafil\nDetails: The serum concentration of Avanafil can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Avanafil"}, {"id": "Cyclosporine_INT_Doxorubicin", "text": "Interaction: Cyclosporine AND Doxorubicin\nDetails: The serum concentration of Doxorubicin can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Doxorubicin"}, {"id": "Cyclosporine_INT_Eluxadoline", "text": "Interaction: Cyclosporine AND Eluxadoline\nDetails: The serum concentration of Eluxadoline can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Eluxadoline"}, {"id": "Cyclosporine_INT_Clofibrate", "text": "Interaction: Cyclosporine AND Clofibrate\nDetails: Cyclosporine may increase the nephrotoxic activities of Clofibrate.\nRisk: Monitor closely.", "source": "Cyclosporine + Clofibrate"}, {"id": "Cyclosporine_INT_Gemfibrozil", "text": "Interaction: Cyclosporine AND Gemfibrozil\nDetails: Cyclosporine may increase the nephrotoxic activities of Gemfibrozil.\nRisk: Monitor closely.", "source": "Cyclosporine + Gemfibrozil"}, {"id": "Cyclosporine_INT_Bezafibrate", "text": "Interaction: Cyclosporine AND Bezafibrate\nDetails: Cyclosporine may increase the nephrotoxic activities of Bezafibrate.\nRisk: Monitor closely.", "source": "Cyclosporine + Bezafibrate"}, {"id": "Cyclosporine_INT_Etofibrate", "text": "Interaction: Cyclosporine AND Etofibrate\nDetails: Cyclosporine may increase the nephrotoxic activities of Etofibrate.\nRisk: Monitor closely.", "source": "Cyclosporine + Etofibrate"}, {"id": "Cyclosporine_INT_Simfibrate", "text": "Interaction: Cyclosporine AND Simfibrate\nDetails: Cyclosporine may increase the nephrotoxic activities of Simfibrate.\nRisk: Monitor closely.", "source": "Cyclosporine + Simfibrate"}, {"id": "Cyclosporine_INT_Clofibride", "text": "Interaction: Cyclosporine AND Clofibride\nDetails: Cyclosporine may increase the nephrotoxic activities of Clofibride.\nRisk: Monitor closely.", "source": "Cyclosporine + Clofibride"}, {"id": "Cyclosporine_INT_Fenofibric acid", "text": "Interaction: Cyclosporine AND Fenofibric acid\nDetails: Cyclosporine may increase the nephrotoxic activities of Fenofibric acid.\nRisk: Monitor closely.", "source": "Cyclosporine + Fenofibric acid"}, {"id": "Cyclosporine_INT_Fenofibrate", "text": "Interaction: Cyclosporine AND Fenofibrate\nDetails: Cyclosporine may increase the nephrotoxic activities of Fenofibrate.\nRisk: Monitor closely.", "source": "Cyclosporine + Fenofibrate"}, {"id": "Cyclosporine_INT_Ciprofibrate", "text": "Interaction: Cyclosporine AND Ciprofibrate\nDetails: Cyclosporine may increase the nephrotoxic activities of Ciprofibrate.\nRisk: Monitor closely.", "source": "Cyclosporine + Ciprofibrate"}, {"id": "Cyclosporine_INT_Ronifibrate", "text": "Interaction: Cyclosporine AND Ronifibrate\nDetails: Cyclosporine may increase the nephrotoxic activities of Ronifibrate.\nRisk: Monitor closely.", "source": "Cyclosporine + Ronifibrate"}, {"id": "Cyclosporine_INT_Aluminium clofibrate", "text": "Interaction: Cyclosporine AND Aluminium clofibrate\nDetails: Cyclosporine may increase the nephrotoxic activities of Aluminium clofibrate.\nRisk: Monitor closely.", "source": "Cyclosporine + Aluminium clofibrate"}, {"id": "Cyclosporine_INT_Ketorolac", "text": "Interaction: Cyclosporine AND Ketorolac\nDetails: Ketorolac may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ketorolac"}, {"id": "Cyclosporine_INT_Diclofenac", "text": "Interaction: Cyclosporine AND Diclofenac\nDetails: Diclofenac may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Diclofenac"}, {"id": "Cyclosporine_INT_Flurbiprofen", "text": "Interaction: Cyclosporine AND Flurbiprofen\nDetails: Flurbiprofen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Flurbiprofen"}, {"id": "Cyclosporine_INT_Bromfenac", "text": "Interaction: Cyclosporine AND Bromfenac\nDetails: Bromfenac may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bromfenac"}, {"id": "Cyclosporine_INT_Nepafenac", "text": "Interaction: Cyclosporine AND Nepafenac\nDetails: Nepafenac may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nepafenac"}, {"id": "Cyclosporine_INT_Etanercept", "text": "Interaction: Cyclosporine AND Etanercept\nDetails: Etanercept may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Etanercept"}, {"id": "Cyclosporine_INT_Masoprocol", "text": "Interaction: Cyclosporine AND Masoprocol\nDetails: Masoprocol may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Masoprocol"}, {"id": "Cyclosporine_INT_Adapalene", "text": "Interaction: Cyclosporine AND Adapalene\nDetails: Adapalene may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Adapalene"}, {"id": "Cyclosporine_INT_Mesalazine", "text": "Interaction: Cyclosporine AND Mesalazine\nDetails: Mesalazine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mesalazine"}, {"id": "Cyclosporine_INT_Indomethacin", "text": "Interaction: Cyclosporine AND Indomethacin\nDetails: Indomethacin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Indomethacin"}, {"id": "Cyclosporine_INT_Pimecrolimus", "text": "Interaction: Cyclosporine AND Pimecrolimus\nDetails: Pimecrolimus may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pimecrolimus"}, {"id": "Cyclosporine_INT_Nabumetone", "text": "Interaction: Cyclosporine AND Nabumetone\nDetails: Nabumetone may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nabumetone"}, {"id": "Cyclosporine_INT_Tenoxicam", "text": "Interaction: Cyclosporine AND Tenoxicam\nDetails: Tenoxicam may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tenoxicam"}, {"id": "Cyclosporine_INT_Celecoxib", "text": "Interaction: Cyclosporine AND Celecoxib\nDetails: Celecoxib may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Celecoxib"}, {"id": "Cyclosporine_INT_Tolmetin", "text": "Interaction: Cyclosporine AND Tolmetin\nDetails: Tolmetin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tolmetin"}, {"id": "Cyclosporine_INT_Rofecoxib", "text": "Interaction: Cyclosporine AND Rofecoxib\nDetails: Rofecoxib may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rofecoxib"}, {"id": "Cyclosporine_INT_Piroxicam", "text": "Interaction: Cyclosporine AND Piroxicam\nDetails: Piroxicam may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Piroxicam"}, {"id": "Cyclosporine_INT_Fenoprofen", "text": "Interaction: Cyclosporine AND Fenoprofen\nDetails: Fenoprofen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Fenoprofen"}, {"id": "Cyclosporine_INT_Valdecoxib", "text": "Interaction: Cyclosporine AND Valdecoxib\nDetails: Valdecoxib may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Valdecoxib"}, {"id": "Cyclosporine_INT_Sulindac", "text": "Interaction: Cyclosporine AND Sulindac\nDetails: Sulindac may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sulindac"}, {"id": "Cyclosporine_INT_Chloroquine", "text": "Interaction: Cyclosporine AND Chloroquine\nDetails: Chloroquine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Chloroquine"}, {"id": "Cyclosporine_INT_Mycophenolate mofetil", "text": "Interaction: Cyclosporine AND Mycophenolate mofetil\nDetails: Mycophenolate mofetil may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mycophenolate mofetil"}, {"id": "Cyclosporine_INT_Zileuton", "text": "Interaction: Cyclosporine AND Zileuton\nDetails: Zileuton may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Zileuton"}, {"id": "Cyclosporine_INT_Etodolac", "text": "Interaction: Cyclosporine AND Etodolac\nDetails: Etodolac may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Etodolac"}, {"id": "Cyclosporine_INT_Olopatadine", "text": "Interaction: Cyclosporine AND Olopatadine\nDetails: Olopatadine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Olopatadine"}, {"id": "Cyclosporine_INT_Mefenamic acid", "text": "Interaction: Cyclosporine AND Mefenamic acid\nDetails: Mefenamic acid may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mefenamic acid"}, {"id": "Cyclosporine_INT_Naproxen", "text": "Interaction: Cyclosporine AND Naproxen\nDetails: Naproxen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Naproxen"}, {"id": "Cyclosporine_INT_Sulfasalazine", "text": "Interaction: Cyclosporine AND Sulfasalazine\nDetails: Sulfasalazine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sulfasalazine"}, {"id": "Cyclosporine_INT_Phenylbutazone", "text": "Interaction: Cyclosporine AND Phenylbutazone\nDetails: Phenylbutazone may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Phenylbutazone"}, {"id": "Cyclosporine_INT_Meloxicam", "text": "Interaction: Cyclosporine AND Meloxicam\nDetails: Meloxicam may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Meloxicam"}, {"id": "Cyclosporine_INT_Carprofen", "text": "Interaction: Cyclosporine AND Carprofen\nDetails: Carprofen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Carprofen"}, {"id": "Cyclosporine_INT_Diflunisal", "text": "Interaction: Cyclosporine AND Diflunisal\nDetails: Diflunisal may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Diflunisal"}, {"id": "Cyclosporine_INT_Suprofen", "text": "Interaction: Cyclosporine AND Suprofen\nDetails: Suprofen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Suprofen"}, {"id": "Cyclosporine_INT_Meclofenamic acid", "text": "Interaction: Cyclosporine AND Meclofenamic acid\nDetails: Meclofenamic acid may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Meclofenamic acid"}, {"id": "Cyclosporine_INT_Acetylsalicylic acid", "text": "Interaction: Cyclosporine AND Acetylsalicylic acid\nDetails: Acetylsalicylic acid may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Acetylsalicylic acid"}, {"id": "Cyclosporine_INT_Azelastine", "text": "Interaction: Cyclosporine AND Azelastine\nDetails: Azelastine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Azelastine"}, {"id": "Cyclosporine_INT_Oxaprozin", "text": "Interaction: Cyclosporine AND Oxaprozin\nDetails: Oxaprozin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Oxaprozin"}, {"id": "Cyclosporine_INT_Ketoprofen", "text": "Interaction: Cyclosporine AND Ketoprofen\nDetails: Ketoprofen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ketoprofen"}, {"id": "Cyclosporine_INT_Balsalazide", "text": "Interaction: Cyclosporine AND Balsalazide\nDetails: Balsalazide may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Balsalazide"}, {"id": "Cyclosporine_INT_Ibuprofen", "text": "Interaction: Cyclosporine AND Ibuprofen\nDetails: Ibuprofen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ibuprofen"}, {"id": "Cyclosporine_INT_Olsalazine", "text": "Interaction: Cyclosporine AND Olsalazine\nDetails: Olsalazine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Olsalazine"}, {"id": "Cyclosporine_INT_Lumiracoxib", "text": "Interaction: Cyclosporine AND Lumiracoxib\nDetails: Lumiracoxib may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lumiracoxib"}, {"id": "Cyclosporine_INT_Magnesium salicylate", "text": "Interaction: Cyclosporine AND Magnesium salicylate\nDetails: Magnesium salicylate may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Magnesium salicylate"}, {"id": "Cyclosporine_INT_Salsalate", "text": "Interaction: Cyclosporine AND Salsalate\nDetails: Salsalate may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Salsalate"}, {"id": "Cyclosporine_INT_Choline magnesium trisalicylate", "text": "Interaction: Cyclosporine AND Choline magnesium trisalicylate\nDetails: Choline magnesium trisalicylate may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Choline magnesium trisalicylate"}, {"id": "Cyclosporine_INT_Antipyrine", "text": "Interaction: Cyclosporine AND Antipyrine\nDetails: Antipyrine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Antipyrine"}, {"id": "Cyclosporine_INT_Tiaprofenic acid", "text": "Interaction: Cyclosporine AND Tiaprofenic acid\nDetails: Tiaprofenic acid may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tiaprofenic acid"}, {"id": "Cyclosporine_INT_Etoricoxib", "text": "Interaction: Cyclosporine AND Etoricoxib\nDetails: Etoricoxib may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Etoricoxib"}, {"id": "Cyclosporine_INT_Castanospermine", "text": "Interaction: Cyclosporine AND Castanospermine\nDetails: Castanospermine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Castanospermine"}, {"id": "Cyclosporine_INT_Resveratrol", "text": "Interaction: Cyclosporine AND Resveratrol\nDetails: Resveratrol may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Resveratrol"}, {"id": "Cyclosporine_INT_Oxyphenbutazone", "text": "Interaction: Cyclosporine AND Oxyphenbutazone\nDetails: Oxyphenbutazone may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Oxyphenbutazone"}, {"id": "Cyclosporine_INT_Niflumic Acid", "text": "Interaction: Cyclosporine AND Niflumic Acid\nDetails: Niflumic Acid may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Niflumic Acid"}, {"id": "Cyclosporine_INT_Nimesulide", "text": "Interaction: Cyclosporine AND Nimesulide\nDetails: Nimesulide may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nimesulide"}, {"id": "Cyclosporine_INT_Benoxaprofen", "text": "Interaction: Cyclosporine AND Benoxaprofen\nDetails: Benoxaprofen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Benoxaprofen"}, {"id": "Cyclosporine_INT_Metamizole", "text": "Interaction: Cyclosporine AND Metamizole\nDetails: Metamizole may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Metamizole"}, {"id": "Cyclosporine_INT_Zomepirac", "text": "Interaction: Cyclosporine AND Zomepirac\nDetails: Zomepirac may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Zomepirac"}, {"id": "Cyclosporine_INT_Pirfenidone", "text": "Interaction: Cyclosporine AND Pirfenidone\nDetails: Pirfenidone may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pirfenidone"}, {"id": "Cyclosporine_INT_SRT501", "text": "Interaction: Cyclosporine AND SRT501\nDetails: SRT501 may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + SRT501"}, {"id": "Cyclosporine_INT_PTC299", "text": "Interaction: Cyclosporine AND PTC299\nDetails: PTC299 may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + PTC299"}, {"id": "Cyclosporine_INT_Tarenflurbil", "text": "Interaction: Cyclosporine AND Tarenflurbil\nDetails: Tarenflurbil may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tarenflurbil"}, {"id": "Cyclosporine_INT_Apremilast", "text": "Interaction: Cyclosporine AND Apremilast\nDetails: Apremilast may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Apremilast"}, {"id": "Cyclosporine_INT_Andrographolide", "text": "Interaction: Cyclosporine AND Andrographolide\nDetails: Andrographolide may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Andrographolide"}, {"id": "Cyclosporine_INT_Icatibant", "text": "Interaction: Cyclosporine AND Icatibant\nDetails: Icatibant may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Icatibant"}, {"id": "Cyclosporine_INT_exisulind", "text": "Interaction: Cyclosporine AND exisulind\nDetails: exisulind may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + exisulind"}, {"id": "Cyclosporine_INT_Lornoxicam", "text": "Interaction: Cyclosporine AND Lornoxicam\nDetails: Lornoxicam may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lornoxicam"}, {"id": "Cyclosporine_INT_Aceclofenac", "text": "Interaction: Cyclosporine AND Aceclofenac\nDetails: Aceclofenac may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Aceclofenac"}, {"id": "Cyclosporine_INT_Zaltoprofen", "text": "Interaction: Cyclosporine AND Zaltoprofen\nDetails: Zaltoprofen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Zaltoprofen"}, {"id": "Cyclosporine_INT_Seratrodast", "text": "Interaction: Cyclosporine AND Seratrodast\nDetails: Seratrodast may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Seratrodast"}, {"id": "Cyclosporine_INT_Azapropazone", "text": "Interaction: Cyclosporine AND Azapropazone\nDetails: Azapropazone may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Azapropazone"}, {"id": "Cyclosporine_INT_Felbinac", "text": "Interaction: Cyclosporine AND Felbinac\nDetails: Felbinac may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Felbinac"}, {"id": "Cyclosporine_INT_Tranilast", "text": "Interaction: Cyclosporine AND Tranilast\nDetails: Tranilast may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tranilast"}, {"id": "Cyclosporine_INT_Ferulic acid", "text": "Interaction: Cyclosporine AND Ferulic acid\nDetails: Ferulic acid may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ferulic acid"}, {"id": "Cyclosporine_INT_Parecoxib", "text": "Interaction: Cyclosporine AND Parecoxib\nDetails: Parecoxib may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Parecoxib"}, {"id": "Cyclosporine_INT_Salicylamide", "text": "Interaction: Cyclosporine AND Salicylamide\nDetails: Salicylamide may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Salicylamide"}, {"id": "Cyclosporine_INT_Teriflunomide", "text": "Interaction: Cyclosporine AND Teriflunomide\nDetails: Teriflunomide may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Teriflunomide"}, {"id": "Cyclosporine_INT_D-Limonene", "text": "Interaction: Cyclosporine AND D-Limonene\nDetails: D-Limonene may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + D-Limonene"}, {"id": "Cyclosporine_INT_Kebuzone", "text": "Interaction: Cyclosporine AND Kebuzone\nDetails: Kebuzone may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Kebuzone"}, {"id": "Cyclosporine_INT_Isoxicam", "text": "Interaction: Cyclosporine AND Isoxicam\nDetails: Isoxicam may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Isoxicam"}, {"id": "Cyclosporine_INT_Indoprofen", "text": "Interaction: Cyclosporine AND Indoprofen\nDetails: Indoprofen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Indoprofen"}, {"id": "Cyclosporine_INT_Ibuproxam", "text": "Interaction: Cyclosporine AND Ibuproxam\nDetails: Ibuproxam may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ibuproxam"}, {"id": "Cyclosporine_INT_Floctafenine", "text": "Interaction: Cyclosporine AND Floctafenine\nDetails: Floctafenine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Floctafenine"}, {"id": "Cyclosporine_INT_Fenbufen", "text": "Interaction: Cyclosporine AND Fenbufen\nDetails: Fenbufen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Fenbufen"}, {"id": "Cyclosporine_INT_Etofenamate", "text": "Interaction: Cyclosporine AND Etofenamate\nDetails: Etofenamate may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Etofenamate"}, {"id": "Cyclosporine_INT_Epirizole", "text": "Interaction: Cyclosporine AND Epirizole\nDetails: Epirizole may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Epirizole"}, {"id": "Cyclosporine_INT_Loxoprofen", "text": "Interaction: Cyclosporine AND Loxoprofen\nDetails: Loxoprofen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Loxoprofen"}, {"id": "Cyclosporine_INT_Droxicam", "text": "Interaction: Cyclosporine AND Droxicam\nDetails: Droxicam may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Droxicam"}, {"id": "Cyclosporine_INT_Tolfenamic Acid", "text": "Interaction: Cyclosporine AND Tolfenamic Acid\nDetails: Tolfenamic Acid may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tolfenamic Acid"}, {"id": "Cyclosporine_INT_Clonixin", "text": "Interaction: Cyclosporine AND Clonixin\nDetails: Clonixin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Clonixin"}, {"id": "Cyclosporine_INT_Propacetamol", "text": "Interaction: Cyclosporine AND Propacetamol\nDetails: Propacetamol may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Propacetamol"}, {"id": "Cyclosporine_INT_Evening primrose oil", "text": "Interaction: Cyclosporine AND Evening primrose oil\nDetails: Evening primrose oil may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Evening primrose oil"}, {"id": "Cyclosporine_INT_Orgotein", "text": "Interaction: Cyclosporine AND Orgotein\nDetails: Orgotein may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Orgotein"}, {"id": "Cyclosporine_INT_Tepoxalin", "text": "Interaction: Cyclosporine AND Tepoxalin\nDetails: Tepoxalin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tepoxalin"}, {"id": "Cyclosporine_INT_Flunixin", "text": "Interaction: Cyclosporine AND Flunixin\nDetails: Flunixin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Flunixin"}, {"id": "Cyclosporine_INT_Curcumin", "text": "Interaction: Cyclosporine AND Curcumin\nDetails: Curcumin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Curcumin"}, {"id": "Cyclosporine_INT_E-6201", "text": "Interaction: Cyclosporine AND E-6201\nDetails: E-6201 may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + E-6201"}, {"id": "Cyclosporine_INT_Anisodamine", "text": "Interaction: Cyclosporine AND Anisodamine\nDetails: Anisodamine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Anisodamine"}, {"id": "Cyclosporine_INT_Duvelisib", "text": "Interaction: Cyclosporine AND Duvelisib\nDetails: Duvelisib may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Duvelisib"}, {"id": "Cyclosporine_INT_Triptolide", "text": "Interaction: Cyclosporine AND Triptolide\nDetails: Triptolide may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Triptolide"}, {"id": "Cyclosporine_INT_Semapimod", "text": "Interaction: Cyclosporine AND Semapimod\nDetails: Semapimod may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Semapimod"}, {"id": "Cyclosporine_INT_Bucillamine", "text": "Interaction: Cyclosporine AND Bucillamine\nDetails: Bucillamine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bucillamine"}, {"id": "Cyclosporine_INT_Lisofylline", "text": "Interaction: Cyclosporine AND Lisofylline\nDetails: Lisofylline may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lisofylline"}, {"id": "Cyclosporine_INT_Indobufen", "text": "Interaction: Cyclosporine AND Indobufen\nDetails: Indobufen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Indobufen"}, {"id": "Cyclosporine_INT_Mizoribine", "text": "Interaction: Cyclosporine AND Mizoribine\nDetails: Mizoribine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mizoribine"}, {"id": "Cyclosporine_INT_Apocynin", "text": "Interaction: Cyclosporine AND Apocynin\nDetails: Apocynin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Apocynin"}, {"id": "Cyclosporine_INT_Higenamine", "text": "Interaction: Cyclosporine AND Higenamine\nDetails: Higenamine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Higenamine"}, {"id": "Cyclosporine_INT_Tinoridine", "text": "Interaction: Cyclosporine AND Tinoridine\nDetails: Tinoridine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tinoridine"}, {"id": "Cyclosporine_INT_Parthenolide", "text": "Interaction: Cyclosporine AND Parthenolide\nDetails: Parthenolide may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Parthenolide"}, {"id": "Cyclosporine_INT_Serrapeptase", "text": "Interaction: Cyclosporine AND Serrapeptase\nDetails: Serrapeptase may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Serrapeptase"}, {"id": "Cyclosporine_INT_Alclofenac", "text": "Interaction: Cyclosporine AND Alclofenac\nDetails: Alclofenac may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Alclofenac"}, {"id": "Cyclosporine_INT_Fentiazac", "text": "Interaction: Cyclosporine AND Fentiazac\nDetails: Fentiazac may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Fentiazac"}, {"id": "Cyclosporine_INT_Tribenoside", "text": "Interaction: Cyclosporine AND Tribenoside\nDetails: Tribenoside may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tribenoside"}, {"id": "Cyclosporine_INT_Suxibuzone", "text": "Interaction: Cyclosporine AND Suxibuzone\nDetails: Suxibuzone may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Suxibuzone"}, {"id": "Cyclosporine_INT_Bumadizone", "text": "Interaction: Cyclosporine AND Bumadizone\nDetails: Bumadizone may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bumadizone"}, {"id": "Cyclosporine_INT_Alminoprofen", "text": "Interaction: Cyclosporine AND Alminoprofen\nDetails: Alminoprofen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Alminoprofen"}, {"id": "Cyclosporine_INT_Flunoxaprofen", "text": "Interaction: Cyclosporine AND Flunoxaprofen\nDetails: Flunoxaprofen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Flunoxaprofen"}, {"id": "Cyclosporine_INT_Bufexamac", "text": "Interaction: Cyclosporine AND Bufexamac\nDetails: Bufexamac may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bufexamac"}, {"id": "Cyclosporine_INT_Feprazone", "text": "Interaction: Cyclosporine AND Feprazone\nDetails: Feprazone may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Feprazone"}, {"id": "Cyclosporine_INT_Difenpiramide", "text": "Interaction: Cyclosporine AND Difenpiramide\nDetails: Difenpiramide may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Difenpiramide"}, {"id": "Cyclosporine_INT_Nifenazone", "text": "Interaction: Cyclosporine AND Nifenazone\nDetails: Nifenazone may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nifenazone"}, {"id": "Cyclosporine_INT_Lonazolac", "text": "Interaction: Cyclosporine AND Lonazolac\nDetails: Lonazolac may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lonazolac"}, {"id": "Cyclosporine_INT_Tenidap", "text": "Interaction: Cyclosporine AND Tenidap\nDetails: Tenidap may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tenidap"}, {"id": "Cyclosporine_INT_Bendazac", "text": "Interaction: Cyclosporine AND Bendazac\nDetails: Bendazac may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bendazac"}, {"id": "Cyclosporine_INT_Pranoprofen", "text": "Interaction: Cyclosporine AND Pranoprofen\nDetails: Pranoprofen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pranoprofen"}, {"id": "Cyclosporine_INT_Propyphenazone", "text": "Interaction: Cyclosporine AND Propyphenazone\nDetails: Propyphenazone may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Propyphenazone"}, {"id": "Cyclosporine_INT_Proglumetacin", "text": "Interaction: Cyclosporine AND Proglumetacin\nDetails: Proglumetacin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Proglumetacin"}, {"id": "Cyclosporine_INT_Guacetisal", "text": "Interaction: Cyclosporine AND Guacetisal\nDetails: Guacetisal may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Guacetisal"}, {"id": "Cyclosporine_INT_Bevonium", "text": "Interaction: Cyclosporine AND Bevonium\nDetails: Bevonium may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bevonium"}, {"id": "Cyclosporine_INT_Ethenzamide", "text": "Interaction: Cyclosporine AND Ethenzamide\nDetails: Ethenzamide may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ethenzamide"}, {"id": "Cyclosporine_INT_Carbaspirin calcium", "text": "Interaction: Cyclosporine AND Carbaspirin calcium\nDetails: Carbaspirin calcium may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Carbaspirin calcium"}, {"id": "Cyclosporine_INT_Mofebutazone", "text": "Interaction: Cyclosporine AND Mofebutazone\nDetails: Mofebutazone may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mofebutazone"}, {"id": "Cyclosporine_INT_Proquazone", "text": "Interaction: Cyclosporine AND Proquazone\nDetails: Proquazone may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Proquazone"}, {"id": "Cyclosporine_INT_Benorilate", "text": "Interaction: Cyclosporine AND Benorilate\nDetails: Benorilate may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Benorilate"}, {"id": "Cyclosporine_INT_Pirprofen", "text": "Interaction: Cyclosporine AND Pirprofen\nDetails: Pirprofen may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pirprofen"}, {"id": "Cyclosporine_INT_Acemetacin", "text": "Interaction: Cyclosporine AND Acemetacin\nDetails: Acemetacin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Acemetacin"}, {"id": "Cyclosporine_INT_Imidazole salicylate", "text": "Interaction: Cyclosporine AND Imidazole salicylate\nDetails: Imidazole salicylate may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Imidazole salicylate"}, {"id": "Cyclosporine_INT_Benzydamine", "text": "Interaction: Cyclosporine AND Benzydamine\nDetails: Benzydamine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Benzydamine"}, {"id": "Cyclosporine_INT_Ombitasvir", "text": "Interaction: Cyclosporine AND Ombitasvir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Ombitasvir.\nRisk: Monitor closely.", "source": "Cyclosporine + Ombitasvir"}, {"id": "Cyclosporine_INT_Paritaprevir", "text": "Interaction: Cyclosporine AND Paritaprevir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Paritaprevir.\nRisk: Monitor closely.", "source": "Cyclosporine + Paritaprevir"}, {"id": "Cyclosporine_INT_Dasabuvir", "text": "Interaction: Cyclosporine AND Dasabuvir\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Dasabuvir.\nRisk: Monitor closely.", "source": "Cyclosporine + Dasabuvir"}, {"id": "Cyclosporine_INT_St. John's Wort", "text": "Interaction: Cyclosporine AND St. John's Wort\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with St. John&#39;s Wort.\nRisk: Monitor closely.", "source": "Cyclosporine + St. John's Wort"}, {"id": "Cyclosporine_INT_Octreotide", "text": "Interaction: Cyclosporine AND Octreotide\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.\nRisk: Monitor closely.", "source": "Cyclosporine + Octreotide"}, {"id": "Cyclosporine_INT_Pasireotide", "text": "Interaction: Cyclosporine AND Pasireotide\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Pasireotide.\nRisk: Monitor closely.", "source": "Cyclosporine + Pasireotide"}, {"id": "Cyclosporine_INT_Lanreotide", "text": "Interaction: Cyclosporine AND Lanreotide\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Lanreotide.\nRisk: Monitor closely.", "source": "Cyclosporine + Lanreotide"}, {"id": "Cyclosporine_INT_Vapreotide", "text": "Interaction: Cyclosporine AND Vapreotide\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Vapreotide.\nRisk: Monitor closely.", "source": "Cyclosporine + Vapreotide"}, {"id": "Cyclosporine_INT_Somatostatin", "text": "Interaction: Cyclosporine AND Somatostatin\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Somatostatin.\nRisk: Monitor closely.", "source": "Cyclosporine + Somatostatin"}, {"id": "Cyclosporine_INT_Linagliptin", "text": "Interaction: Cyclosporine AND Linagliptin\nDetails: The serum concentration of Linagliptin can be decreased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Linagliptin"}, {"id": "Cyclosporine_INT_Diltiazem", "text": "Interaction: Cyclosporine AND Diltiazem\nDetails: The metabolism of Cyclosporine can be decreased when combined with Diltiazem.\nRisk: Monitor closely.", "source": "Cyclosporine + Diltiazem"}, {"id": "Cyclosporine_INT_Verapamil", "text": "Interaction: Cyclosporine AND Verapamil\nDetails: The metabolism of Cyclosporine can be decreased when combined with Verapamil.\nRisk: Monitor closely.", "source": "Cyclosporine + Verapamil"}, {"id": "Cyclosporine_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Cyclosporine AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Cyclosporine_INT_Yellow fever vaccine", "text": "Interaction: Cyclosporine AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Yellow fever vaccine"}, {"id": "Cyclosporine_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Cyclosporine AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Cyclosporine_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Cyclosporine AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Cyclosporine_INT_Rotavirus Vaccine", "text": "Interaction: Cyclosporine AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rotavirus Vaccine"}, {"id": "Cyclosporine_INT_G17DT", "text": "Interaction: Cyclosporine AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + G17DT"}, {"id": "Cyclosporine_INT_INGN 201", "text": "Interaction: Cyclosporine AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + INGN 201"}, {"id": "Cyclosporine_INT_INGN 225", "text": "Interaction: Cyclosporine AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + INGN 225"}, {"id": "Cyclosporine_INT_Rindopepimut", "text": "Interaction: Cyclosporine AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rindopepimut"}, {"id": "Cyclosporine_INT_SRP 299", "text": "Interaction: Cyclosporine AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + SRP 299"}, {"id": "Cyclosporine_INT_GI-5005", "text": "Interaction: Cyclosporine AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + GI-5005"}, {"id": "Cyclosporine_INT_TG4010", "text": "Interaction: Cyclosporine AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + TG4010"}, {"id": "Cyclosporine_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Cyclosporine AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rabies virus inactivated antigen, A"}, {"id": "Cyclosporine_INT_Tecemotide", "text": "Interaction: Cyclosporine AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tecemotide"}, {"id": "Cyclosporine_INT_Rubella virus vaccine", "text": "Interaction: Cyclosporine AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rubella virus vaccine"}, {"id": "Cyclosporine_INT_Hepatitis A Vaccine", "text": "Interaction: Cyclosporine AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Hepatitis A Vaccine"}, {"id": "Cyclosporine_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Cyclosporine AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Salmonella typhi ty21a live antigen"}, {"id": "Cyclosporine_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Cyclosporine AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Hepatitis B Vaccine (Recombinant)"}, {"id": "Cyclosporine_INT_Ambrisentan", "text": "Interaction: Cyclosporine AND Ambrisentan\nDetails: The serum concentration of Ambrisentan can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ambrisentan"}, {"id": "Cyclosporine_INT_Amiodarone", "text": "Interaction: Cyclosporine AND Amiodarone\nDetails: The metabolism of Cyclosporine can be decreased when combined with Amiodarone.\nRisk: Monitor closely.", "source": "Cyclosporine + Amiodarone"}, {"id": "Cyclosporine_INT_Boceprevir", "text": "Interaction: Cyclosporine AND Boceprevir\nDetails: The serum concentration of Boceprevir can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Boceprevir"}, {"id": "Cyclosporine_INT_Perhexiline", "text": "Interaction: Cyclosporine AND Perhexiline\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Perhexiline.\nRisk: Monitor closely.", "source": "Cyclosporine + Perhexiline"}, {"id": "Cyclosporine_INT_Bepridil", "text": "Interaction: Cyclosporine AND Bepridil\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Bepridil.\nRisk: Monitor closely.", "source": "Cyclosporine + Bepridil"}, {"id": "Cyclosporine_INT_Mibefradil", "text": "Interaction: Cyclosporine AND Mibefradil\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Mibefradil.\nRisk: Monitor closely.", "source": "Cyclosporine + Mibefradil"}, {"id": "Cyclosporine_INT_Nilvadipine", "text": "Interaction: Cyclosporine AND Nilvadipine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Nilvadipine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nilvadipine"}, {"id": "Cyclosporine_INT_Fendiline", "text": "Interaction: Cyclosporine AND Fendiline\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Fendiline.\nRisk: Monitor closely.", "source": "Cyclosporine + Fendiline"}, {"id": "Cyclosporine_INT_Barnidipine", "text": "Interaction: Cyclosporine AND Barnidipine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Barnidipine.\nRisk: Monitor closely.", "source": "Cyclosporine + Barnidipine"}, {"id": "Cyclosporine_INT_Benidipine", "text": "Interaction: Cyclosporine AND Benidipine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Benidipine.\nRisk: Monitor closely.", "source": "Cyclosporine + Benidipine"}, {"id": "Cyclosporine_INT_Cilnidipine", "text": "Interaction: Cyclosporine AND Cilnidipine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Cilnidipine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cilnidipine"}, {"id": "Cyclosporine_INT_Lacidipine", "text": "Interaction: Cyclosporine AND Lacidipine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Lacidipine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lacidipine"}, {"id": "Cyclosporine_INT_Gallopamil", "text": "Interaction: Cyclosporine AND Gallopamil\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Gallopamil.\nRisk: Monitor closely.", "source": "Cyclosporine + Gallopamil"}, {"id": "Cyclosporine_INT_Lidoflazine", "text": "Interaction: Cyclosporine AND Lidoflazine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Lidoflazine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lidoflazine"}, {"id": "Cyclosporine_INT_Pregabalin", "text": "Interaction: Cyclosporine AND Pregabalin\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Pregabalin.\nRisk: Monitor closely.", "source": "Cyclosporine + Pregabalin"}, {"id": "Cyclosporine_INT_Lamotrigine", "text": "Interaction: Cyclosporine AND Lamotrigine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Lamotrigine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lamotrigine"}, {"id": "Cyclosporine_INT_Cinnarizine", "text": "Interaction: Cyclosporine AND Cinnarizine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Cinnarizine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cinnarizine"}, {"id": "Cyclosporine_INT_Magnesium Sulfate", "text": "Interaction: Cyclosporine AND Magnesium Sulfate\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Magnesium Sulfate.\nRisk: Monitor closely.", "source": "Cyclosporine + Magnesium Sulfate"}, {"id": "Cyclosporine_INT_Risedronate", "text": "Interaction: Cyclosporine AND Risedronate\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Risedronate.\nRisk: Monitor closely.", "source": "Cyclosporine + Risedronate"}, {"id": "Cyclosporine_INT_Gabapentin", "text": "Interaction: Cyclosporine AND Gabapentin\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Gabapentin.\nRisk: Monitor closely.", "source": "Cyclosporine + Gabapentin"}, {"id": "Cyclosporine_INT_Nitrendipine", "text": "Interaction: Cyclosporine AND Nitrendipine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Nitrendipine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nitrendipine"}, {"id": "Cyclosporine_INT_Amrinone", "text": "Interaction: Cyclosporine AND Amrinone\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Amrinone.\nRisk: Monitor closely.", "source": "Cyclosporine + Amrinone"}, {"id": "Cyclosporine_INT_Prenylamine", "text": "Interaction: Cyclosporine AND Prenylamine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Prenylamine.\nRisk: Monitor closely.", "source": "Cyclosporine + Prenylamine"}, {"id": "Cyclosporine_INT_Flunarizine", "text": "Interaction: Cyclosporine AND Flunarizine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Flunarizine.\nRisk: Monitor closely.", "source": "Cyclosporine + Flunarizine"}, {"id": "Cyclosporine_INT_Azimilide", "text": "Interaction: Cyclosporine AND Azimilide\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Azimilide.\nRisk: Monitor closely.", "source": "Cyclosporine + Azimilide"}, {"id": "Cyclosporine_INT_Ziconotide", "text": "Interaction: Cyclosporine AND Ziconotide\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Ziconotide.\nRisk: Monitor closely.", "source": "Cyclosporine + Ziconotide"}, {"id": "Cyclosporine_INT_Dotarizine", "text": "Interaction: Cyclosporine AND Dotarizine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Dotarizine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dotarizine"}, {"id": "Cyclosporine_INT_Xylometazoline", "text": "Interaction: Cyclosporine AND Xylometazoline\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Xylometazoline.\nRisk: Monitor closely.", "source": "Cyclosporine + Xylometazoline"}, {"id": "Cyclosporine_INT_Eperisone", "text": "Interaction: Cyclosporine AND Eperisone\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Eperisone.\nRisk: Monitor closely.", "source": "Cyclosporine + Eperisone"}, {"id": "Cyclosporine_INT_Pinaverium", "text": "Interaction: Cyclosporine AND Pinaverium\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Pinaverium.\nRisk: Monitor closely.", "source": "Cyclosporine + Pinaverium"}, {"id": "Cyclosporine_INT_Azelnidipine", "text": "Interaction: Cyclosporine AND Azelnidipine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Azelnidipine.\nRisk: Monitor closely.", "source": "Cyclosporine + Azelnidipine"}, {"id": "Cyclosporine_INT_Darodipine", "text": "Interaction: Cyclosporine AND Darodipine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Darodipine.\nRisk: Monitor closely.", "source": "Cyclosporine + Darodipine"}, {"id": "Cyclosporine_INT_Efonidipine", "text": "Interaction: Cyclosporine AND Efonidipine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Efonidipine.\nRisk: Monitor closely.", "source": "Cyclosporine + Efonidipine"}, {"id": "Cyclosporine_INT_Manidipine", "text": "Interaction: Cyclosporine AND Manidipine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Manidipine.\nRisk: Monitor closely.", "source": "Cyclosporine + Manidipine"}, {"id": "Cyclosporine_INT_Niguldipine", "text": "Interaction: Cyclosporine AND Niguldipine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Niguldipine.\nRisk: Monitor closely.", "source": "Cyclosporine + Niguldipine"}, {"id": "Cyclosporine_INT_Niludipine", "text": "Interaction: Cyclosporine AND Niludipine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Niludipine.\nRisk: Monitor closely.", "source": "Cyclosporine + Niludipine"}, {"id": "Cyclosporine_INT_Carboxyamidotriazole", "text": "Interaction: Cyclosporine AND Carboxyamidotriazole\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Carboxyamidotriazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Carboxyamidotriazole"}, {"id": "Cyclosporine_INT_Naftopidil", "text": "Interaction: Cyclosporine AND Naftopidil\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Naftopidil.\nRisk: Monitor closely.", "source": "Cyclosporine + Naftopidil"}, {"id": "Cyclosporine_INT_Tetrahydropalmatine", "text": "Interaction: Cyclosporine AND Tetrahydropalmatine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Tetrahydropalmatine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tetrahydropalmatine"}, {"id": "Cyclosporine_INT_Vinpocetine", "text": "Interaction: Cyclosporine AND Vinpocetine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Vinpocetine.\nRisk: Monitor closely.", "source": "Cyclosporine + Vinpocetine"}, {"id": "Cyclosporine_INT_Bencyclane", "text": "Interaction: Cyclosporine AND Bencyclane\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Bencyclane.\nRisk: Monitor closely.", "source": "Cyclosporine + Bencyclane"}, {"id": "Cyclosporine_INT_Otilonium", "text": "Interaction: Cyclosporine AND Otilonium\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Otilonium.\nRisk: Monitor closely.", "source": "Cyclosporine + Otilonium"}, {"id": "Cyclosporine_INT_Terodiline", "text": "Interaction: Cyclosporine AND Terodiline\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Terodiline.\nRisk: Monitor closely.", "source": "Cyclosporine + Terodiline"}, {"id": "Cyclosporine_INT_Caroverine", "text": "Interaction: Cyclosporine AND Caroverine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Caroverine.\nRisk: Monitor closely.", "source": "Cyclosporine + Caroverine"}, {"id": "Cyclosporine_INT_Carbamazepine", "text": "Interaction: Cyclosporine AND Carbamazepine\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Carbamazepine.\nRisk: Monitor closely.", "source": "Cyclosporine + Carbamazepine"}, {"id": "Cyclosporine_INT_Carvedilol", "text": "Interaction: Cyclosporine AND Carvedilol\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Carvedilol.\nRisk: Monitor closely.", "source": "Cyclosporine + Carvedilol"}, {"id": "Cyclosporine_INT_Caspofungin", "text": "Interaction: Cyclosporine AND Caspofungin\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Caspofungin.\nRisk: Monitor closely.", "source": "Cyclosporine + Caspofungin"}, {"id": "Cyclosporine_INT_Chloramphenicol", "text": "Interaction: Cyclosporine AND Chloramphenicol\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Chloramphenicol.\nRisk: Monitor closely.", "source": "Cyclosporine + Chloramphenicol"}, {"id": "Cyclosporine_INT_Colesevelam", "text": "Interaction: Cyclosporine AND Colesevelam\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Colesevelam.\nRisk: Monitor closely.", "source": "Cyclosporine + Colesevelam"}, {"id": "Cyclosporine_INT_Dabrafenib", "text": "Interaction: Cyclosporine AND Dabrafenib\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Dabrafenib.\nRisk: Monitor closely.", "source": "Cyclosporine + Dabrafenib"}, {"id": "Cyclosporine_INT_Deferasirox", "text": "Interaction: Cyclosporine AND Deferasirox\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Deferasirox.\nRisk: Monitor closely.", "source": "Cyclosporine + Deferasirox"}, {"id": "Cyclosporine_INT_Digoxin", "text": "Interaction: Cyclosporine AND Digoxin\nDetails: The serum concentration of Digoxin can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Digoxin"}, {"id": "Cyclosporine_INT_Fesoterodine", "text": "Interaction: Cyclosporine AND Fesoterodine\nDetails: The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Fesoterodine"}, {"id": "Cyclosporine_INT_Clarithromycin", "text": "Interaction: Cyclosporine AND Clarithromycin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Clarithromycin.\nRisk: Monitor closely.", "source": "Cyclosporine + Clarithromycin"}, {"id": "Cyclosporine_INT_Erythromycin", "text": "Interaction: Cyclosporine AND Erythromycin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Erythromycin.\nRisk: Monitor closely.", "source": "Cyclosporine + Erythromycin"}, {"id": "Cyclosporine_INT_Telithromycin", "text": "Interaction: Cyclosporine AND Telithromycin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Telithromycin.\nRisk: Monitor closely.", "source": "Cyclosporine + Telithromycin"}, {"id": "Cyclosporine_INT_Azithromycin", "text": "Interaction: Cyclosporine AND Azithromycin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Azithromycin.\nRisk: Monitor closely.", "source": "Cyclosporine + Azithromycin"}, {"id": "Cyclosporine_INT_Carbomycin", "text": "Interaction: Cyclosporine AND Carbomycin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Carbomycin.\nRisk: Monitor closely.", "source": "Cyclosporine + Carbomycin"}, {"id": "Cyclosporine_INT_Josamycin", "text": "Interaction: Cyclosporine AND Josamycin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Josamycin.\nRisk: Monitor closely.", "source": "Cyclosporine + Josamycin"}, {"id": "Cyclosporine_INT_Kitasamycin", "text": "Interaction: Cyclosporine AND Kitasamycin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Kitasamycin.\nRisk: Monitor closely.", "source": "Cyclosporine + Kitasamycin"}, {"id": "Cyclosporine_INT_Oleandomycin", "text": "Interaction: Cyclosporine AND Oleandomycin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Oleandomycin.\nRisk: Monitor closely.", "source": "Cyclosporine + Oleandomycin"}, {"id": "Cyclosporine_INT_Solithromycin", "text": "Interaction: Cyclosporine AND Solithromycin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Solithromycin.\nRisk: Monitor closely.", "source": "Cyclosporine + Solithromycin"}, {"id": "Cyclosporine_INT_Tylosin", "text": "Interaction: Cyclosporine AND Tylosin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Tylosin.\nRisk: Monitor closely.", "source": "Cyclosporine + Tylosin"}, {"id": "Cyclosporine_INT_Fluconazole", "text": "Interaction: Cyclosporine AND Fluconazole\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Fluconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Fluconazole"}, {"id": "Cyclosporine_INT_Fosaprepitant", "text": "Interaction: Cyclosporine AND Fosaprepitant\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Fosaprepitant.\nRisk: Monitor closely.", "source": "Cyclosporine + Fosaprepitant"}, {"id": "Cyclosporine_INT_Glyburide", "text": "Interaction: Cyclosporine AND Glyburide\nDetails: The therapeutic efficacy of Glyburide can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Glyburide"}, {"id": "Cyclosporine_INT_Griseofulvin", "text": "Interaction: Cyclosporine AND Griseofulvin\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Griseofulvin.\nRisk: Monitor closely.", "source": "Cyclosporine + Griseofulvin"}, {"id": "Cyclosporine_INT_Succinylcholine", "text": "Interaction: Cyclosporine AND Succinylcholine\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Succinylcholine.\nRisk: Monitor closely.", "source": "Cyclosporine + Succinylcholine"}, {"id": "Cyclosporine_INT_Cisatracurium besylate", "text": "Interaction: Cyclosporine AND Cisatracurium besylate\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Cisatracurium besylate.\nRisk: Monitor closely.", "source": "Cyclosporine + Cisatracurium besylate"}, {"id": "Cyclosporine_INT_Rocuronium", "text": "Interaction: Cyclosporine AND Rocuronium\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Rocuronium.\nRisk: Monitor closely.", "source": "Cyclosporine + Rocuronium"}, {"id": "Cyclosporine_INT_Atracurium besylate", "text": "Interaction: Cyclosporine AND Atracurium besylate\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Atracurium besylate.\nRisk: Monitor closely.", "source": "Cyclosporine + Atracurium besylate"}, {"id": "Cyclosporine_INT_Pancuronium", "text": "Interaction: Cyclosporine AND Pancuronium\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Pancuronium.\nRisk: Monitor closely.", "source": "Cyclosporine + Pancuronium"}, {"id": "Cyclosporine_INT_Vecuronium", "text": "Interaction: Cyclosporine AND Vecuronium\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Vecuronium.\nRisk: Monitor closely.", "source": "Cyclosporine + Vecuronium"}, {"id": "Cyclosporine_INT_Metocurine Iodide", "text": "Interaction: Cyclosporine AND Metocurine Iodide\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Metocurine Iodide.\nRisk: Monitor closely.", "source": "Cyclosporine + Metocurine Iodide"}, {"id": "Cyclosporine_INT_Gallamine Triethiodide", "text": "Interaction: Cyclosporine AND Gallamine Triethiodide\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Gallamine Triethiodide.\nRisk: Monitor closely.", "source": "Cyclosporine + Gallamine Triethiodide"}, {"id": "Cyclosporine_INT_Doxacurium chloride", "text": "Interaction: Cyclosporine AND Doxacurium chloride\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Doxacurium chloride.\nRisk: Monitor closely.", "source": "Cyclosporine + Doxacurium chloride"}, {"id": "Cyclosporine_INT_Tubocurarine", "text": "Interaction: Cyclosporine AND Tubocurarine\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Tubocurarine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tubocurarine"}, {"id": "Cyclosporine_INT_Mivacurium", "text": "Interaction: Cyclosporine AND Mivacurium\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Mivacurium.\nRisk: Monitor closely.", "source": "Cyclosporine + Mivacurium"}, {"id": "Cyclosporine_INT_Decamethonium", "text": "Interaction: Cyclosporine AND Decamethonium\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Decamethonium.\nRisk: Monitor closely.", "source": "Cyclosporine + Decamethonium"}, {"id": "Cyclosporine_INT_Metocurine", "text": "Interaction: Cyclosporine AND Metocurine\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Metocurine.\nRisk: Monitor closely.", "source": "Cyclosporine + Metocurine"}, {"id": "Cyclosporine_INT_Pipecuronium", "text": "Interaction: Cyclosporine AND Pipecuronium\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Pipecuronium.\nRisk: Monitor closely.", "source": "Cyclosporine + Pipecuronium"}, {"id": "Cyclosporine_INT_Domoic Acid", "text": "Interaction: Cyclosporine AND Domoic Acid\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Domoic Acid.\nRisk: Monitor closely.", "source": "Cyclosporine + Domoic Acid"}, {"id": "Cyclosporine_INT_Rapacuronium", "text": "Interaction: Cyclosporine AND Rapacuronium\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Rapacuronium.\nRisk: Monitor closely.", "source": "Cyclosporine + Rapacuronium"}, {"id": "Cyclosporine_INT_Pyrantel", "text": "Interaction: Cyclosporine AND Pyrantel\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Pyrantel.\nRisk: Monitor closely.", "source": "Cyclosporine + Pyrantel"}, {"id": "Cyclosporine_INT_Neosaxitoxin", "text": "Interaction: Cyclosporine AND Neosaxitoxin\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Neosaxitoxin.\nRisk: Monitor closely.", "source": "Cyclosporine + Neosaxitoxin"}, {"id": "Cyclosporine_INT_Atracurium", "text": "Interaction: Cyclosporine AND Atracurium\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Atracurium.\nRisk: Monitor closely.", "source": "Cyclosporine + Atracurium"}, {"id": "Cyclosporine_INT_Cisatracurium", "text": "Interaction: Cyclosporine AND Cisatracurium\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Cisatracurium.\nRisk: Monitor closely.", "source": "Cyclosporine + Cisatracurium"}, {"id": "Cyclosporine_INT_Gallamine", "text": "Interaction: Cyclosporine AND Gallamine\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Gallamine.\nRisk: Monitor closely.", "source": "Cyclosporine + Gallamine"}, {"id": "Cyclosporine_INT_Alcuronium", "text": "Interaction: Cyclosporine AND Alcuronium\nDetails: Cyclosporine may increase the neuromuscular blocking activities of Alcuronium.\nRisk: Monitor closely.", "source": "Cyclosporine + Alcuronium"}, {"id": "Cyclosporine_INT_Imatinib", "text": "Interaction: Cyclosporine AND Imatinib\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Imatinib.\nRisk: Monitor closely.", "source": "Cyclosporine + Imatinib"}, {"id": "Cyclosporine_INT_Imipenem", "text": "Interaction: Cyclosporine AND Imipenem\nDetails: Cyclosporine may increase the neurotoxic activities of Imipenem.\nRisk: Monitor closely.", "source": "Cyclosporine + Imipenem"}, {"id": "Cyclosporine_INT_Ledipasvir", "text": "Interaction: Cyclosporine AND Ledipasvir\nDetails: The serum concentration of Ledipasvir can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ledipasvir"}, {"id": "Cyclosporine_INT_Luliconazole", "text": "Interaction: Cyclosporine AND Luliconazole\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Luliconazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Luliconazole"}, {"id": "Cyclosporine_INT_Melphalan", "text": "Interaction: Cyclosporine AND Melphalan\nDetails: Melphalan may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Melphalan"}, {"id": "Cyclosporine_INT_Methylprednisolone", "text": "Interaction: Cyclosporine AND Methylprednisolone\nDetails: The serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Methylprednisolone"}, {"id": "Cyclosporine_INT_Metoclopramide", "text": "Interaction: Cyclosporine AND Metoclopramide\nDetails: Metoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects.\nRisk: Monitor closely.", "source": "Cyclosporine + Metoclopramide"}, {"id": "Cyclosporine_INT_Metreleptin", "text": "Interaction: Cyclosporine AND Metreleptin\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Metreleptin.\nRisk: Monitor closely.", "source": "Cyclosporine + Metreleptin"}, {"id": "Cyclosporine_INT_Modafinil", "text": "Interaction: Cyclosporine AND Modafinil\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Modafinil.\nRisk: Monitor closely.", "source": "Cyclosporine + Modafinil"}, {"id": "Cyclosporine_INT_Nafcillin", "text": "Interaction: Cyclosporine AND Nafcillin\nDetails: The metabolism of Cyclosporine can be increased when combined with Nafcillin.\nRisk: Monitor closely.", "source": "Cyclosporine + Nafcillin"}, {"id": "Cyclosporine_INT_Naloxegol", "text": "Interaction: Cyclosporine AND Naloxegol\nDetails: The serum concentration of Naloxegol can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Naloxegol"}, {"id": "Cyclosporine_INT_Netupitant", "text": "Interaction: Cyclosporine AND Netupitant\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Netupitant.\nRisk: Monitor closely.", "source": "Cyclosporine + Netupitant"}, {"id": "Cyclosporine_INT_Amikacin", "text": "Interaction: Cyclosporine AND Amikacin\nDetails: Amikacin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Amikacin"}, {"id": "Cyclosporine_INT_Tobramycin", "text": "Interaction: Cyclosporine AND Tobramycin\nDetails: Tobramycin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tobramycin"}, {"id": "Cyclosporine_INT_Gentamicin", "text": "Interaction: Cyclosporine AND Gentamicin\nDetails: Gentamicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Gentamicin"}, {"id": "Cyclosporine_INT_Neomycin", "text": "Interaction: Cyclosporine AND Neomycin\nDetails: Neomycin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Neomycin"}, {"id": "Cyclosporine_INT_Streptomycin", "text": "Interaction: Cyclosporine AND Streptomycin\nDetails: Streptomycin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Streptomycin"}, {"id": "Cyclosporine_INT_Valrubicin", "text": "Interaction: Cyclosporine AND Valrubicin\nDetails: Valrubicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Valrubicin"}, {"id": "Cyclosporine_INT_Streptozocin", "text": "Interaction: Cyclosporine AND Streptozocin\nDetails: Streptozocin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Streptozocin"}, {"id": "Cyclosporine_INT_Epirubicin", "text": "Interaction: Cyclosporine AND Epirubicin\nDetails: Epirubicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Epirubicin"}, {"id": "Cyclosporine_INT_Framycetin", "text": "Interaction: Cyclosporine AND Framycetin\nDetails: Framycetin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Framycetin"}, {"id": "Cyclosporine_INT_Daunorubicin", "text": "Interaction: Cyclosporine AND Daunorubicin\nDetails: Daunorubicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Daunorubicin"}, {"id": "Cyclosporine_INT_Spectinomycin", "text": "Interaction: Cyclosporine AND Spectinomycin\nDetails: Spectinomycin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Spectinomycin"}, {"id": "Cyclosporine_INT_Netilmicin", "text": "Interaction: Cyclosporine AND Netilmicin\nDetails: Netilmicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Netilmicin"}, {"id": "Cyclosporine_INT_Doxorubicin", "text": "Interaction: Cyclosporine AND Doxorubicin\nDetails: Doxorubicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Doxorubicin"}, {"id": "Cyclosporine_INT_Kanamycin", "text": "Interaction: Cyclosporine AND Kanamycin\nDetails: Kanamycin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Kanamycin"}, {"id": "Cyclosporine_INT_Idarubicin", "text": "Interaction: Cyclosporine AND Idarubicin\nDetails: Idarubicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Idarubicin"}, {"id": "Cyclosporine_INT_Paromomycin", "text": "Interaction: Cyclosporine AND Paromomycin\nDetails: Paromomycin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Paromomycin"}, {"id": "Cyclosporine_INT_Metrizamide", "text": "Interaction: Cyclosporine AND Metrizamide\nDetails: Metrizamide may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Metrizamide"}, {"id": "Cyclosporine_INT_Ribostamycin", "text": "Interaction: Cyclosporine AND Ribostamycin\nDetails: Ribostamycin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ribostamycin"}, {"id": "Cyclosporine_INT_Geneticin", "text": "Interaction: Cyclosporine AND Geneticin\nDetails: Geneticin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Geneticin"}, {"id": "Cyclosporine_INT_Apramycin", "text": "Interaction: Cyclosporine AND Apramycin\nDetails: Apramycin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Apramycin"}, {"id": "Cyclosporine_INT_GENTAMICIN C1A", "text": "Interaction: Cyclosporine AND GENTAMICIN C1A\nDetails: GENTAMICIN C1A may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + GENTAMICIN C1A"}, {"id": "Cyclosporine_INT_Neamine", "text": "Interaction: Cyclosporine AND Neamine\nDetails: Neamine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Neamine"}, {"id": "Cyclosporine_INT_SP1049C", "text": "Interaction: Cyclosporine AND SP1049C\nDetails: SP1049C may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + SP1049C"}, {"id": "Cyclosporine_INT_INNO-206", "text": "Interaction: Cyclosporine AND INNO-206\nDetails: INNO-206 may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + INNO-206"}, {"id": "Cyclosporine_INT_Amrubicin", "text": "Interaction: Cyclosporine AND Amrubicin\nDetails: Amrubicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Amrubicin"}, {"id": "Cyclosporine_INT_annamycin", "text": "Interaction: Cyclosporine AND annamycin\nDetails: annamycin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + annamycin"}, {"id": "Cyclosporine_INT_Arbekacin", "text": "Interaction: Cyclosporine AND Arbekacin\nDetails: Arbekacin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Arbekacin"}, {"id": "Cyclosporine_INT_Plicamycin", "text": "Interaction: Cyclosporine AND Plicamycin\nDetails: Plicamycin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Plicamycin"}, {"id": "Cyclosporine_INT_Puromycin", "text": "Interaction: Cyclosporine AND Puromycin\nDetails: Puromycin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Puromycin"}, {"id": "Cyclosporine_INT_Dihydrostreptomycin", "text": "Interaction: Cyclosporine AND Dihydrostreptomycin\nDetails: Dihydrostreptomycin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dihydrostreptomycin"}, {"id": "Cyclosporine_INT_Hygromycin B", "text": "Interaction: Cyclosporine AND Hygromycin B\nDetails: Hygromycin B may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Hygromycin B"}, {"id": "Cyclosporine_INT_Pirarubicin", "text": "Interaction: Cyclosporine AND Pirarubicin\nDetails: Pirarubicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pirarubicin"}, {"id": "Cyclosporine_INT_Aclarubicin", "text": "Interaction: Cyclosporine AND Aclarubicin\nDetails: Aclarubicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Aclarubicin"}, {"id": "Cyclosporine_INT_Zorubicin", "text": "Interaction: Cyclosporine AND Zorubicin\nDetails: Zorubicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Zorubicin"}, {"id": "Cyclosporine_INT_Sabarubicin", "text": "Interaction: Cyclosporine AND Sabarubicin\nDetails: Sabarubicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sabarubicin"}, {"id": "Cyclosporine_INT_Sisomicin", "text": "Interaction: Cyclosporine AND Sisomicin\nDetails: Sisomicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sisomicin"}, {"id": "Cyclosporine_INT_Plazomicin", "text": "Interaction: Cyclosporine AND Plazomicin\nDetails: Plazomicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Plazomicin"}, {"id": "Cyclosporine_INT_Zoptarelin doxorubicin", "text": "Interaction: Cyclosporine AND Zoptarelin doxorubicin\nDetails: Zoptarelin doxorubicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Zoptarelin doxorubicin"}, {"id": "Cyclosporine_INT_GPX-150", "text": "Interaction: Cyclosporine AND GPX-150\nDetails: GPX-150 may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + GPX-150"}, {"id": "Cyclosporine_INT_Dibekacin", "text": "Interaction: Cyclosporine AND Dibekacin\nDetails: Dibekacin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dibekacin"}, {"id": "Cyclosporine_INT_Micronomicin", "text": "Interaction: Cyclosporine AND Micronomicin\nDetails: Micronomicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Micronomicin"}, {"id": "Cyclosporine_INT_Isepamicin", "text": "Interaction: Cyclosporine AND Isepamicin\nDetails: Isepamicin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Isepamicin"}, {"id": "Cyclosporine_INT_Bekanamycin", "text": "Interaction: Cyclosporine AND Bekanamycin\nDetails: Bekanamycin may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bekanamycin"}, {"id": "Cyclosporine_INT_Norfloxacin", "text": "Interaction: Cyclosporine AND Norfloxacin\nDetails: The metabolism of Cyclosporine can be decreased when combined with Norfloxacin.\nRisk: Monitor closely.", "source": "Cyclosporine + Norfloxacin"}, {"id": "Cyclosporine_INT_Omeprazole", "text": "Interaction: Cyclosporine AND Omeprazole\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Omeprazole.\nRisk: Monitor closely.", "source": "Cyclosporine + Omeprazole"}, {"id": "Cyclosporine_INT_Torasemide", "text": "Interaction: Cyclosporine AND Torasemide\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Torasemide.\nRisk: Monitor closely.", "source": "Cyclosporine + Torasemide"}, {"id": "Cyclosporine_INT_Furosemide", "text": "Interaction: Cyclosporine AND Furosemide\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Furosemide.\nRisk: Monitor closely.", "source": "Cyclosporine + Furosemide"}, {"id": "Cyclosporine_INT_Bumetanide", "text": "Interaction: Cyclosporine AND Bumetanide\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Bumetanide.\nRisk: Monitor closely.", "source": "Cyclosporine + Bumetanide"}, {"id": "Cyclosporine_INT_Etacrynic acid", "text": "Interaction: Cyclosporine AND Etacrynic acid\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid.\nRisk: Monitor closely.", "source": "Cyclosporine + Etacrynic acid"}, {"id": "Cyclosporine_INT_Piretanide", "text": "Interaction: Cyclosporine AND Piretanide\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Piretanide.\nRisk: Monitor closely.", "source": "Cyclosporine + Piretanide"}, {"id": "Cyclosporine_INT_Palbociclib", "text": "Interaction: Cyclosporine AND Palbociclib\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Palbociclib.\nRisk: Monitor closely.", "source": "Cyclosporine + Palbociclib"}, {"id": "Cyclosporine_INT_Prednisone", "text": "Interaction: Cyclosporine AND Prednisone\nDetails: The serum concentration of the active metabolites of Prednisone can be increased when Prednisone is used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Prednisone"}, {"id": "Cyclosporine_INT_Prucalopride", "text": "Interaction: Cyclosporine AND Prucalopride\nDetails: The serum concentration of Prucalopride can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Prucalopride"}, {"id": "Cyclosporine_INT_Pyrazinamide", "text": "Interaction: Cyclosporine AND Pyrazinamide\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Pyrazinamide.\nRisk: Monitor closely.", "source": "Cyclosporine + Pyrazinamide"}, {"id": "Cyclosporine_INT_Quinupristin", "text": "Interaction: Cyclosporine AND Quinupristin\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Quinupristin.\nRisk: Monitor closely.", "source": "Cyclosporine + Quinupristin"}, {"id": "Cyclosporine_INT_Repaglinide", "text": "Interaction: Cyclosporine AND Repaglinide\nDetails: The serum concentration of Repaglinide can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Repaglinide"}, {"id": "Cyclosporine_INT_Rifaximin", "text": "Interaction: Cyclosporine AND Rifaximin\nDetails: The serum concentration of Rifaximin can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rifaximin"}, {"id": "Cyclosporine_INT_Dronabinol", "text": "Interaction: Cyclosporine AND Dronabinol\nDetails: The serum concentration of Dronabinol can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dronabinol"}, {"id": "Cyclosporine_INT_Sevelamer", "text": "Interaction: Cyclosporine AND Sevelamer\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Sevelamer.\nRisk: Monitor closely.", "source": "Cyclosporine + Sevelamer"}, {"id": "Cyclosporine_INT_Siltuximab", "text": "Interaction: Cyclosporine AND Siltuximab\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Siltuximab.\nRisk: Monitor closely.", "source": "Cyclosporine + Siltuximab"}, {"id": "Cyclosporine_INT_Sulfinpyrazone", "text": "Interaction: Cyclosporine AND Sulfinpyrazone\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Sulfinpyrazone.\nRisk: Monitor closely.", "source": "Cyclosporine + Sulfinpyrazone"}, {"id": "Cyclosporine_INT_Ticagrelor", "text": "Interaction: Cyclosporine AND Ticagrelor\nDetails: The serum concentration of Ticagrelor can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ticagrelor"}, {"id": "Cyclosporine_INT_Tocilizumab", "text": "Interaction: Cyclosporine AND Tocilizumab\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Tocilizumab.\nRisk: Monitor closely.", "source": "Cyclosporine + Tocilizumab"}, {"id": "Cyclosporine_INT_Vitamin E", "text": "Interaction: Cyclosporine AND Vitamin E\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Vitamin E.\nRisk: Monitor closely.", "source": "Cyclosporine + Vitamin E"}, {"id": "Cyclosporine_INT_Brexpiprazole", "text": "Interaction: Cyclosporine AND Brexpiprazole\nDetails: The serum concentration of Brexpiprazole can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Brexpiprazole"}, {"id": "Cyclosporine_INT_Busulfan", "text": "Interaction: Cyclosporine AND Busulfan\nDetails: The serum concentration of Busulfan can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Busulfan"}, {"id": "Cyclosporine_INT_Osimertinib", "text": "Interaction: Cyclosporine AND Osimertinib\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Osimertinib.\nRisk: Monitor closely.", "source": "Cyclosporine + Osimertinib"}, {"id": "Cyclosporine_INT_Hydrocodone", "text": "Interaction: Cyclosporine AND Hydrocodone\nDetails: The serum concentration of Hydrocodone can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Hydrocodone"}, {"id": "Cyclosporine_INT_Ifosfamide", "text": "Interaction: Cyclosporine AND Ifosfamide\nDetails: The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Cyclosporine resulting in a loss in efficacy.\nRisk: Monitor closely.", "source": "Cyclosporine + Ifosfamide"}, {"id": "Cyclosporine_INT_Ceritinib", "text": "Interaction: Cyclosporine AND Ceritinib\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Ceritinib.\nRisk: Monitor closely.", "source": "Cyclosporine + Ceritinib"}, {"id": "Cyclosporine_INT_Bortezomib", "text": "Interaction: Cyclosporine AND Bortezomib\nDetails: The metabolism of Cyclosporine can be decreased when combined with Bortezomib.\nRisk: Monitor closely.", "source": "Cyclosporine + Bortezomib"}, {"id": "Cyclosporine_INT_Ticlopidine", "text": "Interaction: Cyclosporine AND Ticlopidine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Ticlopidine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ticlopidine"}, {"id": "Cyclosporine_INT_Ziprasidone", "text": "Interaction: Cyclosporine AND Ziprasidone\nDetails: The metabolism of Cyclosporine can be decreased when combined with Ziprasidone.\nRisk: Monitor closely.", "source": "Cyclosporine + Ziprasidone"}, {"id": "Cyclosporine_INT_Dihydroergotamine", "text": "Interaction: Cyclosporine AND Dihydroergotamine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Dihydroergotamine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dihydroergotamine"}, {"id": "Cyclosporine_INT_Delavirdine", "text": "Interaction: Cyclosporine AND Delavirdine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Delavirdine.\nRisk: Monitor closely.", "source": "Cyclosporine + Delavirdine"}, {"id": "Cyclosporine_INT_Sildenafil", "text": "Interaction: Cyclosporine AND Sildenafil\nDetails: The metabolism of Cyclosporine can be decreased when combined with Sildenafil.\nRisk: Monitor closely.", "source": "Cyclosporine + Sildenafil"}, {"id": "Cyclosporine_INT_Fluvoxamine", "text": "Interaction: Cyclosporine AND Fluvoxamine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Fluvoxamine.\nRisk: Monitor closely.", "source": "Cyclosporine + Fluvoxamine"}, {"id": "Cyclosporine_INT_Venlafaxine", "text": "Interaction: Cyclosporine AND Venlafaxine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Venlafaxine.\nRisk: Monitor closely.", "source": "Cyclosporine + Venlafaxine"}, {"id": "Cyclosporine_INT_Flunisolide", "text": "Interaction: Cyclosporine AND Flunisolide\nDetails: The metabolism of Flunisolide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Flunisolide"}, {"id": "Cyclosporine_INT_Cevimeline", "text": "Interaction: Cyclosporine AND Cevimeline\nDetails: The metabolism of Cevimeline can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cevimeline"}, {"id": "Cyclosporine_INT_Pantoprazole", "text": "Interaction: Cyclosporine AND Pantoprazole\nDetails: The metabolism of Pantoprazole can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pantoprazole"}, {"id": "Cyclosporine_INT_Reboxetine", "text": "Interaction: Cyclosporine AND Reboxetine\nDetails: The metabolism of Reboxetine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Reboxetine"}, {"id": "Cyclosporine_INT_Alclometasone", "text": "Interaction: Cyclosporine AND Alclometasone\nDetails: The metabolism of Alclometasone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Alclometasone"}, {"id": "Cyclosporine_INT_Disopyramide", "text": "Interaction: Cyclosporine AND Disopyramide\nDetails: The metabolism of Disopyramide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Disopyramide"}, {"id": "Cyclosporine_INT_Conjugated estrogens", "text": "Interaction: Cyclosporine AND Conjugated estrogens\nDetails: The metabolism of Conjugated estrogens can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Conjugated estrogens"}, {"id": "Cyclosporine_INT_Etonogestrel", "text": "Interaction: Cyclosporine AND Etonogestrel\nDetails: The metabolism of Etonogestrel can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Etonogestrel"}, {"id": "Cyclosporine_INT_Bupivacaine", "text": "Interaction: Cyclosporine AND Bupivacaine\nDetails: The metabolism of Bupivacaine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bupivacaine"}, {"id": "Cyclosporine_INT_Bexarotene", "text": "Interaction: Cyclosporine AND Bexarotene\nDetails: The metabolism of Bexarotene can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bexarotene"}, {"id": "Cyclosporine_INT_Gefitinib", "text": "Interaction: Cyclosporine AND Gefitinib\nDetails: The metabolism of Gefitinib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Gefitinib"}, {"id": "Cyclosporine_INT_Fluorometholone", "text": "Interaction: Cyclosporine AND Fluorometholone\nDetails: The metabolism of Fluorometholone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Fluorometholone"}, {"id": "Cyclosporine_INT_Hydromorphone", "text": "Interaction: Cyclosporine AND Hydromorphone\nDetails: The metabolism of Hydromorphone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Hydromorphone"}, {"id": "Cyclosporine_INT_Ipratropium bromide", "text": "Interaction: Cyclosporine AND Ipratropium bromide\nDetails: The metabolism of Ipratropium bromide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ipratropium bromide"}, {"id": "Cyclosporine_INT_Terfenadine", "text": "Interaction: Cyclosporine AND Terfenadine\nDetails: The metabolism of Terfenadine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Terfenadine"}, {"id": "Cyclosporine_INT_Alfuzosin", "text": "Interaction: Cyclosporine AND Alfuzosin\nDetails: The metabolism of Alfuzosin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Alfuzosin"}, {"id": "Cyclosporine_INT_Vinorelbine", "text": "Interaction: Cyclosporine AND Vinorelbine\nDetails: The metabolism of Vinorelbine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Vinorelbine"}, {"id": "Cyclosporine_INT_Grepafloxacin", "text": "Interaction: Cyclosporine AND Grepafloxacin\nDetails: The metabolism of Grepafloxacin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Grepafloxacin"}, {"id": "Cyclosporine_INT_Mirtazapine", "text": "Interaction: Cyclosporine AND Mirtazapine\nDetails: The metabolism of Mirtazapine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mirtazapine"}, {"id": "Cyclosporine_INT_Sorafenib", "text": "Interaction: Cyclosporine AND Sorafenib\nDetails: The metabolism of Sorafenib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sorafenib"}, {"id": "Cyclosporine_INT_Eszopiclone", "text": "Interaction: Cyclosporine AND Eszopiclone\nDetails: The metabolism of Eszopiclone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Eszopiclone"}, {"id": "Cyclosporine_INT_Alprazolam", "text": "Interaction: Cyclosporine AND Alprazolam\nDetails: The metabolism of Alprazolam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Alprazolam"}, {"id": "Cyclosporine_INT_Prochlorperazine", "text": "Interaction: Cyclosporine AND Prochlorperazine\nDetails: The metabolism of Prochlorperazine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Prochlorperazine"}, {"id": "Cyclosporine_INT_Loratadine", "text": "Interaction: Cyclosporine AND Loratadine\nDetails: The metabolism of Loratadine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Loratadine"}, {"id": "Cyclosporine_INT_Quinine", "text": "Interaction: Cyclosporine AND Quinine\nDetails: The metabolism of Quinine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Quinine"}, {"id": "Cyclosporine_INT_Montelukast", "text": "Interaction: Cyclosporine AND Montelukast\nDetails: The metabolism of Montelukast can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Montelukast"}, {"id": "Cyclosporine_INT_Darifenacin", "text": "Interaction: Cyclosporine AND Darifenacin\nDetails: The metabolism of Darifenacin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Darifenacin"}, {"id": "Cyclosporine_INT_Albendazole", "text": "Interaction: Cyclosporine AND Albendazole\nDetails: The metabolism of Albendazole can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Albendazole"}, {"id": "Cyclosporine_INT_Erlotinib", "text": "Interaction: Cyclosporine AND Erlotinib\nDetails: The metabolism of Erlotinib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Erlotinib"}, {"id": "Cyclosporine_INT_Toremifene", "text": "Interaction: Cyclosporine AND Toremifene\nDetails: The metabolism of Toremifene can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Toremifene"}, {"id": "Cyclosporine_INT_Vincristine", "text": "Interaction: Cyclosporine AND Vincristine\nDetails: The metabolism of Vincristine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Vincristine"}, {"id": "Cyclosporine_INT_Vinblastine", "text": "Interaction: Cyclosporine AND Vinblastine\nDetails: The metabolism of Vinblastine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Vinblastine"}, {"id": "Cyclosporine_INT_Fluticasone propionate", "text": "Interaction: Cyclosporine AND Fluticasone propionate\nDetails: The metabolism of Fluticasone propionate can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Fluticasone propionate"}, {"id": "Cyclosporine_INT_Ethosuximide", "text": "Interaction: Cyclosporine AND Ethosuximide\nDetails: The metabolism of Ethosuximide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ethosuximide"}, {"id": "Cyclosporine_INT_Medroxyprogesterone acetate", "text": "Interaction: Cyclosporine AND Medroxyprogesterone acetate\nDetails: The metabolism of Medroxyprogesterone acetate can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Medroxyprogesterone acetate"}, {"id": "Cyclosporine_INT_Astemizole", "text": "Interaction: Cyclosporine AND Astemizole\nDetails: The metabolism of Astemizole can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Astemizole"}, {"id": "Cyclosporine_INT_Mebendazole", "text": "Interaction: Cyclosporine AND Mebendazole\nDetails: The metabolism of Mebendazole can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mebendazole"}, {"id": "Cyclosporine_INT_Galantamine", "text": "Interaction: Cyclosporine AND Galantamine\nDetails: The metabolism of Galantamine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Galantamine"}, {"id": "Cyclosporine_INT_Tamoxifen", "text": "Interaction: Cyclosporine AND Tamoxifen\nDetails: The metabolism of Tamoxifen can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tamoxifen"}, {"id": "Cyclosporine_INT_Midazolam", "text": "Interaction: Cyclosporine AND Midazolam\nDetails: The metabolism of Midazolam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Midazolam"}, {"id": "Cyclosporine_INT_Ergotamine", "text": "Interaction: Cyclosporine AND Ergotamine\nDetails: The metabolism of Ergotamine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ergotamine"}, {"id": "Cyclosporine_INT_Norethisterone", "text": "Interaction: Cyclosporine AND Norethisterone\nDetails: The metabolism of Norethisterone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Norethisterone"}, {"id": "Cyclosporine_INT_Nateglinide", "text": "Interaction: Cyclosporine AND Nateglinide\nDetails: The metabolism of Nateglinide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nateglinide"}, {"id": "Cyclosporine_INT_Esomeprazole", "text": "Interaction: Cyclosporine AND Esomeprazole\nDetails: The metabolism of Esomeprazole can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Esomeprazole"}, {"id": "Cyclosporine_INT_Hydrocortisone", "text": "Interaction: Cyclosporine AND Hydrocortisone\nDetails: The metabolism of Hydrocortisone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Hydrocortisone"}, {"id": "Cyclosporine_INT_Dolasetron", "text": "Interaction: Cyclosporine AND Dolasetron\nDetails: The metabolism of Dolasetron can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dolasetron"}, {"id": "Cyclosporine_INT_Clopidogrel", "text": "Interaction: Cyclosporine AND Clopidogrel\nDetails: The metabolism of Clopidogrel can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Clopidogrel"}, {"id": "Cyclosporine_INT_Irinotecan", "text": "Interaction: Cyclosporine AND Irinotecan\nDetails: The metabolism of Irinotecan can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Irinotecan"}, {"id": "Cyclosporine_INT_Roxithromycin", "text": "Interaction: Cyclosporine AND Roxithromycin\nDetails: The metabolism of Roxithromycin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Roxithromycin"}, {"id": "Cyclosporine_INT_Alfentanil", "text": "Interaction: Cyclosporine AND Alfentanil\nDetails: The metabolism of Alfentanil can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Alfentanil"}, {"id": "Cyclosporine_INT_Tadalafil", "text": "Interaction: Cyclosporine AND Tadalafil\nDetails: The metabolism of Tadalafil can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tadalafil"}, {"id": "Cyclosporine_INT_Diazepam", "text": "Interaction: Cyclosporine AND Diazepam\nDetails: The metabolism of Diazepam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Diazepam"}, {"id": "Cyclosporine_INT_Loperamide", "text": "Interaction: Cyclosporine AND Loperamide\nDetails: The metabolism of Loperamide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Loperamide"}, {"id": "Cyclosporine_INT_Donepezil", "text": "Interaction: Cyclosporine AND Donepezil\nDetails: The metabolism of Donepezil can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Donepezil"}, {"id": "Cyclosporine_INT_Vardenafil", "text": "Interaction: Cyclosporine AND Vardenafil\nDetails: The metabolism of Vardenafil can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Vardenafil"}, {"id": "Cyclosporine_INT_Isosorbide Dinitrate", "text": "Interaction: Cyclosporine AND Isosorbide Dinitrate\nDetails: The metabolism of Isosorbide Dinitrate can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Isosorbide Dinitrate"}, {"id": "Cyclosporine_INT_Granisetron", "text": "Interaction: Cyclosporine AND Granisetron\nDetails: The metabolism of Granisetron can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Granisetron"}, {"id": "Cyclosporine_INT_Triazolam", "text": "Interaction: Cyclosporine AND Triazolam\nDetails: The metabolism of Triazolam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Triazolam"}, {"id": "Cyclosporine_INT_Ondansetron", "text": "Interaction: Cyclosporine AND Ondansetron\nDetails: The metabolism of Ondansetron can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ondansetron"}, {"id": "Cyclosporine_INT_Tiagabine", "text": "Interaction: Cyclosporine AND Tiagabine\nDetails: The metabolism of Tiagabine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tiagabine"}, {"id": "Cyclosporine_INT_Cocaine", "text": "Interaction: Cyclosporine AND Cocaine\nDetails: The metabolism of Cocaine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cocaine"}, {"id": "Cyclosporine_INT_Zonisamide", "text": "Interaction: Cyclosporine AND Zonisamide\nDetails: The metabolism of Zonisamide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Zonisamide"}, {"id": "Cyclosporine_INT_Paricalcitol", "text": "Interaction: Cyclosporine AND Paricalcitol\nDetails: The metabolism of Paricalcitol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Paricalcitol"}, {"id": "Cyclosporine_INT_Tinidazole", "text": "Interaction: Cyclosporine AND Tinidazole\nDetails: The metabolism of Tinidazole can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tinidazole"}, {"id": "Cyclosporine_INT_Almotriptan", "text": "Interaction: Cyclosporine AND Almotriptan\nDetails: The metabolism of Almotriptan can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Almotriptan"}, {"id": "Cyclosporine_INT_Buprenorphine", "text": "Interaction: Cyclosporine AND Buprenorphine\nDetails: The metabolism of Buprenorphine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Buprenorphine"}, {"id": "Cyclosporine_INT_Zaleplon", "text": "Interaction: Cyclosporine AND Zaleplon\nDetails: The metabolism of Zaleplon can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Zaleplon"}, {"id": "Cyclosporine_INT_Ethinyl Estradiol", "text": "Interaction: Cyclosporine AND Ethinyl Estradiol\nDetails: The metabolism of Ethinyl Estradiol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ethinyl Estradiol"}, {"id": "Cyclosporine_INT_Exemestane", "text": "Interaction: Cyclosporine AND Exemestane\nDetails: The metabolism of Exemestane can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Exemestane"}, {"id": "Cyclosporine_INT_Levobupivacaine", "text": "Interaction: Cyclosporine AND Levobupivacaine\nDetails: The metabolism of Levobupivacaine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Levobupivacaine"}, {"id": "Cyclosporine_INT_Letrozole", "text": "Interaction: Cyclosporine AND Letrozole\nDetails: The metabolism of Letrozole can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Letrozole"}, {"id": "Cyclosporine_INT_Cinacalcet", "text": "Interaction: Cyclosporine AND Cinacalcet\nDetails: The metabolism of Cinacalcet can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cinacalcet"}, {"id": "Cyclosporine_INT_Isosorbide Mononitrate", "text": "Interaction: Cyclosporine AND Isosorbide Mononitrate\nDetails: The metabolism of Isosorbide Mononitrate can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Isosorbide Mononitrate"}, {"id": "Cyclosporine_INT_Oxybutynin", "text": "Interaction: Cyclosporine AND Oxybutynin\nDetails: The metabolism of Oxybutynin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Oxybutynin"}, {"id": "Cyclosporine_INT_Clonazepam", "text": "Interaction: Cyclosporine AND Clonazepam\nDetails: The metabolism of Clonazepam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Clonazepam"}, {"id": "Cyclosporine_INT_Sibutramine", "text": "Interaction: Cyclosporine AND Sibutramine\nDetails: The metabolism of Sibutramine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sibutramine"}, {"id": "Cyclosporine_INT_Chlorphenamine", "text": "Interaction: Cyclosporine AND Chlorphenamine\nDetails: The metabolism of Chlorphenamine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Chlorphenamine"}, {"id": "Cyclosporine_INT_Dutasteride", "text": "Interaction: Cyclosporine AND Dutasteride\nDetails: The metabolism of Dutasteride can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dutasteride"}, {"id": "Cyclosporine_INT_Rabeprazole", "text": "Interaction: Cyclosporine AND Rabeprazole\nDetails: The metabolism of Rabeprazole can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rabeprazole"}, {"id": "Cyclosporine_INT_Pioglitazone", "text": "Interaction: Cyclosporine AND Pioglitazone\nDetails: The metabolism of Pioglitazone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pioglitazone"}, {"id": "Cyclosporine_INT_Escitalopram", "text": "Interaction: Cyclosporine AND Escitalopram\nDetails: The metabolism of Escitalopram can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Escitalopram"}, {"id": "Cyclosporine_INT_Clindamycin", "text": "Interaction: Cyclosporine AND Clindamycin\nDetails: The metabolism of Clindamycin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Clindamycin"}, {"id": "Cyclosporine_INT_Estazolam", "text": "Interaction: Cyclosporine AND Estazolam\nDetails: The metabolism of Estazolam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Estazolam"}, {"id": "Cyclosporine_INT_Finasteride", "text": "Interaction: Cyclosporine AND Finasteride\nDetails: The metabolism of Finasteride can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Finasteride"}, {"id": "Cyclosporine_INT_Quetiapine", "text": "Interaction: Cyclosporine AND Quetiapine\nDetails: The metabolism of Quetiapine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Quetiapine"}, {"id": "Cyclosporine_INT_Levomethadyl Acetate", "text": "Interaction: Cyclosporine AND Levomethadyl Acetate\nDetails: The metabolism of Levomethadyl Acetate can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Levomethadyl Acetate"}, {"id": "Cyclosporine_INT_Paclitaxel", "text": "Interaction: Cyclosporine AND Paclitaxel\nDetails: The metabolism of Paclitaxel can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Paclitaxel"}, {"id": "Cyclosporine_INT_Retapamulin", "text": "Interaction: Cyclosporine AND Retapamulin\nDetails: The metabolism of Retapamulin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Retapamulin"}, {"id": "Cyclosporine_INT_Lapatinib", "text": "Interaction: Cyclosporine AND Lapatinib\nDetails: The metabolism of Lapatinib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lapatinib"}, {"id": "Cyclosporine_INT_Troglitazone", "text": "Interaction: Cyclosporine AND Troglitazone\nDetails: The metabolism of Troglitazone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Troglitazone"}, {"id": "Cyclosporine_INT_Ciclesonide", "text": "Interaction: Cyclosporine AND Ciclesonide\nDetails: The metabolism of Ciclesonide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ciclesonide"}, {"id": "Cyclosporine_INT_Alosetron", "text": "Interaction: Cyclosporine AND Alosetron\nDetails: The metabolism of Alosetron can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Alosetron"}, {"id": "Cyclosporine_INT_Maraviroc", "text": "Interaction: Cyclosporine AND Maraviroc\nDetails: The metabolism of Maraviroc can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Maraviroc"}, {"id": "Cyclosporine_INT_Tiotropium", "text": "Interaction: Cyclosporine AND Tiotropium\nDetails: The metabolism of Tiotropium can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tiotropium"}, {"id": "Cyclosporine_INT_Palonosetron", "text": "Interaction: Cyclosporine AND Palonosetron\nDetails: The metabolism of Palonosetron can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Palonosetron"}, {"id": "Cyclosporine_INT_Sertindole", "text": "Interaction: Cyclosporine AND Sertindole\nDetails: The metabolism of Sertindole can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sertindole"}, {"id": "Cyclosporine_INT_Tesmilifene", "text": "Interaction: Cyclosporine AND Tesmilifene\nDetails: The metabolism of Tesmilifene can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tesmilifene"}, {"id": "Cyclosporine_INT_Methadone", "text": "Interaction: Cyclosporine AND Methadone\nDetails: The metabolism of Methadone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Methadone"}, {"id": "Cyclosporine_INT_Rimonabant", "text": "Interaction: Cyclosporine AND Rimonabant\nDetails: The metabolism of Rimonabant can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rimonabant"}, {"id": "Cyclosporine_INT_Udenafil", "text": "Interaction: Cyclosporine AND Udenafil\nDetails: The metabolism of Udenafil can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Udenafil"}, {"id": "Cyclosporine_INT_Vicriviroc", "text": "Interaction: Cyclosporine AND Vicriviroc\nDetails: The metabolism of Vicriviroc can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Vicriviroc"}, {"id": "Cyclosporine_INT_Laquinimod", "text": "Interaction: Cyclosporine AND Laquinimod\nDetails: The metabolism of Laquinimod can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Laquinimod"}, {"id": "Cyclosporine_INT_Cabergoline", "text": "Interaction: Cyclosporine AND Cabergoline\nDetails: The metabolism of Cabergoline can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cabergoline"}, {"id": "Cyclosporine_INT_Ropinirole", "text": "Interaction: Cyclosporine AND Ropinirole\nDetails: The metabolism of Ropinirole can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ropinirole"}, {"id": "Cyclosporine_INT_Lisuride", "text": "Interaction: Cyclosporine AND Lisuride\nDetails: The metabolism of Lisuride can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lisuride"}, {"id": "Cyclosporine_INT_Pergolide", "text": "Interaction: Cyclosporine AND Pergolide\nDetails: The metabolism of Pergolide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pergolide"}, {"id": "Cyclosporine_INT_Rotigotine", "text": "Interaction: Cyclosporine AND Rotigotine\nDetails: The metabolism of Rotigotine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rotigotine"}, {"id": "Cyclosporine_INT_Cerivastatin", "text": "Interaction: Cyclosporine AND Cerivastatin\nDetails: The metabolism of Cerivastatin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cerivastatin"}, {"id": "Cyclosporine_INT_Risperidone", "text": "Interaction: Cyclosporine AND Risperidone\nDetails: The metabolism of Risperidone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Risperidone"}, {"id": "Cyclosporine_INT_Selegiline", "text": "Interaction: Cyclosporine AND Selegiline\nDetails: The metabolism of Selegiline can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Selegiline"}, {"id": "Cyclosporine_INT_Halothane", "text": "Interaction: Cyclosporine AND Halothane\nDetails: The metabolism of Halothane can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Halothane"}, {"id": "Cyclosporine_INT_Trazodone", "text": "Interaction: Cyclosporine AND Trazodone\nDetails: The metabolism of Trazodone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Trazodone"}, {"id": "Cyclosporine_INT_Amitriptyline", "text": "Interaction: Cyclosporine AND Amitriptyline\nDetails: The metabolism of Amitriptyline can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Amitriptyline"}, {"id": "Cyclosporine_INT_Nortriptyline", "text": "Interaction: Cyclosporine AND Nortriptyline\nDetails: The metabolism of Nortriptyline can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nortriptyline"}, {"id": "Cyclosporine_INT_Citalopram", "text": "Interaction: Cyclosporine AND Citalopram\nDetails: The metabolism of Citalopram can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Citalopram"}, {"id": "Cyclosporine_INT_Cyclobenzaprine", "text": "Interaction: Cyclosporine AND Cyclobenzaprine\nDetails: The metabolism of Cyclobenzaprine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cyclobenzaprine"}, {"id": "Cyclosporine_INT_Fluoxetine", "text": "Interaction: Cyclosporine AND Fluoxetine\nDetails: The metabolism of Fluoxetine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Fluoxetine"}, {"id": "Cyclosporine_INT_Sertraline", "text": "Interaction: Cyclosporine AND Sertraline\nDetails: The metabolism of Sertraline can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sertraline"}, {"id": "Cyclosporine_INT_Mianserin", "text": "Interaction: Cyclosporine AND Mianserin\nDetails: The metabolism of Mianserin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mianserin"}, {"id": "Cyclosporine_INT_Dapsone", "text": "Interaction: Cyclosporine AND Dapsone\nDetails: The metabolism of Dapsone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dapsone"}, {"id": "Cyclosporine_INT_Trabectedin", "text": "Interaction: Cyclosporine AND Trabectedin\nDetails: The metabolism of Trabectedin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Trabectedin"}, {"id": "Cyclosporine_INT_Phenprocoumon", "text": "Interaction: Cyclosporine AND Phenprocoumon\nDetails: The metabolism of Phenprocoumon can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Phenprocoumon"}, {"id": "Cyclosporine_INT_Warfarin", "text": "Interaction: Cyclosporine AND Warfarin\nDetails: The metabolism of Warfarin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Warfarin"}, {"id": "Cyclosporine_INT_Ergocalciferol", "text": "Interaction: Cyclosporine AND Ergocalciferol\nDetails: The metabolism of Ergocalciferol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ergocalciferol"}, {"id": "Cyclosporine_INT_Estradiol", "text": "Interaction: Cyclosporine AND Estradiol\nDetails: The metabolism of Estradiol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Estradiol"}, {"id": "Cyclosporine_INT_Caffeine", "text": "Interaction: Cyclosporine AND Caffeine\nDetails: The metabolism of Caffeine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Caffeine"}, {"id": "Cyclosporine_INT_Codeine", "text": "Interaction: Cyclosporine AND Codeine\nDetails: The metabolism of Codeine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Codeine"}, {"id": "Cyclosporine_INT_Dextromethorphan", "text": "Interaction: Cyclosporine AND Dextromethorphan\nDetails: The metabolism of Dextromethorphan can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dextromethorphan"}, {"id": "Cyclosporine_INT_Haloperidol", "text": "Interaction: Cyclosporine AND Haloperidol\nDetails: The metabolism of Haloperidol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Haloperidol"}, {"id": "Cyclosporine_INT_Lidocaine", "text": "Interaction: Cyclosporine AND Lidocaine\nDetails: The metabolism of Lidocaine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lidocaine"}, {"id": "Cyclosporine_INT_Propranolol", "text": "Interaction: Cyclosporine AND Propranolol\nDetails: The metabolism of Propranolol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Propranolol"}, {"id": "Cyclosporine_INT_Benzphetamine", "text": "Interaction: Cyclosporine AND Benzphetamine\nDetails: The metabolism of Benzphetamine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Benzphetamine"}, {"id": "Cyclosporine_INT_Bisoprolol", "text": "Interaction: Cyclosporine AND Bisoprolol\nDetails: The metabolism of Bisoprolol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bisoprolol"}, {"id": "Cyclosporine_INT_Bromazepam", "text": "Interaction: Cyclosporine AND Bromazepam\nDetails: The metabolism of Bromazepam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bromazepam"}, {"id": "Cyclosporine_INT_Calcitriol", "text": "Interaction: Cyclosporine AND Calcitriol\nDetails: The metabolism of Calcitriol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Calcitriol"}, {"id": "Cyclosporine_INT_Chlordiazepoxide", "text": "Interaction: Cyclosporine AND Chlordiazepoxide\nDetails: The metabolism of Chlordiazepoxide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Chlordiazepoxide"}, {"id": "Cyclosporine_INT_Clobazam", "text": "Interaction: Cyclosporine AND Clobazam\nDetails: The metabolism of Clobazam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Clobazam"}, {"id": "Cyclosporine_INT_Clorazepate", "text": "Interaction: Cyclosporine AND Clorazepate\nDetails: The metabolism of Clorazepate can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Clorazepate"}, {"id": "Cyclosporine_INT_Dantrolene", "text": "Interaction: Cyclosporine AND Dantrolene\nDetails: The metabolism of Dantrolene can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dantrolene"}, {"id": "Cyclosporine_INT_Digitoxin", "text": "Interaction: Cyclosporine AND Digitoxin\nDetails: The metabolism of Digitoxin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Digitoxin"}, {"id": "Cyclosporine_INT_Estrone sulfate", "text": "Interaction: Cyclosporine AND Estrone sulfate\nDetails: The metabolism of Estrone sulfate can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Estrone sulfate"}, {"id": "Cyclosporine_INT_Felbamate", "text": "Interaction: Cyclosporine AND Felbamate\nDetails: The metabolism of Felbamate can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Felbamate"}, {"id": "Cyclosporine_INT_Flurazepam", "text": "Interaction: Cyclosporine AND Flurazepam\nDetails: The metabolism of Flurazepam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Flurazepam"}, {"id": "Cyclosporine_INT_Flutamide", "text": "Interaction: Cyclosporine AND Flutamide\nDetails: The metabolism of Flutamide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Flutamide"}, {"id": "Cyclosporine_INT_Guanfacine", "text": "Interaction: Cyclosporine AND Guanfacine\nDetails: The metabolism of Guanfacine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Guanfacine"}, {"id": "Cyclosporine_INT_Ixabepilone", "text": "Interaction: Cyclosporine AND Ixabepilone\nDetails: The metabolism of Ixabepilone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ixabepilone"}, {"id": "Cyclosporine_INT_Lansoprazole", "text": "Interaction: Cyclosporine AND Lansoprazole\nDetails: The metabolism of Lansoprazole can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lansoprazole"}, {"id": "Cyclosporine_INT_Levonorgestrel", "text": "Interaction: Cyclosporine AND Levonorgestrel\nDetails: The metabolism of Levonorgestrel can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Levonorgestrel"}, {"id": "Cyclosporine_INT_Mefloquine", "text": "Interaction: Cyclosporine AND Mefloquine\nDetails: The metabolism of Mefloquine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mefloquine"}, {"id": "Cyclosporine_INT_Nilotinib", "text": "Interaction: Cyclosporine AND Nilotinib\nDetails: The metabolism of Nilotinib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nilotinib"}, {"id": "Cyclosporine_INT_Pipotiazine", "text": "Interaction: Cyclosporine AND Pipotiazine\nDetails: The metabolism of Pipotiazine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pipotiazine"}, {"id": "Cyclosporine_INT_Praziquantel", "text": "Interaction: Cyclosporine AND Praziquantel\nDetails: The metabolism of Praziquantel can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Praziquantel"}, {"id": "Cyclosporine_INT_Primaquine", "text": "Interaction: Cyclosporine AND Primaquine\nDetails: The metabolism of Primaquine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Primaquine"}, {"id": "Cyclosporine_INT_Dextropropoxyphene", "text": "Interaction: Cyclosporine AND Dextropropoxyphene\nDetails: The metabolism of Dextropropoxyphene can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dextropropoxyphene"}, {"id": "Cyclosporine_INT_Romidepsin", "text": "Interaction: Cyclosporine AND Romidepsin\nDetails: The metabolism of Romidepsin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Romidepsin"}, {"id": "Cyclosporine_INT_Spiramycin", "text": "Interaction: Cyclosporine AND Spiramycin\nDetails: The metabolism of Spiramycin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Spiramycin"}, {"id": "Cyclosporine_INT_Tamsulosin", "text": "Interaction: Cyclosporine AND Tamsulosin\nDetails: The metabolism of Tamsulosin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tamsulosin"}, {"id": "Cyclosporine_INT_Teniposide", "text": "Interaction: Cyclosporine AND Teniposide\nDetails: The metabolism of Teniposide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Teniposide"}, {"id": "Cyclosporine_INT_Tetracycline", "text": "Interaction: Cyclosporine AND Tetracycline\nDetails: The metabolism of Tetracycline can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tetracycline"}, {"id": "Cyclosporine_INT_Theophylline", "text": "Interaction: Cyclosporine AND Theophylline\nDetails: The metabolism of Theophylline can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Theophylline"}, {"id": "Cyclosporine_INT_Tolterodine", "text": "Interaction: Cyclosporine AND Tolterodine\nDetails: The metabolism of Tolterodine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tolterodine"}, {"id": "Cyclosporine_INT_Tramadol", "text": "Interaction: Cyclosporine AND Tramadol\nDetails: The metabolism of Tramadol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tramadol"}, {"id": "Cyclosporine_INT_Trimethoprim", "text": "Interaction: Cyclosporine AND Trimethoprim\nDetails: The metabolism of Trimethoprim can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Trimethoprim"}, {"id": "Cyclosporine_INT_Trimipramine", "text": "Interaction: Cyclosporine AND Trimipramine\nDetails: The metabolism of Trimipramine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Trimipramine"}, {"id": "Cyclosporine_INT_Ergoloid mesylate", "text": "Interaction: Cyclosporine AND Ergoloid mesylate\nDetails: The metabolism of Ergoloid mesylate can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ergoloid mesylate"}, {"id": "Cyclosporine_INT_Ergonovine", "text": "Interaction: Cyclosporine AND Ergonovine\nDetails: The metabolism of Ergonovine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ergonovine"}, {"id": "Cyclosporine_INT_Ketamine", "text": "Interaction: Cyclosporine AND Ketamine\nDetails: The metabolism of Ketamine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ketamine"}, {"id": "Cyclosporine_INT_Sufentanil", "text": "Interaction: Cyclosporine AND Sufentanil\nDetails: The metabolism of Sufentanil can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sufentanil"}, {"id": "Cyclosporine_INT_Bicalutamide", "text": "Interaction: Cyclosporine AND Bicalutamide\nDetails: The metabolism of Bicalutamide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bicalutamide"}, {"id": "Cyclosporine_INT_Metronidazole", "text": "Interaction: Cyclosporine AND Metronidazole\nDetails: The metabolism of Metronidazole can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Metronidazole"}, {"id": "Cyclosporine_INT_Aminophenazone", "text": "Interaction: Cyclosporine AND Aminophenazone\nDetails: The metabolism of Aminophenazone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Aminophenazone"}, {"id": "Cyclosporine_INT_Clozapine", "text": "Interaction: Cyclosporine AND Clozapine\nDetails: The metabolism of Clozapine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Clozapine"}, {"id": "Cyclosporine_INT_Promazine", "text": "Interaction: Cyclosporine AND Promazine\nDetails: The metabolism of Promazine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Promazine"}, {"id": "Cyclosporine_INT_Zafirlukast", "text": "Interaction: Cyclosporine AND Zafirlukast\nDetails: The metabolism of Zafirlukast can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Zafirlukast"}, {"id": "Cyclosporine_INT_Ketobemidone", "text": "Interaction: Cyclosporine AND Ketobemidone\nDetails: The metabolism of Ketobemidone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ketobemidone"}, {"id": "Cyclosporine_INT_Clomipramine", "text": "Interaction: Cyclosporine AND Clomipramine\nDetails: The metabolism of Clomipramine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Clomipramine"}, {"id": "Cyclosporine_INT_Estrone", "text": "Interaction: Cyclosporine AND Estrone\nDetails: The metabolism of Estrone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Estrone"}, {"id": "Cyclosporine_INT_Imipramine", "text": "Interaction: Cyclosporine AND Imipramine\nDetails: The metabolism of Imipramine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Imipramine"}, {"id": "Cyclosporine_INT_Adinazolam", "text": "Interaction: Cyclosporine AND Adinazolam\nDetails: The metabolism of Adinazolam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Adinazolam"}, {"id": "Cyclosporine_INT_Temazepam", "text": "Interaction: Cyclosporine AND Temazepam\nDetails: The metabolism of Temazepam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Temazepam"}, {"id": "Cyclosporine_INT_Vanoxerine", "text": "Interaction: Cyclosporine AND Vanoxerine\nDetails: The metabolism of Vanoxerine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Vanoxerine"}, {"id": "Cyclosporine_INT_Cholecalciferol", "text": "Interaction: Cyclosporine AND Cholecalciferol\nDetails: The metabolism of Cholecalciferol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cholecalciferol"}, {"id": "Cyclosporine_INT_Oxymorphone", "text": "Interaction: Cyclosporine AND Oxymorphone\nDetails: The metabolism of Oxymorphone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Oxymorphone"}, {"id": "Cyclosporine_INT_Orphenadrine", "text": "Interaction: Cyclosporine AND Orphenadrine\nDetails: The metabolism of Orphenadrine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Orphenadrine"}, {"id": "Cyclosporine_INT_Cabazitaxel", "text": "Interaction: Cyclosporine AND Cabazitaxel\nDetails: The metabolism of Cabazitaxel can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cabazitaxel"}, {"id": "Cyclosporine_INT_Desvenlafaxine", "text": "Interaction: Cyclosporine AND Desvenlafaxine\nDetails: The metabolism of Desvenlafaxine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Desvenlafaxine"}, {"id": "Cyclosporine_INT_Lumefantrine", "text": "Interaction: Cyclosporine AND Lumefantrine\nDetails: The metabolism of Lumefantrine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lumefantrine"}, {"id": "Cyclosporine_INT_Allylestrenol", "text": "Interaction: Cyclosporine AND Allylestrenol\nDetails: The metabolism of Allylestrenol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Allylestrenol"}, {"id": "Cyclosporine_INT_Ambroxol", "text": "Interaction: Cyclosporine AND Ambroxol\nDetails: The metabolism of Ambroxol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ambroxol"}, {"id": "Cyclosporine_INT_Aminophylline", "text": "Interaction: Cyclosporine AND Aminophylline\nDetails: The metabolism of Aminophylline can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Aminophylline"}, {"id": "Cyclosporine_INT_Brinzolamide", "text": "Interaction: Cyclosporine AND Brinzolamide\nDetails: The metabolism of Brinzolamide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Brinzolamide"}, {"id": "Cyclosporine_INT_Brompheniramine", "text": "Interaction: Cyclosporine AND Brompheniramine\nDetails: The metabolism of Brompheniramine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Brompheniramine"}, {"id": "Cyclosporine_INT_Bupropion", "text": "Interaction: Cyclosporine AND Bupropion\nDetails: The metabolism of Bupropion can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bupropion"}, {"id": "Cyclosporine_INT_Carbinoxamine", "text": "Interaction: Cyclosporine AND Carbinoxamine\nDetails: The metabolism of Carbinoxamine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Carbinoxamine"}, {"id": "Cyclosporine_INT_Cephalexin", "text": "Interaction: Cyclosporine AND Cephalexin\nDetails: The metabolism of Cephalexin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cephalexin"}, {"id": "Cyclosporine_INT_Chlorpromazine", "text": "Interaction: Cyclosporine AND Chlorpromazine\nDetails: The metabolism of Chlorpromazine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Chlorpromazine"}, {"id": "Cyclosporine_INT_Chlorzoxazone", "text": "Interaction: Cyclosporine AND Chlorzoxazone\nDetails: The metabolism of Chlorzoxazone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Chlorzoxazone"}, {"id": "Cyclosporine_INT_Clofazimine", "text": "Interaction: Cyclosporine AND Clofazimine\nDetails: The metabolism of Clofazimine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Clofazimine"}, {"id": "Cyclosporine_INT_clomethiazole", "text": "Interaction: Cyclosporine AND clomethiazole\nDetails: The metabolism of clomethiazole can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + clomethiazole"}, {"id": "Cyclosporine_INT_Clotiazepam", "text": "Interaction: Cyclosporine AND Clotiazepam\nDetails: The metabolism of Clotiazepam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Clotiazepam"}, {"id": "Cyclosporine_INT_Cytarabine", "text": "Interaction: Cyclosporine AND Cytarabine\nDetails: The metabolism of Cytarabine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cytarabine"}, {"id": "Cyclosporine_INT_Dihydrocodeine", "text": "Interaction: Cyclosporine AND Dihydrocodeine\nDetails: The metabolism of Dihydrocodeine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dihydrocodeine"}, {"id": "Cyclosporine_INT_Disulfiram", "text": "Interaction: Cyclosporine AND Disulfiram\nDetails: The metabolism of Disulfiram can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Disulfiram"}, {"id": "Cyclosporine_INT_Dorzolamide", "text": "Interaction: Cyclosporine AND Dorzolamide\nDetails: The metabolism of Dorzolamide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dorzolamide"}, {"id": "Cyclosporine_INT_Epinastine", "text": "Interaction: Cyclosporine AND Epinastine\nDetails: The metabolism of Epinastine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Epinastine"}, {"id": "Cyclosporine_INT_Estramustine", "text": "Interaction: Cyclosporine AND Estramustine\nDetails: The metabolism of Estramustine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Estramustine"}, {"id": "Cyclosporine_INT_Ethanol", "text": "Interaction: Cyclosporine AND Ethanol\nDetails: The metabolism of Ethanol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ethanol"}, {"id": "Cyclosporine_INT_Ethylmorphine", "text": "Interaction: Cyclosporine AND Ethylmorphine\nDetails: The metabolism of Ethylmorphine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ethylmorphine"}, {"id": "Cyclosporine_INT_Famciclovir", "text": "Interaction: Cyclosporine AND Famciclovir\nDetails: The metabolism of Famciclovir can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Famciclovir"}, {"id": "Cyclosporine_INT_Flunitrazepam", "text": "Interaction: Cyclosporine AND Flunitrazepam\nDetails: The metabolism of Flunitrazepam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Flunitrazepam"}, {"id": "Cyclosporine_INT_Fulvestrant", "text": "Interaction: Cyclosporine AND Fulvestrant\nDetails: The metabolism of Fulvestrant can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Fulvestrant"}, {"id": "Cyclosporine_INT_Glipizide", "text": "Interaction: Cyclosporine AND Glipizide\nDetails: The metabolism of Glipizide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Glipizide"}, {"id": "Cyclosporine_INT_Histamine", "text": "Interaction: Cyclosporine AND Histamine\nDetails: The metabolism of Histamine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Histamine"}, {"id": "Cyclosporine_INT_Imiquimod", "text": "Interaction: Cyclosporine AND Imiquimod\nDetails: The metabolism of Imiquimod can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Imiquimod"}, {"id": "Cyclosporine_INT_Ivermectin", "text": "Interaction: Cyclosporine AND Ivermectin\nDetails: The metabolism of Ivermectin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ivermectin"}, {"id": "Cyclosporine_INT_Levothyroxine", "text": "Interaction: Cyclosporine AND Levothyroxine\nDetails: The metabolism of Levothyroxine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Levothyroxine"}, {"id": "Cyclosporine_INT_Quinacrine", "text": "Interaction: Cyclosporine AND Quinacrine\nDetails: The metabolism of Quinacrine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Quinacrine"}, {"id": "Cyclosporine_INT_Methaqualone", "text": "Interaction: Cyclosporine AND Methaqualone\nDetails: The metabolism of Methaqualone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Methaqualone"}, {"id": "Cyclosporine_INT_Methoxsalen", "text": "Interaction: Cyclosporine AND Methoxsalen\nDetails: The metabolism of Methoxsalen can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Methoxsalen"}, {"id": "Cyclosporine_INT_Methoxyflurane", "text": "Interaction: Cyclosporine AND Methoxyflurane\nDetails: The metabolism of Methoxyflurane can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Methoxyflurane"}, {"id": "Cyclosporine_INT_Mexiletine", "text": "Interaction: Cyclosporine AND Mexiletine\nDetails: The metabolism of Mexiletine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mexiletine"}, {"id": "Cyclosporine_INT_Morphine", "text": "Interaction: Cyclosporine AND Morphine\nDetails: The metabolism of Morphine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Morphine"}, {"id": "Cyclosporine_INT_Naloxone", "text": "Interaction: Cyclosporine AND Naloxone\nDetails: The metabolism of Naloxone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Naloxone"}, {"id": "Cyclosporine_INT_Nicotine", "text": "Interaction: Cyclosporine AND Nicotine\nDetails: The metabolism of Nicotine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nicotine"}, {"id": "Cyclosporine_INT_Nitrazepam", "text": "Interaction: Cyclosporine AND Nitrazepam\nDetails: The metabolism of Nitrazepam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nitrazepam"}, {"id": "Cyclosporine_INT_Oxazepam", "text": "Interaction: Cyclosporine AND Oxazepam\nDetails: The metabolism of Oxazepam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Oxazepam"}, {"id": "Cyclosporine_INT_Acetaminophen", "text": "Interaction: Cyclosporine AND Acetaminophen\nDetails: The metabolism of Acetaminophen can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Acetaminophen"}, {"id": "Cyclosporine_INT_Permethrin", "text": "Interaction: Cyclosporine AND Permethrin\nDetails: The metabolism of Permethrin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Permethrin"}, {"id": "Cyclosporine_INT_Perphenazine", "text": "Interaction: Cyclosporine AND Perphenazine\nDetails: The metabolism of Perphenazine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Perphenazine"}, {"id": "Cyclosporine_INT_Pethidine", "text": "Interaction: Cyclosporine AND Pethidine\nDetails: The metabolism of Pethidine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pethidine"}, {"id": "Cyclosporine_INT_Phenacetin", "text": "Interaction: Cyclosporine AND Phenacetin\nDetails: The metabolism of Phenacetin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Phenacetin"}, {"id": "Cyclosporine_INT_Phenoxybenzamine", "text": "Interaction: Cyclosporine AND Phenoxybenzamine\nDetails: The metabolism of Phenoxybenzamine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Phenoxybenzamine"}, {"id": "Cyclosporine_INT_Pilocarpine", "text": "Interaction: Cyclosporine AND Pilocarpine\nDetails: The metabolism of Pilocarpine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pilocarpine"}, {"id": "Cyclosporine_INT_Podofilox", "text": "Interaction: Cyclosporine AND Podofilox\nDetails: The metabolism of Podofilox can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Podofilox"}, {"id": "Cyclosporine_INT_Prazepam", "text": "Interaction: Cyclosporine AND Prazepam\nDetails: The metabolism of Prazepam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Prazepam"}, {"id": "Cyclosporine_INT_Proguanil", "text": "Interaction: Cyclosporine AND Proguanil\nDetails: The metabolism of Proguanil can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Proguanil"}, {"id": "Cyclosporine_INT_Propofol", "text": "Interaction: Cyclosporine AND Propofol\nDetails: The metabolism of Propofol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Propofol"}, {"id": "Cyclosporine_INT_Quazepam", "text": "Interaction: Cyclosporine AND Quazepam\nDetails: The metabolism of Quazepam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Quazepam"}, {"id": "Cyclosporine_INT_Raloxifene", "text": "Interaction: Cyclosporine AND Raloxifene\nDetails: The metabolism of Raloxifene can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Raloxifene"}, {"id": "Cyclosporine_INT_Ropivacaine", "text": "Interaction: Cyclosporine AND Ropivacaine\nDetails: The metabolism of Ropivacaine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ropivacaine"}, {"id": "Cyclosporine_INT_Sevoflurane", "text": "Interaction: Cyclosporine AND Sevoflurane\nDetails: The metabolism of Sevoflurane can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sevoflurane"}, {"id": "Cyclosporine_INT_Thiotepa", "text": "Interaction: Cyclosporine AND Thiotepa\nDetails: The metabolism of Thiotepa can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Thiotepa"}, {"id": "Cyclosporine_INT_Trimethadione", "text": "Interaction: Cyclosporine AND Trimethadione\nDetails: The metabolism of Trimethadione can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Trimethadione"}, {"id": "Cyclosporine_INT_Troleandomycin", "text": "Interaction: Cyclosporine AND Troleandomycin\nDetails: The metabolism of Troleandomycin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Troleandomycin"}, {"id": "Cyclosporine_INT_Yohimbine", "text": "Interaction: Cyclosporine AND Yohimbine\nDetails: The metabolism of Yohimbine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Yohimbine"}, {"id": "Cyclosporine_INT_Zalcitabine", "text": "Interaction: Cyclosporine AND Zalcitabine\nDetails: The metabolism of Zalcitabine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Zalcitabine"}, {"id": "Cyclosporine_INT_Zidovudine", "text": "Interaction: Cyclosporine AND Zidovudine\nDetails: The metabolism of Zidovudine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Zidovudine"}, {"id": "Cyclosporine_INT_Cortisone acetate", "text": "Interaction: Cyclosporine AND Cortisone acetate\nDetails: The metabolism of Cortisone acetate can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cortisone acetate"}, {"id": "Cyclosporine_INT_Paramethasone", "text": "Interaction: Cyclosporine AND Paramethasone\nDetails: The metabolism of Paramethasone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Paramethasone"}, {"id": "Cyclosporine_INT_Ketazolam", "text": "Interaction: Cyclosporine AND Ketazolam\nDetails: The metabolism of Ketazolam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ketazolam"}, {"id": "Cyclosporine_INT_Paramethadione", "text": "Interaction: Cyclosporine AND Paramethadione\nDetails: The metabolism of Paramethadione can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Paramethadione"}, {"id": "Cyclosporine_INT_Tretinoin", "text": "Interaction: Cyclosporine AND Tretinoin\nDetails: The metabolism of Tretinoin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tretinoin"}, {"id": "Cyclosporine_INT_Ramelteon", "text": "Interaction: Cyclosporine AND Ramelteon\nDetails: The metabolism of Ramelteon can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ramelteon"}, {"id": "Cyclosporine_INT_Iloperidone", "text": "Interaction: Cyclosporine AND Iloperidone\nDetails: The metabolism of Iloperidone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Iloperidone"}, {"id": "Cyclosporine_INT_Acenocoumarol", "text": "Interaction: Cyclosporine AND Acenocoumarol\nDetails: The metabolism of Acenocoumarol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Acenocoumarol"}, {"id": "Cyclosporine_INT_Clonidine", "text": "Interaction: Cyclosporine AND Clonidine\nDetails: The metabolism of Clonidine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Clonidine"}, {"id": "Cyclosporine_INT_Prasterone", "text": "Interaction: Cyclosporine AND Prasterone\nDetails: The metabolism of Prasterone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Prasterone"}, {"id": "Cyclosporine_INT_Indapamide", "text": "Interaction: Cyclosporine AND Indapamide\nDetails: The metabolism of Indapamide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Indapamide"}, {"id": "Cyclosporine_INT_Banoxantrone", "text": "Interaction: Cyclosporine AND Banoxantrone\nDetails: The metabolism of Banoxantrone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Banoxantrone"}, {"id": "Cyclosporine_INT_Indacaterol", "text": "Interaction: Cyclosporine AND Indacaterol\nDetails: The metabolism of Indacaterol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Indacaterol"}, {"id": "Cyclosporine_INT_Benzyl alcohol", "text": "Interaction: Cyclosporine AND Benzyl alcohol\nDetails: The metabolism of Benzyl alcohol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Benzyl alcohol"}, {"id": "Cyclosporine_INT_Celiprolol", "text": "Interaction: Cyclosporine AND Celiprolol\nDetails: The metabolism of Celiprolol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Celiprolol"}, {"id": "Cyclosporine_INT_Chenodeoxycholic acid", "text": "Interaction: Cyclosporine AND Chenodeoxycholic acid\nDetails: The metabolism of Chenodeoxycholic acid can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Chenodeoxycholic acid"}, {"id": "Cyclosporine_INT_Pinacidil", "text": "Interaction: Cyclosporine AND Pinacidil\nDetails: The metabolism of Pinacidil can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pinacidil"}, {"id": "Cyclosporine_INT_Vismodegib", "text": "Interaction: Cyclosporine AND Vismodegib\nDetails: The metabolism of Vismodegib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Vismodegib"}, {"id": "Cyclosporine_INT_Triamcinolone", "text": "Interaction: Cyclosporine AND Triamcinolone\nDetails: The metabolism of Triamcinolone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Triamcinolone"}, {"id": "Cyclosporine_INT_Prasugrel", "text": "Interaction: Cyclosporine AND Prasugrel\nDetails: The metabolism of Prasugrel can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Prasugrel"}, {"id": "Cyclosporine_INT_Asenapine", "text": "Interaction: Cyclosporine AND Asenapine\nDetails: The metabolism of Asenapine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Asenapine"}, {"id": "Cyclosporine_INT_Estradiol valerate/Dienogest", "text": "Interaction: Cyclosporine AND Estradiol valerate/Dienogest\nDetails: The metabolism of Estradiol valerate/Dienogest can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Estradiol valerate/Dienogest"}, {"id": "Cyclosporine_INT_Lorcaserin", "text": "Interaction: Cyclosporine AND Lorcaserin\nDetails: The metabolism of Lorcaserin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lorcaserin"}, {"id": "Cyclosporine_INT_Vandetanib", "text": "Interaction: Cyclosporine AND Vandetanib\nDetails: The metabolism of Vandetanib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Vandetanib"}, {"id": "Cyclosporine_INT_Cabozantinib", "text": "Interaction: Cyclosporine AND Cabozantinib\nDetails: The metabolism of Cabozantinib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cabozantinib"}, {"id": "Cyclosporine_INT_Ruxolitinib", "text": "Interaction: Cyclosporine AND Ruxolitinib\nDetails: The metabolism of Ruxolitinib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ruxolitinib"}, {"id": "Cyclosporine_INT_Abiraterone", "text": "Interaction: Cyclosporine AND Abiraterone\nDetails: The metabolism of Abiraterone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Abiraterone"}, {"id": "Cyclosporine_INT_Perampanel", "text": "Interaction: Cyclosporine AND Perampanel\nDetails: The metabolism of Perampanel can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Perampanel"}, {"id": "Cyclosporine_INT_Axitinib", "text": "Interaction: Cyclosporine AND Axitinib\nDetails: The metabolism of Axitinib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Axitinib"}, {"id": "Cyclosporine_INT_Mirabegron", "text": "Interaction: Cyclosporine AND Mirabegron\nDetails: The metabolism of Mirabegron can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mirabegron"}, {"id": "Cyclosporine_INT_Regorafenib", "text": "Interaction: Cyclosporine AND Regorafenib\nDetails: The metabolism of Regorafenib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Regorafenib"}, {"id": "Cyclosporine_INT_Ponatinib", "text": "Interaction: Cyclosporine AND Ponatinib\nDetails: The metabolism of Ponatinib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ponatinib"}, {"id": "Cyclosporine_INT_Bedaquiline", "text": "Interaction: Cyclosporine AND Bedaquiline\nDetails: The metabolism of Bedaquiline can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bedaquiline"}, {"id": "Cyclosporine_INT_Fluticasone furoate", "text": "Interaction: Cyclosporine AND Fluticasone furoate\nDetails: The metabolism of Fluticasone furoate can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Fluticasone furoate"}, {"id": "Cyclosporine_INT_Canagliflozin", "text": "Interaction: Cyclosporine AND Canagliflozin\nDetails: The metabolism of Canagliflozin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Canagliflozin"}, {"id": "Cyclosporine_INT_Ospemifene", "text": "Interaction: Cyclosporine AND Ospemifene\nDetails: The metabolism of Ospemifene can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Ospemifene"}, {"id": "Cyclosporine_INT_Pomalidomide", "text": "Interaction: Cyclosporine AND Pomalidomide\nDetails: The metabolism of Pomalidomide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Pomalidomide"}, {"id": "Cyclosporine_INT_Trastuzumab emtansine", "text": "Interaction: Cyclosporine AND Trastuzumab emtansine\nDetails: The metabolism of Trastuzumab emtansine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Trastuzumab emtansine"}, {"id": "Cyclosporine_INT_Taurochenodeoxycholic acid", "text": "Interaction: Cyclosporine AND Taurochenodeoxycholic acid\nDetails: The metabolism of Taurochenodeoxycholic acid can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Taurochenodeoxycholic acid"}, {"id": "Cyclosporine_INT_Doxepin", "text": "Interaction: Cyclosporine AND Doxepin\nDetails: The metabolism of Doxepin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Doxepin"}, {"id": "Cyclosporine_INT_Levomilnacipran", "text": "Interaction: Cyclosporine AND Levomilnacipran\nDetails: The metabolism of Levomilnacipran can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Levomilnacipran"}, {"id": "Cyclosporine_INT_Macitentan", "text": "Interaction: Cyclosporine AND Macitentan\nDetails: The metabolism of Macitentan can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Macitentan"}, {"id": "Cyclosporine_INT_Dapagliflozin", "text": "Interaction: Cyclosporine AND Dapagliflozin\nDetails: The metabolism of Dapagliflozin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dapagliflozin"}, {"id": "Cyclosporine_INT_Lenvatinib", "text": "Interaction: Cyclosporine AND Lenvatinib\nDetails: The metabolism of Lenvatinib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lenvatinib"}, {"id": "Cyclosporine_INT_Vortioxetine", "text": "Interaction: Cyclosporine AND Vortioxetine\nDetails: The metabolism of Vortioxetine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Vortioxetine"}, {"id": "Cyclosporine_INT_Vilanterol", "text": "Interaction: Cyclosporine AND Vilanterol\nDetails: The metabolism of Vilanterol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Vilanterol"}, {"id": "Cyclosporine_INT_Elvitegravir", "text": "Interaction: Cyclosporine AND Elvitegravir\nDetails: The metabolism of Elvitegravir can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Elvitegravir"}, {"id": "Cyclosporine_INT_Cariprazine", "text": "Interaction: Cyclosporine AND Cariprazine\nDetails: The metabolism of Cariprazine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cariprazine"}, {"id": "Cyclosporine_INT_Rolapitant", "text": "Interaction: Cyclosporine AND Rolapitant\nDetails: The metabolism of Rolapitant can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rolapitant"}, {"id": "Cyclosporine_INT_Daclatasvir", "text": "Interaction: Cyclosporine AND Daclatasvir\nDetails: The metabolism of Daclatasvir can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Daclatasvir"}, {"id": "Cyclosporine_INT_Levocetirizine", "text": "Interaction: Cyclosporine AND Levocetirizine\nDetails: The metabolism of Levocetirizine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Levocetirizine"}, {"id": "Cyclosporine_INT_Isavuconazonium", "text": "Interaction: Cyclosporine AND Isavuconazonium\nDetails: The metabolism of Isavuconazonium can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Isavuconazonium"}, {"id": "Cyclosporine_INT_Panobinostat", "text": "Interaction: Cyclosporine AND Panobinostat\nDetails: The metabolism of Panobinostat can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Panobinostat"}, {"id": "Cyclosporine_INT_Selexipag", "text": "Interaction: Cyclosporine AND Selexipag\nDetails: The metabolism of Selexipag can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Selexipag"}, {"id": "Cyclosporine_INT_Hydroxyprogesterone caproate", "text": "Interaction: Cyclosporine AND Hydroxyprogesterone caproate\nDetails: The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Hydroxyprogesterone caproate"}, {"id": "Cyclosporine_INT_Riociguat", "text": "Interaction: Cyclosporine AND Riociguat\nDetails: The metabolism of Riociguat can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Riociguat"}, {"id": "Cyclosporine_INT_Synthetic Conjugated Estrogens, A", "text": "Interaction: Cyclosporine AND Synthetic Conjugated Estrogens, A\nDetails: The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Synthetic Conjugated Estrogens, A"}, {"id": "Cyclosporine_INT_Synthetic Conjugated Estrogens, B", "text": "Interaction: Cyclosporine AND Synthetic Conjugated Estrogens, B\nDetails: The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Synthetic Conjugated Estrogens, B"}, {"id": "Cyclosporine_INT_Norgestrel", "text": "Interaction: Cyclosporine AND Norgestrel\nDetails: The metabolism of Norgestrel can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Norgestrel"}, {"id": "Cyclosporine_INT_Venetoclax", "text": "Interaction: Cyclosporine AND Venetoclax\nDetails: The metabolism of Venetoclax can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Venetoclax"}, {"id": "Cyclosporine_INT_Estrogens, esterified", "text": "Interaction: Cyclosporine AND Estrogens, esterified\nDetails: The metabolism of Estrogens, esterified can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Estrogens, esterified"}, {"id": "Cyclosporine_INT_Rucaparib", "text": "Interaction: Cyclosporine AND Rucaparib\nDetails: The metabolism of Rucaparib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rucaparib"}, {"id": "Cyclosporine_INT_Propoxyphene napsylate", "text": "Interaction: Cyclosporine AND Propoxyphene napsylate\nDetails: The metabolism of Propoxyphene napsylate can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Propoxyphene napsylate"}, {"id": "Cyclosporine_INT_Deflazacort", "text": "Interaction: Cyclosporine AND Deflazacort\nDetails: The metabolism of Deflazacort can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Deflazacort"}, {"id": "Cyclosporine_INT_Icotinib", "text": "Interaction: Cyclosporine AND Icotinib\nDetails: The metabolism of Icotinib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Icotinib"}, {"id": "Cyclosporine_INT_Safinamide", "text": "Interaction: Cyclosporine AND Safinamide\nDetails: The metabolism of Safinamide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Safinamide"}, {"id": "Cyclosporine_INT_Deutetrabenazine", "text": "Interaction: Cyclosporine AND Deutetrabenazine\nDetails: The metabolism of Deutetrabenazine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Deutetrabenazine"}, {"id": "Cyclosporine_INT_Dexchlorpheniramine maleate", "text": "Interaction: Cyclosporine AND Dexchlorpheniramine maleate\nDetails: The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dexchlorpheniramine maleate"}, {"id": "Cyclosporine_INT_Velpatasvir", "text": "Interaction: Cyclosporine AND Velpatasvir\nDetails: The metabolism of Velpatasvir can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Velpatasvir"}, {"id": "Cyclosporine_INT_Brivaracetam", "text": "Interaction: Cyclosporine AND Brivaracetam\nDetails: The metabolism of Brivaracetam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Brivaracetam"}, {"id": "Cyclosporine_INT_Valbenazine", "text": "Interaction: Cyclosporine AND Valbenazine\nDetails: The metabolism of Valbenazine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Valbenazine"}, {"id": "Cyclosporine_INT_Odanacatib", "text": "Interaction: Cyclosporine AND Odanacatib\nDetails: The metabolism of Odanacatib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Odanacatib"}, {"id": "Cyclosporine_INT_Dexlansoprazole", "text": "Interaction: Cyclosporine AND Dexlansoprazole\nDetails: The metabolism of Dexlansoprazole can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dexlansoprazole"}, {"id": "Cyclosporine_INT_Grazoprevir", "text": "Interaction: Cyclosporine AND Grazoprevir\nDetails: The metabolism of Grazoprevir can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Grazoprevir"}, {"id": "Cyclosporine_INT_Perospirone", "text": "Interaction: Cyclosporine AND Perospirone\nDetails: The metabolism of Perospirone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Perospirone"}, {"id": "Cyclosporine_INT_Etizolam", "text": "Interaction: Cyclosporine AND Etizolam\nDetails: The metabolism of Etizolam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Etizolam"}, {"id": "Cyclosporine_INT_Rupatadine", "text": "Interaction: Cyclosporine AND Rupatadine\nDetails: The metabolism of Rupatadine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rupatadine"}, {"id": "Cyclosporine_INT_Imidafenacin", "text": "Interaction: Cyclosporine AND Imidafenacin\nDetails: The metabolism of Imidafenacin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Imidafenacin"}, {"id": "Cyclosporine_INT_Dienogest", "text": "Interaction: Cyclosporine AND Dienogest\nDetails: The metabolism of Dienogest can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dienogest"}, {"id": "Cyclosporine_INT_Neratinib", "text": "Interaction: Cyclosporine AND Neratinib\nDetails: The metabolism of Neratinib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Neratinib"}, {"id": "Cyclosporine_INT_Voxilaprevir", "text": "Interaction: Cyclosporine AND Voxilaprevir\nDetails: The metabolism of Voxilaprevir can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Voxilaprevir"}, {"id": "Cyclosporine_INT_Enasidenib", "text": "Interaction: Cyclosporine AND Enasidenib\nDetails: The metabolism of Enasidenib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Enasidenib"}, {"id": "Cyclosporine_INT_Midostaurin", "text": "Interaction: Cyclosporine AND Midostaurin\nDetails: The metabolism of Midostaurin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Midostaurin"}, {"id": "Cyclosporine_INT_Elbasvir", "text": "Interaction: Cyclosporine AND Elbasvir\nDetails: The metabolism of Elbasvir can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Elbasvir"}, {"id": "Cyclosporine_INT_Copanlisib", "text": "Interaction: Cyclosporine AND Copanlisib\nDetails: The metabolism of Copanlisib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Copanlisib"}, {"id": "Cyclosporine_INT_Abemaciclib", "text": "Interaction: Cyclosporine AND Abemaciclib\nDetails: The metabolism of Abemaciclib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Abemaciclib"}, {"id": "Cyclosporine_INT_Brigatinib", "text": "Interaction: Cyclosporine AND Brigatinib\nDetails: The metabolism of Brigatinib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Brigatinib"}, {"id": "Cyclosporine_INT_Baricitinib", "text": "Interaction: Cyclosporine AND Baricitinib\nDetails: The metabolism of Baricitinib can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Baricitinib"}, {"id": "Cyclosporine_INT_Atomoxetine", "text": "Interaction: Cyclosporine AND Atomoxetine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Atomoxetine.\nRisk: Monitor closely.", "source": "Cyclosporine + Atomoxetine"}, {"id": "Cyclosporine_INT_Clemastine", "text": "Interaction: Cyclosporine AND Clemastine\nDetails: The metabolism of Cyclosporine can be decreased when combined with Clemastine.\nRisk: Monitor closely.", "source": "Cyclosporine + Clemastine"}, {"id": "Cyclosporine_INT_Doxycycline", "text": "Interaction: Cyclosporine AND Doxycycline\nDetails: The metabolism of Cyclosporine can be decreased when combined with Doxycycline.\nRisk: Monitor closely.", "source": "Cyclosporine + Doxycycline"}, {"id": "Cyclosporine_INT_Nimodipine", "text": "Interaction: Cyclosporine AND Nimodipine\nDetails: The serum concentration of Nimodipine can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nimodipine"}, {"id": "Cyclosporine_INT_Dofetilide", "text": "Interaction: Cyclosporine AND Dofetilide\nDetails: The serum concentration of Dofetilide can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dofetilide"}, {"id": "Cyclosporine_INT_Propafenone", "text": "Interaction: Cyclosporine AND Propafenone\nDetails: The serum concentration of Propafenone can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Propafenone"}, {"id": "Cyclosporine_INT_Brentuximab vedotin", "text": "Interaction: Cyclosporine AND Brentuximab vedotin\nDetails: The serum concentration of Brentuximab vedotin can be decreased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Brentuximab vedotin"}, {"id": "Cyclosporine_INT_Zuclopenthixol", "text": "Interaction: Cyclosporine AND Zuclopenthixol\nDetails: The serum concentration of Zuclopenthixol can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Zuclopenthixol"}, {"id": "Cyclosporine_INT_Losartan", "text": "Interaction: Cyclosporine AND Losartan\nDetails: The metabolism of Losartan can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Losartan"}, {"id": "Cyclosporine_INT_Amlodipine", "text": "Interaction: Cyclosporine AND Amlodipine\nDetails: The metabolism of Amlodipine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Amlodipine"}, {"id": "Cyclosporine_INT_Clevidipine", "text": "Interaction: Cyclosporine AND Clevidipine\nDetails: The metabolism of Clevidipine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Clevidipine"}, {"id": "Cyclosporine_INT_Felodipine", "text": "Interaction: Cyclosporine AND Felodipine\nDetails: The metabolism of Felodipine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Felodipine"}, {"id": "Cyclosporine_INT_Isradipine", "text": "Interaction: Cyclosporine AND Isradipine\nDetails: The metabolism of Isradipine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Isradipine"}, {"id": "Cyclosporine_INT_Nicardipine", "text": "Interaction: Cyclosporine AND Nicardipine\nDetails: The metabolism of Nicardipine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nicardipine"}, {"id": "Cyclosporine_INT_Nifedipine", "text": "Interaction: Cyclosporine AND Nifedipine\nDetails: The metabolism of Nifedipine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nifedipine"}, {"id": "Cyclosporine_INT_Nisoldipine", "text": "Interaction: Cyclosporine AND Nisoldipine\nDetails: The metabolism of Nisoldipine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nisoldipine"}, {"id": "Cyclosporine_INT_Salmeterol", "text": "Interaction: Cyclosporine AND Salmeterol\nDetails: The serum concentration of Salmeterol can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Salmeterol"}, {"id": "Cyclosporine_INT_Denosumab", "text": "Interaction: Cyclosporine AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Denosumab"}, {"id": "Cyclosporine_INT_Sucralfate", "text": "Interaction: Cyclosporine AND Sucralfate\nDetails: Sucralfate can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy.\nRisk: Monitor closely.", "source": "Cyclosporine + Sucralfate"}, {"id": "Cyclosporine_INT_Sipuleucel-T", "text": "Interaction: Cyclosporine AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sipuleucel-T"}, {"id": "Cyclosporine_INT_Glimepiride", "text": "Interaction: Cyclosporine AND Glimepiride\nDetails: The metabolism of Glimepiride can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Glimepiride"}, {"id": "Cyclosporine_INT_Formoterol", "text": "Interaction: Cyclosporine AND Formoterol\nDetails: The metabolism of Formoterol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Formoterol"}, {"id": "Cyclosporine_INT_Rosiglitazone", "text": "Interaction: Cyclosporine AND Rosiglitazone\nDetails: The metabolism of Rosiglitazone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rosiglitazone"}, {"id": "Cyclosporine_INT_Mephenytoin", "text": "Interaction: Cyclosporine AND Mephenytoin\nDetails: The metabolism of Mephenytoin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mephenytoin"}, {"id": "Cyclosporine_INT_Tolbutamide", "text": "Interaction: Cyclosporine AND Tolbutamide\nDetails: The metabolism of Tolbutamide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tolbutamide"}, {"id": "Cyclosporine_INT_Melatonin", "text": "Interaction: Cyclosporine AND Melatonin\nDetails: The metabolism of Melatonin can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Melatonin"}, {"id": "Cyclosporine_INT_Arachidonic Acid", "text": "Interaction: Cyclosporine AND Arachidonic Acid\nDetails: The metabolism of Arachidonic Acid can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Arachidonic Acid"}, {"id": "Cyclosporine_INT_Mestranol", "text": "Interaction: Cyclosporine AND Mestranol\nDetails: The metabolism of Mestranol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Mestranol"}, {"id": "Cyclosporine_INT_Thalidomide", "text": "Interaction: Cyclosporine AND Thalidomide\nDetails: The metabolism of Thalidomide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Thalidomide"}, {"id": "Cyclosporine_INT_Valproic Acid", "text": "Interaction: Cyclosporine AND Valproic Acid\nDetails: The metabolism of Valproic Acid can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Valproic Acid"}, {"id": "Cyclosporine_INT_Diphenhydramine", "text": "Interaction: Cyclosporine AND Diphenhydramine\nDetails: The metabolism of Diphenhydramine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Diphenhydramine"}, {"id": "Cyclosporine_INT_Chlorpropamide", "text": "Interaction: Cyclosporine AND Chlorpropamide\nDetails: The metabolism of Chlorpropamide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Chlorpropamide"}, {"id": "Cyclosporine_INT_Gliclazide", "text": "Interaction: Cyclosporine AND Gliclazide\nDetails: The metabolism of Gliclazide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Gliclazide"}, {"id": "Cyclosporine_INT_Licofelone", "text": "Interaction: Cyclosporine AND Licofelone\nDetails: The metabolism of Licofelone can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Licofelone"}, {"id": "Cyclosporine_INT_Gavestinel", "text": "Interaction: Cyclosporine AND Gavestinel\nDetails: The metabolism of Gavestinel can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Gavestinel"}, {"id": "Cyclosporine_INT_Sulfamoxole", "text": "Interaction: Cyclosporine AND Sulfamoxole\nDetails: The metabolism of Sulfamoxole can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sulfamoxole"}, {"id": "Cyclosporine_INT_Dicoumarol", "text": "Interaction: Cyclosporine AND Dicoumarol\nDetails: The metabolism of Dicoumarol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dicoumarol"}, {"id": "Cyclosporine_INT_Dopamine", "text": "Interaction: Cyclosporine AND Dopamine\nDetails: The metabolism of Dopamine can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Dopamine"}, {"id": "Cyclosporine_INT_Epoprostenol", "text": "Interaction: Cyclosporine AND Epoprostenol\nDetails: The metabolism of Epoprostenol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Epoprostenol"}, {"id": "Cyclosporine_INT_Moclobemide", "text": "Interaction: Cyclosporine AND Moclobemide\nDetails: The metabolism of Moclobemide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Moclobemide"}, {"id": "Cyclosporine_INT_Arformoterol", "text": "Interaction: Cyclosporine AND Arformoterol\nDetails: The metabolism of Arformoterol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Arformoterol"}, {"id": "Cyclosporine_INT_indisulam", "text": "Interaction: Cyclosporine AND indisulam\nDetails: The metabolism of indisulam can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + indisulam"}, {"id": "Cyclosporine_INT_Niclosamide", "text": "Interaction: Cyclosporine AND Niclosamide\nDetails: The metabolism of Niclosamide can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Niclosamide"}, {"id": "Cyclosporine_INT_Treprostinil", "text": "Interaction: Cyclosporine AND Treprostinil\nDetails: The metabolism of Treprostinil can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Treprostinil"}, {"id": "Cyclosporine_INT_Tapentadol", "text": "Interaction: Cyclosporine AND Tapentadol\nDetails: The metabolism of Tapentadol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tapentadol"}, {"id": "Cyclosporine_INT_Olodaterol", "text": "Interaction: Cyclosporine AND Olodaterol\nDetails: The metabolism of Olodaterol can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Olodaterol"}, {"id": "Cyclosporine_INT_Lesinurad", "text": "Interaction: Cyclosporine AND Lesinurad\nDetails: The metabolism of Lesinurad can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Lesinurad"}, {"id": "Cyclosporine_INT_Doconexent", "text": "Interaction: Cyclosporine AND Doconexent\nDetails: The metabolism of Doconexent can be decreased when combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Doconexent"}, {"id": "Cyclosporine_INT_Trastuzumab", "text": "Interaction: Cyclosporine AND Trastuzumab\nDetails: Trastuzumab may increase the neutropenic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Trastuzumab"}, {"id": "Cyclosporine_INT_Vilazodone", "text": "Interaction: Cyclosporine AND Vilazodone\nDetails: The serum concentration of Vilazodone can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Vilazodone"}, {"id": "Cyclosporine_INT_Vindesine", "text": "Interaction: Cyclosporine AND Vindesine\nDetails: The serum concentration of Vindesine can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Vindesine"}, {"id": "Cyclosporine_INT_Lumacaftor", "text": "Interaction: Cyclosporine AND Lumacaftor\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Lumacaftor.\nRisk: Monitor closely.", "source": "Cyclosporine + Lumacaftor"}, {"id": "Cyclosporine_INT_Nintedanib", "text": "Interaction: Cyclosporine AND Nintedanib\nDetails: The serum concentration of Nintedanib can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Nintedanib"}, {"id": "Cyclosporine_INT_Dexamethasone", "text": "Interaction: Cyclosporine AND Dexamethasone\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Dexamethasone.\nRisk: Monitor closely.", "source": "Cyclosporine + Dexamethasone"}, {"id": "Cyclosporine_INT_Fimasartan", "text": "Interaction: Cyclosporine AND Fimasartan\nDetails: The serum concentration of Fimasartan can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Fimasartan"}, {"id": "Cyclosporine_INT_Minoxidil", "text": "Interaction: Cyclosporine AND Minoxidil\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Minoxidil.\nRisk: Monitor closely.", "source": "Cyclosporine + Minoxidil"}, {"id": "Cyclosporine_INT_Prednisolone", "text": "Interaction: Cyclosporine AND Prednisolone\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Prednisolone.\nRisk: Monitor closely.", "source": "Cyclosporine + Prednisolone"}, {"id": "Cyclosporine_INT_Rilpivirine", "text": "Interaction: Cyclosporine AND Rilpivirine\nDetails: The serum concentration of Rilpivirine can be increased when it is combined with Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Rilpivirine"}, {"id": "Cyclosporine_INT_Vitamin C", "text": "Interaction: Cyclosporine AND Vitamin C\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Vitamin C.\nRisk: Monitor closely.", "source": "Cyclosporine + Vitamin C"}, {"id": "Cyclosporine_INT_Sulfisoxazole", "text": "Interaction: Cyclosporine AND Sulfisoxazole\nDetails: Sulfisoxazole may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sulfisoxazole"}, {"id": "Cyclosporine_INT_Sulfadiazine", "text": "Interaction: Cyclosporine AND Sulfadiazine\nDetails: Sulfadiazine may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sulfadiazine"}, {"id": "Cyclosporine_INT_Sulfamethoxazole", "text": "Interaction: Cyclosporine AND Sulfamethoxazole\nDetails: Sulfamethoxazole may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sulfamethoxazole"}, {"id": "Cyclosporine_INT_Valsartan", "text": "Interaction: Cyclosporine AND Valsartan\nDetails: Valsartan may increase the hyperkalemic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Valsartan"}, {"id": "Cyclosporine_INT_Olmesartan", "text": "Interaction: Cyclosporine AND Olmesartan\nDetails: Olmesartan may increase the hyperkalemic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Olmesartan"}, {"id": "Cyclosporine_INT_Candesartan cilexetil", "text": "Interaction: Cyclosporine AND Candesartan cilexetil\nDetails: Candesartan cilexetil may increase the hyperkalemic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Candesartan cilexetil"}, {"id": "Cyclosporine_INT_Eprosartan", "text": "Interaction: Cyclosporine AND Eprosartan\nDetails: Eprosartan may increase the hyperkalemic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Eprosartan"}, {"id": "Cyclosporine_INT_Telmisartan", "text": "Interaction: Cyclosporine AND Telmisartan\nDetails: Telmisartan may increase the hyperkalemic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Telmisartan"}, {"id": "Cyclosporine_INT_Irbesartan", "text": "Interaction: Cyclosporine AND Irbesartan\nDetails: Irbesartan may increase the hyperkalemic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Irbesartan"}, {"id": "Cyclosporine_INT_Saprisartan", "text": "Interaction: Cyclosporine AND Saprisartan\nDetails: Saprisartan may increase the hyperkalemic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Saprisartan"}, {"id": "Cyclosporine_INT_Tasosartan", "text": "Interaction: Cyclosporine AND Tasosartan\nDetails: Tasosartan may increase the hyperkalemic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Tasosartan"}, {"id": "Cyclosporine_INT_Azilsartan medoxomil", "text": "Interaction: Cyclosporine AND Azilsartan medoxomil\nDetails: Azilsartan medoxomil may increase the hyperkalemic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Azilsartan medoxomil"}, {"id": "Cyclosporine_INT_Candesartan", "text": "Interaction: Cyclosporine AND Candesartan\nDetails: Candesartan may increase the hyperkalemic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Candesartan"}, {"id": "Cyclosporine_INT_Saralasin", "text": "Interaction: Cyclosporine AND Saralasin\nDetails: Saralasin may increase the hyperkalemic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Saralasin"}, {"id": "Cyclosporine_INT_Sacubitril", "text": "Interaction: Cyclosporine AND Sacubitril\nDetails: Sacubitril may increase the hyperkalemic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Sacubitril"}, {"id": "Cyclosporine_INT_Forasartan", "text": "Interaction: Cyclosporine AND Forasartan\nDetails: Forasartan may increase the hyperkalemic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Forasartan"}, {"id": "Cyclosporine_INT_Acetazolamide", "text": "Interaction: Cyclosporine AND Acetazolamide\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Acetazolamide.\nRisk: Monitor closely.", "source": "Cyclosporine + Acetazolamide"}, {"id": "Cyclosporine_INT_Adalimumab", "text": "Interaction: Cyclosporine AND Adalimumab\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Adalimumab.\nRisk: Monitor closely.", "source": "Cyclosporine + Adalimumab"}, {"id": "Cyclosporine_INT_Amphotericin B", "text": "Interaction: Cyclosporine AND Amphotericin B\nDetails: Amphotericin B may increase the nephrotoxic activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Amphotericin B"}, {"id": "Cyclosporine_INT_Aprepitant", "text": "Interaction: Cyclosporine AND Aprepitant\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Aprepitant.\nRisk: Monitor closely.", "source": "Cyclosporine + Aprepitant"}, {"id": "Cyclosporine_INT_Armodafinil", "text": "Interaction: Cyclosporine AND Armodafinil\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Armodafinil.\nRisk: Monitor closely.", "source": "Cyclosporine + Armodafinil"}, {"id": "Cyclosporine_INT_Bromocriptine", "text": "Interaction: Cyclosporine AND Bromocriptine\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Bromocriptine.\nRisk: Monitor closely.", "source": "Cyclosporine + Bromocriptine"}, {"id": "Cyclosporine_INT_Cyclophosphamide", "text": "Interaction: Cyclosporine AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the immunosuppressive activities of Cyclosporine.\nRisk: Monitor closely.", "source": "Cyclosporine + Cyclophosphamide"}, {"id": "Cyclosporine_INT_Dasatinib", "text": "Interaction: Cyclosporine AND Dasatinib\nDetails: The serum concentration of Cyclosporine can be increased when it is combined with Dasatinib.\nRisk: Monitor closely.", "source": "Cyclosporine + Dasatinib"}, {"id": "Alefacept_GEN", "text": "Drug: Alefacept\nDescription: Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD....", "source": "Alefacept"}, {"id": "Alefacept_CLIN", "text": "Drug: Alefacept\nMechanism: Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen....\nToxicity: While it has been found to cross the placenta in monkeys, it is not yet known if it also diffuses into breast milk. ...", "source": "Alefacept"}, {"id": "Alefacept_INT_Natalizumab", "text": "Interaction: Alefacept AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Alefacept is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Alefacept + Natalizumab"}, {"id": "Alefacept_INT_Pimecrolimus", "text": "Interaction: Alefacept AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Pimecrolimus"}, {"id": "Alefacept_INT_Tofacitinib", "text": "Interaction: Alefacept AND Tofacitinib\nDetails: Alefacept may increase the immunosuppressive activities of Tofacitinib.\nRisk: Monitor closely.", "source": "Alefacept + Tofacitinib"}, {"id": "Alefacept_INT_Tacrolimus", "text": "Interaction: Alefacept AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Tacrolimus"}, {"id": "Alefacept_INT_BCG vaccine", "text": "Interaction: Alefacept AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + BCG vaccine"}, {"id": "Alefacept_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Alefacept AND Rabies virus inactivated antigen, A\nDetails: The risk or severity of adverse effects can be increased when Alefacept is combined with Rabies virus inactivated antigen, A.\nRisk: Monitor closely.", "source": "Alefacept + Rabies virus inactivated antigen, A"}, {"id": "Alefacept_INT_Leflunomide", "text": "Interaction: Alefacept AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Alefacept is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Alefacept + Leflunomide"}, {"id": "Alefacept_INT_Fingolimod", "text": "Interaction: Alefacept AND Fingolimod\nDetails: Alefacept may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Alefacept + Fingolimod"}, {"id": "Alefacept_INT_Roflumilast", "text": "Interaction: Alefacept AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Roflumilast"}, {"id": "Alefacept_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Alefacept AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Alefacept_INT_Yellow fever vaccine", "text": "Interaction: Alefacept AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Yellow fever vaccine"}, {"id": "Alefacept_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Alefacept AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Alefacept_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Alefacept AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Alefacept_INT_Rotavirus Vaccine", "text": "Interaction: Alefacept AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Rotavirus Vaccine"}, {"id": "Alefacept_INT_G17DT", "text": "Interaction: Alefacept AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + G17DT"}, {"id": "Alefacept_INT_INGN 201", "text": "Interaction: Alefacept AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + INGN 201"}, {"id": "Alefacept_INT_INGN 225", "text": "Interaction: Alefacept AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + INGN 225"}, {"id": "Alefacept_INT_Rindopepimut", "text": "Interaction: Alefacept AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Rindopepimut"}, {"id": "Alefacept_INT_SRP 299", "text": "Interaction: Alefacept AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + SRP 299"}, {"id": "Alefacept_INT_GI-5005", "text": "Interaction: Alefacept AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + GI-5005"}, {"id": "Alefacept_INT_TG4010", "text": "Interaction: Alefacept AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + TG4010"}, {"id": "Alefacept_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Alefacept AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Rabies virus inactivated antigen, A"}, {"id": "Alefacept_INT_Tecemotide", "text": "Interaction: Alefacept AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Tecemotide"}, {"id": "Alefacept_INT_Rubella virus vaccine", "text": "Interaction: Alefacept AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Rubella virus vaccine"}, {"id": "Alefacept_INT_Hepatitis A Vaccine", "text": "Interaction: Alefacept AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Hepatitis A Vaccine"}, {"id": "Alefacept_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Alefacept AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Salmonella typhi ty21a live antigen"}, {"id": "Alefacept_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Alefacept AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Hepatitis B Vaccine (Recombinant)"}, {"id": "Alefacept_INT_Denosumab", "text": "Interaction: Alefacept AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Denosumab"}, {"id": "Alefacept_INT_Sipuleucel-T", "text": "Interaction: Alefacept AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Sipuleucel-T"}, {"id": "Alefacept_INT_Trastuzumab", "text": "Interaction: Alefacept AND Trastuzumab\nDetails: Trastuzumab may increase the neutropenic activities of Alefacept.\nRisk: Monitor closely.", "source": "Alefacept + Trastuzumab"}, {"id": "Felypressin_GEN", "text": "Drug: Felypressin\nDescription: A synthetic nonapeptide comprising cysteinyl, phenylalanyl, phenylalanyl, glutaminyl, asparaginyl, cysteinyl, prolyl, lysyl, and glycinamide residues in sequence, with a disulfide bridge joining the two cysteine residues. Its antidiuretic effects are less than those of vasopressin. It is used as a v...", "source": "Felypressin"}, {"id": "Felypressin_CLIN", "text": "Drug: Felypressin\nMechanism: Felypressin binds to the vasopressin receptor V1a. This causes contraction of the smooth muscle in the vascular bed, especially capillaries, small arterioles and venules....\nToxicity: ...", "source": "Felypressin"}, {"id": "Urofollitropin_GEN", "text": "Drug: Urofollitropin\nDescription: Urofollitropin is a purified form of follicle-stimulating hormone (FSH) that is manufactured by extraction from human urine and then purified. It consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and ...", "source": "Urofollitropin"}, {"id": "Urofollitropin_CLIN", "text": "Drug: Urofollitropin\nMechanism: FSH binds to the follicle stimulating hormone receptor which is a G-coupled transmembrane receptor. Binding of the FSH to its receptor seems to induce phosphorylation and activation of the PI3K (Phosp...\nToxicity: ...", "source": "Urofollitropin"}, {"id": "Efalizumab_GEN", "text": "Drug: Efalizumab\nDescription: Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin....", "source": "Efalizumab"}, {"id": "Efalizumab_CLIN", "text": "Drug: Efalizumab\nMechanism: Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a....\nToxicity: ...", "source": "Efalizumab"}, {"id": "Efalizumab_INT_Natalizumab", "text": "Interaction: Efalizumab AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Efalizumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Natalizumab"}, {"id": "Efalizumab_INT_Pimecrolimus", "text": "Interaction: Efalizumab AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Pimecrolimus"}, {"id": "Efalizumab_INT_Tofacitinib", "text": "Interaction: Efalizumab AND Tofacitinib\nDetails: Efalizumab may increase the immunosuppressive activities of Tofacitinib.\nRisk: Monitor closely.", "source": "Efalizumab + Tofacitinib"}, {"id": "Efalizumab_INT_Tacrolimus", "text": "Interaction: Efalizumab AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Tacrolimus"}, {"id": "Efalizumab_INT_BCG vaccine", "text": "Interaction: Efalizumab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + BCG vaccine"}, {"id": "Efalizumab_INT_Leflunomide", "text": "Interaction: Efalizumab AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Efalizumab is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Efalizumab + Leflunomide"}, {"id": "Efalizumab_INT_Fingolimod", "text": "Interaction: Efalizumab AND Fingolimod\nDetails: Efalizumab may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Efalizumab + Fingolimod"}, {"id": "Efalizumab_INT_Roflumilast", "text": "Interaction: Efalizumab AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Roflumilast"}, {"id": "Efalizumab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Efalizumab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Efalizumab_INT_Yellow fever vaccine", "text": "Interaction: Efalizumab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Yellow fever vaccine"}, {"id": "Efalizumab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Efalizumab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Efalizumab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Efalizumab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Efalizumab_INT_Rotavirus Vaccine", "text": "Interaction: Efalizumab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Rotavirus Vaccine"}, {"id": "Efalizumab_INT_G17DT", "text": "Interaction: Efalizumab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + G17DT"}, {"id": "Efalizumab_INT_INGN 201", "text": "Interaction: Efalizumab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + INGN 201"}, {"id": "Efalizumab_INT_INGN 225", "text": "Interaction: Efalizumab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + INGN 225"}, {"id": "Efalizumab_INT_Rindopepimut", "text": "Interaction: Efalizumab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Rindopepimut"}, {"id": "Efalizumab_INT_SRP 299", "text": "Interaction: Efalizumab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + SRP 299"}, {"id": "Efalizumab_INT_GI-5005", "text": "Interaction: Efalizumab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + GI-5005"}, {"id": "Efalizumab_INT_TG4010", "text": "Interaction: Efalizumab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + TG4010"}, {"id": "Efalizumab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Efalizumab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Rabies virus inactivated antigen, A"}, {"id": "Efalizumab_INT_Tecemotide", "text": "Interaction: Efalizumab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Tecemotide"}, {"id": "Efalizumab_INT_Rubella virus vaccine", "text": "Interaction: Efalizumab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Rubella virus vaccine"}, {"id": "Efalizumab_INT_Hepatitis A Vaccine", "text": "Interaction: Efalizumab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Hepatitis A Vaccine"}, {"id": "Efalizumab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Efalizumab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Salmonella typhi ty21a live antigen"}, {"id": "Efalizumab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Efalizumab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Efalizumab_INT_Denosumab", "text": "Interaction: Efalizumab AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Denosumab"}, {"id": "Efalizumab_INT_Sipuleucel-T", "text": "Interaction: Efalizumab AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Sipuleucel-T"}, {"id": "Efalizumab_INT_Trastuzumab", "text": "Interaction: Efalizumab AND Trastuzumab\nDetails: Trastuzumab may increase the neutropenic activities of Efalizumab.\nRisk: Monitor closely.", "source": "Efalizumab + Trastuzumab"}, {"id": "Choriogonadotropin alfa_GEN", "text": "Drug: Choriogonadotropin alfa\nDescription: Recombinant human chorionic gonadotropin with 2 subunits, alpha = 92 residues, beta = 145 residues, each with N-and O-linked carbohydrate moieties linked to ASN-52 and ASN-78 (on alpha subunit) and ASN-13, ASN-30, SER-121, SER-127, SER-132 and SER-138 (on beta subunit). The primary structure of the ...", "source": "Choriogonadotropin alfa"}, {"id": "Choriogonadotropin alfa_CLIN", "text": "Drug: Choriogonadotropin alfa\nMechanism: Choriogonadotropin alfa binds to the Follicle stimulating hormone receptor which results in ovulation in the absence of sufficient endogenous Luteinizing hormone....\nToxicity: ...", "source": "Choriogonadotropin alfa"}, {"id": "Antithymocyte immunoglobulin (rabbit)_GEN", "text": "Drug: Antithymocyte immunoglobulin (rabbit)\nDescription: Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of actio...", "source": "Antithymocyte immunoglobulin (rabbit)"}, {"id": "Antithymocyte immunoglobulin (rabbit)_CLIN", "text": "Drug: Antithymocyte immunoglobulin (rabbit)\nMechanism: Binds to multiple, T-cell specific antigens leading to T-lymphocyte cell death via complement mediated cytotoxicity or apoptosis....\nToxicity: Not known whether ATG (rabbit) distributes into human milk; however, other immunoglobulins are distributed into human milk....", "source": "Antithymocyte immunoglobulin (rabbit)"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Natalizumab", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Natalizumab"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Pimecrolimus", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Pimecrolimus"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Tofacitinib", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Tofacitinib\nDetails: Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Tofacitinib.\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Tofacitinib"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Tacrolimus", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Tacrolimus"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_BCG vaccine", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + BCG vaccine"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Leflunomide", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Leflunomide"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Fingolimod", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Fingolimod\nDetails: Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Fingolimod"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Roflumilast", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Roflumilast"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Yellow fever vaccine", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Yellow fever vaccine"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Rotavirus Vaccine", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Rotavirus Vaccine"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_G17DT", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + G17DT"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_INGN 201", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + INGN 201"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_INGN 225", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + INGN 225"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Rindopepimut", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Rindopepimut"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_SRP 299", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + SRP 299"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_GI-5005", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + GI-5005"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_TG4010", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + TG4010"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Rabies virus inactivated antigen, A"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Tecemotide", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Tecemotide"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Rubella virus vaccine", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Rubella virus vaccine"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Hepatitis A Vaccine", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Hepatitis A Vaccine"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Salmonella typhi ty21a live antigen"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Hepatitis B Vaccine (Recombinant)"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Denosumab", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Denosumab"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Sipuleucel-T", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Sipuleucel-T"}, {"id": "Antithymocyte immunoglobulin (rabbit)_INT_Trastuzumab", "text": "Interaction: Antithymocyte immunoglobulin (rabbit) AND Trastuzumab\nDetails: Trastuzumab may increase the neutropenic activities of Antithymocyte immunoglobulin (rabbit).\nRisk: Monitor closely.", "source": "Antithymocyte immunoglobulin (rabbit) + Trastuzumab"}, {"id": "Filgrastim_GEN", "text": "Drug: Filgrastim\nDescription: Filgrastim is a recombinant, non-pegylated human granulocyte colony stimulating factor (G-CSF) analogue manufactured by recombinant DNA technology using a strain of E. coli. It is marketed as the brand name Neupogen by Amgen. Chemically, it consists of 175 amino acid residues. The protein has an ami...", "source": "Filgrastim"}, {"id": "Filgrastim_CLIN", "text": "Drug: Filgrastim\nMechanism: Filgrastim binds to the G-CSF receptor and stimulates the production of neutrophils in the bone marrow. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their ...\nToxicity: ...", "source": "Filgrastim"}, {"id": "Filgrastim_INT_Topotecan", "text": "Interaction: Filgrastim AND Topotecan\nDetails: The risk or severity of adverse effects can be increased when Filgrastim is combined with Topotecan.\nRisk: Monitor closely.", "source": "Filgrastim + Topotecan"}, {"id": "Filgrastim_INT_Bleomycin", "text": "Interaction: Filgrastim AND Bleomycin\nDetails: The risk or severity of adverse effects can be increased when Filgrastim is combined with Bleomycin.\nRisk: Monitor closely.", "source": "Filgrastim + Bleomycin"}, {"id": "Filgrastim_INT_Cyclophosphamide", "text": "Interaction: Filgrastim AND Cyclophosphamide\nDetails: The risk or severity of adverse effects can be increased when Filgrastim is combined with Cyclophosphamide.\nRisk: Monitor closely.", "source": "Filgrastim + Cyclophosphamide"}, {"id": "Coagulation Factor IX (Recombinant)_GEN", "text": "Drug: Coagulation Factor IX (Recombinant)\nDescription: Recombinant Coagulation Factor IX is a purified Factor IX glycoprotein produced by recombinant DNA technology. It has a primary amino acid sequence that is identical to the Ala148 allelic form of human factor IX, and has structural and functional characteristics similar to those of endogenous factor...", "source": "Coagulation Factor IX (Recombinant)"}, {"id": "Coagulation Factor IX (Recombinant)_CLIN", "text": "Drug: Coagulation Factor IX (Recombinant)\nMechanism: Coagulation Factor IX is an important protein in the process of hemostasis and normal blood clotting as it plays a key role within the coagulation cascade. It is located within the blood plasma as a z...\nToxicity: ...", "source": "Coagulation Factor IX (Recombinant)"}, {"id": "Coagulation Factor IX (Recombinant)_INT_Aminocaproic Acid", "text": "Interaction: Coagulation Factor IX (Recombinant) AND Aminocaproic Acid\nDetails: The risk or severity of adverse effects can be increased when Aminocaproic Acid is combined with Coagulation Factor IX (Recombinant).\nRisk: Monitor closely.", "source": "Coagulation Factor IX (Recombinant) + Aminocaproic Acid"}, {"id": "Becaplermin_GEN", "text": "Drug: Becaplermin\nDescription: Becaplermin is produced by recombinant DNA technology by insertion of the gene for the B chain of platelet derived growth factor (PDGF) into the yeast, Saccharomyces cerevisiae. Becaplermin has a molecular weight of approximately 25 KD and is a homodimer composed of two identical polypeptide chains ...", "source": "Becaplermin"}, {"id": "Becaplermin_CLIN", "text": "Drug: Becaplermin\nMechanism: Binds to the beta platelet-derived growth factor (PDGF) receptor, a tyrosine kinase receptor. PDGF is known to exist as a dimer, and activates its signaling pathway by a ligand induced receptor dimeri...\nToxicity: ...", "source": "Becaplermin"}, {"id": "Becaplermin_INT_Acemetacin", "text": "Interaction: Becaplermin AND Acemetacin\nDetails: The risk or severity of bleeding can be increased when Becaplermin is combined with Acemetacin.\nRisk: Monitor closely.", "source": "Becaplermin + Acemetacin"}, {"id": "Becaplermin_INT_Apixaban", "text": "Interaction: Becaplermin AND Apixaban\nDetails: Apixaban may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Apixaban"}, {"id": "Becaplermin_INT_Dabigatran etexilate", "text": "Interaction: Becaplermin AND Dabigatran etexilate\nDetails: Dabigatran etexilate may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Dabigatran etexilate"}, {"id": "Becaplermin_INT_Edoxaban", "text": "Interaction: Becaplermin AND Edoxaban\nDetails: Edoxaban may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Edoxaban"}, {"id": "Becaplermin_INT_Rivaroxaban", "text": "Interaction: Becaplermin AND Rivaroxaban\nDetails: Becaplermin may increase the anticoagulant activities of Rivaroxaban.\nRisk: Monitor closely.", "source": "Becaplermin + Rivaroxaban"}, {"id": "Becaplermin_INT_Urokinase", "text": "Interaction: Becaplermin AND Urokinase\nDetails: Urokinase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Urokinase"}, {"id": "Becaplermin_INT_Vorapaxar", "text": "Interaction: Becaplermin AND Vorapaxar\nDetails: The risk or severity of adverse effects can be increased when Vorapaxar is combined with Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Vorapaxar"}, {"id": "Becaplermin_INT_Hemin", "text": "Interaction: Becaplermin AND Hemin\nDetails: Hemin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Hemin"}, {"id": "Becaplermin_INT_Diethylstilbestrol", "text": "Interaction: Becaplermin AND Diethylstilbestrol\nDetails: Diethylstilbestrol may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Diethylstilbestrol"}, {"id": "Becaplermin_INT_Chlorotrianisene", "text": "Interaction: Becaplermin AND Chlorotrianisene\nDetails: Chlorotrianisene may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Chlorotrianisene"}, {"id": "Becaplermin_INT_Conjugated estrogens", "text": "Interaction: Becaplermin AND Conjugated estrogens\nDetails: Conjugated estrogens may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Conjugated estrogens"}, {"id": "Becaplermin_INT_Estrone", "text": "Interaction: Becaplermin AND Estrone\nDetails: Estrone may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Estrone"}, {"id": "Becaplermin_INT_Estradiol", "text": "Interaction: Becaplermin AND Estradiol\nDetails: Estradiol may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Estradiol"}, {"id": "Becaplermin_INT_Dienestrol", "text": "Interaction: Becaplermin AND Dienestrol\nDetails: Dienestrol may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Dienestrol"}, {"id": "Becaplermin_INT_Ethinyl Estradiol", "text": "Interaction: Becaplermin AND Ethinyl Estradiol\nDetails: Ethinyl Estradiol may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ethinyl Estradiol"}, {"id": "Becaplermin_INT_Polyestradiol phosphate", "text": "Interaction: Becaplermin AND Polyestradiol phosphate\nDetails: Polyestradiol phosphate may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Polyestradiol phosphate"}, {"id": "Becaplermin_INT_Mestranol", "text": "Interaction: Becaplermin AND Mestranol\nDetails: Mestranol may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Mestranol"}, {"id": "Becaplermin_INT_Genistein", "text": "Interaction: Becaplermin AND Genistein\nDetails: Genistein may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Genistein"}, {"id": "Becaplermin_INT_Quinestrol", "text": "Interaction: Becaplermin AND Quinestrol\nDetails: Quinestrol may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Quinestrol"}, {"id": "Becaplermin_INT_Hexestrol", "text": "Interaction: Becaplermin AND Hexestrol\nDetails: Hexestrol may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Hexestrol"}, {"id": "Becaplermin_INT_Synthetic Conjugated Estrogens, A", "text": "Interaction: Becaplermin AND Synthetic Conjugated Estrogens, A\nDetails: Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Synthetic Conjugated Estrogens, A"}, {"id": "Becaplermin_INT_Synthetic Conjugated Estrogens, B", "text": "Interaction: Becaplermin AND Synthetic Conjugated Estrogens, B\nDetails: Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Synthetic Conjugated Estrogens, B"}, {"id": "Becaplermin_INT_Zeranol", "text": "Interaction: Becaplermin AND Zeranol\nDetails: Zeranol may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Zeranol"}, {"id": "Becaplermin_INT_Equol", "text": "Interaction: Becaplermin AND Equol\nDetails: Equol may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Equol"}, {"id": "Becaplermin_INT_Secoisolariciresinol", "text": "Interaction: Becaplermin AND Secoisolariciresinol\nDetails: Secoisolariciresinol may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Secoisolariciresinol"}, {"id": "Becaplermin_INT_Daidzein", "text": "Interaction: Becaplermin AND Daidzein\nDetails: Daidzein may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Daidzein"}, {"id": "Becaplermin_INT_Epimestrol", "text": "Interaction: Becaplermin AND Epimestrol\nDetails: Epimestrol may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Epimestrol"}, {"id": "Becaplermin_INT_Estriol", "text": "Interaction: Becaplermin AND Estriol\nDetails: Estriol may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Estriol"}, {"id": "Becaplermin_INT_Promestriene", "text": "Interaction: Becaplermin AND Promestriene\nDetails: Promestriene may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Promestriene"}, {"id": "Becaplermin_INT_Methallenestril", "text": "Interaction: Becaplermin AND Methallenestril\nDetails: Methallenestril may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Methallenestril"}, {"id": "Becaplermin_INT_Moxestrol", "text": "Interaction: Becaplermin AND Moxestrol\nDetails: Moxestrol may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Moxestrol"}, {"id": "Becaplermin_INT_Estrogens, esterified", "text": "Interaction: Becaplermin AND Estrogens, esterified\nDetails: Estrogens, esterified may decrease the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Estrogens, esterified"}, {"id": "Becaplermin_INT_Omacetaxine mepesuccinate", "text": "Interaction: Becaplermin AND Omacetaxine mepesuccinate\nDetails: The risk or severity of bleeding can be increased when Becaplermin is combined with Omacetaxine mepesuccinate.\nRisk: Monitor closely.", "source": "Becaplermin + Omacetaxine mepesuccinate"}, {"id": "Becaplermin_INT_Allylestrenol", "text": "Interaction: Becaplermin AND Allylestrenol\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Allylestrenol.\nRisk: Monitor closely.", "source": "Becaplermin + Allylestrenol"}, {"id": "Becaplermin_INT_Etonogestrel", "text": "Interaction: Becaplermin AND Etonogestrel\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Etonogestrel.\nRisk: Monitor closely.", "source": "Becaplermin + Etonogestrel"}, {"id": "Becaplermin_INT_Medroxyprogesterone acetate", "text": "Interaction: Becaplermin AND Medroxyprogesterone acetate\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Medroxyprogesterone acetate.\nRisk: Monitor closely.", "source": "Becaplermin + Medroxyprogesterone acetate"}, {"id": "Becaplermin_INT_Dienogest", "text": "Interaction: Becaplermin AND Dienogest\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Dienogest.\nRisk: Monitor closely.", "source": "Becaplermin + Dienogest"}, {"id": "Becaplermin_INT_Progesterone", "text": "Interaction: Becaplermin AND Progesterone\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Progesterone.\nRisk: Monitor closely.", "source": "Becaplermin + Progesterone"}, {"id": "Becaplermin_INT_Norethisterone", "text": "Interaction: Becaplermin AND Norethisterone\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Norethisterone.\nRisk: Monitor closely.", "source": "Becaplermin + Norethisterone"}, {"id": "Becaplermin_INT_Hydroxyprogesterone caproate", "text": "Interaction: Becaplermin AND Hydroxyprogesterone caproate\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Hydroxyprogesterone caproate.\nRisk: Monitor closely.", "source": "Becaplermin + Hydroxyprogesterone caproate"}, {"id": "Becaplermin_INT_Desogestrel", "text": "Interaction: Becaplermin AND Desogestrel\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Desogestrel.\nRisk: Monitor closely.", "source": "Becaplermin + Desogestrel"}, {"id": "Becaplermin_INT_Dydrogesterone", "text": "Interaction: Becaplermin AND Dydrogesterone\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Dydrogesterone.\nRisk: Monitor closely.", "source": "Becaplermin + Dydrogesterone"}, {"id": "Becaplermin_INT_Gestodene", "text": "Interaction: Becaplermin AND Gestodene\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Gestodene.\nRisk: Monitor closely.", "source": "Becaplermin + Gestodene"}, {"id": "Becaplermin_INT_Altrenogest", "text": "Interaction: Becaplermin AND Altrenogest\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Altrenogest.\nRisk: Monitor closely.", "source": "Becaplermin + Altrenogest"}, {"id": "Becaplermin_INT_Gestrinone", "text": "Interaction: Becaplermin AND Gestrinone\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Gestrinone.\nRisk: Monitor closely.", "source": "Becaplermin + Gestrinone"}, {"id": "Becaplermin_INT_Medrogestone", "text": "Interaction: Becaplermin AND Medrogestone\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Medrogestone.\nRisk: Monitor closely.", "source": "Becaplermin + Medrogestone"}, {"id": "Becaplermin_INT_Nomegestrol", "text": "Interaction: Becaplermin AND Nomegestrol\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Nomegestrol.\nRisk: Monitor closely.", "source": "Becaplermin + Nomegestrol"}, {"id": "Becaplermin_INT_Gestonorone", "text": "Interaction: Becaplermin AND Gestonorone\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Gestonorone.\nRisk: Monitor closely.", "source": "Becaplermin + Gestonorone"}, {"id": "Becaplermin_INT_Methylestrenolone", "text": "Interaction: Becaplermin AND Methylestrenolone\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Methylestrenolone.\nRisk: Monitor closely.", "source": "Becaplermin + Methylestrenolone"}, {"id": "Becaplermin_INT_Norgestrienone", "text": "Interaction: Becaplermin AND Norgestrienone\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Norgestrienone.\nRisk: Monitor closely.", "source": "Becaplermin + Norgestrienone"}, {"id": "Becaplermin_INT_Promegestone", "text": "Interaction: Becaplermin AND Promegestone\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Promegestone.\nRisk: Monitor closely.", "source": "Becaplermin + Promegestone"}, {"id": "Becaplermin_INT_Demegestone", "text": "Interaction: Becaplermin AND Demegestone\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Demegestone.\nRisk: Monitor closely.", "source": "Becaplermin + Demegestone"}, {"id": "Becaplermin_INT_Megestrol acetate", "text": "Interaction: Becaplermin AND Megestrol acetate\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Megestrol acetate.\nRisk: Monitor closely.", "source": "Becaplermin + Megestrol acetate"}, {"id": "Becaplermin_INT_Levonorgestrel", "text": "Interaction: Becaplermin AND Levonorgestrel\nDetails: The therapeutic efficacy of Becaplermin can be decreased when used in combination with Levonorgestrel.\nRisk: Monitor closely.", "source": "Becaplermin + Levonorgestrel"}, {"id": "Becaplermin_INT_Pentosan Polysulfate", "text": "Interaction: Becaplermin AND Pentosan Polysulfate\nDetails: Pentosan Polysulfate may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Pentosan Polysulfate"}, {"id": "Becaplermin_INT_Dasatinib", "text": "Interaction: Becaplermin AND Dasatinib\nDetails: Dasatinib may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Dasatinib"}, {"id": "Becaplermin_INT_Deferasirox", "text": "Interaction: Becaplermin AND Deferasirox\nDetails: The risk or severity of adverse effects can be increased when Becaplermin is combined with Deferasirox.\nRisk: Monitor closely.", "source": "Becaplermin + Deferasirox"}, {"id": "Becaplermin_INT_Deoxycholic Acid", "text": "Interaction: Becaplermin AND Deoxycholic Acid\nDetails: The risk or severity of adverse effects can be increased when Becaplermin is combined with Deoxycholic Acid.\nRisk: Monitor closely.", "source": "Becaplermin + Deoxycholic Acid"}, {"id": "Becaplermin_INT_Ibritumomab tiuxetan", "text": "Interaction: Becaplermin AND Ibritumomab tiuxetan\nDetails: The risk or severity of adverse effects can be increased when Becaplermin is combined with Ibritumomab tiuxetan.\nRisk: Monitor closely.", "source": "Becaplermin + Ibritumomab tiuxetan"}, {"id": "Becaplermin_INT_Ibrutinib", "text": "Interaction: Becaplermin AND Ibrutinib\nDetails: The risk or severity of adverse effects can be increased when Ibrutinib is combined with Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ibrutinib"}, {"id": "Becaplermin_INT_Nintedanib", "text": "Interaction: Becaplermin AND Nintedanib\nDetails: The risk or severity of adverse effects can be increased when Becaplermin is combined with Nintedanib.\nRisk: Monitor closely.", "source": "Becaplermin + Nintedanib"}, {"id": "Becaplermin_INT_Obinutuzumab", "text": "Interaction: Becaplermin AND Obinutuzumab\nDetails: The risk or severity of adverse effects can be increased when Becaplermin is combined with Obinutuzumab.\nRisk: Monitor closely.", "source": "Becaplermin + Obinutuzumab"}, {"id": "Becaplermin_INT_Collagenase clostridium histolyticum", "text": "Interaction: Becaplermin AND Collagenase clostridium histolyticum\nDetails: The risk or severity of adverse effects can be increased when Becaplermin is combined with Collagenase clostridium histolyticum.\nRisk: Monitor closely.", "source": "Becaplermin + Collagenase clostridium histolyticum"}, {"id": "Becaplermin_INT_Sugammadex", "text": "Interaction: Becaplermin AND Sugammadex\nDetails: Sugammadex may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Sugammadex"}, {"id": "Becaplermin_INT_Limaprost", "text": "Interaction: Becaplermin AND Limaprost\nDetails: The risk or severity of adverse effects can be increased when Limaprost is combined with Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Limaprost"}, {"id": "Becaplermin_INT_Tibolone", "text": "Interaction: Becaplermin AND Tibolone\nDetails: Tibolone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tibolone"}, {"id": "Becaplermin_INT_Ketorolac", "text": "Interaction: Becaplermin AND Ketorolac\nDetails: Ketorolac may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ketorolac"}, {"id": "Becaplermin_INT_Diclofenac", "text": "Interaction: Becaplermin AND Diclofenac\nDetails: Diclofenac may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Diclofenac"}, {"id": "Becaplermin_INT_Flurbiprofen", "text": "Interaction: Becaplermin AND Flurbiprofen\nDetails: Flurbiprofen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Flurbiprofen"}, {"id": "Becaplermin_INT_Bromfenac", "text": "Interaction: Becaplermin AND Bromfenac\nDetails: Bromfenac may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Bromfenac"}, {"id": "Becaplermin_INT_Nepafenac", "text": "Interaction: Becaplermin AND Nepafenac\nDetails: Nepafenac may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Nepafenac"}, {"id": "Becaplermin_INT_Etanercept", "text": "Interaction: Becaplermin AND Etanercept\nDetails: Etanercept may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Etanercept"}, {"id": "Becaplermin_INT_Masoprocol", "text": "Interaction: Becaplermin AND Masoprocol\nDetails: Masoprocol may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Masoprocol"}, {"id": "Becaplermin_INT_Adapalene", "text": "Interaction: Becaplermin AND Adapalene\nDetails: Adapalene may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Adapalene"}, {"id": "Becaplermin_INT_Mesalazine", "text": "Interaction: Becaplermin AND Mesalazine\nDetails: Mesalazine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Mesalazine"}, {"id": "Becaplermin_INT_Indomethacin", "text": "Interaction: Becaplermin AND Indomethacin\nDetails: Indomethacin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Indomethacin"}, {"id": "Becaplermin_INT_Pimecrolimus", "text": "Interaction: Becaplermin AND Pimecrolimus\nDetails: Pimecrolimus may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Pimecrolimus"}, {"id": "Becaplermin_INT_Nabumetone", "text": "Interaction: Becaplermin AND Nabumetone\nDetails: Nabumetone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Nabumetone"}, {"id": "Becaplermin_INT_Tenoxicam", "text": "Interaction: Becaplermin AND Tenoxicam\nDetails: Tenoxicam may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tenoxicam"}, {"id": "Becaplermin_INT_Celecoxib", "text": "Interaction: Becaplermin AND Celecoxib\nDetails: Celecoxib may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Celecoxib"}, {"id": "Becaplermin_INT_Tolmetin", "text": "Interaction: Becaplermin AND Tolmetin\nDetails: Tolmetin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tolmetin"}, {"id": "Becaplermin_INT_Rofecoxib", "text": "Interaction: Becaplermin AND Rofecoxib\nDetails: Rofecoxib may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Rofecoxib"}, {"id": "Becaplermin_INT_Piroxicam", "text": "Interaction: Becaplermin AND Piroxicam\nDetails: Piroxicam may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Piroxicam"}, {"id": "Becaplermin_INT_Fenoprofen", "text": "Interaction: Becaplermin AND Fenoprofen\nDetails: Fenoprofen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Fenoprofen"}, {"id": "Becaplermin_INT_Valdecoxib", "text": "Interaction: Becaplermin AND Valdecoxib\nDetails: Valdecoxib may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Valdecoxib"}, {"id": "Becaplermin_INT_Sulindac", "text": "Interaction: Becaplermin AND Sulindac\nDetails: Sulindac may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Sulindac"}, {"id": "Becaplermin_INT_Chloroquine", "text": "Interaction: Becaplermin AND Chloroquine\nDetails: Chloroquine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Chloroquine"}, {"id": "Becaplermin_INT_Mycophenolate mofetil", "text": "Interaction: Becaplermin AND Mycophenolate mofetil\nDetails: Mycophenolate mofetil may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Mycophenolate mofetil"}, {"id": "Becaplermin_INT_Naftifine", "text": "Interaction: Becaplermin AND Naftifine\nDetails: Naftifine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Naftifine"}, {"id": "Becaplermin_INT_Zileuton", "text": "Interaction: Becaplermin AND Zileuton\nDetails: Zileuton may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Zileuton"}, {"id": "Becaplermin_INT_Etodolac", "text": "Interaction: Becaplermin AND Etodolac\nDetails: Etodolac may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Etodolac"}, {"id": "Becaplermin_INT_Olopatadine", "text": "Interaction: Becaplermin AND Olopatadine\nDetails: Olopatadine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Olopatadine"}, {"id": "Becaplermin_INT_Mefenamic acid", "text": "Interaction: Becaplermin AND Mefenamic acid\nDetails: Mefenamic acid may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Mefenamic acid"}, {"id": "Becaplermin_INT_Naproxen", "text": "Interaction: Becaplermin AND Naproxen\nDetails: Naproxen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Naproxen"}, {"id": "Becaplermin_INT_Sulfasalazine", "text": "Interaction: Becaplermin AND Sulfasalazine\nDetails: Sulfasalazine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Sulfasalazine"}, {"id": "Becaplermin_INT_Phenylbutazone", "text": "Interaction: Becaplermin AND Phenylbutazone\nDetails: Phenylbutazone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Phenylbutazone"}, {"id": "Becaplermin_INT_Meloxicam", "text": "Interaction: Becaplermin AND Meloxicam\nDetails: Meloxicam may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Meloxicam"}, {"id": "Becaplermin_INT_Carprofen", "text": "Interaction: Becaplermin AND Carprofen\nDetails: Carprofen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Carprofen"}, {"id": "Becaplermin_INT_Diflunisal", "text": "Interaction: Becaplermin AND Diflunisal\nDetails: Diflunisal may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Diflunisal"}, {"id": "Becaplermin_INT_Suprofen", "text": "Interaction: Becaplermin AND Suprofen\nDetails: Suprofen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Suprofen"}, {"id": "Becaplermin_INT_Salicylic acid", "text": "Interaction: Becaplermin AND Salicylic acid\nDetails: Salicylic acid may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Salicylic acid"}, {"id": "Becaplermin_INT_Meclofenamic acid", "text": "Interaction: Becaplermin AND Meclofenamic acid\nDetails: Meclofenamic acid may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Meclofenamic acid"}, {"id": "Becaplermin_INT_Acetylsalicylic acid", "text": "Interaction: Becaplermin AND Acetylsalicylic acid\nDetails: Acetylsalicylic acid may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Acetylsalicylic acid"}, {"id": "Becaplermin_INT_Azelastine", "text": "Interaction: Becaplermin AND Azelastine\nDetails: Azelastine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Azelastine"}, {"id": "Becaplermin_INT_Oxaprozin", "text": "Interaction: Becaplermin AND Oxaprozin\nDetails: Oxaprozin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Oxaprozin"}, {"id": "Becaplermin_INT_Ketoprofen", "text": "Interaction: Becaplermin AND Ketoprofen\nDetails: Ketoprofen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ketoprofen"}, {"id": "Becaplermin_INT_Balsalazide", "text": "Interaction: Becaplermin AND Balsalazide\nDetails: Balsalazide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Balsalazide"}, {"id": "Becaplermin_INT_Mycophenolic acid", "text": "Interaction: Becaplermin AND Mycophenolic acid\nDetails: Mycophenolic acid may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Mycophenolic acid"}, {"id": "Becaplermin_INT_Ibuprofen", "text": "Interaction: Becaplermin AND Ibuprofen\nDetails: Ibuprofen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ibuprofen"}, {"id": "Becaplermin_INT_Leflunomide", "text": "Interaction: Becaplermin AND Leflunomide\nDetails: Leflunomide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Leflunomide"}, {"id": "Becaplermin_INT_Olsalazine", "text": "Interaction: Becaplermin AND Olsalazine\nDetails: Olsalazine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Olsalazine"}, {"id": "Becaplermin_INT_Lumiracoxib", "text": "Interaction: Becaplermin AND Lumiracoxib\nDetails: Lumiracoxib may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Lumiracoxib"}, {"id": "Becaplermin_INT_Magnesium salicylate", "text": "Interaction: Becaplermin AND Magnesium salicylate\nDetails: Magnesium salicylate may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Magnesium salicylate"}, {"id": "Becaplermin_INT_Salsalate", "text": "Interaction: Becaplermin AND Salsalate\nDetails: Salsalate may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Salsalate"}, {"id": "Becaplermin_INT_Choline magnesium trisalicylate", "text": "Interaction: Becaplermin AND Choline magnesium trisalicylate\nDetails: Choline magnesium trisalicylate may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Choline magnesium trisalicylate"}, {"id": "Becaplermin_INT_Antipyrine", "text": "Interaction: Becaplermin AND Antipyrine\nDetails: Antipyrine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Antipyrine"}, {"id": "Becaplermin_INT_Tiaprofenic acid", "text": "Interaction: Becaplermin AND Tiaprofenic acid\nDetails: Tiaprofenic acid may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tiaprofenic acid"}, {"id": "Becaplermin_INT_Etoricoxib", "text": "Interaction: Becaplermin AND Etoricoxib\nDetails: Etoricoxib may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Etoricoxib"}, {"id": "Becaplermin_INT_Castanospermine", "text": "Interaction: Becaplermin AND Castanospermine\nDetails: Castanospermine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Castanospermine"}, {"id": "Becaplermin_INT_Resveratrol", "text": "Interaction: Becaplermin AND Resveratrol\nDetails: Resveratrol may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Resveratrol"}, {"id": "Becaplermin_INT_Oxyphenbutazone", "text": "Interaction: Becaplermin AND Oxyphenbutazone\nDetails: Oxyphenbutazone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Oxyphenbutazone"}, {"id": "Becaplermin_INT_Niflumic Acid", "text": "Interaction: Becaplermin AND Niflumic Acid\nDetails: Niflumic Acid may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Niflumic Acid"}, {"id": "Becaplermin_INT_Nimesulide", "text": "Interaction: Becaplermin AND Nimesulide\nDetails: Nimesulide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Nimesulide"}, {"id": "Becaplermin_INT_Benoxaprofen", "text": "Interaction: Becaplermin AND Benoxaprofen\nDetails: Benoxaprofen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Benoxaprofen"}, {"id": "Becaplermin_INT_Metamizole", "text": "Interaction: Becaplermin AND Metamizole\nDetails: Metamizole may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Metamizole"}, {"id": "Becaplermin_INT_Zomepirac", "text": "Interaction: Becaplermin AND Zomepirac\nDetails: Zomepirac may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Zomepirac"}, {"id": "Becaplermin_INT_Pirfenidone", "text": "Interaction: Becaplermin AND Pirfenidone\nDetails: Pirfenidone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Pirfenidone"}, {"id": "Becaplermin_INT_SRT501", "text": "Interaction: Becaplermin AND SRT501\nDetails: SRT501 may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + SRT501"}, {"id": "Becaplermin_INT_PTC299", "text": "Interaction: Becaplermin AND PTC299\nDetails: PTC299 may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + PTC299"}, {"id": "Becaplermin_INT_Tarenflurbil", "text": "Interaction: Becaplermin AND Tarenflurbil\nDetails: Tarenflurbil may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tarenflurbil"}, {"id": "Becaplermin_INT_Apremilast", "text": "Interaction: Becaplermin AND Apremilast\nDetails: Apremilast may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Apremilast"}, {"id": "Becaplermin_INT_Andrographolide", "text": "Interaction: Becaplermin AND Andrographolide\nDetails: Andrographolide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Andrographolide"}, {"id": "Becaplermin_INT_Icatibant", "text": "Interaction: Becaplermin AND Icatibant\nDetails: Icatibant may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Icatibant"}, {"id": "Becaplermin_INT_exisulind", "text": "Interaction: Becaplermin AND exisulind\nDetails: exisulind may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + exisulind"}, {"id": "Becaplermin_INT_Lornoxicam", "text": "Interaction: Becaplermin AND Lornoxicam\nDetails: Lornoxicam may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Lornoxicam"}, {"id": "Becaplermin_INT_Aceclofenac", "text": "Interaction: Becaplermin AND Aceclofenac\nDetails: Aceclofenac may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Aceclofenac"}, {"id": "Becaplermin_INT_Zaltoprofen", "text": "Interaction: Becaplermin AND Zaltoprofen\nDetails: Zaltoprofen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Zaltoprofen"}, {"id": "Becaplermin_INT_Seratrodast", "text": "Interaction: Becaplermin AND Seratrodast\nDetails: Seratrodast may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Seratrodast"}, {"id": "Becaplermin_INT_Azapropazone", "text": "Interaction: Becaplermin AND Azapropazone\nDetails: Azapropazone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Azapropazone"}, {"id": "Becaplermin_INT_Felbinac", "text": "Interaction: Becaplermin AND Felbinac\nDetails: Felbinac may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Felbinac"}, {"id": "Becaplermin_INT_Tranilast", "text": "Interaction: Becaplermin AND Tranilast\nDetails: Tranilast may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tranilast"}, {"id": "Becaplermin_INT_Ferulic acid", "text": "Interaction: Becaplermin AND Ferulic acid\nDetails: Ferulic acid may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ferulic acid"}, {"id": "Becaplermin_INT_Parecoxib", "text": "Interaction: Becaplermin AND Parecoxib\nDetails: Parecoxib may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Parecoxib"}, {"id": "Becaplermin_INT_Salicylamide", "text": "Interaction: Becaplermin AND Salicylamide\nDetails: Salicylamide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Salicylamide"}, {"id": "Becaplermin_INT_Teriflunomide", "text": "Interaction: Becaplermin AND Teriflunomide\nDetails: Teriflunomide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Teriflunomide"}, {"id": "Becaplermin_INT_D-Limonene", "text": "Interaction: Becaplermin AND D-Limonene\nDetails: D-Limonene may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + D-Limonene"}, {"id": "Becaplermin_INT_Kebuzone", "text": "Interaction: Becaplermin AND Kebuzone\nDetails: Kebuzone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Kebuzone"}, {"id": "Becaplermin_INT_Isoxicam", "text": "Interaction: Becaplermin AND Isoxicam\nDetails: Isoxicam may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Isoxicam"}, {"id": "Becaplermin_INT_Indoprofen", "text": "Interaction: Becaplermin AND Indoprofen\nDetails: Indoprofen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Indoprofen"}, {"id": "Becaplermin_INT_Ibuproxam", "text": "Interaction: Becaplermin AND Ibuproxam\nDetails: Ibuproxam may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ibuproxam"}, {"id": "Becaplermin_INT_Floctafenine", "text": "Interaction: Becaplermin AND Floctafenine\nDetails: Floctafenine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Floctafenine"}, {"id": "Becaplermin_INT_Fenbufen", "text": "Interaction: Becaplermin AND Fenbufen\nDetails: Fenbufen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Fenbufen"}, {"id": "Becaplermin_INT_Etofenamate", "text": "Interaction: Becaplermin AND Etofenamate\nDetails: Etofenamate may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Etofenamate"}, {"id": "Becaplermin_INT_Epirizole", "text": "Interaction: Becaplermin AND Epirizole\nDetails: Epirizole may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Epirizole"}, {"id": "Becaplermin_INT_Loxoprofen", "text": "Interaction: Becaplermin AND Loxoprofen\nDetails: Loxoprofen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Loxoprofen"}, {"id": "Becaplermin_INT_Droxicam", "text": "Interaction: Becaplermin AND Droxicam\nDetails: Droxicam may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Droxicam"}, {"id": "Becaplermin_INT_Tolfenamic Acid", "text": "Interaction: Becaplermin AND Tolfenamic Acid\nDetails: Tolfenamic Acid may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tolfenamic Acid"}, {"id": "Becaplermin_INT_Clonixin", "text": "Interaction: Becaplermin AND Clonixin\nDetails: Clonixin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Clonixin"}, {"id": "Becaplermin_INT_Propacetamol", "text": "Interaction: Becaplermin AND Propacetamol\nDetails: Propacetamol may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Propacetamol"}, {"id": "Becaplermin_INT_Evening primrose oil", "text": "Interaction: Becaplermin AND Evening primrose oil\nDetails: Evening primrose oil may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Evening primrose oil"}, {"id": "Becaplermin_INT_Orgotein", "text": "Interaction: Becaplermin AND Orgotein\nDetails: Orgotein may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Orgotein"}, {"id": "Becaplermin_INT_Tepoxalin", "text": "Interaction: Becaplermin AND Tepoxalin\nDetails: Tepoxalin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tepoxalin"}, {"id": "Becaplermin_INT_Flunixin", "text": "Interaction: Becaplermin AND Flunixin\nDetails: Flunixin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Flunixin"}, {"id": "Becaplermin_INT_Curcumin", "text": "Interaction: Becaplermin AND Curcumin\nDetails: Curcumin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Curcumin"}, {"id": "Becaplermin_INT_E-6201", "text": "Interaction: Becaplermin AND E-6201\nDetails: E-6201 may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + E-6201"}, {"id": "Becaplermin_INT_Anisodamine", "text": "Interaction: Becaplermin AND Anisodamine\nDetails: Anisodamine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Anisodamine"}, {"id": "Becaplermin_INT_Duvelisib", "text": "Interaction: Becaplermin AND Duvelisib\nDetails: Duvelisib may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Duvelisib"}, {"id": "Becaplermin_INT_Triptolide", "text": "Interaction: Becaplermin AND Triptolide\nDetails: Triptolide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Triptolide"}, {"id": "Becaplermin_INT_Semapimod", "text": "Interaction: Becaplermin AND Semapimod\nDetails: Semapimod may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Semapimod"}, {"id": "Becaplermin_INT_Bucillamine", "text": "Interaction: Becaplermin AND Bucillamine\nDetails: Bucillamine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Bucillamine"}, {"id": "Becaplermin_INT_Lisofylline", "text": "Interaction: Becaplermin AND Lisofylline\nDetails: Lisofylline may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Lisofylline"}, {"id": "Becaplermin_INT_Nitroaspirin", "text": "Interaction: Becaplermin AND Nitroaspirin\nDetails: Nitroaspirin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Nitroaspirin"}, {"id": "Becaplermin_INT_Nafamostat", "text": "Interaction: Becaplermin AND Nafamostat\nDetails: Nafamostat may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Nafamostat"}, {"id": "Becaplermin_INT_Mizoribine", "text": "Interaction: Becaplermin AND Mizoribine\nDetails: Mizoribine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Mizoribine"}, {"id": "Becaplermin_INT_Apocynin", "text": "Interaction: Becaplermin AND Apocynin\nDetails: Apocynin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Apocynin"}, {"id": "Becaplermin_INT_Higenamine", "text": "Interaction: Becaplermin AND Higenamine\nDetails: Higenamine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Higenamine"}, {"id": "Becaplermin_INT_Tinoridine", "text": "Interaction: Becaplermin AND Tinoridine\nDetails: Tinoridine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tinoridine"}, {"id": "Becaplermin_INT_Parthenolide", "text": "Interaction: Becaplermin AND Parthenolide\nDetails: Parthenolide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Parthenolide"}, {"id": "Becaplermin_INT_Serrapeptase", "text": "Interaction: Becaplermin AND Serrapeptase\nDetails: Serrapeptase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Serrapeptase"}, {"id": "Becaplermin_INT_Alclofenac", "text": "Interaction: Becaplermin AND Alclofenac\nDetails: Alclofenac may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Alclofenac"}, {"id": "Becaplermin_INT_Fentiazac", "text": "Interaction: Becaplermin AND Fentiazac\nDetails: Fentiazac may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Fentiazac"}, {"id": "Becaplermin_INT_Tribenoside", "text": "Interaction: Becaplermin AND Tribenoside\nDetails: Tribenoside may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tribenoside"}, {"id": "Becaplermin_INT_Suxibuzone", "text": "Interaction: Becaplermin AND Suxibuzone\nDetails: Suxibuzone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Suxibuzone"}, {"id": "Becaplermin_INT_Bumadizone", "text": "Interaction: Becaplermin AND Bumadizone\nDetails: Bumadizone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Bumadizone"}, {"id": "Becaplermin_INT_Alminoprofen", "text": "Interaction: Becaplermin AND Alminoprofen\nDetails: Alminoprofen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Alminoprofen"}, {"id": "Becaplermin_INT_Flunoxaprofen", "text": "Interaction: Becaplermin AND Flunoxaprofen\nDetails: Flunoxaprofen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Flunoxaprofen"}, {"id": "Becaplermin_INT_Bufexamac", "text": "Interaction: Becaplermin AND Bufexamac\nDetails: Bufexamac may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Bufexamac"}, {"id": "Becaplermin_INT_Feprazone", "text": "Interaction: Becaplermin AND Feprazone\nDetails: Feprazone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Feprazone"}, {"id": "Becaplermin_INT_Difenpiramide", "text": "Interaction: Becaplermin AND Difenpiramide\nDetails: Difenpiramide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Difenpiramide"}, {"id": "Becaplermin_INT_Nifenazone", "text": "Interaction: Becaplermin AND Nifenazone\nDetails: Nifenazone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Nifenazone"}, {"id": "Becaplermin_INT_Lonazolac", "text": "Interaction: Becaplermin AND Lonazolac\nDetails: Lonazolac may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Lonazolac"}, {"id": "Becaplermin_INT_Tenidap", "text": "Interaction: Becaplermin AND Tenidap\nDetails: Tenidap may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tenidap"}, {"id": "Becaplermin_INT_Bendazac", "text": "Interaction: Becaplermin AND Bendazac\nDetails: Bendazac may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Bendazac"}, {"id": "Becaplermin_INT_Pranoprofen", "text": "Interaction: Becaplermin AND Pranoprofen\nDetails: Pranoprofen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Pranoprofen"}, {"id": "Becaplermin_INT_Propyphenazone", "text": "Interaction: Becaplermin AND Propyphenazone\nDetails: Propyphenazone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Propyphenazone"}, {"id": "Becaplermin_INT_Proglumetacin", "text": "Interaction: Becaplermin AND Proglumetacin\nDetails: Proglumetacin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Proglumetacin"}, {"id": "Becaplermin_INT_Guacetisal", "text": "Interaction: Becaplermin AND Guacetisal\nDetails: Guacetisal may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Guacetisal"}, {"id": "Becaplermin_INT_Bevonium", "text": "Interaction: Becaplermin AND Bevonium\nDetails: Bevonium may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Bevonium"}, {"id": "Becaplermin_INT_Ethenzamide", "text": "Interaction: Becaplermin AND Ethenzamide\nDetails: Ethenzamide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ethenzamide"}, {"id": "Becaplermin_INT_Carbaspirin calcium", "text": "Interaction: Becaplermin AND Carbaspirin calcium\nDetails: Carbaspirin calcium may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Carbaspirin calcium"}, {"id": "Becaplermin_INT_Mofebutazone", "text": "Interaction: Becaplermin AND Mofebutazone\nDetails: Mofebutazone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Mofebutazone"}, {"id": "Becaplermin_INT_Proquazone", "text": "Interaction: Becaplermin AND Proquazone\nDetails: Proquazone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Proquazone"}, {"id": "Becaplermin_INT_Benorilate", "text": "Interaction: Becaplermin AND Benorilate\nDetails: Benorilate may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Benorilate"}, {"id": "Becaplermin_INT_Pirprofen", "text": "Interaction: Becaplermin AND Pirprofen\nDetails: Pirprofen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Pirprofen"}, {"id": "Becaplermin_INT_Imidazole salicylate", "text": "Interaction: Becaplermin AND Imidazole salicylate\nDetails: Imidazole salicylate may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Imidazole salicylate"}, {"id": "Becaplermin_INT_Benzydamine", "text": "Interaction: Becaplermin AND Benzydamine\nDetails: Benzydamine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Benzydamine"}, {"id": "Becaplermin_INT_Tipranavir", "text": "Interaction: Becaplermin AND Tipranavir\nDetails: Tipranavir may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tipranavir"}, {"id": "Becaplermin_INT_Omega-3 fatty acids", "text": "Interaction: Becaplermin AND Omega-3 fatty acids\nDetails: Omega-3 fatty acids may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Omega-3 fatty acids"}, {"id": "Becaplermin_INT_Vitamin E", "text": "Interaction: Becaplermin AND Vitamin E\nDetails: Vitamin E may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Vitamin E"}, {"id": "Becaplermin_INT_Tositumomab", "text": "Interaction: Becaplermin AND Tositumomab\nDetails: The risk or severity of adverse effects can be increased when Becaplermin is combined with Tositumomab.\nRisk: Monitor closely.", "source": "Becaplermin + Tositumomab"}, {"id": "Becaplermin_INT_Lepirudin", "text": "Interaction: Becaplermin AND Lepirudin\nDetails: Lepirudin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Lepirudin"}, {"id": "Becaplermin_INT_Bivalirudin", "text": "Interaction: Becaplermin AND Bivalirudin\nDetails: Bivalirudin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Bivalirudin"}, {"id": "Becaplermin_INT_Abciximab", "text": "Interaction: Becaplermin AND Abciximab\nDetails: Abciximab may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Abciximab"}, {"id": "Becaplermin_INT_Dicoumarol", "text": "Interaction: Becaplermin AND Dicoumarol\nDetails: Becaplermin may increase the anticoagulant activities of Dicoumarol.\nRisk: Monitor closely.", "source": "Becaplermin + Dicoumarol"}, {"id": "Becaplermin_INT_Argatroban", "text": "Interaction: Becaplermin AND Argatroban\nDetails: Becaplermin may increase the anticoagulant activities of Argatroban.\nRisk: Monitor closely.", "source": "Becaplermin + Argatroban"}, {"id": "Becaplermin_INT_Ardeparin", "text": "Interaction: Becaplermin AND Ardeparin\nDetails: Becaplermin may increase the anticoagulant activities of Ardeparin.\nRisk: Monitor closely.", "source": "Becaplermin + Ardeparin"}, {"id": "Becaplermin_INT_Phenindione", "text": "Interaction: Becaplermin AND Phenindione\nDetails: Becaplermin may increase the anticoagulant activities of Phenindione.\nRisk: Monitor closely.", "source": "Becaplermin + Phenindione"}, {"id": "Becaplermin_INT_Fondaparinux sodium", "text": "Interaction: Becaplermin AND Fondaparinux sodium\nDetails: Becaplermin may increase the anticoagulant activities of Fondaparinux sodium.\nRisk: Monitor closely.", "source": "Becaplermin + Fondaparinux sodium"}, {"id": "Becaplermin_INT_Warfarin", "text": "Interaction: Becaplermin AND Warfarin\nDetails: Becaplermin may increase the anticoagulant activities of Warfarin.\nRisk: Monitor closely.", "source": "Becaplermin + Warfarin"}, {"id": "Becaplermin_INT_Phenprocoumon", "text": "Interaction: Becaplermin AND Phenprocoumon\nDetails: Becaplermin may increase the anticoagulant activities of Phenprocoumon.\nRisk: Monitor closely.", "source": "Becaplermin + Phenprocoumon"}, {"id": "Becaplermin_INT_Edetic Acid", "text": "Interaction: Becaplermin AND Edetic Acid\nDetails: Becaplermin may increase the anticoagulant activities of Edetic Acid.\nRisk: Monitor closely.", "source": "Becaplermin + Edetic Acid"}, {"id": "Becaplermin_INT_Heparin", "text": "Interaction: Becaplermin AND Heparin\nDetails: Becaplermin may increase the anticoagulant activities of Heparin.\nRisk: Monitor closely.", "source": "Becaplermin + Heparin"}, {"id": "Becaplermin_INT_Enoxaparin", "text": "Interaction: Becaplermin AND Enoxaparin\nDetails: Becaplermin may increase the anticoagulant activities of Enoxaparin.\nRisk: Monitor closely.", "source": "Becaplermin + Enoxaparin"}, {"id": "Becaplermin_INT_Acenocoumarol", "text": "Interaction: Becaplermin AND Acenocoumarol\nDetails: Becaplermin may increase the anticoagulant activities of Acenocoumarol.\nRisk: Monitor closely.", "source": "Becaplermin + Acenocoumarol"}, {"id": "Becaplermin_INT_Citric Acid", "text": "Interaction: Becaplermin AND Citric Acid\nDetails: Becaplermin may increase the anticoagulant activities of Citric Acid.\nRisk: Monitor closely.", "source": "Becaplermin + Citric Acid"}, {"id": "Becaplermin_INT_Ximelagatran", "text": "Interaction: Becaplermin AND Ximelagatran\nDetails: Becaplermin may increase the anticoagulant activities of Ximelagatran.\nRisk: Monitor closely.", "source": "Becaplermin + Ximelagatran"}, {"id": "Becaplermin_INT_Ancrod", "text": "Interaction: Becaplermin AND Ancrod\nDetails: Becaplermin may increase the anticoagulant activities of Ancrod.\nRisk: Monitor closely.", "source": "Becaplermin + Ancrod"}, {"id": "Becaplermin_INT_Pentaerythritol Tetranitrate", "text": "Interaction: Becaplermin AND Pentaerythritol Tetranitrate\nDetails: Becaplermin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.\nRisk: Monitor closely.", "source": "Becaplermin + Pentaerythritol Tetranitrate"}, {"id": "Becaplermin_INT_Sulodexide", "text": "Interaction: Becaplermin AND Sulodexide\nDetails: Becaplermin may increase the anticoagulant activities of Sulodexide.\nRisk: Monitor closely.", "source": "Becaplermin + Sulodexide"}, {"id": "Becaplermin_INT_Idraparinux", "text": "Interaction: Becaplermin AND Idraparinux\nDetails: Becaplermin may increase the anticoagulant activities of Idraparinux.\nRisk: Monitor closely.", "source": "Becaplermin + Idraparinux"}, {"id": "Becaplermin_INT_Otamixaban", "text": "Interaction: Becaplermin AND Otamixaban\nDetails: Becaplermin may increase the anticoagulant activities of Otamixaban.\nRisk: Monitor closely.", "source": "Becaplermin + Otamixaban"}, {"id": "Becaplermin_INT_Danaparoid", "text": "Interaction: Becaplermin AND Danaparoid\nDetails: Becaplermin may increase the anticoagulant activities of Danaparoid.\nRisk: Monitor closely.", "source": "Becaplermin + Danaparoid"}, {"id": "Becaplermin_INT_Dalteparin", "text": "Interaction: Becaplermin AND Dalteparin\nDetails: Becaplermin may increase the anticoagulant activities of Dalteparin.\nRisk: Monitor closely.", "source": "Becaplermin + Dalteparin"}, {"id": "Becaplermin_INT_Ethyl biscoumacetate", "text": "Interaction: Becaplermin AND Ethyl biscoumacetate\nDetails: Becaplermin may increase the anticoagulant activities of Ethyl biscoumacetate.\nRisk: Monitor closely.", "source": "Becaplermin + Ethyl biscoumacetate"}, {"id": "Becaplermin_INT_Nadroparin", "text": "Interaction: Becaplermin AND Nadroparin\nDetails: Becaplermin may increase the anticoagulant activities of Nadroparin.\nRisk: Monitor closely.", "source": "Becaplermin + Nadroparin"}, {"id": "Becaplermin_INT_Dextran", "text": "Interaction: Becaplermin AND Dextran\nDetails: Becaplermin may increase the anticoagulant activities of Dextran.\nRisk: Monitor closely.", "source": "Becaplermin + Dextran"}, {"id": "Becaplermin_INT_Reviparin", "text": "Interaction: Becaplermin AND Reviparin\nDetails: Becaplermin may increase the anticoagulant activities of Reviparin.\nRisk: Monitor closely.", "source": "Becaplermin + Reviparin"}, {"id": "Becaplermin_INT_Certoparin", "text": "Interaction: Becaplermin AND Certoparin\nDetails: Becaplermin may increase the anticoagulant activities of Certoparin.\nRisk: Monitor closely.", "source": "Becaplermin + Certoparin"}, {"id": "Becaplermin_INT_Dextran 70", "text": "Interaction: Becaplermin AND Dextran 70\nDetails: Becaplermin may increase the anticoagulant activities of Dextran 70.\nRisk: Monitor closely.", "source": "Becaplermin + Dextran 70"}, {"id": "Becaplermin_INT_Desirudin", "text": "Interaction: Becaplermin AND Desirudin\nDetails: Becaplermin may increase the anticoagulant activities of Desirudin.\nRisk: Monitor closely.", "source": "Becaplermin + Desirudin"}, {"id": "Becaplermin_INT_Dextran 40", "text": "Interaction: Becaplermin AND Dextran 40\nDetails: Becaplermin may increase the anticoagulant activities of Dextran 40.\nRisk: Monitor closely.", "source": "Becaplermin + Dextran 40"}, {"id": "Becaplermin_INT_Dextran 75", "text": "Interaction: Becaplermin AND Dextran 75\nDetails: Becaplermin may increase the anticoagulant activities of Dextran 75.\nRisk: Monitor closely.", "source": "Becaplermin + Dextran 75"}, {"id": "Becaplermin_INT_Protocatechualdehyde", "text": "Interaction: Becaplermin AND Protocatechualdehyde\nDetails: Becaplermin may increase the anticoagulant activities of Protocatechualdehyde.\nRisk: Monitor closely.", "source": "Becaplermin + Protocatechualdehyde"}, {"id": "Becaplermin_INT_Protein C", "text": "Interaction: Becaplermin AND Protein C\nDetails: Becaplermin may increase the anticoagulant activities of Protein C.\nRisk: Monitor closely.", "source": "Becaplermin + Protein C"}, {"id": "Becaplermin_INT_Antithrombin III human", "text": "Interaction: Becaplermin AND Antithrombin III human\nDetails: Becaplermin may increase the anticoagulant activities of Antithrombin III human.\nRisk: Monitor closely.", "source": "Becaplermin + Antithrombin III human"}, {"id": "Becaplermin_INT_Fondaparinux", "text": "Interaction: Becaplermin AND Fondaparinux\nDetails: Becaplermin may increase the anticoagulant activities of Fondaparinux.\nRisk: Monitor closely.", "source": "Becaplermin + Fondaparinux"}, {"id": "Becaplermin_INT_Letaxaban", "text": "Interaction: Becaplermin AND Letaxaban\nDetails: Becaplermin may increase the anticoagulant activities of Letaxaban.\nRisk: Monitor closely.", "source": "Becaplermin + Letaxaban"}, {"id": "Becaplermin_INT_Darexaban", "text": "Interaction: Becaplermin AND Darexaban\nDetails: Becaplermin may increase the anticoagulant activities of Darexaban.\nRisk: Monitor closely.", "source": "Becaplermin + Darexaban"}, {"id": "Becaplermin_INT_Gabexate", "text": "Interaction: Becaplermin AND Gabexate\nDetails: Becaplermin may increase the anticoagulant activities of Gabexate.\nRisk: Monitor closely.", "source": "Becaplermin + Gabexate"}, {"id": "Becaplermin_INT_Troxerutin", "text": "Interaction: Becaplermin AND Troxerutin\nDetails: Becaplermin may increase the anticoagulant activities of Troxerutin.\nRisk: Monitor closely.", "source": "Becaplermin + Troxerutin"}, {"id": "Becaplermin_INT_Fluindione", "text": "Interaction: Becaplermin AND Fluindione\nDetails: Becaplermin may increase the anticoagulant activities of Fluindione.\nRisk: Monitor closely.", "source": "Becaplermin + Fluindione"}, {"id": "Becaplermin_INT_Protein S human", "text": "Interaction: Becaplermin AND Protein S human\nDetails: Becaplermin may increase the anticoagulant activities of Protein S human.\nRisk: Monitor closely.", "source": "Becaplermin + Protein S human"}, {"id": "Becaplermin_INT_Melagatran", "text": "Interaction: Becaplermin AND Melagatran\nDetails: Becaplermin may increase the anticoagulant activities of Melagatran.\nRisk: Monitor closely.", "source": "Becaplermin + Melagatran"}, {"id": "Becaplermin_INT_Aminosalicylic Acid", "text": "Interaction: Becaplermin AND Aminosalicylic Acid\nDetails: Aminosalicylic Acid may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Aminosalicylic Acid"}, {"id": "Becaplermin_INT_dersalazine", "text": "Interaction: Becaplermin AND dersalazine\nDetails: dersalazine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + dersalazine"}, {"id": "Becaplermin_INT_Aloxiprin", "text": "Interaction: Becaplermin AND Aloxiprin\nDetails: Aloxiprin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Aloxiprin"}, {"id": "Becaplermin_INT_Hemoglobin crosfumaril", "text": "Interaction: Becaplermin AND Hemoglobin crosfumaril\nDetails: Hemoglobin crosfumaril may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Hemoglobin crosfumaril"}, {"id": "Becaplermin_INT_Methyl salicylate", "text": "Interaction: Becaplermin AND Methyl salicylate\nDetails: Methyl salicylate may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Methyl salicylate"}, {"id": "Becaplermin_INT_Trolamine salicylate", "text": "Interaction: Becaplermin AND Trolamine salicylate\nDetails: Trolamine salicylate may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Trolamine salicylate"}, {"id": "Becaplermin_INT_Alteplase", "text": "Interaction: Becaplermin AND Alteplase\nDetails: Alteplase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Alteplase"}, {"id": "Becaplermin_INT_Reteplase", "text": "Interaction: Becaplermin AND Reteplase\nDetails: Reteplase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Reteplase"}, {"id": "Becaplermin_INT_Anistreplase", "text": "Interaction: Becaplermin AND Anistreplase\nDetails: Anistreplase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Anistreplase"}, {"id": "Becaplermin_INT_Tenecteplase", "text": "Interaction: Becaplermin AND Tenecteplase\nDetails: Tenecteplase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tenecteplase"}, {"id": "Becaplermin_INT_Drotrecogin alfa", "text": "Interaction: Becaplermin AND Drotrecogin alfa\nDetails: Drotrecogin alfa may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Drotrecogin alfa"}, {"id": "Becaplermin_INT_Ticlopidine", "text": "Interaction: Becaplermin AND Ticlopidine\nDetails: Ticlopidine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ticlopidine"}, {"id": "Becaplermin_INT_Tirofiban", "text": "Interaction: Becaplermin AND Tirofiban\nDetails: Tirofiban may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tirofiban"}, {"id": "Becaplermin_INT_Cilostazol", "text": "Interaction: Becaplermin AND Cilostazol\nDetails: Cilostazol may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Cilostazol"}, {"id": "Becaplermin_INT_Defibrotide", "text": "Interaction: Becaplermin AND Defibrotide\nDetails: Defibrotide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Defibrotide"}, {"id": "Becaplermin_INT_Tinzaparin", "text": "Interaction: Becaplermin AND Tinzaparin\nDetails: Tinzaparin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tinzaparin"}, {"id": "Becaplermin_INT_Brinase", "text": "Interaction: Becaplermin AND Brinase\nDetails: Brinase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Brinase"}, {"id": "Becaplermin_INT_Saruplase", "text": "Interaction: Becaplermin AND Saruplase\nDetails: Saruplase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Saruplase"}, {"id": "Becaplermin_INT_Streptokinase", "text": "Interaction: Becaplermin AND Streptokinase\nDetails: Streptokinase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Streptokinase"}, {"id": "Becaplermin_INT_Anagrelide", "text": "Interaction: Becaplermin AND Anagrelide\nDetails: Anagrelide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Anagrelide"}, {"id": "Becaplermin_INT_Rosiglitazone", "text": "Interaction: Becaplermin AND Rosiglitazone\nDetails: Rosiglitazone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Rosiglitazone"}, {"id": "Becaplermin_INT_Desmoteplase", "text": "Interaction: Becaplermin AND Desmoteplase\nDetails: Desmoteplase may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Desmoteplase"}, {"id": "Becaplermin_INT_Fibrinolysin", "text": "Interaction: Becaplermin AND Fibrinolysin\nDetails: Fibrinolysin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Fibrinolysin"}, {"id": "Becaplermin_INT_ALX-0081", "text": "Interaction: Becaplermin AND ALX-0081\nDetails: ALX-0081 may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + ALX-0081"}, {"id": "Becaplermin_INT_eplivanserine", "text": "Interaction: Becaplermin AND eplivanserine\nDetails: eplivanserine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + eplivanserine"}, {"id": "Becaplermin_INT_Astaxanthin", "text": "Interaction: Becaplermin AND Astaxanthin\nDetails: Astaxanthin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Astaxanthin"}, {"id": "Becaplermin_INT_Batroxobin", "text": "Interaction: Becaplermin AND Batroxobin\nDetails: Batroxobin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Batroxobin"}, {"id": "Becaplermin_INT_Ozagrel", "text": "Interaction: Becaplermin AND Ozagrel\nDetails: Ozagrel may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ozagrel"}, {"id": "Becaplermin_INT_Sarpogrelate", "text": "Interaction: Becaplermin AND Sarpogrelate\nDetails: Sarpogrelate may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Sarpogrelate"}, {"id": "Becaplermin_INT_Eplivanserin", "text": "Interaction: Becaplermin AND Eplivanserin\nDetails: Eplivanserin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Eplivanserin"}, {"id": "Becaplermin_INT_Eptifibatide", "text": "Interaction: Becaplermin AND Eptifibatide\nDetails: Eptifibatide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Eptifibatide"}, {"id": "Becaplermin_INT_Treprostinil", "text": "Interaction: Becaplermin AND Treprostinil\nDetails: Treprostinil may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Treprostinil"}, {"id": "Becaplermin_INT_Clopidogrel", "text": "Interaction: Becaplermin AND Clopidogrel\nDetails: Clopidogrel may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Clopidogrel"}, {"id": "Becaplermin_INT_Dipyridamole", "text": "Interaction: Becaplermin AND Dipyridamole\nDetails: Dipyridamole may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Dipyridamole"}, {"id": "Becaplermin_INT_Iloprost", "text": "Interaction: Becaplermin AND Iloprost\nDetails: Iloprost may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Iloprost"}, {"id": "Becaplermin_INT_Epoprostenol", "text": "Interaction: Becaplermin AND Epoprostenol\nDetails: Epoprostenol may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Epoprostenol"}, {"id": "Becaplermin_INT_Beraprost", "text": "Interaction: Becaplermin AND Beraprost\nDetails: Beraprost may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Beraprost"}, {"id": "Becaplermin_INT_Prasugrel", "text": "Interaction: Becaplermin AND Prasugrel\nDetails: Prasugrel may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Prasugrel"}, {"id": "Becaplermin_INT_Cangrelor", "text": "Interaction: Becaplermin AND Cangrelor\nDetails: Cangrelor may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Cangrelor"}, {"id": "Becaplermin_INT_Triflusal", "text": "Interaction: Becaplermin AND Triflusal\nDetails: Triflusal may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Triflusal"}, {"id": "Becaplermin_INT_Ticagrelor", "text": "Interaction: Becaplermin AND Ticagrelor\nDetails: Ticagrelor may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ticagrelor"}, {"id": "Becaplermin_INT_Ditazole", "text": "Interaction: Becaplermin AND Ditazole\nDetails: Ditazole may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ditazole"}, {"id": "Becaplermin_INT_Bemiparin", "text": "Interaction: Becaplermin AND Bemiparin\nDetails: Bemiparin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Bemiparin"}, {"id": "Becaplermin_INT_Parnaparin", "text": "Interaction: Becaplermin AND Parnaparin\nDetails: Parnaparin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Parnaparin"}, {"id": "Becaplermin_INT_Selexipag", "text": "Interaction: Becaplermin AND Selexipag\nDetails: Selexipag may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Selexipag"}, {"id": "Becaplermin_INT_Indobufen", "text": "Interaction: Becaplermin AND Indobufen\nDetails: Indobufen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Indobufen"}, {"id": "Becaplermin_INT_Clorindione", "text": "Interaction: Becaplermin AND Clorindione\nDetails: Clorindione may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Clorindione"}, {"id": "Becaplermin_INT_Picotamide", "text": "Interaction: Becaplermin AND Picotamide\nDetails: Picotamide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Picotamide"}, {"id": "Becaplermin_INT_Diphenadione", "text": "Interaction: Becaplermin AND Diphenadione\nDetails: Diphenadione may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Diphenadione"}, {"id": "Becaplermin_INT_Cloricromen", "text": "Interaction: Becaplermin AND Cloricromen\nDetails: Cloricromen may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Cloricromen"}, {"id": "Becaplermin_INT_Tioclomarol", "text": "Interaction: Becaplermin AND Tioclomarol\nDetails: Tioclomarol may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tioclomarol"}, {"id": "Becaplermin_INT_Milrinone", "text": "Interaction: Becaplermin AND Milrinone\nDetails: Milrinone may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Milrinone"}, {"id": "Becaplermin_INT_Epinastine", "text": "Interaction: Becaplermin AND Epinastine\nDetails: Epinastine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Epinastine"}, {"id": "Becaplermin_INT_Alprostadil", "text": "Interaction: Becaplermin AND Alprostadil\nDetails: Alprostadil may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Alprostadil"}, {"id": "Becaplermin_INT_Pentoxifylline", "text": "Interaction: Becaplermin AND Pentoxifylline\nDetails: Pentoxifylline may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Pentoxifylline"}, {"id": "Becaplermin_INT_Ridogrel", "text": "Interaction: Becaplermin AND Ridogrel\nDetails: Ridogrel may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ridogrel"}, {"id": "Becaplermin_INT_Sevoflurane", "text": "Interaction: Becaplermin AND Sevoflurane\nDetails: Sevoflurane may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Sevoflurane"}, {"id": "Becaplermin_INT_Tesmilifene", "text": "Interaction: Becaplermin AND Tesmilifene\nDetails: Tesmilifene may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Tesmilifene"}, {"id": "Becaplermin_INT_Ibudilast", "text": "Interaction: Becaplermin AND Ibudilast\nDetails: Ibudilast may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ibudilast"}, {"id": "Becaplermin_INT_Icosapent ethyl", "text": "Interaction: Becaplermin AND Icosapent ethyl\nDetails: Icosapent ethyl may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Icosapent ethyl"}, {"id": "Becaplermin_INT_Ifenprodil", "text": "Interaction: Becaplermin AND Ifenprodil\nDetails: Ifenprodil may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ifenprodil"}, {"id": "Becaplermin_INT_Trapidil", "text": "Interaction: Becaplermin AND Trapidil\nDetails: Trapidil may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Trapidil"}, {"id": "Becaplermin_INT_Naftopidil", "text": "Interaction: Becaplermin AND Naftopidil\nDetails: Naftopidil may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Naftopidil"}, {"id": "Becaplermin_INT_Ifetroban", "text": "Interaction: Becaplermin AND Ifetroban\nDetails: Ifetroban may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ifetroban"}, {"id": "Becaplermin_INT_Ketanserin", "text": "Interaction: Becaplermin AND Ketanserin\nDetails: Ketanserin may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ketanserin"}, {"id": "Becaplermin_INT_Butylphthalide", "text": "Interaction: Becaplermin AND Butylphthalide\nDetails: Butylphthalide may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Butylphthalide"}, {"id": "Becaplermin_INT_Hydroxytyrosol", "text": "Interaction: Becaplermin AND Hydroxytyrosol\nDetails: Hydroxytyrosol may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Hydroxytyrosol"}, {"id": "Becaplermin_INT_Ramatroban", "text": "Interaction: Becaplermin AND Ramatroban\nDetails: Ramatroban may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Ramatroban"}, {"id": "Becaplermin_INT_Linsidomine", "text": "Interaction: Becaplermin AND Linsidomine\nDetails: Linsidomine may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Linsidomine"}, {"id": "Becaplermin_INT_Buflomedil", "text": "Interaction: Becaplermin AND Buflomedil\nDetails: Buflomedil may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Buflomedil"}, {"id": "Becaplermin_INT_Relcovaptan", "text": "Interaction: Becaplermin AND Relcovaptan\nDetails: Relcovaptan may increase the anticoagulant activities of Becaplermin.\nRisk: Monitor closely.", "source": "Becaplermin + Relcovaptan"}, {"id": "Agalsidase beta_GEN", "text": "Drug: Agalsidase beta\nDescription: Recombinant human alpha-galactosidase A. The mature protein is composed of 2 subunits of 398 residues. Protein is glycosylated and produced by CHO cells...", "source": "Agalsidase beta"}, {"id": "Agalsidase beta_CLIN", "text": "Drug: Agalsidase beta\nMechanism: Alpha-galactosidase A catalyzes the hydrolysis of globotriaosylceramide (GL-3) and other a-galactyl-terminated neutral glycosphingolipids, such as galabiosylceramide and blood group B substances to ce...\nToxicity: ...", "source": "Agalsidase beta"}, {"id": "Agalsidase beta_INT_Gentamicin", "text": "Interaction: Agalsidase beta AND Gentamicin\nDetails: The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Gentamicin.\nRisk: Monitor closely.", "source": "Agalsidase beta + Gentamicin"}, {"id": "Agalsidase beta_INT_Amiodarone", "text": "Interaction: Agalsidase beta AND Amiodarone\nDetails: The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Amiodarone.\nRisk: Monitor closely.", "source": "Agalsidase beta + Amiodarone"}, {"id": "Agalsidase beta_INT_Chloroquine", "text": "Interaction: Agalsidase beta AND Chloroquine\nDetails: The therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Chloroquine.\nRisk: Monitor closely.", "source": "Agalsidase beta + Chloroquine"}, {"id": "Octreotide_GEN", "text": "Drug: Octreotide\nDescription: Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin....", "source": "Octreotide"}, {"id": "Octreotide_CLIN", "text": "Drug: Octreotide\nMechanism: Octreotide binds to somatostatin receptors. These receptors are coupled via pertussis toxin sensitive G proteins which lead to inhibition of adenylyl cyclase. Octreotide binding to these receptors als...\nToxicity: ...", "source": "Octreotide"}, {"id": "Octreotide_INT_Ceritinib", "text": "Interaction: Octreotide AND Ceritinib\nDetails: Octreotide may increase the bradycardic activities of Ceritinib.\nRisk: Monitor closely.", "source": "Octreotide + Ceritinib"}, {"id": "Octreotide_INT_Trastuzumab", "text": "Interaction: Octreotide AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Trastuzumab"}, {"id": "Octreotide_INT_Mifepristone", "text": "Interaction: Octreotide AND Mifepristone\nDetails: Mifepristone may increase the QTc-prolonging activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Mifepristone"}, {"id": "Octreotide_INT_Dofetilide", "text": "Interaction: Octreotide AND Dofetilide\nDetails: Octreotide may increase the QTc-prolonging activities of Dofetilide.\nRisk: Monitor closely.", "source": "Octreotide + Dofetilide"}, {"id": "Octreotide_INT_Citalopram", "text": "Interaction: Octreotide AND Citalopram\nDetails: Octreotide may increase the QTc-prolonging activities of Citalopram.\nRisk: Monitor closely.", "source": "Octreotide + Citalopram"}, {"id": "Octreotide_INT_Ziprasidone", "text": "Interaction: Octreotide AND Ziprasidone\nDetails: Octreotide may increase the QTc-prolonging activities of Ziprasidone.\nRisk: Monitor closely.", "source": "Octreotide + Ziprasidone"}, {"id": "Octreotide_INT_Anagrelide", "text": "Interaction: Octreotide AND Anagrelide\nDetails: Octreotide may increase the QTc-prolonging activities of Anagrelide.\nRisk: Monitor closely.", "source": "Octreotide + Anagrelide"}, {"id": "Octreotide_INT_Disopyramide", "text": "Interaction: Octreotide AND Disopyramide\nDetails: Octreotide may increase the QTc-prolonging activities of Disopyramide.\nRisk: Monitor closely.", "source": "Octreotide + Disopyramide"}, {"id": "Octreotide_INT_Ibutilide", "text": "Interaction: Octreotide AND Ibutilide\nDetails: Octreotide may increase the QTc-prolonging activities of Ibutilide.\nRisk: Monitor closely.", "source": "Octreotide + Ibutilide"}, {"id": "Octreotide_INT_Quinine", "text": "Interaction: Octreotide AND Quinine\nDetails: Octreotide may increase the QTc-prolonging activities of Quinine.\nRisk: Monitor closely.", "source": "Octreotide + Quinine"}, {"id": "Octreotide_INT_Fluoxetine", "text": "Interaction: Octreotide AND Fluoxetine\nDetails: Octreotide may increase the QTc-prolonging activities of Fluoxetine.\nRisk: Monitor closely.", "source": "Octreotide + Fluoxetine"}, {"id": "Octreotide_INT_Sotalol", "text": "Interaction: Octreotide AND Sotalol\nDetails: Octreotide may increase the QTc-prolonging activities of Sotalol.\nRisk: Monitor closely.", "source": "Octreotide + Sotalol"}, {"id": "Octreotide_INT_Toremifene", "text": "Interaction: Octreotide AND Toremifene\nDetails: Octreotide may increase the QTc-prolonging activities of Toremifene.\nRisk: Monitor closely.", "source": "Octreotide + Toremifene"}, {"id": "Octreotide_INT_Cisapride", "text": "Interaction: Octreotide AND Cisapride\nDetails: Octreotide may increase the QTc-prolonging activities of Cisapride.\nRisk: Monitor closely.", "source": "Octreotide + Cisapride"}, {"id": "Octreotide_INT_Thioridazine", "text": "Interaction: Octreotide AND Thioridazine\nDetails: Octreotide may increase the QTc-prolonging activities of Thioridazine.\nRisk: Monitor closely.", "source": "Octreotide + Thioridazine"}, {"id": "Octreotide_INT_Flupentixol", "text": "Interaction: Octreotide AND Flupentixol\nDetails: Octreotide may increase the QTc-prolonging activities of Flupentixol.\nRisk: Monitor closely.", "source": "Octreotide + Flupentixol"}, {"id": "Octreotide_INT_Quinidine", "text": "Interaction: Octreotide AND Quinidine\nDetails: Octreotide may increase the QTc-prolonging activities of Quinidine.\nRisk: Monitor closely.", "source": "Octreotide + Quinidine"}, {"id": "Octreotide_INT_Procainamide", "text": "Interaction: Octreotide AND Procainamide\nDetails: Octreotide may increase the QTc-prolonging activities of Procainamide.\nRisk: Monitor closely.", "source": "Octreotide + Procainamide"}, {"id": "Octreotide_INT_Pimozide", "text": "Interaction: Octreotide AND Pimozide\nDetails: Octreotide may increase the QTc-prolonging activities of Pimozide.\nRisk: Monitor closely.", "source": "Octreotide + Pimozide"}, {"id": "Octreotide_INT_Amiodarone", "text": "Interaction: Octreotide AND Amiodarone\nDetails: Octreotide may increase the QTc-prolonging activities of Amiodarone.\nRisk: Monitor closely.", "source": "Octreotide + Amiodarone"}, {"id": "Octreotide_INT_Arsenic trioxide", "text": "Interaction: Octreotide AND Arsenic trioxide\nDetails: Octreotide may increase the QTc-prolonging activities of Arsenic trioxide.\nRisk: Monitor closely.", "source": "Octreotide + Arsenic trioxide"}, {"id": "Octreotide_INT_Escitalopram", "text": "Interaction: Octreotide AND Escitalopram\nDetails: Octreotide may increase the QTc-prolonging activities of Escitalopram.\nRisk: Monitor closely.", "source": "Octreotide + Escitalopram"}, {"id": "Octreotide_INT_Domperidone", "text": "Interaction: Octreotide AND Domperidone\nDetails: Octreotide may increase the QTc-prolonging activities of Domperidone.\nRisk: Monitor closely.", "source": "Octreotide + Domperidone"}, {"id": "Octreotide_INT_Quetiapine", "text": "Interaction: Octreotide AND Quetiapine\nDetails: Octreotide may increase the QTc-prolonging activities of Quetiapine.\nRisk: Monitor closely.", "source": "Octreotide + Quetiapine"}, {"id": "Octreotide_INT_Paliperidone", "text": "Interaction: Octreotide AND Paliperidone\nDetails: Octreotide may increase the QTc-prolonging activities of Paliperidone.\nRisk: Monitor closely.", "source": "Octreotide + Paliperidone"}, {"id": "Octreotide_INT_Lopinavir", "text": "Interaction: Octreotide AND Lopinavir\nDetails: Octreotide may increase the QTc-prolonging activities of Lopinavir.\nRisk: Monitor closely.", "source": "Octreotide + Lopinavir"}, {"id": "Octreotide_INT_Zuclopenthixol", "text": "Interaction: Octreotide AND Zuclopenthixol\nDetails: Octreotide may increase the QTc-prolonging activities of Zuclopenthixol.\nRisk: Monitor closely.", "source": "Octreotide + Zuclopenthixol"}, {"id": "Octreotide_INT_Tetrabenazine", "text": "Interaction: Octreotide AND Tetrabenazine\nDetails: Octreotide may increase the QTc-prolonging activities of Tetrabenazine.\nRisk: Monitor closely.", "source": "Octreotide + Tetrabenazine"}, {"id": "Octreotide_INT_Dronedarone", "text": "Interaction: Octreotide AND Dronedarone\nDetails: Octreotide may increase the QTc-prolonging activities of Dronedarone.\nRisk: Monitor closely.", "source": "Octreotide + Dronedarone"}, {"id": "Octreotide_INT_Nilotinib", "text": "Interaction: Octreotide AND Nilotinib\nDetails: Octreotide may increase the QTc-prolonging activities of Nilotinib.\nRisk: Monitor closely.", "source": "Octreotide + Nilotinib"}, {"id": "Octreotide_INT_Iloperidone", "text": "Interaction: Octreotide AND Iloperidone\nDetails: Octreotide may increase the QTc-prolonging activities of Iloperidone.\nRisk: Monitor closely.", "source": "Octreotide + Iloperidone"}, {"id": "Octreotide_INT_Vandetanib", "text": "Interaction: Octreotide AND Vandetanib\nDetails: Octreotide may increase the QTc-prolonging activities of Vandetanib.\nRisk: Monitor closely.", "source": "Octreotide + Vandetanib"}, {"id": "Octreotide_INT_Asenapine", "text": "Interaction: Octreotide AND Asenapine\nDetails: Octreotide may increase the QTc-prolonging activities of Asenapine.\nRisk: Monitor closely.", "source": "Octreotide + Asenapine"}, {"id": "Octreotide_INT_Artemether", "text": "Interaction: Octreotide AND Artemether\nDetails: Octreotide may increase the QTc-prolonging activities of Artemether.\nRisk: Monitor closely.", "source": "Octreotide + Artemether"}, {"id": "Octreotide_INT_Lumefantrine", "text": "Interaction: Octreotide AND Lumefantrine\nDetails: Octreotide may increase the QTc-prolonging activities of Lumefantrine.\nRisk: Monitor closely.", "source": "Octreotide + Lumefantrine"}, {"id": "Octreotide_INT_Vemurafenib", "text": "Interaction: Octreotide AND Vemurafenib\nDetails: Octreotide may increase the QTc-prolonging activities of Vemurafenib.\nRisk: Monitor closely.", "source": "Octreotide + Vemurafenib"}, {"id": "Octreotide_INT_Eliglustat", "text": "Interaction: Octreotide AND Eliglustat\nDetails: Octreotide may increase the QTc-prolonging activities of Eliglustat.\nRisk: Monitor closely.", "source": "Octreotide + Eliglustat"}, {"id": "Octreotide_INT_Dotatate gallium Ga-68", "text": "Interaction: Octreotide AND Dotatate gallium Ga-68\nDetails: The therapeutic efficacy of Dotatate gallium Ga-68 can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Dotatate gallium Ga-68"}, {"id": "Octreotide_INT_Cyclosporine", "text": "Interaction: Octreotide AND Cyclosporine\nDetails: The serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Cyclosporine"}, {"id": "Octreotide_INT_Paclitaxel", "text": "Interaction: Octreotide AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Paclitaxel"}, {"id": "Octreotide_INT_Docetaxel", "text": "Interaction: Octreotide AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Docetaxel"}, {"id": "Octreotide_INT_Cabazitaxel", "text": "Interaction: Octreotide AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Cabazitaxel"}, {"id": "Octreotide_INT_Digoxin", "text": "Interaction: Octreotide AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Digoxin"}, {"id": "Octreotide_INT_Acetyldigitoxin", "text": "Interaction: Octreotide AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Acetyldigitoxin"}, {"id": "Octreotide_INT_Deslanoside", "text": "Interaction: Octreotide AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Deslanoside"}, {"id": "Octreotide_INT_Ouabain", "text": "Interaction: Octreotide AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Ouabain"}, {"id": "Octreotide_INT_Digitoxin", "text": "Interaction: Octreotide AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Digitoxin"}, {"id": "Octreotide_INT_Cymarin", "text": "Interaction: Octreotide AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Cymarin"}, {"id": "Octreotide_INT_Proscillaridin", "text": "Interaction: Octreotide AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Proscillaridin"}, {"id": "Octreotide_INT_Metildigoxin", "text": "Interaction: Octreotide AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Metildigoxin"}, {"id": "Octreotide_INT_Peruvoside", "text": "Interaction: Octreotide AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Peruvoside"}, {"id": "Octreotide_INT_Lanatoside C", "text": "Interaction: Octreotide AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Lanatoside C"}, {"id": "Octreotide_INT_Gitoformate", "text": "Interaction: Octreotide AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Gitoformate"}, {"id": "Octreotide_INT_Acetyldigoxin", "text": "Interaction: Octreotide AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Acetyldigoxin"}, {"id": "Octreotide_INT_Oleandrin", "text": "Interaction: Octreotide AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Oleandrin"}, {"id": "Octreotide_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Octreotide AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Digoxin Immune Fab (Ovine)"}, {"id": "Octreotide_INT_Bretylium", "text": "Interaction: Octreotide AND Bretylium\nDetails: Bretylium may increase the bradycardic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Bretylium"}, {"id": "Octreotide_INT_Bevacizumab", "text": "Interaction: Octreotide AND Bevacizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Bevacizumab"}, {"id": "Octreotide_INT_Bromocriptine", "text": "Interaction: Octreotide AND Bromocriptine\nDetails: The serum concentration of Bromocriptine can be increased when it is combined with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Bromocriptine"}, {"id": "Octreotide_INT_Cyclophosphamide", "text": "Interaction: Octreotide AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Cyclophosphamide"}, {"id": "Octreotide_INT_Codeine", "text": "Interaction: Octreotide AND Codeine\nDetails: The metabolism of Codeine can be decreased when combined with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Codeine"}, {"id": "Octreotide_INT_Ivabradine", "text": "Interaction: Octreotide AND Ivabradine\nDetails: Octreotide may increase the bradycardic activities of Ivabradine.\nRisk: Monitor closely.", "source": "Octreotide + Ivabradine"}, {"id": "Octreotide_INT_Lacosamide", "text": "Interaction: Octreotide AND Lacosamide\nDetails: Octreotide may increase the atrioventricular blocking (AV block) activities of Lacosamide.\nRisk: Monitor closely.", "source": "Octreotide + Lacosamide"}, {"id": "Octreotide_INT_Pegvisomant", "text": "Interaction: Octreotide AND Pegvisomant\nDetails: The risk or severity of adverse effects can be increased when Octreotide is combined with Pegvisomant.\nRisk: Monitor closely.", "source": "Octreotide + Pegvisomant"}, {"id": "Octreotide_INT_Ruxolitinib", "text": "Interaction: Octreotide AND Ruxolitinib\nDetails: Ruxolitinib may increase the bradycardic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Ruxolitinib"}, {"id": "Octreotide_INT_Tofacitinib", "text": "Interaction: Octreotide AND Tofacitinib\nDetails: Tofacitinib may increase the bradycardic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Tofacitinib"}, {"id": "Octreotide_INT_Leuprolide", "text": "Interaction: Octreotide AND Leuprolide\nDetails: Octreotide may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Octreotide + Leuprolide"}, {"id": "Octreotide_INT_Goserelin", "text": "Interaction: Octreotide AND Goserelin\nDetails: Octreotide may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Octreotide + Goserelin"}, {"id": "Octreotide_INT_Erythromycin", "text": "Interaction: Octreotide AND Erythromycin\nDetails: Octreotide may increase the QTc-prolonging activities of Erythromycin.\nRisk: Monitor closely.", "source": "Octreotide + Erythromycin"}, {"id": "Octreotide_INT_Azithromycin", "text": "Interaction: Octreotide AND Azithromycin\nDetails: Octreotide may increase the QTc-prolonging activities of Azithromycin.\nRisk: Monitor closely.", "source": "Octreotide + Azithromycin"}, {"id": "Octreotide_INT_Moxifloxacin", "text": "Interaction: Octreotide AND Moxifloxacin\nDetails: Octreotide may increase the QTc-prolonging activities of Moxifloxacin.\nRisk: Monitor closely.", "source": "Octreotide + Moxifloxacin"}, {"id": "Octreotide_INT_Sulfisoxazole", "text": "Interaction: Octreotide AND Sulfisoxazole\nDetails: Octreotide may increase the QTc-prolonging activities of Sulfisoxazole.\nRisk: Monitor closely.", "source": "Octreotide + Sulfisoxazole"}, {"id": "Octreotide_INT_Methadone", "text": "Interaction: Octreotide AND Methadone\nDetails: Octreotide may increase the QTc-prolonging activities of Methadone.\nRisk: Monitor closely.", "source": "Octreotide + Methadone"}, {"id": "Octreotide_INT_Clozapine", "text": "Interaction: Octreotide AND Clozapine\nDetails: Octreotide may increase the QTc-prolonging activities of Clozapine.\nRisk: Monitor closely.", "source": "Octreotide + Clozapine"}, {"id": "Octreotide_INT_Promazine", "text": "Interaction: Octreotide AND Promazine\nDetails: Octreotide may increase the QTc-prolonging activities of Promazine.\nRisk: Monitor closely.", "source": "Octreotide + Promazine"}, {"id": "Octreotide_INT_Droperidol", "text": "Interaction: Octreotide AND Droperidol\nDetails: Octreotide may increase the QTc-prolonging activities of Droperidol.\nRisk: Monitor closely.", "source": "Octreotide + Droperidol"}, {"id": "Octreotide_INT_Chlorpromazine", "text": "Interaction: Octreotide AND Chlorpromazine\nDetails: Octreotide may increase the QTc-prolonging activities of Chlorpromazine.\nRisk: Monitor closely.", "source": "Octreotide + Chlorpromazine"}, {"id": "Octreotide_INT_Haloperidol", "text": "Interaction: Octreotide AND Haloperidol\nDetails: Octreotide may increase the QTc-prolonging activities of Haloperidol.\nRisk: Monitor closely.", "source": "Octreotide + Haloperidol"}, {"id": "Octreotide_INT_Ciprofloxacin", "text": "Interaction: Octreotide AND Ciprofloxacin\nDetails: Octreotide may increase the QTc-prolonging activities of Ciprofloxacin.\nRisk: Monitor closely.", "source": "Octreotide + Ciprofloxacin"}, {"id": "Octreotide_INT_Perflutren", "text": "Interaction: Octreotide AND Perflutren\nDetails: Octreotide may increase the QTc-prolonging activities of Perflutren.\nRisk: Monitor closely.", "source": "Octreotide + Perflutren"}, {"id": "Octreotide_INT_Chloroquine", "text": "Interaction: Octreotide AND Chloroquine\nDetails: Octreotide may increase the QTc-prolonging activities of Chloroquine.\nRisk: Monitor closely.", "source": "Octreotide + Chloroquine"}, {"id": "Octreotide_INT_Pentamidine", "text": "Interaction: Octreotide AND Pentamidine\nDetails: Octreotide may increase the QTc-prolonging activities of Pentamidine.\nRisk: Monitor closely.", "source": "Octreotide + Pentamidine"}, {"id": "Octreotide_INT_Gadobenic acid", "text": "Interaction: Octreotide AND Gadobenic acid\nDetails: Octreotide may increase the QTc-prolonging activities of Gadobenic acid.\nRisk: Monitor closely.", "source": "Octreotide + Gadobenic acid"}, {"id": "Octreotide_INT_Dolasetron", "text": "Interaction: Octreotide AND Dolasetron\nDetails: Octreotide may increase the QTc-prolonging activities of Dolasetron.\nRisk: Monitor closely.", "source": "Octreotide + Dolasetron"}, {"id": "Octreotide_INT_Granisetron", "text": "Interaction: Octreotide AND Granisetron\nDetails: Octreotide may increase the QTc-prolonging activities of Granisetron.\nRisk: Monitor closely.", "source": "Octreotide + Granisetron"}, {"id": "Octreotide_INT_Ondansetron", "text": "Interaction: Octreotide AND Ondansetron\nDetails: Octreotide may increase the QTc-prolonging activities of Ondansetron.\nRisk: Monitor closely.", "source": "Octreotide + Ondansetron"}, {"id": "Octreotide_INT_Telithromycin", "text": "Interaction: Octreotide AND Telithromycin\nDetails: Octreotide may increase the QTc-prolonging activities of Telithromycin.\nRisk: Monitor closely.", "source": "Octreotide + Telithromycin"}, {"id": "Octreotide_INT_Primaquine", "text": "Interaction: Octreotide AND Primaquine\nDetails: Octreotide may increase the QTc-prolonging activities of Primaquine.\nRisk: Monitor closely.", "source": "Octreotide + Primaquine"}, {"id": "Octreotide_INT_Levofloxacin", "text": "Interaction: Octreotide AND Levofloxacin\nDetails: Octreotide may increase the QTc-prolonging activities of Levofloxacin.\nRisk: Monitor closely.", "source": "Octreotide + Levofloxacin"}, {"id": "Octreotide_INT_Gemifloxacin", "text": "Interaction: Octreotide AND Gemifloxacin\nDetails: Octreotide may increase the QTc-prolonging activities of Gemifloxacin.\nRisk: Monitor closely.", "source": "Octreotide + Gemifloxacin"}, {"id": "Octreotide_INT_Ofloxacin", "text": "Interaction: Octreotide AND Ofloxacin\nDetails: Octreotide may increase the QTc-prolonging activities of Ofloxacin.\nRisk: Monitor closely.", "source": "Octreotide + Ofloxacin"}, {"id": "Octreotide_INT_Propafenone", "text": "Interaction: Octreotide AND Propafenone\nDetails: Octreotide may increase the QTc-prolonging activities of Propafenone.\nRisk: Monitor closely.", "source": "Octreotide + Propafenone"}, {"id": "Octreotide_INT_Flecainide", "text": "Interaction: Octreotide AND Flecainide\nDetails: Octreotide may increase the QTc-prolonging activities of Flecainide.\nRisk: Monitor closely.", "source": "Octreotide + Flecainide"}, {"id": "Octreotide_INT_Clarithromycin", "text": "Interaction: Octreotide AND Clarithromycin\nDetails: Octreotide may increase the QTc-prolonging activities of Clarithromycin.\nRisk: Monitor closely.", "source": "Octreotide + Clarithromycin"}, {"id": "Octreotide_INT_Saquinavir", "text": "Interaction: Octreotide AND Saquinavir\nDetails: Octreotide may increase the QTc-prolonging activities of Saquinavir.\nRisk: Monitor closely.", "source": "Octreotide + Saquinavir"}, {"id": "Octreotide_INT_Telavancin", "text": "Interaction: Octreotide AND Telavancin\nDetails: Octreotide may increase the QTc-prolonging activities of Telavancin.\nRisk: Monitor closely.", "source": "Octreotide + Telavancin"}, {"id": "Octreotide_INT_Pazopanib", "text": "Interaction: Octreotide AND Pazopanib\nDetails: Octreotide may increase the QTc-prolonging activities of Pazopanib.\nRisk: Monitor closely.", "source": "Octreotide + Pazopanib"}, {"id": "Octreotide_INT_Panobinostat", "text": "Interaction: Octreotide AND Panobinostat\nDetails: Octreotide may increase the QTc-prolonging activities of Panobinostat.\nRisk: Monitor closely.", "source": "Octreotide + Panobinostat"}, {"id": "Octreotide_INT_Crizotinib", "text": "Interaction: Octreotide AND Crizotinib\nDetails: Octreotide may increase the QTc-prolonging activities of Crizotinib.\nRisk: Monitor closely.", "source": "Octreotide + Crizotinib"}, {"id": "Octreotide_INT_Bedaquiline", "text": "Interaction: Octreotide AND Bedaquiline\nDetails: Octreotide may increase the QTc-prolonging activities of Bedaquiline.\nRisk: Monitor closely.", "source": "Octreotide + Bedaquiline"}, {"id": "Octreotide_INT_Lenvatinib", "text": "Interaction: Octreotide AND Lenvatinib\nDetails: Octreotide may increase the QTc-prolonging activities of Lenvatinib.\nRisk: Monitor closely.", "source": "Octreotide + Lenvatinib"}, {"id": "Octreotide_INT_Insulin Human", "text": "Interaction: Octreotide AND Insulin Human\nDetails: Insulin Human may increase the hypoglycemic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Insulin Human"}, {"id": "Octreotide_INT_Insulin Lispro", "text": "Interaction: Octreotide AND Insulin Lispro\nDetails: Insulin Lispro may increase the hypoglycemic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Insulin Lispro"}, {"id": "Octreotide_INT_Insulin Glargine", "text": "Interaction: Octreotide AND Insulin Glargine\nDetails: Insulin Glargine may increase the hypoglycemic activities of Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Insulin Glargine"}, {"id": "Octreotide_INT_Glimepiride", "text": "Interaction: Octreotide AND Glimepiride\nDetails: Octreotide may increase the hypoglycemic activities of Glimepiride.\nRisk: Monitor closely.", "source": "Octreotide + Glimepiride"}, {"id": "Octreotide_INT_Sulfadiazine", "text": "Interaction: Octreotide AND Sulfadiazine\nDetails: Octreotide may increase the hypoglycemic activities of Sulfadiazine.\nRisk: Monitor closely.", "source": "Octreotide + Sulfadiazine"}, {"id": "Octreotide_INT_Chlorpropamide", "text": "Interaction: Octreotide AND Chlorpropamide\nDetails: Octreotide may increase the hypoglycemic activities of Chlorpropamide.\nRisk: Monitor closely.", "source": "Octreotide + Chlorpropamide"}, {"id": "Octreotide_INT_Nateglinide", "text": "Interaction: Octreotide AND Nateglinide\nDetails: Octreotide may increase the hypoglycemic activities of Nateglinide.\nRisk: Monitor closely.", "source": "Octreotide + Nateglinide"}, {"id": "Octreotide_INT_Tolazamide", "text": "Interaction: Octreotide AND Tolazamide\nDetails: Octreotide may increase the hypoglycemic activities of Tolazamide.\nRisk: Monitor closely.", "source": "Octreotide + Tolazamide"}, {"id": "Octreotide_INT_Repaglinide", "text": "Interaction: Octreotide AND Repaglinide\nDetails: Octreotide may increase the hypoglycemic activities of Repaglinide.\nRisk: Monitor closely.", "source": "Octreotide + Repaglinide"}, {"id": "Octreotide_INT_Sulfamethoxazole", "text": "Interaction: Octreotide AND Sulfamethoxazole\nDetails: Octreotide may increase the hypoglycemic activities of Sulfamethoxazole.\nRisk: Monitor closely.", "source": "Octreotide + Sulfamethoxazole"}, {"id": "Octreotide_INT_Glyburide", "text": "Interaction: Octreotide AND Glyburide\nDetails: Octreotide may increase the hypoglycemic activities of Glyburide.\nRisk: Monitor closely.", "source": "Octreotide + Glyburide"}, {"id": "Octreotide_INT_Glipizide", "text": "Interaction: Octreotide AND Glipizide\nDetails: Octreotide may increase the hypoglycemic activities of Glipizide.\nRisk: Monitor closely.", "source": "Octreotide + Glipizide"}, {"id": "Octreotide_INT_Gliclazide", "text": "Interaction: Octreotide AND Gliclazide\nDetails: Octreotide may increase the hypoglycemic activities of Gliclazide.\nRisk: Monitor closely.", "source": "Octreotide + Gliclazide"}, {"id": "Octreotide_INT_Tolbutamide", "text": "Interaction: Octreotide AND Tolbutamide\nDetails: Octreotide may increase the hypoglycemic activities of Tolbutamide.\nRisk: Monitor closely.", "source": "Octreotide + Tolbutamide"}, {"id": "Octreotide_INT_Sunitinib", "text": "Interaction: Octreotide AND Sunitinib\nDetails: Octreotide may increase the hypoglycemic activities of Sunitinib.\nRisk: Monitor closely.", "source": "Octreotide + Sunitinib"}, {"id": "Octreotide_INT_Mecasermin", "text": "Interaction: Octreotide AND Mecasermin\nDetails: Octreotide may increase the hypoglycemic activities of Mecasermin.\nRisk: Monitor closely.", "source": "Octreotide + Mecasermin"}, {"id": "Octreotide_INT_Insulin Aspart", "text": "Interaction: Octreotide AND Insulin Aspart\nDetails: Octreotide may increase the hypoglycemic activities of Insulin Aspart.\nRisk: Monitor closely.", "source": "Octreotide + Insulin Aspart"}, {"id": "Octreotide_INT_Insulin Detemir", "text": "Interaction: Octreotide AND Insulin Detemir\nDetails: Octreotide may increase the hypoglycemic activities of Insulin Detemir.\nRisk: Monitor closely.", "source": "Octreotide + Insulin Detemir"}, {"id": "Octreotide_INT_Insulin Glulisine", "text": "Interaction: Octreotide AND Insulin Glulisine\nDetails: Octreotide may increase the hypoglycemic activities of Insulin Glulisine.\nRisk: Monitor closely.", "source": "Octreotide + Insulin Glulisine"}, {"id": "Octreotide_INT_Pasireotide", "text": "Interaction: Octreotide AND Pasireotide\nDetails: Octreotide may increase the hypoglycemic activities of Pasireotide.\nRisk: Monitor closely.", "source": "Octreotide + Pasireotide"}, {"id": "Octreotide_INT_Lanreotide", "text": "Interaction: Octreotide AND Lanreotide\nDetails: Octreotide may increase the hypoglycemic activities of Lanreotide.\nRisk: Monitor closely.", "source": "Octreotide + Lanreotide"}, {"id": "Octreotide_INT_Esmolol", "text": "Interaction: Octreotide AND Esmolol\nDetails: Octreotide may increase the bradycardic activities of Esmolol.\nRisk: Monitor closely.", "source": "Octreotide + Esmolol"}, {"id": "Octreotide_INT_Betaxolol", "text": "Interaction: Octreotide AND Betaxolol\nDetails: Octreotide may increase the bradycardic activities of Betaxolol.\nRisk: Monitor closely.", "source": "Octreotide + Betaxolol"}, {"id": "Octreotide_INT_Metoprolol", "text": "Interaction: Octreotide AND Metoprolol\nDetails: Octreotide may increase the bradycardic activities of Metoprolol.\nRisk: Monitor closely.", "source": "Octreotide + Metoprolol"}, {"id": "Octreotide_INT_Atenolol", "text": "Interaction: Octreotide AND Atenolol\nDetails: Octreotide may increase the bradycardic activities of Atenolol.\nRisk: Monitor closely.", "source": "Octreotide + Atenolol"}, {"id": "Octreotide_INT_Diltiazem", "text": "Interaction: Octreotide AND Diltiazem\nDetails: Octreotide may increase the bradycardic activities of Diltiazem.\nRisk: Monitor closely.", "source": "Octreotide + Diltiazem"}, {"id": "Octreotide_INT_Timolol", "text": "Interaction: Octreotide AND Timolol\nDetails: Octreotide may increase the bradycardic activities of Timolol.\nRisk: Monitor closely.", "source": "Octreotide + Timolol"}, {"id": "Octreotide_INT_Bendroflumethiazide", "text": "Interaction: Octreotide AND Bendroflumethiazide\nDetails: Octreotide may increase the bradycardic activities of Bendroflumethiazide.\nRisk: Monitor closely.", "source": "Octreotide + Bendroflumethiazide"}, {"id": "Octreotide_INT_Carteolol", "text": "Interaction: Octreotide AND Carteolol\nDetails: Octreotide may increase the bradycardic activities of Carteolol.\nRisk: Monitor closely.", "source": "Octreotide + Carteolol"}, {"id": "Octreotide_INT_Propranolol", "text": "Interaction: Octreotide AND Propranolol\nDetails: Octreotide may increase the bradycardic activities of Propranolol.\nRisk: Monitor closely.", "source": "Octreotide + Propranolol"}, {"id": "Octreotide_INT_Clonidine", "text": "Interaction: Octreotide AND Clonidine\nDetails: Octreotide may increase the bradycardic activities of Clonidine.\nRisk: Monitor closely.", "source": "Octreotide + Clonidine"}, {"id": "Octreotide_INT_Labetalol", "text": "Interaction: Octreotide AND Labetalol\nDetails: Octreotide may increase the bradycardic activities of Labetalol.\nRisk: Monitor closely.", "source": "Octreotide + Labetalol"}, {"id": "Octreotide_INT_Bisoprolol", "text": "Interaction: Octreotide AND Bisoprolol\nDetails: Octreotide may increase the bradycardic activities of Bisoprolol.\nRisk: Monitor closely.", "source": "Octreotide + Bisoprolol"}, {"id": "Octreotide_INT_Dexmedetomidine", "text": "Interaction: Octreotide AND Dexmedetomidine\nDetails: Octreotide may increase the bradycardic activities of Dexmedetomidine.\nRisk: Monitor closely.", "source": "Octreotide + Dexmedetomidine"}, {"id": "Octreotide_INT_Verapamil", "text": "Interaction: Octreotide AND Verapamil\nDetails: Octreotide may increase the bradycardic activities of Verapamil.\nRisk: Monitor closely.", "source": "Octreotide + Verapamil"}, {"id": "Octreotide_INT_Galantamine", "text": "Interaction: Octreotide AND Galantamine\nDetails: Octreotide may increase the bradycardic activities of Galantamine.\nRisk: Monitor closely.", "source": "Octreotide + Galantamine"}, {"id": "Octreotide_INT_Tizanidine", "text": "Interaction: Octreotide AND Tizanidine\nDetails: Octreotide may increase the bradycardic activities of Tizanidine.\nRisk: Monitor closely.", "source": "Octreotide + Tizanidine"}, {"id": "Octreotide_INT_Sufentanil", "text": "Interaction: Octreotide AND Sufentanil\nDetails: Octreotide may increase the bradycardic activities of Sufentanil.\nRisk: Monitor closely.", "source": "Octreotide + Sufentanil"}, {"id": "Octreotide_INT_Donepezil", "text": "Interaction: Octreotide AND Donepezil\nDetails: Octreotide may increase the bradycardic activities of Donepezil.\nRisk: Monitor closely.", "source": "Octreotide + Donepezil"}, {"id": "Octreotide_INT_Pindolol", "text": "Interaction: Octreotide AND Pindolol\nDetails: Octreotide may increase the bradycardic activities of Pindolol.\nRisk: Monitor closely.", "source": "Octreotide + Pindolol"}, {"id": "Octreotide_INT_Methyldopa", "text": "Interaction: Octreotide AND Methyldopa\nDetails: Octreotide may increase the bradycardic activities of Methyldopa.\nRisk: Monitor closely.", "source": "Octreotide + Methyldopa"}, {"id": "Octreotide_INT_Rivastigmine", "text": "Interaction: Octreotide AND Rivastigmine\nDetails: Octreotide may increase the bradycardic activities of Rivastigmine.\nRisk: Monitor closely.", "source": "Octreotide + Rivastigmine"}, {"id": "Octreotide_INT_Guanfacine", "text": "Interaction: Octreotide AND Guanfacine\nDetails: Octreotide may increase the bradycardic activities of Guanfacine.\nRisk: Monitor closely.", "source": "Octreotide + Guanfacine"}, {"id": "Octreotide_INT_Carvedilol", "text": "Interaction: Octreotide AND Carvedilol\nDetails: Octreotide may increase the bradycardic activities of Carvedilol.\nRisk: Monitor closely.", "source": "Octreotide + Carvedilol"}, {"id": "Octreotide_INT_Acebutolol", "text": "Interaction: Octreotide AND Acebutolol\nDetails: Octreotide may increase the bradycardic activities of Acebutolol.\nRisk: Monitor closely.", "source": "Octreotide + Acebutolol"}, {"id": "Octreotide_INT_Nadolol", "text": "Interaction: Octreotide AND Nadolol\nDetails: Octreotide may increase the bradycardic activities of Nadolol.\nRisk: Monitor closely.", "source": "Octreotide + Nadolol"}, {"id": "Octreotide_INT_Levobunolol", "text": "Interaction: Octreotide AND Levobunolol\nDetails: Octreotide may increase the bradycardic activities of Levobunolol.\nRisk: Monitor closely.", "source": "Octreotide + Levobunolol"}, {"id": "Octreotide_INT_Metipranolol", "text": "Interaction: Octreotide AND Metipranolol\nDetails: Octreotide may increase the bradycardic activities of Metipranolol.\nRisk: Monitor closely.", "source": "Octreotide + Metipranolol"}, {"id": "Octreotide_INT_Penbutolol", "text": "Interaction: Octreotide AND Penbutolol\nDetails: Octreotide may increase the bradycardic activities of Penbutolol.\nRisk: Monitor closely.", "source": "Octreotide + Penbutolol"}, {"id": "Octreotide_INT_Nebivolol", "text": "Interaction: Octreotide AND Nebivolol\nDetails: Octreotide may increase the bradycardic activities of Nebivolol.\nRisk: Monitor closely.", "source": "Octreotide + Nebivolol"}, {"id": "Octreotide_INT_Lucinactant", "text": "Interaction: Octreotide AND Lucinactant\nDetails: Octreotide may increase the bradycardic activities of Lucinactant.\nRisk: Monitor closely.", "source": "Octreotide + Lucinactant"}, {"id": "Octreotide_INT_Calfactant", "text": "Interaction: Octreotide AND Calfactant\nDetails: Octreotide may increase the bradycardic activities of Calfactant.\nRisk: Monitor closely.", "source": "Octreotide + Calfactant"}, {"id": "Octreotide_INT_Beractant", "text": "Interaction: Octreotide AND Beractant\nDetails: Octreotide may increase the bradycardic activities of Beractant.\nRisk: Monitor closely.", "source": "Octreotide + Beractant"}, {"id": "Octreotide_INT_Fingolimod", "text": "Interaction: Octreotide AND Fingolimod\nDetails: Octreotide may increase the bradycardic activities of Fingolimod.\nRisk: Monitor closely.", "source": "Octreotide + Fingolimod"}, {"id": "Octreotide_INT_Poractant alfa", "text": "Interaction: Octreotide AND Poractant alfa\nDetails: Octreotide may increase the bradycardic activities of Poractant alfa.\nRisk: Monitor closely.", "source": "Octreotide + Poractant alfa"}, {"id": "Octreotide_INT_Insulin Pork", "text": "Interaction: Octreotide AND Insulin Pork\nDetails: The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Insulin Pork"}, {"id": "Octreotide_INT_Troglitazone", "text": "Interaction: Octreotide AND Troglitazone\nDetails: The therapeutic efficacy of Troglitazone can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Troglitazone"}, {"id": "Octreotide_INT_Acarbose", "text": "Interaction: Octreotide AND Acarbose\nDetails: The therapeutic efficacy of Acarbose can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Acarbose"}, {"id": "Octreotide_INT_Metformin", "text": "Interaction: Octreotide AND Metformin\nDetails: The therapeutic efficacy of Metformin can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Metformin"}, {"id": "Octreotide_INT_Rosiglitazone", "text": "Interaction: Octreotide AND Rosiglitazone\nDetails: The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Rosiglitazone"}, {"id": "Octreotide_INT_Acetohexamide", "text": "Interaction: Octreotide AND Acetohexamide\nDetails: The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Acetohexamide"}, {"id": "Octreotide_INT_Miglustat", "text": "Interaction: Octreotide AND Miglustat\nDetails: The therapeutic efficacy of Miglustat can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Miglustat"}, {"id": "Octreotide_INT_Miglitol", "text": "Interaction: Octreotide AND Miglitol\nDetails: The therapeutic efficacy of Miglitol can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Miglitol"}, {"id": "Octreotide_INT_Phenformin", "text": "Interaction: Octreotide AND Phenformin\nDetails: The therapeutic efficacy of Phenformin can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Phenformin"}, {"id": "Octreotide_INT_Pioglitazone", "text": "Interaction: Octreotide AND Pioglitazone\nDetails: The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Pioglitazone"}, {"id": "Octreotide_INT_Gliquidone", "text": "Interaction: Octreotide AND Gliquidone\nDetails: The therapeutic efficacy of Gliquidone can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Gliquidone"}, {"id": "Octreotide_INT_Mitiglinide", "text": "Interaction: Octreotide AND Mitiglinide\nDetails: The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Mitiglinide"}, {"id": "Octreotide_INT_Sitagliptin", "text": "Interaction: Octreotide AND Sitagliptin\nDetails: The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Sitagliptin"}, {"id": "Octreotide_INT_Exenatide", "text": "Interaction: Octreotide AND Exenatide\nDetails: The therapeutic efficacy of Exenatide can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Exenatide"}, {"id": "Octreotide_INT_Pramlintide", "text": "Interaction: Octreotide AND Pramlintide\nDetails: The therapeutic efficacy of Pramlintide can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Pramlintide"}, {"id": "Octreotide_INT_AICA ribonucleotide", "text": "Interaction: Octreotide AND AICA ribonucleotide\nDetails: The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + AICA ribonucleotide"}, {"id": "Octreotide_INT_Castanospermine", "text": "Interaction: Octreotide AND Castanospermine\nDetails: The therapeutic efficacy of Castanospermine can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Castanospermine"}, {"id": "Octreotide_INT_Buformin", "text": "Interaction: Octreotide AND Buformin\nDetails: The therapeutic efficacy of Buformin can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Buformin"}, {"id": "Octreotide_INT_Vildagliptin", "text": "Interaction: Octreotide AND Vildagliptin\nDetails: The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Vildagliptin"}, {"id": "Octreotide_INT_Voglibose", "text": "Interaction: Octreotide AND Voglibose\nDetails: The therapeutic efficacy of Voglibose can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Voglibose"}, {"id": "Octreotide_INT_Alogliptin", "text": "Interaction: Octreotide AND Alogliptin\nDetails: The therapeutic efficacy of Alogliptin can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Alogliptin"}, {"id": "Octreotide_INT_Sulodexide", "text": "Interaction: Octreotide AND Sulodexide\nDetails: The therapeutic efficacy of Sulodexide can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Sulodexide"}, {"id": "Octreotide_INT_Saxagliptin", "text": "Interaction: Octreotide AND Saxagliptin\nDetails: The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Saxagliptin"}, {"id": "Octreotide_INT_Liraglutide", "text": "Interaction: Octreotide AND Liraglutide\nDetails: The therapeutic efficacy of Liraglutide can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Liraglutide"}, {"id": "Octreotide_INT_Linagliptin", "text": "Interaction: Octreotide AND Linagliptin\nDetails: The therapeutic efficacy of Linagliptin can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Linagliptin"}, {"id": "Octreotide_INT_Canagliflozin", "text": "Interaction: Octreotide AND Canagliflozin\nDetails: The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Canagliflozin"}, {"id": "Octreotide_INT_Glibornuride", "text": "Interaction: Octreotide AND Glibornuride\nDetails: The therapeutic efficacy of Glibornuride can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Glibornuride"}, {"id": "Octreotide_INT_Empagliflozin", "text": "Interaction: Octreotide AND Empagliflozin\nDetails: The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Empagliflozin"}, {"id": "Octreotide_INT_Dulaglutide", "text": "Interaction: Octreotide AND Dulaglutide\nDetails: The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Dulaglutide"}, {"id": "Octreotide_INT_Ciglitazone", "text": "Interaction: Octreotide AND Ciglitazone\nDetails: The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Ciglitazone"}, {"id": "Octreotide_INT_Allicin", "text": "Interaction: Octreotide AND Allicin\nDetails: The therapeutic efficacy of Allicin can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Allicin"}, {"id": "Octreotide_INT_2,4-thiazolidinedione", "text": "Interaction: Octreotide AND 2,4-thiazolidinedione\nDetails: The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + 2,4-thiazolidinedione"}, {"id": "Octreotide_INT_Bempedoic acid", "text": "Interaction: Octreotide AND Bempedoic acid\nDetails: The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Bempedoic acid"}, {"id": "Octreotide_INT_Gusperimus", "text": "Interaction: Octreotide AND Gusperimus\nDetails: The therapeutic efficacy of Gusperimus can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Gusperimus"}, {"id": "Octreotide_INT_Sotagliflozin", "text": "Interaction: Octreotide AND Sotagliflozin\nDetails: The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Sotagliflozin"}, {"id": "Octreotide_INT_Balaglitazone", "text": "Interaction: Octreotide AND Balaglitazone\nDetails: The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Balaglitazone"}, {"id": "Octreotide_INT_Deoxyspergualin", "text": "Interaction: Octreotide AND Deoxyspergualin\nDetails: The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Deoxyspergualin"}, {"id": "Octreotide_INT_Carbutamide", "text": "Interaction: Octreotide AND Carbutamide\nDetails: The therapeutic efficacy of Carbutamide can be decreased when used in combination with Octreotide.\nRisk: Monitor closely.", "source": "Octreotide + Carbutamide"}, {"id": "Interferon Alfa-2b, Recombinant_GEN", "text": "Drug: Interferon Alfa-2b, Recombinant\nDescription: Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an ...", "source": "Interferon Alfa-2b, Recombinant"}, {"id": "Interferon Alfa-2b, Recombinant_CLIN", "text": "Drug: Interferon Alfa-2b, Recombinant\nMechanism: Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which upon dimerization activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves...\nToxicity: There is limited experience with overdosage. Postmarketing surveillance includes reports of patients receiving a single dose as great as 10 times the recommended dose. In general, the primary effects ...", "source": "Interferon Alfa-2b, Recombinant"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Telbivudine", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Telbivudine\nDetails: The risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Telbivudine.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Telbivudine"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Trastuzumab", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Trastuzumab"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Aldesleukin", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Aldesleukin\nDetails: The risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Aldesleukin.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Aldesleukin"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Tizanidine", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Tizanidine\nDetails: The serum concentration of Tizanidine can be increased when it is combined with Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Tizanidine"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Paclitaxel", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Paclitaxel"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Docetaxel", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Docetaxel"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Cabazitaxel", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Cabazitaxel"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Digoxin", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Digoxin"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Acetyldigitoxin", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Acetyldigitoxin"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Deslanoside", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Deslanoside"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Ouabain", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Ouabain"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Digitoxin", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Digitoxin"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Cymarin", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Cymarin"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Proscillaridin", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Proscillaridin"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Metildigoxin", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Metildigoxin"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Peruvoside", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Peruvoside"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Lanatoside C", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Lanatoside C"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Gitoformate", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Gitoformate"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Acetyldigoxin", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Acetyldigoxin"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Oleandrin", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Oleandrin"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Digoxin Immune Fab (Ovine)"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Bevacizumab", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Bevacizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Bevacizumab"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Cyclophosphamide", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Cyclophosphamide\nDetails: Cyclophosphamide may increase the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Cyclophosphamide"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Ambroxol acefyllinate", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Ambroxol acefyllinate\nDetails: The metabolism of Ambroxol acefyllinate can be decreased when combined with Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Ambroxol acefyllinate"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Theophylline", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Theophylline\nDetails: The metabolism of Theophylline can be decreased when combined with Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Theophylline"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Dyphylline", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Dyphylline\nDetails: The metabolism of Dyphylline can be decreased when combined with Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Dyphylline"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Aminophylline", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Aminophylline\nDetails: The metabolism of Aminophylline can be decreased when combined with Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Aminophylline"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Methadone", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Methadone\nDetails: The serum concentration of Methadone can be increased when it is combined with Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Methadone"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Ribavirin", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Ribavirin\nDetails: The risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Ribavirin.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Ribavirin"}, {"id": "Interferon Alfa-2b, Recombinant_INT_Zidovudine", "text": "Interaction: Interferon Alfa-2b, Recombinant AND Zidovudine\nDetails: The risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Zidovudine.\nRisk: Monitor closely.", "source": "Interferon Alfa-2b, Recombinant + Zidovudine"}, {"id": "Abarelix_GEN", "text": "Drug: Abarelix\nDescription: Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market....", "source": "Abarelix"}, {"id": "Abarelix_CLIN", "text": "Drug: Abarelix\nMechanism: Abarelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion....\nToxicity: The maximum tolerated dose of abarelix has not been determined. The maximum dose used in clinical studies was 150 mg. There have been no reports of accidental overdose with abarelix....", "source": "Abarelix"}, {"id": "Oxytocin_GEN", "text": "Drug: Oxytocin\nDescription: Synthetic 9 residue cyclic peptide. The hormone is prepared synthetically to avoid possible contamination with vasopressin (ADH) and other small polypeptides with biologic activity....", "source": "Oxytocin"}, {"id": "Oxytocin_CLIN", "text": "Drug: Oxytocin\nMechanism: Uterine motility depends on the formation of the contractile protein actomyosin under the influence of the Ca2+-dependent phosphorylating enzyme myosin light-chain kinase. Oxytocin promotes contractio...\nToxicity: Oxytocin can produce a severe water intoxication due to its antidiuretic effect. Prolonged IV infusions of more 40milliunits/min are usually the cause. Severe water intoxication with convulsions, coma...", "source": "Oxytocin"}, {"id": "Oxytocin_INT_Carboprost Tromethamine", "text": "Interaction: Oxytocin AND Carboprost Tromethamine\nDetails: The risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Oxytocin.\nRisk: Monitor closely.", "source": "Oxytocin + Carboprost Tromethamine"}, {"id": "Oxytocin_INT_Mifepristone", "text": "Interaction: Oxytocin AND Mifepristone\nDetails: Mifepristone may increase the QTc-prolonging activities of Oxytocin.\nRisk: Monitor closely.", "source": "Oxytocin + Mifepristone"}, {"id": "Oxytocin_INT_Dinoprostone", "text": "Interaction: Oxytocin AND Dinoprostone\nDetails: The risk or severity of adverse effects can be increased when Dinoprostone is combined with Oxytocin.\nRisk: Monitor closely.", "source": "Oxytocin + Dinoprostone"}, {"id": "Oxytocin_INT_Misoprostol", "text": "Interaction: Oxytocin AND Misoprostol\nDetails: The risk or severity of adverse effects can be increased when Misoprostol is combined with Oxytocin.\nRisk: Monitor closely.", "source": "Oxytocin + Misoprostol"}, {"id": "Oxytocin_INT_Dofetilide", "text": "Interaction: Oxytocin AND Dofetilide\nDetails: Oxytocin may increase the QTc-prolonging activities of Dofetilide.\nRisk: Monitor closely.", "source": "Oxytocin + Dofetilide"}, {"id": "Oxytocin_INT_Citalopram", "text": "Interaction: Oxytocin AND Citalopram\nDetails: Oxytocin may increase the QTc-prolonging activities of Citalopram.\nRisk: Monitor closely.", "source": "Oxytocin + Citalopram"}, {"id": "Oxytocin_INT_Ziprasidone", "text": "Interaction: Oxytocin AND Ziprasidone\nDetails: Oxytocin may increase the QTc-prolonging activities of Ziprasidone.\nRisk: Monitor closely.", "source": "Oxytocin + Ziprasidone"}, {"id": "Oxytocin_INT_Anagrelide", "text": "Interaction: Oxytocin AND Anagrelide\nDetails: Oxytocin may increase the QTc-prolonging activities of Anagrelide.\nRisk: Monitor closely.", "source": "Oxytocin + Anagrelide"}, {"id": "Oxytocin_INT_Disopyramide", "text": "Interaction: Oxytocin AND Disopyramide\nDetails: Oxytocin may increase the QTc-prolonging activities of Disopyramide.\nRisk: Monitor closely.", "source": "Oxytocin + Disopyramide"}, {"id": "Oxytocin_INT_Ibutilide", "text": "Interaction: Oxytocin AND Ibutilide\nDetails: Oxytocin may increase the QTc-prolonging activities of Ibutilide.\nRisk: Monitor closely.", "source": "Oxytocin + Ibutilide"}, {"id": "Oxytocin_INT_Quinine", "text": "Interaction: Oxytocin AND Quinine\nDetails: Oxytocin may increase the QTc-prolonging activities of Quinine.\nRisk: Monitor closely.", "source": "Oxytocin + Quinine"}, {"id": "Oxytocin_INT_Fluoxetine", "text": "Interaction: Oxytocin AND Fluoxetine\nDetails: Oxytocin may increase the QTc-prolonging activities of Fluoxetine.\nRisk: Monitor closely.", "source": "Oxytocin + Fluoxetine"}, {"id": "Oxytocin_INT_Sotalol", "text": "Interaction: Oxytocin AND Sotalol\nDetails: Oxytocin may increase the QTc-prolonging activities of Sotalol.\nRisk: Monitor closely.", "source": "Oxytocin + Sotalol"}, {"id": "Oxytocin_INT_Toremifene", "text": "Interaction: Oxytocin AND Toremifene\nDetails: Oxytocin may increase the QTc-prolonging activities of Toremifene.\nRisk: Monitor closely.", "source": "Oxytocin + Toremifene"}, {"id": "Oxytocin_INT_Cisapride", "text": "Interaction: Oxytocin AND Cisapride\nDetails: Oxytocin may increase the QTc-prolonging activities of Cisapride.\nRisk: Monitor closely.", "source": "Oxytocin + Cisapride"}, {"id": "Oxytocin_INT_Thioridazine", "text": "Interaction: Oxytocin AND Thioridazine\nDetails: Oxytocin may increase the QTc-prolonging activities of Thioridazine.\nRisk: Monitor closely.", "source": "Oxytocin + Thioridazine"}, {"id": "Oxytocin_INT_Flupentixol", "text": "Interaction: Oxytocin AND Flupentixol\nDetails: Oxytocin may increase the QTc-prolonging activities of Flupentixol.\nRisk: Monitor closely.", "source": "Oxytocin + Flupentixol"}, {"id": "Oxytocin_INT_Quinidine", "text": "Interaction: Oxytocin AND Quinidine\nDetails: Oxytocin may increase the QTc-prolonging activities of Quinidine.\nRisk: Monitor closely.", "source": "Oxytocin + Quinidine"}, {"id": "Oxytocin_INT_Procainamide", "text": "Interaction: Oxytocin AND Procainamide\nDetails: Oxytocin may increase the QTc-prolonging activities of Procainamide.\nRisk: Monitor closely.", "source": "Oxytocin + Procainamide"}, {"id": "Oxytocin_INT_Pimozide", "text": "Interaction: Oxytocin AND Pimozide\nDetails: Oxytocin may increase the QTc-prolonging activities of Pimozide.\nRisk: Monitor closely.", "source": "Oxytocin + Pimozide"}, {"id": "Oxytocin_INT_Amiodarone", "text": "Interaction: Oxytocin AND Amiodarone\nDetails: Oxytocin may increase the QTc-prolonging activities of Amiodarone.\nRisk: Monitor closely.", "source": "Oxytocin + Amiodarone"}, {"id": "Oxytocin_INT_Arsenic trioxide", "text": "Interaction: Oxytocin AND Arsenic trioxide\nDetails: Oxytocin may increase the QTc-prolonging activities of Arsenic trioxide.\nRisk: Monitor closely.", "source": "Oxytocin + Arsenic trioxide"}, {"id": "Oxytocin_INT_Escitalopram", "text": "Interaction: Oxytocin AND Escitalopram\nDetails: Oxytocin may increase the QTc-prolonging activities of Escitalopram.\nRisk: Monitor closely.", "source": "Oxytocin + Escitalopram"}, {"id": "Oxytocin_INT_Domperidone", "text": "Interaction: Oxytocin AND Domperidone\nDetails: Oxytocin may increase the QTc-prolonging activities of Domperidone.\nRisk: Monitor closely.", "source": "Oxytocin + Domperidone"}, {"id": "Oxytocin_INT_Quetiapine", "text": "Interaction: Oxytocin AND Quetiapine\nDetails: Oxytocin may increase the QTc-prolonging activities of Quetiapine.\nRisk: Monitor closely.", "source": "Oxytocin + Quetiapine"}, {"id": "Oxytocin_INT_Paliperidone", "text": "Interaction: Oxytocin AND Paliperidone\nDetails: Oxytocin may increase the QTc-prolonging activities of Paliperidone.\nRisk: Monitor closely.", "source": "Oxytocin + Paliperidone"}, {"id": "Oxytocin_INT_Lopinavir", "text": "Interaction: Oxytocin AND Lopinavir\nDetails: Oxytocin may increase the QTc-prolonging activities of Lopinavir.\nRisk: Monitor closely.", "source": "Oxytocin + Lopinavir"}, {"id": "Oxytocin_INT_Zuclopenthixol", "text": "Interaction: Oxytocin AND Zuclopenthixol\nDetails: Oxytocin may increase the QTc-prolonging activities of Zuclopenthixol.\nRisk: Monitor closely.", "source": "Oxytocin + Zuclopenthixol"}, {"id": "Oxytocin_INT_Tetrabenazine", "text": "Interaction: Oxytocin AND Tetrabenazine\nDetails: Oxytocin may increase the QTc-prolonging activities of Tetrabenazine.\nRisk: Monitor closely.", "source": "Oxytocin + Tetrabenazine"}, {"id": "Oxytocin_INT_Dronedarone", "text": "Interaction: Oxytocin AND Dronedarone\nDetails: Oxytocin may increase the QTc-prolonging activities of Dronedarone.\nRisk: Monitor closely.", "source": "Oxytocin + Dronedarone"}, {"id": "Oxytocin_INT_Nilotinib", "text": "Interaction: Oxytocin AND Nilotinib\nDetails: Oxytocin may increase the QTc-prolonging activities of Nilotinib.\nRisk: Monitor closely.", "source": "Oxytocin + Nilotinib"}, {"id": "Oxytocin_INT_Iloperidone", "text": "Interaction: Oxytocin AND Iloperidone\nDetails: Oxytocin may increase the QTc-prolonging activities of Iloperidone.\nRisk: Monitor closely.", "source": "Oxytocin + Iloperidone"}, {"id": "Oxytocin_INT_Vandetanib", "text": "Interaction: Oxytocin AND Vandetanib\nDetails: Oxytocin may increase the QTc-prolonging activities of Vandetanib.\nRisk: Monitor closely.", "source": "Oxytocin + Vandetanib"}, {"id": "Oxytocin_INT_Asenapine", "text": "Interaction: Oxytocin AND Asenapine\nDetails: Oxytocin may increase the QTc-prolonging activities of Asenapine.\nRisk: Monitor closely.", "source": "Oxytocin + Asenapine"}, {"id": "Oxytocin_INT_Artemether", "text": "Interaction: Oxytocin AND Artemether\nDetails: Oxytocin may increase the QTc-prolonging activities of Artemether.\nRisk: Monitor closely.", "source": "Oxytocin + Artemether"}, {"id": "Oxytocin_INT_Lumefantrine", "text": "Interaction: Oxytocin AND Lumefantrine\nDetails: Oxytocin may increase the QTc-prolonging activities of Lumefantrine.\nRisk: Monitor closely.", "source": "Oxytocin + Lumefantrine"}, {"id": "Oxytocin_INT_Vemurafenib", "text": "Interaction: Oxytocin AND Vemurafenib\nDetails: Oxytocin may increase the QTc-prolonging activities of Vemurafenib.\nRisk: Monitor closely.", "source": "Oxytocin + Vemurafenib"}, {"id": "Oxytocin_INT_Eliglustat", "text": "Interaction: Oxytocin AND Eliglustat\nDetails: Oxytocin may increase the QTc-prolonging activities of Eliglustat.\nRisk: Monitor closely.", "source": "Oxytocin + Eliglustat"}, {"id": "Oxytocin_INT_Leuprolide", "text": "Interaction: Oxytocin AND Leuprolide\nDetails: Oxytocin may increase the QTc-prolonging activities of Leuprolide.\nRisk: Monitor closely.", "source": "Oxytocin + Leuprolide"}, {"id": "Oxytocin_INT_Goserelin", "text": "Interaction: Oxytocin AND Goserelin\nDetails: Oxytocin may increase the QTc-prolonging activities of Goserelin.\nRisk: Monitor closely.", "source": "Oxytocin + Goserelin"}, {"id": "Oxytocin_INT_Erythromycin", "text": "Interaction: Oxytocin AND Erythromycin\nDetails: Oxytocin may increase the QTc-prolonging activities of Erythromycin.\nRisk: Monitor closely.", "source": "Oxytocin + Erythromycin"}, {"id": "Oxytocin_INT_Azithromycin", "text": "Interaction: Oxytocin AND Azithromycin\nDetails: Oxytocin may increase the QTc-prolonging activities of Azithromycin.\nRisk: Monitor closely.", "source": "Oxytocin + Azithromycin"}, {"id": "Oxytocin_INT_Moxifloxacin", "text": "Interaction: Oxytocin AND Moxifloxacin\nDetails: Oxytocin may increase the QTc-prolonging activities of Moxifloxacin.\nRisk: Monitor closely.", "source": "Oxytocin + Moxifloxacin"}, {"id": "Oxytocin_INT_Sulfisoxazole", "text": "Interaction: Oxytocin AND Sulfisoxazole\nDetails: Oxytocin may increase the QTc-prolonging activities of Sulfisoxazole.\nRisk: Monitor closely.", "source": "Oxytocin + Sulfisoxazole"}, {"id": "Oxytocin_INT_Methadone", "text": "Interaction: Oxytocin AND Methadone\nDetails: Oxytocin may increase the QTc-prolonging activities of Methadone.\nRisk: Monitor closely.", "source": "Oxytocin + Methadone"}, {"id": "Oxytocin_INT_Clozapine", "text": "Interaction: Oxytocin AND Clozapine\nDetails: Oxytocin may increase the QTc-prolonging activities of Clozapine.\nRisk: Monitor closely.", "source": "Oxytocin + Clozapine"}, {"id": "Oxytocin_INT_Promazine", "text": "Interaction: Oxytocin AND Promazine\nDetails: Oxytocin may increase the QTc-prolonging activities of Promazine.\nRisk: Monitor closely.", "source": "Oxytocin + Promazine"}, {"id": "Oxytocin_INT_Droperidol", "text": "Interaction: Oxytocin AND Droperidol\nDetails: Oxytocin may increase the QTc-prolonging activities of Droperidol.\nRisk: Monitor closely.", "source": "Oxytocin + Droperidol"}, {"id": "Oxytocin_INT_Chlorpromazine", "text": "Interaction: Oxytocin AND Chlorpromazine\nDetails: Oxytocin may increase the QTc-prolonging activities of Chlorpromazine.\nRisk: Monitor closely.", "source": "Oxytocin + Chlorpromazine"}, {"id": "Oxytocin_INT_Haloperidol", "text": "Interaction: Oxytocin AND Haloperidol\nDetails: Oxytocin may increase the QTc-prolonging activities of Haloperidol.\nRisk: Monitor closely.", "source": "Oxytocin + Haloperidol"}, {"id": "Oxytocin_INT_Ciprofloxacin", "text": "Interaction: Oxytocin AND Ciprofloxacin\nDetails: Oxytocin may increase the QTc-prolonging activities of Ciprofloxacin.\nRisk: Monitor closely.", "source": "Oxytocin + Ciprofloxacin"}, {"id": "Oxytocin_INT_Perflutren", "text": "Interaction: Oxytocin AND Perflutren\nDetails: Oxytocin may increase the QTc-prolonging activities of Perflutren.\nRisk: Monitor closely.", "source": "Oxytocin + Perflutren"}, {"id": "Oxytocin_INT_Chloroquine", "text": "Interaction: Oxytocin AND Chloroquine\nDetails: Oxytocin may increase the QTc-prolonging activities of Chloroquine.\nRisk: Monitor closely.", "source": "Oxytocin + Chloroquine"}, {"id": "Oxytocin_INT_Pentamidine", "text": "Interaction: Oxytocin AND Pentamidine\nDetails: Oxytocin may increase the QTc-prolonging activities of Pentamidine.\nRisk: Monitor closely.", "source": "Oxytocin + Pentamidine"}, {"id": "Oxytocin_INT_Gadobenic acid", "text": "Interaction: Oxytocin AND Gadobenic acid\nDetails: Oxytocin may increase the QTc-prolonging activities of Gadobenic acid.\nRisk: Monitor closely.", "source": "Oxytocin + Gadobenic acid"}, {"id": "Oxytocin_INT_Dolasetron", "text": "Interaction: Oxytocin AND Dolasetron\nDetails: Oxytocin may increase the QTc-prolonging activities of Dolasetron.\nRisk: Monitor closely.", "source": "Oxytocin + Dolasetron"}, {"id": "Oxytocin_INT_Granisetron", "text": "Interaction: Oxytocin AND Granisetron\nDetails: Oxytocin may increase the QTc-prolonging activities of Granisetron.\nRisk: Monitor closely.", "source": "Oxytocin + Granisetron"}, {"id": "Oxytocin_INT_Ondansetron", "text": "Interaction: Oxytocin AND Ondansetron\nDetails: Oxytocin may increase the QTc-prolonging activities of Ondansetron.\nRisk: Monitor closely.", "source": "Oxytocin + Ondansetron"}, {"id": "Oxytocin_INT_Telithromycin", "text": "Interaction: Oxytocin AND Telithromycin\nDetails: Oxytocin may increase the QTc-prolonging activities of Telithromycin.\nRisk: Monitor closely.", "source": "Oxytocin + Telithromycin"}, {"id": "Oxytocin_INT_Primaquine", "text": "Interaction: Oxytocin AND Primaquine\nDetails: Oxytocin may increase the QTc-prolonging activities of Primaquine.\nRisk: Monitor closely.", "source": "Oxytocin + Primaquine"}, {"id": "Oxytocin_INT_Levofloxacin", "text": "Interaction: Oxytocin AND Levofloxacin\nDetails: Oxytocin may increase the QTc-prolonging activities of Levofloxacin.\nRisk: Monitor closely.", "source": "Oxytocin + Levofloxacin"}, {"id": "Oxytocin_INT_Gemifloxacin", "text": "Interaction: Oxytocin AND Gemifloxacin\nDetails: Oxytocin may increase the QTc-prolonging activities of Gemifloxacin.\nRisk: Monitor closely.", "source": "Oxytocin + Gemifloxacin"}, {"id": "Oxytocin_INT_Ofloxacin", "text": "Interaction: Oxytocin AND Ofloxacin\nDetails: Oxytocin may increase the QTc-prolonging activities of Ofloxacin.\nRisk: Monitor closely.", "source": "Oxytocin + Ofloxacin"}, {"id": "Oxytocin_INT_Propafenone", "text": "Interaction: Oxytocin AND Propafenone\nDetails: Oxytocin may increase the QTc-prolonging activities of Propafenone.\nRisk: Monitor closely.", "source": "Oxytocin + Propafenone"}, {"id": "Oxytocin_INT_Flecainide", "text": "Interaction: Oxytocin AND Flecainide\nDetails: Oxytocin may increase the QTc-prolonging activities of Flecainide.\nRisk: Monitor closely.", "source": "Oxytocin + Flecainide"}, {"id": "Oxytocin_INT_Clarithromycin", "text": "Interaction: Oxytocin AND Clarithromycin\nDetails: Oxytocin may increase the QTc-prolonging activities of Clarithromycin.\nRisk: Monitor closely.", "source": "Oxytocin + Clarithromycin"}, {"id": "Oxytocin_INT_Saquinavir", "text": "Interaction: Oxytocin AND Saquinavir\nDetails: Oxytocin may increase the QTc-prolonging activities of Saquinavir.\nRisk: Monitor closely.", "source": "Oxytocin + Saquinavir"}, {"id": "Oxytocin_INT_Telavancin", "text": "Interaction: Oxytocin AND Telavancin\nDetails: Oxytocin may increase the QTc-prolonging activities of Telavancin.\nRisk: Monitor closely.", "source": "Oxytocin + Telavancin"}, {"id": "Oxytocin_INT_Pazopanib", "text": "Interaction: Oxytocin AND Pazopanib\nDetails: Oxytocin may increase the QTc-prolonging activities of Pazopanib.\nRisk: Monitor closely.", "source": "Oxytocin + Pazopanib"}, {"id": "Oxytocin_INT_Panobinostat", "text": "Interaction: Oxytocin AND Panobinostat\nDetails: Oxytocin may increase the QTc-prolonging activities of Panobinostat.\nRisk: Monitor closely.", "source": "Oxytocin + Panobinostat"}, {"id": "Oxytocin_INT_Crizotinib", "text": "Interaction: Oxytocin AND Crizotinib\nDetails: Oxytocin may increase the QTc-prolonging activities of Crizotinib.\nRisk: Monitor closely.", "source": "Oxytocin + Crizotinib"}, {"id": "Oxytocin_INT_Bedaquiline", "text": "Interaction: Oxytocin AND Bedaquiline\nDetails: Oxytocin may increase the QTc-prolonging activities of Bedaquiline.\nRisk: Monitor closely.", "source": "Oxytocin + Bedaquiline"}, {"id": "Oxytocin_INT_Ceritinib", "text": "Interaction: Oxytocin AND Ceritinib\nDetails: Oxytocin may increase the QTc-prolonging activities of Ceritinib.\nRisk: Monitor closely.", "source": "Oxytocin + Ceritinib"}, {"id": "Oxytocin_INT_Lenvatinib", "text": "Interaction: Oxytocin AND Lenvatinib\nDetails: Oxytocin may increase the QTc-prolonging activities of Lenvatinib.\nRisk: Monitor closely.", "source": "Oxytocin + Lenvatinib"}, {"id": "Natalizumab_GEN", "text": "Drug: Natalizumab\nDescription: Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifo...", "source": "Natalizumab"}, {"id": "Natalizumab_CLIN", "text": "Drug: Natalizumab\nMechanism: Binds to the &alpha;4-subunit of &alpha;4b 1 and &alpha;4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the &alpha;4-mediated adhesion of leukocytes to their...\nToxicity: ...", "source": "Natalizumab"}, {"id": "Natalizumab_INT_Vedolizumab", "text": "Interaction: Natalizumab AND Vedolizumab\nDetails: The risk or severity of adverse effects can be increased when Vedolizumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Vedolizumab"}, {"id": "Natalizumab_INT_Etanercept", "text": "Interaction: Natalizumab AND Etanercept\nDetails: The risk or severity of adverse effects can be increased when Etanercept is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Etanercept"}, {"id": "Natalizumab_INT_Basiliximab", "text": "Interaction: Natalizumab AND Basiliximab\nDetails: The risk or severity of adverse effects can be increased when Basiliximab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Basiliximab"}, {"id": "Natalizumab_INT_Muromonab", "text": "Interaction: Natalizumab AND Muromonab\nDetails: The risk or severity of adverse effects can be increased when Muromonab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Muromonab"}, {"id": "Natalizumab_INT_Cyclosporine", "text": "Interaction: Natalizumab AND Cyclosporine\nDetails: The risk or severity of adverse effects can be increased when Cyclosporine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Cyclosporine"}, {"id": "Natalizumab_INT_Daclizumab", "text": "Interaction: Natalizumab AND Daclizumab\nDetails: The risk or severity of adverse effects can be increased when Daclizumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Daclizumab"}, {"id": "Natalizumab_INT_Cladribine", "text": "Interaction: Natalizumab AND Cladribine\nDetails: The risk or severity of adverse effects can be increased when Cladribine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Cladribine"}, {"id": "Natalizumab_INT_Gemcitabine", "text": "Interaction: Natalizumab AND Gemcitabine\nDetails: The risk or severity of adverse effects can be increased when Gemcitabine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Gemcitabine"}, {"id": "Natalizumab_INT_Cyclophosphamide", "text": "Interaction: Natalizumab AND Cyclophosphamide\nDetails: The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Cyclophosphamide"}, {"id": "Natalizumab_INT_Fluorouracil", "text": "Interaction: Natalizumab AND Fluorouracil\nDetails: The risk or severity of adverse effects can be increased when Fluorouracil is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Fluorouracil"}, {"id": "Natalizumab_INT_Methotrexate", "text": "Interaction: Natalizumab AND Methotrexate\nDetails: The risk or severity of adverse effects can be increased when Methotrexate is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Methotrexate"}, {"id": "Natalizumab_INT_Triamcinolone", "text": "Interaction: Natalizumab AND Triamcinolone\nDetails: The risk or severity of adverse effects can be increased when Triamcinolone is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Triamcinolone"}, {"id": "Natalizumab_INT_Mycophenolate mofetil", "text": "Interaction: Natalizumab AND Mycophenolate mofetil\nDetails: The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Mycophenolate mofetil"}, {"id": "Natalizumab_INT_Tacrolimus", "text": "Interaction: Natalizumab AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Tacrolimus"}, {"id": "Natalizumab_INT_Sirolimus", "text": "Interaction: Natalizumab AND Sirolimus\nDetails: The risk or severity of adverse effects can be increased when Sirolimus is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Sirolimus"}, {"id": "Natalizumab_INT_Cytarabine", "text": "Interaction: Natalizumab AND Cytarabine\nDetails: The risk or severity of adverse effects can be increased when Cytarabine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Cytarabine"}, {"id": "Natalizumab_INT_Azathioprine", "text": "Interaction: Natalizumab AND Azathioprine\nDetails: The risk or severity of adverse effects can be increased when Azathioprine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Azathioprine"}, {"id": "Natalizumab_INT_Busulfan", "text": "Interaction: Natalizumab AND Busulfan\nDetails: The risk or severity of adverse effects can be increased when Busulfan is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Busulfan"}, {"id": "Natalizumab_INT_Mycophenolic acid", "text": "Interaction: Natalizumab AND Mycophenolic acid\nDetails: The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Mycophenolic acid"}, {"id": "Natalizumab_INT_Mercaptopurine", "text": "Interaction: Natalizumab AND Mercaptopurine\nDetails: The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Mercaptopurine"}, {"id": "Natalizumab_INT_Thalidomide", "text": "Interaction: Natalizumab AND Thalidomide\nDetails: The risk or severity of adverse effects can be increased when Thalidomide is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Thalidomide"}, {"id": "Natalizumab_INT_Melphalan", "text": "Interaction: Natalizumab AND Melphalan\nDetails: The risk or severity of adverse effects can be increased when Melphalan is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Melphalan"}, {"id": "Natalizumab_INT_Fludarabine", "text": "Interaction: Natalizumab AND Fludarabine\nDetails: The risk or severity of adverse effects can be increased when Fludarabine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Fludarabine"}, {"id": "Natalizumab_INT_Abatacept", "text": "Interaction: Natalizumab AND Abatacept\nDetails: The risk or severity of adverse effects can be increased when Abatacept is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Abatacept"}, {"id": "Natalizumab_INT_Everolimus", "text": "Interaction: Natalizumab AND Everolimus\nDetails: The risk or severity of adverse effects can be increased when Everolimus is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Everolimus"}, {"id": "Natalizumab_INT_Belatacept", "text": "Interaction: Natalizumab AND Belatacept\nDetails: The risk or severity of adverse effects can be increased when Belatacept is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Belatacept"}, {"id": "Natalizumab_INT_Belimumab", "text": "Interaction: Natalizumab AND Belimumab\nDetails: The risk or severity of adverse effects can be increased when Belimumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Belimumab"}, {"id": "Natalizumab_INT_Teriflunomide", "text": "Interaction: Natalizumab AND Teriflunomide\nDetails: The risk or severity of adverse effects can be increased when Teriflunomide is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Teriflunomide"}, {"id": "Natalizumab_INT_Certolizumab pegol", "text": "Interaction: Natalizumab AND Certolizumab pegol\nDetails: The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Certolizumab pegol"}, {"id": "Natalizumab_INT_Anakinra", "text": "Interaction: Natalizumab AND Anakinra\nDetails: The risk or severity of adverse effects can be increased when Anakinra is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Anakinra"}, {"id": "Natalizumab_INT_Adalimumab", "text": "Interaction: Natalizumab AND Adalimumab\nDetails: The risk or severity of adverse effects can be increased when Adalimumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Adalimumab"}, {"id": "Natalizumab_INT_Infliximab", "text": "Interaction: Natalizumab AND Infliximab\nDetails: The risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Infliximab"}, {"id": "Natalizumab_INT_Alemtuzumab", "text": "Interaction: Natalizumab AND Alemtuzumab\nDetails: The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Alemtuzumab"}, {"id": "Natalizumab_INT_Lenalidomide", "text": "Interaction: Natalizumab AND Lenalidomide\nDetails: The risk or severity of adverse effects can be increased when Lenalidomide is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Lenalidomide"}, {"id": "Natalizumab_INT_Eculizumab", "text": "Interaction: Natalizumab AND Eculizumab\nDetails: The risk or severity of adverse effects can be increased when Eculizumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Eculizumab"}, {"id": "Natalizumab_INT_Ustekinumab", "text": "Interaction: Natalizumab AND Ustekinumab\nDetails: The risk or severity of adverse effects can be increased when Ustekinumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Ustekinumab"}, {"id": "Natalizumab_INT_Canakinumab", "text": "Interaction: Natalizumab AND Canakinumab\nDetails: The risk or severity of adverse effects can be increased when Canakinumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Canakinumab"}, {"id": "Natalizumab_INT_Tocilizumab", "text": "Interaction: Natalizumab AND Tocilizumab\nDetails: The risk or severity of adverse effects can be increased when Tocilizumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Tocilizumab"}, {"id": "Natalizumab_INT_Rilonacept", "text": "Interaction: Natalizumab AND Rilonacept\nDetails: The risk or severity of adverse effects can be increased when Rilonacept is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Rilonacept"}, {"id": "Natalizumab_INT_Golimumab", "text": "Interaction: Natalizumab AND Golimumab\nDetails: The risk or severity of adverse effects can be increased when Golimumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Golimumab"}, {"id": "Natalizumab_INT_Tofacitinib", "text": "Interaction: Natalizumab AND Tofacitinib\nDetails: The risk or severity of adverse effects can be increased when Tofacitinib is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Tofacitinib"}, {"id": "Natalizumab_INT_Pomalidomide", "text": "Interaction: Natalizumab AND Pomalidomide\nDetails: The risk or severity of adverse effects can be increased when Pomalidomide is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Pomalidomide"}, {"id": "Natalizumab_INT_Secukinumab", "text": "Interaction: Natalizumab AND Secukinumab\nDetails: The risk or severity of adverse effects can be increased when Secukinumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Secukinumab"}, {"id": "Natalizumab_INT_Siltuximab", "text": "Interaction: Natalizumab AND Siltuximab\nDetails: The risk or severity of adverse effects can be increased when Siltuximab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Siltuximab"}, {"id": "Natalizumab_INT_Gusperimus", "text": "Interaction: Natalizumab AND Gusperimus\nDetails: The risk or severity of adverse effects can be increased when Gusperimus is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Gusperimus"}, {"id": "Natalizumab_INT_Voclosporin", "text": "Interaction: Natalizumab AND Voclosporin\nDetails: The risk or severity of adverse effects can be increased when Voclosporin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Voclosporin"}, {"id": "Natalizumab_INT_Antithymocyte immunoglobulin (rabbit)", "text": "Interaction: Natalizumab AND Antithymocyte immunoglobulin (rabbit)\nDetails: The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Antithymocyte immunoglobulin (rabbit)"}, {"id": "Natalizumab_INT_Antilymphocyte immunoglobulin (horse)", "text": "Interaction: Natalizumab AND Antilymphocyte immunoglobulin (horse)\nDetails: The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Antilymphocyte immunoglobulin (horse)"}, {"id": "Natalizumab_INT_Mepolizumab", "text": "Interaction: Natalizumab AND Mepolizumab\nDetails: The risk or severity of adverse effects can be increased when Mepolizumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Mepolizumab"}, {"id": "Natalizumab_INT_Thiotepa", "text": "Interaction: Natalizumab AND Thiotepa\nDetails: The risk or severity of adverse effects can be increased when Thiotepa is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Thiotepa"}, {"id": "Natalizumab_INT_Glatiramer Acetate", "text": "Interaction: Natalizumab AND Glatiramer Acetate\nDetails: The risk or severity of adverse effects can be increased when Glatiramer Acetate is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Glatiramer Acetate"}, {"id": "Natalizumab_INT_Glimepiride", "text": "Interaction: Natalizumab AND Glimepiride\nDetails: The risk or severity of adverse effects can be increased when Glimepiride is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Glimepiride"}, {"id": "Natalizumab_INT_Pimecrolimus", "text": "Interaction: Natalizumab AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Pimecrolimus"}, {"id": "Natalizumab_INT_Stepronin", "text": "Interaction: Natalizumab AND Stepronin\nDetails: The risk or severity of adverse effects can be increased when Stepronin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Stepronin"}, {"id": "Natalizumab_INT_Castanospermine", "text": "Interaction: Natalizumab AND Castanospermine\nDetails: The risk or severity of adverse effects can be increased when Castanospermine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Castanospermine"}, {"id": "Natalizumab_INT_2-Methoxyethanol", "text": "Interaction: Natalizumab AND 2-Methoxyethanol\nDetails: The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + 2-Methoxyethanol"}, {"id": "Natalizumab_INT_Seocalcitol", "text": "Interaction: Natalizumab AND Seocalcitol\nDetails: The risk or severity of adverse effects can be increased when Seocalcitol is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Seocalcitol"}, {"id": "Natalizumab_INT_Gallium nitrate", "text": "Interaction: Natalizumab AND Gallium nitrate\nDetails: The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Gallium nitrate"}, {"id": "Natalizumab_INT_Icatibant", "text": "Interaction: Natalizumab AND Icatibant\nDetails: The risk or severity of adverse effects can be increased when Icatibant is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Icatibant"}, {"id": "Natalizumab_INT_Alicaforsen", "text": "Interaction: Natalizumab AND Alicaforsen\nDetails: The risk or severity of adverse effects can be increased when Alicaforsen is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Alicaforsen"}, {"id": "Natalizumab_INT_Human C1-esterase inhibitor", "text": "Interaction: Natalizumab AND Human C1-esterase inhibitor\nDetails: The risk or severity of adverse effects can be increased when Human C1-esterase inhibitor is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Human C1-esterase inhibitor"}, {"id": "Natalizumab_INT_GS 0573", "text": "Interaction: Natalizumab AND GS 0573\nDetails: The risk or severity of adverse effects can be increased when GS 0573 is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + GS 0573"}, {"id": "Natalizumab_INT_Dimethyl fumarate", "text": "Interaction: Natalizumab AND Dimethyl fumarate\nDetails: The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Dimethyl fumarate"}, {"id": "Natalizumab_INT_Tepoxalin", "text": "Interaction: Natalizumab AND Tepoxalin\nDetails: The risk or severity of adverse effects can be increased when Tepoxalin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Tepoxalin"}, {"id": "Natalizumab_INT_Pirarubicin", "text": "Interaction: Natalizumab AND Pirarubicin\nDetails: The risk or severity of adverse effects can be increased when Pirarubicin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Pirarubicin"}, {"id": "Natalizumab_INT_Deflazacort", "text": "Interaction: Natalizumab AND Deflazacort\nDetails: The risk or severity of adverse effects can be increased when Deflazacort is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Deflazacort"}, {"id": "Natalizumab_INT_Benznidazole", "text": "Interaction: Natalizumab AND Benznidazole\nDetails: The risk or severity of adverse effects can be increased when Benznidazole is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Benznidazole"}, {"id": "Natalizumab_INT_Triptolide", "text": "Interaction: Natalizumab AND Triptolide\nDetails: The risk or severity of adverse effects can be increased when Triptolide is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Triptolide"}, {"id": "Natalizumab_INT_Semapimod", "text": "Interaction: Natalizumab AND Semapimod\nDetails: The risk or severity of adverse effects can be increased when Semapimod is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Semapimod"}, {"id": "Natalizumab_INT_Lisofylline", "text": "Interaction: Natalizumab AND Lisofylline\nDetails: The risk or severity of adverse effects can be increased when Lisofylline is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Lisofylline"}, {"id": "Natalizumab_INT_Nafamostat", "text": "Interaction: Natalizumab AND Nafamostat\nDetails: The risk or severity of adverse effects can be increased when Nafamostat is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Nafamostat"}, {"id": "Natalizumab_INT_Mizoribine", "text": "Interaction: Natalizumab AND Mizoribine\nDetails: The risk or severity of adverse effects can be increased when Mizoribine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Mizoribine"}, {"id": "Natalizumab_INT_Trofosfamide", "text": "Interaction: Natalizumab AND Trofosfamide\nDetails: The risk or severity of adverse effects can be increased when Trofosfamide is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Trofosfamide"}, {"id": "Natalizumab_INT_Doxifluridine", "text": "Interaction: Natalizumab AND Doxifluridine\nDetails: The risk or severity of adverse effects can be increased when Doxifluridine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Doxifluridine"}, {"id": "Natalizumab_INT_Deoxyspergualin", "text": "Interaction: Natalizumab AND Deoxyspergualin\nDetails: The risk or severity of adverse effects can be increased when Deoxyspergualin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Deoxyspergualin"}, {"id": "Natalizumab_INT_Acteoside", "text": "Interaction: Natalizumab AND Acteoside\nDetails: The risk or severity of adverse effects can be increased when Acteoside is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Acteoside"}, {"id": "Natalizumab_INT_Hypericin", "text": "Interaction: Natalizumab AND Hypericin\nDetails: The risk or severity of adverse effects can be increased when Hypericin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Hypericin"}, {"id": "Natalizumab_INT_Paquinimod", "text": "Interaction: Natalizumab AND Paquinimod\nDetails: The risk or severity of adverse effects can be increased when Paquinimod is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Paquinimod"}, {"id": "Natalizumab_INT_Adefovir", "text": "Interaction: Natalizumab AND Adefovir\nDetails: The risk or severity of adverse effects can be increased when Adefovir is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Adefovir"}, {"id": "Natalizumab_INT_Alefacept", "text": "Interaction: Natalizumab AND Alefacept\nDetails: The risk or severity of adverse effects can be increased when Alefacept is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Alefacept"}, {"id": "Natalizumab_INT_Efalizumab", "text": "Interaction: Natalizumab AND Efalizumab\nDetails: The risk or severity of adverse effects can be increased when Efalizumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Efalizumab"}, {"id": "Natalizumab_INT_Pirfenidone", "text": "Interaction: Natalizumab AND Pirfenidone\nDetails: The risk or severity of adverse effects can be increased when Pirfenidone is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Pirfenidone"}, {"id": "Natalizumab_INT_Afelimomab", "text": "Interaction: Natalizumab AND Afelimomab\nDetails: The risk or severity of adverse effects can be increased when Afelimomab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Afelimomab"}, {"id": "Natalizumab_INT_Briakinumab", "text": "Interaction: Natalizumab AND Briakinumab\nDetails: The risk or severity of adverse effects can be increased when Briakinumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Briakinumab"}, {"id": "Natalizumab_INT_Apremilast", "text": "Interaction: Natalizumab AND Apremilast\nDetails: The risk or severity of adverse effects can be increased when Apremilast is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Apremilast"}, {"id": "Natalizumab_INT_Abetimus", "text": "Interaction: Natalizumab AND Abetimus\nDetails: The risk or severity of adverse effects can be increased when Abetimus is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Abetimus"}, {"id": "Natalizumab_INT_Brodalumab", "text": "Interaction: Natalizumab AND Brodalumab\nDetails: The risk or severity of adverse effects can be increased when Brodalumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Brodalumab"}, {"id": "Natalizumab_INT_Begelomab", "text": "Interaction: Natalizumab AND Begelomab\nDetails: The risk or severity of adverse effects can be increased when Begelomab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Begelomab"}, {"id": "Natalizumab_INT_Gemtuzumab ozogamicin", "text": "Interaction: Natalizumab AND Gemtuzumab ozogamicin\nDetails: The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Gemtuzumab ozogamicin"}, {"id": "Natalizumab_INT_Pegaspargase", "text": "Interaction: Natalizumab AND Pegaspargase\nDetails: The risk or severity of adverse effects can be increased when Pegaspargase is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Pegaspargase"}, {"id": "Natalizumab_INT_Rituximab", "text": "Interaction: Natalizumab AND Rituximab\nDetails: The risk or severity of adverse effects can be increased when Rituximab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Rituximab"}, {"id": "Natalizumab_INT_Ibritumomab tiuxetan", "text": "Interaction: Natalizumab AND Ibritumomab tiuxetan\nDetails: The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Ibritumomab tiuxetan"}, {"id": "Natalizumab_INT_Tositumomab", "text": "Interaction: Natalizumab AND Tositumomab\nDetails: The risk or severity of adverse effects can be increased when Tositumomab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Tositumomab"}, {"id": "Natalizumab_INT_L-Phenylalanine", "text": "Interaction: Natalizumab AND L-Phenylalanine\nDetails: The risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + L-Phenylalanine"}, {"id": "Natalizumab_INT_Carmustine", "text": "Interaction: Natalizumab AND Carmustine\nDetails: The risk or severity of adverse effects can be increased when Carmustine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Carmustine"}, {"id": "Natalizumab_INT_Amsacrine", "text": "Interaction: Natalizumab AND Amsacrine\nDetails: The risk or severity of adverse effects can be increased when Amsacrine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Amsacrine"}, {"id": "Natalizumab_INT_Bleomycin", "text": "Interaction: Natalizumab AND Bleomycin\nDetails: The risk or severity of adverse effects can be increased when Bleomycin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Bleomycin"}, {"id": "Natalizumab_INT_Chlorambucil", "text": "Interaction: Natalizumab AND Chlorambucil\nDetails: The risk or severity of adverse effects can be increased when Chlorambucil is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Chlorambucil"}, {"id": "Natalizumab_INT_Mitomycin", "text": "Interaction: Natalizumab AND Mitomycin\nDetails: The risk or severity of adverse effects can be increased when Mitomycin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Mitomycin"}, {"id": "Natalizumab_INT_Vindesine", "text": "Interaction: Natalizumab AND Vindesine\nDetails: The risk or severity of adverse effects can be increased when Vindesine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Vindesine"}, {"id": "Natalizumab_INT_Floxuridine", "text": "Interaction: Natalizumab AND Floxuridine\nDetails: The risk or severity of adverse effects can be increased when Floxuridine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Floxuridine"}, {"id": "Natalizumab_INT_Tioguanine", "text": "Interaction: Natalizumab AND Tioguanine\nDetails: The risk or severity of adverse effects can be increased when Tioguanine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Tioguanine"}, {"id": "Natalizumab_INT_Vinorelbine", "text": "Interaction: Natalizumab AND Vinorelbine\nDetails: The risk or severity of adverse effects can be increased when Vinorelbine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Vinorelbine"}, {"id": "Natalizumab_INT_Sorafenib", "text": "Interaction: Natalizumab AND Sorafenib\nDetails: The risk or severity of adverse effects can be increased when Sorafenib is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Sorafenib"}, {"id": "Natalizumab_INT_Streptozocin", "text": "Interaction: Natalizumab AND Streptozocin\nDetails: The risk or severity of adverse effects can be increased when Streptozocin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Streptozocin"}, {"id": "Natalizumab_INT_Betamethasone", "text": "Interaction: Natalizumab AND Betamethasone\nDetails: The risk or severity of adverse effects can be increased when Betamethasone is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Betamethasone"}, {"id": "Natalizumab_INT_Teniposide", "text": "Interaction: Natalizumab AND Teniposide\nDetails: The risk or severity of adverse effects can be increased when Teniposide is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Teniposide"}, {"id": "Natalizumab_INT_Epirubicin", "text": "Interaction: Natalizumab AND Epirubicin\nDetails: The risk or severity of adverse effects can be increased when Epirubicin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Epirubicin"}, {"id": "Natalizumab_INT_Altretamine", "text": "Interaction: Natalizumab AND Altretamine\nDetails: The risk or severity of adverse effects can be increased when Altretamine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Altretamine"}, {"id": "Natalizumab_INT_Cisplatin", "text": "Interaction: Natalizumab AND Cisplatin\nDetails: The risk or severity of adverse effects can be increased when Cisplatin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Cisplatin"}, {"id": "Natalizumab_INT_Oxaliplatin", "text": "Interaction: Natalizumab AND Oxaliplatin\nDetails: The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Oxaliplatin"}, {"id": "Natalizumab_INT_Vincristine", "text": "Interaction: Natalizumab AND Vincristine\nDetails: The risk or severity of adverse effects can be increased when Vincristine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Vincristine"}, {"id": "Natalizumab_INT_Pentostatin", "text": "Interaction: Natalizumab AND Pentostatin\nDetails: The risk or severity of adverse effects can be increased when Pentostatin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Pentostatin"}, {"id": "Natalizumab_INT_Vinblastine", "text": "Interaction: Natalizumab AND Vinblastine\nDetails: The risk or severity of adverse effects can be increased when Vinblastine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Vinblastine"}, {"id": "Natalizumab_INT_Imatinib", "text": "Interaction: Natalizumab AND Imatinib\nDetails: The risk or severity of adverse effects can be increased when Imatinib is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Imatinib"}, {"id": "Natalizumab_INT_Clofarabine", "text": "Interaction: Natalizumab AND Clofarabine\nDetails: The risk or severity of adverse effects can be increased when Clofarabine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Clofarabine"}, {"id": "Natalizumab_INT_Prednisone", "text": "Interaction: Natalizumab AND Prednisone\nDetails: The risk or severity of adverse effects can be increased when Prednisone is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Prednisone"}, {"id": "Natalizumab_INT_Pemetrexed", "text": "Interaction: Natalizumab AND Pemetrexed\nDetails: The risk or severity of adverse effects can be increased when Pemetrexed is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Pemetrexed"}, {"id": "Natalizumab_INT_Fludrocortisone", "text": "Interaction: Natalizumab AND Fludrocortisone\nDetails: The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Fludrocortisone"}, {"id": "Natalizumab_INT_Daunorubicin", "text": "Interaction: Natalizumab AND Daunorubicin\nDetails: The risk or severity of adverse effects can be increased when Daunorubicin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Daunorubicin"}, {"id": "Natalizumab_INT_Imiquimod", "text": "Interaction: Natalizumab AND Imiquimod\nDetails: The risk or severity of adverse effects can be increased when Imiquimod is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Imiquimod"}, {"id": "Natalizumab_INT_Hydrocortisone", "text": "Interaction: Natalizumab AND Hydrocortisone\nDetails: The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Hydrocortisone"}, {"id": "Natalizumab_INT_Tretinoin", "text": "Interaction: Natalizumab AND Tretinoin\nDetails: The risk or severity of adverse effects can be increased when Tretinoin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Tretinoin"}, {"id": "Natalizumab_INT_Irinotecan", "text": "Interaction: Natalizumab AND Irinotecan\nDetails: The risk or severity of adverse effects can be increased when Irinotecan is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Irinotecan"}, {"id": "Natalizumab_INT_Etoposide", "text": "Interaction: Natalizumab AND Etoposide\nDetails: The risk or severity of adverse effects can be increased when Etoposide is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Etoposide"}, {"id": "Natalizumab_INT_Dacarbazine", "text": "Interaction: Natalizumab AND Dacarbazine\nDetails: The risk or severity of adverse effects can be increased when Dacarbazine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Dacarbazine"}, {"id": "Natalizumab_INT_Temozolomide", "text": "Interaction: Natalizumab AND Temozolomide\nDetails: The risk or severity of adverse effects can be increased when Temozolomide is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Temozolomide"}, {"id": "Natalizumab_INT_Prednisolone", "text": "Interaction: Natalizumab AND Prednisolone\nDetails: The risk or severity of adverse effects can be increased when Prednisolone is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Prednisolone"}, {"id": "Natalizumab_INT_Mechlorethamine", "text": "Interaction: Natalizumab AND Mechlorethamine\nDetails: The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Mechlorethamine"}, {"id": "Natalizumab_INT_Azacitidine", "text": "Interaction: Natalizumab AND Azacitidine\nDetails: The risk or severity of adverse effects can be increased when Azacitidine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Azacitidine"}, {"id": "Natalizumab_INT_Carboplatin", "text": "Interaction: Natalizumab AND Carboplatin\nDetails: The risk or severity of adverse effects can be increased when Carboplatin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Carboplatin"}, {"id": "Natalizumab_INT_Methylprednisolone", "text": "Interaction: Natalizumab AND Methylprednisolone\nDetails: The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Methylprednisolone"}, {"id": "Natalizumab_INT_Dactinomycin", "text": "Interaction: Natalizumab AND Dactinomycin\nDetails: The risk or severity of adverse effects can be increased when Dactinomycin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Dactinomycin"}, {"id": "Natalizumab_INT_Doxorubicin", "text": "Interaction: Natalizumab AND Doxorubicin\nDetails: The risk or severity of adverse effects can be increased when Doxorubicin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Doxorubicin"}, {"id": "Natalizumab_INT_Hydroxyurea", "text": "Interaction: Natalizumab AND Hydroxyurea\nDetails: The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Hydroxyurea"}, {"id": "Natalizumab_INT_Topotecan", "text": "Interaction: Natalizumab AND Topotecan\nDetails: The risk or severity of adverse effects can be increased when Topotecan is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Topotecan"}, {"id": "Natalizumab_INT_Capecitabine", "text": "Interaction: Natalizumab AND Capecitabine\nDetails: The risk or severity of adverse effects can be increased when Capecitabine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Capecitabine"}, {"id": "Natalizumab_INT_Procarbazine", "text": "Interaction: Natalizumab AND Procarbazine\nDetails: The risk or severity of adverse effects can be increased when Procarbazine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Procarbazine"}, {"id": "Natalizumab_INT_Idarubicin", "text": "Interaction: Natalizumab AND Idarubicin\nDetails: The risk or severity of adverse effects can be increased when Idarubicin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Idarubicin"}, {"id": "Natalizumab_INT_Ifosfamide", "text": "Interaction: Natalizumab AND Ifosfamide\nDetails: The risk or severity of adverse effects can be increased when Ifosfamide is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Ifosfamide"}, {"id": "Natalizumab_INT_Estramustine", "text": "Interaction: Natalizumab AND Estramustine\nDetails: The risk or severity of adverse effects can be increased when Estramustine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Estramustine"}, {"id": "Natalizumab_INT_Mitoxantrone", "text": "Interaction: Natalizumab AND Mitoxantrone\nDetails: The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Mitoxantrone"}, {"id": "Natalizumab_INT_Lomustine", "text": "Interaction: Natalizumab AND Lomustine\nDetails: The risk or severity of adverse effects can be increased when Lomustine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Lomustine"}, {"id": "Natalizumab_INT_Budesonide", "text": "Interaction: Natalizumab AND Budesonide\nDetails: The risk or severity of adverse effects can be increased when Budesonide is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Budesonide"}, {"id": "Natalizumab_INT_Paclitaxel", "text": "Interaction: Natalizumab AND Paclitaxel\nDetails: The risk or severity of adverse effects can be increased when Paclitaxel is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Paclitaxel"}, {"id": "Natalizumab_INT_Dexamethasone", "text": "Interaction: Natalizumab AND Dexamethasone\nDetails: The risk or severity of adverse effects can be increased when Dexamethasone is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Dexamethasone"}, {"id": "Natalizumab_INT_Docetaxel", "text": "Interaction: Natalizumab AND Docetaxel\nDetails: The risk or severity of adverse effects can be increased when Docetaxel is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Docetaxel"}, {"id": "Natalizumab_INT_Dasatinib", "text": "Interaction: Natalizumab AND Dasatinib\nDetails: The risk or severity of adverse effects can be increased when Dasatinib is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Dasatinib"}, {"id": "Natalizumab_INT_Sunitinib", "text": "Interaction: Natalizumab AND Sunitinib\nDetails: The risk or severity of adverse effects can be increased when Sunitinib is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Sunitinib"}, {"id": "Natalizumab_INT_Nelarabine", "text": "Interaction: Natalizumab AND Nelarabine\nDetails: The risk or severity of adverse effects can be increased when Nelarabine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Nelarabine"}, {"id": "Natalizumab_INT_Corticotropin", "text": "Interaction: Natalizumab AND Corticotropin\nDetails: The risk or severity of adverse effects can be increased when Corticotropin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Corticotropin"}, {"id": "Natalizumab_INT_Cortisone acetate", "text": "Interaction: Natalizumab AND Cortisone acetate\nDetails: The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Cortisone acetate"}, {"id": "Natalizumab_INT_Nilotinib", "text": "Interaction: Natalizumab AND Nilotinib\nDetails: The risk or severity of adverse effects can be increased when Nilotinib is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Nilotinib"}, {"id": "Natalizumab_INT_Trabectedin", "text": "Interaction: Natalizumab AND Trabectedin\nDetails: The risk or severity of adverse effects can be increased when Trabectedin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Trabectedin"}, {"id": "Natalizumab_INT_Trastuzumab emtansine", "text": "Interaction: Natalizumab AND Trastuzumab emtansine\nDetails: The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Trastuzumab emtansine"}, {"id": "Natalizumab_INT_Temsirolimus", "text": "Interaction: Natalizumab AND Temsirolimus\nDetails: The risk or severity of adverse effects can be increased when Temsirolimus is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Temsirolimus"}, {"id": "Natalizumab_INT_Pazopanib", "text": "Interaction: Natalizumab AND Pazopanib\nDetails: The risk or severity of adverse effects can be increased when Pazopanib is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Pazopanib"}, {"id": "Natalizumab_INT_Panobinostat", "text": "Interaction: Natalizumab AND Panobinostat\nDetails: The risk or severity of adverse effects can be increased when Panobinostat is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Panobinostat"}, {"id": "Natalizumab_INT_Cabazitaxel", "text": "Interaction: Natalizumab AND Cabazitaxel\nDetails: The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Cabazitaxel"}, {"id": "Natalizumab_INT_Pralatrexate", "text": "Interaction: Natalizumab AND Pralatrexate\nDetails: The risk or severity of adverse effects can be increased when Pralatrexate is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Pralatrexate"}, {"id": "Natalizumab_INT_Brentuximab vedotin", "text": "Interaction: Natalizumab AND Brentuximab vedotin\nDetails: The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Brentuximab vedotin"}, {"id": "Natalizumab_INT_Ruxolitinib", "text": "Interaction: Natalizumab AND Ruxolitinib\nDetails: The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Ruxolitinib"}, {"id": "Natalizumab_INT_Obinutuzumab", "text": "Interaction: Natalizumab AND Obinutuzumab\nDetails: The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Obinutuzumab"}, {"id": "Natalizumab_INT_Blinatumomab", "text": "Interaction: Natalizumab AND Blinatumomab\nDetails: The risk or severity of adverse effects can be increased when Blinatumomab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Blinatumomab"}, {"id": "Natalizumab_INT_Ibrutinib", "text": "Interaction: Natalizumab AND Ibrutinib\nDetails: The risk or severity of adverse effects can be increased when Ibrutinib is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Ibrutinib"}, {"id": "Natalizumab_INT_Idelalisib", "text": "Interaction: Natalizumab AND Idelalisib\nDetails: The risk or severity of adverse effects can be increased when Idelalisib is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Idelalisib"}, {"id": "Natalizumab_INT_Palbociclib", "text": "Interaction: Natalizumab AND Palbociclib\nDetails: The risk or severity of adverse effects can be increased when Palbociclib is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Palbociclib"}, {"id": "Natalizumab_INT_Dinutuximab", "text": "Interaction: Natalizumab AND Dinutuximab\nDetails: The risk or severity of adverse effects can be increased when Dinutuximab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Dinutuximab"}, {"id": "Natalizumab_INT_Vilanterol", "text": "Interaction: Natalizumab AND Vilanterol\nDetails: The risk or severity of adverse effects can be increased when Vilanterol is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Vilanterol"}, {"id": "Natalizumab_INT_BCG vaccine", "text": "Interaction: Natalizumab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + BCG vaccine"}, {"id": "Natalizumab_INT_Leflunomide", "text": "Interaction: Natalizumab AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Natalizumab is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Natalizumab + Leflunomide"}, {"id": "Natalizumab_INT_Fingolimod", "text": "Interaction: Natalizumab AND Fingolimod\nDetails: Natalizumab may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Natalizumab + Fingolimod"}, {"id": "Natalizumab_INT_Roflumilast", "text": "Interaction: Natalizumab AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Roflumilast"}, {"id": "Natalizumab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Natalizumab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Natalizumab_INT_Yellow fever vaccine", "text": "Interaction: Natalizumab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Yellow fever vaccine"}, {"id": "Natalizumab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Natalizumab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Natalizumab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Natalizumab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Natalizumab_INT_Rotavirus Vaccine", "text": "Interaction: Natalizumab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Rotavirus Vaccine"}, {"id": "Natalizumab_INT_G17DT", "text": "Interaction: Natalizumab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + G17DT"}, {"id": "Natalizumab_INT_INGN 201", "text": "Interaction: Natalizumab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + INGN 201"}, {"id": "Natalizumab_INT_INGN 225", "text": "Interaction: Natalizumab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + INGN 225"}, {"id": "Natalizumab_INT_Rindopepimut", "text": "Interaction: Natalizumab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Rindopepimut"}, {"id": "Natalizumab_INT_SRP 299", "text": "Interaction: Natalizumab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + SRP 299"}, {"id": "Natalizumab_INT_GI-5005", "text": "Interaction: Natalizumab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + GI-5005"}, {"id": "Natalizumab_INT_TG4010", "text": "Interaction: Natalizumab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + TG4010"}, {"id": "Natalizumab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Natalizumab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Rabies virus inactivated antigen, A"}, {"id": "Natalizumab_INT_Tecemotide", "text": "Interaction: Natalizumab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Tecemotide"}, {"id": "Natalizumab_INT_Rubella virus vaccine", "text": "Interaction: Natalizumab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Rubella virus vaccine"}, {"id": "Natalizumab_INT_Hepatitis A Vaccine", "text": "Interaction: Natalizumab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Hepatitis A Vaccine"}, {"id": "Natalizumab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Natalizumab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Salmonella typhi ty21a live antigen"}, {"id": "Natalizumab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Natalizumab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Natalizumab_INT_Denosumab", "text": "Interaction: Natalizumab AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Denosumab"}, {"id": "Natalizumab_INT_Sipuleucel-T", "text": "Interaction: Natalizumab AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Sipuleucel-T"}, {"id": "Natalizumab_INT_Trastuzumab", "text": "Interaction: Natalizumab AND Trastuzumab\nDetails: Trastuzumab may increase the neutropenic activities of Natalizumab.\nRisk: Monitor closely.", "source": "Natalizumab + Trastuzumab"}, {"id": "Enfuvirtide_GEN", "text": "Drug: Enfuvirtide\nDescription: Enfuvirtide is a 36 residue synthetic peptide that inhibits HIV-1 fusion with CD4 cells. It is an N-terminal acetylated, C-terminal amide. As an HIV fusion inhibitor, it is the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection....", "source": "Enfuvirtide"}, {"id": "Enfuvirtide_CLIN", "text": "Drug: Enfuvirtide\nMechanism: Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membrane...\nToxicity: ...", "source": "Enfuvirtide"}, {"id": "Enfuvirtide_INT_Dabrafenib", "text": "Interaction: Enfuvirtide AND Dabrafenib\nDetails: The serum concentration of Enfuvirtide can be decreased when it is combined with Dabrafenib.\nRisk: Monitor closely.", "source": "Enfuvirtide + Dabrafenib"}, {"id": "Enfuvirtide_INT_Fluvoxamine", "text": "Interaction: Enfuvirtide AND Fluvoxamine\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Fluvoxamine.\nRisk: Monitor closely.", "source": "Enfuvirtide + Fluvoxamine"}, {"id": "Enfuvirtide_INT_Ticlopidine", "text": "Interaction: Enfuvirtide AND Ticlopidine\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Ticlopidine.\nRisk: Monitor closely.", "source": "Enfuvirtide + Ticlopidine"}, {"id": "Enfuvirtide_INT_Fluconazole", "text": "Interaction: Enfuvirtide AND Fluconazole\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Fluconazole.\nRisk: Monitor closely.", "source": "Enfuvirtide + Fluconazole"}, {"id": "Enfuvirtide_INT_Chloramphenicol", "text": "Interaction: Enfuvirtide AND Chloramphenicol\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Chloramphenicol.\nRisk: Monitor closely.", "source": "Enfuvirtide + Chloramphenicol"}, {"id": "Enfuvirtide_INT_Delavirdine", "text": "Interaction: Enfuvirtide AND Delavirdine\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Delavirdine.\nRisk: Monitor closely.", "source": "Enfuvirtide + Delavirdine"}, {"id": "Enfuvirtide_INT_Gemfibrozil", "text": "Interaction: Enfuvirtide AND Gemfibrozil\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Gemfibrozil.\nRisk: Monitor closely.", "source": "Enfuvirtide + Gemfibrozil"}, {"id": "Enfuvirtide_INT_Stiripentol", "text": "Interaction: Enfuvirtide AND Stiripentol\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Stiripentol.\nRisk: Monitor closely.", "source": "Enfuvirtide + Stiripentol"}, {"id": "Enfuvirtide_INT_Phenytoin", "text": "Interaction: Enfuvirtide AND Phenytoin\nDetails: The metabolism of Enfuvirtide can be increased when combined with Phenytoin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Phenytoin"}, {"id": "Enfuvirtide_INT_Fosphenytoin", "text": "Interaction: Enfuvirtide AND Fosphenytoin\nDetails: The metabolism of Enfuvirtide can be increased when combined with Fosphenytoin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Fosphenytoin"}, {"id": "Enfuvirtide_INT_Carbamazepine", "text": "Interaction: Enfuvirtide AND Carbamazepine\nDetails: The metabolism of Enfuvirtide can be increased when combined with Carbamazepine.\nRisk: Monitor closely.", "source": "Enfuvirtide + Carbamazepine"}, {"id": "Enfuvirtide_INT_Rifampicin", "text": "Interaction: Enfuvirtide AND Rifampicin\nDetails: The metabolism of Enfuvirtide can be increased when combined with Rifampicin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Rifampicin"}, {"id": "Enfuvirtide_INT_Lumacaftor", "text": "Interaction: Enfuvirtide AND Lumacaftor\nDetails: The serum concentration of Enfuvirtide can be decreased when it is combined with Lumacaftor.\nRisk: Monitor closely.", "source": "Enfuvirtide + Lumacaftor"}, {"id": "Enfuvirtide_INT_Luliconazole", "text": "Interaction: Enfuvirtide AND Luliconazole\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Luliconazole.\nRisk: Monitor closely.", "source": "Enfuvirtide + Luliconazole"}, {"id": "Enfuvirtide_INT_Nelfinavir", "text": "Interaction: Enfuvirtide AND Nelfinavir\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Nelfinavir.\nRisk: Monitor closely.", "source": "Enfuvirtide + Nelfinavir"}, {"id": "Enfuvirtide_INT_Indinavir", "text": "Interaction: Enfuvirtide AND Indinavir\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Indinavir.\nRisk: Monitor closely.", "source": "Enfuvirtide + Indinavir"}, {"id": "Enfuvirtide_INT_Ritonavir", "text": "Interaction: Enfuvirtide AND Ritonavir\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Ritonavir.\nRisk: Monitor closely.", "source": "Enfuvirtide + Ritonavir"}, {"id": "Enfuvirtide_INT_Amprenavir", "text": "Interaction: Enfuvirtide AND Amprenavir\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Amprenavir.\nRisk: Monitor closely.", "source": "Enfuvirtide + Amprenavir"}, {"id": "Enfuvirtide_INT_Atazanavir", "text": "Interaction: Enfuvirtide AND Atazanavir\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Atazanavir.\nRisk: Monitor closely.", "source": "Enfuvirtide + Atazanavir"}, {"id": "Enfuvirtide_INT_Saquinavir", "text": "Interaction: Enfuvirtide AND Saquinavir\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Saquinavir.\nRisk: Monitor closely.", "source": "Enfuvirtide + Saquinavir"}, {"id": "Enfuvirtide_INT_Darunavir", "text": "Interaction: Enfuvirtide AND Darunavir\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Darunavir.\nRisk: Monitor closely.", "source": "Enfuvirtide + Darunavir"}, {"id": "Enfuvirtide_INT_Fosamprenavir", "text": "Interaction: Enfuvirtide AND Fosamprenavir\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Fosamprenavir.\nRisk: Monitor closely.", "source": "Enfuvirtide + Fosamprenavir"}, {"id": "Enfuvirtide_INT_Tipranavir", "text": "Interaction: Enfuvirtide AND Tipranavir\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Tipranavir.\nRisk: Monitor closely.", "source": "Enfuvirtide + Tipranavir"}, {"id": "Enfuvirtide_INT_Lepirudin", "text": "Interaction: Enfuvirtide AND Lepirudin\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Lepirudin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Lepirudin"}, {"id": "Enfuvirtide_INT_Bivalirudin", "text": "Interaction: Enfuvirtide AND Bivalirudin\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Bivalirudin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Bivalirudin"}, {"id": "Enfuvirtide_INT_Alpha-1-proteinase inhibitor", "text": "Interaction: Enfuvirtide AND Alpha-1-proteinase inhibitor\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Alpha-1-proteinase inhibitor.\nRisk: Monitor closely.", "source": "Enfuvirtide + Alpha-1-proteinase inhibitor"}, {"id": "Enfuvirtide_INT_Ramipril", "text": "Interaction: Enfuvirtide AND Ramipril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Ramipril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Ramipril"}, {"id": "Enfuvirtide_INT_Remikiren", "text": "Interaction: Enfuvirtide AND Remikiren\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Remikiren.\nRisk: Monitor closely.", "source": "Enfuvirtide + Remikiren"}, {"id": "Enfuvirtide_INT_Argatroban", "text": "Interaction: Enfuvirtide AND Argatroban\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Argatroban.\nRisk: Monitor closely.", "source": "Enfuvirtide + Argatroban"}, {"id": "Enfuvirtide_INT_Fosinopril", "text": "Interaction: Enfuvirtide AND Fosinopril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Fosinopril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Fosinopril"}, {"id": "Enfuvirtide_INT_Trandolapril", "text": "Interaction: Enfuvirtide AND Trandolapril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Trandolapril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Trandolapril"}, {"id": "Enfuvirtide_INT_Benazepril", "text": "Interaction: Enfuvirtide AND Benazepril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Benazepril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Benazepril"}, {"id": "Enfuvirtide_INT_Enalapril", "text": "Interaction: Enfuvirtide AND Enalapril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Enalapril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Enalapril"}, {"id": "Enfuvirtide_INT_Candoxatril", "text": "Interaction: Enfuvirtide AND Candoxatril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Candoxatril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Candoxatril"}, {"id": "Enfuvirtide_INT_Isoflurophate", "text": "Interaction: Enfuvirtide AND Isoflurophate\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Isoflurophate.\nRisk: Monitor closely.", "source": "Enfuvirtide + Isoflurophate"}, {"id": "Enfuvirtide_INT_Moexipril", "text": "Interaction: Enfuvirtide AND Moexipril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Moexipril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Moexipril"}, {"id": "Enfuvirtide_INT_Lisinopril", "text": "Interaction: Enfuvirtide AND Lisinopril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Lisinopril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Lisinopril"}, {"id": "Enfuvirtide_INT_Perindopril", "text": "Interaction: Enfuvirtide AND Perindopril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Perindopril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Perindopril"}, {"id": "Enfuvirtide_INT_Quinapril", "text": "Interaction: Enfuvirtide AND Quinapril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Quinapril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Quinapril"}, {"id": "Enfuvirtide_INT_Omapatrilat", "text": "Interaction: Enfuvirtide AND Omapatrilat\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Omapatrilat.\nRisk: Monitor closely.", "source": "Enfuvirtide + Omapatrilat"}, {"id": "Enfuvirtide_INT_Captopril", "text": "Interaction: Enfuvirtide AND Captopril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Captopril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Captopril"}, {"id": "Enfuvirtide_INT_Sitagliptin", "text": "Interaction: Enfuvirtide AND Sitagliptin\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Sitagliptin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Sitagliptin"}, {"id": "Enfuvirtide_INT_Cilazapril", "text": "Interaction: Enfuvirtide AND Cilazapril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Cilazapril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Cilazapril"}, {"id": "Enfuvirtide_INT_Spirapril", "text": "Interaction: Enfuvirtide AND Spirapril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Spirapril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Spirapril"}, {"id": "Enfuvirtide_INT_Cilastatin", "text": "Interaction: Enfuvirtide AND Cilastatin\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Cilastatin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Cilastatin"}, {"id": "Enfuvirtide_INT_Lopinavir", "text": "Interaction: Enfuvirtide AND Lopinavir\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Lopinavir.\nRisk: Monitor closely.", "source": "Enfuvirtide + Lopinavir"}, {"id": "Enfuvirtide_INT_Chymostatin", "text": "Interaction: Enfuvirtide AND Chymostatin\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Chymostatin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Chymostatin"}, {"id": "Enfuvirtide_INT_GM6001", "text": "Interaction: Enfuvirtide AND GM6001\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with GM6001.\nRisk: Monitor closely.", "source": "Enfuvirtide + GM6001"}, {"id": "Enfuvirtide_INT_1,10-Phenanthroline", "text": "Interaction: Enfuvirtide AND 1,10-Phenanthroline\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with 1,10-Phenanthroline.\nRisk: Monitor closely.", "source": "Enfuvirtide + 1,10-Phenanthroline"}, {"id": "Enfuvirtide_INT_Geldanamycin", "text": "Interaction: Enfuvirtide AND Geldanamycin\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Geldanamycin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Geldanamycin"}, {"id": "Enfuvirtide_INT_Phosphoramidon", "text": "Interaction: Enfuvirtide AND Phosphoramidon\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Phosphoramidon.\nRisk: Monitor closely.", "source": "Enfuvirtide + Phosphoramidon"}, {"id": "Enfuvirtide_INT_N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline", "text": "Interaction: Enfuvirtide AND N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.\nRisk: Monitor closely.", "source": "Enfuvirtide + N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline"}, {"id": "Enfuvirtide_INT_Benzamidine", "text": "Interaction: Enfuvirtide AND Benzamidine\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Benzamidine.\nRisk: Monitor closely.", "source": "Enfuvirtide + Benzamidine"}, {"id": "Enfuvirtide_INT_Enalkiren", "text": "Interaction: Enfuvirtide AND Enalkiren\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Enalkiren.\nRisk: Monitor closely.", "source": "Enfuvirtide + Enalkiren"}, {"id": "Enfuvirtide_INT_Ubenimex", "text": "Interaction: Enfuvirtide AND Ubenimex\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Ubenimex.\nRisk: Monitor closely.", "source": "Enfuvirtide + Ubenimex"}, {"id": "Enfuvirtide_INT_Batimastat", "text": "Interaction: Enfuvirtide AND Batimastat\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Batimastat.\nRisk: Monitor closely.", "source": "Enfuvirtide + Batimastat"}, {"id": "Enfuvirtide_INT_3,4-Dichloroisocoumarin", "text": "Interaction: Enfuvirtide AND 3,4-Dichloroisocoumarin\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with 3,4-Dichloroisocoumarin.\nRisk: Monitor closely.", "source": "Enfuvirtide + 3,4-Dichloroisocoumarin"}, {"id": "Enfuvirtide_INT_Cholesterol", "text": "Interaction: Enfuvirtide AND Cholesterol\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Cholesterol.\nRisk: Monitor closely.", "source": "Enfuvirtide + Cholesterol"}, {"id": "Enfuvirtide_INT_Vildagliptin", "text": "Interaction: Enfuvirtide AND Vildagliptin\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Vildagliptin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Vildagliptin"}, {"id": "Enfuvirtide_INT_Ximelagatran", "text": "Interaction: Enfuvirtide AND Ximelagatran\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Ximelagatran.\nRisk: Monitor closely.", "source": "Enfuvirtide + Ximelagatran"}, {"id": "Enfuvirtide_INT_Prinomastat", "text": "Interaction: Enfuvirtide AND Prinomastat\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Prinomastat.\nRisk: Monitor closely.", "source": "Enfuvirtide + Prinomastat"}, {"id": "Enfuvirtide_INT_Elafin", "text": "Interaction: Enfuvirtide AND Elafin\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Elafin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Elafin"}, {"id": "Enfuvirtide_INT_Ecabet", "text": "Interaction: Enfuvirtide AND Ecabet\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Ecabet.\nRisk: Monitor closely.", "source": "Enfuvirtide + Ecabet"}, {"id": "Enfuvirtide_INT_Alogliptin", "text": "Interaction: Enfuvirtide AND Alogliptin\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Alogliptin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Alogliptin"}, {"id": "Enfuvirtide_INT_Rivaroxaban", "text": "Interaction: Enfuvirtide AND Rivaroxaban\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Rivaroxaban.\nRisk: Monitor closely.", "source": "Enfuvirtide + Rivaroxaban"}, {"id": "Enfuvirtide_INT_Simeprevir", "text": "Interaction: Enfuvirtide AND Simeprevir\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Simeprevir.\nRisk: Monitor closely.", "source": "Enfuvirtide + Simeprevir"}, {"id": "Enfuvirtide_INT_Saxagliptin", "text": "Interaction: Enfuvirtide AND Saxagliptin\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Saxagliptin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Saxagliptin"}, {"id": "Enfuvirtide_INT_Idraparinux", "text": "Interaction: Enfuvirtide AND Idraparinux\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Idraparinux.\nRisk: Monitor closely.", "source": "Enfuvirtide + Idraparinux"}, {"id": "Enfuvirtide_INT_Apixaban", "text": "Interaction: Enfuvirtide AND Apixaban\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Apixaban.\nRisk: Monitor closely.", "source": "Enfuvirtide + Apixaban"}, {"id": "Enfuvirtide_INT_Otamixaban", "text": "Interaction: Enfuvirtide AND Otamixaban\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Otamixaban.\nRisk: Monitor closely.", "source": "Enfuvirtide + Otamixaban"}, {"id": "Enfuvirtide_INT_Aprotinin", "text": "Interaction: Enfuvirtide AND Aprotinin\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Aprotinin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Aprotinin"}, {"id": "Enfuvirtide_INT_Dabigatran etexilate", "text": "Interaction: Enfuvirtide AND Dabigatran etexilate\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Dabigatran etexilate.\nRisk: Monitor closely.", "source": "Enfuvirtide + Dabigatran etexilate"}, {"id": "Enfuvirtide_INT_4-(2-Aminoethyl)Benzenesulfonyl Fluoride", "text": "Interaction: Enfuvirtide AND 4-(2-Aminoethyl)Benzenesulfonyl Fluoride\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.\nRisk: Monitor closely.", "source": "Enfuvirtide + 4-(2-Aminoethyl)Benzenesulfonyl Fluoride"}, {"id": "Enfuvirtide_INT_Z-Val-Ala-Asp fluoromethyl ketone", "text": "Interaction: Enfuvirtide AND Z-Val-Ala-Asp fluoromethyl ketone\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.\nRisk: Monitor closely.", "source": "Enfuvirtide + Z-Val-Ala-Asp fluoromethyl ketone"}, {"id": "Enfuvirtide_INT_Thiorphan", "text": "Interaction: Enfuvirtide AND Thiorphan\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Thiorphan.\nRisk: Monitor closely.", "source": "Enfuvirtide + Thiorphan"}, {"id": "Enfuvirtide_INT_Temocapril", "text": "Interaction: Enfuvirtide AND Temocapril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Temocapril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Temocapril"}, {"id": "Enfuvirtide_INT_Linagliptin", "text": "Interaction: Enfuvirtide AND Linagliptin\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Linagliptin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Linagliptin"}, {"id": "Enfuvirtide_INT_Edoxaban", "text": "Interaction: Enfuvirtide AND Edoxaban\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Edoxaban.\nRisk: Monitor closely.", "source": "Enfuvirtide + Edoxaban"}, {"id": "Enfuvirtide_INT_Enalaprilat", "text": "Interaction: Enfuvirtide AND Enalaprilat\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Enalaprilat.\nRisk: Monitor closely.", "source": "Enfuvirtide + Enalaprilat"}, {"id": "Enfuvirtide_INT_Ixazomib", "text": "Interaction: Enfuvirtide AND Ixazomib\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Ixazomib.\nRisk: Monitor closely.", "source": "Enfuvirtide + Ixazomib"}, {"id": "Enfuvirtide_INT_Antithrombin III human", "text": "Interaction: Enfuvirtide AND Antithrombin III human\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Antithrombin III human.\nRisk: Monitor closely.", "source": "Enfuvirtide + Antithrombin III human"}, {"id": "Enfuvirtide_INT_Candoxatrilat", "text": "Interaction: Enfuvirtide AND Candoxatrilat\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Candoxatrilat.\nRisk: Monitor closely.", "source": "Enfuvirtide + Candoxatrilat"}, {"id": "Enfuvirtide_INT_Racecadotril", "text": "Interaction: Enfuvirtide AND Racecadotril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Racecadotril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Racecadotril"}, {"id": "Enfuvirtide_INT_Imidapril", "text": "Interaction: Enfuvirtide AND Imidapril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Imidapril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Imidapril"}, {"id": "Enfuvirtide_INT_Delanzomib", "text": "Interaction: Enfuvirtide AND Delanzomib\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Delanzomib.\nRisk: Monitor closely.", "source": "Enfuvirtide + Delanzomib"}, {"id": "Enfuvirtide_INT_Letaxaban", "text": "Interaction: Enfuvirtide AND Letaxaban\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Letaxaban.\nRisk: Monitor closely.", "source": "Enfuvirtide + Letaxaban"}, {"id": "Enfuvirtide_INT_Ulinastatin", "text": "Interaction: Enfuvirtide AND Ulinastatin\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Ulinastatin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Ulinastatin"}, {"id": "Enfuvirtide_INT_Epigallocatechin Gallate", "text": "Interaction: Enfuvirtide AND Epigallocatechin Gallate\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Epigallocatechin Gallate.\nRisk: Monitor closely.", "source": "Enfuvirtide + Epigallocatechin Gallate"}, {"id": "Enfuvirtide_INT_S-3304", "text": "Interaction: Enfuvirtide AND S-3304\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with S-3304.\nRisk: Monitor closely.", "source": "Enfuvirtide + S-3304"}, {"id": "Enfuvirtide_INT_Darexaban", "text": "Interaction: Enfuvirtide AND Darexaban\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Darexaban.\nRisk: Monitor closely.", "source": "Enfuvirtide + Darexaban"}, {"id": "Enfuvirtide_INT_Nitroaspirin", "text": "Interaction: Enfuvirtide AND Nitroaspirin\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Nitroaspirin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Nitroaspirin"}, {"id": "Enfuvirtide_INT_Nafamostat", "text": "Interaction: Enfuvirtide AND Nafamostat\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Nafamostat.\nRisk: Monitor closely.", "source": "Enfuvirtide + Nafamostat"}, {"id": "Enfuvirtide_INT_Gabexate", "text": "Interaction: Enfuvirtide AND Gabexate\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Gabexate.\nRisk: Monitor closely.", "source": "Enfuvirtide + Gabexate"}, {"id": "Enfuvirtide_INT_Sivelestat", "text": "Interaction: Enfuvirtide AND Sivelestat\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Sivelestat.\nRisk: Monitor closely.", "source": "Enfuvirtide + Sivelestat"}, {"id": "Enfuvirtide_INT_Zofenopril", "text": "Interaction: Enfuvirtide AND Zofenopril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Zofenopril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Zofenopril"}, {"id": "Enfuvirtide_INT_Delapril", "text": "Interaction: Enfuvirtide AND Delapril\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Delapril.\nRisk: Monitor closely.", "source": "Enfuvirtide + Delapril"}, {"id": "Enfuvirtide_INT_Melagatran", "text": "Interaction: Enfuvirtide AND Melagatran\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Melagatran.\nRisk: Monitor closely.", "source": "Enfuvirtide + Melagatran"}, {"id": "Enfuvirtide_INT_Camostat", "text": "Interaction: Enfuvirtide AND Camostat\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Camostat.\nRisk: Monitor closely.", "source": "Enfuvirtide + Camostat"}, {"id": "Enfuvirtide_INT_Telaprevir", "text": "Interaction: Enfuvirtide AND Telaprevir\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Telaprevir.\nRisk: Monitor closely.", "source": "Enfuvirtide + Telaprevir"}, {"id": "Enfuvirtide_INT_Boceprevir", "text": "Interaction: Enfuvirtide AND Boceprevir\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Boceprevir.\nRisk: Monitor closely.", "source": "Enfuvirtide + Boceprevir"}, {"id": "Enfuvirtide_INT_Asunaprevir", "text": "Interaction: Enfuvirtide AND Asunaprevir\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Asunaprevir.\nRisk: Monitor closely.", "source": "Enfuvirtide + Asunaprevir"}, {"id": "Enfuvirtide_INT_Faldaprevir", "text": "Interaction: Enfuvirtide AND Faldaprevir\nDetails: The serum concentration of Enfuvirtide can be increased when it is combined with Faldaprevir.\nRisk: Monitor closely.", "source": "Enfuvirtide + Faldaprevir"}, {"id": "Enfuvirtide_INT_Cyproterone acetate", "text": "Interaction: Enfuvirtide AND Cyproterone acetate\nDetails: The serum concentration of Enfuvirtide can be decreased when it is combined with Cyproterone acetate.\nRisk: Monitor closely.", "source": "Enfuvirtide + Cyproterone acetate"}, {"id": "Enfuvirtide_INT_Bortezomib", "text": "Interaction: Enfuvirtide AND Bortezomib\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Bortezomib.\nRisk: Monitor closely.", "source": "Enfuvirtide + Bortezomib"}, {"id": "Enfuvirtide_INT_Pantoprazole", "text": "Interaction: Enfuvirtide AND Pantoprazole\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Pantoprazole.\nRisk: Monitor closely.", "source": "Enfuvirtide + Pantoprazole"}, {"id": "Enfuvirtide_INT_Citalopram", "text": "Interaction: Enfuvirtide AND Citalopram\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Citalopram.\nRisk: Monitor closely.", "source": "Enfuvirtide + Citalopram"}, {"id": "Enfuvirtide_INT_Topiramate", "text": "Interaction: Enfuvirtide AND Topiramate\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Topiramate.\nRisk: Monitor closely.", "source": "Enfuvirtide + Topiramate"}, {"id": "Enfuvirtide_INT_Omeprazole", "text": "Interaction: Enfuvirtide AND Omeprazole\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Omeprazole.\nRisk: Monitor closely.", "source": "Enfuvirtide + Omeprazole"}, {"id": "Enfuvirtide_INT_Voriconazole", "text": "Interaction: Enfuvirtide AND Voriconazole\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Voriconazole.\nRisk: Monitor closely.", "source": "Enfuvirtide + Voriconazole"}, {"id": "Enfuvirtide_INT_Esomeprazole", "text": "Interaction: Enfuvirtide AND Esomeprazole\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Esomeprazole.\nRisk: Monitor closely.", "source": "Enfuvirtide + Esomeprazole"}, {"id": "Enfuvirtide_INT_Sertraline", "text": "Interaction: Enfuvirtide AND Sertraline\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Sertraline.\nRisk: Monitor closely.", "source": "Enfuvirtide + Sertraline"}, {"id": "Enfuvirtide_INT_Moclobemide", "text": "Interaction: Enfuvirtide AND Moclobemide\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Moclobemide.\nRisk: Monitor closely.", "source": "Enfuvirtide + Moclobemide"}, {"id": "Enfuvirtide_INT_Nicardipine", "text": "Interaction: Enfuvirtide AND Nicardipine\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Nicardipine.\nRisk: Monitor closely.", "source": "Enfuvirtide + Nicardipine"}, {"id": "Enfuvirtide_INT_Efavirenz", "text": "Interaction: Enfuvirtide AND Efavirenz\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Efavirenz.\nRisk: Monitor closely.", "source": "Enfuvirtide + Efavirenz"}, {"id": "Enfuvirtide_INT_Modafinil", "text": "Interaction: Enfuvirtide AND Modafinil\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Modafinil.\nRisk: Monitor closely.", "source": "Enfuvirtide + Modafinil"}, {"id": "Enfuvirtide_INT_Tranylcypromine", "text": "Interaction: Enfuvirtide AND Tranylcypromine\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Tranylcypromine.\nRisk: Monitor closely.", "source": "Enfuvirtide + Tranylcypromine"}, {"id": "Enfuvirtide_INT_Ketoconazole", "text": "Interaction: Enfuvirtide AND Ketoconazole\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Ketoconazole.\nRisk: Monitor closely.", "source": "Enfuvirtide + Ketoconazole"}, {"id": "Enfuvirtide_INT_Cimetidine", "text": "Interaction: Enfuvirtide AND Cimetidine\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Cimetidine.\nRisk: Monitor closely.", "source": "Enfuvirtide + Cimetidine"}, {"id": "Enfuvirtide_INT_Fluoxetine", "text": "Interaction: Enfuvirtide AND Fluoxetine\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Fluoxetine.\nRisk: Monitor closely.", "source": "Enfuvirtide + Fluoxetine"}, {"id": "Enfuvirtide_INT_Etravirine", "text": "Interaction: Enfuvirtide AND Etravirine\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Etravirine.\nRisk: Monitor closely.", "source": "Enfuvirtide + Etravirine"}, {"id": "Enfuvirtide_INT_Armodafinil", "text": "Interaction: Enfuvirtide AND Armodafinil\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Armodafinil.\nRisk: Monitor closely.", "source": "Enfuvirtide + Armodafinil"}, {"id": "Enfuvirtide_INT_Isoniazid", "text": "Interaction: Enfuvirtide AND Isoniazid\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Isoniazid.\nRisk: Monitor closely.", "source": "Enfuvirtide + Isoniazid"}, {"id": "Enfuvirtide_INT_Clotrimazole", "text": "Interaction: Enfuvirtide AND Clotrimazole\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Clotrimazole.\nRisk: Monitor closely.", "source": "Enfuvirtide + Clotrimazole"}, {"id": "Enfuvirtide_INT_Cholecalciferol", "text": "Interaction: Enfuvirtide AND Cholecalciferol\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Cholecalciferol.\nRisk: Monitor closely.", "source": "Enfuvirtide + Cholecalciferol"}, {"id": "Enfuvirtide_INT_Eslicarbazepine acetate", "text": "Interaction: Enfuvirtide AND Eslicarbazepine acetate\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Eslicarbazepine acetate.\nRisk: Monitor closely.", "source": "Enfuvirtide + Eslicarbazepine acetate"}, {"id": "Enfuvirtide_INT_Abiraterone", "text": "Interaction: Enfuvirtide AND Abiraterone\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Abiraterone.\nRisk: Monitor closely.", "source": "Enfuvirtide + Abiraterone"}, {"id": "Enfuvirtide_INT_Zucapsaicin", "text": "Interaction: Enfuvirtide AND Zucapsaicin\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Zucapsaicin.\nRisk: Monitor closely.", "source": "Enfuvirtide + Zucapsaicin"}, {"id": "Enfuvirtide_INT_Lobeglitazone", "text": "Interaction: Enfuvirtide AND Lobeglitazone\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Lobeglitazone.\nRisk: Monitor closely.", "source": "Enfuvirtide + Lobeglitazone"}, {"id": "Enfuvirtide_INT_Rucaparib", "text": "Interaction: Enfuvirtide AND Rucaparib\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Rucaparib.\nRisk: Monitor closely.", "source": "Enfuvirtide + Rucaparib"}, {"id": "Enfuvirtide_INT_Nicotine", "text": "Interaction: Enfuvirtide AND Nicotine\nDetails: The metabolism of Enfuvirtide can be decreased when combined with Nicotine.\nRisk: Monitor closely.", "source": "Enfuvirtide + Nicotine"}, {"id": "Palivizumab_GEN", "text": "Drug: Palivizumab\nDescription: Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived fro...", "source": "Palivizumab"}, {"id": "Palivizumab_CLIN", "text": "Drug: Palivizumab\nMechanism: Palivizumab binds to the fusion glycoprotein of RSV. This prevents its binding and uptake by host cellular receptors....\nToxicity: ...", "source": "Palivizumab"}, {"id": "Palivizumab_INT_Belimumab", "text": "Interaction: Palivizumab AND Belimumab\nDetails: The risk or severity of adverse effects can be increased when Palivizumab is combined with Belimumab.\nRisk: Monitor closely.", "source": "Palivizumab + Belimumab"}, {"id": "Palivizumab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Palivizumab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Palivizumab_INT_Yellow fever vaccine", "text": "Interaction: Palivizumab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + Yellow fever vaccine"}, {"id": "Palivizumab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Palivizumab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Palivizumab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Palivizumab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Palivizumab_INT_Rotavirus Vaccine", "text": "Interaction: Palivizumab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + Rotavirus Vaccine"}, {"id": "Palivizumab_INT_G17DT", "text": "Interaction: Palivizumab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + G17DT"}, {"id": "Palivizumab_INT_INGN 201", "text": "Interaction: Palivizumab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + INGN 201"}, {"id": "Palivizumab_INT_INGN 225", "text": "Interaction: Palivizumab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + INGN 225"}, {"id": "Palivizumab_INT_Rindopepimut", "text": "Interaction: Palivizumab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + Rindopepimut"}, {"id": "Palivizumab_INT_SRP 299", "text": "Interaction: Palivizumab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + SRP 299"}, {"id": "Palivizumab_INT_GI-5005", "text": "Interaction: Palivizumab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + GI-5005"}, {"id": "Palivizumab_INT_TG4010", "text": "Interaction: Palivizumab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + TG4010"}, {"id": "Palivizumab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Palivizumab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + Rabies virus inactivated antigen, A"}, {"id": "Palivizumab_INT_Tecemotide", "text": "Interaction: Palivizumab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + Tecemotide"}, {"id": "Palivizumab_INT_BCG vaccine", "text": "Interaction: Palivizumab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + BCG vaccine"}, {"id": "Palivizumab_INT_Rubella virus vaccine", "text": "Interaction: Palivizumab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + Rubella virus vaccine"}, {"id": "Palivizumab_INT_Hepatitis A Vaccine", "text": "Interaction: Palivizumab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + Hepatitis A Vaccine"}, {"id": "Palivizumab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Palivizumab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + Salmonella typhi ty21a live antigen"}, {"id": "Palivizumab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Palivizumab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Palivizumab.\nRisk: Monitor closely.", "source": "Palivizumab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Daclizumab_GEN", "text": "Drug: Daclizumab\nDescription: Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antib...", "source": "Daclizumab"}, {"id": "Daclizumab_CLIN", "text": "Drug: Daclizumab\nMechanism: Zenepax binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymp...\nToxicity: ...", "source": "Daclizumab"}, {"id": "Daclizumab_INT_Natalizumab", "text": "Interaction: Daclizumab AND Natalizumab\nDetails: The risk or severity of adverse effects can be increased when Daclizumab is combined with Natalizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Natalizumab"}, {"id": "Daclizumab_INT_Pimecrolimus", "text": "Interaction: Daclizumab AND Pimecrolimus\nDetails: The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Pimecrolimus"}, {"id": "Daclizumab_INT_Tofacitinib", "text": "Interaction: Daclizumab AND Tofacitinib\nDetails: Daclizumab may increase the immunosuppressive activities of Tofacitinib.\nRisk: Monitor closely.", "source": "Daclizumab + Tofacitinib"}, {"id": "Daclizumab_INT_Tacrolimus", "text": "Interaction: Daclizumab AND Tacrolimus\nDetails: The risk or severity of adverse effects can be increased when Tacrolimus is combined with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Tacrolimus"}, {"id": "Daclizumab_INT_Belimumab", "text": "Interaction: Daclizumab AND Belimumab\nDetails: The risk or severity of adverse effects can be increased when Daclizumab is combined with Belimumab.\nRisk: Monitor closely.", "source": "Daclizumab + Belimumab"}, {"id": "Daclizumab_INT_BCG vaccine", "text": "Interaction: Daclizumab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + BCG vaccine"}, {"id": "Daclizumab_INT_Leflunomide", "text": "Interaction: Daclizumab AND Leflunomide\nDetails: The risk or severity of adverse effects can be increased when Daclizumab is combined with Leflunomide.\nRisk: Monitor closely.", "source": "Daclizumab + Leflunomide"}, {"id": "Daclizumab_INT_Fingolimod", "text": "Interaction: Daclizumab AND Fingolimod\nDetails: Daclizumab may increase the immunosuppressive activities of Fingolimod.\nRisk: Monitor closely.", "source": "Daclizumab + Fingolimod"}, {"id": "Daclizumab_INT_Roflumilast", "text": "Interaction: Daclizumab AND Roflumilast\nDetails: Roflumilast may increase the immunosuppressive activities of Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Roflumilast"}, {"id": "Daclizumab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Daclizumab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Daclizumab_INT_Yellow fever vaccine", "text": "Interaction: Daclizumab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Yellow fever vaccine"}, {"id": "Daclizumab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Daclizumab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Daclizumab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Daclizumab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Daclizumab_INT_Rotavirus Vaccine", "text": "Interaction: Daclizumab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Rotavirus Vaccine"}, {"id": "Daclizumab_INT_G17DT", "text": "Interaction: Daclizumab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + G17DT"}, {"id": "Daclizumab_INT_INGN 201", "text": "Interaction: Daclizumab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + INGN 201"}, {"id": "Daclizumab_INT_INGN 225", "text": "Interaction: Daclizumab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + INGN 225"}, {"id": "Daclizumab_INT_Rindopepimut", "text": "Interaction: Daclizumab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Rindopepimut"}, {"id": "Daclizumab_INT_SRP 299", "text": "Interaction: Daclizumab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + SRP 299"}, {"id": "Daclizumab_INT_GI-5005", "text": "Interaction: Daclizumab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + GI-5005"}, {"id": "Daclizumab_INT_TG4010", "text": "Interaction: Daclizumab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + TG4010"}, {"id": "Daclizumab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Daclizumab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Rabies virus inactivated antigen, A"}, {"id": "Daclizumab_INT_Tecemotide", "text": "Interaction: Daclizumab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Tecemotide"}, {"id": "Daclizumab_INT_Rubella virus vaccine", "text": "Interaction: Daclizumab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Rubella virus vaccine"}, {"id": "Daclizumab_INT_Hepatitis A Vaccine", "text": "Interaction: Daclizumab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Hepatitis A Vaccine"}, {"id": "Daclizumab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Daclizumab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Salmonella typhi ty21a live antigen"}, {"id": "Daclizumab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Daclizumab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Daclizumab_INT_Denosumab", "text": "Interaction: Daclizumab AND Denosumab\nDetails: The risk or severity of adverse effects can be increased when Denosumab is combined with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Denosumab"}, {"id": "Daclizumab_INT_Sipuleucel-T", "text": "Interaction: Daclizumab AND Sipuleucel-T\nDetails: The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Sipuleucel-T"}, {"id": "Daclizumab_INT_Trastuzumab", "text": "Interaction: Daclizumab AND Trastuzumab\nDetails: Trastuzumab may increase the neutropenic activities of Daclizumab.\nRisk: Monitor closely.", "source": "Daclizumab + Trastuzumab"}, {"id": "Bevacizumab_GEN", "text": "Drug: Bevacizumab\nDescription: ...", "source": "Bevacizumab"}, {"id": "Bevacizumab_GEN", "text": "Drug: Bevacizumab\nDescription: A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produ...", "source": "Bevacizumab"}, {"id": "Bevacizumab_CLIN", "text": "Drug: Bevacizumab\nMechanism: Bevacizumab contains human framework regions with antigen binding regions of a humanised murine antibody that binds to VEGF. Bevacizumab is produced by recombinant DNA technology in a Chinese hamster ...\nToxicity: Category C in pregnancy. No studies on lactating patients: recommended to discontinue the drug or discontinue lactation. No extensive studies in pediatrics. In geriatrics: increased risk of proteinuri...", "source": "Bevacizumab"}, {"id": "Bevacizumab_INT_Metamizole", "text": "Interaction: Bevacizumab AND Metamizole\nDetails: The risk or severity of myelosuppression can be increased when Metamizole is combined with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Metamizole"}, {"id": "Bevacizumab_INT_Sunitinib", "text": "Interaction: Bevacizumab AND Sunitinib\nDetails: The risk or severity of adverse effects can be increased when Sunitinib is combined with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Sunitinib"}, {"id": "Bevacizumab_INT_Clozapine", "text": "Interaction: Bevacizumab AND Clozapine\nDetails: The risk or severity of adverse effects can be increased when Bevacizumab is combined with Clozapine.\nRisk: Monitor closely.", "source": "Bevacizumab + Clozapine"}, {"id": "Bevacizumab_INT_Belimumab", "text": "Interaction: Bevacizumab AND Belimumab\nDetails: The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belimumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Belimumab"}, {"id": "Bevacizumab_INT_Trastuzumab", "text": "Interaction: Bevacizumab AND Trastuzumab\nDetails: Trastuzumab may increase the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Trastuzumab"}, {"id": "Bevacizumab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Bevacizumab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Bevacizumab_INT_Yellow fever vaccine", "text": "Interaction: Bevacizumab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Yellow fever vaccine"}, {"id": "Bevacizumab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Bevacizumab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Bevacizumab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Bevacizumab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Bevacizumab_INT_Rotavirus Vaccine", "text": "Interaction: Bevacizumab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Rotavirus Vaccine"}, {"id": "Bevacizumab_INT_G17DT", "text": "Interaction: Bevacizumab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + G17DT"}, {"id": "Bevacizumab_INT_INGN 201", "text": "Interaction: Bevacizumab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + INGN 201"}, {"id": "Bevacizumab_INT_INGN 225", "text": "Interaction: Bevacizumab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + INGN 225"}, {"id": "Bevacizumab_INT_Rindopepimut", "text": "Interaction: Bevacizumab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Rindopepimut"}, {"id": "Bevacizumab_INT_SRP 299", "text": "Interaction: Bevacizumab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + SRP 299"}, {"id": "Bevacizumab_INT_GI-5005", "text": "Interaction: Bevacizumab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + GI-5005"}, {"id": "Bevacizumab_INT_TG4010", "text": "Interaction: Bevacizumab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + TG4010"}, {"id": "Bevacizumab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Bevacizumab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Rabies virus inactivated antigen, A"}, {"id": "Bevacizumab_INT_Tecemotide", "text": "Interaction: Bevacizumab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Tecemotide"}, {"id": "Bevacizumab_INT_BCG vaccine", "text": "Interaction: Bevacizumab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + BCG vaccine"}, {"id": "Bevacizumab_INT_Rubella virus vaccine", "text": "Interaction: Bevacizumab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Rubella virus vaccine"}, {"id": "Bevacizumab_INT_Hepatitis A Vaccine", "text": "Interaction: Bevacizumab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Hepatitis A Vaccine"}, {"id": "Bevacizumab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Bevacizumab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Salmonella typhi ty21a live antigen"}, {"id": "Bevacizumab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Bevacizumab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Bevacizumab_INT_Digoxin", "text": "Interaction: Bevacizumab AND Digoxin\nDetails: Digoxin may decrease the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Digoxin"}, {"id": "Bevacizumab_INT_Acetyldigitoxin", "text": "Interaction: Bevacizumab AND Acetyldigitoxin\nDetails: Acetyldigitoxin may decrease the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Acetyldigitoxin"}, {"id": "Bevacizumab_INT_Deslanoside", "text": "Interaction: Bevacizumab AND Deslanoside\nDetails: Deslanoside may decrease the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Deslanoside"}, {"id": "Bevacizumab_INT_Ouabain", "text": "Interaction: Bevacizumab AND Ouabain\nDetails: Ouabain may decrease the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Ouabain"}, {"id": "Bevacizumab_INT_Digitoxin", "text": "Interaction: Bevacizumab AND Digitoxin\nDetails: Digitoxin may decrease the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Digitoxin"}, {"id": "Bevacizumab_INT_Cymarin", "text": "Interaction: Bevacizumab AND Cymarin\nDetails: Cymarin may decrease the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Cymarin"}, {"id": "Bevacizumab_INT_Proscillaridin", "text": "Interaction: Bevacizumab AND Proscillaridin\nDetails: Proscillaridin may decrease the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Proscillaridin"}, {"id": "Bevacizumab_INT_Metildigoxin", "text": "Interaction: Bevacizumab AND Metildigoxin\nDetails: Metildigoxin may decrease the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Metildigoxin"}, {"id": "Bevacizumab_INT_Peruvoside", "text": "Interaction: Bevacizumab AND Peruvoside\nDetails: Peruvoside may decrease the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Peruvoside"}, {"id": "Bevacizumab_INT_Lanatoside C", "text": "Interaction: Bevacizumab AND Lanatoside C\nDetails: Lanatoside C may decrease the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Lanatoside C"}, {"id": "Bevacizumab_INT_Gitoformate", "text": "Interaction: Bevacizumab AND Gitoformate\nDetails: Gitoformate may decrease the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Gitoformate"}, {"id": "Bevacizumab_INT_Acetyldigoxin", "text": "Interaction: Bevacizumab AND Acetyldigoxin\nDetails: Acetyldigoxin may decrease the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Acetyldigoxin"}, {"id": "Bevacizumab_INT_Oleandrin", "text": "Interaction: Bevacizumab AND Oleandrin\nDetails: Oleandrin may decrease the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Oleandrin"}, {"id": "Bevacizumab_INT_Digoxin Immune Fab (Ovine)", "text": "Interaction: Bevacizumab AND Digoxin Immune Fab (Ovine)\nDetails: Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Bevacizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Digoxin Immune Fab (Ovine)"}, {"id": "Bevacizumab_INT_Cetuximab", "text": "Interaction: Bevacizumab AND Cetuximab\nDetails: Bevacizumab may increase the cardiotoxic activities of Cetuximab.\nRisk: Monitor closely.", "source": "Bevacizumab + Cetuximab"}, {"id": "Bevacizumab_INT_Denileukin diftitox", "text": "Interaction: Bevacizumab AND Denileukin diftitox\nDetails: Bevacizumab may increase the cardiotoxic activities of Denileukin diftitox.\nRisk: Monitor closely.", "source": "Bevacizumab + Denileukin diftitox"}, {"id": "Bevacizumab_INT_Asparaginase", "text": "Interaction: Bevacizumab AND Asparaginase\nDetails: Bevacizumab may increase the cardiotoxic activities of Asparaginase.\nRisk: Monitor closely.", "source": "Bevacizumab + Asparaginase"}, {"id": "Bevacizumab_INT_Pegaspargase", "text": "Interaction: Bevacizumab AND Pegaspargase\nDetails: Bevacizumab may increase the cardiotoxic activities of Pegaspargase.\nRisk: Monitor closely.", "source": "Bevacizumab + Pegaspargase"}, {"id": "Bevacizumab_INT_Rituximab", "text": "Interaction: Bevacizumab AND Rituximab\nDetails: Bevacizumab may increase the cardiotoxic activities of Rituximab.\nRisk: Monitor closely.", "source": "Bevacizumab + Rituximab"}, {"id": "Bevacizumab_INT_Bortezomib", "text": "Interaction: Bevacizumab AND Bortezomib\nDetails: Bevacizumab may increase the cardiotoxic activities of Bortezomib.\nRisk: Monitor closely.", "source": "Bevacizumab + Bortezomib"}, {"id": "Bevacizumab_INT_Pipobroman", "text": "Interaction: Bevacizumab AND Pipobroman\nDetails: Bevacizumab may increase the cardiotoxic activities of Pipobroman.\nRisk: Monitor closely.", "source": "Bevacizumab + Pipobroman"}, {"id": "Bevacizumab_INT_Cladribine", "text": "Interaction: Bevacizumab AND Cladribine\nDetails: Bevacizumab may increase the cardiotoxic activities of Cladribine.\nRisk: Monitor closely.", "source": "Bevacizumab + Cladribine"}, {"id": "Bevacizumab_INT_Carmustine", "text": "Interaction: Bevacizumab AND Carmustine\nDetails: Bevacizumab may increase the cardiotoxic activities of Carmustine.\nRisk: Monitor closely.", "source": "Bevacizumab + Carmustine"}, {"id": "Bevacizumab_INT_Amsacrine", "text": "Interaction: Bevacizumab AND Amsacrine\nDetails: Bevacizumab may increase the cardiotoxic activities of Amsacrine.\nRisk: Monitor closely.", "source": "Bevacizumab + Amsacrine"}, {"id": "Bevacizumab_INT_Bleomycin", "text": "Interaction: Bevacizumab AND Bleomycin\nDetails: Bevacizumab may increase the cardiotoxic activities of Bleomycin.\nRisk: Monitor closely.", "source": "Bevacizumab + Bleomycin"}, {"id": "Bevacizumab_INT_Chlorambucil", "text": "Interaction: Bevacizumab AND Chlorambucil\nDetails: Bevacizumab may increase the cardiotoxic activities of Chlorambucil.\nRisk: Monitor closely.", "source": "Bevacizumab + Chlorambucil"}, {"id": "Bevacizumab_INT_Raltitrexed", "text": "Interaction: Bevacizumab AND Raltitrexed\nDetails: Bevacizumab may increase the cardiotoxic activities of Raltitrexed.\nRisk: Monitor closely.", "source": "Bevacizumab + Raltitrexed"}, {"id": "Bevacizumab_INT_Mitomycin", "text": "Interaction: Bevacizumab AND Mitomycin\nDetails: Bevacizumab may increase the cardiotoxic activities of Mitomycin.\nRisk: Monitor closely.", "source": "Bevacizumab + Mitomycin"}, {"id": "Bevacizumab_INT_Bexarotene", "text": "Interaction: Bevacizumab AND Bexarotene\nDetails: Bevacizumab may increase the cardiotoxic activities of Bexarotene.\nRisk: Monitor closely.", "source": "Bevacizumab + Bexarotene"}, {"id": "Bevacizumab_INT_Vindesine", "text": "Interaction: Bevacizumab AND Vindesine\nDetails: Bevacizumab may increase the cardiotoxic activities of Vindesine.\nRisk: Monitor closely.", "source": "Bevacizumab + Vindesine"}, {"id": "Bevacizumab_INT_Gefitinib", "text": "Interaction: Bevacizumab AND Gefitinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Gefitinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Gefitinib"}, {"id": "Bevacizumab_INT_Tioguanine", "text": "Interaction: Bevacizumab AND Tioguanine\nDetails: Bevacizumab may increase the cardiotoxic activities of Tioguanine.\nRisk: Monitor closely.", "source": "Bevacizumab + Tioguanine"}, {"id": "Bevacizumab_INT_Vinorelbine", "text": "Interaction: Bevacizumab AND Vinorelbine\nDetails: Bevacizumab may increase the cardiotoxic activities of Vinorelbine.\nRisk: Monitor closely.", "source": "Bevacizumab + Vinorelbine"}, {"id": "Bevacizumab_INT_Valrubicin", "text": "Interaction: Bevacizumab AND Valrubicin\nDetails: Bevacizumab may increase the cardiotoxic activities of Valrubicin.\nRisk: Monitor closely.", "source": "Bevacizumab + Valrubicin"}, {"id": "Bevacizumab_INT_Streptozocin", "text": "Interaction: Bevacizumab AND Streptozocin\nDetails: Bevacizumab may increase the cardiotoxic activities of Streptozocin.\nRisk: Monitor closely.", "source": "Bevacizumab + Streptozocin"}, {"id": "Bevacizumab_INT_Gemcitabine", "text": "Interaction: Bevacizumab AND Gemcitabine\nDetails: Bevacizumab may increase the cardiotoxic activities of Gemcitabine.\nRisk: Monitor closely.", "source": "Bevacizumab + Gemcitabine"}, {"id": "Bevacizumab_INT_Teniposide", "text": "Interaction: Bevacizumab AND Teniposide\nDetails: Bevacizumab may increase the cardiotoxic activities of Teniposide.\nRisk: Monitor closely.", "source": "Bevacizumab + Teniposide"}, {"id": "Bevacizumab_INT_Epirubicin", "text": "Interaction: Bevacizumab AND Epirubicin\nDetails: Bevacizumab may increase the cardiotoxic activities of Epirubicin.\nRisk: Monitor closely.", "source": "Bevacizumab + Epirubicin"}, {"id": "Bevacizumab_INT_Altretamine", "text": "Interaction: Bevacizumab AND Altretamine\nDetails: Bevacizumab may increase the cardiotoxic activities of Altretamine.\nRisk: Monitor closely.", "source": "Bevacizumab + Altretamine"}, {"id": "Bevacizumab_INT_Cisplatin", "text": "Interaction: Bevacizumab AND Cisplatin\nDetails: Bevacizumab may increase the cardiotoxic activities of Cisplatin.\nRisk: Monitor closely.", "source": "Bevacizumab + Cisplatin"}, {"id": "Bevacizumab_INT_Alitretinoin", "text": "Interaction: Bevacizumab AND Alitretinoin\nDetails: Bevacizumab may increase the cardiotoxic activities of Alitretinoin.\nRisk: Monitor closely.", "source": "Bevacizumab + Alitretinoin"}, {"id": "Bevacizumab_INT_Oxaliplatin", "text": "Interaction: Bevacizumab AND Oxaliplatin\nDetails: Bevacizumab may increase the cardiotoxic activities of Oxaliplatin.\nRisk: Monitor closely.", "source": "Bevacizumab + Oxaliplatin"}, {"id": "Bevacizumab_INT_Erlotinib", "text": "Interaction: Bevacizumab AND Erlotinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Erlotinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Erlotinib"}, {"id": "Bevacizumab_INT_Cyclophosphamide", "text": "Interaction: Bevacizumab AND Cyclophosphamide\nDetails: Bevacizumab may increase the cardiotoxic activities of Cyclophosphamide.\nRisk: Monitor closely.", "source": "Bevacizumab + Cyclophosphamide"}, {"id": "Bevacizumab_INT_Vincristine", "text": "Interaction: Bevacizumab AND Vincristine\nDetails: Bevacizumab may increase the cardiotoxic activities of Vincristine.\nRisk: Monitor closely.", "source": "Bevacizumab + Vincristine"}, {"id": "Bevacizumab_INT_Fluorouracil", "text": "Interaction: Bevacizumab AND Fluorouracil\nDetails: Bevacizumab may increase the cardiotoxic activities of Fluorouracil.\nRisk: Monitor closely.", "source": "Bevacizumab + Fluorouracil"}, {"id": "Bevacizumab_INT_Pentostatin", "text": "Interaction: Bevacizumab AND Pentostatin\nDetails: Bevacizumab may increase the cardiotoxic activities of Pentostatin.\nRisk: Monitor closely.", "source": "Bevacizumab + Pentostatin"}, {"id": "Bevacizumab_INT_Methotrexate", "text": "Interaction: Bevacizumab AND Methotrexate\nDetails: Bevacizumab may increase the cardiotoxic activities of Methotrexate.\nRisk: Monitor closely.", "source": "Bevacizumab + Methotrexate"}, {"id": "Bevacizumab_INT_Vinblastine", "text": "Interaction: Bevacizumab AND Vinblastine\nDetails: Bevacizumab may increase the cardiotoxic activities of Vinblastine.\nRisk: Monitor closely.", "source": "Bevacizumab + Vinblastine"}, {"id": "Bevacizumab_INT_Imatinib", "text": "Interaction: Bevacizumab AND Imatinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Imatinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Imatinib"}, {"id": "Bevacizumab_INT_Clofarabine", "text": "Interaction: Bevacizumab AND Clofarabine\nDetails: Bevacizumab may increase the cardiotoxic activities of Clofarabine.\nRisk: Monitor closely.", "source": "Bevacizumab + Clofarabine"}, {"id": "Bevacizumab_INT_Pemetrexed", "text": "Interaction: Bevacizumab AND Pemetrexed\nDetails: Bevacizumab may increase the cardiotoxic activities of Pemetrexed.\nRisk: Monitor closely.", "source": "Bevacizumab + Pemetrexed"}, {"id": "Bevacizumab_INT_Mitotane", "text": "Interaction: Bevacizumab AND Mitotane\nDetails: Bevacizumab may increase the cardiotoxic activities of Mitotane.\nRisk: Monitor closely.", "source": "Bevacizumab + Mitotane"}, {"id": "Bevacizumab_INT_Daunorubicin", "text": "Interaction: Bevacizumab AND Daunorubicin\nDetails: Bevacizumab may increase the cardiotoxic activities of Daunorubicin.\nRisk: Monitor closely.", "source": "Bevacizumab + Daunorubicin"}, {"id": "Bevacizumab_INT_Porfimer sodium", "text": "Interaction: Bevacizumab AND Porfimer sodium\nDetails: Bevacizumab may increase the cardiotoxic activities of Porfimer sodium.\nRisk: Monitor closely.", "source": "Bevacizumab + Porfimer sodium"}, {"id": "Bevacizumab_INT_Etoposide", "text": "Interaction: Bevacizumab AND Etoposide\nDetails: Bevacizumab may increase the cardiotoxic activities of Etoposide.\nRisk: Monitor closely.", "source": "Bevacizumab + Etoposide"}, {"id": "Bevacizumab_INT_Dacarbazine", "text": "Interaction: Bevacizumab AND Dacarbazine\nDetails: Bevacizumab may increase the cardiotoxic activities of Dacarbazine.\nRisk: Monitor closely.", "source": "Bevacizumab + Dacarbazine"}, {"id": "Bevacizumab_INT_Temozolomide", "text": "Interaction: Bevacizumab AND Temozolomide\nDetails: Bevacizumab may increase the cardiotoxic activities of Temozolomide.\nRisk: Monitor closely.", "source": "Bevacizumab + Temozolomide"}, {"id": "Bevacizumab_INT_Mechlorethamine", "text": "Interaction: Bevacizumab AND Mechlorethamine\nDetails: Bevacizumab may increase the cardiotoxic activities of Mechlorethamine.\nRisk: Monitor closely.", "source": "Bevacizumab + Mechlorethamine"}, {"id": "Bevacizumab_INT_Azacitidine", "text": "Interaction: Bevacizumab AND Azacitidine\nDetails: Bevacizumab may increase the cardiotoxic activities of Azacitidine.\nRisk: Monitor closely.", "source": "Bevacizumab + Azacitidine"}, {"id": "Bevacizumab_INT_Carboplatin", "text": "Interaction: Bevacizumab AND Carboplatin\nDetails: Bevacizumab may increase the cardiotoxic activities of Carboplatin.\nRisk: Monitor closely.", "source": "Bevacizumab + Carboplatin"}, {"id": "Bevacizumab_INT_Dactinomycin", "text": "Interaction: Bevacizumab AND Dactinomycin\nDetails: Bevacizumab may increase the cardiotoxic activities of Dactinomycin.\nRisk: Monitor closely.", "source": "Bevacizumab + Dactinomycin"}, {"id": "Bevacizumab_INT_Cytarabine", "text": "Interaction: Bevacizumab AND Cytarabine\nDetails: Bevacizumab may increase the cardiotoxic activities of Cytarabine.\nRisk: Monitor closely.", "source": "Bevacizumab + Cytarabine"}, {"id": "Bevacizumab_INT_Doxorubicin", "text": "Interaction: Bevacizumab AND Doxorubicin\nDetails: Bevacizumab may increase the cardiotoxic activities of Doxorubicin.\nRisk: Monitor closely.", "source": "Bevacizumab + Doxorubicin"}, {"id": "Bevacizumab_INT_Hydroxyurea", "text": "Interaction: Bevacizumab AND Hydroxyurea\nDetails: Bevacizumab may increase the cardiotoxic activities of Hydroxyurea.\nRisk: Monitor closely.", "source": "Bevacizumab + Hydroxyurea"}, {"id": "Bevacizumab_INT_Busulfan", "text": "Interaction: Bevacizumab AND Busulfan\nDetails: Bevacizumab may increase the cardiotoxic activities of Busulfan.\nRisk: Monitor closely.", "source": "Bevacizumab + Busulfan"}, {"id": "Bevacizumab_INT_Topotecan", "text": "Interaction: Bevacizumab AND Topotecan\nDetails: Bevacizumab may increase the cardiotoxic activities of Topotecan.\nRisk: Monitor closely.", "source": "Bevacizumab + Topotecan"}, {"id": "Bevacizumab_INT_Mercaptopurine", "text": "Interaction: Bevacizumab AND Mercaptopurine\nDetails: Bevacizumab may increase the cardiotoxic activities of Mercaptopurine.\nRisk: Monitor closely.", "source": "Bevacizumab + Mercaptopurine"}, {"id": "Bevacizumab_INT_Melphalan", "text": "Interaction: Bevacizumab AND Melphalan\nDetails: Bevacizumab may increase the cardiotoxic activities of Melphalan.\nRisk: Monitor closely.", "source": "Bevacizumab + Melphalan"}, {"id": "Bevacizumab_INT_Fludarabine", "text": "Interaction: Bevacizumab AND Fludarabine\nDetails: Bevacizumab may increase the cardiotoxic activities of Fludarabine.\nRisk: Monitor closely.", "source": "Bevacizumab + Fludarabine"}, {"id": "Bevacizumab_INT_Capecitabine", "text": "Interaction: Bevacizumab AND Capecitabine\nDetails: Bevacizumab may increase the cardiotoxic activities of Capecitabine.\nRisk: Monitor closely.", "source": "Bevacizumab + Capecitabine"}, {"id": "Bevacizumab_INT_Procarbazine", "text": "Interaction: Bevacizumab AND Procarbazine\nDetails: Bevacizumab may increase the cardiotoxic activities of Procarbazine.\nRisk: Monitor closely.", "source": "Bevacizumab + Procarbazine"}, {"id": "Bevacizumab_INT_Arsenic trioxide", "text": "Interaction: Bevacizumab AND Arsenic trioxide\nDetails: Bevacizumab may increase the cardiotoxic activities of Arsenic trioxide.\nRisk: Monitor closely.", "source": "Bevacizumab + Arsenic trioxide"}, {"id": "Bevacizumab_INT_Idarubicin", "text": "Interaction: Bevacizumab AND Idarubicin\nDetails: Bevacizumab may increase the cardiotoxic activities of Idarubicin.\nRisk: Monitor closely.", "source": "Bevacizumab + Idarubicin"}, {"id": "Bevacizumab_INT_Ifosfamide", "text": "Interaction: Bevacizumab AND Ifosfamide\nDetails: Bevacizumab may increase the cardiotoxic activities of Ifosfamide.\nRisk: Monitor closely.", "source": "Bevacizumab + Ifosfamide"}, {"id": "Bevacizumab_INT_Estramustine", "text": "Interaction: Bevacizumab AND Estramustine\nDetails: Bevacizumab may increase the cardiotoxic activities of Estramustine.\nRisk: Monitor closely.", "source": "Bevacizumab + Estramustine"}, {"id": "Bevacizumab_INT_Mitoxantrone", "text": "Interaction: Bevacizumab AND Mitoxantrone\nDetails: Bevacizumab may increase the cardiotoxic activities of Mitoxantrone.\nRisk: Monitor closely.", "source": "Bevacizumab + Mitoxantrone"}, {"id": "Bevacizumab_INT_Lomustine", "text": "Interaction: Bevacizumab AND Lomustine\nDetails: Bevacizumab may increase the cardiotoxic activities of Lomustine.\nRisk: Monitor closely.", "source": "Bevacizumab + Lomustine"}, {"id": "Bevacizumab_INT_Paclitaxel", "text": "Interaction: Bevacizumab AND Paclitaxel\nDetails: Bevacizumab may increase the cardiotoxic activities of Paclitaxel.\nRisk: Monitor closely.", "source": "Bevacizumab + Paclitaxel"}, {"id": "Bevacizumab_INT_Docetaxel", "text": "Interaction: Bevacizumab AND Docetaxel\nDetails: Bevacizumab may increase the cardiotoxic activities of Docetaxel.\nRisk: Monitor closely.", "source": "Bevacizumab + Docetaxel"}, {"id": "Bevacizumab_INT_Dasatinib", "text": "Interaction: Bevacizumab AND Dasatinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Dasatinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Dasatinib"}, {"id": "Bevacizumab_INT_Lapatinib", "text": "Interaction: Bevacizumab AND Lapatinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Lapatinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Lapatinib"}, {"id": "Bevacizumab_INT_Decitabine", "text": "Interaction: Bevacizumab AND Decitabine\nDetails: Bevacizumab may increase the cardiotoxic activities of Decitabine.\nRisk: Monitor closely.", "source": "Bevacizumab + Decitabine"}, {"id": "Bevacizumab_INT_Panitumumab", "text": "Interaction: Bevacizumab AND Panitumumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Panitumumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Panitumumab"}, {"id": "Bevacizumab_INT_Vorinostat", "text": "Interaction: Bevacizumab AND Vorinostat\nDetails: Bevacizumab may increase the cardiotoxic activities of Vorinostat.\nRisk: Monitor closely.", "source": "Bevacizumab + Vorinostat"}, {"id": "Bevacizumab_INT_Fotemustine", "text": "Interaction: Bevacizumab AND Fotemustine\nDetails: Bevacizumab may increase the cardiotoxic activities of Fotemustine.\nRisk: Monitor closely.", "source": "Bevacizumab + Fotemustine"}, {"id": "Bevacizumab_INT_Thiotepa", "text": "Interaction: Bevacizumab AND Thiotepa\nDetails: Bevacizumab may increase the cardiotoxic activities of Thiotepa.\nRisk: Monitor closely.", "source": "Bevacizumab + Thiotepa"}, {"id": "Bevacizumab_INT_Omacetaxine mepesuccinate", "text": "Interaction: Bevacizumab AND Omacetaxine mepesuccinate\nDetails: Bevacizumab may increase the cardiotoxic activities of Omacetaxine mepesuccinate.\nRisk: Monitor closely.", "source": "Bevacizumab + Omacetaxine mepesuccinate"}, {"id": "Bevacizumab_INT_Satraplatin", "text": "Interaction: Bevacizumab AND Satraplatin\nDetails: Bevacizumab may increase the cardiotoxic activities of Satraplatin.\nRisk: Monitor closely.", "source": "Bevacizumab + Satraplatin"}, {"id": "Bevacizumab_INT_Belinostat", "text": "Interaction: Bevacizumab AND Belinostat\nDetails: Bevacizumab may increase the cardiotoxic activities of Belinostat.\nRisk: Monitor closely.", "source": "Bevacizumab + Belinostat"}, {"id": "Bevacizumab_INT_Trabectedin", "text": "Interaction: Bevacizumab AND Trabectedin\nDetails: Bevacizumab may increase the cardiotoxic activities of Trabectedin.\nRisk: Monitor closely.", "source": "Bevacizumab + Trabectedin"}, {"id": "Bevacizumab_INT_Ramucirumab", "text": "Interaction: Bevacizumab AND Ramucirumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Ramucirumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Ramucirumab"}, {"id": "Bevacizumab_INT_Trastuzumab emtansine", "text": "Interaction: Bevacizumab AND Trastuzumab emtansine\nDetails: Bevacizumab may increase the cardiotoxic activities of Trastuzumab emtansine.\nRisk: Monitor closely.", "source": "Bevacizumab + Trastuzumab emtansine"}, {"id": "Bevacizumab_INT_Romidepsin", "text": "Interaction: Bevacizumab AND Romidepsin\nDetails: Bevacizumab may increase the cardiotoxic activities of Romidepsin.\nRisk: Monitor closely.", "source": "Bevacizumab + Romidepsin"}, {"id": "Bevacizumab_INT_Pixantrone", "text": "Interaction: Bevacizumab AND Pixantrone\nDetails: Bevacizumab may increase the cardiotoxic activities of Pixantrone.\nRisk: Monitor closely.", "source": "Bevacizumab + Pixantrone"}, {"id": "Bevacizumab_INT_Amrubicin", "text": "Interaction: Bevacizumab AND Amrubicin\nDetails: Bevacizumab may increase the cardiotoxic activities of Amrubicin.\nRisk: Monitor closely.", "source": "Bevacizumab + Amrubicin"}, {"id": "Bevacizumab_INT_Lonidamine", "text": "Interaction: Bevacizumab AND Lonidamine\nDetails: Bevacizumab may increase the cardiotoxic activities of Lonidamine.\nRisk: Monitor closely.", "source": "Bevacizumab + Lonidamine"}, {"id": "Bevacizumab_INT_Temsirolimus", "text": "Interaction: Bevacizumab AND Temsirolimus\nDetails: Bevacizumab may increase the cardiotoxic activities of Temsirolimus.\nRisk: Monitor closely.", "source": "Bevacizumab + Temsirolimus"}, {"id": "Bevacizumab_INT_Pertuzumab", "text": "Interaction: Bevacizumab AND Pertuzumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Pertuzumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Pertuzumab"}, {"id": "Bevacizumab_INT_Panobinostat", "text": "Interaction: Bevacizumab AND Panobinostat\nDetails: Bevacizumab may increase the cardiotoxic activities of Panobinostat.\nRisk: Monitor closely.", "source": "Bevacizumab + Panobinostat"}, {"id": "Bevacizumab_INT_Bendamustine", "text": "Interaction: Bevacizumab AND Bendamustine\nDetails: Bevacizumab may increase the cardiotoxic activities of Bendamustine.\nRisk: Monitor closely.", "source": "Bevacizumab + Bendamustine"}, {"id": "Bevacizumab_INT_Plicamycin", "text": "Interaction: Bevacizumab AND Plicamycin\nDetails: Bevacizumab may increase the cardiotoxic activities of Plicamycin.\nRisk: Monitor closely.", "source": "Bevacizumab + Plicamycin"}, {"id": "Bevacizumab_INT_Ponatinib", "text": "Interaction: Bevacizumab AND Ponatinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Ponatinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Ponatinib"}, {"id": "Bevacizumab_INT_Trametinib", "text": "Interaction: Bevacizumab AND Trametinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Trametinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Trametinib"}, {"id": "Bevacizumab_INT_Dabrafenib", "text": "Interaction: Bevacizumab AND Dabrafenib\nDetails: Bevacizumab may increase the cardiotoxic activities of Dabrafenib.\nRisk: Monitor closely.", "source": "Bevacizumab + Dabrafenib"}, {"id": "Bevacizumab_INT_Obinutuzumab", "text": "Interaction: Bevacizumab AND Obinutuzumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Obinutuzumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Obinutuzumab"}, {"id": "Bevacizumab_INT_Carmofur", "text": "Interaction: Bevacizumab AND Carmofur\nDetails: Bevacizumab may increase the cardiotoxic activities of Carmofur.\nRisk: Monitor closely.", "source": "Bevacizumab + Carmofur"}, {"id": "Bevacizumab_INT_Miltefosine", "text": "Interaction: Bevacizumab AND Miltefosine\nDetails: Bevacizumab may increase the cardiotoxic activities of Miltefosine.\nRisk: Monitor closely.", "source": "Bevacizumab + Miltefosine"}, {"id": "Bevacizumab_INT_Nivolumab", "text": "Interaction: Bevacizumab AND Nivolumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Nivolumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Nivolumab"}, {"id": "Bevacizumab_INT_Pembrolizumab", "text": "Interaction: Bevacizumab AND Pembrolizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Pembrolizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Pembrolizumab"}, {"id": "Bevacizumab_INT_Blinatumomab", "text": "Interaction: Bevacizumab AND Blinatumomab\nDetails: Bevacizumab may increase the cardiotoxic activities of Blinatumomab.\nRisk: Monitor closely.", "source": "Bevacizumab + Blinatumomab"}, {"id": "Bevacizumab_INT_Idelalisib", "text": "Interaction: Bevacizumab AND Idelalisib\nDetails: Bevacizumab may increase the cardiotoxic activities of Idelalisib.\nRisk: Monitor closely.", "source": "Bevacizumab + Idelalisib"}, {"id": "Bevacizumab_INT_Ceritinib", "text": "Interaction: Bevacizumab AND Ceritinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Ceritinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Ceritinib"}, {"id": "Bevacizumab_INT_Palbociclib", "text": "Interaction: Bevacizumab AND Palbociclib\nDetails: Bevacizumab may increase the cardiotoxic activities of Palbociclib.\nRisk: Monitor closely.", "source": "Bevacizumab + Palbociclib"}, {"id": "Bevacizumab_INT_Olaparib", "text": "Interaction: Bevacizumab AND Olaparib\nDetails: Bevacizumab may increase the cardiotoxic activities of Olaparib.\nRisk: Monitor closely.", "source": "Bevacizumab + Olaparib"}, {"id": "Bevacizumab_INT_Lenvatinib", "text": "Interaction: Bevacizumab AND Lenvatinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Lenvatinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Lenvatinib"}, {"id": "Bevacizumab_INT_Nintedanib", "text": "Interaction: Bevacizumab AND Nintedanib\nDetails: Bevacizumab may increase the cardiotoxic activities of Nintedanib.\nRisk: Monitor closely.", "source": "Bevacizumab + Nintedanib"}, {"id": "Bevacizumab_INT_Tegafur", "text": "Interaction: Bevacizumab AND Tegafur\nDetails: Bevacizumab may increase the cardiotoxic activities of Tegafur.\nRisk: Monitor closely.", "source": "Bevacizumab + Tegafur"}, {"id": "Bevacizumab_INT_Ixazomib", "text": "Interaction: Bevacizumab AND Ixazomib\nDetails: Bevacizumab may increase the cardiotoxic activities of Ixazomib.\nRisk: Monitor closely.", "source": "Bevacizumab + Ixazomib"}, {"id": "Bevacizumab_INT_Pirarubicin", "text": "Interaction: Bevacizumab AND Pirarubicin\nDetails: Bevacizumab may increase the cardiotoxic activities of Pirarubicin.\nRisk: Monitor closely.", "source": "Bevacizumab + Pirarubicin"}, {"id": "Bevacizumab_INT_Aclarubicin", "text": "Interaction: Bevacizumab AND Aclarubicin\nDetails: Bevacizumab may increase the cardiotoxic activities of Aclarubicin.\nRisk: Monitor closely.", "source": "Bevacizumab + Aclarubicin"}, {"id": "Bevacizumab_INT_Zorubicin", "text": "Interaction: Bevacizumab AND Zorubicin\nDetails: Bevacizumab may increase the cardiotoxic activities of Zorubicin.\nRisk: Monitor closely.", "source": "Bevacizumab + Zorubicin"}, {"id": "Bevacizumab_INT_Temoporfin", "text": "Interaction: Bevacizumab AND Temoporfin\nDetails: Bevacizumab may increase the cardiotoxic activities of Temoporfin.\nRisk: Monitor closely.", "source": "Bevacizumab + Temoporfin"}, {"id": "Bevacizumab_INT_Prednimustine", "text": "Interaction: Bevacizumab AND Prednimustine\nDetails: Bevacizumab may increase the cardiotoxic activities of Prednimustine.\nRisk: Monitor closely.", "source": "Bevacizumab + Prednimustine"}, {"id": "Bevacizumab_INT_Trofosfamide", "text": "Interaction: Bevacizumab AND Trofosfamide\nDetails: Bevacizumab may increase the cardiotoxic activities of Trofosfamide.\nRisk: Monitor closely.", "source": "Bevacizumab + Trofosfamide"}, {"id": "Bevacizumab_INT_Mitoguazone", "text": "Interaction: Bevacizumab AND Mitoguazone\nDetails: Bevacizumab may increase the cardiotoxic activities of Mitoguazone.\nRisk: Monitor closely.", "source": "Bevacizumab + Mitoguazone"}, {"id": "Bevacizumab_INT_Nimustine", "text": "Interaction: Bevacizumab AND Nimustine\nDetails: Bevacizumab may increase the cardiotoxic activities of Nimustine.\nRisk: Monitor closely.", "source": "Bevacizumab + Nimustine"}, {"id": "Bevacizumab_INT_Treosulfan", "text": "Interaction: Bevacizumab AND Treosulfan\nDetails: Bevacizumab may increase the cardiotoxic activities of Treosulfan.\nRisk: Monitor closely.", "source": "Bevacizumab + Treosulfan"}, {"id": "Bevacizumab_INT_Cediranib", "text": "Interaction: Bevacizumab AND Cediranib\nDetails: Bevacizumab may increase the cardiotoxic activities of Cediranib.\nRisk: Monitor closely.", "source": "Bevacizumab + Cediranib"}, {"id": "Bevacizumab_INT_Gemtuzumab ozogamicin", "text": "Interaction: Bevacizumab AND Gemtuzumab ozogamicin\nDetails: Bevacizumab may increase the cardiotoxic activities of Gemtuzumab ozogamicin.\nRisk: Monitor closely.", "source": "Bevacizumab + Gemtuzumab ozogamicin"}, {"id": "Bevacizumab_INT_Tiazofurine", "text": "Interaction: Bevacizumab AND Tiazofurine\nDetails: Bevacizumab may increase the cardiotoxic activities of Tiazofurine.\nRisk: Monitor closely.", "source": "Bevacizumab + Tiazofurine"}, {"id": "Bevacizumab_INT_Triaziquone", "text": "Interaction: Bevacizumab AND Triaziquone\nDetails: Bevacizumab may increase the cardiotoxic activities of Triaziquone.\nRisk: Monitor closely.", "source": "Bevacizumab + Triaziquone"}, {"id": "Bevacizumab_INT_Demecolcine", "text": "Interaction: Bevacizumab AND Demecolcine\nDetails: Bevacizumab may increase the cardiotoxic activities of Demecolcine.\nRisk: Monitor closely.", "source": "Bevacizumab + Demecolcine"}, {"id": "Bevacizumab_INT_Etoglucid", "text": "Interaction: Bevacizumab AND Etoglucid\nDetails: Bevacizumab may increase the cardiotoxic activities of Etoglucid.\nRisk: Monitor closely.", "source": "Bevacizumab + Etoglucid"}, {"id": "Bevacizumab_INT_Mitobronitol", "text": "Interaction: Bevacizumab AND Mitobronitol\nDetails: Bevacizumab may increase the cardiotoxic activities of Mitobronitol.\nRisk: Monitor closely.", "source": "Bevacizumab + Mitobronitol"}, {"id": "Bevacizumab_INT_Semustine", "text": "Interaction: Bevacizumab AND Semustine\nDetails: Bevacizumab may increase the cardiotoxic activities of Semustine.\nRisk: Monitor closely.", "source": "Bevacizumab + Semustine"}, {"id": "Bevacizumab_INT_Carboquone", "text": "Interaction: Bevacizumab AND Carboquone\nDetails: Bevacizumab may increase the cardiotoxic activities of Carboquone.\nRisk: Monitor closely.", "source": "Bevacizumab + Carboquone"}, {"id": "Bevacizumab_INT_Ranimustine", "text": "Interaction: Bevacizumab AND Ranimustine\nDetails: Bevacizumab may increase the cardiotoxic activities of Ranimustine.\nRisk: Monitor closely.", "source": "Bevacizumab + Ranimustine"}, {"id": "Bevacizumab_INT_Leuprolide", "text": "Interaction: Bevacizumab AND Leuprolide\nDetails: Bevacizumab may increase the cardiotoxic activities of Leuprolide.\nRisk: Monitor closely.", "source": "Bevacizumab + Leuprolide"}, {"id": "Bevacizumab_INT_Aldesleukin", "text": "Interaction: Bevacizumab AND Aldesleukin\nDetails: Bevacizumab may increase the cardiotoxic activities of Aldesleukin.\nRisk: Monitor closely.", "source": "Bevacizumab + Aldesleukin"}, {"id": "Bevacizumab_INT_Alemtuzumab", "text": "Interaction: Bevacizumab AND Alemtuzumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Alemtuzumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Alemtuzumab"}, {"id": "Bevacizumab_INT_Megestrol acetate", "text": "Interaction: Bevacizumab AND Megestrol acetate\nDetails: Bevacizumab may increase the cardiotoxic activities of Megestrol acetate.\nRisk: Monitor closely.", "source": "Bevacizumab + Megestrol acetate"}, {"id": "Bevacizumab_INT_Lenalidomide", "text": "Interaction: Bevacizumab AND Lenalidomide\nDetails: Bevacizumab may increase the cardiotoxic activities of Lenalidomide.\nRisk: Monitor closely.", "source": "Bevacizumab + Lenalidomide"}, {"id": "Bevacizumab_INT_Flutamide", "text": "Interaction: Bevacizumab AND Flutamide\nDetails: Bevacizumab may increase the cardiotoxic activities of Flutamide.\nRisk: Monitor closely.", "source": "Bevacizumab + Flutamide"}, {"id": "Bevacizumab_INT_Nilutamide", "text": "Interaction: Bevacizumab AND Nilutamide\nDetails: Bevacizumab may increase the cardiotoxic activities of Nilutamide.\nRisk: Monitor closely.", "source": "Bevacizumab + Nilutamide"}, {"id": "Bevacizumab_INT_Tamoxifen", "text": "Interaction: Bevacizumab AND Tamoxifen\nDetails: Bevacizumab may increase the cardiotoxic activities of Tamoxifen.\nRisk: Monitor closely.", "source": "Bevacizumab + Tamoxifen"}, {"id": "Bevacizumab_INT_Tretinoin", "text": "Interaction: Bevacizumab AND Tretinoin\nDetails: Bevacizumab may increase the cardiotoxic activities of Tretinoin.\nRisk: Monitor closely.", "source": "Bevacizumab + Tretinoin"}, {"id": "Bevacizumab_INT_Fulvestrant", "text": "Interaction: Bevacizumab AND Fulvestrant\nDetails: Bevacizumab may increase the cardiotoxic activities of Fulvestrant.\nRisk: Monitor closely.", "source": "Bevacizumab + Fulvestrant"}, {"id": "Bevacizumab_INT_Exemestane", "text": "Interaction: Bevacizumab AND Exemestane\nDetails: Bevacizumab may increase the cardiotoxic activities of Exemestane.\nRisk: Monitor closely.", "source": "Bevacizumab + Exemestane"}, {"id": "Bevacizumab_INT_Letrozole", "text": "Interaction: Bevacizumab AND Letrozole\nDetails: Bevacizumab may increase the cardiotoxic activities of Letrozole.\nRisk: Monitor closely.", "source": "Bevacizumab + Letrozole"}, {"id": "Bevacizumab_INT_Bicalutamide", "text": "Interaction: Bevacizumab AND Bicalutamide\nDetails: Bevacizumab may increase the cardiotoxic activities of Bicalutamide.\nRisk: Monitor closely.", "source": "Bevacizumab + Bicalutamide"}, {"id": "Bevacizumab_INT_Anastrozole", "text": "Interaction: Bevacizumab AND Anastrozole\nDetails: Bevacizumab may increase the cardiotoxic activities of Anastrozole.\nRisk: Monitor closely.", "source": "Bevacizumab + Anastrozole"}, {"id": "Bevacizumab_INT_Everolimus", "text": "Interaction: Bevacizumab AND Everolimus\nDetails: Bevacizumab may increase the cardiotoxic activities of Everolimus.\nRisk: Monitor closely.", "source": "Bevacizumab + Everolimus"}, {"id": "Bevacizumab_INT_Nelarabine", "text": "Interaction: Bevacizumab AND Nelarabine\nDetails: Bevacizumab may increase the cardiotoxic activities of Nelarabine.\nRisk: Monitor closely.", "source": "Bevacizumab + Nelarabine"}, {"id": "Bevacizumab_INT_Nilotinib", "text": "Interaction: Bevacizumab AND Nilotinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Nilotinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Nilotinib"}, {"id": "Bevacizumab_INT_Vandetanib", "text": "Interaction: Bevacizumab AND Vandetanib\nDetails: Bevacizumab may increase the cardiotoxic activities of Vandetanib.\nRisk: Monitor closely.", "source": "Bevacizumab + Vandetanib"}, {"id": "Bevacizumab_INT_Ipilimumab", "text": "Interaction: Bevacizumab AND Ipilimumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Ipilimumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Ipilimumab"}, {"id": "Bevacizumab_INT_Pazopanib", "text": "Interaction: Bevacizumab AND Pazopanib\nDetails: Bevacizumab may increase the cardiotoxic activities of Pazopanib.\nRisk: Monitor closely.", "source": "Bevacizumab + Pazopanib"}, {"id": "Bevacizumab_INT_Catumaxomab", "text": "Interaction: Bevacizumab AND Catumaxomab\nDetails: Bevacizumab may increase the cardiotoxic activities of Catumaxomab.\nRisk: Monitor closely.", "source": "Bevacizumab + Catumaxomab"}, {"id": "Bevacizumab_INT_Bosutinib", "text": "Interaction: Bevacizumab AND Bosutinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Bosutinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Bosutinib"}, {"id": "Bevacizumab_INT_Axitinib", "text": "Interaction: Bevacizumab AND Axitinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Axitinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Axitinib"}, {"id": "Bevacizumab_INT_Ofatumumab", "text": "Interaction: Bevacizumab AND Ofatumumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Ofatumumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Ofatumumab"}, {"id": "Bevacizumab_INT_Cabazitaxel", "text": "Interaction: Bevacizumab AND Cabazitaxel\nDetails: Bevacizumab may increase the cardiotoxic activities of Cabazitaxel.\nRisk: Monitor closely.", "source": "Bevacizumab + Cabazitaxel"}, {"id": "Bevacizumab_INT_Vismodegib", "text": "Interaction: Bevacizumab AND Vismodegib\nDetails: Bevacizumab may increase the cardiotoxic activities of Vismodegib.\nRisk: Monitor closely.", "source": "Bevacizumab + Vismodegib"}, {"id": "Bevacizumab_INT_Crizotinib", "text": "Interaction: Bevacizumab AND Crizotinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Crizotinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Crizotinib"}, {"id": "Bevacizumab_INT_Brentuximab vedotin", "text": "Interaction: Bevacizumab AND Brentuximab vedotin\nDetails: Bevacizumab may increase the cardiotoxic activities of Brentuximab vedotin.\nRisk: Monitor closely.", "source": "Bevacizumab + Brentuximab vedotin"}, {"id": "Bevacizumab_INT_Eribulin", "text": "Interaction: Bevacizumab AND Eribulin\nDetails: Bevacizumab may increase the cardiotoxic activities of Eribulin.\nRisk: Monitor closely.", "source": "Bevacizumab + Eribulin"}, {"id": "Bevacizumab_INT_Ruxolitinib", "text": "Interaction: Bevacizumab AND Ruxolitinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Ruxolitinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Ruxolitinib"}, {"id": "Bevacizumab_INT_Vemurafenib", "text": "Interaction: Bevacizumab AND Vemurafenib\nDetails: Bevacizumab may increase the cardiotoxic activities of Vemurafenib.\nRisk: Monitor closely.", "source": "Bevacizumab + Vemurafenib"}, {"id": "Bevacizumab_INT_Carfilzomib", "text": "Interaction: Bevacizumab AND Carfilzomib\nDetails: Bevacizumab may increase the cardiotoxic activities of Carfilzomib.\nRisk: Monitor closely.", "source": "Bevacizumab + Carfilzomib"}, {"id": "Bevacizumab_INT_Regorafenib", "text": "Interaction: Bevacizumab AND Regorafenib\nDetails: Bevacizumab may increase the cardiotoxic activities of Regorafenib.\nRisk: Monitor closely.", "source": "Bevacizumab + Regorafenib"}, {"id": "Bevacizumab_INT_Afatinib", "text": "Interaction: Bevacizumab AND Afatinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Afatinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Afatinib"}, {"id": "Bevacizumab_INT_Ibrutinib", "text": "Interaction: Bevacizumab AND Ibrutinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Ibrutinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Ibrutinib"}, {"id": "Bevacizumab_INT_Necitumumab", "text": "Interaction: Bevacizumab AND Necitumumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Necitumumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Necitumumab"}, {"id": "Bevacizumab_INT_Abiraterone", "text": "Interaction: Bevacizumab AND Abiraterone\nDetails: Bevacizumab may increase the cardiotoxic activities of Abiraterone.\nRisk: Monitor closely.", "source": "Bevacizumab + Abiraterone"}, {"id": "Bevacizumab_INT_Midostaurin", "text": "Interaction: Bevacizumab AND Midostaurin\nDetails: Bevacizumab may increase the cardiotoxic activities of Midostaurin.\nRisk: Monitor closely.", "source": "Bevacizumab + Midostaurin"}, {"id": "Bevacizumab_INT_Triptorelin", "text": "Interaction: Bevacizumab AND Triptorelin\nDetails: Bevacizumab may increase the cardiotoxic activities of Triptorelin.\nRisk: Monitor closely.", "source": "Bevacizumab + Triptorelin"}, {"id": "Bevacizumab_INT_Pomalidomide", "text": "Interaction: Bevacizumab AND Pomalidomide\nDetails: Bevacizumab may increase the cardiotoxic activities of Pomalidomide.\nRisk: Monitor closely.", "source": "Bevacizumab + Pomalidomide"}, {"id": "Bevacizumab_INT_Osimertinib", "text": "Interaction: Bevacizumab AND Osimertinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Osimertinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Osimertinib"}, {"id": "Bevacizumab_INT_Daratumumab", "text": "Interaction: Bevacizumab AND Daratumumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Daratumumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Daratumumab"}, {"id": "Bevacizumab_INT_Goserelin", "text": "Interaction: Bevacizumab AND Goserelin\nDetails: Bevacizumab may increase the cardiotoxic activities of Goserelin.\nRisk: Monitor closely.", "source": "Bevacizumab + Goserelin"}, {"id": "Bevacizumab_INT_Oprelvekin", "text": "Interaction: Bevacizumab AND Oprelvekin\nDetails: Bevacizumab may increase the cardiotoxic activities of Oprelvekin.\nRisk: Monitor closely.", "source": "Bevacizumab + Oprelvekin"}, {"id": "Bevacizumab_INT_Interferon beta-1a", "text": "Interaction: Bevacizumab AND Interferon beta-1a\nDetails: Bevacizumab may increase the cardiotoxic activities of Interferon beta-1a.\nRisk: Monitor closely.", "source": "Bevacizumab + Interferon beta-1a"}, {"id": "Bevacizumab_INT_Tositumomab", "text": "Interaction: Bevacizumab AND Tositumomab\nDetails: Bevacizumab may increase the cardiotoxic activities of Tositumomab.\nRisk: Monitor closely.", "source": "Bevacizumab + Tositumomab"}, {"id": "Bevacizumab_INT_Octreotide", "text": "Interaction: Bevacizumab AND Octreotide\nDetails: Bevacizumab may increase the cardiotoxic activities of Octreotide.\nRisk: Monitor closely.", "source": "Bevacizumab + Octreotide"}, {"id": "Bevacizumab_INT_Vitamin A", "text": "Interaction: Bevacizumab AND Vitamin A\nDetails: Bevacizumab may increase the cardiotoxic activities of Vitamin A.\nRisk: Monitor closely.", "source": "Bevacizumab + Vitamin A"}, {"id": "Bevacizumab_INT_Moxifloxacin", "text": "Interaction: Bevacizumab AND Moxifloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Moxifloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Moxifloxacin"}, {"id": "Bevacizumab_INT_Cabergoline", "text": "Interaction: Bevacizumab AND Cabergoline\nDetails: Bevacizumab may increase the cardiotoxic activities of Cabergoline.\nRisk: Monitor closely.", "source": "Bevacizumab + Cabergoline"}, {"id": "Bevacizumab_INT_Diethylstilbestrol", "text": "Interaction: Bevacizumab AND Diethylstilbestrol\nDetails: Bevacizumab may increase the cardiotoxic activities of Diethylstilbestrol.\nRisk: Monitor closely.", "source": "Bevacizumab + Diethylstilbestrol"}, {"id": "Bevacizumab_INT_Chlorotrianisene", "text": "Interaction: Bevacizumab AND Chlorotrianisene\nDetails: Bevacizumab may increase the cardiotoxic activities of Chlorotrianisene.\nRisk: Monitor closely.", "source": "Bevacizumab + Chlorotrianisene"}, {"id": "Bevacizumab_INT_Pamidronate", "text": "Interaction: Bevacizumab AND Pamidronate\nDetails: Bevacizumab may increase the cardiotoxic activities of Pamidronate.\nRisk: Monitor closely.", "source": "Bevacizumab + Pamidronate"}, {"id": "Bevacizumab_INT_Floxuridine", "text": "Interaction: Bevacizumab AND Floxuridine\nDetails: Bevacizumab may increase the cardiotoxic activities of Floxuridine.\nRisk: Monitor closely.", "source": "Bevacizumab + Floxuridine"}, {"id": "Bevacizumab_INT_Aminoglutethimide", "text": "Interaction: Bevacizumab AND Aminoglutethimide\nDetails: Bevacizumab may increase the cardiotoxic activities of Aminoglutethimide.\nRisk: Monitor closely.", "source": "Bevacizumab + Aminoglutethimide"}, {"id": "Bevacizumab_INT_Grepafloxacin", "text": "Interaction: Bevacizumab AND Grepafloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Grepafloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Grepafloxacin"}, {"id": "Bevacizumab_INT_Dexrazoxane", "text": "Interaction: Bevacizumab AND Dexrazoxane\nDetails: Bevacizumab may increase the cardiotoxic activities of Dexrazoxane.\nRisk: Monitor closely.", "source": "Bevacizumab + Dexrazoxane"}, {"id": "Bevacizumab_INT_Verteporfin", "text": "Interaction: Bevacizumab AND Verteporfin\nDetails: Bevacizumab may increase the cardiotoxic activities of Verteporfin.\nRisk: Monitor closely.", "source": "Bevacizumab + Verteporfin"}, {"id": "Bevacizumab_INT_Enoxacin", "text": "Interaction: Bevacizumab AND Enoxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Enoxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Enoxacin"}, {"id": "Bevacizumab_INT_Pefloxacin", "text": "Interaction: Bevacizumab AND Pefloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Pefloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Pefloxacin"}, {"id": "Bevacizumab_INT_Albendazole", "text": "Interaction: Bevacizumab AND Albendazole\nDetails: Bevacizumab may increase the cardiotoxic activities of Albendazole.\nRisk: Monitor closely.", "source": "Bevacizumab + Albendazole"}, {"id": "Bevacizumab_INT_Ciprofloxacin", "text": "Interaction: Bevacizumab AND Ciprofloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Ciprofloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Ciprofloxacin"}, {"id": "Bevacizumab_INT_Toremifene", "text": "Interaction: Bevacizumab AND Toremifene\nDetails: Bevacizumab may increase the cardiotoxic activities of Toremifene.\nRisk: Monitor closely.", "source": "Bevacizumab + Toremifene"}, {"id": "Bevacizumab_INT_Azelaic Acid", "text": "Interaction: Bevacizumab AND Azelaic Acid\nDetails: Bevacizumab may increase the cardiotoxic activities of Azelaic Acid.\nRisk: Monitor closely.", "source": "Bevacizumab + Azelaic Acid"}, {"id": "Bevacizumab_INT_Medroxyprogesterone acetate", "text": "Interaction: Bevacizumab AND Medroxyprogesterone acetate\nDetails: Bevacizumab may increase the cardiotoxic activities of Medroxyprogesterone acetate.\nRisk: Monitor closely.", "source": "Bevacizumab + Medroxyprogesterone acetate"}, {"id": "Bevacizumab_INT_Sulindac", "text": "Interaction: Bevacizumab AND Sulindac\nDetails: Bevacizumab may increase the cardiotoxic activities of Sulindac.\nRisk: Monitor closely.", "source": "Bevacizumab + Sulindac"}, {"id": "Bevacizumab_INT_Prednisone", "text": "Interaction: Bevacizumab AND Prednisone\nDetails: Bevacizumab may increase the cardiotoxic activities of Prednisone.\nRisk: Monitor closely.", "source": "Bevacizumab + Prednisone"}, {"id": "Bevacizumab_INT_Mebendazole", "text": "Interaction: Bevacizumab AND Mebendazole\nDetails: Bevacizumab may increase the cardiotoxic activities of Mebendazole.\nRisk: Monitor closely.", "source": "Bevacizumab + Mebendazole"}, {"id": "Bevacizumab_INT_Trovafloxacin", "text": "Interaction: Bevacizumab AND Trovafloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Trovafloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Trovafloxacin"}, {"id": "Bevacizumab_INT_Imiquimod", "text": "Interaction: Bevacizumab AND Imiquimod\nDetails: Bevacizumab may increase the cardiotoxic activities of Imiquimod.\nRisk: Monitor closely.", "source": "Bevacizumab + Imiquimod"}, {"id": "Bevacizumab_INT_Nalidixic Acid", "text": "Interaction: Bevacizumab AND Nalidixic Acid\nDetails: Bevacizumab may increase the cardiotoxic activities of Nalidixic Acid.\nRisk: Monitor closely.", "source": "Bevacizumab + Nalidixic Acid"}, {"id": "Bevacizumab_INT_Uracil mustard", "text": "Interaction: Bevacizumab AND Uracil mustard\nDetails: Bevacizumab may increase the cardiotoxic activities of Uracil mustard.\nRisk: Monitor closely.", "source": "Bevacizumab + Uracil mustard"}, {"id": "Bevacizumab_INT_Cinoxacin", "text": "Interaction: Bevacizumab AND Cinoxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Cinoxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Cinoxacin"}, {"id": "Bevacizumab_INT_Prednisolone", "text": "Interaction: Bevacizumab AND Prednisolone\nDetails: Bevacizumab may increase the cardiotoxic activities of Prednisolone.\nRisk: Monitor closely.", "source": "Bevacizumab + Prednisolone"}, {"id": "Bevacizumab_INT_Sirolimus", "text": "Interaction: Bevacizumab AND Sirolimus\nDetails: Bevacizumab may increase the cardiotoxic activities of Sirolimus.\nRisk: Monitor closely.", "source": "Bevacizumab + Sirolimus"}, {"id": "Bevacizumab_INT_Testolactone", "text": "Interaction: Bevacizumab AND Testolactone\nDetails: Bevacizumab may increase the cardiotoxic activities of Testolactone.\nRisk: Monitor closely.", "source": "Bevacizumab + Testolactone"}, {"id": "Bevacizumab_INT_Methylprednisolone", "text": "Interaction: Bevacizumab AND Methylprednisolone\nDetails: Bevacizumab may increase the cardiotoxic activities of Methylprednisolone.\nRisk: Monitor closely.", "source": "Bevacizumab + Methylprednisolone"}, {"id": "Bevacizumab_INT_Ethiodized oil", "text": "Interaction: Bevacizumab AND Ethiodized oil\nDetails: Bevacizumab may increase the cardiotoxic activities of Ethiodized oil.\nRisk: Monitor closely.", "source": "Bevacizumab + Ethiodized oil"}, {"id": "Bevacizumab_INT_Lomefloxacin", "text": "Interaction: Bevacizumab AND Lomefloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Lomefloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Lomefloxacin"}, {"id": "Bevacizumab_INT_Azathioprine", "text": "Interaction: Bevacizumab AND Azathioprine\nDetails: Bevacizumab may increase the cardiotoxic activities of Azathioprine.\nRisk: Monitor closely.", "source": "Bevacizumab + Azathioprine"}, {"id": "Bevacizumab_INT_Mycophenolic acid", "text": "Interaction: Bevacizumab AND Mycophenolic acid\nDetails: Bevacizumab may increase the cardiotoxic activities of Mycophenolic acid.\nRisk: Monitor closely.", "source": "Bevacizumab + Mycophenolic acid"}, {"id": "Bevacizumab_INT_Thalidomide", "text": "Interaction: Bevacizumab AND Thalidomide\nDetails: Bevacizumab may increase the cardiotoxic activities of Thalidomide.\nRisk: Monitor closely.", "source": "Bevacizumab + Thalidomide"}, {"id": "Bevacizumab_INT_Gatifloxacin", "text": "Interaction: Bevacizumab AND Gatifloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Gatifloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Gatifloxacin"}, {"id": "Bevacizumab_INT_Norfloxacin", "text": "Interaction: Bevacizumab AND Norfloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Norfloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Norfloxacin"}, {"id": "Bevacizumab_INT_Leflunomide", "text": "Interaction: Bevacizumab AND Leflunomide\nDetails: Bevacizumab may increase the cardiotoxic activities of Leflunomide.\nRisk: Monitor closely.", "source": "Bevacizumab + Leflunomide"}, {"id": "Bevacizumab_INT_Quinacrine", "text": "Interaction: Bevacizumab AND Quinacrine\nDetails: Bevacizumab may increase the cardiotoxic activities of Quinacrine.\nRisk: Monitor closely.", "source": "Bevacizumab + Quinacrine"}, {"id": "Bevacizumab_INT_Trilostane", "text": "Interaction: Bevacizumab AND Trilostane\nDetails: Bevacizumab may increase the cardiotoxic activities of Trilostane.\nRisk: Monitor closely.", "source": "Bevacizumab + Trilostane"}, {"id": "Bevacizumab_INT_Levofloxacin", "text": "Interaction: Bevacizumab AND Levofloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Levofloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Levofloxacin"}, {"id": "Bevacizumab_INT_Gemifloxacin", "text": "Interaction: Bevacizumab AND Gemifloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Gemifloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Gemifloxacin"}, {"id": "Bevacizumab_INT_Trimetrexate", "text": "Interaction: Bevacizumab AND Trimetrexate\nDetails: Bevacizumab may increase the cardiotoxic activities of Trimetrexate.\nRisk: Monitor closely.", "source": "Bevacizumab + Trimetrexate"}, {"id": "Bevacizumab_INT_Ofloxacin", "text": "Interaction: Bevacizumab AND Ofloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Ofloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Ofloxacin"}, {"id": "Bevacizumab_INT_Podofilox", "text": "Interaction: Bevacizumab AND Podofilox\nDetails: Bevacizumab may increase the cardiotoxic activities of Podofilox.\nRisk: Monitor closely.", "source": "Bevacizumab + Podofilox"}, {"id": "Bevacizumab_INT_Sparfloxacin", "text": "Interaction: Bevacizumab AND Sparfloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Sparfloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Sparfloxacin"}, {"id": "Bevacizumab_INT_Dexamethasone", "text": "Interaction: Bevacizumab AND Dexamethasone\nDetails: Bevacizumab may increase the cardiotoxic activities of Dexamethasone.\nRisk: Monitor closely.", "source": "Bevacizumab + Dexamethasone"}, {"id": "Bevacizumab_INT_Ranibizumab", "text": "Interaction: Bevacizumab AND Ranibizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Ranibizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Ranibizumab"}, {"id": "Bevacizumab_INT_Colchicine", "text": "Interaction: Bevacizumab AND Colchicine\nDetails: Bevacizumab may increase the cardiotoxic activities of Colchicine.\nRisk: Monitor closely.", "source": "Bevacizumab + Colchicine"}, {"id": "Bevacizumab_INT_Temafloxacin", "text": "Interaction: Bevacizumab AND Temafloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Temafloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Temafloxacin"}, {"id": "Bevacizumab_INT_Genistein", "text": "Interaction: Bevacizumab AND Genistein\nDetails: Bevacizumab may increase the cardiotoxic activities of Genistein.\nRisk: Monitor closely.", "source": "Bevacizumab + Genistein"}, {"id": "Bevacizumab_INT_8-azaguanine", "text": "Interaction: Bevacizumab AND 8-azaguanine\nDetails: Bevacizumab may increase the cardiotoxic activities of 8-azaguanine.\nRisk: Monitor closely.", "source": "Bevacizumab + 8-azaguanine"}, {"id": "Bevacizumab_INT_7-Hydroxystaurosporine", "text": "Interaction: Bevacizumab AND 7-Hydroxystaurosporine\nDetails: Bevacizumab may increase the cardiotoxic activities of 7-Hydroxystaurosporine.\nRisk: Monitor closely.", "source": "Bevacizumab + 7-Hydroxystaurosporine"}, {"id": "Bevacizumab_INT_Hadacidin", "text": "Interaction: Bevacizumab AND Hadacidin\nDetails: Bevacizumab may increase the cardiotoxic activities of Hadacidin.\nRisk: Monitor closely.", "source": "Bevacizumab + Hadacidin"}, {"id": "Bevacizumab_INT_Formycin", "text": "Interaction: Bevacizumab AND Formycin\nDetails: Bevacizumab may increase the cardiotoxic activities of Formycin.\nRisk: Monitor closely.", "source": "Bevacizumab + Formycin"}, {"id": "Bevacizumab_INT_Calcipotriol", "text": "Interaction: Bevacizumab AND Calcipotriol\nDetails: Bevacizumab may increase the cardiotoxic activities of Calcipotriol.\nRisk: Monitor closely.", "source": "Bevacizumab + Calcipotriol"}, {"id": "Bevacizumab_INT_2-Methoxyestradiol", "text": "Interaction: Bevacizumab AND 2-Methoxyestradiol\nDetails: Bevacizumab may increase the cardiotoxic activities of 2-Methoxyestradiol.\nRisk: Monitor closely.", "source": "Bevacizumab + 2-Methoxyestradiol"}, {"id": "Bevacizumab_INT_Geldanamycin", "text": "Interaction: Bevacizumab AND Geldanamycin\nDetails: Bevacizumab may increase the cardiotoxic activities of Geldanamycin.\nRisk: Monitor closely.", "source": "Bevacizumab + Geldanamycin"}, {"id": "Bevacizumab_INT_Fumagillin", "text": "Interaction: Bevacizumab AND Fumagillin\nDetails: Bevacizumab may increase the cardiotoxic activities of Fumagillin.\nRisk: Monitor closely.", "source": "Bevacizumab + Fumagillin"}, {"id": "Bevacizumab_INT_Resveratrol", "text": "Interaction: Bevacizumab AND Resveratrol\nDetails: Bevacizumab may increase the cardiotoxic activities of Resveratrol.\nRisk: Monitor closely.", "source": "Bevacizumab + Resveratrol"}, {"id": "Bevacizumab_INT_Arotinoid acid", "text": "Interaction: Bevacizumab AND Arotinoid acid\nDetails: Bevacizumab may increase the cardiotoxic activities of Arotinoid acid.\nRisk: Monitor closely.", "source": "Bevacizumab + Arotinoid acid"}, {"id": "Bevacizumab_INT_Arsanilic acid", "text": "Interaction: Bevacizumab AND Arsanilic acid\nDetails: Bevacizumab may increase the cardiotoxic activities of Arsanilic acid.\nRisk: Monitor closely.", "source": "Bevacizumab + Arsanilic acid"}, {"id": "Bevacizumab_INT_Patupilone", "text": "Interaction: Bevacizumab AND Patupilone\nDetails: Bevacizumab may increase the cardiotoxic activities of Patupilone.\nRisk: Monitor closely.", "source": "Bevacizumab + Patupilone"}, {"id": "Bevacizumab_INT_3-Methoxybenzamide", "text": "Interaction: Bevacizumab AND 3-Methoxybenzamide\nDetails: Bevacizumab may increase the cardiotoxic activities of 3-Methoxybenzamide.\nRisk: Monitor closely.", "source": "Bevacizumab + 3-Methoxybenzamide"}, {"id": "Bevacizumab_INT_Tubercidin", "text": "Interaction: Bevacizumab AND Tubercidin\nDetails: Bevacizumab may increase the cardiotoxic activities of Tubercidin.\nRisk: Monitor closely.", "source": "Bevacizumab + Tubercidin"}, {"id": "Bevacizumab_INT_Ubenimex", "text": "Interaction: Bevacizumab AND Ubenimex\nDetails: Bevacizumab may increase the cardiotoxic activities of Ubenimex.\nRisk: Monitor closely.", "source": "Bevacizumab + Ubenimex"}, {"id": "Bevacizumab_INT_Sparfosic acid", "text": "Interaction: Bevacizumab AND Sparfosic acid\nDetails: Bevacizumab may increase the cardiotoxic activities of Sparfosic acid.\nRisk: Monitor closely.", "source": "Bevacizumab + Sparfosic acid"}, {"id": "Bevacizumab_INT_Alvocidib", "text": "Interaction: Bevacizumab AND Alvocidib\nDetails: Bevacizumab may increase the cardiotoxic activities of Alvocidib.\nRisk: Monitor closely.", "source": "Bevacizumab + Alvocidib"}, {"id": "Bevacizumab_INT_2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide", "text": "Interaction: Bevacizumab AND 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide\nDetails: Bevacizumab may increase the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.\nRisk: Monitor closely.", "source": "Bevacizumab + 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide"}, {"id": "Bevacizumab_INT_Rhodamine 6G", "text": "Interaction: Bevacizumab AND Rhodamine 6G\nDetails: Bevacizumab may increase the cardiotoxic activities of Rhodamine 6G.\nRisk: Monitor closely.", "source": "Bevacizumab + Rhodamine 6G"}, {"id": "Bevacizumab_INT_Batimastat", "text": "Interaction: Bevacizumab AND Batimastat\nDetails: Bevacizumab may increase the cardiotoxic activities of Batimastat.\nRisk: Monitor closely.", "source": "Bevacizumab + Batimastat"}, {"id": "Bevacizumab_INT_3,4-Dihydroxybenzoic Acid", "text": "Interaction: Bevacizumab AND 3,4-Dihydroxybenzoic Acid\nDetails: Bevacizumab may increase the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.\nRisk: Monitor closely.", "source": "Bevacizumab + 3,4-Dihydroxybenzoic Acid"}, {"id": "Bevacizumab_INT_Sparsomycin", "text": "Interaction: Bevacizumab AND Sparsomycin\nDetails: Bevacizumab may increase the cardiotoxic activities of Sparsomycin.\nRisk: Monitor closely.", "source": "Bevacizumab + Sparsomycin"}, {"id": "Bevacizumab_INT_Tretazicar", "text": "Interaction: Bevacizumab AND Tretazicar\nDetails: Bevacizumab may increase the cardiotoxic activities of Tretazicar.\nRisk: Monitor closely.", "source": "Bevacizumab + Tretazicar"}, {"id": "Bevacizumab_INT_Seocalcitol", "text": "Interaction: Bevacizumab AND Seocalcitol\nDetails: Bevacizumab may increase the cardiotoxic activities of Seocalcitol.\nRisk: Monitor closely.", "source": "Bevacizumab + Seocalcitol"}, {"id": "Bevacizumab_INT_Nebularine", "text": "Interaction: Bevacizumab AND Nebularine\nDetails: Bevacizumab may increase the cardiotoxic activities of Nebularine.\nRisk: Monitor closely.", "source": "Bevacizumab + Nebularine"}, {"id": "Bevacizumab_INT_Afimoxifene", "text": "Interaction: Bevacizumab AND Afimoxifene\nDetails: Bevacizumab may increase the cardiotoxic activities of Afimoxifene.\nRisk: Monitor closely.", "source": "Bevacizumab + Afimoxifene"}, {"id": "Bevacizumab_INT_Cholesterol", "text": "Interaction: Bevacizumab AND Cholesterol\nDetails: Bevacizumab may increase the cardiotoxic activities of Cholesterol.\nRisk: Monitor closely.", "source": "Bevacizumab + Cholesterol"}, {"id": "Bevacizumab_INT_Fleroxacin", "text": "Interaction: Bevacizumab AND Fleroxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Fleroxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Fleroxacin"}, {"id": "Bevacizumab_INT_Metoprine", "text": "Interaction: Bevacizumab AND Metoprine\nDetails: Bevacizumab may increase the cardiotoxic activities of Metoprine.\nRisk: Monitor closely.", "source": "Bevacizumab + Metoprine"}, {"id": "Bevacizumab_INT_Camptothecin", "text": "Interaction: Bevacizumab AND Camptothecin\nDetails: Bevacizumab may increase the cardiotoxic activities of Camptothecin.\nRisk: Monitor closely.", "source": "Bevacizumab + Camptothecin"}, {"id": "Bevacizumab_INT_Suramin", "text": "Interaction: Bevacizumab AND Suramin\nDetails: Bevacizumab may increase the cardiotoxic activities of Suramin.\nRisk: Monitor closely.", "source": "Bevacizumab + Suramin"}, {"id": "Bevacizumab_INT_Ethyl carbamate", "text": "Interaction: Bevacizumab AND Ethyl carbamate\nDetails: Bevacizumab may increase the cardiotoxic activities of Ethyl carbamate.\nRisk: Monitor closely.", "source": "Bevacizumab + Ethyl carbamate"}, {"id": "Bevacizumab_INT_Cyproterone acetate", "text": "Interaction: Bevacizumab AND Cyproterone acetate\nDetails: Bevacizumab may increase the cardiotoxic activities of Cyproterone acetate.\nRisk: Monitor closely.", "source": "Bevacizumab + Cyproterone acetate"}, {"id": "Bevacizumab_INT_Tirapazamine", "text": "Interaction: Bevacizumab AND Tirapazamine\nDetails: Bevacizumab may increase the cardiotoxic activities of Tirapazamine.\nRisk: Monitor closely.", "source": "Bevacizumab + Tirapazamine"}, {"id": "Bevacizumab_INT_Halofuginone", "text": "Interaction: Bevacizumab AND Halofuginone\nDetails: Bevacizumab may increase the cardiotoxic activities of Halofuginone.\nRisk: Monitor closely.", "source": "Bevacizumab + Halofuginone"}, {"id": "Bevacizumab_INT_Vapreotide", "text": "Interaction: Bevacizumab AND Vapreotide\nDetails: Bevacizumab may increase the cardiotoxic activities of Vapreotide.\nRisk: Monitor closely.", "source": "Bevacizumab + Vapreotide"}, {"id": "Bevacizumab_INT_Thymalfasin", "text": "Interaction: Bevacizumab AND Thymalfasin\nDetails: Bevacizumab may increase the cardiotoxic activities of Thymalfasin.\nRisk: Monitor closely.", "source": "Bevacizumab + Thymalfasin"}, {"id": "Bevacizumab_INT_Ranpirnase", "text": "Interaction: Bevacizumab AND Ranpirnase\nDetails: Bevacizumab may increase the cardiotoxic activities of Ranpirnase.\nRisk: Monitor closely.", "source": "Bevacizumab + Ranpirnase"}, {"id": "Bevacizumab_INT_Pirfenidone", "text": "Interaction: Bevacizumab AND Pirfenidone\nDetails: Bevacizumab may increase the cardiotoxic activities of Pirfenidone.\nRisk: Monitor closely.", "source": "Bevacizumab + Pirfenidone"}, {"id": "Bevacizumab_INT_Tipifarnib", "text": "Interaction: Bevacizumab AND Tipifarnib\nDetails: Bevacizumab may increase the cardiotoxic activities of Tipifarnib.\nRisk: Monitor closely.", "source": "Bevacizumab + Tipifarnib"}, {"id": "Bevacizumab_INT_Troxacitabine", "text": "Interaction: Bevacizumab AND Troxacitabine\nDetails: Bevacizumab may increase the cardiotoxic activities of Troxacitabine.\nRisk: Monitor closely.", "source": "Bevacizumab + Troxacitabine"}, {"id": "Bevacizumab_INT_Amonafide", "text": "Interaction: Bevacizumab AND Amonafide\nDetails: Bevacizumab may increase the cardiotoxic activities of Amonafide.\nRisk: Monitor closely.", "source": "Bevacizumab + Amonafide"}, {"id": "Bevacizumab_INT_SRT501", "text": "Interaction: Bevacizumab AND SRT501\nDetails: Bevacizumab may increase the cardiotoxic activities of SRT501.\nRisk: Monitor closely.", "source": "Bevacizumab + SRT501"}, {"id": "Bevacizumab_INT_Fenretinide", "text": "Interaction: Bevacizumab AND Fenretinide\nDetails: Bevacizumab may increase the cardiotoxic activities of Fenretinide.\nRisk: Monitor closely.", "source": "Bevacizumab + Fenretinide"}, {"id": "Bevacizumab_INT_Tiomolibdate ion", "text": "Interaction: Bevacizumab AND Tiomolibdate ion\nDetails: Bevacizumab may increase the cardiotoxic activities of Tiomolibdate ion.\nRisk: Monitor closely.", "source": "Bevacizumab + Tiomolibdate ion"}, {"id": "Bevacizumab_INT_Elsamitrucin", "text": "Interaction: Bevacizumab AND Elsamitrucin\nDetails: Bevacizumab may increase the cardiotoxic activities of Elsamitrucin.\nRisk: Monitor closely.", "source": "Bevacizumab + Elsamitrucin"}, {"id": "Bevacizumab_INT_Gallium nitrate", "text": "Interaction: Bevacizumab AND Gallium nitrate\nDetails: Bevacizumab may increase the cardiotoxic activities of Gallium nitrate.\nRisk: Monitor closely.", "source": "Bevacizumab + Gallium nitrate"}, {"id": "Bevacizumab_INT_Ecabet", "text": "Interaction: Bevacizumab AND Ecabet\nDetails: Bevacizumab may increase the cardiotoxic activities of Ecabet.\nRisk: Monitor closely.", "source": "Bevacizumab + Ecabet"}, {"id": "Bevacizumab_INT_Canertinib", "text": "Interaction: Bevacizumab AND Canertinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Canertinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Canertinib"}, {"id": "Bevacizumab_INT_motexafin gadolinium", "text": "Interaction: Bevacizumab AND motexafin gadolinium\nDetails: Bevacizumab may increase the cardiotoxic activities of motexafin gadolinium.\nRisk: Monitor closely.", "source": "Bevacizumab + motexafin gadolinium"}, {"id": "Bevacizumab_INT_Alanosine", "text": "Interaction: Bevacizumab AND Alanosine\nDetails: Bevacizumab may increase the cardiotoxic activities of Alanosine.\nRisk: Monitor closely.", "source": "Bevacizumab + Alanosine"}, {"id": "Bevacizumab_INT_Palifosfamide", "text": "Interaction: Bevacizumab AND Palifosfamide\nDetails: Bevacizumab may increase the cardiotoxic activities of Palifosfamide.\nRisk: Monitor closely.", "source": "Bevacizumab + Palifosfamide"}, {"id": "Bevacizumab_INT_AP 12009", "text": "Interaction: Bevacizumab AND AP 12009\nDetails: Bevacizumab may increase the cardiotoxic activities of AP 12009.\nRisk: Monitor closely.", "source": "Bevacizumab + AP 12009"}, {"id": "Bevacizumab_INT_Oglufanide", "text": "Interaction: Bevacizumab AND Oglufanide\nDetails: Bevacizumab may increase the cardiotoxic activities of Oglufanide.\nRisk: Monitor closely.", "source": "Bevacizumab + Oglufanide"}, {"id": "Bevacizumab_INT_Irofulven", "text": "Interaction: Bevacizumab AND Irofulven\nDetails: Bevacizumab may increase the cardiotoxic activities of Irofulven.\nRisk: Monitor closely.", "source": "Bevacizumab + Irofulven"}, {"id": "Bevacizumab_INT_KOS-1584", "text": "Interaction: Bevacizumab AND KOS-1584\nDetails: Bevacizumab may increase the cardiotoxic activities of KOS-1584.\nRisk: Monitor closely.", "source": "Bevacizumab + KOS-1584"}, {"id": "Bevacizumab_INT_BSI-201", "text": "Interaction: Bevacizumab AND BSI-201\nDetails: Bevacizumab may increase the cardiotoxic activities of BSI-201.\nRisk: Monitor closely.", "source": "Bevacizumab + BSI-201"}, {"id": "Bevacizumab_INT_Rubitecan", "text": "Interaction: Bevacizumab AND Rubitecan\nDetails: Bevacizumab may increase the cardiotoxic activities of Rubitecan.\nRisk: Monitor closely.", "source": "Bevacizumab + Rubitecan"}, {"id": "Bevacizumab_INT_Garenoxacin", "text": "Interaction: Bevacizumab AND Garenoxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Garenoxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Garenoxacin"}, {"id": "Bevacizumab_INT_Plevitrexed", "text": "Interaction: Bevacizumab AND Plevitrexed\nDetails: Bevacizumab may increase the cardiotoxic activities of Plevitrexed.\nRisk: Monitor closely.", "source": "Bevacizumab + Plevitrexed"}, {"id": "Bevacizumab_INT_Seliciclib", "text": "Interaction: Bevacizumab AND Seliciclib\nDetails: Bevacizumab may increase the cardiotoxic activities of Seliciclib.\nRisk: Monitor closely.", "source": "Bevacizumab + Seliciclib"}, {"id": "Bevacizumab_INT_Vadimezan", "text": "Interaction: Bevacizumab AND Vadimezan\nDetails: Bevacizumab may increase the cardiotoxic activities of Vadimezan.\nRisk: Monitor closely.", "source": "Bevacizumab + Vadimezan"}, {"id": "Bevacizumab_INT_Eflornithine", "text": "Interaction: Bevacizumab AND Eflornithine\nDetails: Bevacizumab may increase the cardiotoxic activities of Eflornithine.\nRisk: Monitor closely.", "source": "Bevacizumab + Eflornithine"}, {"id": "Bevacizumab_INT_exisulind", "text": "Interaction: Bevacizumab AND exisulind\nDetails: Bevacizumab may increase the cardiotoxic activities of exisulind.\nRisk: Monitor closely.", "source": "Bevacizumab + exisulind"}, {"id": "Bevacizumab_INT_Maxacalcitol", "text": "Interaction: Bevacizumab AND Maxacalcitol\nDetails: Bevacizumab may increase the cardiotoxic activities of Maxacalcitol.\nRisk: Monitor closely.", "source": "Bevacizumab + Maxacalcitol"}, {"id": "Bevacizumab_INT_AP24534", "text": "Interaction: Bevacizumab AND AP24534\nDetails: Bevacizumab may increase the cardiotoxic activities of AP24534.\nRisk: Monitor closely.", "source": "Bevacizumab + AP24534"}, {"id": "Bevacizumab_INT_annamycin", "text": "Interaction: Bevacizumab AND annamycin\nDetails: Bevacizumab may increase the cardiotoxic activities of annamycin.\nRisk: Monitor closely.", "source": "Bevacizumab + annamycin"}, {"id": "Bevacizumab_INT_Endostatin", "text": "Interaction: Bevacizumab AND Endostatin\nDetails: Bevacizumab may increase the cardiotoxic activities of Endostatin.\nRisk: Monitor closely.", "source": "Bevacizumab + Endostatin"}, {"id": "Bevacizumab_INT_Tezacitabine", "text": "Interaction: Bevacizumab AND Tezacitabine\nDetails: Bevacizumab may increase the cardiotoxic activities of Tezacitabine.\nRisk: Monitor closely.", "source": "Bevacizumab + Tezacitabine"}, {"id": "Bevacizumab_INT_Semaxanib", "text": "Interaction: Bevacizumab AND Semaxanib\nDetails: Bevacizumab may increase the cardiotoxic activities of Semaxanib.\nRisk: Monitor closely.", "source": "Bevacizumab + Semaxanib"}, {"id": "Bevacizumab_INT_diethylnorspermine", "text": "Interaction: Bevacizumab AND diethylnorspermine\nDetails: Bevacizumab may increase the cardiotoxic activities of diethylnorspermine.\nRisk: Monitor closely.", "source": "Bevacizumab + diethylnorspermine"}, {"id": "Bevacizumab_INT_squalamine", "text": "Interaction: Bevacizumab AND squalamine\nDetails: Bevacizumab may increase the cardiotoxic activities of squalamine.\nRisk: Monitor closely.", "source": "Bevacizumab + squalamine"}, {"id": "Bevacizumab_INT_porfiromycin", "text": "Interaction: Bevacizumab AND porfiromycin\nDetails: Bevacizumab may increase the cardiotoxic activities of porfiromycin.\nRisk: Monitor closely.", "source": "Bevacizumab + porfiromycin"}, {"id": "Bevacizumab_INT_MLN576", "text": "Interaction: Bevacizumab AND MLN576\nDetails: Bevacizumab may increase the cardiotoxic activities of MLN576.\nRisk: Monitor closely.", "source": "Bevacizumab + MLN576"}, {"id": "Bevacizumab_INT_Iobenguane", "text": "Interaction: Bevacizumab AND Iobenguane\nDetails: Bevacizumab may increase the cardiotoxic activities of Iobenguane.\nRisk: Monitor closely.", "source": "Bevacizumab + Iobenguane"}, {"id": "Bevacizumab_INT_Methyltestosterone", "text": "Interaction: Bevacizumab AND Methyltestosterone\nDetails: Bevacizumab may increase the cardiotoxic activities of Methyltestosterone.\nRisk: Monitor closely.", "source": "Bevacizumab + Methyltestosterone"}, {"id": "Bevacizumab_INT_Ginsenoside C", "text": "Interaction: Bevacizumab AND Ginsenoside C\nDetails: Bevacizumab may increase the cardiotoxic activities of Ginsenoside C.\nRisk: Monitor closely.", "source": "Bevacizumab + Ginsenoside C"}, {"id": "Bevacizumab_INT_Besifloxacin", "text": "Interaction: Bevacizumab AND Besifloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Besifloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Besifloxacin"}, {"id": "Bevacizumab_INT_Hydroxyprogesterone caproate", "text": "Interaction: Bevacizumab AND Hydroxyprogesterone caproate\nDetails: Bevacizumab may increase the cardiotoxic activities of Hydroxyprogesterone caproate.\nRisk: Monitor closely.", "source": "Bevacizumab + Hydroxyprogesterone caproate"}, {"id": "Bevacizumab_INT_Lanreotide", "text": "Interaction: Bevacizumab AND Lanreotide\nDetails: Bevacizumab may increase the cardiotoxic activities of Lanreotide.\nRisk: Monitor closely.", "source": "Bevacizumab + Lanreotide"}, {"id": "Bevacizumab_INT_Phenylbutyric acid", "text": "Interaction: Bevacizumab AND Phenylbutyric acid\nDetails: Bevacizumab may increase the cardiotoxic activities of Phenylbutyric acid.\nRisk: Monitor closely.", "source": "Bevacizumab + Phenylbutyric acid"}, {"id": "Bevacizumab_INT_Veliparib", "text": "Interaction: Bevacizumab AND Veliparib\nDetails: Bevacizumab may increase the cardiotoxic activities of Veliparib.\nRisk: Monitor closely.", "source": "Bevacizumab + Veliparib"}, {"id": "Bevacizumab_INT_Hexestrol", "text": "Interaction: Bevacizumab AND Hexestrol\nDetails: Bevacizumab may increase the cardiotoxic activities of Hexestrol.\nRisk: Monitor closely.", "source": "Bevacizumab + Hexestrol"}, {"id": "Bevacizumab_INT_nocodazole", "text": "Interaction: Bevacizumab AND nocodazole\nDetails: Bevacizumab may increase the cardiotoxic activities of nocodazole.\nRisk: Monitor closely.", "source": "Bevacizumab + nocodazole"}, {"id": "Bevacizumab_INT_Puromycin", "text": "Interaction: Bevacizumab AND Puromycin\nDetails: Bevacizumab may increase the cardiotoxic activities of Puromycin.\nRisk: Monitor closely.", "source": "Bevacizumab + Puromycin"}, {"id": "Bevacizumab_INT_GS 0573", "text": "Interaction: Bevacizumab AND GS 0573\nDetails: Bevacizumab may increase the cardiotoxic activities of GS 0573.\nRisk: Monitor closely.", "source": "Bevacizumab + GS 0573"}, {"id": "Bevacizumab_INT_Formestane", "text": "Interaction: Bevacizumab AND Formestane\nDetails: Bevacizumab may increase the cardiotoxic activities of Formestane.\nRisk: Monitor closely.", "source": "Bevacizumab + Formestane"}, {"id": "Bevacizumab_INT_Radium Ra 223 Dichloride", "text": "Interaction: Bevacizumab AND Radium Ra 223 Dichloride\nDetails: Bevacizumab may increase the cardiotoxic activities of Radium Ra 223 Dichloride.\nRisk: Monitor closely.", "source": "Bevacizumab + Radium Ra 223 Dichloride"}, {"id": "Bevacizumab_INT_Flumequine", "text": "Interaction: Bevacizumab AND Flumequine\nDetails: Bevacizumab may increase the cardiotoxic activities of Flumequine.\nRisk: Monitor closely.", "source": "Bevacizumab + Flumequine"}, {"id": "Bevacizumab_INT_Siltuximab", "text": "Interaction: Bevacizumab AND Siltuximab\nDetails: Bevacizumab may increase the cardiotoxic activities of Siltuximab.\nRisk: Monitor closely.", "source": "Bevacizumab + Siltuximab"}, {"id": "Bevacizumab_INT_Tibolone", "text": "Interaction: Bevacizumab AND Tibolone\nDetails: Bevacizumab may increase the cardiotoxic activities of Tibolone.\nRisk: Monitor closely.", "source": "Bevacizumab + Tibolone"}, {"id": "Bevacizumab_INT_Podophyllin", "text": "Interaction: Bevacizumab AND Podophyllin\nDetails: Bevacizumab may increase the cardiotoxic activities of Podophyllin.\nRisk: Monitor closely.", "source": "Bevacizumab + Podophyllin"}, {"id": "Bevacizumab_INT_Dienogest", "text": "Interaction: Bevacizumab AND Dienogest\nDetails: Bevacizumab may increase the cardiotoxic activities of Dienogest.\nRisk: Monitor closely.", "source": "Bevacizumab + Dienogest"}, {"id": "Bevacizumab_INT_Medrogestone", "text": "Interaction: Bevacizumab AND Medrogestone\nDetails: Bevacizumab may increase the cardiotoxic activities of Medrogestone.\nRisk: Monitor closely.", "source": "Bevacizumab + Medrogestone"}, {"id": "Bevacizumab_INT_Niguldipine", "text": "Interaction: Bevacizumab AND Niguldipine\nDetails: Bevacizumab may increase the cardiotoxic activities of Niguldipine.\nRisk: Monitor closely.", "source": "Bevacizumab + Niguldipine"}, {"id": "Bevacizumab_INT_Pirlindole", "text": "Interaction: Bevacizumab AND Pirlindole\nDetails: Bevacizumab may increase the cardiotoxic activities of Pirlindole.\nRisk: Monitor closely.", "source": "Bevacizumab + Pirlindole"}, {"id": "Bevacizumab_INT_Phenylacetic acid", "text": "Interaction: Bevacizumab AND Phenylacetic acid\nDetails: Bevacizumab may increase the cardiotoxic activities of Phenylacetic acid.\nRisk: Monitor closely.", "source": "Bevacizumab + Phenylacetic acid"}, {"id": "Bevacizumab_INT_Alatrofloxacin", "text": "Interaction: Bevacizumab AND Alatrofloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Alatrofloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Alatrofloxacin"}, {"id": "Bevacizumab_INT_Isosorbide", "text": "Interaction: Bevacizumab AND Isosorbide\nDetails: Bevacizumab may increase the cardiotoxic activities of Isosorbide.\nRisk: Monitor closely.", "source": "Bevacizumab + Isosorbide"}, {"id": "Bevacizumab_INT_Mequinol", "text": "Interaction: Bevacizumab AND Mequinol\nDetails: Bevacizumab may increase the cardiotoxic activities of Mequinol.\nRisk: Monitor closely.", "source": "Bevacizumab + Mequinol"}, {"id": "Bevacizumab_INT_Lycopene", "text": "Interaction: Bevacizumab AND Lycopene\nDetails: Bevacizumab may increase the cardiotoxic activities of Lycopene.\nRisk: Monitor closely.", "source": "Bevacizumab + Lycopene"}, {"id": "Bevacizumab_INT_Roquinimex", "text": "Interaction: Bevacizumab AND Roquinimex\nDetails: Bevacizumab may increase the cardiotoxic activities of Roquinimex.\nRisk: Monitor closely.", "source": "Bevacizumab + Roquinimex"}, {"id": "Bevacizumab_INT_Enrofloxacin", "text": "Interaction: Bevacizumab AND Enrofloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Enrofloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Enrofloxacin"}, {"id": "Bevacizumab_INT_Rabusertib", "text": "Interaction: Bevacizumab AND Rabusertib\nDetails: Bevacizumab may increase the cardiotoxic activities of Rabusertib.\nRisk: Monitor closely.", "source": "Bevacizumab + Rabusertib"}, {"id": "Bevacizumab_INT_Curcumin", "text": "Interaction: Bevacizumab AND Curcumin\nDetails: Bevacizumab may increase the cardiotoxic activities of Curcumin.\nRisk: Monitor closely.", "source": "Bevacizumab + Curcumin"}, {"id": "Bevacizumab_INT_2-chloroethyl-3-sarcosinamide-1-nitrosourea", "text": "Interaction: Bevacizumab AND 2-chloroethyl-3-sarcosinamide-1-nitrosourea\nDetails: Bevacizumab may increase the cardiotoxic activities of 2-chloroethyl-3-sarcosinamide-1-nitrosourea.\nRisk: Monitor closely.", "source": "Bevacizumab + 2-chloroethyl-3-sarcosinamide-1-nitrosourea"}, {"id": "Bevacizumab_INT_Misonidazole", "text": "Interaction: Bevacizumab AND Misonidazole\nDetails: Bevacizumab may increase the cardiotoxic activities of Misonidazole.\nRisk: Monitor closely.", "source": "Bevacizumab + Misonidazole"}, {"id": "Bevacizumab_INT_Bryostatin 1", "text": "Interaction: Bevacizumab AND Bryostatin 1\nDetails: Bevacizumab may increase the cardiotoxic activities of Bryostatin 1.\nRisk: Monitor closely.", "source": "Bevacizumab + Bryostatin 1"}, {"id": "Bevacizumab_INT_Talazoparib", "text": "Interaction: Bevacizumab AND Talazoparib\nDetails: Bevacizumab may increase the cardiotoxic activities of Talazoparib.\nRisk: Monitor closely.", "source": "Bevacizumab + Talazoparib"}, {"id": "Bevacizumab_INT_Tremelimumab", "text": "Interaction: Bevacizumab AND Tremelimumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Tremelimumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Tremelimumab"}, {"id": "Bevacizumab_INT_Pazufloxacin", "text": "Interaction: Bevacizumab AND Pazufloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Pazufloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Pazufloxacin"}, {"id": "Bevacizumab_INT_Niraparib", "text": "Interaction: Bevacizumab AND Niraparib\nDetails: Bevacizumab may increase the cardiotoxic activities of Niraparib.\nRisk: Monitor closely.", "source": "Bevacizumab + Niraparib"}, {"id": "Bevacizumab_INT_Saracatinib", "text": "Interaction: Bevacizumab AND Saracatinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Saracatinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Saracatinib"}, {"id": "Bevacizumab_INT_Talaporfin", "text": "Interaction: Bevacizumab AND Talaporfin\nDetails: Bevacizumab may increase the cardiotoxic activities of Talaporfin.\nRisk: Monitor closely.", "source": "Bevacizumab + Talaporfin"}, {"id": "Bevacizumab_INT_Crenolanib", "text": "Interaction: Bevacizumab AND Crenolanib\nDetails: Bevacizumab may increase the cardiotoxic activities of Crenolanib.\nRisk: Monitor closely.", "source": "Bevacizumab + Crenolanib"}, {"id": "Bevacizumab_INT_Entinostat", "text": "Interaction: Bevacizumab AND Entinostat\nDetails: Bevacizumab may increase the cardiotoxic activities of Entinostat.\nRisk: Monitor closely.", "source": "Bevacizumab + Entinostat"}, {"id": "Bevacizumab_INT_3,3'-diindolylmethane", "text": "Interaction: Bevacizumab AND 3,3'-diindolylmethane\nDetails: Bevacizumab may increase the cardiotoxic activities of 3,3&#39;-diindolylmethane.\nRisk: Monitor closely.", "source": "Bevacizumab + 3,3'-diindolylmethane"}, {"id": "Bevacizumab_INT_Acridine Carboxamide", "text": "Interaction: Bevacizumab AND Acridine Carboxamide\nDetails: Bevacizumab may increase the cardiotoxic activities of Acridine Carboxamide.\nRisk: Monitor closely.", "source": "Bevacizumab + Acridine Carboxamide"}, {"id": "Bevacizumab_INT_Infigratinib", "text": "Interaction: Bevacizumab AND Infigratinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Infigratinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Infigratinib"}, {"id": "Bevacizumab_INT_Prulifloxacin", "text": "Interaction: Bevacizumab AND Prulifloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Prulifloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Prulifloxacin"}, {"id": "Bevacizumab_INT_Efatutazone", "text": "Interaction: Bevacizumab AND Efatutazone\nDetails: Bevacizumab may increase the cardiotoxic activities of Efatutazone.\nRisk: Monitor closely.", "source": "Bevacizumab + Efatutazone"}, {"id": "Bevacizumab_INT_6-O-benzylguanine", "text": "Interaction: Bevacizumab AND 6-O-benzylguanine\nDetails: Bevacizumab may increase the cardiotoxic activities of 6-O-benzylguanine.\nRisk: Monitor closely.", "source": "Bevacizumab + 6-O-benzylguanine"}, {"id": "Bevacizumab_INT_Carboxyamidotriazole", "text": "Interaction: Bevacizumab AND Carboxyamidotriazole\nDetails: Bevacizumab may increase the cardiotoxic activities of Carboxyamidotriazole.\nRisk: Monitor closely.", "source": "Bevacizumab + Carboxyamidotriazole"}, {"id": "Bevacizumab_INT_Triptolide", "text": "Interaction: Bevacizumab AND Triptolide\nDetails: Bevacizumab may increase the cardiotoxic activities of Triptolide.\nRisk: Monitor closely.", "source": "Bevacizumab + Triptolide"}, {"id": "Bevacizumab_INT_Broxuridine", "text": "Interaction: Bevacizumab AND Broxuridine\nDetails: Bevacizumab may increase the cardiotoxic activities of Broxuridine.\nRisk: Monitor closely.", "source": "Bevacizumab + Broxuridine"}, {"id": "Bevacizumab_INT_Trebananib", "text": "Interaction: Bevacizumab AND Trebananib\nDetails: Bevacizumab may increase the cardiotoxic activities of Trebananib.\nRisk: Monitor closely.", "source": "Bevacizumab + Trebananib"}, {"id": "Bevacizumab_INT_Anecortave", "text": "Interaction: Bevacizumab AND Anecortave\nDetails: Bevacizumab may increase the cardiotoxic activities of Anecortave.\nRisk: Monitor closely.", "source": "Bevacizumab + Anecortave"}, {"id": "Bevacizumab_INT_Vesnarinone", "text": "Interaction: Bevacizumab AND Vesnarinone\nDetails: Bevacizumab may increase the cardiotoxic activities of Vesnarinone.\nRisk: Monitor closely.", "source": "Bevacizumab + Vesnarinone"}, {"id": "Bevacizumab_INT_Mafosfamide", "text": "Interaction: Bevacizumab AND Mafosfamide\nDetails: Bevacizumab may increase the cardiotoxic activities of Mafosfamide.\nRisk: Monitor closely.", "source": "Bevacizumab + Mafosfamide"}, {"id": "Bevacizumab_INT_LCL-161", "text": "Interaction: Bevacizumab AND LCL-161\nDetails: Bevacizumab may increase the cardiotoxic activities of LCL-161.\nRisk: Monitor closely.", "source": "Bevacizumab + LCL-161"}, {"id": "Bevacizumab_INT_Taselisib", "text": "Interaction: Bevacizumab AND Taselisib\nDetails: Bevacizumab may increase the cardiotoxic activities of Taselisib.\nRisk: Monitor closely.", "source": "Bevacizumab + Taselisib"}, {"id": "Bevacizumab_INT_Zuretinol acetate", "text": "Interaction: Bevacizumab AND Zuretinol acetate\nDetails: Bevacizumab may increase the cardiotoxic activities of Zuretinol acetate.\nRisk: Monitor closely.", "source": "Bevacizumab + Zuretinol acetate"}, {"id": "Bevacizumab_INT_Epigallocatechin Gallate", "text": "Interaction: Bevacizumab AND Epigallocatechin Gallate\nDetails: Bevacizumab may increase the cardiotoxic activities of Epigallocatechin Gallate.\nRisk: Monitor closely.", "source": "Bevacizumab + Epigallocatechin Gallate"}, {"id": "Bevacizumab_INT_Namitecan", "text": "Interaction: Bevacizumab AND Namitecan\nDetails: Bevacizumab may increase the cardiotoxic activities of Namitecan.\nRisk: Monitor closely.", "source": "Bevacizumab + Namitecan"}, {"id": "Bevacizumab_INT_Duligotuzumab", "text": "Interaction: Bevacizumab AND Duligotuzumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Duligotuzumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Duligotuzumab"}, {"id": "Bevacizumab_INT_Cordycepin", "text": "Interaction: Bevacizumab AND Cordycepin\nDetails: Bevacizumab may increase the cardiotoxic activities of Cordycepin.\nRisk: Monitor closely.", "source": "Bevacizumab + Cordycepin"}, {"id": "Bevacizumab_INT_Binetrakin", "text": "Interaction: Bevacizumab AND Binetrakin\nDetails: Bevacizumab may increase the cardiotoxic activities of Binetrakin.\nRisk: Monitor closely.", "source": "Bevacizumab + Binetrakin"}, {"id": "Bevacizumab_INT_Exatecan", "text": "Interaction: Bevacizumab AND Exatecan\nDetails: Bevacizumab may increase the cardiotoxic activities of Exatecan.\nRisk: Monitor closely.", "source": "Bevacizumab + Exatecan"}, {"id": "Bevacizumab_INT_Lurtotecan", "text": "Interaction: Bevacizumab AND Lurtotecan\nDetails: Bevacizumab may increase the cardiotoxic activities of Lurtotecan.\nRisk: Monitor closely.", "source": "Bevacizumab + Lurtotecan"}, {"id": "Bevacizumab_INT_KRN-7000", "text": "Interaction: Bevacizumab AND KRN-7000\nDetails: Bevacizumab may increase the cardiotoxic activities of KRN-7000.\nRisk: Monitor closely.", "source": "Bevacizumab + KRN-7000"}, {"id": "Bevacizumab_INT_Epofolate", "text": "Interaction: Bevacizumab AND Epofolate\nDetails: Bevacizumab may increase the cardiotoxic activities of Epofolate.\nRisk: Monitor closely.", "source": "Bevacizumab + Epofolate"}, {"id": "Bevacizumab_INT_OBP-801", "text": "Interaction: Bevacizumab AND OBP-801\nDetails: Bevacizumab may increase the cardiotoxic activities of OBP-801.\nRisk: Monitor closely.", "source": "Bevacizumab + OBP-801"}, {"id": "Bevacizumab_INT_Rucaparib", "text": "Interaction: Bevacizumab AND Rucaparib\nDetails: Bevacizumab may increase the cardiotoxic activities of Rucaparib.\nRisk: Monitor closely.", "source": "Bevacizumab + Rucaparib"}, {"id": "Bevacizumab_INT_Navitoclax", "text": "Interaction: Bevacizumab AND Navitoclax\nDetails: Bevacizumab may increase the cardiotoxic activities of Navitoclax.\nRisk: Monitor closely.", "source": "Bevacizumab + Navitoclax"}, {"id": "Bevacizumab_INT_Bizelesin", "text": "Interaction: Bevacizumab AND Bizelesin\nDetails: Bevacizumab may increase the cardiotoxic activities of Bizelesin.\nRisk: Monitor closely.", "source": "Bevacizumab + Bizelesin"}, {"id": "Bevacizumab_INT_Indirubin", "text": "Interaction: Bevacizumab AND Indirubin\nDetails: Bevacizumab may increase the cardiotoxic activities of Indirubin.\nRisk: Monitor closely.", "source": "Bevacizumab + Indirubin"}, {"id": "Bevacizumab_INT_Merestinib", "text": "Interaction: Bevacizumab AND Merestinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Merestinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Merestinib"}, {"id": "Bevacizumab_INT_10-hydroxycamptothecin", "text": "Interaction: Bevacizumab AND 10-hydroxycamptothecin\nDetails: Bevacizumab may increase the cardiotoxic activities of 10-hydroxycamptothecin.\nRisk: Monitor closely.", "source": "Bevacizumab + 10-hydroxycamptothecin"}, {"id": "Bevacizumab_INT_Sulforaphane", "text": "Interaction: Bevacizumab AND Sulforaphane\nDetails: Bevacizumab may increase the cardiotoxic activities of Sulforaphane.\nRisk: Monitor closely.", "source": "Bevacizumab + Sulforaphane"}, {"id": "Bevacizumab_INT_Nadifloxacin", "text": "Interaction: Bevacizumab AND Nadifloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Nadifloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Nadifloxacin"}, {"id": "Bevacizumab_INT_Belotecan", "text": "Interaction: Bevacizumab AND Belotecan\nDetails: Bevacizumab may increase the cardiotoxic activities of Belotecan.\nRisk: Monitor closely.", "source": "Bevacizumab + Belotecan"}, {"id": "Bevacizumab_INT_Taurolidine", "text": "Interaction: Bevacizumab AND Taurolidine\nDetails: Bevacizumab may increase the cardiotoxic activities of Taurolidine.\nRisk: Monitor closely.", "source": "Bevacizumab + Taurolidine"}, {"id": "Bevacizumab_INT_9-aminocamptothecin", "text": "Interaction: Bevacizumab AND 9-aminocamptothecin\nDetails: Bevacizumab may increase the cardiotoxic activities of 9-aminocamptothecin.\nRisk: Monitor closely.", "source": "Bevacizumab + 9-aminocamptothecin"}, {"id": "Bevacizumab_INT_Molgramostim", "text": "Interaction: Bevacizumab AND Molgramostim\nDetails: Bevacizumab may increase the cardiotoxic activities of Molgramostim.\nRisk: Monitor closely.", "source": "Bevacizumab + Molgramostim"}, {"id": "Bevacizumab_INT_Oltipraz", "text": "Interaction: Bevacizumab AND Oltipraz\nDetails: Bevacizumab may increase the cardiotoxic activities of Oltipraz.\nRisk: Monitor closely.", "source": "Bevacizumab + Oltipraz"}, {"id": "Bevacizumab_INT_Pyrazoloacridine", "text": "Interaction: Bevacizumab AND Pyrazoloacridine\nDetails: Bevacizumab may increase the cardiotoxic activities of Pyrazoloacridine.\nRisk: Monitor closely.", "source": "Bevacizumab + Pyrazoloacridine"}, {"id": "Bevacizumab_INT_Fosbretabulin", "text": "Interaction: Bevacizumab AND Fosbretabulin\nDetails: Bevacizumab may increase the cardiotoxic activities of Fosbretabulin.\nRisk: Monitor closely.", "source": "Bevacizumab + Fosbretabulin"}, {"id": "Bevacizumab_INT_Apaziquone", "text": "Interaction: Bevacizumab AND Apaziquone\nDetails: Bevacizumab may increase the cardiotoxic activities of Apaziquone.\nRisk: Monitor closely.", "source": "Bevacizumab + Apaziquone"}, {"id": "Bevacizumab_INT_Combretastatin", "text": "Interaction: Bevacizumab AND Combretastatin\nDetails: Bevacizumab may increase the cardiotoxic activities of Combretastatin.\nRisk: Monitor closely.", "source": "Bevacizumab + Combretastatin"}, {"id": "Bevacizumab_INT_Mizoribine", "text": "Interaction: Bevacizumab AND Mizoribine\nDetails: Bevacizumab may increase the cardiotoxic activities of Mizoribine.\nRisk: Monitor closely.", "source": "Bevacizumab + Mizoribine"}, {"id": "Bevacizumab_INT_Onapristone", "text": "Interaction: Bevacizumab AND Onapristone\nDetails: Bevacizumab may increase the cardiotoxic activities of Onapristone.\nRisk: Monitor closely.", "source": "Bevacizumab + Onapristone"}, {"id": "Bevacizumab_INT_Soblidotin", "text": "Interaction: Bevacizumab AND Soblidotin\nDetails: Bevacizumab may increase the cardiotoxic activities of Soblidotin.\nRisk: Monitor closely.", "source": "Bevacizumab + Soblidotin"}, {"id": "Bevacizumab_INT_Salirasib", "text": "Interaction: Bevacizumab AND Salirasib\nDetails: Bevacizumab may increase the cardiotoxic activities of Salirasib.\nRisk: Monitor closely.", "source": "Bevacizumab + Salirasib"}, {"id": "Bevacizumab_INT_Gusperimus", "text": "Interaction: Bevacizumab AND Gusperimus\nDetails: Bevacizumab may increase the cardiotoxic activities of Gusperimus.\nRisk: Monitor closely.", "source": "Bevacizumab + Gusperimus"}, {"id": "Bevacizumab_INT_Phenethyl Isothiocyanate", "text": "Interaction: Bevacizumab AND Phenethyl Isothiocyanate\nDetails: Bevacizumab may increase the cardiotoxic activities of Phenethyl Isothiocyanate.\nRisk: Monitor closely.", "source": "Bevacizumab + Phenethyl Isothiocyanate"}, {"id": "Bevacizumab_INT_Methylselenocysteine", "text": "Interaction: Bevacizumab AND Methylselenocysteine\nDetails: Bevacizumab may increase the cardiotoxic activities of Methylselenocysteine.\nRisk: Monitor closely.", "source": "Bevacizumab + Methylselenocysteine"}, {"id": "Bevacizumab_INT_Dolastatin 10", "text": "Interaction: Bevacizumab AND Dolastatin 10\nDetails: Bevacizumab may increase the cardiotoxic activities of Dolastatin 10.\nRisk: Monitor closely.", "source": "Bevacizumab + Dolastatin 10"}, {"id": "Bevacizumab_INT_Etanidazole", "text": "Interaction: Bevacizumab AND Etanidazole\nDetails: Bevacizumab may increase the cardiotoxic activities of Etanidazole.\nRisk: Monitor closely.", "source": "Bevacizumab + Etanidazole"}, {"id": "Bevacizumab_INT_Lometrexol", "text": "Interaction: Bevacizumab AND Lometrexol\nDetails: Bevacizumab may increase the cardiotoxic activities of Lometrexol.\nRisk: Monitor closely.", "source": "Bevacizumab + Lometrexol"}, {"id": "Bevacizumab_INT_Buthionine Sulfoximine", "text": "Interaction: Bevacizumab AND Buthionine Sulfoximine\nDetails: Bevacizumab may increase the cardiotoxic activities of Buthionine Sulfoximine.\nRisk: Monitor closely.", "source": "Bevacizumab + Buthionine Sulfoximine"}, {"id": "Bevacizumab_INT_Dianhydrogalactitol", "text": "Interaction: Bevacizumab AND Dianhydrogalactitol\nDetails: Bevacizumab may increase the cardiotoxic activities of Dianhydrogalactitol.\nRisk: Monitor closely.", "source": "Bevacizumab + Dianhydrogalactitol"}, {"id": "Bevacizumab_INT_Indole-3-carbinol", "text": "Interaction: Bevacizumab AND Indole-3-carbinol\nDetails: Bevacizumab may increase the cardiotoxic activities of Indole-3-carbinol.\nRisk: Monitor closely.", "source": "Bevacizumab + Indole-3-carbinol"}, {"id": "Bevacizumab_INT_Fiacitabine", "text": "Interaction: Bevacizumab AND Fiacitabine\nDetails: Bevacizumab may increase the cardiotoxic activities of Fiacitabine.\nRisk: Monitor closely.", "source": "Bevacizumab + Fiacitabine"}, {"id": "Bevacizumab_INT_Nolatrexed", "text": "Interaction: Bevacizumab AND Nolatrexed\nDetails: Bevacizumab may increase the cardiotoxic activities of Nolatrexed.\nRisk: Monitor closely.", "source": "Bevacizumab + Nolatrexed"}, {"id": "Bevacizumab_INT_Mitolactol", "text": "Interaction: Bevacizumab AND Mitolactol\nDetails: Bevacizumab may increase the cardiotoxic activities of Mitolactol.\nRisk: Monitor closely.", "source": "Bevacizumab + Mitolactol"}, {"id": "Bevacizumab_INT_Pinometostat", "text": "Interaction: Bevacizumab AND Pinometostat\nDetails: Bevacizumab may increase the cardiotoxic activities of Pinometostat.\nRisk: Monitor closely.", "source": "Bevacizumab + Pinometostat"}, {"id": "Bevacizumab_INT_Doxifluridine", "text": "Interaction: Bevacizumab AND Doxifluridine\nDetails: Bevacizumab may increase the cardiotoxic activities of Doxifluridine.\nRisk: Monitor closely.", "source": "Bevacizumab + Doxifluridine"}, {"id": "Bevacizumab_INT_Didox", "text": "Interaction: Bevacizumab AND Didox\nDetails: Bevacizumab may increase the cardiotoxic activities of Didox.\nRisk: Monitor closely.", "source": "Bevacizumab + Didox"}, {"id": "Bevacizumab_INT_Penclomedine", "text": "Interaction: Bevacizumab AND Penclomedine\nDetails: Bevacizumab may increase the cardiotoxic activities of Penclomedine.\nRisk: Monitor closely.", "source": "Bevacizumab + Penclomedine"}, {"id": "Bevacizumab_INT_Deoxyspergualin", "text": "Interaction: Bevacizumab AND Deoxyspergualin\nDetails: Bevacizumab may increase the cardiotoxic activities of Deoxyspergualin.\nRisk: Monitor closely.", "source": "Bevacizumab + Deoxyspergualin"}, {"id": "Bevacizumab_INT_Acteoside", "text": "Interaction: Bevacizumab AND Acteoside\nDetails: Bevacizumab may increase the cardiotoxic activities of Acteoside.\nRisk: Monitor closely.", "source": "Bevacizumab + Acteoside"}, {"id": "Bevacizumab_INT_Hypericin", "text": "Interaction: Bevacizumab AND Hypericin\nDetails: Bevacizumab may increase the cardiotoxic activities of Hypericin.\nRisk: Monitor closely.", "source": "Bevacizumab + Hypericin"}, {"id": "Bevacizumab_INT_Irsogladine", "text": "Interaction: Bevacizumab AND Irsogladine\nDetails: Bevacizumab may increase the cardiotoxic activities of Irsogladine.\nRisk: Monitor closely.", "source": "Bevacizumab + Irsogladine"}, {"id": "Bevacizumab_INT_Liarozole", "text": "Interaction: Bevacizumab AND Liarozole\nDetails: Bevacizumab may increase the cardiotoxic activities of Liarozole.\nRisk: Monitor closely.", "source": "Bevacizumab + Liarozole"}, {"id": "Bevacizumab_INT_Sizofiran", "text": "Interaction: Bevacizumab AND Sizofiran\nDetails: Bevacizumab may increase the cardiotoxic activities of Sizofiran.\nRisk: Monitor closely.", "source": "Bevacizumab + Sizofiran"}, {"id": "Bevacizumab_INT_Nedaplatin", "text": "Interaction: Bevacizumab AND Nedaplatin\nDetails: Bevacizumab may increase the cardiotoxic activities of Nedaplatin.\nRisk: Monitor closely.", "source": "Bevacizumab + Nedaplatin"}, {"id": "Bevacizumab_INT_Sitafloxacin", "text": "Interaction: Bevacizumab AND Sitafloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Sitafloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Sitafloxacin"}, {"id": "Bevacizumab_INT_Lentinan", "text": "Interaction: Bevacizumab AND Lentinan\nDetails: Bevacizumab may increase the cardiotoxic activities of Lentinan.\nRisk: Monitor closely.", "source": "Bevacizumab + Lentinan"}, {"id": "Bevacizumab_INT_Oxolinic acid", "text": "Interaction: Bevacizumab AND Oxolinic acid\nDetails: Bevacizumab may increase the cardiotoxic activities of Oxolinic acid.\nRisk: Monitor closely.", "source": "Bevacizumab + Oxolinic acid"}, {"id": "Bevacizumab_INT_Vorozole", "text": "Interaction: Bevacizumab AND Vorozole\nDetails: Bevacizumab may increase the cardiotoxic activities of Vorozole.\nRisk: Monitor closely.", "source": "Bevacizumab + Vorozole"}, {"id": "Bevacizumab_INT_Rufloxacin", "text": "Interaction: Bevacizumab AND Rufloxacin\nDetails: Bevacizumab may increase the cardiotoxic activities of Rufloxacin.\nRisk: Monitor closely.", "source": "Bevacizumab + Rufloxacin"}, {"id": "Bevacizumab_INT_Iniparib", "text": "Interaction: Bevacizumab AND Iniparib\nDetails: Bevacizumab may increase the cardiotoxic activities of Iniparib.\nRisk: Monitor closely.", "source": "Bevacizumab + Iniparib"}, {"id": "Bevacizumab_INT_Coumermycin A1", "text": "Interaction: Bevacizumab AND Coumermycin A1\nDetails: Bevacizumab may increase the cardiotoxic activities of Coumermycin A1.\nRisk: Monitor closely.", "source": "Bevacizumab + Coumermycin A1"}, {"id": "Bevacizumab_INT_Toyocamycin", "text": "Interaction: Bevacizumab AND Toyocamycin\nDetails: Bevacizumab may increase the cardiotoxic activities of Toyocamycin.\nRisk: Monitor closely.", "source": "Bevacizumab + Toyocamycin"}, {"id": "Bevacizumab_INT_Masoprocol", "text": "Interaction: Bevacizumab AND Masoprocol\nDetails: Bevacizumab may increase the cardiotoxic activities of Masoprocol.\nRisk: Monitor closely.", "source": "Bevacizumab + Masoprocol"}, {"id": "Bevacizumab_INT_Anagrelide", "text": "Interaction: Bevacizumab AND Anagrelide\nDetails: Bevacizumab may increase the cardiotoxic activities of Anagrelide.\nRisk: Monitor closely.", "source": "Bevacizumab + Anagrelide"}, {"id": "Bevacizumab_INT_Trifluridine", "text": "Interaction: Bevacizumab AND Trifluridine\nDetails: Bevacizumab may increase the cardiotoxic activities of Trifluridine.\nRisk: Monitor closely.", "source": "Bevacizumab + Trifluridine"}, {"id": "Bevacizumab_INT_Aminolevulinic acid", "text": "Interaction: Bevacizumab AND Aminolevulinic acid\nDetails: Bevacizumab may increase the cardiotoxic activities of Aminolevulinic acid.\nRisk: Monitor closely.", "source": "Bevacizumab + Aminolevulinic acid"}, {"id": "Bevacizumab_INT_Methyl aminolevulinate", "text": "Interaction: Bevacizumab AND Methyl aminolevulinate\nDetails: Bevacizumab may increase the cardiotoxic activities of Methyl aminolevulinate.\nRisk: Monitor closely.", "source": "Bevacizumab + Methyl aminolevulinate"}, {"id": "Bevacizumab_INT_Ixabepilone", "text": "Interaction: Bevacizumab AND Ixabepilone\nDetails: Bevacizumab may increase the cardiotoxic activities of Ixabepilone.\nRisk: Monitor closely.", "source": "Bevacizumab + Ixabepilone"}, {"id": "Bevacizumab_INT_EG009", "text": "Interaction: Bevacizumab AND EG009\nDetails: Bevacizumab may increase the cardiotoxic activities of EG009.\nRisk: Monitor closely.", "source": "Bevacizumab + EG009"}, {"id": "Bevacizumab_INT_Vintafolide", "text": "Interaction: Bevacizumab AND Vintafolide\nDetails: Bevacizumab may increase the cardiotoxic activities of Vintafolide.\nRisk: Monitor closely.", "source": "Bevacizumab + Vintafolide"}, {"id": "Bevacizumab_INT_Ridaforolimus", "text": "Interaction: Bevacizumab AND Ridaforolimus\nDetails: Bevacizumab may increase the cardiotoxic activities of Ridaforolimus.\nRisk: Monitor closely.", "source": "Bevacizumab + Ridaforolimus"}, {"id": "Bevacizumab_INT_Pralatrexate", "text": "Interaction: Bevacizumab AND Pralatrexate\nDetails: Bevacizumab may increase the cardiotoxic activities of Pralatrexate.\nRisk: Monitor closely.", "source": "Bevacizumab + Pralatrexate"}, {"id": "Bevacizumab_INT_Efaproxiral", "text": "Interaction: Bevacizumab AND Efaproxiral\nDetails: Bevacizumab may increase the cardiotoxic activities of Efaproxiral.\nRisk: Monitor closely.", "source": "Bevacizumab + Efaproxiral"}, {"id": "Bevacizumab_INT_Cabozantinib", "text": "Interaction: Bevacizumab AND Cabozantinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Cabozantinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Cabozantinib"}, {"id": "Bevacizumab_INT_Dinutuximab", "text": "Interaction: Bevacizumab AND Dinutuximab\nDetails: Bevacizumab may increase the cardiotoxic activities of Dinutuximab.\nRisk: Monitor closely.", "source": "Bevacizumab + Dinutuximab"}, {"id": "Bevacizumab_INT_Sonidegib", "text": "Interaction: Bevacizumab AND Sonidegib\nDetails: Bevacizumab may increase the cardiotoxic activities of Sonidegib.\nRisk: Monitor closely.", "source": "Bevacizumab + Sonidegib"}, {"id": "Bevacizumab_INT_Masitinib", "text": "Interaction: Bevacizumab AND Masitinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Masitinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Masitinib"}, {"id": "Bevacizumab_INT_Vinflunine", "text": "Interaction: Bevacizumab AND Vinflunine\nDetails: Bevacizumab may increase the cardiotoxic activities of Vinflunine.\nRisk: Monitor closely.", "source": "Bevacizumab + Vinflunine"}, {"id": "Bevacizumab_INT_Tivozanib", "text": "Interaction: Bevacizumab AND Tivozanib\nDetails: Bevacizumab may increase the cardiotoxic activities of Tivozanib.\nRisk: Monitor closely.", "source": "Bevacizumab + Tivozanib"}, {"id": "Bevacizumab_INT_Mannosulfan", "text": "Interaction: Bevacizumab AND Mannosulfan\nDetails: Bevacizumab may increase the cardiotoxic activities of Mannosulfan.\nRisk: Monitor closely.", "source": "Bevacizumab + Mannosulfan"}, {"id": "Bevacizumab_INT_Edrecolomab", "text": "Interaction: Bevacizumab AND Edrecolomab\nDetails: Bevacizumab may increase the cardiotoxic activities of Edrecolomab.\nRisk: Monitor closely.", "source": "Bevacizumab + Edrecolomab"}, {"id": "Bevacizumab_INT_Paclitaxel poliglumex", "text": "Interaction: Bevacizumab AND Paclitaxel poliglumex\nDetails: Bevacizumab may increase the cardiotoxic activities of Paclitaxel poliglumex.\nRisk: Monitor closely.", "source": "Bevacizumab + Paclitaxel poliglumex"}, {"id": "Bevacizumab_INT_Oblimersen", "text": "Interaction: Bevacizumab AND Oblimersen\nDetails: Bevacizumab may increase the cardiotoxic activities of Oblimersen.\nRisk: Monitor closely.", "source": "Bevacizumab + Oblimersen"}, {"id": "Bevacizumab_INT_Interferon Alfa-2b, Recombinant", "text": "Interaction: Bevacizumab AND Interferon Alfa-2b, Recombinant\nDetails: Bevacizumab may increase the cardiotoxic activities of Interferon Alfa-2b, Recombinant.\nRisk: Monitor closely.", "source": "Bevacizumab + Interferon Alfa-2b, Recombinant"}, {"id": "Bevacizumab_INT_Mycophenolate mofetil", "text": "Interaction: Bevacizumab AND Mycophenolate mofetil\nDetails: Bevacizumab may increase the cardiotoxic activities of Mycophenolate mofetil.\nRisk: Monitor closely.", "source": "Bevacizumab + Mycophenolate mofetil"}, {"id": "Bevacizumab_INT_Cobimetinib", "text": "Interaction: Bevacizumab AND Cobimetinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Cobimetinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Cobimetinib"}, {"id": "Bevacizumab_INT_Elotuzumab", "text": "Interaction: Bevacizumab AND Elotuzumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Elotuzumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Elotuzumab"}, {"id": "Bevacizumab_INT_Degarelix", "text": "Interaction: Bevacizumab AND Degarelix\nDetails: Bevacizumab may increase the cardiotoxic activities of Degarelix.\nRisk: Monitor closely.", "source": "Bevacizumab + Degarelix"}, {"id": "Bevacizumab_INT_Buserelin", "text": "Interaction: Bevacizumab AND Buserelin\nDetails: Bevacizumab may increase the cardiotoxic activities of Buserelin.\nRisk: Monitor closely.", "source": "Bevacizumab + Buserelin"}, {"id": "Bevacizumab_INT_Aflibercept", "text": "Interaction: Bevacizumab AND Aflibercept\nDetails: Bevacizumab may increase the cardiotoxic activities of Aflibercept.\nRisk: Monitor closely.", "source": "Bevacizumab + Aflibercept"}, {"id": "Bevacizumab_INT_Enzalutamide", "text": "Interaction: Bevacizumab AND Enzalutamide\nDetails: Bevacizumab may increase the cardiotoxic activities of Enzalutamide.\nRisk: Monitor closely.", "source": "Bevacizumab + Enzalutamide"}, {"id": "Bevacizumab_INT_Alectinib", "text": "Interaction: Bevacizumab AND Alectinib\nDetails: Bevacizumab may increase the cardiotoxic activities of Alectinib.\nRisk: Monitor closely.", "source": "Bevacizumab + Alectinib"}, {"id": "Bevacizumab_INT_Venetoclax", "text": "Interaction: Bevacizumab AND Venetoclax\nDetails: Bevacizumab may increase the cardiotoxic activities of Venetoclax.\nRisk: Monitor closely.", "source": "Bevacizumab + Venetoclax"}, {"id": "Bevacizumab_INT_Atezolizumab", "text": "Interaction: Bevacizumab AND Atezolizumab\nDetails: Bevacizumab may increase the cardiotoxic activities of Atezolizumab.\nRisk: Monitor closely.", "source": "Bevacizumab + Atezolizumab"}, {"id": "Bevacizumab_INT_Irinotecan", "text": "Interaction: Bevacizumab AND Irinotecan\nDetails: The risk or severity of adverse effects can be increased when Bevacizumab is combined with Irinotecan.\nRisk: Monitor closely.", "source": "Bevacizumab + Irinotecan"}, {"id": "Bevacizumab_INT_Sorafenib", "text": "Interaction: Bevacizumab AND Sorafenib\nDetails: The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sorafenib.\nRisk: Monitor closely.", "source": "Bevacizumab + Sorafenib"}, {"id": "Technetium Tc-99m arcitumomab_GEN", "text": "Drug: Technetium Tc-99m arcitumomab\nDescription: Reduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen (CEA) covalently labeled with Technitium 99. The molecule has a molecular weight of ~54,000 Daltons....", "source": "Technetium Tc-99m arcitumomab"}, {"id": "Technetium Tc-99m arcitumomab_CLIN", "text": "Drug: Technetium Tc-99m arcitumomab\nMechanism: Binds selectively to cell-surface carcinoembryonic antigen (CEA) expressed on colorectal tumors....\nToxicity: ...", "source": "Technetium Tc-99m arcitumomab"}, {"id": "Technetium Tc-99m arcitumomab_INT_Varicella Zoster Vaccine (Live/Attenuated)", "text": "Interaction: Technetium Tc-99m arcitumomab AND Varicella Zoster Vaccine (Live/Attenuated)\nDetails: The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + Varicella Zoster Vaccine (Live/Attenuated)"}, {"id": "Technetium Tc-99m arcitumomab_INT_Yellow fever vaccine", "text": "Interaction: Technetium Tc-99m arcitumomab AND Yellow fever vaccine\nDetails: The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + Yellow fever vaccine"}, {"id": "Technetium Tc-99m arcitumomab_INT_Clostridium tetani toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Technetium Tc-99m arcitumomab AND Clostridium tetani toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + Clostridium tetani toxoid antigen (formaldehyde inactivated)"}, {"id": "Technetium Tc-99m arcitumomab_INT_Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)", "text": "Interaction: Technetium Tc-99m arcitumomab AND Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)\nDetails: The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)"}, {"id": "Technetium Tc-99m arcitumomab_INT_Rotavirus Vaccine", "text": "Interaction: Technetium Tc-99m arcitumomab AND Rotavirus Vaccine\nDetails: The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + Rotavirus Vaccine"}, {"id": "Technetium Tc-99m arcitumomab_INT_G17DT", "text": "Interaction: Technetium Tc-99m arcitumomab AND G17DT\nDetails: The therapeutic efficacy of G17DT can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + G17DT"}, {"id": "Technetium Tc-99m arcitumomab_INT_INGN 201", "text": "Interaction: Technetium Tc-99m arcitumomab AND INGN 201\nDetails: The therapeutic efficacy of INGN 201 can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + INGN 201"}, {"id": "Technetium Tc-99m arcitumomab_INT_INGN 225", "text": "Interaction: Technetium Tc-99m arcitumomab AND INGN 225\nDetails: The therapeutic efficacy of INGN 225 can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + INGN 225"}, {"id": "Technetium Tc-99m arcitumomab_INT_Rindopepimut", "text": "Interaction: Technetium Tc-99m arcitumomab AND Rindopepimut\nDetails: The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + Rindopepimut"}, {"id": "Technetium Tc-99m arcitumomab_INT_SRP 299", "text": "Interaction: Technetium Tc-99m arcitumomab AND SRP 299\nDetails: The therapeutic efficacy of SRP 299 can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + SRP 299"}, {"id": "Technetium Tc-99m arcitumomab_INT_GI-5005", "text": "Interaction: Technetium Tc-99m arcitumomab AND GI-5005\nDetails: The therapeutic efficacy of GI-5005 can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + GI-5005"}, {"id": "Technetium Tc-99m arcitumomab_INT_TG4010", "text": "Interaction: Technetium Tc-99m arcitumomab AND TG4010\nDetails: The therapeutic efficacy of TG4010 can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + TG4010"}, {"id": "Technetium Tc-99m arcitumomab_INT_Rabies virus inactivated antigen, A", "text": "Interaction: Technetium Tc-99m arcitumomab AND Rabies virus inactivated antigen, A\nDetails: The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + Rabies virus inactivated antigen, A"}, {"id": "Technetium Tc-99m arcitumomab_INT_Tecemotide", "text": "Interaction: Technetium Tc-99m arcitumomab AND Tecemotide\nDetails: The therapeutic efficacy of Tecemotide can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + Tecemotide"}, {"id": "Technetium Tc-99m arcitumomab_INT_BCG vaccine", "text": "Interaction: Technetium Tc-99m arcitumomab AND BCG vaccine\nDetails: The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + BCG vaccine"}, {"id": "Technetium Tc-99m arcitumomab_INT_Rubella virus vaccine", "text": "Interaction: Technetium Tc-99m arcitumomab AND Rubella virus vaccine\nDetails: The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + Rubella virus vaccine"}, {"id": "Technetium Tc-99m arcitumomab_INT_Hepatitis A Vaccine", "text": "Interaction: Technetium Tc-99m arcitumomab AND Hepatitis A Vaccine\nDetails: The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + Hepatitis A Vaccine"}, {"id": "Technetium Tc-99m arcitumomab_INT_Salmonella typhi ty21a live antigen", "text": "Interaction: Technetium Tc-99m arcitumomab AND Salmonella typhi ty21a live antigen\nDetails: The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + Salmonella typhi ty21a live antigen"}, {"id": "Technetium Tc-99m arcitumomab_INT_Hepatitis B Vaccine (Recombinant)", "text": "Interaction: Technetium Tc-99m arcitumomab AND Hepatitis B Vaccine (Recombinant)\nDetails: The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Technetium Tc-99m arcitumomab.\nRisk: Monitor closely.", "source": "Technetium Tc-99m arcitumomab + Hepatitis B Vaccine (Recombinant)"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Histidine_GEN", "text": "Drug: Histidine\nDescription: ...", "source": "Histidine"}, {"id": "L-Aspartic Acid_GEN", "text": "Drug: L-Aspartic Acid\nDescription: ...", "source": "L-Aspartic Acid"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "Calcium_GEN", "text": "Drug: Calcium\nDescription: ...", "source": "Calcium"}, {"id": "Zinc_GEN", "text": "Drug: Zinc\nDescription: ...", "source": "Zinc"}, {"id": "Pantothenic acid_GEN", "text": "Drug: Pantothenic acid\nDescription: ...", "source": "Pantothenic acid"}, {"id": "3,4-Dihydrouracil_GEN", "text": "Drug: 3,4-Dihydrouracil\nDescription: ...", "source": "3,4-Dihydrouracil"}, {"id": "Beta-Alanine_GEN", "text": "Drug: Beta-Alanine\nDescription: ...", "source": "Beta-Alanine"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "Riboflavin Monophosphate_GEN", "text": "Drug: Riboflavin Monophosphate\nDescription: ...", "source": "Riboflavin Monophosphate"}, {"id": "Uracil_GEN", "text": "Drug: Uracil\nDescription: ...", "source": "Uracil"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Ademetionine_GEN", "text": "Drug: Ademetionine\nDescription: ...", "source": "Ademetionine"}, {"id": "Vitamin C_GEN", "text": "Drug: Vitamin C\nDescription: ...", "source": "Vitamin C"}, {"id": "L-Tyrosine_GEN", "text": "Drug: L-Tyrosine\nDescription: ...", "source": "L-Tyrosine"}, {"id": "Norepinephrine_GEN", "text": "Drug: Norepinephrine\nDescription: ...", "source": "Norepinephrine"}, {"id": "Epinephrine_GEN", "text": "Drug: Epinephrine\nDescription: ...", "source": "Epinephrine"}, {"id": "Dopamine_GEN", "text": "Drug: Dopamine\nDescription: ...", "source": "Dopamine"}, {"id": "Levodopa_GEN", "text": "Drug: Levodopa\nDescription: ...", "source": "Levodopa"}, {"id": "Iron_GEN", "text": "Drug: Iron\nDescription: ...", "source": "Iron"}, {"id": "Pyrroloquinoline Quinone_GEN", "text": "Drug: Pyrroloquinoline Quinone\nDescription: ...", "source": "Pyrroloquinoline Quinone"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Pyruvic acid_GEN", "text": "Drug: Pyruvic acid\nDescription: ...", "source": "Pyruvic acid"}, {"id": "Adenosine monophosphate_GEN", "text": "Drug: Adenosine monophosphate\nDescription: ...", "source": "Adenosine monophosphate"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "L-Cysteine_GEN", "text": "Drug: L-Cysteine\nDescription: ...", "source": "L-Cysteine"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "ATP_GEN", "text": "Drug: ATP\nDescription: ...", "source": "ATP"}, {"id": "Iron_GEN", "text": "Drug: Iron\nDescription: ...", "source": "Iron"}, {"id": "Zinc_GEN", "text": "Drug: Zinc\nDescription: ...", "source": "Zinc"}, {"id": "gamma-Glutamylcysteine_GEN", "text": "Drug: gamma-Glutamylcysteine\nDescription: ...", "source": "gamma-Glutamylcysteine"}, {"id": "Pyrophosphoric acid_GEN", "text": "Drug: Pyrophosphoric acid\nDescription: ...", "source": "Pyrophosphoric acid"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "L-Aspartic Acid_GEN", "text": "Drug: L-Aspartic Acid\nDescription: ...", "source": "L-Aspartic Acid"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "Calcium_GEN", "text": "Drug: Calcium\nDescription: ...", "source": "Calcium"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Tetrahydrofolic acid_GEN", "text": "Drug: Tetrahydrofolic acid\nDescription: ...", "source": "Tetrahydrofolic acid"}, {"id": "Ademetionine_GEN", "text": "Drug: Ademetionine\nDescription: ...", "source": "Ademetionine"}, {"id": "Choline_GEN", "text": "Drug: Choline\nDescription: ...", "source": "Choline"}, {"id": "Adenosine monophosphate_GEN", "text": "Drug: Adenosine monophosphate\nDescription: ...", "source": "Adenosine monophosphate"}, {"id": "Serine_GEN", "text": "Drug: Serine\nDescription: ...", "source": "Serine"}, {"id": "L-Methionine_GEN", "text": "Drug: L-Methionine\nDescription: ...", "source": "L-Methionine"}, {"id": "Glycine_GEN", "text": "Drug: Glycine\nDescription: ...", "source": "Glycine"}, {"id": "L-Cysteine_GEN", "text": "Drug: L-Cysteine\nDescription: ...", "source": "L-Cysteine"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "ATP_GEN", "text": "Drug: ATP\nDescription: ...", "source": "ATP"}, {"id": "Adenosine_GEN", "text": "Drug: Adenosine\nDescription: ...", "source": "Adenosine"}, {"id": "Potassium_GEN", "text": "Drug: Potassium\nDescription: ...", "source": "Potassium"}, {"id": "Magnesium_GEN", "text": "Drug: Magnesium\nDescription: ...", "source": "Magnesium"}, {"id": "Zinc_GEN", "text": "Drug: Zinc\nDescription: ...", "source": "Zinc"}, {"id": "Putrescine_GEN", "text": "Drug: Putrescine\nDescription: ...", "source": "Putrescine"}, {"id": "N,N-dimethylglycine_GEN", "text": "Drug: N,N-dimethylglycine\nDescription: ...", "source": "N,N-dimethylglycine"}, {"id": "4-(Methylsulfanyl)-2-Oxobutanoic Acid_GEN", "text": "Drug: 4-(Methylsulfanyl)-2-Oxobutanoic Acid\nDescription: ...", "source": "4-(Methylsulfanyl)-2-Oxobutanoic Acid"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "Spermidine_GEN", "text": "Drug: Spermidine\nDescription: ...", "source": "Spermidine"}, {"id": "Pyrophosphoric acid_GEN", "text": "Drug: Pyrophosphoric acid\nDescription: ...", "source": "Pyrophosphoric acid"}, {"id": "L-Homoserine_GEN", "text": "Drug: L-Homoserine\nDescription: ...", "source": "L-Homoserine"}, {"id": "2-Oxobutanoic Acid_GEN", "text": "Drug: 2-Oxobutanoic Acid\nDescription: ...", "source": "2-Oxobutanoic Acid"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Ademetionine_GEN", "text": "Drug: Ademetionine\nDescription: ...", "source": "Ademetionine"}, {"id": "L-Arginine_GEN", "text": "Drug: L-Arginine\nDescription: ...", "source": "L-Arginine"}, {"id": "L-Aspartic Acid_GEN", "text": "Drug: L-Aspartic Acid\nDescription: ...", "source": "L-Aspartic Acid"}, {"id": "Ornithine_GEN", "text": "Drug: Ornithine\nDescription: ...", "source": "Ornithine"}, {"id": "Adenosine monophosphate_GEN", "text": "Drug: Adenosine monophosphate\nDescription: ...", "source": "Adenosine monophosphate"}, {"id": "Succinic acid_GEN", "text": "Drug: Succinic acid\nDescription: ...", "source": "Succinic acid"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "Glycine_GEN", "text": "Drug: Glycine\nDescription: ...", "source": "Glycine"}, {"id": "Creatine_GEN", "text": "Drug: Creatine\nDescription: ...", "source": "Creatine"}, {"id": "L-Citrulline_GEN", "text": "Drug: L-Citrulline\nDescription: ...", "source": "L-Citrulline"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "ATP_GEN", "text": "Drug: ATP\nDescription: ...", "source": "ATP"}, {"id": "L-Proline_GEN", "text": "Drug: L-Proline\nDescription: ...", "source": "L-Proline"}, {"id": "Sapropterin_GEN", "text": "Drug: Sapropterin\nDescription: ...", "source": "Sapropterin"}, {"id": "Nitric Oxide_GEN", "text": "Drug: Nitric Oxide\nDescription: ...", "source": "Nitric Oxide"}, {"id": "Mesoheme_GEN", "text": "Drug: Mesoheme\nDescription: ...", "source": "Mesoheme"}, {"id": "Glycocyamine_GEN", "text": "Drug: Glycocyamine\nDescription: ...", "source": "Glycocyamine"}, {"id": "3,4-Dihydro-2h-Pyrrolium-5-Carboxylate_GEN", "text": "Drug: 3,4-Dihydro-2h-Pyrrolium-5-Carboxylate\nDescription: ...", "source": "3,4-Dihydro-2h-Pyrrolium-5-Carboxylate"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "Riboflavin Monophosphate_GEN", "text": "Drug: Riboflavin Monophosphate\nDescription: ...", "source": "Riboflavin Monophosphate"}, {"id": "Urea_GEN", "text": "Drug: Urea\nDescription: ...", "source": "Urea"}, {"id": "Pyrophosphoric acid_GEN", "text": "Drug: Pyrophosphoric acid\nDescription: ...", "source": "Pyrophosphoric acid"}, {"id": "Maleic Acid_GEN", "text": "Drug: Maleic Acid\nDescription: ...", "source": "Maleic Acid"}, {"id": "4-Carboxy-4-Aminobutanal_GEN", "text": "Drug: 4-Carboxy-4-Aminobutanal\nDescription: ...", "source": "4-Carboxy-4-Aminobutanal"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Biotin_GEN", "text": "Drug: Biotin\nDescription: ...", "source": "Biotin"}, {"id": "Succinic acid_GEN", "text": "Drug: Succinic acid\nDescription: ...", "source": "Succinic acid"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "Pyridoxal_GEN", "text": "Drug: Pyridoxal\nDescription: ...", "source": "Pyridoxal"}, {"id": "L-Leucine_GEN", "text": "Drug: L-Leucine\nDescription: ...", "source": "L-Leucine"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "L-Valine_GEN", "text": "Drug: L-Valine\nDescription: ...", "source": "L-Valine"}, {"id": "L-Isoleucine_GEN", "text": "Drug: L-Isoleucine\nDescription: ...", "source": "L-Isoleucine"}, {"id": "ATP_GEN", "text": "Drug: ATP\nDescription: ...", "source": "ATP"}, {"id": "Acetoacetic Acid_GEN", "text": "Drug: Acetoacetic Acid\nDescription: ...", "source": "Acetoacetic Acid"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "2-Oxo-4-Methylpentanoic Acid_GEN", "text": "Drug: 2-Oxo-4-Methylpentanoic Acid\nDescription: ...", "source": "2-Oxo-4-Methylpentanoic Acid"}, {"id": "Alpha-ketoisovalerate_GEN", "text": "Drug: Alpha-ketoisovalerate\nDescription: ...", "source": "Alpha-ketoisovalerate"}, {"id": "Methylmalonic Acid_GEN", "text": "Drug: Methylmalonic Acid\nDescription: ...", "source": "Methylmalonic Acid"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "L-Lysine_GEN", "text": "Drug: L-Lysine\nDescription: ...", "source": "L-Lysine"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "N-(5-Amino-5-Carboxypentyl)Glutamic Acid_GEN", "text": "Drug: N-(5-Amino-5-Carboxypentyl)Glutamic Acid\nDescription: ...", "source": "N-(5-Amino-5-Carboxypentyl)Glutamic Acid"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Glycine_GEN", "text": "Drug: Glycine\nDescription: ...", "source": "Glycine"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "Aminolevulinic acid_GEN", "text": "Drug: Aminolevulinic acid\nDescription: ...", "source": "Aminolevulinic acid"}, {"id": "Iron_GEN", "text": "Drug: Iron\nDescription: ...", "source": "Iron"}, {"id": "Zinc_GEN", "text": "Drug: Zinc\nDescription: ...", "source": "Zinc"}, {"id": "Protoporphyrin_GEN", "text": "Drug: Protoporphyrin\nDescription: ...", "source": "Protoporphyrin"}, {"id": "Mesoheme_GEN", "text": "Drug: Mesoheme\nDescription: ...", "source": "Mesoheme"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "Uridine-5'-Diphosphate_GEN", "text": "Drug: Uridine-5'-Diphosphate\nDescription: ...", "source": "Uridine-5'-Diphosphate"}, {"id": "Coproporphyrinogen III_GEN", "text": "Drug: Coproporphyrinogen III\nDescription: ...", "source": "Coproporphyrinogen III"}, {"id": "FARNESYL DIPHOSPHATE_GEN", "text": "Drug: FARNESYL DIPHOSPHATE\nDescription: ...", "source": "FARNESYL DIPHOSPHATE"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Glycine_GEN", "text": "Drug: Glycine\nDescription: ...", "source": "Glycine"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "Aminolevulinic acid_GEN", "text": "Drug: Aminolevulinic acid\nDescription: ...", "source": "Aminolevulinic acid"}, {"id": "Iron_GEN", "text": "Drug: Iron\nDescription: ...", "source": "Iron"}, {"id": "Zinc_GEN", "text": "Drug: Zinc\nDescription: ...", "source": "Zinc"}, {"id": "Protoporphyrin_GEN", "text": "Drug: Protoporphyrin\nDescription: ...", "source": "Protoporphyrin"}, {"id": "Mesoheme_GEN", "text": "Drug: Mesoheme\nDescription: ...", "source": "Mesoheme"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "Uridine-5'-Diphosphate_GEN", "text": "Drug: Uridine-5'-Diphosphate\nDescription: ...", "source": "Uridine-5'-Diphosphate"}, {"id": "Coproporphyrinogen III_GEN", "text": "Drug: Coproporphyrinogen III\nDescription: ...", "source": "Coproporphyrinogen III"}, {"id": "FARNESYL DIPHOSPHATE_GEN", "text": "Drug: FARNESYL DIPHOSPHATE\nDescription: ...", "source": "FARNESYL DIPHOSPHATE"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Serine_GEN", "text": "Drug: Serine\nDescription: ...", "source": "Serine"}, {"id": "ATP_GEN", "text": "Drug: ATP\nDescription: ...", "source": "ATP"}, {"id": "Calcium_GEN", "text": "Drug: Calcium\nDescription: ...", "source": "Calcium"}, {"id": "Magnesium_GEN", "text": "Drug: Magnesium\nDescription: ...", "source": "Magnesium"}, {"id": "Zinc_GEN", "text": "Drug: Zinc\nDescription: ...", "source": "Zinc"}, {"id": "Uridine diphosphate glucose_GEN", "text": "Drug: Uridine diphosphate glucose\nDescription: ...", "source": "Uridine diphosphate glucose"}, {"id": "Hexadecanal_GEN", "text": "Drug: Hexadecanal\nDescription: ...", "source": "Hexadecanal"}, {"id": "Uridine-5'-Diphosphate_GEN", "text": "Drug: Uridine-5'-Diphosphate\nDescription: ...", "source": "Uridine-5'-Diphosphate"}, {"id": "N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium_GEN", "text": "Drug: N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium\nDescription: ...", "source": "N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Pyruvic acid_GEN", "text": "Drug: Pyruvic acid\nDescription: ...", "source": "Pyruvic acid"}, {"id": "Biotin_GEN", "text": "Drug: Biotin\nDescription: ...", "source": "Biotin"}, {"id": "Adenosine monophosphate_GEN", "text": "Drug: Adenosine monophosphate\nDescription: ...", "source": "Adenosine monophosphate"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "Glycine_GEN", "text": "Drug: Glycine\nDescription: ...", "source": "Glycine"}, {"id": "L-Alanine_GEN", "text": "Drug: L-Alanine\nDescription: ...", "source": "L-Alanine"}, {"id": "ATP_GEN", "text": "Drug: ATP\nDescription: ...", "source": "ATP"}, {"id": "Zinc_GEN", "text": "Drug: Zinc\nDescription: ...", "source": "Zinc"}, {"id": "Pyrophosphoric acid_GEN", "text": "Drug: Pyrophosphoric acid\nDescription: ...", "source": "Pyrophosphoric acid"}, {"id": "Glyoxylic acid_GEN", "text": "Drug: Glyoxylic acid\nDescription: ...", "source": "Glyoxylic acid"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Ademetionine_GEN", "text": "Drug: Ademetionine\nDescription: ...", "source": "Ademetionine"}, {"id": "L-Arginine_GEN", "text": "Drug: L-Arginine\nDescription: ...", "source": "L-Arginine"}, {"id": "L-Aspartic Acid_GEN", "text": "Drug: L-Aspartic Acid\nDescription: ...", "source": "L-Aspartic Acid"}, {"id": "Ornithine_GEN", "text": "Drug: Ornithine\nDescription: ...", "source": "Ornithine"}, {"id": "Adenosine monophosphate_GEN", "text": "Drug: Adenosine monophosphate\nDescription: ...", "source": "Adenosine monophosphate"}, {"id": "Succinic acid_GEN", "text": "Drug: Succinic acid\nDescription: ...", "source": "Succinic acid"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "Glycine_GEN", "text": "Drug: Glycine\nDescription: ...", "source": "Glycine"}, {"id": "Creatine_GEN", "text": "Drug: Creatine\nDescription: ...", "source": "Creatine"}, {"id": "L-Citrulline_GEN", "text": "Drug: L-Citrulline\nDescription: ...", "source": "L-Citrulline"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "ATP_GEN", "text": "Drug: ATP\nDescription: ...", "source": "ATP"}, {"id": "L-Proline_GEN", "text": "Drug: L-Proline\nDescription: ...", "source": "L-Proline"}, {"id": "Sapropterin_GEN", "text": "Drug: Sapropterin\nDescription: ...", "source": "Sapropterin"}, {"id": "Nitric Oxide_GEN", "text": "Drug: Nitric Oxide\nDescription: ...", "source": "Nitric Oxide"}, {"id": "Mesoheme_GEN", "text": "Drug: Mesoheme\nDescription: ...", "source": "Mesoheme"}, {"id": "Glycocyamine_GEN", "text": "Drug: Glycocyamine\nDescription: ...", "source": "Glycocyamine"}, {"id": "3,4-Dihydro-2h-Pyrrolium-5-Carboxylate_GEN", "text": "Drug: 3,4-Dihydro-2h-Pyrrolium-5-Carboxylate\nDescription: ...", "source": "3,4-Dihydro-2h-Pyrrolium-5-Carboxylate"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "Riboflavin Monophosphate_GEN", "text": "Drug: Riboflavin Monophosphate\nDescription: ...", "source": "Riboflavin Monophosphate"}, {"id": "Urea_GEN", "text": "Drug: Urea\nDescription: ...", "source": "Urea"}, {"id": "Pyrophosphoric acid_GEN", "text": "Drug: Pyrophosphoric acid\nDescription: ...", "source": "Pyrophosphoric acid"}, {"id": "Maleic Acid_GEN", "text": "Drug: Maleic Acid\nDescription: ...", "source": "Maleic Acid"}, {"id": "4-Carboxy-4-Aminobutanal_GEN", "text": "Drug: 4-Carboxy-4-Aminobutanal\nDescription: ...", "source": "4-Carboxy-4-Aminobutanal"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Ademetionine_GEN", "text": "Drug: Ademetionine\nDescription: ...", "source": "Ademetionine"}, {"id": "L-Arginine_GEN", "text": "Drug: L-Arginine\nDescription: ...", "source": "L-Arginine"}, {"id": "L-Aspartic Acid_GEN", "text": "Drug: L-Aspartic Acid\nDescription: ...", "source": "L-Aspartic Acid"}, {"id": "Ornithine_GEN", "text": "Drug: Ornithine\nDescription: ...", "source": "Ornithine"}, {"id": "Adenosine monophosphate_GEN", "text": "Drug: Adenosine monophosphate\nDescription: ...", "source": "Adenosine monophosphate"}, {"id": "Succinic acid_GEN", "text": "Drug: Succinic acid\nDescription: ...", "source": "Succinic acid"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "Glycine_GEN", "text": "Drug: Glycine\nDescription: ...", "source": "Glycine"}, {"id": "Creatine_GEN", "text": "Drug: Creatine\nDescription: ...", "source": "Creatine"}, {"id": "L-Citrulline_GEN", "text": "Drug: L-Citrulline\nDescription: ...", "source": "L-Citrulline"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "ATP_GEN", "text": "Drug: ATP\nDescription: ...", "source": "ATP"}, {"id": "L-Proline_GEN", "text": "Drug: L-Proline\nDescription: ...", "source": "L-Proline"}, {"id": "Sapropterin_GEN", "text": "Drug: Sapropterin\nDescription: ...", "source": "Sapropterin"}, {"id": "Nitric Oxide_GEN", "text": "Drug: Nitric Oxide\nDescription: ...", "source": "Nitric Oxide"}, {"id": "Mesoheme_GEN", "text": "Drug: Mesoheme\nDescription: ...", "source": "Mesoheme"}, {"id": "Glycocyamine_GEN", "text": "Drug: Glycocyamine\nDescription: ...", "source": "Glycocyamine"}, {"id": "3,4-Dihydro-2h-Pyrrolium-5-Carboxylate_GEN", "text": "Drug: 3,4-Dihydro-2h-Pyrrolium-5-Carboxylate\nDescription: ...", "source": "3,4-Dihydro-2h-Pyrrolium-5-Carboxylate"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "Riboflavin Monophosphate_GEN", "text": "Drug: Riboflavin Monophosphate\nDescription: ...", "source": "Riboflavin Monophosphate"}, {"id": "Urea_GEN", "text": "Drug: Urea\nDescription: ...", "source": "Urea"}, {"id": "Pyrophosphoric acid_GEN", "text": "Drug: Pyrophosphoric acid\nDescription: ...", "source": "Pyrophosphoric acid"}, {"id": "Maleic Acid_GEN", "text": "Drug: Maleic Acid\nDescription: ...", "source": "Maleic Acid"}, {"id": "4-Carboxy-4-Aminobutanal_GEN", "text": "Drug: 4-Carboxy-4-Aminobutanal\nDescription: ...", "source": "4-Carboxy-4-Aminobutanal"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "L-Phenylalanine_GEN", "text": "Drug: L-Phenylalanine\nDescription: ...", "source": "L-Phenylalanine"}, {"id": "Adenosine monophosphate_GEN", "text": "Drug: Adenosine monophosphate\nDescription: ...", "source": "Adenosine monophosphate"}, {"id": "L-Tyrosine_GEN", "text": "Drug: L-Tyrosine\nDescription: ...", "source": "L-Tyrosine"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "ATP_GEN", "text": "Drug: ATP\nDescription: ...", "source": "ATP"}, {"id": "Calcium_GEN", "text": "Drug: Calcium\nDescription: ...", "source": "Calcium"}, {"id": "Magnesium_GEN", "text": "Drug: Magnesium\nDescription: ...", "source": "Magnesium"}, {"id": "Iron_GEN", "text": "Drug: Iron\nDescription: ...", "source": "Iron"}, {"id": "Acetoacetic Acid_GEN", "text": "Drug: Acetoacetic Acid\nDescription: ...", "source": "Acetoacetic Acid"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "Phenylpyruvic acid_GEN", "text": "Drug: Phenylpyruvic acid\nDescription: ...", "source": "Phenylpyruvic acid"}, {"id": "Pyrophosphoric acid_GEN", "text": "Drug: Pyrophosphoric acid\nDescription: ...", "source": "Pyrophosphoric acid"}, {"id": "Maleic Acid_GEN", "text": "Drug: Maleic Acid\nDescription: ...", "source": "Maleic Acid"}, {"id": "3-(4-HYDROXY-PHENYL)PYRUVIC ACID_GEN", "text": "Drug: 3-(4-HYDROXY-PHENYL)PYRUVIC ACID\nDescription: ...", "source": "3-(4-HYDROXY-PHENYL)PYRUVIC ACID"}, {"id": "2-(3,6-DIHYDROXYPHENYL)ACETIC ACID_GEN", "text": "Drug: 2-(3,6-DIHYDROXYPHENYL)ACETIC ACID\nDescription: ...", "source": "2-(3,6-DIHYDROXYPHENYL)ACETIC ACID"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "L-Phenylalanine_GEN", "text": "Drug: L-Phenylalanine\nDescription: ...", "source": "L-Phenylalanine"}, {"id": "Adenosine monophosphate_GEN", "text": "Drug: Adenosine monophosphate\nDescription: ...", "source": "Adenosine monophosphate"}, {"id": "L-Tyrosine_GEN", "text": "Drug: L-Tyrosine\nDescription: ...", "source": "L-Tyrosine"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "ATP_GEN", "text": "Drug: ATP\nDescription: ...", "source": "ATP"}, {"id": "Calcium_GEN", "text": "Drug: Calcium\nDescription: ...", "source": "Calcium"}, {"id": "Magnesium_GEN", "text": "Drug: Magnesium\nDescription: ...", "source": "Magnesium"}, {"id": "Iron_GEN", "text": "Drug: Iron\nDescription: ...", "source": "Iron"}, {"id": "Acetoacetic Acid_GEN", "text": "Drug: Acetoacetic Acid\nDescription: ...", "source": "Acetoacetic Acid"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "Phenylpyruvic acid_GEN", "text": "Drug: Phenylpyruvic acid\nDescription: ...", "source": "Phenylpyruvic acid"}, {"id": "Pyrophosphoric acid_GEN", "text": "Drug: Pyrophosphoric acid\nDescription: ...", "source": "Pyrophosphoric acid"}, {"id": "Maleic Acid_GEN", "text": "Drug: Maleic Acid\nDescription: ...", "source": "Maleic Acid"}, {"id": "3-(4-HYDROXY-PHENYL)PYRUVIC ACID_GEN", "text": "Drug: 3-(4-HYDROXY-PHENYL)PYRUVIC ACID\nDescription: ...", "source": "3-(4-HYDROXY-PHENYL)PYRUVIC ACID"}, {"id": "2-(3,6-DIHYDROXYPHENYL)ACETIC ACID_GEN", "text": "Drug: 2-(3,6-DIHYDROXYPHENYL)ACETIC ACID\nDescription: ...", "source": "2-(3,6-DIHYDROXYPHENYL)ACETIC ACID"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Pyridoxal_GEN", "text": "Drug: Pyridoxal\nDescription: ...", "source": "Pyridoxal"}, {"id": "Pyridoxine_GEN", "text": "Drug: Pyridoxine\nDescription: ...", "source": "Pyridoxine"}, {"id": "Magnesium_GEN", "text": "Drug: Magnesium\nDescription: ...", "source": "Magnesium"}, {"id": "Zinc_GEN", "text": "Drug: Zinc\nDescription: ...", "source": "Zinc"}, {"id": "Pyridoxamine-5'-Phosphate_GEN", "text": "Drug: Pyridoxamine-5'-Phosphate\nDescription: ...", "source": "Pyridoxamine-5'-Phosphate"}, {"id": "Pyridoxine phosphate_GEN", "text": "Drug: Pyridoxine phosphate\nDescription: ...", "source": "Pyridoxine phosphate"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "Riboflavin Monophosphate_GEN", "text": "Drug: Riboflavin Monophosphate\nDescription: ...", "source": "Riboflavin Monophosphate"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Ademetionine_GEN", "text": "Drug: Ademetionine\nDescription: ...", "source": "Ademetionine"}, {"id": "L-Arginine_GEN", "text": "Drug: L-Arginine\nDescription: ...", "source": "L-Arginine"}, {"id": "L-Aspartic Acid_GEN", "text": "Drug: L-Aspartic Acid\nDescription: ...", "source": "L-Aspartic Acid"}, {"id": "Ornithine_GEN", "text": "Drug: Ornithine\nDescription: ...", "source": "Ornithine"}, {"id": "Adenosine monophosphate_GEN", "text": "Drug: Adenosine monophosphate\nDescription: ...", "source": "Adenosine monophosphate"}, {"id": "Succinic acid_GEN", "text": "Drug: Succinic acid\nDescription: ...", "source": "Succinic acid"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "Glycine_GEN", "text": "Drug: Glycine\nDescription: ...", "source": "Glycine"}, {"id": "Creatine_GEN", "text": "Drug: Creatine\nDescription: ...", "source": "Creatine"}, {"id": "L-Citrulline_GEN", "text": "Drug: L-Citrulline\nDescription: ...", "source": "L-Citrulline"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "ATP_GEN", "text": "Drug: ATP\nDescription: ...", "source": "ATP"}, {"id": "L-Proline_GEN", "text": "Drug: L-Proline\nDescription: ...", "source": "L-Proline"}, {"id": "Sapropterin_GEN", "text": "Drug: Sapropterin\nDescription: ...", "source": "Sapropterin"}, {"id": "Nitric Oxide_GEN", "text": "Drug: Nitric Oxide\nDescription: ...", "source": "Nitric Oxide"}, {"id": "Mesoheme_GEN", "text": "Drug: Mesoheme\nDescription: ...", "source": "Mesoheme"}, {"id": "Glycocyamine_GEN", "text": "Drug: Glycocyamine\nDescription: ...", "source": "Glycocyamine"}, {"id": "3,4-Dihydro-2h-Pyrrolium-5-Carboxylate_GEN", "text": "Drug: 3,4-Dihydro-2h-Pyrrolium-5-Carboxylate\nDescription: ...", "source": "3,4-Dihydro-2h-Pyrrolium-5-Carboxylate"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "Riboflavin Monophosphate_GEN", "text": "Drug: Riboflavin Monophosphate\nDescription: ...", "source": "Riboflavin Monophosphate"}, {"id": "Urea_GEN", "text": "Drug: Urea\nDescription: ...", "source": "Urea"}, {"id": "Pyrophosphoric acid_GEN", "text": "Drug: Pyrophosphoric acid\nDescription: ...", "source": "Pyrophosphoric acid"}, {"id": "Maleic Acid_GEN", "text": "Drug: Maleic Acid\nDescription: ...", "source": "Maleic Acid"}, {"id": "4-Carboxy-4-Aminobutanal_GEN", "text": "Drug: 4-Carboxy-4-Aminobutanal\nDescription: ...", "source": "4-Carboxy-4-Aminobutanal"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Ademetionine_GEN", "text": "Drug: Ademetionine\nDescription: ...", "source": "Ademetionine"}, {"id": "L-Arginine_GEN", "text": "Drug: L-Arginine\nDescription: ...", "source": "L-Arginine"}, {"id": "L-Aspartic Acid_GEN", "text": "Drug: L-Aspartic Acid\nDescription: ...", "source": "L-Aspartic Acid"}, {"id": "Ornithine_GEN", "text": "Drug: Ornithine\nDescription: ...", "source": "Ornithine"}, {"id": "Adenosine monophosphate_GEN", "text": "Drug: Adenosine monophosphate\nDescription: ...", "source": "Adenosine monophosphate"}, {"id": "Succinic acid_GEN", "text": "Drug: Succinic acid\nDescription: ...", "source": "Succinic acid"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "Glycine_GEN", "text": "Drug: Glycine\nDescription: ...", "source": "Glycine"}, {"id": "Creatine_GEN", "text": "Drug: Creatine\nDescription: ...", "source": "Creatine"}, {"id": "L-Citrulline_GEN", "text": "Drug: L-Citrulline\nDescription: ...", "source": "L-Citrulline"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "ATP_GEN", "text": "Drug: ATP\nDescription: ...", "source": "ATP"}, {"id": "L-Proline_GEN", "text": "Drug: L-Proline\nDescription: ...", "source": "L-Proline"}, {"id": "Sapropterin_GEN", "text": "Drug: Sapropterin\nDescription: ...", "source": "Sapropterin"}, {"id": "Nitric Oxide_GEN", "text": "Drug: Nitric Oxide\nDescription: ...", "source": "Nitric Oxide"}, {"id": "Mesoheme_GEN", "text": "Drug: Mesoheme\nDescription: ...", "source": "Mesoheme"}, {"id": "Glycocyamine_GEN", "text": "Drug: Glycocyamine\nDescription: ...", "source": "Glycocyamine"}, {"id": "3,4-Dihydro-2h-Pyrrolium-5-Carboxylate_GEN", "text": "Drug: 3,4-Dihydro-2h-Pyrrolium-5-Carboxylate\nDescription: ...", "source": "3,4-Dihydro-2h-Pyrrolium-5-Carboxylate"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "Riboflavin Monophosphate_GEN", "text": "Drug: Riboflavin Monophosphate\nDescription: ...", "source": "Riboflavin Monophosphate"}, {"id": "Urea_GEN", "text": "Drug: Urea\nDescription: ...", "source": "Urea"}, {"id": "Pyrophosphoric acid_GEN", "text": "Drug: Pyrophosphoric acid\nDescription: ...", "source": "Pyrophosphoric acid"}, {"id": "Maleic Acid_GEN", "text": "Drug: Maleic Acid\nDescription: ...", "source": "Maleic Acid"}, {"id": "4-Carboxy-4-Aminobutanal_GEN", "text": "Drug: 4-Carboxy-4-Aminobutanal\nDescription: ...", "source": "4-Carboxy-4-Aminobutanal"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Ademetionine_GEN", "text": "Drug: Ademetionine\nDescription: ...", "source": "Ademetionine"}, {"id": "L-Arginine_GEN", "text": "Drug: L-Arginine\nDescription: ...", "source": "L-Arginine"}, {"id": "L-Aspartic Acid_GEN", "text": "Drug: L-Aspartic Acid\nDescription: ...", "source": "L-Aspartic Acid"}, {"id": "Ornithine_GEN", "text": "Drug: Ornithine\nDescription: ...", "source": "Ornithine"}, {"id": "Adenosine monophosphate_GEN", "text": "Drug: Adenosine monophosphate\nDescription: ...", "source": "Adenosine monophosphate"}, {"id": "Succinic acid_GEN", "text": "Drug: Succinic acid\nDescription: ...", "source": "Succinic acid"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "Glycine_GEN", "text": "Drug: Glycine\nDescription: ...", "source": "Glycine"}, {"id": "Creatine_GEN", "text": "Drug: Creatine\nDescription: ...", "source": "Creatine"}, {"id": "L-Citrulline_GEN", "text": "Drug: L-Citrulline\nDescription: ...", "source": "L-Citrulline"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "ATP_GEN", "text": "Drug: ATP\nDescription: ...", "source": "ATP"}, {"id": "L-Proline_GEN", "text": "Drug: L-Proline\nDescription: ...", "source": "L-Proline"}, {"id": "Sapropterin_GEN", "text": "Drug: Sapropterin\nDescription: ...", "source": "Sapropterin"}, {"id": "Nitric Oxide_GEN", "text": "Drug: Nitric Oxide\nDescription: ...", "source": "Nitric Oxide"}, {"id": "Mesoheme_GEN", "text": "Drug: Mesoheme\nDescription: ...", "source": "Mesoheme"}, {"id": "Glycocyamine_GEN", "text": "Drug: Glycocyamine\nDescription: ...", "source": "Glycocyamine"}, {"id": "3,4-Dihydro-2h-Pyrrolium-5-Carboxylate_GEN", "text": "Drug: 3,4-Dihydro-2h-Pyrrolium-5-Carboxylate\nDescription: ...", "source": "3,4-Dihydro-2h-Pyrrolium-5-Carboxylate"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "Riboflavin Monophosphate_GEN", "text": "Drug: Riboflavin Monophosphate\nDescription: ...", "source": "Riboflavin Monophosphate"}, {"id": "Urea_GEN", "text": "Drug: Urea\nDescription: ...", "source": "Urea"}, {"id": "Pyrophosphoric acid_GEN", "text": "Drug: Pyrophosphoric acid\nDescription: ...", "source": "Pyrophosphoric acid"}, {"id": "Maleic Acid_GEN", "text": "Drug: Maleic Acid\nDescription: ...", "source": "Maleic Acid"}, {"id": "4-Carboxy-4-Aminobutanal_GEN", "text": "Drug: 4-Carboxy-4-Aminobutanal\nDescription: ...", "source": "4-Carboxy-4-Aminobutanal"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Ademetionine_GEN", "text": "Drug: Ademetionine\nDescription: ...", "source": "Ademetionine"}, {"id": "L-Arginine_GEN", "text": "Drug: L-Arginine\nDescription: ...", "source": "L-Arginine"}, {"id": "L-Aspartic Acid_GEN", "text": "Drug: L-Aspartic Acid\nDescription: ...", "source": "L-Aspartic Acid"}, {"id": "Ornithine_GEN", "text": "Drug: Ornithine\nDescription: ...", "source": "Ornithine"}, {"id": "Adenosine monophosphate_GEN", "text": "Drug: Adenosine monophosphate\nDescription: ...", "source": "Adenosine monophosphate"}, {"id": "Succinic acid_GEN", "text": "Drug: Succinic acid\nDescription: ...", "source": "Succinic acid"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "Glycine_GEN", "text": "Drug: Glycine\nDescription: ...", "source": "Glycine"}, {"id": "Creatine_GEN", "text": "Drug: Creatine\nDescription: ...", "source": "Creatine"}, {"id": "L-Citrulline_GEN", "text": "Drug: L-Citrulline\nDescription: ...", "source": "L-Citrulline"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "ATP_GEN", "text": "Drug: ATP\nDescription: ...", "source": "ATP"}, {"id": "L-Proline_GEN", "text": "Drug: L-Proline\nDescription: ...", "source": "L-Proline"}, {"id": "Sapropterin_GEN", "text": "Drug: Sapropterin\nDescription: ...", "source": "Sapropterin"}, {"id": "Nitric Oxide_GEN", "text": "Drug: Nitric Oxide\nDescription: ...", "source": "Nitric Oxide"}, {"id": "Mesoheme_GEN", "text": "Drug: Mesoheme\nDescription: ...", "source": "Mesoheme"}, {"id": "Glycocyamine_GEN", "text": "Drug: Glycocyamine\nDescription: ...", "source": "Glycocyamine"}, {"id": "3,4-Dihydro-2h-Pyrrolium-5-Carboxylate_GEN", "text": "Drug: 3,4-Dihydro-2h-Pyrrolium-5-Carboxylate\nDescription: ...", "source": "3,4-Dihydro-2h-Pyrrolium-5-Carboxylate"}, {"id": "Flavin adenine dinucleotide_GEN", "text": "Drug: Flavin adenine dinucleotide\nDescription: ...", "source": "Flavin adenine dinucleotide"}, {"id": "Riboflavin Monophosphate_GEN", "text": "Drug: Riboflavin Monophosphate\nDescription: ...", "source": "Riboflavin Monophosphate"}, {"id": "Urea_GEN", "text": "Drug: Urea\nDescription: ...", "source": "Urea"}, {"id": "Pyrophosphoric acid_GEN", "text": "Drug: Pyrophosphoric acid\nDescription: ...", "source": "Pyrophosphoric acid"}, {"id": "Maleic Acid_GEN", "text": "Drug: Maleic Acid\nDescription: ...", "source": "Maleic Acid"}, {"id": "4-Carboxy-4-Aminobutanal_GEN", "text": "Drug: 4-Carboxy-4-Aminobutanal\nDescription: ...", "source": "4-Carboxy-4-Aminobutanal"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}, {"id": "ATP_GEN", "text": "Drug: ATP\nDescription: ...", "source": "ATP"}, {"id": "Calcium_GEN", "text": "Drug: Calcium\nDescription: ...", "source": "Calcium"}, {"id": "Magnesium_GEN", "text": "Drug: Magnesium\nDescription: ...", "source": "Magnesium"}, {"id": "Uridine diphosphate glucose_GEN", "text": "Drug: Uridine diphosphate glucose\nDescription: ...", "source": "Uridine diphosphate glucose"}, {"id": "Maltose_GEN", "text": "Drug: Maltose\nDescription: ...", "source": "Maltose"}, {"id": "Uridine-5'-Diphosphate_GEN", "text": "Drug: Uridine-5'-Diphosphate\nDescription: ...", "source": "Uridine-5'-Diphosphate"}, {"id": "Pyrophosphoric acid_GEN", "text": "Drug: Pyrophosphoric acid\nDescription: ...", "source": "Pyrophosphoric acid"}, {"id": "Pyridoxal Phosphate_GEN", "text": "Drug: Pyridoxal Phosphate\nDescription: ...", "source": "Pyridoxal Phosphate"}, {"id": "Pyruvic acid_GEN", "text": "Drug: Pyruvic acid\nDescription: ...", "source": "Pyruvic acid"}, {"id": "Biotin_GEN", "text": "Drug: Biotin\nDescription: ...", "source": "Biotin"}, {"id": "L-Aspartic Acid_GEN", "text": "Drug: L-Aspartic Acid\nDescription: ...", "source": "L-Aspartic Acid"}, {"id": "L-Glutamine_GEN", "text": "Drug: L-Glutamine\nDescription: ...", "source": "L-Glutamine"}, {"id": "Adenosine monophosphate_GEN", "text": "Drug: Adenosine monophosphate\nDescription: ...", "source": "Adenosine monophosphate"}, {"id": "Succinic acid_GEN", "text": "Drug: Succinic acid\nDescription: ...", "source": "Succinic acid"}, {"id": "Glutamic Acid_GEN", "text": "Drug: Glutamic Acid\nDescription: ...", "source": "Glutamic Acid"}, {"id": "Glutathione_GEN", "text": "Drug: Glutathione\nDescription: ...", "source": "Glutathione"}, {"id": "Glycine_GEN", "text": "Drug: Glycine\nDescription: ...", "source": "Glycine"}, {"id": "L-Cysteine_GEN", "text": "Drug: L-Cysteine\nDescription: ...", "source": "L-Cysteine"}, {"id": "NADH_GEN", "text": "Drug: NADH\nDescription: ...", "source": "NADH"}]